<SEC-DOCUMENT>0000912057-19-000021.txt : 20190524
<SEC-HEADER>0000912057-19-000021.hdr.sgml : 20190524
<ACCEPTANCE-DATETIME>20190117172726
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000912057-19-000021
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		33
FILED AS OF DATE:		20190117
<PUBLIC-REL-DATE>20190524
DATE AS OF CHANGE:		20190219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Akero Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001744659
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-02467
		FILM NUMBER:		19531610

	BUSINESS ADDRESS:	
		STREET 1:		170 HARBOR WAY
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		202-525-8399

	MAIL ADDRESS:	
		STREET 1:		170 HARBOR WAY
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg45201_table_of_contents">  Table of contents</A> <BR>
<A HREF="#fa45201_akero_therapeutics,_in__fa402109">  Akero Therapeutics, Inc. Index to financial statements</A><BR></font>
</P>

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As confidentially submitted to the Securities and Exchange Commission on January&nbsp;17, 2019. This draft registration statement has not been publicly filed
with the Securities and Exchange Commission and all information herein remains confidential.  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> &nbsp;<BR>  </B></FONT></P>


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> <div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>FORM S-1<BR>  </B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>REGISTRATION STATEMENT<BR>
Under<BR>
The Securities Act of 1933  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>AKERO THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT  style="font-size:8pt;line-height:9pt;">(Exact name of registrant as specified in its charter) </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Delaware</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 2836</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(Primary Standard Industrial<BR>
Classification Code Number)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 81-5266573</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(I.R.S. Employer<BR>
Identification Number)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>170 Harbor Way, 3<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">rd</font>&nbsp;Floor<BR>
South San Francisco, CA 94080<BR>
(650)&nbsp;487-6488</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Andrew Cheng<BR>
President and Chief Executive Officer<BR>
170 Harbor Way, 3<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">rd</font>&nbsp;Floor<BR>
South San Francisco, CA 94080<BR>
(650)&nbsp;487-6488</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(Name, address, including zip code, and telephone number, including area code, of agent for service) </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Copies to:</B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Mitchell Bloom, Esq.<BR>
John Mutkoski, Esq.<BR>
Laurie Burlingame, Esq.<BR>
Goodwin Procter&nbsp;LLP<BR>
100 Northern Avenue<BR>
Boston, MA 02210<BR>
(617)&nbsp;570-1000</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Jonathan Young<BR>
Chief Operating Officer<BR>
170 Harbor Way, 3<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">rd</font>&nbsp;Floor<BR>
South San Francisco, CA 94080<BR>
(650)&nbsp;487-6488</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> Divakar Gupta, Esq.<BR>
Richard C. Segal, Esq.<BR>
Charles S. Kim, Esq.<BR>
Cooley&nbsp;LLP<BR>
1114 Avenue of the Americas<BR>
New York, NY 10036<BR>
(212)&nbsp;479-6000</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Approximate date of commencement of proposed sale to the public:<BR>
As soon as practicable after the effective date of this registration statement.  </B></FONT></P>


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933, as
amended, check the following box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth
company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule&nbsp;12b-2 of the Exchange Act. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="112pt" style="font-family:arial;"></TD>
<TD WIDTH="10%" style="font-family:arial;"></TD>
<TD WIDTH="86pt" style="font-family:arial;"></TD>
<TD WIDTH="10%" style="font-family:arial;"></TD>
<TD WIDTH="106pt" style="font-family:arial;"></TD>
<TD WIDTH="10%" style="font-family:arial;"></TD>
<TD WIDTH="133pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Large Accelerated Filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Accelerated Filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Non-Accelerated Filer&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;text-align:center;"><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_GRID,"text-align:center;" -->


 Smaller Reporting Company&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></font> <p align=center style="font-family:arial;margin-top:0pt;margin-left:0pt;"> <FONT  style="font-size:8pt;line-height:9pt;"> Emerging Growth Company&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>CALCULATION OF REGISTRATION FEE  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="60%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="111" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="111" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:3pt;text-indent:-3pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:arial;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Title of each Class of Securities<BR>
to be Registered</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Proposed Maximum<BR>
Aggregate Offering<BR>
Price(1)(2)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount of<BR>
Registration Fee</B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:3pt;text-indent:-3pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B> </B></FONT><FONT  style="font-size:8pt;line-height:9pt;">Common Stock, par value $0.0001 per share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:arial;border-bottom:double #000000 2.25pt;"><p style="font-family:arial;margin-left:3pt;text-indent:-3pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;Estimated
solely for the purpose of calculating the registration fee pursuant to Rule&nbsp;457(o) under the Securities Act of 1933, as amended.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;Includes
the offering price of shares that the underwriters may purchase pursuant to an option to purchase additional shares. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file&nbsp;a further
amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until this
registration statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine.</B></FONT></P>
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT  style="font-size:8pt;line-height:9pt;">
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=957688,FOLIO='blank',FILE='DISK114:[18ZFG1.18ZFG45201]BA45201A.;9',USER='SMENEZE',CD='16-JAN-2019;21:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;"><FONT COLOR="#FF4040" SIZE=2><B>The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and
Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is
not permitted. </B></FONT></P>

<P style="font-family:arial;"><FONT COLOR="#FF4040" SIZE=2><B>Subject to Completion, dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B>Preliminary prospectus</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=5><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=5><B>
<IMG SRC="g480743.jpg" ALT="LOGO" WIDTH="352" HEIGHT="109">
  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=5><B><I> Common stock  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This is an initial public offering of shares of common stock by Akero Therapeutics,&nbsp;Inc. We are offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock to be
sold in the offering. The initial public offering price is expected to be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior
to this offering, there has been no public market for our common stock. We intend to apply for listing of our common stock on The Nasdaq Global Market under the symbol "AKRO." </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
are an "emerging growth company" as defined under the federal securities laws and, as such, have elected to comply with certain reduced public company reporting requirements. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Per Share</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Total </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2><B> </B></FONT><FONT SIZE=2>Initial public offering price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discounts and commissions(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds to Akero Therapeutics,&nbsp;Inc., before expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:0%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;See
"Underwriting" for a description of the compensation payable to the underwriters. </FONT></P>
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>We
have granted the underwriters an option for a period of 30&nbsp;days to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B>Investing in our common stock involves a high degree of risk. See "Risk factors" beginning on page&nbsp;9.</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the accuracy or adequacy of
this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters expect to deliver the shares to purchasers on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4><B>J.P. Morgan</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4><B>Jefferies</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4><B>Evercore ISI</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Roth Capital Partners  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=295581,FOLIO='blank',FILE='DISK114:[18ZFG1.18ZFG45201]BC45201A.;17',USER='MTITUSS',CD='17-JAN-2019;10:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> <A NAME="BG45201A_main_toc"></A>  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B> <A NAME="bg45201_table_of_contents"> </A> </B></FONT><FONT SIZE=4><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Table of contents    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
<A NAME="BG45201_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="25pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Page</B></FONT><BR></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#ca45201_prospectus_summary"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prospectus summary</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#ca45201_prospectus_summary"><FONT SIZE=2>1</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#cg45201_risk_factors"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk factors</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#cg45201_risk_factors"><FONT SIZE=2>9</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#co45201_special_note_regarding_forward-looking_statements"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Special note regarding forward-looking statements</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#co45201_special_note_regarding_forward-looking_statements"><FONT SIZE=2>63</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#co45201_market,_industry,_and_other_data"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Market, industry, and other data</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#co45201_market,_industry,_and_other_data"><FONT SIZE=2>65</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#co45201_use_of_proceeds"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of proceeds</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#co45201_use_of_proceeds"><FONT SIZE=2>66</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#co45201_dividend_policy"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dividend policy</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#co45201_dividend_policy"><FONT SIZE=2>67</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#co45201_capitalization"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalization</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#co45201_capitalization"><FONT SIZE=2>68</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#co45201_dilution"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#co45201_dilution"><FONT SIZE=2>70</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#cq45201_selected_financial_data"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selected financial data</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#cq45201_selected_financial_data"><FONT SIZE=2>73</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#cq45201_management_s_discussion_and_an__man03466"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management's discussion and analysis of financial condition and results of
operations</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#cq45201_management_s_discussion_and_an__man03466"><FONT SIZE=2>75</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#cu45201_business"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Business</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#cu45201_business"><FONT SIZE=2>91</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#dg45201_management"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dg45201_management"><FONT SIZE=2>144</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#di45201_executive_compensation"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive compensation</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#di45201_executive_compensation"><FONT SIZE=2>152</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#dk45201_director_compensation"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Director compensation</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dk45201_director_compensation"><FONT SIZE=2>162</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#dk45201_certain_relationships_and_related_party_transactions"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Certain relationships and related party transactions</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dk45201_certain_relationships_and_related_party_transactions"><FONT SIZE=2>164</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#dm45201_principal_stockholders"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal stockholders</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dm45201_principal_stockholders"><FONT SIZE=2>168</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#dm45201_description_of_capital_stock"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of capital stock</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dm45201_description_of_capital_stock"><FONT SIZE=2>171</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#do45201_shares_eligible_for_future_sale"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares eligible for future sale</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#do45201_shares_eligible_for_future_sale"><FONT SIZE=2>177</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#do45201_material_u.s._federal_income_t__mat03146"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Material U.S. federal income tax considerations for non-U.S. holders of common
stock</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#do45201_material_u.s._federal_income_t__mat03146"><FONT SIZE=2>179</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#dq45201_underwriting"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dq45201_underwriting"><FONT SIZE=2>183</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#dq45201_legal_matters"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal matters</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dq45201_legal_matters"><FONT SIZE=2>196</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#dq45201_experts"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dq45201_experts"><FONT SIZE=2>196</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#dq45201_where_you_can_find_more_information"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where you can find more information</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#dq45201_where_you_can_find_more_information"><FONT SIZE=2>196</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><A HREF="#fa45201_akero_therapeutics,_in__fa402109"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Index to financial statements</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><A HREF="#fa45201_akero_therapeutics,_in__fa402109"><FONT SIZE=2>F-1</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2><B>We are responsible for the information contained in this prospectus. We have not, and the underwriters have not, authorized anyone to provide you with any other information
other than in this prospectus, and we take no responsibility for, and the underwriters have not taken responsibility for, any other information others may give you. We are not, and the underwriters
are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as
of any date other than its date.</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Through and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 (the 25th&nbsp;day after the
date of this prospectus), all dealers that effect transactions in these securities, whether or not
participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their
unsold allotments or subscriptions.</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
investors outside the United States: Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction
where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution
of this prospectus outside of the United States. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
prospectus contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos,
artwork and other visual displays, may appear without the &reg; or <SUP>TM</SUP> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the
fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies' trade names or
trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=455945,FOLIO='blank',FILE='DISK114:[18ZFG1.18ZFG45201]BG45201A.;16',USER='SMENEZE',CD='16-JAN-2019;21:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ca45201_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">

 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B> <A NAME="ca45201_prospectus_summary"> </A>
<A NAME="toc_ca45201_1"> </A> </B></FONT><FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Prospectus summary    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information
that you should consider in making your investment decision. Before investing in our common stock, you should read the entire prospectus carefully, including our financial statements and the related
notes included elsewhere in this prospectus and the sections entitled "Risk factors" and "Management's discussion and analysis of financial condition and results of operations." Except where the
context otherwise requires or where otherwise indicated, the terms "Akero," "we," "us," "our," "our company," "the company," and "our business" refer to Akero Therapeutics,&nbsp;Inc., together with
its subsidiary, as appropriate.</I></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic
diseases with high unmet medical need. Our initial focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease,
or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. Our lead product candidate, AKR-001, which we are developing as a
potential treatment for patients with NASH, is an analog of fibroblast growth factor 21, or FGF21. FGF21 is an endogenously-expressed hormone that regulates metabolism of lipids, carbohydrates and
proteins throughout the body. FGF21 also plays a critical role in protecting many types of cells from various forms of stress. FGF21 agonists have shown evidence of therapeutic benefit in clinical
trials of patients with NASH, many of whom are dyslipidemic and insulin resistant. In previous clinical trials in patients with type&nbsp;2 diabetes, or T2D, administration of AKR-001 was associated
with a substantial improvement in lipid metabolism and insulin sensitivity. We believe these data demonstrate AKR-001's potential to serve as a cornerstone for the treatment of NASH. We plan to
initiate a Phase&nbsp;2a clinical trial for AKR-001 in NASH patients with fibrosis in the middle of 2019. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>NASH
is primarily driven by chronic excess caloric intake, which results in people becoming overweight and obese. Nearly half of NASH patients have T2D and nearly three-quarters have metabolic
syndrome. The underlying insulin resistance among these patients contributes to accumulation of excess fat in the liver, which leads to stress on hepatocytes. This cellular stress triggers localized
inflammation and can ultimately lead to fibrosis and scarring in the liver, or cirrhosis. As NASH progresses, cardiovascular-related morbidity and mortality also increase. The most frequent cause of
death in patients with NASH is cardiovascular disease. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
prevalence of NASH in the United States is projected to increase from an estimated 17.3&nbsp;million in 2016 to 27.0&nbsp;million by 2030. In particular, the prevalence of patients with
advanced fibrosis in the United States is projected to more than double between 2016 and 2030. We believe the unmet medical need will remain high for this population despite investigational NASH
therapies currently in late-stage clinical development, as many of these therapies have shown limited efficacy or may be limited by unwanted side effects. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Our lead product candidate, AKR-001  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>AKR-001 is an FGF21 agonist with unique properties that we believe has the potential to address the core processes underlying NASH
pathogenesis, thereby enabling it to restore healthy fat metabolism in the liver, reduce hepatocyte stress, mitigate inflammation and resolve fibrosis. FGF21 is an endocrine hormone that acts on the
liver, pancreas, muscle and adipose tissue to regulate the metabolism of lipids, carbohydrates </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=798238,FOLIO='1',FILE='DISK114:[18ZFG1.18ZFG45201]CA45201A.;39',USER='MTITUSS',CD='17-JAN-2019;10:41' -->
<A NAME="page_ca45201_1_2"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:arial;"><FONT SIZE=2>and
proteins. Acting as a paracrine hormone, FGF21 also plays a critical role in protecting cells against stress. These attributes make FGF21 agonism a compelling therapeutic mechanism, but native
FGF21 is limited by its short half-life in the bloodstream. AKR-001 has been engineered to increase human FGF21's half-life sufficiently to enable once-weekly dosing, while retaining the native
biological activity of FGF21. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>AKR-001
has been administered to a total of 83 patients with T2D in two Phase&nbsp;1 clinical trials. In a Phase 1b clinical trial, it was observed that AKR-001 substantially improved plasma
lipoprotein levels, including reductions of up to 69% in triglycerides and 30% in non-high density lipoprotein cholesterol. In these clinical trials, it was also observed that administration of
AKR-001 was associated with substantially improved markers of insulin sensitivity, including reductions of up to 37% in C-peptide and 55% in the homeostatic model assessment of insulin resistance. We
believe these results indicate the potential of AKR-001 to redirect calories away from the liver, reduce liver fat, alleviate hepatocyte stress, inhibit inflammation and resolve fibrosis in patients
with NASH, as well as reduce susceptibility to cardiovascular disease. This belief is also supported by data from Phase&nbsp;2 clinical trials of other endocrine FGF analogs in patients with NASH,
in which substantial reductions in liver fat content and biomarkers of liver fibrosis were observed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
therefore believe that AKR-001 has the potential to be a best-in-class endocrine FGF agonist for treatment of this rapidly-growing patient population that lacks effective treatment options. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
June 2018, we acquired exclusive global development and commercialization rights to AKR-001 from Amgen&nbsp;Inc., which leveraged its deep protein engineering expertise to design and develop
AKR-001. As of December&nbsp;31, 2018, our patent portfolio relating to AKR-001 and other peptides included 113 issued patents and 40 pending patents worldwide, with expected patent exclusivity up
to 2034 in the United States, including potential patent term extension. Since AKR-001 is a biologic, marketing approval would also provide twelve years of market exclusivity from the approval date of
a Biologics License Application in the United States. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Our strategy  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our goal is to become a leading biotechnology company focused on developing and commercializing transformative treatments for patients with
serious metabolic diseases with high unmet medical need. The key components of our strategy are to:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Rapidly advance AKR-001 through clinical development in NASH; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Scale our capabilities to support development and commercialization of AKR-001; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Enhance our position as a leading metabolic disease company by leveraging our knowledge of FGF21 biology; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Develop, acquire or in-license product candidates that enhance our potential to become a leading metabolic disease company. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Our
management team has extensive experience in drug discovery, development and commercialization, and has been involved in the approvals of more than 20 products. Our Chief Executive Officer, Andrew
Cheng, MD, PhD, previously Chief Medical Officer at Gilead, was responsible for clinical development for Gilead's HIV program. Our Chief Scientific Officer, Tim Rolph, DPhil, formerly Chief Scientific
Officer of Pfizer's Cardiovascular&nbsp;&amp; Metabolic Disease Research Unit, oversaw Pfizer's FGF21 program. We are also supported by our board of directors and a group of leading institutional
investors. We believe that our team is well positioned to leverage its collective experience in drug development and in-depth knowledge </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=323689,FOLIO='2',FILE='DISK114:[18ZFG1.18ZFG45201]CA45201A.;39',USER='MTITUSS',CD='17-JAN-2019;10:41' -->
<A NAME="page_ca45201_1_3"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:arial;"><FONT SIZE=2>of
FGF21 biology and metabolic diseases to develop and commercialize products that will have significant benefits for patients with NASH and other serious metabolic diseases. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Risks associated with our business  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our ability to execute on our business strategy is subject to a number of risks, which are discussed more fully in the section of this
prospectus entitled "Risk factors." You should carefully consider these risks before making an investment in our common stock. These risks include, among others, the
following:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We have incurred significant losses since our inception and we expect to incur losses for the foreseeable future. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We currently have a limited operating history, have not generated any revenue to date, and may never become profitable. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We currently have no products that are approved for commercial sale and our inability to obtain regulatory approval for AKR-001 or any future
product candidate would substantially harm our business. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We are heavily dependent on the success of AKR-001, our only product candidate. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> If we breach our license agreement with Amgen related to AKR-001, we could lose the ability to continue development and commercialization of
AKR-001. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully
than us. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our success depends, in part, on our ability to obtain, maintain, protect and defend our intellectual property, which is difficult and costly,
and we may not be able to ensure that we will be able to do so. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We will require additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we
may not complete the development and commercialization of our product candidate or develop any future product candidates. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our product candidate and any future product candidates must undergo rigorous clinical trials and regulatory approvals, and success in
preclinical studies or earlier-stage clinical trials may not be indicative of results in future clinical trials. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We are subject to many manufacturing risks, any of which could substantially increase our costs, delay clinical programs and limit supply of
our products. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Corporate information  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We were incorporated in January 2017 under the laws of the State of Delaware under the name Pippin Pharmaceuticals,&nbsp;Inc. On
May&nbsp;16, 2018, we changed our name to Akero Therapeutics,&nbsp;Inc. Our principal executive offices are located at 170 Harbor Way, 3<SUP>rd</SUP>&nbsp;Floor, South San Francisco, CA
94080, and our telephone number is (650)-487-6488. Our website address is www.akerotx.com. The information contained in or accessible from our website is not incorporated into this prospectus, and you
should not consider it part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=422589,FOLIO='3',FILE='DISK114:[18ZFG1.18ZFG45201]CA45201A.;39',USER='MTITUSS',CD='17-JAN-2019;10:41' -->
<A NAME="page_ca45201_1_4"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Implications of being an emerging growth company and a smaller reporting company  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We qualify as an "emerging growth company" as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. As an
emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions
include:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> two years of audited financial statements in addition to any required unaudited interim financial statements with correspondingly reduced
"Management's discussion and analysis of financial condition and results of operations" disclosure; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reduced disclosure about our executive compensation arrangements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> no non-binding advisory votes on executive compensation or golden parachute arrangements; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
may take advantage of these exemptions for up to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that
is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal year following the
fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; or
(iv)&nbsp;the last day of the fiscal year in which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or SEC, which means the market value of
our common stock that is held by non-affiliates exceeds $700&nbsp;million as of the prior June&nbsp;30th. We may choose to take advantage of some but not all of these exemptions. We have taken
advantage of reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you
hold stock. We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an emerging growth
company, we may rely on certain of these exemptions, including without limitation, providing an auditor's attestation report on our system of internal controls over financial reporting pursuant to
Section&nbsp;404(b) of the Sarbanes-Oxley Act. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are also a "smaller reporting company" as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take
advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that our voting and non-voting common stock held by
non-affiliates is more than $250&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100&nbsp;million during the most recently
completed fiscal year and our voting and non-voting common stock held by non-affiliates is more than $700&nbsp;million measured on the last business day of our second fiscal quarter. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=926344,FOLIO='4',FILE='DISK114:[18ZFG1.18ZFG45201]CA45201A.;39',USER='MTITUSS',CD='17-JAN-2019;10:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cc45201_1_5"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B> <A NAME="cc45201_the_offering"> </A>
<A NAME="toc_cc45201_1"> </A> </B></FONT><FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The offering    <BR>  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common&nbsp;stock&nbsp;offered&nbsp;by us</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common&nbsp;stock&nbsp;to&nbsp;be&nbsp;outstanding immediately after this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
(or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their option to purchase additional shares in full)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Option to purchase additional shares</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We have granted the underwriters an option exercisable for a period of 30&nbsp;days to purchase up to additional shares of
our common stock.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of proceeds</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We estimate that we will receive net proceeds from the sale of shares of our common stock in this offering of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to
purchase additional shares in full, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this
prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds from this offering, together with our existing cash, for development of our product
candidate, AKR-001, including completion of our contemplated Phase&nbsp;2a clinical trial and a subsequent Phase&nbsp;2b clinical trial, for third-party drug substance and drug product manufacturing, as well as potential pipeline expansion and for
working capital and general corporate purposes. For a more complete description of our intended use of the proceeds from this offering, see "Use of proceeds."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk factors</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>You should carefully read the "Risk factors" section of this prospectus for a discussion of factors that you should consider
before deciding to invest in our common stock.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proposed Nasdaq Global Market symbol</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>"AKRO"</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
number of shares of our common stock to be outstanding after this offering is based on 65,465,104 shares of our common stock outstanding as of December&nbsp;31, 2018, after giving effect to the
automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of 64,730,410 shares of our common stock immediately prior to the completion of this offering, and
excludes:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 5,656,243 shares of common stock issuable upon the exercise of stock options outstanding as of December&nbsp;31, 2018 under our 2018 Stock
Option and Grant Plan, or the 2018 Plan, at a weighted-average exercise price of $0.20 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 3,748,823 shares of common stock reserved for future issuance as of December&nbsp;31, 2018 under the 2018 Plan, which will cease to be
available for issuance at the time that our 2019 Stock Option and Grant Plan, or the 2019 Plan, becomes effective; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock that will become available for future issuance under the 2019 Plan,
which will become effective in
connection with this offering; and </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=8,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=3756,FOLIO='5',FILE='DISK114:[18ZFG1.18ZFG45201]CC45201A.;12',USER='SMENEZE',CD='16-JAN-2019;21:29' -->
<A NAME="page_cc45201_1_6"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for future issuance under our 2019 Employee Stock Purchase Plan which will
become effective
in connection with this offering. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Unless
otherwise indicated, all information in this prospectus assumes or gives effect to the following:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the filing and effectiveness of our fourth amended and restated certificate of incorporation and second amended and restated bylaws prior to
the completion of this offering; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a one-for-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reverse stock split of our common stock effected
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common
stock immediately prior to the completion of this offering; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> no exercise of the outstanding options referred to above; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> no exercise by the underwriters of their option to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our
common stock in this offering. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=9,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=670802,FOLIO='6',FILE='DISK114:[18ZFG1.18ZFG45201]CC45201A.;12',USER='SMENEZE',CD='16-JAN-2019;21:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ce45201_1_7"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">

 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B> <A NAME="ce45201_summary_financial_data"> </A>
<A NAME="toc_ce45201_1"> </A> </B></FONT><FONT SIZE=4><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Summary financial data    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You should read the following summary financial data together with our financial statements and the related notes appearing at the end of this
prospectus and the "Selected financial data" and "Management's discussion and analysis of financial condition and results of operations" sections of this prospectus. We have derived the statement of
operations data for the period January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017 from our audited financial statements appearing elsewhere in this prospectus. The statement of
operations data for the period January&nbsp;24, 2017 (inception) through September&nbsp;30, 2017, for the nine months ended September&nbsp;30, 2018 and the balance sheet data as of
September&nbsp;30, 2018 have been derived from our unaudited financial statements appearing elsewhere in this prospectus and have been prepared on the same basis as the audited financial statements.
In the opinion of management, the unaudited data reflects all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the financial information in those
statements. Our historical results are not necessarily indicative of the results that may be expected in the future and our results as of and for the nine months ended September&nbsp;30, 2018 are
not necessarily indicative of the results that may be expected as of and for the year ended December&nbsp;31, 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="105pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="105pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>(in thousands, except share and per share amounts)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24, 2017<BR>
(Inception) through<BR>
December&nbsp;31,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24, 2017<BR>
(Inception) through<BR>
September&nbsp;30,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Nine months<BR>
ended<BR>
September&nbsp;30,<BR>
2018 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Statement of Operation Data:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,486</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,123</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9,898</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,078</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>896</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>912 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Total operating expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,564</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10,810 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,564</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(10,810</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Other expense:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of preferred stock tranche obligation</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(8,400</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Change in fair value of anti-dilution right liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1,032</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(9,432</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,564</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(20,242</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accruing dividends on convertible preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(213</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(166</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Accretion of convertible preferred stock to redemption value</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(321</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,777</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,185</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(20,563</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Net loss per share attributable to common stockholders&#151;basic and diluted(1)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(76.98</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding&#151;basic and diluted(1)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>267,108 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Pro forma net loss per share attributable to common stockholders&#151;basic and diluted (unaudited)(1)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma weighted average common shares outstanding&#151;basic and diluted (unaudited)(1)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;See
Note&nbsp;10 to our financial statements appearing at the end of this prospectus for details on the calculation of basic and diluted net loss per share attributable to common
stockholders and the calculation of basic and diluted pro forma net loss per share attributable to common stockholders. </FONT></P>
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=10,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=998957,FOLIO='7',FILE='DISK114:[18ZFG1.18ZFG45201]CE45201A.;32',USER='MTITUSS',CD='17-JAN-2019;10:45' -->
<A NAME="page_ce45201_1_8"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>As of September&nbsp;30, 2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Actual</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Pro forma(1)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Pro forma<BR>
as adjusted(2)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Balance Sheet Data:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,832</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Working capital(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,416</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8,455</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Preferred stock tranche obligation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anti-dilution right liability</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,671</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>14,108</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' deficit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(25,093</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;The
pro forma balance sheet data gives effect to (i)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock prior to the completion of this offering and (ii)&nbsp;the filing and effectiveness of our fourth amended and restated certificate of incorporation.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;The
pro forma as adjusted balance sheet data gives effect to (i)&nbsp;the pro forma adjustments set forth in footnote (1)&nbsp;above and (ii)&nbsp;the issuance and sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of
the price range set forth on the cover
page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each $1.00 increase (decrease) in the assumed initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each
of cash, working capital, total assets and total stockholders' equity (deficit) by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of
this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1,000,000 shares in
the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, working capital, total assets and
total stockholders' equity (deficit) by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;We
define working capital as current assets less current liabilities. </FONT></P>
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=11,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=456162,FOLIO='8',FILE='DISK114:[18ZFG1.18ZFG45201]CE45201A.;32',USER='MTITUSS',CD='17-JAN-2019;10:45' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cg45201_1_9"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B> <A NAME="cg45201_risk_factors"> </A>
<A NAME="toc_cg45201_1"> </A> </B></FONT><FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risk factors    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Investment in our common stock involves a high degree of risk and uncertainty. You should carefully consider each of
the risks and uncertainties described below before you decide to buy our common stock. You should also refer to the other information in this prospectus, including our financial statements and related
notes. If any of the following risks and uncertainties materialize, our business, financial condition, liquidity and results of operations could be materially and adversely affected. This could cause
the trading price of our common stock to decline, and you could lose all or part of your investment.</I></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Risks related to our business, technology and industry  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I> We have incurred significant losses since our inception and we expect to incur losses for the foreseeable future.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have no products approved for commercial sale and have not generated any revenue to date, and we continue to incur significant research and development and
other expenses related to our ongoing operations. As a result, we are not profitable and have incurred significant losses in each period since our inception in January 2017. For the period from our
inception through December&nbsp;31, 2017 and the nine months ended September&nbsp;30, 2018, we reported net losses of $4.6&nbsp;million and $20.2&nbsp;million, respectively. As of
September&nbsp;30, 2018, we had an accumulated deficit of $25.1&nbsp;million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase
as we continue our research and development of, and seek regulatory approvals for, our product candidate. We anticipate that our expenses will increase substantially if, and as,
we:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> conduct larger scale clinical trials for our product candidate, AKR-001, and any future product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> discover and develop new product candidates, and conduct nonclinical studies and clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> manufacture, or have manufactured, clinical and commercial supplies of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek regulatory approvals for our product candidate or any future product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> commercialize AKR-001 or any future product candidates, if approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> attempt to transition from a company with a research focus to a company capable of supporting commercial activities, including establishing
sales, marketing and distribution infrastructure; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> hire additional clinical, scientific, and management personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> add operational, financial, and management information systems and personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> identify additional compounds or product candidates and acquire rights from third parties to those compounds or product candidates through
licenses; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> incur additional costs associated with operating as a public company following the completion of this offering. </FONT></DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>Even
if we succeed in commercializing AKR-001 or any future product candidates, we may continue to incur substantial research and development and other expenditures to develop and market additional
product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will
depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=12,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=252648,FOLIO='9',FILE='DISK114:[18ZFG1.18ZFG45201]CG45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:41' -->
<A NAME="page_cg45201_1_10"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>


<P style="font-family:arial;"><FONT SIZE=2>and
expected future losses have had and will continue to have an adverse effect on our stockholders' equity and working capital. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We currently have a limited operating history, have not generated any revenue to date, and may never become profitable.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a clinical-stage biotechnology company with a limited operating history. Our operations to date have been limited to organizing and staffing our
company, acquiring, developing and securing our technology and product candidate, AKR-001, and conducting nonclinical studies of AKR-001. We have not yet demonstrated our ability to conduct or
complete clinical trials, obtain regulatory approval, formulate and manufacture a commercial-scale product, or conduct sales and marketing activities necessary for successful product
commercialization. Investment in biotechnology product development is highly speculative because it entails substantial upfront expenditures in contract research organizations and contract
manufacturing organizations and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become
commercially viable. Consequently, any predictions you may make about our future success or viability may not be as accurate as they could be if we had a longer operating history. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Though
AKR-001 is ready for Phase&nbsp;2a clinical development, we do not expect to receive revenue from AKR-001 for a number of years, if ever. To date, we have not generated any revenue and we
will not be able to generate product revenue unless and until AKR-001, or any future product candidate, successfully completes clinical trials, receives regulatory approval, and is commercialized. We
may seek to obtain revenue from collaboration or licensing agreements with third parties. Our ability to generate future product revenue from AKR-001 or any future product candidates also depends on a
number of additional factors, including our, or our current and future collaborators', ability to:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> successfully complete nonclinical studies and clinical trials for AKR-001 and any future product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek and obtain marketing approvals for any product candidates that complete clinical development; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establish and maintain supply and manufacturing relationships with third parties, and ensure adequate and legally compliant manufacturing of
bulk drug substances and drug products to maintain that supply; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> launch and commercialize any product candidates for which we obtain marketing approval, and, if launched independently, successfully establish
a sales, marketing and distribution infrastructure; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> demonstrate the necessary safety data post-approval to ensure continued regulatory approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtain coverage and adequate product reimbursement from third-party payors, including government payors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> achieve market acceptance for any approved products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> address any competing technological and market developments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> maintain our rights under our existing license agreement with Amgen&nbsp;Inc., or Amgen, and any similar agreements we may enter into in the
future; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter in the future and performing our
obligations in such collaborations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establish, maintain, protect and enforce our intellectual property rights; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> attract, hire and retain qualified personnel. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=13,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=453175,FOLIO='10',FILE='DISK114:[18ZFG1.18ZFG45201]CG45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:41' -->
<A NAME="page_cg45201_1_11"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>In
addition, because of the numerous risks and uncertainties associated with biotechnology product development, including that our product candidate may not advance through development or achieve the
endpoints of applicable clinical trials, we are unable to predict the timing or amount of increased expenses,
or if or when we will achieve or maintain profitability. In addition, our expenses could increase beyond expectations if we decide, or are required by the U.S. Food and Drug Administration, or FDA, or
foreign regulatory authorities, to perform nonclinical studies or clinical trials in addition to those that we currently anticipate. Even if we complete the development and regulatory processes
described above, we anticipate incurring significant costs associated with launching and commercializing any approved product. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>If
we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our
company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could
cause you to lose all or part of your investment. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We will require additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and
commercialization of our product candidate or develop any future product candidates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As a research and development company, our operations have consumed substantial amounts of cash since inception. We expect our research and development
expenses to increase substantially in connection with our ongoing activities, particularly as we advance AKR-001 into later-stage clinical development. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of September&nbsp;30, 2018, we had $7.8&nbsp;million of cash. We believe that the net proceeds from this offering, together with our existing cash, will fund our projected operating
requirements through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our forecast of the period of time through which our financial resources will adequately support our operations is a forward-looking statement and involves risks
and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this "Risk factors" section. We have based this estimate on
assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future funding requirements, both short and long-term, will depend on
many factors, including, but not limited to:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the initiation, progress, timing, costs and results of nonclinical studies and clinical trials for our product candidate or any future product
candidates we may develop; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to maintain our license to AKR-001 from Amgen; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and comparable foreign regulatory authorities,
including the potential for such authorities to require that we perform more nonclinical studies or clinical trials than those that we currently expect or change their requirements on studies that had
previously been agreed to; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including the amount and timing
of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing any patents or other intellectual property
rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the effect of competing technological and market developments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> market acceptance of any approved product candidates, including product pricing, as well as product coverage and the adequacy of reimbursement
by third-party payors; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=14,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=157322,FOLIO='11',FILE='DISK114:[18ZFG1.18ZFG45201]CG45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:41' -->
<A NAME="page_cg45201_1_12"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of acquiring, licensing or investing in additional businesses, products, product candidates and technologies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost and timing of selecting, auditing and potentially validating a manufacturing site for commercial-scale manufacturing; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval
and that we determine to commercialize; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our need to implement additional internal systems and infrastructure, including financial and reporting systems. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
do not have any committed external source of funds or other support for our development efforts and we cannot be certain that additional funding will be available on acceptable terms, or at all.
Until we can generate sufficient revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity
offerings, debt financings, collaborations, strategic alliances, licensing arrangements, and other marketing or distribution arrangements. If we raise additional funds through public or private equity
offerings, the terms of these securities may include liquidation or other preferences that adversely affect our stockholders' rights. Further, to the extent that we raise additional capital through
the sale of common stock or securities
convertible or exchangeable into common stock, your ownership interest will be diluted. If we raise additional capital through debt financing, we could be subject to fixed payment obligations and may
be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional
capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to
our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also could be required to seek collaborators for one or
more of our current or any future product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek
to develop or commercialize ourselves. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue
the development or commercialization of one or more of our products or product candidates or one or more of our other research and development initiatives. Any of the above events could significantly
harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We are heavily dependent on the success of AKR-001, our only product candidate.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We currently have no products that are approved for commercial sale and may never be able to develop marketable products. We expect that a substantial portion
of our efforts and expenditures over the next several years will be devoted to AKR-001, which is currently our only product candidate. Accordingly, our business currently depends heavily on the
successful development, regulatory approval, and commercialization of AKR-001. We cannot be certain that AKR-001 will receive regulatory approval or be successfully commercialized even if we receive
regulatory approval. If we were required to discontinue development of AKR-001 or if AKR-001 does not receive regulatory approval or fails to achieve significant market acceptance, we would be delayed
by many years in our ability to achieve profitability, if ever. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
research, testing, manufacturing, safety, efficacy, labeling, approval, sale, marketing, and distribution of AKR-001 is, and will remain, subject to comprehensive regulation by the FDA and foreign
regulatory authorities. Failure to obtain regulatory approval for AKR-001 in the United States, Europe, Japan or other jurisdictions will prevent us from commercializing and marketing AKR-001 in such
jurisdictions. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=15,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=297466,FOLIO='12',FILE='DISK114:[18ZFG1.18ZFG45201]CG45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:41' -->
<A NAME="page_cg45201_1_13"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</FONT><P style="font-family:arial;"><FONT SIZE=2>Further,
all clinical development of AKR-001 to date has been conducted in patients with type&nbsp;2 diabetes, or T2D. While we believe that the data from clinical trials of AKR-001 in patients with
T2D supports development of AKR-001 for the treatment of patients with nonalcoholic steatohepatitis, or NASH, there is currently no available clinical data regarding the safety or efficacy of AKR-001
in patients with NASH. In addition, we did not control the majority of the nonclinical development or any of the clinical development thus far of AKR-001, and we have relied on Amgen to have conducted
such research and development in accordance with the applicable protocol, legal, regulatory, and scientific standards, have accurately reported the results of all nonclinical studies and clinical
trials conducted prior to our license of AKR-001, and have correctly collected and interpreted the data from these studies and trials. Our future clinical trials may not be able to replicate the
results from Amgen's clinical trials. To the extent any of foregoing has not occurred, our expected development time and development costs for AKR-001 may be increased. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if we were to successfully obtain approval from the FDA and foreign regulatory authorities for AKR-001, any approval might contain significant limitations related to use, including limitations on
the stage of disease AKR-001 is approved to treat, as well as restrictions for specified age groups, warnings, precautions or contraindications. Furthermore, even if we obtain regulatory approval for
AKR-001, we will still need to develop a commercial infrastructure or develop relationships with collaborators to commercialize, establish a commercially viable pricing structure and obtain coverage
and adequate reimbursement from third-party payors, including government healthcare programs otherwise. If we, or any future collaborators, are unable to successfully commercialize AKR-001, we may not
be able to generate sufficient revenue to continue our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We may be required to make significant payments under our license agreement for AKR-001.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We acquired worldwide, exclusive rights to AKR-001 pursuant to our license agreement with Amgen, which we refer to as the Amgen Agreement. Under the Amgen
Agreement, in consideration for the license, we made an upfront payment of $5.0&nbsp;million to Amgen and also issued 2,653,333 shares of our Series&nbsp;A convertible preferred stock to Amgen at
the time of the initial closing of our Series A Preferred Stock financing in June 2018, with a subsequent 3,205,128 shares of our Series&nbsp;A convertible preferred stock issued at the time of the
second closing of the Series A Preferred Stock financing in November 2018. As additional consideration for the license, we are required to pay Amgen aggregate milestone payments of up to
$40.0&nbsp;million upon the achievement of specified clinical and regulatory milestones and aggregate milestone payments of up to $75.0&nbsp;million upon the achievement of specified commercial
milestones. Commencing on the first commercial sale of licensed products, we are obligated to pay tiered royalties of low to high single-digit percentages on annual net sales of the products covered
by the license. If milestone or other non-royalty obligations become due, we may not have sufficient funds available to meet our obligations, which will materially adversely affect our business
operations and financial condition. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> If we are not successful in discovering, developing, receiving regulatory approval for and commercializing AKR-001 and any future product candidates, our ability to expand our
business and achieve our strategic objectives would be impaired.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Although we plan to devote a majority of our resources to the continued nonclinical and clinical testing and potential approval of AKR-001 for the treatment
of patients with NASH, another key element of our strategy is to discover, develop and commercialize a portfolio of products. We are seeking to do so through our internal discovery programs, but our
resources are limited, and those that we have are geared towards nonclinical and clinical testing and seeking regulatory approval of AKR-001 for the treatment of patients with NASH. We may also
explore strategic collaborations for the development or acquisition of new product candidates, but we may not be successful in entering into such relationships. While we plan to initiate a
Phase&nbsp;2a clinical trial for AKR-001 for the treatment in patients with NASH, AKR-001 is our only product </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>

<!-- ZEQ.=5,SEQ=16,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=533404,FOLIO='13',FILE='DISK114:[18ZFG1.18ZFG45201]CG45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:41' -->
<A NAME="page_cg45201_1_14"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>candidate
in clinical stages of development. Research programs to identify product candidates require substantial technical, financial and human resources, regardless of whether any product candidates
are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons,
including:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the research methodology used may not be successful in identifying potential product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> competitors may develop alternatives that render our product candidates obsolete; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> product candidates we develop may nevertheless be covered by third parties' patents or other exclusive rights; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be
effective or otherwise does not meet applicable regulatory criteria; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an approved product may not be accepted as safe and effective by trial participants, the medical community or third-party payors; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> intellectual property or other proprietary rights of third parties for product candidates we develop may potentially block our entry into
certain markets, or make such entry economically impracticable. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>If
we fail to develop and successfully commercialize other product candidates, our business and future prospects may be harmed and our business will be more vulnerable to any problems that we
encounter in developing and commercializing our product candidate. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Our product candidate and any future product candidates must undergo rigorous clinical trials and regulatory approvals, and success in nonclinical studies or earlier-stage clinical
trials may not be indicative of results in future clinical trials.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>AKR-001 and any future product candidates will be subject to rigorous and extensive clinical trials and extensive regulatory approval processes implemented by
the FDA and similar regulatory bodies in other jurisdictions. The approval process is typically lengthy and expensive, and approval is never certain. We have no experience in conducting the clinical
trials required to obtain regulatory approval. We may not be able to conduct clinical trials at preferred sites, enlist clinical investigators, enroll sufficient numbers of participants or begin or
successfully complete clinical trials in a timely fashion, if at all. Our anticipated clinical trials may be insufficient to demonstrate that our potential products will be active, safe or effective.
Additional clinical trials may be required if clinical trial results are negative or inconclusive, which will require us to incur additional costs and significant delays. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Success
in nonclinical studies and earlier-stage clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the
effectiveness and safety of a product candidate. In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical
trial may not become apparent until the clinical trial is well advanced. Because we have no experience designing clinical trials, we may be unable to design and execute a clinical trial to support
regulatory approval. In addition, there is a high failure rate for drugs and products proceeding through clinical trials. In fact, many companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in late-stage clinical trials even after achieving promising results in nonclinical studies and earlier-stage clinical trials. Similarly, the outcome of nonclinical
studies may not predict the success of clinical trials. Moreover, data obtained from </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=17,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=1016286,FOLIO='14',FILE='DISK114:[18ZFG1.18ZFG45201]CG45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:41' -->
<A NAME="page_cg45201_1_15"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>nonclinical
and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a
result of many factors, including due to changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition,
results of operations and prospects. Further, these risks may be elevated with respect to AKR-001 since all clinical development to date has been conducted in patients with T2D, rather than NASH. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>From
time to time, we may publish interim "top-line" or preliminary data from our clinical trials. Preliminary or interim data from clinical trials that we may complete are subject to the risk that
one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or interim data also remain subject to audit and
verification procedures
that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final
data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business and financial prospects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We are subject to many manufacturing risks, any of which could substantially increase our costs, delay clinical programs and limit supply of our products.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To date, we have not manufactured a product candidate as a company. While we received a supply of AKR-001 drug substance from Amgen that we believe will be
sufficient for use in our Phase&nbsp;2a clinical trial, we have contracted with a third party manufacturer to make new drug substance to support future clinical trials and for commercial sale, if
approved. Our contract manufacturer may not be able to adopt, adapt or scale up the manufacturing process as practiced by Amgen in a timely manner to support our future clinical trials. The process of
manufacturing our product is complex, highly regulated and subject to several risks, including:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the manufacturing process is susceptible to product loss due to contamination by adventitious microorganisms, equipment failure, improper
installation or operation of equipment, vendor or operator error and improper storage conditions. Even minor deviations from normal manufacturing processes could result in reduced production yields
and quality as well as other supply disruptions. If microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, the
manufacturing facilities may need to be closed for an extended period of time to investigate and eliminate the contamination; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the manufacturing facilities in which our products are made could be adversely affected by equipment failures, labor and raw material
shortages, financial difficulties of our contract manufacturers, natural disasters, power failures, local political unrest and numerous other factors; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any adverse developments affecting manufacturing operations for our products may result in shipment delays, inventory shortages, lot failures,
product withdrawals or recalls or other interruptions in the supply of our products. We may also have to record inventory write-offs and incur other charges and expenses for products that fail to meet
specifications, undertake costly remediation efforts or seek more expensive manufacturing alternatives. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>The
manufacture of our product candidate requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of
these products sometimes encounter difficulties in production, especially during scale-up from the manufacturing process used for early clinical trials to a validated process needed for pivotal
clinical studies and commercial launch. These problems include failure to meet target production costs and yields, sub-par quality control testing, including stability of the product, quality
assurance system failures, operator error </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=18,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=21553,FOLIO='15',FILE='DISK114:[18ZFG1.18ZFG45201]CG45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:41' -->
<A NAME="page_cg45201_1_16"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>and
shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. We cannot assure you that any product quality issues relating to the
manufacture of our product candidate or any future product candidates will not occur in the future. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
do not have and we do not currently plan to acquire or build the facilities or internal capabilities to manufacture bulk drug substance or filled drug product for use in clinical trials or
commercialization. To a
large extent, that makes us dependent on the goodwill of our contract manufacturing partners to quickly fix deviations that will inevitably occur during the manufacturing of our product. Any delay or
interruption in the supply of clinical trial materials could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the
period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials altogether. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, we plan to develop a new drug product formulation for late stage clinical trials and commercialization. Our current drug product is an Amgen early-stage platform formulation, which is
stored as a frozen liquid and is therefore not well-suited to larger clinical trials or commercialization. We plan to enter into a contract with a formulation development company to explore both a new
refrigerated liquid formulation and a freeze-dried, or lyophilized, formulation. Based on the results of these parallel efforts, we plan to select one approach to progress for use in subsequent
Phase&nbsp;2b clinical development. We also plan to begin development of a pen-type autoinjector for the new drug product formulation. There is no assurance that we will be successful in developing
a new drug product formulation or an autoinjector on a timely basis or at all, which could impede our development and commercialization strategy for AKR-001. Further, the FDA or other similar foreign
regulatory bodies could require nonclinical studies or clinical trials to support introduction of any new formulation and autoinjector, which could increase our development costs and delay or prevent
us from proceeding with future clinical trials or commercialization of AKR-001, if approved. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We may encounter difficulties in managing our growth, which could adversely affect our operations.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of September 30, 2018, we had four full-time employees. As we continue development and pursue the potential commercialization of our product candidate, as
well as function as a public company, we will need to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these
capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic collaborators, suppliers and other third parties. Our future
financial performance and our ability to develop and commercialize our product candidate and to compete effectively will depend, in part, on our ability to manage any future growth effectively. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
may acquire additional technology and complementary businesses in the future. Acquisitions involve many risks, any of which could materially harm our business, including the diversion of
management's attention from core business concerns, failure to effectively exploit acquired technologies, failure to successfully integrate the acquired business or realize expected synergies or the
loss of key employees from either our business or the acquired businesses. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We expect to incur significant additional costs as a result of being a public company, which may adversely affect our operating results and financial condition.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We expect to incur costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley
Act, as well as rules implemented by the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, or the Dodd-Frank Act, the SEC and The Nasdaq Global Market. Our management and other
personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations are expected to </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=19,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=49305,FOLIO='16',FILE='DISK114:[18ZFG1.18ZFG45201]CG45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:41' -->
<A NAME="page_cg45201_1_17"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>increase
our accounting, legal and financial compliance costs and make some activities more time-consuming and costly. In addition, we will incur additional costs associated with our public company
reporting requirements and we expect those costs to increase in the future. For example, we will be required to devote significant resources to complete the assessment and documentation of our
internal control system and financial process under Section&nbsp;404 of the Sarbanes-Oxley Act, or Section 404, including an assessment of the design of our information systems associated with our
internal controls. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
date, we have never conducted a review of our internal control for the purpose of providing the reports required by these rules. During the course of our review and testing, we may identify
deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we fail to remediate our existing material weakness in our internal control over financial
reporting or if new material weaknesses are identified or arise in the future, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our
independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results,
cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we will be required to timely file accurate
quarterly and annual reports with the SEC under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any failure to report our financial results on an accurate and timely basis could
result in sanctions, lawsuits, delisting of our shares from The Nasdaq Global Market or other adverse consequences. We will incur significant costs to remediate any material weaknesses we identify
through these efforts. The increased costs will increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. We also
expect these rules and regulations to make it more expensive for us to maintain directors' and officers' liability insurance and we may be required to accept reduced policy limits and coverage or
incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified persons to serve on our board of directors, our
board committees, or as executive officers. We cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>New
laws and regulations, as well as changes to existing laws and regulations affecting public companies, including the provisions of the Sarbanes-Oxley Act, the Dodd-Frank Act and rules adopted by
the SEC and The Nasdaq Global Market, would likely result in increased costs to us as we respond to their requirements, which may adversely affect our operating results and financial condition. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We have identified a material weakness in our internal control over financial reporting. If we do not remediate the material weakness in our internal control over financial
reporting, or if we fail to establish and maintain effective internal control, we may not be able to accurately report our financial results or file our periodic reports in a timely manner, which may
cause investors to lose confidence in our reported financial information and may lead to a decline in the market price of our stock.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Effective internal control over financial reporting is necessary for us to provide reliable financial reports in a timely manner. In connection with the
preparation of our financial statements for the period January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017, we concluded that there was a material weakness in our internal control
over financial reporting. A material weakness is a significant deficiency, or a combination of significant deficiencies, in internal control over financial reporting such that it is reasonably
possible that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses that we identified related to the lack
of segregation of duties. As of September&nbsp;30, 2018, this material weaknesses remains unremediated. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=20,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=750118,FOLIO='17',FILE='DISK114:[18ZFG1.18ZFG45201]CG45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:41' -->
<A NAME="page_cg45201_1_18"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>While
we have established certain procedures and control over our financial reporting processes, we cannot assure you that these efforts will remediate our material weaknesses and significant
deficiencies in a timely manner, or at all, or prevent restatements of our financial statements in the future. If we are unable to successfully remediate our material weaknesses, or identify any
future significant deficiencies or material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law
requirements regarding timely filing of periodic reports, and the market price of our stock may decline as a result. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
are not currently required to comply with the SEC's rules that implement Section&nbsp;404 of the Sarbanes-Oxley Act, and are therefore not yet required to make a formal assessment of the
effectiveness of our internal control over financial reporting for that purpose. However, upon becoming a public company, we will be required to comply with certain of these rules, which will require
management to certify financial and other information in our quarterly and annual reports and provide an annual management report on the effectiveness of our internal control over financial reporting
commencing with our second annual report. This assessment will need to include the disclosure of any material weaknesses or significant deficiencies in our internal control over financial reporting
identified by our management or our independent registered public accounting firm. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are implementing measures designed to improve our internal control over financial reporting to remediate this material weakness, including formalizing our processes and internal control
documentation and strengthening supervisory reviews by our financial management; hiring additional qualified accounting and finance personnel and engaging financial consultants to enable the
implementation of internal control over financial reporting and segregating duties amongst accounting and finance personnel; and planning to implement certain accounting systems to automate manual
processes, such as tracking and accounting for stock-based awards. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Ensuring
that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming
effort that needs to be re-evaluated frequently. We expect to incur additional costs to remediate these control deficiencies, though there can be no assurance that our efforts will be successful or
avoid potential future material weaknesses. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements in accordance with generally accepted accounting principles. If we are unable to successfully remediate our existing or any future material weaknesses in our
internal control over financial reporting, or if we identify any additional material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to
maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our
financial reporting, and our stock price may decline as a result. We also could become subject to investigations by Nasdaq, the Securities and Exchange Commission, or SEC, or other regulatory
authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could
also restrict our future access to the capital markets. In addition, investors' perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on
a timely basis may harm our stock price and make it more difficult for us to effectively market and sell our products to new and existing customers. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>When
we lose our status as an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act, our independent registered public accounting firm
will be required to attest to the effectiveness of our internal controls over financial reporting pursuant to </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=21,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=442601,FOLIO='18',FILE='DISK114:[18ZFG1.18ZFG45201]CG45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:41' -->
<A NAME="page_cg45201_1_19"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>Section&nbsp;404.
We could be an "emerging growth company" for up to five years from the closing of our initial public offering. An independent assessment of the effectiveness of our internal
controls could detect problems that our management's assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to
incur the expense of remediation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We must attract and retain highly skilled employees in order to succeed. If we are not able to retain our current senior management team and our scientific advisors or continue to
attract and retain qualified scientific, technical and business personnel, our business will suffer.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel and we face significant
competition for experienced personnel. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our
business plan and harm our operating results. We are dependent on the members of our management team and our scientific advisors for our business success, including our President and Chief Executive
Officer, Andrew Cheng, our Executive Vice President and Chief Operating Officer, Jonathan Young, our Chief Scientific Officer, Tim Rolph, and our Chief Development Officer, Kitty Yale. We do not
maintain "key person" insurance for any of our key personnel. An important element of our strategy is to take advantage of the research and development expertise of our current management and to
utilize the expertise of our scientific advisors in the NASH field. We currently have employment agreements with all of our executive officers. Our employment agreements with our executive officers
are terminable by them without notice and some provide for severance and change in control benefits. The loss of any one of our executive officers or key scientific consultants could result in a
significant loss in the knowledge and experience that we, as an organization, possess and could cause significant delays, or outright failure, in the development and further commercialization of our
product candidate or any future product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There
is intense competition for qualified personnel, including management in the technical fields in which we operate, and we may not be able to attract and retain qualified personnel necessary for
the successful research, development and commercialization of our product candidate or any future product candidates. In particular, we have experienced a very competitive hiring environment in the
San Francisco Bay Area, where we are headquartered, and in Cambridge, Massachusetts, where we have a second office. Many of
the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do.
They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer.
If we are unable to continue to attract and retain high-quality personnel, the rate and success with which we can discover and develop product candidates and our business will be limited. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory
standards and requirements.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, agents,
contractors, or collaborators that would violate the law or regulation, including, without limitation, healthcare, employment, foreign corrupt practices, environmental, competition, and patient
privacy and other privacy laws and regulations. Such improper actions could subject us to civil or criminal investigations, and monetary and injunctive penalties, and could adversely impact our
ability to conduct business, operating results, and reputation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could
include </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=22,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=439881,FOLIO='19',FILE='DISK114:[18ZFG1.18ZFG45201]CG45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:41' -->
<A NAME="page_cg45201_1_20"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>intentional,
reckless and/or negligent conduct that fails to comply with the laws enforced by the FDA and other similar foreign regulatory bodies, fails to provide true, complete and accurate
information to the FDA and other similar foreign regulatory bodies, fails to comply with manufacturing standards we have established, fails to comply with healthcare fraud and abuse laws in the United
States and similar foreign laws, or fails to report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates
and begin commercializing those products in the United States, our potential exposure under these laws will increase significantly, and our costs associated with compliance with these laws are also
likely to increase. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. These laws may impact, among other things, our current
activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. If any such actions are instituted against us, and we are not
successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties,
damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future
earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. It is not always possible to identify and deter
employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government
investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending
ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from
government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, and the curtailment or restructuring of our operations. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I> We may develop AKR-001, and potentially future product candidates, in combination with other therapies, which exposes us to additional risks.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may develop AKR-001 and future product candidates in combination with one or more currently approved therapies. Even if any product candidate we develop
were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory
authorities outside of the United States could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with
these existing therapies. This could result in our own products being removed from the market or being less successful commercially. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
may also evaluate AKR-001 or any other future product candidates in combination with one or more other therapies that have not yet been approved for marketing by the FDA or similar regulatory
authorities outside of the United States. We will not be able to market and sell AKR-001 or any product candidate we develop in combination with any such unapproved therapies that do not ultimately
obtain marketing approval. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval of, or if safety, efficacy,
manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with AKR-001 or any other product candidate we develop, we may be unable to obtain approval of or market
AKR-001 or any other product candidate we develop. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=23,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=341715,FOLIO='20',FILE='DISK114:[18ZFG1.18ZFG45201]CG45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ci45201_1_21"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside
our control, including difficulties in identifying patients with NASH and significant competition for recruiting such patients in clinical trials.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Identifying and qualifying patients to participate in our clinical trials is critical to our success. We may encounter delays in enrolling, or be unable to
enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. In
particular, as a result of the inherent difficulties in diagnosing NASH and the significant competition for recruiting patients with NASH in clinical trials, there may be delays in enrolling the
patients we need to complete clinical trials on a timely basis, or at all. This risk may be more significant for us than other companies conducting clinical trials for the treatment of patients with
NASH because we plan to enroll only patients with a biopsy-confirmed diagnosis of NASH in our planned Phase&nbsp;2a clinical trial and subsequent clinical trials. We have engaged Summit Research
Network, a third party investigator, to assist with patient enrollment for our Phase&nbsp;2a clinical trial; however, there can be no assurance that we will be able to maintain our relationships
with this third party or that this third party will be successful in helping us identify patients. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Factors
that may generally affect patient enrollment include:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the size and nature of the patient population; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number and location of clinical sites we enroll; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> competition with other companies for clinical sites or patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the eligibility and exclusion criteria for the trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the design of the clinical trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> inability to obtain and maintain patient consents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> risk that enrolled participants will drop out before completion; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> competing clinical trials and clinicians' and patients' perceptions as to the potential advantages of the drug being studied in relation to
other available therapies, including any new drugs that may be approved for the indications we are investigating. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, if any significant adverse events or other side effects are observed in any of our future clinical trials, it may make it more difficult for us to recruit patients to our clinical trials
and patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. Our inability to enroll a sufficient
number of patients for our clinical trials would result in significant delays, which would increase our costs and have an adverse effect on our company. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I> We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than us.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The biotechnology industry is intensely competitive and subject to rapid and significant technological change. Our competitors include multinational
pharmaceutical companies, specialized biotechnology companies and universities and other research institutions. A number of pharmaceutical companies, including AbbVie,&nbsp;Inc.,
Allergan&nbsp;plc, AstraZeneca&nbsp;PLC/MedImmune&nbsp;LLC, Bayer AG, Bristol-Myers Squibb </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=24,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=695428,FOLIO='21',FILE='DISK114:[18ZFG1.18ZFG45201]CI45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:47' -->
<A NAME="page_ci45201_1_22"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>Company,
Eisai,&nbsp;Inc., Eli Lilly and Company, GlaxoSmithKline&nbsp;plc, Johnson&nbsp;&amp; Johnson, Merck&nbsp;&amp;&nbsp;Co.,&nbsp;Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk
A/S, Pfizer&nbsp;Inc., Roche Holding AG, Sanofi and Takeda Pharmaceutical Company Limited, as well as large and small biotechnology companies such as Albireo Pharma,&nbsp;Inc., Amgen, Cirius
Therapeutics,&nbsp;Inc., Conatus Pharmaceuticals&nbsp;Inc., CymaBay Therapeutics,&nbsp;Inc., Enanta Pharmaceuticals,&nbsp;Inc., Galectin Therapeutics&nbsp;Inc., Galmed
Pharmaceuticals&nbsp;Ltd., Genfit&nbsp;SA, Gilead Sciences,&nbsp;Inc., Intercept Pharmaceuticals,&nbsp;Inc., Inventiva Pharma&nbsp;SA, Madrigal Pharmaceuticals,&nbsp;Inc., MannKind
Corporation, MediciNova,&nbsp;Inc., Metacrine,&nbsp;Inc., Nalpropion Pharmaceuticals,&nbsp;Inc., NGM Biopharmaceuticals,&nbsp;Inc., Terns Pharmaceuticals,&nbsp;Inc., Viking
Therapeutics,&nbsp;Inc., Vivus,&nbsp;Inc. and Zafgen,&nbsp;Inc., are pursuing the development or marketing of pharmaceuticals that target NASH. It is also probable that the number of companies
seeking to develop products and therapies for the treatment of serious metabolic diseases, such as NASH, will increase. Many of our competitors have substantially greater financial, technical, human
and other resources than we do and may be better equipped to develop, manufacture and market technologically superior products. In addition, many of these competitors have significantly greater
experience than we have in undertaking nonclinical studies and human clinical trials of new pharmaceutical products and in obtaining regulatory approvals of human therapeutic products. Accordingly,
our competitors may succeed in obtaining FDA approval for superior products. In addition, many competitors have greater name recognition and more extensive collaborative relationships. Smaller and
earlier-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
competitors may obtain regulatory approval of their products more rapidly than we do or may obtain patent protection or other intellectual property rights that limit our ability to develop or
commercialize our product candidate or any future product candidates. Our competitors may also develop drugs that are
more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than we are in manufacturing and
marketing their products. If we are unable to compete effectively against these companies, then we may not be able to commercialize our product candidate or any future product candidates or achieve a
competitive position in the market. This would adversely affect our ability to generate revenue. Our competitors also compete with us in recruiting and retaining qualified scientific, management and
commercial personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our business and operations would suffer in the event of computer system failures, cyber-attacks or
deficiencies in our or related parties' cyber security.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Given our limited operating history, we are still in the process of implementing our internal security measures. Our internal computer systems and those of
current and future third parties on which we rely may fail and are vulnerable to damage from computer viruses and unauthorized access. Our information technology and other internal infrastructure
systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. While we have not, to our knowledge,
experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our
development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our product candidate or any future product candidates and to conduct
clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in
a loss of, or damage to, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=25,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=630720,FOLIO='22',FILE='DISK114:[18ZFG1.18ZFG45201]CI45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:47' -->
<A NAME="page_ci45201_1_23"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>our
data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and
commercialization of our product candidate or any future product candidates could be hindered or delayed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Comprehensive tax reform legislation could adversely affect our business and financial condition.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On December&nbsp;22, 2017, President Trump signed into law the "Tax Cuts and Jobs Act," or the Tax Act, which significantly revised the Internal Revenue
Code of 1986, as amended, or the Code. The Tax Act, among other things, includes a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, a limitation of the tax
deduction for net interest expense to 30% of adjusted earnings (except for certain small businesses), a limitation of the deduction for net operating losses to 80% of current year taxable income and
an elimination of net operating loss carrybacks, in each case, for losses arising in taxable years beginning after December&nbsp;31, 2017 (though any such net operating losses may be carried forward
indefinitely), and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain
drugs for rare diseases or conditions generally referred to as "orphan drugs"). We continue to examine the impact this tax reform legislation may have on our business. However, the effect of the Tax
Act on our business, whether adverse or favorable, is uncertain, and may not become evident for some period of time. We urge investors to consult with their legal and tax advisers regarding the
implications of the Tax Act on an investment in our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We might not be able to utilize a significant portion of our net operating loss carryforwards and research
and development tax credit carryforwards.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of December&nbsp;31, 2017, we had federal and state net operating loss, or NOL, carryforwards of $4.6&nbsp;million and $4.5&nbsp;million,
respectively, and federal and state research and development tax credit carryforwards of $87,000 and $40,000, respectively. If not utilized, such NOL carryforwards and research and development credits
will expire at various dates beginning in 2027. We do not anticipate
generating revenue from sales of products for the foreseeable future, if ever, and we may never achieve profitability. These NOL and tax credit carryforwards could expire unused and be unavailable to
offset future income tax liabilities. Under the Tax Act, NOL carryforwards generated in tax years beginning after December&nbsp;31, 2017 are not subject to expiration. However, utilization of NOL
carryforwards generated in tax years beginning after December&nbsp;31, 2017 are limited to a maximum of 80% of the taxable income for such year determined without regard to such NOL carryforwards.
In addition, under Section&nbsp;382 of the Code, the amount of benefits from our NOL carryforwards may be impaired or limited if we incur a cumulative ownership change of more than 50%, as
interpreted by the U.S. Internal Revenue Service, over a three-year period. We may have experienced ownership changes in the past and may experience ownership changes in the future as a result of this
offering and subsequent shifts in our stock ownership, some of which are outside our control. As a result, our use of federal NOL carryforwards could be limited. State NOL carryforwards may be
similarly limited. Any such disallowances may result in greater tax liabilities than we would incur in the absence of such a limitation and any increased liabilities could adversely affect our
business, results of operations, financial position and cash flows. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We use and generate materials that may expose us to material liability.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our research programs involve the use of hazardous materials and chemicals, which are currently only handled by third parties. We are subject to foreign,
federal, state and local environmental and health and safety laws and regulations governing, among other matters, the use, manufacture, handling, storage and disposal of hazardous materials and waste
products. We may incur significant costs to comply with these current or future environmental and health and safety laws and regulations. In addition, we cannot </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=26,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=950905,FOLIO='23',FILE='DISK114:[18ZFG1.18ZFG45201]CI45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:47' -->
<A NAME="page_ci45201_1_24"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>completely
eliminate the risk of contamination or injury from hazardous materials and may incur material liability as a result of such contamination or injury. In the event of an accident, an injured
party may seek to hold us liable for any damages that result. Any liability could exceed the limits or fall outside the coverage of our workers' compensation, property and business interruption
insurance and we may not be able to maintain insurance on acceptable terms, if at all. We currently carry no insurance specifically covering environmental claims. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Risks related to government regulation  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy,
time-consuming and inherently unpredictable. Our inability to obtain regulatory approval for AKR-001 or any future product candidate would substantially harm our business.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The time required to obtain approval from the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the
commencement of nonclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of regulatory authorities. In addition, approval policies, regulations
or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate's development and may vary among jurisdictions. For example, the FDA recently
published draft guidance regarding NASH clinical development on which we are relying, in part, in designing our Phase&nbsp;2a clinical trial of AKR-001 in that indication. However, this guidance is
not yet final and is subject to change, and the FDA or comparable foreign regulatory authorities may adopt new or contradictory guidance in the future. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>AKR-001
or our future product candidates could fail to receive regulatory approval from the FDA or a comparable foreign regulatory authority for many reasons,
including:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> disagreement with the design or implementation of our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to demonstrate that a product candidate is safe and effective for its proposed indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure of clinical trials to meet the level of statistical significance required for approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to demonstrate that a product candidate's clinical and other benefits outweigh its safety risks; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> disagreement with our interpretation of data from nonclinical studies or clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the insufficiency of data collected from clinical trials of our product candidate or any future product candidates to obtain regulatory
approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to obtain approval of the manufacturing processes or facilities of third-party manufacturers with whom we contract for clinical and
commercial supplies; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in the approval policies or regulations that render our nonclinical and clinical data insufficient for approval. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA or a comparable foreign regulatory authority may require more information, including additional nonclinical or clinical data to support approval, which may delay or prevent approval and our
commercialization plans, or we may decide to abandon the development program for other reasons. If we were to obtain approval, regulatory authorities may approve any of our product candidate or any
future product candidates for fewer or more limited indications than we request, may require labeling or a Risk Evaluation Mitigation Strategy, or REMS, that includes significant use or distribution
restrictions or safety warnings, precautions, or contraindications, may grant approval contingent on the performance of costly </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=27,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=581290,FOLIO='24',FILE='DISK114:[18ZFG1.18ZFG45201]CI45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:47' -->
<A NAME="page_ci45201_1_25"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>post-marketing
clinical trials or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product
candidate. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Failures or delays in the commencement or completion of, or ambiguous or negative results from, our planned
clinical trials of our product candidates could result in increased costs to us and could delay, prevent, or limit our ability to generate revenue and continue our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We do not know whether any of our planned clinical trials will begin or be completed on schedule, if at all, as the commencement and completion of clinical
trials can be delayed or prevented for a number of reasons, including, among others:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA or comparable foreign regulatory authorities may not authorize us or our investigators to commence our planned clinical trials or any
other clinical trials we may initiate, or may suspend our clinical trials, for example, through imposition of a clinical hold, and may request additional data to permit allowance of our
investigational new drug, or IND; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> delays in filing or receiving allowance of additional IND applications that may be required; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> lack of adequate funding to continue our clinical trials and nonclinical studies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> negative results from our ongoing nonclinical studies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> delays in reaching or failing to reach agreement on acceptable terms with prospective CROs and clinical study sites, the terms of which can be
subject to extensive negotiation and may vary significantly among different CROs and study sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> inadequate quantity or quality of a product candidate or other materials necessary to conduct clinical trials, for example delays in the
manufacturing of sufficient supply of finished drug product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> difficulties obtaining ethics committee or Institutional Review Board, or IRB, approval to conduct a clinical study at a prospective site or
sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> challenges in recruiting and enrolling subjects to participate in clinical trials, the proximity of subjects to study sites, eligibility
criteria for the clinical study, the nature of the clinical study protocol, the availability of approved effective treatments for the relevant disease, and competition from other clinical study
programs for similar indications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> severe or unexpected drug-related side effects experienced by subjects in a clinical trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may decide, or regulatory authorities may require us, to conduct additional nonclinical or clinical trials or abandon product development
programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> delays in validating, or inability to validate, any endpoints utilized in a clinical trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA or comparable foreign regulatory authorities may disagree with our clinical study design and our interpretation of data from clinical
trials, or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> difficulties retaining subjects who have enrolled in a clinical trial but may be prone to withdraw due to rigors of the clinical trials, lack
of efficacy, side effects, personal issues, or loss of interest. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Clinical
trials may also be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical study may be suspended or terminated by us, the FDA or comparable
foreign regulatory </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=28,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=281810,FOLIO='25',FILE='DISK114:[18ZFG1.18ZFG45201]CI45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:47' -->
<A NAME="page_ci45201_1_26"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</FONT><P style="font-family:arial;"><FONT SIZE=2>authorities,
the IRBs at the sites where the IRBs are overseeing a clinical study, a data and safety monitoring board, or DSMB, overseeing the clinical study at issue or other regulatory authorities
due to a number of factors, including, among others:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to conduct the clinical study in accordance with regulatory requirements or our clinical protocols; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> inspection of the clinical study operations or study sites by the FDA or other regulatory authorities that reveals deficiencies or violations
that require us to undertake corrective action, including in response to the imposition of a clinical hold; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> unforeseen safety issues or safety signals, including any that could be identified in our ongoing nonclinical studies or clinical trials,
adverse side effects or lack of effectiveness; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in government regulations or administrative actions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> problems with clinical supply materials; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> lack of adequate funding to continue clinical trials. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Any
inability to successfully complete nonclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, if we make changes to a
product candidate, such as changes to the formulation, we may need to conduct additional nonclinical studies or clinical trials to bridge or demonstrate the comparability of our modified product
candidate to earlier versions, which could delay our clinical development plan or marketing approval for our current product candidate and any future product candidates. Clinical trial delays could
also shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to
market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have no experience in conducting clinical trials and have never obtained approval for any product
candidates, and may be unable to do so successfully.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As a company, we have no experience in designing, conducting or completing clinical trials and have never progressed a product candidate through to regulatory
approval. In part because of this lack of experience, our clinical trials may require more time and incur greater costs than we anticipate. We cannot be certain that the planned clinical trials will
begin or conclude on time, if at all. Large-scale trials will require significant additional financial and management resources. Any performance failure on the part of such third parties could delay
the clinical development of our product candidate or any future product candidates or delay or prevent us from obtaining regulatory approval or commercializing our current or any future product
candidates, depriving us of potential product revenue and resulting in additional losses. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The advancement of healthcare reform may negatively impact our ability to profitably sell our product
candidate or any future product candidates, if approved.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could
prevent or delay marketing approval of our product candidate or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product for
which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&nbsp;changes
to our manufacturing arrangements; (ii)&nbsp;additions or modifications to product labeling; (iii)&nbsp;the recall or discontinuation of our products; or (iv)&nbsp;additional record-keeping
requirements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=29,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=773755,FOLIO='26',FILE='DISK114:[18ZFG1.18ZFG45201]CI45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:47' -->
<A NAME="page_ci45201_1_27"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>In
March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the Affordable Care Act, was enacted, which
includes measures that have significantly changed the way health care is financed by both governmental and private insurers. Some of the provisions of the Affordable Care Act have yet to be
implemented, and there have been judicial, congressional, and executive branch challenges to certain aspects of the Affordable Care Act. Since January 2017, President Trump has signed two Executive
Orders and other directives designed to delay the implementation of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health insurance mandated by the
Affordable Care Act. One Executive Order directs federal agencies with authorities and responsibilities under the Affordable Care Act to waive, defer, grant exemptions from, or delay the
implementation of any provision of the Affordable Care Act that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of
pharmaceuticals or medical devices. The second Executive Order terminates the cost-sharing subsidies that reimburse insurers under the Affordable Care Act. Several state Attorneys General filed suit
to stop the Trump administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October&nbsp;25, 2017. Further, on
June&nbsp;14, 2018, U.S. Court of Appeals for the Federal Circuit ruled that the federal government was not required to pay more than $12&nbsp;billion in Affordable Care Act risk corridor payments
to third-party payors who argued were owed to them. The effects of this gap in reimbursement on third-party payors, the viability of the Affordable Care Act marketplace, providers, and potentially our
business, are not yet known. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Congress
has also considered legislation that would repeal or repeal and replace all or part of the Affordable Care Act. While Congress has not passed comprehensive repeal legislation, two bills
affecting the implementation of certain taxes under the Affordable Care Act have been signed into law. The Tax Act includes a provision repealing, effective January&nbsp;1, 2019, the tax-based
shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the
"individual mandate." On January&nbsp;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain Affordable Care
Act-mandated fees, including the so-called "Cadillac" tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share,
and the medical device excise tax on non-exempt medical devices. The
Bipartisan Budget Act of 2018, or the BBA, among other things, amends the Affordable Care Act, effective January&nbsp;1, 2019, to close the coverage gap in most Medicare drug plans, commonly
referred to as the "donut hole." In July 2018, the Centers for Medicare and Medicaid Services, or CMS, published a final rule permitting further collections and payments to and from certain Affordable
Care Act qualified health plans and health insurance issuers under the Affordable Care Act risk adjustment program in response to the outcome of federal district court litigation regarding the method
CMS uses to determine this risk adjustment. Moreover, CMS issued a final rule in 2018 that will give states greater flexibility, starting in 2020, in setting benchmarks for insurers in the individual
and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the Affordable Care Act for plans sold through such marketplaces. On
December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of
the Affordable Care Act, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the Affordable Care Act are invalid as well. While the Trump Administration and CMS
have both stated that the ruling will have no immediate effect, and on December&nbsp;30, 2018 the Texas District Court Judge issued an order staying the judgment pending appeal, it is unclear how
this decision, subsequent appeals and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act and our business. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=30,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=597926,FOLIO='27',FILE='DISK114:[18ZFG1.18ZFG45201]CI45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:47' -->
<A NAME="page_ci45201_1_28"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>In
addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. In August 2011, President Obama signed into law the Budget Control Act of 2011, which,
among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a
targeted deficit reduction, which triggered the legislation's automatic reduction to several government programs. This
includes aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year through 2025 unless Congress takes additional action. These reductions were extended through 2027
under the BBA. In January 2013, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers,
and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Recently,
there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S.
congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under
Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. At the federal level, the Trump
administration's budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for
example, measures to permit Medicare Part&nbsp;D plans to negotiate the price of certain drugs under Medicare Part&nbsp;B, to allow some states to negotiate drug prices under Medicaid, and to
eliminate cost sharing for generic drugs for low-income patients. Additionally, the Trump administration released a "Blueprint" to lower drug prices and reduce out of pocket costs of drugs that
contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their
products and reduce the out of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services, or HHS, has already started the process of soliciting feedback on some
of these measures and, at the same time, is immediately implementing others under its existing authority. For example, in September 2018, CMS announced that it will allow Medicare Advantage Plans the
option to use step therapy for Part&nbsp;B drugs beginning January&nbsp;1, 2019, and in October 2018, CMS proposed a new rule that would require direct-to-consumer television advertisements of
prescription drugs and biological products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that
drug or biological product. Although a number of these, and other proposed measures will require authorization through additional legislation to become effective, Congress and the Trump administration
have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and
implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and
marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
expect that the healthcare reform measures that have been adopted and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price
that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in
payments from private third-party payors. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=31,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=929479,FOLIO='28',FILE='DISK114:[18ZFG1.18ZFG45201]CI45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:47' -->
<A NAME="page_ci45201_1_29"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>Further,
on May&nbsp;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or the Right to Try Act, was signed into law. The law, among other
things, provides a federal framework for certain patients to request access certain investigational new drug products that have completed a Phase&nbsp;I clinical trial and that are undergoing
investigation for FDA approval. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There
have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or
lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize
our product. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect
our overall financial condition and ability to develop product candidates. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud
and abuse, transparency and other healthcare laws and regulations, which, if violated, could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative
burdens and diminished profits and future earnings.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we
obtain marketing approval. Our current and future arrangements with healthcare providers, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws
and regulations that may constrain the business or financial arrangements and relationships through which we research, and if approved, market, sell and distribute our products. Restrictions under
applicable federal and state healthcare laws and regulations, include the following:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the federal Anti-Kickback Statute prohibits persons from, among other things, knowingly and willfully soliciting, offering, receiving or
providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, the referral of an individual for the furnishing or arranging for the furnishing, or the
purchase, lease or order, or arranging for or recommending purchase, lease or order, of any good or service for which payment may be made under a federal healthcare program, such as Medicare and
Medicaid; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which can be enforced
through civil whistleblower or </FONT><FONT SIZE=2><I>qui tam</I></FONT><FONT SIZE=2> actions, prohibit individuals or entities from, among other things knowingly presenting, or causing to be
presented, to the federal government or a government contractor, grantee, or other recipient of federal funds, claims for payment that are false or fraudulent or making a false statement to avoid,
decrease or conceal an obligation to pay money to the federal government; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal liability for knowingly and willfully
executing a scheme to defraud any healthcare benefit program, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a
healthcare offense or knowingly and willfully making false statements relating to healthcare matters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their implementing regulations,
imposes obligations on certain healthcare providers, health plans </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=32,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=918880,FOLIO='29',FILE='DISK114:[18ZFG1.18ZFG45201]CI45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:47' -->
<A NAME="page_ci45201_1_30"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <UL>

<P style="font-family:arial;"><FONT SIZE=2>and
healthcare clearinghouses, known as covered entities, as well as their business associates, which are individuals and entities that perform certain services involving the use or disclosure of
individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health
information; </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the federal Open Payments program, created under Section&nbsp;6002 of the Affordable Care Act and its implementing regulations, requires
manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children's Health Insurance Program (with certain exceptions) to report
annually to CMS information related to "payments or other transfers of value" made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching
hospitals, as well as ownership and investment interests held by physicians (as defined above) and their immediate family members; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> analogous state, local, and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or
marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require
pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict
payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other
healthcare providers or marketing expenditures; state and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws that govern the privacy and
security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Efforts
to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities
will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If
our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative
penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations,
and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with
applicable laws, that person or entity may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Failure to comply with health and data protection laws and regulations could lead to government enforcement
actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We and any potential collaborators may be subject to federal, state, and foreign data protection laws and regulations (i.e.,&nbsp;laws and regulations that
address privacy and data security). In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state
health information privacy laws, and federal and state consumer protection laws (e.g.,&nbsp;Section&nbsp;5 of the Federal Trade Commission Act and California Consumer Privacy Act of 2018
("CCPA")), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. The state
of California, for example, recently adopted the California Consumer Privacy Act of 2018 (the "CCPA"), which </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=33,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=392290,FOLIO='30',FILE='DISK114:[18ZFG1.18ZFG45201]CI45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:47' -->
<A NAME="page_ci45201_1_31"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>will
come into effect beginning in January 2020. The CCPA has been characterized as the first "GDPR-like" privacy statute to be enacted in the United States because it mirrors a number of the key
provisions of the European Union General Data Protection Regulation ("GDPR") (discussed below in the European Data Collection subsection). The CCPA establishes a new privacy framework for covered
businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers in the
State of California, imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for
businesses that fail to implement reasonable security procedures and practices to prevent data breaches. In addition, we may obtain health information from third parties (including research
institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA, as amended by HITECH. Depending on the facts and circumstances, we could be
subject to civil, criminal, and administrative penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is
not authorized or permitted by HIPAA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Compliance
with U.S. and international data protection laws and regulations, including the EU GDPR and other EU data protection laws could require us to take on more onerous obligations in our
contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could
result in government enforcement actions (which could include civil, criminal and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating
results and business. Moreover, clinical trial subjects, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share
this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals' privacy rights, failed to comply with data protection laws, or
breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Governments outside the United States tend to impose strict price controls, which may adversely affect our
revenue, if any.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these
countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. In addition, there can be considerable pressure by
governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing
negotiations. To obtain coverage and reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our drug candidate to
other available procedures. If reimbursement of our drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly
materially. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we are able to obtain regulatory approvals for our product candidate or any future product
candidates, if they exhibit harmful side effects after approval, our regulatory approvals could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product
liability claims.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Clinical trials are conducted in representative samples of the potential patient population which may have significant variability. Even if we receive
regulatory approval for AKR-001 or any of our future product candidates, we will have tested them in only a small number of patients during our clinical trials. Clinical </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=34,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=615464,FOLIO='31',FILE='DISK114:[18ZFG1.18ZFG45201]CI45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:47' -->
<A NAME="page_ci45201_1_32"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</FONT><P style="font-family:arial;"><FONT SIZE=2>trials
are by design based on a limited number of subjects and of limited duration for exposure to the product used to determine whether, on a potentially statistically significant basis, the planned
safety and efficacy of any product candidate can be achieved. As with the results of any statistical sampling, we cannot be sure that all side effects of our product candidates may be uncovered, and
it may be the case that only with a significantly larger number of patients exposed to the product candidate for a longer duration, may a more complete safety profile be identified. Further, even
larger clinical trials may not identify rare serious adverse effects or the duration of such studies may not be sufficient to identify when those events may occur. If our applications for marketing
are approved and more patients begin to use our product, new risks and side effects associated with our products may be discovered. There have been other
products that have been approved by the regulatory authorities but for which safety concerns have been uncovered following approval. Such safety concerns have led to labelling changes or withdrawal of
products from the market, and any of our product candidates may be subject to similar risks. Additionally, we may be required to conduct additional nonclinical and clinical trials, require additional
warnings on the label of our product, reformulate our product or make changes, create a medication guide outlining the risks of such side effects for distribution to patients and obtain new approvals
for our and our suppliers' manufacturing facilities for AKR-001 and any future product candidates. We might have to withdraw or recall our products from the marketplace. We may also experience a
significant drop in the potential sales of our product if and when regulatory approvals for such product are obtained, experience harm to our reputation in the marketplace or become subject to
lawsuits, including class actions. Any of these results could decrease or prevent any sales of our approved product or substantially increase the costs and expenses of commercializing and marketing
our product. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if our current product candidate or any future product candidates receive regulatory approval, they will
remain subject to extensive regulatory scrutiny and may still face future development and regulatory difficulties.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even if we obtained regulatory approval for a product candidate, regulatory authorities may still impose significant restrictions on our product candidates,
including their indicated uses or marketing, or impose ongoing requirements for potentially costly post-approval studies. For example, if AKR-001 is approved by the FDA based on a surrogate endpoint
pursuant to accelerated approval regulations (Subpart&nbsp;E regulations), we will be required to conduct additional confirmatory clinical trials demonstrating the clinical benefit on the ultimate
outcome of NASH. Further, even if we obtained regulatory approval for a product candidate, it would be subject to ongoing requirements by the FDA and comparable foreign regulatory authorities
governing the manufacture, quality control, further development, labeling, packaging, storage, distribution, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of
safety and other post-market information. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA and comparable foreign regulatory authorities will continue to closely monitor the safety profile of any product even after approval. If the FDA or comparable foreign regulatory authorities
become aware of new safety information after approval of our product candidate or any future product candidates, they may require labeling changes or establishment of a risk evaluation and mitigation
strategy or similar strategy, impose significant restrictions on a product's indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies or post-market
surveillance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP,
regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the
facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=35,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=1008803,FOLIO='32',FILE='DISK114:[18ZFG1.18ZFG45201]CI45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:47' -->
<A NAME="page_ci45201_1_33"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>us,
including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, our product candidate or any future product candidates or the manufacturing
facilities for our product candidate or any future product candidates fail to comply with applicable regulatory requirements, or undesirable side effects caused by such products are identified, a
regulatory agency may:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings about such product; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> require that we conduct post-marketing studies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due
dates for specific actions and penalties for noncompliance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek an injunction or impose civil or criminal penalties or monetary fines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> suspend marketing of, withdraw regulatory approval of or recall such product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> suspend any ongoing clinical studies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> refuse to approve pending applications or supplements to applications filed by us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> suspend or impose restrictions on operations, including costly new manufacturing requirements; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seize or detain products, refuse to permit the import or export of products or require us to initiate a product recall. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>The
occurrence of any event or penalty described above may inhibit our ability to commercialize our product and generate revenue. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Advertising
and promotion of any product candidate that obtains approval in the United States will be heavily scrutinized by the FDA, the Department of Justice, the Department of Health and Human
Services' Office of Inspector General, state attorneys general, members of Congress and the public. Violations, including promotion of our products for unapproved (or off-label) uses, are subject to
enforcement letters, inquiries and investigations, and civil and criminal sanctions by the government. Additionally, comparable foreign regulatory authorities will heavily scrutinize advertising and
promotion of any product candidate that obtains approval outside of the United States. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the United States, engaging in the impermissible promotion of our products for off-label uses can also subject us to false claims litigation under federal and state statutes, which can lead to
civil and criminal penalties and fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. These false claims statutes include the federal
False Claims Act, which allows any individual to bring a lawsuit against a pharmaceutical company on behalf of the federal government alleging submission of false or fraudulent claims, or causing to
present such false or fraudulent claims, for payment by a federal program such as Medicare or Medicaid. If the government prevails in the lawsuit, the individual will share in any fines or settlement
funds. Since 2004, these federal False Claims Act lawsuits against pharmaceutical companies have increased significantly in volume and breadth, leading to several substantial civil and criminal
settlements regarding certain sales practices promoting off-label drug uses involving fines in excess of $1&nbsp;billion. This growth in litigation has increased the risk that a pharmaceutical </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=36,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=7969,FOLIO='33',FILE='DISK114:[18ZFG1.18ZFG45201]CI45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:47' -->
<A NAME="page_ci45201_1_34"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>company
will have to defend a false claim action, pay settlement fines or restitution, agree to comply with burdensome reporting and compliance obligations and be excluded from Medicare, Medicaid and
other federal and state healthcare programs. If we do not lawfully promote our approved products, we may become subject to such litigation and, if we do not successfully defend against such actions,
those actions may have a material adverse effect on our business, financial condition and results of operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA's policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidate or any future product candidates. If
we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing
approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Healthcare insurance coverage and reimbursement may be limited or unavailable for our product candidate, if
approved, which could make it difficult for us to sell our product candidate or other therapies profitably.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The success of our product candidate, if approved, depends on the availability of coverage and adequate reimbursement from third-party payors including
governmental healthcare programs, such as Medicare and Medicaid, commercial payors, and health maintenance organizations. We cannot be sure that coverage and reimbursement will be available for, or
accurately estimate the potential revenue from, our product candidates or assure that coverage and reimbursement will be available for any product that we may develop. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Patients
who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate
reimbursement from third-party payors is critical to new product acceptance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Third-party
payors decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including
the third-party payor's determination that use of a product is:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a covered benefit under its health plan; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> safe, effective and medically necessary; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT
SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> appropriate for the specific patient; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> cost-effective; and </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> neither
experimental nor investigational. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>In
the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, obtaining coverage and reimbursement approval of a product from a
third-party payor is a time consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost effectiveness data for the use of our products on a
payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. There is significant uncertainty related to the insurance coverage and reimbursement of newly
approved products. In the United States, the principal decisions about reimbursement for new medicines are typically made by CMS, an agency within HHS, as CMS decides whether and to what extent a new
medicine will be covered and reimbursed under Medicare. Private third-party payors tend to follow Medicare coverage and reimbursement limitations to a substantial degree, but also have their own
methods and approval process apart from Medicare determinations. Even if we obtain coverage for a given product, the resulting reimbursement payment </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=37,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=136958,FOLIO='34',FILE='DISK114:[18ZFG1.18ZFG45201]CI45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:47' -->
<A NAME="page_ci45201_1_35"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>rates
might not be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our
product candidate or any future product candidates outside the United States.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We intend to market any approved products in the United States, the European Union, Japan and other foreign jurisdictions. Even if our products are approved
for marketing in the United States, in order to market and sell our products in other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory
requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval.
The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, we must
secure product reimbursement approvals before regulatory authorities will approve the product for sale in that country. Obtaining foreign regulatory approvals and compliance with foreign regulatory
requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. Further, clinical trials conducted in
one country may not be accepted by regulatory authorities in other countries and regulatory approval in one country does not ensure approval in any other country, while a failure or delay in obtaining
regulatory approval in one country may have a negative effect on the regulatory approval process in others. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Also,
regulatory approval for our product candidate or any future product candidates may be withdrawn if we fail to comply with regulatory requirements, if problems occur after the product candidate
reaches the market or for other reasons. If we fail to comply with the regulatory requirements in international markets and fail to receive applicable marketing approvals, our target market will be
reduced and our ability to
realize the full market potential of our product candidate or any future product candidates will be harmed and our business will be adversely affected. We may not obtain foreign regulatory approvals
on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions. Approval by one regulatory authority outside the United States
does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. If we fail to obtain approval of our product candidate or any future product candidates by
regulatory authorities in another country we will be unable to commercialize our product in that country, and the commercial prospects of that product candidate and our business prospects could
decline. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our activities in the United States subject us to various laws relating to foreign investment and the export
of certain technologies, and our failure to comply with these laws or adequately monitor the compliance of our suppliers and others we do business with could subject us to substantial fines, penalties
and even injunctions, the imposition of which on us could have a material adverse effect on the success of our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because we have a U.S. subsidiary and substantial operations in the United States, we are subject to U.S. laws that regulate foreign investments in U.S.
businesses and access by foreign persons to technology developed and produced in the United States. These laws include Section&nbsp;721 of the Defense Production Act of 1950, as amended by the
Foreign Investment Risk Review Modernization Act of 2018, and the regulations at 31 C.F.R. Parts&nbsp;800 and 801, as amended, administered by the Committee on Foreign Investment in the United
States; and the Export Control Reform Act of 2018, which is being implemented in part through Commerce Department rulemakings to impose new export control restrictions on "emerging and foundational
technologies" yet to be fully identified. Application of these laws, including as they are </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=15,SEQ=38,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=981565,FOLIO='35',FILE='DISK114:[18ZFG1.18ZFG45201]CI45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:47' -->
<A NAME="page_ci45201_1_36"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>implemented
through regulations being developed, may negatively impact our business in various ways, including by restricting our access to capital and markets; limiting the collaborations we may
pursue; regulating the export our products, services, and technology from the United States and abroad; increasing our costs and the time necessary to obtain required authorizations and to ensure
compliance; and threatening monetary fines and other penalties if we do not. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption
laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability
and other serious consequences for violations, which can harm our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various
economic and trade sanctions regulations administered by the U.S. Treasury Department's Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S.
domestic bribery statute contained in 18 U.S.C. &sect;&nbsp;201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the
countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing,
promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products
sell our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect
interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal
activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and
regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract
and fraud litigation, reputational harm, and other consequences. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and
retain key leadership and other personnel, prevent new or existing product candidates from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing
normal functions on which the operation of our business may rely, which could negatively impact our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to
hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In
addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political
process, which is inherently fluid and unpredictable. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Disruptions
at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For
example, over the last several years, including beginning on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC,
have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to
timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, upon completion of this offering and in our operations as a public company,
future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=16,SEQ=39,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=7058,FOLIO='36',FILE='DISK114:[18ZFG1.18ZFG45201]CI45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ck45201_1_37"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Risks related to our intellectual property  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our success depends upon our ability to obtain and maintain intellectual property protection for our products
and technologies. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our success will depend in significant part on our and our current or future licensors', licensees' or collaborators' ability to establish and maintain
adequate protection of our intellectual property covering the product candidates we plan to develop, and the ability to develop these product candidates and commercialize the products resulting
therefrom, without infringing the intellectual property rights of others. We strive to protect and enhance the proprietary technologies that we believe are important to our business, including seeking
patents intended to cover our products and compositions, their methods of use, and any other inventions that are important to the development of our business. In addition to taking other steps to
protect our intellectual property, we have applied for, and intend to continue to apply for, patents with claims covering our technologies, processes and product candidates when and where we deem it
appropriate to do so. Our in-licensed patents and patent applications in both United States and certain foreign jurisdictions relate to AKR-001 and related Fc-fusion polypeptides. There can be no
assurance that the claims of our patents or any patent application that issues as a patent, will exclude others from making, using or selling our product candidate or any future product candidates or
products that are substantially similar to our product candidate or any future product candidates. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we
do not consider appropriate for, patent protection. In countries where we have not and do not seek patent protection, third parties may be able to manufacture and sell our product candidate or any
future product candidates without our permission, and we may not be able to stop them from doing so. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>With
respect to patent rights, we do not know whether any of the pending patent applications for our product candidate or any future product candidates will result in the issuance of patents that
effectively protect our technologies, processes and product candidates, or if any of our issued patents or our current or future licensors', licensees' or collaborators' issued patents will
effectively prevent others from commercializing competitive technologies, processes and products. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and
patent applications in the United States and other jurisdictions are typically not published until 18&nbsp;months after filing or in some cases not at all, until they are issued as a patent.
Therefore, we cannot be certain that we or our current or future licensors, licensees or collaborators were the first to make or file on the inventions claimed in our owned or licensed patents or
pending patent applications, or that we or our current or future licensors, licensees or
collaborators were the first to file for patent protection of such inventions. There is also no assurance that all of the potentially relevant prior art relating to our patents and patent applications
has been found, which could be used by a third party to challenge the validity of our patents, should they issue, or prevent a patent from issuing from a pending patent application. Any of the
foregoing could harm our competitive position, business, financial condition, results of operations, and prospects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
changes we make to our product candidate or any future product candidates, including formulations that may be required for commercialization, or that cause them to have what we view as more
advantageous properties may not be covered by our existing patents and patent applications, and we may be required to file new applications and/or seek other forms of protection for any such altered
product candidates. The patent landscape surrounding the technology underlying our product candidate or any future product candidates is crowded, and there can be no assurance that we would be able to
secure </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=40,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=184592,FOLIO='37',FILE='DISK114:[18ZFG1.18ZFG45201]CK45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:50' -->
<A NAME="page_ck45201_1_38"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>patent
protection that would adequately cover an alternative to our product candidate or any future product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
patent prosecution process is expensive and time-consuming, and we and our current or future licensors, licensees or collaborators may not be able to prepare, file and prosecute all necessary or
desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our current or future licensors, licensees or collaborators will fail to identify patentable
aspects of inventions
made in the course of development and commercialization activities before it is too late to obtain patent protection for them. Moreover, in some circumstances, we may not have the right to control the
preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering technology that we license from or license to third parties and may be reliant on our
current or future licensors, licensees or collaborators to perform these activities, which means that these patent applications may not be prosecuted, and these patents enforced, in a manner
consistent with the best interests of our business. If our current or future licensors, licensees or collaborators fail to establish, maintain, protect or enforce such patents and other intellectual
property rights, such rights may be reduced or eliminated. If our current or future licensors, licensees or collaborators are not fully cooperative or disagree with us as to the prosecution,
maintenance or enforcement of any patent rights, such patent rights could be compromised. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
patent positions of biotechnology and pharmaceutical companies, including our patent position, involve complex legal and factual questions, which in recent years have been the subject of much
litigation, and, therefore, the issuance, scope, validity, enforceability, and commercial value of any patent claims that we have rights or may obtain cannot be predicted with certainty. No consistent
policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. Changes in either the patent laws
or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. As a result, the issuance, scope,
validity, enforceability and commercial value of our and our current or future licensors', licensees' or collaborators' patent rights are highly uncertain. Our and our current or future licensors',
licensees' or collaborators' pending and future patent applications may not result in patents being issued that protect our technology or product candidates, or products resulting therefrom, in whole
or in part, or that effectively prevent others from commercializing competitive technologies and products. The patent examination process may require us or our current or future licensors, licensees
or collaborators to narrow the scope of the claims of pending and future patent applications, which would limit the scope of patent protection that is obtained, if any. Our and our current or future
licensors', licensees' or collaborators' patent applications cannot be enforced against third parties practicing the technology that is currently claimed in such applications unless and until a patent
issues from such applications, and then only to the extent the claims that issue are broad enough to cover the technology being practiced by third parties. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Furthermore,
given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after the
resulting products are commercialized. As a result, our owned and in-licensed patents may not provide us with sufficient rights to exclude others from commercializing products similar or identical to
ours. We expect to seek extensions of patent terms for our issued patents, where available. This includes in the United States under the Hatch-Waxman Act, which permits a patent term extension of up
to five years beyond the original expiration date of the patent as compensation for regulatory delays. However, such a patent term extension cannot lengthen the remaining term of a patent beyond a
total of 14&nbsp;years from the product's approval date. Only one patent applicable to an approved drug is eligible for the extension and the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=41,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=88018,FOLIO='38',FILE='DISK114:[18ZFG1.18ZFG45201]CK45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:50' -->
<A NAME="page_ck45201_1_39"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>application
for the extension must be submitted prior to the expiration of the patent and within 60&nbsp;days of product approval. During the period of patent term extension, the claims of a patent
are not enforceable for their full scope, but are instead limited to the scope of the approved product. In addition, the applicable authorities, including the FDA in the United States, and any
equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more
limited extensions than we request. In addition, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to the expiration of
relevant patents or otherwise failing to satisfy applicable requirements. If this occurs, any period during which we have the right to exclusively market our product will be shorter than we would
otherwise expect, and our competitors may obtain approval of and launch products earlier than might otherwise be the case. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we breach our license agreement with Amgen related to AKR-001, we could lose the ability to continue the
development and commercialization of AKR-001.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are dependent on patents, know-how and proprietary technology in-licensed from Amgen. Our commercial success depends upon our ability to develop,
manufacture, market and sell our product candidate or any future product candidates and use our and our licensor's proprietary technologies without infringing the proprietary rights of third parties.
Amgen may have the right to terminate the license agreement in full in the event we materially breach or default in the performance of any of the
obligations under the license agreement. A termination of the license agreement with Amgen could result in the loss of significant rights and could harm our ability to commercialize our product
candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Disputes
may also arise between us and Amgen, as well as any future potential licensors, regarding intellectual property subject to a license agreement,
including:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the scope of rights granted under the license agreement and other interpretation-related issues; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the
licensing agreement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our right to sublicense patent and other rights to third parties under collaborative development relationships; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our
product candidate and what activities satisfy those diligence obligations; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our
partners. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>If
disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop
and commercialize the affected product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, the Amgen Agreement under which we currently license intellectual property is complex, and certain provisions may be susceptible to multiple interpretations. The resolution of any
contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property, or increase what we believe to be our financial or
other obligations under the Amgen Agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over
intellectual property </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=42,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=1016217,FOLIO='39',FILE='DISK114:[18ZFG1.18ZFG45201]CK45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:50' -->
<A NAME="page_ck45201_1_40"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>that
we have licensed prevent or impair our ability to maintain our current licensing arrangement on commercially acceptable terms, we may be unable to successfully develop and commercialize the
affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below.
If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Patent terms may be inadequate to protect our competitive position on our product candidate or any future
product candidates for an adequate amount of time.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20&nbsp;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Currently, our composition
of matter patents expire in 2029 in the United States and in 2034, including potential patent term extensions, in other jurisdictions. Even if patents covering our product candidate or any future
product candidate are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory
review of new product candidates, patents protecting our product candidate or any future product candidate might expire before or shortly after we or our partners commercialize those candidates. As a
result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to protect our intellectual property rights throughout the world.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The legal protection afforded to inventors and owners of intellectual property in countries outside of the United States may not be as protective or effective
as that in the United States and we may, therefore, be unable to acquire and enforce intellectual property rights outside the United States to the same extent as in the United States. Whether filed in
the United States or abroad, our patent applications may be challenged or may fail to result in issued patents. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
addition, our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing or commercializing competing
products. Furthermore, others may independently develop or commercialize similar or alternative technologies or drugs, or design around our patents. Our patents may be challenged, invalidated,
circumvented or narrowed, or fail to provide us with any competitive advantages. In many foreign countries, patent applications and/or issued patents, or parts thereof, must be translated into the
native language. If our patent applications or issued patents are translated incorrectly, they may not adequately cover our technologies; in some countries, it may not be possible to rectify an
incorrect translation, which may result in patent protection that does not adequately cover our technologies in those countries. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Filing,
prosecuting, enforcing and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some
countries outside the
United States are less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and certain
state laws in the United States. Consequently, we and our licensor may not be able to prevent third parties from practicing our and our licensor's inventions in all countries outside the United
States, or from selling or importing products made using our and our licensor's inventions in and into the United States or other </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=43,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=771075,FOLIO='40',FILE='DISK114:[18ZFG1.18ZFG45201]CK45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:50' -->
<A NAME="page_ck45201_1_41"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>jurisdictions.
Competitors may use our and our licensor's technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise
infringing products to territories where we and our licensor have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product
candidate or any future product candidates and our and our licensor's patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain
developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology. This could make it difficult for us and our
licensor to stop the infringement of our and our licensor's patents or the marketing of competing products in violation of our and our licensor's proprietary rights, generally. Proceedings to enforce
our and our licensor's patent rights in foreign jurisdictions could result in substantial costs and divert our and our licensor's efforts and attention from other aspects of our business, could put
our and our licensor's patents at risk of being invalidated or interpreted narrowly, could place our and our licensor's patent applications at risk of not issuing and could
provoke third parties to assert claims against us or our licensor. We or our licensor may not prevail in any lawsuits that we or our licensor initiate and the damages or other remedies awarded, if
any, may not be commercially meaningful. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
requirements for patentability differ in certain countries, particularly developing countries. For example, China has a heightened requirement for patentability and, specifically, requires a
detailed description of medical uses of a claimed drug. In addition, India, certain countries in Europe and certain developing countries, including Thailand, have compulsory licensing laws under which
a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensor may have limited remedies if patents are infringed or if we or our licensor are compelled to
grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. In addition, many countries limit the enforceability
of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. Accordingly,
our and our licensor's efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or
license. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Obtaining and maintaining our patent protection depends on compliance with various procedural, document
submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Periodic maintenance and annuity fees on issued United States patents and most foreign patent applications and patents must be paid to the U.S. Patent and
Trademark Office, or USPTO, and foreign patent agencies, respectively, in order to maintain such patents and patent applications. The USPTO and various foreign governmental patent agencies require
compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application, examination and issuance processes. While an inadvertent lapse can, in some
cases, be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or
patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent
application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensor fail
to maintain the patents and patent applications covering our product candidate or any future product </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=44,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=901381,FOLIO='41',FILE='DISK114:[18ZFG1.18ZFG45201]CK45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:50' -->
<A NAME="page_ck45201_1_42"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</FONT><P style="font-family:arial;"><FONT SIZE=2>candidates,
our competitors might be able to enter the market with similar or identical products or technology, which would have a material adverse effect on our business, financial condition and
results of operations. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be unable to obtain intellectual property rights or technology necessary to develop and commercialize
our product candidate or any future product candidates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Several third parties are actively researching and seeking and obtaining patent protection in the NASH field, and there are issued third-party patents and
published third-party patent applications in these fields. However, we may not be aware of all third-party intellectual property rights potentially relating to our product candidate or any future
product candidates and technologies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Depending
on what patent claims ultimately issue and how courts construe the issued patent claims, as well as depending on the ultimate formulation and method of use of our product candidate or any
future product candidates, we may need to obtain a license under such patents. There can be no assurance that such licenses will be available on commercially reasonable terms, or at all. If a third
party does not offer us a necessary license or offers a license only on terms that are unattractive or unacceptable to us, we might be unable to develop and commercialize one or more of our product
candidate or any future product candidates, which would have a material adverse effect on our business, financial condition and results of operations. Moreover, even if we obtain licenses to such
intellectual property, but subsequently fail to meet our obligations under our license agreements, or such license agreements are terminated for any other reasons, we may lose our rights to
in-licensed technologies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party
intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater
clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license
or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights to required
third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could
have a material adverse effect on our business, financial condition, results of operations and prospects. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may become involved in lawsuits or other proceedings to protect or enforce our intellectual property,
which could be expensive, time-consuming and unsuccessful and have a material adverse effect on the success of our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Third parties may infringe our or our licensor's patents or misappropriate or otherwise violate our or our licensor's intellectual property rights. In the
future, we or our licensor may initiate legal proceedings to enforce or defend our or our licensor's intellectual property rights, to protect our or our licensor's trade secrets or to determine the
validity or scope of intellectual property rights we own or control. Also, third parties may initiate legal proceedings against us or our licensor to challenge the validity or scope of intellectual
property rights we own, control or to which we have rights. For example, generic or biosimilar drug manufacturers or other competitors or third parties may challenge the scope, validity or
enforceability of our or our licensor's patents, requiring us or our licensor to engage in complex, lengthy and costly litigation or other proceedings. These proceedings can be expensive and
time-consuming and many of our or our licensor's adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can.
Moreover, the outcome </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=45,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=881927,FOLIO='42',FILE='DISK114:[18ZFG1.18ZFG45201]CK45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:50' -->
<A NAME="page_ck45201_1_43"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>following
legal assertions of invalidity and unenforceability is unpredictable. Accordingly, despite our or our licensor's efforts, we or our licensor may not be able to prevent third parties from
infringing upon or misappropriating intellectual property rights we own, control or have rights to, particularly in countries where the laws may not protect those rights as fully as in the United
States. Litigation could result in substantial costs and diversion of management resources, which could harm our business and financial results. In addition, if we or our licensor initiated legal
proceedings against a third party to enforce a patent covering a product candidate, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United
States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements,
including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant
information from the USPTO, or made a misleading statement, during prosecution. In an infringement or declaratory judgment proceeding, a court may decide that a patent owned by or licensed to us is
invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our or our licensor's patents do not cover the technology in question. An adverse
result in any litigation proceeding could put one or more of our or our licensor's patents at risk of being invalidated, narrowed, held unenforceable or interpreted in such a manner that would not
preclude third parties from entering the market with competing products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Third-party
pre-issuance submission of prior art to the USPTO, or opposition, derivation, revocation, reexamination, </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2> review or interference
proceedings, or other pre-issuance or post-grant proceedings or other patent office proceedings or litigation in the United States or other jurisdictions provoked by third parties or brought by us or
our licensor, may be necessary to determine the inventorship, priority, patentability or validity of inventions with respect to our or our licensor's patents or patent applications. An unfavorable
outcome could leave our technology or product candidates without patent protection, allow third parties to commercialize our technology or product candidates and compete directly with us, without
payment to us, or could require us or our licensor to obtain license rights from the prevailing party in order to be able to manufacture or commercialize our product candidate or any future product
candidates without infringing third-party patent rights. Our business could be harmed if the prevailing party does not offer us or our licensor a license on commercially reasonable terms, or at all.
Even if we or our licensor obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensor. In addition, if the breadth or
strength of protection provided by our or our licensor's patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize
current or any future product candidates. Even if we successfully defend such litigation or proceeding, we may incur substantial costs and it may distract our management and other employees. In
addition, the uncertainties associated with
litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third
parties, or enter into collaborations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised
by disclosure during this type of litigation. In addition, many foreign jurisdictions have rules of discovery that are different than those in the United States and which may make defending or
enforcing our or our licensor's patents extremely difficult. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities
analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=46,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=664612,FOLIO='43',FILE='DISK114:[18ZFG1.18ZFG45201]CK45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:50' -->
<A NAME="page_ck45201_1_44"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Third parties may initiate legal proceedings against us alleging that we infringe their intellectual property
rights or we may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, the outcome of which would be
uncertain and could have a material adverse effect on the success of our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our commercial success depends upon our ability to develop, manufacture, market and sell any product candidates that we may develop and use our proprietary
technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. The biotechnology and pharmaceutical industries are
characterized by extensive litigation regarding patents and other intellectual property rights. Third parties may initiate legal proceedings against us or our licensor alleging that we or our licensor
infringe their intellectual property rights or we or our licensor may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by
third parties, including in oppositions, interferences, revocations, reexaminations, </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2> review or derivation proceedings before the USPTO or
its counterparts in other jurisdictions. These proceedings can be expensive and time-consuming and many of our or our licensor's adversaries in these proceedings may have the ability to dedicate
substantially greater resources to prosecuting these legal actions than we or our licensor can. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>An
unfavorable outcome in any such proceeding could require us or our licensor to cease using the related technology or developing or commercializing our product candidate or any future product
candidates, or to attempt to license rights to it from the prevailing party, which may not be available on commercially reasonable terms, or at all. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
could be found liable for monetary damages, including treble damages and attorneys' fees, if we are found to have willfully infringed a patent. A finding of infringement could prevent us from
commercializing our product candidate or any future product candidates or force us to cease some of our business operations, which could materially harm our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
perform searches of patent and scientific databases in order to identify documents that may be of potential relevance to the freedom-to-operate and/or patentability of our product candidate or any
future product candidates. In general, such searches are conducted based on keywords, sequences, inventors/authors and assignees/entities to capture U.S. and European patents and patent applications,
PCT publications and scientific journal articles. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
patent landscape around our AKR-001 product candidate is complex, and we may not be aware of all third-party intellectual property rights potentially relating to our product candidate or any
future product candidates and technologies. Moreover, it is possible that we are or may become aware of patents or pending patent applications that we think do not relate to our product candidate or
any future product
candidates or that we believe are invalid or unenforceable, but that may nevertheless be interpreted to encompass our product candidate or any future product candidates and to be valid and
enforceable. As to pending third-party applications, we cannot predict with any certainty which claims will issue, if any, or the scope of such issued claims. If any third party intellectual property
claims are asserted against us, even if we believe the claims are without merit, there is no assurance that a court would find in our favor, e.g.,&nbsp;on questions of infringement, validity,
enforceability or priority. A court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability
and the ability of our licensor to commercialize any product candidates we may develop and any other product candidates or technologies covered by the asserted third-party patents. In order to
successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and
convincing evidence </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=47,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=438236,FOLIO='44',FILE='DISK114:[18ZFG1.18ZFG45201]CK45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:50' -->
<A NAME="page_ck45201_1_45"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>as
to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If any such third-party patents
(including those that may issue from such applications) were successfully asserted against us or our licensor or other commercialization partners and we were unable to successfully challenge the
validity or enforceability of any such asserted patents, then we or our licensor and other commercialization partners may be prevented from commercializing our product candidate or any future product
candidates, or may be required to pay significant damages, including treble damages and attorneys' fees if we are found to willfully infringe the asserted patents, or obtain a license to such patents,
which may not be available on commercially reasonable terms, or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties
access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. Defense of these claims, regardless of their merit, would involve
substantial litigation expense and would be a substantial diversion of employee
resources from our business. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk
that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material
adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. Any of the foregoing
would have a material adverse effect on our business, financial condition and operating results. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to claims by third parties asserting that our employees or we have misappropriated a third
party's intellectual property, or claiming ownership of what we regard as our own intellectual property.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Many of our employees, including our senior management, were previously employed at other biotechnology or pharmaceutical companies, including our competitors
or potential competitors. Some of these employees executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. We may be subject to claims
that we or these employees have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee's former employer,
or that third parties have an interest in our patents as an inventor or co-inventor. Litigation may be necessary to defend against these claims. If we fail in prosecuting or defending any such claims,
in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain other damages. Such intellectual property rights could be awarded to a third party,
and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms, or at all. Even if
we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such
intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment
of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may
bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of
operations and prospects. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=48,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=224048,FOLIO='45',FILE='DISK114:[18ZFG1.18ZFG45201]CK45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:50' -->
<A NAME="page_ck45201_1_46"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our inability to protect our confidential information and trade secrets would harm our business and
competitive position.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In addition to seeking patents for some of our technology and products, in our activities we also rely substantially on trade secrets, including unpatented
know-how, technology and other proprietary materials and information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and
confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and
other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. However, these steps may be inadequate, we may fail to enter
into agreements with all such parties or any of these parties may breach the agreements and disclose our proprietary information and there may be no adequate remedy available for such breach of an
agreement. We cannot assure you that our proprietary information will not be disclosed or that we can meaningfully protect our trade secrets. Enforcing a claim that a party illegally disclosed or
misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts both within and outside the United States may be less willing, or
unwilling, to protect trade secrets. If a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology
or information to compete with us, which could harm our competitive position. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Intellectual property rights do not necessarily address all potential threats.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not
adequately protect our business or permit us to maintain our competitive advantage. For example:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> others may be able to make products that are similar to any product candidates we may develop or utilize similar technology but that are not
covered by the claims of the patents that we license or may own in the future; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we, or our current or future collaborators, might not have been the first to make the inventions covered by the issued patents and pending
patent applications that we license or may own in the future; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we, or our current or future collaborators, might not have been the first to file patent applications covering certain of our or their
inventions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or
licensed intellectual property rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> it is possible that our pending patent applications or those that we may own in the future will not lead to issued patents; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information
learned from such activities to develop competitive products for sale in our major commercial markets; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may not develop additional proprietary technologies that are patentable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the patents of others may harm our business; and </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=49,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=184628,FOLIO='46',FILE='DISK114:[18ZFG1.18ZFG45201]CK45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:50' -->
<A NAME="page_ck45201_1_47"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may choose not to file&nbsp;a patent application in order to maintain certain trade secrets or know-how, and a third party may
subsequently file&nbsp;a patent covering such intellectual property. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Should
any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court
or the USPTO.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If we or our licensing partner initiate legal proceedings against a third party to enforce a patent covering our product candidate or any future product
candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant
counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties
may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. These types of mechanisms include </FONT><FONT SIZE=2><I>inter
partes</I></FONT><FONT SIZE=2> review, post grant review, and equivalent proceedings in foreign jurisdictions (e.g.,&nbsp;opposition proceedings). These types of proceedings could result in
revocation or amendment to our patents such that they no longer cover our product candidates. The outcome for any particular patent following legal assertions of invalidity and unenforceability is
unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware
during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least
part, and perhaps all, of the patent protection on our product candidates. A loss of patent protection for our product candidates could have a material adverse impact on our ability to commercialize
or license our technology and product candidates and, resultantly, on our business, financial condition, prospects and results of operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Likewise,
our in-licensed U.S. patents directed to our proprietary technologies and our product candidates are expected to expire in 2034, including potential patent term extensions, without taking
into account any possible patent term adjustments or extensions. Our earliest in-licensed patents may expire before, or soon
after, our first product achieves marketing approval in the United States or foreign jurisdictions. Upon the expiration of our current patents, we may lose the right to exclude others from practicing
these inventions. The expiration of these patents could also have a similar material adverse effect on our business, financial condition, prospects and results of operations. We in-license pending
patent applications directed to proprietary technologies or our product candidates that, if issued as patents, are expected to expire from 2034, including potential patent term extensions, through
2036, without taking into account any possible patent term adjustments or extensions. However, we cannot be assured that the USPTO or relevant foreign patent offices will grant any of these patent
applications. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in patent law could diminish the value of patents in general, thereby impairing our ability to
protect our product candidate or any future product candidates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.
Obtaining and enforcing patents in the biotechnology industry involves technological and legal complexity, and obtaining and enforcing biotechnology patents is costly, time-consuming and inherently
uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances, weakening the rights of patent
owners in certain situations or ruling that certain subject matter is not eligible for patent protection. In addition to increasing uncertainty with regard to our and our licensor's ability to </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=50,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=45608,FOLIO='47',FILE='DISK114:[18ZFG1.18ZFG45201]CK45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:50' -->
<A NAME="page_ck45201_1_48"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>obtain
patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts, the USPTO
and equivalent bodies in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our and our licensor's ability to obtain new patents or
to enforce existing patents and patents we and our licensor may obtain in the future. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Patent
reform laws, such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, as well as changes in how patent laws are interpreted, could increase the uncertainties and costs surrounding
the prosecution of our and our licensor's patent applications and the enforcement or defense of our or our licensor's issued patents. The Leahy-Smith Act includes a number of significant changes to
U.S. patent law. These include provisions that affect the filing and prosecution strategies associated with patent applications, including a change from a "first-to-invent" to a
"first-inventor-to-file" patent system, and may also affect patent prosecution and litigation, such as by allowing third-party submission of prior art to the USPTO during patent prosecution and
additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2> review
and derivation proceedings. The USPTO has developed regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the
Leahy-Smith Act and, in particular, the "first-inventor-to-file" provisions, became effective in 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation
of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensor's patent applications and the
enforcement or defense of our or our licensor's issued patents, all of which could have a material adverse effect on our business, financial condition and results of operations. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Risks related to our reliance on third parties  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will rely on third parties to conduct our clinical trials. If these third parties do not successfully
carry out their contractual duties or meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize any potential product
candidates.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We will depend upon third parties, including independent investigators, to conduct our clinical trials under agreements with universities, medical
institutions, CROs, strategic partners and others. We expect to have to negotiate budgets and contracts with CROs and trial sites, which may result in delays to our development timelines and increased
costs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
will rely heavily on third parties over the course of our clinical trials, and, as a result, will have limited control over the clinical investigators and limited visibility into their day-to-day
activities, including with respect to their compliance with the approved clinical protocol. Nevertheless, our reliance on third parties does not relieve us of our regulatory responsibilities and we
will be responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards. We and these third parties
are required to comply with good clinical practice, or GCP, requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates
in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical investigators and trial sites. If we or any of these third
parties fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may
require us to suspend or terminate these trials or perform additional nonclinical studies or clinical trials before approving our marketing applications. We cannot be certain that, upon inspection,
regulatory authorities will determine that any of our clinical trials comply with the GCP requirements. In addition, our </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=51,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=659865,FOLIO='48',FILE='DISK114:[18ZFG1.18ZFG45201]CK45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:50' -->
<A NAME="page_ck45201_1_49"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>clinical
trials must be conducted with products produced under current good manufacturing practice, or cGMP, requirements and may require a large number of patients. Our failure or any failure by
these third parties to comply with these applicable regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval
process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
third parties who may conduct our future clinical trials will not be our employees and, except for remedies that may be available to us under our agreements with those third parties, we cannot
control whether or not they devote sufficient time and resources to our ongoing nonclinical and clinical programs. These third parties may also have relationships with other commercial entities,
including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do
not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised
due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete
development of, obtain regulatory approval of or successfully commercialize our product candidates in a timely manner or at all. As a result, our financial results and the commercial prospects for our
product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially
reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As
a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no
assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and
prospects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the clinical data they obtain is compromised due to the
failure (including by clinical sites or investigators) to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and
we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of
operations and the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenues could be delayed significantly. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We contract with third parties for the manufacture of our product candidate or any future product candidates
for nonclinical testing and expect to continue to do so for clinical trials and for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of
our product candidate or any future product candidates or medicines or that such supply will not be available to us at an acceptable cost, which could delay, prevent or impair our development or
commercialization efforts.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We do not have any manufacturing facilities. We currently rely, and expect to continue to rely, on third-party manufacturers for the manufacture of our
product candidate or any future product candidates for nonclinical and clinical testing and for commercial supply of any of these product candidates for which we obtain marketing approval. Reliance on
third-party manufacturers may expose us to different risks than if </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=52,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=365380,FOLIO='49',FILE='DISK114:[18ZFG1.18ZFG45201]CK45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:50' -->
<A NAME="page_ck45201_1_50"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>we
were to manufacture product candidates ourselves. To the extent any issues arise with our third-party manufacturers, we may be unable to establish any agreements with any other third-party
manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks,
including:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the possible breach of the manufacturing agreement by the third party; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reliance on the third party for regulatory compliance, quality assurance and safety and pharmacovigilance reporting. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Third-party
manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of third-party manufacturers, to
comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation,
seizures or recalls of product candidates or medicines, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our
business and results of operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
medicines that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP
regulations and that might be capable of manufacturing for us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply
for bulk drug substances. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer. Although we believe that there are several
potential alternative manufacturers who could manufacture our product candidate or any future product candidates, we may incur added costs and delays in identifying and qualifying any such
replacement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
current and anticipated future dependence upon others for the manufacture of our product candidate or any future product candidates or medicines may adversely affect our future profit margins and
our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The manufacture of our product candidates is complex and we may encounter difficulties in production. If we
or any of our third-party manufacturers encounter such difficulties, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our product candidates for clinical
trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The processes involved in manufacturing our drug product candidates are complex, expensive, highly-regulated, and subject to multiple risks. Further, as
product candidates are developed through nonclinical studies to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as
manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these
changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=53,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=640008,FOLIO='50',FILE='DISK114:[18ZFG1.18ZFG45201]CK45201A.;20',USER='SCAVALI',CD='17-JAN-2019;10:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cm45201_1_51"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In addition, the manufacturing process for any products that we may develop is subject to FDA and other comparable foreign regulatory authority approval processes and
continuous oversight, and we will need to contract with manufacturers who can meet all applicable FDA and foreign regulatory authority requirements, including, for example, complying with cGMPs, on an
ongoing basis. If we or our third-party manufacturers are unable to reliably produce products to specifications acceptable to the FDA or other
regulatory authorities, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no
assurance that either we or our contract manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in
sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require
bridging or comparability nonclinical or clinical trials or the repetition of one or more clinical trials, increase clinical study costs, delay approval of our product candidate, impair
commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations, and growth prospects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We may seek to establish collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may pursue collaborations in order to develop and commercialize AKR-001 and any future product candidates. We face significant competition in seeking
appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator's resources and expertise, the terms and
conditions of the proposed collaboration and the proposed collaborator's evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of
approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such
product candidate to patients, the potential of competing products and the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such
ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborators may also consider alternative product candidates or technologies for similar
indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Collaborations
are complex and time-consuming to negotiate and document. In addition, there have been a significant number of business combinations among large pharmaceutical companies that have
resulted in a reduced number of potential future collaborators. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which
we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or
marketing activities or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or
commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we may not be
able to further develop our product candidate or any future product candidates or bring them to market and generate product revenue. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=54,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=698897,FOLIO='51',FILE='DISK114:[18ZFG1.18ZFG45201]CM45201A.;13',USER='SMENEZE',CD='16-JAN-2019;21:29' -->
<A NAME="page_cm45201_1_52"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Risks related to commercialization  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Even if we commercialize our product candidate or any future product candidates, these products may become subject to unfavorable pricing regulations, third-party reimbursement
practices or healthcare reform initiatives, which could harm our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The regulations that govern marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Current and future
legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of
a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In
some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for
a product in a particular country, but then be subject to price regulations that delay or limit our commercial launch of the product, possibly for lengthy time periods, which could negatively impact
the revenue we generate from the sale of the product in that particular country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if
our product candidate or any future product candidates obtain marketing approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
ability to commercialize any products successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available
from third-party payors such as government health administration authorities, private health insurers and other organizations. Third-party payors determine which medications they will cover and
establish reimbursement levels. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are
requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage and reimbursement
will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price
of, any product candidate for which we obtain marketing approval, if any. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not be able to
successfully commercialize any product candidate for which marketing approval is obtained, if any. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There
may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or
comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including
research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary.
Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be
incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any
future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and
profitable reimbursement rates third-party payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to
commercialize products and our overall financial condition. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=55,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=1047574,FOLIO='52',FILE='DISK114:[18ZFG1.18ZFG45201]CM45201A.;13',USER='SMENEZE',CD='16-JAN-2019;21:29' -->
<A NAME="page_cm45201_1_53"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2><B><I> If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop,
we may not be successful in commercializing those product candidates if and when they are approved.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We do not currently have an infrastructure for the sales, marketing, and distribution of pharmaceutical products. In order to market our product candidates,
if approved by the FDA or any other regulatory body, we must build our sales, marketing, managerial, and other non-technical capabilities, or make arrangements with third parties to perform these
services. There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and
training a sales force or reimbursement specialists is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales
force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization
expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>If
we enter into arrangements with third parties to perform sales, marketing, commercial support, and distribution services, our product revenue or the profitability of product revenue may be lower
than if we were to market and sell any products we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize our product candidates
or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and
market our products effectively and they could expose our company to regulatory enforcement and legal risk in the execution of their sales and commercialization activities. If we do not establish
commercialization capabilities successfully,
either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates if approved. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we are unable to establish adequate sales, marketing, and distribution capabilities, whether independently or with third parties, or if we are unable to do so on commercially reasonable terms, our
business, results of operations, financial condition, and prospects will be materially adversely affected. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Our product candidate or any future product candidates may not achieve adequate market acceptance among physicians, patients, third-party payors and others in the medical community
necessary for commercial success.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even if our product candidate or any future product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians,
patients, third-party payors, pharmaceutical companies and others in the medical community. Demonstrating the safety and efficacy of our product candidate or any future product candidates and
obtaining regulatory approvals will not guarantee future revenue. Our commercial success also depends on coverage and adequate reimbursement of our product candidate or any future product candidates
by third-party payors, including government payors and private insurers, which may be difficult or time-consuming to obtain, may be limited in scope and may not be obtained in all jurisdictions in
which we may seek to market our products. Third-party payors closely examine medical products to determine whether they should be covered by reimbursement and, if so, the level of reimbursement that
will apply. We cannot be certain that third-party payors will sufficiently reimburse sales of our product, or enable us to sell our product at a profitable price. Similar concerns could also limit the
reimbursement amounts that health insurers or government agencies in other countries are prepared to pay for our products. In many regions, including Europe, Japan and Canada, where we may market our
products, the pricing of prescription drugs is controlled by the government or regulatory agencies. Regulatory agencies in these countries could determine that the pricing for our products should </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=56,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=871299,FOLIO='53',FILE='DISK114:[18ZFG1.18ZFG45201]CM45201A.;13',USER='SMENEZE',CD='16-JAN-2019;21:29' -->
<A NAME="page_cm45201_1_54"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>be
based on prices of other commercially available drugs for the same disease, rather than allowing us to market our products at a premium as new drugs. The degree of market acceptance of any of our
approved product candidates will depend on a number of factors, including:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the efficacy and safety profile of the product candidate as demonstrated in clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing of market introduction of the product candidate as well as competitive products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the clinical indications for which the product candidate is approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> acceptance of the product candidate as a safe and effective treatment by clinics and patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the potential and perceived advantages of the product candidate over alternative treatments, including any similar generic treatments; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of treatment in relation to alternative treatments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the availability of coverage and adequate reimbursement and pricing by third-party payors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the relative convenience and ease of administration; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the frequency and severity of adverse events; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the effectiveness of sales and marketing efforts; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> unfavorable publicity relating to our product candidate or any future product candidates. </FONT></DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>Sales
of medical products also depend on the willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe,
therapeutically effective and cost effective. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of influential
physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians' organizations, hospitals, other healthcare providers, government
agencies or private insurers will determine that our product is safe, therapeutically effective and cost effective as compared with competing treatments. If any product candidate is approved but does
not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We face an inherent risk of product liability exposure related to the testing of our product candidate or any future product candidates in human clinical
trials and will face an even greater risk if we commercialize any resulting products. Product liability claims may be brought against us by subjects enrolled in our clinical trials, patients, their
family members, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against claims that our product candidate or any future product
candidates or products that we may develop caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> decreased demand for any product candidates or products that we may develop; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> termination of clinical trial sites or entire trial
programs; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> injury to our reputation and significant negative media attention; </FONT><FONT SIZE=2>
 </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> withdrawal of clinical trial participants; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=57,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=609071,FOLIO='54',FILE='DISK114:[18ZFG1.18ZFG45201]CM45201A.;13',USER='SMENEZE',CD='16-JAN-2019;21:29' -->
<A NAME="page_cm45201_1_55"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> significant costs to defend the related litigation; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> substantial monetary awards to trial subjects or patients; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT
SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> loss of revenue; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> diversion of management and scientific resources from our business operations; </FONT><FONT SIZE=2>
 </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the inability to commercialize any products that we may develop; and </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a decline in our stock price. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Our
clinical trial liability insurance coverage may not adequately cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount
adequate to satisfy any liability that may arise. Our inability to obtain product liability insurance at an acceptable cost or to otherwise protect against potential product liability claims could
prevent or delay the commercialization of any products or product candidates that we develop. We intend to expand our insurance coverage for products to include the sale of commercial products if we
obtain marketing approval for our product candidate or any future product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products
approved for marketing. Large judgments have been awarded in lawsuits based on drugs that had unanticipated side effects. If we are sued for any injury caused by our products, product candidates or
processes, our liability could exceed our product liability insurance coverage and our total assets. Claims against us, regardless of their merit or potential outcome, may also generate negative
publicity or hurt our ability to obtain physician adoption of our product or expand our business. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Risks related to this offering and our common stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We do not know whether an active, liquid and orderly trading market will develop for our common stock or what the market price of our common stock will be and, as a result, it may be
difficult for you to sell your shares of our common stock and you may not be able to resell your shares at or above the initial public offering price.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior to this offering, no market for shares of our common stock existed and an active trading market for our shares may never develop or be sustained
following this offering. We will determine the initial public offering price for our common stock through negotiations with the underwriters, and the negotiated price may not be indicative of the
market price of our common stock after this offering. The market value of our common stock may decrease from the initial public offering price. As a result of these and other factors, you may be
unable to resell your shares of our common stock at or above the initial public offering price. The lack of an active market may impair your ability to sell your shares at the time you wish to sell
them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares. Furthermore, an inactive market may also impair our ability to raise
capital by selling shares of our common stock and may impair our ability to enter into strategic collaborations or acquire companies or products by using shares of our common stock as consideration. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> The market price of our stock may be volatile, and you could lose all or part of your investment.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The trading price of our common stock following this offering is likely to be highly volatile and subject to wide fluctuations in response to various factors,
some of which we cannot control. In addition to the factors discussed in this "Risk factors" section and elsewhere in this prospectus, these factors include:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> developments associated with our license with Amgen, including any termination or other change in our relationship with Amgen; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the success of competitive products or technologies; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=58,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=875967,FOLIO='55',FILE='DISK114:[18ZFG1.18ZFG45201]CM45201A.;13',USER='SMENEZE',CD='16-JAN-2019;21:29' -->
<A NAME="page_cm45201_1_56"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> regulatory actions with respect to our product candidate or any future product candidates or our competitors' product candidates or products; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> results of clinical trials of our product candidate or any future product candidates or those of our competitors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> actual or anticipated changes in our growth rate relative to our competitors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> announcements by us or our competitors or collaborators of significant acquisitions, strategic collaborations, joint ventures, collaborations
or capital commitments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> regulatory, legal or payor developments in the United States and other countries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> developments or disputes concerning patent applications, issued patents or other proprietary rights; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the recruitment or departure of key personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the level of expenses related to any of our product candidate or any future product candidates or clinical development programs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the results of our efforts to in-license or acquire additional product candidates or products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> variations in our financial results or those of companies that are perceived to be similar to us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> fluctuations in the valuation of companies perceived by investors to be comparable to us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> announcement or expectation of additional financing efforts; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> sales of our common stock by us, our insiders or our other stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in the structure of healthcare payment systems; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> market conditions in the pharmaceutical and biotechnology sectors; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> general economic, industry and market conditions. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, the stock market in general, and the market for biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or
disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating
performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this "Risk factors" section, could have a dramatic and material adverse
impact on the market price of our common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our management will have broad discretion in the application of the net proceeds from this offering, and you will be relying on the judgment of our management
regarding the application of these proceeds. You will not have the opportunity, as part of your investment decision, to assess whether we are using the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=59,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=148820,FOLIO='56',FILE='DISK114:[18ZFG1.18ZFG45201]CM45201A.;13',USER='SMENEZE',CD='16-JAN-2019;21:29' -->
<A NAME="page_cm45201_1_57"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</FONT><P style="font-family:arial;"><FONT SIZE=2>proceeds
appropriately. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment. If we do not invest or apply the net proceeds from this offering
in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Because of potential volatility in our trading price and trading volume, we may incur significant costs from class action securities litigation.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Holders of stock in companies that have a volatile stock price frequently bring securities class action litigation against the company that issued the stock.
We may be the target of this type of litigation in the future. If any of our stockholders were to bring a lawsuit of this type against us, even if the lawsuit is without merit, we could incur
substantial costs defending the lawsuit. A stockholder lawsuit could also divert the time and attention of our management. Securities litigation against us could result in substantial costs and divert
our management's attention from other business concerns, which could seriously harm our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior to this offering, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned
approximately 79% of our voting stock as of December&nbsp;31, 2018 and, upon completion of this offering, that same group will hold approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding voting stock (no
purchases of shares in this offering by any members of this group), in each case assuming the conversion of all outstanding shares of our convertible preferred stock into shares of our common stock in
connection with the completion of this offering. After this offering, this group of stockholders will have the ability to control us through this ownership position. These stockholders may be able to
determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any
merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest
as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances
their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> We are an "emerging growth company" as defined in the JOBS Act and a "smaller reporting company" as defined in the Exchange Act and will be able to avail ourselves of reduced
disclosure requirements applicable to emerging growth companies and smaller reporting companies, which could make our common stock less attractive to investors and adversely affect the market price of
our common stock.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For so long as we remain an "emerging growth company" as defined in the JOBS Act, we may take advantage of certain exemptions from various requirements
applicable to public companies that are not "emerging growth companies" including:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the provisions of Section&nbsp;404(b) of the Sarbanes-Oxley Act requiring that our independent registered public accounting firm provide an
attestation report on the effectiveness of our internal control over financial reporting; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the "say on pay" provisions (requiring a non-binding shareholder vote to approve compensation of certain executive officers) and the "say on
golden parachute" provisions (requiring a non-binding shareholder vote to approve golden parachute arrangements for certain executive officers in connection </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=60,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=879950,FOLIO='57',FILE='DISK114:[18ZFG1.18ZFG45201]CM45201A.;13',USER='SMENEZE',CD='16-JAN-2019;21:29' -->
<A NAME="page_cm45201_1_58"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>with
mergers and certain other business combinations) of the Dodd-Frank Act and some of the disclosure requirements of the Dodd-Frank Act relating to compensation of our executive officers; and </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the requirement to provide detailed compensation discussion and analysis in proxy statements and reports filed under the Exchange Act and
instead provide a reduced level of disclosure concerning executive compensation. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
may take advantage of these reporting exemptions until we are no longer an emerging growth company, which in certain circumstances could be for up to five years. We will remain an emerging growth
company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the completion of this offering, (b)&nbsp;in which we have total annual gross
revenue of at least $1.07&nbsp;billion or (c)&nbsp;in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by non-affiliates to
exceed $700.0&nbsp;million as of the prior June&nbsp;30th, and (2)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in non-convertible debt during the prior three-year period.
We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a
less active trading market for our common stock and our stock price may be more volatile. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are also a "smaller reporting company" as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take
advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that our voting and non-voting common stock held by
non-affiliates is more than $250&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100&nbsp;million during the most recently
completed fiscal year and our voting and non-voting common stock held by non-affiliates is more than $700&nbsp;million measured on the last business day of our second fiscal quarter. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Although
we are still evaluating the JOBS Act, we currently intend to take advantage of some, but not all, of the reduced regulatory and reporting requirements that will be available to us so long as
we qualify as an "emerging growth company" and "smaller reporting company." We have elected to avail ourselves of this exemption and, therefore, we are not subject to the same new or revised
accounting standards as other public companies that are not emerging growth companies or smaller reporting company. As a result, changes in rules of U.S. generally accepted accounting principles or
their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations. In
addition, our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting so long as we
qualify as an "emerging growth company," which may increase the risk that material weaknesses or significant deficiencies in our internal control over financial reporting go undetected. Likewise, so
long as we qualify as a "smaller reporting company" or an "emerging growth company," we may elect not to provide you with certain information, including certain financial information and certain
information regarding compensation of our executive officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for investors and
securities analysts to evaluate our company. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock
less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile and may decline. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=61,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=1029465,FOLIO='58',FILE='DISK114:[18ZFG1.18ZFG45201]CM45201A.;13',USER='SMENEZE',CD='16-JAN-2019;21:29' -->
<A NAME="page_cm45201_1_59"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2><B><I> Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that
the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. After this offering, we will have&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;outstanding shares of common stock
based on the number of shares outstanding as of December&nbsp;31, 2018, assuming the conversion of all outstanding shares of our convertible preferred stock
into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common
stock upon the completion of this offering. This includes the shares that we sell in this offering, which may be resold in the public market immediately without restriction, unless purchased by our
affiliates. Substantially all of the remaining shares of our common stock outstanding immediately after the completion of this offering will not be able to be sold immediately following this offering
as a result of securities laws or lock-up agreements, but will be able to be sold after this offering as described in the section titled "Shares eligible for future sale." Moreover, after this
offering, holders of an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will have rights, subject to certain conditions, to require us to file registration statements
covering their
shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also intend to register all shares of common stock that we may issue under our
equity compensation plans for resale under the Securities Act. Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to
affiliates and the lock-up agreements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
lock-up agreements pertaining to this offering will expire 180&nbsp;days from the date of this prospectus, subject to earlier release of all or a portion of the shares subject to such agreements
by J.P. Morgan Securities&nbsp;LLC, Jefferies&nbsp;LLC and Evercore Group L.L.C. in their sole discretion. After the lock-up agreements expire, based upon the number of shares of common stock, on
an as-converted basis, outstanding as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common
stock will be eligible for sale in the public market. Approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of
these additional shares are held by directors, executive officers and other affiliates and will be subject to certain limitations of Rule&nbsp;144 under the Securities Act of 1933, as amended, or
the Securities Act. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The initial public offering price is substantially higher than the pro forma as adjusted net tangible book value per share of our common stock as of
September&nbsp;30, 2018 after giving effect to this offering. Accordingly, investors purchasing common stock in this offering will pay a price per share that substantially exceeds the book value of
our tangible assets after subtracting our liabilities. As a result, investors purchasing common stock in this offering will incur immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, based on an assumed
initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover of this prospectus, after deducting underwriting discounts and commissions and
estimated offering expenses payable by us. Further, investors purchasing common stock in this offering will contribute approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total amount invested by stockholders since
our inception, but will own only approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the shares of common stock outstanding after this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2018, options to purchase 5,656,243&nbsp;shares of our common stock at a weighted average exercise price of $0.20 per share were outstanding. The exercise of any of these
options would result in additional dilution. As a result of the dilution to investors purchasing shares in this offering, investors may receive significantly less than the purchase price paid in this
offering, if anything, in the event of a liquidation. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=62,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=441528,FOLIO='59',FILE='DISK114:[18ZFG1.18ZFG45201]CM45201A.;13',USER='SMENEZE',CD='16-JAN-2019;21:29' -->
<A NAME="page_cm45201_1_60"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2><B><I> We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or
paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon completion of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and
procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized
and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how
well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These
inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be
circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control
system, misstatements due to error or fraud may occur and not be detected. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Anti-takeover provisions under our organizational documents and Delaware law could delay or prevent a change of control, which could limit the market price of our common stock and
may prevent or frustrate attempts by our stockholders to replace or remove our current management.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our fourth amended and restated certificate of incorporation and second amended and restated bylaws, which are to become effective at or prior to the
completion of this offering, contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some
of these provisions include:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at
one time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our
stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a requirement that special meetings of stockholders may only be called only by the chairman of the board of directors, the chief executive
officer, or by a majority of the total number of authorized directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> advance notice requirements for stockholder proposals and nominations for election to our board of directors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any
other vote required by law, upon the approval of not less than two-thirds (<SUP>2</SUP>/<SMALL>3</SMALL>) of all outstanding shares of our voting stock then entitled to vote in the election of directors; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=63,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=895943,FOLIO='60',FILE='DISK114:[18ZFG1.18ZFG45201]CM45201A.;13',USER='SMENEZE',CD='16-JAN-2019;21:29' -->
<A NAME="page_cm45201_1_61"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a requirement of approval of not less than two-thirds (<SUP>2</SUP>/<SMALL>3</SMALL>) of all outstanding shares of our voting stock to amend any bylaws by
stockholder action or to amend specific provisions of our certificate of incorporation; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval,
which preferred stock may include rights superior to the rights of the holders of common stock. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporate Law, which may prohibit certain business combinations
with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our fourth amended and restated certificate of incorporation and second
amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current
board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for
you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our
board of directors could cause the market price of our common stock to decline. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Our second amended and restated bylaws to be effective upon the effectiveness of this registration statement designate certain courts as the sole and exclusive forum for certain
types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors,
officers, or employees.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our second amended and restated bylaws that will become effective prior to completion of this offering provide that, unless we consent in writing to an
alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for state law claims for (i)&nbsp;any derivative action or proceeding brought on our behalf,
(ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers, and employees to us or our stockholders, (iii)&nbsp;any action asserting a claim arising
pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our second amended and restated bylaws or (iv)&nbsp;any action asserting a
claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. This
exclusive forum provision will not apply to any causes of action arising under the Exchange Act. In addition, our second amended and restated bylaws will provide that any person or entity purchasing
or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions. We have chosen the United States District Court for the
District of Massachusetts as the exclusive forum for causes of action arising under the Securities Act because our principal executive offices are located in Cambridge, Massachusetts. Some companies
that have adopted similar federal district court forum selection provisions are currently subject to a suit in the Court of Chancery of the State of Delaware brought by stockholders who assert that
the federal district court forum selection provision is not enforceable. We recognize that the federal district court forum selection clause may impose additional litigation costs on stockholders who
assert the provision is not enforceable and may impose more general additional litigation costs in pursuing any such claims, particularly if the stockholders do not reside in or near the Commonwealth
of Massachusetts. Additionally, the forum selection clauses in our second amended and restated bylaws may limit our stockholders' ability to obtain a favorable judicial forum for disputes with us.
Alternatively, if the federal district court forum selection provision is found inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may
incur </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=64,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=389996,FOLIO='61',FILE='DISK114:[18ZFG1.18ZFG45201]CM45201A.;13',USER='SMENEZE',CD='16-JAN-2019;21:29' -->
<A NAME="page_cm45201_1_62"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>additional
costs associated with resolving such matters in other jurisdictions, which could have an adverse effect on our business, financial condition or results of operations. The United States
District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or
would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
have chosen the Court of Chancery of the State of Delaware as the exclusive forum for such causes of action because we are incorporated in the State of Delaware and we are familiar with the
procedures and rules applicable in such forum. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The trading market for our common stock will depend, in part, on the research and reports that securities or industry analysts publish about us or our
business. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities or industry analysts commence coverage of our company or if they cease to
cover our company, the trading price for
our stock would likely be negatively impacted. In the event that securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade our stock or publish
inaccurate or unfavorable research about our business, our stock price would likely decline. In addition, if our operating results fail to meet the forecast of analysts, our stock price would likely
decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading
volume to decline. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=65,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=121238,FOLIO='62',FILE='DISK114:[18ZFG1.18ZFG45201]CM45201A.;13',USER='SMENEZE',CD='16-JAN-2019;21:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_co45201_1_63"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B> <A NAME="co45201_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_co45201_1"> </A> </B></FONT><FONT SIZE=4><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Special note regarding forward-looking statements    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus contains forward-looking statements that are based on management's beliefs and assumptions and on information currently
available to management. Some of the statements in the section captioned "Prospectus summary," "Risk factors," "Management's discussion and analysis of financial condition and results of operations,"
"Business" and elsewhere in this prospectus contain forward-looking statements. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would,"
"should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology,
although not all forward-looking statements contain these words. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These
statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed
or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus, we caution you that these
statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this prospectus
include, but are not limited to, statements about:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the success, cost and timing of our product development activities and clinical trials, including statements regarding the timing of initiation
and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to advance any product candidate into or successfully complete any clinical trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability or the potential to successfully manufacture our product candidates for clinical trials or for commercial use, if approved; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the potential for our identified research priorities to advance our technologies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to obtain and maintain regulatory approval, if obtained, of AKR-001 or any future product candidates, and any related restrictions,
limitations and/or warnings in the label of an approved product candidate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the ability to license additional intellectual property relating to any future product candidates and to comply with our existing license
agreements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to commercialize our products in light of the intellectual property rights of others; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the success of competing therapies that are or become available; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our
product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the commercialization of our product candidates, if approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our plans to research, develop and commercialize our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to attract collaborators with development, regulatory and commercialization expertise; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> future agreements with third parties in connection with the commercialization of our product candidates and any other approved product; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=66,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=356930,FOLIO='63',FILE='DISK114:[18ZFG1.18ZFG45201]CO45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:50' -->
<A NAME="page_co45201_1_64"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the size and growth potential of the markets for our product candidates, and our ability to serve those markets; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the rate and degree of market acceptance of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> regulatory developments in the United States and foreign countries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to attract and retain key scientific or management personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the impact of laws and regulations; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, you should refer to the "Risk factors" section of this prospectus for a discussion of other important factors that may cause actual results to differ materially from those expressed or
implied by the forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate. Furthermore, if the
forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements
as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this prospectus
represent our views as of the date of this prospectus. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking
statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as
representing our views as of any date subsequent to the date of this prospectus. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant
subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms&nbsp;a reasonable basis for such statements, such
information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant
information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
market data and certain other statistical information used throughout this prospectus are based on independent industry publications, governmental publications, reports by market research firms or
other independent sources that we believe to be reliable sources. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from
sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosure contained in this prospectus, and we
believe these industry publications and third-party research, surveys and studies are reliable. While we are not aware of any misstatements regarding any third-party information presented in this
prospectus, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors,
including those discussed under the section entitled "Risk factors" and elsewhere in this prospectus. Some data are also based on our good faith estimates. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=67,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=564106,FOLIO='64',FILE='DISK114:[18ZFG1.18ZFG45201]CO45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:50' -->
<A NAME="page_co45201_1_65"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="co45201_market,_industry,_and_other_data"> </A>
<A NAME="toc_co45201_2"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Market, industry, and other data    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus contains estimates, projections and other information concerning our industry, our business and the markets for our products,
including data regarding the estimated size of those markets, their projected growth rates, the perceptions and preferences of patients and physicians regarding certain therapies and other patient
data and reimbursement data, as well as market research, estimates and forecasts prepared by our management. We obtained the industry, market and other data throughout this prospectus from our own
internal estimates and research, as well as from publicly available information, industry publications and research, surveys and studies conducted by third-parties, including governmental agencies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Information
that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially
from events and circumstances that are assumed in this information based on various factors, including those discussed in "Risk factors." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=68,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=622517,FOLIO='65',FILE='DISK114:[18ZFG1.18ZFG45201]CO45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:50' -->
<A NAME="page_co45201_1_66"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="co45201_use_of_proceeds"> </A>
<A NAME="toc_co45201_3"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Use of proceeds    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We estimate that the net proceeds to us from the sale of the shares of our common stock in this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase additional shares in full, based upon an assumed initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Each
$1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase
(decrease) the net proceeds to us from this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same
and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1,000,000 shares in the number of shares offered by us
would increase (decrease) the net proceeds to us from this
offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the assumed initial public offering price remains the same and after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. We do not expect that a change in the initial public offering price or the number of shares by these amounts would have a material effect on our uses of the proceeds
from this offering, although it may accelerate the time at which we will need to seek additional capital. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
currently expect to use the net proceeds from this offering, together with our existing cash as of December&nbsp;31, 2018, as follows:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to complete our contemplated Phase&nbsp;2a clinical trial and subsequent Phase&nbsp;2b clinical trial of our
lead product candidate, AKR-001, in patients with NASH; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for new AKR-001 drug substance and drug product manufactured by third parties; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for nonclinical studies, exploration of potential additional indications for AKR-001, internal discovery efforts
and potential in-licensing to diversify our pipeline; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the remainder for working capital and general corporate purposes. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Based
on our current plans, we believe our existing cash, together with the net proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure requirements
through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, although there can be no assurance in that regard. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
may also use a portion of our net proceeds to co-develop, acquire or invest in products, technologies or businesses that are complementary to our business. However, we currently have no agreements
or commitments to complete any such transaction. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
cannot specify with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering. Due to uncertainties inherent in the product development process,
it is difficult to estimate the exact amounts of the net proceeds that will be used for any particular purpose. We may use our existing cash and the future payments, if any, generated from any future
collaboration agreements to fund our operations, either of which may alter the amount of net proceeds used for a particular purpose. In addition, the amount, allocation and timing of our actual
expenditures will depend upon numerous factors, including the results of our research and development efforts, the timing and success of clinical trials and the timing of regulatory submissions.
Accordingly, we will have broad discretion in using these proceeds. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pending
the uses described above, we plan to invest the net proceeds of this offering in short- and immediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit
or direct or guaranteed obligations of the U.S. government. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=69,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=262885,FOLIO='66',FILE='DISK114:[18ZFG1.18ZFG45201]CO45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:50' -->
<A NAME="page_co45201_1_67"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="co45201_dividend_policy"> </A>
<A NAME="toc_co45201_4"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Dividend policy    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have never declared or paid any cash dividends on our common stock or any other securities. We anticipate that we will retain all available
funds and any future earnings, if any, for use in the operation of our business and do not anticipate paying cash dividends in the foreseeable future. In addition, future debt instruments may
materially restrict our ability to pay dividends on our common stock. Payment of future cash dividends, if any, will be at the discretion of the board of directors after taking into account various
factors, including our financial condition, operating results, current and anticipated cash needs, the requirements of then-existing debt instruments and other factors the board of directors deems
relevant. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>67</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=70,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=784048,FOLIO='67',FILE='DISK114:[18ZFG1.18ZFG45201]CO45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:50' -->
<A NAME="page_co45201_1_68"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="co45201_capitalization"> </A>
<A NAME="toc_co45201_5"> </A></FONT> <FONT SIZE=4><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Capitalization    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth our cash and our capitalization as of September&nbsp;30, 2018:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> on an actual basis; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> on a pro forma basis to give effect to the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock prior to the completion of this offering and the filing and effectiveness of our fourth amended and restated certificate of incorporation prior to the
completion of this offering; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> on a pro forma as adjusted basis to give further effect to the issuance and sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at
an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>The
pro forma as adjusted information below is illustrative only, and our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price
and other terms of this offering determined at pricing. You should read the information in this table together with our financial statements and the related notes appearing at the end of this
prospectus and the "Selected financial data" and "Management's discussion and analysis of financial condition and results of operations" sections of this prospectus. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="51pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="58pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of September&nbsp;30, 2018 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands, except share and per share amounts)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Actual</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pro forma</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pro forma<BR>
as adjusted(1)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Cash</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">7,832</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Preferred stock tranche obligation</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">15,750</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Anti-dilution right liability</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,671</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Series&nbsp;A redeemable convertible preferred stock, $0.0001 par value; 70,858,462 shares authorized, 22,653,333 shares issued and outstanding, actual; no
shares authorized, issued or outstanding, pro forma and pro forma as adjusted</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">14,108</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Stockholders' equity (deficit):</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Preferred stock, $0.0001 par value; no shares authorized, issued or outstanding,
actual;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized and no shares issued or outstanding, pro forma and pro forma as adjusted</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Common stock, $0.0001 par value; 80,000,000 shares authorized, 696,000 shares issued and outstanding,
actual;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro
forma;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma as
adjusted</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Additional paid-in capital</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Accumulated deficit</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(25,093</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total stockholders' equity (deficit)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(25,093</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total capitalization</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">7,436</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;Each
$1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this
prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, total stockholders' equity and total capitalization by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number
of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us. Each increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro forma as
adjusted amount of each of cash, total stockholders' equity and total capitalization by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no change in the assumed initial public offering price per share and
after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>68</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=71,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=245170,FOLIO='68',FILE='DISK114:[18ZFG1.18ZFG45201]CO45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:50' -->
<A NAME="page_co45201_1_69"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>


<P style="font-family:arial;"><FONT SIZE=2>The
number of shares of our common stock in the table above is based on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock outstanding as of September&nbsp;30, 2018, after
giving effect to the
automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock immediately
prior to the completion of this offering,
and excludes:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 2,277,264 shares of common stock issuable upon the exercise of stock options outstanding as of September&nbsp;30, 2018 under our 2018 Stock
Option and Grant Plan, or the 2018 Plan, at a weighted-average exercise price of $0.20 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 906,736 shares of common stock reserved for future issuance as of September&nbsp;30, 2018 under the 2018 Plan, which will cease to be
available for issuance at the time that our 2019 Stock Option and Grant Plan, or the 2019 Plan, becomes effective; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock that will become available for future issuance
under the 2019 Plan in connection with the
effectiveness of the registration statement of which this prospectus is a part; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for future issuance under our 2019
Employee Stock Purchase Plan which will become
effective in connection with this offering. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>69</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=72,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=632301,FOLIO='69',FILE='DISK114:[18ZFG1.18ZFG45201]CO45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:50' -->
<A NAME="page_co45201_1_70"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="co45201_dilution"> </A>
<A NAME="toc_co45201_6"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Dilution    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
historical net tangible book value (deficit) as of September&nbsp;30, 2018 was $(25.2) million, or $(36.14) per share of our common stock. Our historical net tangible book value (deficit) is the
amount of our total tangible assets less our total liabilities and the carrying values of our convertible preferred stock, which is not included within stockholders' equity (deficit). Our historical
net tangible book value (deficit) per share represents historical net tangible book value (deficit) divided by the 696,000 shares of our common stock outstanding as September&nbsp;30, 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
pro forma net tangible book value as of September&nbsp;30, 2018 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of our common stock. Pro forma net tangible book
value represents the amount of our total tangible assets less our total liabilities, after giving effect to (i)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred
stock into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock prior to the completion of this offering and (ii)&nbsp;the filing and effectiveness of our
fourth amended and restated certificate
of incorporation and second amended and restated bylaws prior to the completion of this offering. Pro forma net tangible book value per share represents pro forma net tangible book value divided by
the total number of shares outstanding as of September&nbsp;30, 2018, after giving effect to the pro forma adjustments described above. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>After
giving further effect to our issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the
midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro
forma as adjusted net tangible book value as of September&nbsp;30, 2018 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This amount represents an immediate increase in
pro forma as adjusted net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to our existing stockholders and immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in pro forma as adjusted net tangible book value
per
share to new investors purchasing common stock in this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dilution
per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the initial public offering price per share paid by
new investors.
The following table illustrates this dilution on a per share basis (without giving effect to any exercise by the underwriters of their option to purchase additional shares): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="37pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="37pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Assumed initial public offering price per share</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Historical net tangible book value (deficit) per share as of September&nbsp;30,
2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(36.14</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Increase per share attributable to the pro forma adjustments described above</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Pro forma increase in historical net tangible book value per share as of September&nbsp;30, 2018 attributable to the conversion of convertible preferred
stock</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Increase in pro forma net tangible book value per share attributable to new investors participating in this offering</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Pro forma as adjusted net tangible book value per share after this offering</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Dilution per share to new investors purchasing common stock in this offering</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Each
$1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would
increase (decrease) our </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>70</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=73,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=663333,FOLIO='70',FILE='DISK114:[18ZFG1.18ZFG45201]CO45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:50' -->
<A NAME="page_co45201_1_71"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>


<P style="font-family:arial;"><FONT SIZE=2>pro
forma as adjusted net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and dilution per share to new investors purchasing common stock in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. An increase of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase our pro forma as adjusted net
tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and decrease dilution per share to new investors purchasing common stock in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no
change in
the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. A decrease of 1,000,000 shares
in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease our pro forma as adjusted net tangible book value per share after this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and increase dilution per share to new investors purchasing common stock in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in the assumed initial public offering price and
after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
the underwriters exercise their option to purchase additional shares in full, our pro forma as adjusted net tangible book value per share after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, representing
an immediate increase in pro forma as adjusted net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to existing stockholders and immediate dilution in pro forma as adjusted net tangible book value per
share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to new investors purchasing common stock in this offering, based on the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and after deducting underwriting
discounts and commissions and estimated offering expenses payable by us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table summarizes on the pro forma as adjusted basis described above, the total number of shares of common stock purchased from us on an as converted to common stock basis, the total
consideration paid or to be paid, and the average price per share paid or to be paid by existing stockholders and by new investors in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. As the table shows, new investors purchasing common stock in
this offering will pay an average price per share substantially higher than our existing stockholders paid. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="74pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Shares purchased </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Total consideration </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Average price per share</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Number</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Percentage</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Amount</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Percentage</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Existing stockholders</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New investors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
table above assumes no exercise of the underwriters' option to purchase additional shares in this offering. If the underwriters' option to purchase additional shares is exercised in full, the
number of shares of our common stock held by existing stockholders would be reduced to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock
outstanding after this offering, and the
number of shares of common stock held by new investors purchasing common stock in this offering would be increased to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding
after this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
discussion and tables above are based on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock outstanding as of September&nbsp;30, 2018, after giving effect to the automatic conversion of all
outstanding
shares of our </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>71</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=74,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=445563,FOLIO='71',FILE='DISK114:[18ZFG1.18ZFG45201]CO45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:50' -->
<A NAME="page_co45201_1_72"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>


<P style="font-family:arial;"><FONT SIZE=2>convertible
preferred stock into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock immediately prior to the completion of this offering, and
excludes:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 2,277,264 shares of common stock issuable upon the exercise of stock options outstanding as of September&nbsp;30, 2018 under our 2018 Stock
Option and Grant Plan, or the 2018 Plan, at a weighted-average exercise price of $0.20 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 906,736 shares of common stock reserved for future issuance as of September&nbsp;30, 2018 under the 2018 Plan, which will cease to be
available for issuance at the time that our 2019 Stock Option and Grant Plan, or the 2019 Plan, becomes effective; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock that will become available for future issuance
under the 2019 Plan in connection with the
effectiveness of the registration statement of which this prospectus is a part; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for future issuance under our 2019
Employee Stock Purchase Plan which will become
effective in connection with this offering. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>To
the extent that new stock options are issued or any outstanding options are exercised, or we issue additional shares of common stock in the future, there will be further dilution to new investors.
In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating
plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>72</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=75,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=849280,FOLIO='72',FILE='DISK114:[18ZFG1.18ZFG45201]CO45201A.;29',USER='MTITUSS',CD='17-JAN-2019;14:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cq45201_1_73"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B> <A NAME="cq45201_selected_financial_data"> </A>
<A NAME="toc_cq45201_1"> </A> </B></FONT><FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Selected financial data    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You should read the following selected financial data together with our financial statements and the related notes appearing at the end of
this prospectus and the "Management's discussion and analysis of financial condition and results of operations" section of this prospectus. We have derived the statement of operations data for the
period January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017 and the balance sheet data as of December&nbsp;31, 2017 from our audited financial statements appearing at the end of this
prospectus. The statement of operations data for the period January&nbsp;24, 2017 (inception) through September&nbsp;30, 2017, for nine months ended September&nbsp;30, 2018 and the balance sheet
data as of September&nbsp;30, 2018 have been derived from our unaudited financial statements appearing at the end of this prospectus and have been prepared on the same basis as the audited financial
statements. In the opinion of management, the unaudited data reflects all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the financial information in
those statements. Our historical results are not necessarily indicative of the results that may be expected in the future and our results as of and for the nine months ended September&nbsp;30, 2018
are not necessarily indicative of the results that may be expected as of and for the year ended December&nbsp;31, 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="96pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="93pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands, except share and per share amounts)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception) through<BR>
December&nbsp;31,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception) through<BR>
September&nbsp;30,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Nine months<BR>
ended<BR>
September&nbsp;30,<BR>
2018 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Statement of Operation Data:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:25pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,486</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,123</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9,898</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:25pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,078</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>896</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>912 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:34pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Total operating expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,564</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10,810 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,564</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(10,810</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Other expense:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:25pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of preferred stock tranche obligation</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(8,400</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:25pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Change in fair value of anti-dilution right liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1,032</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:34pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(9,432</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,564</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(20,242</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accruing dividends on convertible preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(213</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(166</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Accretion of convertible preferred stock to redemption value</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(321</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,777</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,185</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(20,563</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Net loss per share attributable to common stockholders&#151;basic and diluted(1)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(76.98</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding&#151;basic and diluted(1)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>267,108 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Pro forma net loss per share attributable to common stockholders&#151;basic and diluted (unaudited)(1)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma weighted average common shares outstanding&#151;basic and diluted (unaudited)(1)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;See
Note&nbsp;10 to our financial statements appearing at the end of this prospectus for details on the calculation of basic and diluted net loss per share attributable to common
stockholders and the calculation of basic and diluted pro forma net loss per share attributable to common stockholders. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>73</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=76,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=720043,FOLIO='73',FILE='DISK114:[18ZFG1.18ZFG45201]CQ45201A.;35',USER='MTITUSS',CD='17-JAN-2019;14:52' -->
<A NAME="page_cq45201_1_74"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>September&nbsp;30,<BR>
2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Balance Sheet Data:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>598</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,832</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Working capital(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>416</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,416</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>658</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8,455</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Preferred stock tranche obligation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anti-dilution right liability</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,671</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>14,108</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' deficit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(4,564</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(25,093</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;We
define working capital as current assets less current liabilities. </FONT></P>
 </DIV>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>74</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=77,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=916628,FOLIO='74',FILE='DISK114:[18ZFG1.18ZFG45201]CQ45201A.;35',USER='MTITUSS',CD='17-JAN-2019;14:52' -->
<A NAME="page_cq45201_1_75"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="cq45201_management_s_discussion_and_an__man03466"> </A>
<A NAME="toc_cq45201_2"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Management's discussion and analysis of financial condition and results of operations    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>You should read the following discussion and analysis of our financial condition and results of operations together
with the "Selected financial data" section of this prospectus and our financial statements and the related notes appearing at the end of this prospectus. This discussion and other parts of this
prospectus contain forward-looking statements that involve risks and uncertainties, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results
could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the
"Risk factors" section of this prospectus.</I></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic
diseases with high unmet medical need. Our initial focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease,
or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. Our lead product candidate,
AKR-001, which we are developing as a potential treatment for patients with NASH, is an analog of fibroblast growth factor 21, or FGF21. FGF21 is an endogenously-expressed hormone that regulates
metabolism of lipids, carbohydrates and proteins throughout the body. FGF21 also plays a critical role in protecting many types of cells from various forms of stress. FGF21 agonists have shown
evidence of therapeutic benefit in clinical trials of patients with NASH, many of whom are dyslipidemic and insulin resistant. In previous clinical trials in patients with type&nbsp;2 diabetes, or
T2D, administration of AKR-001 was associated with a substantial improvement in lipid metabolism and insulin sensitivity. We believe these data demonstrate AKR-001's potential to serve as a
cornerstone for the treatment of NASH. We plan to initiate a Phase&nbsp;2a clinical trial for AKR-001 in NASH patients with fibrosis in the middle of 2019. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
were incorporated in January 2017 and received initial seed funding in the amount of $5.0&nbsp;million from Apple Tree Partners. Since our inception, we have devoted substantially all of our
efforts to organizing and staffing our company, business planning, raising capital, in-licensing rights to AKR-001, research and development activities for AKR-001, building our intellectual property
portfolio and providing general and administrative support for these operations. To date, we have principally raised capital through the issuance of convertible preferred stock. Through
September&nbsp;30, 2018, we had received gross proceeds of $20.0&nbsp;million from sales of our convertible preferred stock. In addition, we received gross proceeds of $25.0&nbsp;million and
$45.5&nbsp;million from the sale of our Series&nbsp;A convertible preferred stock, or Series&nbsp;A preferred stock, and Series&nbsp;B convertible preferred stock, or Series&nbsp;B preferred
stock, respectively, in November 2018 and December 2018, respectively. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have incurred significant operating losses since inception. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and
eventual commercialization of AKR-001 and any future product candidates. Our net losses were $4.6&nbsp;million and $20.2&nbsp;million for the period January&nbsp;24, 2017 (inception) through
December&nbsp;31, 2017 and the nine months ended September&nbsp;30, 2018, respectively. As of September&nbsp;30, 2018, we had an accumulated deficit of $25.1&nbsp;million. We expect to
continue to incur significant expenses for at least the next several years as we advance AKR-001 through later-stage clinical development, develop additional product candidates and seek regulatory
approval of any product candidates that complete clinical development. In addition, if we obtain marketing approval for any product candidates, we expect to incur significant commercialization
expenses </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>75</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=78,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=317249,FOLIO='75',FILE='DISK114:[18ZFG1.18ZFG45201]CQ45201A.;35',USER='MTITUSS',CD='17-JAN-2019;14:52' -->
<A NAME="page_cq45201_1_76"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>related
to product manufacturing, marketing, sales and distribution. We may also incur expenses in connection with the in-licensing or acquisition of additional product candidates. Furthermore, upon
the completion of this offering, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations, compliance and other
expenses that we did not incur as a private company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales,
if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital sources, which may include collaborations with other companies or other strategic
transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such
agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of one or more of our product candidates or delay our pursuit of potential
in-licenses or acquisitions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because
of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or
maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then
we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of September&nbsp;30, 2018, we had cash of $7.8&nbsp;million. We believe that the anticipated net proceeds from this offering, together with our existing cash as of September&nbsp;30, 2018,
will enable us to fund our operating expenses and capital expenditure requirements
through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be wrong, and we
could exhaust
our available capital resources sooner than we expect. See "Liquidity and capital resources." </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Components of our results of operations  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revenue  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products in the near future, if at all. If
our development efforts for AKR-001 or additional product candidates that we may develop in the future are successful and result in marketing approval or if we enter into collaboration or license
agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from such collaboration or license agreements. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Operating expenses  </I></B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and development expenses  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Research and development expenses consist primarily of costs incurred in connection with the development of AKR-001, as well as unrelated discovery program
expenses. We expense research and development costs as incurred. These expenses include:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> employee-related expenses, including salaries, related benefits and stock-based compensation expense, for employees engaged in research and
development functions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> expenses incurred under agreements with contract research organizations, or CROs, that are primarily engaged in the oversight and conduct of
our clinical trials; contract manufacturing organizations, or CMOs, that are primarily engaged to provide drug substance and product for our clinical trials, research </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>76</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=79,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=16215,FOLIO='76',FILE='DISK114:[18ZFG1.18ZFG45201]CQ45201A.;35',USER='MTITUSS',CD='17-JAN-2019;14:52' -->
<A NAME="page_cq45201_1_77"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <UL>

<P style="font-family:arial;"><FONT SIZE=2>and
development programs, as well as investigative sites and consultants that conduct our clinical trials, nonclinical studies and other scientific development services; </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of acquiring and manufacturing nonclinical and clinical trial materials, including manufacturing registration and validation batches; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> costs related to compliance with quality and regulatory requirements; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> payments made under third-party licensing agreements. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Advance
payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an
expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Product
candidates in later stages of clinical development, such as AKR-001, generally have higher development costs than those in earlier stages of clinical development, primarily due to the
increased size and duration of later-stage clinical trials. We expect that our research and development expenses will increase substantially in connection with our planned clinical development
activities in the near term and in the future. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the clinical
development of AKR-001 and any future product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
clinical development costs may vary significantly based on factors such as:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> per patient trial costs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number of trials required for approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number of sites included in the trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the countries in which the trials are conducted; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the length of time required to enroll eligible patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number of patients that participate in the trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number of doses that patients receive; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the drop-out or discontinuation rates of patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> potential additional safety monitoring requested by regulatory agencies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the duration of patient participation in the trials and follow-up; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost and timing of manufacturing our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the phase of development of our product candidates; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the efficacy and safety profile of our product candidates. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>77</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=80,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=688813,FOLIO='77',FILE='DISK114:[18ZFG1.18ZFG45201]CQ45201A.;35',USER='MTITUSS',CD='17-JAN-2019;14:52' -->
<A NAME="page_cq45201_1_78"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>The
successful development and commercialization of product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with product development and
commercialization, including the following:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing and progress of nonclinical and clinical development activities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number and scope of nonclinical and clinical programs we decide to pursue; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> raising necessary additional funds; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the progress of the development efforts of parties with whom we may enter into collaboration arrangements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to maintain our current development program and to establish new ones; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to establish new licensing or collaboration arrangements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the successful initiation and completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the U.S.
Food and Drug Administration, or FDA, or any comparable foreign regulatory authority; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the receipt and related terms of regulatory approvals from applicable regulatory authorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the availability of drug substance and drug product for use in production of our product candidate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establishing and maintaining agreements with third-party manufacturers for clinical supply for our clinical trials and commercial
manufacturing, if our product candidate is approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to obtain and maintain patents, trade secret protection and regulatory exclusivity, both in the United States and internationally; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to protect our rights in our intellectual property portfolio; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the commercialization of our product candidate, if and when approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtaining and maintaining third-party insurance coverage and adequate reimbursement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the acceptance of our product candidate, if approved, by patients, the medical community and third-party payors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> competition with other product; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a continued acceptable safety profile of our therapies following approval. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>A
change in the outcome of any of these variables with respect to the development of our product candidates could significantly change the costs and timing associated with the development of that
product candidate. We may never succeed in obtaining regulatory approval for any of our product candidates. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General and administrative expenses  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, corporate and business development,
and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax and administrative
consulting services; insurance costs; administrative travel expenses; marketing expenses and other operating costs. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>78</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=81,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=197401,FOLIO='78',FILE='DISK114:[18ZFG1.18ZFG45201]CQ45201A.;35',USER='MTITUSS',CD='17-JAN-2019;14:52' -->
<A NAME="page_cq45201_1_79"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>We
anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support development of AKR-001 and our continued research activities. We also
anticipate that we will incur increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with
being a public company. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other expense  </I></B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Change in fair value of preferred stock tranche obligation  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In connection with our June 2018 issuance and sale of Series&nbsp;A preferred stock, we provided for a first tranche closing, a second tranche closing, and
a call option to purchase additional shares of Series&nbsp;A preferred stock. We classified the preferred stock tranche obligation for the future purchase and option to purchase Series&nbsp;A
preferred stock as a liability on our balance sheets as the preferred stock tranche obligation is a freestanding financial instrument that will require us to transfer equity instruments upon future
closings of the Series&nbsp;A preferred stock. The preferred stock tranche obligation liability was initially recorded at fair value upon the date of issuance and is subsequently remeasured to fair
value at each reporting date. Changes in the fair value of the preferred stock tranche obligation are recognized as a component of other expense in the statements of operations and comprehensive loss.
Changes in the fair value of the preferred stock tranche obligation were recognized until the tranche obligations were fulfilled or otherwise extinguished in the fourth quarter of 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2018, in connection with our issuance and sale of Series&nbsp;A preferred stock, we satisfied our obligation to issue additional shares under the second tranche closing. In December
2018, in connection with our issuance and sale of Series&nbsp;B preferred stock, we terminated the option to purchase Series&nbsp;A preferred stock provided under the Series&nbsp;A Preferred
Stock Purchase Agreement, or 2018 Series&nbsp;A Agreement. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Change in fair value of anti-dilution right  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>We classified the anti-dilution right under our license agreement with Amgen&nbsp;Inc., or the Amgen Agreement, as a derivative liability on our balance
sheets as the anti-dilution right represents a freestanding financial instrument that may require us to transfer equity instruments upon future equity closings. The anti-dilution right liability was
initially recorded at fair value upon the date of issuance and is subsequently remeasured to fair value at each reporting date. The issuance date fair value of the derivative liability was recognized
as a research and development expense upon entering into the agreement with Amgen. Changes in the fair value of the anti-dilution right liability are recognized as a component of other expense in the
statements of operations and comprehensive loss. Changes in the fair value of the anti-dilution right liability were recognized until the anti-dilution rights obligation was satisfied in the fourth
quarter of 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2018, in connection with our issuance and sale of Series&nbsp;A preferred stock, we satisfied our anti-dilution rights obligation under the Amgen Agreement. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>79</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=82,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=508143,FOLIO='79',FILE='DISK114:[18ZFG1.18ZFG45201]CQ45201A.;35',USER='MTITUSS',CD='17-JAN-2019;14:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cs45201_1_80"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income taxes  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since our inception, we have not recorded any income tax benefits for the net losses we have incurred in each period or for our earned research and
development tax credits, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss carryforwards and tax credits will not be
realized. As of December&nbsp;31, 2017, we had U.S. federal and state net operating loss carryforwards of $4.6&nbsp;million and $4.5&nbsp;million, respectively, which may be available to offset
future income tax liabilities and expire at various dates beginning in 2027. As of December&nbsp;31, 2017, we also had U.S. federal and state research and development tax credit carryforwards of
$87,000 and $40,000, respectively, which may be available to offset future tax liabilities which expire at various dates beginning in 2027. We have recorded a full valuation allowance against our net
deferred tax assets at each balance sheet date. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On
December&nbsp;22, 2017, the Tax Cuts and Jobs Act, or the TCJA, was signed into United States law. The TCJA includes a number of changes to existing tax law, including, among other things, a
permanent reduction in the federal corporate income tax rate from a top marginal tax rate of 35% to a flat rate of 21%, effective as of January&nbsp;1, 2018, as well as limitation of the deduction
for net operating losses to 80% of annual taxable income and elimination of net operating loss carrybacks, in each case, for losses arising in taxable years beginning after December&nbsp;31, 2017
(though any such net operating losses may be carried forward indefinitely). The federal tax rate change resulted in a reduction in the gross amount of our deferred tax assets recorded as of
December&nbsp;31, 2017, and a corresponding reduction in our valuation allowance. As a result, no income tax expense or benefit was recognized as of the enactment date of the TCJA. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Results of operations  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Comparison of the period January&nbsp;24, 2017 (Inception) through September&nbsp;30, 2017 and the nine
months ended September&nbsp;30, 2018  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table summarizes our results of operations for the period January&nbsp;24, 2017 (inception) through September&nbsp;30, 2017 and the nine
months ended September&nbsp;30, 2018: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="102pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception) through<BR>
September&nbsp;30,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Nine months<BR>
ended<BR>
September&nbsp;30,<BR>
2018 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,123</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9,898</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>896</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>912 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10,810 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(10,810</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other expense:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Change in fair value of preferred stock tranche obligation</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(8,400</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of anti-dilution right liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1,032</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Total other expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(9,432</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(20,242</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>80</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=83,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=996599,FOLIO='80',FILE='DISK114:[18ZFG1.18ZFG45201]CS45201A.;33',USER='SCAVALI',CD='17-JAN-2019;12:58' -->
<A NAME="page_cs45201_1_81"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and development expenses  </I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 </UL>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="102pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception) through<BR>
September&nbsp;30,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Nine months<BR>
ended<BR>
September&nbsp;30,<BR>
2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Change </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Direct program expenses: AKR-001</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>170</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9,384</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9,214</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Personnel related</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>718</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>514</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(204</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Discovery programs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,235</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(2,235</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total research and development expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,123</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9,898</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,775 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Research
and development expenses were $3.1&nbsp;million for the period ended September&nbsp;30, 2017, compared to $9.9&nbsp;million for the nine months ended September&nbsp;30, 2018. The
increase of $6.8&nbsp;million was primarily due to a $9.2&nbsp;million increase in direct costs related to our AKR-001 program, partially offset by a $0.2&nbsp;million decrease in personnel
related costs and a $2.2&nbsp;million decrease in costs related to our discovery programs. The increase in direct costs related to our AKR-001 program was primarily due to $8.1&nbsp;million in
expenses in connection with the Amgen Agreement. Pursuant to the agreement, we paid Amgen&nbsp;Inc., or Amgen, an upfront cash payment of $5.0&nbsp;million and issued shares of Series&nbsp;A
preferred stock to Amgen with a fair value of $1.3&nbsp;million. Additionally, we recorded an expense of $1.6&nbsp;million associated with our obligation to issue equity securities to Amgen in
accordance with anti-dilution rights provided in the Amgen license agreement. The remaining increase in direct costs related to AKR-001 program was primarily due to costs incurred with external CROs
as well as toxicology, regulatory, and chemistry, manufacturing and controls, or CMC. The decrease in personnel related costs of $0.2&nbsp;million was primarily due to recruiting costs for research
and development personnel incurred in the period ended September&nbsp;30, 2017 that were not repeated in the nine months ended September&nbsp;30, 2018. The decrease in discovery programs of
$2.2&nbsp;million was primarily due to consulting fees associated with our prior discovery programs that were incurred in the period ended September&nbsp;30, 2017 that were not repeated in the
nine months ended September&nbsp;30, 2018. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General and administrative expenses  </I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 </UL>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="102pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="40pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception) through<BR>
September&nbsp;30,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Nine months<BR>
ended<BR>
September&nbsp;30,<BR>
2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Change </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Personnel related</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>328</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>540</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>212</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal and professional fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>263</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>302</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Consulting fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>267</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(267</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>32 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Total general and administrative expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>896</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>912</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>16 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>General
and administrative expenses were $0.9&nbsp;million for the period ended September&nbsp;30, 2017 and for the nine months ended September&nbsp;30, 2018. The increase in personnel related
costs of $0.2&nbsp;million was primarily due to hiring of additional personnel in our general and administrative functions. The increases in legal and professional fees and other expenses of
$0.1&nbsp;million were primarily due to increased legal costs associated with our financing activities in the period ended September&nbsp;30, 2018. These increases were partially offset by a
decrease in consulting fees of $0.3&nbsp;million as a result of costs incurred in the period </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>81</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=84,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=142578,FOLIO='81',FILE='DISK114:[18ZFG1.18ZFG45201]CS45201A.;33',USER='SCAVALI',CD='17-JAN-2019;12:58' -->
<A NAME="page_cs45201_1_82"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>ending
September&nbsp;30, 2017 associated with Apple Tree Partners for general and administrative activities during the Company's formation that were not repeated in the nine months ended
September&nbsp;30, 2018. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other expense  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Other expense was $9.4&nbsp;million during the nine months ended September&nbsp;30, 2018. We did not record other expense for the period ended
September&nbsp;30, 2017. The increase is primarily due to $8.4&nbsp;million and $1.0&nbsp;million in losses related to the changes in fair value of the preferred stock tranche obligation and the
fair value of the anti-dilution right liability, respectively. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Liquidity and capital resources  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since our inception, we have incurred significant operating losses. We have not yet commercialized any products and we do not expect to
generate revenue from sales of products for several years, if at all. To date, we have funded our operations primarily with proceeds from the sale of our convertible preferred stock. Through
September&nbsp;30, 2018, we had received gross proceeds of $20.0&nbsp;million from sales of our convertible preferred stock. As of September&nbsp;30, 2018, we had cash of $7.8&nbsp;million. In
addition, in November 2018 and December 2018, we received $25.0&nbsp;million and $45.5&nbsp;million of gross cash proceeds from sales of our Series&nbsp;A and Series&nbsp;B preferred stock,
respectively. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash flows  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table summarizes our sources and uses of cash for each of the periods presented: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="102pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="102pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24,<BR>
2017<BR>
(inception) through<BR>
December&nbsp;31,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24,<BR>
2017<BR>
(inception) through<BR>
September&nbsp;30,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Nine months<BR>
ended<BR>
September&nbsp;30,<BR>
2018 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Net cash used in operating activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,382</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3,726</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,550</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in investing activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(5,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Net cash provided by financing activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,784 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net increase in cash and restricted cash</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>618</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>274</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,234 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Operating activities  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>During the nine months ended September&nbsp;30, 2018, operating activities used $2.6&nbsp;million of cash, resulting from our net loss of
$20.2&nbsp;million, partially offset by non-cash charges of $17.5&nbsp;million related to our issuance of preferred stock to Amgen and changes in the fair value of preferred stock tranche
obligation and net cash provided by changes in operating assets and liabilities of $0.2&nbsp;million. Net cash provided by changes in our operating assets and liabilities primarily consisted of a
$0.5&nbsp;million increase in accounts payable due to outstanding invoices to CROs and other vendors in connection with our increased level of operating activities in 2018 and a $0.3&nbsp;million
increase in accrued expenses, which was primarily due to increased costs associated with our AKR-001 program. Increases were partially offset by an increase in prepaid expenses and other assets of
$0.6&nbsp;million primarily attributed to CRO deposits related to our clinical trials for AKR-001. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During
the period January&nbsp;24, 2017 (inception) through September&nbsp;30, 2017, operating activities used $3.7&nbsp;million of cash, resulting from our net loss of $4.0&nbsp;million,
partially offset by changes in operating assets and liabilities of $0.3&nbsp;million. Net cash provided by changes in our operating assets and liabilities </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>82</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=85,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=1017942,FOLIO='82',FILE='DISK114:[18ZFG1.18ZFG45201]CS45201A.;33',USER='SCAVALI',CD='17-JAN-2019;12:58' -->
<A NAME="page_cs45201_1_83"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>primarily
consisted of a $0.2&nbsp;million increase in accounts payable and a $0.1&nbsp;million increase in accrued expenses due to outstanding invoices to consultants assisting in our initial
research and development activities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During
the period January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017, operating activities used $4.4&nbsp;million of cash, resulting from our net loss of $4.6&nbsp;million,
partially offset by changes in operating assets and liabilities of $0.2&nbsp;million. Net cash provided by changes in our operating assets and liabilities primarily consisted of a
$0.2&nbsp;million increase in accrued expenses due to accrued compensation and accounting and tax fees. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Investing activities  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>During the nine months ended September&nbsp;30, 2018, net cash used in investing activities was $5.0&nbsp;million, consisting of licensing fees related to
the acquisition of technology under the Amgen Agreement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
did not have any investing activities during the period from January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017 and September&nbsp;30, 2017. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Financing activities  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>During the nine months ended September&nbsp;30, 2018, net cash provided by financing activities was $14.8&nbsp;million, consisting of proceeds from our
issuance of Series&nbsp;A preferred stock in June 2018, net of issuance costs of $0.2&nbsp;million. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During
the period ended September&nbsp;30, 2017, cash provided by financing activities was $4.0&nbsp;million, consisting of proceeds from our issuance of Series&nbsp;A preferred stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During
the period January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017, cash provided by financing activities was $5.0&nbsp;million, consisting of proceeds from our issuance of
Series&nbsp;A preferred stock. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Funding requirements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the later-stage clinical development of
our product candidate. In addition, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. The timing and amount of our operating
expenditures will depend largely on:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the initiation, progress, timing, costs and results of nonclinical studies and clinical trials for our product candidate or any future product
candidates we may develop; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to maintain our license to AKR-001 from Amgen; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and comparable foreign regulatory authorities,
including the potential for such authorities to require that we perform more nonclinical studies or clinical trials than those that we currently expect or change their requirements on studies that had
previously been agreed to; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including the amount and timing
of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing any patents or other intellectual property
rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the effect of competing technological and market developments; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>83</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=86,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=324477,FOLIO='83',FILE='DISK114:[18ZFG1.18ZFG45201]CS45201A.;33',USER='SCAVALI',CD='17-JAN-2019;12:58' -->
<A NAME="page_cs45201_1_84"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> market acceptance of any approved product candidates, including product pricing, as well as product coverage and the adequacy of reimbursement
by third-party payors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of acquiring, licensing or investing in additional businesses, products, product candidates and technologies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost and timing of selecting, auditing and potentially validating a manufacturing site for commercial-scale manufacturing; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval
and that we determine to commercialize; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our need to implement additional internal systems and infrastructure, including financial and reporting systems. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that the anticipated net proceeds from this offering, together with our existing cash as of September&nbsp;30, 2018, will enable us to fund our operating expenses and capital expenditure
requirements through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital
resources sooner than we expect. We expect that
we will require additional funding to complete the clinical development of AKR-001, commercialize AKR-001, if we receive regulatory approval, and pursue in-licenses or acquisitions of other product
candidates. If we receive regulatory approval for AKR-001 or other product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and
distribution, depending on where we choose to commercialize AKR-001 ourselves. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Until
such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic
alliances, and marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership
interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and
preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital
expenditures or declaring dividends. If we raise funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish
valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are
unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, reduce or eliminate our product development or future
commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>84</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=87,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=358593,FOLIO='84',FILE='DISK114:[18ZFG1.18ZFG45201]CS45201A.;33',USER='SCAVALI',CD='17-JAN-2019;12:58' -->
<A NAME="page_cs45201_1_85"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Contractual obligations and commitments  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We had no contractual obligations as of December&nbsp;31, 2017. The following table summarizes our contractual obligations as of
September&nbsp;30, 2018 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="30pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Payments due by period </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Total</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Less than 1<BR>
year</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>1 to 3<BR>
years</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>4 to 5<BR>
years</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>More than 5<BR>
years</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Manufacturing commitments(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>473</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>473</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating lease commitments(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>481</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>481</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;Amounts
in the table reflect the non-cancelable purchase commitments under agreements with our external CROs, which we have engaged to manufacture clinical development materials and
to conduct clinical development activities and clinical trials. </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Amounts
in the table reflect minimum payments due under our lease for office space at a monthly commitment fee of $1,000. This lease is an operating lease and expires in a 9-month
period after which the agreement becomes cancelable by either party upon a 60-day written notice. In October&nbsp;2018 we entered into a lease agreement for office space in San Francisco,
California. The lease is an operating lease and expires in April&nbsp;2019 with the option to renew on a month to month basis thereafter. Minimum payments due for the initial six month term total
$30,000 and are excluded from the table above. </FONT></P>
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Apart
from the contracts with payment commitments that we have reflected in the table, we have entered into other contracts in the normal course of business with certain CROs, CMOs, and other third
parties for nonclinical research studies and testing, clinical trials and manufacturing services. These contracts do not contain any minimum purchase commitments and are cancelable by us upon prior
notice and, as a result, are not included in the table of contractual obligations and commitments above. Payments due upon cancellation consist only of payments for services provided and expenses
incurred, including non-cancelable obligations of our service providers, up to the date of cancellation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, under the Amgen Agreement, we are required to make milestone payments and pay royalties based upon specified milestones. We have not included any such contingent payment obligations in
the table above as the amount, timing and likelihood of such payments are not known. Such contingent payment obligations are described below. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
the Amgen Agreement, we are obligated to make aggregate milestone payments of up to $40.0&nbsp;million upon the achievement of specified clinical and regulatory milestones and aggregate
milestone payments of up to $75.0&nbsp;million upon the achievement of specified commercial milestones for all products licensed under the agreement. Commencing on the first commercial sale of
licensed products, we are obligated to pay tiered royalties on escalating tiers of annual net sales of licensed products ranging from low to high single-digit percentages. See
"Business&#151;Exclusive license agreement with Amgen&nbsp;Inc." </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Critical accounting policies and significant judgments and estimates  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our financial statements are prepared in accordance with generally accepted accounting principles, or GAAP, in the United States. The
preparation of our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the
disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are
reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We
evaluate our </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>85</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=88,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=65953,FOLIO='85',FILE='DISK114:[18ZFG1.18ZFG45201]CS45201A.;33',USER='SCAVALI',CD='17-JAN-2019;12:58' -->
<A NAME="page_cs45201_1_86"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>estimates
and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>While
our significant accounting policies are described in more detail in Note&nbsp;2 to our financial statements appearing at the end of this prospectus, we believe that the following accounting
policies are those most critical to the judgments and estimates used in the preparation of our financial statements. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Accrued research and development expenses  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves
reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and
the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services
performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the
financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the
service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include fees paid to:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> vendors in connection with nonclinical development activities; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> CROs and investigative sites in connection with nonclinical studies
and clinical trials; and </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> CMOs in connection with the production of nonclinical and clinical trial materials. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
base the expense recorded related to external research and development on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CMOs and CROs
that supply, conduct and manage nonclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result
in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we
estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies
from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our
understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in
any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-based compensation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We measure stock-based awards granted to employees, directors, and nonemployees based on their fair value on the date of the grant and recognize compensation
expense for those awards over the requisite service period, which is generally the vesting period of the respective award. For
stock-based awards with service-based vesting conditions, we recognize compensation expense using the straight-line method. For stock-based awards with service-based vesting conditions, we recognize
compensation expense using the graded-vesting method over the requisite service period, commencing when achievement of the performance condition becomes probable. The fair value of each stock option
grant is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the
expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and our expected </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>86</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=89,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=675138,FOLIO='86',FILE='DISK114:[18ZFG1.18ZFG45201]CS45201A.;33',USER='SCAVALI',CD='17-JAN-2019;12:58' -->
<A NAME="page_cs45201_1_87"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>dividend
yield. The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of our common stock on that same date. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Determination of the fair value of common stock  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>As there has been no public market for our common stock to date, the estimated fair value of our common stock has been determined by our board of directors as
of the date of each option grant with input from management, considering our most recently available third-party valuations of
common stock, and our board of directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation
through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants' Accounting and Valuation
Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Our common stock valuation was prepared using the option-pricing method, or OPM, which used a market approach to
estimate our enterprise value. The third-party valuation resulted in a valuation of our common stock of $0.15 per share as of June&nbsp;7, 2018 and $0.38 as of September&nbsp;8, 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
assumptions underlying these valuations were highly complex and subjective and represented management's best estimates, which involved inherent uncertainties and the application of management's
judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could be materially different. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Once
a public trading market for our common stock has been established in connection with the completion of this offering, it will no longer be necessary for our board of directors to estimate the
fair value of our common stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our common stock will be determined based on the
quoted market price of our common stock. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Options granted  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth by grant date the number of shares subject to options granted between January&nbsp;24, 2017 and December&nbsp;31, 2018, the
per share exercise price of the options, the fair value of common stock per share on each grant date, and the per share estimated fair value of the options: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="77pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="88pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="94pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="87pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Grant date</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Number of<BR>
shares subject<BR>
options<BR>
granted</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Per share<BR>
exercise price of<BR>
options</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Fair value per<BR>
common share on<BR>
grant date(1)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Per share<BR>
estimated fair<BR>
value of options </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 July&nbsp;30, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>875,598</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.09</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>September&nbsp;8, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,341,666</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 September&nbsp;8, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>60,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>September&nbsp;27, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>331,666</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 October&nbsp;18, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,282,543</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>October&nbsp;18, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>897,436</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.28 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;For
options granted on July&nbsp;30, 2018 through October&nbsp;18, 2018, our board of directors initially determined that the fair value of our common stock was $0.20 per share as
of each respective grant date. However, as described below, the fair value of our common stock at the date of these grants was adjusted in connection with retrospective fair value assessments for
accounting purposes. </FONT></P>
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>In
the course of preparing for this offering, in June 2018 and September 2018, we performed retrospective fair value assessments for accounting purposes. We applied the fair values of our common stock
from our retrospective fair value assessments to determine the fair value of these awards and calculate stock-based compensation expense for accounting purposes. These reassessed values were based, in
part, upon third- </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>87</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=90,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=1034351,FOLIO='87',FILE='DISK114:[18ZFG1.18ZFG45201]CS45201A.;33',USER='SCAVALI',CD='17-JAN-2019;12:58' -->
<A NAME="page_cs45201_1_88"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>party
valuations of our common stock prepared as of each grant date on a retrospective basis. The third-party valuations were prepared using the hybrid method and used market approaches to determine
our enterprise value. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Valuation of preferred stock tranche obligation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In connection with our issuance of Series&nbsp;A preferred stock in June 2018, we recognized a preferred stock tranche obligation. We classify the preferred
stock tranche obligation for the future purchase, and option to purchase, Series&nbsp;A preferred stock as a liability on our balance sheets as the preferred stock tranche obligation is a
freestanding financial instrument that will require us to transfer equity instruments upon future closings of the Series&nbsp;A preferred stock. The preferred stock tranche obligation was initially
recorded at fair value upon the date of issuance and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of the preferred stock tranche obligation are recognized
as a component of other expense in the statements of operations and comprehensive loss. Changes in the fair value of the preferred stock tranche obligation were recognized until the tranche
obligations were fulfilled or otherwise extinguished in the fourth quarter of 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
fair value of the liability was estimated based on results of a third-party valuation performed in connection with the issuance of Series&nbsp;A preferred stock in June 2018. We determined that
this valuation represented the fair value of the liability at the reporting date. The liability includes (i)&nbsp;an obligation to issue shares in a second tranche of Series&nbsp;A preferred stock
and (ii)&nbsp;an obligation to issue shares under the call option to purchase Series&nbsp;A preferred stock following the second tranche. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
fair value of the obligation to purchase a second tranche of Series&nbsp;A preferred stock was estimated by utilizing the future value of the underlying Series&nbsp;A preferred stock, the
Series&nbsp;A original issue price and the number of shares subject to future purchase. The future value of the Series&nbsp;A preferred stock was determined through a backsolve calculation. The
present value of the forward contract was then multiplied by a probability of occurrence for the second tranche closing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
fair value of the obligation for the call option to purchase Series&nbsp;A preferred stock was estimated using the hybrid method which employed the Black-Scholes option-pricing model adjusted to
reflect the timing and probability of closing a second tranche of Series&nbsp;A preferred stock. The hybrid method incorporates assumptions and estimates to value the obligation. Estimates and
assumptions impacting the fair value measurement include the fair value per share of the underlying shares of our Series&nbsp;A preferred stock, risk-free interest rate, expected dividend yield,
expected volatility of the price of the underlying preferred stock, the remaining years to liquidity, the discount rate and probability (expressed as a percentage) of closing a second Tranche. The
most significant assumption in the hybrid model impacting the fair value of the call option is the fair value of our preferred stock as of each remeasurement date. We determine the fair value per
share of the underlying preferred stock by taking into consideration our most recent sales of our preferred stock, results obtained from third-party valuations and additional factors that are deemed
relevant. We have historically been a private company and lack company-specific historical and implied volatility information of our stock. Therefore, we estimate expected stock volatility based on
the historical volatility of publicly traded peer companies for a term equal to the remaining contractual term of the call option. The risk-free interest rate is determined by reference to the U.S.
Treasury yield curve for time periods approximately equal to the remaining years to liquidity. We have estimated a 0% dividend yield based on the expected dividend yield and the fact that we have
never paid or declared dividends. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2018, in connection with our issuance and sale of Series&nbsp;A preferred stock, we satisfied our obligation to issue additional shares under the second tranche closing. In December
2018, in connection </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>88</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=91,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=789003,FOLIO='88',FILE='DISK114:[18ZFG1.18ZFG45201]CS45201A.;33',USER='SCAVALI',CD='17-JAN-2019;12:58' -->
<A NAME="page_cs45201_1_89"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>with
our issuance and sale of Series&nbsp;B preferred stock, we terminated the option to purchase Series&nbsp;A preferred stock provided under the 2018 Series&nbsp;A Agreement. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Valuation of anti-dilution right  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We assessed the anti-dilution rights provided to Amgen pursuant to the Amgen Agreement and determined that the rights (i)&nbsp;met the definition of a
freestanding financial instrument that was not indexed to our own stock and (ii)&nbsp;did not meet the definition of a derivative. As the rights did not meet the definition of a derivative and did
not qualify for equity classification, we determined to classify the anti-dilution rights as a liability on our balance sheet. The anti-dilution right liability was initially recorded at fair value
upon the license agreement and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of the anti-dilution right liability are recognized as a component of other
expense in the statements of operations and comprehensive loss. Changes in the fair value of the anti-dilution right liability were recognized until the anti-dilution obligation was satisfied in the
fourth quarter of 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
fair value of the anti-dilution right was estimated using a probability weighted scenario which considers as inputs the probability of occurrence of events that would trigger the issuance of
shares, including a (i)&nbsp;second tranche closing of Series&nbsp;A preferred stock, (ii)&nbsp;initial public offering, and (ii)&nbsp;no future sale of equity securities. The weighted average
fair values of each scenario were calculated utilizing the fair value per share of the underlying Series&nbsp;A preferred stock and common stock. Changes in our estimated fair value and the
probability of achieving different financing scenarios can have a significant impact on the fair value of the anti-dilution right liability. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2018, in connection with our issuance and sale of Series&nbsp;A preferred stock, we satisfied our anti-dilution rights obligation under the Amgen Agreement. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Emerging growth company status  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under Section&nbsp;107(b) of the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, an "emerging growth company" can delay the
adoption of new or revised accounting standards until such time as those standards would apply to private companies. We have elected this exemption to delay adopting new or revised accounting
standards until such time as those standards apply to private companies. Where allowable we have early adopted certain standards as described in Note&nbsp;2 of our financial statements. There are
other exemptions and reduced reporting requirements provided by the JOBS Act that we are currently evaluating. For example, as an "emerging growth company," we are exempt from Sections&nbsp;14A(a)
and (b)&nbsp;of the Exchange Act which would otherwise require us to (1)&nbsp;submit certain executive compensation matters to shareholder advisory votes, such as "say-on-pay," "say-on-frequency,"
and "golden parachutes;" and (2)&nbsp;disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of our chief
executive officer's compensation to our median employee compensation. We also intend to rely on an exemption from the rule requiring us to provide an auditor's attestation report on our internal
controls over financial reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act. We will continue to remain an "emerging growth company" until the earliest of the following:
(1)&nbsp;the last day of the fiscal year following the fifth anniversary of the date of the completion of this offering; (2)&nbsp;the last day of the fiscal year in which our total annual gross
revenue is equal to or more than $1.07&nbsp;billion; (3)&nbsp;the date on which we have issued more than $1&nbsp;billion in nonconvertible debt during the previous three years; or (4)&nbsp;the
date on which we are deemed to be a large accelerated filer under the rules of the SEC. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>89</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=92,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=321279,FOLIO='89',FILE='DISK114:[18ZFG1.18ZFG45201]CS45201A.;33',USER='SCAVALI',CD='17-JAN-2019;12:58' -->
<A NAME="page_cs45201_1_90"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Off-balance sheet arrangements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and
regulations of the Securities and Exchange Commission. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Recently issued accounting pronouncements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is
disclosed in Note&nbsp;2 to our financial statements appearing at the end of this prospectus. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Quantitative and qualitative disclosures about market risks  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our primary exposure to market risk relates to changes in interest rates. As of December&nbsp;31, 2017 and September&nbsp;30, 2018, we had
cash of $0.6&nbsp;million and $7.8&nbsp;million, respectively. As of December&nbsp;31, 2017 and September&nbsp;30, 2018, we had no debt outstanding and are therefore not exposed to interest
rate risk with respect to debt. Our exposure to interest rate sensitivity is affected by changes in the general level of U.S. interest rates. If market interest rates were to increase immediately and
uniformly by 100 basis points, or one percentage point, from levels at December&nbsp;31, 2017 and September&nbsp;30, 2018, the net fair value of our interest sensitive marketable securities would
not experience a material change in fair market value. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>All
of our employees and our operations are currently located in the United States. We have, from time to time, engaged in contracts with contractors or other vendors in a currency other than the U.S.
dollar. To date, we have had minimal exposure to fluctuations in foreign currency exchange rates as the time period between the date that transactions are initiated, and the date of payment or receipt
of payment is generally of short duration. Accordingly, we believe we do not have a material exposure to foreign currency risk. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Inflation
generally affects us by increasing our cost of labor. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the period
January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017 or the nine months ended September&nbsp;30, 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>90</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=93,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=871778,FOLIO='90',FILE='DISK114:[18ZFG1.18ZFG45201]CS45201A.;33',USER='SCAVALI',CD='17-JAN-2019;12:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cu45201_1_91"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B> <A NAME="cu45201_business"> </A>
<A NAME="toc_cu45201_1"> </A> </B></FONT><FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Business    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic
diseases with high unmet medical need. Our initial focus is on nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver
disease, or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. Our lead product candidate, AKR-001, which we are developing
as a potential treatment for patients with NASH, is an analog of fibroblast growth factor 21, or FGF21. FGF21 is an endogenously-expressed hormone that regulates metabolism of lipids, carbohydrates
and proteins throughout the body. FGF21 also plays a critical role in protecting many types of cells from various forms of stress. FGF21 agonists have shown evidence of therapeutic benefit in clinical
trials of patients with NASH, many of whom are dyslipidemic and insulin resistant. In previous clinical trials in patients with type&nbsp;2 diabetes, or T2D, administration of AKR-001 was associated
with a substantial improvement in lipid metabolism and insulin sensitivity. We believe these data demonstrate AKR-001's potential to serve as a cornerstone for the treatment of NASH. We plan to
initiate a Phase&nbsp;2a clinical trial for AKR-001 in NASH patients with fibrosis in the middle of 2019. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
rapidly-rising prevalence of NAFLD and NASH is driven by the global obesity epidemic. Poor diet and lack of exercise lead to caloric overburdening of the liver and accumulation of excessive liver
fat. In patients with NASH, excessive liver fat leads to hepatocyte stress, which triggers localized inflammation and, as disease progresses, can lead to fibrosis and ultimately cirrhosis. The
prevalence of NASH in the United States is projected to increase from an estimated 17.3&nbsp;million in 2016 to 27.0&nbsp;million by 2030. In particular, the prevalence of patients with advanced
fibrosis in the United States is projected to more than double between 2016 and 2030. NASH is the liver manifestation of metabolic syndrome and is frequently associated with insulin resistance and
T2D. Additionally, patients with NASH have high rates of cardiovascular-related events, such as stroke and heart attack, with cardiovascular disease being the leading cause of death in patients with
NASH. There are currently no approved therapies for NASH, while emerging potential NASH therapies in late-stage clinical development have shown limited efficacy or may be limited by unwanted side
effects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>AKR-001
is an FGF21 agonist with unique properties that we believe has the potential to address the core processes underlying NASH pathogenesis thereby enabling it to restore healthy fat metabolism in
the liver, reduce hepatocyte stress, mitigate inflammation and resolve fibrosis. FGF21 is an endocrine hormone that acts on the liver, pancreas, muscle and adipose tissue to regulate the metabolism of
lipids, carbohydrates and proteins. Acting as a paracrine hormone, FGF21 also plays a critical role in protecting cells against stress. These attributes make FGF21 agonism a compelling therapeutic
mechanism, but native FGF21 is limited by its short half-life in the bloodstream. AKR-001 has been engineered to increase human FGF21's half-life sufficiently to enable once-weekly dosing, while
retaining the native biological activity of FGF21. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>AKR-001
has been administered to a total of 83 patients with T2D in two Phase&nbsp;1 clinical trials. In a Phase&nbsp;1b clinical trial, it was observed that AKR-001 substantially improved plasma
lipoprotein levels, including reductions of up to 69% in triglycerides and 30% in non-high density lipoprotein cholesterol, or non-HDL-C. In these clinical trials, it was also observed that
administration of AKR-001 was associated with substantially improved markers of insulin sensitivity, including reductions of up to 37% in C-peptide and 55% in the homeostatic model assessment of
insulin resistance, or HOMA-IR. We believe these results indicate the potential of AKR-001 to redirect calories away from the liver, reduce liver fat, alleviate </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>91</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=94,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=1021898,FOLIO='91',FILE='DISK114:[18ZFG1.18ZFG45201]CU45201A.;43',USER='SCAVALI',CD='17-JAN-2019;14:44' -->
<A NAME="page_cu45201_1_92"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>hepatocyte
stress, inhibit inflammation and resolve fibrosis in patients with NASH, as well as reduce susceptibility to cardiovascular disease. This belief is also supported by data from
Phase&nbsp;2 clinical trials other endocrine FGF analogs in patients with NASH, in which substantial reductions in liver fat content and biomarkers of liver fibrosis were observed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
therefore believe that AKR-001 has the potential to be a best-in-class endocrine FGF agonist for treatment of this rapidly-growing patient population that lacks effective treatment options. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
June 2018, we acquired exclusive global development and commercialization rights to AKR-001 from Amgen&nbsp;Inc., or Amgen, which leveraged its deep protein engineering expertise to design and
develop AKR-001. As of December&nbsp;31, 2018, our patent portfolio relating to AKR-001 and other peptides included 113 issued patents and 40 pending patents worldwide, with expected patent
exclusivity up to 2034 in the United States, including potential patent term extension. Since AKR-001 is a biologic, marketing approval would also provide twelve years of market exclusivity from the
approval date of a Biologics License Application, or BLA, in the United States. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
management team has extensive experience in drug discovery, development and commercialization, and has been involved in the approvals of more than 20 medicines. Our Chief Executive Officer, Andrew
Cheng, MD, PhD, previously Chief Medical Officer at Gilead, was responsible for clinical development for Gilead's HIV program. Our Chief Scientific Officer, Tim Rolph, DPhil, formerly Chief Scientific
Officer of Pfizer's Cardiovascular&nbsp;&amp; Metabolic Disease Research Unit, previously oversaw Pfizer's FGF21 program. We are supported by our board of directors and a group of leading institutional
investors. We believe that our team is well positioned to leverage its collective experience in drug development and in-depth knowledge of FGF21 biology and metabolic diseases to develop and
commercialize products that will have significant benefits for patients with NASH and other serious metabolic diseases with high unmet medical need. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Our strategy  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our goal is to become a leading biotechnology company focused on developing and commercializing transformative treatments for serious
metabolic diseases with high unmet medical need. The key components of our strategy are to: </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Rapidly advance AKR-001 through clinical development in
NASH.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We believe that AKR-001's differentiated profile as an FGF21 agonist has the potential to result in a best-in-class endocrine FGF agonist
for the treatment of NASH. We plan to initiate a Phase&nbsp;2a clinical trial in the middle of 2019, which will assess the efficacy and safety of AKR-001 in patients with NASH and inform dose
selection for larger, longer-term trials. Consistent with recently-published draft guidance from the U.S. Food and Drug Administration, or FDA, on NASH development, we are committed to exploring ways
to accelerate development of AKR-001 through innovative clinical trial designs.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I> Scale our capabilities to support development and commercialization of
AKR-001.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We plan to scale our manufacturing and organizational capabilities to capitalize on our exclusive, global rights to market AKR-001 for
all indications. We have contracted with a third-party manufacturer to support future clinical trials and the potential commercialization of AKR-001 with commercial-scale manufacturing. When
appropriate, we intend to develop the commercial infrastructure required for bringing AKR-001 to patients with NASH in the United States, if approved. We also plan to evaluate options for delivering
AKR-001, if approved, to patients in other key markets, such as Europe, Japan and China, which may include strategic collaborations. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>92</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=95,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=44346,FOLIO='92',FILE='DISK114:[18ZFG1.18ZFG45201]CU45201A.;43',USER='SCAVALI',CD='17-JAN-2019;14:44' -->
<A NAME="page_cu45201_1_93"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I>Enhance our position as a leading metabolic disease company by leveraging our knowledge of FGF21
biology.</I></B></FONT><FONT SIZE=2> Numerous publications have shown that increases in endogenous FGF21 expression occur in response to various types of metabolic and cellular stress arising from
obesity, diabetes, mitochondrial diseases and cardiovascular disease, as well as NASH. AKR-001 has been engineered to reproduce the biological activity profile of native FGF21 while also addressing
certain therapeutic limitations, such as a short half-life. We plan to explore opportunities to develop AKR-001 for additional indications where there is a compelling scientific rationale, strong
clinical tractability and significant unmet medical need. Our strategy also includes evaluating the potential of novel oral therapeutic mechanisms to boost levels of endogenous FGF21, which may have
utility in a broad population of NASH patients, including those with early-stage disease. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I>Develop, acquire or in-license product candidates that enhance our potential to become a leading metabolic disease
company.</I></B></FONT><FONT SIZE=2> To supplement our own in-house research and development efforts, we are continually evaluating opportunities to build a robust pipeline of potential best-in-class
treatments for metabolic diseases. Our initial focus is on NASH, but we plan to evaluate programs outside of NASH that may provide compelling synergies with our development efforts. Additional NASH
assets may be selected for their potential as stand-alone monotherapies or for eventual use in combination with other products. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


NASH overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are developing AKR-001 as a potential treatment for patients with NASH, a disease with high unmet medical need and no approved therapies.
NASH is a severe form of NAFLD, which is driven by the global obesity epidemic. Patients with NAFLD have an excessive accumulation of fat in the liver resulting from an excess of caloric intake over
energy needs. In patients with NASH, excessive liver fat leads to hepatocyte stress, which triggers localized inflammation and can ultimately lead to fibrosis and scarring in the liver, or cirrhosis. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Patients
with NASH are at increased risk of liver-related morbidity and mortality, including liver failure and hepatocellular carcinoma. As NASH progresses, cardiovascular-related morbidity and
mortality also increase, such that the most frequent cause of death in patients with NASH is cardiovascular disease. In particular, the prevalence of patients with advanced fibrosis in the United
States is projected to more than double between 2016 and 2030. We believe that AKR-001 has the potential to be a best-in-class endocrine FGF agonist for treatment of this rapidly-growing patient
population. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Etiology of NASH  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>NASH is primarily driven by chronic excess caloric intake, or ingesting more energy than the body expends over a sustained period, which results in people
becoming overweight and obese. Body fat, also known as adipose tissue, and muscle respond to becoming saturated with energy by reducing sensitivity to insulin, which would otherwise drive uptake of
energy by these peripheral tissues. Consequently, the liver becomes the repository for the energy that is unwanted by the rest of the body. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>While
there is a lack of scientific consensus on how best to characterize NASH pathogenesis, we believe there are five core processes:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Caloric overburdening of the liver; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Excessive liver and fat oxidation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Hepatocyte cell stress, injury and death; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>93</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=96,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=751701,FOLIO='93',FILE='DISK114:[18ZFG1.18ZFG45201]CU45201A.;43',USER='SCAVALI',CD='17-JAN-2019;14:44' -->
<A NAME="page_cu45201_1_94"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Localized inflammation triggered by hepatocyte death; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Fibrosis. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>These
processes can lead to cirrhosis, liver failure, cancer and death. Figures&nbsp;1 and 2 below illustrate these five processes. Figure&nbsp;1 shows how multiple organs of the body contribute
to caloric overburdening of the liver, which manifests as excessive accumulation of liver fat, or steatosis, and high rates of fat oxidation within the liver. Figure&nbsp;2 depicts the
cellular-level processes that arise from hepatocyte stress caused by high levels of certain lipid molecules, or lipotoxicity, and oxidative stress. Hepatocyte stress leads to cell death, which in turn
activates local inflammatory responses in the liver, potentially leading to fibrosis. Parenthetical references in the text below correspond to sequential labels in Figures&nbsp;1 and 2. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="cu45201_figure_1_#151;nash_pathogenesi__fig04790"> </A>
<A NAME="toc_cu45201_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Figure&nbsp;1&#151;NASH pathogenesis: Caloric overburdening causes excessive deposition of liver fat and high rates of fat oxidation    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g894662.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="372">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>94</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=97,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=780120,FOLIO='94',FILE='DISK114:[18ZFG1.18ZFG45201]CU45201A.;43',USER='SCAVALI',CD='17-JAN-2019;14:44' -->
<A NAME="page_cu45201_1_95"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2><A
NAME="cu45201_figure_2_#151;nash_pathogenesi__fig04614"> </A>
<A NAME="toc_cu45201_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Figure&nbsp;2&#151;NASH pathogenesis: Oxidative stress and lipotoxicity induce hepatocyte death, local inflammation and fibrosis    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g919117.jpg" ALT="GRAPHIC" WIDTH="654" HEIGHT="313">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Caloric overburdening of the liver  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>When intake of energy chronically exceeds demand, the body adapts its metabolism to find alternate locations to store the excess energy. Absorption of dietary
fat (A), dietary carbohydrates and protein (B1), and lipids from adipose tissue (D1) all contribute to caloric overburdening of the liver. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Excessive deposition of fat and high rates of fat oxidation in the liver  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Healthy individuals typically have liver fat levels of less than 5%. In patients with NASH, liver fat levels typically range from 10% to 30%. Liver fat, and
fat oxidation, increase in response to caloric overburdening of the liver. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
largest source of liver fat is from adipose tissue (D1), accounting for approximately 40% to 50%, on average, of liver fat in patients with NASH. Flux of fat from adipose tissue to the liver
through lipolysis (D2) is driven by resistance to insulin. This resistance to insulin also means dietary fat transported as chylomicrons&nbsp;(A) and very low density lipoprotein, or VLDL (D3), a
form of fat packaged by the liver for delivery to the body's organs, are not taken up by adipose tissue. As a result the level of plasma triglycerides (D4) increases, manifesting as
hypertriglyceridemia, which is frequently observed in NASH. The second largest source of fat in liver is from synthesis of new fat, known as de novo lipogenesis, or DNL (B2), which utilizes dietary
carbohydrates and protein (B1) and accounts for approximately 30% to 40%, on average, of liver fat in patients with NASH. The final source of liver fat is fat ingested in diet&nbsp;(A), accounting
for approximately 10% to 20%, on average, of liver fat in patients with NASH. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
liver responds to increased flow of fat from adipose tissue by increasing the rate at which it burns fat, a process known as fat oxidation (E), which in turn releases substantial amounts of
energy. Initially, this surplus energy is consumed by additional DNL. However, if the high rate of DNL continues chronically,
hepatocytes become saturated with stores of fat, or fat depots (C), and the rate of DNL slows. In this situation, excess energy from fat oxidation causes oxidative stress, which together with
lipotoxicity arising from fat depots, results in hepatocyte stress (G). </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>95</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=98,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=583574,FOLIO='95',FILE='DISK114:[18ZFG1.18ZFG45201]CU45201A.;43',USER='SCAVALI',CD='17-JAN-2019;14:44' -->
<A NAME="page_cu45201_1_96"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Hepatocyte stress, injury and death  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Later-stage NASH pathogenesis is driven by hepatocyte stress and cell death, or apoptosis, which lead to inflammation and fibrosis. In particular, increased
fat oxidation in the liver leads to formation of highly-reactive molecules, known as free radicals, that cause oxidative stress. A free radical is an energetically unstable, reactive entity containing
an atom of oxygen with an unpaired electron. A free radical is stabilized by pairing this electron with an electron acquired by the oxygen atom from another molecule. Cells have defense mechanisms to
neutralize free-radicals by donation of an electron from molecules known as anti-oxidants. When the quantity of free radicals exceeds the capacity of anti-oxidants to neutralize them, free radicals
react with other constituents of cells such as DNA, proteins, or lipids to acquire an electron. The attack on these macromolecules leads to mitochondrial stress (G1), DNA damage (G2), formation of
lipid peroxides (G3) and synthesis of damaged proteins (G4), all of which disrupt cellular processes and homeostasis, thereby increasing hepatocyte stress. Damaged proteins stress the endoplasmic
reticulum, or ER (G5), which is the cell's machinery for making proteins. Accumulation of damaged proteins in the ER impairs assembly of proteins thereby triggering the unfolded protein response. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Apoptosis
of hepatocytes manifests as ballooning of the cells, a characteristic microscopic feature of NASH liver tissue. Hepatocyte stress, injury and death are the bridge between oxidative stress
and lipotoxicity arising from excessive delivery of fat and calories to the liver and the downstream sequelae of inflammation and fibrosis. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Inflammatory response to hepatocyte stress and death  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Hepatocytes undergoing apoptosis release danger signal molecules known as damage-associated molecular patterns, or DAMPs (J1). DAMPs activate a population of
specialist immune-effector cells resident within the liver, known as Kupffer cells (J2), which typically clear debris from dying liver cells and defend against microbial infections. Once activated,
Kupffer cells release various pro-inflammatory molecules, including cytokines (such as TNF<FONT FACE="SYMBOL">a</FONT>, TGF-<FONT FACE="SYMBOL">b</FONT>, IL-1, and IL-6),
chemokines (such as MCP-1/CCL2), prostanoids and nitric oxide (J3). Cytokines and chemokines serve to attract other immune system cells stored in the bone marrow, known as monocytes, which in turn
become pro-inflammatory macrophages and amplify inflammation within the liver. Among the cytokines released, TNF<FONT FACE="SYMBOL">a</FONT> and TGF-<FONT FACE="SYMBOL">b</FONT>
also act to induce apoptosis of neighboring hepatocytes (J4), thereby creating a cycle of hepatocyte death that stimulates more inflammation and results in extensive loss of hepatocytes and metabolic
capacity. This, in turn, places more stress on the remaining hepatocytes. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fibrosis and cirrhosis  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>High local levels of cytokines, particularly TGF-<FONT FACE="SYMBOL">b</FONT>, activate another group of liver-resident cells known as hepatic
stellate cells, or HSC, (K1). HSCs are normally dormant. However, when activated, they produce large amounts of collagen. At first, in a process known as fibrogenesis (K2), the extracellular collagen
forms isolated fibrotic structures largely surrounded by healthy cells. As collagen continues to be deposited, the fibrotic structures interconnect, a process known as bridging fibrosis (K3). When
hepatic stellate cells are chronically activated, collagen deposition becomes excessive and ultimately leads to scarring, or cirrhosis. If a liver progresses to cirrhosis, blood flow through the liver
is greatly reduced,
causing inadequate delivery of oxygen and nutrients, which in extreme cases results in acute liver failure and death. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Disease diagnosis and disease burden  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>NASH is currently diagnosed only through liver biopsy and its severity is measured using scoring systems that assess the extent and severity of steatosis,
lobular inflammation, hepatocellular ballooning and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>96</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=99,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=1013698,FOLIO='96',FILE='DISK114:[18ZFG1.18ZFG45201]CU45201A.;43',USER='SCAVALI',CD='17-JAN-2019;14:44' -->
<A NAME="page_cu45201_1_97"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</FONT><P style="font-family:arial;"><FONT SIZE=2>fibrosis.
Some patients may be diagnosed with NASH after presenting with symptoms such as general fatigue and nondescript abdominal discomfort. However, NASH diagnosis more commonly follows detection
of elevated liver enzymes on routine lab tests or detection of an enlarged steatotic liver by abdominal imaging. Although non-invasive methods, including a combination of imaging such as MRI-PDFF and
plasma biomarkers of fibrosis, such as PRO-C3, are being evaluated as potential diagnostic tools, none have yet been validated for use in formal NASH diagnosis. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Two
different scoring systems are most commonly used in the United States to measure the severity of NASH: the NAFLD activity score, or NAS, and fibrosis stage. The NAS, which was developed for, and
generally only used in, clinical trials, is a measure of liver histology that grades disease activity in patients with NAFLD and NASH. A patient may receive a composite NAS score of zero to eight,
which is comprised of three individual scores: (1)&nbsp;steatosis, scored zero to three according to the percentage of a microscopic field showing steatosis, (2)&nbsp;lobular inflammation, scored
zero to three according to the number of immune cell foci per 20x optical field in a microscope, and (3)&nbsp;hepatocellular ballooning, scored zero to two according to the number of ballooning
cells in a microscopic field. In addition, fibrosis staging is used to classify the extent and severity of fibrosis. A scoring system based on a scale from zero to four (F0-F4) is used. Early,
discrete fibrosis is classified as F1 or F2, whereas bridging fibrosis is classified as F3. As more hepatocytes die and scarring becomes extensive, the liver becomes cirrhotic, which is classified as
stage&nbsp;F4. F0 corresponds to steatohepatitis with no evidence of fibrosis. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>About
10-20% of NAFLD patients progress to NASH, which puts them at increased risk of liver damage and other complications. Fibrosis is generally reversible in its early-to-mid stages. However,
late-stage fibrosis can be irreversible and prevents the liver from performing its natural functions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
shown in Figure&nbsp;3 below, NASH is commonly associated with metabolic comorbidities, including obesity, T2D, dyslipidemia and metabolic syndrome, and with hypertension. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="cu45201_figure_3_#151;prevalence_of_co__fig02129"> </A>
<A NAME="toc_cu45201_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Figure 3&#151;Prevalence of comorbidities among NASH patients    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g249259.jpg" ALT="GRAPHIC" WIDTH="496" HEIGHT="180">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Liver-related
mortality increases with the fibrosis stage, as shown in Figure&nbsp;4 below. As compared to healthy individuals, patients with NASH also experience higher all-cause morbidity and
mortality resulting from major adverse cardiovascular events, or MACE, and non-liver cancers. The most common cause of
death in NASH patients is cardiovascular disease. As with liver-related mortality, all-cause mortality also increases with fibrosis stage. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>97</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=100,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=607298,FOLIO='97',FILE='DISK114:[18ZFG1.18ZFG45201]CU45201A.;43',USER='SCAVALI',CD='17-JAN-2019;14:44' -->
<A NAME="page_cu45201_1_98"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="cu45201_figure_4_#151;all-cause_nash_mortality"> </A>
<A NAME="toc_cu45201_5"> </A>
<BR></FONT><FONT SIZE=2><B>  Figure 4&#151;All-cause NASH mortality    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g374807.jpg" ALT="GRAPHIC" WIDTH="477" HEIGHT="238">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Market size and trends  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>More than one billion people worldwide were estimated to have NAFLD in 2016, including an estimated 85&nbsp;million individuals in the United States.
Approximately 10-20% of patients with NAFLD progress to NASH, including an estimated 17.3&nbsp;million individuals in the United States and 16.4&nbsp;million aggregate individuals in France,
Germany, Italy, Spain, the United Kingdom, and Japan in 2016. As the population ages, the prevalence of NASH is projected to increase approximately 50% by 2030 to a total of 27.0&nbsp;million
individuals in the United States and 22.5&nbsp;million aggregate individuals in France, Germany, Italy, Spain, the United Kingdom and Japan. However, NASH afflicts all age groups, including
teenagers and young adults, for whom the loss of quality-adjusted life years will be very substantial unless progression to late-stage diseases can be halted or reversed. In the absence of approved
therapies, direct healthcare costs associated with NAFLD and NASH in the United States were estimated to be approximately $100&nbsp;billion in 2016. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
shown in the Figure&nbsp;5 below, growth in prevalence of NASH in the United States from 2015 to 2030 is projected to be greatest, at approximately 140%, in patients with stage F3-F4 fibrosis. By
2030, there are projected to be eight&nbsp;million individuals in the United States and six&nbsp;million aggregate individuals in France, Germany, Italy, Spain, the United Kingdom, and Japan with
stage F3-F4 NASH. This rapid growth in advanced fibrosis reflects the time required for the late 20<SUP>th</SUP> century obesity epidemic to result in patients progressing through NAFLD to advanced
NASH. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>98</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=101,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=783888,FOLIO='98',FILE='DISK114:[18ZFG1.18ZFG45201]CU45201A.;43',USER='SCAVALI',CD='17-JAN-2019;14:44' -->
<A NAME="page_cu45201_1_99"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="cu45201_figure_5_#151;united_states_na__fig02147"> </A>
<A NAME="toc_cu45201_6"> </A>
<BR></FONT><FONT SIZE=2><B>  Figure 5&#151;United States NASH prevalence by fibrosis stage    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g310115.jpg" ALT="GRAPHIC" WIDTH="478" HEIGHT="258">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Emerging therapies in development  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There are no therapies currently approved for the treatment of NASH. The current standard of care is diet and exercise. Although diet and exercise are
effective in the treatment of NASH when maintained, adherence to this treatment regimen is generally poor. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
multistep progression of NASH pathogenesis offers multiple potential approaches for therapeutic intervention. Some of the most advanced therapeutic candidates in development have targeted
inflammation and fibrosis, but not the early stages of NASH pathogenesis. The mechanisms of these therapies are generally labeled as "anti-fibrotic." Early indications from long-term clinical trials
suggest that focusing on suppressing inflammation and fibrosis may not deliver sustained reversal or resolution of NASH, because the processes underlying NASH pathogenesis are not being addressed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Therapeutic
mechanisms that target earlier-stages of NASH pathogenesis, including excessive liver fat accumulation, are generally characterized as "metabolic." Two relevant precedents indicate that
targeting the processes underlying inflammation and fibrosis of the liver can lead to reversal of fibrosis, even without a directly anti-fibrotic intervention. For example, anti-viral treatment of
hepatitis C has been shown
to reverse fibrosis when viral load is suppressed, even though the treatment does not act directly on fibrosis. This is attributable to the capacity of liver to regenerate, or heal itself once the
chronic underlying driver of inflammation and fibrosis has been addressed. The current standard of care for NASH treatment provides additional precedent. A sustained weight loss of 10% or more through
diet and exercise has been shown to reverse NASH fibrosis, including advanced fibrosis, without any direct pharmacological anti-fibrotic effect. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Early
indications from Phase&nbsp;2 clinical trials of third-party agents suggest that metabolic mechanisms may have robust effects on certain measures of NASH disease progression, including
reductions in fibrosis. However, some of these metabolic therapeutic mechanisms have unwanted side effects that may limit their ability to be used as treatment for patients with NASH. For instance,
some NASH candidates have been shown to increase plasma levels of low-density lipoprotein cholesterol, or LDL-C, or triglycerides, each of which is an independent causal risk factor for cardiovascular
disease. We believe interventions that may increase cardiovascular risk will be carefully scrutinized by prescribing physicians, as patients with NASH are already at increased risk for cardiovascular
events. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Figure&nbsp;6
provides some examples of therapeutic approaches to NASH and potential limitations of these therapeutic targets. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>99</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=102,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=987201,FOLIO='99',FILE='DISK114:[18ZFG1.18ZFG45201]CU45201A.;43',USER='SCAVALI',CD='17-JAN-2019;14:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cw45201_1_100"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> <A NAME="cw45201_figure_6_#151;selected__cw402149"> </A>
<A NAME="toc_cw45201_1"> </A> </B></FONT><FONT SIZE=2><B>Figure 6&#151;Selected NASH interventions under development    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g997105.jpg" ALT="GRAPHIC" WIDTH="480" HEIGHT="346">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Some
NASH candidates are being evaluated for use in combination with one or more other candidates that intervene in different processes underlying NASH pathogenesis. In other cases, combination
approaches are being evaluated to mitigate unwanted side effects, such as using statins in combination with FXR and FGFR4 agonists to reduce LDL-C. However, combining multiple interventions,
particularly multiple small molecules, places an additional burden of drug metabolism and clearance upon already stressed hepatocytes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Some
individual interventions, including PPAR, FGF19 and FGF21 agonists, target multiple processes underlying NASH pathogenesis. Of these, we believe AKR-001 has unique properties with the potential
to address each of the five core processes underlying NASH pathogenesis, thereby reducing liver fat, hepatocytes stress and reversing fibrosis in patients with NASH. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Our approach to NASH: harnessing FGF21's natural potential for therapeutic effect  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>FGF21 is an endogenous hormone that has both local, or paracrine, effects on cells and systemic, or endocrine, effects on metabolic organs.
FGF21's natural recruitment to alleviate many forms of cellular stress, and to regulate whole-body metabolism, make it a compelling therapeutic target. However, native FGF21 has several limitations
that prevent it from being used effectively as a therapy, including a half-life estimated to be less than one hour. AKR-001 is a recombinantly-engineered version of FGF21 designed to retain the native
biological activity of FGF21 while enhancing its therapeutic utility. Specifically,
AKR-001 features Fc-mediated half-life extension and substitution of specific amino acids within the protein sequence of FGF21. AKR-001 has a resulting half-life of three to 3.5&nbsp;days in humans,
which enables once-weekly subcutaneous administration. Pharmacology studies have shown AKR-001 reproduces the balanced potency of native FGF21, acting specifically on three cell-surface receptors.
AKR-001 also reproduces native FGF21's weak potency as an agonist of another cell-surface receptor known to be associated with higher plasma LDL-C. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>100</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=103,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=400859,FOLIO='100',FILE='DISK114:[18ZFG1.18ZFG45201]CW45201A.;47',USER='SCAVALI',CD='17-JAN-2019;12:22' -->
<A NAME="page_cw45201_1_101"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>We
believe that AKR-001, with its activity on both liver and adipose tissue, has the potential to intervene in the five core processes relevant to NASH pathogenesis. Specifically, we believe that
AKR-001 can:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Redirect calories away from the liver; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Restore healthy fat metabolism in the liver; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT
SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Reduce hepatocyte stress; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Mitigate inflammation; and </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Resolve fibrosis.
</FONT></DD></DL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview of FGF21 biology  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Fibroblast growth factors, or FGFs, are a large family of cell-signaling proteins involved in the regulation of many processes within the body. A sub-family
of FGFs, known as endocrine FGFs, which include FGF21 and FGF19, are unique among FGFs because they initiate their biological effects by binding tightly to a cell surface receptor known as </FONT> <FONT SIZE=2><I>Beta</I></FONT><FONT SIZE=2> Klotho,
or </FONT><FONT SIZE=2><I><FONT FACE="SYMBOL">b</FONT></I></FONT><FONT SIZE=2>Klotho. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After
this initial binding, FGF21 and FGF19 trigger signaling pathways within cells, such as hepatocytes and adipocytes, by binding to a second class of cell-surface receptor, known as the FGF
receptors, or FGFRs. Both FGF21 and FGF19 bind to three specific FGFRs, known as FGFR1c, FGFR2c, and FGFR3c, which, based on nonclinical studies and clinical trials, appear to be responsible for
mediating the desired therapeutic actions of FGF21 and FGF19 in NASH. However, unlike FGF21, FGF19 also binds specifically to another FGFR known as FGFR4. We believe, based on published nonclinical
studies and clinical trials, that activation of FGFR4 brings little therapeutic benefit and is instead associated with undesirable biological effects such as elevating LDL-C and potentially increasing
the risk of developing hepatocellular carcinoma. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
illustrated in Figure&nbsp;7, the C-terminus of FGF21 initially binds to </FONT><FONT SIZE=2><I><FONT FACE="SYMBOL">b</FONT></I></FONT><FONT SIZE=2>Klotho (A). This enables the
N-terminus to form an expanded complex with one of the FGFRs (B). Once the co-receptor complex has formed with </FONT> <FONT SIZE=2><I><FONT FACE="SYMBOL">b</FONT></I></FONT><FONT SIZE=2>Klotho and one of the FGFRs, a series of intracellular
signaling cascades is initiated (C). These signaling
cascades enable FGF21 to exert its biological functions, which include regulation of energy homeostasis, glucose-lipid-protein metabolism and insulin sensitivity, and modulation of pathways that
mitigate against intracellular stress. FGF21 cannot signal through cell
membranes without both an intact C-terminus and an intact N-terminus to bind, respectively, to </FONT><FONT SIZE=2><I><FONT FACE="SYMBOL">b</FONT></I></FONT><FONT SIZE=2>Klotho and FGFR. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> Figure&nbsp;7&#151;FGF21's two-step receptor binding with </B></FONT><FONT SIZE=2><B><I><FONT FACE="SYMBOL">b</FONT></I></B></FONT><FONT SIZE=2><B>Klotho and FGFRs  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g273067.jpg" ALT="GRAPHIC" WIDTH="387" HEIGHT="213">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>101</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=104,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=775653,FOLIO='101',FILE='DISK114:[18ZFG1.18ZFG45201]CW45201A.;47',USER='SCAVALI',CD='17-JAN-2019;12:22' -->
<A NAME="page_cw45201_1_102"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Overcoming the limitations of native FGF21 as a therapeutic by rational engineering of a recombinant protein  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>FGF21's role in regulating whole-body metabolism and alleviating cellular stress makes it an attractive candidate with potential to treat metabolic diseases.
Numerous nonclinical studies show that elevated levels of FGF21 protect against development of NASH histopathology and fibrosis resulting from a range of insults, including excess intake of fat and
fructose, excess alcohol, a diet deficient in methionine and choline, and chemical toxins, such as carbon tetrachloride and nitrosamine. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>However,
there are several inherent limitations that mean using an unmodified form of human FGF21 would not be effective:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B>FGF21 is rapidly broken down in the bloodstream and cleared through the kidneys.</B></FONT><FONT SIZE=2> The half-life
of FGF21 is estimated to be less than one hour based on nonclinical studies in rodents and non-human primates. Extending the half-life of FGF21 requires reducing renal clearance and protection of both
ends of the protein from proteolysis, the body's natural process for breaking-down a protein by cleaving it at specific sites. If the C-terminus of FGF21 protein is not intact, FGF21 is unable to bind
to </FONT><FONT SIZE=2><I><FONT FACE="SYMBOL">b</FONT></I></FONT><FONT SIZE=2>Klotho, and if the N-terminus is not intact, it is unable to signal through one of the FGFRs. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B>Recombinantly-expressed human FGF21, or rhFGF21, molecules are susceptible to aggregation when formulated into a
sol</B></FONT><FONT SIZE=2>u</FONT><FONT SIZE=2><B>tion suitable for injection into humans</B></FONT><FONT SIZE=2>. Aggregation can disrupt binding of rhFGF21 to its receptors, thereby causing it to
lose its biological activity. Aggregates of rhFGF21 can become so large they are insoluble and fall out of solution, or precipitate, leading to loss of biological activity in storage. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B>FGF21's cell signaling depends on binding affinity to a co-receptor complex of  </B></FONT><FONT SIZE=2><B><I><FONT FACE="SYMBOL">b</FONT></I></B></FONT><FONT SIZE=2><B>Klotho
and FGFR1c/2c/3c, which have tissue-dependent expression.</B></FONT><FONT SIZE=2> Reproducing native
FGF21's biology depends on retaining both binding affinity to </FONT><FONT SIZE=2><I><FONT FACE="SYMBOL">b</FONT></I></FONT><FONT SIZE=2>Klotho and balanced signaling through FGFR1c,
FGFR2c and FGFR3c. For example, in adipose tissue FGFR1c appears to be the major signaling co-receptor, while in the liver FGFR2c and FGFR3c appear to be more important as signaling receptors. Thus,
it is necessary to ensure effective exposure to FGFR's throughout the body. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>AKR-001
has been engineered to: (1) protect against proteolysis and reduce renal clearance, (2)&nbsp;provide a half-life of up to 3.5&nbsp;days in humans by protecting against proteolysis,
(3)&nbsp;minimize potential for aggregation in solution and (4)&nbsp;improve binding affinity for </FONT><FONT SIZE=2><I><FONT FACE="SYMBOL">b</FONT></I></FONT><FONT SIZE=2>Klotho,
while (5)&nbsp;retaining balanced agonism across FGFR1c, FGFR2c and FGFR3c. Figure&nbsp;8 below illustrates the structural engineering of AKR-001, which is also further described in the text that
follows. We believe AKR-001's differentiated profile has the potential to result in a best-in-class endocrine FGF agonist for treatment of NASH. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>102</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=105,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=389498,FOLIO='102',FILE='DISK114:[18ZFG1.18ZFG45201]CW45201A.;47',USER='SCAVALI',CD='17-JAN-2019;12:22' -->
<A NAME="page_cw45201_1_103"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> Figure&nbsp;8&#151;Protein engineering of AKR-001  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g819588.jpg" ALT="GRAPHIC" WIDTH="360" HEIGHT="192">
  </B></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B> Fc-fusion (A).</B></FONT><FONT SIZE=2>&nbsp;&nbsp;AKR-001 is an
Fc-fusion protein, whereby a modified FGF21 is fused to the fragment crystallizable, or Fc, region of human immunoglobulin, or Ig, sub-type G1 antibody. Fusion with Fc is an established approach for
increasing a biological molecule's half-life, enabling a longer dosing interval during which therapeutic concentrations can be maintained. Fc-fusion technology has been leveraged to produce multiple
highly successful therapeutics approved by the FDA and the European Medicines Agency, or EMA, including Enbrel and Trulicity. These and other Fc-fusion protein products elicit minimal immune reactions
in humans. AKR-001 is manufactured as a dimer, with two Fc-FGF21 molecules linked by two disulfide bridges to form&nbsp;a single molecule. The N-terminus of the FGF21 moiety is connected to the Fc
portion of AKR-001 through a polyglycine linker. Our patents include claims directed to Fc fusion with a recombinantly modified FGF21.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B> FGF21 mutation at position 98
(B).</B></FONT><FONT SIZE=2>&nbsp;&nbsp;rhFGF21 is susceptible to aggregation, which can disrupt binding of rhFGF21 to its receptors, thereby reducing its biological activity, and
cause instability of FGF21 during storage in solution. Substitution of a hydrophilic arginine residue for the hydrophobic leucine residue at position 98, labeled as L98R, was found to yield the lowest
rate of aggregation of any FGF21 modification tested during AKR-001's development. We expect that AKR-001's resistance to aggregation will be consistent across large manufacturing lots and confer
adequate stability in formulation for injection. Our patents include claims directed to an FGF21 polypeptide comprising this point mutation at position 98 in combination with other advantageous amino
acid substitutions.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B> FGF21 mutation at position 171
(C).</B></FONT><FONT SIZE=2>&nbsp;&nbsp;FGF21 is cleaved between amino acid positions 171 and 172 near the C-terminus of FGF21 by the proteolytic endopeptidase enzyme fibroblast
activation protein, or FAP. FAP's action on FGF21 prevents binding to </FONT><FONT SIZE=2><I><FONT FACE="SYMBOL">b</FONT></I></FONT><FONT SIZE=2>Klotho. Therefore, FGF21 loses its
biological activity when cleaved by FAP. AKR-001 remedies this limitation through a point mutation that substitutes a glycine for the proline residue at position&nbsp;171, which is labeled as P171G.
An FGF21 agonist without protection against FAP is likely to remain susceptible to FAP-induced degradation, thus losing its biological activity even if the N-terminus remains intact. Protecting
against FAP appears to be particularly critical to using FGF21 as a therapeutic agent in patients with NASH because FAP is the most over-expressed protein in liver of patients with NASH relative to
protein expression by healthy livers. Our patents include claims directed to an FGF21 polypeptide comprising this point mutation at position 171 in combination with other advantageous amino acid
substitutions.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B> FGF21 mutation at position 180
(D).</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Stabilization of FGF21 at position 171 was found to increase FGF21's susceptibility to degradation at position 180. Subsequent empirical
studies led to the discovery that substituting glutamic acid for alanine at position 180, labeled as A180E, confers further resistance to proteolysis and increases affinity for </FONT> <FONT SIZE=2><I><FONT FACE="SYMBOL">b</FONT></I></FONT><FONT
SIZE=2>Klotho. Our patents include claims directed to an FGF polypeptide </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>103</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=106,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=541767,FOLIO='103',FILE='DISK114:[18ZFG1.18ZFG45201]CW45201A.;47',USER='SCAVALI',CD='17-JAN-2019;12:22' -->
<A NAME="page_cw45201_1_104"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <UL>

<P style="font-family:arial;"><FONT SIZE=2>comprising
this point mutation at position 180 in combination with other advantageous amino acid substitutions. </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
believe these modifications result in the improved half-life and adequate stability that have been observed with AKR-001, while preserving FGF21's balanced potency. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Demonstrating AKR-001's reproduction of FGF21's balanced potency  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The engineering of AKR-001 was an empirical discovery process that incorporated </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> and </FONT> <FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> measurements of receptor agonism to
assess which of many tested discovery candidates yielded the most attractive drug properties. AKR-001 was
selected for clinical evaluation over earlier discovery candidates, which included a proprietary PEGylated FGF21 analog, identified as AMG-PEG21, and two versions of a two-point mutation Fc-fusion
protein known as RG (with mutations at positions 98 and 171, but not 180), one of which had the Fc fused to the C-terminus (FGF21-Fc(RG)) while the other had it fused to the N-terminus of the modified
FGF21 (Fc-FGF21(RG)). In comparative receptor agonism assays, as shown in Figure&nbsp;9 below, AKR-001 exhibited the greatest potency for each of FGFR1c, FGFR2c, and FGFR3c among the candidates
tested. Furthermore, as shown in Figure&nbsp;10 below, the potency of AKR-001 for FGFR1c, FGFR2c and FGFR3c was comparable to that of recombinantly-expressed human FGF19, or rhFGF19, and rhFGF21.
However, neither rhFGF21 nor AKR-001 are agonists of FGFR4, in contrast to rhFGF19's potent agonism of FGFR4. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Figure&nbsp;11
shows the EC50 for each of the six compounds referenced above for each of FGFR1c, FGFR2c, FGFR3c, and FGFR4. EC50 refers to the half-maximal effective concentration, or the
concentration at which one half of the maximal FGF agonist effect is observed. Non-linear regression is used to model an agonist concentration-response curve, allowing interpolation of the EC50 from
the observed data. For very low-potency agonists, such as FGF21's interaction with FGFR4, the agonist effect appears to be partial at the highest dose tested, so the EC50 cannot be calculated
precisely. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> Figure&nbsp;9&#151;Comparison of AKR-001's agonism of FGF receptors with three FGF21 discovery candidates identified prior to selecting AKR-001 for clinical evaluation  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g977903.jpg" ALT="GRAPHIC" WIDTH="669" HEIGHT="193">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>104</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=107,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=432171,FOLIO='104',FILE='DISK114:[18ZFG1.18ZFG45201]CW45201A.;47',USER='SCAVALI',CD='17-JAN-2019;12:22' -->
<A NAME="page_cw45201_1_105"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> Figure&nbsp;10&#151;Comparison of AKR-001's agonism of FGF receptors with unmodified rhFGF19 and rhFGF21  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g524389.jpg" ALT="GRAPHIC" WIDTH="450" HEIGHT="427">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> Figure&nbsp;11&#151;Relative potency of rhFGF21, AKR-001, rhFGF19 and other discovery candidates<BR>
against FGF&nbsp;receptors  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g311426.jpg" ALT="GRAPHIC" WIDTH="616" HEIGHT="249">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clinical validation of FGF agonism  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Data from clinical trials evaluating three different FGF compounds acting on FGFR1c, FGFR2c and/or FGFR3c further validate the potential of FGF21 agonism as a
NASH treatment. One compound is an FGF19 agonist analog, which has been observed to substantially reduce liver fat and to reverse liver inflammation and fibrosis in patients with NASH, but also
appears to increase LDL-C. Published nonclinical and clinical data suggest that activation of FGFR4 increases LDL-C but does not meaningfully contribute to the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>105</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=108,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=485493,FOLIO='105',FILE='DISK114:[18ZFG1.18ZFG45201]CW45201A.;47',USER='SCAVALI',CD='17-JAN-2019;12:22' -->
<A NAME="page_cw45201_1_106"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</FONT><P style="font-family:arial;"><FONT SIZE=2>pharmacodynamic
effects of FGF19 on lipid metabolism in the liver. Consequently, we believe the optimal NASH therapeutic profile for an FGF agonist is to have high, balanced potency for FGFR1c, 2c and
3c with minimal activity at FGFR4. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
second compound is a PEGylated FGF21 analog, which has been observed to extend FGF21 half-life to approximately 24&nbsp;hours but does not have any modifications to FGF21's amino acid sequence.
Although the effects do not appear to be as substantial as those seen with FGF19 agonism, clinical data suggest that the PEGylated FGF21 analog reduced liver fat and had positive effects on markers of
liver injury and fibrosis in NASH patients. PEGylation of other compounds has been shown to result in increased concentrations in liver relative to exposure in other organs, which may lead to greater
activity on FGF receptors in the liver (FGFR2c and FGFR3c) than in adipose tissue (FGFR1c). Such an effect could account for the apparently smaller effects on adipose tissue lipolysis than those
effects observed with FGF19 agonism. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
third compound is a monoclonal antibody, or mAb, designed to target only FGFR1c and its co-receptor, </FONT><FONT SIZE=2><I><FONT FACE="SYMBOL">b</FONT></I></FONT><FONT SIZE=2>Klotho.
Consistent with nonclinical data, preliminary clinical data in patients with NASH suggest that administration of this FGFR1c-specific agonist was associated with substantial reductions in liver fat
and improvements in lipoproteins, which may be attributable to lower rates of adipose tissue lipolysis. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Taken
together, clinical trials of these three compounds provide important evidence that activation of FGFR1c, FGFR2c, and FGFR3c has significant potential to treat patients with NASH. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


AKR-001 seeks to address the five core processes underlying NASH pathogenesis  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We believe intervening in the core processes underlying NASH pathogenesis is the most effective way to restore health to the liver of patients with NASH and
reduce risk of cardiovascular disease, which is the leading contributor to mortality and morbidity among these patients. Figures&nbsp;12 and 13 below illustrate how we believe AKR-001 can intervene
in each of the five core processes underlying NASH pathogenesis. Figure&nbsp;12 illustrates how AKR-001 acts to leverage whole-body metabolism to redirect calories away from the liver to peripheral
adipose tissue, thereby reducing fat deposited in the liver and decreasing the rate of fat oxidation by the liver. Figure&nbsp;13 depicts how AKR-001 acts to alleviate hepatocyte stress and to
reduce inflammation and fibrosis of the liver. In nonclinical studies, it has been observed that FGF21 agonism protects hepatocytes and other cell types against cellular stress by modulating multiple
specialized intracellular proteins called transcription factors, or TFs. As master regulators of gene expression, TFs ensure proteins appropriate to the needs of cells are produced at the right time
and in the right amounts. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>106</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=109,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=474478,FOLIO='106',FILE='DISK114:[18ZFG1.18ZFG45201]CW45201A.;47',USER='SCAVALI',CD='17-JAN-2019;12:22' -->
<A NAME="page_cw45201_1_107"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> Figure&nbsp;12&#151;AKR-001's redirection of calories away from liver leads to lower fat deposition<BR>
and reduced rate of oxidation of fat  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g354508.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="448">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> Figure&nbsp;13&#151;AKR-001's suppression of pathways leading to cell death reduces<BR>
downstream liver inflammation and fibrosis  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g685001.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="343">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>107</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=110,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=722121,FOLIO='107',FILE='DISK114:[18ZFG1.18ZFG45201]CW45201A.;47',USER='SCAVALI',CD='17-JAN-2019;12:22' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cy45201_1_108"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


FGF21 leverages whole-body metabolism to redirect calories away from liver to peripheral adipose tissue  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We believe AKR-001 intervenes in the first step of NASH pathogenesis by redirecting calories, including calories derived from dietary fat (A1), carbohydrates
and protein (B1) in the GI tract, away from the liver. This effect of AKR-001 appears to be mediated by enhancing insulin's action (A2 and B4) on adipose tissue to increase uptake of energy, which is
stored as fat within adipose tissue (D1). Enhancing insulin's action also suppresses release of fat from adipose tissue, or lipolysis, back to the liver (D2). At the same time, it promotes greater
uptake by adipose tissue of two forms of triglyceride transported by blood: VLDL secreted by liver (D3) and chylomicrons secreted by the GI tract (A2), thereby reducing plasma triglycerides (D4). The
net effect of a sustained redirection of energy away from liver is to reduce both the amount of fat in liver and the rate of fat oxidation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
beneficial impact of enhancing adipose tissue's sensitivity to insulin is clinically precedented by the observed ability of pioglitazone to reduce liver fat in patients with NASH. Likewise, FGF21
agonism has also been shown to improve insulin sensitivity in nonclinical studies. Translation of this effect to humans has been observed clinically with AKR-001. However, in contrast with
pioglitazone, no weight gain was observed in clinical trials with AKR-001. FGF21 agonism also reduced plasma triglyceride levels in nonclinical studies. Again, the reduction in plasma triglyceride has
been observed clinically with AKR-001, and with a third party's FGFR1c-specific FGF21 agonist that likely acts primarily on adipose tissue. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Reducing fat deposited in liver and rates of fat oxidation by liver  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Redirecting calories away from the liver to peripheral adipose tissue helps reduce accumulation of fat in the liver and decreases the rate of fat oxidation by
the liver in patients with NASH. Specifically, AKR-001 is expected to act on all three sources of increased liver fat by:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reducing flow of fat from adipose tissue to liver by activating the FGFR1c receptor expressed in adipose tissue (D2), which leads to lower
rates of fat oxidation (E); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> redirecting carbohydrates and protein absorbed from the GI tract away from the liver to adipose tissue&nbsp;(B1), thereby reducing
DNL-dependent deposition of fat in the liver (B2 and C); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> redirecting fat absorbed from the GI tract (A1) away from liver to adipose tissue (A2), which also reduces the amount of fat deposited in liver
(C). </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Nonclinical
studies provide evidence that FGF21 agonism is associated with reduced steatosis. Mice with five-fold increases in FGF21 plasma levels due to overexpression of FGF21, as well as mice
treated with rhFGF21, were observed to have less fat in the liver when fed a high-fat diet than appropriate controls. On the other hand, FGF21 knockout mice had higher liver fat, resulting in liver
inflammation and fibrosis. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>FGF21
agonism directly suppresses DNL in liver by suppressing a TF known as SREBP1c. Suppression of SREBP1c reduces the amount of lipid droplets, comprised of triglyceride and phospholipid species,
deposited within hepatocytes, and lowers the amount of triglyceride secreted as VLDL into the circulation. FGF21's inhibition of SREBP1c is believed to be mediated through FGFRs expressed in the
liver, predominantly FGFR2c and 3c (B3). High levels of plasma triglyceride increase susceptibility of NASH patients to cardiovascular disease. Substantial reduction of plasma triglyceride by FGF21
would therefore be predicted to reduce risk of cardiovascular disease. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Reducing liver cell stress, injury and death  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A key driver of NASH progression is hepatocyte stress (G), which is triggered by increased oxidative stress as well as stress caused by lipotoxicity, or
excessive amounts of certain lipids, in the liver (F). FGF21 </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>108</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=111,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=447605,FOLIO='108',FILE='DISK114:[18ZFG1.18ZFG45201]CY45201A.;33',USER='MTITUSS',CD='17-JAN-2019;14:52' -->
<A NAME="page_cy45201_1_109"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>inhibits
oxidative stress and lipotoxicity in two ways. First, as described above, FGF21 leverages multiple body systems to reduce the flux of fat through the liver, which limits fat oxidation and
thus oxidative stress, and reduces levels of lipotoxic species e.g.&nbsp;saturated long-chain fatty acids. Second, FGF21 directly alleviates oxidative stress through induction of TFs known as
PGC1<FONT FACE="SYMBOL">a</FONT> and NRF2, which induce expression of anti-oxidant enzymes that protect against oxidative stress by neutralizing free radicals.
PGC1<FONT FACE="SYMBOL">a</FONT> also improves mitochondrial function, which reduces oxidative stress. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Alleviating
oxidative stress and lipotoxicity reduces hepatocyte stress in the forms of less mitochondrial stress&nbsp;(G1), less DNA damage (G2), fewer lipid peroxides (G3), and less damaged
proteins (G4). FGF21 agonism also directly limits stress caused by damaged proteins, through induction of a TF known as TFEB, which increases the capacity of lysosomes to break-down misfolded and
damaged proteins arising from oxidative stress (H). This both reduces the UPR, and allows cells to synthesize new proteins, such as the anti-oxidant enzymes necessary to protect against oxidative
stress. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>By
reducing hepatocyte stress, FGF21 agonism mitigates progression from hepatocyte stress to apoptosis&nbsp;(I). FGF21 agonism also directly inhibits apoptosis by suppressing expression of a TF
known as ATF4, which triggers apoptosis, particularly in response to ER stress. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Reducing inflammation and fibrosis  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Inhibiting apoptosis helps mitigate the amount of danger signaling through DAMPs that trigger inflammation. In addition, data from nonclinical studies suggest
that FGF21 agonism directly suppresses activation of macrophages, and by inference Kupffer cells (J2), thereby reducing release of pro-inflammatory cytokines&nbsp;(J3), and promoting a pro-repair
macrophage phenotype. By inhibiting hepatocyte apoptosis and suppressing release of pro-apoptotic TNF<FONT FACE="SYMBOL">a</FONT> and TGF<FONT FACE="SYMBOL">b</FONT> from Kupffer
cells, FGF21 agonism interrupts the pathological cycle of increased hepatocyte apoptosis and inflammation (J4). Further, in nonclinical studies in human-derived and rodent-derived hepatic stellate
cell lines, FGF21 agonism was observed to directly inhibit collagen-producing myofibroblasts (K1), thereby reducing fibrogenesis (K2) and fibrosis (K3). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
sum, as shown in Figure&nbsp;14 below, we believe FGF21 acts on both liver and adipose tissue to reduce the caloric burden on the liver, thereby lowering both the level of fat and rate of fat
oxidation in hepatocytes; and acts directly and indirectly on the liver to reduce hepatocyte stress, inflammation and fibrosis. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>109</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=112,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=826968,FOLIO='109',FILE='DISK114:[18ZFG1.18ZFG45201]CY45201A.;33',USER='MTITUSS',CD='17-JAN-2019;14:52' -->
<A NAME="page_cy45201_1_110"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="cy45201_figure_14_#151;akr-001_s_inter__fig02651"> </A>
<A NAME="toc_cy45201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Figure&nbsp;14&#151;AKR-001's intervention in processes underlying NASH pathogenesis    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g1014474.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="324">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


AKR-001 clinical development  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>AKR-001 has been administered to a total of 83 patients with T2D in two Phase&nbsp;1 clinical trials. In a Phase&nbsp;1b clinical trial,
it was observed that AKR-001 substantially improved plasma lipoprotein levels, including reductions of up to 69% in triglycerides and 30% in non-HDL-C. In these clinical trials, it was also observed
that administration of AKR-001 was associated with substantially improved markers of insulin sensitivity, including reductions of up to 37% in C-peptide and 55% in HOMA-IR. No changes in body weight
were observed, except for isolated significant reductions at the highest dose tested. AKR-001's effects were observed to be rapid, sustained and durable for two to three weeks after cessation of
dosing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These
results are consistent with effects that would be expected for balanced agonism of FGFR1c, FGFR2c, and FGFR3c, without activating FGFR4, and suggest that AKR-001 has substantial potential as a
treatment for NASH. The observed magnitude and significance of AKR-001's biological effects on lipoprotein parameters and markers of insulin sensitivity are more robust and substantial than those
reported to date in clinical trials of any other endocrine FGF agonist. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
plan to submit to the FDA's Division of Gastroenterology and Inborn Errors Products an Investigational New Drug, or IND, application to permit patients with NASH to be treated with AKR-001. The
prior IND for AKR-001 permitted treatment of patients with T2D, having been approved by FDA's Division of Metabolism and Endocrinology Products. If we receive FDA acceptance of our new IND, we plan to
initiate a Phase&nbsp;2a
clinical trial to assess the efficacy and safety of AKR-001 in patients with NASH, which will help inform dose selection for larger, longer-term trials. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;1b clinical trial of AKR-001 in patients with T2D for 28 days  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A Phase&nbsp;1b clinical trial was conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AKR-001 in patients with T2D.
This trial was a multicenter, randomized, double-blind, placebo-controlled, ascending multiple-dose clinical trial. Sixty-nine patients enrolled into one of eight cohorts were randomized to receive
AKR-001 or placebo. Fifty-two patients received AKR-001 and 17 </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>110</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=113,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=320815,FOLIO='110',FILE='DISK114:[18ZFG1.18ZFG45201]CY45201A.;33',USER='MTITUSS',CD='17-JAN-2019;14:52' -->
<A NAME="page_cy45201_1_111"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>received
placebo. Doses of 7mg, 21mg, 70mg and 140mg were administered subcutaneously either once every two weeks, or Q2W, or once weekly, or QW, over a 28-day treatment period. Patients in Q2W
cohorts received doses of on Days 1 and 15, while subjects in QW cohorts received doses on Days 1, 8, 15 and 22. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


AKR-001 exhibited linear, dose-proportional pharmacokinetics  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Linear, dose-proportional pharmacokinetics were observed across the range of AKR-001 doses tested. The observed median time of maximum serum concentration, or
Tmax, ranged from two to 3.5&nbsp;days. The observed half-life of the intact C-terminus of AKR-001 ranged from three to 3.5&nbsp;days. By contrast, half-life of the intact C-terminus of other
FGF21 analogs evaluated clinically has ranged from six to 24&nbsp;hours. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
shown in Figure&nbsp;15 below, there was an approximately two-fold accumulation of AKR-001 observed in serum following repeated QW administration, with steady state achieved by the third or
fourth dose. No meaningful accumulation was observed following administration of two Q2W doses. QW dosing was also associated with a four-fold smaller peak-to-trough ratio than observed with Q2W
dosing, suggesting that serum concentrations of AKR-001 are maintained more effectively with QW than Q2W dosing. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="cy45201_figure_15__pharmacokinetics_of__fig02842"> </A>
<A NAME="toc_cy45201_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Figure&nbsp;15: Pharmacokinetics of AKR-001 administered weekly and every other week    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g401598.jpg" ALT="GRAPHIC" WIDTH="625" HEIGHT="340">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


AKR-001 effects on pharmacodynamic measures of lipoproteins and insulin sensitivity following once-weekly or
every-other-week dosing  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Figures 16 and 17 below show effects on pharmacodynamic measures for patients treated with AKR-001 either QW or Q2W, respectively. Fasting levels of plasma
glucose, insulin, C-peptide, plasma triglyceride, HDL-C, LDL-C and calculated HOMA-IR, as well as post-meal levels of free fatty acids, or FFA, and body weight were analyzed in accordance with the
pre-specified statistical analysis plan. Fasting levels of plasma non-HDL-C, adiponectin and apolipoprotein B, or ApoB, have been derived from post-hoc analyses using a statistical methodology similar
to that used for all pre-specified endpoints. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
shown in Figure&nbsp;16 below, dose-proportional effects on pharmacodynamic measures were observed for the QW cohorts, with maximal or near-maximal effects achieved with the 70mg QW dose of
AKR-001. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>111</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=114,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=354829,FOLIO='111',FILE='DISK114:[18ZFG1.18ZFG45201]CY45201A.;33',USER='MTITUSS',CD='17-JAN-2019;14:52' -->
<A NAME="page_cy45201_1_112"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>Significant
decreases in triglycerides and increases in HDL-C were observed for all dose groups, with additional significant decreases in non-HDL-C observed at doses greater than or equal to 70mg QW.
Multiple markers of insulin sensitivity were also observed to be improved following treatment at a dose of
70mg QW. Significant decreases in C-peptide observed following the fourth dose of 21mg QW suggests that insulin sensitivity may be improved by longer-term treatment with doses lower than 70mg QW. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>As
discussed above, AKR-001 acts to redirect calories away from the liver to peripheral tissues, such as adipose tissue. Importantly, though, AKR-001 appeared to to be generally weight-neutral in the
four-week Phase&nbsp;1b clinical trial, consistent with reports from earlier clinical studies with third party FGF21 analogues. With AKR-001, there was a trend toward slight weight loss of up to 3%
at 140mg QW and up to 2% at 70mg&nbsp;QW, which we do not believe contributed to the substantial improvement of lipoproteins and markers of insulin sensitivity observed at 70mg QW. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
shown in Figure&nbsp;17 below, dose-related changes in fasting lipoprotein markers were also observed following Q2W dosing of AKR-001, with significant increases in HDL-C and adiponectin
following treatment at doses greater than or equal to 21mg Q2W, and significant decreases in triglycerides at doses greater than or equal to 70mg Q2W, illustrating the biological impact of AKR-001's
half-life extension to up to 3.5&nbsp;days even with an inter-dose interval equivalent to four half-lives. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
comparison of the magnitude of pharmacodynamic changes between the 70mg QW and 140mg Q2W cohorts underscores the additional benefit likely to be gained from weekly dosing. These two doses yielded
approximately equivalent total drug exposure (7-day exposure of 31,900&nbsp;day*ng/mL for 70mg QW vs. 14-day exposure of 55,600&nbsp;day*ng/mL for 140mg Q2W). However, the magnitude and level of
significance for effects at 70mg QW were much higher than at 140mg Q2W. On most measures, the effects observed at 70mg QW were two-fold or more higher than the corresponding changes at 140mg Q2W. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
Figure&nbsp;5 below, N represents the number of patients in a particular group. P or p-values represent the probability that random chance caused the result (e.g.,&nbsp;a p-value&nbsp;= 0.001
means there is a 0.1% probability that the difference between placebo and treatment groups is due to random chance). A p-value 0.05 or less is a commonly-used threshold for statistical significance
and may be supportive of a finding of efficacy by regulatory authorities. However, regulatory authorities, including the FDA and EMA, do not set strict statistical significance thresholds as a
criteria for marketing approval, instead maintaining flexibility to evaluate the overall risks and benefits of a treatment. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>112</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=115,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=812731,FOLIO='112',FILE='DISK114:[18ZFG1.18ZFG45201]CY45201A.;33',USER='MTITUSS',CD='17-JAN-2019;14:52' -->
<A NAME="page_cy45201_1_113"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="cy45201_figure_16__pharmacodynamic_eff__fig02475"> </A>
<A NAME="toc_cy45201_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Figure&nbsp;16: Pharmacodynamic effects of AKR-001 administered once-weekly (QW)    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g292183.jpg" ALT="GRAPHIC" WIDTH="685" HEIGHT="487">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>113</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=116,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=188209,FOLIO='113',FILE='DISK114:[18ZFG1.18ZFG45201]CY45201A.;33',USER='MTITUSS',CD='17-JAN-2019;14:52' -->
<A NAME="page_cy45201_1_114"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="cy45201_figure_17__pharmacodynamic_eff__fig02732"> </A>
<A NAME="toc_cy45201_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Figure&nbsp;17: Pharmacodynamic effects of AKR-001 administered every other week (Q2W)    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g387862.jpg" ALT="GRAPHIC" WIDTH="685" HEIGHT="487">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>114</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=117,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=583879,FOLIO='114',FILE='DISK114:[18ZFG1.18ZFG45201]CY45201A.;33',USER='MTITUSS',CD='17-JAN-2019;14:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_da45201_1_115"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


AKR-001 dose-related effects within target dose range of 21mg to 70mg QW  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have identified AKR-001 doses in the range of 21mg to 70mg QW as the target dose range for evaluation in future clinical trials in patients with NASH. In
the Phase&nbsp;1b clinical trial in patients with T2D, decreases in triglycerides and increases in HDL-C were observed even at the 7mg QW dose; however, improvements in insulin sensitivity, which we
believe will have a therapeutic effect on NASH pathogenesis, appear to require at least a 21mg QW dose. Among all doses tested to date, 70mg QW appears to offer the greatest potential for the
treatment of patients with NASH. The 140mg QW dose level did not appear to confer any meaningful benefit beyond the 70mg QW dose. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Figures&nbsp;18
and 19 below illustrate the dose-related changes from baseline for lipoproteins and markers of insulin sensitivity, respectively, observed following administration of 21mg and 70mg
QW doses of AKR-001, compared to placebo. Significant improvements for each marker of insulin sensitivity were observed at the 70mg QW dose, consistent with agonism of FGFR1c in adipose tissue. At
21mg QW, there were also indications of improved sensitivity to insulin, with a significantly lower level of C-peptide observed after the fourth dose, and a trend toward lower levels of insulin and
lower calculated value of HOMA-IR. These data are consistent with the results of our pharmacokinetic and pharmacodynamic modeling, which suggests that a dose between 21mg and 70mg QW could provide
roughly 60% to 75% or more of the beneficial effects observed at 70mg QW. Although liver fat was not measured in this trial, we believe the magnitude and robustness of effects on lipoproteins at 21mg
and 70mg QW will likely translate into substantial reductions in liver fat with longer-term treatment. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Figure&nbsp;20
below provides the data underlying the graphs, shown in units of mg/dL. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="da45201_figure_18__akr-001_effects_(pe__fig04125"> </A>
<A NAME="toc_da45201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Figure&nbsp;18: AKR-001 effects (percent change from baseline) on lipoproteins and free fatty acids: placebo, 21mg QW, and 70mg QW    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g253653.jpg" ALT="GRAPHIC" WIDTH="616" HEIGHT="463">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>115</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=118,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=893046,FOLIO='115',FILE='DISK114:[18ZFG1.18ZFG45201]DA45201A.;35',USER='MTITUSS',CD='17-JAN-2019;14:45' -->
<A NAME="page_da45201_1_116"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="da45201_figure_19__akr-001_effects_(pe__fig04080"> </A>
<A NAME="toc_da45201_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Figure&nbsp;19: AKR-001 effects (percent change from baseline) on markers of insulin sensitivity: placebo, 21mg QW, and 70mg QW    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g815469.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="519">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>116</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=119,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=46645,FOLIO='116',FILE='DISK114:[18ZFG1.18ZFG45201]DA45201A.;35',USER='MTITUSS',CD='17-JAN-2019;14:45' -->
<A NAME="page_da45201_1_117"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="da45201_figure_20__absolute_change_in___fig03717"> </A>
<A NAME="toc_da45201_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Figure&nbsp;20: Absolute change in metabolic and lipoprotein parameters<BR>  at target dose range of 21mg-70mg QW    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g1011603.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="322">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


AKR-001 70mg QW showed rapid, durable effects  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>AKR-001's effects on lipoproteins and markers of insulin sensitivity were observed to be rapid, consistent, and durable at the 70mg QW dose, with significant
effects persisting after the fourth and final dose (on Day 22)&nbsp;for up to five weeks (on Day 57). Figure&nbsp;21 below shows the observed effect of AKR-001 administered at the 70mg QW dose on
HDL-C, non-HDL-C, and triglycerides at all time points from baseline through Day 57, plotted against serum AKR-001 concentration. Figure&nbsp;22 below similarly provides an integrated-time course
plot for markers of insulin sensitivity: glucose, insulin, C-peptide, and HOMA-IR. Data is shown in both figures as placebo-corrected percent change from baseline, which makes it possible to compare
the magnitude of effects on multiple endpoints in the context of exposure to AKR-001. The red arrows indicate dosing on Days 1, 8, 15 and 22. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
shown below, maximal or near maximal effects were observed by the third dose of 70mg QW for lipoproteins, and by the fourth dose for markers of insulin sensitivity. Reductions in triglyceride and
increases in HDL-C were significant at all time points from Day 4 through Day 57, while non-HDL-C was significantly lower from Day 15 through Day 57. Taken together with published clinical data for
third-party FGF21 analogs, the time-course and magnitude of changes in lipoproteins observed at the 70mg QW dose suggest that AKR-001 has the potential to rapidly and durably reduce liver fat in
patients with NASH. Notably, AKR-001's effects appear to be sustained for three weeks after the final dose, including significant increases of 39% in HDL-C and significant reductions of 28% and 67% in
non-HDL-C and triglycerides, respectively, observed on Day 43. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Figure&nbsp;23
below shows time-course plots for apolipoprotein-B, or ApoB, and adiponectin. These endpoints were measured only on Days 4, 15, 29 and 57. Significant improvements on both measures
were observed by Day 15 at the 70mg QW dose of AKR-001. On both measures, a greater effect was observed on Day 29 than Day 15. No results were available for AKR-001 70mg QW on Day 57. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>117</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=120,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=767063,FOLIO='117',FILE='DISK114:[18ZFG1.18ZFG45201]DA45201A.;35',USER='MTITUSS',CD='17-JAN-2019;14:45' -->
<A NAME="page_da45201_1_118"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="da45201_figure_21__time-course_plots_o__fig02240"> </A>
<A NAME="toc_da45201_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Figure&nbsp;21: Time-course plots of AKR-001 70mg QW lipoprotein effects    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g239315.jpg" ALT="GRAPHIC" WIDTH="603" HEIGHT="409">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="da45201_figure_22__time-course_plots_o__fig03174"> </A>
<A NAME="toc_da45201_5"> </A>
<BR></FONT><FONT SIZE=2><B>  Figure&nbsp;22: Time-course plots of AKR-001 70mg QW effects on markers of insulin sensitivity    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g363172.jpg" ALT="GRAPHIC" WIDTH="603" HEIGHT="412">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>118</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=121,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=300563,FOLIO='118',FILE='DISK114:[18ZFG1.18ZFG45201]DA45201A.;35',USER='MTITUSS',CD='17-JAN-2019;14:45' -->
<A NAME="page_da45201_1_119"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="da45201_figure_23__time-course_plots_o__fig03174"> </A>
<A NAME="toc_da45201_6"> </A>
<BR></FONT><FONT SIZE=2><B>  Figure&nbsp;23: Time-course plots of AKR-001 70mg QW effects on apolipoprotein B and adiponectin    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g471160.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="334">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;1a clinical trial in type&nbsp;2 diabetic patients  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>An earlier Phase&nbsp;1a, randomized, double-blind, placebo-controlled, ascending single-dose clinical trial was conducted by Amgen in patients with T2D to
evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AKR-001. A total of 42 patients received a single-dose of either placebo (N=11) or AKR-001 (N=31) and completed the trial.
Single subcutaneous AKR-001 doses of 2.1mg, 7mg, 21mg, 70mg, or 21mg (N=6 per cohort) were administered. In addition, one patient received a single 70mg IV dose of AKR-001. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


AKR-001 safety and tolerability  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>AKR-001 was reported to be well-tolerated among a total population of 83 patients with T2D in the Phase&nbsp;1a and Phase&nbsp;1b clinical trials. There
were no patient deaths and no serious adverse events attributable to treatment with AKR-001. The most common adverse events were gastrointestinal disorders, such as mild diarrhea and nausea,
consistent with the experience following treatment with other FGF21 investigational drug products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Withdrawals
from investigational product due to adverse events, or AEs, were reported for six subjects in the Phase&nbsp;1b clinical trial (AKR-001, N=5; placebo, N=1). Four of the patients to
withdraw were in the 140mg QW group. We do not plan to investigate this dose level further. The reasons for withdrawal by each of the four subjects dosed at 140mg QW were reported to be diarrhea;
vomiting; tremor; and tremor/nausea for each of the four subjects, respectively. The remaining two withdrawals (one following treatment with 7mg QW; one on placebo) were attributed by the investigator
to hyperglycemia. Subjects were washed off anti-diabetic medications two&nbsp;weeks prior to the first dose and remained so until end of study. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
most common treatment-related, treatment-emergent AEs at doses from 7mg to 70mg QW were nausea, diarrhea and increased appetite. All of the treatment-related AEs were assessed as mild in severity,
except for one instance of moderate severity. All of these treatment-related AEs were transient. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Eleven
of 83 subjects were observed to be positive for anti-AKR-001 antibodies post-baseline. Antibodies from the 11 subjects were non-neutralizing and did not appear to affect the pharmacokinetics or
safety </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>119</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=122,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=9986,FOLIO='119',FILE='DISK114:[18ZFG1.18ZFG45201]DA45201A.;35',USER='MTITUSS',CD='17-JAN-2019;14:45' -->
<A NAME="page_da45201_1_120"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>profile
of AKR-001. Three of seven patients in the Phase&nbsp;1b clinical trial who developed anti-AKR-001 antibodies returned for follow-up approximately two months after receiving the final dose
of AKR-001. In all three of these patients, anti-AKR-001 antibodies could no longer be detected. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Planned Phase&nbsp;2a clinical trial design  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have submitted a Phase&nbsp;2a clinical trial synopsis to FDA in conjunction with a pre-IND meeting request. As proposed, our Phase&nbsp;2a clinical
trial will be a multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial in biopsy-confirmed patients with NASH, with patients randomized to receive weekly subcutaneous dosing of
AKR-001 or placebo for up to 16&nbsp;weeks. Three active treatment arms have been proposed, with a maximum dose of 70mg QW, the highest tolerated dose in the Phase&nbsp;1b clinical trial in T2D
patients. Evaluating the highest-tolerated dose from Phase&nbsp;1 clinical trials and testing multiple doses is consistent with FDA guidance. We have engaged Summit Research Network, a leading third
party investigator with broad expertise in NASH patient enrollment, to assist with patient enrollment for our Phase&nbsp;2a clinical trial. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
primary endpoint of change from baseline in hepatic fat fraction (absolute percent as measured by MRI-PDFF) has been proposed, along with multiple secondary and exploratory endpoints relevant to
NASH, including lipoprotein levels, indices of glycemic control and markers of liver injury and fibrosis. Proposed safety endpoints include incidence of treatment-related, treatment-emergent adverse
events, clinical chemistry and hematology, vital signs, electrocardiogram, body weight and incidence of anti-AKR-001 antibodies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect that the final Phase&nbsp;2a clinical trial design submitted with our IND application will incorporate pre-IND meeting comments from FDA. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Potential improvement of cardiovascular risk factors  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We believe the effects observed following treatment with AKR-001 in clinical trials to date, particularly the 70mg QW dose level, indicate that AKR-001 has
potential to have cardiovascular benefits when tested in patients with NASH, for whom cardiovascular disease is the leading cause of death. Figure&nbsp;24 below describes the extent of reduction in
cardiovascular risk associated with improvement in individual lipoproteins, which are believed to be causal of cardiovascular disease. We believe these help to provide context for the changes in
lipoproteins observed in the Phase&nbsp;1b clinical trial of AKR-001. If the magnitude of improvement in lipoprotein profiles is reproduced in patients with NASH in larger, longer-term trials,
AKR-001 could have the potential to improve cardiovascular outcomes. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>120</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>

<!-- ZEQ.=6,SEQ=123,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=254778,FOLIO='120',FILE='DISK114:[18ZFG1.18ZFG45201]DA45201A.;35',USER='MTITUSS',CD='17-JAN-2019;14:45' -->
<A NAME="page_da45201_1_121"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="da45201_figure_24__rationale_for_akr-0__fig02403"> </A>
<A NAME="toc_da45201_7"> </A>
<BR></FONT><FONT SIZE=2><B>  Figure&nbsp;24: Rationale for AKR-001's potential cardiovascular benefits    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g991841.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="264">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Additional clinical data supporting FGF21 in treatment of NASH  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other endocrine FGF analogs in development have shown encouraging signs of liver fat reduction, improved lipid profiles and reduced fibrosis in clinical
trials in patients with NASH. Daily injections of an FGF19 analog were reported to be associated with a 67% relative reduction in liver fat as measured by MRI-PDFF on Day 85, as well as improvements
in fibrosis as measured by liver biopsy. Daily and weekly injections of a PEGylated FGF21 analog were reported to be associated with 38% and 26% relative reductions in liver fat, respectively,
compared with 6% for placebo, along with positive changes in Pro-C3, a marker of liver fibrosis. A single injection of a mAb developed to mimic FGF21's effects on FGFR1c and
<FONT FACE="SYMBOL">b</FONT>Klotho, but with no activity on FGFR2c and 3c, was reported to be associated with a 37% relative reduction of liver fat as measured by MRI-PDFF on Day 36. The
pattern and magnitude of changes in plasma lipoproteins varied across these three analogs. The FGF19 analog and FGF21 mAb both substantially reduced plasma triglyceride and increased HDL-C in
comparison to the PEGylated FGF21 analog. Treatment with the FGF19 analog was associated with a placebo-corrected 46 mg/dL corresponding to a 40-50% increase in fasting LDL-C, consistent with FGF19's
potent agonism of FGFR4. Neither the FGF19 analog nor the PEGylated FGF21 analog were reported to result in significant reductions in insulin, glucose or C-peptide when evaluated in patients with T2D
in earlier clinical trials. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Exclusive license agreement with Amgen&nbsp;Inc.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In June 2018, we entered into an exclusive license agreement with Amgen&nbsp;Inc., or Amgen, pursuant to which we have been granted an
exclusive, royalty-bearing license to certain intellectual property rights owned or controlled by Amgen, to commercially develop, manufacture, use, distribute and sell therapeutic products, or
Products. In particular, we have been granted licenses under patents filed in both the United States and foreign jurisdictions that are owned or controlled by Amgen, including an exclusive license
under certain patents claiming polypeptides comprised of an FGF21 portion with certain point mutations, a linker, and an Fc domain. Our exclusively licensed patents include, but are not limited to,
the composition of AKR-001 and methods of using the same. In connection with the license, Amgen also licensed and transferred to us certain know-how related to the manufacture of AKR-001 as well as
certain quantities of AKR-001 drug substance manufactured to GMP for clinical use, master cell bank, not-for-human use AKR-001 drug product suitable for nonclinical studies and critical reagents. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>121</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=124,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=417517,FOLIO='121',FILE='DISK114:[18ZFG1.18ZFG45201]DA45201A.;35',USER='MTITUSS',CD='17-JAN-2019;14:45' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dc45201_1_122"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant to the terms of the license agreement, we must use commercially reasonable efforts to develop and commercialize a Product in each of several major market territories.
In addition, Amgen provided us, at its expense, consulting support in connection with the transfer of the licensed materials and the exploitation of the Products. We are also entitled to sublicense
the rights granted to us under the license agreement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
initial consideration for the license, we paid Amgen an upfront payment of $5.0&nbsp;million and also issued 2,653,333 shares of our Series&nbsp;A preferred stock to Amgen at the time of the
initial closing in June 2018 with a subsequent 3,205,128 shares of our Series&nbsp;A preferred stock issued at the time of the second closing in November 2018, representing 10% of total shares
outstanding at such times. As additional consideration for the license, we are required to pay Amgen up to $40.0&nbsp;million upon the achievement of specified clinical and regulatory milestones and
aggregate milestone payments of up to $75.0&nbsp;million upon the achievement of specific commercial milestones. No development or commercial milestones have been achieved to date under the license
agreement. We are also required to pay tiered royalties of low to high single-digit percentages on annual net sales of the products covered by the license. The royalty rate with respect to the net
sales is subject to customary reductions, including in the event that the exploitation of a Product is not covered by a valid claim with the licensed patent rights. The royalty term will terminate on
a country-by-country basis on the later of (i)&nbsp;the expiration date of the last valid claim within the licensed patent rights, (ii)&nbsp;the loss of regulatory exclusivity in such country, and
(iii)&nbsp;the tenth anniversary of the first commercial sale of such product in such country. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
license agreement shall expire upon the expiration of the last-to-expire royalty term for the Products in the territory. Upon expiration of the license agreement, the licenses granted to us shall
be considered fully paid-up, irrevocable and non-exclusive. Either we or Amgen may terminate the license agreement if the other party commits a material breach of the agreement or defaults in the
performance thereunder and fails to cure that breach within 90&nbsp;days (or 30&nbsp;days in the case of failure to make any payment as and when due under the agreement) after written notice is
provided or in the event of bankruptcy, insolvency, dissolution or winding up. Amgen shall have the right to terminate the license agreement in full upon written notice to us in the event we, our
affiliates or sublicensees, directly challenge the patentability, enforceability or validity of any licensed patents, unless, in the event of a sublicensee challenge, we terminate the sublicense
within 60&nbsp;days notice. We shall have the right to terminate the license agreement within 90&nbsp;days written notice to Amgen if we conclude, due to scientific, technical, regulatory or
commercial reasons, that the exploitation of the Products is no longer commercially practicable. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
connection with the license agreement, Amgen entered into certain stockholder agreements related to this investment. See "Certain relationship and related party transactions." </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Intellectual property  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our success depends in part upon our ability to protect our core technology and intellectual property. To protect our intellectual property
rights, we rely on patents, trademarks, copyrights and trade secret laws, confidentiality procedures, and employee disclosure and invention assignment agreements. Our intellectual property is critical
to our business and we strive to protect it through a variety of approaches, including by obtaining and maintaining patent protection in the United States and
internationally for our product candidates, novel biological discoveries, new targets and applications, and other inventions that are important to our business. For our product candidates, we
generally intend to pursue patent protection covering compositions of matter, methods of making and methods of use, including combination therapies. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>122</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=125,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=805699,FOLIO='122',FILE='DISK114:[18ZFG1.18ZFG45201]DC45201A.;24',USER='SCAVALI',CD='17-JAN-2019;14:24' -->
<A NAME="page_dc45201_1_123"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>As
we continue the development of our product candidates, we intend to identify additional means of obtaining patent protection that would potentially enhance commercial success, including through
claims covering additional methods of use and biomarkers and complementary diagnostic and/or companion diagnostic related claims. As of December&nbsp;31, 2018, we have licensed from
Amgen&nbsp;Inc. approximately 153 patents and pending patent applications in the U.S. and foreign jurisdictions, including 113 granted U.S. and foreign patents and 40 pending U.S. and foreign patent
applications. There are currently no pending U.S. provisional patent applications. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2018, our patent portfolio relating to AKR-001 includes twelve issued U.S. patents, two pending U.S. patent applications, and issued and pending foreign counterpart patents
in Europe, Asia, Canada, Australia, and Mexico. Seven issued U.S. patents include claims directed to the AKR-001 product, the FGF21 polypeptide component of the AKR-001 product, nucleic acids encoding
the product and related polypeptides, polypeptide multimers, related compositions, and methods of using AKR-001 to, e.g.,&nbsp;treat diabetes, lower blood glucose in patients suffering from a
metabolic disorder, improve glucose tolerance, lower body weight, or reduce triglyceride levels in patients. These issued U.S. patents are expected to expire in 2029. One pending U.S. patent
application, and related foreign counterparts, is directed to a method of treating nonalcoholic steatohepatitis (NASH); if issued, the resulting U.S. patent is expected to
expire in 2029. One pending U.S. patent application and related foreign counterparts are directed to a method of treating a patient with excess bile acid; if issued, the resulting U.S. patent is
expected to expire in 2036. The portfolio further includes five issued U.S. patents that are directed to related polypeptides and methods of use. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition to patents, we rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and know-how
can be difficult to protect. We seek to protect our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors, and non-solicitation,
confidentiality, and invention assignment agreements with our employees and consultants. We have also executed agreements requiring assignment of inventions with selected scientific advisors and
collaborators. The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to
grant us ownership of technologies that are developed through our relationship with the respective counterparty. We cannot guarantee, however, that we have executed such agreements with all applicable
counterparties, such agreements will not be breached, or that these agreements will afford us adequate protection of our intellectual property and proprietary rights. For more information, see "Risk
factors&#151;Risks related to our intellectual property." </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Manufacturing and supply  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We manage several external commercial manufacturing organizations, or CMOs, to develop and manufacture our product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>AKR-001
drug substance is manufactured by fermentation of a recombinant strain of the bacterium </FONT><FONT SIZE=2><I>E. coli.</I></FONT><FONT SIZE=2> Product accumulates as insoluble particles
(inclusion bodies) within the cells and is recovered by cell disruption, followed by solubilization of the inclusion bodies, protein refolding and several chromatographic separation steps to yield
product with target quality attributes. We have an agreement with Boehringer Ingelheim Biopharmaceuticals&nbsp;GmbH to manufacture GMP drug substance for future clinical trials and commercial
supply. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
acquired approximately 475 grams of AKR-001 drug substance, or DS, as part of our license from Amgen, divided into 10 one-liter bottles and stored in frozen storage at &#150;30 degrees
Celsius. We plan to </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>123</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=126,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=651567,FOLIO='123',FILE='DISK114:[18ZFG1.18ZFG45201]DC45201A.;24',USER='SCAVALI',CD='17-JAN-2019;14:24' -->
<A NAME="page_dc45201_1_124"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>use
this DS manufactured by Amgen in compliance with GMP, to support our planned Phase&nbsp;2a trial. Approximately 100 grams of this material was used to dose two 120-day toxicity studies in rats
and non-human primates. We have converted the remaining drug substance, approximately 375 grams, to drug product, or DP. The new GMP DP was manufactured pursuant to a contract with Vetter Pharma
International GmbH. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
new GMP DP is an Amgen early-stage platform formulation, which is stored as a frozen liquid. We plan to enter into a contract with a formulation development company to explore both a new
refrigerated liquid formulation and a freeze-dried, or lyophilized, formulation. Based on the results of these parallel efforts, we plan to select one approach to progress for use in subsequent
Phase&nbsp;2b clinical development. We also plan to begin development of a pen-type autoinjector for the new drug product formulation. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Sales and marketing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Successful marketing of a new drug for the treatment of NASH will require a targeted commercial infrastructure. We expect to begin making
plans for commercialization following completion of our planned Phase&nbsp;2a clinical trial. We have contracted with a third-party manufacturer to support future clinical trials and the potential
commercialization of AKR-001 with commercial-scale manufacturing. When
appropriate, we intend to develop the commercial infrastructure required for bringing AKR-001 to patients in the United States, if approved. We also plan to evaluate options for delivering AKR-001, if
approved, to patients in other key markets, such as Europe, Japan and China, which may include strategic collaborations. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Competition  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The biotechnology industry is intensely competitive and subject to rapid and significant technological change. Our competitors include
multinational pharmaceutical companies, specialized biotechnology companies and universities and other research institutions. A number of pharmaceutical companies, including AbbVie,&nbsp;Inc.,
Allergan&nbsp;plc, AstraZeneca&nbsp;PLC/MedImmune&nbsp;LLC, Bayer AG, Bristol-Myers Squibb Company, Eisai,&nbsp;Inc., Eli Lilly and Company, GlaxoSmithKline&nbsp;plc, Johnson&nbsp;&amp;
Johnson, Merck&nbsp;&amp;&nbsp;Co.,&nbsp;Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Pfizer&nbsp;Inc., Roche Holding AG, Sanofi and Takeda Pharmaceutical Company Limited, as well
as large and small biotechnology companies such as Albireo Pharma,&nbsp;Inc., Amgen&nbsp;Inc., Cirius Therapeutics,&nbsp;Inc., Conatus Pharmaceuticals&nbsp;Inc., CymaBay
Therapeutics,&nbsp;Inc., Enanta Pharmaceuticals,&nbsp;Inc., Galectin Therapeutics&nbsp;Inc., Galmed Pharmaceuticals&nbsp;Ltd., Genfit&nbsp;SA, Gilead Sciences,&nbsp;Inc., Intercept
Pharmaceuticals,&nbsp;Inc., Inventiva Pharma&nbsp;SA, Madrigal Pharmaceuticals,&nbsp;Inc., MannKind Corporation, MediciNova,&nbsp;Inc., Metacrine,&nbsp;Inc., Nalpropion
Pharmaceuticals,&nbsp;Inc., NGM Biopharmaceuticals,&nbsp;Inc., Terns Pharmaceuticals,&nbsp;Inc., Viking Therapeutics,&nbsp;Inc., Vivus,&nbsp;Inc. and Zafgen,&nbsp;Inc., are pursuing the
development or marketing of pharmaceuticals that target NASH. It is also probable that the number of companies seeking to develop products and therapies for the treatment of serious metabolic
diseases, such as NASH, will increase. Many of our competitors have substantially greater financial, technical, human and other resources than we do and may be better equipped to develop, manufacture
and market technologically superior products. In addition, many of these competitors have significantly greater experience than we have in undertaking nonclinical studies and human clinical trials of
new pharmaceutical products and in obtaining regulatory approvals of human therapeutic products. Accordingly, our competitors may succeed in obtaining FDA approval for superior products. Many of our
competitors have established distribution channels for the commercialization of their products, whereas we have no such channel or capabilities. In addition, many competitors have greater name
recognition and more extensive collaborative relationships. Smaller and earlier-stage companies may </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>124</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=127,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=820376,FOLIO='124',FILE='DISK114:[18ZFG1.18ZFG45201]DC45201A.;24',USER='SCAVALI',CD='17-JAN-2019;14:24' -->
<A NAME="page_dc45201_1_125"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>also
prove to be significant competitors, particularly through collaborative arrangements with large, established companies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
competitors may obtain regulatory approval of their products more rapidly than we do or may obtain patent protection or other intellectual property rights that limit our ability to develop or
commercialize our product candidate or any future product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better
safety profile than our products and these competitors may also be more successful than we are in manufacturing and marketing their products. If we are unable to compete effectively against these
companies, then we may not be able to commercialize our product candidate or any future product candidates or achieve a competitive position in the market. This would adversely affect our ability to
generate revenue. Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration
for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Government regulation  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among
other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval,
advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to
navigate the various nonclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure
of our product candidates. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


U.S. biological product development  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, and the Public Health Service
Act, or PHS Act, and other federal, state, local and foreign statutes and regulations. The process required by the FDA before a biological product may be marketed in the United States generally
involves the following:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> completion of nonclinical laboratory tests and animal studies performed in accordance with the FDA's Good Laboratory Practice (GLP) regulation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> submission to the FDA of an investigational new drug application, or IND, which must become effective before clinical trials may begin and must
be updated annually or when significant changes are made; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approval of a clinical trial protocol and related documentation by an independent Institutional Review Board, or IRB, or ethics committee at
each clinical site before the trial may be initiated; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> performance of adequate and well-controlled human clinical trials according to FDA's regulations commonly referred to as Good Clinical
Practices, or GCPs, and any additional requirements for the protection of human research subjects and their health information, to establish the safety, purity and potency of the proposed biologic
product candidate for its intended use; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> preparation of and submission to the FDA of a Biologics License Application, or BLA, for marketing authorization that includes substantive
evidence of safety, purity, and potency from results of nonclinical testing and clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> satisfactory completion of an FDA Advisory Committee review, if applicable; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>125</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=128,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=911412,FOLIO='125',FILE='DISK114:[18ZFG1.18ZFG45201]DC45201A.;24',USER='SCAVALI',CD='17-JAN-2019;14:24' -->
<A NAME="page_dc45201_1_126"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a determination by the FDA within 60&nbsp;days of its receipt of a BLA to file the application for review; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess
compliance with current Good Manufacturing Practices, or cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product's identify, strength, quality
and purity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the BLA in accordance with any applicable
expedited programs or designations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> payment of user fees for FDA review of the BLA (unless a fee waiver applies); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> FDA review and approval, or licensure, of the BLA to permit commercial marketing of the product for particular indications for use in the
United States. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nonclinical and clinical development  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Before testing any biological product candidate in humans, the product candidate enters the nonclinical testing stage. Nonclinical tests, also referred to as
nonclinical studies, include laboratory evaluations of product biological characteristics, chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of
the product candidate. The conduct of the nonclinical tests must comply with federal regulations and requirements including GLPs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior
to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug
product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of the nonclinical tests,
including animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls (CMC)
information; and any available human data or
literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30&nbsp;days after receipt
by the FDA, unless the FDA places the clinical trial on a clinical hold within the 30-day time period. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must
resolve any outstanding concerns or questions before the clinical trial can begin. The FDA also may impose clinical holds on a biological product candidate at any time before or during clinical trials
due to, among other considerations, unreasonable or significant safety concerns, inability to assess safety concerns, lack of qualified investigators, a misleading or materially incomplete
investigator brochure, study design deficiencies, interference with the conduct or completion of a study designed to be adequate and well-controlled for the same or another investigational drug,
insufficient quantities of investigational product, lack of effectiveness, or non-compliance. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing a clinical trial
to begin, or that, once begun, issues or circumstances will not arise that delay, suspend or terminate such studies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Clinical
trials involve the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or
under the study sponsor's control, in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study.
Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, dosing procedures, subject selection and exclusion criteria, and the parameters to be used in
monitoring subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. A separate </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>126</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=129,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=729286,FOLIO='126',FILE='DISK114:[18ZFG1.18ZFG45201]DC45201A.;24',USER='SCAVALI',CD='17-JAN-2019;14:24' -->
<A NAME="page_dc45201_1_127"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>submission
to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each
site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its related documentation before the clinical trial begins at that site, and must monitor the
study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an
unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study
sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and
may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the
reporting of ongoing clinical studies and clinical study results to public registries. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not
conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA may accept a well-designed and well-conducted foreign clinical study not conducted
under an IND if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Clinical
trials typically are conducted in three sequential phases that may overlap or be combined:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I>Phase&nbsp;1&#151;</I></B></FONT><FONT SIZE=2>The investigational product is initially introduced into healthy
human subjects. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with
increasing doses, and, if possible, to gain early evidence on effectiveness. In the cases of some products for severe of life-threatening diseases, especially when the product may be too inherently
toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in the targeted patient population. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I>Phase&nbsp;2&#151;</I></B></FONT><FONT SIZE=2>The investigational product is administered to a limited patient
population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple
Phase&nbsp;2 clinical trials may be conducted to obtain information prior to beginning Phase&nbsp;3 clinical trials. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B><I>Phase&nbsp;3&#151;</I></B></FONT><FONT SIZE=2>The investigational product is administered to an expanded patient
population to further evaluate dosage, to provide significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These
clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval or licensure and product labeling. </FONT></DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>In
some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so called
Phase&nbsp;4 studies may be made a condition to approval of the BLA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During
all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress
reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected
adverse events, any findings from other studies, tests in laboratory animals or </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> testing that suggest a significant risk for human </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>127</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=130,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=768574,FOLIO='127',FILE='DISK114:[18ZFG1.18ZFG45201]DC45201A.;24',USER='SCAVALI',CD='17-JAN-2019;14:24' -->
<A NAME="page_dc45201_1_128"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>subjects,
or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety
report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected
adverse reaction within seven calendar days after the sponsor's initial receipt of the information. Phase&nbsp;1, Phase&nbsp;2 and Phase&nbsp;3 clinical trials may not be completed successfully
within any specified period, if at all. The FDA or the sponsor, acting on its own or based on a recommendation from the sponsor's data safety monitoring board may suspend a clinical trial at any time
on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial
at its institution if the clinical trial is not being conducted in accordance with the IRB's requirements or if the biological product has been associated with unexpected serious harm to patients. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Concurrent
with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a
process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product
candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally,
appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


BLA submission and review  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,
nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. FDA approval of a BLA must be obtained before a
biologic may be marketed in the United States. The BLA must include all relevant data available from pertinent nonclinical and clinical studies, including negative or ambiguous results as well as
positive findings, together with detailed information relating to the product's chemistry, manufacturing, controls, and proposed labeling, among other things. The submission of a BLA requires payment
of a substantial application user fee to FDA, unless a waiver or exemption applies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Within
60&nbsp;days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the FDA accepts it for filing. The FDA may refuse to
file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional
information. The resubmitted application also is subject to review before the FDA accepts it for filing. Under the performance goals and
policies implemented by the FDA under the Prescription Drug User Fee Act, or PDUFA, for original BLAs, the FDA targets ten months from the filing date in which to complete its initial review of a
standard application and respond to the applicant, and six months from the filing date for an application with priority review. In both standard and priority reviews, the FDA does not always meet its
PDUFA goal dates, and the review process is often significantly extended by FDA requests for additional information or clarification. This review typically takes twelve months from the date the BLA is
submitted to the FDA because the FDA has approximately two months to make a "filing" decision. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the BLA
sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>128</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=131,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=812259,FOLIO='128',FILE='DISK114:[18ZFG1.18ZFG45201]DC45201A.;24',USER='SCAVALI',CD='17-JAN-2019;14:24' -->
<A NAME="page_dc45201_1_129"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>Once
the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews a BLA to determine, among other things, whether a proposed product is safe, pure
and potent, for its intended use, and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product's continued safety, purity and potency.
Further, the FDA may convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers
such recommendations carefully when making decisions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Before
approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve a product unless it determines that the manufacturing
processes
and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will
typically inspect one or more clinical sites to assure compliance with GCP requirements. If the FDA determines that the application, manufacturing process or manufacturing facilities are not
acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA
ultimately may decide that the application does not satisfy the regulatory criteria for approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After
the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or
a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe
all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the
Complete Response letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may
recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a
BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For
example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or
potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician
communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other
things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing
requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase&nbsp;4 post-market studies and surveillance to further assess and
monitor the product's safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expedited development and review programs  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The FDA has various programs, including Fast Track designation, breakthrough therapy designation, accelerated approval and priority review, that are intended
to expedite or simplify the process for the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>129</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=132,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=945855,FOLIO='129',FILE='DISK114:[18ZFG1.18ZFG45201]DC45201A.;24',USER='SCAVALI',CD='17-JAN-2019;14:24' -->
<A NAME="page_dc45201_1_130"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>development
and FDA review of biologics that are intended for the treatment of serious or life-threatening diseases or conditions. These programs do not change the standards for approval but may help
expedite the development or approval process. To be eligible for Fast Track designation, new biological products must be intended to treat a serious or life-threatening condition and demonstrate the
potential to address an unmet medical need for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of
a new biologic may request the FDA to designate the biologic as a Fast Track product at any time during the clinical development of the product. One benefit of Fast Track designation, for example, is
that the FDA may consider for review sections of the marketing application for a product that has received Fast Track designation on a rolling basis before the complete application is submitted. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Under
the FDA's breakthrough therapy program, products intended to treat a serious or life-threatening disease or condition may be eligible for the benefits of the Fast Track program when preliminary
clinical evidence demonstrates that such product may have substantial improvement on one or more clinically significant endpoints over existing therapies. Additionally, the FDA will seek to ensure the
sponsor of a breakthrough therapy product receives timely advice and interactive communications to help the sponsor design and conduct a development program as efficiently as possible. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
product is eligible for priority review if it treats a serious or life-threatening disease or condition and has the potential, if approved, to provide a significant improvement in safety and
effectiveness. The FDA
will attempt to direct additional resources to the evaluation of an application for a new biological product designated for priority review in an effort to facilitate the review. Under priority
review, the FDA's goal is to review an application in six months once it is filed, compared to ten months for a standard review. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additionally,
a product may be eligible for accelerated approval (also referred to as Subpart&nbsp;E approval). Biological products studied for their safety and effectiveness in treating serious or
life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments, as demonstrated by a surrogate or intermediate clinical endpoint, may receive accelerated approval.
Specifically, this means that they may be approved on the basis of clinical data establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical
benefit, or on the basis of an effect on an intermediate clinical endpoint other than survival or irreversible morbidity. As a condition of approval, the FDA may require that a sponsor of a biological
product receiving accelerated approval perform adequate and well-controlled post-marketing confirmatory clinical trials. In addition, the FDA currently requires as a condition for accelerated approval
pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pediatric information  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under the Pediatric Research Equity Act, a BLA or supplement to a BLA must contain data to assess the safety and efficacy of the drug for the claimed
indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals
for submission of pediatric data or full or partial waivers. A sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage
form, new dosing regimen, or new route of administration must submit an initial Pediatric Study Plan, or PSP, within 60&nbsp;days of an end-of-Phase&nbsp;2 meeting or, if there is no such meeting,
as early as practicable before the initiation of the Phase&nbsp;3 of Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct,
including study objectives and design, age groups, relevant endpoints, and statistical approach, or a justification for not including such detailed information, and any request for a deferral of
pediatric assessments or a full or partial </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>130</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=133,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=908204,FOLIO='130',FILE='DISK114:[18ZFG1.18ZFG45201]DC45201A.;24',USER='SCAVALI',CD='17-JAN-2019;14:24' -->
<A NAME="page_dc45201_1_131"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>waiver
of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an
agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from nonclinical studies, early phase clinical trials, and/or other clinical
development programs. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Post-Approval requirements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other
things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval,
most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under
which FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and
certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for ongoing compliance with cGMP, which impose certain procedural and documentation
requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval
before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may
decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory
compliance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously
unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in
revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other
restrictions under a REMS program. Other potential consequences include, among other things:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> fines, warning letters or holds on post-approval clinical studies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product
approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> product seizure or detention, or refusal of the FDA to permit the import or export of products; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> injunctions or the imposition of civil or criminal penalties. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by
the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply
with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally
available products for uses that are not described in the product's labeling and that differ from those tested by us and approved by the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>131</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=134,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=628759,FOLIO='131',FILE='DISK114:[18ZFG1.18ZFG45201]DC45201A.;24',USER='SCAVALI',CD='17-JAN-2019;14:24' -->
<A NAME="page_dc45201_1_132"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>FDA.
Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not
regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer's communications on the subject of off-label use of their products. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


U.S. patent term restoration and marketing exclusivity  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for
limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up
to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent
beyond a total of 14&nbsp;years from the product's approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a
BLA plus the time between the submission data of a BLA and the approval of that application. Only one patent applicable to an approved biological product is eligible for the extension and the
application for the extension must be submitted prior to the expiration of the patent. In addition, a patent can only be extended once and only for a single product. The United States
Patent and Trademark Office, or U.S. PTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for
restoration of patent term for one of our patents, if and as applicable, to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other
factors involved in the filing of the relevant BLA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
biological product can obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods, including some regulatory
exclusivity periods tied to patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a
pediatric study in accordance with an FDA-issued "Written Request" for such a study. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, signed into law in 2010, includes a subtitle
called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an
FDA-approved reference biological product. To date, a number of biosimilars have been licensed under the BPCIA, and numerous biosimilars have been approved in Europe. The FDA has issued several
guidance documents outlining an approach to review and approval of biosimilars. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Biosimilarity,
which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through
analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be
expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference
biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.
Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to
implementation of the abbreviated approval pathway that are still being worked out by the FDA. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>132</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=135,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=905690,FOLIO='132',FILE='DISK114:[18ZFG1.18ZFG45201]DC45201A.;24',USER='SCAVALI',CD='17-JAN-2019;14:24' -->
<A NAME="page_dc45201_1_133"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>Under
the BPCIA, a reference biological product is granted four and 12&nbsp;year exclusivity periods from the time of first licensure of the product. FDA will not accept an application for a
biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product, and FDA will not approve an application for
a biosimilar or interchangeable product based on the reference biological product until twelve years after the date of first licensure of the reference product. "First licensure" typically means the
initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for)
a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor,
predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration,
dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or
potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity, or potency to assess
whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the "first licensure"
of a biological product is determined on a case-by-case basis with data submitted by the sponsor. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other
aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the
BPCIA is subject to significant uncertainty. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other U.S. healthcare and Data Privacy laws and compliance requirements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States, our current and future operations are subject to regulation by various federal, state and local authorities in addition to the FDA,
including but not limited to, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, or HHS (such as the Office of Inspector
General, Office for Civil Rights and the Health Resources and Service Administration), the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local
governments. For example, our clinical research, sales, marketing and scientific/educational grant programs may have to comply with the anti-fraud and abuse provisions of the Social Security Act, the
false claims laws, the privacy and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws, each as amended, as applicable. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly,
overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering, arranging for or recommending the purchase, lease or order of any item or service reimbursable, in
whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The federal Anti-Kickback Statute has
been interpreted to apply to arrangements between therapeutic product manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory
exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be
alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a
particular applicable statutory exception or regulatory safe harbor </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>133</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=136,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=887045,FOLIO='133',FILE='DISK114:[18ZFG1.18ZFG45201]DC45201A.;24',USER='SCAVALI',CD='17-JAN-2019;14:24' -->
<A NAME="page_dc45201_1_134"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>does
not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all
of its facts and circumstances. Our practices may not meet the criteria for protection under a statutory exception or regulatory safe harbor. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additionally,
the intent standard under the federal Anti-Kickback Statute was amended by the Affordable Care Act, such that a person or entity does not need to have actual knowledge of the statute or
specific intent to violate it in order to have committed a violation. In addition, the Affordable Care Act codified case law that a claim including items or services resulting from a violation of the
federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act, or FCA (discussed below). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
federal false claims and civil monetary penalty laws, including the FCA, which can be enforced by private citizens through civil qui tam actions, prohibit any person or entity from, among other
things, knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to, or approval by, the federal government, including federal healthcare programs, such as Medicare
and Medicaid, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or knowingly making a false
statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government. A claim includes "any request or demand" for money or property presented to the U.S.
government. For instance, historically, pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that
the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies' marketing of the product for
unapproved, off-label, and thus generally non-reimbursable, uses. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>HIPAA
created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false
or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors,
willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any
materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the federal Anti-Kickback Statute, the Affordable
Care Act amended the intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to
violate it in order to have committed a violation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Also,
many states have similar, and typically more prohibitive, fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in
several states, apply regardless of the payor. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for
Economic and Clinical Health Act, or HITECH, and their implementing regulations, as well as the California Consumer Privacy Act of 2018 (the "CCPA"), impose requirements relating to the privacy,
security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA's privacy and security standards directly applicable to business associates,
independent contractors, or agents of covered entities, which include certain healthcare providers, health plans, and healthcare clearinghouses, that receive or obtain protected health information in
connection with providing a service on behalf of a </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>134</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=137,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=673506,FOLIO='134',FILE='DISK114:[18ZFG1.18ZFG45201]DC45201A.;24',USER='SCAVALI',CD='17-JAN-2019;14:24' -->
<A NAME="page_dc45201_1_135"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>covered
entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys
general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys' fees and costs associated with pursuing federal civil actions. In
addition, many state laws govern the privacy and security of health information in specified circumstances. For example, in California the CCPA establishes a new privacy framework for covered
businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers in the State of California, imposing special rules on the collection of
consumer data from minors, and creating a new and potentially
severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. Many of the state laws
differ from each other in significant ways and are often not pre-empted by HIPAA, and may have a more prohibitive effect than HIPAA, thus complicating compliance efforts. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
may develop products that, once approved, may be administered by a physician. Under currently applicable U.S. law, certain products not usually self-administered (including injectable drugs) may be
eligible for coverage under Medicare through Medicare Part&nbsp;B. Medicare Part&nbsp;B is part of original Medicare, the federal health care program that provides health care benefits to the aged
and disabled, and covers outpatient services and supplies, including certain pharmaceutical products, that are medically necessary to treat a beneficiary's health condition. As a condition of
receiving Medicare Part&nbsp;B reimbursement for a manufacturer's eligible drugs, the manufacturer is required to participate in other government healthcare programs, including the Medicaid Drug
Rebate Program and the 340B Drug Pricing Program. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary
of HHS as a condition for states to receive federal matching funds for the manufacturer's outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer must
extend discounts to entities that participate in the program. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in
some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or
private payors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additionally,
the federal Physician Payments Sunshine Act, or the Sunshine Act, within the Affordable Care Act, and its implementing regulations, require that certain manufacturers of drugs, devices,
biological and medical supplies for which payment is available under Medicare, Medicaid or the Children's Health Insurance Program (with certain exceptions) report annually to CMS information related
to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, physicians and
teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members. In addition, many states also govern the reporting of
payments or other transfers of value, many of which differ from each other in significant ways, are often not pre-empted, and may have a more prohibitive effect than the Sunshine Act, thus further
complicating compliance efforts. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state,
including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also
impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new
technology capable of tracking and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>135</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=138,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=71034,FOLIO='135',FILE='DISK114:[18ZFG1.18ZFG45201]DC45201A.;24',USER='SCAVALI',CD='17-JAN-2019;14:24' -->
<A NAME="page_dc45201_1_136"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>tracing
product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs,
file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to
prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit
certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Ensuring
business arrangements with third parties comply with applicable healthcare laws and regulations is a costly endeavor. If our operations are found to be in violation of any of the federal and
state healthcare laws described above or any other current or future governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and/or
administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private "qui tam"
actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens,
diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of
non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Coverage, pricing and reimbursement  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may obtain regulatory approval. In the
United States and in foreign markets, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide
coverage and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, such as Medicare and Medicaid, private
managed care providers, health insurers and other organizations. Adequate coverage and reimbursement from third-party payors are critical to new product acceptance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
ability to commercialize any products successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available
from third-party payors. Third-party payors decide which therapeutics they will pay for and establish reimbursement levels. Coverage and reimbursement by a third-party payor may depend upon a number
of factors, including the third-party payor's determination that use of a therapeutic is:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a covered benefit under its health plan; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> safe, effective and medically necessary; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT
SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> appropriate for the specific patient; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> cost-effective; and </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> neither
experimental nor investigational. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
cannot be sure that reimbursement will be available for any product that we commercialize and, if coverage and reimbursement are available, what the level of reimbursement will be. Coverage may
also be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Reimbursement may impact the demand for, or the price of, any product
for which we obtain regulatory approval. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>136</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=15,SEQ=139,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=252692,FOLIO='136',FILE='DISK114:[18ZFG1.18ZFG45201]DC45201A.;24',USER='SCAVALI',CD='17-JAN-2019;14:24' -->
<A NAME="page_dc45201_1_137"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>Third-party
payors are increasingly challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning
their safety and efficacy. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with branded drugs and drugs administered under the
supervision of a physician. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs
required to obtain FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. Obtaining coverage and reimbursement approval of a product from a government or
other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our product on
a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. A third-party payor's decision to provide coverage for a product does not imply that an adequate
reimbursement rate will be approved. Further, in the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Private third-party payors tend to
follow Medicare coverage and reimbursement limitations to a substantial degree, but also have their own methods and approval process apart from Medicare determinations. Therefore, one payor's
determination to provide coverage for a product does not assure
that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return
on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any product candidate that we
successfully develop. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Different
pricing and reimbursement schemes exist in other countries. In the European Union, governments influence the price of pharmaceutical products through their pricing and reimbursement rules
and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may
only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost
effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits.
The downward pressure on health care costs has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border
imports from low-priced markets exert a commercial pressure on pricing within a country. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if third-party payors fail to provide coverage and adequate reimbursement. In
addition, emphasis on managed care, the increasing influence of health maintenance organizations, and additional legislative changes in the United States has increased, and we expect will continue to
increase, the pressure on healthcare pricing. The downward pressure on the rise in healthcare costs in general, particularly prescription medicines, medical devices and surgical procedures and other
treatments, has become very intense. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more
products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Healthcare reform  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>137</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=16,SEQ=140,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=746826,FOLIO='137',FILE='DISK114:[18ZFG1.18ZFG45201]DC45201A.;24',USER='SCAVALI',CD='17-JAN-2019;14:24' -->
<A NAME="page_dc45201_1_138"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>ability
to profitably sell product candidates for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting
changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular
focus of these efforts and has been significantly affected by major legislative initiatives. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
example, the Affordable Care Act has substantially changed healthcare financing and delivery by both governmental and private insurers. Among the Affordable Care Act provisions of importance to
the pharmaceutical and biotechnology industries, in addition to those otherwise described above, are the following:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents
apportioned among these entities according to their market share in some government healthcare programs that began in 2011; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January&nbsp;1,
2010, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer
Price, or AMP; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a new Medicare Part&nbsp;D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts, which
through subsequent legislative amendments, will be increased to 70%, starting in 2019, off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a
condition for the manufacturers' outpatient drugs to be covered under Medicare Part&nbsp;D; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> extension of manufacturers' Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care
organizations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional
individuals beginning in 2014 and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing
manufacturers' Medicaid rebate liability; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> expansion of the entities eligible for discounts under the 340B Drug Discount Program; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research,
along with funding for such research; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> expansion of healthcare fraud and abuse laws, including the FCA and the federal Anti-Kickback Statute, new government investigative powers, and
enhanced penalties for noncompliance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled,
infused, instilled, implanted, or injected; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> requirements to report certain financial arrangements with physicians and teaching hospitals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare
and Medicaid spending; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a licensure framework for follow on biologic products. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>138</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=17,SEQ=141,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=115422,FOLIO='138',FILE='DISK114:[18ZFG1.18ZFG45201]DC45201A.;24',USER='SCAVALI',CD='17-JAN-2019;14:24' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_de45201_1_139"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Some of the provisions of the Affordable Care Act have yet to be implemented, and there have been legal and political challenges to certain aspects of the Affordable Care Act.
Since January 2017, President Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act.
Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the Affordable Care Act. While Congress has not passed comprehensive repeal legislation, two
bills affecting the implementation of certain taxes under the
Affordable Care Act have been signed into law. The Tax Cuts and Jobs Act of 2017, or Tax Act, includes a provision repealing, effective January&nbsp;1, 2019, the tax-based shared responsibility
payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the "individual mandate." On
January&nbsp;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain Affordable Care Act-mandated fees, including
the so-called "Cadillac" tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise
tax on non-exempt medical devices. The Bipartisan Budget Act of 2018, or the BBA, among other things, amends the Affordable Care Act, effective January&nbsp;1, 2019, to close the coverage gap in
most Medicare drug plans, commonly referred to as the "donut hole". In July 2018, CMS announced that it is suspending further collections and payments to and from certain Affordable Care Act qualified
health plans and health insurance issuers under the Affordable Care Act risk adjustment program pending the outcome of federal district court litigation regarding the method CMS uses to determine this
risk adjustment. On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and
inserverable feature of the Affordable Care Act, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the Affordable Care Act are invalid as well. While the Trump
Administration and CMS have both stated that the ruling will have no immediate effect and on December&nbsp;30, 2018 the Texas District Court Judge issued an order staying the judgment pending
appeal, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other
legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which,
among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a
targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation's automatic reduction to several government programs. This includes aggregate
reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April&nbsp;1, 2013 and, due to legislation amendments to the statute, including the BBA,
will stay in effect through 2027 unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further
reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to
recover overpayments to providers from three to five years. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additionally,
there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S.
Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under
Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump
administration's budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>139</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=142,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=518958,FOLIO='139',FILE='DISK114:[18ZFG1.18ZFG45201]DE45201A.;15',USER='MTITUSS',CD='17-JAN-2019;14:54' -->
<A NAME="page_de45201_1_140"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>budget
process or in other future legislation, including, for example, measures to permit Medicare Part&nbsp;D plans to negotiate the price of certain drugs under Medicare Part&nbsp;B, to allow
some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Further, the Trump administration released a "Blueprint", or plan, to
lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare
programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. HHS has already started the process of soliciting
feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. For example, in September 2018, CMS announced that it will allow Medicare
Advantage Plans the option to use step therapy for Part&nbsp;B drugs beginning January&nbsp;1, 2019, and in October 2018, CMS proposed a new rule that would require direct-to-consumer television
advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or
list price, of that drug or biological product. While a number of these and other proposed measures will require authorization through additional legislation to become effective, Congress and the
Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Individual states in the United States have also
increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain
product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Further,
on May&nbsp;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or the Right to Try Act, was signed into law. The law, among other
things, provides a federal framework for certain patients to request access to certain investigational new drug products that
have completed a Phase&nbsp;I clinical trial and that are undergoing investigation for FDA approval. There is no obligation for a pharmaceutical manufacturer to make its drug products available to
eligible patients as a result of the Right to Try Act. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Foreign Corrupt Practices Act  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of
value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or
business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and
records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for
international operations. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Government regulations outside the United States  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, research and
development, clinical trials, testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving
biological products as well as authorization and approval of our products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Whether
or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing
of the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>140</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=143,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=434997,FOLIO='140',FILE='DISK114:[18ZFG1.18ZFG45201]DE45201A.;15',USER='MTITUSS',CD='17-JAN-2019;14:54' -->
<A NAME="page_de45201_1_141"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>product
in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the
commencement of human clinical trials. In the European Union, for example, a Clinical Trial Application, or CTA, must be submitted for each clinical trial to each country's national health authority
and an independent ethics committee, much like the FDA and an IRB, respectively. Once the CTA is approved in accordance with a country's requirements, the corresponding clinical trial may proceed. The
requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in
accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulation in the European Union  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the European Union, medicinal products are subject to extensive pre- and post-market regulation by regulatory authorities at both the European Union and
national levels. To obtain regulatory approval of an investigational product under European Union regulatory systems, we must submit a Marketing Authorization Application, or MAA. The application used
to submit the BLA in the United States is similar to that required in the European Union, with the exception of, among other things, region-specific document requirements. The European Union also
provides opportunities for market exclusivity. For example, in the European Union, upon receiving marketing authorization, innovative medicinal products generally receive eight years of data
exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents regulatory authorities in the European Union from referencing the innovator's data to assess a
generic or biosimilar application. During the additional two-year period of market exclusivity, a generic or biosimilar marketing authorization can be submitted, and the innovator's data may be
referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity. However, there is no guarantee that a product will be considered by the European
Union's regulatory authorities to be an innovative medicinal product, and products may not qualify for data exclusivity. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pediatric development in the European Union  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the European Union, companies developing a new medicinal product must agree upon a Pediatric Investigation Plan, or PIP, with the EMA, and must conduct
pediatric clinical trials in accordance with that PIP, unless a waiver applies, (e.g.,&nbsp;because the relevant disease or condition occurs only in adults). The marketing authorization application
for the product must include the results of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has been granted, in which case the pediatric
clinical trials must be completed at a later date. Products that are granted a marketing authorization on the basis of the pediatric clinical trials conducted in accordance with the PIP are eligible
for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a two year
extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Post-approval controls in the European Union  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The holder of a marketing authorization must establish and maintain a pharmacovigilance system and appoint an individual qualified person for
pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports,
or PSURs. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>141</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=144,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=813515,FOLIO='141',FILE='DISK114:[18ZFG1.18ZFG45201]DE45201A.;15',USER='MTITUSS',CD='17-JAN-2019;14:54' -->
<A NAME="page_de45201_1_142"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>All
new MAAs must include a risk management plan, or RMP, describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated
with the product. The regulatory authorities may also impose specific obligations as a condition of the marketing authorization. Such risk-minimization measures or postauthorization obligations may
include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. RMPs and PSURs are routinely available to
third parties requesting access, subject to limited redactions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>All
advertising and promotional activities for the product must be consistent with the approved Summary of Product Characteristics, or SmPC, and therefore all off-label promotion is prohibited.
Direct-to-consumer advertising of prescription medicines is also prohibited in the European Union. Although general requirements for advertising and promotion of medicinal products are established
under EU directives, the details are governed by regulations in each European Union Member State and can differ from one country to another. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


European data collection  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The collection and use of personal health data in the European Union is governed by the provisions of the Data Protection Directive, and as of May 2018 the
General Data Protection Regulation, or GDPR. This directive imposes more stringent requirements relating to the consent of the individuals to whom the personal data relates, the information provided
to the individuals, notification of data processing obligations to the competent national data protection authorities, and the security and confidentiality of the personal data. The Data Protection
Directive and GDPR also impose strict rules on the transfer of personal data out of the European Union to the United States. Failure to comply with the requirements of the Data Protection Directive,
the GDPR, and the related national data protection laws of the European Union Member States may result in fines and other administrative penalties. The GDPR introduces new data protection requirements
in the European Union and substantial fines for breaches of the data protection rules, specifically fines are increased to levels of up to 4% total worldwide annual turnover or up to
&euro;20&nbsp;million (whichever is higher). The GDPR regulations may impose additional responsibility and liability in relation to personal data that we process and we may be required to
put in place additional mechanisms ensuring compliance with the new data protection rules. We are subject to the GDPR if we
have a presence or "establishment" in the European Union or E.U. (e.g.&nbsp;E.U. based subsidiary or operations), when conducting clinical trials with E.U. based data subjects (whether the trials
are conducted directly by us or through a clinical vendor or partner) or offering approved products or services (if relevant) to E.U. based data subjects (regardless of whether involving our E.U.
based subsidiary or operations). The GDPR regulations may be onerous and adversely affect our business, financial condition, results of operations, and prospects. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


European Union drug marketing  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Much like the Anti Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the
prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to physicians is
governed by the national anti bribery laws of European Union Member States. Infringement of these laws could result in substantial fines and imprisonment. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Payments
made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the
physician's employer, his or her competent professional organization, and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national
laws, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>142</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=145,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=523566,FOLIO='142',FILE='DISK114:[18ZFG1.18ZFG45201]DE45201A.;15',USER='MTITUSS',CD='17-JAN-2019;14:54' -->
<A NAME="page_de45201_1_143"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>industry
codes, or professional codes of conduct, applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands,
administrative penalties, fines, or imprisonment. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rest of world regulation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For other countries outside the European Union and the United States, such as countries in Eastern Europe, Latin America, Middle East, or Asia, the
requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to country. Additionally, the clinical trials must be conducted in accordance
with GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of
products, operating restrictions, or criminal prosecution. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Additional regulation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In addition to the foregoing, local, state and federal laws regarding such matters as safe working conditions, manufacturing practices, environmental
protection, fire hazard control and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our
business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations
result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with
applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our
future operations. We may incur significant costs to comply with such laws and regulations now or in the future. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Employees  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of December&nbsp;31, 2018, we employed seven full-time employees and one part-time employee, including five with M.D. and/or Ph.D.
degrees. Of these employees, six are in research and development and two are general and administrative. We have never had a work stoppage, and none of our employees is represented by a labor
organization or under any collective-bargaining arrangements. We consider our employee relations to be good. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Facilities  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We lease our office space, which consists of 383 square feet located at 170 Harbor Way, South San Francisco, California. Our lease expires on
April&nbsp;30, 2019, subject to automatic renewals for successive thirty (30)&nbsp;day periods. We believe our current office and laboratory space is sufficient to meet our needs until the
expiration of our lease, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Legal proceedings  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of the date of this prospectus, we were not subject to any material legal proceedings. From time to time, we may be involved in legal
proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement
costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>143</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=146,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=711455,FOLIO='143',FILE='DISK114:[18ZFG1.18ZFG45201]DE45201A.;15',USER='MTITUSS',CD='17-JAN-2019;14:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dg45201_1_144"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="dg45201_management"> </A>
<A NAME="toc_dg45201_1"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Management    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth the name and position of each of our executive officers and directors, and each such person's age as of
December&nbsp;31, 2018: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="22pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="284pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Name</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Age</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Position </B></FONT><BR></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Executive Officers</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Cheng, M.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>President, Chief Executive Officer and Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jonathan Young, J.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>49</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Executive Vice President and Chief Operating Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Timothy Rolph, DPhil</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>64</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Chief Scientific Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kitty Yale</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>47</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Chief Development Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Non-Employee Directors</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kevin Bitterman, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>42</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mark Iwicki</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Aaron Kantoff</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Aaron Royston, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Graham Walmsley, M.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>32</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Director </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;Member
of the Audit Committee  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Member
of the Compensation Committee  </FONT></P>


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Member
of the Nominating and Corporate Governance Committee </FONT></P>
 </DIV>
 <P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Executive team  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Andrew Cheng, M.D., Ph.D.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Cheng has served as our President and Chief Executive Officer since September 2018. Before joining the Company,
Dr.&nbsp;Cheng was formerly at Gilead Sciences,&nbsp;Inc., a biotechnology company, as the Chief Medical Officer from March 2018 through September 2018, Executive Vice President from February 2015
through September 2018 and Senior Vice President from February 2009 through February 2015. During his nearly 20&nbsp;year tenure, he was responsible for the clinical development for the HIV program
resulting in 11 FDA/EMA approved products. His past responsibilities also included medical affairs and the creation of the development operations department (regulatory affairs, clinical operations,
pharmacovigilance, project management, clinical pharmacology and biometrics) which covered clinical development support in multiple therapeutic areas including oncology, inflammation, respiratory,
cardiovascular, HIV and liver diseases. Dr.&nbsp;Cheng currently serves on the board of directors of Syntimmune,&nbsp;Inc., a biotechnology company, which was acquired by Alexion. Dr.&nbsp;Cheng
holds a B.A. in biology from the Johns Hopkins University and a M.D. and Ph.D. in cellular and molecular biology from Columbia University College of Physicians and Surgeons. He is also board certified
in internal medicine. We believe Dr.&nbsp;Cheng is qualified to serve as a member of our board of directors due to his extensive experience in clinical development across multiple therapeutic areas. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Jonathan Young, J.D., Ph.D.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Young served as our co-founder, President and Chief Executive Officer from April 2017 to September 2018, and since September
2018 as our co-founder, Executive Vice President and Chief Operating Officer. Before joining the Company, Dr.&nbsp;Young served as a Venture Partner at Apple Tree Partners, a venture capital firm,
from October 2016 to September 2018. From August 2014 to October 2016, he served as Vice President of Policy/Advocacy and General Counsel at Braeburn Pharmaceuticals,&nbsp;Inc. From October 2006
through August 2014, Dr.&nbsp;Young served in positions of increasing responsibility at FoxKiser&nbsp;LLP, a legal services firm, ultimately as Partner and General Counsel. Dr.&nbsp;Young </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>144</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=147,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=524403,FOLIO='144',FILE='DISK114:[18ZFG1.18ZFG45201]DG45201A.;17',USER='SCAVALI',CD='17-JAN-2019;13:52' -->
<A NAME="page_dg45201_1_145"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>holds
a B.A. in history from Messiah College, an M.A. and Ph.D. in american history from the University of North Carolina at Chapel Hill and a J.D. from Yale Law School. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Timothy Rolph, DPhil.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Rolph has served as our co-founder and Chief Scientific Officer since April 2017. Before joining our company, Dr.&nbsp;Rolph
served as a Venture Partner at Apple Tree Partners, a venture capital firm, from October 2016 to April 2017. From March 1994 to October 2016, Dr.&nbsp;Rolph served in various roles at
Pfizer&nbsp;Inc., a pharmaceutical company, most recently as Senior Vice President, Program Value Enhancement from July 2014 to October 2016 and as Chief Scientific Officer, Cardiovascular and
Metabolic and Endocrine Disease from January 2009 to June 2014. During his tenure at Pfizer&nbsp;Inc., Dr.&nbsp;Rolph also oversaw the Company's FGF21 program. Dr.&nbsp;Rolph holds a B.Sc. in
biochemistry from the University of London and a DPhil in muscle development from University of Oxford. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Kitty Yale.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Ms.&nbsp;Yale has served as our Chief Development Officer since October 2018. Before joining the Company, Ms.&nbsp;Yale served in various roles at
Gilead Sciences,&nbsp;Inc., a biotechnology company, from October 2001 to October 2018, where she held senior clinical research and operations roles and led global clinical operations and management
of the Company's oncology, HIV, inflammation and liver disease trials. Most recently, Ms.&nbsp;Yale served as Vice President of Clinical Operations at Gilead Sciences,&nbsp;Inc. from July 2016 to
October 2018. Ms.&nbsp;Yale holds a B.Sc. in applied biology from Glasgow Caledonian University. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Non-executive directors  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Kevin Bitterman, Ph.D.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Bitterman has served as a member of our board of directors since June 2018. Dr.&nbsp;Bitterman currently serves as a partner at
venture firm Atlas Venture, or Atlas, a venture capital firm, where he has been employed since June 2017 and where he focuses on investments in life science companies. Prior to joining Atlas in June
2017, Dr.&nbsp;Bitterman was a partner at Polaris Partners, an investment firm, as a member of the healthcare team since July 2004. Dr.&nbsp;Bitterman was also the founding CEO at Editas
Medicine&nbsp;Inc., a pharmaceutical company, Visterra&nbsp;Inc., a biotechnology company, and Morphic Rock,&nbsp;LLC, a biotechnology company. During the past five years, Dr.&nbsp;Bitterman
has served on the board of directors of Editas Medicine,&nbsp;Inc., Kala Pharmaceuticals,&nbsp;Inc., a pharmaceutical company, Genocea Biosciences,&nbsp;Inc., a biosciences company, as well as
on the board of directors of several private companies. Dr.&nbsp;Bitterman also serves as board chair of the New England Venture Capital Association. Dr.&nbsp;Bitterman received a B.A. in biology
from Rutgers College and a Ph.D. in genetics from Harvard Medical School. We believe that Dr.&nbsp;Bitterman is qualified to serve on our board of directors due to his extensive experience investing
in, guiding, and leading start-up and early phase companies, as well as his experience as a director of other companies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Mark Iwicki.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Iwicki has served as a member of our board of directors since November 2018. Mr.&nbsp;Iwicki currently serves as the Chairman and Chief
Executive Officer of Kala Pharmaceuticals,&nbsp;Inc., a pharmaceutical company, where he has been employed since April 2015. From December 2012 to January 2014, Mr.&nbsp;Iwicki served as President
and Chief Executive Officer and director at Blend Therapeutics,&nbsp;Inc., now known as Tarveda Therapeutics,&nbsp;Inc., a biotechnology company. From 2007 to June 2012, Mr.&nbsp;Iwicki served
in several roles, including Chief Commercial Officer, President and Chief Operating Officer and Director and Chief Executive Officer at Sunovion Pharmaceuticals,&nbsp;Inc., formerly
Sepracor,&nbsp;Inc., a pharmaceutical company. From 1998 to 2007, Mr.&nbsp;Iwicki held executive positions, including Vice President and Business Unit Head, at Novartis Pharmaceuticals
Corporation, a pharmaceutical company. Mr.&nbsp;Iwicki currently serves on the board of directors of Pulmatrix,&nbsp;Inc., a biopharmaceutical company, Aimmune Therapeutics,&nbsp;Inc., a
biopharmaceutical company, Kala Pharmaceuticals,&nbsp;Inc. as well as on the board of directors of several private companies, including Nimbus Therapeutics,&nbsp;LLC, a biotechnology company, and
Taris Biomedical,&nbsp;LLC, a pharmaceutical company. Mr.&nbsp;Iwicki received a B.A. in business administration </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>145</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=148,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=466828,FOLIO='145',FILE='DISK114:[18ZFG1.18ZFG45201]DG45201A.;17',USER='SCAVALI',CD='17-JAN-2019;13:52' -->
<A NAME="page_dg45201_1_146"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>from
Ball State University and an M.B.A. from Loyola University. We believe that Mr.&nbsp;Iwicki is qualified to serve on our Board due to his executive management and operational experience in the
life science industry. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Aaron Kantoff.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Kantoff has served as a member of our board of directors since June 2018. Mr.&nbsp;Kantoff currently serves as a Partner of Apple Tree
Partners IV,&nbsp;L.P., a venture capital firm, where he has been employed since August 2011 and where he has been involved with investing in and building many of their portfolio companies. Prior to
joining Apple Tree Partners in August 2011, Mr.&nbsp;Kantoff was a Managing Member at Recess Global&nbsp;LLC, an investment company focused on funding start-ups. In addition to his role with Apple
Tree Partners, Mr.&nbsp;Kantoff served as Executive Director of Business Development&nbsp;&amp; Corporate Strategy of Braeburn Pharmaceuticals, a pharmaceutical company, from December 2012 to December
2014. Mr.&nbsp;Kantoff currently serves on the board of directors of several private biotech companies, including Corvidia Therapeutics,&nbsp;Inc., a biotechnology company, Elstar
Therapeutics,&nbsp;Inc., a multi-functional antibody company, Limelight Bio,&nbsp;Inc., a gene therapy company, and is also a Board Observer of Stoke Therapeutics, an antisense oligonucleotide
company. He was also previously a board member of Syntimmune,&nbsp;Inc., a biotechnology company, which was acquired by Alexion. Mr.&nbsp;Kantoff received a B.S. in financial and international
business from the New York University Sterns School of Business. We believe that Mr.&nbsp;Kantoff is qualified to serve on our board of directors due to his significant experience in early and
late-stage biotech companies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Aaron Royston, M.D., M.B.A.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Royston has served as a member of our board of directors since June 2018. Dr.&nbsp;Royston is a Partner at venBio, a life
sciences investment firm, and has been with venBio since November 2015. Prior to joining venBio, Dr.&nbsp;Royston worked for Vivo Capital, a global life sciences investment firm from July 2014 to
October 2015. Previously, he worked at Bain&nbsp;&amp; Company from July 2013 to July 2014, where he advised biotechnology companies on a broad range of strategic and operational issues. Earlier in his
career, Dr.&nbsp;Royston coordinated clinical research at Mount Sinai Medical Center, where his research has been published and presented in multiple medical journals and conferences. In 2011,
Dr.&nbsp;Royston was recognized by the Obama Administration as a Champion of Change for his work in technology and innovation. Dr.&nbsp;Royston currently serves on the board of directors of Menlo
Therapeutics,&nbsp;Inc., a biopharmaceutical company, as well as several private companies including Harmony Biosciences&nbsp;LLC, Impel Neuropharma,&nbsp;Inc. and Neurogastrx,&nbsp;Inc.
Dr.&nbsp;Royston received a B.S. in biological sciences from Duke University, and an M.D. and M.B.A. from the University of Pennsylvania. We believe that Dr.&nbsp;Royston is qualified to serve on
our board of directors due to his clinical and biotechnology industry experience. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Graham Walmsley, M.D., Ph.D.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Walmsley has served as a member of our board of directors since June 2018. Dr.&nbsp;Walmsley currently serves as a
Principal at Versant Ventures, where he has been employed since July 2016 after he received his Ph.D. from Stanford University School of Medicine and where he specializes in healthcare and
biotechnology investments. At Versant, Dr.&nbsp;Walmsley has contributed to the deployment of capital into early and mid-stage private biotechnology companies across multiple funds. In addition,
Dr.&nbsp;Walmsley served as Head of Business Development at Jecure Therapeutics,&nbsp;Inc., a biotechnology company, since June 2017 through its acquisition by Roche/Genentech in November 2018.
Dr.&nbsp;Walmsley currently serves as a board observer for Turnstone Biologics&nbsp;Inc., an immuno-oncology company, BlueRock Therapeutics,&nbsp;LP, an engineered cell therapy company and
Aligos Therapeutics,&nbsp;Inc., a biotechnology company. He was previously a board observer for CODA Biotherapeutics,&nbsp;Inc., a biopharmaceutical company. Dr.&nbsp;Walmsley received a B.A. in
molecular and cell biology from the University of California, Berkeley and an M.D. and Ph.D. from Stanford University School of Medicine. We believe that </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>146</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=149,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=732815,FOLIO='146',FILE='DISK114:[18ZFG1.18ZFG45201]DG45201A.;17',USER='SCAVALI',CD='17-JAN-2019;13:52' -->
<A NAME="page_dg45201_1_147"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>


<P style="font-family:arial;"><FONT SIZE=2>Dr.&nbsp;Walmsley
is qualified to serve on our board of directors due to his significant experience in the healthcare and biotechnology industry. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Family relationships  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There are no family relationships among any of our directors or executive officers. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Composition of our board of directors  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors consists of six members, each of whom are members pursuant to the board composition provisions of our third amended and
restated certificate of incorporation and agreements with our stockholders. These board composition provisions will terminate upon the completion of this offering. Upon the termination of these
provisions, there will be no further contractual obligations regarding the election of our directors. Our nominating and corporate governance committee and our board of directors may therefore
consider a broad range of factors relating to the qualifications and background of nominees. Our nominating and corporate governance committee's and our board of directors' priority in selecting board
members is the identification of persons who will further the interests of our stockholders through their established record of professional accomplishment, the ability to contribute positively to the
collaborative culture among board members, knowledge of our business, understanding of the competitive landscape, and professional and personal experiences and expertise relevant to our growth
strategy. Our directors hold office until their successors have been elected and qualified or until the earlier of their resignation or removal. Our fourth amended and restated certificate of
incorporation that will become effective upon the completion of this offering and our second amended and restated bylaws that will become effective on the date on which the registration statement of
which this prospectus is a part is declared effective by the SEC also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least two-thirds of the
votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of
directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
have no formal policy regarding board diversity. Our priority in selection of board members is identification of members who will further the interests of our stockholders through his or her
established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business and understanding of the competitive
landscape. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director independence  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors has determined that all members of the board of directors, except Andrew Cheng,&nbsp;M.D.,&nbsp;Ph.D., are independent directors,
including for purposes of the rules of The Nasdaq Global Market and the Securities and Exchange Commission, or SEC. In making such independence determination, our board of directors considered the
relationships that each non-employee director has with us and all other facts and circumstances that our board of directors deemed relevant in determining their independence, including the beneficial
ownership of our capital stock by each non-employee director. In considering the independence of the directors listed above, our board of directors considered the association of our directors with the
holders of more than 5% of our common stock. Upon the completion of this offering, we expect that the composition and functioning of our board of directors and each of our committees will comply with
all applicable requirements of The Nasdaq Global Market and the rules and regulations of the SEC. Andrew Cheng, M.D., Ph.D. is not an independent director under these rules because he is currently
employed as the chief executive officer of our company. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>147</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=150,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=745703,FOLIO='147',FILE='DISK114:[18ZFG1.18ZFG45201]DG45201A.;17',USER='SCAVALI',CD='17-JAN-2019;13:52' -->
<A NAME="page_dg45201_1_148"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Staggered board  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In accordance with the terms of our fourth amended and restated certificate of incorporation that will become effective upon the completion of this offering
and our second amended and restated bylaws that will become effective on the date on which the registration statement of which this prospectus is a part is declared effective by the SEC, our board of
directors will be divided into three staggered classes of directors and each will be assigned to one of the three classes. At each annual meeting of the stockholders, a class of directors will be
elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor
directors at the annual meeting of stockholders to be held during the years 2020 for Class&nbsp;I directors, 2021 for Class&nbsp;II directors and 2022 for Class&nbsp;III directors. </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our Class&nbsp;I directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our Class&nbsp;II directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; and </FONT><FONT SIZE=2>
 </FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our Class&nbsp;III directors will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Our
fourth amended and restated certificate of incorporation that will become effective upon the completion of this offering and our second amended and restated bylaws that will become effective on
the date the registration statement of which this prospectus is a part is declared effective by the SEC will provide that the number of directors shall be fixed from time to time by a resolution of
the majority of our board of directors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
division of our board of directors into three classes with staggered three-year terms may delay or prevent stockholder efforts to effect a change of our management or a change in control. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Board leadership structure and board's role in risk oversight  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Risk is inherent with every business, and how well a business manages risk can ultimately determine its success. We face a number of risks,
including risks relating to our financial condition, development and commercialization activities, operations, strategic direction and intellectual property as more fully discussed in the section
entitled "Risk factors" appearing elsewhere in this prospectus. Management is responsible for the day-to-day management of risks we face, while our board of directors, as a whole and through its
committees, has responsibility for the oversight of risk management. In its risk oversight role, our board of directors has the responsibility to satisfy itself that the risk management processes
designed and implemented by management are adequate and functioning as designed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
role of the board of directors in overseeing the management of our risks is conducted primarily through committees of the board of directors, as disclosed in the descriptions of each of the
committees below and in the charters of each of the committees. The full board of directors (or the appropriate board committee in the case of risks that are under the purview of a particular
committee) discusses with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a board committee is responsible for evaluating and overseeing
the management of a particular risk or risks, the chairman of the relevant committee reports on the discussion to the full board of directors during the committee reports portion of the next board
meeting. This enables the board of directors and its committees to coordinate the risk oversight role, particularly with respect to risk interrelationships. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>148</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=151,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=481590,FOLIO='148',FILE='DISK114:[18ZFG1.18ZFG45201]DG45201A.;17',USER='SCAVALI',CD='17-JAN-2019;13:52' -->
<A NAME="page_dg45201_1_149"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Committees of our board of directors  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors has established an audit committee, a compensation committee, and a nominating and corporate governance committee, each
of which will operate pursuant to a charter adopted by our board of directors and will be effective upon the effectiveness of the registration statement of which this prospectus is a part. Upon the
effectiveness of the registration statement of which this prospectus is a part, the composition and functioning of all of our committees will comply with all applicable requirements of the
Sarbanes-Oxley Act of 2002, Nasdaq and SEC rules and regulations. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit committee  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will serve on the audit committee, which will be chaired
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our board of directors has
determined that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;are "independent" for audit committee purposes as that term is defined in
the rules of the SEC and the applicable Nasdaq rules, and each has sufficient knowledge in
financial and auditing matters to serve on the audit committee. Our board of directors has
designated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as an "audit committee financial expert," as defined under the applicable
rules of
the SEC. The audit committee's responsibilities include:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> appointing, approving the compensation of, and assessing the independence of our independent registered public accounting firm; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> pre-approving auditing and permissible non-audit services, and the terms of such services, to be provided by our independent registered public
accounting firm; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reviewing the overall audit plan with our independent registered public accounting firm and members of management responsible for preparing our
financial statements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements
and related disclosures as well as critical accounting policies and practices used by us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> coordinating the oversight and reviewing the adequacy of our internal control over financial reporting; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> recommending, based upon the audit committee's review and discussions with management and our independent registered public accounting firm,
whether our audited financial statements shall be included in our Annual Report on Form&nbsp;10-K; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to our financial
statements and accounting matters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> preparing the audit committee report required by SEC rules to be included in our annual proxy statement; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reviewing all related person transactions for potential conflict of interest situations and voting with respect to all such transactions; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reviewing quarterly earnings releases. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>149</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=152,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=666403,FOLIO='149',FILE='DISK114:[18ZFG1.18ZFG45201]DG45201A.;17',USER='SCAVALI',CD='17-JAN-2019;13:52' -->
<A NAME="page_dg45201_1_150"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation committee  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will serve on the compensation committee, which will be chaired
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our board of
directors has determined that each member of the compensation committee is "independent" as defined in the applicable Nasdaq rules. The compensation committee's responsibilities
include:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> annually reviewing and recommending to the board of directors the corporate goals and objectives relevant to the compensation of our principal
executive officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> evaluating the performance of our principal executive officers in light of such corporate goals and objectives and based on such evaluation:
(i)&nbsp;determining cash compensation of our principal executive officer; and (ii)&nbsp;reviewing and approving grants and awards to our principal executive officer under equity-based plans; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reviewing and approving or recommending to the board of directors the cash compensation of our other executive officers; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reviewing and establishing our overall management compensation, philosophy and policy; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> overseeing and administering our compensation and similar plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> evaluating and assessing potential and current compensation advisors in accordance with the independence standards identified in the applicable
Nasdaq rules; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reviewing and approving our policies and procedures for the grant of equity-based awards; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reviewing and recommending to the board of directors the compensation of our directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> preparing the compensation committee report required by SEC rules, if and when required, to be included in our annual proxy statement; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reviewing and approving the retention, termination or compensation of any consulting firm or outside advisor to assist in the evaluation of
compensation matters. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominating and corporate governance committee  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will serve on the nominating and corporate governance committee, which will be chaired by
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our board of directors has determined that each member of the nominating and corporate
governance committee is "independent" as defined in the applicable Nasdaq rules. The nominating
and corporate governance committee's responsibilities include:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> developing and recommending to the board of directors criteria for board and committee membership; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by stockholders; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reviewing the composition of the board of directors to ensure that it is composed of members containing the appropriate skills and expertise to
advise us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> identifying individuals qualified to become members of the board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> recommending to the board of directors the persons to be nominated for election as directors and to each of the board's committees; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>150</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=153,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=1008836,FOLIO='150',FILE='DISK114:[18ZFG1.18ZFG45201]DG45201A.;17',USER='SCAVALI',CD='17-JAN-2019;13:52' -->
<A NAME="page_dg45201_1_151"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> developing and recommending to the board of directors a code of business conduct and ethics and a set of corporate governance guidelines; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> overseeing the evaluation of our board of directors and management. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Our
board of directors may from time to time establish other committees. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Compensation committee interlocks and insider participation  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>None of the members of our compensation committee has at any time during the prior three years been one of our officers or employees. None of
our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers
serving on our board of directors or compensation committee. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Code of business conduct and ethics  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We will have adopted a written code of business conduct and ethics, effective upon the effectiveness of the registration statement of which
this prospectus is a part, that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal
accounting officer or controller, or persons performing similar functions. Following the effectiveness of the registration statement of which this prospectus is a part, a current copy of the code will
be posted on the investor relations section of our website, which is located at www.akerotx.com. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and
ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form&nbsp;8-K. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>151</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=154,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=211154,FOLIO='151',FILE='DISK114:[18ZFG1.18ZFG45201]DG45201A.;17',USER='SCAVALI',CD='17-JAN-2019;13:52' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_di45201_1_152"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B> <A NAME="di45201_executive_compensation"> </A>
<A NAME="toc_di45201_1"> </A> </B></FONT><FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Executive compensation    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Executive compensation overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Historically, our executive compensation program has reflected our growth and development-oriented corporate culture. To date, the
compensation of our Chief Executive Officer and President and our other executive officers identified in the 2018 Summary Compensation Table below, who we refer to as the named executive officers, has
consisted of a combination of base salary, bonuses and long-term incentive compensation in the form of restricted common stock awards and incentive stock options. Our named executive officers who are
full-time employees, like all other full-time employees, are eligible to participate in our retirement and health and welfare benefit plans. As we transition from a private company to a publicly
traded company, we will evaluate our compensation values and philosophy and compensation plans and arrangements as circumstances merit. At a minimum, we expect to review executive compensation
annually with input from a compensation consultant. As part of this review process, we expect the board of directors and the compensation committee to apply our values and philosophy, while
considering the compensation levels needed to ensure our executive compensation program remains competitive with our peers. In connection with our executive compensation program, we will also review
whether we are meeting our retention objectives and the potential cost of replacing a key employee. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


2018 Summary compensation table  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table presents information regarding the total compensation awarded to, earned by, and paid to our named executive officers for
services rendered to us in all capacities for the years indicated. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="32pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="75pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Name and principal position</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Year</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Salary<BR>
($)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Bonus<BR>
($)(1)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Option<BR>
awards<BR>
($)(2)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>All other<BR>
compensation<BR>
($)(3)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Total<BR>
($) </B></FONT><BR></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Andrew Cheng, M.D., Ph.D.</FONT><FONT SIZE=2><I>, </I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>132,813</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>65,205</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>849,477</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>160</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>1,047,655</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Executive Officer and<BR>
President(4)</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jonathan Young, J.D., Ph.D.,</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
400,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
100,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
159,073</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>454</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>659,527</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Executive Vice President,<BR>
Chief Operating Officer and former<BR>
Chief Executive Officer(5)</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Timothy Rolph, DPhil.,</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
400,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
100,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
159,073</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>454</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>659,527</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Scientific Officer</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kitty Yale,</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
78,125</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
29,666</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
212,369</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>106</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>320,266</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Development Officer(6)</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;The
amounts in this column reflect discretionary cash bonuses paid for performance in 2018. The amounts reported for Dr.&nbsp;Cheng and Ms.&nbsp;Yale have been prorated to reflect
their partial year of service.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;The
amounts reported in the "Option Awards" column reflect the aggregate grant date fair value of share- based compensation awarded during the year computed in accordance with the
provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718. See Note&nbsp;7 to our financial statements appearing at the end of this prospectus regarding
assumptions underlying the valuation of equity awards.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Amounts
in this column represent Company-paid life insurance premiums.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(4)&nbsp;&nbsp;&nbsp;The
amount reported in the "Salary" column for Dr.&nbsp;Cheng represents his salary starting September&nbsp;10, 2018, the date his employment with the Company commenced. His
annual salary for 2018 was $425,000.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(5)&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Young
served as our Chief Executive Officer until Dr.&nbsp;Cheng commenced employment on September&nbsp;10, 2018.  </FONT></P>


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(6)&nbsp;&nbsp;&nbsp;The
amount reported in the "Salary" column for Ms.&nbsp;Yale represents her salary starting October&nbsp;15, 2018, the date her employment with the Company commenced. Her annual
salary was $375,000. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>152</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=155,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=214772,FOLIO='152',FILE='DISK114:[18ZFG1.18ZFG45201]DI45201A.;26',USER='SMENEZE',CD='16-JAN-2019;21:30' -->
<A NAME="page_di45201_1_153"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Narrative to summary compensation table  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Base salaries  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We use base salaries to recognize the experience, skills, knowledge and responsibilities required of all our employees, including our named executive
officers. Base salaries are reviewed annually, typically in connection with our annual performance review process, and adjusted from time to time to realign salaries with market levels after taking
into account individual responsibilities, performance and experience. For the year ended December&nbsp;31, 2018, the annual base salaries for each of Drs. Cheng, Young and Rolph and Ms.&nbsp;Yale
were $425,000, $400,000, $400,000 and $375,000, respectively. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Bonuses  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We pay discretionary cash bonuses to reward our executives for their performance over the fiscal year. For 2018, the target bonus for Dr.&nbsp;Cheng was
equal to up to 40&nbsp;percent of his base salary, the target bonus for each of Dr.&nbsp;Young and Dr.&nbsp;Rolph was up to 20&nbsp;percent of his respective base salary, and the target bonus
for Ms.&nbsp;Yale was equal to up to 30&nbsp;percent of her base salary. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Equity compensation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive officers, we believe that equity grants provide
our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders. In addition, we believe that equity
grants with a time-based vesting feature promote executive retention because this feature incentivizes our executive officers to remain in our employment
during the vesting period. During the year ended December&nbsp;31, 2018, we granted options to purchase shares of our common stock to each of the named executive officers, as described in more
detail in the "Outstanding equity awards at 2018 fiscal year-end" table. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Employment arrangements with our named executive officers  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Andrew Cheng, M.D., Ph.D.  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On August&nbsp;7, 2018, we entered into an employment agreement with Dr.&nbsp;Cheng, or the Cheng Employment Agreement, which sets forth the terms of his
employment with us. Pursuant to the terms of the Cheng Employment Agreement, Dr.&nbsp;Cheng is employed as our CEO and president, and he serves as a member of our board of directors. As compensation
for Dr.&nbsp;Cheng's services, we pay him a base salary of $425,000, and he is eligible to receive an annual bonus with a target of 40% of his base salary. Dr.&nbsp;Cheng is eligible to
participate in our employee benefit plans available for executives, subject to the terms of those plans. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Cheng Employment Agreement further provides that if Dr.&nbsp;Cheng's employment is terminated by us without Cause (as defined in the Cheng Employment Agreement) or Dr.&nbsp;Cheng resigns for
Good Reason (as defined in the Cheng Employment Agreement), he will be entitled to receive as severance base salary continuation, plus payment by the Company of COBRA premiums if Dr.&nbsp;Cheng
elects to extend our health care benefits through COBRA, each for a period of 12&nbsp;months. Any such severance payment is conditioned upon execution by Dr.&nbsp;Cheng of a general release of
claims in favor of the Company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Cheng Employment Agreement also granted Dr.&nbsp;Cheng an option to purchase a number of shares of our common stock equal to approximately 5% of our equity on a fully diluted basis, or the
Initial Option. Twenty five percent of the Initial Option vest on the one-year anniversary of the Commencement Date (as defined in the Cheng Employment Agreement), and the remainder of the shares vest
in equal monthly installments for a period of 36&nbsp;months thereafter, provided Dr.&nbsp;Cheng remains employed with us as of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>153</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=156,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=16219,FOLIO='153',FILE='DISK114:[18ZFG1.18ZFG45201]DI45201A.;26',USER='SMENEZE',CD='16-JAN-2019;21:30' -->
<A NAME="page_di45201_1_154"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>each
such vesting date; provided, however, in the event that Dr.&nbsp;Cheng's service is terminated (i)&nbsp;by Dr.&nbsp;Cheng for Good Reason (both as defined in the Cheng Employment
Agreement); or (ii)&nbsp;due to Dr.&nbsp;Cheng's death or disability, 100% of the unvested Initial Option will vest and become exercisable, provided Dr.&nbsp;Cheng remained employed through the
date of his termination. In addition, 100% of the unvested Initial Option will vest 6&nbsp;months following a Sale Event (as defined in the Akero Therapeutics,&nbsp;Inc. 2018 Stock Option and
Grant Plan (the "2018 Plan")) or sooner if terminated for any reason other than for Cause following such Sale Event. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Jonathan Young, J.D., Ph.D.  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On August&nbsp;1, 2018, we entered into an amended and restated employment agreement with Dr.&nbsp;Young, or the Young Employment Agreement, which sets
forth the terms of his employment with us. Dr.&nbsp;Young served as the President and CEO until we employed Dr.&nbsp;Cheng as the President and CEO on September&nbsp;7, 2018, and at such time,
Dr.&nbsp;Young's role transitioned to Executive Vice President and COO. As compensation for Dr.&nbsp;Young's services, we pay him a base salary of $400,000, and he is eligible to receive an annual
bonus with a target of up to 20% of his base salary, subject to his employment on the date of payment. Dr.&nbsp;Young is eligible to participate in our employee benefit plans available for
executives, subject to the terms of those plans. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Young Employment Agreement further provides that if Dr.&nbsp;Young's employment is terminated by us without Cause (as defined in the Young Agreement) or Dr.&nbsp;Young resigns for Good Reason
(as defined in the Young Employment Agreement), he will be entitled to receive as severance base salary continuation, plus payment of COBRA premiums by the Company if Dr.&nbsp;Young elects to extend
our health care benefits through COBRA, each for a period of 9&nbsp;months. Any such severance payment is conditioned upon execution by Dr.&nbsp;Young of a general release of claims in favor of
the Company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Young Employment Agreement also grants Dr.&nbsp;Young an option to purchase a number of shares of our common stock equal to approximately 1.4% of our equity on a fully diluted basis, or the
Initial Option. The number of shares underlying the Initial Option is equal to 1.4% of our fully diluted capitalization through tranche&nbsp;1 of our series&nbsp;A financing as determined on the
grant date. Twenty-five percent of the Initial Option vests on the date of grant, and the remainder of the shares will vest in equal monthly installments for a period of 36&nbsp;months thereafter,
provided Mr.&nbsp;Young remains engaged in a Service Relationship (as defined in the 2018 Plan) with the Company on each such vesting date. Any grants of an option to purchase shares of our common
stock after the grant of the Initial Option, or the Subsequent Option, will vest in equal monthly installments and will vest in full 48&nbsp;months following the date of grant, provided that
Dr.&nbsp;Young remains employed on each such vesting date. In addition, 100% of the unvested Initial Option or any Subsequent Option will vest 6&nbsp;months following a Sale Event (as defined in
the 2018 Plan) or sooner if terminated for any reason other than for Cause following such Sale Event. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Timothy Rolph, DPhil.  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On August&nbsp;1, 2018, we entered into an amended and restated employment agreement with Dr.&nbsp;Rolph, or the Rolph Employment Agreement, which sets
forth the terms of his employment with us. Pursuant to the terms of the Rolph Employment Agreement, Dr.&nbsp;Rolph is employed as our Chief Scientific Officer, and as compensation for
Dr.&nbsp;Rolph's services, we pay him a base salary of $400,000. Dr.&nbsp;Rolph is eligible to receive an annual bonus with a target of up to 20% of his base salary. Dr.&nbsp;Rolph is eligible
to participate in our employee benefit plans available for executives, subject to the terms of those plans. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Rolph Employment Agreement further provides that if Dr.&nbsp;Rolph's employment is terminated by us without Cause (as defined in the Rolph Employment Agreement) or Dr.&nbsp;Rolph resigns for
Good Reason (as </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>154</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=157,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=148063,FOLIO='154',FILE='DISK114:[18ZFG1.18ZFG45201]DI45201A.;26',USER='SMENEZE',CD='16-JAN-2019;21:30' -->
<A NAME="page_di45201_1_155"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>defined
in the Rolph Employment Agreement), he will be entitled to receive as severance base salary continuation, plus payment of COBRA premiums by the Company if Dr.&nbsp;Rolph elects to extend our
health care benefits through COBRA, each for a period of 9&nbsp;months. Any such severance payment is conditioned upon execution by Dr.&nbsp;Rolph of a general release of claims in favor of the
Company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Rolph Employment Agreement grants Dr.&nbsp;Rolph an option to purchase a number of shares of our common stock equal to approximately 1.4% of our equity on a fully diluted basis, or the Initial
Option. The number of shares underlying the Initial Option is equal to 1.4% of our fully diluted capitalization through tranche&nbsp;1 of our series&nbsp;A financing as determined on the grant
date. Twenty-five percent of the Initial Option vests on the date of grant, and the remainder of the shares vest in equal monthly installments for a period of 36&nbsp;months thereafter, provided
Dr.&nbsp;Rolph remains engaged in a Service Relationship (as defined in the 2018 Plan) with the Company on each such vesting date. Any grants of an option to purchase shares of our common stock
after the grant of the Initial Option, or the Subsequent Option, will vest in equal monthly installments and will vest in full 48&nbsp;months following the date of grant, provided that
Dr.&nbsp;Rolph remains employed on each such vesting date. In addition, 100% of the unvested Initial Option or any Subsequent Option will vest 6&nbsp;months following a Sale Event (as defined in
the 2018 Plan) or sooner if terminated for any reason other than for Cause following such Sale Event. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Kitty Yale  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On September&nbsp;26, 2018, we entered into an employment agreement with Ms.&nbsp;Yale, or the Yale Employment Agreement, which sets forth the terms of
her employment with us. Pursuant to the terms of the Yale Employment Agreement, Ms.&nbsp;Yale is employed as our Chief Development Officer, and as compensation for Ms.&nbsp;Yale's services, we pay
her a base salary of $375,000. Ms.&nbsp;Yale is eligible to receive an annual bonus with a target of up to 30% of her base salary. Ms.&nbsp;Yale is eligible to participate in our employee benefit
plans available for executives, subject to terms of those plans. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Yale Employment Agreement further provides that if Ms.&nbsp;Yale's employment is terminated by us without Cause (as defined in the Yale Employment Agreement) or Ms.&nbsp;Yale resigns for Good
Reason (as defined in the Yale Employment Agreement), she will be entitled to receive as severance base salary continuation, plus payment of COBRA premiums by the Company if Ms.&nbsp;Yale elects to
extend our health care benefits through COBRA, each for a period of 9&nbsp;months. Any such severance payment is conditioned upon execution by Ms.&nbsp;Yale of a general release of claims in favor
of the Company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Yale Employment Agreement also grants Ms.&nbsp;Yale an option to purchase a number of shares of our common stock equal to approximately 1.25% of our equity on a fully diluted basis, or the
Initial Option. Twenty-five percent of the Initial Option vest on the one-year anniversary of the Commencement Date (as defined in the Yale Employment Agreement), and the remainder of the shares vest
in equal monthly installments for a period of 36&nbsp;months thereafter, provided Ms.&nbsp;Yale remains employed with us as of each such vesting date. In addition, 100% of the unvested Initial
Option will vest 6&nbsp;months following a Sale Event (as defined in the 2018 Plan) or sooner if terminated for any reason other than for Cause following such Sale Event. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>155</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=158,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=36217,FOLIO='155',FILE='DISK114:[18ZFG1.18ZFG45201]DI45201A.;26',USER='SMENEZE',CD='16-JAN-2019;21:30' -->
<A NAME="page_di45201_1_156"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Outstanding equity awards at 2018 fiscal year-end  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth information concerning outstanding equity awards held by each of our named executive officers as of
December&nbsp;31, 2018. All equity awards set forth in the table below were granted under our 2018 Plan. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="74pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="58pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="40pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="51pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=4 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Stock awards </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=12 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Option awards(1) </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ROWSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Market<BR>
value of<BR>
shares or<BR>
units of<BR>
stock that<BR>
have not<BR>
vested ($)(2)</B></FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Vesting<BR>
commencement<BR>
date</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
securities<BR>
underlying<BR>
unexercised<BR>
options (#)<BR>
exercisable</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
securities<BR>
underlying<BR>
unexercised<BR>
options (#)<BR>
unexercisable</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Option<BR>
exercise<BR>
price ($)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Option<BR>
expiration<BR>
date</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
shares or<BR>
units of<BR>
stock that<BR>
have not<BR>
vested (#)</B></FONT><BR></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Andrew Cheng</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">9/1/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,326,666</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">9/07/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10/1/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,602,564</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10/17/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Jonathan Young</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
8/1/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
123,823</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
247,643</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
0.20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
8/01/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10/1/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">18,697</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">430,021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10/17/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">82,167</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(5)</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">41,083</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(6)</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Timothy Rolph</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
8/1/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
123,823</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
247,643</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
0.20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
8/01/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10/18/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">18,697</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">430,021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10/17/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">82,167</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(7)</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">41,083</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(6)</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Kitty Yale</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
10/1/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
331,666</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
0.20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
9/26/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10/1/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">400,641</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10/17/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151; </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;Represents
stock options granted to our named executive officers under our 2018 Plan. Unless otherwise noted, stock options vest over four years with 25% of the shares vesting on the
first anniversary of the vesting commencement date, and the remaining shares vesting in 36 equal monthly installments thereafter, subject to continued service. Upon the earlier of the date that is six
months following a sale event, or a termination of the executive's employment following such sale event other than for cause, the vesting of each stock option shall accelerate and vest in full. </FONT></P>


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;The
market price of our common stock is based on the assumed initial public offering price of the common stock of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range on the
cover page of this prospectus.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;This
option vests over three years with 25% of the shares vesting on the vesting commencement date and the remaining shares vesting in 36 equal monthly installments thereafter,
subject to continued service.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(4)&nbsp;&nbsp;&nbsp;This
option vests in 48 equal monthly installments following the vesting commencement date, subject to continued service.  </FONT></P>


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(5)&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Young
purchased 232,000 shares of stock on March&nbsp;16, 2017, and on March&nbsp;29, 2018, amended the vesting terms applicable to such shares. 77,333 of such shares
vested on March&nbsp;29, 2018, 38,667 of the shares vested on May&nbsp;1, 2018, and the remaining 116,000 shares vest in 24 equal monthly installments thereafter, subject to continued service. Any
unvested shares will have their vesting accelerate in full upon a change in control, subject to Dr.&nbsp;Young's continued service through such date.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(6)&nbsp;&nbsp;&nbsp;Each
of Mr.&nbsp;Young and Dr.&nbsp;Rolph purchased 116,000 shares of stock on March&nbsp;29, 2018. 58,000 of such shares vested on May&nbsp;1, 2018, and the remaining 58,000
shares vest in 24 equal monthly installments, subject to continued service through each such date. Any unvested shares will have their vesting accelerate in full upon a change in control, subject to
the executive's continued service through such date.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(7)&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Rolph
purchased 232,000 shares of stock on March&nbsp;16, 2017, and on March&nbsp;29, 2018, amended the vesting terms applicable to such shares. 77,333 of such shares
vested on March&nbsp;29, 2018, 38,667 of the shares vested on May&nbsp;1, 2018, and the remaining 116,000 shares vest in 24 equal monthly installments thereafter, subject to continued service. Any
unvested shares will have their vesting accelerate in full upon a change in control, subject to Dr.&nbsp;Rolph's continued service through such date. </FONT></P>
 </DIV>
 <P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Employee benefit and equity compensation plans  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2019 Stock Option and Grant Plan  </I></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our 2019 Stock Option and Grant Plan, or 2019 Plan, was adopted by our board of directors
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and approved by our stockholders on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and will become effective as of the date immediately prior to the date of the
effectiveness of the registration statement of which this prospectus is a part. The 2019 Plan allows the
board of directors' compensation committee to make equity-based incentive awards to our officers, employees, directors and other key persons (including consultants). </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>156</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=159,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=371309,FOLIO='156',FILE='DISK114:[18ZFG1.18ZFG45201]DI45201A.;26',USER='SMENEZE',CD='16-JAN-2019;21:30' -->
<A NAME="page_di45201_1_157"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</FONT><P style="font-family:arial;"><FONT SIZE=2>The
2019 Plan will replace our 2018 Plan. Our 2019 Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have initially reserved&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, or the Initial Limit, for the
issuance of awards under the 2019 Plan, plus the number of shares of common stock remaining
available for issuance under our 2018 Plan. The 2019 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January&nbsp;1,
beginning on January&nbsp;1, 2020, by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding number of shares of our common stock on the immediately preceding December&nbsp;31 or such lesser number of shares as
determined by our compensation committee, or the Annual Increase. This number is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
shares we issue under the 2019 Plan will be authorized but unissued shares or shares that we reacquire. The shares of common stock underlying any awards that are forfeited, cancelled, held back
upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated
(other than by exercise) under each of the 2019 Plan and the 2018 Plan will be added back to the shares of common stock available for issuance under the 2019 Plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
maximum aggregate number of shares that may be issued in the form of incentive stock options shall not exceed the Initial Limit cumulatively increased on January&nbsp;1, 2020 and on each
January&nbsp;1 thereafter by the lesser of the Annual Increase for such year or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of
common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
2019 Plan will be administered by our compensation committee. Our compensation committee has full power to select, from among the individuals eligible for awards, the individuals to whom awards
will be granted, to make any combination of awards to participants, and to determine the specific terms and conditions of each award, subject to the provisions of the 2019 Plan. Persons eligible to
participate in the 2019 Plan will be those full or part-time officers, employees, non-employee directors and other key persons (including consultants) as selected from time to time by our compensation
committee in its discretion. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
2019 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under Section&nbsp;422 of the Code and options that do not so qualify. The
option exercise price of each option will be determined by our compensation committee but may not be less than 100% of the fair market value of our common stock on the date of grant. The term of each
option will be fixed by our compensation committee and may not exceed 10&nbsp;years from the date of grant. Our compensation committee will determine at what time or times each option may be
exercised. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
compensation committee may award stock appreciation rights subject to such conditions and restrictions as it may determine. Stock appreciation rights entitle the recipient to shares of common
stock, or cash, equal to the value of the appreciation in our stock price over the exercise price. The exercise price of each stock appreciation right may not be less than 100% of the fair market
value of the common stock on the date of grant. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
compensation committee may award shares of restricted common stock and restricted stock units to participants subject to such conditions and restrictions as it may determine. These conditions and
restrictions may include the achievement of certain performance goals and continued employment with us through a specified vesting period. Our compensation committee may also grant shares of common
stock that are free from any restrictions under the 2019 Plan. Unrestricted stock may be granted to participants in recognition of past services or other valid consideration and may be issued in lieu
of cash compensation due to such participant. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>157</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=160,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=808636,FOLIO='157',FILE='DISK114:[18ZFG1.18ZFG45201]DI45201A.;26',USER='SMENEZE',CD='16-JAN-2019;21:30' -->
<A NAME="page_di45201_1_158"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>Our
compensation committee may grant cash bonuses under the 2019 Plan to participants, subject to the achievement of certain performance goals. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
2019 Plan provides that in the case of, and subject to, the consummation of a "sale event" as defined in the 2019 Plan, all outstanding awards may be assumed, substituted or otherwise continued by
the successor entity. To the extent that the successor entity does not assume, substitute or otherwise continue such awards, then (i)&nbsp;all stock options and stock appreciation rights will
automatically become fully exercisable and the restrictions and conditions on all other awards with time-based conditions will automatically be deemed waived, and awards with conditions and
restrictions relating to the attainment of performance goals may become vested and non-forfeitable in connection with a sale event in the compensation committee's discretion and (ii)&nbsp;upon the
effectiveness of the sale event, the 2019 Plan and all awards will automatically terminate. In the event of such termination, (i)&nbsp;individuals holding options and stock appreciation rights will
be permitted to exercise such options and stock appreciation rights (to the extent exercisable) prior to the sale event; or (ii)&nbsp;we may make or provide for a cash payment to participants
holding options and stock appreciation rights equal to the difference between the per share cash consideration payable to stockholders in the sale event and the exercise price of the options or stock
appreciation rights (to the extent exercisable). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
board of directors may amend or discontinue the 2019 Plan and our compensation committee may amend the exercise price of options and amend or cancel outstanding awards for purposes of satisfying
changes in law or any other lawful purpose, but no such action may adversely affect rights under an award without the holder's consent. Certain amendments to the 2019 Plan require the approval of our
stockholders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No
awards may be granted under the 2019 Plan after the date that is ten years from the date of stockholder approval. No awards under the 2019 Plan have been made prior to the date of this prospectus. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2018 Stock Option and Grant Plan  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our 2018 Stock Option and Grant Plan, or 2018 Plan, was approved and adopted by our board of directors and stockholders on June&nbsp;7, 2018. Under the 2018
Plan, we have reserved for issuance an aggregate of 3,184,000 share of our common stock for the issuance of stock options and other equity awards under the 2018 Plan. This number of shares of common
stock reserved for issuance is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. As of
December&nbsp;31, 2018, options to purchase 5,656,243 shares of common stock were outstanding under the 2018 Plan. Our board of directors has determined not to make any further awards under the 2018
Plan following the completion of this offering, but all outstanding awards under the 2018 Plan will continue to be governed by their existing terms. The maximum number of shares that may be issued as
incentive stock options may not exceed 80,000,000. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
shares of common stock underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us
prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2018 Plan will be added back to the shares of common stock available
for issuance under the 2018 Plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
board of directors has acted as administrator of the 2018 Plan. The administrator has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be
granted, to make any combination of awards to participants, and to determine the specific terms and conditions of each award, subject to the provisions of our 2018 Plan. Persons eligible to
participate in our 2018 Plan will </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>158</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=161,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=928493,FOLIO='158',FILE='DISK114:[18ZFG1.18ZFG45201]DI45201A.;26',USER='SMENEZE',CD='16-JAN-2019;21:30' -->
<A NAME="page_di45201_1_159"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>be
those full or part-time officers, employees, non-employee directors, and consultants as selected from time to time by the administrator in its discretion. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
2018 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under Section&nbsp;422 of the Code and options that do not so qualify. The
option exercise price of each option will be determined by our Committee but may not be less than 100% of the fair market value of our common stock on the date of grant, or in the case of an incentive
stock option granted to a 10% owner, the exercise price shall not be less than 110% of the fair market value of our common stock on the date of grant. The term of each option will be fixed by our
Committee and may not exceed ten years from the date of grant. Our Committee will determine at what time or times each option may be exercised. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
Committee may award restricted shares of common stock and restricted stock units to participants subject to such conditions and restrictions as it may determine. These conditions and restrictions
may include the achievement of certain performance goals and/or continued employment with us through a specified vesting period. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
Committee may also grant shares of common stock that are free from any restrictions under our 2018 Plan. Unrestricted stock may be granted to participants in recognition of past services or for
other valid consideration and may be issued in lieu of cash compensation due to such participant. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
2018 Plan provides that upon the effectiveness of a Sale Event (as defined in our 2018 Plan) an acquirer or successor entity may assume, continue or substitute outstanding awards under our 2018
Plan. To the extent that awards granted under our 2018 Plan are not assumed or continued or substituted by the successor entity, except as may be otherwise provided in the relevant award certificate,
all awards with time-based or performance-based vesting, conditions or restrictions shall be forfeited as of the effective time of the Sale Event. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Upon
the effective time of the sale event, all outstanding awards granted under our 2018 Plan and our 2018 Plan shall terminate. In the event of such termination, individuals holding options will be
permitted to exercise such options within a specified period of time prior to the Sale Event. In addition, in connection with the termination of our 2018 Plan upon a Sale Event, we may make or provide
for a payment, in cash or in kind, to participants holding vested and exercisable options equal to the difference between the per share cash consideration payable to stockholders in the Sale Event and
the exercise price of the options. Our board of directors may amend or discontinue our 2018 Plan and our Committee may amend or cancel outstanding awards for purposes of satisfying changes in law or
any other lawful purpose, but no such action may adversely affect rights under an award without the holder's consent. Certain amendments to our 2018 Plan require the approval of our stockholders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No
awards may be granted under our 2018 Plan after the date that is ten years from the effective date of our 2018 Plan. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employee stock purchase plan  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, our board of directors adopted the Employee Stock Purchase Plan, or
the ESPP, and on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, our stockholders approved the ESPP.
The ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section&nbsp;423(b) of the Code. The ESPP initially reserves and authorizes the issuance of up to a total
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each
January&nbsp;1,
beginning on January&nbsp;1, 2020 and each January&nbsp;1 thereafter through January&nbsp;1, 2029, by </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>159</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=162,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=852498,FOLIO='159',FILE='DISK114:[18ZFG1.18ZFG45201]DI45201A.;26',USER='SMENEZE',CD='16-JAN-2019;21:30' -->
<A NAME="page_di45201_1_160"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>the
least of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding number of shares of our common stock on the immediately preceding December&nbsp;31, (ii)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares or
(iii)&nbsp;such number of shares as determined by the ESPP administrator. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend or other
change in our capitalization. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>All
employees whose customary employment is for more than 20&nbsp;hours per week and have completed at least&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months of employment are eligible to participate in the ESPP.
However,
any participating employee
who would own 5% or more of the total combined voting power or value of all classes of stock after an option were granted under the ESPP would not be eligible to purchase shares under the ESPP. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
will make one or more offerings each year to our employees to purchase shares under the ESPP. Offerings will usually begin on each January&nbsp;1 and July&nbsp;1 and will continue for six-month
periods, referred to as offering periods. Each eligible employee may elect to participate in any offering by submitting an enrollment form at least 15 business days before the relevant offering date. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Each
employee who is a participant in the ESPP may purchase shares by authorizing payroll deductions of up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of his or her base compensation during an offering period.
Unless the
participating employee has previously withdrawn from the offering, his or her accumulated payroll deductions will be used to purchase shares on the last business day of the offering period at a price
equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Under applicable tax rules, an employee may purchase
no more than $25,000 worth of shares of common stock, valued at the start of the purchase period, under the ESPP in any calendar year. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
accumulated payroll deductions of any employee who is not a participant on the last day of an offering period will be refunded. An employee's rights under the ESPP terminate upon voluntary
withdrawal from the plan or when the employee ceases employment with us for any reason. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Senior executive cash incentive bonus plan  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, our board of directors adopted the Senior Executive Cash Incentive
Bonus Plan, or the Bonus Plan. The Bonus Plan provides
for cash bonus payments based upon the attainment of performance targets established by our compensation committee. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
payment targets will be related to financial and operational measures or objectives with respect to our company, or corporate performance goals, as well as individual performance objectives. Our
compensation committee may select corporate performance goals from among the following: achievement of specified research and development, publication, clinical and/or regulatory milestones, adjusted
billings, earnings before interest, taxes, depreciation and amortization, net income (loss) (either before or after interest, taxes, depreciation and/or amortization), changes in the market price of
our common stock, economic value-added, funds from operations or similar measure, sales or revenue, acquisitions or strategic transactions, operating income (loss), cash flow (including, but not
limited to, operating cash flow and free cash flow), return on capital, assets, equity, or investment, stockholder returns, return on sales, gross or net profit levels, productivity, efficiency,
margins, operating efficiency, customer satisfaction, working
capital, earnings (loss) per share of stock, bookings, new bookings or renewals, sales or market shares; number of customers number of new customers or customer references; operating income and/or net
annual recurring revenue, any of which may be measured in absolute terms, as compared to any incremental increase, in terms of growth, or as compared to results of a peer group, against the market as
a whole, compared to applicable market indices and/or measured on a pre-tax or post-tax basis. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>160</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=163,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=236008,FOLIO='160',FILE='DISK114:[18ZFG1.18ZFG45201]DI45201A.;26',USER='SMENEZE',CD='16-JAN-2019;21:30' -->
<A NAME="page_di45201_1_161"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>Each
executive officer who is selected to participate in the Bonus Plan will have a target bonus opportunity set for each performance period. The bonus formulas will be adopted in each performance
period by the compensation committee and communicated to each executive. The corporate performance goals will be measured at the end of each performance period after our financial reports have been
published or such other appropriate time as the compensation committee determines. If the corporate performance goals and individual performance objectives are met, payments will be made as soon as
practicable following the end of each performance period. Subject to the rights contained in any agreement between the executive officer and us, an executive officer must be employed by us on the
bonus payment date to be eligible to receive a bonus payment. The Bonus Plan also permits the compensation committee to adjust or approve additional bonuses to executive officers in its sole
discretion. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


401(k) Plan  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We maintain a tax-qualified retirement plan, or the 401(k) Plan, that provides eligible U.S. employees with an opportunity to save for retirement on a tax
advantaged basis. Eligible employees are able to defer eligible compensation subject to applicable annual Code limits. Employees' pre-tax or Roth contributions are allocated to each participant's
individual account and are then invested in selected investment alternatives according to the participants' directions. Employees are immediately and fully vested in their contributions. Our 401(k)
Plan is intended to be qualified under Section&nbsp;401(a) of the Code with our 401(k) Plan's related trust intended to be tax exempt under Section&nbsp;501(a) of the Code. As a tax-qualified
retirement plan, contributions to our 401(k) Plan and earnings on those contributions are not taxable to the employees until distributed from our 401(k) Plan. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>161</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=164,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=201348,FOLIO='161',FILE='DISK114:[18ZFG1.18ZFG45201]DI45201A.;26',USER='SMENEZE',CD='16-JAN-2019;21:30' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dk45201_1_162"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B> <A NAME="dk45201_director_compensation"> </A>
<A NAME="toc_dk45201_1"> </A> </B></FONT><FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Director compensation    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table presents the total compensation for each person who served as a non-employee member of our board of directors and received
compensation for such service during the fiscal year ended December&nbsp;31, 2018. Other than as set forth in the table and described more fully below, we did not pay any compensation, make any
equity awards to, or pay any other compensation to any of the non-employee members of our board of directors in 2018. Andrew Cheng, our President and Chief Executive Officer, did not receive any
compensation for his service as a member of our board of directors during 2018. Dr.&nbsp;Cheng's compensation for service as an employee for fiscal year 2018 is presented in "Executive
compensation&#151;2018 Summary compensation table." We reimburse non-employee members of our board of directors for reasonable travel expenses. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Director compensation table&#151;2018  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="40pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="40pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Name</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Fees earned or<BR>
paid in cash<BR>
($)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Option<BR>
awards<BR>
($)(1)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Total<BR>
($) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Kevin Bitterman</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mark Iwicki</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>67,958</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>74,208</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Aaron Kantoff</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Aaron Royston</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Graham Walmsley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;The
amounts reported in the "Option Awards" column reflect the aggregate grant date fair value of share- based compensation awarded during the year computed in accordance with the
provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718. See Note&nbsp;7 to our financial statements appearing at the end of this prospectus regarding
assumptions underlying the valuation of equity awards.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2018, Mr.&nbsp;Iwicki held an unexercised option to purchase 234,338 shares of our common stock.  </FONT></P>


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Iwicki
serves as the Lead Director of our Board of Directors. We pay Mr.&nbsp;Iwicki a $25,000 fee for his services, which fee was prorated for the 2018 calendar year
based on his start date. </FONT></P>
 </DIV>
 <P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Non-Employee director compensation policy  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors will adopt a non-employee director compensation policy, effective upon effectiveness of the registration statement of
which this prospectus forms&nbsp;a part that is designed to enable us to attract and retain, on a long-term basis, highly qualified non-employee directors. Under the policy, each director who is not
an employee will be paid cash compensation from and after the completion of this offering, as set forth below: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="58pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Member<BR>
annual fee<BR>
($)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Chairman<BR>
additional<BR>
annual fee<BR>
($) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Board of Directors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Compensation Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nominating and Corporate Governance Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>162</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=165,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=1014295,FOLIO='162',FILE='DISK114:[18ZFG1.18ZFG45201]DK45201A.;22',USER='MTITUSS',CD='17-JAN-2019;12:06' -->
<A NAME="page_dk45201_1_163"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>In
addition, each non-employee director serving on our board of directors upon completion of this offering and each non-employee director elected or appointed to our board of directors following the
completion of this offering will be granted a one-time equity award of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares on the date of such director's election or appointment to the board of directors, which
will vest annually
over three years, subject to continued
service through such vesting dates. On the date of each annual meeting of stockholders of our company, each non-employee director will be granted an annual equity award
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares,
which will vest in full of the earlier to occur of the first anniversary of the date of grant or the next annual meeting, subject to continued service as a director through such vesting date. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>163</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=166,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=673165,FOLIO='163',FILE='DISK114:[18ZFG1.18ZFG45201]DK45201A.;22',USER='MTITUSS',CD='17-JAN-2019;12:06' -->
<A NAME="page_dk45201_1_164"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="dk45201_certain_relationships_and_related_party_transactions"> </A>
<A NAME="toc_dk45201_2"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Certain relationships and related party transactions    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following includes a summary of transactions since our inception on January&nbsp;24, 2017 to which we have been a party in which the
amount involved exceeded or will exceed $120,000 (or, if less, 1% of the average of our total asset amounts as of December&nbsp;31, 2017 and 2018), and in which any of our directors, executive
officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or
indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under "Executive compensation" and "Director
compensation." We also describe below certain other transactions with our directors, executive officers and stockholders. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Sales of securities  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Common stock  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In March 2017, we issued 232,00 shares of our common stock to Jonathan Young, our co-founder and Chief Operating Officer, and 232,000 shares of our common
stock to Timothy Rolph, our Chief Scientific Officer, each with a $0.0001 purchase price per share for total proceeds of $23.20, respectively. In March 2018, we issued 116,000 shares of our common
stock to Jonathan Young and 116,000 shares of our common stock to Timothy Rolph, each with a $0.0001 purchase price per share for total proceeds of $11.60, respectively. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;A convertible preferred stock financing  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In June 2018, with a subsequent closing in November 2018, we issued an aggregate of 50,858,462 shares of our Series&nbsp;A convertible preferred stock at a
purchase price of $1.00 per share pursuant to agreements entered into with investors, for an aggregate purchase price of approximately $45.0&nbsp;million. Each share of our Series&nbsp;A
convertible Preferred Stock will automatically convert into one share of our common stock immediately prior to the completion of this offering. All purchasers of our convertible preferred stock are
entitled to specified registration rights. See "Description of capital stock&#151;Registration rights" for more information regarding these registration rights. The following table summarizes
purchases of our Series&nbsp;A convertible preferred stock by related persons: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Participant</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Shares of<BR>
series&nbsp;A<BR>
convertible<BR>
preferred<BR>
stock</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Total<BR>
purchase<BR>
price </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Apple Tree Partners IV,&nbsp;L.P.(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>13,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>13,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>venBio Global Strategic Fund II,&nbsp;L.P.(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10,666,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10,666,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Versant Venture Capital VI,&nbsp;L.P.(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10,666,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10,666,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Atlas Venture Fund XI,&nbsp;L.P.(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10,666,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10,666,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Amgen&nbsp;Inc.(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,858,461</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(6) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;Apple
Tree Partners IV,&nbsp;L.P., or ATP, is a holder of five percent or more of our capital stock. Aaron Kantoff is a partner at ATP and a member of our board of directors. </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;venBio
Global Strategic Fund II,&nbsp;L.P., or venBio, is a holder of five percent or more of our capital stock. Aaron Royston, M.D., M.B.A., is a partner at venBio and a member of
our board of directors.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Versant
Venture Capital VI,&nbsp;L.P., or Versant, is a holder of five percent or more of our capital stock. Graham Walmsley is a principal at Versant and a member of our board of
directors.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(4)&nbsp;&nbsp;&nbsp;Atlas
Venture Fund XI,&nbsp;L.P., or Atlas Fund XI, together with its affiliate fund Atlas Venture Opportunity Fund&nbsp;I, L.P., or Atlas Fund I, is a holder of five percent or
more of our capital stock. Kevin Bitterman, Ph.D., is a partner at Atlas Fund XI, Atlas Fund&nbsp;I and a member of our board of directors. </FONT></P>
 </DIV>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>164</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=167,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=274512,FOLIO='164',FILE='DISK114:[18ZFG1.18ZFG45201]DK45201A.;22',USER='MTITUSS',CD='17-JAN-2019;12:06' -->
<A NAME="page_dk45201_1_165"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(5)&nbsp;&nbsp;&nbsp;&nbsp;Amgen&nbsp;Inc.,
or Amgen, is a holder of five percent or more of our capital stock.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(6)&nbsp;&nbsp;&nbsp;The
shares of Series&nbsp;A convertible preferred stock issued to Amgen were partial consideration for the exclusive license agreement entered into simultaneously with the sale and
issuance of the Series&nbsp;A convertible preferred stock. </FONT></P>
 </DIV>
 <P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;B convertible preferred stock financing  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In December 2018, we sold an aggregate of 13,871,948 shares of our Series&nbsp;B convertible preferred stock at a purchase price of $3.28 per share pursuant
to agreements entered into with investors, for an aggregate purchase price of approximately $45.5&nbsp;million. Each share of our Series&nbsp;B convertible preferred stock will automatically
convert into one share of our common stock immediately
prior to the completion of this offering. All purchasers of our convertible preferred stock are entitled to specified registration rights. See "Description of capital stock&#151;Registration
rights" for more information regarding these registration rights. The following table summarizes purchases of our Series&nbsp;B convertible preferred stock by related persons: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="84pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Participant</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Shares of<BR>
series&nbsp;B<BR>
convertible<BR>
preferred<BR>
stock</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Total<BR>
purchase<BR>
price </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Apple Tree Partners IV,&nbsp;L.P.(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>880,568</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,888,263.04</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Atlas Venture Opportunity Fund I,&nbsp;L.P.(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>722,737</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,370,577.36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 venBio Global Strategic Fund II,&nbsp;L.P.(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>722,737</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,370,577.36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Versant Venture Capital VI,&nbsp;L.P.(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>722,737</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,370,577.36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Entities affiliated with Janus Henderson(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,268,292</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>13,999,997.76 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;Apple
Tree Partners IV,&nbsp;L.P., or ATP is a holder of five percent or more of our capital stock. Aaron Kantoff is a partner at ATP and a member of our board of directors. </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Atlas
Venture Opportunity Fund I,&nbsp;L.P., or Atlas Fund I, together with its affiliate fund Atlas Venture Fund&nbsp;XI, L.P., or Atlas Fund XI, is a holder of five percent or
more of our capital stock. Kevin Bitterman, Ph.D., is a partner at Atlas Fund&nbsp;I, Atlas Fund&nbsp;XI and a member of our board of directors.  </FONT></P>


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;venBio
Global Strategic Fund II,&nbsp;L.P., or venBio, is a holder of five percent or more of our capital stock. Aaron Royston, M.D., M.B.A., is a partner at venBio and a member of
our board of directors.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(4)&nbsp;&nbsp;&nbsp;Versant
Venture Capital VI,&nbsp;L.P., or Versant, is a holder of five percent or more of our capital stock. Graham Walmsley is a principal at Versant and a member of our board of
directors.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(5)&nbsp;&nbsp;&nbsp;&nbsp;Consists
of: (i)&nbsp;2,642,075 shares of Series&nbsp;B convertible preferred stock purchased and received by Janus Henderson Global Life Sciences Fund, (ii)&nbsp;1,610,974
shares of Series&nbsp;B convertible preferred stock purchased and received by Janus Henderson Capital Funds&nbsp;PLC, and (iii)&nbsp;15,243 shares of Series&nbsp;B convertible preferred stock
purchased and received by Janus Henderson Horizon Fund&#151;Biotechnology Fund. </FONT></P>
 </DIV>
 <P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Services agreement  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On June&nbsp;7, 2017, we entered into a services agreement with Apple Tree Life Sciences,&nbsp;Inc., or ATLS, an affiliate of Apple Tree
Partners IV,&nbsp;L.P., under which ATLS provided us with personnel, advisory and consulting services relating to potential investment and/or acquisition, development and implementation of a plan to
obtain regulatory approval of any acquired candidates, general scientific leadership, and management of research and development. The services agreement was terminated in December 2018. From June 2017
to January 2019, we paid ATLS an aggregate of $2.1&nbsp;million for services provided under the services agreement, inclusive of the services provided by Jonathan Young, Tim Rolph and Paul
DaSilva-Jardine. Paul DaSilva-Jardine served as our Chief Discovery Officer from March 2017 until October 2017. Jonathan Young and Tim Rolph have served as executive officers since March 2017. Former
director Seth Harrison, who served on our board of directors from January 2017 to June 2018, is the President and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>165</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=168,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=1036081,FOLIO='165',FILE='DISK114:[18ZFG1.18ZFG45201]DK45201A.;22',USER='MTITUSS',CD='17-JAN-2019;12:06' -->
<A NAME="page_dk45201_1_166"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>director
of ATLS, as well as the director of the general partner of Apple Tree Partners IV,&nbsp;L.P. Other directors affiliated with ATLS are listed in the "Principal stockholders" section below. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


License agreement  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On June&nbsp;7, 2018, we entered into an exclusive license agreement with Amgen. Amgen granted us an exclusive license to certain patents
and a non-exclusive license to certain related know-how to commercially develop, manufacture, use and distribute throughout the world therapeutic products that incorporate such patents and related
know-how. We paid Amgen an upfront fee of $5.0&nbsp;million and issued to Amgen an aggregate of 5,858,461 shares of Series&nbsp;A convertible preferred stock. We will also make certain milestone
payments to Amgen and royalty payments on future sales of licensed products. For more information regarding the license agreement see "Business&#151;Exclusive license agreement with
Amgen&nbsp;Inc." </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Amended and restated investors' rights agreement  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a party to an investors' rights agreement, effective as of December&nbsp;10, 2018, with holders of our convertible preferred stock,
including our 5% stockholder and entities affiliated with our directors. The investor rights agreement provides these holders the right, following the completion of this offering, to demand that we
file&nbsp;a registration statement or request that their shares be covered by a registration statement that we are otherwise filing. The investor rights agreement also provides a right of first
refusal to purchase future securities sold by us, which such right shall terminate immediately prior to the consummation of this offering. See "Description of capital stock&#151;Registration
rights" for additional information regarding these registration rights. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Amended and restated voting agreement  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are party to a voting agreement, effective as of December&nbsp;10, 2018, with certain of our stockholders. Each of Apple Tree, Atlas,
venBio, and Versant have appointed representatives to our Board of Directors. The voting agreement will terminate upon the completion of this offering, and members previously elected to our board of
directors pursuant to this agreement will continue to serve as directors until they resign, are removed or their successors are duly elected by the holders of our common stock. The composition of our
board of directors after this offering is described in more detail under "Management&#151;Board composition and election of directors." </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Amended and restated right of first refusal and co-sale agreement  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a party to an amended and restated right of first refusal and co-sale agreement, effective as of December&nbsp;10, 2018, with holders
of our convertible preferred stock, including some of our 5% stockholders and entities affiliated with our directors. The right of first refusal and co-sale agreement provides the key holders the
right to purchase all or any portion of transfer stock, as well as the right of co-sale and participation in any proposed transfers. The agreement will terminate upon completion of this offering. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Employment agreements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have entered into employment agreements with our named executive officers. For more information regarding the agreements with our named
executive officers, see "Executive compensation&#151;Employment agreements." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>166</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=169,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=282999,FOLIO='166',FILE='DISK114:[18ZFG1.18ZFG45201]DK45201A.;22',USER='MTITUSS',CD='17-JAN-2019;12:06' -->
<A NAME="page_dk45201_1_167"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Director compensation  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>See "Director compensation" for information regarding compensation of our directors. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Indemnification agreements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In connection with this offering, we intend to enter into agreements to indemnify our directors and executive officers. These agreements will,
among other things, require us to indemnify these individuals for certain expenses (including attorneys' fees), judgments, fines and settlement amounts reasonably incurred by such person in any action
or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person's status as a member of our board of directors to
the maximum extent allowed under Delaware law. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Stock option grants to executive officers and directors  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have granted stock options to our executive officers and certain of our directors as more fully described in the sections entitled
"Executive compensation" and "Director compensation." </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Policies for approval of related party transactions  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors reviews and approves transactions with directors, officers and holders of five percent or more of our voting securities
and their affiliates, each a related party. Prior to this offering, the material facts as to the related party's relationship or interest in the transaction are disclosed to our board of directors
prior to their consideration of such transaction, and the transaction is not considered approved by our board of directors unless a majority of the directors who are not interested in the transaction
approve the transaction. Further, when stockholders are entitled to vote on a transaction with a related party, the material facts of the related party's relationship or interest in the transaction
are disclosed to the stockholders, who must approve the transaction in good faith. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
connection with this offering, we expect to adopt a written related party transactions policy that such transactions must be approved by our audit committee. This policy will become effective on
the date on which the registration statement of which this prospectus is a part is declared effective by the SEC. Pursuant to this policy, the audit committee has the primary responsibility for
reviewing and approving or disapproving "related party transactions," which are transactions between us and related persons in which the aggregate amount involved exceeds or may be expected to exceed
$120,000 and in which a related person has or will have a direct or indirect material interest. For purposes of this policy, a related person will be defined as a director, executive officer, nominee
for director, or greater than 5% beneficial owner of our common stock, in each case since the beginning of the most recently completed year, and their immediate family members. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>167</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=170,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=799079,FOLIO='167',FILE='DISK114:[18ZFG1.18ZFG45201]DK45201A.;22',USER='MTITUSS',CD='17-JAN-2019;12:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dm45201_1_168"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B> <A NAME="dm45201_principal_stockholders"> </A>
<A NAME="toc_dm45201_1"> </A> </B></FONT><FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Principal stockholders    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth certain information known to us regarding beneficial ownership of our capital stock as of December&nbsp;31,
2018, as adjusted to reflect the sale of common stock offered by us in this offering, for:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each of our named executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each of our directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> all of our executive officers and directors as a group; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each person or group of affiliated persons known by us to beneficially own more than 5% of our common stock. </FONT></DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>Beneficial
ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Under those rules, beneficial ownership
includes any shares as to which the individual or entity has sole or shared voting power or investment power, and includes securities that the individual or entity has the right to acquire, such as
through the exercise of stock options, within 60&nbsp;days of December&nbsp;31, 2018. Except as noted by footnote, and subject to community property laws where applicable, we believe, based on the
information provided to us, that the persons and entities named in the table below have sole voting and investment power with respect to all common stock shown as beneficially owned by them. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
percentage of beneficial ownership prior to this offering in the table below is based on 65,465,104 shares of common stock deemed to be outstanding as of December&nbsp;31, 2018, assuming the
conversion of all outstanding shares of our convertible preferred stock upon the completion of this offering into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock upon the
completion of this
offering, and the percentage of beneficial ownership at this offering in the table below is based on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock assumed to be outstanding after the closing
of the offering.
The information in the table below assumes no exercise of the underwriters' option to purchase additional shares. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>168</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=171,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=676468,FOLIO='168',FILE='DISK114:[18ZFG1.18ZFG45201]DM45201A.;29',USER='MTITUSS',CD='17-JAN-2019;11:28' -->
<A NAME="page_dm45201_1_169"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>Except
as otherwise noted below, the address for persons listed in the table is c/o Akero Therapeutics,&nbsp;Inc., 170 Harbor Way, 3rd&nbsp;Floor, South San Francisco, CA 94080. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=3 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Percentage of shares<BR>
beneficially owned </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Number of<BR>
shares<BR>
beneficially<BR>
owned</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Name and address of beneficial owner</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Before<BR>
offering</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>After<BR>
offering</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>5% or Greater Stockholders:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amgen&nbsp;Inc.(1)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,858,461</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7.8%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Apple Tree Partner IV,&nbsp;L.P.(2)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>13,880,568</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>18.5%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Atlas Venture(3)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11,389,404</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>15.2%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Entities affiliated with Janus Henderson(4)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,268,292</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5.7%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>venBio Global Strategic Fund II,&nbsp;L.P.(5)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11,389,404</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>15.2%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Versant Venture Capital VI,&nbsp;L.P.(6)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11,389,404</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>15.2%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Named Executive Officers and Directors:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Andrew Cheng, M.D., Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jonathan Young, J.D., Ph.D.(7)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>541,785</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Timothy Rolph, DPhil(8)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>541,785</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>*%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kitty Yale</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Kevin Bitterman, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mark Iwicki</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Aaron Kantoff</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Aaron Royston, M.D., M.B.A</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Graham Walmsley, M.D., Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Executive Officers and Directors as a group (9 persons)(9)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,083,570</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.4%</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents
beneficial ownership of less than one percent.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;Consists
of 5,858,461 shares of Series&nbsp;A convertible preferred stock issued to Amgen&nbsp;Inc. in connection with a license agreement. The mailing address of
Amgen&nbsp;Inc. is One Amgen Center Drive, Thousand Oaks, CA 91320.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Consists
of (a)&nbsp;13,000,000 shares of Series&nbsp;A convertible preferred stock purchased and received by Apple Tree Partners IV,&nbsp;L.P., or ATP, and (b)&nbsp;880,568
shares of Series&nbsp;B convertible preferred stock purchased and received by ATP. ATP is managed by ATP III&nbsp;GP,&nbsp;Ltd., the sole director of which is Dr.&nbsp;Seth L. Harrison The
mailing address of Apple Tree Partners IV,&nbsp;L.P. is 230 Park Avenue, Suite&nbsp;2800, New York, NY&nbsp;10169.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Consists
of (a)&nbsp;10,666,667 shares of Series&nbsp;A convertible preferred stock purchased and received by Atlas Venture Fund XI,&nbsp;L.P., or Atlas Fund XI and
(b)&nbsp;722,737 shares of Series&nbsp;B convertible preferred stock purchased and received by Atlas Venture Opportunity Fund I,&nbsp;L.P., or Atlas Fund I. Atlas Fund XI is managed by Atlas
Venture Associates XI,&nbsp;LLC, or AVA XI&nbsp;LLC. Atlas Fund I is managed by Atlas Venture Associates Opportunity I,&nbsp;L.P., which is managed by Atlas Venture Associates Opportunity
I,&nbsp;LLC, AVAO&nbsp;LLC. Bruce Booth, Jean-Francois Formela, David Grayzel, Jason Rhodes, and Kevin Bitterman are the members of AVA IX&nbsp;LLC and AVAO&nbsp;LLC and collectively make
investment decisions on behalf of Atlas Fund XI and Atlas Fund&nbsp;I. Kevin Bitterman is also a member of our board of directors. Mr.&nbsp;Bitterman disclaims beneficial ownership of the shares
listed, except to the extent of his pecuniary interest therein. The mailing address of Atlas Fund XI and Atlas Fund&nbsp;I is 400 Technology Square, 10<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">th</font>&nbsp;Floor, Cambridge, MA
02139.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(4)&nbsp;&nbsp;&nbsp;Consists
of (a)&nbsp;2,642,075 shares of Series&nbsp;B convertible preferred stock purchased and received by Janus Henderson Global Life Sciences Fund, (b)&nbsp;1,610,927 shares
of Series&nbsp;B convertible preferred stock purchased and received by Janus Henderson Capital Funds&nbsp;PLC, and (c)&nbsp;15,243 shares of Series&nbsp;B convertible preferred stock purchased
and received by Janus Henderson Horizon Fund Biotechnology Fund. The mailing address for Janus Henderson Global Life Sciences Fund is 151 Detroit Street, Denver, CO 80206.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(5)&nbsp;&nbsp;&nbsp;&nbsp;Consists
of (a)&nbsp;10,666,667 shares of Series&nbsp;A convertible preferred stock purchased and received by venBio Global Strategic Fund II,&nbsp;L.P., or venBio L and
(b)&nbsp;722,737 shares of Series&nbsp;B convertible preferred stock purchased and received by venBio. venBio Global Strategic&nbsp;GP&nbsp;II,&nbsp;L.P., or the General Partner, is the sole
general partner of venBio Global Strategic Fund II&nbsp;LP, or venBio. venBio Global Strategic&nbsp;GP II,&nbsp;Ltd., or&nbsp;GP&nbsp;Ltd., is the sole general partner of the General
Partner. Robert Adelman and Corey Goodman are directors of the&nbsp;GP&nbsp;Ltd. As the sole general partner of the Fund, the General Partner may be deemed to own beneficially the venBio Shares.
As the sole general partner of the General Partner, the&nbsp;GP&nbsp;Ltd. likewise may be deemed to own beneficially the venBio Shares. As directors of the&nbsp;GP&nbsp;Ltd., each of the
Directors likewise may be deemed to own beneficially the venBio Shares. The address for venBio, the General Partner and&nbsp;GP&nbsp;Ltd. is c/o venBio Partners,&nbsp;LLC, 1700 Owens Street,
Suite&nbsp;595, San Francisco, CA 94158. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>169</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=172,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=46809,FOLIO='169',FILE='DISK114:[18ZFG1.18ZFG45201]DM45201A.;29',USER='MTITUSS',CD='17-JAN-2019;11:28' -->
<A NAME="page_dm45201_1_170"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(6)&nbsp;&nbsp;&nbsp;Consists
of (a)&nbsp;10,666,667 shares of Series&nbsp;A convertible preferred stock purchased and received by Versant Venture Capital VI,&nbsp;L.P., or Versant VI&nbsp;LP and
(b)&nbsp;722,737 shares of Series&nbsp;B convertible preferred stock purchased and received by Versant VI&nbsp;LP. Versant Ventures&nbsp;VI&nbsp;GP-GP,&nbsp;LLC, or Versant VI&nbsp;LLC
is the ultimate general partner of Versant VI&nbsp;LP. Thomas Woiwode, Bradley Bolzon, Kirk Nielsen, Robin Praeger, and Jerel Davis, are the managing directors of Versant VI&nbsp;LLC and may be
deemed to share voting and investment power over the shares held by Versant VI&nbsp;LP. The mailing address for Versant Venture Capital VI,&nbsp;L.P. is One Sansome, Suite&nbsp;3630, San
Francisco, CA&nbsp;94104.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(7)&nbsp;&nbsp;&nbsp;&nbsp;Consists
of (a)&nbsp;348,000 shares of restricted common stock and (b)&nbsp;193,785 shares of common stock underlying options exercisable within 60&nbsp;days of
December&nbsp;31, 2018.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(8)&nbsp;&nbsp;&nbsp;Consists
of (a)&nbsp;348,000 shares of restricted common stock and (b)&nbsp;193,785 shares of common stock underlying options exercisable within 60&nbsp;days of
December&nbsp;31, 2018.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(9)&nbsp;&nbsp;&nbsp;See
notes&nbsp;(7) and (8)&nbsp;above. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>170</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=173,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=1034535,FOLIO='170',FILE='DISK114:[18ZFG1.18ZFG45201]DM45201A.;29',USER='MTITUSS',CD='17-JAN-2019;11:28' -->
<A NAME="page_dm45201_1_171"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="dm45201_description_of_capital_stock"> </A>
<A NAME="toc_dm45201_2"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Description of capital stock    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>The following descriptions are summaries of the material terms of our fourth amended and restated certificate of
incorporation, which will be effective upon the completion of this offering and fourth amended and restated bylaws, which will be effective on the date of the effectiveness of the
registration statement of which this prospectus is a part. The descriptions of the common stock and convertible preferred stock give effect to changes to our capital structure that will occur
immediately prior to the completion of this offering. We refer in this section to our fourth amended and restated certificate of incorporation as our certificate of incorporation, and we refer to our
second amended and restated bylaws as our bylaws.</I></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


General  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon completion of this offering, our authorized capital stock will consist of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, par value $0.0001 per
share, and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of convertible preferred stock, par value $0.0001 per share, all of which shares of convertible preferred stock will be undesignated. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2018, 734,694 shares of our common stock and 64,730,410 shares of convertible preferred stock were outstanding and held by 25 stockholders of record. This amount does not
take into account the conversion of all outstanding shares of our convertible preferred stock into common stock upon the completion of this offering. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Common stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The
holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally
available for that purpose, subject to any preferential dividend rights of any outstanding convertible preferred stock. Our common stock has no preemptive rights, conversion rights or other
subscription rights or redemption or sinking fund provisions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and
any liquidation preference of any outstanding convertible preferred stock. The shares to be issued by us in this offering will be, when issued and paid for, validly issued, fully paid and
non-assessable. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Preferred stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon the completion of this offering, all outstanding shares of our convertible preferred stock will be converted into shares of our common
stock. Upon the consummation of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of
preferred stock in
one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights,
terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common
stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our
liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. Immediately after
consummation </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>171</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=174,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=650737,FOLIO='171',FILE='DISK114:[18ZFG1.18ZFG45201]DM45201A.;29',USER='MTITUSS',CD='17-JAN-2019;11:28' -->
<A NAME="page_dm45201_1_172"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>of
this offering, no shares of convertible preferred stock will be outstanding, and we have no present plan to issue any shares of convertible preferred stock. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Options  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of December&nbsp;31, 2018, options to purchase 5,656,243 shares of our common stock were outstanding, of which 303,787 were vested and
exercisable as of that date. For additional information regarding the terms of this plan, see "Executive compensation&#151;Employee benefit and equity compensation plans&#151;2018 Stock
Option and Grant Plan." </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Registration rights  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon the completion of this offering, the holders of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, including those issuable upon the conversion
of convertible preferred stock will be entitled to rights with respect to the registration of these securities under the Securities Act. These rights are provided under the terms of an amended and
restated investors' rights agreement between us and holders of our convertible preferred stock. The amended and restated investors' rights agreement includes demand registration rights, short-form
registration rights and piggyback registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be borne by us and all selling expenses, including
underwriting discounts and selling commissions, will be borne by the holders of the shares being registered. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Demand registration rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Beginning 180&nbsp;days after the effective date of this registration statement, the holders of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, including those
issuable upon the conversion of convertible preferred stock upon completion of this offering, are entitled to demand registration rights. Under the terms of the amended and restated investors' rights
agreement, we will be required, upon the written request of a majority of the holders of convertible preferred stock, to file&nbsp;a registration statement and use best efforts to effect the
registration of all or a portion of these shares for public resale at an aggregate price of at least $10.0&nbsp;million. We are required to effect only one registration pursuant to this provision of
the amended and restated investors' rights agreement. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Short-Form registration rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant to the amended and restated investors' rights agreement, if we are eligible to file&nbsp;a registration statement on Form&nbsp;S-3, upon the
written request of at least 20% of these holders to sell registrable securities at an aggregate price of at least $5.0&nbsp;million, we will be required to use commercially reasonable efforts to
effect a registration of such shares. We are required to effect only one registration in any twelve-month period pursuant to this provision of the investors' rights agreement. The right to have such
shares registered on Form&nbsp;S-3 is further subject to other specified conditions and limitations. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Piggyback registration rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant to the amended and restated investors' rights agreement, if we register any of our securities either for our own account or for the account of other
security holders, the holders of these shares are entitled to include their shares in the registration. Subject to certain exceptions contained in the amended and restated investors' rights agreement,
we and the underwriters may terminate or withdraw any registration initiated before the effective date of such registration in our sole discretion. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>172</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=175,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=411317,FOLIO='172',FILE='DISK114:[18ZFG1.18ZFG45201]DM45201A.;29',USER='MTITUSS',CD='17-JAN-2019;11:28' -->
<A NAME="page_dm45201_1_173"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indemnification  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our amended and restated investors' rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of
registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or
omissions attributable to them. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expiration of registration rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The demand registration rights and short form registration rights granted under the investors' rights agreement will terminate on the third anniversary of the
completion of this offering or at such time after this offering when the holders' shares may be sold without restriction pursuant to Rule&nbsp;144 within a three-month period. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Anti-Takeover effects of our certificate of incorporation and bylaws and delaware law  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our certificate of incorporation and bylaws include a number of provisions that may have the effect of delaying, deferring or preventing
another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than
pursue non-negotiated takeover attempts. These provisions include the items described below. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board composition and filling vacancies  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our certificate of incorporation provides for the division of our board of directors into three classes serving staggered three-year terms, with one class
being elected each year. Our certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of two-thirds or more of the
shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our
board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of
directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


No written consent of stockholders  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting,
and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment
of our bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Meetings of stockholders  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our certificate of incorporation and bylaws provide that only a majority of the members of our board of directors then in office may call special meetings of
stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be
conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>173</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=176,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=500899,FOLIO='173',FILE='DISK114:[18ZFG1.18ZFG45201]DM45201A.;29',USER='MTITUSS',CD='17-JAN-2019;11:28' -->
<A NAME="page_dm45201_1_174"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Advance notice requirements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new
business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the
meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90&nbsp;days nor more than 120&nbsp;days prior to the
first anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form and content of all stockholders' notices. These requirements may preclude
stockholders from bringing matters before the stockholders at an annual or special meeting. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amendment to certificate of incorporation and bylaws  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our certificate of
incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as
a class, except that the amendment of the provisions relating to stockholder action, board composition, limitation of liability and the amendment of our bylaws and certificate of incorporation must be
approved by not less than two-thirds of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote thereon as a
class. Our bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative
vote of at least two-thirds of the outstanding shares entitled to vote on the amendment, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote
of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Undesignated preferred stock  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our certificate of incorporation provides for 5,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred
stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its
fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock
to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or
stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred
stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely
affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Choice of forum  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of
the State of Delaware (or, if the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) will be the sole
and exclusive forum for state law claims for: (1)&nbsp;any derivative action or proceeding brought on our behalf; (2)&nbsp;any action asserting a claim of breach of a fiduciary duty or other </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>174</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=177,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=393405,FOLIO='174',FILE='DISK114:[18ZFG1.18ZFG45201]DM45201A.;29',USER='MTITUSS',CD='17-JAN-2019;11:28' -->
<A NAME="page_dm45201_1_175"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>wrongdoing
by any of our directors, officers, employees or agents to us or our stockholders; (3)&nbsp;any action asserting a claim against us arising pursuant to any provision of the General
Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; (4)&nbsp;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation
or bylaws; or (5)&nbsp;any action asserting a claim governed by the internal affairs doctrine. Our certificate of incorporation also provides that any person or entity purchasing or otherwise
acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the
choice of forum provision contained in our certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the United States District Court for the Southern District of New York will be the
exclusive forum for any private action asserting violations by us or any of our directors or officers of the Securities Act or the Exchange Act, or the rules and regulations promulgated thereunder,
and of all suits in equity and actions at law brought to enforce any liability or duty created by those statutes or the rules and regulations under such statutes. If any action the subject matter of
which is within the scope of the preceding sentence is filed in a court other than the United States District Court for the Southern District of New York, the plaintiff or plaintiffs shall be deemed
by this provision of the bylaws (i)&nbsp;to have consented to removal of the action by us to the United States District Court for the Southern District of New York, in the case of an action filed in
a state court, and (ii)&nbsp;to have consented to transfer of the action to the United States District Court for the Southern District of New York. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Section&nbsp;203 of the Delaware general corporation law  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In
general, Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a "business combination" with an "interested stockholder" for a three-year period following the time that
this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an
interested stockholder is prohibited unless it satisfies one of the following conditions:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in
the stockholder becoming an interested stockholder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at
least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are
directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an
annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Section&nbsp;203
defines a business combination to include:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any merger or consolidation involving the corporation and the interested stockholder; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>175</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=178,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=484593,FOLIO='175',FILE='DISK114:[18ZFG1.18ZFG45201]DM45201A.;29',USER='MTITUSS',CD='17-JAN-2019;11:28' -->
<A NAME="page_dm45201_1_176"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the
interested stockholder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any
class or series of the corporation beneficially owned by the interested stockholder; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or
through the corporation. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In general, Section&nbsp;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding
voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Nasdaq global market listing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We intend to apply for listing of our common stock on The Nasdaq Global Market under the symbol "AKRO." </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Transfer agent and registrar  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The transfer agent and registrar for our common stock will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The transfer agent and registrar's address
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Limitations of liability and indemnification matters  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For a discussion of liability and indemnification, see "Executive compensation." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>176</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=179,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=548000,FOLIO='176',FILE='DISK114:[18ZFG1.18ZFG45201]DM45201A.;29',USER='MTITUSS',CD='17-JAN-2019;11:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_do45201_1_177"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B> <A NAME="do45201_shares_eligible_for_future_sale"> </A>
<A NAME="toc_do45201_1"> </A> </B></FONT><FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Shares eligible for future sale    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior to this offering, there has been no public market for our commons stock. Future sales of our common stock in the public market, or the
availability of such shares for sale in the public market, could adversely affect market prices prevailing from time to time. As described below, only a limited number of shares will be available for
sale shortly after this offering due to contractual and legal restrictions on resale. Nevertheless, sales of our common stock in the public market after such restrictions lapse, or the perception that
those sales may occur, could adversely affect the prevailing market price at such time and our ability to raise equity capital in the future. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Based
on the number of shares outstanding as of December&nbsp;31, 2018, upon the completion of this offering,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will be
outstanding. Of the outstanding
shares, all of the shares sold in this offering will be freely tradable, except that any shares held by our affiliates, as that term is defined in Rule&nbsp;144 under the Securities Act, may only be
sold in compliance with the limitations described below. All remaining shares of common stock held by existing stockholders immediately prior to the completion of this offering will be "restricted
securities" as such term is defined in Rule&nbsp;144. These restricted securities were issued and sold by us, or will be issued and sold by us, in private transactions and are eligible for public
sale only if registered under the Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule&nbsp;144 or
Rule&nbsp;701, summarized below. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Rule&nbsp;144  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In general, a person who has beneficially owned restricted stock for at least six months would be entitled to sell their securities provided
that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90&nbsp;days preceding, a sale and (ii)&nbsp;we are subject to the Securities
Exchange Act of 1934, as amended, or the Exchange Act, periodic reporting requirements for at least 90&nbsp;days before the sale. Persons who have beneficially owned restricted shares for at least
six months but who are our affiliates at the time of, or any time during the 90&nbsp;days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to
sell within any three-month period only a number of securities that does not exceed the greater of either of the following:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 1% of the number of shares then outstanding, which will equal approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
immediately after this offering, assuming no
exercise of the underwriters' option to purchase additional shares, based on the number of shares outstanding as of December&nbsp;31, 2018; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the average weekly trading volume of our common stock on The Nasdaq Global Market during the four calendar weeks preceding the filing of a
notice on Form&nbsp;144 with respect to the sale; </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>provided,
in each case, that we are subject to the Exchange Act periodic reporting requirements for at least 90&nbsp;days before the sale. Such sales both by affiliates and by non-affiliates must
also comply with the manner of sale, current public information and notice provisions of Rule&nbsp;144. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Rule&nbsp;701  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Rule&nbsp;701 under the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon
Rule&nbsp;144 but without compliance with certain restrictions of Rule&nbsp;144, including the holding period requirement. Most of our employees, executive officers or directors who purchased
shares under a written compensatory plan or contract may be entitled to rely on the resale provisions of Rule&nbsp;701, but all </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>177</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=180,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=278851,FOLIO='177',FILE='DISK114:[18ZFG1.18ZFG45201]DO45201A.;11',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_do45201_1_178"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>holders
of Rule&nbsp;701 shares are required to wait until 90&nbsp;days after the date of this prospectus before selling their shares. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>However,
substantially all Rule&nbsp;701 shares are subject to lock-up agreements as described below and under "Underwriting" included elsewhere in this prospectus and will become eligible for sale
upon the expiration of the restrictions set forth in those agreements. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Lock-up agreements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We, our directors and executive officers and holders of substantially all of our common stock have signed a lock-up agreement that prevent us
and them from selling any of our common stock or any securities convertible into or exercisable or exchangeable for common stock for a period of not less than 180&nbsp;days from the date of this
prospectus without the prior written consent of J.P. Morgan Securities&nbsp;LLC, Jefferies&nbsp;LLC and Evercore Group L.L.C., subject to certain exceptions. J.P. Morgan Securities&nbsp;LLC,
Jefferies&nbsp;LLC and Evercore Group L.L.C. may waive these restrictions with respect to some or all of the subject securities in their sole discretion. See "Underwriting" appearing elsewhere in
this prospectus for more information. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Rule&nbsp;10b5-1 trading plans  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Following the completion of this offering, certain of our officers, directors and significant stockholders may adopt written plans, known as
Rule&nbsp;10b5-1 trading plans, in which they will
contract with a broker to buy or sell shares of our common stock on a periodic basis to diversify their assets and investments. Under these 10b5-1 trading plans, a broker may execute trades pursuant
to parameters established by the officer, director or stockholder when entering into the plan, without further direction from such officer, director or stockholder. Such sales would not commence until
the expiration of the applicable lock-up agreements entered into by such officer, director or stockholder in connection with this offering. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Registration rights  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon completion of this offering, certain holders of our securities will be entitled to various rights with respect to registration of their
shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately
upon the effectiveness of the registration. See "Description of capital stock&#151;Registration rights" appearing elsewhere in this prospectus for more information. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Equity incentive plans  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We intend to file one or more registration statements on Form&nbsp;S-8 under the Securities Act to register our shares issued or reserved
for issuance under our equity incentive plans. The first such registration statement is expected to be filed soon after the date of this prospectus and will automatically become effective upon filing
with the SEC. Accordingly, shares registered under such registration statement will be available for sale in the open market, unless such shares are subject to vesting restrictions with us or the
lock-up restrictions described above. As of December&nbsp;31, 2018, we estimate that such registration statement on Form&nbsp;S-8 will cover
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>178</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=181,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=775591,FOLIO='178',FILE='DISK114:[18ZFG1.18ZFG45201]DO45201A.;11',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_do45201_1_179"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="do45201_material_u.s._federal_income_t__mat03146"> </A>
<A NAME="toc_do45201_2"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Material U.S. federal income tax considerations for<BR>  non-U.S. holders of common stock    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following discussion is a summary of the material U.S. federal income tax considerations applicable to non-U.S. holders (as defined below)
with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering. For purposes of this discussion, a non-U.S. holder means a beneficial owner of our
common stock that is for U.S. federal income tax purposes:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a non-resident alien individual; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a foreign corporation or any other foreign organization taxable as a corporation for U.S. federal income tax purposes; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a foreign estate or trust, the income of which is not subject to U.S. federal income tax on a net income basis. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>This
discussion does not address the tax treatment of partnerships or other entities that are pass-through entities for U.S. federal income tax purposes or persons that hold their common stock through
partnerships or other pass-through entities. A partner in a partnership or other pass-through entity that will hold our common stock should consult his, her or its tax advisor regarding the tax
consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through entity, as applicable. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
discussion is based on current provisions of the U.S. Internal Revenue Code of 1986, as amended, which we refer to as the Code, existing and proposed U.S. Treasury Regulations promulgated
thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus and, all of which are subject to change or to differing interpretation, possibly
with retroactive effect. Any such change or differing interpretation could alter the tax consequences to non-U.S. holders described in this prospectus. There can be no assurance that the Internal
Revenue Service, which we refer to as the IRS, will not challenge one or more of the tax consequences described herein. We assume in this discussion that a non-U.S. holder holds shares of our common
stock as a capital asset within the meaning of Section&nbsp;1221 of the Code, generally property held for investment. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder's individual circumstances nor does
it address any U.S. state, local or non-U.S. taxes, the alternative minimum tax, the Medicare tax on net investment income, the rules regarding qualified small business stock within the meaning of
Section&nbsp;1202 of the Code, or any other aspect of any U.S. federal tax other than the income tax. This discussion also does not consider any specific facts or circumstances that may apply to a
non-U.S. holder and does not address the special tax rules applicable to particular non-U.S. holders, such as:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> insurance companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> tax-exempt or governmental organizations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> financial institutions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> brokers or dealers in securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> regulated investment companies; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>179</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=182,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=390315,FOLIO='179',FILE='DISK114:[18ZFG1.18ZFG45201]DO45201A.;11',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_do45201_1_180"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> pension plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> "controlled foreign corporations," "passive foreign investment companies," and corporations that accumulate earnings to avoid U.S. federal
income tax; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> "qualified foreign pension funds," or entities wholly owned by a "qualified foreign pension fund"; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> persons deemed to sell our common stock under the constructive sale provisions of the Code; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> persons that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other integrated investment; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> certain U.S. expatriates. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>This
discussion is for general information only and is not tax advice. Accordingly, all prospective non-U.S. holders of our common stock should consult their tax advisors with respect to the U.S.
federal, state, local and non-U.S. tax consequences of the purchase, ownership and disposition of our common stock. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Distributions on our common stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Distributions, if any, on our common stock will constitute dividends for U.S. federal income tax purposes to the extent paid from our current
or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a
tax-free return of the non-U.S. holder's investment, up
to such holder's tax basis in the common stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below in "Gain on sale or other taxable disposition of our
common stock." Any such distributions will also be subject to the discussions below under the sections titled "Backup withholding and information reporting" and "Withholding and information reporting
requirements&#151;FATCA." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject
to the discussion in the following two paragraphs in this section, dividends paid to a non-U.S. holder generally will be subject to withholding of U.S. federal income tax at a 30% rate or such
lower rate as may be specified by an applicable income tax treaty between the United States and such holder's country of residence. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dividends
that are treated as effectively connected with a trade or business conducted by a non-U.S. holder within the United States and, if an applicable income tax treaty so provides, that are
attributable to a permanent establishment or a fixed base maintained by the non-U.S. holder within the United States, are generally exempt from the 30% withholding tax if the non-U.S. holder satisfies
applicable certification and disclosure requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S. federal income tax
rates applicable to United States persons (as defined in the Code). Any U.S. effectively connected income received by a non-U.S. holder that is a corporation may also, under certain circumstances, be
subject to an additional "branch profits tax" at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder's country of residence. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>A
non-U.S. holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder's country of residence generally will be required to provide a
properly executed IRS Form&nbsp;W-8BEN or W-8BEN-E (or successor form) to the applicable withholding agent and satisfy applicable certification and other requirements. Non-U.S. holders are urged to
consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A non-U.S. holder that </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>180</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=183,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=997402,FOLIO='180',FILE='DISK114:[18ZFG1.18ZFG45201]DO45201A.;11',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_do45201_1_181"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>is
eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing a U.S. tax return with the IRS. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Gain on sale or other taxable disposition of our common stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject to the discussions below under "Backup withholding and information reporting" and "Withholding and information reporting
requirements&#151;FATCA," a non-U.S. holder generally will not be subject to any U.S. federal income tax on any gain realized upon such holder's sale or other taxable disposition of shares of
our common stock unless:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the gain is effectively connected with the non-U.S. holder's conduct of a U.S. trade or business and, if an applicable income tax treaty so
provides, is attributable to a permanent establishment or a fixed-base maintained by such non-U.S. holder in the United States, in which case the non-U.S. holder generally will be taxed on a net
income basis at the graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the non-U.S. holder is a foreign corporation, the branch profits tax
described above in "Distributions on our common stock" also may apply; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the non-U.S. holder is a nonresident alien individual who is present in the United States for 183&nbsp;days or more in the taxable year of
the disposition and certain other conditions are met, in which case the non-U.S. holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty between
the United States and such holder's country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital losses of the non-U.S. holder, if any (even
though the individual is not considered a resident of the United States), provided that the non-U.S. holder has timely filed U.S. federal income tax returns with respect to such losses; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we are, or have been, at any time during the five-year period preceding such sale of other taxable disposition (or the non-U.S. holder's
holding period, if shorter) a "U.S. real property holding corporation," unless our common stock is regularly traded on an established securities market and the non-U.S. holder holds no more than 5% of
our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the 5-year period ending on the date of the disposition or the period that the non-U.S. holder
held our common stock. Generally, a corporation is a U.S. real property holding corporation only if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the
fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have
been, a U.S. real property holding corporation, or that we are likely to become one in the future. No assurance can be provided that our common stock will be regularly traded on an established
securities market for purposes of the rules described above. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Backup withholding and information reporting  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We must report annually to the IRS and to each non-U.S. holder the gross amount of the distributions on our common stock paid to such holder
and the tax withheld, if any, with respect to such distributions. Non-U.S. holders may have to comply with specific certification procedures to establish that the holder is not a United States person
(as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Dividends paid to non-U.S. holders subject to withholding of U.S.
federal income tax, as described above in "Distributions on our common stock," generally will be exempt from U.S. backup withholding. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>181</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=184,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=454779,FOLIO='181',FILE='DISK114:[18ZFG1.18ZFG45201]DO45201A.;11',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_do45201_1_182"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>Information
reporting and backup withholding will generally apply to the proceeds of a disposition of our common stock by a non-U.S. holder effected by or through the U.S. office of any broker, U.S.
or foreign, unless the holder certifies its status as a non-U.S. holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup
withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office of a broker. However, for
information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions
effected through a U.S. office of a broker. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Non-U.S.
holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them. Copies of information returns may be made available to
the tax authorities of the country in which the non-U.S. holder resides or is incorporated under the provisions of a specific treaty or agreement. Backup withholding is not an additional tax. Any
amounts withheld under the backup withholding rules from a payment to a non-U.S. holder can be refunded or credited against the non-U.S. holder's U.S. federal income tax liability, if any, provided
that an appropriate claim is filed with the IRS in a timely manner. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Withholding and information reporting requirements&#151;FATCA  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Provisions of the Code commonly referred to as the Foreign Account Tax Compliance Act, or FATCA, generally impose a U.S. federal withholding
tax at a rate of 30% on payments of dividends on our common stock paid to a foreign entity unless (i)&nbsp;if the foreign entity is a "foreign financial institution," such foreign entity undertakes
certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a "foreign financial institution," such foreign entity identifies certain of its
U.S. investors, if any, or (iii)&nbsp;the foreign entity is otherwise exempt under FATCA. Such withholding may also apply to payments of proceeds of sales or other dispositions of our common stock,
although under recently proposed regulations (the preamble to which specifies that taxpayers are permitted to rely on them pending finalization), no withholding will apply to payments of gross
proceeds. Under certain circumstances, a non-U.S. holder may be eligible for refunds or credits of this withholding
tax. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. Non-U.S. holders should consult their tax
advisors regarding the possible implications of this legislation on their investment in our common stock and the entities through which they hold our common stock, including, without limitation, the
process and deadlines for meeting the applicable requirements to prevent the imposition of the 30% withholding tax under FATCA. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>182</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=185,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=885216,FOLIO='182',FILE='DISK114:[18ZFG1.18ZFG45201]DO45201A.;11',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dq45201_1_183"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B> <A NAME="dq45201_underwriting"> </A>
<A NAME="toc_dq45201_1"> </A> </B></FONT><FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Underwriting    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are offering the shares of common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities&nbsp;LLC,
Jefferies&nbsp;LLC and Evercore Group L.L.C. are acting as joint book-running managers of the offering and as representatives of the underwriters. We have entered into an underwriting agreement with
the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public
offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus, the number of shares of common stock listed next to its name in the following table: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="58pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Name</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Number<BR>
of shares </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>J.P. Morgan Securities&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jefferies&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Evercore Group L.L.C.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Roth Capital Partners,&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
underwriters are committed to purchase all the shares of common stock offered by us if they purchase any shares. The underwriting agreement also provides that if an underwriter defaults, the
purchase commitments of non-defaulting underwriters may also be increased or the offering may be terminated. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters propose to offer the common stock directly to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers at that price less
a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. Any such dealers may resell shares to certain other brokers or dealers at a discount of up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share from the initial
public offering price. After the initial offering of the shares to the public, if all of the shares of common stock are not sold at the initial public offering price, the underwriters may change the
offering price and the other selling terms. Sales of shares made outside of the United States may be made by affiliates of the underwriters. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters have an option to buy up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock from us to
cover sales of shares by the underwriters which exceed the number of shares specified in the
table above. The underwriters have 30&nbsp;days from the date of this prospectus to exercise this option to purchase additional shares. If any shares are purchased with this option to purchase
additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will
offer the additional shares on the same terms as those on which the shares are being offered. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share of common stock. The underwriting fee is
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>183</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=186,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=383490,FOLIO='183',FILE='DISK114:[18ZFG1.18ZFG45201]DQ45201A.;12',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_dq45201_1_184"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>underwriters
assuming both no exercise and full exercise of the underwriters' option to purchase additional shares. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="101pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="101pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Without<BR>
option to purchase<BR>
additional shares<BR>
exercise</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>With full<BR>
option to purchase<BR>
additional shares<BR>
exercise </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Per Share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>We
estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal and accounting expenses, but excluding the underwriting discounts and
commissions, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have agreed to reimburse the underwriters for expenses relating to the clearance of this offering with the Financial Industry
Regulatory
Authority,&nbsp;Inc. in an amount up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>A
prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may
agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to
underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have agreed that we will not (i)&nbsp;offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or file with the Securities and Exchange Commission a registration statement under the Securities Act
relating to, any shares of our common stock or securities convertible into or exchangeable or exercisable for any shares of our common stock, or publicly disclose the intention to make any offer,
sale, pledge, disposition or filing, or (ii)&nbsp;enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of
common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise),
in each case without the prior written consent of the representatives for a period of 180&nbsp;days after the date of this prospectus, subject to certain exceptions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
directors and executive officers, and substantially all of our securityholders have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to
which each of these persons or entities, with limited exceptions, for a period of 180&nbsp;days after the date of this prospectus, may not, without the prior written consent of the representatives,
(1)&nbsp;offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant
to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock
(including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by such directors, executive officers, managers and members in accordance with the
rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant) or (2)&nbsp;enter into any swap or other agreement that transfers, in whole or in
part, any of the economic consequences of ownership of the common stock or such other securities, whether any such transaction described in clause&nbsp;(1) or (2)&nbsp;above is to be settled by
delivery of common stock or such other securities, in cash or otherwise, or (3)&nbsp;make any demand for or exercise any </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>184</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=187,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=46596,FOLIO='184',FILE='DISK114:[18ZFG1.18ZFG45201]DQ45201A.;12',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_dq45201_1_185"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>right
with respect to the registration of any shares of our common stock or any security convertible into or exercisable or exchangeable for our common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
restrictions described in the immediately preceding paragraph do not apply to, among other items: </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the
securities to be sold by the securityholder pursuant to the underwriting agreement,
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>sales
or transfers of shares of common stock acquired in open market transactions after the consummation of this offering,
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>transfers
of shares of common stock (i)&nbsp;as a bona fide gift or gifts, (ii)&nbsp;by will, other testamentary document or intestate succession to the legal
representative, heir, beneficiary or a member of the immediate family of the securityholder in a transaction not involving a disposition for value or (iii)&nbsp;by operation of law, such as pursuant
to a qualified domestic order or as required by a divorce settlement,
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>if
the securityholder is an individual, transfers of shares of common stock or any security directly or indirectly convertible into common stock in a transaction not
involving a disposition for value to any trust for the direct or indirect benefit of the securityholder or the immediate family of the securityholder, or limited partnerships the partners of which are
the securityholder and/or the immediate family members of the securityholder, in each case for estate planning purposes,
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>if
the securityholder is a trust, distributions of shares of common stock or any security directly or indirectly convertible into common stock to its beneficiaries
in a transaction not involving a disposition for value,
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>if
the securityholder is a corporation, limited liability company, partnership (whether general, limited or otherwise) or other entity, distribution of shares of
common stock or any security directly or indirectly convertible into common stock to current or former members, stockholders, limited partners, general partners, subsidiaries or affiliates of the
securityholder or to any investment fund or other entity that controls or manages the securityholder (including, for the avoidance of doubt, a fund managed by the same manager or managing member or
general partner or management company or by an entity controlling, controlled by, or under common control with such manager or managing member or general partner or management company as the
securityholder or who shares a common investment advisor with the securityholder) in a transaction not involving a disposition for value,
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>transfers
of shares of common stock to our company in connection with the exercise of options, warrants or other rights to acquire common stock or any security
convertible into or exercisable for our common stock by way of net exercise and/or to cover withholding tax obligations in connection with such exercise pursuant to an employee benefit plan, option,
warrant or other right disclosed in this prospectus, provided that any such shares issued upon exercise of such option, warrant or other right shall be subject to the restrictions set forth herein;
provided that no public report or filing required to be made under Section&nbsp;16(a) of the Exchange Act or other public filing, report or announcement shall be required or shall be voluntarily
made during the period beginning on the date hereof and continuing to and including the date that is 30&nbsp;days after the date of this prospectus, or the "30 Day Period," and after such
30th&nbsp;day, if the securityholder is required to file&nbsp;a report under Section&nbsp;16(a) of the Exchange Act during the restricted period, the securityholder shall clearly indicate in the
footnotes thereto that such transfer is pursuant to the circumstances described in this clause&nbsp;(7), and provided, further that no other public announcement shall be made voluntarily in
connection with such transfer, and </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>185</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=188,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=1013376,FOLIO='185',FILE='DISK114:[18ZFG1.18ZFG45201]DQ45201A.;12',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_dq45201_1_186"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>transfers
of shares of common stock to a bona fide third party pursuant to a merger, consolidation, tender offer or other similar transaction made to all holders of
common stock and involving a change of control of our company after this offering and approved by our board of directors, provided that in the event that such transaction is not completed, the shares
of common stock held by the securityholder shall remain subject to the restrictions contained in the lockup agreement, and provided further that in the event any shares of common stock not transferred
in the change of control shall remain subject to the restrictions contained in the lockup agreement. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>provided
that in the case of any transfer or distribution pursuant to clause&nbsp;(3), (4), (5), (6)&nbsp;or (7)&nbsp;each donee, transferee, heir, beneficiary or distributee shall execute and
deliver to the representative a lockup agreement; and provided, further, that in the case of any transfer or distribution pursuant to clause&nbsp;(2), (3), (4), (5), or (6), no filing by any party
(the securityholder, beneficiary, heir, donor, donee, transferor or transferee) under the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with
such transfer or distribution (other than a filing on a Form&nbsp;5 and any required Schedule&nbsp;13F, 13G or 13G/A, in each case made after the expiration of the restricted period referred to
above). If the securityholder is an officer or director of our company, the securityholder further agrees that the foregoing provisions shall be equally applicable to any issuer-directed securities
the securityholder may purchase in this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, notwithstanding anything to the contrary contained in the lockup agreement, the securityholder may (i)&nbsp;exercise options or warrants to purchase common stock (provided that any
common stock received upon such exercise or exchange will be subject to the restrictions provided for in the lockup agreement) and (ii)&nbsp;enter into any plan designed to satisfy the requirements
of Rule&nbsp;10b5-1, or a "10b5-1 Plan," under the Exchange Act (other than the entry into such a plan in such a manner as to allow the sale of common stock within the restricted period); provided,
however, that no sale of common stock may be made under such 10b5-1 Plan during the restricted period, and provided further that no filing by any party under the Exchange Act or other public
announcement shall be required or shall be made voluntarily in connection with the establishment of such plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
intend to apply for listing of our common stock on The Nasdaq Global Market under the symbol "AKRO." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of common stock in the open market for the
purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of the common
stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open
market to cover positions created by short sales. Short sales may be "covered" shorts, which are short positions in an amount not greater than the underwriters' option to purchase additional shares
referred to above, or may be "naked" shorts, which are short positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase
additional shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares available for
purchase in the open market compared to the price
at which the underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned that there may be
downward </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>186</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=189,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=864968,FOLIO='186',FILE='DISK114:[18ZFG1.18ZFG45201]DQ45201A.;12',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_dq45201_1_187"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>pressure
on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position,
they will purchase shares in the open market to cover the position. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters have advised us that, pursuant to Regulation&nbsp;M of the Securities Act of 1933, they may also engage in other activities that stabilize, maintain or otherwise affect the price of
the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in stabilizing transactions or to cover
short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These
activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market price of the common stock, and, as a result, the
price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The
underwriters may carry out these transactions on The Nasdaq Global Market, in the over-the-counter market or otherwise. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior
to this offering, there has been no public market for our common stock. The initial public offering price will be determined by negotiations between us and the representatives of the
underwriters. In determining the initial public offering price, we and the representatives of the underwriters expect to consider a number of factors including: </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>the
information set forth in this prospectus and otherwise available to the representatives; </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>our
prospects and the history and prospects for the industry in which we compete; </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>an
assessment of our management; </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>our
prospects for future earnings; </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
general condition of the securities markets at the time of this offering; </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>other
factors deemed relevant by the underwriters and us. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Neither
we nor the underwriters can assure investors that an active trading market will develop for our common shares, or that the shares will trade in the public market at or above the initial public
offering price. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Other relationships  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the
future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may
continue to receive customary fees and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of
customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>187</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=190,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=1027339,FOLIO='187',FILE='DISK114:[18ZFG1.18ZFG45201]DQ45201A.;12',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_dq45201_1_188"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Selling restrictions  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities
offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this
prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances
that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe
any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by
this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in the European Economic Area  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a "Relevant Member
State"), with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State, no offer of shares may be made to the public in that Relevant Member
State other than: </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the underwriters; or </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
any other circumstances falling within Article&nbsp;3(2) of the Prospectus Directive, </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>provided
that no such offer of shares shall require the Company or any underwriter to publish a prospectus pursuant to Article&nbsp;3 of the Prospectus Directive or supplement a prospectus pursuant
to Article&nbsp;16 of the Prospectus Directive and each person who initially acquires any shares or to whom any
offer is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters and the Company that it is a "qualified investor" within the meaning of the law in that
Relevant Member State implementing Article&nbsp;2(1)(e) of the Prospectus Directive. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the case of any shares being offered to a financial intermediary as that term is used in Article&nbsp;3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have
represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their
offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant Member State to qualified investors as so
defined or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>For
the purposes of this provision, the expression an "offer of shares to the public" in relation to any shares in any Relevant Member State means the communication in any form and by means of
sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase shares, as the same may be varied in that Member State by any measure
implementing the Prospectus Directive in that Member State, the expression "Prospectus Directive" means Directive&nbsp;2003/71/EC (as amended, including by Directive&nbsp;2010/73/EU), and includes
any relevant implementing measure in the Relevant Member State. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>188</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=191,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=845472,FOLIO='188',FILE='DISK114:[18ZFG1.18ZFG45201]DQ45201A.;12',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_dq45201_1_189"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in the United Kingdom  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are "qualified investors" (as defined in the Prospectus Directive) (i)&nbsp;who have professional experience in matters relating to investments falling within
Article&nbsp;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") and/or (ii)&nbsp;who are high net worth companies (or persons to whom
it may otherwise be lawfully communicated) falling within Article&nbsp;49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as "relevant persons") or otherwise in
circumstances which have not resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the Financial Services and Markets Act 2000. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any
investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in Canada  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument&nbsp;45-106 Prospectus Exemptions or subsection&nbsp;73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument&nbsp;31-103
Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus
requirements of applicable securities laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a
misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province or
territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a legal
advisor. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to section&nbsp;3A.3 of National Instrument&nbsp;33-105 Underwriting Conflicts (NI&nbsp;33-105), the underwriters are not required to comply with the disclosure requirements of
NI&nbsp;33-105 regarding underwriter conflicts of interest in connection with this offering. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in Switzerland  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange
or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance
prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any
other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed
or otherwise made publicly available in Switzerland. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Neither
this document nor any other offering or marketing material relating to the offering, the Company or the shares has been or will be filed with or approved by any Swiss regulatory authority. In
particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>189</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=192,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=852926,FOLIO='189',FILE='DISK114:[18ZFG1.18ZFG45201]DQ45201A.;12',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_dq45201_1_190"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>Market
Supervisory Authority FINMA (FINMA), and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor
protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in the Dubai International Financial Centre  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This document relates to an Exempt Offer in accordance with the Markets Rules&nbsp;2012 of the Dubai Financial Services Authority, or DFSA.
This document is intended for distribution only to persons of a type specified in the Markets Rules&nbsp;2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA
has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set
forth herein and has no responsibility for this document. The securities to which this document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the
securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this document you should consult an authorized financial advisor. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
relation to its use in the Dubai International Finance Centre, or DIFC, this document is strictly private and confidential and is being distributed to a limited number of investors and must not be
provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to
the public in the DIFC. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in the United Arab Emirates  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The shares have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai
International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities.
Further, this prospectus does not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and is
not intended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or the Dubai Financial
Services Authority. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in Australia  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> does not constitute a product disclosure document or a prospectus under Chapter&nbsp;6D.2 of the Corporations Act 2001 (Cth), or the
Corporations Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> has not been, and will not be, lodged with the Australian Securities and Investments Commission, or ASIC, as a disclosure document for the
purposes of the Corporations Act and does not purport to include the information required of a disclosure document under Chapter&nbsp;6D.2 of the Corporations Act; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> does not constitute or involve a recommendation to acquire, an offer or invitation for issue or sale, an offer or invitation to arrange the
issue or sale, or an issue or sale, of interests to a "retail client" (as defined in section&nbsp;761G of the Corporations Act and applicable regulations) in Australia; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of
investors, or Exempt Investors, available under section&nbsp;708 of the Corporations Act. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>190</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=193,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=323473,FOLIO='190',FILE='DISK114:[18ZFG1.18ZFG45201]DQ45201A.;12',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_dq45201_1_191"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>The
shares may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the shares may be issued, and no draft or definitive offering
memorandum, advertisement or other offering material relating to any shares may be distributed in Australia, except where disclosure to investors is not required under Chapter&nbsp;6D of the
Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares, you represent and warrant to us that you are an Exempt
Investor. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
any offer of shares under this document will be made without disclosure in Australia under Chapter&nbsp;6D.2 of the Corporations Act, the offer of those securities for resale in Australia within
12&nbsp;months may, under section&nbsp;707 of the Corporations Act, require disclosure to investors under Chapter&nbsp;6D.2 if none of the exemptions in section&nbsp;708 applies to that
resale. By applying for the shares you undertake to us that you will not, for a period of 12&nbsp;months from the date of issue of the shares, offer, transfer, assign or otherwise alienate those
securities to investors in Australia except in circumstances where disclosure to investors is not required under Chapter&nbsp;6D.2 of the Corporations Act or where a compliant disclosure document is
prepared and lodged with ASIC. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in Japan  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The shares have not been and will not be registered pursuant to Article&nbsp;4, Paragraph&nbsp;1 of the Financial Instruments and Exchange
Act. Accordingly, none of the shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any "resident" of Japan (which term as used herein
means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to or for
the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other
applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in Hong Kong  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
"professional investors" as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in
the document being a "prospectus" as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32)&nbsp;of Hong Kong or which do not constitute an offer to the public within
the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of
issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the
securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" as defined in the
Securities and Futures Ordinance and any rules made under that Ordinance. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in Singapore  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares may not be circulated or distributed, nor may the
shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional
investor under Section&nbsp;274 of the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>191</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=194,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=842366,FOLIO='191',FILE='DISK114:[18ZFG1.18ZFG45201]DQ45201A.;12',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_dq45201_1_192"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>Securities
and Futures Act, Chapter&nbsp;289 of Singapore (the "SFA"), (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in
accordance with the conditions specified in Section&nbsp;275 of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Where
the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which
is owned by one or more individuals, each of whom is an accredited investor; or </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>securities
(as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months
after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or
Section&nbsp;276(4)(i)(B) of the SFA; </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;where
no consideration is or will be given for the transfer; </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;where
the transfer is by operation of law; </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as
specified in Section&nbsp;276(7) of the SFA; or </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as
specified in Regulation&nbsp;32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations&nbsp;2005 of Singapore. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Solely
for the purposes of its obligations pursuant to Section&nbsp;309B of the SFA, we have determined, and hereby notify all relevant persons (as defined in the CMP Regulations&nbsp;2018), that
the shares are "prescribed capital markets products" (as defined in the CMP Regulations&nbsp;2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of
Investment Products and MAS Notice&nbsp;FAA-N16: Notice on Recommendations on Investment Products). </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in Bermuda  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Shares may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which
regulates the sale of securities in Bermuda. Additionally, non-Bermudian persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted
to do so under applicable Bermuda legislation. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in Saudi Arabia  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities
Regulations as issued by the board of the Saudi Arabian Capital Market Authority, or CMA, pursuant to resolution number&nbsp;2-11-2004 dated 4&nbsp;October 2004 as amended by resolution
number&nbsp;1-28-2008, as amended (the "CMA Regulations"). The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability
whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>192</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=195,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=752418,FOLIO='192',FILE='DISK114:[18ZFG1.18ZFG45201]DQ45201A.;12',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_dq45201_1_193"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>purchasers
of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this
document, you should consult an authorised financial adviser. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in the British Virgin Islands  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The shares are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by
or on behalf of the Company. The Company may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands), or BVI Companies, but only where the offer will
be made to, and received by, the relevant BVI Company entirely outside of the British Virgin Islands. This prospectus has not been, and will not be, registered with the Financial Services Commission
of the British Virgin Islands. No registered prospectus has been or will be prepared in respect of the shares for the purposes of the Securities and Investment Business Act, 2010, or SIBA, or the
Public Issuers Code of the British Virgin Islands. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in China  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus does not constitute a public offer of shares, whether by sale or subscription, in the People's Republic of China, the PRC. The
shares are not being offered or sold directly or indirectly in the PRC to or for the benefit of, legal or natural persons of the PRC. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Further,
no legal or natural persons of the PRC may directly or indirectly purchase any of the shares or any beneficial interest therein without obtaining all prior PRC's governmental approvals that
are required, whether statutorily or otherwise. Persons who come into possession of this document are required by the issuer and its representatives to observe these restrictions. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in Korea  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The shares have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees
and regulations thereunder (the "FSCMA"), and the shares have been and will be offered in Korea as a private placement under the FSCMA. None of the shares may be offered, sold or delivered directly or
indirectly, or offered or sold to any person for re-offering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the
applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of Korea and the decrees and regulations thereunder (the "FETL"). Furthermore, the
purchaser of the shares shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase of the shares. By the
purchase of the shares, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased the shares pursuant to the applicable laws
and regulations of Korea. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in Malaysia  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No prospectus or other offering material or document in connection with the offer and sale of the shares has been or will be registered with
the Securities Commission of Malaysia, or the Commission, for the Commission's approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or
material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the
subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder
of a Capital Markets </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>193</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=196,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=209087,FOLIO='193',FILE='DISK114:[18ZFG1.18ZFG45201]DQ45201A.;12',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_dq45201_1_194"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>Services
Licence; (iii)&nbsp;a person who acquires the shares, as principal, if the offer is on terms that the shares may only be acquired at a consideration of not less than RM250,000 (or its
equivalent in foreign currencies) for each transaction; (iv)&nbsp;an individual whose total net personal assets or total net joint assets with his or her spouse exceeds RM3&nbsp;million (or its
equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in
foreign currencies) per annum in the preceding twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign
currencies), per annum in the preceding twelve months; (vii)&nbsp;a corporation with total net assets exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last
audited accounts; (viii)&nbsp;a partnership with total net assets exceeding RM10&nbsp;million (or its equivalent in foreign currencies); (ix)&nbsp;a bank licensee or insurance licensee as
defined in the Labuan Financial Services and Securities Act 2010; (x)&nbsp;an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and
(xi)&nbsp;any other person as may be specified by the Commission; provided that, in the each of the preceding categories&nbsp;(i) to (xi), the distribution of the shares is made by a holder of a
Capital Markets Services Licence who carries on the business of dealing in securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute
and may not be used for the purpose of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of a
prospectus with the Commission under the Capital Markets and Services Act 2007. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in Taiwan  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The shares have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws
and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of
Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorised to offer, sell, give advice regarding or otherwise
intermediate the offering and sale of the shares in Taiwan. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Notice to prospective investors in South Africa  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Due to restrictions under the securities laws of South Africa, the shares are not offered, and the offer shall not be transferred, sold,
renounced or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions applies: </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
offer, transfer, sale, renunciation or delivery is to: </FONT></P>

<UL>

<P style="font-family:arial;"><FONT SIZE=2>i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;persons
whose ordinary business is to deal in securities, as principal or agent; </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
South African Public Investment Corporation; </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>iii)&nbsp;&nbsp;&nbsp;&nbsp;persons
or entities regulated by the Reserve Bank of South Africa; </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>iv)&nbsp;&nbsp;&nbsp;&nbsp;authorised
financial service providers under South African law; </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;financial
institutions recognised as such under South African law; </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>vi)&nbsp;&nbsp;&nbsp;&nbsp;a
wholly-owned subsidiary of any person or entity contemplated in (c), (d)&nbsp;or (e), acting as agent in the capacity of an authorised portfolio manager for a pension fund or
collective investment scheme (in each case duly registered as such under South African law); or </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>194</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=197,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=541614,FOLIO='194',FILE='DISK114:[18ZFG1.18ZFG45201]DQ45201A.;12',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_dq45201_1_195"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <UL>

<P style="font-family:arial;"><FONT SIZE=2>vii)&nbsp;&nbsp;&nbsp;any
combination of the person in (a)&nbsp;to (f); or </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>No
"offer to the public" (as such term is defined in the South African Companies Act, No.&nbsp;71 of 2008 (as amended or re-enacted) (the "South African Companies Act")) in South Africa is being
made in connection with the issue of the shares. Accordingly, this document does not, nor is it intended to, constitute a "registered prospectus" (as that term is defined in the South African
Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and/or filed with, the South African Companies and Intellectual Property Commission or any
other regulatory authority in South Africa. Any issue or offering of the shares in South Africa constitutes an offer of the shares in South Africa for subscription or sale in South Africa only to
persons who fall within the exemption from "offers to the public" set out in section&nbsp;96(1)(a) of the South African Companies Act. Accordingly, this document must not be acted on or relied on by
persons in South Africa who do not fall within section&nbsp;96(1)(a) of the South African Companies Act (such persons being referred to as "SA Relevant Persons"). Any investment or investment
activity to which this document relates is available in South Africa only to&nbsp;SA Relevant Persons and will be engaged in South Africa only with&nbsp;SA relevant persons. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>195</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=198,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=673333,FOLIO='195',FILE='DISK114:[18ZFG1.18ZFG45201]DQ45201A.;12',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<A NAME="page_dq45201_1_196"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="dq45201_legal_matters"> </A>
<A NAME="toc_dq45201_2"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Legal matters    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The validity of the shares of common stock offered by this prospectus will be passed upon for us by Goodwin Procter&nbsp;LLP, Boston,
Massachusetts. Certain legal matters related to this offering will be passed upon for the underwriters by Cooley&nbsp;LLP, New York, New York. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="dq45201_experts"> </A>
<A NAME="toc_dq45201_3"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Experts    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The financial statements as of December&nbsp;31, 2017, and for the period January&nbsp;24, 2017 (inception) through December&nbsp;31,
2017, included in this Prospectus, have been audited by Deloitte&nbsp;&amp; Touche&nbsp;LLP, an independent registered public accounting firm, as stated in their report appearing herein. Such
financial statements have been so included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="dq45201_where_you_can_find_more_information"> </A>
<A NAME="toc_dq45201_4"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Where you can find more information    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have filed with the SEC a registration statement on Form&nbsp;S-1 under the Securities Act with respect to the common stock we are
offering by this prospectus. This prospectus does not contain
all of the information included in the registration statement. For further information pertaining to us and our common stock, you should refer to the registration statement and to its exhibits.
Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references are not necessarily complete, and you should refer to the exhibits attached to the
registration statement for copies of the actual contract, agreement or other document. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
the completion of the offering, we will be subject to the informational requirements of the Exchange Act and will file annual, quarterly and current reports, proxy statements and other
information with the SEC. You can read our SEC filings, including the registration statement, at the SEC's website at www.sec.gov. You may also read and copy any document we file with the SEC at its
public reference facility at 100&nbsp;F Street, N.E., Room&nbsp;1580, Washington, D.C. 20549. We also maintain a website at www.akerotx.com. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You
may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100&nbsp;F Street, N.E., Washington, D.C. 20549. Please call the SEC at
1-800-SEC-0330 for further information on the operation of the public reference facilities. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>196</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=199,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=749289,FOLIO='196',FILE='DISK114:[18ZFG1.18ZFG45201]DQ45201A.;12',USER='MTITUSS',CD='17-JAN-2019;11:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fa45201_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fa45201_akero_therapeutics,_in__fa402109"> </A></FONT> <FONT SIZE=3><B><BR>  Akero Therapeutics,&nbsp;Inc.<BR>  Index to financial statements    <BR>  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><A
NAME="FA45201_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="30pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Page</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#report"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Report of Independent Registered Public Accounting Firm</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#report"><FONT SIZE=2>F-2</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#balance"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance Sheets</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#balance"><FONT SIZE=2>F-3</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#comprehensive"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Operations and Comprehensive Loss</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#comprehensive"><FONT SIZE=2>F-4</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#Deficit"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#Deficit"><FONT SIZE=2>F-5</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#cashflow"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Cash Flows</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#cashflow"><FONT SIZE=2>F-6</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#notes"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes to Financial Statements</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#notes"><FONT SIZE=2>F-7</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=200,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=887382,FOLIO='F-1',FILE='DISK114:[18ZFG1.18ZFG45201]FA45201A.;9',USER='SCAVALI',CD='17-JAN-2019;12:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fc45201_1_2"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="report"></A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A
NAME="fc45201_report_of_independent___fc402276"> </A>
<A NAME="toc_fc45201_1"> </A></FONT> <FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Report of independent registered public accounting firm    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
the stockholders and the Board of Directors of Akero Therapeutics,&nbsp;Inc. </FONT></P>


<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Opinion on the financial statements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have audited the accompanying balance sheet of Akero Therapeutics,&nbsp;Inc. (the "Company") as of December&nbsp;31, 2017, the related
statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders' deficit, and cash flows, for the period January&nbsp;24, 2017 (inception) through
December&nbsp;31, 2017, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the
financial position of the Company as of December&nbsp;31, 2017, and the results of its operations and its cash flows for the period January&nbsp;24, 2017 (inception) through December&nbsp;31,
2017, in conformity with accounting principles generally accepted in the United States of America. </FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Basis for opinion  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with
respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
conducted our audit in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor
were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but
not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.
Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>/s/
Deloitte&nbsp;&amp; Touche&nbsp;LLP<BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Parsippany,
NJ<BR>
January&nbsp;17, 2019 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have served as the Company's auditor since 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=201,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=911092,FOLIO='F-2',FILE='DISK114:[18ZFG1.18ZFG45201]FC45201A.;9',USER='MTITUSS',CD='17-JAN-2019;09:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fe45201_1_3"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="balance"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fe45201_akero_therapeutics,_inc._balan__ake03328"> </A>
<A NAME="toc_fe45201_1"> </A></FONT> <FONT SIZE=3><B><BR>  Akero Therapeutics,&nbsp;Inc.<BR>  Balance sheets<BR>  (In thousands, except share and per share amounts)  <BR>        <BR>  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>September&nbsp;30,<BR>
2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pro forma<BR>
September&nbsp;30,<BR>
2018 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Assets</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current assets:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>598</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,832</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,832</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>40</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>603</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>603 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>638</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,435</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,435</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Restricted cash</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>658</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,455</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,455 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current liabilities:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>60</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>519</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>519</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>162</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>500</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>500 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>222</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preferred stock tranche obligation</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>15,750</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anti-dilution right liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,671</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,671 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>222</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>19,440</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,690 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commitments and contingencies (Note&nbsp;11)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:9pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A redeemable convertible preferred stock, $0.0001 par value; 5,000,000 shares and 70,858,462 shares authorized as of
December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited), respectively; 5,000,000 shares and 22,653,333 shares issued and outstanding as of December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited), respectively; aggregate liquidation
preference of $5,213 and $22,653 as of December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited), respectively; no shares issued or outstanding, pro forma as of September&nbsp;30, 2018 (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
5,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
14,108</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' equity (deficit):</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, $0.0001 par value, 7,000,000 shares and 80,000,000 shares authorized as of December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited),
respectively; 696,000 shares issued and outstanding as of December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited); 23,349,333 shares issued and outstanding, pro forma as of September&nbsp;30, 2018 (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>29,854</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,564</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(25,093</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(25,093</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity (deficit)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,564</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(25,093</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,765 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>658</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,455</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,455 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"> <FONT  style="font-size:8pt;line-height:9pt;"><I>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</i></font></p><p align=left style="font-family:arial;"><font></FONT><FONT  style="font-size:8pt;line-height:9pt;"><I>The accompanying notes are an integral part of these financial statements.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=202,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=661708,FOLIO='F-3',FILE='DISK114:[18ZFG1.18ZFG45201]FE45201A.;11',USER='SMENEZE',CD='16-JAN-2019;21:30' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fg45201_1_4"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="comprehensive"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fg45201_akero_therapeutics,_inc._state__ake04758"> </A>
<A NAME="toc_fg45201_1"> </A></FONT> <FONT SIZE=3><B><BR>  Akero Therapeutics,&nbsp;Inc.<BR>  Statements of operations and comprehensive loss<BR>  (In thousands, except share and per share amounts)  <BR>        <BR>  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="107pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="111pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception)<BR>
through<BR>
December&nbsp;31, 2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception)<BR>
through<BR>
September&nbsp;30, 2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Nine months<BR>
ended<BR>
September&nbsp;30,<BR>
2018 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,486</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,123</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9,898</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,078</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>896</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>912 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,564</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10,810 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,564</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(10,810</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other expense:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of preferred stock tranche obligation</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(8,400</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of anti-dilution right liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1,032</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(9,432</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss and comprehensive loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,564</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(20,242</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accruing dividends on redeemable convertible preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(213</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(166</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of redeemable convertible preferred stock to redemption value</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(321</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,777</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,185</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(20,563</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share attributable to common stockholders&#151;basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(76.98</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding&#151;basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>267,108 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share attributable to common stockholders&#151;basic and diluted (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1.71</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.93</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma weighted average common shares outstanding&#151;basic and diluted (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,661,730</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12,703,494 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"> <FONT  style="font-size:8pt;line-height:9pt;"><I>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</i></font></p><p align=left style="font-family:arial;"><font></FONT><FONT  style="font-size:8pt;line-height:9pt;"><I>The accompanying notes are an integral part of these financial statements.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=203,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=453686,FOLIO='F-4',FILE='DISK114:[18ZFG1.18ZFG45201]FG45201A.;14',USER='SMENEZE',CD='16-JAN-2019;21:30' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fi45201_1_5"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<!-- COMMAND=ROTATED_TABLE WIDTH="150%" -->

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><A NAME="Deficit"></A>Akero Therapeutics,&nbsp;Inc.<BR>
Statements of redeemable convertible preferred stock and stockholders' deficit<BR>
(In thousands, except share amounts)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="72pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
</TR>

<TR style="font-size:1.5pt;" VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH ALIGN="CENTER" style="font-family:arial;border-right:solid #000000 1.0pt;"><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B><BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH ALIGN="CENTER" style="font-family:arial;border-right:solid #000000 1.0pt;"><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B><BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
<TH style="font-family:arial;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:arial;">&nbsp;<BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=3 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Series&nbsp;A redeemable<BR>
convertible preferred stock </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=4 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Common stock </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=4 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Treasury stock </B></FONT></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ROWSPAN=3 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Additional<BR>
paid-in<BR>
capital</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ROWSPAN=3 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Total<BR>
stockholders'<BR>
deficit</B></FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ROWSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Accumulated<BR>
deficit</B></FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Shares</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Amount</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Shares</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Amount</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Shares</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Amount</B></FONT><BR></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balances at January&nbsp;24, 2017 (inception)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issuance of founders' common stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>696,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issuance of Series&nbsp;A redeemable convertible preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,564)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,564) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balances at December&nbsp;31, 2017</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>696,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,564)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,564) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balances at January&nbsp;24, 2017 (inception)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issuance of founders' common stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>696,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issuance of Series&nbsp;A redeemable convertible preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,019)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,019) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balances at September&nbsp;30, 2017 (unaudited)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>696,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;(4,019)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;(4,019) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balances at January&nbsp;1, 2018</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>696,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;(4,564)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;(4,564)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issuance of Series&nbsp;A redeemable convertible preferred stock, net of issuance costs of $216</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>17,653,333</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,787</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Repurchase of founders' common stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(232,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>232,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issuance of treasury stock as founders' common stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>232,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(232,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock-based compensation expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>34&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>34&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of redeemable convertible preferred stock to redemption value</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>321</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(34)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(287)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(321)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(20,242)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(20,242) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balances at September&nbsp;30, 2018 (unaudited)</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>22,653,333</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,108</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>696,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;&#151;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$(25,093)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>$(25,093) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>The accompanying notes are an integral part of these financial statements.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=204,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=443069,FOLIO='F-5',FILE='DISK114:[18ZFG1.18ZFG45201]FI45201A.;43',USER='SMENEZE',CD='16-JAN-2019;21:30' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fk45201_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><A
NAME="cashflow"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fk45201_akero_therapeutics,_inc._state__ake02391"> </A>
<A NAME="toc_fk45201_1"> </A></FONT> <FONT SIZE=3><B><BR>  Akero Therapeutics,&nbsp;Inc.<BR>  Statements of cash flows<BR>  (In thousands)  <BR>        <BR>  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="96pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="100pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception)<BR>
through<BR>
December&nbsp;31, 2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception)<BR>
through<BR>
September&nbsp;30, 2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Nine months<BR>
ended<BR>
September&nbsp;30,<BR>
2018 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(unaudited) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from operating activities:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,564</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(20,242</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustments to reconcile net loss to net cash used in operating activities:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock-based compensation expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>34</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares issued in connection with Amgen Agreement</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,353</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Acquisition of technology in connection with Amgen Agreement</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issuance date fair value of anti-dilution right liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,639</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of preferred stock tranche obligation</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,400</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of anti-dilution right liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,032</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in operating assets and liabilities:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(40</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(55</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(563</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>60</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>243</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>459</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>162</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>105</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>338 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,382</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3,726</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,550</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from investing activities:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Acquisition of technology in connection with Amgen Agreement</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(5,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in investing activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(5,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from financing activities:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of redeemable convertible preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>15,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payment of preferred stock issuance costs</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(216</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by financing activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,784 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Net increase in cash and restricted cash</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>618</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>274</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,234</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and restricted cash at beginning of period</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>618 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and restricted cash at end of period</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>618</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>274</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,852 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Supplemental disclosure of non-cash investing and financing activities:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of redeemable convertible preferred stock to redemption value</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>321</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issuance date fair value of preferred stock tranche obligation</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,350</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred offering costs included in accounts payable and accrued expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>60</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares issued in connection with Amgen Agreement</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,353 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"> <FONT  style="font-size:8pt;line-height:9pt;"><I>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</i></font></p><p align=left style="font-family:arial;"><font></FONT><FONT  style="font-size:8pt;line-height:9pt;"><I>The accompanying notes are an integral part of these financial statements.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=205,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=476223,FOLIO='F-6',FILE='DISK114:[18ZFG1.18ZFG45201]FK45201A.;14',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fm45201_1_7"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fm45201_akero_therapeutics,_inc._notes__ake04170"> </A>
<A NAME="toc_fm45201_1"> </A></FONT> <FONT SIZE=3><B><BR>  Akero Therapeutics, Inc.<BR>  Notes to Financial Statements<BR>  (Amounts in thousands, except share and per share data)  <BR>        <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
<A NAME="notes"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nature of the business and basis of presentation  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Akero Therapeutics,&nbsp;Inc. ("Akero" or the "Company") is a clinical-stage biotechnology company focused on developing and commercializing transformative
treatments for patients with serious metabolic diseases. Akero's initial focus is on nonalcoholic steatohepatitis ("NASH"), a disease without any approved therapies. NASH is a severe form of
nonalcoholic fatty liver disease ("NAFLD"), characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, failure, cancer of the liver, and death. We are developing AKR-001,
an analog of fibroblast growth factor 21 ("FGF21"), for NASH and plan to initiate a Phase&nbsp;2a clinical trial for AKR-001 in NASH patients with fibrosis in the middle of 2019. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, ability to secure additional capital to fund operations,
completion and success of clinical testing, compliance with governmental regulations, development by competitors of new technological innovations, dependence on key personnel and protection of
proprietary technology. Drug candidates currently under development will require extensive clinical testing prior to regulatory
approval and commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the
Company's drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include all adjustments necessary for
the fair presentation of the Company's financial statements for the periods presented. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Going concern  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In accordance with Accounting Standards Update ("ASU") No.&nbsp;2014-15, </FONT><FONT SIZE=2><I>Disclosure of Uncertainties about an Entity's Ability to
Continue as a Going Concern (Subtopic 205-40)</I></FONT><FONT SIZE=2>, the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial
doubt and the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since
its inception, the Company has funded its operations primarily with proceeds from sales of redeemable convertible preferred stock. The Company has incurred recurring losses since its inception,
including net losses of $4,564 for the period from January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017 and $20,242 for the nine months ended September&nbsp;30, 2018 (unaudited). In
addition, as of December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited), the Company had an accumulated deficit of $4,564 and $25,093, respectively. The Company expects to continue to
generate operating losses for the foreseeable future. As of January&nbsp;17, 2019, the issuance date of these financial statements, the Company expects that its existing cash of $7,832 as of
September&nbsp;30, 2018 (unaudited), together with $70,500 of gross cash proceeds received from the Company's sale of Series&nbsp;A redeemable convertible preferred stock (the "Series&nbsp;A
Preferred Stock") and Series&nbsp;B redeemable convertible preferred stock (the "Series&nbsp;B Preferred Stock") in November 2018 and December 2018, respectively (see Note&nbsp;14), will be
sufficient to fund its operating expenses and capital expenditure requirements for at least 12&nbsp;months from the issuance date of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=206,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=732818,FOLIO='F-7',FILE='DISK114:[18ZFG1.18ZFG45201]FM45201A.;30',USER='MTITUSS',CD='17-JAN-2019;09:25' -->
<A NAME="page_fm45201_1_8"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>these
financial statements. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company is seeking to complete an initial public offering ("IPO") of its common stock. In the event the Company does not complete an IPO, the Company expects to seek additional funding through
private equity financings, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain financing on
acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
the Company is unable to obtain funding, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or
commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no
assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Summary of significant accounting policies  </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Use of estimates  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The preparation of the Company's financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period.
Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual of research and development expenses and the valuations of common stock,
preferred stock tranche obligation, anti-dilution right liability and the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience, known trends and other
market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances,
facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Unaudited interim financial information  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The accompanying balance sheet as of September&nbsp;30, 2018, the statements of operations and comprehensive loss and of cash flows for the period
January&nbsp;24, 2017 (inception) through September&nbsp;30, 2017 and the nine months ended September&nbsp;30, 2018 and the statement of redeemable convertible preferred stock and stockholders'
deficit for the period January&nbsp;24, 2017 (inception) through September&nbsp;30, 2017 and the nine months ended September&nbsp;30, 2018 are unaudited. The unaudited interim financial
statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments,
necessary for the fair statement of the Company's financial position as of September&nbsp;30, 2018 and the results of its operations and its cash flows for the period January&nbsp;24, 2017
(inception) through September&nbsp;30, 2017 and the nine months ended September&nbsp;30, 2018. The financial data and other information disclosed in these notes related to the period
January&nbsp;24, 2017 (inception) through September&nbsp;30, 2017 and the nine months ended September&nbsp;30, 2018 is also unaudited. The results for the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=207,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=930547,FOLIO='F-8',FILE='DISK114:[18ZFG1.18ZFG45201]FM45201A.;30',USER='MTITUSS',CD='17-JAN-2019;09:25' -->
<A NAME="page_fm45201_1_9"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>nine
months ended September&nbsp;30, 2018 are not necessarily indicative of results to be expected for the year ended December&nbsp;31, 2018, any other interim periods, or any future year or
period. </FONT></P>

<UL>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Unaudited pro forma information  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The accompanying unaudited pro forma balance sheet as of September&nbsp;30, 2018 has been prepared assuming the automatic conversion of all outstanding
shares of redeemable convertible preferred stock into 22,653,333 shares of common stock and the extinguishment of the preferred stock tranche obligation liability upon an IPO, as if the proposed IPO
had occurred on September&nbsp;30, 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the accompanying statements of operations, the unaudited pro forma basic and diluted net loss per share attributable to common stockholders for the period January&nbsp;24, 2017 (inception)
through December&nbsp;31, 2017 and the nine months ended September&nbsp;30, 2018 have been prepared assuming the automatic conversion of all outstanding shares of redeemable convertible preferred
stock into shares of common stock upon an IPO, as if the proposed IPO had occurred on the later of January&nbsp;24, 2017 (inception) or the issuance date of the redeemable convertible preferred
stock. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restricted cash  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>As of December&nbsp;31, 2017, and September&nbsp;30, 2018 (unaudited), the Company was required to maintain a separate cash balance of $20 to
collateralize corporate credit cards with a bank, which was classified as restricted cash (non-current) on its balance sheets. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Concentrations of credit risk  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. Periodically, the Company maintains
deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not
experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. At
December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited), all of the Company's cash was held at one accredited financial institution. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Deferred offering costs  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process preferred stock or
common equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of
redeemable convertible preferred stock or in stockholders' equity (deficit) as a reduction of additional paid-in capital generated as a result of such offering. Should an in-process equity financing
be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. As of December&nbsp;31, 2017, the
Company did not have any deferred offering costs. As of September&nbsp;30, 2018 (unaudited), the Company recorded deferred offering costs of $60 in the accompanying balance sheets. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-9</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=208,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=140175,FOLIO='F-9',FILE='DISK114:[18ZFG1.18ZFG45201]FM45201A.;30',USER='MTITUSS',CD='17-JAN-2019;09:25' -->
<A NAME="page_fm45201_1_10"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fair value measurements  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an
asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered
unobservable:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Level&nbsp;1&#151;Quoted prices in active markets for identical assets or liabilities. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Level&nbsp;2&#151;Observable inputs (other than Level&nbsp;1 quoted prices), such as quoted prices in active markets for similar
assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market
data. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Level&nbsp;3&#151;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair
value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </FONT></DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>The
Company's preferred stock tranche obligation and anti-dilution right liability are carried at fair value, determined according to Level&nbsp;3 inputs in the fair value hierarchy described above
(See Note&nbsp;3). In November 2018, in connection with the Company's issuance and sale of Series&nbsp;A Preferred Stock at the Second Tranche Closing (as defined below), the Company satisfied its
obligation to issue additional shares under the Second Tranche Closing (See Note&nbsp;5) and accordingly reclassified the carrying value of the preferred stock tranche obligation associated with the
future purchase obligation, equal to the then current fair value, to the carrying value of the Series&nbsp;A Preferred Stock (see Note&nbsp;14). Also, in November 2018, in connection with the
Company's issuance and sale of Series&nbsp;A Preferred Stock, the Company satisfied its anti-dilution obligation under the Amgen Agreement (as defined below) (see Note&nbsp;14). In December 2018,
in connection with the Company's issuance and sale of Series&nbsp;B Preferred Stock, the Company terminated the option to purchase Series&nbsp;A Preferred Stock provided under the 2018
Series&nbsp;A Agreement (as defined below) (see Note&nbsp;14). The carrying values of the Company's prepaid expenses and other current assets, accounts payable and accrued expenses approximate
their fair values due to the short-term nature of these assets and liabilities. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Segment information  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company's
singular focus is developing and commercializing transformative treatments for serious metabolic diseases, with an initial focus on NASH. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and development costs  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred to discover, research and develop drug
candidates, including personnel expenses, stock-based compensation expense, allocated facility-related and depreciation expenses, third-party license fees and external costs including fees paid to
consultants and clinical research organizations ("CROs"), in </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-10</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=209,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=314599,FOLIO='F-10',FILE='DISK114:[18ZFG1.18ZFG45201]FM45201A.;30',USER='MTITUSS',CD='17-JAN-2019;09:25' -->
<A NAME="page_fm45201_1_11"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>connection
with nonclinical studies and clinical trials, and other related clinical trial fees, such as for investigator grants, patient screening, laboratory work, clinical trial database management,
clinical trial material management and statistical compilation and analysis. Non-refundable prepayments for goods or services that will be used or rendered for future research and development
activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the
goods will be delivered or the services rendered. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Costs
incurred in obtaining technology licenses are charged immediately to research and development expense if the technology licensed has not reached technological feasibility and has no alternative
future uses. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research contract costs and accruals  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company has entered into various research and development and other agreements with commercial firms, researchers, universities and others for provisions
of goods and services. These agreements are generally cancelable, and the related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated
ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of
events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ
materially from the Company's estimates. The Company's historical accrual estimates have not been materially different from the actual costs. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Patent costs  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the
recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-based compensation  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company measures all stock-based awards granted to employees and nonemployees based on the fair value on the date of the grant and recognizes compensation
expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company accounts for forfeitures as they occur. For stock-based awards
with service-based vesting conditions, the Company recognizes compensation expense using the straight-line method. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the
expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and the Company's expected dividend yield.
The Company historically has been a private company and lacks company-specific historical and implied volatility information for its shares. Therefore, it estimates its expected share price volatility
based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded
share price. The expected term of the Company's </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-11</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=210,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=336180,FOLIO='F-11',FILE='DISK114:[18ZFG1.18ZFG45201]FM45201A.;30',USER='MTITUSS',CD='17-JAN-2019;09:25' -->
<A NAME="page_fm45201_1_12"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>stock
options has been determined utilizing the "simplified" method for awards that qualify as "plain-vanilla" options. The risk-free interest rate is determined by reference to the U.S. Treasury
yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never
paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. The fair value of each restricted common stock award is estimated on the date of grant
based on the fair value of the Company's common stock on that same date. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company classifies stock-based compensation expense in its statement of operations and comprehensive loss in the same manner in which the award recipient's payroll costs are classified or in which
the award recipient's service payments are classified. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preferred stock tranche obligation  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company classifies the preferred stock tranche obligation for the future purchase, and option to purchase, Series&nbsp;A Preferred Stock (see
Note&nbsp;5) as a liability on its balance sheets as the preferred stock tranche obligation is a freestanding financial instrument that will require the Company to transfer equity instruments upon
future closings of the Series&nbsp;A Preferred Stock. The preferred stock tranche obligation was initially recorded at fair value upon the date of issuance and was subsequently remeasured to fair
value at each reporting date. Changes in the fair value of the preferred stock tranche obligation are recognized as a component of other expense in the statements of operations and comprehensive loss.
Changes in the fair value of the preferred stock tranche obligation were recognized until the tranche obligations were fulfilled or otherwise extinguished in the fourth quarter of 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2018, in connection with the Company's issuance and sale of Series&nbsp;A Preferred Stock, the Company satisfied its obligation to issue additional shares under the Second Tranche
Closing. In December 2018, in connection with the Company's issuance and sale of Series&nbsp;B Preferred Stock, the Company terminated the option to purchase Series&nbsp;A Preferred Stock provided
under the 2018 Series&nbsp;A Agreement (see Note&nbsp;14). </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Anti-dilution right liability  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company classifies the anti-dilution right under its license agreement with Amgen&nbsp;Inc. ("Amgen") (see Note&nbsp;8) as a derivative liability on
its balance sheets as the anti-dilution right represents a freestanding financial instrument that may require the Company to transfer equity instruments upon future equity closings. The anti-dilution
right liability was initially recorded at fair value upon the date of issuance and is subsequently remeasured to fair value at each reporting date. The issuance date fair value of the anti-dilution
right liability was recognized as a research and development expense upon entering into the agreement with Amgen. Changes in the fair value of the anti-dilution right liability are recognized as a
component of other expense in the statements of operations and comprehensive loss. Changes in the fair value of the anti-dilution right liability were recognized until the anti-dilution right was
satisfied in the fourth quarter of 2018. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2018, in connection with the Company's issuance and sale of Series&nbsp;A Preferred Stock, the Company satisfied its anti-dilution right under the Amgen Agreement (see Note&nbsp;14). </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-12</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=211,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=481167,FOLIO='F-12',FILE='DISK114:[18ZFG1.18ZFG45201]FM45201A.;30',USER='MTITUSS',CD='17-JAN-2019;09:25' -->
<A NAME="page_fm45201_1_13"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Classification and accretion of redeemable convertible preferred stock  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company has classified its redeemable convertible preferred stock outside of stockholders' equity (deficit) because the shares contain certain redemption
features that are not solely within the control of the Company. Costs incurred in connection with the issuance of redeemable convertible preferred stock, as well as the recognition of the preferred
stock tranche obligation, are recorded as a reduction of gross proceeds from issuance. The net carrying value of redeemable convertible preferred stock are accreted to their redemption values through
a charge to additional paid-in capital or accumulated deficit over the period from date of issuance to the earliest date on which the holders could, at their option, elect to redeem their shares. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comprehensive loss  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Comprehensive loss includes net loss as well as other changes in stockholders' equity (deficit) that result from transactions and economic events other than
those with stockholders. There was no difference between net loss and comprehensive loss for each of the periods presented in the accompanying financial statements. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income taxes  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the
expected future tax consequences of events that have been recognized in the financial statements or in the Company's tax returns. Deferred tax assets and liabilities are determined based on the
difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred
tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the
extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is
established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible
tax planning strategies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax
position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be
sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that
has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are
considered appropriate as well as the related net interest and penalties. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net income (loss) per share  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company follows the two-class method when computing net income (loss) per share as the Company has issued shares that meet the definition of participating
securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-13</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=212,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=601176,FOLIO='F-13',FILE='DISK114:[18ZFG1.18ZFG45201]FM45201A.;30',USER='MTITUSS',CD='17-JAN-2019;09:25' -->
<A NAME="page_fm45201_1_14"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>declared
or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and
participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Basic
net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares
outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to reallocate undistributed
earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common
stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential
dilutive common shares. For purpose of this calculation, unvested restricted common stock and redeemable convertible preferred stock are considered potential dilutive common shares. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
Company's redeemable convertible preferred stock contractually entitles the holders of such shares to participate in dividends but does not contractually require the holders of such shares to
participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders, such losses are not allocated to such participating
securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per
share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common
stockholders for the period January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017, the period January&nbsp;24, 2017 (inception) through September&nbsp;30, 2017 (unaudited) and the
nine months ended September&nbsp;30, 2018 (unaudited), respectively. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Emerging growth company  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the "JOBS Act"). Under the JOBS Act,
companies have extended transition periods available for complying with new or revised accounting standards. The Company has elected this exemption to delay adopting new or revised accounting
standards until such time as those standards apply to private companies. Where allowable, we have early adopted certain standards as described in Note&nbsp;2. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recently adopted accounting pronouncements  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In May 2014, the FASB issued ASU No.&nbsp;2014-09, </FONT><FONT SIZE=2><I>Revenue from Contracts with Customers (Topic&nbsp;606)</I></FONT><FONT SIZE=2>
("ASU&nbsp;2014-09"), which supersedes existing revenue recognition guidance under GAAP. This standard's core principle is that a company will recognize revenue when it transfers promised goods or
services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to
achieve this principle and will require companies to use more judgment and make more estimates than under the current guidance. The Company expects that these judgments and estimates will include
identifying performance obligations in the customer contract, estimating the amount of variable consideration to
include in the transaction price and allocating the transaction price to each separate performance obligation. ASU&nbsp;2014-09 also requires additional disclosure about the nature, amount, timing
and uncertainty of revenue and cash flows </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-14</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=213,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=641699,FOLIO='F-14',FILE='DISK114:[18ZFG1.18ZFG45201]FM45201A.;30',USER='MTITUSS',CD='17-JAN-2019;09:25' -->
<A NAME="page_fm45201_1_15"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>arising
from customer contracts. In August 2015, the FASB issued ASU&nbsp;No.&nbsp;2015-14, </FONT><FONT SIZE=2><I>Revenue from Contracts with Customers (Topic 606): Deferral of the Effective
Date</I></FONT><FONT SIZE=2>, which delayed the effective date of ASU&nbsp;2014-09 such that the standard is effective for non-public entities for annual periods beginning after December&nbsp;15,
2018 and for interim periods beginning after December&nbsp;15, 2019. The FASB subsequently issued amendments to ASU&nbsp;2014-09 that have the same effective date and transition date. The Company
early adopted ASU&nbsp;2014-09 as of January&nbsp;1, 2018 and the adoption had no impact on the Company's financial position, results of operations or cash flows as the Company does not currently
have any revenue-generating arrangements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
August 2016, the FASB issued ASU No.&nbsp;2016-15, </FONT><FONT SIZE=2><I>Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (Topic 230)</I></FONT><FONT SIZE=2>
("ASU&nbsp;2016-15"), to address diversity in practice in how certain cash receipts and cash payments are presented in the statement of cash flows. For non-public entities, ASU&nbsp;2016-15 is
effective for annual reporting periods beginning after December&nbsp;15, 2018, including interim periods within those fiscal years. The adoption of ASU&nbsp;2016-15 is required to be applied
retrospectively. The Company early adopted ASU&nbsp;2016-15 as of January&nbsp;1, 2018, and its adoption had no impact on the Company's financial position, results of operations or cash flows. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
January 2017, the FASB issued ASU No.&nbsp;2017-01, </FONT><FONT SIZE=2><I>Business Combinations (Topic 805): Clarifying the Definition of a Business</I></FONT><FONT SIZE=2>
("ASU&nbsp;2017-01"), which clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when
substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the asset is not a business.
For non-public entities, ASU&nbsp;2017-01 is effective for annual reporting periods beginning after December&nbsp;15, 2018, including interim periods within those fiscal years. Early adoption is
permitted. The Company early adopted ASU&nbsp;2017-01 as of January&nbsp;1, 2018, and its adoption had no impact on the Company's financial position, results of operations or cash flows. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
May 2017, the FASB issued ASU No.&nbsp;2017-09, </FONT><FONT SIZE=2><I>Compensation&#151;Stock Compensation (Topic 718): Scope of Modification Accounting</I></FONT><FONT SIZE=2>
("ASU&nbsp;2017-09"). The amendments in ASU&nbsp;2017-09 clarifies that modification accounting is required only if the fair value, the vesting conditions or the classification of the awards (as
equity or liability) changes as a result of the change in terms or conditions. For non-public entities, ASU&nbsp;2017-09 is effective for annual reporting periods beginning after December&nbsp;15,
2017, including interim periods within those fiscal years. The Company adopted ASU&nbsp;2017-09 as of January&nbsp;1, 2018. The adoption of ASU&nbsp;2017-09 did not have a material impact on the
Company's financial position, results of operations or cash flows, but will impact the accounting for modifications of stock-based awards, if any, after the date of adoption. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
June 2018, the FASB issued ASU No.&nbsp;2018-07, </FONT><FONT SIZE=2><I>Compensation&#151;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment
Accounting</I></FONT><FONT SIZE=2> ("ASU 2018-07"). These amendments expand the scope of </FONT><FONT SIZE=2><I>Topic 718, Compensation&#151;Stock Compensation</I></FONT><FONT SIZE=2> (which
currently only includes stock-based payments to employees) to include stock-based payments issued to nonemployees for goods or services. Consequently, the accounting for stock-based payments to
nonemployees and employees will be substantially aligned. The ASU </FONT><FONT SIZE=2><I>supersedes Subtopic 505-50, Equity&#151;Equity-Based Payments to Non-Employees</I></FONT><FONT SIZE=2>.
This standard is effective for non-public companies for annual periods beginning after </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-15</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=214,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=91410,FOLIO='F-15',FILE='DISK114:[18ZFG1.18ZFG45201]FM45201A.;30',USER='MTITUSS',CD='17-JAN-2019;09:25' -->
<A NAME="page_fm45201_1_16"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>December&nbsp;15,
2019, including interim periods within those fiscal years, with early adoption permitted as long as ASU 2014-09 has been adopted by the Company. The Company early adopted this
guidance as of January&nbsp;1, 2018. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recently issued accounting pronouncements  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In February 2016, the FASB issued ASU No.&nbsp;2016-02</FONT><FONT SIZE=2><I>, Leases (Topic 842)</I></FONT><FONT SIZE=2> ("ASU 2016-02"), which sets out
the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e.,&nbsp;lessees and lessors). The new standard requires lessees to apply a
dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will
determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and
a lease liability for all leases with a term of greater than 12&nbsp;months regardless of their classification. Leases with a term of 12&nbsp;months or less may be accounted for similar to
existing guidance for operating leases today. For non-public entities, ASU 2016-02 is effective for annual reporting periods beginning after December&nbsp;15, 2019, including interim periods within
those fiscal years, and early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
July 2017, the FASB issued ASU No.&nbsp;2017-11, </FONT><FONT SIZE=2><I>Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815)
(Part&nbsp;I) Accounting for Certain Financial Instruments with Down Round Features (Part&nbsp;II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of
Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</I></FONT><FONT SIZE=2> ("ASU 2017-11"). Part&nbsp;I applies to entities that issue
financial instruments such as warrants, convertible debt or convertible preferred stock that contain down-round features. Part&nbsp;II replaces the indefinite deferral for certain mandatorily
redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within Accounting Standards Codification ("ASC") Topic 480 with a scope exception
and does not impact the accounting for these mandatorily redeemable instruments. For non-public entities, ASU 2017-11 is effective for annual reporting periods beginning after December&nbsp;15,
2019, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU 2017-11 will have on its financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
August 2018, the FASB issued No. ASU 2018-13, </FONT><FONT SIZE=2><I>Fair Value Measurement (Topic 820)&#151;Disclosure Framework</I></FONT><FONT SIZE=2> ("ASU 2018-13"), which improves the
disclosure requirements for fair value measurements. ASU&nbsp;2018-13 is effective for us beginning December&nbsp;15, 2019, including interim periods within those fiscal years. Early adoption is
permitted for any removed or modified disclosures. The Company is currently evaluating the impact that the adoption of ASU 2018-13 will have on its financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-16</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=215,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=954071,FOLIO='F-16',FILE='DISK114:[18ZFG1.18ZFG45201]FM45201A.;30',USER='MTITUSS',CD='17-JAN-2019;09:25' -->
<A NAME="page_fm45201_1_17"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=3><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value of financial assets and liabilities  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following tables present information about the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level
of the fair value hierarchy used to determine such fair values: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="40pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Fair value measurements<BR>
as of September&nbsp;30, 2018 using: </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Level&nbsp;1</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Level&nbsp;2</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Level&nbsp;3</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Total</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(unaudited) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Liabilities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preferred stock tranche obligation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Anti-dilution right liability</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,671</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,671 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>18,421</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>18,421 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>At
December&nbsp;31, 2017, the Company did not have any financial assets or liabilities measured at fair value on a recurring basis. During the period January&nbsp;24, 2017 (inception) through
December&nbsp;31, 2017 and nine months ended September&nbsp;30, 2018 (unaudited), there were no transfers between Level&nbsp;1, Level&nbsp;2 and Level&nbsp;3. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Valuation of preferred stock tranche obligation  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The fair value of the preferred stock tranche obligation recognized in connection with the Company's issuance of Series&nbsp;A Preferred Stock in June 2018
(see Note&nbsp;5) was determined based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. The fair value of the
liability was estimated based on results of a third-party valuation performed in connection with the June 2018 Series&nbsp;A issuance. The Company determined that this valuation represented the fair
value of the liability at the reporting date. The liability included (i)&nbsp;an obligation to issue shares in a second tranche of Series&nbsp;A Preferred Stock and (ii)&nbsp;an obligation to
issue shares under the call option to purchase Series&nbsp;A Preferred Stock following the Second Tranche Closing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
fair value of the obligation to purchase a second tranche of Series&nbsp;A Preferred Stock was estimated by utilizing the future value of the underlying Series&nbsp;A Preferred stock, the
Series&nbsp;A original issue price and the number of shares subject to future purchase. The future value of the Series&nbsp;A Preferred Stock was determined through a backsolve calculation. The
present value of the forward contract was then multiplied by a probability of occurrence for the Second Tranche Closing. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
fair value of the obligation for the call option to purchase Series&nbsp;A Preferred Stock was estimated using the hybrid model, which employed the Black-Scholes option-pricing model adjusted to
reflect the timing and probability of closing a second tranche of Series&nbsp;A Preferred Stock. The hybrid method incorporates assumptions and estimates, to value the obligation. Estimates and
assumptions impacting the fair value measurement include the fair value of the underlying shares of Series&nbsp;A Preferred Stock, the remaining contractual term of the preferred stock tranche
obligation, risk-free interest rate, expected dividend yield, expected volatility of the price of the underlying preferred stock, the remaining years to liquidity, the discount rate and probability
(expressed as a percentage) of closing a second tranche. The </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-17</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=216,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=508818,FOLIO='F-17',FILE='DISK114:[18ZFG1.18ZFG45201]FM45201A.;30',USER='MTITUSS',CD='17-JAN-2019;09:25' -->
<A NAME="page_fm45201_1_18"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>most
significant assumption in the hybrid model impacting the fair value of the call option is the fair value of the preferred stock as of each remeasurement date. The Company determined the fair
value per share of the underlying preferred stock by taking into consideration the most recent sales of preferred stock, results obtained from third-party valuations and additional factors that are
deemed relevant. The Company has historically been a private company and lack company-specific historical and implied volatility information of its stock. Therefore, the Company estimates expected
stock volatility based on the historical
volatility of publicly traded peer companies for a term equal to the remaining contractual term of the call option. The risk-free interest rate is determined by reference to the U.S. Treasury yield
curve for time periods approximately equal to the remaining years to liquidity. The Company has estimated a 0% dividend yield based on the expected dividend yield and the fact that the Company has
never paid or declared dividends. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Valuation of anti-dilution right liability  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The fair value of the anti-dilution right liability recognized in connection with the anti-dilution provisions set forth in the Company's license agreement
with Amgen (see Note&nbsp;8) was determined based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
fair value of the anti-dilution right was estimated using a probability weighted scenario which considers as inputs the probability of occurrence of events that would trigger the issuance of
shares, including a (i)&nbsp;Second Tranche Closing of Series&nbsp;A Preferred Stock, (ii)&nbsp;initial public offering, and (ii)&nbsp;no future sale of equity securities. The weighted average
fair values of each scenario were calculated utilizing the fair value per share of the underlying Series&nbsp;A Preferred Stock and common stock. Changes in the estimated fair value and the
probability of achieving different financing scenarios can have a significant impact on the fair value of the anti-dilution right liability. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table presents a roll forward of the fair values of the Company's preferred stock tranche obligation and anti-dilution right liability for the nine months ended September&nbsp;30, 2018
(unaudited), for which fair value is determined using Level&nbsp;3 inputs: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="83pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Preferred stock<BR>
tranche<BR>
obligation</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Anti-dilution<BR>
right<BR>
liability </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Balance as of December&nbsp;31, 2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Initial fair value of anti-dilution right liability in connection with Amgen license agreement</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,639</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Initial fair value of preferred stock tranche obligation in connection with the issuance of Series&nbsp;A Preferred Stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,350</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,400</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,032 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Balance as of September&nbsp;30, 2018 (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>15,750</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,671 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-18</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=217,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=654722,FOLIO='F-18',FILE='DISK114:[18ZFG1.18ZFG45201]FM45201A.;30',USER='MTITUSS',CD='17-JAN-2019;09:25' -->
<A NAME="page_fm45201_1_19"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>4.&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Accrued expenses consisted of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="75pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>December&nbsp;31,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>September&nbsp;30,<BR>
2018 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (unaudited) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Accrued employee compensation and benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>160</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>134</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued external research and development expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>264</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Other accrued expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>102 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>162</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>500 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=3><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Redeemable convertible preferred stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited), the Company's certificate of incorporation, as amended and restated (the "Amended and
Restated Certificate of Incorporation"), authorized the Company to issue 5,000,000 shares and 70,858,462 shares, respectively, of Series&nbsp;A Preferred Stock, par value $0.0001 per share. The
Series&nbsp;A Preferred Stock is classified outside of stockholders' equity (deficit) because the shares contain redemption features that are not solely within the control of the Company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During
2017, the Company issued and sold 5,000,000 shares of Series&nbsp;A Preferred Stock to Apple Tree Partner IV,&nbsp;L.P. ("Apple Tree") at a price of $1.00 ("Series&nbsp;A Original Issue
Price") per share for aggregate proceeds of $5,000. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
June 2018, the Company entered into a Series&nbsp;A Preferred Stock Agreement ("2018 Series&nbsp;A Agreement"), which provides for a First Tranche Closing, Second Tranche Closing and a call
option to purchase additional shares of Series&nbsp;A Preferred Stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
June 2018, the Company completed its First Tranche Closing, and issued and sold 15,000,000 shares of Series&nbsp;A Preferred Stock at a price of $1.00 ("2018 Series&nbsp;A Agreement Purchase
Price") per share for aggregate proceeds of $14,784, net of issuance costs of $216. Upon the execution of the Company's license agreement with Amgen (see Note&nbsp;8), the Company issued an
additional 2,653,333 shares of Series&nbsp;A Preferred Stock to Amgen in June 2018 for a total value of $1,353. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Second Tranche Closing was contingent upon the achievement of the Second Tranche Closing Milestone Event ("Milestone Event"), as reasonably determined by a majority of the Company's board of
directors, prior to December&nbsp;31, 2019 or waiver of the Milestone Event through written elections by a majority of the purchasers of shares of Series&nbsp;A Preferred Stock, subject to the
provisions included in the Amended and Restated Certificate of Incorporation ("Special Mandatory Conversion" as defined below). The Milestone Event is defined as the earlier of (a)&nbsp;a successful
completion of a 90 or 120&nbsp;day chronic toxicity animal studies, and (b)&nbsp;identification of sufficient therapeutic index for a Phase&nbsp;2 clinical trial. Upon achievement or waiver of
the Milestone Event, Amgen would be issued a number of additional shares for no consideration provided that Amgen's total holdings equal ten percent (10%) of the total outstanding and issued common
stock of the Company on a fully diluted and as converted basis of the Second Tranche Closing, provided that the percentage shall only be based on the First Tranche Closing and a maximum of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-19</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=218,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=266237,FOLIO='F-19',FILE='DISK114:[18ZFG1.18ZFG45201]FM45201A.;30',USER='MTITUSS',CD='17-JAN-2019;09:25' -->
<A NAME="page_fm45201_1_20"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>25,000,000
shares of Series&nbsp;A Preferred Stock issued in the Second Tranche Closing. An additional 25,000,000 shares of Series&nbsp;A Preferred Stock will be issued upon the Second Tranche
Closing at a price equal to the 2018 Series&nbsp;A Agreement Purchase Price. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additionally,
the 2018 Series&nbsp;A Agreement contains a call option such that, following the Second Tranche Closing, the stockholders of Series&nbsp;A Preferred Stock have the right, but not the
obligation, to purchase up to $20,000 of additional shares of Series&nbsp;A Preferred Stock at any time prior to January&nbsp;14, 2022 at a price equal to the 2018 Series&nbsp;A Agreement
Purchase Price, upon the written election of the Requisite Preferred (as defined below). Each of the four Series&nbsp;A stockholders, other than Amgen, will be allocated the right to purchase 22.5%
of the Series&nbsp;A Preferred Stock ("Call Amount") and Amgen will be allocated the right to purchase 10% of Series&nbsp;A Preferred Stock ("Amgen Call Amount"), with participating investors
having the option to purchase any shares not purchased by other investors on a pro rata basis. If Amgen elects not to participate in the Amgen Call Amount, Apple Tree shall have the right to purchase
70% of the Amgen Call Amount and the remaining Series&nbsp;A stockholders will be allocated the remaining 30% on a pro rata basis. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
Company concluded that the rights to participate in the future issuance of Series&nbsp;A Preferred Stock meet the definition of a freestanding financial instrument that was required to be
recognized as a liability at fair value as (i)&nbsp;the instruments were legally detachable from the Series&nbsp;A Preferred Stock and (ii)&nbsp;will require the Company to transfer equity
instruments upon future closings of the Series&nbsp;A Preferred Stock. Upon the First Tranche Closing, the Company recognized a preferred stock tranche obligation of $7,350 with a corresponding
reduction to the carrying value of the Series&nbsp;A Preferred Stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
the First Tranche Closing in June 2018, the initial carrying value of the Series&nbsp;A Preferred Stock was recorded at $8,787, equal to $15,000 of gross proceeds received by the Company and
the fair value of $1,353 for the issuance of shares to Amgen, reduced by accrued issuance costs of $216 and the fair value of the preferred stock tranche obligation of $7,350. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
issuance of each tranche of Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities and determined that such features did not require the Company
to separately account for these features. The Company also concluded that no beneficial conversion feature existed on the issuance date of each tranche of Preferred Stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2018, upon the waiver of the Milestone Event through written elections by a majority of the shareholders of Series&nbsp;A Preferred Stock, the Company closed the second tranche of its
Series&nbsp;A preferred financing through the issuance and sale of an aggregate of 25,000,000 shares of Series&nbsp;A Preferred Stock, at an issuance price of $1.00 per share, for proceeds of
$25,000, before issuance costs of $5 (See Note&nbsp;14). In November 2018, in connection with the Company's issuance and sale of Series&nbsp;A Preferred Stock, the Company satisfied its obligation
to issue additional shares under the Second Tranche Closing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2018, pursuant to the terms of the Amgen Agreement, the Company issued an additional 3,205,128 shares of Series&nbsp;A Preferred Stock to Amgen upon completion of the Series&nbsp;A
Second Tranche Closing satisfying its anti-dilution right under the Amgen Agreement (see Note&nbsp;14). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
December 2018, the Company issued and sold 13,871,948 shares of Series&nbsp;B Preferred Stock, at an issuance price of $3.28 per share, for proceeds of approximately $45,500 before issuance costs
of $219 </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-20</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=219,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=420965,FOLIO='F-20',FILE='DISK114:[18ZFG1.18ZFG45201]FM45201A.;30',USER='MTITUSS',CD='17-JAN-2019;09:25' -->
<A NAME="page_fm45201_1_21"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>(see
Note&nbsp;14). In connection with the Company's issuance and sale of Series&nbsp;B Preferred Stock, the Company terminated the option to purchase Series&nbsp;A Preferred Stock provided
under the 2018 Series&nbsp;A Agreement (see Note&nbsp;14). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of each balance sheet date, the Preferred Stock consisted of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="78pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>December&nbsp;31, 2017 </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Preferred<BR>
stock<BR>
authorized</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Preferred<BR>
stock<BR>
issued and<BR>
outstanding</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Carrying<BR>
value</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Liquidation<BR>
preference</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Common stock<BR>
issuable upon<BR>
conversion</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Series&nbsp;A Preferred Stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,213</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,000,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,213</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,000,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="78pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>September&nbsp;30, 2018 (unaudited) </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Preferred<BR>
stock<BR>
authorized</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Preferred<BR>
stock<BR>
issued and<BR>
outstanding</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Carrying<BR>
value</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Liquidation<BR>
preference</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Common stock<BR>
issuable upon<BR>
conversion</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Series&nbsp;A Preferred Stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>70,858,462</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>22,653,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>14,108</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>22,653</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>22,653,333 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>70,858,462</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>22,653,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>14,108</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>22,653</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>22,653,333 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
holders of the Preferred Stock have the following rights and preferences: </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The holders of Preferred Stock are entitled to vote, together with the holders of common stock as a single class, on all matters submitted to stockholders for
a vote and have the right to vote the number of shares equal to the number of shares of common stock into which each share of Preferred Stock could convert on the record date for determination of
stockholders entitled to vote. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
holders of Series&nbsp;A Preferred Stock, voting exclusively and as a separate class, are entitled to elect four directors of the Company. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-21</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=15,SEQ=220,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=586431,FOLIO='F-21',FILE='DISK114:[18ZFG1.18ZFG45201]FM45201A.;30',USER='MTITUSS',CD='17-JAN-2019;09:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fo45201_1_22"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fo45201_akero_therapeutics,_inc._notes__ake04170"> </A>
<A NAME="toc_fo45201_1"> </A></FONT> <FONT SIZE=3><B><BR>  Akero Therapeutics, Inc.<BR>  Notes to Financial Statements<BR>  (Amounts in thousands, except share and per share data)  <BR>        <BR>  </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Each share of Preferred Stock is convertible, at the option of the holder, at any time and from time to time, and without the payment of additional
consideration by the holder thereof, into such number of fully paid and non-assessable shares of common stock as is determined by dividing the Series&nbsp;A Original Issue Price by the
Series&nbsp;A Conversion Price (as defined below) in effect at the time of conversion. The Series&nbsp;A Original Issue Price and Series&nbsp;A Conversion Price were equal to $1.00 as of
December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited). Such Series&nbsp;A Original Issue Price and Series&nbsp;A Conversion Price, and the rate at which each series of preferred stock
may be converted into common stock, are subject to adjustment from time to time to reflect future share dividends, splits, combinations, recapitalizations and similar events. The Series&nbsp;A
Conversion Price is also subject to adjustments based on weighted-average anti-dilution provisions set forth in the Amended and Restated Certificate of Incorporation in the event that additional
options or convertible securities are issued at a purchase price less than the Series&nbsp;A Conversion Price then in effect. As of December&nbsp;31, 2017 and September&nbsp;30, 2018
(unaudited), each share of Series&nbsp;A Preferred Stock was convertible into one share of common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Upon
either (a)&nbsp;the closing of the sale of shares of common stock to the public at a price of at least $5.00 per share (subject to appropriate adjustment in the event of any share dividend,
share split, combination or other similar recapitalization with respect to the applicable class of common stock) in an initial public offering resulting in at least $60,000 of gross proceeds to the
Company or (b)&nbsp;the date and time, or the occurrence of an event, specified by vote or written consent of the holders of a majority of the outstanding shares of Preferred Stock ("Requisite
Preferred"), voting together as a single class on an as-if-converted to common stock basis, all outstanding shares of Series&nbsp;A Preferred Stock shall automatically be converted into shares of
common stock at the then effective conversion rate. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unless
waived by the Requisite Preferred, in the event that any holder of shares of Series&nbsp;A Preferred Stock, other than Amgen, does not participate in the Series&nbsp;A Second Tranche
Closing, by purchasing in the aggregate such holder's applicable Second Tranche shares, then each ten shares of Series&nbsp;A Preferred Stock held by such holder shall automatically be converted
into one share of common stock ("Special Mandatory Conversion"). </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The holders of Series&nbsp;A Preferred Stock are entitled to receive noncumulative dividends when, as and if declared by the board of directors. Dividends
accrue on Series&nbsp;A Preferred Stock at a rate of $0.08 per share, or 8%, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization with respect to the Series&nbsp;A Preferred Stock; however, such dividends are only payable in any calendar year when and as if declared by the board of directors or, as applicable
in the case of a liquidation, dissolution, or winding up of the Company or Deemed Liquidation Event (as defined below). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company may not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company, other than dividends on shares of common stock payable in shares of
common stock, unless the holders of the Series&nbsp;A Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series&nbsp;A
Preferred Stock in an amount at least equal to the greater of (i)&nbsp;the amount of the dividend for such share of Series&nbsp;A Preferred Stock not previously paid during the applicable fiscal
year of the Company and (ii)&nbsp;(A)&nbsp;in the case of a dividend on </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-22</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=221,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=1044324,FOLIO='F-22',FILE='DISK114:[18ZFG1.18ZFG45201]FO45201A.;46',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<A NAME="page_fo45201_1_23"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>common
stock or any class or series that is convertible into common stock, that dividend per share of Series&nbsp;A Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on
each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into common stock and (2)&nbsp;the number of shares of common stock issuable
upon conversion of a share of Series&nbsp;A Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a
dividend on any class or series that is not convertible into common stock, at a rate per share of Series&nbsp;A Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable
on each share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend,
stock split, combination or other similar recapitalization with respect to such class or series) and (2)&nbsp;multiplying such fraction by an amount equal to the applicable Series&nbsp;A Original
Issue Price; provided that if the Company declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Company, the dividend payable to
the holders of Series&nbsp;A Preferred Stock shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest Series&nbsp;A Preferred Stock
dividend. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior
to the 2018 Series&nbsp;A Agreement, the holders of Series&nbsp;A Preferred Stock were entitled to cumulative dividends of $0.08 per share, or 8%. As part of the Amended and Restated
Certificate of Incorporation in connection with the 2018 Series&nbsp;A Agreement in June 2018, the rights of the holders of Preferred Stock were amended as described above. For the computation of
net loss per share attributable to common stockholders, accruing undeclared dividends on Series&nbsp;A Preferred Stock increased the net loss attributable to common stockholders for the period
January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017 and the period January&nbsp;24, 2017 (inception) through September&nbsp;30, 2017 (unaudited) by $213 and $166, respectively.
The Company determined that the modification did not have any impact on its financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Through
December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited), no cash dividends have been declared or paid. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidation  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or Deemed Liquidation Event (as defined below), each holder
of the then-outstanding Series&nbsp;A Preferred Stock will be entitled to receive an amount equal to the greater of (i)&nbsp;the Series&nbsp;A Original Issue Price plus any dividends declared
but unpaid thereon, or (ii)&nbsp;the amount per share that would have been payable had all shares of Series&nbsp;A Preferred Stock been converted into common stock immediately prior to such
liquidation, dissolution, winding-up or Deemed Liquidation Event. If upon any such liquidation, dissolution, or winding-up or Deemed Liquidation Event, the assets available for distribution to
stockholders are insufficient to pay the holders of shares of Series&nbsp;A Preferred Stock the full amounts to which they are entitled, the holders of shares of Series&nbsp;A Preferred Stock
shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon
such distribution if all amounts payable on or with respect to such shares were paid in full. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After
the payment of all preferential amounts to the holders of shares of Series&nbsp;A Preferred Stock, the remaining assets of the Company available for distribution to its stockholders shall be
distributed among </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-23</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=222,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=226618,FOLIO='F-23',FILE='DISK114:[18ZFG1.18ZFG45201]FO45201A.;46',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<A NAME="page_fo45201_1_24"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
holders of shares of Series&nbsp;A Preferred Stock and common stock, pro rata based on the number of shares held by each such holder. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unless
the holders of the Requisite Preferred elect otherwise, a Deemed Liquidation Event shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by
voting power of the outstanding shares of the surviving or acquiring corporation) or a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of the
Company. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Redemption  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>At the written request of the Requisite Preferred, the shares of Series&nbsp;A Preferred Stock outstanding are redeemable, at any time on or after
June&nbsp;7, 2025, in three equal annual installments commencing no more than 60&nbsp;days after written notice is received by the Company, at a price equal to the Series&nbsp;A Original Issue
Price plus all declared but unpaid dividends thereon. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited), the Company's certificate of incorporation, as amended and restated, authorized the
Company to issue 7,000,000 shares and 80,000,000 shares, respectively, of $0.0001 par value common stock. The voting, dividend and liquidation rights of the holders of the Company's common stock are
subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock set forth above. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Each
share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders. The holders of common stock, voting exclusively and as a separate class,
are entitled to elect one director of the Company. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend
rights of Preferred Stock. Through December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited), no cash dividends had been declared or paid. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited), there were 696,000 shares of common stock issued and outstanding pursuant to restricted stock agreements with the founders
(see Note&nbsp;7). As of December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited), the Company had reserved 5,000,000 shares and 23,563,069 shares, respectively, of common stock for the
conversion of outstanding shares of Preferred
Stock (see Note&nbsp;5) and the number of shares remaining available for future issuance under the 2018 Stock Option and Grant Plan (see Note&nbsp;7). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation  </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2018 Stock option and grant plan  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company's 2018 Stock Option and Grant Plan (the "2018 Plan") provides for the Company to grant incentive stock options or nonqualified stock options,
restricted stock awards and other stock-based awards to employees, directors and consultants of the Company. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
total number of shares of common stock that may be issued under the 2018 Plan was 3,184,000 shares as of September&nbsp;30, 2018 (unaudited), of which 906,736 shares remained available for
future grants. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-24</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=223,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=522356,FOLIO='F-24',FILE='DISK114:[18ZFG1.18ZFG45201]FO45201A.;46',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<A NAME="page_fo45201_1_25"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
2018 Plan is administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions
are determined at the discretion of the board of directors, or its committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market
value of the share of common stock on the date of grant and the term of stock option may not be greater than ten years. All incentive options granted to any person possessing more than 10% of the
total combined voting power of all classes of shares may not have an exercise price of less than 110% of the fair market value of the common stock on the grant date. Stock options granted to
employees, officers, members of the board of directors and consultants will typically vest over a four-year period. The Company's board of directors values the Company's common stock, taking into
consideration its most recently available valuation of common stock performed by third parties as well as additional factors which may have changed since the date of the most recent contemporaneous
valuation through the date of grant. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Shares
that are expired, terminated, surrendered or canceled under the 2018 Plan without having been fully exercised will be available for future awards. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During
the period January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017, no shares were granted under the 2018 Plan. During the nine months ended September&nbsp;30, 2018 (unaudited),
the Company granted options to purchase 2,277,264 shares of common stock to employees, directors and consultants of the Company. The Company recorded stock-based compensation expense for options
granted of $34 during the nine months ended September&nbsp;30, 2018 (unaudited). </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock option valuation  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees, directors and consultants were as follows,
presented on a weighted average basis: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="75pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Period<BR>
January&nbsp;24,<BR>
2017<BR>
(inception)<BR>
through<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Period<BR>
January&nbsp;24,<BR>
2017<BR>
(inception)<BR>
through<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Nine months<BR>
ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>2018</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(unaudited) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Weighted average risk-free interest rate</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>n/a</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>n/a</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.86</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (in years)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>n/a</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>n/a</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5.87</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Expected volatility</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>n/a</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>n/a</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>70.86</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>n/a</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>n/a</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.00</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Weighted average fair value of common stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>n/a</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>n/a</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.29 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-25</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=224,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=415282,FOLIO='F-25',FILE='DISK114:[18ZFG1.18ZFG45201]FO45201A.;46',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<A NAME="page_fo45201_1_26"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock options  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The following table summarizes the Company's stock option activity since December&nbsp;31, 2017: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="58pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="54pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Number of<BR>
options</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Weighted-<BR>
average<BR>
exercise<BR>
price</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Weighted-<BR>
average<BR>
remaining<BR>
contractual<BR>
term (years)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Aggregate<BR>
intrinsic<BR>
value </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Outstanding as of December&nbsp;31, 2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,277,264</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.20</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9.91</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Exercised</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding as of September&nbsp;30, 2018 (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,277,264</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.20</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9.91</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>410 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Options exercisable as of September&nbsp;30, 2018 (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>252,143</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.20</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9.85</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>45</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options unvested as of September&nbsp;30, 2018 (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,025,121</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.20</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9.91</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>365 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company's common stock for those stock options
that had exercise prices lower than the fair value of the Company's common stock. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
weighted average grant-date fair value per share of stock options granted during the nine months ended September&nbsp;30, 2018 (unaudited) was $0.21. The total fair value of options vested
during the nine months ended September&nbsp;30, 2018 (unaudited) was $26. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restricted common stock  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In March 2017, the Company issued an aggregate of 696,000 shares of restricted common stock under restricted stock agreements with the founders. Pursuant to
the terms of the agreements, the restricted common stock is subject to a vesting schedule over a four-year period commencing in January 2017 and culminating in January 2020. During the vesting period,
the Company has the right to repurchase up to all unvested shares at the amount paid if the relationship between the recipient and the Company ceases. Subject to the continued employment or other
business relationship with the Company, all of the restricted common stock becomes fully vested within four years of the date of issuance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
October 2017, 232,000 shares of restricted common stock were subject to repurchase by the Company when one of the founders terminated his relationship with the Company. The Company repurchased the
shares in March 2018 for an immaterial amount and immediately reissued the shares to the remaining founders. In connection with the repurchase and reissuance of the shares, the Company amended the
restricted stock agreements with the remaining founders such that the restricted common stock is now subject to a vesting schedule over a two-year period commencing in May 2018 and culminating in May
2020. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-26</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=225,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=527163,FOLIO='F-26',FILE='DISK114:[18ZFG1.18ZFG45201]FO45201A.;46',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<A NAME="page_fo45201_1_27"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table summarizes restricted stock activity for the period January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017 and the nine months ended September&nbsp;30, 2018
(unaudited): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="58pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Number of<BR>
shares</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Grant-date<BR>
fair value </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Unvested restricted common stock as of January&nbsp;24, 2017 (inception)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>696,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.0001</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Vested</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unvested restricted common stock as of December&nbsp;31, 2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>696,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.0001</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Granted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(406,001</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.0001 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Unvested restricted common stock as of September&nbsp;30, 2018 (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>289,999</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.0001 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>During
the period January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017, no shares of restricted common stock had vested. The Company accounted for the acceleration of vesting under the
amended restricted stock agreement as a modification of the original awards and recognized the remaining unvested shares prospectively over the revised vesting period. The total fair value of
restricted stock vested during the nine months ended September&nbsp;30, 2018 (unaudited) was insignificant. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-based compensation  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>During the period January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017, the Company did not grant any options and accordingly did not record
any stock-based compensation expense for the period January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017. The Company recorded total stock-based compensation for options granted during
the nine months ended September&nbsp;30, 2018 (unaudited) of $34, with $18 classified as research and development expense and $16 classified as general and administrative expense in the statements
of operations and comprehensive loss. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of September&nbsp;30, 2018 (unaudited), total unrecognized compensation cost related to the unvested stock-based awards was $451, which is expected to be recognized over weighted average periods
of 3.48&nbsp;years. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amgen license agreement  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In June 2018, the Company entered into a license agreement (the "Amgen Agreement") with Amgen pursuant to which the Company was granted an exclusive license to
certain patents and intellectual property related to a long-acting FGF21 analog in order to commercially develop, manufacture, use and distribute FGF21 as a treatment for NASH and other serious
metabolic diseases. The Amgen Agreement provides the Company with exclusive global rights to the licensed products and the right to grant sublicenses that cover AKR-001 to third parties. The Company
is obligated to use commercially reasonable efforts to develop and commercialize the licensed products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
exchange for these rights, the Company made an upfront payment of $5,000 and issued 2,653,333 shares of Series&nbsp;A Preferred Stock with a fair value of $1,353 to Amgen. The total consideration
transferred to Amgen under the agreement of $6,353 is included within research and development expense in the statements of operations and comprehensive loss. The Company accounted for the acquisition
of technology as an asset acquisition because it did not meet the definition of a business. The Company </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-27</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=226,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=69739,FOLIO='F-27',FILE='DISK114:[18ZFG1.18ZFG45201]FO45201A.;46',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<A NAME="page_fo45201_1_28"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>recorded
the total consideration transferred to Amgen as research and development expense in the statements of operations and comprehensive loss because the acquired technology represented in-process
research and development and had no alternative future use. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, under the Amgen Agreement, Amgen is entitled to a 10% ownership interest of the outstanding shares of the Company's common stock, on a fully diluted and converted basis as of the Second
Tranche Closing, provided that the percentage shall only be based on the First Tranche Closing and a maximum of $25,000 worth of shares of Series&nbsp;A Preferred Stock issued in the Second Tranche
Closing. The Company was obligated to issue additional shares of Series&nbsp;A Preferred Stock, or such other class or series of stock issued, until the Company had raised aggregate cumulative
proceeds of $25,000 from sales of equity securities. The Company assessed the Amgen anti-dilution right and determined that the right (i)&nbsp;meets the definition of a freestanding financial
instrument that was not indexed to the Company's own stock and (ii)&nbsp;meets the definition of a derivative and did not qualify for equity classification. The initial fair value of the
anti-dilution right liability of $1,639 was recorded as research and development expense in June 2018. The Company remeasured the liability associated with the anti-dilution right as of
September&nbsp;30, 2018 (unaudited) and determined that the fair value of the anti-dilution right liability was $2,671. The Company recognized a loss of $1,032 within other expense in the statements
of operations and comprehensive loss for the nine months ended September&nbsp;30, 2018 (unaudited), related to the change in fair value of the anti-dilution right liability. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
the Amgen Agreement, the Company is obligated to make aggregate milestone payments to Amgen of up to $40,000 upon the achievement of specified clinical and regulatory milestones and aggregate
milestone payments of up to $75,000 upon the achievement of specified commercial milestones for all products licensed under the agreement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
the Amgen Agreement, the Company is obligated to pay Amgen tiered royalties ranging from a low to high single-digit percentages on annual net sales of the licensed products, beginning on the
first commercial sale of such licensed products in each country and expiring on a country-by-country basis on the latest of (i)&nbsp;the expiration of the last valid patent claim covering such
licensed products in such country, (ii)&nbsp;the loss of regulatory exclusivity in such country, and (iii)&nbsp;ten years after the first commercial sale of such licensed product in such country.
The royalty payments are subject to reduction under specified conditions set forth in the agreement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company is solely responsible for all development, manufacturing, and commercial activities and costs of the licensed products, including clinical studies or other tests necessary to support the
use of a licensed product. The Company is also responsible for costs related to the filing, prosecution and maintenance of the licensed patent rights. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Amgen Agreement will remain in effect until the expiration of the royalty term in all countries for all licensed products. The agreement may be terminated by either party with at least
90&nbsp;days' notice in the event of material breach by the other party that remains uncured for 90&nbsp;days, by either party for insolvency or bankruptcy of the other party and immediately by
Amgen if the Company challenges the licensed patents. The Company may also terminate the agreement with 90&nbsp;days' written notice for discretionary reasons such as scientific, technical,
regulatory or commercial issues, as defined in the agreement. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-28</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=227,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=251270,FOLIO='F-28',FILE='DISK114:[18ZFG1.18ZFG45201]FO45201A.;46',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<A NAME="page_fo45201_1_29"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During
the nine months ended September&nbsp;30, 2018 (unaudited), the Company recorded research and development expense of $8,016 in connection with the Amgen Agreement, including the upfront cash
payment of $5,000, the fair value of $1,353 of shares of Series&nbsp;A Preferred Stock issued to Amgen, the fair value of $1,639 for the issuance of the anti-dilution right liability and $24 of
other research and development expenses. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes  </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 U.S. tax reform  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>On December&nbsp;22, 2017, the Tax Cuts and Jobs Act (the "TCJA") was signed into United States law. The TCJA includes a number of changes to existing tax
law, including, among other things, a permanent reduction in the federal corporate income tax rate from a top marginal tax rate of 35% to a flat rate of 21%, effective as of January&nbsp;1, 2018, as
well as limitation of the deduction for net operating losses to 80% of annual taxable income and elimination of net operating loss carrybacks, in each case, for losses arising in taxable years
beginning after December&nbsp;31, 2017 (though any such net operating losses may be carried forward indefinitely). The federal tax rate change resulted in a reduction in the gross amount of the
Company's deferred tax assets recorded as of December&nbsp;31, 2017 and a corresponding reduction in the Company's valuation allowance. As a result, no income tax expense or benefit was recognized
as of the enactment date of the TCJA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
staff of the Securities and Exchange Commission issued Staff Accounting Bulletin No.&nbsp;118 to address the application of U.S.&nbsp;GAAP in situations when a registrant does not have the
necessary information available, prepared or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the TCJA. The Company is still in the
process of analyzing the impact to the Company of the TCJA and its analysis is not yet complete. Where the Company has been able to make reasonable estimates of the effects related to the TCJA, the
Company has recorded provisional amounts. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
connection with the initial analysis of the impact of the TCJA, the Company remeasured its deferred tax assets and liabilities based on the rates at which they are expected to reverse in the
future, which is generally 21% for federal tax purposes. The remeasurement of the Company's deferred tax assets was offset by a change in the valuation allowance. All of the Company's recorded income
tax benefits and provisions related to the TCJA are provisional. The provisional amounts recorded by the Company are based on guidance, interpretations and other information available as of
December&nbsp;31, 2017. The impact of the changes in U.S. tax law may be refined as further guidance, interpretations or information becomes available or upon completion by the Company of its
evaluation of the impact of the changes in U.S. tax law. Provisional amounts will be finalized no later than the fourth quarter of 2018, which is one year from when the TCJA was signed into law. The
ultimate impact to the Company's financial statements of the TCJA may differ from the provisional amounts. During the nine months ended September&nbsp;30, 2018 (unaudited), the Company did not make
any adjustments to the provisional amounts recorded as a result of the TCJA. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income taxes  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>During the period January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017, the period January&nbsp;24, 2017 (inception) through
September&nbsp;30, 2017 (unaudited) and the nine months ended September&nbsp;30, 2018 (unaudited), the Company recorded no income tax benefits for the net operating losses incurred or for the
research and development tax credits generated in each period due to its uncertainty of realizing a benefit </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-29</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=228,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=850895,FOLIO='F-29',FILE='DISK114:[18ZFG1.18ZFG45201]FO45201A.;46',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<A NAME="page_fo45201_1_30"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>from
those items. All of the Company's operating losses since inception have been generated in the United States. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
summary of the Company's current and deferred tax provision is as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="102pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception) through<BR>
December&nbsp;31,<BR>
2017 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Current income tax provision:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Federal</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 State</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current income tax provision</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Deferred income tax benefit:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Federal</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,045</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 State</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(317</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total deferred income tax benefit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,362</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Change in deferred tax asset valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,362 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total provision for income taxes</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>A
reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate is as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="102pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception) through<BR>
December&nbsp;31,<BR>
2017 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Federal statutory income tax rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>34.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>State income taxes, net of federal benefit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Research and development tax credits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other permanent differences</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(0.0)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Remeasurement of deferred taxes due to the TCJA</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(12.0)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in deferred tax asset valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(29.8) </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Effective income tax rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (0.0)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-30</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=229,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=928400,FOLIO='F-30',FILE='DISK114:[18ZFG1.18ZFG45201]FO45201A.;46',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<A NAME="page_fo45201_1_31"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Net
deferred tax assets as of December&nbsp;31, 2017 consisted of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="72pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>December&nbsp;31,<BR>
2017 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Net operating loss carry forwards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,243</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development tax credit carry forwards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>119 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Total deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,362</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,362</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2017, the Company had U.S. federal and state net operating loss carryforwards of $4,561 and $4,521, respectively, which may be available to offset future taxable income and
begin to expire in 2027. As of December&nbsp;31, 2017, the Company also had U.S. federal and state research and development tax credit carryforwards of $87 and $40, respectively, which may be
available to offset future tax liabilities and begin to expire in 2027. During the nine months ended September&nbsp;30, 2018 (unaudited), gross deferred tax assets, before valuation allowance,
increased by approximately $14,222 due to the operating loss incurred by the Company during that period. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Utilization
of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under
Sections&nbsp;382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future.
These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by
Section&nbsp;382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has
not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated
with such a study. If the Company has experienced a change of control, as defined by Section&nbsp;382, at any time since inception, utilization of the net operating loss carryforwards or research
and development tax credit carryforwards would be subject to an annual limitation under Section&nbsp;382, which is determined by first multiplying the value of the Company's stock at the time of the
ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net
operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are
being presented as an uncertain tax position. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company's history of cumulative net losses
incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the
Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December&nbsp;31, 2017 and
September&nbsp;30, 2018 (unaudited). Management reevaluates the positive and negative evidence at each reporting period. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-31</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=230,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=233117,FOLIO='F-31',FILE='DISK114:[18ZFG1.18ZFG45201]FO45201A.;46',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<A NAME="page_fo45201_1_32"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Changes
in the valuation allowance for deferred tax assets during the period ended December&nbsp;31, 2017 related primarily to the increase in net operating loss carryforwards and research and
development tax credit carryforwards in and 2017, and the impact of the TCJA in 2017, and were as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="72pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>December&nbsp;31,<BR>
2017 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Valuation allowance as of January&nbsp;24, 2017 (inception)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increases recorded to income tax provision</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>593</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Decreases recorded as a benefit to income tax provision</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,955</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Valuation allowance as of December&nbsp;31, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,362</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited), the Company had not recorded any amounts for unrecognized tax benefits. The Company's policy is to record interest and
penalties related to income taxes as part of its income tax provision. As of December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited), the Company had no accrued interest or penalties
related to uncertain tax positions and no amounts had been recognized in the Company's statements of operations and comprehensive loss. The Company files income
tax returns in the U.S. and Massachusetts, as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal
and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under statute from 2017 to the present. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>10.&nbsp;&nbsp;&nbsp;Net loss per share and unaudited pro forma net loss per share  </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net loss per share  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Basic and diluted net loss per share attributable to common stockholders was calculated as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="102pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="102pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception) through<BR>
December&nbsp;31,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception) through<BR>
September&nbsp;30,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Nine months<BR>
ended<BR>
September&nbsp;30,<BR>
2018 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>(unaudited) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Numerator:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,564</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,019</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(20,242</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Accruing dividends on redeemable convertible preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(213</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(166</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of redeemable convertible preferred stock to redemption value</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(321</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,777</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,185</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(20,563</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Denominator:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Weighted average common shares outstanding&#151;basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>267,108 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share attributable to common stockholders&#151;basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(76.98</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-32</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=231,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=483367,FOLIO='F-32',FILE='DISK114:[18ZFG1.18ZFG45201]FO45201A.;46',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fq45201_1_33"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fq45201_akero_therapeutics,_inc._notes__ake04170"> </A>
<A NAME="toc_fq45201_1"> </A></FONT> <FONT SIZE=3><B><BR>  Akero Therapeutics, Inc.<BR>  Notes to Financial Statements<BR>  (Amounts in thousands, except share and per share data)  <BR>        <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of December&nbsp;31, 2017, there were no vested shares of common stock outstanding. Therefore, net loss per share attributable to common stockholders, basic and diluted,
is not presented for the periods January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017 and January&nbsp;24, 2017 (inception) through September&nbsp;30, 2017 (unaudited). The table
above only reflects the net loss per share attributable to common stockholders, basic and diluted, for the nine months ended September&nbsp;30, 2018 (unaudited). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company excluded 428,892 shares of restricted common stock, presented on a weighted average basis, from the calculations of basic net loss per share attributable to common stockholders for nine
months ended September&nbsp;30, 2018 (unaudited), respectively, because those shares had not vested. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior
to the execution of the 2018 Series&nbsp;A Agreement in June 2018, the holders of Series&nbsp;A Preferred Stock were entitled to cumulative dividends of $0.08 per share, or 8%. The
cumulative accrual of dividends on Series&nbsp;A Preferred Stock are included in the calculation of net loss attributable to common stockholders for the period January&nbsp;24, 2017 (inception)
through December&nbsp;31, 2017 and the period January&nbsp;24, 2017 (inception) through September&nbsp;30, 2017 (unaudited), however, were not presented for the nine months ended
September&nbsp;30, 2018 (unaudited) after the June 2018 Amendment to our Certificate of Incorporation in which the cumulative dividends clause was removed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company's potentially dilutive securities, which include stock options, unvested restricted common stock and redeemable convertible preferred stock, have been excluded from the computation of
diluted net loss per share attributable to common stockholders as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to
calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding
at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="105pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="105pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception) through<BR>
December&nbsp;31,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception) through<BR>
September&nbsp;30,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Nine months<BR>
ended<BR>
September&nbsp;30,<BR>
2018 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (unaudited) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Options to purchase common stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,277,264</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unvested restricted common stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>696,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>696,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>289,999</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Redeemable convertible preferred stock (as converted to common stock)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>22,653,333 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,696,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,696,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>25,220,597 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Unaudited pro forma net loss per share  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Unaudited pro forma basic and diluted net loss per share attributable to common stockholders for the period January&nbsp;24, 2017 (inception) through
December&nbsp;31, 2017 and the nine months ended September&nbsp;30, 2018 have been prepared to give effect to adjustments arising upon the closing of an IPO. Unaudited pro forma net loss
attributable to common stockholders used in the calculation of unaudited pro forma basic and diluted net loss per share attributable to common stockholders does not include the effects of
(i)&nbsp;the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-33</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=232,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=220057,FOLIO='F-33',FILE='DISK114:[18ZFG1.18ZFG45201]FQ45201A.;35',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<A NAME="page_fq45201_1_34"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>cumulative
accruing dividends on Preferred Stock during the period January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017, (ii)&nbsp;the change in fair value of the preferred stock
tranche obligation and (iii)&nbsp;the accretion of Preferred Stock to redemption value because the calculation gives effect to the conversion of all shares of Preferred Stock as if the proposed IPO
had occurred on the later of January&nbsp;1, 2017 or the issuance date of the Preferred Stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unaudited
pro forma basic and diluted weighted average common shares outstanding used in the calculations of unaudited pro forma basic and diluted net loss per share attributable to common
stockholders for the period January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017 and nine months ended September&nbsp;30, 2018 have been prepared to give effect, upon an IPO, to the
automatic conversion of all outstanding shares of Preferred Stock into shares of common stock as if the proposed IPO had occurred on the later of January&nbsp;1, 2017 or the issuance date of the
Preferred Stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unaudited
pro forma basic and diluted net loss per share attributable to common stockholders was calculated as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="105pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception) through<BR>
December&nbsp;31,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Nine months<BR>
ended<BR>
September&nbsp;30,<BR>
2018 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (unaudited) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Numerator:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,777</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(20,563</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Accruing dividends on redeemable convertible preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>213</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of redeemable convertible preferred stock to redemption value</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>321</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Change in fair value of preferred stock tranche obligation</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>8,400 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,564</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(11,842</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Denominator:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding&#151;basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>267,108 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Pro forma adjustment to reflect automatic conversion of redeemable convertible preferred stock into common stock upon the closing of the proposed IPO</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,661,730</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12,436,386 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma weighted average common shares outstanding&#151;basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,661,730</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12,703,494 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Pro forma net loss per share attributable to common stockholders&#151;basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1.71</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.93</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-34</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=233,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=271695,FOLIO='F-34',FILE='DISK114:[18ZFG1.18ZFG45201]FQ45201A.;35',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<A NAME="page_fq45201_1_35"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>11.&nbsp;&nbsp;&nbsp;Commitments and contingencies  </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Lease agreements  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>During the period January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017 and the nine months ended September&nbsp;30, 2018 (unaudited) the
Company did not enter into any lease agreements and incurred no rent expense. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company entered into a use and occupancy agreement for its new office space on August&nbsp;15, 2018, with Atlas Venture Life Science Advisors,&nbsp;LLC, a related party (See Note&nbsp;12).
The agreement commenced on August&nbsp;15, 2018 and continues for an initial 9-month period after which the agreement becomes cancelable by either party upon 60&nbsp;days written notice. Monthly
lease payments include base rent for the office space of approximately $12 annually and non-rent shared tenant occupancy costs. The Company recognizes rent expense on a straight-line basis over the
lease period and has recorded rent expense of $3 for the nine months ended September&nbsp;30, 2018 (unaudited). As of September&nbsp;30, 2018 (unaudited), total future minimum commitments due
under the lease are $8, with $3 due in the remaining months of 2018 and $5 due in 2019. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and manufacturing commitments  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>During the nine months ended September&nbsp;30, 2018 (unaudited), the Company entered into agreements with contract research organizations and contract
manufacturing organizations to provide services in connection with its nonclinical studies and clinical trials and to manufacture clinical development materials, respectively. As of
September&nbsp;30, 2018 (unaudited), the Company had non-cancelable purchase commitments under these agreements totaling $473. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indemnification agreements  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other
parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In
addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them
against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under
these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any
indemnification claims and has not accrued any liabilities related to such obligations in its financial statements as of December&nbsp;31, 2017 or September&nbsp;30, 2018 (unaudited). </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Legal proceedings  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. At each reporting date, the
Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting
for contingencies. The Company expenses as incurred the costs related to such legal proceedings. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-35</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=234,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=625711,FOLIO='F-35',FILE='DISK114:[18ZFG1.18ZFG45201]FQ45201A.;35',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<A NAME="page_fq45201_1_36"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>12.&nbsp;&nbsp;&nbsp;Related party transactions  </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Apple Tree Life Sciences,&nbsp;Inc.  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>During the period January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017 and nine months ended September&nbsp;30, 2018 (unaudited), the
Company issued 5,000,000 shares and 3,000,000 shares, respectively, of Series&nbsp;A Preferred Stock to Apple Tree Partners IV,&nbsp;L.P. ("Apple Tree"). A partner of Apple Tree Life
Sciences,&nbsp;Inc. ("ATLS") has served on the Company's board of directors since June 2018. The Company's founders, including the current Executive Vice President and Chief Operating Officer and
Chief Scientific Officer, were formerly employees of ATLS until April 2017. From inception to September 2017, the Company received certain services from ATLS, including consulting, finance, human
resources, legal, and other operational support, as well as research and development recruiting expenses. ATLS charged the Company a service fee consisting of allocated internal time incurred on
behalf of the Company by ATLS
employees, plus a pre-determined mark-up. Further, the Company paid or reimbursed ATLS at cost for any expenses incurred by third parties on its behalf. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Expenses
from services rendered by ATLS, inclusive of the mark-up, are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="107pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="105pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception) through<BR>
December&nbsp;31,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>For the period<BR>
January&nbsp;24, 2017<BR>
(inception) through<BR>
September&nbsp;30,<BR>
2017</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Nine months<BR>
ended<BR>
September&nbsp;30,<BR>
2018 </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (unaudited)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B> (unaudited) </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Research and development expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,750</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,750</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>348</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>340</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,098</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,090</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited), the Company did not owe any amounts to Apple Tree. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Atlas Venture Life Science Advisors,&nbsp;LLC  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In June 2018, the Company issued 4,000,000 shares of Series&nbsp;A Preferred Stock to Atlas Venture Fund XI,&nbsp;L.P. ("Atlas") and a principal of Atlas
was elected to the board of directors. During the nine months ended September&nbsp;30, 2018 (unaudited), the Company incurred fees for certain research and development consulting services from Atlas
totaling $18. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
August 2018, the Company entered into a use and occupancy agreement for its new office space with Atlas. The agreement commences on August&nbsp;15, 2018 and continues for an initial 9-month
period after which the agreement becomes cancelable by either party upon 60&nbsp;days written notice. Base rent for the office space is approximately $12 annually (See Note&nbsp;11). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of September&nbsp;30, 2018 (unaudited), the Company owed $11 to Atlas, which was included in accrued expenses in its balance sheets. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-36</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=235,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=584071,FOLIO='F-36',FILE='DISK114:[18ZFG1.18ZFG45201]FQ45201A.;35',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<A NAME="page_fq45201_1_37"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>13.&nbsp;&nbsp;&nbsp;Benefit plans  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company established a defined contribution savings plan under Section&nbsp;401(k) of the Internal Revenue Code. This plan covers all employees who meet
minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Matching contributions to the plan may be made at the discretion of the
Company's board of directors. The Company made no contributions to the plan during the period January&nbsp;24, 2017 (inception) through December&nbsp;31, 2017, the period January&nbsp;24, 2017
(inception) through September&nbsp;30, 2017 (unaudited) and the nine months ended September&nbsp;30, 2018 (unaudited), respectively. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=3><B>14.&nbsp;&nbsp;&nbsp;Subsequent events  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For its financial statements as of December&nbsp;31, 2017 and for the period then ended and for its interim financial statements as of September&nbsp;30,
2018 and for the nine months then ended, the Company evaluated subsequent events through January&nbsp;17, 2019, the date on which those financial statements were issued. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock option grants  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In October 2018, the Company granted options to employees for the purchase of 3,511,645 shares of common stock at an exercise price of $0.20 per share. The
options have service-based vesting conditions and vest over a term of four years. The aggregate grant-date fair value of these options was $1,009, which is expected to be recognized as stock-based
compensation expense over a period of four years from the date of grant. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Lease agreements  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In October 2018, the Company entered into a lease agreement for office space in San Francisco, California. The lease expires in April 2019 with an option to
automatically renew for successive
30 day periods. Monthly lease payments to be paid under the agreement total $5 which are subject to a 3% annual increase if the lease has not yet expired or been terminated. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sale of Series&nbsp;A Preferred Stock  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In November 2018, upon the waiver of the Milestone Event through written elections by a majority of the shareholders of Series&nbsp;A Preferred Stock, the
Company closed the second tranche of its Series&nbsp;A preferred financing through the issuance and sale of an aggregate of 25,000,000 shares of Series&nbsp;A Preferred Stock, at an issuance price
of $1.00 per share, for proceeds of $25,000,000 before issuance costs of $5. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2018, in connection with the Company's issuance and sale of Series&nbsp;A Preferred Stock, the Company satisfied its obligation to issue additional shares under the Second Tranche
Closing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2018, as pursuant to the terms of the Amgen Agreement, the Company issued an additional 3,205,128 shares of Series&nbsp;A Preferred Stock to Amgen upon completion of the Series&nbsp;A
second closing and satisfied its obligation to issue additional shares of Series&nbsp;A Preferred Stock, or such other class or series of stock issued, until the Company has raised aggregate
cumulative proceeds of $25,000 from sales of equity securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-37</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=236,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=758225,FOLIO='F-37',FILE='DISK114:[18ZFG1.18ZFG45201]FQ45201A.;35',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<A NAME="page_fq45201_1_38"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B><BR>
Akero Therapeutics, Inc.<BR>
Notes to Financial Statements<BR>
(Amounts in thousands, except share and per share data) </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sale of Series&nbsp;B Preferred Stock  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In December 2018, the Company issued and sold 13,871,948 shares of Series&nbsp;B Preferred Stock, at an issuance price of $3.28 per share, for proceeds of
approximately $45,500 before issuance costs of $219. The rights and preferences of the Series&nbsp;B Preferred Stock are similar to the Company's Series&nbsp;A Preferred Stock, except that, the
redemption rights associated with the Series&nbsp;A Preferred Stock were terminated and in the event of any voluntary or involuntary liquidation event, dissolution, winding up of the Company or
Deemed Liquidation Event, each holder of then outstanding Series&nbsp;A and Series&nbsp;B Preferred Stock will be entitled to receive a pro rata share before any payment shall be made to the
holders of Common Stock of an amount equal to the greater of (i)&nbsp;the Original Issue Price plus any dividends declared but unpaid thereon, or (ii)&nbsp;the amount per share that would have
been payable had all shares of preferred stock been converted into common stock immediately prior to such liquidation, dissolution, winding-up or Deemed Liquidation Event. The Original Issue Price of
the Series&nbsp;B preferred stock are $3.28 per share. Dividends accrue on Series&nbsp;B Preferred Stock at a rate of $0.2624 per share subject to appropriate adjustment in the event of any stock
dividend, stock split, combination or other similar recapitalization with respect to the Series&nbsp;B Preferred Stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
December 2018, in connection with the Company's issuance and sale of Series&nbsp;B Preferred Stock, the Company terminated the option to purchase Series&nbsp;A Preferred Stock provided under
the 2018 Series&nbsp;A Agreement. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Decrease in shares available for issuance  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In December 2018, the Company effected a decrease in the total number of shares of the Company's common stock authorized and Preferred stock authorized to
75,000,000 and 64,730,410, respectively. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Increase in shares available for grant of stock options under 2018 Plan  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In December 2018, the Company effected an increase in the total number of shares of the Company's common stock reserved for issuance under the 2018 Plan from
3,184,000 to 9,443,760. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Akero Securities Corporation  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In December 2018, Akero Securities Corporation ("Akero Securities") was incorporated under the laws of Massachusetts. The principal activities of this company
is to engage exclusively in buying, selling, dealing in or holding securities on its own behalf. Akero Securities is authorized to issue 1,000 shares of common stock at $0.0001 per share. In December
2018, the Company entered into a subscription agreement with Akero Securities and purchased all the authorized shares of common stock at par value which resulted in Akero Securities becoming a wholly
owned subsidiary of the Company. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-38</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=237,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=524519,FOLIO='F-38',FILE='DISK114:[18ZFG1.18ZFG45201]FQ45201A.;35',USER='MTITUSS',CD='17-JAN-2019;09:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> <div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=5><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=5><B>
<IMG SRC="g480743.jpg" ALT="LOGO" WIDTH="352" HEIGHT="109">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=5><B><I>Common stock  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=6><B>Prospectus  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4><B>J.P. Morgan</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4><B>Jefferies</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4><B>Evercore ISI</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Roth Capital Partners  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=238,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=805454,FOLIO='blank',FILE='DISK114:[18ZFG1.18ZFG45201]HO45201A.;13',USER='MTITUSS',CD='17-JAN-2019;11:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ja45201_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B> <A NAME="ja45201_part_ii"> </A>
<A NAME="toc_ja45201_1"> </A> </B></FONT><FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Part II    <BR>  </B></FONT></P>

<P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Information not required in prospectus  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="ja45201_item_13._other_expense__ja401985"> </A>
<A NAME="toc_ja45201_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;Other expenses of issuance and distribution.    <BR>    </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth the fees and expenses, other than underwriting discounts and commissions, payable in connection with the registration of the
common stock hereunder. All amounts are estimates except the SEC registration fee, FINRA filing fee and Nasdaq Global Market listing fee. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

</FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Amount<BR>
to be paid </B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><b>



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

</B></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2><B></b></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SEC registration fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FINRA filing fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nasdaq Global Market listing fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Printing and engraving expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounting fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Transfer agent and registrar fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miscellaneous</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>* </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>* </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
be completed by amendment. </FONT></P>
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2><A
NAME="ja45201_item_14._indemnification_of_directors_and_officers."> </A>
<A NAME="toc_ja45201_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of directors and officers.    <BR>    </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Section&nbsp;145
of the Delaware General Corporation Law (the "DGCL") authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions,
suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The
indemnity may cover expenses (including attorneys' fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action,
suit or proceeding. Section&nbsp;145 permits corporations to pay expenses (including attorneys' fees) incurred by directors and officers in advance of the final disposition of such action, suit or
proceeding. In addition, Section&nbsp;145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against
them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer
against such liability under Section&nbsp;145. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have adopted provisions in our certificate of incorporation to be in effect upon the completion of this offering and bylaws to be in effect upon the effectiveness of this registration statement
that limit or eliminate the personal liability of our directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be
personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any breach of the director's duty of loyalty to us or our stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=239,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=60709,FOLIO='II-1',FILE='DISK114:[18ZFG1.18ZFG45201]JA45201A.;23',USER='SCAVALI',CD='17-JAN-2019;13:59' -->
<A NAME="page_ja45201_1_2"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any transaction from which the director derived an improper personal benefit. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>These
limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
addition, our bylaws provide that:</FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the fullest extent permitted
by the DGCL, as it now exists or may in the future be amended; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we will advance reasonable expenses, including attorneys' fees, to our directors and, in the discretion of our board of directors, to our
officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
have entered into indemnification agreements with each of our directors and intend to enter into such agreements with our executive officers. These agreements provide that we will indemnify each of
our directors, our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys' fees (but excluding judgments,
fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and we will indemnify our directors
and officers for any action or proceeding arising out of that person's services as a director or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors
or officers may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to
the same proceedings arising out of such director's or officer's services as a director referenced herein. Nonetheless, we have agreed in the indemnification agreements that our obligations to those
same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those
directors are secondary. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
also maintain general liability insurance which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or
officers, including liabilities under the Securities Act of 1933, as amended (the "Securities Act"). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriting agreement filed as Exhibit&nbsp;1.1 to this registration statement provides for indemnification of us and our directors and officers by the underwriters against certain liabilities
under the Securities Act and the Securities Exchange Act of 1934.  </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="ja45201_item_15._recent_sales_of_unregistered_securities."> </A>
<A NAME="toc_ja45201_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;Recent sales of unregistered securities.    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since our inception on January&nbsp;24, 2017, we have issued the following securities that were not registered under the Securities Act: </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2><B>(a)</B></FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B>Issuances of capital stock</B></FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Set
forth below is information regarding securities we have issued within the past three years that were not registered under the Securities Act. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=240,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=411929,FOLIO='II-2',FILE='DISK114:[18ZFG1.18ZFG45201]JA45201A.;23',USER='SCAVALI',CD='17-JAN-2019;13:59' -->
<A NAME="page_ja45201_1_3"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2>In
June 2018, with subsequent filings in November 2018, we issued and sold an aggregate of 50,858,462 Series&nbsp;A preferred shares at a price per share of $1.00 for aggregate cash consideration of
approximately $45.0&nbsp;million; including an aggregate of 5,858,461 shares of common stock to an accredited investor in connection with the Amgen License. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
December 2018, we issued and sold an aggregate of 13,871,948 Series&nbsp;B preferred shares at a price per share of $3.28 for aggregate cash consideration of approximately $45.5&nbsp;million. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No
underwriters were involved in the foregoing sales of securities. Unless otherwise stated, the sales of securities described above were deemed to be exempt from registration pursuant to
Section&nbsp;4(a)(2) of the Securities Act, including Regulation&nbsp;D and Rule&nbsp;506 promulgated thereunder, as transactions by an issuer not involving a public offering. All of the
purchasers in these transactions represented to us in connection with their purchase that they were acquiring the securities for investment and not distribution, that they could bear the risks of the
investment and could hold the securities for an indefinite period of time. Such purchasers received written disclosures that the securities had not been registered under the Securities Act and that
any resale must be made pursuant to a registration or an available exemption from such registration. All of the foregoing securities are deemed restricted securities for the purposes of the Securities
Act.  </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2><B>(a)</B></FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><B>Grants and exercises of stock options</B></FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
have granted stock options to purchase an aggregate of 5,788,909 shares of our common stock, with an exercise price of $0.20 per share, to employees, directors and consultants pursuant to the 2018
Plan. Since 2018, 38,694 shares of common stock have been issued upon the exercise of stock options pursuant to the 2018 Plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
issuances of the securities described above were deemed to be exempt from registration pursuant to Section&nbsp;4(a)(2) of the Securities Act or Rule&nbsp;701 promulgated under the Securities
Act as transactions pursuant to compensatory benefit plans. The shares of common stock issued upon the exercise of options are deemed to be restricted securities for purposes of the Securities Act. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=241,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=569925,FOLIO='II-3',FILE='DISK114:[18ZFG1.18ZFG45201]JA45201A.;23',USER='SCAVALI',CD='17-JAN-2019;13:59' -->
<A NAME="page_ja45201_1_4"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</FONT><P style="font-family:arial;"><FONT SIZE=2><A
NAME="ja45201_item_16._exhibits_and_financial_statement_schedules."> </A>
<A NAME="toc_ja45201_5"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits and financial statement schedules.    <BR>    </B></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>Exhibits </FONT></DD></DL>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 2.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 2.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2><B>Exhibit<BR>
number</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Description </B></FONT><BR></TH>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;<font><B>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </B></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B></b></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Underwriting Agreement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Third Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Fourth Amended and Restated Certificate of Incorporation of Registrant, to be in effect prior to the completion of this offering.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.3</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Amended and Restated Bylaws of the Registrant, as currently in effect.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Second Amended and Restated Bylaws of the Registrant, to be in effect prior to the completion of this offering.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Specimen Common Stock Certificate.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Second Amended and Restated Investors' Rights Agreement among the Registrant and certain of its stockholders, dated December&nbsp;10, 2018.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Opinion of Goodwin Procter&nbsp;LLP.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>#</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>2018 Stock Option and Grant Plan, and form of award agreements thereunder.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>#*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>2019 Stock Option and Grant Plan, and form of award agreements thereunder.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>#*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>2019 Employee Stock Purchase Plan.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>#*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Sublease Agreement between the Registrant and Trucode Gene Repair,&nbsp;Inc., dated October&nbsp;23, 2018</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>#*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Employment Agreement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Exclusive License Agreement, by and between the Registrant and Amgen&nbsp;Inc., dated June&nbsp;7, 2018</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>21.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>List of Subsidiaries of the Registrant.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Consent of Deloitte&nbsp;&amp; Touche LLP, independent registered public accounting firm.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>23.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Consent of Goodwin Procter&nbsp;LLP (included in Exhibit&nbsp;5.1).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>24.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Power of Attorney (included on signature page). </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
be filed by amendment.  </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#134;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Application
has been made to the Securities and Exchange Commission for confidential treatment of certain provisions. Omitted material for which confidential treatment has
been requested has been filed separately with the Securities and Exchange Commission.  </FONT></P>


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">#&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicates
a management contract or any compensatory plan, contract or arrangement. </FONT></P>
 </DIV>
 <DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>Financial
Statements Schedules: </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>Schedules
have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=242,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=759324,FOLIO='II-4',FILE='DISK114:[18ZFG1.18ZFG45201]JA45201A.;23',USER='SCAVALI',CD='17-JAN-2019;13:59' -->
<A NAME="page_ja45201_1_5"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P style="font-family:arial;"><FONT SIZE=2><A
NAME="ja45201_item_17._undertakings."> </A>
<A NAME="toc_ja45201_6"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;Undertakings.    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, or the Act, may be permitted to directors, officers and
controlling persons of the Registrant
pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a
director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with
the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Registrant hereby undertakes that: </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>(a)&nbsp;&nbsp;&nbsp;&nbsp;The
Registrant will provide to the underwriter at the closing as specified in the underwriting agreement, certificates in such denominations and registered in such names as required
by the underwriter to permit prompt delivery to each purchaser. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>(b)&nbsp;&nbsp;&nbsp;For
purposes of determining any liability under the Securities Act of 1933, as amended, the information omitted from a form of prospectus filed as part of this registration statement
in reliance upon Rule&nbsp;430A and contained in the form of prospectus filed by the Registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act of 1933, as
amended, shall be deemed to be part of this registration statement as of the time it was declared effective. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>(c)&nbsp;&nbsp;&nbsp;&nbsp;For
the purpose of determining any liability under the Securities Act of 1933, as amended, each post-effective amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=243,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=8214,FOLIO='II-5',FILE='DISK114:[18ZFG1.18ZFG45201]JA45201A.;23',USER='SCAVALI',CD='17-JAN-2019;13:59' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_jc45201_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A> </FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B> <A NAME="jc45201_signatures"> </A>
<A NAME="toc_jc45201_1"> </A> </B></FONT><FONT SIZE=4><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Signatures    <BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement on Form&nbsp;S-1 to
be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, California, on the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019.
 </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="20pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="37pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="39%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=5 style="font-family:arial;"><FONT SIZE=2><B> AKERO THERAPEUTICS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:arial;"><p style="font-family:arial;margin-top:13pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2>  </FONT><FONT SIZE=2>&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Name:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Andrew Cheng, M.D., Ph.D.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Title:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><I> President, Chief Executive Officer and Director</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:12.0pt;text-indent:-12.0pt;"><FONT SIZE=3><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:12.0pt;text-indent:-12.0pt;" -->


Power of attorney and signatures  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Each individual whose signature appears below hereby constitutes and appoints Andrew Cheng and Jonathan Young as such person's true and lawful
attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person's name, place and stead, in any and all capacities, to sign any and all amendments
(including post-effective amendments) to this Registration Statement (or any Registration Statement for the same offering that is to be effective upon filing pursuant to Rule&nbsp;462(b) under the
Securities Act of 1933), and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said
attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as
such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be
done by virtue hereof. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to the requirements of the Securities Act of 1933, as amended, this Registration Statement and Power of Attorney has been signed by the following person in the capacities and on the date
indicated. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="38%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="102pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=2><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=2><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=2><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Andrew Cheng, M.D., Ph.D.</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2>President, Chief Executive Officer and Director (Principal Executive Officer)</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Jonathan Young, J.D., Ph.D.</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>Executive Vice President, Chief Operating Officer (Principal Financial Officer and Principal Accounting Officer)</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Kevin Bitterman, Ph.D.</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=244,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=368269,FOLIO='II-6',FILE='DISK114:[18ZFG1.18ZFG45201]JC45201A.;10',USER='SMENEZE',CD='16-JAN-2019;21:30' -->
<A NAME="page_jc45201_1_7"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg45201a_main_toc">Table of Contents</A></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Confidential Treatment Requested by Akero Therapeutics, Inc.<BR>
Pursuant to 17 C.F.R. Section 200.83 </B></FONT></P>
 <font color="??????" style="display:none;">&#8203;</font>

 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="38%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="38%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="102pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=2><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=2><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=2><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Mark Iwicki</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Aaron Kantoff</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Aaron Royston, M.D.</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Graham Walmsley, M.D., Ph.D.</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=245,EFW="2237524",CP="AKERO THERAPEUTICS",DN="1",CHK=267454,FOLIO='II-7',FILE='DISK114:[18ZFG1.18ZFG45201]JC45201A.;10',USER='SMENEZE',CD='16-JAN-2019;21:30' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 3.1<a name="41952-2-KG-01_Exhibit3_1_043604"></a></font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THIRD AMENDED AND RESTATED</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATE OF INCORPORATION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OF</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AKERO THERAPEUTICS,&nbsp;INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(Pursuant to Sections 242 and 245 of the</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">General Corporation Law of the State of Delaware)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Akero Therapeutics,&nbsp;Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the &#147;<b>General Corporation Law</b>&#148;),</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DOES HEREBY CERTIFY:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>That the name of this corporation is Akero Therapeutics,&nbsp;Inc. and that this corporation was originally incorporated pursuant to the General Corporation Law on January&nbsp;24, 2017 under the name Pippin Pharmaceuticals,&nbsp;Inc., its name was changed to Pippin Therapeutics,&nbsp;Inc. on February&nbsp;6, 2017 and its name was again changed to Akero Therapeutics,&nbsp;Inc. on May&nbsp;16, 2018.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>That the Board of Directors duly adopted resolutions proposing to amend and restate the Second Amended and Restated Certificate of Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RESOLVED</font></b>, that the Second Amended and Restated Certificate of Incorporation of this corporation be amended and restated in its entirety to read as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FIRST:&#160; </font></b>&#160;The name of this corporation is Akero Therapeutics,&nbsp;Inc.&#160; (the &#147;<b>Corporation</b>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SECOND:&#160; </font></b>&#160;The address of the Corporation&#146;s registered office in the State of Delaware is located at 1209 Orange Street, Wilmington, Delaware, 19801, New Castle County.&#160; The name of the registered agent at such address is The Corporation Trust Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THIRD:&#160; </font></b>&#160;The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FOURTH:&#160; </font></b>&#160;The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i)&nbsp;75,000,000&#160; shares of Common Stock, $0.0001 par value per share (&#147;<b>Common Stock</b>&#148;) and (ii)&nbsp;64,730,410 shares of Preferred Stock, $0.0001 par value per share (&#147;<b>Preferred Stock</b>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following is a statement of the designations and the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=29337,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:37 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>COMMON STOCK</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>General</u>.&#160; The voting, dividend and liquidation rights of the holders of Common Stock are subject to and qualified by the rights, powers and preferences of the holders of Preferred Stock set forth herein.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Voting</u>.&#160; The holders of the Common Stock are entitled to one vote for each share of Common Stock held at all meetings of stockholders (and written actions in lieu of meetings); <u>provided</u>, <u>however</u>, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Third Amended and Restated Certificate of Incorporation that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to this Third Amended and Restated Certificate of Incorporation or pursuant to the General Corporation Law. There shall be no cumulative voting. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Preferred Stock that may be required by the terms of this Third Amended and Restated Certificate of Incorporation) the affirmative vote of the holders of a majority of the shares of capital stock of the Corporation, irrespective of the provisions of Section&nbsp;242(b)(2)&nbsp;of the General Corporation Law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">B.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>PREFERRED STOCK</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">50,858,462 shares of the authorized and unissued Preferred Stock of the Corporation are hereby designated&#160; &#147;<b>Series&nbsp;A Preferred Stock</b>&#148; with the following rights, preferences, powers, privileges and restrictions, qualifications and limitations.&#160; 13,871,948 shares of the authorized and unissued Preferred Stock of the Corporation are hereby designated&#160; &#147;<b>Series&nbsp;B Preferred Stock</b>&#148; with the following rights, preferences, powers, privileges and restrictions, qualifications and limitations. Unless otherwise indicated, references to &#147;sections&#148; or &#147;subsections&#148; in this Part&nbsp;B of this Article&nbsp;Fourth refer to sections and subsections of Part&nbsp;B of this Article&nbsp;Fourth.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Dividends</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>From and after the date of the issuance of any shares of Series&nbsp;A Preferred Stock, dividends (the &#147;<b>Series&nbsp;A Preferred Dividends</b>&#148;) at the rate per annum of $0.080 per share of Series&nbsp;A Preferred Stock subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&nbsp;A Preferred Stock, shall be payable, in any calendar year when and as declared by the Corporation&#146;s Board of Directors (the &#147;<b>Board of Directors</b>&#148;), out of any assets legally available therefor.&#160; From and after the date of the issuance of any shares of Series&nbsp;B Preferred Stock, dividends (the &#147;<b>Series&nbsp;B Preferred Dividends</b>&#148; and collectively with the Series&nbsp;A Preferred Dividends, the &#147;<b>Preferred Dividends</b>&#148;) at the rate per annum of $0.2624 per share of Series&nbsp;B Preferred Stock subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&nbsp;B Preferred Stock, shall be payable, in any calendar year when and as declared by the Board of Directors, out of any assets legally available therefor.&#160; The Preferred Dividends will be paid out on a pari passu basis.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends on</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="41952-2-KG-01_PB_2_043858_6847"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=850717,FOLIO='2',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:37 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in this Third Amended and Restated Certificate of Incorporation) the holders of Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Preferred Stock in an amount at least equal to the greater of (i)&nbsp;the amount of the Preferred Dividend for such share of Preferred Stock not previously paid during the applicable fiscal year of the Corporation and (ii)&nbsp;in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of such series of Preferred Stock as would equal the product of (A)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (B)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of such series of Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (ii)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of each series of Preferred Stock determined by (A)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (B)&nbsp;multiplying such fraction by an amount equal to the applicable Original Issue Price (as defined below); <u>provided</u> that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend payable to the holders of Preferred Stock pursuant to this <u>Section&nbsp;1</u> shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest dividend to such holders of each series of Preferred Stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The &#147;<b><font style="font-weight:bold;">S</font>eries&nbsp;A Original Issue Price</b>&#148; shall mean $1.00 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&nbsp;A Preferred Stock. The &#147;<b>Series&nbsp;B Original Issue Price</b>&#148; shall mean $3.28 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&nbsp;B Preferred Stock. For purposes hereof, the &#147;<b>Original Issue Price</b>&#148; shall mean the Series&nbsp;A Original Issue Price, in the case of the Series&nbsp;A Preferred Stock, and the Series&nbsp;B Original Issue Price, in the case of the Series&nbsp;B Preferred Stock, as applicable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Liquidation, Dissolution or Winding-Up; Certain Mergers, Consolidations and Asset Sales</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Preferential Payments to Holders of Preferred Stock</u>.&#160; In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event (as defined below), the holders of shares of Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, pari passu pro rata and before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the Original Issue Price together with any dividends declared but unpaid thereon.&#160; If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Preferred Stock the full amount to which they shall be entitled under this <u>Subsection 2.1</u>, the holders of shares of Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="41952-2-KG-01_PB_3_043950_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=460280,FOLIO='3',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:37 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Payments to Holders of Common Stock and Preferred Stock</u>.&#160; In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Corporation or Deemed Liquidation Event, after the payment of all preferential amounts required to be paid to the holders of shares of Preferred Stock in accordance with <u>Section&nbsp;2.1</u>, the remaining assets of the Corporation available for distribution to its stockholders shall be distributed among the holders of shares of Preferred Stock and Common Stock, pro rata based on the number of shares held by each such holder, treating for this purpose all such securities as if they had been converted to Common Stock pursuant to the terms of this Third Amended and Restated Certificate of Incorporation immediately prior to such liquidation, dissolution, or winding up of the Corporation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Deemed Liquidation Events</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.3.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Definition</u>.&#160; Each of the following events shall be considered a &#147;<b>Deemed Liquidation Event</b>&#148; unless the holders of a majority of the then outstanding shares of Preferred Stock, voting together as a single class on an as-converted basis (the &#147;<b>Requisite Preferred</b>&#148;) elect otherwise by written notice sent to the Corporation at least five days prior to the effective date of any such event:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a merger or consolidation in which: (i)&nbsp;the Corporation is a constituent party, or (ii)&nbsp;a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to such merger or consolidation; except any such merger or consolidation involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (1)&nbsp;the surviving or resulting corporation; or (2)&nbsp;if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole, or the sale or disposition (whether by merger, consolidation or otherwise) of one or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.3.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Effecting a Deemed Liquidation Event</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in <u>Subsection 2.3.1(a)(i)</u>&nbsp;unless the agreement or plan of merger or consolidation for such transaction (the &#147;<b>Merger Agreement</b>&#148;) provides that the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="41952-2-KG-01_PB_4_044117_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=119908,FOLIO='4',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:37 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">consideration payable to the stockholders of the Corporation shall be allocated among the holders of capital stock of the Corporation in accordance with <u>Subsections 2.1</u> and <u>2.2</u>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the event of a Deemed Liquidation Event referred to in <u>Subsection 2.3.1(a)(ii)</u>, or <u>2.3.1(b)</u>&nbsp;above, if the Corporation does not effect a dissolution of the Corporation under the General Corporation Law within ninety (90) days after such Deemed Liquidation Event, then (i)&nbsp;the Corporation shall send a written notice to each holder of Preferred Stock no later than the ninetieth (90<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>) day after the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) pursuant to the terms of the following <u>clause</u> (ii)&nbsp;to require the redemption of such shares of Preferred Stock, and (ii)&nbsp;if the holders representing the Requisite Preferred so request in a written instrument delivered to the Corporation not later than one hundred twenty (120) days after such Deemed Liquidation Event, the Corporation shall use the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities associated with the assets sold or technology licensed, as determined in good faith by the Board of Directors, including the approval of a majority of the Preferred Directors then in office, together with any other assets of the Corporation available for distribution to its stockholders (the &#147;<b>Net Proceeds</b>&#148;)), all to the extent permitted by Delaware law governing distributions to stockholders, on the one hundred fiftieth (150<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>) day after such Deemed Liquidation Event, to redeem all outstanding shares of Preferred Stock at a price per share equal to the Liquidation Amount, as applicable.&#160; Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Net Proceeds are not sufficient to redeem all outstanding shares of Preferred Stock, or if the Corporation does not have sufficient lawfully available funds to effect such redemption, the Corporation shall redeem each holder&#146;s shares of Preferred Stock ratably (based on the respective amounts that each holder would have received if all outstanding shares of Preferred Stock were redeemed as provided in clause (ii)&nbsp;above) to the fullest extent of such Net Proceeds or such lawfully available funds, as the case may be, and shall redeem the remaining shares ratably (in the same manner) as soon as it may lawfully do so under Delaware law governing distributions to stockholders. The provisions of <u>Subsections 2.3.2(c)(ii)</u>&nbsp;through <u>2.3.2(c)(iv)</u>&nbsp;below shall apply, with such necessary changes in the details thereof as are necessitated by the context, to the redemption of the Preferred Stock pursuant to this <u>Subsection 2.3.2(b)</u>.&#160; Prior to the distribution or redemption provided for in this <u>Subsection 2.3.2(b)</u>, the Corporation shall not expend or dissipate the consideration received for such Deemed Liquidation Event, except to discharge expenses incurred in connection with such Deemed Liquidation Event or in the ordinary course of business.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.3.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Amount Deemed Paid or Distributed</u>.&#160; The amount deemed paid or distributed to the holders of capital stock of the Corporation upon any such Deemed Liquidation Event shall be the cash or the value of the property, rights or securities paid or distributed to such holders by the Corporation or the acquiring person, firm or other entity.&#160; The value of such property, rights or securities shall be determined in good faith by the Board of Directors, including the approval of a majority of the Preferred Directors (as defined herein) then in office.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.3.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Allocation of Escrow and Contingent Consideration</u>. In the event of a Deemed Liquidation Event pursuant to <u>Subsection 2.3.1(a)(i)</u>, if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the &#147;<b>Additional Consideration</b>&#148;), the Merger Agreement shall provide that (a)</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="41952-2-KG-01_PB_5_044220_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=958031,FOLIO='5',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:37 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the portion of such consideration that is not Additional Consideration (such portion, the &#147;<b>Initial Consideration</b>&#148;) shall be allocated among the holders of capital stock of the Corporation in accordance with <u>Subsections 2.1</u> and <u>2.2</u> as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event; and (b)&nbsp;any Additional Consideration which becomes payable to the stockholders of the Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with <u>Subsections 2.1</u> and <u>2.2</u> after taking into account the previous payment of the Initial Consideration as part of the same transaction.&#160; For the purposes of this <u>Subsection 2.3.4</u>, consideration placed into escrow or retained as holdback to be available for satisfaction of indemnification or similar obligations in connection with such Deemed Liquidation Event shall be deemed to be Additional Consideration.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Voting</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>General</u>.&#160; On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of a meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter.&#160; Except as provided by law or by the other provisions of this Third Amended and Restated Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class on an as-converted basis.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Election of Directors</u>.&#160; The holders of record of the shares of Series&nbsp;B Preferred Stock, exclusively and as a separate class, shall be entitled to elect four (4)&nbsp;directors of the Corporation (the &#147;<b><font style="font-weight:bold;">Preferred </font>Directors</b>&#148;), the Requisite Preferred shall be entitled to elect two (2)&nbsp;directors of the Corporation, and the holders of record of the shares of Common Stock, exclusively and as a separate class, shall be entitled to elect one (1)&nbsp;director of the Corporation.&#160; Any director elected as provided in the preceding sentence may be removed without cause by, and only by, the affirmative vote of the holders of the shares of the class or series of capital stock entitled to elect such director or directors, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders. If the holders of shares of Preferred Stock or Common Stock, as the case may be, fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, voting exclusively and as a separate class, pursuant to the first sentence of this <u>Subsection&nbsp;3.2</u>, then any directorship not so filled shall remain vacant until such time as the holders of the Preferred Stock or Common Stock, as the case may be, elect a person to fill such directorship by vote or written consent in lieu of a meeting; and no such directorship may be filled by stockholders of the Corporation other than by the stockholders of the Corporation that are entitled to elect a person to fill such directorship, voting exclusively and as a separate class.&#160; The holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Preferred Stock), exclusively and voting together as a single class on an as-converted basis, shall be entitled to elect the balance of the total number of directors of the Corporation.&#160; At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the class or series entitled to elect such director shall constitute a quorum for the purpose of electing such director.&#160; Except as otherwise provided in this <u>Subsection&nbsp;3.2</u>, a vacancy in any directorship filled by the holders of any class or series shall</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="41952-2-KG-01_PB_6_044306_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=962608,FOLIO='6',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:37 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">be filled only by vote or written consent in lieu of a meeting of the holders of such class or series or by any remaining director or directors elected by the holders of such class or series pursuant to this <u>Subsection&nbsp;3.2</u>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Preferred Stock Protective Provisions</u>. At any time when any shares of Preferred Stock are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or this Third Amended and Restated Certificate of Incorporation) the written consent or affirmative vote of the Requisite Preferred given in writing or by vote at a meeting, consenting or voting (as the case may be) as a separate class, and any such act or transaction entered into without such consent or vote shall be null and void <i>ab initio</i>, and of no force or effect:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>liquidate, dissolve or wind-up the business and affairs of the Corporation, effect any merger or consolidation or any other Deemed Liquidation Event, or consent to any of the foregoing;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>waive, amend, alter or repeal any provision of this Third Amended and Restated Certificate of Incorporation or the Bylaws of the Corporation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>alter, amend, waive, repeal or change the powers, preferences or rights of the Preferred Stock (including without limitation any consent rights contained in this <u>Subsection 3.3</u>);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>(i)&nbsp;create, or authorize the creation of, or issue or obligate itself to issue, shares of any additional class or series of capital stock, or any other security convertible into or exercisable for any equity security, unless the same ranks junior to the Preferred Stock with respect to the rights, preferences and privileges of such additional class or series of capital stock or any other security, the distribution of assets on the liquidation, dissolution or winding up of the Corporation, and the payment of dividends and rights of redemption; (ii)&nbsp;increase or decrease the authorized number of shares of Preferred Stock, (iii)&nbsp;increase or decrease the authorized number of shares of any additional class or series of capital stock, or any other security convertible into or exercisable for any equity security of the Corporation, or (iv)&nbsp;increase or decrease the authorized number of shares of Common Stock;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>(i)&nbsp;reclassify, alter or amend any existing security of the Corporation that is pari passu with the Preferred Stock in respect of the rights, preferences and privileges of such existing security, the distribution of assets on the liquidation, dissolution or winding up of the Corporation, or the payment of dividends or right of redemption, if such reclassification, alteration or amendment would render such other security senior to the Preferred Stock in respect of any such right, preference, or privilege or (ii)&nbsp;reclassify, alter or amend any existing security of the Corporation that is junior to the Preferred Stock in respect of the rights, preferences and privileges of such existing security, the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to, or pari passu with, the Preferred Stock in respect of any such right, preference or privilege;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any shares of capital</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="41952-2-KG-01_PB_7_044340_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=423227,FOLIO='7',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:37 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">stock of the Corporation other than (i)&nbsp;redemptions of or dividends or distributions on Preferred Stock as expressly authorized herein, (ii)&nbsp;repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for the Corporation or any subsidiary in connection with the cessation of such employment or service at the lower of the original purchase price or the then-current fair market value thereof pursuant to stock restriction agreements or pursuant to equity incentive agreements with such persons and (iii)&nbsp;repurchases of stock upon exercise of the Corporation&#146;s right of first refusal;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3.7</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>create, or authorize the creation of, or issue, or authorize the issuance of any debt security or other indebtedness for borrowed money, including but not limited to obligations and contingent obligations under guarantees but not including equipment leases or lines of credit, or permit any subsidiary to take any such action with respect to any debt security or other indebtedness for borrowed money, if the aggregate indebtedness of the Corporation and its subsidiaries for borrowed money following such action would exceed $500,000;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3.8</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>approve, authorize or effect any corporate strategic relationship involving the payment, contribution or assignment by the Company, or to the Company, of assets in excess of $500,000;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3.9</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>create, or hold capital stock in, any subsidiary that is not wholly owned (either directly or through one or more other subsidiaries) by the Corporation, or permit any subsidiary to create, or authorize the creation of, or issue or obligate itself to issue, any shares of any class or series of capital stock, or sell, transfer or otherwise dispose of any capital stock of any direct or indirect subsidiary of the Corporation, or permit any direct or indirect subsidiary to sell, lease, transfer, exclusively license or otherwise dispose (in a single transaction or series of related transactions) of all or substantially all of the assets of such subsidiary;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3.10</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>sell, assign, license, pledge or encumber material technology or intellectual property, other than licenses granted in the ordinary course of business; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3.11</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>increase or decrease the authorized number of directors constituting the Board of Directors.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Optional Conversion</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The holders of the Preferred Stock shall have conversion rights as follows (the &#147;<b>Conversion Rights</b>&#148;):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Right to Convert</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Conversion Ratio</u>.&#160; Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing the Original Issue Price by the Applicable Preferred Stock Conversion Price (as defined below) in effect at the time of conversion.&#160; For purposes hereof, the &#147;<b>Applicable Preferred Stock Conversion Price</b>&#148; shall</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="41952-2-KG-03_PB_8_054814_4504"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=250523,FOLIO='8',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 06:02 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">initially (as of the Series&nbsp;B Original Issue Date) be equal to (a)&nbsp;in the case of the Series&nbsp;A Preferred Stock, $1.00 and (b)&nbsp;in the case of the Series&nbsp;B Preferred Stock, $3.28. Such initial Applicable Preferred Stock Conversion Price, and the rate at which shares of Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided below.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination of Conversion Rights</u>. In the event of a liquidation, dissolution or winding-up of the Corporation or a Deemed Liquidation Event, the Conversion Rights shall terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable on such event to the holders of Preferred Stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Fractional Shares</u>.&#160; No fractional shares of Common Stock shall be issued upon conversion of Preferred Stock.&#160; In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Board of Directors, including the approval of a majority of the Preferred Directors then in office.&#160; Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Preferred Stock the holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Mechanics of Conversion</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notice of Conversion</u>.&#160; In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of Common Stock, such holder shall (a)&nbsp;provide written notice to the Corporation&#146;s transfer agent at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent) that such holder elects to convert all or any number of such holder&#146;s shares of Preferred Stock and, if applicable, any event on which such conversion is contingent, and (b), if such holder&#146;s shares are certificated, surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent).&#160; Such notice shall state such holder&#146;s name or the names of the nominees in which such holder wishes the shares of Common Stock to be issued.&#160; If required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in writing.&#160; The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of such notice and, if applicable, certificates (or lost certificate affidavit and agreement) shall be the time of conversion (the &#147;<b>Conversion Time</b>&#148;), and the shares of Common Stock issuable upon conversion of the specified shares shall be deemed to be outstanding of record as of such date.&#160; The Corporation shall, as soon as practicable after the Conversion Time (i)&nbsp;issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number of shares of Common Stock issuable upon such conversion in accordance with the provisions hereof and a certificate for the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="41952-2-KG-03_PB_9_054849_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=845263,FOLIO='9',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 06:02 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">number (if any) of the shares of Preferred Stock represented by the surrendered certificate that were not converted into Common Stock, (ii)&nbsp;pay in cash such amount as provided in <u>Subsection&nbsp;4.2</u> in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and (iii)&nbsp;pay all declared but unpaid dividends on the shares of Preferred Stock converted.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Reservation of Shares</u>.&#160; The Corporation shall at all times when the Preferred Stock shall be outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the Preferred Stock, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain the requisite stockholder approval of any necessary amendment to the Certificate of Incorporation. Before taking any action which would cause an adjustment reducing the Applicable Preferred Stock Conversion Price below the then par value of the shares of Common Stock issuable upon conversion of the Preferred Stock, the Corporation will take any corporate action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally issue fully paid and non-assessable shares of Common Stock at such adjusted Applicable Preferred Stock Conversion Price.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Effect of Conversion</u>.&#160; All shares of Preferred Stock which shall have been surrendered for conversion as herein provided shall no longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common Stock in exchange therefor, to receive payment in lieu of any fraction of a share otherwise issuable upon such conversion as provided in <u>Subsection&nbsp;4.2</u> and to receive payment of any dividends declared but unpaid thereon.&#160; Any shares of Preferred Stock so converted shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Further Adjustment</u>.&#160; Upon any such conversion, no adjustment to the Applicable Preferred Stock Conversion Price shall be made for any declared but unpaid dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Taxes</u>.&#160; The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance or delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this <u>Section&nbsp;4</u>.&#160; The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="41952-2-KG-03_PB_10_054911_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=225745,FOLIO='10',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 06:02 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Adjustments to Applicable Preferred Stock Conversion Price for Diluting Issues</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Special Definitions</u>.&#160; For purposes of this Article&nbsp;Fourth, the following definitions shall apply:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Option</b>&#148; shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b><font style="font-weight:bold;">S</font>eries&nbsp;B Original Issue Date</b>&#148; shall mean the date on which the first share of Series&nbsp;B Preferred Stock was issued.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Convertible Securities</b>&#148; shall mean any evidence of indebtedness, shares or other securities directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<b>Additional Shares of Common Stock</b>&#148; shall mean all shares of Common Stock issued (or, pursuant to <u>Subsection&nbsp;4.4.3</u> below, deemed to be issued) by the Corporation after the Series&nbsp;B Original Issue Date, other than (1)&nbsp;the following shares of Common Stock and (2)&nbsp;shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1)&nbsp;and (2), collectively, &#147;<b>Exempted Securities</b>&#148;):</p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shares of Common Stock, Options or Convertible   Securities issued as a dividend or distribution on Series&nbsp;B Preferred   Stock;</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shares of Common Stock, Options or Convertible   Securities issued by reason of a dividend, stock split, split-up or other   distribution on shares of Common Stock that is covered by <u>Subsection 4.5</u>,   <u>4.6</u>, <u>4.7</u> or <u>4.8</u> and approved by the Board of Directors,   including the approval of a majority of the Preferred Directors then in   office;</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shares of Common Stock or Options issued to employees   or directors of, or consultants or advisors to, the Corporation or any of its   subsidiaries pursuant to a plan, agreement or arrangement approved by the   Board of Directors, including the approval of a majority of the Preferred   Directors then in office;</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shares of Common Stock or Convertible Securities   actually issued upon the exercise of Options outstanding as of the   Series&nbsp;B Original Issue Date or shares of Common</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="41952-2-KG-03_PB_11_055430_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=405118,FOLIO='11',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 06:02 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock actually issued upon the conversion or   exchange of Convertible Securities outstanding as of the Series&nbsp;B   Original Issue Date, in each case provided such issuance is pursuant to the   terms of such Option or Convertible Security;</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shares of Common Stock, Options or Convertible   Securities issued to banks, equipment lessors or other financial   institutions, or to real property lessors, pursuant to commercial credit   arrangements, equipment leasing or commercial real property leasing   transactions approved by the Board of Directors, including the approval of a   majority of the Preferred Directors then in office;</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shares of Common Stock, Options or Convertible   Securities issued to suppliers or third party service providers in connection   with the provision of goods or services pursuant to transactions approved by   the Board of Directors, including the approval of a majority of the Preferred   Directors then in office;</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shares of Common Stock, Options or Convertible   Securities issued as acquisition consideration pursuant to the acquisition of   another corporation by the Corporation by merger, purchase of substantially   all of the assets or other reorganization or to a joint venture agreement, <u>provided</u>   that such issuances are approved by the Board of Directors, including the   approval of a majority of the Preferred Directors then in office;</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(viii)</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shares of Common Stock, Options or Convertible   Securities issued in connection with sponsored research, collaboration,   technology license, development, marketing or other similar agreements or   strategic partnerships approved by the Board of Directors, including the   approval of a majority of the Preferred Directors then in office;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="41952-2-KG-03_PB_12_055504_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=334823,FOLIO='12',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 06:02 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ix)</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shares of Common Stock issued in connection with a   firmly underwritten public offering of shares of Common Stock of the Company   at a pre-money valuation of at least $300,000,000 (subject to appropriate   adjustment in the event of any stock dividend, stock split, combination or   other similar recapitalization with respect to the Common Stock or Preferred   Stock) and for a total offering of not less than $60,000,000 (before   deduction of underwriters&#146; commissions and expenses);</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(x)</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">shares of Common Stock issued upon the conversion of   Preferred Stock; and</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(xi)</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">securities deemed at the time of issuance to be   Exempted Securities by the Requisite Preferred.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Adjustment of Conversion Price</u>.&#160; No adjustment in the Applicable Preferred Stock Conversion Price shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Requisite Preferred, agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Deemed Issuance of Additional Shares of Common Stock</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If the Corporation at any time or from time to time after the Series&nbsp;B Original Issue Date shall issue any Options or Convertible Securities (excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, shall be deemed to be Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the Applicable Preferred Stock Conversion Price pursuant to the terms of <u>Subsection 4.4.4</u>, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase or decrease in the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any such Option or Convertible Security or (2)&nbsp;any increase or decrease in</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="41952-2-KG-03_PB_13_055630_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=50506,FOLIO='13',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 06:02 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease becoming effective, the Applicable Preferred Stock Conversion Price computed upon the original issuance of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted to the Applicable Preferred Stock Conversion Price as would have been obtained had such revised terms been in effect upon the original date of issuance of such Option or Convertible Security.&#160; Notwithstanding the foregoing, no readjustment pursuant to this clause&nbsp;(b)&nbsp;shall have the effect of increasing the Applicable Preferred Stock Conversion Price to an amount which exceeds the lower of (i)&nbsp;the Applicable Preferred Stock Conversion Price in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii)&nbsp;the Applicable Preferred Stock Conversion Price that would have resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted Securities), the issuance of which did not result in an adjustment to the Applicable Preferred Stock Conversion Price pursuant to the terms of <u>Subsection 4.4.4</u> (either because the consideration per share (determined pursuant to <u>Subsection 4.4.5</u>) of the Additional Shares of Common Stock subject thereto was equal to or greater than the Applicable Preferred Stock Conversion Price then in effect, or because such Option or Convertible Security was issued before the Series&nbsp;B Original Issue Date), are revised after the Series&nbsp;B Original Issue Date as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase in the number of shares of Common Stock issuable upon the exercise, conversion or exchange of any such Option or Convertible Security or (2)&nbsp;any decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common Stock subject thereto (determined in the manner provided in <u>Subsection 4.4.3(a))</u> shall be deemed to have been issued effective upon such increase or decrease becoming effective.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Upon the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof) which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Applicable Preferred Stock Conversion Price pursuant to the terms of <u>Subsection&nbsp;4.4.4</u>, the Applicable Preferred Stock Conversion Price shall be readjusted to the Applicable Preferred Stock Conversion Price as would have been obtained had such Option or Convertible Security (or portion thereof) never been issued.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible Security is issued or amended but is subject to adjustment based upon subsequent events, any adjustment to, as applicable, the Applicable Preferred Stock Conversion Price provided for in this <u>Subsection&nbsp;4.4.3</u> shall be effected at the time of such issuance or amendment based on such number of shares or amount of consideration</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">14<a name="41952-2-KG-05_PB_14_054909_5486"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=163965,FOLIO='14',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 06:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">without regard to any provisions for subsequent adjustments (and any subsequent adjustments shall be treated as provided in clauses (b)&nbsp;and (c)&nbsp;of this <u>Subsection&nbsp;4.4.3</u>).&#160; If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at all at the time such Option or Convertible Security is issued or amended, any adjustment to, as applicable, the Applicable Preferred Stock Conversion Price that would result under the terms of this <u>Subsection&nbsp;4.4.3</u> at the time of such issuance or amendment shall instead be effected at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to the Applicable Preferred Stock Conversion Price that such issuance or amendment took place at the time such calculation can first be made.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4.4&#160;&#160;&#160;&#160;&#160;&#160; <u>Adjustment of the Applicable Preferred Stock Conversion Price Upon Issuance of Additional Shares of Common Stock</u>.&#160; In the event the Corporation shall at any time after the Series&nbsp;B Original Issue Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to <u>Subsection&nbsp;4.4.3</u>), without consideration or for a consideration per share less than the Applicable Preferred Stock Conversion Price in effect immediately prior to such issuance or deemed issuance, then the Applicable Preferred Stock Conversion Price shall be reduced, concurrently with such issue, to a price (calculated to the nearest one-hundredth of a cent) determined in accordance with the following formula:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CP</font><font size="1" style="font-size:6.5pt;position:relative;top:1.0pt;">2</font>&#160;= CP<font size="1" style="font-size:6.5pt;position:relative;top:1.0pt;">1</font>*&#160; (A + B) &#247; (A + C).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For purposes of the foregoing formula, the following definitions shall apply:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#147;CP</font><font size="1" style="font-size:6.5pt;position:relative;top:1.0pt;">2</font>&#148; shall mean the Applicable Preferred Stock Conversion Price in effect immediately after such issuance or deemed issuance of Additional Shares of Common Stock;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#147;CP</font><font size="1" style="font-size:6.5pt;position:relative;top:1.0pt;">1</font>&#148; shall mean the Applicable Preferred Stock Conversion Price in effect immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#147;A&#148; shall mean the number of shares of Common Stock outstanding immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issuance or deemed issuance or upon conversion or exchange of Convertible Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issuance or deemed issuance);</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#147;B&#148; shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had been issued or deemed issued at a price per share equal to CP</font><font size="1" style="font-size:6.5pt;position:relative;top:1.0pt;">1</font>&#160;(determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP<font size="1" style="font-size:6.5pt;position:relative;top:1.0pt;">1</font>); and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#147;C&#148; shall mean the number of such Additional Shares of Common Stock issued or deemed issued in such transaction.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">15<a name="41952-2-KG-05_PB_15_054935_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=195392,FOLIO='15',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 06:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4.5&#160;&#160;&#160;&#160;&#160;&#160; <u>Determination of Consideration</u>.&#160; For purposes of this <u>Subsection 4.4</u>, the consideration received by the Corporation for the issuance or deemed issuance of any Additional Shares of Common Stock shall be computed as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Cash and Property</u>:&#160; Such consideration shall:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 3.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation, excluding amounts paid or payable for accrued interest;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 3.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of such issue, as determined in good faith by the Board of Directors, including the approval of a majority of the Preferred Directors then in office; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 3.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>in the event Additional Shares of Common Stock are issued together with other shares or securities or other assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in clauses (i)&nbsp;and (ii)&nbsp;above, as determined in good faith by the Board of Directors, including the approval of a majority of the Preferred Directors then in office.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Options and Convertible Securities</u>.&#160; The consideration per share received by the Corporation for Additional Shares of Common Stock deemed to have been issued pursuant to <u>Subsection 4.4.3</u>, relating to Options and Convertible Securities, shall be determined by dividing:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 3.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The total amount, if any, received or receivable by the Corporation as consideration for the issue of such Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration) payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">16<a name="41952-2-KG-05_PB_16_055002_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=16,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=455592,FOLIO='16',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 06:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 3.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Securities and the conversion or exchange of such Convertible Securities, by</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 3.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4.6&#160;&#160;&#160;&#160;&#160;&#160; <u>Multiple Closing Dates</u>.&#160; In the event the Corporation shall issue on more than one date Additional Shares of Common Stock that are a part of one transaction or a series of related transactions and that would result in an adjustment to the Applicable Preferred Stock Conversion Price pursuant to the terms of <u>Subsection 4.4.4</u>, and such issuance dates occur within a period of no more than ninety (90) days from the first such issuance to the final such issuance, then, upon the final such issuance, the Applicable Preferred Stock Conversion Price shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving effect to any additional adjustments as a result of any such subsequent issuances within such period).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Adjustment for Stock Splits and Combinations</u>.&#160; If the Corporation shall at any time or from time to time after the Series&nbsp;B Original Issue Date effect a subdivision of the outstanding Common Stock, the Applicable Preferred Stock Conversion Price in effect immediately before that subdivision shall be proportionately decreased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding.&#160; If the Corporation shall at any time or from time to time after the Series&nbsp;B Original Issue Date combine the outstanding shares of Common Stock, the Applicable Preferred Stock Conversion Price in effect immediately before the combination shall be proportionately increased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding.&#160; Any adjustment under this subsection shall become effective at the close of business on the date the subdivision or combination becomes effective.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Adjustment for Certain Dividends and Distributions</u>.&#160; In the event the Corporation at any time or from time to time after the Series&nbsp;B Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable on the Common Stock in additional shares of Common Stock, then and in each such event the Applicable Preferred Stock Conversion Price in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a record date shall have been fixed, as of the close of business on such record date, by multiplying the Applicable Preferred Stock Conversion Price then in effect by a fraction:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">17<a name="41952-2-KG-05_PB_17_055022_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=17,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=434756,FOLIO='17',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 06:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date, and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding the foregoing (a)&nbsp;if such record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, the Applicable Preferred Stock Conversion Price shall be recomputed accordingly as of the close of business on such record date and thereafter the Applicable Preferred Stock Conversion Price shall be adjusted pursuant to this subsection as of the time of actual payment of such dividends or distributions; and (b)&nbsp;no such adjustment shall be made if the holders of Preferred Stock simultaneously receive a dividend or other distribution of shares of Common Stock in a number equal to the number of shares of Common Stock as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Adjustments for Other Dividends and Distributions</u>.&#160; In the event the Corporation at any time or from time to time after the Series&nbsp;B Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation (other than a distribution of shares of Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of <u>Section&nbsp;1</u> do not apply to such dividend or distribution, then and in each such event the holders of Preferred Stock shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such securities or other property as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Adjustment for Merger or Reorganization,&nbsp;etc</u>.&#160; Subject to the provisions of <u>Subsection 2.3</u>, if there shall occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a transaction covered by <u>Subsections 4.4</u>, <u>4.6</u> or <u>4.7</u>), then, following any such reorganization, recapitalization, reclassification, consolidation or merger, each share of Preferred Stock shall thereafter be convertible in lieu of the Common Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation issuable upon conversion of one share of Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as determined in good faith by the Board of Directors, including the approval of a majority of the Preferred Directors then in office) shall be made in the application of the provisions in this <u>Section&nbsp;4</u> with respect to the rights and interests thereafter of the holders of the Preferred Stock, to the end that the provisions set forth in this <u>Section&nbsp;4</u> (including provisions with respect to changes in and other adjustments of the Applicable Preferred Stock Conversion Price) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">18<a name="41952-2-KG-05_PB_18_055051_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=18,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=852065,FOLIO='18',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 06:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">conversion of the Preferred Stock.&#160; For the avoidance of doubt, nothing in this <u>Subsection 4.8</u> shall be construed as preventing the holders of Preferred Stock from seeking any appraisal rights to which they are otherwise entitled under the General Corporation Law in connection with a merger triggering an adjustment hereunder, nor shall this <u>Subsection 4.8</u> be deemed conclusive evidence of the fair value of the shares of Preferred Stock in any such appraisal proceeding.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Certificate as to Adjustments</u>.&#160; Upon the occurrence of each adjustment or readjustment of the Applicable Preferred Stock Conversion Price pursuant to this <u>Section&nbsp;4</u>, the Corporation at its expense shall, as promptly as reasonably practicable but in any event not later than ten (10)&nbsp;days thereafter, compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of the Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property into which such series of&#160; Preferred Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, as promptly as reasonably practicable after the written request at any time of any holder of Preferred Stock (but in any event not later than ten (10)&nbsp;days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (i)&nbsp;the Applicable Preferred Stock Conversion Price then in effect, and (ii)&nbsp;the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of the Preferred Stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.10&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Notice of Record Date</u>.&#160; In the event:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or any other securities, or to receive any other security; or</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; of any capital reorganization of the Corporation, any reclassification of the Common Stock of the Corporation, or any Deemed Liquidation Event; or</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:2.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; of the voluntary or involuntary dissolution, liquidation or winding-up of the Corporation,</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">then, and in each such case, the Corporation will send or cause to be sent to the holders of the Preferred Stock a notice specifying, as the case may be, (i)&nbsp;the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii)&nbsp;the effective date on which such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation, winding-up, or Deemed Liquidation Event is proposed to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up, and the amount per share and character of such exchange applicable to the Preferred Stock and the Common Stock.&#160; Such notice shall be sent at least ten (10)&nbsp;days prior to the record date or effective date for the event specified in such notice.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">19<a name="41952-2-KG-05_PB_19_055125_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=19,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=704394,FOLIO='19',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 06:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Mandatory Conversion</u>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Trigger Events</u>.&#160; Upon either (a)&nbsp;the closing of the sale of shares of Common Stock to the public in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, at a pre-money valuation of at least $300,000,000 resulting in at least $60,000,000 of gross proceeds (before deduction of underwriters&#146; discounts and commissions and offering expenses) or (b)&nbsp;the date and time, or the occurrence of an event, specified by vote or written consent of the holders of a majority of the then outstanding shares of Series&nbsp;B Preferred Stock, voting as a separate class on an as-converted basis, and the Requisite Preferred (the time of such closing or the date and time specified or the time of the event specified in such vote or written consent is referred to herein as the &#147;<b>Mandatory Conversion Time</b>&#148;), then (i)&nbsp;all outstanding shares of Preferred Stock shall automatically be converted into shares of Common Stock, at conversion rate specified in <u>Subsection 4.1.1</u>, and (ii)&nbsp;such shares may not be reissued by the Corporation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Procedural Requirements</u>.&#160; All holders of record of shares of Preferred Stock shall be sent written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this <u>Section&nbsp;5</u>.&#160; Such notice need not be sent in advance of the occurrence of the Mandatory Conversion Time.&#160; Upon receipt of such notice, each holder of shares of Preferred Stock in certificated form shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice.&#160; If so required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing.&#160; All rights with respect to the Preferred Stock converted pursuant to <u>Subsection 5.1</u>, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this <u>Subsection 5.2</u>.&#160; As soon as practicable after the Mandatory Conversion Time and, if applicable, the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation shall (a)&nbsp;issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof, and (b)&nbsp;pay cash as provided in <u>Subsection 4.2</u> in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends on the shares of Preferred Stock converted.&#160; Such converted Preferred Stock shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Redeemed or Otherwise Acquired Shares</u>.&#160; Any shares of Preferred Stock that are redeemed or otherwise acquired by the Corporation or any of its subsidiaries shall be</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">20<a name="41952-2-KG-05_PB_20_055149_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=20,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=696293,FOLIO='20',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 06:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">automatically and immediately cancelled and retired and shall not be reissued, sold or transferred.&#160; Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Preferred Stock following redemption.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Waiver</u>.&#160; Except as specifically stated herein, any of the rights, powers, preferences and other terms of the Series&nbsp;A Preferred Stock set forth herein may be waived on behalf of all holders of Series&nbsp;A Preferred Stock by the affirmative written consent or vote of the holders of at least a majority of Series&nbsp;A Preferred Stock, voting exclusively as a separate class. Except as specifically stated herein, any of the rights, powers, preferences and other terms of the Series&nbsp;B Preferred Stock set forth herein may be waived on behalf of all holders of Series&nbsp;B Preferred Stock by the affirmative written consent or vote of the holders of at least a majority of Series&nbsp;B Preferred Stock, voting exclusively as a separate class.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Notices</u>.&#160; Any notice required or permitted by the provisions of this Article&nbsp;Fourth to be given to a holder of shares of Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication in compliance with the provisions of the General Corporation Law, and shall be deemed sent upon such mailing or electronic transmission.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FIFTH:&#160; </font></b>Subject to any additional vote required by the Certificate of Incorporation or Bylaws, in furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIXTH:&#160; </font></b>Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws of the Corporation may provide.&#160; The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors or in the Bylaws of the Corporation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SEVENTH:&#160; </font></b>Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EIGHTH:&#160; </font></b>To the fullest extent permitted under the General Corporation Law, as amended from time to time, no director of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director.&#160; Any amendment or repeal of this paragraph shall not adversely affect any right or protection of a director of the Corporation hereunder in respect of any act or omission occurring prior to the time of such amendment or repeal.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NINTH:&#160; </font></b>To the fullest extent permitted by law, a director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director.&#160; If the General Corporation Law or any other law of the State of Delaware is amended after approval by the stockholders of this Article&nbsp;Ninth to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law as so amended.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:36.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any repeal or modification of the foregoing provisions of this Article&nbsp;Ninth by the stockholders of the Corporation shall not adversely affect any right or protection of a director of</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">21<a name="41952-2-KG-05_PB_21_055210_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=21,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=1048530,FOLIO='21',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 06:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to any acts or omissions of such director occurring prior to, such repeal or modification.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TENTH:&#160; </font></b>&#160;&#160;To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which General Corporation Law permits the Corporation to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by <u>Section&nbsp;145</u> of the General Corporation Law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any amendment, repeal or modification of the foregoing provisions of this Article&nbsp;Tenth shall not (a)&nbsp;adversely affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or modification or (b)&nbsp;increase the liability of any director of the Corporation with respect to any acts or omissions of such director, officer or agent occurring prior to, such amendment, repeal or modification.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ELEVENTH:&#160; </font></b>The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in being offered an opportunity to participate in, any Excluded Opportunity.&#160; An &#147;<b>Excluded Opportunity</b>&#148; is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of (i)&nbsp;any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii)&nbsp;any holder of Preferred Stock or any partner, member, director, stockholder, employee, affiliate or agent of any such holder, other than someone who is an employee of the Corporation or any of its subsidiaries (collectively, &#147;<b>Covered Persons</b>&#148;), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person&#146;s capacity as a director of the Corporation while such Covered Person is performing services in such capacity.&#160; Any repeal or modification of this Article&nbsp;Eleventh will only be prospective and will not affect the rights under this Article&nbsp;Eleventh in effect at the time of the occurrence of any actions or omissions to act giving rise to liability.&#160; Notwithstanding anything to the contrary contained elsewhere in this Amended and Restated Certificate of Incorporation, the affirmative vote of the holders of at least a majority of the shares of Preferred Stock the outstanding, will be required to amend or repeal, or to adopt any provisions inconsistent with this Article&nbsp;Eleventh.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TWELFTH:&#160; </font></b>Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&nbsp;any derivative action or proceeding brought on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation&#146;s stockholders, (iii)&nbsp;any action asserting a claim against the Corporation, its directors, officers or employees arising pursuant to any provision of the Delaware General Corporation Law or the Corporation&#146;s certificate of incorporation or bylaws or (iv)&nbsp;any action asserting a claim against the Corporation, its directors, officers or employees governed by the internal affairs doctrine, except for, as to each of (i)&nbsp;through (iv)&nbsp;above, any claim as to which the Court of Chancery determines that there is an indispensable party not</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">22<a name="41952-2-KG-05_PB_22_055324_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=22,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=447630,FOLIO='22',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 06:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. If any provision or provisions of this Article&nbsp;Twelfth shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Article&nbsp;Twelfth (including, without limitation, each portion of any sentence of this Article&nbsp;Twelfth containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; That the foregoing amendment and restatement was approved by the holders of the requisite number of shares of this corporation in accordance with Section&nbsp;228 of the General Corporation Law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; That this Third Amended and Restated Certificate of Incorporation, which restates and integrates and further amends the provisions of this Corporation&#146;s Second Amended and Restated Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">23<a name="41952-2-KG-05_PB_23_055435_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=23,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=269356,FOLIO='23',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 06:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF</font></b>, this Third Amended and Restated Certificate of Incorporation has been executed by a duly authorized officer of this corporation on this 10<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>&#160;day of December, 2018.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Andrew Cheng</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Andrew Cheng</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and Chief   Executive Officer</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">24<a name="41952-2-KG-05_PB_24_055620_7091"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=24,EFW="2237524",CP="AKERO THERAPEUTICS",DN="2",CHK=591059,FOLIO='24',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KG-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 06:23 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 3.3<a name="41952-2-KK_Exhibit3_3_064630"></a></font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMENDED AND RESTATED BYLAWS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OF</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AKERO THERAPEUTICS,&nbsp;INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(the &#147;<u>Corporation</u>&#148;)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>MEETINGS OF STOCKHOLDERS</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Annual Meeting</u>.&#160; If required by applicable law, an annual meeting of stockholders shall be held for the election of directors at such date, time and place, if any, either within or without the State of Delaware, as may be designated by resolution of the Board of Directors from time to time.&#160; Any other proper business may be transacted at the annual meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Special Meetings</u>. Special meetings of stockholders for any purpose or purposes may be called at any time by the Board of Directors, but such special meetings may not be called by any other person or persons. Business transacted at any special meeting of stockholders shall be limited to the purposes stated in the notice.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notice of Meetings</u>.&#160; Whenever stockholders are required or permitted to take any action at a meeting, a notice of the meeting shall be given that shall state the place, if any, date and hour of the meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is called. Unless otherwise provided by law, the Certificate of Incorporation or these Bylaws, the notice of any meeting shall be given not less than ten (10)&nbsp;nor more than sixty (60) days before the date of the meeting to each stockholder entitled to vote at such meeting.&#160;&#160; If mailed, such notice shall be deemed to be given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder&#146;s address as it appears on the records of the Corporation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Adjournments</u>. Any meeting of stockholders, annual or special, may adjourn from time to time to reconvene at the same or some other place and notice need not be given of any such adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30) days, or if after the adjournment a new record date is fixed for the adjourned meeting, notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Quorum</u>. Except as otherwise provided by law, the Certificate of Incorporation or these Bylaws, at each meeting of stockholders the presence in person or by proxy of the holders of a majority in voting power of the outstanding shares of stock entitled to vote at the meeting shall be necessary and sufficient to constitute a quorum.&#160; In the absence of a quorum, the stockholders so present may, by a majority in voting power thereof, adjourn the meeting from time to time in the manner provided in <u>Section&nbsp;1.4</u> until a quorum shall attend.&#160; At any such adjourned meeting at which the requisite amount of stock entitled to vote shall be</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2237524",CP="AKERO THERAPEUTICS",DN="3",CHK=726399,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KK_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:38 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">represented, any business may be transacted which might have been transacted at the meeting as originally noticed; but only those stockholders entitled to vote at the meeting as originally noticed shall be entitled to vote at any adjournment or adjournments thereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Organization</u>.&#160; Meetings of stockholders shall be presided over by the Chairperson of the Board, if any, or in his or her absence by the Vice Chairperson of the Board, if any, or in his or her absence by the President, or in his or her absence by a Vice President, or in the absence of the foregoing persons by a chairperson designated by the Board of Directors, or in the absence of such designation by a chairperson chosen at the meeting.&#160; The Secretary shall act as secretary of the meeting, but in his or her absence the chairperson of the meeting may appoint any person to act as secretary of the meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.7</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Voting; Proxies</u>. Except as otherwise provided by or pursuant to the provisions of the Certificate of Incorporation, each stockholder entitled to vote at any meeting of stockholders shall be entitled to one vote for each share of stock held by such stockholder which has voting power upon the matter in question.&#160; Each stockholder entitled to vote at a meeting of stockholders or to express consent to corporate action in writing without a meeting may authorize another person or persons to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three (3)&nbsp;years from its date, unless the proxy provides for a longer period.&#160; A proxy shall be irrevocable if it states that it is irrevocable and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power.&#160; A stockholder may revoke any proxy which is not irrevocable by attending the meeting and voting in person or by delivering to the Secretary a revocation of the proxy or a new proxy bearing a later date. Voting at meetings of stockholders need not be by written ballot.&#160; At all meetings of stockholders for the election of directors at which a quorum is present a plurality of the votes cast shall be sufficient to elect.&#160; All other elections and questions presented to the stockholders at a meeting at which a quorum is present shall, unless otherwise provided by the Certificate of Incorporation, these Bylaws, the rules&nbsp;or regulations of any stock exchange applicable to the Corporation, or applicable law or pursuant to any regulation applicable to the Corporation or its securities, be decided by the affirmative vote of the holders of a majority in voting power of the shares of stock of the Corporation which are present in person or by proxy and entitled to vote thereon.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.8</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Fixing Date For Determination of Stockholders of Record</u>.&#160; In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date: (1)&nbsp;in the case of determination of stockholders entitled to vote at any meeting of stockholders or adjournment thereof, shall, unless otherwise required by law, not be more than sixty (60) nor less than ten (10)&nbsp;days before the date of such meeting; (2)&nbsp;in the case of determination of stockholders entitled to express consent to corporate action in writing without a meeting, shall not be more than ten (10)&nbsp;days from the date upon which the resolution fixing the record date is adopted by the Board of Directors; and (3)&nbsp;in the case of any other action, shall not be more than sixty (60) days prior to</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="41952-2-KK_PB_2_065028_7980"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2237524",CP="AKERO THERAPEUTICS",DN="3",CHK=182131,FOLIO='2',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KK_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:38 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">such other action.&#160; If no record date is fixed: (1)&nbsp;the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day preceding the day on which notice is given or, if notice is waived, at the close of business on the day preceding the day on which the meeting is held; (2)&nbsp;the record date for determining stockholders entitled to express consent to corporate action in writing without a meeting, when no prior action of the Board of Directors is required by law, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation in accordance with applicable law or, if prior action by the Board of Directors is required by law, shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action; and (3)&nbsp;the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.&#160; A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <u>provided</u>, <u>however</u>, that the Board of Directors may fix a new record date for any adjourned meeting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.9</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Action by Written Consent of Stockholders</u>. Any action required or permitted to be taken at any meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not fewer than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voting.&#160; Prompt notice of the taking of any such action shall be given to those stockholders who did not consent in writing.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>BOARD OF DIRECTORS</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Number, Qualification</u>. The business, property, and affairs of the Corporation shall be managed by or under the direction of a Board of Directors.&#160; The Board of Directors shall consist of one (1)&nbsp;or more members, the number thereof to be determined from time to time by resolution of the Board of Directors.&#160; Directors need not be stockholders.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Election; Resignation; Vacancies</u>. The Board of Directors shall initially consist of the persons named as directors in the Certificate of Incorporation or elected by the incorporator of the Corporation and each director so elected shall hold office until the first annual meeting of stockholders or until his or her successor is duly elected and qualified. At the first annual meeting of stockholders and at each annual meeting thereafter, the stockholders shall elect directors each of whom shall hold office for a term of one year or until his or her successor is duly elected and qualified, subject to such director&#146;s earlier death, resignation, disqualification or removal. Any director may resign at any time upon notice to the Corporation. Unless otherwise provided by law or the Certificate of Incorporation, any newly created directorship or any vacancy occurring in the Board of Directors for any cause may be filled by a majority of the remaining members of the Board of Directors, although such majority is less than a quorum, or by a plurality of the votes cast at a meeting of stockholders, and each director so elected shall hold office until the next annual meeting of stockholders or until his or her successor is elected and qualified.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="41952-2-KK_PB_3_065046_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2237524",CP="AKERO THERAPEUTICS",DN="3",CHK=824951,FOLIO='3',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KK_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:38 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Regular Meetings</u>. Regular meetings of the Board of Directors may be held at such places within or without the State of Delaware and at such times as the Board of Directors may from time to time determine.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Special Meetings</u>.&#160; Special meetings of the Board of Directors may be held at any time or place within or without the State of Delaware whenever called by the President, any Vice President, the Secretary or by any member of the Board of Directors. Notice of a special meeting of the Board of Directors shall be given by the person or persons calling the meeting at least twenty-four hours before the special meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Telephonic Meetings Permitted</u>.&#160; Members of the Board of Directors, or any committee designated by the Board of Directors, may participate in a meeting thereof by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other and such participation in a meeting shall constitute presence in person at such meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Quorum, Vote Required For Action</u>. At all meetings of the Board of Directors, the directors entitled to cast a majority of the votes of the whole Board of Directors shall constitute a quorum for the transaction of business.&#160; Except in cases in which the Certificate of Incorporation, these Bylaws or applicable law otherwise provides, a majority of the votes entitled to be cast by the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.7</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Organization</u>.&#160; Meetings of the Board of Directors shall be presided over by the Chairperson of the Board, if any, or in his or her absence by the Vice Chairperson of the Board, if any, or in their absence by a chairperson chosen at the meeting.&#160; The Secretary shall act as secretary of the meeting, but in his or her absence the chairperson of the meeting may appoint any person to act as secretary of the meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.8</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Action by Unanimous Consent of Directors</u>.&#160; Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting if all members of the Board of Directors or such committee, as the case may be, consent thereto in writing or by electronic transmission and the writing(s)&nbsp;or electronic transmission(s)&nbsp;are filed with the minutes of proceedings of the Board of Directors or such committee in accordance with applicable law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>COMMITTEES.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Committees</u>. The Board of Directors may designate one or more committees, each committee to consist of one or more of the directors of the Corporation.&#160; The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee.&#160; In the absence or disqualification of a member of the committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he, she or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="41952-2-KK_PB_4_065102_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2237524",CP="AKERO THERAPEUTICS",DN="3",CHK=171848,FOLIO='4',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KK_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:38 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">meeting in place of any such absent or disqualified member.&#160; Any such committee, to the extent permitted by law and to the extent provided in the resolution of the Board of Directors, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation and may authorize the seal of the Corporation to be affixed to all papers which may require it.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Committee Rules</u>.&#160; Unless the Board of Directors otherwise provides, each committee designated by the Board of Directors may make, alter and repeal rules&nbsp;for the conduct of its business.&#160; In the absence of such rules, each committee shall conduct its business in the same manner as the Board of Directors conducts its business pursuant to Article&nbsp;II of these Bylaws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>OFFICERS.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Officers; Elections; Term of Office; Resignation, Removal, Vacancies</u>.&#160; The Board of Directors shall elect a President and Secretary and it may, if it so determines, choose a Chairperson of the Board and a Vice Chairperson of the Board from among its members.&#160; The Board of Directors may also choose one or more Vice Presidents, one or more Assistant Secretaries, a Treasurer and one or more Assistant Treasurers and such other officers as it shall from time to time deem necessary or desirable.&#160; Each such officer shall hold office until the first meeting of the Board of Directors after each annual meeting and until his or her successor is elected and qualified or until his or her earlier resignation or removal.&#160; Any officer may resign at any time upon written notice to the Corporation.&#160; The Board of Directors may remove any officer with or without cause at any time, but such removal shall be without prejudice to the contractual rights of such officer, if any, with the Corporation. Any number of offices may be held by the same person. Any vacancy occurring in any office of the Corporation by death, resignation, removal or otherwise may be filled for the unexpired portion of the term by the Board of Directors at any regular or special meeting.&#160; Election of an officer or agent shall not of itself create contract rights between the Corporation and such officer or agent.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Powers and Duties of Officers</u>.&#160; The officers of the Corporation shall have such powers and duties in the management of the Corporation as may be prescribed in a resolution by the Board of Directors and, to the extent not so provided, as generally pertain to their respective offices, subject to the control of the Board of Directors.&#160; The Board of Directors may require any officer, agent or employee to give security for the faithful performance of his or her duties.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>STOCK.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Certificates</u>.&#160; The shares of the Corporation shall be represented by certificates, provided that the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of stock shall be uncertificated shares.&#160; Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation. Every holder of stock represented by certificates shall be entitled to have a certificate signed by or in the name of the Corporation by the Chairperson or Vice Chairperson of the Board of Directors, if any, or the President or a Vice President, and by the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="41952-2-KK_PB_5_065123_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2237524",CP="AKERO THERAPEUTICS",DN="3",CHK=697699,FOLIO='5',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KK_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:38 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary, of the Corporation certifying the number of shares owned by such holder in the Corporation.&#160; Any of or all the signatures on the certificate may be a facsimile.&#160; In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were such officer, transfer agent or registrar at the date of issue.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Lost, Stolen or Destroyed Stock Certificates</u>.&#160; The corporation may issue a new certificate of stock in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such owner&#146;s legal representative, to give the Corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>INDEMNIFICATION AND ADVANCEMENT OF EXPENSES</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Right to Indemnification</u>. The corporation shall indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any person (a &#147;<u>Covered Person</u>&#148;) who was or is made or is threatened to be made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#147;<u>proceeding</u>&#148;), by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or nonprofit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys&#146; fees) reasonably incurred by such Covered Person.&#160; Notwithstanding the preceding sentence, except as provided in <u>Section&nbsp;6.3</u>, the Corporation shall be required to indemnify a Covered Person in connection with a proceeding (or part thereof) commenced by such Covered Person only if the commencement of such proceeding (or part thereof) by the Covered Person was authorized in the specific case by the Board of Directors of the Corporation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Prepayment of Expenses</u>.&#160; The corporation shall to the fullest extent not prohibited by applicable law pay the expenses (including attorneys&#146; fees) incurred by a Covered Person in defending any proceeding in advance of its final disposition; <u>provided</u>, <u>however</u>, that, to the extent required by law, such payment of expenses in advance of the final disposition of the proceeding shall be made only upon receipt of an undertaking by the Covered Person to repay all amounts advanced if it should be ultimately determined that the Covered Person is not entitled to be indemnified under this Article&nbsp;VI or otherwise.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Claims</u>.&#160; If a claim for indemnification (following the final disposition of such proceeding) or advancement of expenses under this Article&nbsp;VI is not paid in full within thirty (30) days after a written claim therefore by the Covered Person has been received by the Corporation, the Covered Person may file suit to recover the unpaid amount of such claim and, if successful in whole or in part, shall be entitled to be paid the expense of prosecuting such claim.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="41952-2-KK_PB_6_065133_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2237524",CP="AKERO THERAPEUTICS",DN="3",CHK=756201,FOLIO='6',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KK_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:38 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In any such action, the Corporation shall have the burden of proving that the Covered Person is not entitled to the requested indemnification or advancement of expenses under applicable law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Non-exclusivity of Rights</u>.&#160; The rights conferred on any Covered Person by this Article&nbsp;VI shall not be exclusive of any other rights which such Covered Person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, these Bylaws, agreement, vote of stockholders or disinterested directors or otherwise.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Other Sources</u>.&#160; The corporation&#146;s obligation, if any, to indemnify or to advance expenses to any Covered Person who was or is serving at its request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, enterprise or nonprofit entity shall be reduced by any amount such Covered Person may collect as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust, enterprise or non-profit enterprise.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Amendment or Repeal</u>.&#160; Any repeal or modification of the foregoing provisions of this Article&nbsp;VI shall not adversely affect any right or protection hereunder of any Covered Person in respect of any act or omission occurring prior to the time of such repeal or modification.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.7</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Other Indemnification and Prepayment of Expenses</u>.&#160; This Article&nbsp;VI shall not limit the right of the Corporation, to the extent and in the manner permitted by law, to indemnify and to advance expenses to persons other than Covered Persons when and as authorized by appropriate corporate action.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.8</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Insurance</u>.&#160; The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the General Corporation Law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>MISCELLANEOUS.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Fiscal Year</u>.&#160; The fiscal year of the Corporation shall be determined by resolution of the Board of Directors.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Seal</u>.&#160; The corporate seal shall have the name of the Corporation inscribed thereon and shall be in such form as may be approved from time to time by the Board of Directors.&#160; Said seal may&nbsp;be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise.&#160; Whenever the Corporation is permitted or required to affix its seal to a document, it shall be sufficient to meet the requirements of any law, rule&nbsp;or regulation relating to a seal to place the word &#147;(<u>SEAL</u>)&#148; adjacent to the signature of the person authorized to execute the document on behalf of the Corporation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Stock of Other Corporations or Other Interests</u>.&#160; Unless otherwise ordered by the Board of Directors, the President, the Secretary, and such attorneys or agents of the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="41952-2-KK_PB_7_065142_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2237524",CP="AKERO THERAPEUTICS",DN="3",CHK=916892,FOLIO='7',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KK_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:38 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporation as may from time to time be authorized by the Board of Directors or the President, shall have full power and authority on behalf of this Corporation to attend and to act and vote in person or by proxy at any meeting of the holders of securities of any corporation or other entity in which this Corporation may own or hold shares or other securities, and at such meetings shall possess and may exercise all the rights and power incident to the ownership of such shares or other securities which this Corporation, as the owner or holder thereof, might have possessed and exercised if present.&#160; The President, the Secretary, or such attorneys or agents, may also execute and deliver on behalf of the Corporation powers of attorney, proxies, consents, waivers, and other instruments relating to the shares or securities owned or held by this Corporation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Manner of Notice</u>.&#160; Except as otherwise provided herein or permitted by applicable law, notices to directors and stockholders shall be in writing and delivered personally or mailed to the directors or stockholders at their addresses appearing on the books of the Corporation.&#160; Notice to directors may be given by facsimile, email, telephone or other means of electronic transmission.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Waiver of Notice of Meetings of Stockholders, Directors and Committees</u>.&#160; Any waiver of notice, given by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice.&#160; Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.&#160; Neither the business to be transacted at nor the purpose of any regular or special meeting of the stockholders, directors or members of a committee of directors need be specified in a waiver of notice.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Form&nbsp;of Records</u>.&#160; Any records maintained by the Corporation in the regular course of its business, including its stock ledger, books of account and minute books, may be kept on, or by means of, or be in the form of, any information storage device or method, provided that the records so kept can be converted into clearly legible paper form within a reasonable time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.7</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Amendment of Bylaws</u>.&#160; These Bylaws may be altered, amended or repealed, in whole or in part, or new Bylaws may be adopted, by the Board of Directors; provided, however, that the stockholders may make additional bylaws and may alter, amend and repeal any bylaws whether adopted by them or otherwise.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adopted: May&nbsp;16, 2018</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="41952-2-KK_PB_8_065157_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2237524",CP="AKERO THERAPEUTICS",DN="3",CHK=694199,FOLIO='8',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KK_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:38 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.1<a name="41952-2-KS-01_Exhibit10_1_065700"></a></font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AKERO THERAPEUTICS,&nbsp;INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2018 STOCK OPTION AND GRANT PLAN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;1.&#160; <u>GENERAL PURPOSE OF THE PLAN; DEFINITIONS</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The name of the plan is the Akero Therapeutics,&nbsp;Inc. 2018 Stock Option and Grant Plan (the &#147;Plan&#148;).&#160; The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of Akero Therapeutics,&nbsp;Inc., a Delaware corporation (including any successor entity, the &#147;Company&#148;) and its Subsidiaries, upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business, to acquire a proprietary interest in the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following terms shall be defined as set forth below:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Affiliate</i>&#148; </font>of any Person means a Person that directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with the first mentioned Person.&#160; A Person shall be deemed to control another Person if such first Person possesses directly or indirectly the power to direct, or cause the direction of, the management and policies of the second Person, whether through the ownership of voting securities, by contract or otherwise.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Award</i>&#148; or &#147;<i>Awards,</i>&#148; except where referring to a particular category of grant under the Plan, shall include Incentive Stock Options, Non-Qualified Stock Options, Restricted Stock Awards, Unrestricted Stock Awards, Restricted Stock Units or any combination of the foregoing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&#147;Award Agreement&#148;</font></i> means a written or electronic agreement setting forth the terms and provisions applicable to an Award granted under the Plan.&#160; Each Award Agreement may contain terms and conditions in addition to those set forth in the Plan; <i>provided, however, </i>in the event of any conflict in the terms of the Plan and the Award Agreement, the terms of the Plan shall govern.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:38.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Board</i>&#148; means the Board of Directors of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Cause</i>&#148; shall have the meaning as set forth in the Award Agreement(s).&#160; In the case that </font>any Award Agreement does not contain a definition of &#147;Cause,&#148; it shall mean (i)&nbsp;the grantee&#146;s dishonest statements or acts with respect to the Company or any Affiliate of the Company, or any current or prospective customers, suppliers vendors or other third parties with which such entity does business; (ii)&nbsp;the grantee&#146;s commission of (A)&nbsp;a felony or (B)&nbsp;any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&nbsp;the grantee&#146;s failure to perform his assigned duties and responsibilities to the reasonable satisfaction of the Company which failure continues, in the reasonable judgment of the Company, after written notice given to the grantee by the Company; (iv)&nbsp;the grantee&#146;s gross negligence, willful misconduct or insubordination with respect to the Company or any Affiliate of the Company; or (v)&nbsp;the grantee&#146;s material violation of any provision of any agreement(s)&nbsp;between the grantee and the Company relating to noncompetition, nonsolicitation, nondisclosure and/or assignment of inventions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=816146,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&#147;Chief Executive Officer&#148; </font></i>means the Chief Executive Officer of the Company or, if there is no Chief Executive Officer, then the President of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Code</i>&#148; means the Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Committee</i>&#148; means the Committee of the Board referred to in Section&nbsp;2.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&#147;Consultant&#148;</font></i> means any natural person that provides bona fide services to the Company (including a Subsidiary), and such services are not in connection with the offer or sale of securities in a capital-raising transaction and do not directly or indirectly promote or maintain a market for the Company&#146;s securities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Disability</i>&#148; means &#147;disability&#148; as defined in Section&nbsp;422(c)&nbsp;of the Code.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Effective Date</i>&#148; means the date on which the Plan is adopted as set forth on the final page&nbsp;of the Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Exchange Act</i>&#148; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations thereunder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Fair Market Value</i>&#148; of the Stock on any given date means the fair market value of the Stock determined in good faith by the Committee based on </font>the reasonable application of a reasonable valuation method not inconsistent with Section&nbsp;409A of the Code.&#160; If the Stock is admitted to trade on a national securities exchange, the determination shall be made by reference to the closing price reported on such exchange.&#160; If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which there is a closing price.&#160; If the date for which Fair Market Value is determined is the first day when trading prices for the Stock are reported on a national securities exchange, the Fair Market Value shall be the &#147;Price to the Public&#148; (or equivalent) set forth on the cover page&nbsp;for the final prospectus relating to the Company&#146;s Initial Public Offering.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&#147;Good Reason&#148;</font></i> shall have the meaning as set forth in the Award Agreement(s).&#160; In the case that any Award Agreement does not contain a definition of &#147;Good Reason,&#148; it shall mean (i)&nbsp;a material diminution in the grantee&#146;s base salary except for across-the-board salary reductions similarly affecting all or substantially all similarly situated employees of the Company or (ii)&nbsp;a change of more than 50 miles in the geographic location at which the grantee provides services to the Company, so long as the grantee provides at least 90 days&#146; notice to the Company following the initial occurrence of any such event and the Company fails to cure such event within 30 days thereafter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Grant Date&#148; </i>means the date that the Committee designates in its approval of an Award in accordance with applicable law as the date on which the Award is granted, which date may not precede the date of such Committee approval.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&#147;Holder&#148;</font></i> means, with respect to an Award or any Shares, the Person holding such Award or Shares, including the initial recipient of the Award or any Permitted Transferee.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="41952-2-KS-01_PB_2_064329_8232"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=518385,FOLIO='2',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Incentive Stock Option</i>&#148; means any Stock Option designated and qualified as an &#147;incentive stock option&#148; as defined in Section&nbsp;422 of the Code.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Initial Public Offering</i>&#148; means the consummation of the first firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act covering the offer and sale by the Company of its equity securities, as a result of or following which the Stock shall be publicly held.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Non-Qualified Stock Option</i>&#148; means any Stock Option that is not an Incentive Stock Option.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Option</i>&#148; or &#147;<i>Stock Option</i>&#148; means any option to purchase shares of Stock granted pursuant to Section&nbsp;5.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Permitted Transferees</i>&#148; shall mean any of the following to whom a Holder may transfer Shares hereunder (as set forth in Section&nbsp;9(a)(ii)(A)): the Holder&#146;s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the Holder&#146;s household (other than a tenant or employee), a trust in which these persons have more than fifty percent of the beneficial interest, a foundation in which these persons control the management of assets, and any other entity in which these persons own more than fifty percent of the voting interests<i>; provided, however,</i> that any such trust does not require or permit distribution of any Shares during the term of the Award Agreement unless subject to its terms. &#160;Upon the death of the Holder, the term Permitted Transferees shall also include such deceased Holder&#146;s estate, executors, administrators, personal representatives, heirs, legatees and distributees, as the case may be.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Person</i>&#148; shall mean any individual, corporation, partnership (limited or general), limited liability company, limited liability partnership, association, trust, joint venture, unincorporated organization or any similar entity.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:38.25pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&#147;Restricted Stock Award&#148;</font></i> means Awards granted pursuant to Section&nbsp;6 and <i>&#147;Restricted Stock&#148;</i> means Shares issued pursuant to such Awards.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&#147;</font></i><i><font style="font-style:italic;">Restricted Stock Unit</font>&#148;</i> means an Award of phantom stock units to a grantee, which may be settled in cash or Shares as determined by the Committee, pursuant to Section&nbsp;8.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Sale Event&#148;</i> means the consummation of (i)&nbsp;the dissolution or liquidation of the Company, (ii)&nbsp;the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (iii)&nbsp;a merger, reorganization or consolidation pursuant to which the holders of the Company&#146;s outstanding voting power immediately prior to such transaction do not own a majority of the outstanding voting power of the surviving or resulting entity (or its ultimate parent, if applicable), (iv)&nbsp;the acquisition of all or a majority of the outstanding voting stock of the Company in a single transaction or a series of related transactions by a Person or group of Persons, or (v)&nbsp;any other acquisition of the business of the Company, as determined by the Board; <i>provided, however, </i>that the Company&#146;s Initial Public Offering, any subsequent public offering or another capital raising event, or a merger effected solely to change the Company&#146;s domicile shall not constitute a &#147;Sale Event.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="41952-2-KS-01_PB_3_064402_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=945795,FOLIO='3',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&#147;Section&nbsp;409A&#148;</font></i> means Section&nbsp;409A of the Code and the regulations and other guidance promulgated thereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Securities Act</i>&#148; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations thereunder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&#147;Service Relationship&#148;</font></i> means any relationship as a full-time employee, part-time employee, director or other key person (including Consultants) of the Company or any Subsidiary or any successor entity (e.g., a Service Relationship shall be deemed to continue without interruption in the event an individual&#146;s status changes from full-time employee to part-time employee or Consultant).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&#147;Shares&#148;</font></i> means shares of Stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Stock</i>&#148; means the Common Stock, par value $0.0001 per share, of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Subsidiary</i>&#148; means any corporation or other entity (other than the Company) in which the Company has more than a 50 percent interest, either directly or indirectly.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&#147;Ten Percent Owner&#148;</font></i> means an employee who owns or is deemed to own (by reason of the attribution rules&nbsp;of Section&nbsp;424(d)&nbsp;of the Code) more than 10 percent of the combined voting power of all classes of stock of the Company or any parent of the Company or any Subsidiary.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&#147;Termination Event&#148;</font></i> means the termination of the Award recipient&#146;s Service Relationship with the Company and its Subsidiaries for any reason whatsoever, regardless of the circumstances thereof, and including, without limitation, upon death, disability, retirement, discharge or resignation for any reason, whether voluntarily or involuntarily.&#160; The following shall not constitute a Termination Event:&#160; (i)&nbsp;a transfer to the service of the Company from a Subsidiary or from the Company to a Subsidiary, or from one Subsidiary to another Subsidiary or (ii)&nbsp;an approved leave of absence for military service or sickness, or for any other purpose approved by the Committee, if the individual&#146;s right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Committee otherwise so provides in writing.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<i>Unrestricted Stock Award</i><i>&#148;</i> means any Award granted pursuant to Section&nbsp;7 and <i>&#147;Unrestricted Stock&#148;</i> means Shares issued pursuant to such Awards.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .8in;text-indent:-.8in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;2.&#160; <u>ADMINISTRATION OF PLAN; COMMITTEE AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Administration of Plan</u>.&#160; The Plan shall be administered by the Board, or at the discretion of the Board, by a committee of the Board, comprised of not less than two directors.&#160; All references herein to the &#147;Committee&#148; shall be deemed to refer to the group then responsible for administration of the Plan at the relevant time (i.e., either the Board of Directors or a committee or committees of the Board, as applicable).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Powers of Committee</u>.&#160; The Committee shall have the power and authority to grant Awards consistent with the terms of the Plan, including the power and authority:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="41952-2-KS-01_PB_4_064434_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=660586,FOLIO='4',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>to select the individuals to whom Awards may from time to time be granted;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>to determine the time or times of grant, and the amount, if any, of Incentive Stock Options, Non-Qualified Stock Options, Restricted Stock Awards, Unrestricted Stock Awards, Restricted Stock Units, or any combination of the foregoing, granted to any one or more grantees;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>to determine the number of Shares to be covered by any Award and, subject to the provisions of the Plan, the price, exercise price, conversion ratio or other price relating thereto;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>to determine and, subject to Section&nbsp;12, to modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the form of Award Agreements;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>to accelerate at any time the exercisability or vesting of all or any portion of any Award;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>to impose any limitations on Awards, including limitations on transfers, repurchase provisions and the like, and to exercise repurchase rights or obligations;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>subject to Section&nbsp;5(a)(ii)&nbsp;and any restrictions imposed by Section&nbsp;409A, to extend at any time the period in which Stock Options may be exercised; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(viii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including Award Agreements); to make all determinations it deems advisable for the administration of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All decisions and interpretations of the Committee shall be binding on all persons, including the Company and all Holders.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Award Agreement</u>.&#160; Awards under the Plan shall be evidenced by Award Agreements that set forth the terms, conditions and limitations for each Award.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Indemnification</u>.&#160; Neither the Board nor the Committee, nor any member of either or any delegate thereof, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Committee (and any delegate thereof) shall be entitled in all cases to indemnification and reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys&#146; fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company&#146;s governing documents, including its certificate of incorporation or bylaws, or any directors&#146; and officers&#146; liability insurance coverage which may</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="41952-2-KS-01_PB_5_064505_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=770610,FOLIO='5',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">be in effect from time to time and/or any indemnification agreement between such individual and the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Foreign Award Recipients</u>.&#160; Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other countries in which the Company and any Subsidiary operate or have employees or other individuals eligible for Awards, the Committee, in its sole discretion, shall have the power and authority to: (i)&nbsp;determine which Subsidiaries, if any, shall be covered by the Plan; (ii)&nbsp;determine which individuals, if any, outside the United States are eligible to participate in the Plan; (iii)&nbsp;modify the terms and conditions of any Award granted to individuals outside the United States to comply with applicable foreign laws; (iv)&nbsp;establish subplans and modify exercise procedures and other terms and procedures, to the extent the Committee determines such actions to be necessary or advisable (and such subplans and/or modifications shall be attached to the Plan as appendices); <u>provided</u>, <u>however</u>, that no such subplans and/or modifications shall increase the share limitation contained in Section&nbsp;3(a)&nbsp;hereof; and (v)&nbsp;take any action, before or after an Award is made, that the Committee determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;3.&#160; <u>STOCK ISSUABLE UNDER THE PLAN; MERGERS AND OTHER TRANSACTIONS; SUBSTITUTION</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Stock Issuable</u>.&#160; The maximum number of Shares reserved and available for issuance under the Plan shall be 3,184,000 Shares, subject to adjustment as provided in Section&nbsp;3(b). For purposes of this limitation, the Shares underlying any Awards that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) and Shares that are withheld upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding shall be added back to the Shares available for issuance under the Plan. Subject to such overall limitations, Shares may be issued up to such maximum number pursuant to any type or types of Award, and no more than 80,000,000 Shares may be issued pursuant to Incentive Stock Options.&#160; The Shares available for issuance under the Plan may be authorized but unissued Shares or Shares reacquired by the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Changes in Stock</u>.&#160; Subject to Section&nbsp;3(c)&nbsp;hereof, if, as a result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Company&#146;s capital stock, the outstanding Shares are increased or decreased or are exchanged for a different number or kind of shares or other securities of the Company, or additional Shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such Shares or other securities, in each case, without the receipt of consideration by the Company, or, if, as a result of any merger or consolidation, or sale of all or substantially all of the assets of the Company, the outstanding Shares are converted into or exchanged for other securities of the Company or any successor entity (or a parent or subsidiary thereof), the Committee shall make an appropriate and proportionate adjustment in (i)&nbsp;the maximum number of Shares reserved for issuance under the Plan, (ii)&nbsp;the number and kind of Shares or other securities subject to any then outstanding Awards under the Plan, (iii)&nbsp;the repurchase price, if any, per Share subject to each outstanding Award, and (iv)&nbsp;the exercise price for each Share subject to any then outstanding Stock Options</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="41952-2-KS-01_PB_6_064532_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=621212,FOLIO='6',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of Stock Options) as to which such Stock Options remain exercisable.&#160; The Committee shall in any event make such adjustments as may be required by Section&nbsp;25102(o)&nbsp;of the California Corporation Code and the rules&nbsp;and regulations promulgated thereunder.&#160; The adjustment by the Committee shall be final, binding and conclusive.&#160; No fractional Shares shall be issued under the Plan resulting from any such adjustment, but the Committee in its discretion may make a cash </font>payment in lieu of fractional shares.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Sale Events</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Options</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the case of and subject to the consummation of a Sale Event, the Plan and all outstanding Options issued hereunder shall terminate upon the effective time of any such Sale Event unless assumed or continued by the successor entity, or new stock options or other awards of the successor entity or parent thereof are substituted therefor, with an equitable or proportionate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree (after taking into account any acceleration hereunder and/or pursuant to the terms of any Award Agreement).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the event of the termination of the Plan and all outstanding Options issued hereunder pursuant to Section&nbsp;3(c), each Holder of Options shall be permitted, within a period of time prior to the consummation of the Sale Event as specified by the Committee, to exercise all such Options which are then exercisable or will become exercisable as of the effective time of the Sale Event; <i>provided, however</i>, that the exercise of Options not exercisable prior to the Sale Event shall be subject to the consummation of the Sale Event.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(C)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notwithstanding anything to the contrary in Section&nbsp;3(c)(i)(A), in the event of a Sale Event, the Company shall have the right, but not the obligation, to make or provide for a cash payment to the Holders of Options, without any consent of the Holders, in exchange for the cancellation thereof, in an amount equal to the difference between (A)&nbsp;the value as determined by the Committee of the consideration payable per share of Stock pursuant to the Sale Event (the &#147;Sale Price&#148;) times the number of Shares subject to outstanding Options being cancelled (to the extent then vested and exercisable, including by reason of acceleration in connection with such Sale Event, at prices not in excess of the Sale Price) and (B)&nbsp;the aggregate exercise price of all such outstanding vested and exercisable Options.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Restricted Stock and Restricted Stock Unit Awards</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the case of and subject to the consummation of a Sale Event, all unvested Restricted Stock and unvested Restricted Stock Unit Awards (other than those becoming vested as a result of the Sale Event) issued hereunder shall be forfeited immediately prior to the effective time of any such Sale Event unless assumed or continued by the successor entity, or awards of the successor entity or parent thereof are</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="41952-2-KS-01_PB_7_064550_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=500792,FOLIO='7',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">substituted therefor, with an equitable or proportionate adjustment as to the number and kind of shares subject to such awards as such parties shall agree (after taking into account any acceleration hereunder and/or pursuant to the terms of any Award Agreement).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the event of the forfeiture of Restricted Stock pursuant to Section&nbsp;3(c)(ii)(A), such Restricted Stock shall be repurchased from the Holder thereof at a price per share equal to the original per share purchase price paid by the Holder (subject to adjustment as provided in Section&nbsp;3(b)) for such Shares.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(C)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notwithstanding anything to the contrary in Section&nbsp;3(c)(ii)(A), in the event of a Sale Event, the Company shall have the right, but not the obligation, to make or provide for a cash payment to the Holders of Restricted Stock or Restricted Stock Unit Awards, without consent of the Holders, in exchange for the cancellation thereof, in an amount equal to the Sale Price times the number of Shares subject to such Awards, to be paid at the time of such Sale Event or upon the later vesting of such Awards.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;4.&#160; <u>ELIGIBILITY</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grantees under the Plan will be such full or part-time officers and other employees, directors, Consultants and key persons of the Company and any Subsidiary who are selected from time to time by the Committee in its sole discretion; <u>provided</u>, <u>however</u>, that Awards shall be granted only to those individuals described in Rule&nbsp;701(c)&nbsp;of the Securities Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;5.&#160; <u>STOCK OPTIONS</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Upon the grant of a Stock Option, the Company and the grantee shall enter into an Award Agreement.&#160; The terms and conditions of each such Award Agreement shall be determined by the Committee, and such terms and conditions may differ among individual Awards and grantees.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock Options granted under the Plan may be either Incentive Stock Options or Non-Qualified Stock Options.&#160; Incentive Stock Options may be granted only to employees of the Company or any Subsidiary that is a &#147;subsidiary corporation&#148; within the meaning of Section&nbsp;424(f)&nbsp;of the Code.&#160; To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a Non-Qualified Stock Option.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Terms of Stock Options</u>.&#160; The Committee in its discretion may grant Stock Options to those individuals who meet the eligibility requirements of Section&nbsp;4.&#160; Stock Options shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Committee shall deem desirable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Exercise Price</u>.&#160; The exercise price per share for the Shares covered by a Stock Option shall be determined by the Committee at the time of grant but shall not be less than 100 percent of the Fair Market Value on the Grant Date.&#160; In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the exercise price per share for the Shares covered by such Incentive Stock Option shall not be less than 110 percent of the Fair Market Value on the Grant Date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="41952-2-KS-01_PB_8_064622_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=731297,FOLIO='8',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Option Term</u>.&#160; The term of each Stock Option shall be fixed by the Committee, but no Stock Option shall be exercisable more than ten years from the Grant Date.&#160; In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term of such Stock Option shall be no more than five years from the Grant Date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Exercisability; Rights of a Stockholder</u>.&#160; Stock Options shall become exercisable and/or vested at such time or times, whether or not in installments, as shall be determined by the Committee at or after the Grant Date.&#160; The Award Agreement may permit a grantee to exercise all or a portion of a Stock Option immediately at grant; provided that the Shares issued upon such exercise shall be subject to restrictions and a vesting schedule identical to the vesting schedule of the related Stock Option, such Shares shall be deemed to be Restricted Stock for purposes of the Plan, and the optionee may be required to enter into an additional or new Award Agreement as a condition to exercise of such Stock Option.&#160; An optionee shall have the rights of a stockholder only as to Shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options.&#160; An optionee shall not be deemed to have acquired any Shares unless and until a Stock Option shall have been exercised pursuant to the terms of the Award Agreement and this Plan and the optionee&#146;s name has been entered on the books of the Company as a stockholder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Method of Exercise</u>.&#160; Stock Options may be exercised by an optionee in whole or in part, by the optionee giving written or electronic notice of exercise to the Company, specifying the number of Shares to be purchased.&#160; Payment of the purchase price may be made by one or more of the following methods (or any combination thereof) to the extent provided in the Award Agreement:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In cash, by certified or bank check, by wire transfer of immediately available funds, or other instrument acceptable to the Committee;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If permitted by the Committee, by the optionee delivering to the Company a promissory note, if the Board has expressly authorized the loan of funds to the optionee for the purpose of enabling or assisting the optionee to effect the exercise of his or her Stock Option; <u>provided</u>, that at least so much of the exercise price as represents the par value of the Stock shall be paid in cash if required by state law;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(C)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If permitted by the Committee and the Initial Public Offering has occurred (or the Stock otherwise becomes publicly-traded), through the delivery (or attestation to the ownership) of Shares that have been purchased by the optionee on the open market or that are beneficially owned by the optionee and are not then subject to restrictions under any Company plan. To the extent required to avoid variable accounting treatment under ASC 718 or other applicable accounting rules, such surrendered Shares if originally purchased from the Company shall have been owned by the optionee for at least six months.&#160; Such surrendered Shares shall be valued at Fair Market Value on the exercise date;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(D)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If permitted by the Committee and the Initial Public Offering has occurred (or the Stock otherwise becomes publicly-traded), by the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="41952-2-KS-01_PB_9_064705_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=24851,FOLIO='9',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:25 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; <u>provided</u> that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Committee shall prescribe as a condition of such payment procedure; or</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(E)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If permitted by the Committee, and only with respect to Stock Options that are not Incentive Stock Options, by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of Shares issuable upon exercise by the largest whole number of Shares with a Fair Market Value that does not exceed the aggregate exercise price.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Payment instruments will be received subject to collection.&#160; No certificates for Shares so purchased will be issued to the optionee or, with respect to uncertificated Stock, no transfer to the optionee on the records of the Company will take place, until the Company has completed all steps it has deemed necessary to satisfy legal requirements relating to the issuance and sale of the Shares, which steps may include, without limitation, (i)&nbsp;receipt of a representation from the optionee at the time of exercise of the Option that the optionee is purchasing the Shares for the optionee&#146;s own account and not with a view to any sale or distribution of the Shares or other representations relating to compliance with applicable law governing the issuance of securities, (ii)&nbsp;the legending of the certificate (or notation on any book entry) representing the Shares to evidence the foregoing restrictions, and (iii)&nbsp;obtaining from optionee payment or provision for all withholding taxes due as a result of the exercise of the Option.&#160; The delivery of certificates representing the shares of Stock (or the transfer to the optionee on the records of the Company with respect to uncertificated Stock) to be purchased pursuant to the exercise of a Stock Option will be contingent upon (A)&nbsp;receipt from the optionee (or a purchaser acting in his or her stead in accordance with the provisions of the Stock Option) by the Company of the full purchase price for such Shares and the fulfillment of any other requirements contained in the Award Agreement or applicable provisions of laws and (B)&nbsp;if required by the Company, the optionee shall have entered into any stockholders agreements or other agreements with the Company and/or certain other of the Company&#146;s stockholders relating to the Stock.&#160; In the event an optionee chooses to pay the purchase price by previously-owned Shares through the attestation method, the number of Shares transferred to the optionee upon the exercise of the Stock Option shall be net of the number of Shares attested to.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Annual Limit on Incentive Stock Options</u>.&#160; To the extent required for &#147;incentive stock option&#148; treatment under Section&nbsp;422 of the Code, the aggregate Fair Market Value (determined as of the Grant Date) of the Shares with respect to which Incentive Stock Options granted under the Plan and any other plan of the Company or its parent and any Subsidiary that become exercisable for the first time by an optionee during any calendar year shall not exceed $100,000 or such other limit as may be in effect from time to time under Section&nbsp;422 of the Code.&#160; To the extent that any Stock Option exceeds this limit, it shall constitute a Non-Qualified Stock Option.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination</u>.&#160; Any portion of a Stock Option that is not vested and exercisable on the date of termination of an optionee&#146;s Service Relationship shall immediately expire and be null and void.&#160; Once any portion of the Stock Option becomes vested and exercisable, the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="41952-2-KS-01_PB_10_064738_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=729892,FOLIO='10',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:25 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">optionee&#146;s right to exercise such portion of the Stock Option (or the optionee&#146;s representatives and legatees as applicable) in the event of a termination of the optionee&#146;s Service Relationship shall continue until the earliest of: (i)&nbsp;the date which is: (A)&nbsp;12 months following the date on which the optionee&#146;s Service Relationship terminates due to death or Disability (or such longer period of time as determined by the Committee and set forth in the applicable Award Agreement), or (B)&nbsp;three months following the date on which the optionee&#146;s Service Relationship terminates if the termination is due to any reason other than death or Disability (or such longer period of time as determined by the Committee and set forth in the applicable Award Agreement), or (ii)&nbsp;the Expiration Date set forth in the Award Agreement; <u>provided</u> that notwithstanding the foregoing, an Award Agreement may provide that if the optionee&#146;s Service Relationship is terminated for Cause, the Stock Option shall terminate immediately and be null and void upon the date of the optionee&#146;s termination and shall not thereafter be exercisable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;6.&#160; <u>RESTRICTED STOCK AWARDS</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Nature of Restricted Stock Awards</u>.&#160;&#160; The Committee may, in its sole discretion, grant (or sell at par value or such other purchase price determined by the Committee) to an eligible individual under Section&nbsp;4 hereof a Restricted Stock Award under the Plan.&#160; The Committee shall determine the restrictions and conditions applicable to each Restricted Stock Award at the time of grant.&#160; Conditions may be based on continuing employment (or other Service Relationship), achievement of pre-established performance goals and objectives and/or such other criteria as the Committee may determine.&#160; Upon the grant of a Restricted Stock Award, the Company and the grantee shall enter into an Award Agreement.&#160; The terms and conditions of each such Award Agreement shall be determined by the Committee, and such terms and conditions may differ among individual Awards and grantees.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Rights as a Stockholder</u>.&#160; Upon the grant of the Restricted Stock Award and payment of any applicable purchase price, a grantee of Restricted Stock shall be considered the record owner of and shall be entitled to vote the Restricted Stock if, and to the extent, such Shares are entitled to voting rights, subject to such conditions contained in the Award Agreement.&#160; The grantee shall be entitled to receive all dividends and any other distributions declared on the Shares; <u>provided</u>, <u>however</u>, that the Company is under no duty to declare any such dividends or to make any such distribution.&#160; Unless the Committee shall otherwise determine, certificates evidencing the Restricted Stock shall remain in the possession of the Company until such Restricted Stock is vested as provided in subsection&nbsp;(d)&nbsp;below of this Section, and the grantee shall be required, as a condition of the grant, to deliver to the Company a stock power endorsed in blank and such other instruments of transfer as the Committee may prescribe.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Restrictions</u>.&#160; Restricted Stock may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically provided herein or in the Award Agreement.&#160; Except as may otherwise be provided by the Committee either in the Award Agreement or, subject to Section&nbsp;12 below, in writing after the Award Agreement is issued, if a grantee&#146;s Service Relationship with the Company and any Subsidiary terminates, the Company or its assigns shall have the right, as may be specified in the relevant instrument, to repurchase some or all of the Shares subject to the Award at such purchase price as is set forth in the Award Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="41952-2-KS-03_PB_11_064932_4516"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=676202,FOLIO='11',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:27 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Vesting of Restricted Stock</u>. The Committee at the time of grant shall specify in the Award Agreement the date or dates and/or the attainment of pre-established performance goals, objectives and other conditions on which the substantial risk of forfeiture imposed shall lapse and the Restricted Stock shall become vested, subject to such further rights of the Company or its assigns as may be specified in the Award Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;7.&#160; <u>UNRESTRICTED STOCK AWARDS</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Committee may, in its sole discretion, grant (or sell at par value or such other purchase price determined by the Committee) to an eligible person under Section&nbsp;4 hereof an Unrestricted Stock Award under the Plan.&#160; Unrestricted Stock Awards may be granted in respect of past services or other valid consideration, or in lieu of cash compensation due to such grantee.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;8.&#160; <u>RESTRICTED STOCK UNITS</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Nature of Restricted Stock Units</u>.&#160; The Committee may, in its sole discretion, grant to an eligible person under Section&nbsp;4 hereof Restricted Stock Units under the Plan.&#160; The Committee shall determine the restrictions and conditions applicable to each Restricted Stock Unit at the time of grant.&#160; Vesting conditions may be based on continuing employment (or other Service Relationship), achievement of pre-established performance goals and objectives and/or other such criteria as the Committee may determine.&#160; Upon the grant of Restricted Stock Units, the grantee and the Company shall enter into an Award Agreement.&#160; The terms and conditions of each such Award Agreement shall be determined by the Committee and may differ among individual Awards and grantees.&#160; On or promptly following the vesting date or dates applicable to any Restricted Stock Unit, but in no event later than March&nbsp;15 of the year following the year in which such vesting occurs, such Restricted Stock Unit(s)&nbsp;shall be settled in the form of cash or shares of Stock, as specified in the Award Agreement.&#160; Restricted Stock Units may not be sold, assigned, transferred, pledged, or otherwise encumbered or disposed of.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Rights as a Stockholder</u>. &#160;A grantee shall have the rights of a stockholder only as to Shares, if any, acquired upon settlement of Restricted Stock Units. A grantee shall not be deemed to have acquired any such Shares unless and until the Restricted Stock Units shall have been settled in Shares pursuant to the terms of the Plan and the Award Agreement, the Company shall have issued and delivered a certificate representing the Shares to the grantee (or transferred on the records of the Company with respect to uncertificated stock), and the grantee&#146;s name has been entered in the books of the Company as a stockholder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination</u>.&#160; Except as may otherwise be provided by the Committee either in the Award Agreement or in writing after the Award Agreement is issued, a grantee&#146;s right in all Restricted Stock Units that have not vested shall automatically terminate upon the grantee&#146;s cessation of Service Relationship with the Company and any Subsidiary for any reason.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="41952-2-KS-03_PB_12_065001_7091"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=346601,FOLIO='12',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:27 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .8in;text-indent:-.8in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;9.&#160; <u>TRANSFER RESTRICTIONS; COMPANY RIGHT OF FIRST REFUSAL; COMPANY REPURCHASE RIGHTS</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Restrictions on Transfer</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Non-Transferability of Stock Options</u>.&#160; Stock Options and, prior to exercise, the Shares issuable upon exercise of such Stock Option, shall not be transferable by the optionee otherwise than by will, or by the laws of descent and distribution, and all Stock Options shall be exercisable, during the optionee&#146;s lifetime, only by the optionee, or by the optionee&#146;s legal representative or guardian in the event of the optionee&#146;s incapacity.&#160; Notwithstanding the foregoing, the Committee, in its sole discretion, may provide in the Award Agreement regarding a given Stock Option that the optionee may transfer by gift, without consideration for the transfer, his or her Non-Qualified Stock Options to his or her family members (as defined in Rule&nbsp;701 of the Securities Act), to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners (to the extent such trusts or partnerships are considered &#147;family members&#148; for purposes of Rule&nbsp;701 of the Securities Act), provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award Agreement, including the execution of a stock power upon the issuance of Shares.&#160; Stock Options, and the Shares issuable upon exercise of such Stock Options, shall be restricted as to any pledge, hypothecation, or other transfer, including any short position, any &#147;put equivalent position&#148; (as defined in the Exchange Act) or any &#147;call equivalent position&#148; (as defined in the Exchange Act) prior to exercise.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Shares</u>.&#160; No Shares shall be sold, assigned, transferred, pledged, hypothecated, given away or in any other manner disposed of or encumbered, whether voluntarily or by operation of law, unless (i)&nbsp;the transfer is in compliance with the terms of the applicable Award Agreement, all applicable securities laws (including, without limitation, the Securities Act), and with the terms and conditions of this Section&nbsp;9, (ii)&nbsp;the transfer does not cause the Company to become subject to the reporting requirements of the Exchange Act, and (iii)&nbsp;the transferee consents in writing to be bound by the provisions of the Plan and the Award Agreement, including this Section&nbsp;9.&#160; In connection with any proposed transfer, the Committee may require the transferor to provide at the transferor&#146;s own expense an opinion of counsel to the transferor, satisfactory to the Committee, that such transfer is in compliance with all foreign, federal and state securities laws (including, without limitation, the Securities Act).&#160; Any attempted transfer of Shares not in accordance with the terms and conditions of this Section&nbsp;9 shall be null and void, and the Company shall not reflect on its records any change in record ownership of any Shares as a result of any such transfer, shall otherwise refuse to recognize any such transfer and shall not in any way give effect to any such transfer of Shares.&#160; The Company shall be entitled to seek protective orders, injunctive relief and other remedies available at law or in equity including, without limitation, seeking specific performance or the rescission of any transfer not made in strict compliance with the provisions of this Section&nbsp;9.&#160; Subject to the foregoing general provisions, and unless otherwise provided in the applicable Award Agreement, Shares may be transferred pursuant to the following specific terms and conditions (provided that with respect to any transfer of Restricted Stock, all vesting and forfeiture provisions shall continue to apply with respect to the original recipient):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="41952-2-KS-03_PB_13_065028_455"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=76685,FOLIO='13',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:27 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Transfers to Permitted Transferees</u>.&#160; The Holder may transfer any or all of the Shares to one or more Permitted Transferees; <i>provided, however</i>, that following such transfer, such Shares shall continue to be subject to the terms of this Plan (including this Section&nbsp;9) and such Permitted Transferee(s)&nbsp;shall, as a condition to any such transfer, deliver a written acknowledgment to that effect to the Company and shall deliver a stock power to the Company with respect to the Shares.&#160; Notwithstanding the foregoing, the Holder may not transfer any of the Shares to a Person whom the Company reasonably determines is a direct competitor or a potential competitor of the Company or any of its Subsidiaries.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Transfers Upon Death</u>.&#160; Upon the death of the Holder, any Shares then held by the Holder at the time of such death and any Shares acquired after the Holder&#146;s death by the Holder&#146;s legal representative shall be subject to the provisions of this Plan, and the Holder&#146;s estate, executors, administrators, personal representatives, heirs, legatees and distributees shall be obligated to convey such Shares to the Company or its assigns under the terms contemplated by the Plan and the Award Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Right of First Refusal</u>.&#160; In the event that a Holder desires at any time to sell or otherwise transfer all or any part of his or her Shares (other than shares of Restricted Stock which by their terms are not transferrable), the Holder first shall give written notice to the Company of the Holder&#146;s intention to make such transfer.&#160; Such notice shall state the number of Shares that the Holder proposes to sell (the &#147;Offered Shares&#148;), the price and the terms at which the proposed sale is to be made and the name and address of the proposed transferee.&#160; At any time within 30 days after the receipt of such notice by the Company, the Company or its assigns may elect to purchase all or any portion of the Offered Shares at the price and on the terms offered by the proposed transferee and specified in the notice.&#160; The Company or its assigns shall exercise this right by mailing or delivering written notice to the Holder within the foregoing 30-day period.&#160; If the Company or its assigns elect to exercise its purchase rights under this Section&nbsp;9(b), the closing for such purchase shall, in any event, take place within 45 days after the receipt by the Company of the initial notice from the Holder.&#160; In the event that the Company or its assigns do not elect to exercise such purchase right, or in the event that the Company or its assigns do not pay the full purchase price within such 45-day period, the Holder shall be required to pay a transaction processing fee of $10,000 to the Company (unless waived by the Committee) and then may, within 60 days thereafter, sell the Offered Shares to the proposed transferee and at the same price and on the same terms as specified in the Holder&#146;s notice.&#160; Any Shares not sold to the proposed transferee shall remain subject to the Plan.&#160; If the Holder is a party to any stockholders agreements or other agreements with the Company and/or certain other of the Company&#146;s stockholders relating to the Shares, (i)&nbsp;the transferring Holder shall comply with the requirements of such stockholders agreements or other agreements relating to any proposed transfer of the Offered Shares, and (ii)&nbsp;any proposed transferee that purchases Offered Shares shall enter into such stockholders agreements or other agreements with the Company and/or certain of the Company&#146;s stockholders relating to the Offered Shares on the same terms and in the same capacity as the transferring Holder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">14<a name="41952-2-KS-03_PB_14_065051_4141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=423385,FOLIO='14',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:27 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Company&#146;s Right of Repurchase</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Right of Repurchase for Unvested Shares Issued Upon the Exercise of an Option</u>.&#160; Upon a Termination Event, the Company or its assigns shall have the right and option to repurchase from a Holder of Shares acquired upon exercise of a Stock Option which are still subject to a risk of forfeiture as of the Termination Event.&#160; Such repurchase rights may be exercised by the Company within the later of (A)&nbsp;six months following the date of such Termination Event or (B)&nbsp;seven months after the acquisition of Shares upon exercise of a Stock Option.&#160; The repurchase price shall be equal to the lower of the original per share price paid by the Holder, subject to adjustment as provided in Section&nbsp;3(b)&nbsp;of the Plan, or the current Fair Market Value of such Shares as of the date the Company elects to exercise its repurchase rights.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Right of Repurchase With Respect to Restricted Stock</u>.&#160; Upon a Termination Event, the Company or its assigns shall have the right and option to repurchase from a Holder of Shares received pursuant to a Restricted Stock Award any Shares that are still subject to a risk of forfeiture as of the Termination Event.&#160; Such repurchase right may be exercised by the Company within six months following the date of such Termination Event.&#160; The repurchase price shall be the lower of the original per share purchase price paid by the Holder, subject to adjustment as provided in Section&nbsp;3(b)&nbsp;of the Plan, or the current Fair Market Value of such Shares as of the date the Company elects to exercise its repurchase rights.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Procedure</u>.&#160; Any repurchase right of the Company shall be exercised by the Company or its assigns by giving the Holder written notice on or before the last day of the repurchase period of its intention to exercise such repurchase right.&#160; Upon such notification, the Holder shall promptly surrender to the Company, free and clear of any liens or encumbrances, any certificates representing the Shares being purchased, together with a duly executed stock power for the transfer of such Shares to the Company or the Company&#146;s assignee or assignees.&#160; Upon the Company&#146;s or its assignee&#146;s receipt of the certificates from the Holder, the Company or its assignee or assignees shall deliver to him, her or them a check for the applicable repurchase price; <i>provided, however</i>, that the Company may pay the repurchase price by offsetting and canceling any indebtedness then owed by the Holder to the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Reserved</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Escrow Arrangement</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Escrow</u>.&#160; In order to carry out the provisions of this Section&nbsp;9 of this Plan more effectively, the Company shall hold any Shares issued pursuant to Awards granted under the Plan in escrow together with separate stock powers executed by the Holder in blank for transfer.&#160; The Company shall not dispose of the Shares except as otherwise provided in this Plan.&#160; In the event of any repurchase by the Company (or any of its assigns), the Company is hereby authorized by the Holder, as the Holder&#146;s attorney-in-fact, to date and complete the stock powers necessary for the transfer of the Shares being purchased and to transfer such Shares in accordance with the terms hereof.&#160; At such time as any Shares are no longer subject to the Company&#146;s repurchase and first refusal rights, the Company shall, at the written request of the Holder, deliver to the Holder a certificate representing such Shares with the balance of the Shares to be held in escrow pursuant to this Section.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">15<a name="41952-2-KS-03_PB_15_065121_8627"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=36601,FOLIO='15',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:27 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Remedy</u>.&#160; Without limitation of any other provision of this Plan or other rights, in the event that a Holder or any other Person is required to sell a Holder&#146;s Shares pursuant to the provisions of Sections 9(b)&nbsp;or (c)&nbsp;hereof and in the further event that he or she refuses or for any reason fails to deliver to the Company or its designated purchaser of such Shares the certificate or certificates evidencing such Shares together with a related stock power, the Company or such designated purchaser may deposit the applicable purchase price for such Shares with a bank designated by the Company, or with the Company&#146;s independent public accounting firm, as agent or trustee, or in escrow, for such Holder or other Person, to be held by such bank or accounting firm for the benefit of and for delivery to him, her, them or it, and/or, in its discretion, pay such purchase price by offsetting any indebtedness then owed by such Holder as provided above.&#160; Upon any such deposit and/or offset by the Company or its designated purchaser of such amount and upon notice to the Person who was required to sell the Shares to be sold pursuant to the provisions of Sections 9(b)&nbsp;or (c), such Shares shall at such time be deemed to have been sold, assigned, transferred and conveyed to such purchaser, such Holder shall have no further rights thereto (other than the right to withdraw the payment thereof held in escrow, if applicable), and the Company shall record such transfer in its stock transfer book or in any appropriate manner.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Lockup Provision</u>.&#160; If requested by the Company, a Holder shall not sell or otherwise transfer or dispose of any Shares (including, without limitation, pursuant to Rule&nbsp;144 under the Securities Act) held by him or her for such period following the effective date of a public offering by the Company of Shares as the Company shall specify reasonably and in good faith.&#160; If requested by the underwriter engaged by the Company, each Holder shall execute a separate letter confirming his or her agreement to comply with this Section.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Adjustments for Changes in Capital Structure</u>.&#160; If, as a result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Common Stock, the outstanding Shares are increased or decreased or are exchanged for a different number or kind of securities of the Company, the restrictions contained in this Section&nbsp;9 shall apply with equal force to additional and/or substitute securities, if any, received by Holder in exchange for, or by virtue of his or her ownership of, Shares.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination</u>.&#160; The terms and provisions of Section&nbsp;9(b)&nbsp;and Section&nbsp;9(c)&nbsp;(except for the Company&#146;s right to repurchase Shares still subject to a risk of forfeiture upon a Termination Event) shall terminate upon the closing of the Company&#146;s Initial Public Offering or upon consummation of any Sale Event, in either case as a result of which Shares are registered under Section&nbsp;12 of the Exchange Act and publicly-traded on any national security exchange.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;10.&#160; <u>TAX WITHHOLDING</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Payment by Grantee</u>. &#160;Each grantee shall, no later than the date as of which the value of an Award or of any Shares or other amounts received thereunder first becomes includable in the gross income of the grantee for income tax purposes, pay to the Company, or make arrangements satisfactory to the Committee regarding payment of, any Federal, state, or local taxes of any kind required by law to be withheld by the Company with respect to such income.&#160; The Company and any Subsidiary shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee.&#160; The</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">16<a name="41952-2-KS-03_PB_16_065139_7906"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=16,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=916894,FOLIO='16',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:27 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company&#146;s obligation to deliver stock certificates (or evidence of book entry) to any grantee is subject to and conditioned on any such tax withholding obligations being satisfied by the grantee.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Payment in Stock</u>.&#160; The Company&#146;s minimum required tax withholding obligation may be satisfied, in whole or in part, by the Company withholding from Shares to be issued pursuant to an Award a number of Shares having an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the minimum withholding amount due.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 78.0pt;text-indent:-78.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;11.&#160; <u>SECTION&nbsp;409A AWARDS.</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To the extent that any Award is determined to constitute &#147;nonqualified deferred compensation&#148; within the meaning of Section&nbsp;409A (a &#147;409A Award&#148;), the Award shall be subject to such additional rules&nbsp;and requirements as may be specified by the Committee from time to time.&#160; In this regard, if any amount under a 409A Award is payable upon a &#147;separation from service&#148; (within the meaning of Section&nbsp;409A) to a grantee who is considered a &#147;specified employee&#148; (within the meaning of Section&nbsp;409A), then no such payment shall be made prior to the date that is the earlier of (i)&nbsp;six months and one day after the grantee&#146;s separation from service, or (ii)&nbsp;the grantee&#146;s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section&nbsp;409A.&#160; The Company makes no representation or warranty and shall have no liability to any grantee under the Plan or any other Person with respect to any penalties or taxes under Section&nbsp;409A that are, or may be, imposed with respect to any Award.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;12.&#160; <u>AMENDMENTS AND TERMINATION</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Board may, at any time, amend or discontinue the Plan and the Committee may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall adversely affect rights under any outstanding Award without the consent of the holder of the Award.&#160; The Committee may exercise its discretion to reduce the exercise price of outstanding Stock Options or effect repricing through cancellation of outstanding Stock Options and by granting such holders new Awards in replacement of the cancelled Stock Options.&#160; To the extent determined by the Committee to be required either by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under Section&nbsp;422 of the Code or otherwise, Plan amendments shall be subject to approval by the Company stockholders entitled to vote at a meeting of stockholders.&#160; Nothing in this Section&nbsp;12 shall limit the Board&#146;s or Committee&#146;s authority to take any action permitted pursuant to Section&nbsp;3(c).&#160; The Board reserves the right to amend the Plan and/or the terms of any outstanding Stock Options to the extent reasonably necessary to comply with the requirements of the exemption pursuant to paragraph (f)(4)&nbsp;of Rule&nbsp;12h-1 of the Exchange Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;13.&#160; <u>STATUS OF PLAN</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">With respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Committee shall otherwise expressly so determine in connection with any Award.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">17<a name="41952-2-KS-03_PB_17_065203_3736"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=17,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=345655,FOLIO='17',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:27 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;14.&#160; <u>GENERAL PROVISIONS</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Distribution; Compliance with Legal Requirements</u>. The Committee may require each person acquiring Shares pursuant to an Award to represent to and agree with the Company in writing that such person is acquiring the Shares without a view to distribution thereof.&#160; No Shares shall be issued pursuant to an Award until all applicable securities law and other legal and stock exchange or similar requirements have been satisfied.&#160; The Committee may require the placing of such stop-orders and restrictive legends on certificates for Stock and Awards as it deems appropriate.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Delivery of Stock Certificates</u>.&#160; Stock certificates to grantees under the Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee, at the grantee&#146;s last known address on file with the Company; provided that stock certificates to be held in escrow pursuant to Section&nbsp;9 of the Plan shall be deemed delivered when the Company shall have recorded the issuance in its records.&#160; Uncertificated Stock shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have given to the grantee by electronic mail (with proof of receipt) or by United States mail, addressed to the grantee, at the grantee&#146;s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic &#147;book entry&#148; records).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Employment Rights</u><b>.&#160; </b>The adoption of the Plan and the grant of Awards do not confer upon any Person any right to continued employment or Service Relationship with the Company or any Subsidiary.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Trading Policy Restrictions</u>.&#160; Option exercises and other Awards under the Plan shall be subject to the Company&#146;s insider trading policy-related restrictions, terms and conditions as may be established by the Committee, or in accordance with policies set by the Committee, from time to time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Designation of Beneficiary</u>.&#160; Each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award on or after the grantee&#146;s death or receive any payment under any Award payable on or after the grantee&#146;s death.&#160; Any such designation shall be on a form provided for that purpose by the Committee and shall not be effective until received by the Committee.&#160; If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee&#146;s estate.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Legend</u>.&#160; Any certificate(s)&nbsp;representing the Shares shall carry substantially the following legend (and with respect to uncertificated Stock, the book entries evidencing such shares shall contain the following notation):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The transferability of this certificate and the shares of stock represented hereby are subject to the restrictions, terms and conditions (including repurchase and restrictions against transfers) contained in the Akero Therapeutics,&nbsp;Inc. 2018 Stock Option and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">18<a name="41952-2-KS-03_PB_18_065227_9621"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=18,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=511078,FOLIO='18',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:27 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant Plan and any agreements entered into thereunder by and between the company and the holder of this certificate (a copy of which is available at the offices of the company for examination).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Information to Holders of Options</u>.&#160; In the event the Company is relying on the exemption from the registration requirements of Section&nbsp;12(g)&nbsp;of the Exchange Act contained in paragraph (f)(1)&nbsp;of Rule&nbsp;12h-1 of the Exchange Act, the Company shall provide the information described in Rule&nbsp;701(e)(3), (4)&nbsp;and (5)&nbsp;of the Securities Act to all holders of Options in accordance with the requirements thereunder.&#160; The foregoing notwithstanding, the Company shall not be required to provide such information unless the optionholder has agreed in writing, on a form prescribed by the Company, to keep such information confidential.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;15.&#160; <u>EFFECTIVE DATE OF PLAN</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Plan shall become effective upon adoption by the Board and shall be approved by stockholders in accordance with applicable state law and the Company&#146;s articles of incorporation and bylaws within 12 months thereafter.&#160; If the stockholders fail to approve the Plan within 12 months after its adoption by the Board of Directors, then any Awards granted or sold under the Plan shall be rescinded and no additional grants or sales shall thereafter be made under the Plan.&#160; </font>Subject to such approval by stockholders and to the requirement that no Shares may be issued hereunder prior to such approval, Stock Options and other Awards may be granted hereunder on and after adoption of the Plan by the Board.&#160; No grants of Stock Options and other Awards may be made hereunder after the tenth anniversary of the date the Plan is adopted by the Board or the date the Plan is approved by the Company&#146;s stockholders, whichever is earlier.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;16.&#160; <u>GOVERNING LAW</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Plan, all Awards and any controversy arising out of or relating to this Plan and all Awards shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to conflict of law principles that would result in the application of any law other than the law of the Commonwealth of Massachusetts.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DATE ADOPTED BY THE BOARD OF DIRECTORS:</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>June&nbsp;7, 2018</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DATE APPROVED BY THE STOCKHOLDERS:</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>June&nbsp;7, 2018</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">19<a name="41952-2-KS-03_PB_19_065249_8715"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=19,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=882244,FOLIO='19',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 13:27 2019' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NON-QUALIFIED STOCK OPTION GRANT NOTICE</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">UNDER THE AKERO THERAPEUTICS,&nbsp;INC.<br> 2018 STOCK OPTION AND GRANT PLAN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the Akero Therapeutics,&nbsp;Inc. 2018 Stock Option and Grant Plan (the &#147;Plan&#148;), Akero Therapeutics,&nbsp;Inc., a Delaware corporation (together with any successor, the &#147;Company&#148;), has granted to the individual named below, an option (the &#147;Stock Option&#148;) to purchase on or prior to the Expiration Date, or such earlier date as is specified herein, all or any part of the number of shares of Common Stock, par value $0.0001 per share (&#147;Common Stock&#148;), of the Company indicated below (the &#147;Shares&#148;), at the Option Exercise Price per share, subject to the terms and conditions set forth in this Non-Qualified Stock Option Grant Notice (the &#147;Grant Notice&#148;), the attached Non-Qualified Stock Option Agreement (the &#147;Agreement&#148;) and the Plan.&#160; This Stock Option is not intended to qualify as an &#147;incentive stock option&#148; as defined in Section&nbsp;422(b)&nbsp;of the Internal Revenue Code of 1986, as amended from time to time (the &#147;Code&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name of Optionee:</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(the   &#147;Optionee&#148;)</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">No.&nbsp;of Shares</font>:</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares   of Common Stock</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant Date:</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Commencement   Date:</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(the   &#147;Vesting Commencement Date&#148;)</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expiration Date:</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(the   &#147;Expiration Date&#148;)</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Option Exercise Price/Share:</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(the   &#147;Option Exercise Price&#148;)</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="26%" valign="top" style="padding:0in 0in 0in 0in;width:26.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Schedule:</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25 percent of the   Shares shall vest and become exercisable on the first anniversary of the   Vesting Commencement Date; provided that the Optionee continues to have a   Service Relationship with the Company at such time. Thereafter, the remaining   75 percent of the Shares shall vest and become exercisable in 36 equal   monthly installments following the first anniversary of the Vesting   Commencement Date, provided the Optionee continues to have a Service   Relationship with the Company on each vesting date. Notwithstanding anything   in the Agreement to the contrary, in the case of a Sale Event, this Stock   Option and the Shares shall be treated as provided in   Section&nbsp;3(c)&nbsp;of the Plan<b>[ provided; however   INSERT ANY ACCELERATED VESTING PROVISION HERE]</b>.(1)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade align="left" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;text-indent:.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&nbsp; Here is a sample double trigger acceleration provision:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding anything herein to the contrary, in the event (and only in the event) that this Stock Option or the Shares are assumed or continued by the Company or its successor entity in the sole discretion of the parties to a Sale Event and thereafter remains in effect following such Sale Event, then [50% of] the then-unvested Shares shall be deemed vested in full upon the date on which the Optionee&#146;s Service Relationship with the Company and its Subsidiaries or successor entity terminates if (A)&nbsp;such termination occurs in connection with and effective as of the date of, or within 12 months following the date of, such Sale Event and (B)&nbsp;such termination is either by the Company without Cause or by the Optionee for Good Reason.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=20,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=630451,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:39 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Attachments</font></b>:&#160; Non-Qualified Stock Option Agreement, 2018 Stock Option and Grant Plan</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="41952-2-KS-05_PB_2_070255_2761"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=21,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=247679,FOLIO='2',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:39 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NON-QUALIFIED STOCK OPTION AGREEMENT<br> UNDER THE AKERO THERAPEUTICS,&nbsp;INC.<br> 2018 STOCK OPTION AND GRANT PLAN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Grant Notice and the Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Vesting, Exercisability and Termination</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>No portion of this Stock Option may be exercised until such portion shall have vested and become exercisable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except as set forth below, and subject to the determination of the Committee in its sole discretion to accelerate the vesting schedule hereunder, this Stock Option shall be vested and exercisable on the respective dates indicated below:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Stock Option shall initially be unvested and unexercisable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Stock Option shall vest and become exercisable in accordance with the Vesting Schedule set forth in the Grant Notice.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination</u>.&#160; Except as may otherwise be provided by the Committee, if the Optionee&#146;s Service Relationship is terminated, the period within which to exercise this Stock Option will be subject to earlier termination as set forth below (and if not exercised within such period, shall thereafter terminate subject, in each case, to Section&nbsp;3(c)&nbsp;of the Plan):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination Due to Death or Disability</u>.&#160; If the Optionee&#146;s Service Relationship terminates by reason of such Optionee&#146;s death or Disability, this Stock Option may be exercised, to the extent exercisable on the date of such termination, by the Optionee, the Optionee&#146;s legal representative or legatee for a period of 12 months from the date of death or Disability or until the Expiration Date, if earlier.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Other Termination</u>.&#160; If the Optionee&#146;s Service Relationship terminates for any reason other than death or Disability, and unless otherwise determined by the Committee, this Stock Option may be exercised, to the extent exercisable on the date of termination, for a period of 90 days from the date of termination or until the Expiration Date, if earlier; <u>provided however</u>, if the Optionee&#146;s Service Relationship is terminated for Cause, this Stock Option shall terminate immediately upon the date of such termination.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For purposes hereof, the Committee&#146;s determination of the reason for termination of the Optionee&#146;s Service Relationship shall be conclusive and binding on the Optionee and his or her representatives or legatees and any Permitted Transferee.&#160; Any portion of this Stock Option that is not vested and exercisable on the date of termination of the Service Relationship shall terminate immediately and be null and void.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="41952-2-KS-05_PB_3_070338_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=22,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=576143,FOLIO='3',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:39 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Exercise of Stock Option</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Optionee may exercise this Stock Option only in the following manner:&#160; Prior to the Expiration Date, the Optionee may deliver a Stock Option exercise notice (an &#147;Exercise Notice&#148;) in the form of <u>Appendix&nbsp;A</u> hereto indicating his or her election to purchase some or all of the Shares with respect to which this Stock Option is then exercisable.&#160; Such notice shall specify the number of Shares to be purchased.&#160; Payment of the purchase price may be made by one or more of the methods described in Section&nbsp;5 of the Plan, subject to the limitations contained in such Section&nbsp;of the Plan, including the requirement that the Committee specifically approve in advance certain payment methods.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Incorporation of Plan</u>.&#160; Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Transferability of Stock Option</u>.&#160; This Stock Option is personal to the Optionee and is not transferable by the Optionee in any manner other than by will or by the laws of descent and distribution.&#160; The Stock Option may be exercised during the Optionee&#146;s lifetime only by the Optionee (or by the Optionee&#146;s guardian or personal representative in the event of the Optionee&#146;s incapacity).&#160; The Optionee may elect to designate a beneficiary by providing written notice of the name of such beneficiary to the Company, and may revoke or change such designation at any time by filing written notice of revocation or change with the Company; such beneficiary may exercise the Optionee&#146;s Stock Option in the event of the Optionee&#146;s death to the extent provided herein.&#160; If the Optionee does not designate a beneficiary, or if the designated beneficiary predeceases the Optionee, the legal representative of the Optionee may exercise this Stock Option to the extent provided herein in the event of the Optionee&#146;s death.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Restrictions on Transfer of Shares</u>.&#160; The Shares acquired upon exercise of the Stock Option shall be subject to certain transfer restrictions and other limitations including, without limitation, the provisions contained in Section&nbsp;9 of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Miscellaneous Provisions</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Equitable Relief</u>.&#160; The parties hereto agree and declare that legal remedies may be inadequate to enforce the provisions of this Agreement and that equitable relief, including specific performance and injunctive relief, may be used to enforce the provisions of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Adjustments for Changes in Capital Structure</u>.&#160; If, as a result of any reorganization, recapitalization, reincorporation, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Common Stock, the outstanding shares of Common Stock are increased or decreased or are exchanged for a different number or kind of securities of the Company, the restrictions contained in this Agreement shall apply with equal force to additional and/or substitute securities, if any, received by the Optionee in exchange for, or by virtue of his or her ownership of, this Stock Option or Shares acquired pursuant thereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="41952-2-KS-05_PB_4_070408_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=23,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=788752,FOLIO='4',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:39 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Change and Modifications</u>.&#160; This Agreement may not be orally changed, modified or terminated, nor shall any oral waiver of any of its terms be effective.&#160; This Agreement may be changed, modified or terminated only by an agreement in writing signed by the Company and the Optionee.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governing Law</u>.&#160; This Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to conflict of law principles that would result in the application of any law other than the law of the State of the Commonwealth of Massachusetts.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Headings</u>.&#160; The headings are intended only for convenience in finding the subject matter and do not constitute part of the text of this Agreement and shall not be considered in the interpretation of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Saving Clause</u>.&#160; If any provision(s)&nbsp;of this Agreement shall be determined to be illegal or unenforceable, such determination shall in no manner affect the legality or enforceability of any other provision hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notices</u>.&#160; All notices, requests, consents and other communications shall be in writing and be deemed given when delivered personally, by telex or facsimile transmission or when received if mailed by first class registered or certified mail, postage prepaid.&#160; Notices to the Company or the Optionee shall be addressed as set forth underneath their signatures below, or to such other address or addresses as may have been furnished by such party in writing to the other.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Benefit and Binding Effect</u>.&#160; This Agreement shall be binding upon and shall inure to the benefit of the parties hereto, their respective successors, assigns, and legal representatives.&#160; The Company has the right to assign this Agreement, and such assignee shall become entitled to all the rights of the Company hereunder to the extent of such assignment.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Counterparts</u>.&#160; For the convenience of the parties and to facilitate execution, this Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same document.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Integration</u>.&#160; This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Dispute Resolution</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except as provided below, any dispute arising out of or relating to the Plan or this Stock Option, this Agreement, or the breach, termination or validity of the Plan, this Stock Option or this Agreement, shall be finally settled by binding arbitration conducted expeditiously in accordance with the J.A.M.S./Endispute Comprehensive Arbitration Rules&nbsp;and Procedures (the &#147;J.A.M.S. Rules&#148;).&#160; The arbitration shall be governed by the United States Arbitration Act, 9</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="41952-2-KS-05_PB_5_070444_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=24,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=398945,FOLIO='5',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:39 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">U.S.C. Sections 1-16, and judgment upon the award rendered by the arbitrators may be entered by any court having jurisdiction thereof.&#160; The place of arbitration shall be Boston, Massachusetts.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The arbitration shall commence within 60 days of the date on which a written demand for arbitration is filed by any party hereto.&#160; In connection with the arbitration proceeding, the arbitrator shall have the power to order the production of documents by each party and any third-party witnesses.&#160; In addition, each party may take up to three depositions as of right, and the arbitrator may in his or her discretion allow additional depositions upon good cause shown by the moving party.&#160; However, the arbitrator shall not have the power to order the answering of interrogatories or the response to requests for admission.&#160; In connection with any arbitration, each party to the arbitration shall provide to the other, no later than seven business days before the date of the arbitration, the identity of all persons that may testify at the arbitration and a copy of all documents that may be introduced at the arbitration or considered or used by a party&#146;s witness or expert.&#160; The arbitrator&#146;s decision and award shall be made and delivered within six months of the selection of the arbitrator.&#160; The arbitrator&#146;s decision shall set forth a reasoned basis for any award of damages or finding of liability.&#160; The arbitrator shall not have power to award damages in excess of actual compensatory damages and shall not multiply actual damages or award punitive damages, and each party hereby irrevocably waives any claim to such damages.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company, the Optionee, each party to the Agreement and any other holder of Shares issued pursuant to this Agreement (each, a &#147;Party&#148;) covenants and agrees that such party will participate in the arbitration in good faith.&#160; This Section&nbsp;7 applies equally to requests for temporary, preliminary or permanent injunctive relief, except that in the case of temporary or preliminary injunctive relief any party may proceed in court without prior arbitration for the limited purpose of avoiding immediate and irreparable harm.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each Party (i)&nbsp;hereby irrevocably submits to the jurisdiction of any United States District Court of competent jurisdiction for the purpose of enforcing the award or decision in any such proceeding, (ii)&nbsp;hereby waives, and agrees not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above named courts, that its property is exempt or immune from attachment or execution (except as protected by applicable law), that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court, and (iii)&nbsp;hereby waives and agrees not to seek any review by any court of any other jurisdiction which may be called upon to grant an enforcement of the judgment of any such court.&#160; Each Party hereby consents to service of process by registered mail at the address to which notices are to be given.&#160; Each Party agrees that its, his or her submission to jurisdiction and its, his or her consent to service of process by mail is made for the express benefit of each other Party.&#160; Final judgment against any Party in any such action, suit or proceeding may be enforced in other jurisdictions by suit, action or proceeding on the judgment, or in any other manner provided by or pursuant to the laws of such other jurisdiction.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Waiver of Statutory Information Rights</u>.&#160; The Optionee understands and agrees that, but for the waiver made herein, the Optionee would be entitled, upon written demand under oath stating the purpose thereof, to inspect for any proper purpose, and to make copies and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="41952-2-KS-05_PB_6_070507_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=25,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=818099,FOLIO='6',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:39 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">extracts from, the Company&#146;s stock ledger, a list of its stockholders, and its other books and records, and the books and records of subsidiaries of the Company, if any, under the circumstances and in the manner provided in Section&nbsp;220 of the General Corporation Law of Delaware (any and all such rights, and any and all such other rights of the Optionee as may be provided for in Section&nbsp;220, the &#147;Inspection Rights&#148;). In light of the foregoing, until the first sale of Stock of the Company to the general public pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission under the Securities Act, the Optionee hereby unconditionally and irrevocably waives the Inspection Rights, whether such Inspection Rights would be exercised or pursued directly or indirectly pursuant to Section&nbsp;220 or otherwise, and covenants and agrees never to directly or indirectly commence, voluntarily aid in any way, prosecute, assign, transfer, or cause to be commenced any claim, action, cause of action, or other proceeding to pursue or exercise the Inspection Rights. The foregoing waiver shall not affect any rights of a director, in his or her capacity as such, under Section&nbsp;220. The foregoing waiver shall not apply to any contractual inspection rights of the Optionee under any other written agreement between the Optionee and the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[SIGNATURE PAGE FOLLOWS]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="41952-2-KS-05_PB_7_070520_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=26,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=914506,FOLIO='7',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:39 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned as of the date first above written.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AKERO   THERAPEUTICS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The undersigned hereby acknowledges receiving and reviewing a copy of the Plan, including, without limitation, Section&nbsp;9 thereof, and understands that this Stock Option is subject to the terms of the Plan and of this Agreement.&#160; This Agreement is hereby accepted, and the terms and conditions of the Plan, the Grant Notice and this Agreement, SPECIFICALLY INCLUDING THE ARBITRATION PROVISIONS SET FORTH IN SECTION&nbsp;7 AND THE WAIVER OF STATUTORY INFORMATION RIGHTS SET FORTH IN SECTION&nbsp;8 OF THIS AGREEMENT, are hereby agreed to, by the undersigned as of the date first above written.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OPTIONEE:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="41952-2-KS-05_PB_8_071112_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=27,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=811342,FOLIO='8',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:39 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[SPOUSE&#146;S CONSENT(2)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I acknowledge that I have read the</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">foregoing Non-Qualified Stock Option Agreement</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and understand the contents thereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade align="left" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;text-indent:.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&nbsp; A spouse&#146;s consent is recommended only if the Optionee&#146;s state of residence is one of the following community property states:&#160; Arizona, California,&nbsp;Idaho, Louisiana, Nevada, New Mexico, Texas, Washington and Wisconsin.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="41952-2-KS-05_PB_9_071606_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=28,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=884537,FOLIO='9',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:39 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DESIGNATED BENEFICIARY:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Beneficiary&#146;s Address:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="41952-2-KS-05_PB_10_072641_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=29,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=766108,FOLIO='10',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:39 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Appendix A</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">STOCK OPTION EXERCISE NOTICE</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Akero Therapeutics,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention: President</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the terms of the grant notice and stock option agreement between the undersigned and Akero Therapeutics,&nbsp;Inc. (the &#147;Company&#148;) dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (the &#147;Agreement&#148;) under the Akero Therapeutics,&nbsp;Inc. 2018 Stock Option and Grant Plan,&nbsp;I, [Insert Name] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, hereby [Circle One] partially/fully exercise such option by including herein payment in the amount of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; representing the purchase price for [Fill in number of Shares] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares.&#160; I have chosen the following form(s)&nbsp;of payment:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>1.<font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Cash</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>2.<font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Certified or bank check payable to Akero Therapeutics,&nbsp;Inc.</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 2.0in;text-indent:-1.0in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>3.<font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Other (as referenced in the Agreement and described in the Plan (please describe))&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with my exercise of the option as set forth above,&nbsp;I hereby represent and warrant to the Company as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I am purchasing the Shares for my own account for investment only, and not for resale or with a view to the distribution thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I have had such an opportunity as I have deemed adequate to obtain from the Company such information as is necessary to permit me to evaluate the merits and risks of my investment in the Company and have consulted with my own advisers with respect to my investment in the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I have sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the purchase of the Shares and to make an informed investment decision with respect to such purchase.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I can afford a complete loss of the value of the Shares and am able to bear the economic risk of holding such Shares for an indefinite period of time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I understand that the Shares may not be registered under the Securities Act of 1933 (it being understood that the Shares are being issued and sold in reliance on the exemption provided in Rule&nbsp;701 thereunder) or any applicable state securities or &#147;blue sky&#148; laws and may not be sold or otherwise transferred or disposed of</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="41952-2-KS-05_PB_11_081824_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=30,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=168350,FOLIO='11',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:39 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">in the absence of an effective registration statement under the Securities Act of 1933 and under any applicable state securities or &#147;blue sky&#148; laws (or exemptions from the registration requirement thereof).&#160; I further acknowledge that certificates representing Shares will bear restrictive legends reflecting the foregoing and/or that book entries for uncertificated Shares will include similar restrictive notations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I have read and understand the Plan and acknowledge and agree that the Shares are subject to all of the relevant terms of the Plan, including without limitation, the transfer restrictions set forth in Section&nbsp;9 of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I understand and agree that the Company has a right of first refusal with respect to the Shares pursuant to Section&nbsp;9(b)&nbsp;of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(viii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I understand and agree that the Company has certain repurchase rights with respect to the Shares pursuant to Section&nbsp;9(c)&nbsp;of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ix)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I understand and agree that I may not sell or otherwise transfer or dispose of the Shares for a period of time following the effective date of a public offering by the Company as described in Section&nbsp;9(f)&nbsp;of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(x)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I understand and agree to the waiver of statutory information rights as set forth in Section&nbsp;8 of the Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sincerely yours,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="41952-2-KS-05_PB_12_081954_7091"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=31,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=911348,FOLIO='12',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:39 2019' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RESTRICTED STOCK AWARD NOTICE<br> UNDER THE AKERO THERAPEUTICS,&nbsp;INC.<br> 2018 STOCK OPTION AND GRANT PLAN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the Akero Therapeutics,&nbsp;Inc. 2018 Stock Option and Grant Plan (the &#147;Plan&#148;), Akero Therapeutics,&nbsp;Inc., a Delaware corporation (together with any successor, the &#147;Company&#148;), hereby grants, sells and issues to the individual named below, the Shares at the Per Share Purchase Price, subject to the terms and conditions set forth in this Restricted Stock Award Notice (the &#147;Award Notice&#148;), the attached Restricted Stock Agreement (the &#147;Agreement&#148;) and the Plan.&#160; The Grantee agrees to the provisions set forth herein and acknowledges that each such provision is a material condition of the Company&#146;s agreement to issue and sell the Shares to him or her.&#160; The Company hereby acknowledges receipt of $<b>[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</b> in full payment for the Shares.&#160; All references to share prices and amounts herein shall be equitably adjusted to reflect stock splits, stock dividends, recapitalizations, mergers, reorganizations and similar changes affecting the capital stock of the Company, and any shares of capital stock of the Company received on or in respect of Shares in connection with any such event (including any shares of capital stock or any right, option or warrant to receive the same or any security convertible into or exchangeable for any such shares or received upon conversion of any such shares) shall be subject to this Agreement on the same basis and extent at the relevant time as the Shares in respect of which they were issued, and shall be deemed Shares as if and to the same extent they were issued at the date hereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name of Grantee:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   (the &#147;Grantee&#148;)</font></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No.&nbsp;of Shares:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Shares of Common Stock (the &#147;Shares&#148;)</font></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant Date:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,</font></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Purchase of Shares:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,</font></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Commencement Date:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   (the &#147;Vesting Commencement Date&#148;)</font></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Per Share Purchase Price:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(the &#147;Per Share Purchase Price&#148;)</font></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Schedule:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25 percent of the Shares shall vest on the first   anniversary of the Vesting Commencement Date; provided that the Grantee   continues to have a Service Relationship with the Company at such time.   Thereafter, the remaining 75 percent of the Shares shall vest in 36 equal   monthly installments following the first anniversary of the Vesting   Commencement Date, provided the Grantee continues to have a Service   Relationship with the Company at such time. Notwithstanding anything in the   Agreement to the contrary in the case of a Sale Event, the Shares of   Restricted Stock shall be treated as provided in Section&nbsp;3(c) </font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=32,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=894916,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 11:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 156.25pt;text-indent:-156.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="73%" valign="top" style="padding:0in 0in 0in 0in;width:73.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of the Plan <b>[provided; however INSERT ANY ACCELERATED VESTING   PROVISION HERE]</b>.(1)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt 156.25pt;text-indent:-156.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 156.25pt;text-indent:-156.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attachments:&#160; Restricted Stock Agreement, 2018 Stock Option and Grant Plan</font></p>
<p style="margin:0in 0in .0001pt 156.25pt;text-indent:-156.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade align="left" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;text-indent:.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&nbsp; Here is a sample double trigger acceleration provision:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding anything herein to the contrary, in the event that the Shares of Restricted Stock are assumed or continued by the Company or its successor entity in the sole discretion of the parties to a Sale Event and thereafter remain in effect following such Sale Event, then [50% of] the then-unvested Shares shall be deemed vested in full upon the date on which the Grantee&#146;s Service Relationship with the Company and its Subsidiaries or successor entity terminates if (A)&nbsp;such termination occurs in connection with and effective as of the date of, or within 12 months following the date of, such Sale Event and (B)&nbsp;such termination is either by the Company without Cause or by the Grantee for Good Reason.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="41952-2-KS-07_PB_2_082819_1259"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=33,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=814542,FOLIO='2',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 11:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RESTRICTED STOCK AGREEMENT<br> UNDER THE AKERO THERAPEUTICS,&nbsp;INC.<br> 2018 STOCK OPTION AND GRANT PLAN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Award Notice and the Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Purchase and Sale of Shares; Vesting; Investment Representations</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Purchase and Sale</u>.&#160; The Company hereby sells to the Grantee, and the Grantee hereby purchases from the Company, the number of Shares set forth in the Award Notice for the Per Share Purchase Price.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Vesting</u>.&#160; Initially, all of the Shares are non-transferable and subject to a substantial risk of forfeiture and are Shares of Restricted Stock.&#160; The risk of forfeiture shall lapse with respect to the Shares on the respective dates indicated on the Vesting Schedule set forth in the Award Notice.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Investment Representations</u>.&#160; In connection with the purchase and sale of the Shares contemplated by Section&nbsp;1(a)&nbsp;above, the Grantee hereby represents and warrants to the Company as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Grantee is purchasing the Shares for the Grantee&#146;s own account for investment only, and not for resale or with a view to the distribution thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Grantee has had such an opportunity as he or she has deemed adequate to obtain from the Company such information as is necessary to permit him or her to evaluate the merits and risks of the Grantee&#146;s investment in the Company and has consulted with the Grantee&#146;s own advisers with respect to the Grantee&#146;s investment in the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Grantee has sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the purchase of the Shares and to make an informed investment decision with respect to such purchase.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Grantee can afford a complete loss of the value of the Shares and is able to bear the economic risk of holding such Shares for an indefinite period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Grantee understands that the Shares are not registered under the Act (it being understood that the Shares are being issued and sold in reliance on the exemption provided in Rule&nbsp;701 thereunder) or any applicable state securities or &#147;blue sky&#148; laws and may not be sold or otherwise transferred or disposed of in the absence of an effective registration statement under the Act and under any applicable state securities or &#147;blue sky&#148; laws (or exemptions from the registration requirements thereof).&#160; The Grantee further acknowledges that certificates representing the Shares will bear</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="41952-2-KS-07_PB_3_082851_455"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=34,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=751732,FOLIO='3',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 11:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">restrictive legends reflecting the foregoing and/or that book entries for uncertificated Shares will include similar restrictive notations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Grantee has read and understands the Plan and acknowledges and agrees that the Shares are subject to all of the relevant terms of the Plan, including without limitation, the transfer restrictions set forth in Section&nbsp;9 of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Grantee understands and agrees that the Company has a right of first refusal with respect to the Shares pursuant to Section&nbsp;9(b)&nbsp;of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(viii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Grantee understands and agree that the Company has certain repurchase rights with respect to the Shares pursuant to Section&nbsp;9(c)&nbsp;of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ix)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Grantee understands and agrees that the Grantee may not sell or otherwise transfer or dispose of the Shares for a period of time following the effective date of a public offering by the Company as described in Section&nbsp;9(f)&nbsp;of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Repurchase Right</u>.&#160; Upon a Termination Event, the Company shall have the right to repurchase Shares of Restricted Stock that are unvested as of the date of such Termination Event as set forth in Section&nbsp;9(c)&nbsp;of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Restrictions on Transfer of Shares</u>.&#160; The Shares (whether or not vested) shall be subject to certain transfer restrictions and other limitations including, without limitation, the provisions contained in Section&nbsp;9 of the Plan</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Incorporation of Plan</u>.&#160; Notwithstanding anything herein to the contrary, this Restricted Stock Award shall be subject to and governed by all the terms and conditions of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Miscellaneous Provisions</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Record Owner; Dividends</u>.&#160; The Grantee and any Permitted Transferees, during the duration of this Agreement, shall be considered the record owners of and shall be entitled to vote the Shares if and to the extent the Shares are entitled to voting rights.&#160; The Grantee and any Permitted Transferees shall be entitled to receive all dividends and any other distributions declared on the Shares; <u>provided</u>, <u>however</u>, that the Company is under no duty to declare any such dividends or to make any such distribution.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Section&nbsp;83(b)&nbsp;Election</u>.&#160; The Grantee shall consult with the Grantee&#146;s tax advisor to determine whether it would be appropriate for the Grantee to make an election under Section&nbsp;83(b)&nbsp;of the Code with respect to this Award.&#160; Any such election must be filed with the Internal Revenue Service within 30 days of the date of this Award.&#160; If the Grantee makes an election under Section&nbsp;83(b)&nbsp;of the Code, the Grantee shall give prompt notice to the Company (and provide a copy of such election to the Company).&#160; A sample Section&nbsp;83(b)&nbsp;election is attached to this Agreement as Exhibit&nbsp;A.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Equitable Relief</u>.&#160; The parties hereto agree and declare that legal remedies may be inadequate to enforce the provisions of this Agreement and that equitable relief,</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="41952-2-KS-07_PB_4_082924_4141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=35,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=958758,FOLIO='4',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 11:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">including specific performance and injunctive relief, may be used to enforce the provisions of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Change and Modifications</u>.&#160; This Agreement may not be orally changed, modified or terminated, nor shall any oral waiver of any of its terms be effective. This Agreement may be changed, modified or terminated only by an agreement in writing signed by the Company and the Grantee.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governing Law</u>.&#160; This Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to conflict of law principles that would result in the application of any law other than the law of the Commonwealth of Massachusetts.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Headings</u>.&#160; The headings are intended only for convenience in finding the subject matter and do not constitute part of the text of this Agreement and shall not be considered in the interpretation of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Saving Clause</u>.&#160; If any provision(s)&nbsp;of this Agreement shall be determined to be illegal or unenforceable, such determination shall in no manner affect the legality or enforceability of any other provision hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notices</u>.&#160; All notices, requests, consents and other communications shall be in writing and be deemed given when delivered personally, by telex or facsimile transmission or when received if mailed by first class registered or certified mail, postage prepaid.&#160; Notices to the Company or the Grantee shall be addressed as set forth underneath their signatures below, or to such other address or addresses as may have been furnished by such party in writing to the other.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Benefit and Binding Effect</u>.&#160; This Agreement shall be binding upon and shall inure to the benefit of the parties hereto, their respective successors, assigns, and legal representatives.&#160; The Company has the right to assign this Agreement, and such assignee shall become entitled to all the rights of the Company hereunder to the extent of such assignment.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Counterparts</u>.&#160; For the convenience of the parties and to facilitate execution, this Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same document.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(k)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Integration</u>.&#160; This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Dispute</u><u> Resolution</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except as provided below, any dispute arising out of or relating to the Plan or the Shares, this Agreement, or the breach, termination or validity of the Plan, the Shares or this Agreement, shall be finally settled by binding arbitration conducted expeditiously in</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="41952-2-KS-07_PB_5_082951_8627"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=36,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=913661,FOLIO='5',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 11:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">accordance with the J.A.M.S./Endispute Comprehensive Arbitration Rules&nbsp;and Procedures (the &#147;J.A.M.S. Rules&#148;).&#160; The arbitration shall be governed by the United States Arbitration Act, 9 U.S.C. Sections 1 - 16, and judgment upon the award rendered by the arbitrators may be entered by any court having jurisdiction thereof.&#160; The place of arbitration shall be Boston, Massachusetts.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The arbitration shall commence within 60 days of the date on which a written demand for arbitration is filed by any party hereto.&#160; In connection with the arbitration proceeding, the arbitrator shall have the power to order the production of documents by each party and any third-party witnesses.&#160; In addition, each party may take up to three depositions as of right, and the arbitrator may in his or her discretion allow additional depositions upon good cause shown by the moving party.&#160; However, the arbitrator shall not have the power to order the answering of interrogatories or the response to requests for admission.&#160; In connection with any arbitration, each party to the arbitration shall provide to the other, no later than seven business days before the date of the arbitration, the identity of all persons that may testify at the arbitration and a copy of all documents that may be introduced at the arbitration or considered or used by a party&#146;s witness or expert.&#160; The arbitrator&#146;s decision and award shall be made and delivered within six months of the selection of the arbitrator.&#160; The arbitrator&#146;s decision shall set forth a reasoned basis for any award of damages or finding of liability.&#160; The arbitrator shall not have power to award damages in excess of actual compensatory damages and shall not multiply actual damages or award punitive damages, and each party hereby irrevocably waives any claim to such damages.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company, the Grantee, each party to the Agreement and any other holder of Shares issued pursuant to this Agreement (each, a &#147;Party&#148;) covenants and agrees that such party will participate in the arbitration in good faith.&#160; This Section&nbsp;6 applies equally to requests for temporary, preliminary or permanent injunctive relief, except that in the case of temporary or preliminary injunctive relief any party may proceed in court without prior arbitration for the limited purpose of avoiding immediate and irreparable harm.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each Party (i)&nbsp;hereby irrevocably submits to the jurisdiction of any United States District Court of competent jurisdiction for the purpose of enforcing the award or decision in any such proceeding, (ii)&nbsp;hereby waives, and agrees not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above named courts, that its property is exempt or immune from attachment or execution (except as protected by applicable law), that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court, and (iii)&nbsp;hereby waives and agrees not to seek any review by any court of any other jurisdiction which may be called upon to grant an enforcement of the judgment of any such court.&#160; Each Party hereby consents to service of process by registered mail at the address to which notices are to be given.&#160; Each Party agrees that its, his or her submission to jurisdiction and its, his or her consent to service of process by mail is made for the express benefit of each other Party.&#160; Final judgment against any Party in any such action, suit or proceeding may be enforced in other jurisdictions by suit, action or proceeding on the judgment, or in any other manner provided by or pursuant to the laws of such other jurisdiction.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="41952-2-KS-07_PB_6_083007_7906"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=37,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=796960,FOLIO='6',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 11:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Waiver of Statutory Information Rights</u>.&#160; The Grantee understands and agrees that, but for the waiver made herein, the Grantee would be entitled, upon written demand under oath stating the purpose thereof, to inspect for any proper purpose, and to make copies and extracts from, the Company&#146;s stock ledger, a list of its stockholders, and its other books and records, and the books and records of subsidiaries of the Company, if any, under the circumstances and in the manner provided in Section&nbsp;220 of the General Corporation Law of Delaware (any and all such rights, and any and all such other rights of the Grantee as may be provided for in Section&nbsp;220, the &#147;Inspection Rights&#148;). In light of the foregoing, until the first sale of Stock of the Company to the general public pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission under the Securities Act, the Grantee hereby unconditionally and irrevocably waives the Inspection Rights, whether such Inspection Rights would be exercised or pursued directly or indirectly pursuant to Section&nbsp;220 or otherwise, and covenants and agrees never to directly or indirectly commence, voluntarily aid in any way, prosecute, assign, transfer, or cause to be commenced any claim, action, cause of action, or other proceeding to pursue or exercise the Inspection Rights. The foregoing waiver shall not affect any rights of a director, in his or her capacity as such, under Section&nbsp;220. The foregoing waiver shall not apply to any contractual inspection rights of the Grantee under any other written agreement between the Grantee and the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[SIGNATURE PAGE FOLLOWS]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="41952-2-KS-07_PB_7_083035_3736"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=38,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=199311,FOLIO='7',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 11:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The foregoing Restricted Stock Agreement is hereby accepted and the terms and conditions thereof are hereby agreed to by the undersigned as of the date of purchase of Shares above written.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AKERO   THERAPEUTICS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The undersigned hereby acknowledges receiving and reviewing a copy of the Plan, including, without limitation, Section&nbsp;9 thereof and understands that the Shares granted hereby are subject to the terms of the Plan and of this Agreement.&#160; This Agreement is hereby accepted, and the terms and conditions of the Plan, the Award Notice and this Agreement, SPECIFICALLY INCLUDING THE ARBITRATION PROVISIONS SET FORTH IN SECTION&nbsp;6 AND THE WAIVER OF STATUTORY INFORMATION RIGHTS SET FORTH IN SECTION&nbsp;7 OF THIS AGREEMENT, are hereby agreed to, by the undersigned as of the date first above written.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">GRANTEE:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="41952-2-KS-07_PB_8_083337_9621"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=39,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=529628,FOLIO='8',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 11:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[SPOUSE&#146;S CONSENT(2)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I acknowledge that I have read the</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">foregoing Restricted Stock Agreement</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and understand the contents thereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade align="left" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;text-indent:.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&nbsp; A spouse&#146;s consent is required only if the Grantee&#146;s state of residence is one of the following community property states:&#160; Arizona, California,&nbsp;Idaho, Louisiana, New Mexico, Nevada, Texas, Washington and Wisconsin.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="41952-2-KS-07_PB_9_083523_8715"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=40,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=629434,FOLIO='9',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 11:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;A</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;83(b)&nbsp;Election</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The undersigned hereby elects pursuant to &#167;83(b)&nbsp;of the Internal Revenue Code of 1986, as amended, to include in gross income as compensation for services the excess (if any) of the fair market value of the shares described below over the amount paid for those shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The name, taxpayer identification number, address of the undersigned, and the taxable year for which this election is being made are:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address:</font></p>
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Social Security No.:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Taxable Year: Calendar Year 20</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The property which is the subject of this election is [number of unvested shares] shares of common stock of Akero Therapeutics,&nbsp;Inc.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The property was transferred to the undersigned on&#160; [date of purchase/transfer].</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The property is subject to the following restrictions:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Shares will be subject to restrictions on transfer and risk of forfeiture upon termination of service relationship and in certain other events.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The fair market value of the property at time of transfer (determined without regard to any restrictions other than nonlapse restrictions as defined in &#167;1.83-3(h)&nbsp;of the Income Tax Regulations) is $[current FMV] per share x [number of unvested shares] shares = $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For the property transferred, the undersigned paid $[exercise price] per share x [number of unvested shares] shares = $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The amount to include in gross income is $[amount reported in Item 5 minus the amount reported in Item 6].</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The undersigned taxpayer will file this election with the Internal Revenue Service Office with which the taxpayer files his or her annual income tax return not later than 30 days after the date of transfer of the property, at the IRS address listed for the taxpayer&#146;s state under &#147;Are you <u>not</u> including a check or money order&nbsp;.&nbsp;.&nbsp;.&#148; given in <i>Where Do You File</i> in the Instructions for Form&nbsp;1040 and the Instructions for Form&nbsp;1040A (which information can also be found at: https://www.irs.gov/uac/where-to-file-addresses-for-taxpayers-and-tax-professionals).&#160; A copy of the election will also be furnished to the person for whom the services were performed.&#160; The undersigned is the person performing services in connection with which the property was transferred.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated:   &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,   20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Taxpayer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="41952-2-KS-07_PB_10_084145_563"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=41,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=394519,FOLIO='10',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 11:19 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AKERO THERAPEUTICS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMENDMENT NO. 1 TO</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2018 STOCK OPTION AND GRANT PLAN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Akero Therapeutics,&nbsp;Inc. 2018 Stock Option and Grant Plan, as amended (the &#147;<u>Plan</u>&#148;) is hereby amended by the Board of Directors as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;3(a)&nbsp;of the Plan is hereby amended to increase the total number of Shares (as defined in the Plan) reserved and available for issuance under the Plan by </font>3,846,154 shares such that Section&nbsp;3(a)&nbsp;of the Plan, as so amended, shall read in its entirety as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 63.0pt;text-indent:-63.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;3.<i>&nbsp;&nbsp;&nbsp;&nbsp;</i><u>STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)<i>&nbsp;&nbsp;&nbsp;</i><u>Stock Issuable</u>.&#160; The maximum number of Shares reserved and available for issuance under the Plan shall be 7,030,154 Shares, subject to adjustment as provided in Section&nbsp;3(b). For purposes of this limitation, the Shares underlying any Awards that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) and Shares that are withheld upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding shall be added back to the Shares available for issuance under the Plan. Subject to such overall limitations, Shares may be issued up to such maximum number pursuant to any type or types of Award, and no more than 80,000,000 Shares may be issued pursuant to Incentive Stock Options.&#160; The Shares available for issuance under the Plan may be authorized but unissued Shares or Shares reacquired by the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ADOPTED BY BOARD OF DIRECTORS: October&nbsp;18, 2018</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ADOPTED BY STOCKHOLDERS: October&nbsp;18, 2018</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=42,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=379029,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-09_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 08:43 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AKERO THERAPEUTICS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMENDMENT NO. 2 TO</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2018 STOCK OPTION AND GRANT PLAN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Akero Therapeutics,&nbsp;Inc. 2018 Stock Option and Grant Plan, as amended (the &#147;<u>Plan</u>&#148;) is hereby amended by the Board of Directors as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;3(a)&nbsp;of the Plan is hereby amended to increase the total number of Shares (as defined in the Plan) reserved and available for issuance under the Plan by </font>2,413,606 shares such that Section&nbsp;3(a)&nbsp;of the Plan, as so amended, shall read in its entirety as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 63.0pt;text-indent:-63.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;3.<i>&nbsp;&nbsp;&nbsp;&nbsp;</i><u>STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)<i>&nbsp;&nbsp;&nbsp;</i><u>Stock Issuable</u>.&#160; The maximum number of Shares reserved and available for issuance under the Plan shall be 9,443,760 Shares, subject to adjustment as provided in Section&nbsp;3(b). For purposes of this limitation, the Shares underlying any Awards that are forfeited, canceled, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) and Shares that are withheld upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding shall be added back to the Shares available for issuance under the Plan. Subject to such overall limitations, Shares may be issued up to such maximum number pursuant to any type or types of Award, and no more than 80,000,000 Shares may be issued pursuant to Incentive Stock Options.&#160; The Shares available for issuance under the Plan may be authorized but unissued Shares or Shares reacquired by the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ADOPTED BY BOARD OF DIRECTORS: December&nbsp;5, 2018</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ADOPTED BY STOCKHOLDERS: December&nbsp;5, 2018</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=43,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=844618,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-11_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 08:44 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INCENTIVE STOCK OPTION GRANT NOTICE</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">UNDER THE AKERO THERAPEUTICS, INC.<br> 2018 STOCK OPTION AND GRANT PLAN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the Akero Therapeutics, Inc. 2018 Stock Option and Grant Plan (the &#147;Plan&#148;), Akero Therapeutics, Inc., a Delaware corporation (together with any successor, the &#147;Company&#148;), has granted to the individual named below, an option (the &#147;Stock Option&#148;) to purchase on or prior to the Expiration Date, or such earlier date as is specified herein, all or any part of the number of shares of Common Stock, par value $0.0001 per share (&#147;Common Stock&#148;), of the Company indicated below (the &#147;Shares&#148;), at the Option Exercise Price per share, subject to the terms and conditions set forth in this Incentive Stock Option Grant Notice (the &#147;Grant Notice&#148;), the attached Incentive Stock Option Agreement (the &#147;Agreement&#148;) and the Plan.&#160; This Stock Option is intended to qualify as an &#147;incentive stock option&#148; as defined in Section 422(b) of the Internal Revenue Code of 1986, as amended from time to time (the &#147;Code&#148;).&#160; To the extent that any portion of the Stock Option does not so qualify, it shall be deemed a non-qualified stock option.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="28%" valign="top" style="padding:0in 0in 0in 0in;width:28.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name of Optionee:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(the   &#147;Optionee&#148;)</font></p>    </td>   </tr>
<tr>
<td width="28%" valign="top" style="padding:0in 0in 0in 0in;width:28.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="28%" valign="top" style="padding:0in 0in 0in 0in;width:28.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No. of Shares:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares   of Common Stock</font></p>    </td>   </tr>
<tr>
<td width="28%" valign="top" style="padding:0in 0in 0in 0in;width:28.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="28%" valign="top" style="padding:0in 0in 0in 0in;width:28.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant Date:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="28%" valign="top" style="padding:0in 0in 0in 0in;width:28.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="28%" valign="top" style="padding:0in 0in 0in 0in;width:28.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Commencement Date:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(the   &#147;Vesting Commencement Date&#148;)</font></p>    </td>   </tr>
<tr>
<td width="28%" valign="top" style="padding:0in 0in 0in 0in;width:28.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="28%" valign="top" style="padding:0in 0in 0in 0in;width:28.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expiration Date:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(the   &#147;Expiration Date&#148;)</font></p>    </td>   </tr>
<tr>
<td width="28%" valign="top" style="padding:0in 0in 0in 0in;width:28.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="28%" valign="top" style="padding:0in 0in 0in 0in;width:28.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Option Exercise Price/Share:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(the   &#147;Option Exercise Price&#148;)</font></p>    </td>   </tr>
<tr>
<td width="28%" valign="top" style="padding:0in 0in 0in 0in;width:28.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="28%" valign="top" style="padding:0in 0in 0in 0in;width:28.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Schedule:</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.94%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25 percent of the Shares shall vest and become   exercisable on the first anniversary of the Vesting Commencement Date;   provided that the Optionee continues to have a Service Relationship with the   Company at such time.&nbsp; Thereafter, the   remaining 75 percent of the Shares shall vest and become exercisable in 36   equal monthly installments following the first anniversary of the Vesting   Commencement Date, provided the Optionee continues to have a Service   Relationship with the Company on each vesting date. Notwithstanding anything   in the Agreement to the contrary, in the case of a Sale Event, this Stock   Option and the Shares shall be treated as provided in Section 3(c) of the   Plan<b>[ provided; however INSERT ANY ACCELERATED   VESTING PROVISION HERE]</b>.(1)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade align="left" style="color:black;"></div>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Here is a sample double trigger acceleration provision:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .55in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding anything herein to the contrary, in the event (and only in the event) that this Stock Option or the Shares are assumed or continued by the Company or its successor entity in the sole discretion of the parties to a Sale Event and thereafter remains in effect following such Sale Event, then [50% of] the then-unvested Shares shall be deemed vested in full upon the date on which the Optionee&#146;s Service Relationship with the Company and its Subsidiaries or successor entity terminates if (A) such termination occurs in connection with and effective as of the date of, or within 12 months following the date of, such Sale Event and (B) such termination is either by the Company without Cause or by the Optionee for Good Reason.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=44,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=887813,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-13_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:40 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Attachments</font></b>:&#160; Incentive Stock Option Agreement, 2018 Stock Option and Grant Plan</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="41952-2-KS-13_PB_2_070709_6203"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=45,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=39716,FOLIO='2',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-13_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:40 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INCENTIVE STOCK OPTION AGREEMENT<br> UNDER THE AKERO THERAPEUTICS, INC.<br> 2018 STOCK OPTION AND GRANT PLAN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Grant Notice and the Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Vesting, Exercisability and Termination</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>No portion of this Stock Option may be exercised until such portion shall have vested and become exercisable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except as set forth below, and subject to the determination of the Committee in its sole discretion to accelerate the vesting schedule hereunder, this Stock Option shall be vested and exercisable on the respective dates indicated below:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Stock Option shall initially be unvested and unexercisable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Stock Option shall vest and become exercisable in accordance with the Vesting Schedule set forth in the Grant Notice.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination</u>.&#160; Except as may otherwise be provided by the Committee, if the Optionee&#146;s Service Relationship is terminated, the period within which to exercise this Stock Option will be subject to earlier termination as set forth below (and if not exercised within such period, shall thereafter terminate subject, in each case, to Section 3(c) of the Plan):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination Due to Death or Disability</u>.&#160; If the Optionee&#146;s Service Relationship terminates by reason of such Optionee&#146;s death or Disability, this Stock Option may be exercised, to the extent exercisable on the date of such termination, by the Optionee, the Optionee&#146;s legal representative or legatee for a period of 12 months from the date of death or Disability or until the Expiration Date, if earlier.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Other Termination</u>.&#160; If the Optionee&#146;s Service Relationship terminates for any reason other than death or Disability, and unless otherwise determined by the Committee, this Stock Option may be exercised, to the extent exercisable on the date of termination, for a period of 90 days from the date of termination or until the Expiration Date, if earlier; <u>provided however</u>, if the Optionee&#146;s Service Relationship is terminated for Cause, this Stock Option shall terminate immediately upon the date of such termination.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For purposes hereof, the Committee&#146;s determination of the reason for termination of the Optionee&#146;s Service Relationship shall be conclusive and binding on the Optionee and his or her representatives or legatees.&#160; Any portion of this Stock Option that is not vested and exercisable on the date of termination of the Service Relationship shall terminate immediately and be null and void.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="41952-2-KS-13_PB_3_070726_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=46,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=892427,FOLIO='3',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-13_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:40 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>It is understood and intended that this Stock Option is intended to qualify as an &#147;incentive stock option&#148; as defined in Section 422 of the Code to the extent permitted under applicable law.&#160; Accordingly, the Optionee understands that in order to obtain the benefits of an incentive stock option under Section 422 of the Code, no sale or other disposition may be made of Shares for which incentive stock option treatment is desired within the one-year period beginning on the day after the day of the transfer of such Shares to him or her, nor within the two-year period beginning on the day after Grant Date of this Stock Option and further that this Stock Option must be exercised within three months after termination of employment as an employee (or 12 months in the case of death or disability) to qualify as an incentive stock option.&#160; If the Optionee disposes (whether by sale, gift, transfer or otherwise) of any such Shares within either of these periods, he or she will notify the Company within 30 days after such disposition.&#160; The Optionee also agrees to provide the Company with any information concerning any such dispositions required by the Company for tax purposes.&#160; Further, to the extent this Stock Option and any other incentive stock options of the Optionee having an aggregate Fair Market Value in excess of $100,000 (determined as of the Grant Date) first become exercisable in any year, such options will not qualify as incentive stock options.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Exercise of Stock Option</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Optionee may exercise this Stock Option only in the following manner:&#160; Prior to the Expiration Date, the Optionee may deliver a Stock Option exercise notice (an &#147;Exercise Notice&#148;) in the form of <u>Appendix A</u> hereto indicating his or her election to purchase some or all of the Shares with respect to which this Stock Option is then exercisable.&#160; Such notice shall specify the number of Shares to be purchased.&#160; Payment of the purchase price may be made by one or more of the methods described in Section 5 of the Plan, subject to the limitations contained in such Section of the Plan, including the requirement that the Committee specifically approve in advance certain payment methods.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Incorporation of Plan</u>.&#160; Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Transferability of Stock Option</u>.&#160; This Stock Option is personal to the Optionee and is not transferable by the Optionee in any manner other than by will or by the laws of descent and distribution.&#160; The Stock Option may be exercised during the Optionee&#146;s lifetime only by the Optionee (or by the Optionee&#146;s guardian or personal representative in the event of the Optionee&#146;s incapacity).&#160; The Optionee may elect to designate a beneficiary by providing written notice of the name of such beneficiary to the Company, and may revoke or change such designation at any time by filing written notice of revocation or change with the Company; such beneficiary may exercise the Optionee&#146;s Stock Option in the event of the Optionee&#146;s death to the extent provided herein.&#160; If the Optionee does not designate a beneficiary, or if the designated beneficiary predeceases the Optionee, the legal representative of the Optionee may exercise this Stock Option to the extent provided herein in the event of the Optionee&#146;s death.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="41952-2-KS-13_PB_4_070739_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=47,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=776458,FOLIO='4',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-13_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:40 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Restrictions on Transfer of Shares</u>.&#160; The Shares acquired upon exercise of the Stock Option shall be subject to certain transfer restrictions and other limitations including, without limitation, the provisions contained in Section 9 of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Miscellaneous Provisions</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Equitable Relief</u>.&#160; The parties hereto agree and declare that legal remedies may be inadequate to enforce the provisions of this Agreement and that equitable relief, including specific performance and injunctive relief, may be used to enforce the provisions of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Adjustments for Changes in Capital Structure</u>.&#160; If, as a result of any reorganization, recapitalization, reincorporation, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Common Stock, the outstanding shares of Common Stock are increased or decreased or are exchanged for a different number or kind of securities of the Company, the restrictions contained in this Agreement shall apply with equal force to additional and/or substitute securities, if any, received by the Optionee in exchange for, or by virtue of his or her ownership of, this Stock Option or Shares acquired pursuant thereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Change and Modifications</u>.&#160; This Agreement may not be orally changed, modified or terminated, nor shall any oral waiver of any of its terms be effective.&#160; This Agreement may be changed, modified or terminated only by an agreement in writing signed by the Company and the Optionee.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governing Law</u>.&#160; This Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to conflict of law principles that would result in the application of any law other than the law of the State of the Commonwealth of Massachusetts.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Headings</u>.&#160; The headings are intended only for convenience in finding the subject matter and do not constitute part of the text of this Agreement and shall not be considered in the interpretation of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Saving Clause</u>.&#160; If any provision(s) of this Agreement shall be determined to be illegal or unenforceable, such determination shall in no manner affect the legality or enforceability of any other provision hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notices</u>.&#160; All notices, requests, consents and other communications shall be in writing and be deemed given when delivered personally, by telex or facsimile transmission or when received if mailed by first class registered or certified mail, postage prepaid.&#160; Notices to the Company or the Optionee shall be addressed as set forth underneath their signatures below, or to such other address or addresses as may have been furnished by such party in writing to the other.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Benefit and Binding Effect</u>.&#160; This Agreement shall be binding upon and shall inure to the benefit of the parties hereto, their respective successors, assigns, and legal</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="41952-2-KS-13_PB_5_070748_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=48,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=689528,FOLIO='5',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-13_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:40 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">representatives.&#160; The Company has the right to assign this Agreement, and such assignee shall become entitled to all the rights of the Company hereunder to the extent of such assignment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Counterparts</u>.&#160; For the convenience of the parties and to facilitate execution, this Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same document.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(j)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Integration</u>.&#160; This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Dispute Resolution</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Except as provided below, any dispute arising out of or relating to the Plan or this Stock Option, this Agreement, or the breach, termination or validity of the Plan, this Stock Option or this Agreement, shall be finally settled by binding arbitration conducted expeditiously in accordance with the J.A.M.S./Endispute Comprehensive Arbitration Rules and Procedures (the &#147;J.A.M.S. Rules&#148;).&#160; The arbitration shall be governed by the United States Arbitration Act, 9 U.S.C. Sections 1 16, and judgment upon the award rendered by the arbitrators may be entered by any court having jurisdiction thereof.&#160; The place of arbitration shall be Boston, Massachusetts.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The arbitration shall commence within 60 days of the date on which a written demand for arbitration is filed by any party hereto.&#160; In connection with the arbitration proceeding, the arbitrator shall have the power to order the production of documents by each party and any third-party witnesses.&#160; In addition, each party may take up to three depositions as of right, and the arbitrator may in his or her discretion allow additional depositions upon good cause shown by the moving party.&#160; However, the arbitrator shall not have the power to order the answering of interrogatories or the response to requests for admission.&#160; In connection with any arbitration, each party to the arbitration shall provide to the other, no later than seven business days before the date of the arbitration, the identity of all persons that may testify at the arbitration and a copy of all documents that may be introduced at the arbitration or considered or used by a party&#146;s witness or expert.&#160; The arbitrator&#146;s decision and award shall be made and delivered within six months of the selection of the arbitrator.&#160; The arbitrator&#146;s decision shall set forth a reasoned basis for any award of damages or finding of liability.&#160; The arbitrator shall not have power to award damages in excess of actual compensatory damages and shall not multiply actual damages or award punitive damages, and each party hereby irrevocably waives any claim to such damages.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company, the Optionee, each party to the Agreement and any other holder of Shares issued pursuant to this Agreement (each, a &#147;Party&#148;) covenants and agrees that such party will participate in the arbitration in good faith.&#160; This Section 7 applies equally to requests for temporary, preliminary or permanent injunctive relief, except that in the case of temporary or preliminary injunctive relief any party may proceed in court without prior arbitration for the limited purpose of avoiding immediate and irreparable harm.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each Party (i) hereby irrevocably submits to the jurisdiction of any United States District Court of competent jurisdiction for the purpose of enforcing the award or decision</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="41952-2-KS-13_PB_6_070800_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=49,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=453705,FOLIO='6',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-13_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:40 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">in any such proceeding, (ii) hereby waives, and agrees not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above named courts, that its property is exempt or immune from attachment or execution (except as protected by applicable law), that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court, and (iii) hereby waives and agrees not to seek any review by any court of any other jurisdiction which may be called upon to grant an enforcement of the judgment of any such court.&#160; Each Party hereby consents to service of process by registered mail at the address to which notices are to be given.&#160; Each Party agrees that its, his or her submission to jurisdiction and its, his or her consent to service of process by mail is made for the express benefit of each other Party.&#160; Final judgment against any Party in any such action, suit or proceeding may be enforced in other jurisdictions by suit, action or proceeding on the judgment, or in any other manner provided by or pursuant to the laws of such other jurisdiction.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Waiver of Statutory Information Rights</u>.&#160; The Optionee understands and agrees that, but for the waiver made herein, the Optionee would be entitled, upon written demand under oath stating the purpose thereof, to inspect for any proper purpose, and to make copies and extracts from, the Company&#146;s stock ledger, a list of its stockholders, and its other books and records, and the books and records of subsidiaries of the Company, if any, under the circumstances and in the manner provided in Section 220 of the General Corporation Law of Delaware (any and all such rights, and any and all such other rights of the Optionee as may be provided for in Section 220, the &#147;Inspection Rights&#148;). In light of the foregoing, until the first sale of Stock of the Company to the general public pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission under the Securities Act, the Optionee hereby unconditionally and irrevocably waives the Inspection Rights, whether such Inspection Rights would be exercised or pursued directly or indirectly pursuant to Section 220 or otherwise, and covenants and agrees never to directly or indirectly commence, voluntarily aid in any way, prosecute, assign, transfer, or cause to be commenced any claim, action, cause of action, or other proceeding to pursue or exercise the Inspection Rights. The foregoing waiver shall not affect any rights of a director, in his or her capacity as such, under Section 220. The foregoing waiver shall not apply to any contractual inspection rights of the Optionee under any other written agreement between the Optionee and the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[SIGNATURE PAGE FOLLOWS]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="41952-2-KS-13_PB_7_070807_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=50,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=94955,FOLIO='7',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-13_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:40 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned as of the date first above written.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AKERO   THERAPEUTICS, INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The undersigned hereby acknowledges receiving and reviewing a copy of the Plan, including, without limitation, Section 9 thereof, and understands that this Stock Option is subject to the terms of the Plan and of this Agreement.&#160; This Agreement is hereby accepted, and the terms and conditions of the Plan, the Grant Notice and this Agreement, SPECIFICALLY INCLUDING THE ARBITRATION PROVISIONS SET FORTH IN SECTION 7 AND THE WAIVER OF STATUTORY INFORMATION RIGHTS SET FORTH IN SECTION 8 OF THIS AGREEMENT, are hereby agreed to, by the undersigned as of the date first above written.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OPTIONEE:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="41952-2-KS-13_PB_8_074728_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=51,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=788902,FOLIO='8',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-13_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:40 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[SPOUSE&#146;S CONSENT(2)</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I acknowledge that I   have read the foregoing Incentive Stock Option Agreement and understand the   contents thereof.</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade align="left" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;text-indent:.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160; A spouse&#146;s consent is recommended only if the Optionee&#146;s state of residence is one of the following community property states:&#160; Arizona, California, Idaho, Louisiana, Nevada, New Mexico, Texas, Washington and Wisconsin.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="41952-2-KS-13_PB_9_074819_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=52,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=468399,FOLIO='9',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-13_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:40 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DESIGNATED BENEFICIARY:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Beneficiary&#146;s Address:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="41952-2-KS-13_PB_10_074859_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=53,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=475993,FOLIO='10',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-13_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:40 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Appendix A</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">STOCK OPTION EXERCISE NOTICE</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Akero Therapeutics, Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention: President</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the terms of the grant notice and stock option agreement between the undersigned and Akero Therapeutics, Inc. (the &#147;Company&#148;) dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(the &#147;Agreement&#148;) under the Akero Therapeutics, Inc. 2018 Stock Option and Grant Plan, I, [Insert Name]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, hereby [Circle One] partially/fully exercise such option by including herein payment in the amount of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; representing the purchase price for [Fill in number of Shares] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares.&#160; I have chosen the following form(s) of payment:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>1.<font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Cash</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>2.<font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Certified or bank check payable to Akero Therapeutics, Inc.</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 2.0in;text-indent:-1.0in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>3.<font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Other (as referenced in the Agreement and described in the Plan (please describe)) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with my exercise of the option as set forth above, I hereby represent and warrant to the Company as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I am purchasing the Shares for my own account for investment only, and not for resale or with a view to the distribution thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I have had such an opportunity as I have deemed adequate to obtain from the Company such information as is necessary to permit me to evaluate the merits and risks of my investment in the Company and have consulted with my own advisers with respect to my investment in the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I have sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the purchase of the Shares and to make an informed investment decision with respect to such purchase.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I can afford a complete loss of the value of the Shares and am able to bear the economic risk of holding such Shares for an indefinite period of time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I understand that the Shares may not be registered under the Securities Act of 1933 (it being understood that the Shares are being issued and sold in reliance on the exemption provided in Rule 701 thereunder) or any applicable state securities or &#147;blue sky&#148; laws and may not be sold or otherwise transferred or disposed of</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="41952-2-KS-13_PB_11_075209_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=54,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=300875,FOLIO='11',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-13_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:40 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">in the absence of an effective registration statement under the Securities Act of 1933 and under any applicable state securities or &#147;blue sky&#148; laws (or exemptions from the registration requirement thereof).&#160; I further acknowledge that certificates representing Shares will bear restrictive legends reflecting the foregoing and/or that book entries for uncertificated Shares will include similar restrictive notations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I have read and understand the Plan and acknowledge and agree that the Shares are subject to all of the relevant terms of the Plan, including without limitation, the transfer restrictions set forth in Section 9 of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I understand and agree that the Company has a right of first refusal with respect to the Shares pursuant to Section 9(b) of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(viii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I understand and agree that the Company has certain repurchase rights with respect to the Shares pursuant to Section 9(c) of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ix)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I understand and agree that I may not sell or otherwise transfer or dispose of the Shares for a period of time following the effective date of a public offering by the Company as described in Section 9(f) of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(x)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>I understand and agree to the waiver of statutory information rights as set forth in Section 8 of the Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sincerely yours,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="41952-2-KS-13_PB_12_075252_7091"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=55,EFW="2237524",CP="AKERO THERAPEUTICS",DN="4",CHK=432916,FOLIO='12',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KS-13_ZFG45202.CHC",USER="GBOATSW",CD='Jan 15 04:40 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.5<a name="41952-2-KW-01_Exhibit10_5_075751"></a></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SUBLEASE AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Sublease Agreement (&#147;<b><i style="font-weight:bold;">Sublease</i></b>&#148;) is dated as of October 23, 2018, for reference purposes only, by and between TRUCODE GENE REPAIR, INC., a Delaware corporation (&#147;<b><i style="font-weight:bold;">Sublandlord</i></b>&#148;), having an address of 170 Harbor Way, Third Floor, South San Francisco, California 94080, and AKERO THERAPEUTICS INC., a Delaware corporation (&#147;<b><i style="font-weight:bold;">Subtenant</i></b>&#148;), having an address of 400 Technology Square, 10</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>&#160;Floor, Cambridge, Massachusetts 02139. This Sublease shall be effective as of the date set forth in <u>Section 2</u>, below.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RECITALS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">A.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sublandlord currently leases certain premises from Britannia Pointe Grand Limited Partnership, a Delaware limited partnership (&#147;<b><i style="font-weight:bold;">Master Landlord</i></b>&#148;), pursuant to the terms and conditions of that certain Lease dated April 10, 2018 (the &#147;<b><i style="font-weight:bold;">Master Lease</i></b>&#148;). Pursuant to the Master Lease, Sublandlord currently leases from Master Landlord those certain premises consisting of approximately 24,606 rentable square feet (as more particularly described in the Master Lease, the &#147;<b><i style="font-weight:bold;">Master Premises</i></b>&#148;), located on the third (3<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">rd</font>) floor of that certain building located at 170 Harbor Way, South San Francisco, California (the &#147;<b><i style="font-weight:bold;">Building</i></b>&#148;), within the project commonly known as Britannia Pointe Grand Business Park (the &#147;<b><i style="font-weight:bold;">Property</i></b>&#148;), as more particularly described in the Master Lease. All terms capitalized but undefined herein shall have the meanings ascribed to them in the Master Lease, a copy of which Master Lease has been made available to Subtenant.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">C.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sublandlord desires to sublease that certain portion of the Master Premises, consisting of approximately 383 square feet contained in offices 316 and 317, and the cubicle across from office 317, as depicted on the attached <u>Exhibit A</u> (the &#147;<b><i style="font-weight:bold;">Sublease Premises</i></b>&#148;) to Subtenant and Subtenant desires to sublease the Sublease Premises from Sublandlord pursuant to the terms and conditions of this Sublease.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NOW, THEREFORE</font></b>, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, Sublandlord and Subtenant hereby agree as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Sublease Premises.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Sublease Premises</b>. Sublandlord hereby subleases to Subtenant the Sublease Premises, and Subtenant hereby subleases the Sublease Premises from Sublandlord, pursuant to the terms and conditions of this Sublease.&#160; Subtenant shall accept the Sublease Premises in the condition and state of repair on the Commencement Date (as defined in <u>Section 3</u> below) in its &#147;AS IS&#148; and &#147;WHERE IS&#148; condition, and Sublandlord makes no representation or warranty regarding the Sublease Premises. Subtenant expressly acknowledges and agrees Sublandlord shall not have any obligation to perform any work to prepare the Sublease Premises for Subtenant&#146;s use and occupancy. By taking possession of the Sublease Premises, Subtenant is deemed to have accepted the Sublease Premises and agreed that the Sublease Premises are in good order and satisfactory condition, with no representation or warranty by Sublandlord as to the condition of the Sublease Premises or the suitability thereof for Subtenant&#146;s use.&#160; Pursuant to</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="41952-2-KW-01_PB_1_075805_455"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2237524",CP="AKERO THERAPEUTICS",DN="5",CHK=226599,FOLIO='1',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KW-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 08:16 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">California Civil Code Section 1938, Sublandlord is required to state as follows regarding the Sublease Premises:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Access; Bathrooms.</b> In connection with Subtenant&#146;s use of the Sublease Premises, Subtenant shall have the non-exclusive right to use, subject to Sublandlord&#146;s reasonable rules and regulations, the Master Premises restrooms, and rights of ingress and egress through the hallways and accessways as are reasonably necessary for Subtenant&#146;s access to the Sublease Premises and the Master Premises restrooms.&#160; Subtenant acknowledges that there will be no separate demise of the Sublease Premises.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Effective Date; Master Landlord&#146;s Consent Required.</b> This Sublease shall not become effective or binding upon either party until the date on which Master Landlord&#146;s written consent to this Sublease is fully-executed and delivered to Sublandlord and Subtenant (the &#147;<b><i style="font-weight:bold;">Effective Date</i></b>&#148;). Sublandlord hereby disclaims any representation or warranty, whether express or implied, to Subtenant that Sublandlord will obtain the consent of Master Landlord to this Sublease, but Sublandlord shall use good faith efforts to obtain the same in accordance with the provisions of the Master Lease and Subtenant shall cooperate with Sublandlord in its efforts to obtain the same. Sublandlord shall request such consent and Subtenant shall pay any fees or charges expressly provided for in the Master Lease with respect to the obtaining of such consent. Subtenant agrees promptly to provide any reasonable financial or other information requested by Master Landlord. Each party agrees promptly to execute and deliver a consent agreement in a form reasonably acceptable to Master Landlord and Subtenant. If Master Landlord&#146;s consent is not received within thirty (30) days of the full execution and delivery hereof, either party by notice to the other given prior to the receipt of Master Landlord&#146;s consent, may terminate this Sublease, in which case this Sublease shall be deemed void <i>ab initio</i> and Sublandlord shall promptly return to Subtenant all sums theretofore paid by Subtenant hereunder. Subtenant waives any claim against Master Landlord arising out of any failure or refusal by Master Landlord to grant consent. Simultaneously with the delivery to Sublandlord of an executed counterpart of this Sublease, and as a precondition to Sublandlord&#146;s obligation to deliver possession of the Sublease Premises to Subtenant, Subtenant shall deliver to Sublandlord (i) the Security Deposit (as defined in <u>Section 6</u> of this Sublease) and (ii) the first installment of monthly Base Rent (as defined below).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="41952-2-KW-01_PB_2_075820_4141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2237524",CP="AKERO THERAPEUTICS",DN="5",CHK=353506,FOLIO='2',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KW-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 08:16 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Term; Renewal.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Initial Term. </b>The initial term of this Sublease (the &#147;<b><i style="font-weight:bold;">Initial Term</i></b>&#148;) shall commence on the date Master Landlord executes and delivers the Consent (the &#147;<b><i style="font-weight:bold;">Commencement Date</i></b>&#148;) and shall expire on April 30, 2019 (as may be extended as set forth herein, the &#147;<b><i style="font-weight:bold;">Expiration Date</i></b>&#148;), subject to extension as set forth in <u>Section 3.2</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Automatic Renewal. </b>Unless Subtenant or Sublandlord timely delivers a Notice of Termination to Sublandlord pursuant to <u>Section 3.3</u>, this Sublease shall automatically renew for successive thirty (30) day periods (each, a &#147;<b><i style="font-weight:bold;">Renewal Term</i></b>&#148;; and the Initial Term, as extended for any Renewal Term, referred to collectively as the &#147;<b><i style="font-weight:bold;">Sublease Term</i></b>&#148;) and each such Renewal Term shall commence on the first day of the month immediately following the expiration of the Initial Term or the preceding Renewal Term, as the case may be, and expire on the last day of the same month.&#160; Upon the commencement of each Renewal Term, the words &#147;<b><i style="font-weight:bold;">Expiration Date</i></b>&#148; as used herein shall automatically be deemed to refer to the last day of such calendar month.&#160; For the avoidance of doubt, the Sublease Term shall not automatically extend beyond the day immediately preceding the &#147;Lease Expiration Date&#148; (as that term is defined in the Master Lease) (&#147;<b><i style="font-weight:bold;">Outside Date</i></b>&#148;) and shall be deemed to expire on the Outside Date, in the absence of a subsequent agreement between Sublandlord and Subtenant (subject to Master Landlord&#146;s consent).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Notice of Termination. </b>Subtenant or Sublandlord may elect that the Sublease Term will expire without automatic renewal pursuant to <u>Section 3.2</u> provided such termination is effective (1) on or after the expiration of the Initial Term, and (2) on the last day of a calendar month provided that Subtenant or Sublandlord provide written notice of termination (&#147;<b><i style="font-weight:bold;">Notice of Termination</i></b>&#148;) to the other party no later than sixty (60) days prior to the effective date of termination.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>RESERVED.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Rent.</b> Provided that Subtenant timely satisfies its rental and other obligations under this Sublease within the cure periods set forth herein, Sublandlord shall be responsible for the timely payment of Base Rent and Additional Rent under the Master Lease during the Sublease Term, and Subtenant shall pay to Sublandlord the following as sublease rent hereunder (&#147;<b><i style="font-weight:bold;">Sublease Rent</i></b>&#148;):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Sublease Base Rent.</b> Beginning on the Commencement Date, and continuing during the Sublease Term, Subtenant shall pay to Sublandlord, as sublease rent (&#147;<b><i style="font-weight:bold;">Base Rent</i></b>&#148;), in lawful money of the United States of America, without any deduction, offset, prior notice or demand, in advance on the first date of each month of the Sublease Term from the Commencement Date through the expiration or earlier termination of this Sublease, the amount of $5,250.00 per month, which amount shall increase by three percent (3%) annually on the first day of the month in which the anniversary of the Commencement Date occurs, if this Sublease has not yet expired or terminated.&#160; Any Sublease Rent obligations for any partial month during the Sublease Term shall be prorated.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="41952-2-KW-01_PB_3_081208_8627"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2237524",CP="AKERO THERAPEUTICS",DN="5",CHK=690584,FOLIO='3',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KW-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 08:16 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Additional Rent. </b>&#160;Except for monthly payments of Direct Expenses pursuant to <u>Section 5.3</u> below, Subtenant shall fully reimburse Sublandlord, within fifteen (15) days of receipt of invoices, for Subtenant&#146;s proportionate share of Additional Rent (as defined in the Master Lease), attributable to the Sublease Premises or Subtenant&#146;s use thereof during the Sublease Term. Subtenant&#146;s proportionate share of Sublandlord&#146;s Direct Expenses shall be 1.56% (referred to herein as &#147;<b><i style="font-weight:bold;">Subtenant&#146;s Proportionate Share</i></b>&#148;).&#160; Notwithstanding anything to the contrary in this Sublease, in the event any cost or expense is incurred under the Master Lease for either party&#146;s sole benefit (including the disproportionate use of utilities) or as a result of such party&#146;s request for certain services (such as after-hours HVAC charges), such party shall pay the entire cost thereof.&#160; Subtenant shall have no audit rights with respect to any Estimate Statement or Statement provided by Master Landlord to Sublandlord, and any such Estimate Statements or Statements shall be binding as between Sublandlord and Subtenant. The intent of the parties is that all payments of Direct Expenses and Additional Rent payable under the Master Lease relating to the Sublease Premises will be passed through to Subtenant during the Sublease Term.&#160; The terms of this <u>Section 5.2</u> shall survive the expiration or earlier termination of the Sublease Term.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Services and Utilities.</b> Subtenant shall be solely responsible, at its sole cost and expense, for payment for all services of any nature furnished with respect to the Sublease Premises in accordance with the Master Lease or this Sublease, including such services referenced in Section 6.1 of the Master Lease. Subtenant shall be responsible for and shall either reimburse Sublandlord for the cost of all utilities provided to the Sublease Premises or pay the provider directly, as directed from time to time by Sublandlord. If the Sublease Premises are not separately metered for a utility, Sublandlord shall reasonably and equitably allocate the cost of such utility among Sublandlord and Subtenant. Subtenant shall make payment for such expense for utilities within ten (10) days of receipt of any and all invoices and statements received from Master Landlord or Sublandlord with respect to the same. If Subtenant desires to use heat, ventilation or air conditioning during hours other than those for which Master Landlord is obligated to supply such utilities pursuant to the Master Lease, Sublandlord shall pass on Subtenant&#146;s request to Master Landlord. Subtenant shall reimburse Sublandlord for all Additional Rent payable by Sublandlord pursuant to the Master Lease equitably allocable to the Sublease Premises.&#160; The terms of this <u>Section 5.3</u> shall survive the expiration or earlier termination of the Sublease Term.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Security Deposit.</b> Subtenant shall deliver to Sublandlord a security deposit in the amount of $5,250.00 (the &#147;<b><i style="font-weight:bold;">Security Deposit</i></b>&#148;) to secure the faithful observance and performance by Subtenant of the terms and conditions of this Sublease. If there is an Event of Default (as defined in Article 19 of the Master Lease) by Subtenant in the observance or performance of any of such terms and conditions beyond the date of any notice and cure period for such Event of Default, Sublandlord may use or apply all or any part of the Security Deposit for the payment of any Sublease Rent not paid when due or for the payment of any other amounts due Sublandlord by reason of such Event of Default, including any costs of Sublandlord&#146;s observing or performing such terms or conditions on Subtenant&#146;s behalf and any deficiencies in reletting or damages incurred by Sublandlord. If Sublandlord shall use or apply all or any part of the Security Deposit, Subtenant shall, within three (3) business days following notice from Sublandlord, deliver to Sublandlord additional funds so as to restore the Security Deposit to the to the amount before such application of funds by Sublandlord. The Security Deposit, or so much</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="41952-2-KW-01_PB_4_081223_7906"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2237524",CP="AKERO THERAPEUTICS",DN="5",CHK=362024,FOLIO='4',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KW-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 08:16 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">thereof as shall not have been used or applied in accordance with this <u>Section 6</u>, shall be returned to Subtenant no later than thirty (30) days following the later of: (i) the expiration or sooner termination of this Sublease, and (ii) the surrender of the Sublease Premises to Sublandlord vacant and in accordance with this Sublease. Subtenant hereby waives the provisions of Section 1950.7 of the California Civil Code. If Sublandlord shall transfer the Security Deposit to an assignee of Sublandlord&#146;s interest under the Master Lease, the Sublandlord making such transfer and assignment shall be deemed released from all liability to Subtenant with respect to the Security Deposit or the return thereof, and Subtenant agrees to look solely to the transferee and assignee with respect thereto. Subtenant shall not assign (other than to an assignee of this Sublease) or encumber its interest in the Security Deposit and no such assignment or encumbrance shall be valid or binding upon Sublandlord.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Furniture, Fixtures, and Equipment</b>. During the Sublease Term, Subtenant shall have the right, at no cost or expense to Subtenant, to use those items of Sublandlord&#146;s furniture, fixtures, and equipment that are located in the Sublease Premises (the &#147;<b><i style="font-weight:bold;">FF&amp;E</i></b>&#148;). Sublandlord has not made, does not make, and will not make, any representations or warranties of any kind, express or implied, to Subtenant with respect to the FF&amp;E including, without limitation, any representations or warranties as to the condition or functionality of the FF&amp;E, or the suitability of the FF&amp;E for Subtenant&#146;s purposes. Subtenant agrees to accept the FF&amp;E for use and, if applicable, for purchase in its &#147;<i>as is, where is, with all faults</i>&#148; condition. From and after the Commencement Date, Subtenant shall be solely responsible, at Subtenant&#146;s sole cost and expense, for maintenance, repair, operation, replacement and, if applicable, removal and any repair and/or restoration of any damage to the Property caused by or resulting from such removal, from time to time, of the FF&amp;E.&#160; The FF&amp;E shall be surrendered with the Sublease Premises at the expiration or earlier termination of the Sublease Term.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Master Lease.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Sublease Subordinate to Master Lease; Subtenant&#146;s Covenants.</b> This Sublease is in all respects subject and subordinate to all of the terms, provisions, covenants, stipulations, conditions and agreements of the Master Lease. Subtenant agrees as follows (to the extent certain provisions of the Master Lease are incorporated below, all references in such incorporated provision to the term &#147;Tenant&#148; shall be deemed to refer to Subtenant, all references to the term &#147;Premises&#148; shall be deemed to refer to the Sublease Premises, all references to the term &#147;Lease&#148; shall be deemed to refer to this Sublease, all references to the term &#147;Lease Term&#148; shall be deemed to refer to the Sublease Term, and all references to the term &#147;Landlord&#148; shall be deemed to refer to Sublandlord, each unless expressly stated, or the context would imply, otherwise):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(a)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Summary of Basic Lease Information</b>. Sections 2.1, 2.3, and 11 of the Summary of Basic Lease Information in the Master Lease are incorporated herein by reference.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(b)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Permitted Use</b>. Sections 5.1 and 5.2 of the Master Lease are incorporated herein by reference, except that the &#147;Permitted Use&#148; hereunder shall be: general office and administrative, consistent with the nature of a first class life sciences project in South San Francisco, California.&#160; Subtenant and Subtenant&#146;s Indemnified Parties (defined below) shall</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="41952-2-KW-01_PB_5_081519_3736"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2237524",CP="AKERO THERAPEUTICS",DN="5",CHK=47336,FOLIO='5',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KW-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 08:16 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">not produce, use, store or generate any Hazardous Materials in our about the Master Premises or Sublease Premises, and Subtenant shall indemnify and hold harmless Master Landlord and Sublandlord for any breach of the obligations in this sentence, consistent with Sections 5.3.1.4.1 and 5.3.1.4.2 of the Master Lease.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(c)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Services and Utilities.</b> Sections 6.1, 6.3 and 6.4 of the Master Lease are incorporated herein by reference, except that references to &#147;Landlord&#148; therein shall mean the Master Landlord only (except that references to &#147;Landlord&#148; in Section 6.3 (except for the reference to Section 19.5 included therein) shall be deemed to refer also to Sublandlord under this Sublease). Any overstandard use by Subtenant shall be subject to Sublandlord&#146;s consent, and Subtenant shall pay all of Master Landlord&#146;s charges and fees for such request and use.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(d)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Repairs and Maintenance.</b> Sections 7.1, 7.3, and 7.4 of the Master Lease are incorporated herein by reference, except that references to &#147;Landlord&#148; therein shall be deemed to refer to Master Landlord only.&#160; With respect to maintenance, Subtenant shall perform all repair, maintenance and replacement obligations of Sublandlord (as described therein), as &#147;Tenant&#148; under the Master Lease, to the extent that such obligations relate to the Sublease Premises during the Sublease Term.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(e)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Additions and Alterations.</b> Article 8 of the Master Lease is incorporated herein by reference, except for the third and fourth grammatical sentences of Section 8.1. Subtenant shall not make any alterations, additions or improvements to the Sublease Premises without the prior written consent of (i) Master Landlord, which consent may be granted or withheld as set forth in Article 8 of the Master Lease, and (ii) Sublandlord, which consent may be withheld or conditioned in Sublandlord&#146;s sole and absolute discretion.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(f)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Covenant Against Liens. </b>Article 9 of the Master Lease is incorporated herein by reference.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(g)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Indemnification and Insurance</b>. Subtenant shall obtain the insurance coverages required by Section 10.3 of the Master Lease, as incorporated herein by reference. Each policy of insurance shall name Sublandlord as an additional insured.&#160; Sections 10.1, 10.4, 10.5 and 10.6 of the Master Lease are incorporated herein by reference, and the indemnification and exculpation in Section 10.1 shall run in favor of both Master Landlord and Sublandlord.&#160; The waiver of subrogation requirements in Section 10.5 of the Master Lease shall operate between Sublandlord and Subtenant, in the same manner as between Master Landlord and Sublandlord.&#160; Subtenant and Sublandlord each hereby waives any claims for consequential, special, or punitive damages against the other arising out of this Sublease or Subtenant&#146;s use of the Sublease Premises (except that this sentence shall not be construed to limit consequential damages recoverable from Subtenant in the event of (1) a holdover by Subtenant, or (2) a release of Hazardous Materials by Subtenant or any Subtenant Indemnified Parties (defined below)).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(h)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Casualty Damage. </b>In the event of a casualty as described in Article 11 of the Master Lease, Subtenant shall only be entitled to an abatement of Sublease Rent to the extent that Sublandlord is entitled to rental abatement under the Master Lease with respect to the Sublease Premises.&#160; Subtenant shall have the right to terminate this Sublease under the same circumstances that &#147;Tenant&#148; is entitled to terminate under Article 11 of the Master Lease, and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="41952-2-KW-01_PB_6_081530_9621"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2237524",CP="AKERO THERAPEUTICS",DN="5",CHK=210395,FOLIO='6',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KW-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 08:16 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">may exercise such right at the same times and in the same manner as &#147;Tenant&#148; may do so under such paragraph, but only in the event that the damage or casualty occurs in the Sublease Premises.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(i)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Nonwaiver. </b>Article 12 of the Master Lease is incorporated herein by reference.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(j)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Condemnation.</b> Article 13 of the Master Lease is incorporated herein by reference, but shall only apply to a condemnation of the Sublease Premises, and Subtenant shall have no rights with respect to a condemnation of any portion of the Master Premises not including the Sublease Premises, or any other premises or portion of the Property and references to &#147;Landlord&#148; therein shall mean Master Landlord.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(k)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Assignment and Subletting.</b> Article 14 of the Master Lease is incorporated herein by reference, provided that, Subtenant shall not assign or sublet the Sublease Premises without the prior written consent of (i) Master Landlord, which may be granted or withheld as set forth in Article 14 of the Master Lease, and (ii) Sublandlord, which consent may be withheld or conditioned in Sublandlord&#146;s sole and absolute discretion.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(l)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Surrender.</b> Article 15 of the Master Lease is incorporated herein by reference, and Subtenant shall be solely obligated to remove or restore the Sublease Premises as required by the Master Lease, as incorporated herein, and this Sublease.&#160; Subtenant shall have no obligation to remove any alterations or improvements made by or for Sublandlord.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(m)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Holding Over. </b>Article 16 of the Master Lease is incorporated herein by reference.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(n)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Subordination; Estoppel Certificate.</b> Articles 17 and 18 of the Master Lease are incorporated herein by reference, and Sublandlord may request an estoppel certificate or other documents from Subtenant pursuant to the requirements therein.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(o)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Events of Default; Remedies. </b>Article 19 of the Master Lease is incorporated herein by reference (except for Section 19.5 of the Master Lease, which is not incorporated herein).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(p)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Covenant of Quiet Enjoyment.</b> Article 20 of the Master Lease is incorporated herein by reference.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(q)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Lines.</b> Article 22 of the Master Lease is incorporated herein, except that Sublandlord&#146;s prior written consent shall be required before Subtenant may install any Lines, which consent may be withheld or conditioned in Sublandlord&#146;s reasonable discretion (provided that Sublandlord may require Subtenant to remove such Lines upon the expiration or earlier termination of the Sublease Term).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(r)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Compliance with Laws. </b>Article 24 of the Master Lease is incorporated herein by reference, except that references to &#147;Landlord&#148; therein shall mean the &#147;Master Landlord&#148; only.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="41952-2-KW-01_PB_7_081541_8715"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2237524",CP="AKERO THERAPEUTICS",DN="5",CHK=575803,FOLIO='7',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KW-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 08:16 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(s)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Late Charges. </b>Article 25 of the Master Lease is incorporated herein by reference and shall apply to the Sublease Rent obligations hereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(t)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Right to Cure Default; Payments by Subtenant. </b>Article 26 of the Master Lease is incorporated herein by reference, and references to &#147;Landlord&#148; therein shall mean both Master Landlord and Sublandlord.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(u)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Entry by Landlord.</b> Article 27 of the Master Lease is incorporated herein by reference, and references to &#147;Landlord&#148; therein shall mean both Master Landlord and Sublandlord.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(v)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Parking</b>. Article 28 of the Master Lease is incorporated herein by reference, provided that Subtenant will have rights to five (5) unreserved parking spaces, and Subtenant shall comply with Sublandlord&#146;s reasonable rules and regulations regarding use of parking.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(w)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Miscellaneous</b>. Except for Sections 29.18, 29.24, 29.26, 29.29 and 29.31, the entirety of Article 29 of the Master Lease is incorporated herein by reference.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(x)</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Consents</b>. If any consent is required of Master Landlord for any action of &#147;Tenant&#148; under the Master Lease, then such consent shall be required from both Master Landlord and Sublandlord under this Sublease.&#160; Any consent or approval requested from Sublandlord in accordance with this Sublease shall be deemed reasonably withheld if Master Landlord withholds its consent or approval in accordance with the Master Lease.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as set forth above, the provisions of the Master Lease are not incorporated into this Sublease except as necessary to effectuate the terms and conditions of this Sublease. Neither party shall take any action or do or permit to be done anything which: (i) is or may be prohibited under the Master Lease; (ii) might result in a violation of or default under any of the terms, covenants, conditions or provisions of the Master Lease or any other instrument to which this Sublease is subordinate; or (iii) would result in any additional cost or other liability to Sublandlord or Subtenant respectively.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Sublandlord Not Responsible for Representations and Covenants of Master Landlord under Master Lease.</b> Sublandlord shall not be deemed to have made any representation made by Master Landlord in any of the provisions of the Master Lease. Moreover, during the Sublease Term, Subtenant acknowledges and agrees that Sublandlord shall not be responsible for Master Landlord&#146;s covenants and obligations under the Master Lease. Without limiting the generality of the foregoing, Sublandlord shall not be obligated (i) to provide any of the services or utilities that Master Landlord has agreed in the Master Lease to provide, (ii) to make any of the repairs or restorations that Master Landlord has agreed in the Master Lease to make, (iii) to comply with any laws or requirements of public authorities with which Master Landlord has agreed in the Master Lease to comply, or (iv) to take any action with respect to the operation, administration or control of the Property or any of the Common Areas that the Master Landlord has agreed in the Master Lease to take, and Sublandlord shall have no liability to Subtenant on account of any failure of Master Landlord to do so, or on account of any failure by Master Landlord to observe or perform any of the terms, covenants or conditions of the Master</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="41952-2-KW-03_PB_8_081808_6478"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2237524",CP="AKERO THERAPEUTICS",DN="5",CHK=973143,FOLIO='8',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KW-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 09:01 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Lease required to be observed or performed by Master Landlord, provided that in the event that Subtenant determines in good faith that Master Landlord has not performed its obligations under the Master Lease, then upon receipt of written notice from Subtenant, Sublandlord shall be obligated to use commercially reasonable efforts to cause such breaches, defaults or failures of Master Landlord under the Master Lease to be resolved or otherwise settled; provided, further however: (A) Sublandlord shall not have any obligation to incur out-of-pocket expenses in connection with its covenants under this <u>Section 8.2</u> and (B) Sublandlord shall not have any obligation to commence litigation or other dispute resolution proceedings to cause Master Landlord to comply with the Master Lease.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Indemnity by Subtenant.</b> Subtenant shall indemnify Sublandlord, its officers, directors, shareholders, agents, representatives and employees (collectively &#147;<b><i style="font-weight:bold;">Sublandlord Indemnified Parties</i></b>&#148;) against, and hold Sublandlord, and the Sublandlord Indemnified Parties harmless from, any and all demands, claims, causes of action, fines, penalties, damages, losses, liabilities, judgments, and expenses (including, without limitation, reasonable attorneys&#146; fees and court costs) (collectively, &#147;<b><i style="font-weight:bold;">Claims</i></b>&#148;) incurred in connection with, or arising from: (a) the use or occupancy of the Sublease Premises, Master Premises or the Property by Subtenant or any persons claiming under Subtenant; (b) any activity, work, or thing done, permitted or suffered by Subtenant in or about the Master Premises or Sublease Premises; (c) any acts, omissions, or negligence of Subtenant or any person claiming under Subtenant, or the contractors, agents, employees, invitees, or visitors of Subtenant or any such person; (d) any breach, violation, or nonperformance by Subtenant or any person claiming under Subtenant or the employees, agents, contractors, invitees, or visitors of Subtenant or any such person of any term, covenant, or provision of this Sublease or any law, ordinance, or governmental requirement of any kind; (e) any injury or damage to the person, or property of Sublandlord, or any Sublandlord Indemnified Parties, or any other person entering upon the Sublease Premises to the extent caused by Subtenant; and (f) Subtenant&#146;s failure to comply with the surrender provisions of this Sublease at the expiration or earlier termination of the Sublease Term, except to the extent any of the foregoing results from the gross negligence or willful misconduct of Sublandlord or its officers, directors, shareholders, agents, contractors, employees, invitees or visitors. If any action or proceeding is brought against Sublandlord, or any Sublandlord Indemnified Parties by reason of any such claim, Subtenant, upon notice from Sublandlord, shall defend the claim at Subtenant&#146;s expense with counsel reasonably satisfactory to Sublandlord.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Indemnity by Sublandlord. </b>Sublandlord shall indemnify Subtenant, its officers, directors, shareholders, agents, representatives and employees (collectively &#147;<b><i style="font-weight:bold;">Subtenant Indemnified Parties</i></b>&#148;) against, and hold Subtenant, and Subtenant&#146;s Indemnified Parties harmless from, any and all Claims incurred in connection with, or arising from: (a) any negligence or willful misconduct of Sublandlord or any Sublandlord Indemnified Party, or (b) any breach, violation, or nonperformance by Sublandlord of any term, covenant or provision of this Sublease, except to the extent resulting from the negligence or willful misconduct of Subtenant or its officers, directors, shareholders, agents, contractors, employees, invitees or visitors. If any action or proceeding is brought against Subtenant, its employees or agents by reason of any such claim, Sublandlord, upon notice from Subtenant, shall defend the claim at Sublandlord&#146;s expense with counsel reasonably satisfactory to Subtenant.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="41952-2-KW-03_PB_9_081821_563"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2237524",CP="AKERO THERAPEUTICS",DN="5",CHK=835655,FOLIO='9',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KW-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 09:01 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Master Landlord Notices.</b>&#160; Sublandlord and Subtenant shall, promptly following receipt thereof, deliver to the other party a copy of any and all notices received from Master Landlord which would have any material effect upon the Sublease Premises or this Sublease.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Sublandlord&#146;s Right to Cure Subtenant Default.</b> Upon an Event of Default (as defined in Article 19 of the Master Lease) by Subtenant under this Sublease (after lapse of any applicable notice and cure periods), Sublandlord may, without waiving or releasing any obligation of Subtenant hereunder and without waiving any rights or remedies at law or otherwise, make such payment or perform such act. All sums so paid or incurred by Sublandlord, together with interest thereon, from the date such sums were paid or incurred, at the annual rate equal to 10% per annum or the highest rate permitted by law, whichever is less, shall be payable to Sublandlord on demand as additional Sublease Rent.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Notices.</b> Any notice, request, demand, consent, approval, or other communication required or permitted under this Sublease shall be in writing. All notices shall be addressed to the addresses set forth in the introductory paragraph, or such other address as the parties may notify each other from time to time, and shall be: (a) personally delivered; (b) sent by certified or registered mail, postage prepaid, return receipt requested; or (c) sent by a nationally recognized overnight courier service, with charges prepaid and a receipt provided therefor. All notices shall be deemed to have been given on the earlier of: (i) the date of actual receipt; or (ii) one (1) business day after being properly deposited with a nationally recognized overnight courier service.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Time Is of the Essence.</b> Time is of the essence with respect to the performance of every provision of this Sublease in which time of performance is a factor.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Attorneys&#146; Fees.</b> If any action or proceeding is instituted by Sublandlord or Subtenant to construe, interpret or enforce the provisions of this Sublease, the prevailing party shall be entitled to the reimbursement of its reasonable attorneys&#146; fees and costs incurred in connection with such proceeding by the non-prevailing party.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">16.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Brokers. </b>Each party represents and warrants that it has not been represented by any broker in connection this Sublease, and each party hereby indemnifies, protects, defends (with legal counsel acceptable to the other party) and holds the other party free and harmless from and against any and all costs and liabilities, including, without limitation, reasonable attorneys&#146; fees, for causes of action or proceedings that may be instituted by any broker, agent or finder, licensed or otherwise, claiming through, under or by reason of the conduct of such party in connection with this Sublease.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">17.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Counterparts.</b> This Sublease may be executed in duplicate counterparts, each of which shall be deemed an original hereof. Electronically transmitted signatures shall be deemed originals.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Entire Agreement/Modification.</b> This Sublease, including the Exhibits, contains all of the agreements of the parties hereto with respect to any matter covered or mentioned in this Sublease, and no prior agreements or understanding or letter or proposal pertaining to any such matters shall be effective for any purpose. This Sublease may only be modified by a writing</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="41952-2-KW-03_PB_10_081831_9497"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2237524",CP="AKERO THERAPEUTICS",DN="5",CHK=477416,FOLIO='10',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KW-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 09:01 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">signed by Sublandlord and Subtenant. No provisions of this Sublease may be amended or added to, whether by conduct, oral or written communication, or otherwise, except by an agreement in writing signed by the parties hereto or their respective successors-in-interest.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">19.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Interpretation.</b> The title and paragraph headings are not a part of this Sublease and shall have no effect upon the construction or interpretation of any part of this Sublease. Unless stated otherwise, references to paragraphs and subparagraphs are to those in this Sublease. This Sublease shall be strictly construed neither against Sublandlord nor Subtenant.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">20.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Authority.</b> Subtenant hereby represents and warrants that Subtenant is a duly formed and existing entity qualified to do business in the State of California and that Subtenant has full right and authority to execute and deliver this Sublease and that each person executing this Sublease on behalf of Subtenant is authorized to do so. Sublandlord hereby represents and warrants that Sublandlord has full right and authority to execute and deliver this Sublease and that each person executing this Sublease on behalf of Sublandlord is authorized to do so.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">21.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Signage.</b> Subtenant shall not be entitled to any signage.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">22.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>OFAC Compliance. </b>Subtenant and all beneficial owners of Subtenant are currently (a) in compliance with and shall at all times during the Sublease Term remain in compliance with the regulations of the Office of Foreign Assets Control (&#147;<b><i style="font-weight:bold;">OFAC</i></b>&#148;) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the &#147;<b><i style="font-weight:bold;">OFAC Rules</i></b>&#148;), (b) not listed on, and shall not during the Sublease Term be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List, or the Sectoral Sanctions Identification List, which are all maintained by OFAC and/or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">23.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sublandlord covenants not to (a) voluntarily surrender or terminate the Master Lease prior to the expiration of the Initial Term, or (b) enter into, without the consent of Subtenant, any amendment to the Master Lease which would adversely affect Subtenant&#146;s rights or increase Subtenant&#146;s monetary obligations under this Sublease.&#160; Notwithstanding anything contained in this Sublease to the contrary, Subtenant shall not be responsible for (i) any default of Sublandlord, its agents, employees or contractors under the Master Lease unless attributable to a default under this Sublease or the Master Lease by Subtenant, its agents, employees, contractors, invitees or anyone claiming by, through or under Subtenant, (ii) conditions at the Subleased Premises, for which the obligation to maintain and repair resides with Master Landlord under the Master Lease and/or which existed as of the Commencement Date, (iii) any violations of law resulting from such conditions described by (ii) above, (iv) the payment of any charges, fees and other costs imposed by Master Landlord on Sublandlord as a result of Sublandlord&#146;s default under the Master Lease (unless due to any default by Subtenant under this Sublease), and (v) making payment of any sums either to Master Landlord or Sublandlord in satisfaction of any charges accruing under the Master Lease (whether denominated as rent, rental, additional rent or otherwise) for any period prior or subsequent to the Term of this Sublease.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="41952-2-KW-03_PB_11_081842_3641"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2237524",CP="AKERO THERAPEUTICS",DN="5",CHK=527961,FOLIO='11',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KW-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 09:01 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">24.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sublandlord represents and warrants to Subtenant that (i) a true, correct and complete copy of the Master Lease (excluding redacted terms not relevant to Subtenant) has been delivered to Subtenant and the Master Lease has not been modified or amended, assigned or sublet in any manner as of the date hereof, (ii) the Master Lease is in full force and effect, (iii) to the best of Sublandlord&#146;s knowledge, Sublandlord is not in default under the Master Lease, and (iv) Sublandlord has not received any notice of default under the Master Lease.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[signature page follows]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="41952-2-KW-03_PB_12_081851_5250"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2237524",CP="AKERO THERAPEUTICS",DN="5",CHK=186497,FOLIO='12',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KW-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 09:01 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, Sublandlord and Subtenant have executed this Sublease as of the date first above written.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SUBLANDLORD:</font></b></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SUBTENANT:</font></b></p>    </td>   </tr>
<tr>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Trucode Gene Repair, Inc.</font></b></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Akero Therapeutics, Inc.</font></b></p>    </td>   </tr>
<tr>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Marshall Fordyce</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Andrew Cheng</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: Marshall Fordyce</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: Andrew Cheng</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: CEO</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: President and   CEO</font></p>    </td>   </tr>
<tr>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:7.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:7.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:7.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">And By:</font></p>    </td>
<td width="40%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Jonathan Young</font></p>    </td>   </tr>
<tr>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:7.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: Jonathan Young</font></p>    </td>   </tr>
<tr>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:7.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: EVP and COO</font></p>    </td>   </tr>
<tr height="0">
<td width="29" style="border:none;"></td>
<td width="310" style="border:none;"></td>
<td width="28" style="border:none;"></td>
<td width="29" style="border:none;"></td>
<td width="27" style="border:none;"></td>
<td width="284" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[Signature Page to Sublease]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2237524",CP="AKERO THERAPEUTICS",DN="5",CHK=941953,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KW-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 09:01 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">EXHIBIT A</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DEPICTION OF SUBLEASE PREMISES</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[To Be Attached]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2237524",CP="AKERO THERAPEUTICS",DN="5",CHK=1011861,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KW-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 09:01 2019' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="720" height="986" src="g419522kw05i001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2237524",CP="AKERO THERAPEUTICS",DN="5",CHK=174454,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-KW-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 08:35 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.7</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXCLUSIVE LICENSE AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">by and between</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMGEN INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">and</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AKERO THERAPEUTICS,&nbsp;INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Dated as of June&nbsp;7, 2018</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">i<a name="41952-2-LA-01_PB_i_061641_2379"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=104585,FOLIO='i',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:39 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TABLE OF CONTENTS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;1.   DEFINITIONS</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;2. LICENSE   GRANT</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1   Grant</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.2   Sublicenses</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.3   Transfer of Licensed Know-How and Licensed Materials</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.4   Reserved Rights and Ongoing Activities</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;3. FEES,   ROYALTIES AND PAYMENTS</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1   Milestones Payments and Royalties</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2   Method of Payment</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3   Currency Conversion</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.4   Late Payments</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.5   Records and Audits</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.6   Taxes</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;4.   PATENT PROSECUTION, MAINTENANCE AND INFRINGEMENT</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1   Prosecution and Maintenance</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2   AMGEN Step-In Right</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3 Enforcement</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4   Defense of Third Party Claims</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.5   Recovery</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.6   Patent Term Extensions and Filings for Regulatory Exclusivity Periods</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.7   Patent Marking</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;5.   OBLIGATIONS OF THE PARTIES</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1   Responsibility</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2   Diligence</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.3   Reports</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.4   Product Supply</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;6.   REPRESENTATIONS</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1   Mutual Warranties</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.2   Additional AMGEN Warranties</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.3   Additional AMGEN Warranties</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.4   Disclaimer</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.5   NEWCO Covenants</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;7.   INDEMNIFICATION</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1   Indemnity</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.2   LIMITATION OF DAMAGES</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.3   Insurance</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;8.   CONFIDENTIALITY</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1   Confidential Information</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30</font></p>    </td>   </tr>
<tr>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.2   Terms of this Agreement; Publicity</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32</font></p>    </td>   </tr>  </table>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">ii<a name="41952-2-LA-01_PB_ii_061647_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=503464,FOLIO='ii',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:39 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.3   Publications</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.4   Relationship to the Confidentiality Agreement</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.5   Attorney-Client Privilege</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;9. TERM   AND TERMINATION</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.1   Term</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.2   Termination by AMGEN</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.3 Termination   by NEWCO</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.4   Termination Upon Bankruptcy</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.5   Effects of Termination</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.6   Survival</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ARTICLE&nbsp;10.   MISCELLANEOUS</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.1   Entire Agreement; Amendment</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.2   Section&nbsp;365(n)&nbsp;of the Bankruptcy Code</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.3   Independent Contractors</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.4   Governing Law; Jurisdiction</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.5   Notice</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.6   Compliance With Law; Severability</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.7   Non-Use of Names</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.8   Successors and Assigns</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.9   Waivers</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.10   No Third Party Beneficiaries</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.11   Headings; Exhibits</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.12   Interpretation</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.13   Equitable Relief</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.14   Force Majeure</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.15   Further Assurances</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.16   Counterparts</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.0%;">
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;List</font></u></b></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit&nbsp;A</font></p>    </td>
<td width="78%" valign="bottom" style="padding:0in 0in 0in 0in;width:78.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Licensed Know-How</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit&nbsp;B</font></p>    </td>
<td width="78%" valign="bottom" style="padding:0in 0in 0in 0in;width:78.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Licensed Patents</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit&nbsp;C</font></p>    </td>
<td width="78%" valign="bottom" style="padding:0in 0in 0in 0in;width:78.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Permitted CMOs</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit&nbsp;D</font></p>    </td>
<td width="78%" valign="bottom" style="padding:0in 0in 0in 0in;width:78.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Product Sequence</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit&nbsp;E</font></p>    </td>
<td width="78%" valign="bottom" style="padding:0in 0in 0in 0in;width:78.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Quality Agreement</font></p>    </td>
<td width="9%" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;text-indent:291.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">iii<a name="41952-2-LA-01_PB_iii_061902_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=760188,FOLIO='iii',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-01_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:39 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXCLUSIVE LICENSE AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This EXCLUSIVE LICENSE AGREEMENT (this &#147;<b>Agreement</b>&#148;) is entered into as of June&nbsp;7, 2018 (the &#147;<b>Effective Date</b>&#148;) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (&#147;<b>AMGEN</b>&#148;), and AKERO THERAPEUTICS,&nbsp;INC., a Delaware corporation having an address at 271 Waverly Oaks, Suite&nbsp;104, Waltham, Massachusetts 02452 (&#147;<b>AKERO</b>&#148;).&#160; AKERO and AMGEN are sometimes referred to herein individually as a &#147;<b>Party</b>&#148; and collectively as the &#147;<b>Parties</b>&#148;.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RECITALS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS,</font></b> AMGEN possesses certain rights to patents and other intellectual property related to the Product (as hereinafter defined);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS,</font></b> AKERO desires to license from AMGEN such intellectual property rights, and to commercially develop, manufacture, use and distribute the Product based upon the same throughout the world, and AMGEN desires to grant such a license to AKERO in accordance with the terms and conditions of this Agreement; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS</font></b>, concurrently with the execution and delivery of this Agreement, the Parties are entering into (i)&nbsp;a stock purchase agreement with the other investors named therein providing for the issuance to AMGEN of Series&nbsp;A Preferred Stock of AKERO and (ii)&nbsp;related financing documents.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NOW, THEREFORE,</font></b> in consideration of the premises and the mutual promises and covenants contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;1.</font></b><b>&#160; DEFINITIONS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All references to particular Exhibits, Articles or Sections shall mean the Exhibits to, and Articles and Sections of, this Agreement, unless otherwise specified. For the purposes of this Agreement and the Exhibits hereto, the following words and phrases shall have the following meanings:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.1&#160; </font></b>&#160;&#147;<b>Abandoned Patent Right</b>&#148; has the meaning set forth in Section&nbsp;4.2&#160; (AMGEN Step-In Right).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.2&#160; </font></b>&#160;&#147;<b>Additional Shares</b>&#148; has the meaning set forth in Section&nbsp;3.1.1(b).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.3&#160; </font></b>&#160;&#147;<b>Affiliate</b>&#148; means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, for as long as such control exists. For purposes of the definition of &#147;Affiliate&#148;, &#147;control&#148; means the direct or indirect ownership of more than fifty percent (50%) of the voting or economic interest of a Person, or the power, whether pursuant to contract, ownership of securities or otherwise, to direct the management and policies of a Person. For clarity, once a Person ceases to be an Affiliate of a Party, then, without any further action, such Person shall cease to have any rights, including license and sublicense rights, under this</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="41952-2-LA-03_PB_1_060517_4656"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=237033,FOLIO='1',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:51 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement by reason of being an Affiliate of such Party.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.4&#160; </font></b>&#160;&#147;<b>Agreement</b>&#148; has the meaning set forth in the Preamble.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.5&#160; </font></b>&#160;&#160;&#147;<b>AKERO</b>&#148; has the meaning set forth in the Preamble.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.6&#160; </font></b>&#160;&#147;<b>AKERO Cell Lines</b>&#148; has the meaning set forth in Section&nbsp;2.3.3(a).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.7&#160; </font></b>&#160;&#147;<b>AKERO Indemnified Parties</b>&#148; has the meaning set forth in Section&nbsp;7.1&#160; (By AMGEN).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.8&#160; </font></b>&#160;&#147;<b>AKERO Manufacturing IP</b>&#148; has the meaning set forth in Section&nbsp;4.8.1.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.9&#160; </font></b>&#160;&#147;<b>AMGEN</b>&#148; has the meaning set forth in the Preamble.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.10&#160; </font></b>&#160;&#147;<b>AMGEN Cell Line</b>&#148; means the proprietary cell line that AMGEN has developed for the generation of the Product.&#160; For avoidance of doubt, the AMGEN Cell Line is a Licensed Material hereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.11&#160; </font></b>&#160;&#160;&#147;<b>AMGEN Indemnified Parties</b>&#148; has the meaning set forth in Section&nbsp;7.1.2 (By AKERO).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.12&#160; </font></b>&#160;&#147;<b>AMGEN Ownership Percentage</b>&#148; has the meaning set forth in Section&nbsp;3.1.1(b).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.13&#160; </font></b><i>&#160;&#147;</i><b>Anti-Corruption Laws</b><i>&#148;</i> means Laws, regulations, or orders prohibiting the provision of a financial or other advantage for a corrupt purpose or otherwise in connection with the improper performance of a relevant function, including without limitation, the U.S. Foreign Corrupt Practices Act (FCPA) and similar laws governing corruption and bribery, whether public, commercial or both, to the extent applicable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.14&#160; </font></b>&#160;&#147;<b>Audited Party</b>&#148; has the meaning set forth in Section&nbsp;3.5&#160; (Records and Audits).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.15&#160; </font></b>&#160;&#147;<b>Biosimilar Version</b>&#148; means (a)&nbsp;in respect of a Product sold in the United States, a biological product approved under the Public Health Service Act section 351(k)&nbsp;that is highly similar to such Product, notwithstanding minor differences in clinically inactive components, and for which there are no clinically meaningful differences between such biological product and the Product in terms of the safety, purity and potency; (b)&nbsp;in respect of a Product sold in the European Union, a biological product approved under Article&nbsp;10(4)&nbsp;of Directive 2001/83/EC and Section&nbsp;4, Part&nbsp;II, Annex I to such Directive based on the demonstration of the similar nature of such biological product and the Product; and (c)&nbsp;in respect of a Product sold outside the United States and the European Union, a biological product approved under a similar pathway to (a)&nbsp;or (b)&nbsp;if such pathway exists and, if such pathway does not exist, a marketing approval granted by a regulatory authority to such Third Party with reference to such Product.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.16&#160; </font></b><i>&#160;&#147;</i><b>CEO Delegate</b><i>&#148;</i> means the Chief Executive Officer of each Party or their respective delegate.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.17&#160; </font></b>&#160;&#147;<b>cGMP</b>&#148; means all applicable standards relating to current good manufacturing practices for fine chemicals, intermediates, bulk products and/or finished pharmaceutical drugs, including (a)&nbsp;all applicable requirements detailed in the FDA&#146;s current Good Manufacturing Practices regulations, 21 C.F.R. Parts 210 and 211, (b)&nbsp;all applicable requirements detailed in the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="41952-2-LA-03_PB_2_060848_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=509480,FOLIO='2',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:51 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">EMA&#146;s &#147;EU guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use,&#148; and (c)&nbsp;all applicable Laws promulgated by any Governmental Authority having jurisdiction over the manufacture of the applicable compound or pharmaceutical drug product, as applicable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.18&#160; </font></b>&#160;&#147;<b>Clinical Trial</b>&#148; means a Phase 1 Clinical Trial, Phase 2 Clinical Trial or Phase 3 Clinical Trial or any equivalent thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.19&#160; </font></b>&#160;&#160;&#147;<b>CMO</b>&#148; means a Third Party commercial manufacturing organization or similar organization providing biopharmaceutical services.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.20&#160; </font></b>&#160;&#160;&#147;<b>Commercially Reasonable Efforts</b>&#148; means those efforts and resources commensurate with those efforts commonly used in the pharmaceutical industry by a company of comparable size in connection with the development or commercialization of pharmaceutical products that are of similar status, including, with respect to commercial potential, the proprietary position of the product, the regulatory status and approval process, the probable profitability of the applicable product and other relevant factors such as technical, legal, scientific or medical factors.&#160; In determining the level of efforts constituting &#147;<b>Commercially Reasonable Efforts</b>,&#148; the following shall not be taken into account: (a)&nbsp;any other pharmaceutical product AKERO is then researching, developing or commercializing, alone or with one or more collaborators or (b)&nbsp;any payment required to be made to AMGEN hereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.21&#160; </font></b>&#160;&#147;<b>Confidential Information</b>&#148; has the meaning set forth in Section&nbsp;8.1.1 (Confidential Information).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.22&#160; </font></b>&#160;&#147;<b>Control</b>&#148; or &#147;<b>Controlled</b>&#148; means, with respect to any Know-How, material, Patent Right, or other intellectual property right, the possession (whether by ownership or license) by a Party or its Affiliate of the ability to grant to the other Party a license, sublicense or access as provided herein to such Know-How, material, Patent Right, or other intellectual property right, without violating the terms of any agreement or other arrangement with any Third Party, or being obligated to pay any royalties or other consideration therefor, in existence as of the time such Party or its Affiliates would first be required hereunder to grant the other Party such license, sublicense or access; <b><i style="font-weight:bold;">provided, however</i></b><i>,</i> that if (a)&nbsp;AMGEN would Control any Know-How, material, Patent Right, or other intellectual property right <i>but for</i> an obligation to pay royalties or other consideration in connection with a transfer or grant to AKERO of such&#160; Know-How, material, Patent Right, or other intellectual property right and (b)&nbsp;AKERO agrees in writing to reimburse AMGEN for all such royalties or other consideration, then such Know-How, material, Patent Right, or other intellectual property right shall be deemed Controlled by AMGEN.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.23&#160; </font></b>&#160;&#147;<b>Covered</b>&#148; by (a)&nbsp;Licensed Know-How means that such Licensed Know-How was used in the Exploitation of the Product, and (b)&nbsp;a Patent Right means that a Valid Claim (absent a license thereunder or ownership thereof) would be Infringed by the Exploitation of the Product; if a Valid Claim is a pending claim, then such pending claim shall be treated as if it were issued as then pending for the purposes of determining Infringement at the time coverage is assessed.&#160; Cognates of the word &#147;<b>Cover</b>&#148; shall have correlative meanings.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.24&#160; </font></b>&#160;&#147;<b>Defending Party</b>&#148; has the meaning set forth in Section&nbsp;4.4 (Defense of Third</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="41952-2-LA-03_PB_3_060947_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=833084,FOLIO='3',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:51 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Party Claims).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.25&#160; </font></b>&#160;<b>&#147;Designated Investment Document Terms&#148;</b> means:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 31.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Sections 1.1 (Sale and Issuance of Preferred Stock), 1.2 (Closing; Delivery), 1.3 (Call Option), 2.1 (Organization, Good Standing, Corporate Power and Qualification), 2.2 (Capitalization), 2.4 (Authorization) and 2.5 (Valid Issuance of Shares) of the Purchase Agreement]</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 31.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Section&nbsp;FOURTH, B.3.3. (Series&nbsp;A Preferred Stock Protective Provisions) of the Amended and Restated Certificate of Incorporation of Akero Therapeutics,&nbsp;Inc., dated as of the date hereof (the &#147;<b>Restated Charter</b>&#148;);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 31.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Article&nbsp;2 (Agreement Among the Company, the Investors and the Stockholders) of the Right of First Refusal and Co-Sale Agreement, dated as of the date hereof, by and among AKERO, the Investors (as such term is defined therein) and the Key Holders (as such term is defined therein) (the &#147;<b>Right of First Refusal and Co-Sale Agreement</b>&#148;);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 31.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Articles 2 (Registration Rights), 3 (Information and Observer Rights) and 4 (Rights to Future Stock Issuances) and Section&nbsp;6.6 (Amendment and Waivers) of the Investors&#146; Rights Agreement, dated as of the date hereof, by and among AKERO and the Investors (as such term is defined therein) (the &#147;<b>Investors&#146; Rights Agreement</b>&#148;);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 31.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Articles 1 (Voting Provisions Regarding Board of Directors) and 5 (&#147;Bad Actor&#148; Matters) and Section&nbsp;7.8(f)&nbsp;of the Voting Agreement, dated as of the date hereof, by and among AKERO, the Key Holders (as such term is defined therein) and the Investors (as such term is defined therein) (the &#147;<b>Voting Agreement</b>&#148;); and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 31.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The terms of the letter agreement, dated as of the date hereof, by and between AKERO and AMGEN (the &#147;<b>Side Letter</b>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.26&#160; </font></b>&#160;&#160;&#147;<b>Disclosing Party</b>&#148; has the meaning set forth in Section&nbsp;8.1.1 (Confidential Information).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.27&#160; </font></b>&#160;&#147;<b>Effective Date</b>&#148; has the meaning set forth in the Preamble.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.28&#160; </font></b>&#160;&#147;<b>EMA</b>&#148; means the European Medicines Agency or any successor entity thereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.29&#160; </font></b>&#160;&#147;<b>Enforcing Party</b>&#148; has the meaning set forth in Section&nbsp;4.3.3&#160; (Cooperation with Respect to Enforcement).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.30&#160; </font></b>&#160;&#147;<b>Exploit</b>&#148; means to research, develop, make, have made, use, offer for sale, sell, import, export or otherwise exploit, or transfer possession of or title in, a product.&#160; Cognates of the word &#147;<b>Exploit</b>&#148; shall have correlative meanings.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.31&#160; </font></b>&#160;&#147;<b>FDA</b>&#148; means the United States Food and Drug Administration or any successor entity thereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.32&#160; </font></b>&#160;&#147;<b>First Commercial Sale</b>&#148; means, with respect to the Product in any country, the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="41952-2-LA-03_PB_4_061203_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=354900,FOLIO='4',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:51 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">first sale for end use or consumption of the Product in such country after Marketing Approval has been granted in such country.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.33&#160; </font></b>&#160;&#147;<b>FTE Rate</b>&#148; means [***] per hour.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.34&#160; </font></b>&#160;&#147;<b>GAAP</b>&#148; means United States generally accepted accounting principles applied on a consistent basis. Unless otherwise defined or stated herein, financial terms shall be calculated under GAAP.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.35&#160; </font></b>&#160;&#160;&#147;<b>Governmental Authority</b>&#148; means any court, agency, department, authority or other instrumentality of any national, state, county, city or other political subdivision.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.36&#160; </font></b><i>&#160;&#147;</i><b>Government Official</b><i>&#148;</i> means (i)&nbsp;any official or employee of any Governmental Authority, or any department, agency, or instrumentality thereof (including without limitation commercial entities owned or controlled, directly or indirectly, by a Governmental Authority), (ii)&nbsp;any political party or official thereof, or any candidate for political office, in the Territory, (iii)&nbsp;any official or employee of any public international organization, or (iv)&nbsp;any family members of any of the foregoing.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.37&#160; </font></b>&#160;&#147;<b>Infringe</b>&#148; or &#147;<b>Infringement</b>&#148; means any infringement as determined by Law, including, without limitation, direct infringement, contributory infringement or any inducement to infringe.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.38&#160; </font></b>&#160;&#147;<b>Initial Product</b>&#148; means AMGEN&#146;s proprietary product known as AMG 876 having an amino acid sequence as set forth on <b><u style="font-weight:bold;">Exhibit&nbsp;D</u></b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.39&#160; </font></b>&#160;&#147;<b>Initiation</b>&#148; means, with respect to a human clinical trial, the first dosing in the first patient in such clinical trial.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.40&#160; </font></b>&#160;&#147;<b>Investment Documents</b>&#148; means the Purchase Agreement, the Restated Charter, the Right of First Refusal and Co-Sale Agreement, the Investors&#146; Rights Agreement, the Voting Agreement and the Side Letter.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.41&#160; </font></b>&#160;&#147;<b>Investors&#146; Rights Agreement</b>&#148; has the meaning set forth in the definition of &#147;Designated Investment Document Terms&#148;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.42&#160; </font></b>&#160;&#147;<b>Issuing Party</b>&#148; has the meaning set forth in Section&nbsp;8.2.2 (Review).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.43&#160; </font></b>&#160;&#147;<b>Know-How</b>&#148; means non-public techniques, technology, trade secrets, inventions (whether patentable or not), methods, know-how, data and results (including pharmacological, toxicological and clinical data and results), analytical and quality control data and results, regulatory documents, and other information, compositions of matter, cells, cell lines, assays, animal models and other physical, biological, or chemical material.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.44&#160; </font></b>&#160;&#147;<b>Law</b>&#148; means, individually and collectively, any and all laws, ordinances, rules, directives, administrative circulars and regulations of any kind whatsoever of any Governmental Authority within the applicable jurisdiction, including, but not limited to, Anti-Corruption Laws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.45&#160; </font></b>&#160;&#147;<b>Licensed Field</b>&#148; means any and all uses.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.46&#160; </font></b>&#160;&#147;<b>Licensed Know-How</b>&#148; means all Know-How that (a)&nbsp;is Controlled by AMGEN</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="41952-2-LA-03_PB_5_061247_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=568832,FOLIO='5',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:51 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">or its Affiliates and (b)&nbsp;is or was actually used by AMGEN or its respective Affiliates in research and development of the Product prior to the Effective Date, including the Know-How set forth on <b><u style="font-weight:bold;">Exhibit&nbsp;A</u></b>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.47&#160; </font></b>&#160;&#147;<b>Licensed Materials</b>&#148; means those materials set forth on Table 1 of <b><u style="font-weight:bold;">Exhibit&nbsp;A</u></b>, including the AMGEN Cell Line, reagents and other biological materials, all to the extent (a)&nbsp;Controlled by AMGEN or its Affiliates, (b)&nbsp;in compliance with applicable Laws and (c)&nbsp;in accordance with the relevant informed consents, if applicable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.48&#160; </font></b>&#160;&#147;<b>Licensed Patents</b>&#148; means the Patent Rights Controlled by AMGEN or its Affiliates as of the Effective Date and set forth on <b><u style="font-weight:bold;">Exhibit&nbsp;B</u></b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.49&#160; </font></b>&#160;&#147;<b>Licensed Technology</b>&#148; means the Licensed Patents and the Licensed Know-How.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.50&#160; </font></b>&#160;&#147;<b>Losses</b>&#148; has the meaning set forth in&nbsp;Section&nbsp;7.1&#160; (By AMGEN).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.51&#160; </font></b>&#160;&#147;<b>Major Market Territory</b>&#148; means the [***].</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.52&#160; </font></b>&#160;&#160;&#147;<b>Marketing Approval</b>&#148; means all approvals, licenses, registrations or authorizations of the Regulatory Authority in a country or region, necessary for the manufacture, use, storage, import, marketing, distribution and sale of the Product in such country or region.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.53&#160; </font></b>&#160;&#147;<b>Milestone Events</b>&#148; shall have the meaning set forth in Section&nbsp;3.1.2 (Milestone Payments).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.54&#160; </font></b>&#160;&#147;<b>Milestone Payments</b>&#148; shall have the meaning set forth in Section&nbsp;3.1.2 (Milestone Payments).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.55&#160; </font></b>&#160;&#160;[***] means, with respect to the Product, the gross sales price of the Product sold by AKERO, its Affiliates or Sublicensee(s)&nbsp;(the &#147;<b>Selling Party</b>&#148;) to Third Parties, less (without duplication):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.25in;text-indent:9.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net Sales will be determined from books and records maintained in accordance with</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="41952-2-LA-03_PB_6_061336_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=801262,FOLIO='6',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:51 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">GAAP, consistently applied throughout the organization and across all products of the entity whose sales of the Product are giving rise to Net Sales.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net Sales shall also include, with respect to the Product sold or otherwise disposed of for any consideration other than an exclusively monetary consideration on bona fide arms&#146;-length terms, an amount equal to the average sales price for the Product having the same dosage form and strength during the applicable reporting period in the country where such sale or other disposal occurred when the Product is sold alone and not with other products, or if the Product is not sold alone in such country during the applicable reporting period, then an amount equal to the average sales price during the applicable reporting period generally achieved for the Product having the same dosage form and strength.&#160; For the avoidance of doubt, disposition of Product for, or use of Product in, clinical trials or other scientific testing, as free samples, or under compassionate use, patient assistance, or test marketing programs or other similar programs or studies, in each case where no consideration is received for such Product, shall not result in any Net Sales.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Where the Product is sold in combination with other pharmaceutical products, diagnostic products, or active ingredients (collectively, &#147;<b>Combination Components</b>&#148;) the Net Sales applicable to such transaction shall be calculated by multiplying the total Net Sales of such combined product by the fraction A/(A+B), where A is the actual price of the Product in the same dosage amount or quantities in the applicable country during the applicable quarter if sold separately, and B is the sum of the actual prices of all Combination Components with which the Product is combined, in the same dosage amount or quantities in the applicable country during the applicable quarter if sold separately. If A or B cannot be determined because values for the Product or Combination Components with which the Product is combined are not available separately in a particular country, then AMGEN and AKERO shall discuss an appropriate allocation for the fair market value of the Product and Combination Components with which the Product is combined to mutually determine Net Sales for the relevant transactions based on an equitable method of determining the same that takes into account variations in potency, the relative contribution of each therapeutically active ingredient or other component, and relative value to the end user of each therapeutically active ingredient or other component.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sales of the Product between or among AKERO and its Affiliates or Sublicensees shall be excluded from the computation of Net Sales and no payments shall be payable on such sales except where such Affiliates or Sublicensees are end users.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.56&#160; </font></b>&#160;&#147;<b>Option</b>&#148; has the meaning set forth in Section&nbsp;4.8.1.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.57&#160; </font></b>&#160;&#147;<b>Option Date</b>&#148; has the meaning set forth in Section&nbsp;4.8.1.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.58&#160; </font></b>&#160;&#147;<b>Option Notice</b>&#148; has the meaning set forth in Section&nbsp;4.8.1.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.59&#160; </font></b>&#160;&#147;<b>Party</b>&#148; has the meaning set forth in the Preamble.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.60&#160; </font></b>&#160;&#147;<b>Patent Rights</b>&#148; means the rights and interests in and to all U.S. and foreign (a)&nbsp;patents, including, without limitation, certificates of invention, registrations, reissues, extensions, substitutions, confirmations, renewals, re-registrations, re-examinations, revalidations, patents of additions or like filing thereof; and (b)&nbsp;patent applications, including, without limitation,</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="41952-2-LA-03_PB_7_061434_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=461744,FOLIO='7',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:51 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">provisional, converted provisional, non-provisional, continued prosecution application, continuation, divisional or continuation-in-part thereof, any patents issuing therefrom, and any substitution, extension, registration, confirmation, reissue, re-examination, renewal or like filing thereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.61&#160; </font></b>&#160;&#160;&#147;<b>Permitted CMO</b>&#148; means (a)&nbsp;a Third Party commercial manufacturing organization identified on <b><u style="font-weight:bold;">Exhibit&nbsp;C</u></b> (and all such Third Party&#146;s Affiliates), as such schedule may be updated by mutual written agreement by the Parties from time to time or (b)&nbsp;any other party deemed to be a Permitted CMO pursuant to the terms of Section&nbsp;2.4.2.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.62&#160; </font></b>&#160;&#147;<b>Permitted CMO Agreement</b>&#148; has the meaning set forth in Section&nbsp;2.3.3(a).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.63&#160; </font></b>&#160;&#147;<b>Permitted CMO Request</b>&#148; has the meaning set forth in Section&nbsp;2.3.3(d).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.64&#160; </font></b>&#160;&#147;<b>Person</b>&#148; means any corporation, limited or general partnership, limited liability company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.65&#160; </font></b>&#160;&#147;<b>Phase&nbsp;1 Clinical Trial</b>&#148; means any initial stage human clinical trial in which the Product is introduced into humans and is conducted mainly, but not limited to, to evaluate the safety, metabolism and pharmacokinetic properties, clinical pharmacology, and if possible, to gain early evidence on effectiveness of the Product that would satisfy the requirements of 21&nbsp;C.F.R. &#167;&nbsp;312.21(a)&nbsp;or its non-U.S. equivalents.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.66&#160; </font></b>&#160;&#160;&#147;<b>Phase&nbsp;2 Clinical Trial</b>&#148; means any human clinical trial of the Product conducted mainly to test the effectiveness and to determine the common short-term side effects and risks associated with the Product for purposes of identifying the appropriate dose for a Phase 3 Clinical Trial for a particular indication or indications that would satisfy the requirements of 21&nbsp;CFR &#167;&nbsp;312.21(b)&nbsp;or its non-U.S. equivalents.&#160; A &#147;<b>Phase 2/3 Clinical Trial</b>&#148; shall be deemed to be a Phase 2 Clinical Trial with respect to the portion of that clinical trial that is regarded as its Phase 2 component, in accordance with the applicable protocol.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.67&#160; </font></b>&#160;&#147;<b>Phase&nbsp;3 Clinical Trial</b>&#148; means any human clinical trial of the Product designed to: (a)&nbsp;gather additional information about the effectiveness and safety of the Product that is needed to evaluate the overall benefit-risk relationship of the Product for its intended use; (b)&nbsp;provide the clinical basis of commercial labeling; and (c)&nbsp;support regulatory approval of the Product, that would satisfy the requirements of 21&nbsp;CFR &#167;&nbsp;312.21(c)&nbsp;or its non-U.S. equivalents.&#160; A &#147;<b>Phase 2/3 Clinical Trial</b>&#148; shall be deemed to be a Phase 3 Clinical Trial with respect to the portion of that clinical trial that is regarded as its Phase 3 component, in accordance with the applicable protocol.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.68&#160; </font></b><b>&#160;&#147;Pivotal Trial&#148; </b>means a clinical trial of a Product in human patients, which trial is designed (a)&nbsp;to establish that the Product is safe and efficacious for its intended use; (b)&nbsp;to define warnings, precautions and adverse reactions that are associated with the Product in the dosage range to be prescribed; (c)&nbsp;to be, either by itself or together with one or more other clinical trials having a comparable design and size, the final human clinical trial in support of Regulatory Approval of the Product and (d)&nbsp;consistent with 21 CFR &#167; 312.21(c)&nbsp;(as hereafter modified or amended) and any of its foreign equivalents. For the avoidance of doubt, it is the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="41952-2-LA-03_PB_8_061526_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=707008,FOLIO='8',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:51 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">intent of the Parties that a pivotal trial shall be a phase III trial, <b><i style="font-weight:bold;">provided,</i></b> that any phase II clinical trial that is subsequently used as a pivotal trial shall be deemed a pivotal trial only upon, and at such time as, an application for Regulatory Approval is accepted by the FDA or a foreign equivalent regulatory authority using such </font>phase II clinical trial as the basis for such Regulatory Approval.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.69&#160; </font></b>&#160;&#160;&#147;<b>Product</b>&#148; means any therapeutic product for use in the Licensed Field that incorporates or practices the Licensed Technology, in any form or formulation, including for clarity, all line extensions of any such product and the Initial Product.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.70&#160; </font></b>&#160;&#147;<b>Product Lots</b>&#148; has the meaning set forth in Section&nbsp;5.4 (Product Supply).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.71&#160; </font></b><i>&#160;&#147;</i><b>Proper Conduct Practices</b><i>&#148; </i>means, in relation to any Person, such Person and each of its Representatives, not, directly or indirectly, (a)&nbsp;making, offering, authorizing, providing or paying anything of value in any form, whether in money, property, services or otherwise to any Governmental Authority, Government Official, or other Person charged with similar public or quasi-public duties, or to any customer, supplier, or any other Person, or to any employee thereof, or failing to disclose fully any such payments in violation of the laws of any relevant jurisdiction to (i)&nbsp;obtain favorable treatment in obtaining or retaining business for it or any of its Affiliates, (ii)&nbsp;pay for favorable treatment for business secured, (iii)&nbsp;obtain special concessions or for special concessions already obtained, for or in respect of it or any of its Affiliates, in each case which would have been in violation of any Law, (iv)&nbsp;influence an act or decision of the recipient (including a decision not to act) in connection with the Person&#146;s or its Affiliate&#146;s business, (v)&nbsp;induce the recipient to use his or her influence to affect any government act or decision in connection with the Person&#146;s or its Affiliate&#146;s business or (vi)&nbsp;induce the recipient to violate his or her duty of loyalty to his or her organization, or as a reward for having done so; (b)&nbsp;engaging in any transactions, establishing or maintaining any fund or assets in which it or any of its Affiliates shall have proprietary rights that have not been recorded in the books and records of it or any of its Affiliates; (c)&nbsp;making any unlawful payment to any agent, employee, officer or director of any Person with which it or any of its Affiliates does business for the purpose of influencing such agent, employee, officer or director to do business with it or any of its Affiliates; (d)&nbsp;violating any provision of applicable Anti-Corruption Laws; (e)&nbsp;making any payment in the nature of bribery, fraud, or any other unlawful payment under the Law of any jurisdiction where it or any of its Affiliates conducts business or is registered; or (f)&nbsp;if such Person or any of its Representatives is a Government Official, improperly using his or her position as a Government Official to influence the award of business or regulatory approvals to or for the benefit of such Person, its Representatives or any of their business operations, or failing to recuse himself or herself from any participation as a Government Official in decisions relating to such Person, its Representatives or any of their business operations.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.72&#160; </font></b>&#160;&#147;<b>Purchase Agreement</b>&#148; has the meaning set forth in Section&nbsp;3.1.1(b).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.73&#160; </font></b>&#160;&#147;<b>Receiving Party</b>&#148; has the meaning set forth in Section&nbsp;8.1.1 (Confidential Information).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.74&#160; </font></b>&#160;&#147;<b>Regulatory Approval</b>&#148; means final approval of an Application by the FDA, or final approval of a comparable document filed with an equivalent health regulatory authority in</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="41952-2-LA-03_PB_9_061611_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=418520,FOLIO='9',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-03_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:51 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">any other country or in the European Union (using the centralized process, decentralized process or mutual recognition or member state national authorization) &#151; but not necessarily also any required pricing and/or reimbursement approvals.&#160; &#147;<b>Application</b>&#148; means a new drug application pursuant to and/or as defined in the United States Federal Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or similar application filed with an equivalent regulatory body in another country or multinational region.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.75&#160; </font></b>&#160;&#147;<b>Regulatory Authority</b>&#148; means any Governmental Authority or other authority responsible for granting Marketing Approvals for the Product, including the FDA, EMA and any corresponding national or regional regulatory authorities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.76&#160; </font></b>&#160;&#147;<b>Regulatory Exclusivity</b>&#148; means, with respect to the Product, any exclusive marketing rights or data exclusivity rights conferred by the applicable Regulatory Authority with respect to the Product (that would satisfy the requirements of 21&nbsp;CFR &#167;&nbsp;314.108 or its non-U.S. equivalents) other than a Patent Right.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.77&#160; </font></b>&#160;&#147;<b>Regulatory Filing</b>&#148; means any all (a)&nbsp;submissions, non-administrative correspondence, notifications, registrations, licenses, authorizations, applications and other filings with any Governmental Authority with respect to the research, clinical investigation, development, manufacture, distribution, pricing, reimbursement, marketing or sale of the Product and (b)&nbsp;Marketing Approvals for the Product.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.78&#160; </font></b>&#160;&#147;<b>Release</b>&#148; has the meaning set forth in Section&nbsp;8.2.2 (Review).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.79&#160; </font></b><i>&#160;&#147;</i><b>Representatives</b><i>&#148; </i>means, as to any Person, such Person&#146;s Affiliates and its and their successors, controlling Persons, directors, officers and employees.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.80&#160; </font></b>&#160;&#147;<b>Restated Charter</b>&#148; has the meaning set forth in the definition of &#147;Designated Investment Document Terms&#148;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.81&#160; </font></b>&#160;&#147;<b>Reviewing Party</b>&#148; has the meaning set forth in Section&nbsp;8.2.2&#160; (Review).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.82&#160; </font></b>&#160;&#147;<b>Right of First Refusal and Co-Sale Agreement</b>&#148; has the meaning set forth in the definition of &#147;Designated Investment Document Terms&#148;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.83&#160; </font></b>&#160;&#147;<b>Royalty Term</b>&#148; has the meaning set forth in Section&nbsp;3.1.4 (Royalty Rate; Royalty Term).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.84&#160; </font></b>&#160;&#147;<b>Safety Database</b>&#148; has the meaning set forth in Section&nbsp;5.5.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.85&#160; </font></b>&#160;&#147;<b>Selling Party</b>&#148; has the meaning set forth in the definition of &#147;Net Sales.&#148;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.86&#160; </font></b>&#160;&#147;<b>Series&nbsp;A Preferred Stock</b>&#148; has the meaning set forth in Section&nbsp;3.1.1(b).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.87&#160; </font></b>&#160;&#147;<b>Side Letter</b>&#148; has the meaning set forth in the definition of &#147;Designated Investment Document Terms&#148;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="41952-2-LA-05_PB_10_060339_1488"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=210082,FOLIO='10',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.88&#160; </font></b>&#160;&#160;&#147;<b>Sublicensee(s)</b>&#148; means any Person other than an Affiliate of AKERO to which AKERO has granted a sublicense under this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.89&#160; </font></b>&#160;&#147;<b>Sublicense Notice</b>&#148; has the meaning set forth in Section&nbsp;2.2.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.90&#160; </font></b>&#160;&#147;<b>Term</b>&#148; has the meaning set forth in Section&nbsp;9.1&#160; (Term).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.91&#160; </font></b>&#160;&#147;<b>Territory</b>&#148; means the entire world.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.92&#160; </font></b>&#160;&#147;<b>Third Party</b>&#148; means a Person other than (a)&nbsp;AMGEN or any of its Affiliates and (b)&nbsp;AKERO or any of its Affiliates.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.93&#160; </font></b>&#160;&#147;<b>Valid Claim</b>&#148; means a claim of any issued and unexpired patent or patent application within the Licensed Patents that has not been (i)&nbsp;revoked or held invalid or unenforceable by a final decision of a court or governmental agency of competent jurisdiction (and which decision can no longer be appealed or was not appealed within the time allowed) or (ii)&nbsp;held to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise; <b><i style="font-weight:bold;">provided, however,</i></b> that if a claim of a pending patent application within the Licensed Patents shall not have issued within [***] after the earliest filing date from which such claim takes priority, such claim shall not constitute a Valid Claim for the purposes of this Agreement unless and until a Patent Right issues with such claim (from and after which time the same would be deemed a Valid Claim).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.94&#160; </font></b>&#160;&#160;&#147;<b>VAT</b>&#148; has the meaning set forth in Section&nbsp;3.6.3 (VAT).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1.95&#160; </font></b>&#160;&#147;<b>Voting Agreement</b>&#148; has the meaning set forth in the definition of &#147;Designated Investment Document Terms&#148;.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;2.</font></b><b>&#160; LICENSE GRANT</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;2.1&#160;&#160; <u>Grant</u>.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.1.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Exclusive License</b>.&#160; Subject to the terms and conditions of this Agreement, AMGEN hereby grants to AKERO (a)&nbsp;an exclusive (even as to AMGEN and its Affiliates), royalty bearing, sublicensable (but only in accordance with Section&nbsp;2.2 (Sublicenses)), license under the Licensed Patents, in each case, solely to Exploit Products in the Licensed Field in the Territory during the Term, and (b)&nbsp;a non-exclusive, royalty bearing, sublicensable (but only in accordance with Section&nbsp;2.2 (Sublicenses)), license under the Licensed Know-How, in each case, solely to Exploit the Product in the Licensed Field in the Territory during the Term.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.1.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Non-Exclusive License.&#160; </b>AMGEN hereby grants to AKERO a nonexclusive, royalty-free, sub-licensable (through multiple tiers) license to Patent [***], solely for the manufacture of the Initial Product during the Term.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;2.2&#160;&#160; <u>Sublicenses</u>.</font></b>&#160; AKERO and its Affiliates shall be entitled, without the prior consent of AMGEN, to grant one or more sublicenses, in full or in part, by a written agreement to Third Parties (with the right to sublicense through multiple tiers), <b><i style="font-weight:bold;">provided, however,</i></b> that as a</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="41952-2-LA-05_PB_11_060359_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=1009263,FOLIO='11',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">condition precedent to and requirement of any such sublicense: (a)&nbsp;any such permitted sublicense shall be consistent with and subject to the terms and conditions of this Agreement; (b)&nbsp;AKERO will continue to be responsible for full performance of AKERO&#146;s obligations under the Agreement and will be responsible for all actions of such Sublicensee as if such Sublicensee were AKERO hereunder; and (c)&nbsp;any such Sublicensee shall agree in writing to be bound by the substantially similar obligations of AKERO hereunder that are relevant to the rights sublicensed to AKERO to Sublicensee under such sublicense agreement, including with respect to Article&nbsp;8 (Confidentiality), and Sections 7.1 (Indemnity), 9.2.2 (Termination for IP Challenge) and 9.5 (Effects of Termination).&#160; Further, within thirty (30) days of sublicensing any rights to [***], AKERO shall provide written notice to AMGEN (a &#147;<b>Sublicense Notice</b>&#148;).&#160; The Sublicense Notice shall include the name of the Third Party and a summary of the sublicense terms.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;2.3&#160;&#160; <u>Transfer of Licensed Know-How and Licensed Materials</u>.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.3.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall transfer to AKERO (or, in the case of AMGEN&#146;s transfer of the AMGEN Cell Line, to the Permitted CMO) the Licensed Know-How and Licensed Materials listed on <b><u style="font-weight:bold;">Exhibit&nbsp;A</u></b>, in accordance with a schedule to be mutually agreed by the Parties,<b><i style="font-weight:bold;"> provided</i></b>, that AMGEN shall use commercially reasonable efforts (except during AMGEN&#146;s summer corporate shutdown period) to provide certain quantities of not-for-human-use drug product, cGMP drug substance and proprietary AMGEN reagents (identified on <b><u style="font-weight:bold;">Exhibit&nbsp;A</u></b> as 30-day deliverables) within thirty (30) days following the Effective Date (and AMGEN shall use commercially reasonable efforts to provide such other Licensed Materials as may be reasonably required by AKERO to undertake AKERO&#146;s planned 120-day toxicology studies in rat and monkey), and <b><i style="font-weight:bold;">provided</i></b>, that such overall transfer must be completed within six (6)&nbsp;months after the Effective Date), <b><i style="font-weight:bold;">provided, further, however</i></b>, that such six (6)-month transfer timeline may be reasonably extended for items that, despite diligent efforts by AMGEN, are not practicable to transfer within such six (6)-month period, in which case AMGEN shall continue to use diligent efforts to transfer such items as promptly as practicable after such period but in any event within twelve (12) months after the Effective Date.&#160; The Licensed Know-How will be transferred in a customary electronic format to the extent available and otherwise in the original paper format, and AMGEN will provide limited consulting support, in accordance with this Section&nbsp;2.3.&#160; AMGEN transfers the Licensed Materials to AKERO &#147;as is&#148; and makes no other representations to AKERO in connection therewith.&#160; The Parties acknowledge that there are extensive documents, materials and information related to the Product, and that it is the intent of the Parties that the transfer of documents, materials and information hereunder be limited.&#160; Accordingly, AMGEN shall not have any obligation to transfer to AKERO any Licensed Know-How or Licensed Materials other than those set forth on <b><u style="font-weight:bold;">Exhibit&nbsp;A</u></b>, except that, during the first twelve (12) months following the Effective Date, AKERO may notify AMGEN of any missing Licensed Know-How and AMGEN agrees to use reasonable efforts to locate such missing Licensed Know-How and deliver it to AKERO promptly, in the format specified above. AKERO shall assist AMGEN in meeting its obligations under any relevant informed consents relating to any information or blood or tissue samples transferred to AKERO, including with respect to the destruction or ceasing the use thereof.&#160; AMGEN shall notify AKERO promptly following the completion of its transfer of the Licensed Know-How and Licensed Materials as set forth herein. Following such notification, AKERO shall promptly either (x)&nbsp;confirm to AMGEN that such</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="41952-2-LA-05_PB_12_060418_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=203775,FOLIO='12',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">transfer is complete or (y)&nbsp;notify AMGEN, with reasonable specificity, of any Licensed Know-How and/or Licensed Materials that remain to be transferred, and, in the case of clause (y)&nbsp;above, promptly following AKERO&#146;s notification, the Parties shall in good faith discuss and attempt to resolve such dispute.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.3.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall provide, at its expense, consulting support (not to exceed [***] in the aggregate) in connection with such transfer and the Exploitation of the Product in the Territory during the six (6)-month period (or up to a twelve&nbsp;(12)-month period if extended in accordance with this Section&nbsp;2.5) after the Effective Date. If AKERO requires additional consulting support in excess of [***] in the aggregate or beyond such period after the Effective Date in connection with such transfer or the Exploitation of the Product in the Territory, then AKERO may request such additional support in writing.&#160; AMGEN shall notify AKERO within ten (10)&nbsp;days after receipt of such request whether it, in its sole discretion, is willing to provide such additional consulting support, which support shall be at AKERO&#146;s expense, at the FTE Rate for the relevant AMGEN employees.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.3.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>With respect to AMGEN&#146;s transfer of the AMGEN Cell Line, the Parties agree that the following procedures shall apply:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:31.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Prior to such transfer, AKERO shall designate, and enter into a binding agreement with, one of the Permitted CMOs, which agreement shall provide for, among other things, (i)&nbsp;confidentiality and non-use provisions at least as protective as those set forth hereunder under Section&nbsp;8.1&#160; (Confidential Information) and (ii)&nbsp;such additional provisions as are required to comply with the manufacturing and other limitations set forth in this Section&nbsp;2.3.3 (such agreement, the &#147;Permitted CMO Agreement&#148;).&#160; Upon AMGEN&#146;s reasonable request, AKERO shall provide to AMGEN a copy of any such Permitted CMO Agreement (including any material amendment thereto) executed by AKERO; provided that the financial terms (and any other terms AKERO is required to keep confidential) of any such agreement may be redacted to the extent not pertinent to AMGEN&#146;s confirmation of the restrictive provisions set forth in this Section&nbsp;2.3.3.&#160; For avoidance of doubt, if AKERO (itself, or through a Third Party, Affiliate, or Sublicensee) uses any Licensed Materials and/or Licensed Know-How (excluding any AMGEN Cell Line, but including any Product sequence set forth on the Exhibit&nbsp;D) to create its own cell lines (&#147;AKERO Cell Lines&#148;), such AKERO Cell Lines shall not be the AMGEN Cell Line, and the Permitted CMO restrictions set forth herein shall not apply to AKERO&#146;s exploitation of AKERO Cell Lines.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.2in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Following AKERO&#146;s and such Permitted CMO&#146;s entry into the Permitted CMO Agreement, AMGEN shall, at the direction and expense (for both internal costs at the FTE Rate and out of pocket costs) of AKERO, transfer the AMGEN Cell Line to the Permitted CMO to generate the Product.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.2in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO agrees that it shall not, and it shall use its commercially reasonable efforts to cause the Permitted CMO not to: (i)&nbsp;reverse engineer or otherwise deconstruct the AMGEN Cell Line or the initial AMGEN cell culture media provided therewith, or to determine or to seek to determine information (including, but not limited to, the gene or amino acid sequence) or characteristics regarding the AMGEN Cell Line or such media, other than as expressly required to manufacture the Product; (ii)&nbsp;clone, express, or otherwise produce any</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="41952-2-LA-05_PB_13_060431_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=16,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=956839,FOLIO='13',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">products or materials (including, without limitation, any progeny or derivatives thereof) from the AMGEN Cell Line, other than as expressly permitted under this Agreement; (iii)&nbsp;notwithstanding anything to the contrary in Section&nbsp;8.3.1 (Right to Publish), publish or otherwise publicly disclose the AMGEN Cell Line; or (iv)&nbsp;permit any non-controlled security access to the AMGEN Cell Line or otherwise transfer or provide any of the AMGEN Cell Line to a Third Party or any of its Affiliates, other than as expressly required to manufacture the Product (provided such access or transfer is in accordance with this Agreement).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.2in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Upon a termination or expiration of the Permitted CMO Agreement (including as a result of the appointment, with prior written notice to AMGEN, by AKERO of a replacement Permitted CMO), the Permitted CMO shall promptly return any remaining AMGEN Cell Lines and related Licensed Know-How and Licensed Materials to AMGEN.&#160; If, at any time, AKERO desires to add a new Third Party commercial manufacturer to <b><u style="font-weight:bold;">Exhibit&nbsp;C</u></b>, it shall notify AMGEN in writing (a &#147;<b>Permitted CMO Request</b>&#148;), and AMGEN shall have the right, for sixty (60) days after receipt of such Permitted CMO Request, to inspect, at a reasonable time and on a reasonable basis (at AMGEN&#146;s cost), such manufacturer&#146;s facilities to confirm its ability to fully comply with the restrictive provisions set forth in this Section&nbsp;2.3.3.&#160; AMGEN may reject a Permitted CMO Request if it reasonably determines that the proposed manufacturer is unable to comply with the restrictive provisions set forth in this Section&nbsp;2.3.3, and AMGEN will promptly notify AKERO thereof (and its reasons therefor).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.2in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO acknowledges that any materials transferred by AMGEN to AKERO under this Agreement are experimental in nature and may have unknown characteristics and therefore agrees to use prudence and reasonable care in the use, handling, storage, transportation and disposition and containment of any such materials. Accordingly, no such materials, other than the Product Lots, shall be used in any human application, including any clinical trial.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;2.4&#160;&#160; <u>Limited Grant</u></font></b>.&#160; AKERO acknowledges that the rights and licenses granted under this Article&nbsp;2 (License Grant) and elsewhere in this Agreement are limited to the scope expressly granted. Accordingly, except for the rights expressly granted under this Agreement, notwithstanding anything in this Agreement to the contrary, nothing in this Agreement shall be construed as granting by implication, estoppel or otherwise, any right, title or interest in, to or under any AMGEN patents other than the Licensed Patents regardless of whether such other patents are dominant or subordinate to any Licensed Patent.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;2.5&#160;&#160; <u>Reserved Rights</u></font></b>.&#160; All rights that are not specifically granted herein are reserved to AMGEN.&#160; The Parties agree, without diminishing the rights granted to AKERO under Section&nbsp;2.1 (Grant), AMGEN shall retain all rights that it Controls to the Licensed Know-How to Exploit any product other than the Product, <i>provided</i> that in no event shall AMGEN retain or have any right during the Term to practice any claim that is issued in a Licensed Patent which claim references a Product or the Initial Product, whether such claim issues before or after the Effective Date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">14<a name="41952-2-LA-05_PB_14_060441_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=17,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=989072,FOLIO='14',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;2.6&#160; </font></b><b>&#160;<u>Limited Exploitation of Rights</u></b>.&#160; Without limiting the provisions of Section&nbsp;2.4 (Limited Grant) or Section&nbsp;2.5 (Reserved Rights), AKERO agrees (on behalf of itself and its Affiliates), and shall cause each of its Sublicensees to agree as a condition to the grant of a sublicense pursuant to Section&nbsp;2.2 (Sublicenses), not to Exploit any Licensed Know-How or Licensed Patents in connection with any products or services other than the Product.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;3.</font></b><b>&#160; FEES, ROYALTIES AND PAYMENTS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;3.1&#160;&#160; <u>Upfront Payment, Milestone Payments and Royalties</u>.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Upfront Payment</u></b>.&#160; In consideration of the rights granted herein to AKERO, AKERO shall make the following upfront payment to AMGEN, in the form of a monetary payment and the issuance of certain equity in AKERO.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 9.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Within ten (10)&nbsp;days following the Effective Date, AKERO shall pay to AMGEN the amount of $5,000,000.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 9.0pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>On the Effective Date, AKERO shall issue and deliver to AMGEN 2,653,333 shares of Series&nbsp;A Preferred Stock (the &#147;<b>Series&nbsp;A Preferred Shares</b>&#148;) of AKERO pursuant to the terms of the Purchase Agreement, dated as of the date hereof, by and among AKERO and certain investors party thereto (the &#147;<b>Purchase Agreement</b>&#148;), such shares evidencing an ownership interest of ten percent (10%) of the outstanding and issued common stock of AKERO calculated on a fully diluted and converted basis (the &#147;<b>AMGEN Ownership Percentage</b>&#148;) as of the Effective Date of this Agreement.&#160; Thereafter, [***].</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Milestone Payments</u></b>.&#160; AKERO shall pay to AMGEN certain milestone payments (&#147;<b>Milestone Payments</b>&#148;) following the first occurrence of certain milestone events, as set forth in Section&nbsp;3.1.3 (Milestone Event/Payment Table) (the &#147;<b>Milestone Events</b>&#148;).&#160; AKERO shall pay to AMGEN the applicable Milestone Payment within [***] after (i)&nbsp;[***], and (ii)&nbsp;[***].&#160; For clarity, (a)&nbsp;each Milestone Payment is payable only once, (b)&nbsp;no Milestone Payment shall be payable for subsequent or repeated achievements of such Milestone Event with respect to one or more of the same or different Products, and (c)&nbsp;no more than $[***] shall be payable to AMGEN under this Section&nbsp;3.1.2.&#160; Each of the Milestone Payments shall be non-refundable and non-creditable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Milestone Event/Payment Table</u></b>.&#160; The Milestone Events and Milestone Payments to be made pursuant to Section&nbsp;3.1.2 (Milestone Payments) shall be as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="90%" style="border-collapse:collapse;margin-left:.25in;">
<tr>
<td width="71%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:71.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Milestone&nbsp;Event</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="25%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:25.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Milestone&nbsp;Payment</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.1%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="71%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:71.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="23%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.74%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.74%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="71%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:71.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="23%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.74%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="71%" valign="top" style="padding:0in 0in 0in 0in;width:71.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.74%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="71%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:71.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="23%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.74%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">15<a name="41952-2-LA-05_PB_15_060807_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=18,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=105084,FOLIO='15',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="90%" style="border-collapse:collapse;margin-left:.25in;">
<tr>
<td width="71%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:71.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Milestone&nbsp;Event</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="25%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:25.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Milestone&nbsp;Payment</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.1%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="71%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:71.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="23%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.74%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="453" style="border:none;"></td>
<td width="18" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="151" style="border:none;"></td>
<td width="7" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade align="left" style="color:black;"></div>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">*</font></i>[***]<i>.</i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Royalty Rate; Royalty Term</u></b><b>.</b>&#160; AKERO shall pay to AMGEN a royalty on annual Net Sales of Products sold by a Selling Party during the applicable Royalty Term as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="90%" style="border-collapse:collapse;margin-left:.25in;">
<tr>
<td width="69%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Net&nbsp;Sales</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="25%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:25.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Royalty&nbsp;Rate</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="69%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net Sales up to   and including $[***]</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">]%</font></p>    </td>   </tr>
<tr>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net Sales   exceeding $[***]</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="bottom" style="padding:0in 0in 0in 0in;width:25.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">]%</font></p>    </td>   </tr>
<tr>
<td width="69%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net Sales   exceeding $[***]</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">]%</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Royalties will be payable on a quarterly basis; any such payments shall be made within [***] after the end of the calendar quarter during which the applicable Net Sales occurred.&#160; AKERO&#146;s obligation to pay royalties with respect to a Product in a particular country shall commence upon the First Commercial Sale of such Product in such country and shall expire on a country-by-country basis on the later of (a)&nbsp;the date on which the Exploitation of such Product is no longer Covered by a Valid Claim of a Licensed Patent in such country, (b)&nbsp;the loss of Regulatory Exclusivity for such Product in such country, or (c)&nbsp;the tenth (10</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>) anniversary of the First Commercial Sale of such Product in such country (the &#147;<b>Royalty Term</b>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1.5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Royalty Reductions</u></b><b>.&#160; </b>On a country-by-country basis, in the event that the Exploitation of a Product is not Covered by a Valid Claim of a Licensed Patent in such country, then the royalty rate set forth in Section&nbsp;3.1.4 (Royalty Rate; Royalty Term) with respect to Net Sales for such Product in such country shall be reduced by [***], effective as of the date such Product is no longer Covered by a Valid Claim of a Licensed Patent in such country.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1.6</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Biosimilar Competition</u></b>. On a country-by-country and Product-by-Product basis, following the marketing approval and launch of a Biosimilar Version, the then-applicable royalty rates for the calculation of the royalty payments on Net Sales of the Product corresponding to the Biosimilar Version for the applicable country for any calendar quarter or portion thereof shall, thereafter, be reduced by [***] and, if the Net Sales of such Product in such country have declined by more than [***] as compared with the average Net Sales in the [***] immediately prior to the entry of the Biosimilar Version in such country for more than [***], the then-applicable royalty rates for the calculation of the royalty payments on Net Sales of such Product shall, thereafter, be reduced by an additional [***]; provided, that, after the removal of such Biosimilar Version from such country, the royalty shall revert to being paid in full for the remainder of the Royalty Term.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1.7</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Third-Party Intellectual Property</u></b><b>.</b>&#160; In the event that a Third Party Controls intellectual property relating to a Product that is reasonably necessary for the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">16<a name="41952-2-LA-05_PB_16_060920_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=19,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=236141,FOLIO='16',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exploitation of a Product, then AKERO shall have the right (but not the obligation) to obtain such license to such Third Party intellectual property; <b><i style="font-weight:bold;">provided, however,</i></b> that AKERO has received written advice from its counsel that it would be advisable to obtain a license to such Third Party intellectual property in connection with the Exploitation of the Product.&#160; In such an event, [***] of the royalties that AKERO actually pays to such Third Party for the Exploitation of the Product in a country during a calendar quarter may be credited against royalties otherwise payable by AKERO to AMGEN under Section&nbsp;3.1&#160; (Royalty Rate; Royalty Term) for Net Sales of the Product in such country in such calendar quarter.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1.8</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Maximum Reduction</u></b><b>.</b>&#160; The maximum aggregate reduction with respect to the royalty rate for a Product in any calendar quarter during the applicable Royalty Term in any country pursuant to Sections 3.1.5 (Royalty Reduction), 3.1.6 (Biosimilar Competition) and 3.1.7 (Third-Party Intellectual Property) shall be [***].</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1.9</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Mutual Convenience of the Parties</u></b><b>.</b>&#160; The royalty and other payment obligations set forth hereunder have been agreed to by the Parties for the purpose of reflecting and advancing their mutual convenience, including the ease of calculating and paying royalties and other amounts to AMGEN.&#160; AKERO hereby stipulates to the fairness and reasonableness of such royalty and other payment obligations and covenants not to allege or assert, nor to allow any of its Affiliates or Sublicensees, as applicable, to allege or assert, nor further to cause or support any other Third Parties to allege or assert, that any such royalty or other payment obligations are unenforceable or illegal in any way.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;3.2&#160;&#160; <u>Method of Payment</u>.</font></b>&#160; Unless otherwise agreed by the Parties, all payments due from AKERO to AMGEN under this Agreement shall be paid in U.S. Dollars by wire transfer or electronic funds transfer of immediately available funds to the following account (or such other account as AMGEN may direct from time to time by written notice to AKERO):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Beneficiary Name:&#160; Amgen Inc.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Beneficiary Account #:&#160; [***]</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ABA#: [***]</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Swift Code:&#160; [***]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">After the First Commercial Sale of the first Product and until expiration of the last Royalty Term, AKERO shall prepare and deliver to AMGEN royalty reports of the sale of the Product by the Selling Parties for each calendar quarter within forty-five (45) days of the end of each such calendar quarter specifying in the aggregate and country-by-country basis: (a)&nbsp;total gross amounts for the Product sold or otherwise disposed of by a Selling Party; (b)&nbsp;amounts deducted by category in accordance with the definition of &#147;Net Sales&#148; in Article&nbsp;1 (Definitions) from gross amounts to calculate Net Sales; (c)&nbsp;Net Sales; and (d)&nbsp;royalties payable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;3.3&#160;&#160; <u>Currency Conversion</u>.&#160; </font></b>In the case of sales outside the United States, payments received by AKERO will be expressed in the U.S. Dollar equivalent calculated on a quarterly basis in the currency of the country of sale and converted to their U.S. Dollar equivalent using the average rate of exchange over the applicable calendar quarter to which the sales relate, in accordance with GAAP and the then current standard methods of AKERO or the applicable</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">17<a name="41952-2-LA-05_PB_17_060942_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=20,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=1021446,FOLIO='17',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-05_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sublicensee, to the extent reasonable and consistently applied; <b><i style="font-weight:bold;">provided, however,</i></b> that if, at such time, AKERO or such Sublicensee does not use a rate for converting into U.S. Dollar equivalents that is maintained in accordance with GAAP, then AKERO or such Sublicensee shall use a rate of exchange which corresponds to the rate of exchange for such currency reported in <i>The Wall Street Journal</i>,&nbsp;Internet U.S. Edition at www.wsj.com, as of the last day of the applicable reporting period (or, if unavailable on such date, the first date thereafter on which such rate is available).&#160; AKERO will inform AMGEN as to the specific exchange rate translation methodology used for a particular country or countries and cause any Sublicensees to comply with the terms of this Section&nbsp;3.3.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;3.4&#160;&#160; <u>Late Payments</u>.</font></b>&#160; In the event that any payment due hereunder is not made when due, the payment shall accrue interest beginning on the day following the due date thereof, calculated at the annual rate of the sum of (a)&nbsp;[***] plus (b)&nbsp;the prime interest rate quoted by <i>The Wall Street Journal</i>,&nbsp;Internet U.S. Edition at www.wsj.com on the date said payment is due, the interest being compounded on the last day of each calendar quarter; <b><i style="font-weight:bold;">provided, however,</i></b> that in no event shall said annual interest rate exceed the maximum rate permitted by Law. Each such payment when made shall be accompanied by all interest so accrued.&#160; Said interest and the payment and acceptance thereof shall not negate or waive the right of any Party to seek any other remedy, legal or equitable, to which it may be entitled because of the delinquency of any payment including, but not limited to, termination of this Agreement as set forth in Article&nbsp;9 (Term and Termination).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;3.5&#160;&#160; <u>Records and Audits</u>.&#160; </font></b>AKERO will keep complete and accurate records of the underlying revenue and expense data relating to the calculations of Net Sales generated in the then current calendar year and payments required under this Agreement, and during the preceding three (3)&nbsp;calendar years. AMGEN will have the right, once annually at its own expense, to have a nationally recognized, independent, certified public accounting firm, selected by it and subject to AKERO&#146;s prior written consent (which shall not be unreasonably withheld, conditioned or delayed), review any such records of AKERO and its Affiliates and Sublicensees (the &#147;<b>Audited Party</b>&#148;) in the location(s)&nbsp;where such records are maintained by the Audited Party upon reasonable written notice (which shall be no less than thirty (30) days&#146; prior written notice) and during regular business hours and under obligations of strict confidence, for the sole purpose of verifying the basis and accuracy of payments made under Article&nbsp;3 (Fees, Royalties and Payments) within the thirty-six (36) month period preceding the date of the request for review. No calendar year will be subject to audit under this Section&nbsp;3.5 more than once. AKERO will receive a copy of each such report concurrently with receipt by AMGEN. Should such inspection lead to the discovery of a discrepancy to AMGEN&#146;s detriment, AKERO will, within forty-five (45) days after receipt of such report from the accounting firm, pay any undisputed amount of the discrepancy together with interest at the rate set forth in Section&nbsp;3.4&#160; (Late Payments).&#160; AMGEN will pay the full cost of the review unless the underpayment of amounts due to AMGEN is [***] for the entire period being examined, in which case AKERO will pay the cost charged by such accounting firm for such review. Should the audit lead to the discovery of a discrepancy to AKERO&#146;s detriment, AKERO may credit the amount of the discrepancy, without interest, against future payments payable to AMGEN under this Agreement, and if there are no such payments payable, then AMGEN shall pay to AKERO the amount of the discrepancy, without</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">18<a name="41952-2-LA-07_PB_18_061225_659"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=21,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=804387,FOLIO='18',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:46 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">interest, within [***] days of AMGEN&#146;s receipt of the report.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;3.6&#160;&#160; <u>Taxes</u>.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.6.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Sales Tax</u></b><b>.</b>&#160; AKERO is responsible for the payment of any state or local, sales or use, or similar fees or taxes arising as a result of the transfer of Licensed Materials by AMGEN to AKERO pursuant to Section&nbsp;2.3&#160; (Transfer of Licensed Know-How and Licensed Materials) and Product Lots pursuant to Section&nbsp;5.4, and AKERO will remit such fees or taxes to AMGEN, as the collection agent, upon invoice.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.6.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Withholding</u></b><b>.</b>&#160; In the event that any Law requires AKERO to withhold taxes with respect to any payment to be made by AKERO pursuant to this Agreement, AKERO will notify AMGEN of such withholding requirement prior to making the payment to AMGEN and provide such assistance to AMGEN, including the provision of such standard documentation as may be required by a tax authority, as may be reasonably necessary in AMGEN&#146;s efforts to claim an exemption from or reduction of such taxes.&#160; AKERO will, in accordance with such Law withhold taxes from the amount due, remit such taxes to the appropriate tax authority, and furnish AMGEN with proof of payment of such taxes within thirty (30) days following the payment.&#160; If taxes are paid to a tax authority, AKERO shall provide reasonable assistance to AMGEN to obtain a refund of taxes withheld, or obtain a credit with respect to taxes paid.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.6.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">VAT</u></b><b>.</b>&#160; All payments due to AMGEN from AKERO pursuant to this Agreement shall be paid exclusive of any value-added tax (&#147;<b>VAT</b>&#148;) (which, if applicable, shall be payable by AKERO upon receipt of a valid VAT invoice).&#160; If AMGEN determines that it is required to report any such tax, AKERO shall promptly provide AMGEN with applicable receipts and other documentation necessary or appropriate for such report.&#160; For clarity, this Section&nbsp;3.6.3 is not intended to limit AKERO&#146;s right to deduct value-added taxes in determining Net Sales.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;4.</font></b><b>&#160; PATENT PROSECUTION, MAINTENANCE AND INFRINGEMENT</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;4.1&#160;&#160; <u>Prosecution and Maintenance</u>.</font></b>&#160; AKERO shall have the first right to file, prosecute and maintain all Patent Rights specified under Licensed Patents, at AKERO&#146;s sole expense using outside counsel reasonably acceptable to AMGEN.&#160; AKERO will use Commercially Reasonable Efforts to prepare, file, prosecute, defend and maintain all Patent Rights specified under Licensed Patents; <b><i style="font-weight:bold;">provided, however, </i></b>that AKERO does not represent or warrant that any patent will issue or be granted based on patent applications contained in the Licensed Patents.&#160; AMGEN shall reasonably cooperate with AKERO&#146;s requests for data, affidavits, and other information and assistance to support prosecution and maintenance of the Patent Rights in the Licensed Patents; <b><i style="font-weight:bold;">provided, however, </i></b>that AKERO shall reimburse AMGEN for its reasonable expenses with respect to such cooperation (including AMGEN&#146;s or its Affiliate&#146;s employee&#146;s time at the FTE Rate), within forty-five (45) days of receiving a written invoice therefor.&#160; AKERO shall keep AMGEN reasonably informed, in person or by telephone or email, regarding the status of such prosecution and maintenance activities, and AKERO shall promptly upon receipt forward to AMGEN copies of any significant office actions, communications, and correspondence relating</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">19<a name="41952-2-LA-07_PB_19_061233_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=22,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=112961,FOLIO='19',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:46 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">to the Licensed Patents.&#160; AMGEN shall have the right to comment on and to discuss prosecution and maintenance activities with AKERO, and AKERO shall consider the same in good faith </font>and shall provide AMGEN with copies of all proposed filings and correspondence to give AMGEN the opportunity to review and comment.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;4.2&#160;&#160; <u>AMGEN Step-In Right</u>.</font></b>&#160; Notwithstanding the foregoing, if AKERO declines to file, prosecute or maintain any Patent Rights, elects to allow any Patent Rights to lapse in any country, or elects to abandon any Patent Rights (in each case to the extent contained in the Licensed Patents) before all appeals within the respective patent office have been exhausted (each, an &#147;<b>Abandoned Patent Right</b>&#148;), then:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall provide AMGEN with reasonable notice of such decision so as to permit AMGEN to decide whether to file, prosecute or maintain such Abandoned Patent Rights and to take any necessary action (which notice shall, in any event, be given no later than sixty (60)&nbsp;days prior to the next deadline for any action that may be taken with respect to such Abandoned Patent Right with the U.S. Patent&nbsp;&amp; Trademark Office or any foreign patent office).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN, at AMGEN&#146;s expense, may assume control of the filing, prosecution and/or maintenance of such Abandoned Patent Rights.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall have the right to transfer the responsibility for such filing, prosecution and maintenance of such Abandoned Patent Rights to patent counsel (outside or internal) selected by AMGEN.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall assist and cooperate with AMGEN&#146;s reasonable requests to support prosecution and maintenance of such Abandoned Patent Rights; <b><i style="font-weight:bold;">provided, however, </i></b>that AMGEN shall reimburse AKERO for its reasonable expenses with respect to such cooperation (including AKERO&#146;s employee&#146;s time at the FTE Rate).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the event a patent issues with respect to any such Abandoned Patent Rights, AMGEN shall provide reasonable notice to AKERO thereof and such Abandoned Patent Right shall be excluded from the license granted by AMGEN to AKERO under Section&nbsp;2.1&#160; (Grant), unless AKERO (i)&nbsp;reimburses AMGEN for its internal and external costs and expenses related to the prosecution and maintenance of such Abandoned Patent Right within sixty (60) days of notice of issuance of any such patent and (ii)&nbsp;assumes, in writing, the responsibility for the continued prosecution and maintenance of such Patent Rights in accordance with the provisions of Section&nbsp;4.1&#160; (Prosecution and Maintenance).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;4.3&#160;&#160; <u>Enforcement</u>.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.3.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">AKERO Enforcement</u></b><b>.</b>&#160; Each Party will notify the other promptly in writing when any Infringement of a Licensed Patent by a Third Party is uncovered or reasonably suspected.&#160; AKERO shall have the first right to enforce any patent within the Licensed Patents</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">20<a name="41952-2-LA-07_PB_20_061256_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=23,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=325159,FOLIO='20',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:46 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">against any Infringement or alleged Infringement thereof, and shall at all times keep AMGEN informed as to the status thereof.&#160; AKERO may, at its own expense, institute suit against any such infringer or alleged infringer and control and defend and settle such suit in a manner consistent with the terms and provisions hereof and recover any damages, awards or settlements resulting therefrom, subject to Section&nbsp;4.5 (Recovery).&#160; AMGEN shall reasonably cooperate in any such litigation (including joining or being named a necessary party thereto) at AKERO&#146;s expense.&#160; AKERO shall not enter into any settlement of any claim described in this Section&nbsp;4.3.1 that admits to the invalidity or unenforceability of the Licensed Patents, incurs any financial liability on the part of AMGEN or requires an admission of liability, wrongdoing or fault on the part of AMGEN, without AMGEN&#146;s prior written consent, in each case, such consent not to be unreasonably withheld.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.3.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">AMGEN Enforcement</u></b><b>.</b>&#160; If AKERO elects not to enforce any patent within the Licensed Patents, then it shall so notify AMGEN in writing within thirty (30) days of receiving notice that an Infringement exists (or such shorter period as may be necessary to prevent exhaustion of a statute of limitations (or laches) applicable to such Infringement), and AMGEN may, in its sole judgment, and at its own expense, take steps to enforce any such patent and control, settle, and defend such suit in a manner consistent with the terms and provisions hereof, and recover any damages, awards or settlements resulting therefrom, subject to Section&nbsp;4.5&#160; (Recovery).&#160; AKERO shall reasonably cooperate in any such litigation (including joining or being named a necessary party thereto) at AMGEN&#146;s expense.&#160; AMGEN shall not enter into any settlement of any claim described in this Section&nbsp;4.3.2 that admits to the invalidity or unenforceability of the Licensed Patents, incurs any financial liability on the part of AKERO or requires an admission of liability, wrongdoing or fault on the part of AKERO without AKERO&#146;s prior written consent, such consent not to be unreasonably withheld.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.3.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Cooperation with Respect to Enforcement</u></b><b>. </b>Irrespective of which Party controls an action pursuant to this Section&nbsp;4.3&#160; , the Parties will collaborate in the choice of counsel with respect to such enforcement action and the enforcing Party will consider in good faith the comments of the other Party with respect to strategic decisions and their implementation with respect to such action.&#160; In furtherance of the foregoing, the Party initiating or defending any such enforcement action (the &#147;<b>Enforcing Party</b>&#148;) shall keep the other Party reasonably informed of the progress of any such enforcement action, and such other Party shall have the individual right to participate with counsel of its own choice at its own expense.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;4.4&#160;&#160; <u>Defense of Third Party Claims</u>.</font></b> If either (a)&nbsp;any Product Exploited by or under authority of AKERO becomes the subject of a Third Party&#146;s claim or assertion of Infringement of a patent relating to the Exploitation of such Product in the Licensed Field in the Territory, or (b)&nbsp;a declaratory judgment action is brought naming either Party as a defendant and alleging invalidity or unenforceability of any of the Licensed Patents, the Party first having notice of the claim or assertion shall promptly notify the other Party, and the Parties shall promptly confer to consider the claim or assertion and the appropriate course of action.&#160; Subject to Article&nbsp;7 (Indemnification), unless the Parties otherwise agree in writing, each Party shall have the right to defend itself against a suit that names it as a defendant (the &#147;<b>Defending Party</b>&#148;).&#160; If AMGEN is named in such legal action but not AKERO, then AKERO shall have the right to join, at its own</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">21<a name="41952-2-LA-07_PB_21_061308_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=24,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=161738,FOLIO='21',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:46 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">expense, any such legal action and to be represented in such action by its own counsel.&#160; Neither Party shall enter into any settlement of any claim described in this Section&nbsp;4.4 that admits to the invalidity, narrowing of scope or unenforceability of the Licensed Patents or this Agreement, incurs any financial liability on the part of the other Party, requires an admission of liability, wrongdoing or fault on the part of the other Party, without such other Party&#146;s prior written consent, in each case, such consent not to be unreasonably withheld, conditioned or delayed.&#160; In any event, the other Party shall reasonably assist the Defending Party and cooperate in any such litigation at the Defending Party&#146;s request and the Defending Party shall reimburse the other Party&#146;s reasonable out-of-pocket costs associated therewith.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;4.5&#160;&#160; <u>Recovery</u>.</font></b>&#160; Except as otherwise provided, the costs and expenses of the Party bringing suit under Section&nbsp;4.3&#160; (Enforcement) shall be borne by such Party, and any damages, settlements or other monetary awards recovered shall be shared as follows: (a)&nbsp;the amount of such recovery actually received by the Party controlling such action shall first be applied to the out-of-pocket costs of each Party in connection with such action; and then (b)&nbsp;the remainder of the recovery shall be shared as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If AKERO is the Enforcing Party, [***] and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If AMGEN is the Enforcing Party, [***].</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;4.6&#160;&#160; <u>Patent Term Extensions and Filings for Regulatory Exclusivity Periods.</u></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO will advise AMGEN when it is considering any patent term extension or supplementary protection certificates or their equivalent for the Licensed Patents.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.3in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Parties will use good faith efforts to mutually agree on (i)&nbsp;which Licensed Patents to list on any patent listings required for any Regulatory Exclusivity for Products or (ii)&nbsp;any patent term extension or supplementary protection certificates or their equivalent for the Licensed Patents; <b><i style="font-weight:bold;">provided,</i></b> that [***].</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;4.7&#160;&#160; <u>Patent Marking</u>.</font></b>&#160; AKERO will mark, and will cause all other Selling Parties to mark, the Product with all Licensed Patents in accordance with applicable Law, which marking obligation will continue for as long as (and only for as long as) required under applicable Law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;4.8&#160;&#160; <u>Right of First Refusal with Respect to AKERO Manufacturing IP.</u></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.8.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If AKERO develops Patent Rights or Know-How that incorporates, uses or is derived from Patent [***] (the &#147;<b>AKERO Manufacturing IP</b>&#148;), AKERO shall notify (the &#147;<b>Option Notice</b>&#148;) AMGEN within [***] (such date, the &#147;<b>Option Date</b>&#148;) and hereby grants to AMGEN, the exclusive option (the &#147;<b>Option</b>&#148;) to negotiate and enter into an exclusive license to AKERO Manufacturing IP subject to AKERO&#146;s retained right and license to use such AKERO Manufacturing IP to Exploit the Product in the Licensed Field in the Territory during the Term. The Option Notice shall include [***].&#160; AMGEN must exercise the Option by providing to AKERO, within the [***] month period immediately following the Option Date, written notice of AMGEN&#146;s desire to negotiate and execute an exclusive license agreement, whereupon the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">22<a name="41952-2-LA-07_PB_22_061407_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=25,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=468132,FOLIO='22',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:46 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Parties shall negotiate in good faith an exclusive license agreement on commercially reasonable terms.&#160; Any exclusive license granted pursuant to this Agreement between AKERO and AMGEN will be an </font>exclusive, sub-licensable (through multiple tiers), transferable, worldwide license to make, use, sell, offer for sale, import and otherwise exploit any products and/or processes under AKERO&#146;s rights in such AKERO Manufacturing IP but subject to AKERO&#146;s retained right and license to use such AKERO Manufacturing IP to Exploit the Product in the Licensed Field in the Territory during the Term.&#160; Any license negotiated under this Section&nbsp;4.8.1 will be on customary terms consistent with pharmaceutical industry licenses between for-profit entities for commercial development, and shall include, but not be limited to, the following provisions: fees and royalties customary for similar technologies and the stage of development, patent prosecution, infringement, indemnity and termination. If AMGEN timely exercises its Option, the terms of the exclusive license will be negotiated in good faith within [***] of the date such Option is exercised, or within such longer period of time as the Parties may mutually agree in writing.&#160; Prior to the expiration of the applicable option period, AKERO will not grant any Person any rights in or to the applicable Manufacturing IP.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.8.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the event such a mutually acceptable exclusive license agreement is not executed within such [***] period, following the date AMGEN exercises the option hereunder, AKERO shall have no further obligation to AMGEN with respect thereto. Further, if the Parties fail to reach agreement on an exclusive license terms during the option period, [***].</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;5.</font></b><b>&#160; OBLIGATIONS OF THE PARTIES</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;5.1&#160;&#160; <u>Responsibility</u>.</font></b>&#160; Following the Effective Date and at all times during the Term (except as expressly stated otherwise herein), AKERO shall be responsible for, and shall bear all costs associated with, the worldwide research, development and commercialization of the Product, including regulatory, manufacturing, distribution, marketing and sales activities. Subject to the express written terms of this Agreement, all decisions concerning the development, marketing and sales of Product including the clinical and regulatory strategy, design, sale, price and promotion of Product covered under this Agreement shall be within the sole discretion of AKERO.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;5.2&#160;&#160; <u>Diligence</u>.&#160; </font></b>AKERO shall (directly and/or through one or more Affiliates and/or Sublicensees) use Commercially Reasonable Efforts to develop and commercialize the Product.&#160; The foregoing shall include use of Commercially Reasonable Efforts with respect to each of the Major Market Territories.&#160; AKERO shall notify AMGEN immediately upon obtaining Marketing Approval for the Product in each country.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;5.3&#160;&#160; <u>Reports</u>.</font></b>&#160; On an annual basis, AKERO shall submit to AMGEN a report providing a status of AKERO&#146;s and its Affiliates&#146; and Sublicensees&#146; activities related to the Exploitation of the Product during the preceding [***] month period, and future activities related to the Exploitation of the Product it then-currently expects to initiate during the following [***] month period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;5.4&#160;&#160; <u>Product Supply</u>.</font></b>&#160; The Parties shall reasonably cooperate and assist each other in transferring ownership of Product drug product and/or Product drug substance (such material,</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">23<a name="41952-2-LA-07_PB_23_061417_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=26,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=960578,FOLIO='23',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:46 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">collectively, the &#147;<b>Product Lots</b>&#148;) set forth in <b><u style="font-weight:bold;">Exhibit&nbsp;A</u></b> attached hereto as promptly as reasonably practicable following the Effective Date; <b><i style="font-weight:bold;">provided, however</i></b>, that neither Party shall be required to pay money to any Third Party, commence any litigation with, or offer or grant any accommodation (financial or otherwise) to any Third Party.&#160; </font>Such Product Lots shall be delivered EXW (Ex Works) (Incoterms 2010) AMGEN, Thousand Oaks, California.&#160; Any expense for shipment shall be borne by AKERO (including any import or export duties or taxes).&#160; Subject to the terms of this Section&nbsp;5.4 and Section&nbsp;6.2 (Additional AMGEN Warranties), AMGEN transfers the Product Lots to AKERO &#147;as is&#148;, and makes no other representation to AKERO in connection therewith.&#160; The Parties have entered into a Quality Agreement substantially in the form attached hereto as <b><u style="font-weight:bold;">Exhibit&nbsp;F</u></b>, dated as of the date hereof, governing the quality of the Product Lots to be supplied pursuant to this Section&nbsp;5.4.&#160; For the avoidance of doubt, Product Lots consisting of drug product as set forth in <b><u style="font-weight:bold;">Exhibit&nbsp;A</u></b> supplied pursuant to this Section&nbsp;5.4 shall be labeled for their intended clinical use as set forth in <b><u style="font-weight:bold;">Exhibit&nbsp;A</u></b> and the labeling of any Product drug product manufactured after the Effective Date shall be the responsibility of AKERO.&#160; Except for the Licensed Materials and such Product Lots to be transferred to AKERO, AKERO shall be responsible for, and shall bear the cost of, obtaining (whether by manufacturing or causing to be manufactured) research, clinical and commercial supplies of the Product.&#160; From and after the Effective Date, AKERO shall be responsible for all costs and expenses in connection with the storage of, and any stability studies performed on, the Product Lots.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;5.5&#160;&#160; <u>Safety Database</u></font></b>.&#160;&#160; Within forty-five (45) days following the Effective Date, AMGEN and AKERO shall initiate the transfer to AKERO of the global safety database for the Product (the &#147;<b>Safety Database</b>&#148;).&nbsp; AMGEN and AKERO shall jointly work to complete the transfer of such Safety Database within ninety (90) days of the Effective Date.&nbsp; Prior to the completion of the transfer of the Safety Database, AKERO and AMGEN shall reasonably cooperate and use diligent efforts to ensure compliance with safety reporting requirements related to the Product and AMGEN shall provide safety information to AKERO as AKERO might reasonably request or otherwise as necessary to satisfy AKERO&#146; regulatory or other legal obligations.&nbsp; Following the completion of the transfer of the Safety Database, AKERO shall assume ownership and control of the global Safety Database.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;6.</font></b><b>REPRESENTATIONS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;6.1&#160;&#160; <u>Mutual Warranties</u>.</font></b>&#160; Each of AMGEN and AKERO represent and warrant that:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>it is duly organized and validly existing under the Law of the jurisdiction of its incorporation, and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the individual executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate action;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>it shall comply with all Applicable Law (including Applicable Law relating</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">24<a name="41952-2-LA-07_PB_24_061428_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=27,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=429602,FOLIO='24',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:46 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">to data protection and privacy), Proper Conduct Practices, Anti-Corruption Laws in connection with the performance of its rights, duties and obligations under this Agreement; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>this Agreement is legally binding upon it and enforceable in accordance with its terms.&#160; The execution, delivery and performance of this Agreement by it does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material applicable Law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;6.2&#160;&#160; <u>Additional AKERO Warranties</u>. </font></b>AKERO represents and warrants that:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>it has not been debarred, excluded or the subject of debarment or exclusion proceedings by any Governmental Authority; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>it has established and maintains reasonable internal policies and controls, including codes of conduct and ethics and reasonable reporting requirements, intended to ensure compliance with Anti-Corruption Laws and other Applicable Law, to the extent applicable to such Party under the laws of the jurisdiction of its incorporation, including healthcare compliance, privacy laws and data protection laws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;6.3&#160;&#160; <u>Additional AMGEN Warranties</u>.</font></b>&#160; AMGEN represents and warrants that, as of the Effective Date (except with respect to clause (f)&nbsp;below):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 103.5pt;text-indent:-31.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN Controls the Patent Rights listed on <b><u style="font-weight:bold;">Exhibit&nbsp;B</u></b> and such Licensed Patents are subject to the licenses granted to AKERO pursuant to this Agreement;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 103.5pt;text-indent:-31.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN has the rights necessary to grant the licenses to AKERO to Licensed Know-How set forth on <b><u style="font-weight:bold;">Exhibit&nbsp;A</u></b> that AMGEN grants pursuant to this Agreement;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 103.5pt;text-indent:-31.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>To AMGEN&#146;s knowledge, the Licensed Patents constitute [***] as of the Effective Date [***];</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 103.5pt;text-indent:-31.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Patent Rights listed on <b><u style="font-weight:bold;">Exhibit&nbsp;B</u></b> are not subject to any liens or encumbrances and AMGEN has not granted to any Third Party any rights or licenses under such Patent Rights or Licensed Know-How that would conflict with the licenses granted to AKERO hereunder.&#160; None of the Licensed Patents is in-licensed by AMGEN. &#160;No patent application or registration within the Licensed Patents is the subject of any pending interference, opposition, cancellation or patent protest pursuant to 37 C.F.R. &#167;1.291 unless otherwise noted on <b><u style="font-weight:bold;">Exhibit&nbsp;B</u></b>;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 103.5pt;text-indent:-31.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>With the exception of Patent [***], AMGEN has no knowledge of any claim or litigation that has been brought or threatened in writing by any Third Party alleging that the Licensed Patents are invalid or unenforceable or that the manufacture, sale, offer for sale, or importation of the Product in the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">25<a name="41952-2-LA-07_PB_25_061552_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=28,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=322346,FOLIO='25',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:46 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.45in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Licensed Field infringes or misappropriates or would infringe or misappropriate any right of any Third Party; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 103.5pt;text-indent:-31.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All Product Lots provided to AKERO by AMGEN pursuant Section&nbsp;5.4, as of the date each such Product Lot is provided to AKERO, shall conform to the applicable specifications and, to the extent identified as cGMP materials in <b><u style="font-weight:bold;">Exhibit&nbsp;A</u></b>, shall have been manufactured, packaged, stored and labeled (as applicable) in accordance with cGMP.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;6.4&#160;&#160; <u>Disclaimer</u>.</font></b>&#160; EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS ARTICLE&nbsp;6 (REPRESENTATIONS), NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED,&nbsp;INCLUDING WARRANTIES OF MERCHANTABILITY, QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR VALIDITY OF PATENT CLAIMS. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY EITHER PARTY THAT EITHER PARTY WILL BE SUCCESSFUL IN OBTAINING ANY PATENT RIGHTS, OR THAT ANY PATENTS WILL ISSUE BASED ON A PENDING APPLICATION.&#160; WITHOUT LIMITING THE RESPECTIVE RIGHTS AND OBLIGATIONS OF THE PARTIES EXPRESSLY SET FORTH HEREIN, EACH PARTY SPECIFICALLY DISCLAIMS ANY GUARANTEE THAT THE PRODUCTS WILL BE SUCCESSFUL,&nbsp;IN WHOLE OR IN PART.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;6.5&#160;&#160; <u>AKERO Covenants</u>.&#160; </font></b>AKERO covenants to AMGEN that:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>it will use its best efforts to comply with (i)&nbsp;all U.S. Laws and the Laws of the country in which such clinical studies are conducted, and (ii)&nbsp;the known or published standards of the FDA and the Regulatory Authority in such country, in each case (clauses (i)&nbsp;and (ii)) in the conduct of all preclinical and clinical studies for the Product and the manufacturing of the Product, and it will use best efforts to cause its contractors to so comply.&#160; Neither AKERO, nor any officer, employee or agent of AKERO, will knowingly make an untrue statement of a material fact to any Regulatory Authority with respect to the Product (whether in any submission to such Regulatory Authority or otherwise), and neither will knowingly fail to disclose a material fact required to be disclosed to any Regulatory Authority with respect to the Product;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>it will not knowingly employ any personnel or knowingly use a contractor or consultant that has been debarred by the FDA (or subject to a similar sanction of a Regulatory Authority), or that is subject of an FDA debarment investigation or proceeding (or similar proceeding of a Regulatory Authority);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>it will not knowingly use in connection with the research, development, manufacture or commercialization to take place pursuant to this Agreement any employee, consultant or investigator that has been</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">26<a name="41952-2-LA-07_PB_26_061610_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=29,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=26798,FOLIO='26',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-07_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:46 2019' -->

<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">debarred, excluded or the subject of debarment or exclusion proceedings by any Governmental Authority;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>it shall promptly provide the other Party with written notice upon receiving a formal notification that it is the target of a formal or informal request for information, subpoena, investigation, litigation, penalty, or claim from any Governmental Authority, or any third party, for violation or potential violation of any applicable Anti-Corruption Law or Proper Conduct Practices;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>prior to beginning any development or commercialization of any Product under this Agreement, each of its employees, agents, independent contractors or Affiliates involved in the development or commercialization of any Product shall be required to undergo compliance training with respect to Proper Conduct Practices and Anti-Corruption Laws;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>it shall use only legitimate and ethical business practices in connection with activities conducted in connection with this Agreement whether directly, through the use of Representatives or otherwise, and shall not take any action that would subject any other Party to penalties under any Applicable Law;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>it shall cause its Affiliates and its and their officers, directors, employees and agents to comply with this Agreement, including the covenants in this Section&nbsp;6.5;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>it shall use its best efforts to comply with all applicable (i)&nbsp;U.S. Laws prohibiting the re-export, directly or indirectly, of certain controlled U.S.-origin items without a license to parties located in certain countries or appearing on certain U.S. Government lists of restricted parties; (ii)&nbsp;U.S. Laws prohibiting participation in non-U.S. boycotts that the United States does not support; (iii)&nbsp;U.S. Laws prohibiting the sale of products to parties from any country subject to U.S. economic sanctions or who are identified on related U.S. Government lists of restricted parties; and (iv)&nbsp;data privacy laws of the applicable jurisdiction, including the national and sub-national laws based on the European Union Data Protection Directive 95/46/EC, and all data breach notification and information securities laws and regulations specific thereto; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>as of the Effective Date to and through the expiration or termination of this Agreement, (i)&nbsp;it, and, to the best of its knowledge, its owners, directors, officers, employees, or any agent, representative, subcontractor or other third party acting for or on such its behalf, shall not, directly or indirectly, offer, pay, promise to pay, or authorize such offer, promise or payment, of anything of value, to any Person for the purposes of obtaining or retaining business through any improper advantage in connection with this Agreement, or that would otherwise violate any applicable Laws, rules&nbsp;and</p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">27<a name="41952-2-LA-09_PB_27_060333_4925"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=30,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=839103,FOLIO='27',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-09_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:47 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">regulations concerning or relating to public or commercial bribery or corruption, and (ii)&nbsp;that its books, accounts, records and invoices related to this Agreement or related to any work conducted for or on behalf of the other Party are and will be complete and accurate.&#160; AMGEN may request from time to time that AKERO complete a compliance certification regarding the foregoing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;7.</font></b><b>&#160; INDEMNIFICATION</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;7.1&#160;&#160; <u>Indemnity</u>.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.1.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">By </u></b><b><u style="font-weight:bold;">AMGEN</u></b><b>.</b>&#160; AMGEN agrees to defend AKERO and its (and its Affiliates&#146;) directors, officers, employees and agents (the &#147;<b>AKERO Indemnified Parties</b>&#148;) at AMGEN&#146;s cost and expense, and will indemnify and hold AKERO and the other AKERO Indemnified Parties harmless from and against any claims, losses, costs, damages, fees or expenses (including legal fees and expenses) (collectively, &#147;<b>Losses</b>&#148;) to the extent resulting from any Third Party claim (including product liability claims) arising out of or otherwise relating to (a)&nbsp;the negligence or willful misconduct of AMGEN or its Affiliates in connection with its activities under this Agreement, (b)&nbsp;the breach of this Agreement or the representations and warranties made hereunder by AMGEN, (c)&nbsp;the death or injury of a person to the extent directly caused by the failure of any Product Lot delivered to AKERO hereunder to be manufactured in compliance with cGMP (to the extent identified as cGMP materials in <b><u style="font-weight:bold;">Exhibit&nbsp;A</u></b>) but excluding any event that could have been avoided or mitigated by the exercise of reasonable or customary care by any AKERO Indemnified Party, its sublicensees or collaborators, the applicable health care professionals or the users of the Product or that results from the storage, processing, handling, transport or maintenance of the Product after delivery or (d)&nbsp;the exercise by AMGEN of rights retained by or conveyed to AMGEN under Sections 2.5 or 9.5.1 after termination of this Agreement; except, in the case of each of (a), (b), (c)&nbsp;and (d)&nbsp;of this Section&nbsp;7.1.1, to the extent such Losses result from clause (a), (b)&nbsp;or (c)&nbsp;of Section&nbsp;7.1.2 (By AKERO).&#160; In the event of any such claim against the AKERO Indemnified Parties by a Third Party, the foregoing indemnity obligations shall be conditioned upon (x)&nbsp;AKERO promptly notifying AMGEN in writing of the claim (<b><i style="font-weight:bold;">provided, however, </i></b>that any failure or delay to notify shall not excuse any obligations of AMGEN except to the extent AMGEN is actually prejudiced thereby) and (y)&nbsp;AKERO granting AMGEN sole management and control, at AMGEN&#146;s sole expense, of the defense of the claim and its settlement (<b><i style="font-weight:bold;">provided, however,</i></b> that AMGEN shall not settle any such claim without the prior written consent of AKERO (not to be unreasonably withheld, conditioned or delayed) if such settlement does not include a complete release from liability or if such settlement would involve AKERO undertaking an obligation (including the payment of money by a AKERO Indemnified Party), would bind or impair a AKERO Indemnified Party, or includes any admission of wrongdoing or that any intellectual property or proprietary right of AKERO or this Agreement is invalid, narrowed in scope or unenforceable), and (z)&nbsp; the AKERO Indemnified Parties cooperating with AMGEN (at AMGEN&#146;s expense).&#160; If, based on the reasonable advice of counsel to the AKERO Indemnified Parties, the AKERO Indemnified Parties have separate defenses from AMGEN or there is a conflict of interest between the AKERO Indemnified Parties</p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">28<a name="41952-2-LA-09_PB_28_060547_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=31,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=546247,FOLIO='28',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-09_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:47 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and AMGEN, then the AKERO Indemnified Parties shall be permitted, at their own expense, to retain counsel of its choosing to represent them in such action or proceeding.&#160;&#160;&#160;&#160; Any obligation of AMGEN under this Section&nbsp;7.1.1 with respect to the failure of any Product or Product Lot delivered to AKERO hereunder to be manufactured in compliance with cGMP shall be subject to clause (c)&nbsp;of this Section&nbsp;7.1.1 and shall not be covered by or subject to clause (a)&nbsp;or (b)&nbsp;of this Section&nbsp;7.1.1.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.1.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">By </u></b><b><u style="font-weight:bold;">AKERO</u></b><b>.</b>&#160; AKERO agrees to defend AMGEN and its (and its Affiliates&#146;) directors, officers, employees and agents (the &#147;<b>AMGEN Indemnified Parties</b>&#148;) at AKERO&#146;s cost and expense, and will indemnify and hold AMGEN and the other AMGEN Indemnified Parties harmless from and against any Losses to the extent resulting from any Third Party claim (including product liability claims) arising out of or otherwise relating to (a)&nbsp;the negligence or willful misconduct of AKERO, its Affiliates, or their respective Sublicensees in connection with its activities under this Agreement, (b)&nbsp;the breach of this Agreement or the representations, warranties and covenants made hereunder by AKERO, or (c)&nbsp;the Exploitation of the Product by or on behalf of AKERO, its Affiliates, or their respective Sublicensees (including from product liability and intellectual property infringement claims); except, in each case, to the extent such Losses result from clause (a), (b), (c)&nbsp;or (d)&nbsp;of Section&nbsp;7.1&#160; (By AMGEN).&#160; In the event of any such claim against the AMGEN Indemnified Parties by a Third Party, the foregoing indemnity obligations shall be conditioned upon (x)&nbsp;AMGEN promptly notifying AKERO in writing of the claim (<b><i style="font-weight:bold;">provided, however,</i></b> that any failure or delay to notify shall not excuse any obligation of AKERO except to the extent AKERO is actually prejudiced thereby) and (y)&nbsp;AMGEN granting AKERO sole management and control, at AKERO&#146;s sole expense, the defense of the claim and its settlement (<b><i style="font-weight:bold;">provided, however,</i></b> that AKERO shall not settle any such claim without the prior written consent of AMGEN if such settlement does not include a complete release from liability or if such settlement would involve undertaking an obligation (including the payment of money by an AMGEN Indemnified Party), would bind or impair an AMGEN Indemnified Party, or includes any admission of wrongdoing or that any intellectual property or proprietary right of AMGEN or this Agreement is invalid, narrowed in scope or unenforceable), and (z)&nbsp; the AMGEN Indemnified Parties cooperating with AKERO (at AKERO&#146;s expense).&#160; If, based on the reasonable advice of counsel to the AMGEN Indemnified Parties, the AMGEN Indemnified Parties have separate defenses from AKERO or there is a conflict of interest between the AMGEN Indemnified Parties and AKERO, then the AMGEN Indemnified Parties shall be permitted, at their own expense, to retain counsel of its choosing to represent them in such action or proceeding.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;7.2&#160;&#160; <u>LIMITATION OF DAMAGES</u>.&#160; </font></b>IN NO EVENT SHALL EITHER PARTY BE LIABLE HEREUNDER TO THE OTHER PARTY FOR ANY PUNITIVE,&nbsp;INDIRECT, SPECIAL,&nbsp;INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING LOST REVENUE, LOST PROFITS, OR LOST SAVINGS) HOWEVER CAUSED AND UNDER ANY THEORY, EVEN IF IT HAS NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. THE LIMITATIONS SET FORTH IN THIS SECTION&nbsp;7.2 SHALL NOT APPLY WITH RESPECT TO (A)&nbsp;ANY BREACH OF ARTICLE&nbsp;8 (CONFIDENTIALITY) OR (B)&nbsp;THE INTENTIONAL MISCONDUCT OR GROSS NEGLIGENCE OF A PARTY.&#160; NOTHING IN THIS SECTION&nbsp;7.2 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION</p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">29<a name="41952-2-LA-09_PB_29_060625_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=32,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=230265,FOLIO='29',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-09_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:47 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">RIGHTS OR OBLIGATIONS OF A PARTY UNDER THIS ARTICLE&nbsp;7 (INDEMNIFICATION) WITH RESPECT TO ANY DAMAGES PAID BY THE OTHER PARTY TO A THIRD PARTY IN CONNECTION WITH A THIRD-PARTY CLAIM.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;7.3&#160; </font></b><b>&#160;<u>Insurance</u></b><b>.&#160; </b>At least [***] days prior to the Initiation of any clinical trial by or on behalf of AKERO or its Affiliates, AKERO shall at its own expense procure and maintain during the Term (and for [***] years thereafter) clinical trial liability insurance coverage adequate to cover its obligations hereunder and which is/are consistent with normal business practices of prudent pharmaceutical companies.&#160; Additionally, at least [***] days prior to First Commercial Sale, AKERO shall at its own expense procure and maintain during the Term (and for [***] years thereafter) product liability insurance coverage adequate to cover its obligations hereunder and which is consistent with normal business practices of prudent pharmaceutical companies.&#160; Each insurance policy required by and procured by AKERO under this Section&nbsp;7.3&#160; shall name AMGEN as an additional insured.&#160; Such insurance shall not be construed to create a limit of AKERO&#146;s liability with respect to its indemnification obligations under this Article&nbsp;7 (Indemnification).&#160; AKERO shall provide AMGEN with a certificate of insurance or other evidence of such insurance, upon request.&#160; AKERO shall provide AMGEN with written notice at least thirty (30) days prior to the cancellation, non-renewal or a material change in such insurance which materially adversely affects the rights of AMGEN hereunder, and ten (10)&nbsp;days prior written notice of cancellation for non-payment of premiums.&#160; AKERO&#146;s insurance hereunder shall be primary with respect to the obligations for which AKERO is liable hereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;8.</font></b><b>&#160; CONFIDENTIALITY</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;8.1&#160; </font></b><b>&#160;<u>Confidential Information</u>.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.1.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Confidential Information</u></b><b>.</b>&#160; Each Party (&#147;<b>Disclosing Party</b>&#148;) may disclose to the other Party (&#147;<b>Receiving Party</b>&#148;), and Receiving Party may acquire during the course and conduct of activities under this Agreement, certain proprietary or confidential information of Disclosing Party in connection with this Agreement.&#160; The term &#147;<b>Confidential Information</b>&#148; will mean all information of any kind, whether in written, oral, graphical, machine-readable or other form, whether or not marked as confidential or proprietary, which are transferred, disclosed or made available by Disclosing Party or at the request of Receiving Party, including any of the foregoing of Third Parties.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.1.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Restrictions</u></b><b>.</b>&#160; During the Term and for [***] years thereafter, Receiving Party will keep all Disclosing Party&#146;s Confidential Information in confidence with the same degree of care with which Receiving Party holds its own confidential information (but in no event less than a commercially reasonable degree of care).&#160; Receiving Party will not use Disclosing Party&#146;s Confidential Information except in connection with the performance of its obligations and exercise of its rights under this Agreement.&#160; Receiving Party has the right to disclose Disclosing Party&#146;s Confidential Information without Disclosing Party&#146;s prior written consent, to the extent and only to the extent reasonably necessary, to Receiving Party&#146;s Affiliates and their employees, subcontractors, consultants or agents who have a need to know such Confidential Information in order to perform its obligations and exercise its rights under this</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">30<a name="41952-2-LA-09_PB_30_060836_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=33,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=753571,FOLIO='30',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-09_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:47 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement and who are required to comply with the restrictions on use and disclosure in this Section&nbsp;8.1.2.&#160; Receiving Party will use diligent efforts to cause those entities and persons to comply with the restrictions on use and disclosure in this Section&nbsp;8.1.2.&#160; Receiving Party assumes responsibility for those entities and persons maintaining Disclosing Party&#146;s Confidential Information in confidence and using same only for the purposes described herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.1.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Exceptions</u></b><b>.</b>&#160; Receiving Party&#146;s obligation of nondisclosure and the limitations upon the right to use the Disclosing Party&#146;s Confidential Information will not apply to the extent that Receiving Party can demonstrate that the Disclosing Party&#146;s Confidential Information:&#160; (a)&nbsp;was known to Receiving Party or any of its Affiliates prior to the time of disclosure; (b)&nbsp;is or becomes public knowledge through no fault or omission of Receiving Party or any of its Affiliates; (c)&nbsp;is obtained by Receiving Party or any of its Affiliates from a Third Party under no obligation of confidentiality to Disclosing Party; or (d)&nbsp;has been independently developed by employees, subcontractors, consultants or agents of Receiving Party or any of its Affiliates without the use of Disclosing Party&#146;s Confidential Information, as evidenced by contemporaneous written records.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.1.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Permitted Disclosures</u></b><b>.</b>&#160; Receiving Party may disclose Disclosing Party&#146;s Confidential Information to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>in order to comply with applicable law (including any securities law or regulation or the rules&nbsp;of a securities exchange) or with a legal or administrative proceeding;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>in connection with prosecuting or defending litigation, Marketing Approvals and other Regulatory Filings and communications, and filing, prosecuting and enforcing Patents in connection with Receiving Party&#146;s rights and obligations pursuant to this Agreement; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>in connection with exercising its rights hereunder, to its Affiliates; potential and future collaborators (including Sublicensees where AKERO is the Receiving Party); potential and permitted acquirers or assignees; and potential investment bankers, investors and lenders;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">provided, however,</font></i></b> that (1)&nbsp;with respect to Sections 8.1.4(a)&nbsp;or 8.1.4(b)&nbsp;(other than Marketing Approvals and other Regulatory Filings and communications), where reasonably possible, Receiving Party will notify Disclosing Party of Receiving Party&#146;s intent to make any disclosure pursuant thereto sufficiently prior to making such disclosure so as to allow Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information to be disclosed, and (2)&nbsp;with respect to Section&nbsp;8.1.4(c), each of those named people and entities are required to comply with the restrictions on use and disclosure in Section&nbsp;8.1.2 (Restrictions) (other than investment bankers, investors and lenders, which must be bound prior to disclosure by</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">31<a name="41952-2-LA-09_PB_31_060847_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=34,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=608337,FOLIO='31',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-09_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:47 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">commercially reasonable obligations of confidentiality).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;8.2&#160; </font></b><b>&#160;<u>Terms of this Agreement; Publicity</u>.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.2.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Restrictions</u></b><b>.</b>&#160; The Parties agree that the terms of this Agreement will be treated as Confidential Information of both Parties, and thus may be disclosed only as permitted by Section&nbsp;8.1.4 (Permitted Disclosures).&#160; Except as required by Law, each Party agrees not to issue any press release or public statement disclosing information relating to this Agreement or the transactions contemplated hereby or the terms hereof without the prior written consent of the other Party not to be unreasonably withheld (or as such consent may need to be obtained in accordance with Section&nbsp;8.2.2 (Review) or Section&nbsp;8.3.1 (Right to Publish)).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.2.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Review</u></b><b>.</b>&#160; In the event either Party (the &#147;<b>Issuing Party</b>&#148;) desires to issue a press release or other public statement disclosing information relating to this Agreement or the transactions contemplated hereby or the terms hereof, the Issuing Party will provide the other Party (the &#147;<b>Reviewing Party</b>&#148;) with a copy of the proposed press release or public statement (the &#147;<b>Release</b>&#148;).&#160; The Issuing Party will specify with each such Release, taking into account the urgency of the matter being disclosed, a reasonable period of time within which the Receiving Party may provide any comments on such Release (but in no event less than five (5)&nbsp;business days). If the Receiving Party provides any comments, the Parties will consult on such Release and work in good faith to prepare a mutually acceptable Release. Either Party may subsequently publicly disclose any information previously contained in any Release, provided that the other Party provided its written consent hereto as stated in Section&nbsp;8.2.1 (Restrictions).&#160; For the avoidance of doubt (and notwithstanding anything contained in this Agreement to the contrary), AKERO, in its sole discretion, may make disclosures relating to the development or commercialization of the Product, including the results of research and any clinical trial conducted by AKERO or any health or safety matter related to the Product.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;8.3&#160; </font></b><b>&#160;<u>Publications</u>.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.3.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Right to Publish</u></b><b>. </b>&#160;Subject to the provisions of Sections 8.1 (Confidential Information), 8.2 (Terms of this Agreement; Publicity), 8.3.2 (Review) and 8.3.3 (Amgen Publications), AKERO shall have the right to publish with respect to Products in publications, and to make scientific presentations on Products.&#160; Neither Party shall publish the sequence of the Product or information concerning the manufacture of the Product without the prior written consent of the other Party.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.3.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Review</u></b><b>.</b>&#160; Except as required by Law or court order, for any proposed publication or presentation regarding the Product, AKERO: (a)&nbsp;shall transmit a copy of the proposed publication for review and comment to AMGEN at least [***] days prior to the submission of such publication to a Third Party; (b)&nbsp;shall postpone such publication for up to an additional [***] days upon request of AMGEN (or its applicable licensee) to allow the consideration of appropriate patent applications or other protection to be filed; (c)&nbsp;upon request of AMGEN (or its applicable licensee) shall remove all Confidential Information of AMGEN (or its applicable licensee) (excluding, for clarity, anything permitted to be disclosed by AKERO pursuant to the last sentence of Section&nbsp;8.2.2 (Review)); and (d)&nbsp;shall consider all reasonable</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">32<a name="41952-2-LA-09_PB_32_060857_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=35,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=539489,FOLIO='32',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-09_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:47 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">comments made by AMGEN (or its applicable licensee).</font> Authorship by AKERO of any publication arising from the Agreement will be undertaken in accordance with the International Committee of Medical Journal Editors (ICMJE) guidelines for authorship. Consistent with those guidelines, authorship will be based upon substantial contribution to the design, analysis, interpretation of data, drafting and/or critically revising any publication(s)&nbsp;derived from the Agreement, and authors must engage in the drafting of the publication or revise it critically for important intellectual content. AKERO agrees to maintain evidence of its compliance with the ICMJE guidelines for authorship, and that it will provide such evidence to AMGEN upon request.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;8.4&#160; </font></b><b>&#160;<u>Relationship to the Confidentiality Agreement</u>.</b>&#160; This Agreement supersedes that certain Confidential Disclosure Agreement between the Parties dated March&nbsp;9, 2017, as amended by Amendment Number 1 to Confidential Disclosure Agreement Number [***] dated March&nbsp;14, 2017; <b><i style="font-weight:bold;">provided, however,</i></b> that all &#147;Confidential Information&#148; disclosed or received by the Parties thereunder will be deemed &#147;Confidential Information&#148; hereunder and will be subject to the terms and conditions of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;8.5&#160;&#160; <u>Attorney-Client Privilege</u>.</font></b>&#160; Neither Party is waiving, nor will be deemed to have waived or diminished, any of its attorney work product protections, attorney-client privileges or similar protections and privileges recognized under the applicable Law of any jurisdiction as a result of disclosing information pursuant to this Agreement, or any of its Confidential Information (including Confidential Information related to pending or threatened litigation) to the receiving Party, regardless of whether the disclosing Party has asserted, or is or may be entitled to assert, such privileges and protections.&#160; The Parties may become joint defendants in proceedings to which the information covered by such protections and privileges relates and may determine that they share a common legal interest in disclosure between them that is subject to such privileges and protections, and in such event, may enter into a joint defense agreement setting forth, among other things, the foregoing principles but are not obligated to do so.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;9.</font></b><b>&#160; TERM AND TERMINATION</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;9.1&#160;&#160; <u>Term</u>.</font></b>&#160; The term of this Agreement (the &#147;<b>Term</b>&#148;) shall commence on the Effective Date, and unless terminated earlier as provided in this Article&nbsp;9 (Term and Termination), shall continue in full force and effect until expiration of the last-to-expire Royalty Term for the Product in the Territory.&#160; Upon expiration of this Agreement, the licenses granted to AKERO by AMGEN under this Agreement to Exploit the Product shall be fully paid-up, irrevocable and non-exclusive.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;9.2&#160;&#160; <u>Termination</u></font></b><b><u style="font-weight:bold;"> by AMGEN</u></b><b>.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.2.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Breach</u></b><b>.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall have the right to terminate this Agreement in full in the event AKERO shall have materially breached or defaulted in the performance of any of its obligations hereunder or the Designated Investment Document Terms and such breach or default shall have continued for [***] days after written notice thereof is provided to AKERO by AMGEN, such notice describing the alleged material breach in sufficient detail to put AKERO on notice.&#160; The</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">33<a name="41952-2-LA-09_PB_33_060904_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=36,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=848988,FOLIO='33',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-09_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:47 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">foregoing [***] day cure period shall be shortened to [***] days for breaches that consist of a failure to pay amounts as and when due hereunder.&#160;&#160; Any termination of this Agreement under this Section&nbsp;9.2.1 shall become effective at the end of the applicable cure period, unless AKERO has cured such breach or default prior to the expiration of such cure period, or, if such breach or default is not susceptible to cure within such cure period, such termination shall be effective upon such written notice of such breach or default from AMGEN.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If AKERO disputes in good faith the existence or materiality of a breach specified in a notice provided by AMGEN to AKERO pursuant to Section&nbsp;9.2.1(a), and AKERO provides notice to AMGEN of such dispute within the applicable cure period, AKERO may require the CEO Delegates to meet and confer in good faith to resolve such breach condition and AMGEN shall not have the right to terminate this Agreement until [***] days following such notice.&#160; The CEO Delegates of the Parties shall, as soon as reasonably practicable, after AKERO&#146;s notice of such dispute, meet and confer in good faith regarding such dispute at such time and place as mutually agreed upon by the Parties.&#160; It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.2.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Termination for IP Challenge</u></b><b>.</b>&#160; AMGEN will have the right to terminate this Agreement in full upon written notice to AKERO in the event AMGEN discovers or receives notice that AKERO or any of its Affiliates or Sublicensees directly challenged in a legal or administrative proceeding the patentability, enforceability or validity of any Licensed Patents; provided, however, that AMGEN will not have the right to terminate this Agreement under this Section&nbsp;9.2.1(a)&nbsp;if (a)&nbsp;for any such challenge by any Sublicensee, AKERO terminates such Sublicense within sixty (60) days of AMGEN&#146;s notice to AKERO under this Section&nbsp;9.2.1(a)&nbsp;or (b)&nbsp;such challenge is dismissed within [***] days of AMGEN&#146;s notice to AKERO under this Section&nbsp;9.2.1(a)&nbsp;and not thereafter continued.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;9.3&#160; </font></b>&#160;<u>Termination</u><u> by AKERO.</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.3.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Breach</u></b><b>.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall have the right to terminate this Agreement in full in the event AMGEN shall have materially breached or defaulted in the performance of any of its obligations hereunder and such breach or default shall have continued for [***] days after written notice thereof is provided to AMGEN by AKERO, such notice describing the alleged material breach in sufficient detail to put AMGEN on notice.&#160; The foregoing [***] day cure period shall be shortened to [***] days for breaches that consist of a failure to pay amounts as and when due hereunder.&#160; Any termination of this Agreement under this Section&nbsp;9.3.1 shall become effective at the end of the applicable cure period, unless AMGEN has cured such breach or default prior to the expiration of such cure period, or, if such breach or default is not susceptible to cure within such cure period, such termination shall be effective upon such written notice of such breach or default from AKERO.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">34<a name="41952-2-LA-09_PB_34_060913_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=37,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=532586,FOLIO='34',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-09_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:47 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If AMGEN disputes in good faith the existence or materiality of a breach specified in a notice provided by AKERO to AMGEN pursuant to Section&nbsp;9.3.1(a), and AMGEN provides notice to AKERO of such dispute within the applicable cure period, AMGEN may require the CEO Delegates to meet and confer in good faith to resolve such breach condition and AKERO shall not have the right to terminate this Agreement until [***] days following such notice.&#160; The CEO Delegates of the Parties shall, as soon as reasonably practicable after AMGEN&#146;s notice of such dispute, meet and confer in good faith regarding such dispute at such time and place as mutually agreed upon by such Parties.&#160; It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.3.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">Discretionary Termination</u></b><b>.</b>&#160;&#160; AKERO will have the right to terminate this Agreement in full [***] days after delivery of written notice to AMGEN thereof if AKERO concludes due to scientific, technical, regulatory or commercial reasons, including (a)&nbsp;safety or efficacy concerns, including adverse events of the Product, (b)&nbsp;concerns relating to the present or future marketability or profitability of the Product, (c)&nbsp;reasons related to patent coverage or (d)&nbsp;existing and anticipated competition, renders the Exploitation of the Product no longer commercially practicable for AKERO.&#160; Following any such notice of termination, AKERO shall have no further obligation pursuant to Section&nbsp;5.2&#160; (Diligence) to further Exploit any Product, however, AKERO shall use its reasonable efforts to facilitate a smooth, orderly and prompt transition of any of the Product Controlled by AKERO prior to the effective date of termination of this Agreement from AKERO to AMGEN.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;9.4&#160;&#160; <u>Termination</u></font></b><b><u style="font-weight:bold;"> Upon Bankruptcy</u></b><b>.</b>&#160; Either Party may terminate this Agreement if, at any time, the other Party shall (a)&nbsp;file in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of that Party or of its assets, (b)&nbsp;propose a written agreement of composition or extension of its debts, (c)&nbsp;be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition has not been dismissed within sixty (60) days after the filing thereof, (d)&nbsp;propose or be a party to any dissolution or liquidation, (e)&nbsp;make an assignment for the benefit of its creditors or (f)&nbsp;admit in writing its inability generally to meet its obligations as they fall due in the general course.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;9.5&#160;&#160; <u>Effects</u></font></b><b><u style="font-weight:bold;"> of Termination</u></b><b>.</b>&#160; Upon termination by either Party under Section&nbsp;9.2&#160; (Termination by AMGEN), Section&nbsp;9.3&#160; (Termination by AKERO) or Section&nbsp;9.4&#160; (Termination Upon Bankruptcy):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO will responsibly wind-down, in accordance with accepted pharmaceutical industry norms and ethical practices and all legal and regulatory requirements, any on-going clinical studies for which it has responsibility hereunder in which patient dosing has commenced or, if reasonably practicable and not adverse to patient safety and requested by AMGEN, AKERO shall complete such trials and AMGEN shall reimburse AKERO its reasonable, out-of-pocket costs&#160; and internal labor costs at the FTE Rate associated therewith.&#160; For the purpose of clarity, except as</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">35<a name="41952-2-LA-09_PB_35_060927_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=38,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=406406,FOLIO='35',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-09_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:47 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">provided for above, AKERO may wind-down any ongoing clinical trials prior to the date of termination in accordance with accepted pharmaceutical industry norms and ethical practices and AKERO will be responsible for any costs associated with such wind-down.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A termination of this Agreement will automatically terminate any sublicense granted by AKERO pursuant to Section&nbsp;2.1&#160; (Sublicenses) unless AMGEN has explicitly approved survival of such sublicense in writing, in which case all rights under such sublicense shall be deemed to survive termination as long as Sublicensee complies with its obligations thereunder, and provided that in no event will AMGEN be obligated to fulfill any of AKERO&#146;s obligations under such sublicense.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All rights and licenses granted by AMGEN to AKERO in Article&nbsp;2 (License Grant) will terminate, and AKERO and its Affiliates, and (subject to Section&nbsp;9.5(b)) Sublicensees will cease all use of Licensed Know-How and Licensed Patents and all Exploitation of any Product, except to the extent required hereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Upon AMGEN&#146;s request, all Marketing Approvals and other Regulatory Filings and communications owned (in whole or in part) or otherwise controlled by AKERO and its Affiliates, and (subject to Section&nbsp;9.5(b)) Sublicensees, and all other documents relating to or necessary to further Exploit the Product, as such items exist as of the effective date of such termination (including all documents related to completed and ongoing clinical studies) will be assigned to AMGEN to the extent practicable (or, if not so assigned, AKERO shall make the benefit of the foregoing reasonably available to AMGEN), and AKERO will provide to AMGEN one (1)&nbsp;copy of the foregoing and all documents contained in or referenced in any such items, together with the raw and summarized data for any clinical studies (and where reasonably available, electronic copies thereof).&#160; All expenses in relation to such assignment will be borne by AMGEN.&#160; In the event of any failure to obtain assignment, AKERO hereby consents and grants to AMGEN the right to access and reference (without any further action required on the part of AKERO, whose authorization to file this consent with any Regulatory Authority is hereby granted) any such item.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKEROS, on behalf of itself and its Affiliates, agrees to grant to AMGEN and its Affiliates, at AMGEN&#146;s request, a perpetual and irrevocable non-exclusive, royalty-free, sub-licensable (through multiple tiers) license to AKEROS Patent Rights solely to Exploit the Product (solely as such AKEROS Patent Rights and Product exist on the effective date of termination) in the Licensed Field in the Territory (but, for clarity, not including any other products other than the Product as it exists on the effective date of termination).&#160; For purposes of this Section&nbsp;9.5(e),</p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">36<a name="41952-2-LA-11_PB_36_061207_8021"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=39,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=1019372,FOLIO='36',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-11_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:48 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>AKEROS Patent Rights</b>&#148; means a </font>[***].&#160; Notwithstanding the foregoing, other than in conjunction with a termination by AKEROS pursuant to Section&nbsp;9.3.2 (Discretionary Termination), the Parties agree that in conjunction with any license granted under this Section&nbsp;9.5(e), they will [***] enter into a customary license agreement pursuant to which AMGEN would pay AKEROS a royalty of (i)&nbsp;[***] of net sales or (ii)&nbsp;in the event that AKEROS has obtained Marketing Approval for the Product, [***] of net sales. AKEROS agrees (and shall cause its Affiliates to so agree) to reasonably cooperate with AMGEN and its designee(s)&nbsp;to facilitate a smooth, orderly and prompt transition of the Exploitation of the Product in the Territory to AMGEN and/or its designee(s)&nbsp;in accordance with a transition plan to be reasonably agreed to by the Parties.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AKERO shall duly execute and deliver, or cause to be duly executed and delivered, such instruments and shall do and cause to be done such activities and things, including the filings of such assignments, agreements, documents and instruments, as may be reasonably necessary under, or as AMGEN may reasonably request in connection with, AMGEN&#146;s rights under this Section&nbsp;9.5&#160; .</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;9.6&#160; </font></b><b>&#160;<u>Survival</u>.</b>&#160; In addition to the termination consequences set forth in Section&nbsp;9.5&#160; (Effects of Termination), the following provisions will survive termination or expiration of this Agreement: Articles 1 (Definitions), 3 (Fees, Royalties and Payments) (with respect to sales made before such expiration or termination and with respect to Milestone Events achieved prior to the expiration or date of notice of termination), 7 (Indemnification), 8 (Confidentiality) and 10 (Miscellaneous) and Sections 2.4 (Limited Grant), 4.3 (Enforcement) through 4.5 (Recovery) (inclusive) (with respect to any action initiated prior to such expiration or termination), 6.3 (Disclaimer) and 9.5 (Effects of Termination), and this Section&nbsp;9.6.&#160; Termination or expiration of this Agreement are neither Party&#146;s exclusive remedy and will not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement nor prejudice either Party&#146;s right to obtain performance of any obligation.&#160; All other rights and obligations will terminate upon expiration of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;10.</font></b><b>&#160; MISCELLANEOUS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.1&#160;&#160; <u>Entire Agreement; Amendment</u>.</font></b>&#160; This Agreement and all Exhibits attached to this Agreement and the Investment Documents constitute the entire agreement between the Parties as to the subject matter hereof.&#160; All prior and contemporaneous negotiations, representations, warranties, agreements, statements, promises and understandings with respect to the subject matter of this Agreement are hereby superseded and merged into, extinguished by and completely expressed by this Agreement.&#160; None of the Parties shall be bound by or charged with any written or oral agreements, representations, warranties, statements, promises or</p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">37<a name="41952-2-LA-11_PB_37_061303_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=40,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=927672,FOLIO='37',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-11_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:48 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">understandings not specifically set forth in this Agreement.&#160; No amendment, supplement or other modification to any provision of this Agreement shall be binding unless in writing and signed by all Parties.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.2&#160;&#160; <u>Section&nbsp;365(n)&nbsp;of the Bankruptcy Code</u>.</font></b>&#160; All rights and licenses granted under or pursuant to any section of this Agreement are, and shall otherwise be deemed to be, for purposes of Section&nbsp;365(n)&nbsp;of the U.S. Bankruptcy Code, licenses of rights to &#147;intellectual property&#148; as defined under Section&nbsp;101(35A) of the U.S. Bankruptcy Code to the extent permitted thereunder. The Parties shall retain and may fully exercise all of their respective rights and elections under the U.S. Bankruptcy Code. Upon the bankruptcy of any Party, the non-bankrupt Party shall further be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property, and such, if not already in its possession, shall be promptly delivered to the non-bankrupt Party, unless the bankrupt Party elects to continue, and continues, to perform all of its obligations under this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.3&#160;&#160; <u>Independent Contractors</u>.</font></b>&#160; The relationship between AKERO and AMGEN created by this Agreement is solely that of independent contractors.&#160; This Agreement does not create any agency, distributorship, employee-employer, partnership, joint venture or similar business relationship between the Parties.&#160; Neither Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever.&#160; Each Party shall use its own discretion and shall have complete and authoritative control over its employees and the details of performing its obligations under this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.4&#160;&#160; <u>Governing Law; Jurisdiction</u>.</font></b>&#160; This Agreement and its effect are subject to and shall be construed and enforced in accordance with the law of the State of New York, without regard to its conflicts of laws, except as to any issue which depends upon the validity, scope or enforceability of any Licensed Patent, which issue shall be determined in accordance with the laws of the country in which such patent was issued.&#160; Each of the Parties hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the courts of the State of New York for any matter arising out of or relating to this Agreement and the transactions contemplated hereby, and agrees not to commence any litigation relating thereto except in such courts.&#160; Each of the Parties hereby irrevocably and unconditionally waives any objection to the laying of venue of any matter arising out of this Agreement or the transactions contemplated hereby in the courts of the State of New York and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such matter brought in any such court has been brought in an inconvenient forum.&#160; The Parties agree that a final judgment in any such matter shall be conclusive and may be enforced in other jurisdictions by suits on the judgment or in any other manner provided by law.&#160; Any proceeding brought by either Party under this Agreement shall be exclusively conducted in the English language.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.5&#160;&#160; <u>Notice</u>.</font></b>&#160; All notices or communication required or permitted to be given by either Party hereunder shall be deemed sufficiently given if mailed by registered mail or certified mail, return receipt requested, or sent by overnight courier, such as Federal Express, to the other Party at its respective address set forth below or to such other address as one Party shall give notice of to the other from time to time hereunder. Mailed notices shall be deemed to be received on the</p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">38<a name="41952-2-LA-11_PB_38_061315_7091"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=41,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=737213,FOLIO='38',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-11_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:48 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">third (3rd) business day following the date of mailing. Notices sent by overnight courier shall be deemed received the following business day.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;">
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If to AKERO:</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Akero   Therapeutics,&nbsp;Inc.</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">230 Park Avenue,   Suite&nbsp;2800</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New York, New York   10169</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attn: Jonathan M.   Young, President and CEO</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">With copies to:</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">via   email</font></i></b>:</p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Akero   Therapeutics,&nbsp;Inc.</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attn: [***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.76%;">
<p style="margin:0in 0in .0001pt .9in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">And:</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Goodwin Procter   LLP</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">100 Northern   Avenue</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Boston, MA 02210</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attn: Christopher   Denn</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If to AMGEN:</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amgen Inc.</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">One Amgen Center   Drive</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thousand Oaks, CA   91320</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="69%" valign="top" style="padding:0in 0in 0in 0in;width:69.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attn: Corporate   Secretary</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.6&#160;&#160; <u>Compliance with Law; Severability</u>.</font></b>&#160; Nothing in this Agreement shall be construed to require the commission of any act contrary to Law.&#160; If any one or more provisions of this Agreement is held to be invalid, illegal or unenforceable, the affected provisions of this Agreement shall be curtailed and limited only to the extent necessary to bring it within the applicable legal requirements and the validity, legality and enforceability of the remaining provisions of this Agreement shall not in any way be affected or impaired thereby.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.7&#160;&#160; <u>Non-Use of Names</u>.</font></b>&#160; AMGEN shall not use the name, trademark, logo, or physical likeness of AKERO or any of its officers, directors or employees, or any adaptation of any of them, in any advertising, promotional or sales literature, without AKERO&#146;s prior written consent. AMGEN shall require its Affiliates to comply with the foregoing.&#160; AKERO shall not use the name, trademark, logo, or physical likeness of AMGEN or any of its officers, directors or employees, or any adaptation of any of them, in any advertising, promotional or sales literature, without AMGEN&#146;s prior written consent.&#160; AKERO shall require its Affiliates and Sublicensees to comply with the foregoing in connection with each such Sublicensee&#146;s sublicense.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.8&#160;&#160; <u>Successors and Assigns</u>.</font></b> &#160;Neither this Agreement nor any of the rights or obligations created herein may be assigned by either Party, in whole or in part, without the prior written consent of the other Party, not to be unreasonably withheld or delayed except that either Party shall be free to assign this Agreement (a)&nbsp;to an Affiliate of such Party (for so long as such Affiliate remains an Affiliate) provided that such Party shall remain liable and responsible to the other Party for the performance and observance of all such duties and obligations by such Affiliate, or (b)&nbsp;in connection with any merger, consolidation or sale of such Party or sale of all</p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">39<a name="41952-2-LA-11_PB_39_061451_455"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=42,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=153560,FOLIO='39',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-11_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:48 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">or substantially all of the assets of the Party that relate to this Agreement, without the prior consent of the non-assigning Party. This Agreement shall bind and inure to the benefit of the successors and permitted assigns of the Parties hereto.&#160; Any assignment of this Agreement in contravention of this Section&nbsp;10.8&#160; shall be null and void.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.9&#160;&#160; <u>Waivers</u>.</font></b>&#160; A Party&#146;s consent to or waiver, express or implied, of any other Party&#146;s breach of its obligations hereunder shall not be deemed to be or construed as a consent to or waiver of any other breach of the same or any other obligations of such breaching Party.&#160; A Party&#146;s failure to complain of any act, or failure to act, by the other Party, to declare the other Party in default, to insist upon the strict performance of any obligation or condition of this Agreement or to exercise any right or remedy consequent upon a breach thereof, no matter how long such failure continues, shall not constitute a waiver by such Party of its rights hereunder, of any such breach, or of any other obligation or condition.&#160; A Party&#146;s consent in any one instance shall not limit or waive the necessity to obtain such Party&#146;s consent in any future instance and in any event no consent or waiver shall be effective for any purpose hereunder unless such consent or waiver is in writing and signed by the Party granting such consent or waiver.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.10&#160;&#160; <u>No Third Party Beneficiaries</u>.</font></b>&#160; Except as expressly provided with respect to AMGEN Indemnified Parties and AKERO Indemnified Parties in Article&nbsp;9 (Indemnification) and AMGEN&#146;s licensees, nothing in this Agreement shall be construed as giving any Person, other than the Parties hereto and their successors and permitted assigns, any right, remedy or claim under or in respect of this Agreement or any provision hereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.11&#160;&#160; <u>Headings; Exhibits</u>.</font></b>&#160; Article&nbsp;and Section&nbsp;headings used herein are for convenient reference only, and are not a part of this Agreement. All Exhibits are incorporated herein by this reference.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.12&#160;&#160; <u>Interpretation</u>.</font></b>&#160; Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word &#147;or&#148; is used in the inclusive sense (and/or). The term &#147;including&#148; (or cognates thereof) as used herein shall mean including (or the cognate thereof), without limiting the generality of any description preceding such term. The term &#147;will&#148; as used herein means &#147;shall.&#148;&#160; All references to a &#147;business day&#148; or &#147;business days&#148; in this Agreement means any day other than a day which is a Saturday, a Sunday or any day banks are authorized or required to be closed in the United States.&#160; The language in all parts of this Agreement shall be deemed to be the language mutually chosen by the Parties. The Parties and their counsel have cooperated in the drafting and preparation of this Agreement, and this Agreement therefore shall not be construed against any Party by virtue of its role as the drafter thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.13&#160;&#160; <u>Equitable Relief</u>.</font></b>&#160; Each Party acknowledges that a breach by it of the provisions of this Agreement may not reasonably or adequately be compensated in damages in an action at law and that such a breach may cause the other Party irreparable injury and damage.&#160; By reason thereof, each Party agrees that the other Party is entitled to seek, in addition to any other remedies it may have under this Agreement or otherwise, preliminary and permanent injunctive and other equitable relief to prevent or curtail any breach of this Agreement by the other Party and is otherwise entitled to specific performance of the terms hereof; <b><i style="font-weight:bold;">provided, however</i></b>, that no specification in this Agreement of a specific legal or equitable remedy will be construed as a</p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">40<a name="41952-2-LA-11_PB_40_061500_4141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=43,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=138164,FOLIO='40',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-11_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:48 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">waiver or prohibition against the pursuing of other legal or equitable remedies in the event of such a breach.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.14&#160;&#160; <u>Force Majeure</u>.</font></b>&#160; Neither Party shall be held liable or responsible to the other Party, nor be deemed to have defaulted under or breached this Agreement, for failure or delay in fulfilling or performing any term of this Agreement to the extent, and for so long as, such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, including fire, floods, embargoes, power shortage or failure, acts of war (whether war be declared or not), insurrections, riots, terrorism, civil commotions, strikes, lockouts or other labor disturbances, acts of God, or any acts, omissions, or delays in acting by any governmental authority or the other Party; <b><i style="font-weight:bold;">provided, however, </i></b>that the affected Party promptly notifies the other Party in writing (and continues to provide monthly status updates to the other Party for the duration of the effect); and <b><i style="font-weight:bold;">provided further, however,</i></b> that the affected Party shall use its commercially reasonable efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence, and shall continue performance with reasonable dispatch whenever such causes are removed.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.15&#160;&#160; <u>Further Assurances</u>.</font></b>&#160; Each Party shall execute, acknowledge, and deliver such further instructions, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;10.16&#160;&#160; <u>Counterparts</u>.</font></b>&#160; This Agreement may be executed in counterparts by a single Party, each of which when taken together shall constitute one and the same agreement, and may be executed through the use of facsimiles or .pdf or other electronically transmitted documents.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[<i>Signature page&nbsp;follows</i>]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">41<a name="41952-2-LA-11_PB_41_061505_8627"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=44,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=602327,FOLIO='41',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-11_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:48 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF,</font></b> the Parties have executed this Agreement as of the date first set forth above.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AKERO   THERAPEUTICS,&nbsp;INC.</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AMGEN INC.</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Jonathan Young</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Sean E. Harper</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: Jonathan   Young</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: Sean E.   Harper</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: President</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: EVP,   Research&nbsp;&amp; Development</font></p>    </td>   </tr>
<tr height="0">
<td width="29" style="border:none;"></td>
<td width="300" style="border:none;"></td>
<td width="24" style="border:none;"></td>
<td width="28" style="border:none;"></td>
<td width="326" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=45,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=293290,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-13_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:51 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;A</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LICENSED KNOW-HOW</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amgen to use commercially reasonable efforts to provide documents and/or Know-How within </font>[***] following the Effective Date, as indicated below.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Note: References to certain Amgen proprietary information and personal information redacted from documents.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[***]</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=46,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=172834,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-13_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:51 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="56%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:56.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="56%" colspan="3" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:56.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=47,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=1025400,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-13_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:51 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="56%" colspan="3" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:56.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="56%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:56.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=48,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=40352,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-13_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:51 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=49,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=563289,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-13_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:51 2019' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="56%" colspan="3" style="padding:0in 0in 0in 0in;width:56.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="56%" colspan="3" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:56.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="56%" colspan="3" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:56.0%;">
<p align="center" style="margin:0in 0in .0001pt .1in;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=50,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=972867,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-15_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="100%" colspan="7" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:100.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=51,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=699137,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-15_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=52,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=761069,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-15_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=53,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=72387,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-15_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=54,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=95581,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-15_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:45.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=55,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=931854,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-15_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="73%" style="border-collapse:collapse;margin-left:1.0in;">
<tr>
<td width="23%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:23.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="22%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="22%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="22%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=56,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=986335,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-17_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="73%" style="border-collapse:collapse;margin-left:1.0in;">
<tr>
<td width="23%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="22%" valign="top" style="padding:0in 0in 0in 0in;width:22.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=57,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=303417,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-17_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="83%" style="border-collapse:collapse;margin-left:.25in;">
<tr>
<td width="30%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="35%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:35.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="30%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=58,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=31975,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-17_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="83%" style="border-collapse:collapse;margin-left:.25in;">
<tr>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=59,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=870430,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-17_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="83%" style="border-collapse:collapse;margin-left:.25in;">
<tr>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=60,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=999290,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-17_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:45 2019' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="83%" style="border-collapse:collapse;margin-left:.25in;">
<tr>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.2%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:35.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=61,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=273941,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-19_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:47 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;B</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LICENSED PATENTS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Country</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Current<br>   Status</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Filing&nbsp;Date</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Filing&nbsp;Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Grant&nbsp;Date</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Grant<br>   Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Amgen&nbsp;Reference&nbsp;No.</font></b></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=62,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=194243,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-19_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:47 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Country</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Current<br>   Status</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Filing&nbsp;Date</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Filing&nbsp;Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Grant&nbsp;Date</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Grant<br>   Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Amgen&nbsp;Reference&nbsp;No.</font></b></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=63,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=413000,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-19_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:47 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Country</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Current<br>   Status</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Filing&nbsp;Date</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Filing&nbsp;Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Grant&nbsp;Date</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Grant<br>   Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Amgen&nbsp;Reference&nbsp;No.</font></b></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=64,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=413000,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-19_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:47 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Country</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Current<br>   Status</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Filing&nbsp;Date</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Filing&nbsp;Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Grant&nbsp;Date</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Grant<br>   Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Amgen&nbsp;Reference&nbsp;No.</font></b></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=65,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=413000,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-19_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:47 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Country</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Current<br>   Status</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Filing&nbsp;Date</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Filing&nbsp;Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Grant&nbsp;Date</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Grant<br>   Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Amgen&nbsp;Reference&nbsp;No.</font></b></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=66,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=413000,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-19_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:47 2019' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Country</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Current<br>   Status</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Filing&nbsp;Date</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Filing&nbsp;Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Grant&nbsp;Date</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Grant<br>   Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Amgen&nbsp;Reference&nbsp;No.</font></b></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=67,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=257060,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-21_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:47 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="top" style="padding:0in 0in 0in 0in;width:16.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=68,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=824004,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-21_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:47 2019' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;C</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PERMITTED CMOs</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="100%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:100.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="48%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:48.98%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="100%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:100.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="48%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:48.98%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">[***]</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=69,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=773131,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-23_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:48 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=70,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=915324,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-23_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:48 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;D</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PRODUCT SEQUENCE</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=71,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=815200,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-23_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:48 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;E</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">QUALITY AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(<i>attached.</i>)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=72,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=910450,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-23_ZFG45202.CHC",USER="GBOATSW",CD='Jan 17 20:48 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;E</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">QUALITY AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Between</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AKERO THERAPEUTICS,&nbsp;INC. (&#147;AKERO&#148;)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">and</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Amgen Inc. (&#147;Amgen&#148; and together, the &#147;Parties&#148;)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Parties have entered into that certain Exclusive License Agreement, dated as of June&nbsp;7, 2018, with respect to the grant by AMGEN to AKERO of a license to, among other things, commercially develop, manufacture, use and distribute a molecule known as AMG 876.&#160; This Quality Agreement is intended by the Parties to set forth a plan for the quality assurance groups of AMGEN and AKERO in connection with the license of AMG 876.&#160; By signing below, the respective quality assurance representatives acknowledge and agree to the provisions of this Quality Agreement.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agreed and accepted for</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agreed and accepted for</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AKERO Therapeutics,&nbsp;Inc.</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Amgen Inc.</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="41%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Jonathan   Young</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Paul   Mowad</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jonathan Young</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Paul Mowad</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director,   Quality</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">June&nbsp;7,2018</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">June&nbsp;7,   2018</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="41952-2-LA-25_PB_1_212339_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=73,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=643848,FOLIO='1',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-25_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 01:22 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TABLE OF CONTENTS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BACKGROUND   INFORMATION</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SCOPE</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DEFINITIONS</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ROLES   AND RESPONSIBILITIES</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COMMUNICATION</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BATCH   DISPOSITION (PRODUCT RELEASE)</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">QUALITY   CONTROL</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">REFERENCE   AND RETENTION SAMPLES</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONTROLLED   DOCUMENTS</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LABELING</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SHIPPING,   RECEIVING, STORAGE AND DESTRUCTION</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INVESTIGATIONS   OF NONCONFORMANCES, DISCREPANCIES</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DISPUTE   RESOLUTION</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PRODUCT   COMPLAINTS</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ADVERSE   EVENTS</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">16.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AUDITS   AND INSPECTIONS</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">17.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">REPROCESSING/   REWORK</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RECALLS   AND CORRECTIONS OF PRODUCT</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">19.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SUBCONTRACTING</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">20.</font></b></p>    </td>
<td width="83%" valign="top" style="padding:0in 0in 0in 0in;width:83.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RESPONSIBLE   PERSONS: CONTACT INFORMATION</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14</font></b></p>    </td>   </tr>
<tr>
<td width="90%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:90.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LIST OF ATTACHMENTS:</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15</font></b></p>    </td>   </tr>
<tr>
<td width="90%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:90.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ATTACHMENT A</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">16</font></b></p>    </td>   </tr>
<tr>
<td width="90%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:90.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ATTACHMENT B</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">17</font></b></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="41952-2-LA-25_PB_2_212501_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=74,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=430040,FOLIO='2',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-25_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 01:22 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This QUALITY AGREEMENT (this &#147;Quality Agreement&#148;) effective as of June&nbsp;7, 2018 (&#147;Effective Date&#148;) is entered into by and between AKERO Therapeutics,&nbsp;Inc., a Delaware corporation having an address at 271 Waverly Oaks, Suite&nbsp;104, Waltham, Massachusetts 02452 (&#147;AKERO&#148;) and Amgen Inc., a Delaware corporation, located at One Amgen Center Drive, Thousand Oaks, California 91320-1799 (&#147;AMGEN&#148;).&#160; AKERO and AMGEN may each be singularly referred to as a &#147;Party&#148; or, collectively, as the &#147;Parties&#148;.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">BACKGROUND INFORMATION</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN and AKERO have entered into that certain Exclusive License Agreement, dated as of June&nbsp;7, 2018, as may be amended or restated from time to time (the &#147;License Agreement&#148;), with respect to, among other things, the grant by AMGEN to AKERO of a license to, among other things, commercially develop, manufacture, use and distribute the Product (as defined below), which contains or comprises the compound known as AMG 876.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Quality Agreement defines the quality obligations and responsibilities of the Parties and their respective affiliates or approved contractors with respect to the license to AKERO in accordance with the License Agreement and the quality aspects of the Product.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">SCOPE</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The provisions of this Quality Agreement are incorporated as part of the provisions of the License Agreement, and this Quality Agreement is entered into in accordance with Section&nbsp;5.4.1. of the License Agreement. The terms of the License Agreement shall remain in full force and effect.&#160; In the event of any conflict between the License Agreement and this Quality Agreement, the License Agreement shall control.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Quality Agreement may be amended only by mutual written agreement of the Parties.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Attachments are part of this Quality Agreement.&#160; If an Attachment conflicts with the body of this Quality Agreement, the body of this Quality Agreement shall control.&#160; Attachments to this Quality Agreement are intended to provide additional definition to the applicable topic and, as such, should be updated to reflect the current information and business process, as applicable.&#160;&#160; Amendment of the Attachments does not require re-approval of this Quality Agreement unless this Quality Agreement itself is affected. Attachments and all amendments of Attachments shall be approved by mutual written agreement of the Parties.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All activities under this Quality Agreement shall be performed in compliance with applicable cGMP regulations.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Quality Agreement shall expire upon termination, cancellation, or expiration, as the case may be, of the License Agreement, or the earlier mutual written agreement of the Parties.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Approval of this Quality Agreement supersedes any and all prior quality agreements between AKERO and Amgen as it relates to the Product.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="41952-2-LA-25_PB_3_212521_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=75,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=252461,FOLIO='3',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-25_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 01:22 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">DEFINITIONS</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All capitalized terms not otherwise defined in this Quality Agreement shall have the meaning ascribed to them in the License Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>As used in this Quality Agreement, the following terms shall have the meanings set forth in this Article.&#160; Any terms defined elsewhere in this Quality Agreement shall be given equal weight and importance as though set forth in this Article.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="89%" style="border-collapse:collapse;margin-left:27.35pt;">
<tr>
<td width="29%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Term</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="68%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:68.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Definition</font></b></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Batch Record</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A single unexecuted or executed record or a   compilation of all executed records, forms, and supporting documents related   to the manufacture of a specific batch of product.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate of Analysis (CoA)</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" style="padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">An approved record for a given batch containing the   analytical test results required by the Specifications for the product or   material.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate of Compliance (CoC)</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate including a statement of compliance with   all applicable laws and regulations, including, without limitation, cGMP for   a specific product batch and may contain the usage decision.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">cGMP</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" style="padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All applicable standards relating to current good   manufacturing practices for fine chemicals, intermediates, bulk products   and/or finished pharmaceutical drugs, including (a)&nbsp;all applicable   requirements detailed in the FDA&#146;s current Good Manufacturing Practices   regulations, 21 C.F.R. Parts 210 and 211, (b)&nbsp;all applicable   requirements detailed in the European Medicine Agency&#146;s (EMA)&#148;EU guidelines   for Good Manufacturing Practice for Medicinal Products for Human and   Veterinary Use,&#148; and (c)&nbsp;all applicable Laws promulgated by any   Governmental Authority having jurisdiction over the manufacture of the   applicable compound or pharmaceutical drug product, as applicable.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Complaint (Product complaint)<br>   Potency, Purity, Strength</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any written, electronic or verbal communication that   alleges deficiencies related to the identity, quality, durability,   reliability, safety, effectiveness or performance of a drug, its labeling or   packaging, or device after release for distribution.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deviation/ Nonconformance</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" style="padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The term &#147;Deviation/Nonconformance&#148; shall mean a   departure from an approved instruction or established standard or operating   procedure incurred during the manufacture, packaging, testing, or storage of   the Product prior to delivery to AKERO, which were determined by AMGEN   procedures to potentially impact the quality, potency, purity, identity,   strength, efficacy, or safety of the Product. The terms Deviation or   Nonconformance can be used interchangeably.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Drug Product (DP)</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The term used when referring to both intermediate   and final drug products, that contain an active ingredient, labeled and   packaged.<br>   The dosage form in the final immediate packaging intended for investigational   use.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Drug Substance (DS)</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" style="padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any substance or mixture of substances intended to   be used in a manufacture of a drug (medicinal) product and that, when used in</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="41952-2-LA-25_PB_4_212720_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=76,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=829632,FOLIO='4',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-25_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 01:22 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="89%" style="border-collapse:collapse;margin-left:27.35pt;">
<tr>
<td width="29%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Term</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="68%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:68.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Definition</font></b></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the production of a drug, becomes an active   ingredient of the drug product. Such substances are intended to furnish   pharmacological activity or other direct effect in the diagnosis, cure,   mitigation, treatment, or prevention of disease or to affect the structure   and function of the body. DS is typically manufactured by either   chemical/enzymatic reactions (Chemical Entity) or cell culture/fermentation   processes (Biological Entity) and purification step(s).</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Manufacturer&#146;s Release</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" style="padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Release of Product to AKERO by AMGEN, according to   AMGEN&#146;s procedures and cGMP regulations.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Master Batch Record</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The original approved record that serves as the   template for the Batch Record for each Product Lot.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Material Change</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" style="padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A change which materially modifies the regulatory filing   for the Product or is determined by AMGEN to have significant potential to   materially affect the safety, quality, identity, potency, strength, or purity   of the Product.<br>   Per AMGEN&#146;s change classification, this would represent a level 2 or level 3   change.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Product</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shall mean the cGMP pharmaceutical Drug Substance   AMG 876 manufactured by AMGEN and supplied to AKERO under the License   Agreement. For the sake of clarity, Product shall not include Drug Product.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Qualified Person</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" style="padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The term &#147;Qualified Person&#148; shall mean personnel who   meet the definition of a Qualified Person in Directive 2001/83/cc and who,   for Product manufactured within or for the European Community, ensures that   each batch has been produced and tested/checked in accordance with the Applicable   Directives and the Product marketing authorization, and must certify in a   register or equivalent document, as operations are carried out and before any   release, that each production batch satisfies the provisions of European   Union regulation.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Recall</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A &#147;recall&#148; or &#147;market withdrawal&#148; (each as defined   per Section&nbsp;7.3 of Title 21 (Food and Drugs) of the Code of Federal   Regulations, or, with respect to a jurisdiction other than the United States,   the equivalent regulations of the applicable Regulatory Authority in such   jurisdiction) of Product or any lots thereof.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Reference Sample</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" style="padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sample collected from the manufacture of Product for   the purpose of being analyzed, should the need arise, to support significant   investigations.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Regulatory Approval</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Final approval of an Application by the FDA, or   final approval of a comparable document filed with an equivalent health   regulatory authority in any other country or in the European Union (using the   centralized process, decentralized process or mutual recognition or member   state national authorization) &#151; but not necessarily also any required pricing   and/or reimbursement approvals.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="41952-2-LA-25_PB_5_212739_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=77,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=61128,FOLIO='5',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-25_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 01:22 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="89%" style="border-collapse:collapse;margin-left:27.35pt;">
<tr>
<td width="29%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Term</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="68%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:68.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Definition</font></b></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Regulatory Authority</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any Governmental Authority or other authority   responsible for granting Marketing Approvals for the Product, including the   FDA, EMA and any corresponding national or regional regulatory authorities.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Reprocessing</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" style="padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Introducing an intermediate or active pharmaceutical   ingredient, including one that does not conform to cGMP or Product standards   or Specifications, back into the process and repeating a step (e.g.,   filtration) that is part of the established manufacturing process.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Reserve Samples</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Term that encompasses both reference and retention   samples.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Retention Samples</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" style="padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A sample taken during the manufacturing process for   identification quality and compliance purposes. The sample is packaged and   stored under controlled conditions for a defined time period following   completion of the process (including fill and finish).</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rework</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subjecting an intermediate that does not conform to   one or more processing steps that are different from the established   manufacturing process to obtain acceptable quality intermediate or Product.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" style="padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Specifications</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" style="padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The set of analytical methods, requirements, and   acceptance criteria as used to judge the identity, purity and potency of all   source materials, raw materials, and finished filled Product, which comprises   the material.</font></p>    </td>   </tr>
<tr>
<td width="29%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:29.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Territory</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:68.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Globally.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">ROLES AND RESPONSIBILITIES</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Without limiting any other provision of this Quality Agreement, the Parties agree that this Quality Agreement is intended to carry out the following guiding principles:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The responsibilities of the Parties with respect to the Product in compliance with license requirements, Regulatory Approvals, cGMPs, applicable Scope of work, and Specifications, are as set forth in the provisions that follow.&#160; This Quality Agreement is intended to further articulate the quality-related obligations of the Parties under the License Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Parties acknowledge that each Party shall have the right to perform responsibilities hereunder through its Affiliates (as defined in the License Agreement) and/or contractors, provided that each Party shall remain responsible and liable for such performance as if such responsibilities were performed (or not performed) by such Party; provided, however, that the Quality Agreement may not be transferred or assigned to a third party by either Party without the other Party&#146;s written consent.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Parties shall comply with all relevant laws, including without limitation applicable legislation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="41952-2-LA-25_PB_6_212817_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=78,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=101574,FOLIO='6',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-25_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 01:22 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">COMMUNICATION</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN and AKERO agree to provide verbal communication to one another as necessary or appropriate to meet the need for timely communication.&#160; Both Parties also agree to follow up and confirm promptly in writing those verbal communications which could materially affect performance under this Agreement or could materially affect the safety, identity, strength, potency, or quality of Product, to ensure clarity of issue(s).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All official communications and documentation between AMGEN and AKERO will be conducted in English.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Routine verbal and written communications required hereunder shall be delivered to the individuals designated on the notification list set forth in <b><u style="font-weight:bold;">Attachment A</u></b> attached to this Quality Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each Party will notify the other within one (1)&nbsp;business day of receipt of any communication with any local Regulatory Authority regarding Product, and forward any written communication within three (3)&nbsp;business days in the original language and English translation, if necessary.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each Party must notify the other in writing of any (potential) theft, counterfeits and illegal diversion of Product manufactured by AMGEN within twenty-four (24) hours upon awareness of such events. Investigation results will be provided upon completion.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">BATCH DISPOSITION (PRODUCT RELEASE)</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>AMGEN Quality Responsibility</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall be responsible for the Manufacturer&#146;s Release of the Product to AKERO.&#160; All the Product provided to AKERO by AMGEN pursuant to the License Agreement shall be manufactured, bulk packaged, tested, stored, and released in accordance with all applicable laws, cGMPs and the Specifications set forth in the License Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall provide to AKERO the disposition package for each batch from Product supplied to AKERO, upon shipment (each, a &#147;<b>Disposition Package</b>&#148;). The documents to be included in each Disposition Package are provided in <b><u style="font-weight:bold;">Attachment B</u>.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>AKERO Quality Responsibility</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.2.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall be solely responsible for the further processing (fill/finish), packaging, labeling, and final release of the Product for distribution and/or use (including investigational use) within the Territory after reviewing the Disposition Package provided by AMGEN.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.2.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A Qualified Person authorized by AKERO will be responsible for certification of Product for distribution/ use in clinical trials in the European Union, according to the requirements set out in the European Union cGMPs.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="41952-2-LA-27_PB_7_213934_9872"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=79,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=236565,FOLIO='7',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-27_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 02:20 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.2.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall be deemed to have conclusively and fully accepted the Product unless AKERO notifies AMGEN in writing of any claim to the effect that the Product received did not meet the Specifications or cGMP within thirty (30) calendar days after transfer of the Product to AKERO.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 22.5pt;text-indent:-22.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">QUALITY CONTROL</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN will conduct release testing of Product according to AMGEN Quality Specifications and its methods, policies and procedures</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Unless it is required by a Regulatory Authority in order to determine if the Product meets Specifications or if the Product is comparable to AKERO&#146;s product, and with AMGEN&#146;s written consent, which consent shall not be unreasonably withheld, conditioned or delayed, AKERO shall accept the Product without performing additional testing.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If additional testing is required, AKERO shall be responsible for sampling upon receipt and conducting testing, as required. Such testing will be conducted by AKERO (or if AMGEN expressly consents in writing, by appropriately qualified laboratories, which consent shall not be unreasonably withheld, conditioned or delayed) by appropriately qualified personnel according to testing procedures mutually agreed by Parties</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Stability Testing of Product</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 103.5pt;text-indent:-45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.4.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN will conduct routine stability testing of the Product according to AMGEN&#146;s stability program, for products manufactured by AMGEN.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 139.5pt;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.4.1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Cell bank stability monitoring responsibilities will become responsibility of AKERO upon physical transfer of the cell bank.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 139.5pt;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.4.1.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Stability Testing of Product and intermediates will become the responsibility of PIPPEN upon physical transfer of the stability samples.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.4.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO will not conduct any stability testing on the Product manufactured by Amgen, unless authorized to do so by AMGEN or required by a Regulatory Authority.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">REFERENCE AND RETENTION SAMPLES</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall retain Reference Samples for each manufactured batch of Product released to AKERO per AMGEN established procedures and cGMP requirements.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall be responsible for retaining Reference Samples for Product distributed in the Territory, per regulatory requirements in the applicable jurisdiction.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall be responsible for retaining Retention Samples per AMGEN requirements for products packaged by AMGEN.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="41952-2-LA-27_PB_8_214003_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=80,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=484877,FOLIO='8',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-27_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 02:20 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 54.7pt;text-indent:-27.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For products packaged by AKERO, AKERO is responsible for retaining additional retention samples as required by applicable Regulatory Authorities.</p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 54.7pt;text-indent:-27.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The retention period to follow will be according to regulatory requirements in Territory.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">CONTROLLED DOCUMENTS</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall make readily available to AKERO, upon request, only documents related to lots of the Product supplied to AKERO which shall include release documentation, summaries of change controls, complaint investigations, deviation/ nonconformances summaries, and stability summary data, as agreed between the Parties.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall retain controlled documents related to manufacturing and analytical data per AMGEN&#146;s established procedures and cGMP requirements.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">LABELING</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall label Drug Substance primary containers per AMGEN&#146;s established procedure.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall be responsible for generating and approving Product labels and packaging for investigational use.&#160; AKERO&#146; Quality and Regulatory Affairs are responsible for reviewing and approving the labels for compliance with Territory regulatory requirements.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall be responsible for all Product labeling and packaging manufacturing operations in accordance with cGMPs.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">SHIPPING, RECEIVING, STORAGE AND DESTRUCTION</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Shipping of Product by AMGEN</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall be responsible to pack the Product for shipment in a qualified shipper in accordance with AMGEN procedures and Specifications.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.1.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Unless otherwise agreed by the Parties, Product shall be shipped in accordance with the License Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Receiving and Storage of Product by AKERO</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.2.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall obtain all government approvals and submit all appropriate documents, forms and reports as required by Governmental Authorities (as defined in the License Agreement) for the import and export of the Product. AKERO shall be responsible for any applicable import clearance.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="41952-2-LA-27_PB_9_214044_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=81,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=940388,FOLIO='9',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-27_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 02:20 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.2.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Upon receipt of shipment, AKERO or its designees shall be responsible for reviewing shipping temperature recording data, inspecting security seals and labels for evidence of tampering, and performing reconciliation of unlabeled Product against shipper upon receipt of shipment per AKERO&#146; procedures.&#160; AKERO shall notify AMGEN Quality within five (5)&nbsp;business days after becoming aware of any discrepancies.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.2.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall be responsible for adequate storage of the Product upon receipt according to the storage requirements specified in the Specifications.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.2.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any nonconformances that occur during Product shipment from AMGEN to AKERO, including temperature excursions, shall be investigated per Section&nbsp;12 of this Quality Agreement, if applicable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Shipping of Product by AKERO</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.3.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall be responsible for performing the necessary shipper qualification required to ensure appropriate storage and transport of Product.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.3.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall ensure that adequate controls are in place to ensure the temperature is monitored throughout transportation of Product.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.3.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall be responsible for evaluating temperature excursions that may occur during the transportation and/or storage of Product for AKERO-sponsored clinical studies to ensure Product was maintained within acceptable storage conditions as listed in Specifications.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Destruction and Reconciliation</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.4.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall be responsible for the destruction of any rejected, unused and partially used Product in accordance with applicable Laws and cGMP.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Product returns</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.5.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Returned products from end-users including patients, hospitals, pharmacies, clinics, healthcare practitioners should not be restocked.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">INVESTIGATIONS OF NONCONFORMANCES, DISCREPANCIES</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Pre-release non-conformances</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall provide to AKERO a list of (pre-release) nonconformances determined to have potential impact on the safety, identity, strength, potency, and quality of the lot in the Disposition package.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="41952-2-LA-27_PB_10_214125_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=82,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=916244,FOLIO='10',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-27_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 02:20 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Post-release nonconformances</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.2.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each party shall notify the other party within reasonable amount of time of any nonconformance determined to have potential impact on the safety, identity, strength, potency, and quality of the lot or portion of the lot which has been released (post-release) to the market in the Territory to enable AKERO and/or AMGEN to comply with applicable regulatory reporting requirements.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.2.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN will provide support, as necessary and reasonable, to enable AKERO to comply with applicable reporting requirements to Regulatory Authorities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.2.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall notify AMGEN immediately of any possible shipping nonconformances, such as temperature excursions, upon reviewing shipping records.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN and AKERO shall each notify the other Party within three (3)&nbsp;business days if they become aware that Product is alleged or proven to be the subject of a recall, field alert or biological product deviation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">DISPUTE RESOLUTION</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall be responsible for performing investigations to resolve disputes relating to non-compliance or nonconformance of Product with the Specifications or cGMPs, and solely shall determine the outcome.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 58.5pt;text-indent:-31.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall communicate to PIPPENAKERO the outcome of such investigation upon completion.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">PRODUCT COMPLAINTS</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall notify AMGEN within one (1)&nbsp;business day after first awareness of any product complaints which may include, but are not limited to, communication that alleges deficiencies relating to identity, quality, durability, reliability, safety, effectiveness or performance of a drug, condition of labeling, or packaging, after it is released by AKERO in the Territory.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-49.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Complaints shall be reported by writing to the following e-mail address: [***]</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall investigate complaints submitted by AKERO according to AMGEN&#146;s applicable policies and procedures.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall provide updates and/ or closure report within forty five (45) calendar days upon receipt of the customer complaint.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">ADVERSE EVENTS</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 58.5pt;text-indent:-31.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Intentionally omitted.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="41952-2-LA-27_PB_11_214206_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=83,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=211094,FOLIO='11',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-27_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 02:20 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">16.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">AUDITS AND INSPECTIONS</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Audits by AKERO</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Upon the request of AKERO and approval by AMGEN, not to be unreasonably withheld, AMGEN shall permit AKERO to conduct a one (1)-time paper-based audit to confirm compliance with this Quality Agreement, Specifications, cGMPs; or in the event of the need for a &#147;<i>For Cause</i>&#148; audit, in the case of a quality or regulatory event, which events may include recall of the supplied Product in the Territory or clinical stock recovery, or repeated product complaints or Deviations, not to exceed two (2)&nbsp;audits per twenty four (24)-month period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All audits require prior written request by AKERO and shall be conducted during normal AMGEN business hours.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall provide AMGEN written notification of a paper-based audit not less than&#160; forty-five (45) calendar days in advance. The written notification must clearly state the scope of the audit and regulatory standards in the Territory, specified in this Quality Agreement, to be used to conduct the audit.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The scope, agenda, and timeline must be approved by Quality Assurance at AMGEN prior to conducting any audit, such approval not to be unreasonably withheld.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All audits of AMGEN are limited to the facilities where the Product is manufactured, or Quality Systems and documentation directly related to the Product, and where Batch Records related to Product provided to AKERO are stored.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<i>For Cause</i>&#148; audits of AMGEN facilities will be conducted in the presence of AMGEN representatives. Audits shall be conducted by not more than two (2)&nbsp;AKERO representatives at each AMGEN facility, and, unless otherwise agreed upon by AMGEN, for not more than three (3)&nbsp;business days at each site.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1.7</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>At AKERO&#146; or AMGEN&#146;s request, an exit meeting shall be held with AKERO and its representatives and AMGEN and its representatives to discuss audit findings, if any.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1.8</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall provide AMGEN with a copy of the audit report within thirty (30) calendar days upon completion of the audit.&#160; AMGEN shall provide AKERO with a written response, identifying corrective actions and timelines, for review and comment within thirty (30) calendar days of receipt of such audit report.&#160; AKERO comments shall be given reasonable consideration prior to implementation of any corrective action plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1.9</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The audit of a third party contract manufacturer (CMO) of AMGEN will be subject to the terms and limitations of AMGEN&#146;s contractual rights and obligations with such contract manufacturer, which shall be disclosed to PIPPEN upon request in the form of a letter including the name of the auditor that performed the audit, that such audit was performed and completed, and that the CMO was in compliance with cGMPs.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1.10</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>All information contained in the audit report shall be deemed confidential information of AMGEN under the License Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1.11</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall be solely responsible for all agreements with AMGEN managed third party contractors and for conducting all audits of non-AMGEN facilities relating to</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="41952-2-LA-29_PB_12_213808_8645"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=84,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=1021816,FOLIO='12',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-29_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 01:24 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">manufacturing, testing and/or storage sites of Product per AMGEN procedures.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 63.0pt;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Audits by AMGEN</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.2.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN shall, consistent with its policies and procedures, schedule and perform internal audits and audits of its subcontractors for Product with respect to facilities, processes and procedures.&#160; AMGEN shall promptly notify AKERO, in writing, of any critical observations directly related to the Product promptly and in any event no later than three (3)&nbsp;business days after AMGEN receives notice thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Regulatory Authority Inspections</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.3.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AKERO shall use commercially reasonable efforts to waive or avoid the need for any inspection by Governmental Authorities (as defined in the License Agreement) of AMGEN&#146;s manufacturing facilities and/or documentation with respect to product and/or placebo.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.3.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each Party shall notify the other within twenty-four (24) hours upon notification by any Regulatory Authority of any intended inspection of AMGEN&#146;s facilities or records relating to the manufacturing, testing, and storage of the supplied Product.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.3.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN will be solely responsible for hosting and managing regulatory inspections at its facilities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 135.0pt;text-indent:-45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.3.3.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Not more than one (1)&nbsp;AKERO representative may be present at such inspections upon approval by AMGEN, given that such approval may not be unreasonably withheld.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.3.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each Party shall inform the other Party of any critical and major regulatory inspection observations by other Government Authorities that are related to the Product and/or Territory.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.3.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Responses to regulatory inspections</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 135.0pt;text-indent:-45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.3.5.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For inspections occurring at AMGEN sites, AMGEN shall be the first to receive the inspection report, unless restricted by regulatory requirements.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 135.0pt;text-indent:-45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.3.5.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Party who received the inspection report shall provide the report to the other Party within twenty-four (24) hours of receipt, and shall be responsible for translation, if required.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 135.0pt;text-indent:-45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.3.5.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Party whose facility was audited shall be responsible for authoring and providing responses to the Regulatory Authority.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 135.0pt;text-indent:-45.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.3.5.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The non-authoring party shall have a right to review and comment on proposed responses. The final response shall be provided to each party.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">17.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">REPROCESSING/ REWORK</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN will not conduct any reprocessing or reworking of materials of Product without prior written approval by AKERO.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="41952-2-LA-29_PB_13_214021_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=85,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=467274,FOLIO='13',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-29_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 01:24 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">RECALLS AND CORRECTIONS OF PRODUCT</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If any problems are discovered and identified as potentially requiring a Product recall, stock recovery, or correction in any country, the discovering Party shall notify the other immediately, and in any event, within twenty-four (24) hours of identification of such problem. Such notice shall be provided prior to executing a recall, stock recoveries, or correction in any country.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>AMGEN (either itself or via participation through a committee) shall have the right to initiate a recall, stock recovery, or correction.&nbsp; PIPPEN shall not conduct such recall, stock recovery, or correction without the prior written consent of AMGEN.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each Party will provide the other Party with reasonable assistance in connection with any such events as may reasonably be requested by such other Party.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each Party shall meet all applicable regulatory requirements related to Product recalls, stock recoveries, and correction.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each Party shall be responsible for Product distributed within the Territory for its own clinical studies.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">19.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">SUBCONTRACTING</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Intentionally omitted.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 27.0pt;text-indent:-27.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">20.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u style="font-weight:bold;">RESPONSIBLE PERSONS: CONTACT INFORMATION</u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The individuals listed in <b><u style="font-weight:bold;">Attachment A</u></b> shall be the key points of contact between AMGEN and AKERO relating to the rights and obligations of the Parties in this Quality Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">14<a name="41952-2-LA-29_PB_14_214125_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=86,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=362185,FOLIO='14',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-29_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 01:24 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LIST OF ATTACHMENTS:</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attachment&nbsp;A: Responsible Persons and Contact Information</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attachment B: AMGEN Disposition Package</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">15<a name="41952-2-LA-29_PB_15_214138_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=87,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=730325,FOLIO='15',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-29_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 01:24 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ATTACHMENT A</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Responsible Persons and Contact Information</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AKERO</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="22%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:22.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Name</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Email&nbsp;Address</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Contact&nbsp;Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="30%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Responsibility</font></b></p>    </td>   </tr>
<tr>
<td width="22%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMGEN</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="22%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:22.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Name</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Email&nbsp;Address</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Contact&nbsp;Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="30%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Responsibility</font></b></p>    </td>   </tr>
<tr>
<td width="22%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:22.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:30.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[***]</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;A version date:&#160; </font></b>June&nbsp;7, 2018</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agreed and accepted for:</font></b></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agreed   and accepted for:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AKERO THERAPEUTICS,&nbsp;INC.</font></b></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMGEN   INC.</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="40%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Jonathan   Young</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="41%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Paul   Mowad</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jonathan   Young</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Paul Mowad</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director,   Quality</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">June&nbsp;7,2018</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">June&nbsp;7,   2018</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=88,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=1116,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-29_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 01:24 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ATTACHMENT B</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMGEN Disposition Package</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following documents are to comprise the AMGEN Disposition Package to support the release of the Product to AKERO:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Stage&nbsp;of&nbsp;Manufacture</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.04%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Disposition&nbsp;Package&nbsp;Documents</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Drug Substance Manufacture</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CoA<br>   CoC<br>   Nonconformance&#146;s lot summary report</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Attachment B version date:&#160; </font></b>June&nbsp;7, 2018</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agreed and accepted for:</font></b></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Agreed and accepted for:</font></b></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AKERO THERAPEUTICS,&nbsp;INC.</font></b></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMGEN INC.</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="40%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Jonathan   Young</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="41%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Paul   Mowad</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jonathan   Young</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Paul Mowad</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director,   Quality</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="43%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">June&nbsp;7,2018</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">June&nbsp;7,   2018</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=89,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=734430,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-29_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 01:24 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT&nbsp;WERE OMITTED AND REPLACED WITH &#147;[***]&#148;. A COMPLETE VERSION OF THIS EXHIBIT&nbsp;HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CHANGE SUMMARY</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Change</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.04%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Justification</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Initial Quality Agreement</font></p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.04%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Required pursuant to License Agreement</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=90,EFW="2237524",CP="AKERO THERAPEUTICS",DN="6",CHK=47034,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LA-29_ZFG45202.CHC",USER="GBOATSW",CD='Jan 18 01:24 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;21.1<a name="41952-2-LE_Exhibit21_1_083529"></a></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Subsidiary of Akero Therapeutics,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Akero Securities Corporation, a Massachusetts corporation</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2237524",CP="AKERO THERAPEUTICS",DN="7",CHK=291277,FOLIO='',FILE="DISK116:[18ZFG2.18ZFG45202]41952-2-LE_ZFG45202.CHC",USER="GBOATSW",CD='Jan 11 08:35 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g239315.jpg
<TEXT>
begin 644 g239315.jpg
M_]C_X  02D9)1@ ! 0$!A0&%  #__@!!1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?1DE'55)%7S$W7S1#7TQ)3D4N15!3_]L
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M25AHPN'Q*$=2=HBGQ]9456-I<W=XE9:HM;:YP]3_Q  < 0$  @,! 0$
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M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&<"(% 1$0   1$1$
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MNU$=G1$G78JNW%A*7R.47A-GRP6"3JS)VN#9&-EZTT2L<49X%Q*12@DD $$
M!,@ 'F>9V "@ !Y@F[G[!Z>,?4_;Q"(B/?(#70$;7:321R(R$+"S>H \%B5W
M('G$@D42P%XW#R",2R0J?31#G6N8[-'X%P:A4M5+%>=6FV$4)J-)7VFHH5*J
M$I7OVGI2R4MG'6N0R05#=:A5V4L2V[%H9^^<" & 0'X" @/Y!]!SG&3^<ERI
MO?72EI6];GL^3<;<LU&I&RMIQ?)$]>I]'H*-VKG*&MZ_B=>57:T5MN2CWMI>
MP,&QKM=G/FUFV<C$2,O%>Y7LT;7+Y[0ELT1G!=M)U*7B-K[.>[4M.S-[Q6[=
M]6^0I,!7E-AMH&KU"K1.K:K%Q3U8VLM<#%ZOU7%3L7'RUA?6JMUNPP5B?R!;
MS+O&T_,8QD).%/#-MPYKNP(-':ELV:I?;+$3[QU.QL77FQG<)6V=:5M<O$0J
MRT?.;;V"#,MFW;M0Q8^3VQ>#C:)6'C'0"B>M?E+QVTGKOKK]*OD!2M<UZN;E
MW\SYZ1VY-A1R3HD_L)CKKB93X6D-K JHZ5;+IUJ+)[%&>SMFXI(&,4PG,=0Y
M]@/*9>;/X7;HE_RE']6"I8QES6,8QC&,8QC&,8QC&,8QC&,8QC&?'L4_#U2
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M7BEU36B#.7;RID]-ZNJ:<?6WJQ&G8D4YG;#,V.5=12X>V-EA\:Y?X4JJVI:
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M'N"B=CUVJZ%(P$4.)3C5Y>PF[E\)"#V3]3K)B4!3!51/S)^&O.HU+IQK86T
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MEOVI\SVRM1OH.&WEH+9L1=J')V%R[8P\K6Y=5"!VE0YM\P;/7C>%N5-6<)K
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M7><?9F9B JJHVA+,Q(  !))  [SR_P"*O!45G?;V41%+.[Z'D2JJJ"69F.I
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M$>WP[C\<YS4S:QC&,8QC&,8QE3O5D^]_@+_&M=/_ /:VOEL65.]63[W^ O\
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M9T^3:%07E'"XJJG=JG\7J<H>#CMRB_?21OO[HRM?+0=2_.E[%\AISY&?,_\
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M"#628+ 9!XU06*8@>^RBG973KWQQ.MLKO'IM[ DXHJQQ?VKCI:I(92OV9JW
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MW$VAO)0E<G+Y8*_7[#,MYQFXDGD2P=Y>NF4I4TRE,GX2D(4HE*0"B4I0 !*
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MKE[XW!H"/YYRFVZA\GK7'_))AL3B939FG+^_Y6"8U>>]\1JQ'/E5F;FEH_Q
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MC&2V4#&,8QC&8OVYM6(T]5"VN7@+?9R+2K&&9PU*A23$LY>/BN%A6<+OGT1
M0,0P9,WC^5L-IG8*OQK5L8'<HFY<,V[G*&8EW3JU;;U,-4D+O9:(I[S92)I*
MNMJ[*(2;=NFZ;/:[:*U;H:>K%MJ4TS>KMIFN3L6Y8O?"V7$"+M$3ABG,HAD,
M([E\#Z8^DGR_3KS94[_;R8+WUV>N\W]6M%MC279MX4#8C%MR9@%A\AYEC7BF
ML>'7\_H1/-X>7I#S\2,$0G(3AK,V*,WXKL*AUZ^2&F*8@M(VV>-6;9"ZKO\
M*1%OJ438*Y*O421 3<W.QCR.3<L?>+]RY*FP<.VF9+@.4VDYG3M<WM(72+IV
MM[9*R,+7YJ[/HROEE))A8)NNIM6(G?N6[U63<U^1?1)&;EP=Y$$"2\*3<JXH
MX(B.GUKZLUM&%J^PMD1$M#6?1ERI]K76J\Y-UFQZ&J2M-K3LJ,U7WD1-,Y.'
M>RJ4G$2\:O%,2R'D5QK#-8Z+1:>O;<,Z_%:KTOKNO;)OD'.:)NMEO%)V0BTI
M3ZS&D[F%Z9VI&7AY2L/:6]:S$-L.PQGA3KC<\>863Z.%LX;"52)A;<J3YU::
M=PR.XA(Z>RT\2JQ[E4LWMQ+(5;TU=_31IU[)COFPA_#F81"OO.13E=C4K1-L
M%?NMI8]5=FDB4)KYEAB&W>C32:+W<T%;W<\6JL>G&+?M*CS#XZ6V'H<F;:-2
MJC[8M#9[(K]7NU@@ZY:2U1]%/)Q)_)1;B2538]HB.D9,2G=G*HPCWSUN==HS
M<+I_=1Y3\<EX>"L!-UZU+#6:?<U>#D5K9%MVTA/,PCA=QJ1G"R1DUVI9F&.X
M,X*@BBG,PZBBI22L>9Q%2/Z9>JV,#%4P^Q-E/*&V84-S-5%TC0'#*R7G6>OU
M-:TR^R3QY3'D@D\C:\#-=W5FJZ=)F)6,9KR<"XCUI2,D/CL>EGJ9O#PL8]V)
ML67-'O;(B_\ >C2BR40\J5K3I1)JG1U7EJM)5ZM1RZ]"@I!)["L47K>06EE$
MO"W=-&K#RL_( H!HTV8+T3Z_CVP:,=]"0CHIZC?Z)\OHZ 0/-LR:O\)'F=H^
M3<DA@:4LD?Y8)66%HK;B,NU9"LD<ZU82>IE,/\<2.]B2#7V@8SJ0A2%*0@ 4
MI0 I2@'8 *4  H  ?0   !^( SMD[G*\8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,CO=^,&K;KN?7O(([6;J^VM=K&10MU)EU*X_M];.V706HVP2M43IW&
MFJ&6*Z)$2915;.6Z(LWC='S$5/SKO*'5TWO>W\;7Z\Y3]L5AJTE8>#NL5[A;
M[*K;F/2>JVC5\FJY69W*)CE#N&,LFS41EXYTP?J.(PK% SH)&9CJZZDUKL:9
MHMCN]+@+)/ZRLR%PH$W),BJ2]2L;<@D+)0DBD9)XS,J00*[:E6,Q?>6B+UJX
M%!$4]-Z[QGSI+7B>6RDUM7C(6RI41RDO&04G\%1DE*R!C&J.A5O)+%6VM:ZB
MU>32[>_6I::?7:*2M;1I=-*LSW*:I!:#1V=9[F2>*>@L]0QQW);-:9985AFR
M+C(>[O=\X*U<ALF@XCC]LS7!(:/1<ZPOCVW:]OYIA$SDTB\A]BL3S]861>E]
ME2:,I:NLDV7945'#H3 H7)&XN1>N^/%,K5VW8YE*A$3LG'0;]]#UNUWF)KDN
M\C%Y%P,Y)52 ?'C8-H9JX:A8I)DP8+K V3 J:[M)OGTW(D]P9Q)62MT9)K*>
ME7*$D"1+!)A9/CY'F'3L>HB>2]^!QO83C3C6/4W=G=^<=36Z:?W^WCLQJCO3
MLZF-!L8IP)!Z;"L]:R5D%2Q.8I?#/6,QYJ_;6L]U5)K>]37JL;"J#Q==HC/U
M.6;3# KYJ"9G<>Y.V.91E)-"K(B[C7B;=\U\Y('#=/S">+(0" ^@#Z_'M](=
M_K#XA^G-E'25%DC=9(W4,CHP='5AV&5E)5E(^002"/D'(>S6LT[$U2Y7GJ6J
MTCPV*UF*2"Q!-&Q62*:&54DBD1@5>-U5E8$, 1G.,8SUF#&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC*Y>8G _C+R-N$!L[D)?]@0"K&/B->UIDRV
M#"52JM5)*675;L8YC(P#LJDS8I1\4'BAG:SA^+=DD!2-V294XY=0G6L5IS2W
M31U= S%EGH*B=3SIYUJ$D[?*)S5C4AXW;;I&+:R,FBS8$>#&L?9XUJJ+1-0&
M+1L1<RRI#K*6\W.A4W8<<QB+O6XFT1L9-Q=DCV4RT*\;LIZ$7%S$2[8AQ#RI
M"-<&%=DY((*-UNRB8@<I1"I_K/TJ!V3JGAEKRTA-#6;OU.^"-9G_ )-VFT4>
MP^ZI;:KE!X,'=*1,5VYU.5!,PBRL%4GX6P1:WA<Q<FS=$(L69M[S9W=5K]39
MV-VQ1USRM5H3.#2IAATK5$![1W\YC-]*AB5;MF)(A*>@U5';;'<U=;2K;#9(
MBV[\*,+EP^09Q;<_#JACA]'Y8J%*CQ4 &X55P5NT4<BFNJ5%N=84D$%%W"@)
M)"H*:+<A1566.!?"DB0HJ**"5,A1,8 S 2?(6*<Z8)N!K3[<(R%G7I4#1WS5
MG%VV1MB^SW&IH&%>MW;D&D$O*6DC87AY%P!*^P76<2G8[%PEF3M:Z^KFJ=?T
M[6M0&?&KT:NQ58@!M-NM=]L8Q4.V3:LO?=TO4S8KC:)+R4R^USEEG)::D%?$
MN_?N5S&4'#LYH.:?59G0H:_/H*NMYVY7\DLA$1CBP1^R'NZ(G<M!F& +D%@K
M$5:5).Q$M#/2'0LL,^10<&:.B"\2KM@V "81W_!E  "=^N6B$)[=@/%09"P/
MT]#L_8 W74KJ':--FWI_Y3U[R2.UD1_E<<=YMC$5K12R>I*XII$R#U021'T"
M[KCUOS4ABNYE.7US:8B-UI-0U7Y 3"LA$+M-/62QV:1JL$U.DF8KJ[Q+APR9
MV-].5M$J,92;!7[ NU.Z=/H:-RWIG?!-KO'D7)4B?H,JI4JELFML)]Y%/E;#
MK:]FE$JS80/$KK)Q<L#F&?-+%5W8G?5YPI'@JZ>)R"2A,2I\,VZSVUJ3&TK1
M+Q.VY:$L.^H-2'AVS79DY7)UQ,Q)X]TB<SZAQ LS1U2DXF$6>&D*A Q$?[<V
ME D9N1RYIS1SG5[Q:3G;[-[$EFM-JFM:[(S49%1"D+0:6M*N(6.61ARD1E9]
MXXEE5['97!4%9E1G&@C'1J30R:VG7_-/6B]<?POK]3OV_P"[A._3/GV8_1/2
M CW!L GT/1ZL>W_L/^7W?RKKW_C7]IXG<'HD5C8\/=((3U:.Q0>X('Y.-24#
M;;\Q)S_C&,E<H6<>$/QAW^H1 /T  ]@_1VSD   [!Z!C&,9KC]:"Y;VH^_\
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MK)$R.%) ) /1(!_092]*]![@[/,&,5.V;FA/Q<7Y7NV+L7/?EM9(N.\AL#)
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M/U/'Z?/Q\O'X[Z^,D5YCR]-B=PG*^2KMS4]@=J-]M?S(T?4$WLC?]W[HU/6
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MW:JY[)B+>/9) !/>4_%Z)7$D"E =I<^^X  #VZD/-HH=P#U[ &Z   [_
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M7<ZF4_\ H 9&[F#Q^AN5/%_?''>=*B#3;NL+73&CE?\ Q<7/R$:JI59P ["
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M(NB0#"-V,[>IN7B;QU>&3="SKNDW;HCA64,J5PN!P5/21U;MN[0TORBU3==
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M=&=L9QW#MW >X?B]?U=\^5*3T)!HBXFIB+B&Y0$QEY209QZ)2AV[F,H\60(
M  @(B)NP (?6'?9DDCB1GE=(T7^9W8*J_P!69B !_4D8SZV,P1/\GN/U:$Q9
M7;M'!0G?QHQTTC-KE$!$!+Y$&$DKX@$! 2^#N'8>X>F85G>H3QRB53(Q\M:+
M0H'8"%@JL]3!0P@(]B*3RL(4?4 +\/NC%[=P\0A5=ASSA.J)78<LX]6<$@Q/
MMJ)G['7P($F:8GYZZ$9^?C[_ !G@NB_=U']Y'?\ NR<.![=A[_#MZ_DRNT.=
M\[8Q,GK7C;M>W"H!@;.'#99HV-W ? <PP\1/D\ ]C&-V<E[%+]V'<PD\-L:]
M\X-P4:S5B.T&-"@Y>-5+(/$9D[6VGC43D=NH^,._G(MP+B2;I#'K-D8<SEX@
MNX9H@FHOW3KMK\6>,^VL2Z.#?<GLQP2R05M+QS?68YY40M%$;WY9[.))6 4S
MF5TC4ER& Z/PRKT>@S'KL!48]_[>NO\ ><L]8N(U9(PQJS)5 BAB'%DHW.B1
M;T$Q#"W,9,JGJ F*(@?L("(>H"/]@F* "(CV  [B(]_" ?6)O@ ?C$<HOXU\
M?N52LG9"U"1L^AXUQ'MD)F9L<5(Q)9<Q7)5&S*-AG#4';J0;@*BYI-%%H5FW
M%1J,F4SH6JDO?W"%ALYB*[4Y);1N/C["X:-%UV;4>_J<A!F9:?3 H^H!X6*8
M 7L'@ /0(OCWXB\PY%JJ]VC^%NVBEE,JL;^ZUFKUX$<K1AHIKJ1;*9" "Q73
MA WDL;2J/,_%D=@#Z1'?[L /OU^O3?\ TY-2Q;9UA4BJ#9]A4N!,EW\:4I9H
M9HX[AZB!6RCSVDQ@#_)(D8WXLP)9.='&FNE. 7X9Y<GH*%;@IN3 P^GH1X=D
MTCA[_ #>V^'X")@SXU<X <;8(X*O*W.6A8/45;%9I,Y3G^DRC:&/"M3=Q^)3
M)&*/P$!^.9YK>A-+5(I/D]JVB1RJ8@)'1*U%N7H"'P'VY\W=/!,'Q\0KB/?U
M[^H]YOS_ !9O_P L'!>.QMW_ )V;=<CMQ_;KZ8X]%5+?/SU(Z]@_[?O\4_HB
M_P"UG_\ \?UR)2_4&AIM86VLM)[5OJQA\*0IQZ3)!0X^A?\ P4E9G!2F'U^W
M1(8 'U !] _,-X<XKF)B4SC;#U!LKW\MY=GZQ5D2#V\)S)RLO6!\0?$0]VJ^
MGP(/QRP]%N@W3(BW23013 "D21(5)(@ '8 *FF!2%  ].P% /AZ>@9^O8._?
ML'?Z^WKC^R',+O7YO^)6X6,]%H..Z72:)1WUY*MB>ON+H'WZ860W]1CQ<_>0
M_P#A55_YAC_QRNGYMNH!=B=[#N:C:]9J#]NTK+-!9XB ]NY2*QU>\T3!] A/
M"("'H?Z1C[%]./9GR^9I3]LJ;ZBEF$7<O/-G,JE/RD6"Q';Y%*#4:&]EDI$P
MK-#*GG%4FQECORN%C$*B>YG&1M_\&.);AJ<N\M\GWL].=9DFW'(]C>,B@J9:
M[0RR>VB@L>$8G6K!7D<1H!(H7H_#"C=>7DW1[^IF/_#OKY_7H9YJJ4ZK4:%:
MUZGP$56X5F4"H1T0R19MP$"E**JH)%*=RY4 I17>.3*NG!^ZBZISF$P^EQC.
MJPPPUHHZ]>&*""%%CBAAC2***-1TJ1QH%1$4 !550H'P !F7&,8S+C&,8QC&
M5.]63[W^ O\ &M=/_P#:VOEJQ9%@;RO"\;&\]XO'H]ETA\U\V]H]H9I]C_;N
MD/97/G-R]UDO9W'F$+Y"W@JIZLGWO\!?XUKI_P#[6U\8RV GW!?S2_J#.V=2
M?<%_-+^H,[8QC&,8QC&,8QC&,8QFLIU<KGS,V)OZ/HNOM-<SZQI75>K]D.=5
MW+4O[W5!PVU.;!VM9LVD;8A+\I=F3=FL>EJ=6D;K&WVN0U/I5Q;2S!_+A"6R
MNMD'S;8.X_O=FR6B=+2.ZD"-MQ2&I=;OMKMTV<=')H;+=TR$7OB*<?#NY"*8
M$2M:DL0K*,?OH]J!019/'+4B2Q]:CKWZ5;;IY.Z9<:_O<C$;@T/P@Y>\CK="
MS^G:)N&G1?'O7CVKQMQD:*QOFW]/-8C<]\?6=Y16#)E(S,':ZRW69[#<U>O1
M;-Q-;%?$(E%2XG\8T]7V"RVS6B?'K2I->6FYIG2N%EHI-9U<M1L%K343253L
MLS7PCI*=(HDDH25<NR&3*)>V,9(G&,8QC*9>;/X7;HE_RE']6"I9<UE,O-G\
M+MT2_P"4H_JP5+&,N:QC&,8QC&,8S1,^R3^&/++9W,>7Y'ZXT-LRY:/H7%^A
M$M>S:U&)R->K9JM.;(D[.H\!J_&823@(V38R<RX9Q:Q&,>J+]<Y6K=PLCO9Y
M_.Y:-GB"S9T@BX0<(J-UT5TDUDED%B&251525*=-5)5,YTU4E"F343,9-0IB
M&,4;5PWE=KAN[CW52K!<D6"6L\%@R*C0SE/5\6C92LGBG2,0ZJ3VR.!UE<Y3
MQRORG4OJK,\M93-'82:$*726'R,9(8$,ODW;*"I('09>^\K4Z/>_-7[_ .G1
MQ3EM9VAO8_F[TSKK3E\:=_+EJOL?6=+@JW:J].,CJ*.&CHKAJE+1JRP^5,UZ
M4B)]@HO'R;98UF0B =NX@'?X=_[?V[A]>:?7)/5^R?L?SF:7FEQNKDS9>G%R
M2LT97>1^DH'NX0U38))ZNHS4@6:YP;1R+=\]D)C3TL91%HU67GM-S;EE%RU-
M7/LEDC:ER^9\6N2FF>0UU::M@7;O:$(AK&:(SI>[*_;*PX@FT+?VJR1)$S*%
M*\?K!%?WNF8.S(KLI9))U'.6 ;?*--62S'O]?9:7CN_>Y;HVY(R\U2X \]C2
M;!(>Q#?K3LL(/^:GKO%=C)B,@CUN/[2<UWTURNJ;S2I5K6JJ/X1V:O:0P[2F
M\I!DJ30@RD?SQ3(]9P)/#SET @(=P'N&0KY1=13AAPNL55J?)W>]=U+8;O"R
M%AJT9-0MSE%9>&BI%*)?OD5:Q69ULBFVD%TFQDW:S=<YS^)-(Z8&.&5]"ZL6
MXXZ?:TJV;CO.V"5MW;K!);-W!,L7-E4CY>:DK*L29EB TCT(FM-7:C%FL8K=
M!G#LDCNC^)-=P?3&ZB*<MU_NH=1-4\"&"\]K;C90Y>F[)Y)69-W'ZE9)V"YC
M*/+/'JH-U9.4A_%'>[:.T;D)-;+=)R,I Q[2H1JMH/ZX;QFAOMQ93:6[%7C>
MM@LV-IO( L$=6)4=:;N]J*1$>W8$<<5=HVL2EF2*,LK%?G)]_=T^LKO0JPS[
MV_+!#0U,I:=YY69#815K.C.M>(NTDX=88^@SL P!W8]);MU;R-U;4-UZ4M[&
M^ZOOK%U)5&W1K648LIIDRE'\*Z70:S3",E$2HRD8_9F*\8-E!4;',4@IB0YL
MJ9J,:KUOU_>DE0:[JW6&O-%\^^+.O&[UO6ZC3&QHW85<@I"7?SCUG$,R#3MC
M^V+24C(.2-P9[B3:'="BU\34B""<K=)_9*?$N4LA-:\P]4[PX/[5:JE:S,/L
MZG3EDJD>[#^#,165AX2/O,8CYP& SBPZUB6:"?VZK\2%,H&6_P "V4DEJSQF
M2MRC4I+*U>737(;^PCJ>9,'OM8BP;&&QZ13U_P#$%B$GD$/B5[QT^8T$2O!O
MDL<?V+QHLL>SK2U*<E@(IF-2\QEIR5_/R,3-:\S& 6 97"WB\@-[Q7'VJUFU
MR])V+>VUFV/1M<)QVM*NO;)>*<7>8)%DLLRQ;K(G852 2\^2L,TH(MHUD@*C
M@R29_-)QI;>T;NF2V]&,*/L6EJZ?VM8-422M_K"M<;VI_7V[-=:STI51=8M@
MIKXSL48R?;?W&]4;K @HIX% 3Q:]ZA?!AAJ^*W4\Y;<?$=4S,VQK4???G5J1
MZXI99*/D)5E75WJ,F<6,ZM'Q4D["'D4FD@5%BZ,HV(*!P#*^B>2W'_DY 3-J
MX];BUYN:MU^;^3DY.:ZM$=:HR*GACVDM[H?.XU99%L_]VOV3[V4Y@4]F=(*^
M'PJ%$:O)2L04Y'GU%Z(QRM%)>E2Q'#')YQ]0NKPB-9% ="K2!B9 ?$% &GX[
M<,UM%AVE217C$B4XV@DED3P;N5764R%"2C@A"H"D=D,2N<<Z*)IK)G25(11-
M0AB*)G*4Y#D.42G(<A@$IB&*(E,4P"4Q1$I@$!$,[XR+(!!!'8/P0?L1^QR2
MRK.X0LSP=W 38U19/7O'O94BW87"N,BF5+4Y-0ZJB0,TA'RTQ9"HY>5=0PIE
M<,!D*HX.4Z<2NI/K7.Z]5[:&1)KNZP]H6B2H*2+1F+IL_:).!$J#A:/D&S-\
M#90Y12*Y*@9OYQ11%4%2B3/B<BM7R6X]/V_7\/)HQ4M+HQSF-<.S*%CU'L/*
MLI=NSDA1356*Q>G9@V75234.W\PCDJ2PH^4>MW3O /<:;Z6D[9?7.HEDD/88
MYQ29<TQ-RB:BQ3N@<NHR0B4&D28$45"('>+.72Y4S+,VH-P$_!YO[;<!Y<FD
MX;Q6;D7"MUZFV%7U$J0Z"_*UH[&AKMC+,E+74YI5@V$=2]'Z+2V9J^O],L_6
M'ZT<*J^4;?/_ +)'W /V /P0#]SV!EQW</Q_S#_JQW#\8?E 0#](]O3*[OW#
M-X_\Z_;W^EE/_OCG13@M=E4U$E.5FVU"*IJ)'34-)G3.10AB'(H0;EV.F<IA
M*H0?0Y!,4?01RX_VHY]U\?A?;[_][N- =_'Z^X/7Z_/1_3XSUY/_ /M__6O_
M *_?_P!'XEE6>0.E[E;%Z/6-CUB9M+<7A?=3-X<3N#, .+PD<Z41382AVI$U
M%%R1KIV9-))54P>4D<Y?KV7<^IJ<10UGV1280Z0")F[ZRQ)'@]A["!&*;I1X
M<>X]O"1N8W?Z,J?HG3MV@XOR4;?G\/$4"/<K&=V.MS23B5F629%"-T(".69&
M7BW+ONF5=>8;E1CT16*FE(G\LIYPUG@3QLKHE4<5&1LZY1*/G66Q2KHIC%^D
M[.-5B8]0!^DBC0Y![!]K\<KO&^4?C!O:<[6>#Z#1V([LT"V-WLMG0C])!&4*
M:R*E?MV0A+*;:VJ]:S_- B*I8^5:9@>XU4]_!9B/^ ![_O[ .?G9>?/&VO'%
M)K:I:T+E$Q?*K5;E'!3&*/8 ([E4X=B<!^)3)N3D,'J!A[AWQT/.JTVLQTM2
M\;-G7'QC_ /GZ+AFS[ /?Q*!#1,ZCX!+V'[:12^Z]1$.W>9E:T]JJG$3+5]=
M4J#.D  5>.K40BZ'P]^PG>"U.\4,'?[I1<QOK',C@4H!V .P    ?Y( 'P "
M_  #Z.P>GPRP_D?XE7_JO\WU&F5OYJ_&^,)*ZJ0 0M[?7MC]0Z/3BBOR2>AG
MKQD/WD"_T5!_S8G_ )9KINZ!OS96Y$(6\U'8$C9+%<62\XPGF<\2*;LW$@D\
M>@H],8L,QA(Z%65(BNS=HMV<<4J3-0BQDR&V(8^/913!G&1K1NPCHYL@R8,6
MB1$&K-FU3*@U:MD$@*FB@@@0B221"E*0A2E  [9BVT:D3L[NZ.CWF_1 7.(@
M8DS6&L"S-I7RP#L'9'E>;^$R3%Y)"9=&3.<BR;A%8Y2)HF$YE,L-TO(010\Q
M17R4DTA55.=1504R%(*BASF.<ZA^WB.<YC&,81,8QC"(CH_AK^'IX+9Y)++:
MN;.?<VHYOS._)6>S)#!8OK%$_I!I6D=)5N6)G=$E>TL:UHI*\C2?(X_3\CV2
M6/?9^_QWU_\ ?_;\ =9\Z<@82S1;N%L43&SD.^3%)[%RS)M(,'28_P"0X:NT
MED% ] $!,03$$ ,02F !"EFT\,H>(VI:&[G;NNX;65:GX=[8?:Y1ZE;:S V>
M4*,17W$05B+3WBY15&+CI )0K84BI/G*2"GB:Y=[GGGM2J\B>34D*["/5)H&
M 3!W<6R<&E0BC >,]XF51.+WW<8 ,Q]H%3V,P>)OY9O7)7G7X>Z7G*:UMC3J
MS6=98DFAFF-F,O&T$G565ZDL,LE62TM5IXF<'T4F$#PRN)!Z>-9.O(=]?;[_
M .[X(^/MGY5*HU2E0C2!ID%#UZ";$*+9A"LV[-H("0O9<_D% 7+A4I2G5>+G
M5<.#"*JJIS&$P^FQ_;Z_UXR^000UH8J\$44$,*+'%#!&L4,2*.E2*- J(B@=
M*J@!1\ 9[^WVQD<MR\6-2[SEXRP7./EV\Y&-"QWO6O2RD0[?QB:JJZ,=)CY+
ME%TW;K+KG;*@DF];><JFB[(D<4PD;C-+;:;5;ZD^NW.OJ;.C(T;O5NP)8A9X
MF#QOX2 @.C %6'3#Y /1(/P@,.F (_8CL?&1J/P^XV*M6S-74M9,1J@V0(L4
M9-!ZJ5JD"1%';YM(H.7:ZH!XW2[A0ZKQ816<F55$39XF5X#\99(#>529&+,)
M"E T;;+(GX1!05!.4CR0?)^(P#Y8^(AB@F  0I3 !LF7C(.QP#@UI0ECAW&)
M0!XCRT6L\@/CX#BL''P.ATPZ_3],\F-#]T4_^$?_ &R #OIR:0'QGAK!LNOK
M^(ZB1V-CCER)*CV%$Q0=01UA!OZE3$7 *F WVZHF#Q9\T.!#^,'_ (*<D-PP
M!""0J28OE%RD13_A$T@]WR\.7[1QW5 0(5, $2E2 W\)EB.,B6_";\/"WG'Q
MBI4;OOO7V+^M(/77Q^7VZW7Q^W7?Z_8=?/2C_10/[NQ^W[$?L/\ G]\KN/Q8
MY0Q F^3O,&TN">G8DZPF7 =U1[N3#[1/31>Y1 !0[$$P=S% Z("(CV^;'J"0
M9#&C-\:^L12B*@(R\0U3.H(=DB)^-Q1U1*44_P"','M10!4H@)U!-XC6'XSQ
M_@OT$7_0-IS+5D=>/L.:<E55Z^WC'9V5F/KKXZ96'7P0<>FH^Q=?[G?^G[D_
MM_NRD[D]&<U5Z[ ([2%.6K+647324U8DZ4;N)/R"@V>65K -T'H@=,JP12CA
MHDP17.Z**2#I5N!L@Z+I7.Z>UO"-*_L)EKZH![6$,6]LS.;@6/\ /#RQ33D:
MU+S"$28_C&(2>NFRA6A1%!)-@=H4]MX@ _'O^@1 ?YP$!SG^WU_KRNP_@S7C
MY);WTO-N;SI:I1U'@_.[->^ZQ^B/"?<5I(K,]3J(%*HCB*.0QGD\>CY]'ZBW
MG)\CK^8@_I^H_3X^P ^_WRNL>'N]+27OL3EI>WB9Q#S8^NH2S-J8OVP&*3QV
M%BT+W()B@/NH0[G[F(( ('^M&=.G2Y3$<6FP[&N3WN!EE96PM6B2I^X^(P@Q
MC"/"@;N'I[P./VH?;CZ]Y_8RR1_A1P/R62WHSMY1]Y=[LMKO&<_'U,NUO6X^
M_C]$ ^_QGH11_P"KW_[1+=_[R<C# \->-5>\L6NJX1^HF !YL\ZE[ )A  #Q
M&2EY%VV$?3OZ-R@ B(@ =\S9":ZU_6?!\G*148'R^PD&'K<-'&*(" @(':,D
MC]P$.X#XN_?Z?0.WLL9:M?QGCFI &KT.FUWCUT:.LI5#\==$F"",D_ ^2>\]
MA57^50/[@!_RS@"@'H =@ .P!W'L ?#L ?  _%V_5CL ?  ]?CZ!ZYSC)OH?
MMGW&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&!]?Z/Z![_^_P#%C&,9!ZO]/7CA
M6?F^]U1EX+\V/(6V<G:H#G8UL> AM:[ L%B>2(.'Q_>]==>UOO9JC(^T5^.%
M\O[O9MO U]FC]U8_O?X"_P :UT__ -K:^0YZDGV015.G;R:G>-TOQ=M.U7D)
M0Z9>!ML3M6"J;-TG<&,F])&EB']-FW"2C ([RSNA?*$<&6 Q$$@((&SWS\V.
MCN+C_P!*_;;>)6@6^T>HCTQ=BH0;AVG(+PR-WN3&SI1*[]%%LB]6CB2A6:KM
M)N@FY.B98B*13@0MCW&FY'4U^JVVXAL"AMHWEU5J>S#.+$;A;$C(JSRRQ!O6
M$C"5(R6<DCR\L@]7LM%/<V&LU<L'N]>Z)L*\,$D1A9!Z**[&)(W\5C"*4=P%
M4 'QZRZLGW!?S2_J#.V=2?<%_-+^H,[97,G,8QC&,8QC&,8QC&,UG>O71.2>
MSKIH]C0>*>I][Z0UUKN_WRUW6W<&JCSQN%5N[B[4&KGK]<U[+V6*L<.):K+-
MKLK7*U&OWNSX:!M"*:;IQ1V[%6\?4^P76M>(FI]C<BSM=;3%8T)K*=W&63AX
MZ!;4ZRI42NFN;)Y U-J>&ABP]@4?,%(FN,QB8T40912)62"!"ZE',+;'!EOU
M9ML+<R]+< 977"'+:)T#MVG;(X>2UDWLKIXW"BO;5CN9UAY)MWDHH]9I;@/!
M:'0I!*BI!IP!6B1A++IC-!N8:F'7JNJ]:FU*A#M-5*:_IAM:-JXT4C(%MK\U
M;C!IB$&P,BU581"-;&,3C&9F[<[5B5! R*1DQ3*QE:=DZF57DN>VE^,.MK?I
MZ0U](,[S#[6>2MRBB[4G=H/=%1^]=74G5](/+,I?W:RI#ME,7>S2T0LW>S5Q
MJ5'K"+J:BKV-?P+5^<?.J3H$*_95[6>PKAOGC?H;F'KHFLM33UXD]&ZRVC=%
MJ_?Z4_U6PW1 37(N3H,/,ZY=UF7B+QJU_=7LGL:1%B@UI\977]UDWK&AV.XT
M?8$U6H]_<M;O9^1I-@4\]-] O;177%3GG"!D%DDG)Y*NNW$6L#])V4B"@F0*
MDL4BI<.ZIX<<=M'1UXC=34)>CH[ KY:C,KQ5SOSA_$5!NO97<73:#(RUIDGN
MKJ379"X6>4JE*ULM5*G4Y:;D)2NPT:_7%<&,C7PPYXM^05H4J&TI_6-#V7/U
MFOK4W3<"^>2DTZE*;6@)NV9;V\SUY7+ Q6V -C1U]6XITK.O]34IGMY#WU3[
MHRFFT,N4^\Z=>>NGTJ-*0\3L1I;=*M>>[RVRMBUA?*QK^41O'$NFS$.2@;*G
MH%A1ME.6C54$[(UHT[.N:J][,+$E&NC)IJVSU+A[QRHFQ:_M6HZU9P5SJU=A
M*U +LI^W!7XQM7*"UU5"3+>CJ6%2BA=X[5[)KK9OL4]:/?PU^B2EFLIJUWC!
MK]YLA_A=NB6/KZ_OE'TC_P";!4@^'P#X?1]/<?B(]V,N:QC&,8QC&,8QC&,9
MX#:FK=?[LUU<]3;4JD1=]>; K\C5[=59UL5S&S,+*(BBY;+%]%$%DS>6Z8OV
MIT7T9(-VDE'N&[YHV73TY*GR-VI]C7\F+WQEV]&7K?\ P'W0UL>U.-:T#)P:
MU[J4@63:MI5FU+8I"(B$I!FX<M83:,*+V/CYAZM7=HUXB4G8;'"N-UK*K.HO
MTBN.?4SG]56+>=SW)57NHH>W0M<2U;/U"%;/6MS?U^1DU)HEFI%M4<+MUJXR
M*Q,S58IIIK.@73<&.D=*[\+WFLH6+.IY,)+'%-K&WYE5C1Y98;5>-WH7Z/@R
MO7N1SA(6FC/U599HY5D7Q"U+E>IV%N"#9: QP\CUSCV$[NL<<D$TB);J6PX*
M357B+2B)Q],\<;QE6[\J)+KRKY<_9%%W;\9N*58O'%;@-7W,6KR<W%9S,'%H
MLZIT$WZE%DC5^46@I<ZB9R&KNIX2:?H3JIVUMVG),*NWCH(^TEQ'XAZ+X2:5
MK&B=!5%O6:E7T"K2,DN"#JTW:R+)$++72\SQ$$'%AM4TL45';Y<B;9FV*VB(
M5E%P;"/C&O\ #PMX@:OX*\=Z5QKU [LDI2Z2ZM#]K-W-:">6Z9?6RS2EGDGM
MAD:]!5N.D7:;B3]W-7)8E!8D2PC6BQUS-05-*K,/)^1U[W^1=!7_ "SBE&S(
M]&DC.9;TH)3\UVLKDRV;TZ=>*R$QTX2M>!5"N\F7C^CGJ ;3<S"_R*W!&MRT
MP7TJB^*L:&OC7Z(*L+]@F/IK,G<TK$LJIP( (=A !#ZA#N'].84W9QMT#R1K
MBE2WWIO6^WZ^9)5)&/V%3X2S^P"M]VM$O)-HO(0KL!^V3>P[QB[2-]NDN0WK
MF;,94H9IJ\B302R031L&CEA=HY$8?9DD0JRL/T*D$99)8HIXVBGCCFB<=/'*
MBR1N/OTR,"K#^A!&:F'/W[%_TW?(R-LG3X<QFD;^^N#3Y6T_:6QKE(:<^19X
MR6%X[@>U4V#?(^RM)L8CV%D:97KX0ZLL0K5!RFS*?]OL9R:)Q\G.<G3XVXBM
M5.2>K=V*7Z6J[TY0;S5995ZNZZEI.LKG\M:58QTI"0\P+P&Z2#RM7:I3+05$
M'ZP-]LG-6CKB:8OW#KD5Q\ZTO&N#6<6;4%BKE!Y35V,]H;MKQKB1.6MP<O81
M:I]C,9:&?N]3V62=K&!K[?K*233(-:\]/K&DY9N.8:RSP+>[)[7YE$&T-ZY(
M7LINZLBV*-.W;E8O+6O^#T$,I9XIIH&5N@V<XVW&M7QG8P<RT]!8&I.$V]2L
MH6!M5.@@M6*U9%"1S4P4ME8PJR112J0.QFTOC,5:.W+0>0VH-;[PU=,$GM?[
M2I\)=*K)@*0+*1<VS3=$:OT45G!6<O&+&6BYN/.J9:-F&3Y@OV6;* &5<Y-+
M')#))#*C1RQ.\<L;J5>.2-BKHZGHJRL"K*1V""#\YTB.1)8TEB=9(Y$62-U(
M971U#(ZD?!5E(((^""#C&,9XSWC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&/A\<KTYY]3SB7T[J<,[OB^)*W23CW#RF:<J M)O:=T%(#%(JP@#.VR$%
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MOB,;AO&XQ1U&J[PT@FDM&R%M*DHHVF[(V2E*SI^+=.*C3%9G8$A8+*UG^+Z
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MFN4_8HC"HRB!P$#I+*)F*88O9<,Y-JH?=6=38EI$%EV- Q[/7,OZ.+VO>S5
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M-T==+H]RI^QU/(M+:<_;X$#78K)/S_+Z'D/U Q_;331_%Z/;:INR"-CIME
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M^?X' OBU\FO"$\R+#NAXU)0#I^8"81JAR^U]K$LZ$^ _E_[ RIVN&-8V>MV
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MZ1>JO57[_-?_ !7LD?'_ $@SCX'8/9[GOSBEX:A?[,Z+O6.&M/ZF_P#/>@!
M4VW^7/!58HS'\H75-W(X5E4(J8&TE:N05CK=B>;UU-1]:69E)&2K</3-H+;!
MCYN,]V(K@Z?RB]4KYH5Q[T%9C[.#>0 6Y2O.Y/\ $GQAJ?8G->=OL/%[>XWZ
MCH.O72<H,S:JOO\ =7:=BE$8]RO%%:UM37T,G* \D4VS!R/O%E[*BX4? )P;
M^SJS(QGSVTO5<>^M_P  ]N>JG=H>2MU8_P 4Z  !3_%Q7/BS=DMXLOW\ZH^6
MW;^R^@ZV<82JOJ<A\=&PBDC,NI_R_P"3.S.)R-NVUC]6*,!!#ZD,D$.I/7FU
MMXA[!K,B]V'$PLQ8M4HV":UWKF8W :(@6FUJ;*2CC8VJJO9:E<]B:(=-X\8G
MD#4J7--;-+Z:DKHBQ.FB#I=&C1MO/EMI76XP&BZ!&Z/UW+;'Y#VB'VKH'4_(
MBNZ4W/LB&UYHE?6D+JG0&P>-'+F]:<IE@GYK9#&VZ=AJQ5:[N?:-$L]@UGO2
M.=S%E;36UP;_ "?S@_[<Z?Y:GY/_ %2YMY 90=/\N^9>F*ML.Z;CL%_E;%L7
M5?4&9Z>UU2>,LG886H[[TELFG5CC?4JFG5M=2]WFPNM=>6^P1+K:DLO%7F%C
MVCYNDW]T2SAYYNZW3J6"S7V-$[_WC' 2$Y2;10U;#\<M)+UY-[HCFG2-8ZFU
M*+UYI60O#NI;6T79[%)V,5+$.P+6W@XR[:_MU491LP25V&2_ /R!^K.<8S7U
MZH27+K8O(RHVOCKJ6ZW2N=.6G5+E4@M%6R?H;386[YZ_M'TOKZ"A3P:S3>3A
M+B3K[<^OG-1A)!-NRLG(NOD</"3Z# K#!\32N12[6?V9N6$V'L+2^R(3J:1O
M!FGT^G;(K<UQIVO;]A<F;31;GOVIOGSF3N6PN0>G)J3KVJ-G24-7:SHUTQ8Z
MFJE>^4&Z_EI8-G@?\K\T/_6P/W1?^=^K&,UY^(^AN0W&OE1JMS6]#Z&B"WG@
M)7VJD3J!OLCCEIN8FH+<>ET;^_WLZ?4O;;6S[VI]4L))?3R+=A"32\&KNN'F
M3@UF64I!1#+49$C[63NPZ^Y,.(%'8,S^_'MY;5FS7L?LE1'EDRG-9NKC%$K#
MEGN.MM%UYQ:57U:A;(IMP\6;0,V<=1^Z(C-M;/R^@GY1_6&,92/Q0USL2)V3
MP8MAS[\0UVPKG4#J=-JVP'VP4HRL:$4VZTEN*BM\I]C32]P7A/3ZM=@*H]N;
M=O=V=(:L:L]*B^92K-*[W.I?@/YQ_P#KFSMC&,8QC&,8QC&,8QC&,8QC&?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g249259.jpg
<TEXT>
begin 644 g249259.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@ _1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?1$E!0D5415-?-$-?0D%2+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M"T"5B!Q#>&%)M:H3R<,;%I0J0S!FI23%PL>5C;-J V$?!^C<;_!/()EEDM'
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M95>)%(33'&);(Q++]=NY=#3'%(H$8A>-79MS^U""[%Z7%R2N2E.J4X,3X)'
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MOUZ7"5UB8MXE"@,0. 3I40-*RTO,K-".5H2@NKFKB><C /=)!H<+9HL-9I'
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M\#O,6RG'*M%M=FMW,MXZ+XI99)\D_%.&2?)/Q3BZ;FD< ',-3M&=3?2&:1P
M<PU.T9U-](8Q-"^2Z3ZG*_YCI\#O,6RG'*M%M=FMW,MXZ+XI99)\D_%.&2?)
M/Q3BZ;FD< ',-3M&=3?2&:1P <PU.T9U-](8Q-"^2Z3ZG*_YCI\#O,6RG'*M
M%M=FMW,MXZ+XI99)\D_%.&2?)/Q3BZ;FD< ',-3M&=3?2&:1P <PU.T9U-](
M8Q-"^2Z3ZG*_YCI\#O,6RG'*M%M=FMW,MXZ+XI99)\D_%.&2?)/Q3BZ;FD<
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MQ5V+:5$@,*"SA,3(J@51))N+A(P#Z5$2 ZP2))G4 B2:BI=L*(EPS%ZQYZ[
M_P!N'3V5'_QH9Z[ _DR_C#IY.QEZ51_DR\G]='&.[P?[. 3ZX4F[IO !D:J
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MC_XT4_H0Q?J!\=2'@]HM+N;+ATC#&*K XFCO5KN[G.[XCEBX6!X:/!*8#00
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MO\WV\W,B"$(>IE#\TZ,]0RKNEW;E&'KK3+.VDW7LT[U=VY1B=^<YQZ:RBO\
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M04E!$BJ*K@Z:A1$ '!.4P6@ V6[\6?A[U,\5!%X/,W5;<N!-:+! '+&#UVE
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MB.7 #(6RG#-8#Y&EL,,<8T:P*M:*PQ#? &*6NJTIORN!RD8.5(0BO!3\8GK
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M1;JLWPXBQ=IKM7K%^U77:O6;E%5N[;KJMUTU453E-"$(AI=X/+!??0H!M!+
MI$6C"E4"5D"+!HQ2#!4C<8E@R$%A!1Z*/+R@,$L*;\&!;D2AC U%(F^W!<6-
M]=3]:-+0)&'V:Z>%;#Z]UP7==)L2-7"!H-%@ZA@L2< 1X(&WXM5BDJ$)1Y09
@EXU/A071TLP(X.17RZR?DRH/2%0T&I(9BB^ZA"$?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g253653.jpg
<TEXT>
begin 644 g253653.jpg
M_]C_X  02D9)1@ ! 0$!A0&%  #__@ _1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?1DE'55)%7S$U7TM?0D%2+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( <\": ,!(@ "$0$#$0'_Q  ?  $  @(" P$!            " D'"@$&
M @,%! O_Q !U$   !00  @,&"0\5"PH$!P$#! 4&!P ! @@)$1(A,1,4%3A1
MMA8R07%R=[&RM0H7&!DB,S=787-V@9&4N",V.5)455A9>'F2EI>8H;/2T]35
MUQHD4W6&DY71UMCP)28G*#5"0T=6MS1$1F(I26-FB,'QX?_$ !X! 0 !!0$!
M 0$            (! 4&!PD! P(*_\0 9!$  00! @$$"0P)#@H)!0    $"
M P0%!A$2!Q,A-@@4,6%Q=7:RM14B-#=!4721L;.T\!<8-5)6<X6AT18R,U=B
M9&5WDI25EM35&2-%4U5CD[;B\4)$5'*!HL'2UB1F@M/A_]H # ,!  (1 Q$
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M3[$0++7&;=$G,].1$3<#;^0)7@4T6=C86LG8QG REM+3%8\62%0X9; HJBI
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MSME)"(;2H6Q+I<$$.9:B992]LY10I?7E2%HX1YE;ZW'CDAIX(>0\7FG>]9#
M<6"^[CLB^%%EPYJ).[&E 0&7-&4T:*-7==VE(BXTH.UI8B,W"*>"GD%!^.IR
M19'1%BZ\.E1<@F!=(",1&X[#327#S;YJRI,#:CQP!63B;<.DE/KG#CTA=ND;
M"?S4=4@LQUB/%S("L50HM9SY8,<I>3::2<TCKSNVY"E28%T:4Y8,I_HTF%R%
MW232'&Z!"QH%$NJ@++E<UCE* U^N)SK/!3"WGX5FX3,C=";.S,G<2^'8>?\
M,J.(J$GDZXORU<V2*",=7-!*-B@[?,%6J@%3A+$EAB=*I94L:R%!L+@+L A=
M80=[]O<\/>VJG/BS?13X./Z[Q#GX,>V57& _.@OK>'O;4![*4I0"E*4 I2E
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MIM\3^\'V4-<X]>[ZTE9"\Z%GT3^$U4=_S:7%-^#W<N)A2^81.3RY?#N)(F7
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MHS2<2N%3$S=R)81M-Y[JCE+]U/7,I .*.KW);"(/SH+ZWA[VU >RE*4 I2E
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MAX ERI,GN1/A4H5+ AVQ# +%2P()<N 'CB$" $&$'CCAACC:].@%*4H!2E*
MJ-XM7XQ(;^SIP^:@E4<U>-Q:OQB0W]G3A\U!*HYKF1V2GMN9_P""8/T+0.RG
M8?\ M#Z7\8:D]/7Q7./;;U[>[7%<X]MO7M[M:&).&S+P]_%(BK_+3S]<M30R
M[+>RP]_C4+^'OXI$5?Y:>?KEJ:&79;V6'O\ &NO/)G[7.@?(S3'H6D<%.5_V
MV>4[^,'67^\61-->0/Q_OW[.GKYTJ]=1KMT@?C_?OV=/7SI5ZZC72"K[&K_B
M(?FVG-"Q[(G_ !TOGN%34X>'C@Q+[%[^8#FJ%=34X>'C@Q+[%[^8#FJT:JZL
M:B\1Y;Z!.7C2W673WCS$>D:QM"4I2H6DT6]Q/ GR"E*4/12E* 4OV7Y=OJ4I
MSY>Y0&L#MV1:8>Q>^$1G6<+GO5/FVG#JD;1=8%:"F:>+BC.,T;6T,J[(P>H3
M<-!MYDP$^&'LLXI>-D5D@49Z.I.HXYAB0$@)V2[\F4M7D31EP33E'QBTR1ZP
M2T%S!-B6[V(U8KCE+9:?L*XSVKC"FE]0?&*Z[Y1+,V37L]-G-I)I=+2D*108
M*@IK(JNW,RTGNQ8<^TC>V//KOU]75SO:U[^ISM:_*][^ISMU\K=O*W)\QETN
M5[7OU6RZ.77U7ZO2WYVOSMRZNN_+EZE 1FT\GE8V8UVC^:%QK)344G9=SEQ"
MS;6%UPLM> ;#R<#2*/R/' Z6BP7.O1K(A-#!?4=+;@93855=G+Z,?,)0=A\#
M!B@/8MY\5%1XR>L]F) >CZ ]TC5#>PA#]I#V2FA2:+WAN\P:\8*SF>P[-U]S
M7&+(F&!1AB);23"CO0#'AAQX''81R1B-SNTO:UK6Y6Y_;O>]_NWO>]_MWJGV
M9_R;S17]0!OU_P"[FH5 1EV"ASCN;"$VJ37XKX3:+@U3BL<*Y)^QVX!O(SFK
M%B987$6PNN)/H8A8D\,L.60G.^>7S.'7?*,OR /&X_\ 17"N_?!;=_V 5M;T
MKYNBC<JN<U%5>ZO3[B;>_P"\?1LLC4V:Y41/<Z/=_P# U2/D >-Q_P"BN%=^
M^"V[_L I\@#QN/\ T5PKOWP6W?\ 8!6UO2O.8B^\3\_Z3WGY?OU_-^@UZM?X
MDX[VOR0Y$E!BGA-K03D5B:L8%4-C]P2F8 I-/LGX!!8A:X&^GAF':V>65\P^
M675?#+ECE:0/HHX_OTD.$7^^:W&_W9JN4I7T:U&HB(FR)W$/FYRN555=U7NJ
M:T\Y\0?C0:^OC%@/777AE**UDA)C@L8;.PVTIM-L251CX!<*XJK!J.:L:#S3
MA^[X=Z7"MCD%D$,+;++HX;^6[\7/]#-PZ_W?=D_[(JDOQ/\ QF@?:R9WPDZ*
MKLJ!G*)V0W*/IK7&I\!BY\*W'XG+V:=1L^);-,D$3F\"22K.U7NV[KN%-]UZ
M#IUR3]BER2ZQY-]&:HS-?4#LKG,%4R%]U;-O@KNL3(JO6*%*[DC9ZU-F(Y=N
MGIZ3/GRW?BY_H9N'7^[[LG_9%3Y;OQ<_T,W#K_=]V3_LBK =*PS[:+E5_P"T
M8#^A6=[]\=[\Z^^;"^TMY$O^RZG_ *P2=[][=[\Z^^6GPOL3QU)V8";)#.@7
MA3$4)5.K! N5<6R6W)15P&15$9,-9C INNRJ3Q"$, "9%[X'1,\@NCD+@%EE
MT*RI=T\?RUKWO"'"+ZK7OXS6XWJ?_P 9JE+PW/%19OV1/WSN4ZG=GZ3+V.7N
M7J?NALO<S^C-*YS(+&M_+Z?Q.2N+#'S42V;E&"Q.L<>[N;8LDCN%G$O"FR;K
ML<MN4?!4-+\H&MM-XM)FXS ZJSV(Q[;$JS3MIX_)V:M9)IE1JRRI#$Q'R*UJ
MO=N[9-]C5PDSBC\86*7^[8X<6MW#<.+C,6!414-(VP&SHZ4.;"+EC.0A 8_"
MZ<<$+Y!F@[8Y&2)47I6SMD#C:UKY=&^7#\6S]#+P[_W>]DO[)*_7N9XU4\^V
M"<^"4>HS5+[%<ENE;F+QEN:.^LUK'TK,O#=<UJRSUH99.%O-^M;QN79ON(NQ
M#;*<J6JJF4R56&2@D-7(7:\2.IHYR1069(HT<[G$XG(QB(KMDW7=?>VD=\N'
MXMGZ&7AW_N][)?V25QEQB.+7CCEE?63AWWMAAEG?E/>R7/EAC?*_+G$EK<^5
MK\NNW74<J]8WSD;ZR+_%Y5<$Y)-(*J)S>1[J?]>=WO\ 5][\Z^^4'V6M7_YS
M'?S%O_[/KNO>VNK:\D\>]VMENNM,@WA*!)KF0D=PIX1S9?<(,X$26TXLIE S
M88.M9@' R&7-!X&, 3 X.(V.=@AQ@[8B9*M?@[Z"T0^U?'_FDCTJ,5F-L5FQ
M$W?ABGEC;OTKPLD<U-U]U=D3<D[5D=+6KROVXY((I';)LG$^-KG;)[B;JNR>
MX9+'+%S-@K& 0ANXC!& NZAX"=R'!SMF$,'T\;] 0/.ULL,\>6>-[<[7M4 G
MUPP]0GRQ8PCRS/?;&0(D2)$:;3,15-4P1>Y#$=S N!N.68K=3M9+T1W*](OD
M=: **+I8[I4U1&,'$]--D D\T0*CAV!WO:UN=_X+7O>_K6MSO?[5JXZ5K6M?
MGV^2U[W\E^=K6YVY7ZKWO:W*_;RKX'W,%.36B$78+&H:ZP$8VA1"T'BQX\98
M> I-@MQNOIE%XU7295D$A"[;%RPCG!082.,83Q<T!H.)T(2-WD2<:K@8Z]K3
MJ5#VJ*(XD6*PGX<S=)Y),++@D^4Y&F-XCIC82,&\RVH"\90<KI<91EL5O!V1
MF>TRJB$BH9<90-@E<U9865)0DOTK=G.W_%N?N=?+R=?97-K\[<[>K]K^"_70
M%-W%FM;XZG!QOU\_EO$.^K?EUZQ[8^ISY>I;EU=77R]-ESN-!^=!?6\/>VJG
M/BS?13X./Z[Q#GX,>V57& _.@OK>'O;4![*4I0"E*4 I>_+_ (_A]:W;?ZE*
M4!")G[>FW/-\HQ'C&#L$&8Z)FH$"I/%LV6+G4$DJCN8)8-#O.Z+<NHF\VF0:
MF*:)F; ,. /T7A((88HA?J;$WGL[HMF*1\HZ<0A6,EE8#P,$ V^$G8H1L\8P
M:(JGW^] S)E2+I?>2HZ[I5[IHP U\&>87#6092IS L]IESN:B V&^"H""+8P
MAT)%30S>8SDR*9N(7,S@5L-D(O9D".:SGEG?)4R)E<CUQ[@!7Q_*&PF."1-)
M@3.:P2<=*(B><(!M](P)&B#:MC9NDC!7$G8 <H@VPQ\"EQ0\@4OHX]XX <K5
MKQN UXU6K^K6%R-DU(YR.P]7US,E'QX%FZ-V3U#L+PRNV5+U=.AE9?\ %IM)
MVIN39S7I]CV=CG1:18CFY^XJ,DQ$B1ZGE1KEZ4U+63CACXFKC+*KO)<;_C%Q
MQKE,(\YQ0VY!--T^W3:@6!** )D,J$0.K)$H6!<!IOAA*JH?P02Z_932B5ER
MY%;Z2<+<ZG@6N$(+G2OGIR2EI 0X"4G$4P$T>/*9D(@4+DPS"DJ&A#RDH#AE
M@PL!3J@=&&-G30ELAS1D40<<3,3/+*_T*S/$U[U3&4*V3NIDLC!4@BNWTA97
M;<M,C:V:PV!GK86RR(Y[8D5RL:J-<][D5[L S5K'7<OD[>(QZXG%V;UF?'XQ
M;#[3J%.25SJ]1UF1$?8?!$K8WS*UB2.:KVQQM5(VUI\5;Q94WVUF9\'N:M=.
MMBSBK>+*F^VLS/@]S5KIU+'DCZH_E6]\W5(F<KO6U/%=+S[ I2E;/-7FQ9PJ
M?%E4O;6>?P>V:LLJM/A4^+*I>VL\_@]LU994-]:];=0^-+7GJ3(T5U2T]XKJ
M^8@I2E8N90*4I0"E*4 I2E *\<NRWLL/?XUY5XY=EO98>_QH"C7XG _(@=<?
M;&W#_#0V J\RJ,_B<#\B!UQ]L;</\-#8"KS* 4I2@%*4H"HWBU?C$AO[.G#Y
MJ"51S5XW%J_&)#?V=.'S4$JCFN9'9*>VYG_@F#]"T#LIV'_M#Z7\8:D]/7Q7
M./;;U[>[7%<X]MO7M[M:&).&S+P]_%(BK_+3S]<M30R[+>RP]_C4+^'OXI$5
M?Y:>?KEJ:&79;V6'O\:Z\\F?M<Z!\C-,>A:1P4Y7_;9Y3OXP=9?[Q9$TUY _
M'^_?LZ>OG2KUU&NW2!^/]^_9T]?.E7KJ-=(*OL:O^(A^;:<T+'LB?\=+Y[A4
MU.'AXX,2^Q>_F YJA74U.'AXX,2^Q>_F YJM&JNK&HO$>6^@3EXTMUET]X\Q
M'I&L;0E*4J%I-%O<3P)\@I2E#T4I2@/RGC7>1,V<[W-&^]2Q@SWJ2![X.&>]
MP<QNX%0.EAW8R-T.Y%PNGCW0;/##I8]+G:G7;N;YLE2"=?)NBE;V(U%0VYO;
MJ Q92B:4(E1F%(DRLE];70 PSJ <4SBPL.!F,0X5=BCD>/-4Z";?!+!3::Q<
M)OC*1<]<I75'>Q6<_P!)*H+U;*(Z$8BY&D[R:8MIY=0)%G0PG0D/5F+X)<?'
M(,-5;#M0$5Q(AW&UAD]82R)X#+$8N'E8#7\VDD"3BDK;];)),ZS.BR-I-MAH
M9#\"0D@2(^$.'E&/),0=7%UY-IZ0RA*::QI=/[*+6P4B,F[G>B&X'*UA6^T/
M0"X&F?:F9H3IRFM[A:QKLEQILI-<GN!,E1=8SF<RA%4R/V?I4-,5N3><1%5Z
MP^QB<<L%<UN7]Q7<^(1U#AS7&.U1T(+;5#TE2"CNM.^-DM.ERWCO+3C5^09X
M9FSCTA!@..=V  E@-62E-'N.OI]V_FL"M@T8QL/@F+"DSQW NF64K+B<IJC+
M-+*H::AU','C N?9I#UJ@B6$^4DR2(N:;T)32V6FS9."<!#,_DZVTPCJJJL=
M).#YCV,DP&:MKBNX6MFDC)QAON11-N1)&*+PN2C0'U(+FEH; 1B@RDRB[G3D
ME8-N%'/H#V;"LRWNTG6SW*K,UZ,QY-%<"!56ZYVB[4)9;ZVFF<1 PCB>(*2-
MGDX8H>,TFD-H8[V&X[.MK>8R#+R,>AK2W?UENL>3X2E.)$M45L)MUB3;FF$L
M2*UFZF2.W^[ML]G9R,@TN(7>XR:8N?M@J$NZ7G13%$<P='K6BF)6>B,*/&6G
MYIK::C>*W*):86&-F5$YGACGF*8,G5)3.GE974SPYI36%<\>5E4X<43IHT+5
M[,UN7&\T5[?$ WZ[;WO_ .;NH=_5O?R_<Y6[+6M8"X2E*4 I2E *4I0&NUQ/
M_&:!]K)G?"3HJNRK$^)_XS0/M9,[X2=%5V5R:Y9/;2UUY0W?.:=SNQ]]I3DT
M\E<?\CQ2E*UH;B-DCAN>*BS?LB?OG<IU.[/TF7L<O<O4$>&YXJ+-^R)^^=RG
M4[L_29>QR]R]=<^2SVM= ^2&GO1=4X.<M/MO\I_E[JOTW=-4+<SQJIY]L$Y\
M$H]1FJ3.YGC53S[8)SX)1ZC-71? ?<'">)\7]!@.:^=^[F:\;Y/Z;.*]8WSD
M;ZR+_%Y5[*]8WSD;ZR+_ !>57=O=3PI\I:C<*@[Z"T0^U?'_ )I(]*0=]!:(
M?:OC_P TD>E08O>S;GPJQ\\\G-1]A4_@M?YEA%_?1JM.2VC%$3..5',SE-^2
M<H"LV(FM+;H@,WMBZV/%$DOM)US59F9.-GFQ&PMF$(-_.8TTS :NKI$?&$,T
M37&\>74%2H7UU5E79G-LZ];(3E/45,G7B">)N[2Z(VMHYHP58RF>!-Q4^-"*
M:I[+-UV--W[.I^D\4JS32F,]G\H*1%V /#)TO)J K2;@01MH*:()AK8MCF8V
MG6,61++$,J*<L9-=^MY.<:2"M(XV1A(6R1=0!%R3EM)'RS%2UE.$*JB>(()D
M4-@]U$Z>('7H1I2^(UBN''=JI +ABN#S5SL01\J16SS+2C<<6V5CWH/1+I5B
M2("L6$$]$!4H'@5<=Q1<G "IY"9WRI2J*+6D\-]&JS-?]TW[.*67<&SFN\<J
M+=!4YGEWP?BM2)ITRE9SH[CTR.M@SKXQ6=JXNMF6]W7W.317#,NOE$03$+#-
M<F&Z0\0;G-!=A(TF&(R+&8J-/+:/0NV8U;YU,V42\2DM.5INAC)[BCF65I4+
MN%UE7$6E=OV,.6RH96PW&"LX+J2[4!LKZ>:1P)>JD?L=;<3>=BPTV\JN5IHS
ME;[86E%))'%! 17E@CA.M,1QS 0ET\HX@&^BEE@(K8.Q\JFE2ACIE@[@Y=$@
MS6^ ]9&RJ,S7J'(WA9J+;A.NM7;T:-!%9Z2I.)0 *DS"N=)(I0J"8.63R*>E
MELQ<<L2*0G)R00P+)A F4  I4XHVQ:,X=Y>%/K,#%\^IBXQN)Y!S_-2PO0N\
MT;79PE#^LVQF&#:9DXG">#'=3Z*^B@OD?:"6=%5RN"6X<A ;605#H;"0/SH+
MZWA[VU4Y\6;Z*?!Q_7>(<_!CVRJXP'YT%];P][:@/92E* 4I2@%[\ONVM]V_
M*J3)3XFDP,23)#9*:P8T-IS0>[H;! V>NZ^_31-"63B:6,&^]E@,OWR,$7Q$
M'[B$$%W3++N>&./*UKLK]GV\?=M6I;L5]'^;_;;D/SJ4ZC1V2VL]4:,P>F+.
ME\Q8P\]W+6X+4M=E=[IH8Z7.LC<EB&9J(V3UWK4:JKT*JIT$P>P^Y/=&<H6I
MM84M9X"KGZN/P5*U2AM2VXFU[$F02)\K%J6:SE<Z/UBH]7-V[B(O23D^6O39
M]+F*OV3Q_KNGRUZ;/I<Q5^R>/]=U5M2H??9TY6OPWRG^PQG]A[WR^^I/O[6?
MD)_:XP_\[S7]Y][Y??4N3AOB52Y(\LQLP%9AQN12WF]$)M*!U.NZN_RA15-6
M &')]]*XI;OD/"][A=W"$"Z7I\,K=5726Z[6OY;6K5$U7\92!_;69WPC:MKO
M'LMZUO<J9'8UZQU-K+36H;NI\O8S%JIG65:TUEE=CHJZXZK*L34KPPM5JR/>
M_=R.=NJ].W0<_.R_Y/\ 1W)[K#2F.T9@:N I7M,R7;=>K+;E9/:3*W8$F<ZW
M8L/1R0Q1LV:YK=FHO#NJJM:G%6\65-]M9F?![FK73K8LXJWBRIOMK,SX/<U:
MZ==,>2/JC^5;WS=4Y3<KO6U/%=+S[ I2E;/-7FQ9PJ?%E4O;6>?P>V:LLJM/
MA4^+*I>VL\_@]LU994-]:];=0^-+7GJ3(T5U2T]XKJ^8@I2E8N90*4I0"E*_
M,8.%2MP<3!DN!F8$L$!B.,$%D,)?+''HA8B9X7%RM?/'Y@/I97YVM:W/*W,#
M]-*HGD'BE;&Z\+"@Z=C==HW0F4Z(#V=V"8\&-&25P]MI&3+U_;:@OM!5V#;)
MI!.,E(09I/DTQ@ N-K&LT*.)4>;,9(RD_,3ZBLI_Y)0XG>U&LX#SC'92&]9F
MM.2$6@U_!O\ (RU-A+4QHQ#. $SD"ZK*;_3X,?\ ([:<#3DN#%V&L!4]BJ#=
M>+J?T4K&!QI .-10$P"^.O'+LM[+#W^-0HU;VJ<NSBXH*!2.,V"QF]%\2#ND
M%RGC63T1MA7XUB<AR%#&:;F53K6O"#0<3&3'RIGTQ-4+/IU&FN,E(ZDT7 0"
MF&LK:,@$['UU6348C<R6+=^JI\HFE+#F!<0P >^3HP /=1L_F0@K9W$%R^9#
MPRRZJ I)^)P/R('7'VQMP_PT-@*O,JC'XF]SQ$X/^M^>&6.>&<B;@YX9XWME
MCGAGN=/^6&>.6-[XY8Y8WMECE:][98WM>U[VO:]7G4 I2E *4I0%1O%J_&)#
M?V=.'S4$JCFMF3=#5]Q[.MUC(K==2(UAFHX5-9,CK:>HJ 9L(\CY)N  &"<*
M%F&)@)EW7/,2]\;X?,XVZ775?7RIJ3OIN,+]K3F_IM0+Y=.2CE#U5RDYG-:?
MTQ:R6+LUL2R"Y%;QD3)'U\73KS-1EF]!,BQS1O8O%&B*K=VJJ*BKT\[&GERY
M*-$\D. T[JG65+#YJI=SDEFA-0S4\D3+68N6*[EDIXRS7=SL,L<B(R9RHCD1
MR-=NU*H*YQ[;>O;W:M>^5-2=]-QA?M:<W]-I;A-2=:]K_'<875_^VG-_3*U!
M]@;E=_ F]_/\)WOX3[_UW3???VSW(-^V-C?Z*U)_<O?3XRP?A[^*1%7^6GGZ
MY:FAEV6]EA[_ !K!&L\2*D&0LSHP65@@O*3:\/=\*J85,DR)KPLXU5:"[B7.
M9B& ^XA*&  G=,K](0///'EA?&U9WR[+>RP]_C72C0F/N8K1&CL7D('5K^.T
MO@*-VLYS'NKVZF*JP6(7/B<^-SHIHWL5T;WL56JK7.;LJ\?N4O*4,WRBZ]S.
M*LMN8S+:SU/D\=;8R2-EJC>S5VU4L-9,R.9C9H)8Y&LECCD:CD1[&N16IIKR
M!^/]^_9T]?.E7KJ-=ND#\?[]^SIZ^=*O74:Z*5?8U?\ $0_-M.;]CV1/^.E\
M]PJ:G#P\<&)?8O?S <U0KJ:G#P\<&)?8O?S <U6C575C47B/+?0)R\:6ZRZ>
M\>8CTC6-H2E*5"TFBWN)X$^04I2AZ*4I0'YS9LJ0*F3QXR 3)DP!C1LV9%P
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M[A9"9\K7MEE:^9J\<NRWLL/?XT!1;\3:%"R?P=M9B!( (J2(/O;@@2*@86#
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M'VKX_P#-)'I4&+WLVY\*L?//)S4?85/X+7^989),DRAW#$,X5+FL,<NEC@9
M"'QQRY<NECB+AGC;+EU<[6M?ZM?+/-AN*94H24D%%/DR"B65R)4ZE)YHL352
M8G=2BF5 '+" EE$J+>XA8\#A@;+B7OF"-AE>]Z]3N=S98+6<3W>B\E-=HM%$
M57*YW(N'0$U&04!#(&%-86%50-9AER2>FIY4R<.&1L\0P2X(@F5^6-1RF?>7
M4C7EI1D^IIGN/(Z:DQE<%&-%AQJHQ<%VHN*,GN$\Y4XN7*&3H330D)62EATN
MU0*DFRTDQ2('7.K)!<V7S$I2J)3Y%"N1D(YD7 R-@ #E@3600=S(1<R(7%,
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M('7'VQMP_P -#8"KS*HS^)P/R('7'VQMP_PT-@*O,H!2E* 4I2@%*4H!2E*
M5XY=EO98>_QKRKQR[+>RP]_C0&FO('X_W[]G3U\Z5>NHUVZ0/Q_OW[.GKYTJ
M]=1J=-7V-7_$0_-M(*V/9$_XZ7SW"IJ</#QP8E]B]_,!S5"NIJ</#QP8E]B]
M_,!S5:-5=6-1>(\M] G+QI;K+I[QYB/2-8VA*4I4+2:+>XG@3Y!2E*'HI2E
M*POL+L-#6JD//>?)_?:5&T31TF!*KM=RN$?- $ #1XJEIY4HFI)106%E75U4
M\2245"14]065I4.%4Y,(FC8X8667CP1D<F; )F^\38Q8P$5.]P#-=Z&! <\
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M32)8/GW,L13MQ9Y(D2P?2OEEW,L4+@@!]+*^5@P\;97ROSO>]:@%*4H!2E*
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MO6QT\/RV/[*W^NG3P_+8_LK?ZZLG_N?=1_30][?]"ZJ?V"4_N?=1_30][?\
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M6ORO?G^'MXV.;OMNFV^V^W3OW-T^4_3'<+FNVWV5%V-4GN@7^%"_SH?\JG=
MO\*%_G0_Y5;5?H>0?SE2?]&D?Z/3T/(/YRI/^C2/]'JE[47[]/Y/_%X?JO15
M]MI]XO\ *_X?#]5Z-53N@7^%"_SH?\JKR^')ECEK^>OCECE;XX[LZ\<K96_^
M$0>KG:][<_J5.#T/(/YRI/\ HTC_ $>OH%2A4D'<$F6+E0KY7SN$6!" #Z>5
MK6RSZ .&&'2RM:W/+ESORMSOU6KZQ0+&[BXM^A4VVV[NW?7OGREGYQO#P[=*
M+OOOW/\ P3Z_F_12E*J"G%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E=&=\G1
MQ'YYKI;[?S*9BF]U;! 9B<['8WVV>=JZ(,4+AHK8*+:B1,+ZL(.?(@8)J2&<
M.9#'"@6(-\S(..8'>:51S+?%D>3&E;994:<8MAV:S0QI'LE.47.L1442CMG^
M;=<Y3CZ,G03;J@$,,C-^"KNQ^@QXCO0=(4U-X.- =[N0+8L9';IYY]7E??#?
M?7-2>T'RN@P \9B0D#7N6AIRBG7W:-ZPZPHDF8&<FTXBKNUYBIWR[L"[%IFS
M3" $8([I9J\ BK:/+3-?[I1&8"VUU 5 +[J\<NRWLL/?XU7SJMN"YM@'H$0>
M*8QHG*AQLQ$/.-UI<"SE!8V;)-DH\MF64V2Y]63#RTS-<<'"T8V<YXHT1%'"
M3<GRC+HR":8YU,&F+)\M17"K6S>\QR9'\3LP)23$H5W26\VVPVP$IJQFQ=+3
MA%]U*:2DX'U$>UP2!/(W8R<%M<(L$*);HT!3M\3@?D0.N/MC;A_AH; 5>95%
MWQ-R. :X/6M1HJ."9*FG_MX:*F2XH8Y<R5-;E3X8+&2XX6680Q<P7%#' &#S
MR#%!$P$#RRPRQRO>C0"E*4 I2E *4I0"E*4 I2E ?#R;#<SRRSS0$7///++/
M//))3\LLL\LKY99997+7OEEEE>^665[WO?*][WO>][UX>A=L\N?H?0N7E\$)
MW+K[.OO:NCS@OO=K18\7%':>75G:D)>9U,2ADE=6Q5.X8F%C">GIS<OX5%53
M9?+,!+'PMD5(GLP3ZC@(GEC.&4"5%Z;N8ZMM\D6;YL28[.R\?*A<JD."[^R!
M; 8 YES&7,+T63CFLF$!:'.N8+ 1GJB2M)R,@F,ET4/(:^X[$6<C#',R_3K,
MDOQ4-K5OF7,62-TCK#VKOPU86HG.S+LQBO:CE3=-\?R66J8V:2%^.N67LHRW
M]ZM-9FO2.5D3:['-Z'69G.7FH4]>]&/5J+TEE_H6;/\ Z?0^OL_Y(3OZ-7Z"
MJ ADA\#)-&2BI@/I=S'+)Q( ;#IXWPRZ H0& F/2PRRQRZ.5N>.5\;\[7O:]
M>$HRAM[@<U\5F>U2 Y542TQZR$52&?(Q5,1_#HHK7Q2'B2/89+)]+3!G@W5H
M=IHP(3X*G&FM*YT(! L)8G9 !W:P(5C-P[F+!AV'N#;*P5QK86L+<*V=[YV#
MN)TKAVSO?+H='I7O?G5->H6*,-662U!,VVEA$9!8YU\3J\SH7LG9T+&YVS9&
M(Y/7Q/8]-VN15J<??JWYK4452>!U-:R\Y/7YIDJ6(6SQO@?TH]&],<FR[LD8
MYKMG;H>VE*5:R[BE*4 I2E *B_L=IGK7MGZ$<Y\C(H]S;%Q<A9KJI9R/1EKJ
M<CO0B537LU17!'[E:BXIL9[D"">4>["5U ^RW@ G)P;D05.R>3[C)L<< J"*
M9,C!%RX 0@PXXXF 0(((6&0@HHHHF6(8888>.68@F>6.&&&.665[8VO>U9FW
MFR$K),0F]@-1-D]855AH(=F27; \-K6SB_+<Z.IPHK8BR,(_=,:[0Q(@(C@>
M#K<;<9MDA3(+HI0XX"[C4#R<CD#0 @&?%K0K4-?F)A3P?@MH!25&:<QDQH*"
M2(N-]M$R\7!*0$5C*L<H"NEQJZ5** U8_:*EAV-!<5XSR&QS8IY S+E,B_?9
M+U;@:82\H%I)CQ.=?QY&PQ&=()H\I. !25&]%Z\JNN.B26KIZP25FD,QW<MJ
MCQ:RFSCK?54-XF\W:GG@'$& I!59N_>?=N.5&4WT\$;6TS#^E;\T^@K;-%;S
M5D<=[RO)4VLV$G//T@P2YE&1D]&C)BPL7V 9:FR&:^F=(RM)9-O.T@J/5GBC
MHQ_'YD;<2S:)S&I.9;^BQ@1O(!]]-QH1>.\(\G:,FA%IXJY'ZJ3VA2TNR^&T
MD292.M<",,:;'A-<'KB9#[GNY6>RDXTD&'<S5IS@7+1%$4=P3';;BF*6T7:3
M$:8!T%%10#JJJ"8"JBH>7%A24EE>/JJ\O+J\N*:DNN%Q+ZHJ+SA7%%065I2/
MJ9TR:%K$F>W+C>:*]OB ;]=M[W_\W-0O+_QZG9:U6W(:XCN5&2W"WU9,74);
M(E51&6D8^45$E53#X6)@BH)JD0',D3Y(V7$#&+'"9@8L9"SQ% %S#RQRO2(Y
MIKAN6N.7J*E17+49R6J1YHUOXVW^F1^_6J\U!C.(.9=4B>:"\2;;5E(PV5K
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ME*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E
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M(7AIQT((4+""?)$;ZWZ>9<'//GCOMLECC\UEA?+JQPQQM?GSMCCC:U^6-K6
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M.>+[;TI0%*.:>R4]<7)N-1)&!\E++?75]I /(W(*(U&X\!$$QTF&H X@&O\
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M@FW&X62>J+W#6U/<($3E3;4>Q(I$Q4^FA$D*7Y4;Q*3416?MY76F]/9-$=I
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MO4;-QO%9G[VJW?\ !8M24J->XWBLS][5;O\ @L6K-J_JEJCR=S?HRT9-R?\
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MKXYWORO?&_._.][\[7M>U[WO>_5>W;5-?!Q]/Q4/UY3>3W8MH"YBE*4 I2E
M*7MSM>WEMRI2@[A63-?#<2IDE1YR<8EU6;XSP42JAFC%V:FJ(*?<LDIR58(,
MZ,ME13%L[)]A[YYEPKVR%N'RO;"V66+?E1Z)]/5<_: C_P"T=7$4K4U_D,Y*
MLI?NY._I*"Q>R-NQ>N3KE,XQ9[5N9]BQ*K(LFR)BR3/>]61L9&WB5K&-;T&\
ML7V2?+;A<9CL/B]=V:F-Q-&IC<?5;AM-RMK4:$$56I DD^&EFD2&"&.-'RR2
M2N1O$][G*KEIW^5'HGT]5S]H"/\ [1T^5((GT]5S]H"1_M'5Q%*H_M?>1_\
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MU*9CA:JJ,EH;Y5 VX4*/I!+J+T3[D)2U]@N;E)B+,Q0[&4I+$7+_ **XU59
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M,K8VJ'RB<5N8,F, RX%C!P8 *XPV?S (5L[BBY?,AX99=55!< X4(?AEQJ.
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M8FA BR(S"JYB,G9KJJ8)D\QB:AD$(("FJ I8#+]*@P@\3'05QQ"Y9Y3MLX2
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M4BUGM1GMN4Y,08O6DN"[G!(/,R-%R8ZBS&D]<AXVHGE&.W ^T1<6&^IC%E'
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MJUXX2!Q9BR+V9NA()^0F-'T6[%L%G06C$@V.99-]H)&L\)*NY)DCEY@K3_\
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0 M;E;[>5_NWO>E<TH#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g273067.jpg
<TEXT>
begin 644 g273067.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #__@!!1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?1DE'55)%7S=?-$-?4$A/5$\N15!3_]L
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M1U)55V9W>)6BM+6WU^$S1DAB9W-TDI.4L]7Q_\0 ' $!  (" P$
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M;:K1M;AA&"VM1>#N03E>IB%.42'*4Q1]Y3 !BC]\![@/GY^??S\_?GD
M#L >0 'N /F#Y@#Y ^3W!GG&;O F8$Q$QF.T[PO+Y,1.-XZ3W3(O<S?T-^Q/
MV%<_C7!Y)Q59)$AE%5"IID 3'4.8")I@4 $144,($3  $!^W,7Z,@3R\WYHR
M7U+=]:Q>Y=4R6Q9,T.A&T%AL:FO;K(K1\_&2#])A56LVM/.U&+!FZ>O$T(]0
M[9HV<.5BD015.3SGQB_S2^)__E]QC_\ 7M16[^&?^<?@#_QKPM_\Y8J7FI_S
MK=:_M IW\78[^?;Y/=G/\Z&T'M#6]RUY2XJHW^DVJ3@:?68J;CJW;*]//XB3
MCX9DR?QTFRB9)XZCW[%XBJT=LW:*+ENY34;JI$6(8@=\ (&]WT=P$! 0[AW#
MN ]A >WGV$ '-KX9_P"+?#W^@])_V"W6N:W_ ):U?_2E_P#[757G&,9WBZM,
M8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$SH[DKR)U7Q*T-M7DCNV?-6M6:<IT
MI=;C+)-C/GH1\<4B;>.B8\ATU).>G9-PQ@J]$I*)JRLY)1\>FH0[D#E[QS$W
MUQ.(.R^=/2[Y6<<--E<.MIVBK5>TT2"1DD8LEOL.L+]5]DMJ2JX=&39>.WHU
M=Q QQ7[AI'A,O8M1\\:M4U'"9%6BDO2Y^8+L7W(FH=**UO\ @=%61W#N=JRD
M[L<'ZC%C8&5?7=OMI1-'>:CKTVF[D8Z/>0"S&7BX^QR#* 5M*ZSMLZ6N+<*.
M8VF.>_&?5W*?0LNZDM>[0A57S=A*IMFMEJ<_&/%HFTTFWQS5R\1C;34IUH\A
MY9NBZ=,7!T$I.)>R$-(1T@ZU*L+S8VCJ_B18^E]/\.[07>*T+MG1'M=B/+PV
MQH?ZL6\=7;@D8%75+;53/<!KM#VK6,)%0M70VNSH,PH_.\M>KK7+MH9PVV/G
MHY7";<_!'I?:MU?R BGM6VK>[E>]V6*@22IE)/7#?8CF+^ *9+)&$?@V>:5Z
M$C):S0OA(K"V.9E8EX7X09/,(L[.,8PB8SP(@'O'M\GX1]P?2(_('RYPFY[+
MUWKEA\*[ O=.HL9W[?"%RM$%560" >(0%U/2$>@ @7[80$_?P^?;MYX1<WQD
M:HCF;Q!L#\L5 <J.-\Y*&."18R'WIJR2D#*B/8$P9L[8LX%01[@! 3$PB AV
M[Y(IF_92#=)VQ=MWC1<A5$'319)RU63.!1(=)R@=1!0IP,42B10?$ @)>X"
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MD^(_$EG=\D,JZAH^F:E;FIC+J%M6TJH&'(Y1<%PF>9T<IN[=P_Q_)V^_\V?
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MN_8MDD)F[5RKA&3.RK6E7XN%0\5D5F'+N/5MHK*M1:@W*9T=\AW )P"\'I$
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M_DZ=88-&.DXB(3A!783\:]="S=,6RJC4?8%XXP-7).RZB#CU3H5E$ <*Y$L
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MFD;"-GA2@$D^;E>.C2L@B(,%'!B-HXJK5J1Z[G/EVB&B?K*Q5"'/<09&,^X
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M-:):<==83T%?ZUIB&W-)O:NFS>[@E-&.(2:H\[;$VCXPH%BKI"DN\7 13IK
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MY?U:@?;%]ICFR@!V Z11[ADD$DX.YZ>:$$DP#CH<D=N@_)6F 3* "'VP@/O
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ML2&IKHR\:E(")@9N)!L5$C"(LSR.!JZMD%!N9*O0UA5D(^#D7$:B@5*3N
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M_P OO#M[A[?S'W#[P$0\\TK-VUCO&C;OU8ZY'5Z\P]_W1)ZKW6J?9KE^ZO\
M;JMM&]IFBKS;"S3EU9B2%V+&R,JB-I!M/R,8LREG+0C*1CSK;J0@ !>P
MF*      41*4  .P     'T!E7-B.L[SW^O,HX  =29G,] >WF=S/D.OMC&,
MJJ+7I=07_1</'?Z-^=/_ /!^8RM_X!^3-A2"9?"   E#L ]B&,0/I^X$OO\
MES76]3Z\4W67I5VHMB[#L\)2J'1=M\%;9<K?99%M$5ZL5J"H-??R\Y-2CQ1)
MK'QL>T247=.G"A$TB%\S>(Q2C8JV[Z4ITC]7OW<97MG;4WFZ9+G;'5TOINTR
MD,X433*858^SWH] KDDS%0PHD>Q\D[;JG(<Z1U$0*H:[@3RP"?9'16(F(&XC
M'N'D)\S\.A5BCU1?G4_^JK_EYA@](=* =&;G<(!Y_4TJ0=Q\Q[?5>UQY=Q[C
MV^COF/J,]+UZ:#MXFA(ZJYEPC4_<#2+G5>MI!!'S  ,JUA]RO9 Y.WVP^SM5
MC]@[ 0P^6=1]53K<=-CG9TGN:>JM$<AF2FW;)K6MA7]4;#J5OUE>K"LRV9KV
M7>M:U'W&'CXZT/&3!L]<.6=;EI9TFDP=KE14;(F7R T@C!W'[D#28P2)Z#ZW
MZ=UV;Z("/?IO[L]_Z-+8WO\ +_6CTCYA\P#]'EEK?*H_H@'Z6_NL>_<!YI;&
M[?>^I'I#W>_N'R@(>7GEKC#_ +Q^'Y!0<GX#SZ#?S[IC&,JH3&,81,8QA$QC
M&$3&,8115YH;=MVD>/MMOM%58MK0U?UF)C'TBS2D6\>:=L#"-<O@8+_T.[<(
M-5EA:I.0,V!P9-1=-8B8HGC!PXYX0^\DDM1;P"&8[$DT'$;&22K-HUJ^R6SE
M-5-:)4CU ,QC[&JU,HDM"'(,98$?&,60K@5HHG9_4N_0FW#]L^O_ .-T;F,Z
ME<(G>X^)='W)JH52;5CG=R":KQG:J2-V8PMNE4(U2(<J+D3A[;%-FB*4<9,[
M9E+E21;KJ,Y!-O(#C)=S&,P-O+'XY^MEF8UAIGFQ[<!V)&!$^6>N.OF)1[-Z
M4T38=I(3>NKG'TO6$J\*\G:RY8.Y";K@J*"9^RI"PE48GCW)/M6#:;5*$*90
MR7>28(MF2?,^5]RT'Q3XV6+C91&J#6SWFI2$/'UV*%)[,>&92(TD;S?)-0Y5
MA4>(D5!-V^$[^7633:1#,D:S.+&(E=ZEVZ*3J66UI8($TIMN%<#7(>_V(HD?
M13-N!V;KXW5YTB5Q*W6$73!FU4< DC(K&(XL*"SYJNG,]M<4.!5BV1,_5UY4
M!,R*DR]+/1]'LJ[E:>M3M7P+)SNQ5'!@=-X\X%3]CJ9P1<.6Y$4Y=-G%D)"K
MQ@X:,G>>@Z_7G \K0YL&J[#3@ B7$1!Z3\<[[;F0?2NJ\M!\?;#,RD4^C$K=
ML>5F(59ZV5;%EX5M7Z[%MY1B*H%,XCU7C1^W;NR%%!P9LJ=NHJEX5!R9Y_!L
MV;LVZ#1H@BV:M44F[9LW2(B@W01(5)%!!%(I$D44DRE3223*5--,I2$*4I0
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M[/P]K^4_%:20.;U/AGDC B8^\3YXZA=1ZQXQ^C!_DS@,4YF?6-<YN8@"?O\
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M\KM[@,( 'FH8?(  /,QA^<PCYX^QO^F/^HO</\.5V_R_DRGJGV?_ -:^*?\
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MS%22.8"&$.V4S7'5)X[&](Q8;33YWT@W" .$ZD6K92;_ #CQM^J>,(Z.1J=
MMC^IZ:[&4,FF0WL0S9G IH@87/A3"S9S Z0?[/-6:-S&P\YR1L1MY^0*ND$
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<")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g292183.jpg
<TEXT>
begin 644 g292183.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@ ^1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?5$%"3$5?,U\T0U]40DPN15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MM(-&3M63<X[I9EDK=##DTXF6EYM0E&ICA.S03+34N\I<NAQ 0X"5 A0%R?\
MIFW[,+HG+)G6^ TEZ94AE3[<JVJ9F)-)FW9?BMRJE34K,,I1,*;65MFY)!25
M0A")R<#&3(AJ0:8,'(9)RT6#6@\*4I6\>)8=9X[.1TJ:@1$%LAI"K]H_&2JE
M,&0C;00Z%SE<I#@+M5J[31(Z>PK?4.\#'M<\+?+UDP+WKTA0Y&K52DZQ 2Q=
M.+U-(B\&#TF 8&-,RT/5PN\GA1J5F<[,JJKM >U1<NT5N?4%A-2_W)MBS5LE
MF;F&U,SLO,*?:D&U.SBI9MAQQR:,LVA2GD2Z'5HNN*<1 BAOZ=MYV8^U%CVD
MA\/2<NXEZ2F)=+#MH.):DDS3C[;;<JF:<6E+*YE;3:[[PHI!(J-"+&/7BN]S
M&2.CU8-LO2YM RV4*.3CF'25&$R=4\B@Y,RPK,[7EW1-97;4H4MJ-"6V856[
M)D&N3J*11G9HE?KXA7XPY%M^A ;G+AD'+2;?#J -RPKCU+C013;M&=5N@LO&
M$ZO*&$UDRKO6: %XZ"%UH77?L6[%==R]:IKN,6Y8TRU*/,6M9KC<\YP9,B=E
M@9E\!!5+,)+@4Y,HXB Y+)!?:4H)<;2HW1;?L*VY9V;9?LBTFW)!H/SJ3(S)
M$K+DJ"9EY26RAN67A46YE2@PXE)4VXI(OB"H1)+7,ZZKV'XA+-$WJJ<90@P%
M9J-*TJ65F%XO*Z+UL-48F5^NNP"+0,Q-ZT%H%#Q0:S>%7;8:S5<OUTVY]L)\
M8,BU XRA:(D9)R#)STF"D9*9#V$X(I/" NN6[-P,8FU-^NR!!%X^D2&XK'71
ML@AM4)L4%=X97=HIG=>M6RY=Q]F8M*SV'I9D3,RT_.RS3LO+*4E F'VW'4K9
MERI:$AYP):*E)2%7D"++-DVK,M,/RUF6C,,S3YE99YB1FGFIF:2%*5+,.-M*
M0],!*%*++94Z$I4HIN22(*A&0)<8+"&[-09(IE@N*#<3AA:RM&E94S1V<&2;
M/*Q0H$*;58 09W,2E"8H% [X<^<@YMA@A+?IIM#R&U773*=3PK'/,-/DLE0K
M6+D0IENBZ'&1Y#9(159HIT%6"%F-*Q(PLI2N&"=J  !HNDRM2WFH.$OW):94
M3E&')?4EAV@TMZ5M*7+2&^*7'BN406@E:U.H5-(92XVVAM:W5ME26D)Q.%*2
MDG.GOIFW;.=2Q-6;,!Y;@:#3.":6'5*;0AM:95;Q;<<6ZA#2' E3JR4MA2@0
M(MA$YIC&/(E:MR+=U(LHY"D;(%8'B[ZV)DV*'$M8(JJO4&H\'O54QYH7E=88
M309&!4!' @-8832)OVYAK\K<FJW"-\DPS6/;QA$LH5.$R)&&!<G$J0I([$GQ
M(.N#:+2)"#Z[<Q%HSON653O*)&T%P>F0HE"B!=RJ=JW7=IK>^H+"8>;EW;8L
MU+SLXY9Z6Q.,+4B=:EWYIR6?P+4)5U$O+/+4)DL@%*6[^*XTA=#/TY;\PR[,
M-6-:2F&I)NT5.F4>0E<B[,R\HW-,8T),RTN8FF$)5+!V\++EW";=6BG\(FQ:
M8V9 MTL$NWRX9EQ4VMEQ>MAT4F1J;%WS17";MZV'D%35!;PX.=BK=^[:M"0I
M>(OB 55VW,;:#T7**IR^Y>%;ELUCE6][K@%(WRIH?,(SW):J$MP 9=+1Z%NK
M0&N0JCI-;P8< $56+Y1;!@@(@/P@.)JJ-*1(:^"ME_4%B(59Z/[K(N*M9Y#-
MFIEYEJ95.*<6IM*F!+J=*V0XE3:Y@?Y#:Q@<<2H@$W].VZXFT%?VF?;39+*W
MK25,2SLLF22AM+I1,*F$M!M]32TN-RQ/W#K9*VVEI!(II")C:O'E]'PL'@IG
MVE73D!$UO4CX8E"2X/!E=X19J$!P8@7<N!PU9B)L457PY4&NB#._9EOMH'7;
MJHJJG-O\'78=7'T4\#<$BP62X /V9,D8L\2HV]6=%=DF1E"J-E:<&XPR!R)[
M9:,N6T^-*34M!TV!]VS;K,9#;UH!6G?J"P[.4I,[:LBPIN8EI5]*YEHJE7IM
M*U2PG0E1,DAU*%*2]-!EG",16!<8B1^G;=M)*%25DS\PEV6F9N74B6="9MB3
M4A$R9)2DI$ZME;B$*9E2\]C.$-DWB*4PB>D3BUD@XZ@6*50S'N4I5&WAAQ0N
MR<"FQ%@6CS><[LJ"A0S,JP <M-KLK%^L.67K\AXJS9K$A@]X-+?H^5'8SY$.
M$9GA*B&2<Q3FR75'F2J !6EAU0A,*V5F^(K3RCD)D&I(C&U8"B+U^@UJ!V ]
MJU.Y?OVZ:[4Z[R[9L=OC!=KV6@RS;+LQCM"31]NU,!)EW7\3PX+;Z5H4RMS"
MET*26RH$&+*+$MIS@<.Q[47]RX\S+8+/FU_<.RQ4F8:8PLGC.2ZD+2^AO$IH
MI4' DI-T'PB;D_C3D&JW$432)QF'%.',2%BL4JT0%3HBD]306F0>JD4>6A-0
M<(6!1,A83@ H4+MAS28H-(KNC)B+7E[MC&+(L2MB!M[;'N?)?*DG%J)/I"^D
MS$(?&:?+QEXO,#V@&+HL<$)@(\/>!##,RK! PXJB5B[>HN7+5-PJV;'0HH7:
MUF(6)=,V4JM"42H2BFB^F:*5/ B64RE3R9@CA%I*G LH25 FQ;96D+39%J*0
MJ95)I6FSYPI,XEU+*I0*#)!F4O*2RI@'BAU26R@+(3$&0CNK@-LX#4*D8AW,
M1:D0BP 4!KHI.*<KOEAI38&TSJ B;-F[IM"P8ZFFJ8(<"O" (J=-<K FN=NY
M*BZ#Y[GRZ#0)Y@ I.4.8X#KO WQFXBG;\I; Q#@4*#+2\(:#D^#.Z!HH4HE.
MF@PFF2S*>+P@DGE= BK=FJR8AK5=B:^H;%DG+,;F+2E6_P"\"859S@<"V)AJ
M5EC-S$P)E&)AN6;8 69AQQ#)*VTI65.)!OROT[;<ZW:CDM9LTX+&,LBTFRV4
M3$L[-S29.7ES++PS"YEV844)EFVUOW(=46PEM9&/J$6*3N(N4*N4JO1R98-S
MSI3H"LOLK<E!)RYPI*BS8L#G187'=T1?L @1L/*188P#$U0NHVN!KM-? J9R
MKIHZ\CL;\@7!-E$0HAEG+4YTD% $2:N*BI*&58Y**4=4)I"DBF#B+8>L@&W)
M@A<ZI&T@EBQ;#7KHF]8M4^7.\;;L4)=4;8LH)8;8>?4;1D[F69D(5+//'C7-
M-3 <;+#B\*'@M!;4H*3?9%AVV5-)%C6L5/NOL,)%G3F)]Z5*Q-,LIX-[KLL6
MW!,-H"ELE"PZE)2JZ%H1/2OQ9R20"4/5RMV+<]*(Y,'-9 H5*>)4:"*"@TH%
M6@,[0P37IG2#F.OV05LYM472*\+O6@UDTN7KE-$^U,#BZILA&_?]4HT0=F"J
M9@@;\U(6_3J5$*8X<0Q7BOO):R2@J@H\.(*KH"FQ<,)B;8 TIO44U6[UH&'M
MW1ENAZWK&8D7+35:<DNSV9F6E'IR7F&YIAF8FYF6E&&W7)93J6R7IN7"RLI2
MRAT//%#(4X+C'T_;<Q/-V8BRYU%H/2TS.,R<PPN4?>EI27F)I]UEN:#*G0EF
M5F"A*,2GEMEEE+CQ2V:MPB<Q.,>0X1T;#*7V5<:AV!0"9L%0/FX(K/Q)-*FN
MJH]#TVZZR^\0VY6[DKI[:'UD]BY;N6+PZV(MUVJ=^O%K)"ASK;+U,@Y$G6NE
M4CZVA)IZ[QW6GYU[W-02JE=F6<04W?\ 87#OC'BJT*E,'=%T#)3L2K_O5C?I
M_P#+V7^LH9\?_(2GZR(_>='^=^LF.<R/\C__ $BU_9+:-]UCVH;IL6>?_CYO
M])\W72)_R?TG#>+I4_Y_ZC_+_6(%A$X2QHR%FZ'(I)EG'Y6>!S,_,"::%TJ#
MBB5,ZN._(JT >(/)E/0H.'<1U5Z+4C"=Z<K<Y/;G#IP5$IG_ $6Y@91,RKF'
MQX7C^C4\J4I=K,3T*C;9==!D=-%XQ+[0,O4% ^JH,J 5TW VZ0]R=@.-G*[3
M:MS'U!8DLT7G+5D2D2[4WA9F&YEY4H^\VPU--R\NIU]V6<==0A+[;:FB5?[=
MP)%Z7^GK<FG4LM65/)4J9=D\3\NY*LIG&&5OO2CDQ,I:8:F6V6UK5+N.)= 2
M?\%]P-0(1:%68L.!0J4\E&E2[J.R8F+-H)W#P)8:90IHY(P:U\JQ<I"D8F^8
M#CU+ S*L*7%*V!RH+E'=OU7086S:L5U3Z<;XSY"D+ED[-&[+N,!=10 Z#$B0
M=Q.";R@."RJ0B=1J6V@E0@&,*;' QDAAM9&5%I?4$%4F L+,/>E1+%O6+,)2
MI%J2*2J77-EI^9:EIA$JVG&Y,.RTPIJ899;00XMQUI"$MD.*(00HTO\ T_;<
MNI25V5/*2F91)AUB6=F9=<TZK W+M3,NEV7>><7>AMMIU:UN!2$@J2H"#X1(
M3EM,YS-*7S/==!*AO5/,'9,;1*J2RX7"A)<(N7+5@Q W/*N@S(!=O6;UBD:7
M"A0:5^S>#UW:;]J[:HL^VV%XU<E./<S5=4)-2Y !78<, 3W$X*/:4PP30$@D
MQ-W$$ "T1(]42G5PXL.PJ#0Q4%L3-P)9(P$FH>D;;E8IG;?LB0DV)^8GF3)S
M(>5+S$OBFVWT2\I,S[[C1E4O<1MJ3E)A]2T!22&\"2IUQM"ZI+Z?MFT)Q^SY
M:0>$[*EE,Q+S 3*.,+F)V5L]EMT3:F0VXY.3LLP$+*5 NXU!+:'%HH]"+=.I
MBMR7BUB;"%[(R;@L:1MG50BL&I R2RA6];TTWYM8AC!!G(WC-'K$SME2H-U0
M7CQHSS<2Z3-E#:D8V1!<'O\ 0+S)T#<;PN0:9/A!O;(70$-:ZR6$%MH->1(\
MX++1VW"E #[(F]4:IQ9 J#(J$W!08(()E,74@)S%!S /=MPQ]063-,RTPQ-%
MQB:FI62:=+$PV@3<[+IF99A[BM(,NZXA;2,#X;4B8?8E7 B9>;:5+_T[;$L]
M,R[\H$/RDK,SSK0?EG%JE).8,M,S#'">6)EIM:'5\27+B5R[$Q--E4LRXZF!
M(0A&YC2PA"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0CTI;@!_R9RF_
MZ4-3_P"0J^/-;'I2W #_ ),Y3?\ 2AJ?_(5?'E'];?\ =M;W_-LC_P!S(1Z]
M_0G_ 'G6!_R;9_\ 2S\8-<N_^=7DC_UW./\ ^I!D5WBQ&7?_ #J\D?\ KN<?
M_P!2#(KO'H5A?Z'8O_2+,_\ "8CS:W?]<MK_ *O:?_FOPA"$;6-5"$(0A"$(
M0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A&LN:<O[R
MC+699V6FIQ)PC0[,#6B4[EMT2N7RA!%TU9:NSQN#B\L YLCA) 9*4%:#D@X;
M:O"1]0D@%"YWK@,#4,G14$LTU8DX1H[:^GK-^H%69_<VON&+,G7)Y$JM+:Y>
M9<<D)VS^'--N(7C:2B=6\E*2@\9MHE10%(5OK#^H[3^G4VI_:W?MW[5D6I!<
MTA3J)F6::M&1M+B2KC;B,#JW)!ME2EA:> ZZ D+*%HRBM5DDWZE9 87OZ[*A
ML."L]T,:1\5\:$ETW +_ ,PRQ- P*I7Q":$)?;M%%XD&VJ; *@CN!C0HL!;4
MDZ76Z@@"FFWKC958RHY+$P(L7[/+FXE\^6LR"NIIJIO"JS-1-:4"15(I1*E;
M.^(-;R[=0.%J"FRJ"EPT(4EXN@,5E\A@NR(NU>?V-9SG/TSG/^\YSCEY[^FU
MC3TV)E4Y:4NR)M<U]A*N2K,DDK3+-AEMI,KB::0U+);1PU!QM)2&W$!)2OJ9
M'^IEM2$F99,E9<P_]HB4_N$TW-/SQ"%3+G%<=5-877%O3*W7 XA3;B[RXVLJ
M!3G"#/TR;&OK4\8O,\ZR"1R^RQ#NY=9Y%$AZ9D)(BAE1W>#+AQ;:T)K8\H7#
M?UFA?;3Z818@ (%\0ET[P*_;HHLEO=C[*9CD@JVG+K#WX^*1'FF:R)?@]J:M
M'O\ CQB;39*.,QHYR%PJG2<54!$JJS((+H*#Y#I)*#*QE(@3?M"  6U=HJP#
MSG.?IG.>CT:9Z=$)SG/1IG.>CT:9SYO[1C.?TNLE];3LQ:=INNHE!)O+2U9#
M"9EIEM;4FIQJ7LQII+TJE9PS"$!]VY(=<4E#:49#?]4[780ZTQ9=E-M+G#.L
MH4[;#ZI9YYQMR=2V],6JZ\IB;4T,4NMQ3#0*RRVA2W%+S8J=_F+;!(96JBC)
M0#E%7D>_37K=$M,'+EM9-$R1H=XK;B'QTLPZX!S+" PM$02VCR2@NO4 CHO
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M+*EGW!]Z]*.\,,ILUDK6^=XG^K*T2;LT+-:<M^9?F4OXVWQ98DINV+4M9]D
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M[_YU>2/_ %W./_ZD&17>+$9=_P#.KR1_Z[G'_P#4@R*[QZ%87^AV+_TBS/\
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MIF&$N.NLMI:^W0[,M*FY5]R&,Z;%HM<]JB,*?BU +3&)^,A"*.C,N,BLT$&
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M'E'];?\ =M;W_-LC_P!S(1Z]_0G_ 'G6!_R;9_\ 2S\8-<N_^=7DC_UW./\
M^I!D5WBQV70<1/*K)"<@XF<JGM<><ITAA%5,Y34@W1.55-J=,Y3_ *3E.<IQ
M7?@XC\L*_B"OHQZ#82D_V.Q?\2?](LSF/_TF/(CS>W4J_OEM?X5?ZO:?(_\
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M;1KP)*Q>1ZL 4%LKMLZ"I!0W0U%TLOWI8A@1B?EH,Y+B\4;@B]1@@I<?@@U
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M C^$1C?,3$_.*"NV;"C@RH)"<(GB>D=0-$<6$)?>%7P!,"G<M3JLEH&Z-%U
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M22M(3@,(L4W:;=(VL"-I!F@,:!#W%A><S4PPITIH-\A2/DX "_*AOX]CZ<.
M ORH;^/8^G'UPA><S4PPITIH-\A2/DX "_*AOX]CZ<.  ORH;^/8^G'UPA><
MS4PPITIH-\A2/DX "_*AOX]CZ<.  ORH;^/8^G'UPA><S4PPITIH-\A2/DX
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M7*X "_*AOX]CZ<.  ORH;^/8^G'UPA><S4PPITIH-\A2/DX "_*AOX]CZ<.
M ORH;^/8^G'UPA><S4PPITIH-\A2/DX "_*AOX]CZ<.  ORH;^/8^G'UPA><
MS4PPITIH-\A2/DX "_*AOX]CZ<.  ORH;^/8^G'UPA><S4PPITIH-\A2/DX
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MS4PPITIH-\A2/DX "_*AOX]CZ<.  ORH;^/8^G'UPA><S4PPITIH-\A2/DX
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MSTPE=#RT:+MF6C3H_P ]'-I].CGYM/\ 71HT_P!80BE6%6!#)X'D#@D#+CG
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M$B8J$,("&!8 N"UD*/#"W9( E^R)H%#C6Z+P%BL<WX [BXPC)+)D'7&$0#,
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M#].6DP5)[T.<>D>F4^-RK3+3HGQ@"TRT^G1/?^;3_6''I'IE/C<JTRTRE/C
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M4P\ (URP5S9!5K<0 ]\DMB@5(8P,C-.!5!9$RI25M6U'EPO!B32Z:!B:R*.
ME!;;)O*$DG]22D7DYG].?/\ [YF*L2A^RE5/F,XVJ)C3L80_1ESO$-43&G8P
MA^C+G>(DE7NTW#>MD>O(OE@3(=L4LD;Z\4ZR6%^M-$Z;2 4MH-QAZH;AQ;"7
MR0&!+ZY"!\C*P&O =%=L5:M7;==%-<6(W1G!+)Y<+!ML>\M6#>)<(-/TJQ4I
MQ .0GE /+DO*V$K%*.W,**X,9$156/ ACTV*!!@ 3PX6&+SV^6CKUL/5'";T
M([1OE\YF&->I7<?,2+JB8T[&$/T9<[Q#5$QIV,(?HRYWB(J9+=+< \CU"XR5
M8O+Q@W24+3$ATIU\4H]Q"0T%D253E55!\K94TWK=!LDB>JFFDR51#6:I\'.\
M&W\RHX6%G>ZXW6ZN[FT[BO,4&V>;^-"X5A2WYPZ9@3IMUTR97;""39$-5*G4
M$A-L7(!>MI=+EIBI5.7AQ=TW3J? BCHZ+P);8N":7";T([1OE\YF&->I7<?,
M3QJB8T[&$/T9<[Q#5$QIV,(?HRYWB,7&->[A-CEVU.,CJL:C6XO!WMS1KQ)<
M)(N/DRW:"6;56[]Q87R!6$9/?*!UQUU:M2%,!%4B&D3\BM0J-.'-)D#-*@Y>
M*NS[?G#NX.(^*(D>@6Y<-G,A<B$P_#*,NOL?B%YR=.K9'6G4<$&@U ?BY!B)
M55F!@W%\91?4R6  [H\L&7 Q6I1*8N"K=^;A-Z$=HWR^<S#&O4KN/F,C&J)C
M3L80_1ESO$-43&G8PA^C+G>(C95;H[@FA\BBS$I898,4F\CS<P*R<"T!LX1(
M$5\ST^WNI/IP4&KO<"+52?VQ *X1I8S' U";4&!=,O+!,C #,1UA@-TGQJR2
MRC>O$%O!+@!WD8DN49RK2Y6H(T2Q4/*$BX,FN4I@1C3"_,;5:+%I78 6PY^5
M)X<<EHL"ID\$-TN."'%YPF]".T;Y?.9AC7J5W'S$X:HF-.QA#]&7.\0U1,:=
MC"'Z,N=XBQT(<)O0CM&^7SF88UZE=Q\Q7'5$QIV,(?HRYWB&J)C3L80_1ESO
M$6.A#A-Z$=HWR^<S#&O4KN/F*XZHF-.QA#]&7.\0U1,:=C"'Z,N=XBQT(<)O
M0CM&^7SF88UZE=Q\Q7'5$QIV,(?HRYWB&J)C3L80_1ESO$6.A#A-Z$=HWR^<
MS#&O4KN/F*XZHF-.QA#]&7.\0U1,:=C"'Z,N=XBQT(<)O0CM&^7SF88UZE=Q
M\Q7'5$QIV,(?HRYWB&J)C3L80_1ESO$6.A#A-Z$=HWR^<S#&O4KN/F*XZHF-
M.QA#]&7.\0U1,:=C"'Z,N=XBQT:3G*4M,YRE*7IG.>B4O]9PX3>A':-\OG,P
MQKU*[CYBN6J)C3L80_1ESO$-43&G8PA^C+G>(B;)'+5Q&V=YO<=<>\>QF13X
M+EO%R\ \K-W)*V5;)#-@A#M.)*^<*QSCA++:J:E5JS5I,FD(C$\D3PQ-[U@]
M.#H4FT\2"#2[5=Q=V=9-N\/F<RG'-&]HHY>9=#6J+&B#HE0&PA%.8CL@B;&E
MW$ZZ;MHLB63/-P5MNY0\R!VE2JE67%+BV"F5MMI*4>86 5MPF]".T;Y?.9AC
M7J5W'S&0'5$QIV,(?HRYWB&J)C3L80_1ESO$6,IJ\J4YZ-&BJNG_ +%=5.G_
M %\G3'ZAPF]".T;Y?.9AC7J5W'S%<=43&G8PA^C+G>(:HF-.QA#]&7.\18Z$
M.$WH1VC?+YS,,:]2NX^8KCJB8T[&$/T9<[Q#5$QIV,(?HRYWB+'0APF]".T;
MY?.9AC7J5W'S%<=43&G8PA^C+G>(:HF-.QA#]&7.\18Z$.$WH1VC?+YS,,:]
M2NX^8KCJB8T[&$/T9<[Q#5$QIV,(?HRYWB+'0APF]".T;Y?.9AC7J5W'S%<=
M43&G8PA^C+G>(:HF-.QA#]&7.\18Z$.$WH1VC?+YS,,:]2NX^8KCJB8T[&$/
MT9<[Q#5$QIV,(?HRYWB+'1I.<I2TSG*4I>F<YZ)2_P!9PX3>A':-\OG,PQKU
M*[CYBN6J)C3L80_1ESO$-43&G8PA^C+G>(B[(W*5V&[=E ,+CQC89Y$NJL&^
M6[M'=PZ<0,RC5(5OD4=)Q+4UGKHFJ+7(8<NEBJE0!*$2@B1/#AHT*7*%0J(R
M3*?*:3 76,@W5BZ]J9QO#8C8TK%[GDR":ET7K'-6LW$1;+%[/H!EE[::%?UN
M,X@X.N":^I!KS7:VP;<K192J"==G (S4=Q1IU!%PM56W";T([1OE\YF&->I7
M<?,7MU1,:=C"'Z,N=XAJB8T[&$/T9<[Q&/11[KT#$ \"%&T^+#X.>CLU%09I
MDX. -Q"E=YC#9.GYLU:R3;DVQJMM@R$]1#\B$4VIX>&XP$VYD)/1EE)K50*:
MD@3A]/V.6>*D?C,;*7%DRQM<YMB7'FLJH)7?5(Y'UHYRI57IEAY6F*RQ2#[Q
MU0%.+EBU;K3-HZH3EFJLJ<VI"+*X"3 MPF]".T;Y?.9AC7J5W'S%C=43&G8P
MA^C+G>(:HF-.QA#]&7.\18Z$.$WH1VC?+YS,,:]2NX^8KCJB8T[&$/T9<[Q#
M5$QIV,(?HRYWB+'0APF]".T;Y?.9AC7J5W'S%<=43&G8PA^C+G>(:HF-.QA#
M]&7.\18Z$.$WH1VC?+YS,,:]2NX^8KCJB8T[&$/T9<[Q#5$QIV,(?HRYWB+'
M0APF]".T;Y?.9AC7J5W'S%<=43&G8PA^C+G>(:HF-.QA#]&7.\18Z$.$WH1V
MC?+YS,,:]2NX^8KCJB8T[&$/T9<[Q#5$QIV,(?HRYWB+'1^:JZ:=$ISEIG.4
MI2TRTSTSE3+F].B4Y\\Y:=$M,.$WH1VC?+YS,,:]2NX^8KGJB8T[&$/T9<[Q
M#5$QIV,(?HRYWB*1('=.%:HU>Q1PM\3ENV.->5#Z*3'C'=YE O"FZOC]>  K
MA#44;.9CY=2Q6JVO0;J@VM5PQ%G=I3K-0EH.XFQK@)%& SN_?*N0O9P9DI?(
M''9AG&P8;LN,,@E.I0P82WF90-PE"BVU01-QVXCQGZ6,L=D$#FB4=PU+)L37
M6JP(DR7"]1"2+=_''M-T.X3>A':-\OG,PQKU*[CYBYNJ)C3L80_1ESO$-43&
MG8PA^C+G>(Q<%^[%.,<XQ9D/X5X$9!7%%C6Z-QM$.V%X<A;ZG=^ZHQ=9 W!Z
MFBLG5AJ?*0G/5;=*B869ML4K<K/[1S8%-,-<>LI4=@GF(TW4-26'DP.;8JQ!
M>H<GLTD0&70Q<3.FO$$S/EBC!U7D6&7)@4KTQ)2@>9U44B1 8U,@<SJS?H(6
MYJ7*[ G"4+G";T([1OE\YF&->I7<?,7EU1,:=C"'Z,N=XAJB8T[&$/T9<[Q%
MC93E.4IR]$Y:9>^4_1/_ %C6'";T([1OE\YF&->I7<?,5QU1,:=C"'Z,N=XA
MJB8T[&$/T9<[Q%CH0X3>A':-\OG,PQKU*[CYBN.J)C3L80_1ESO$-43&G8PA
M^C+G>(L="'";T([1OE\YF&->I7<?,5QU1,:=C"'Z,N=XAJB8T[&$/T9<[Q%C
MH0X3>A':-\OG,PQKU*[CYBN.J)C3L80_1ESO$-43&G8PA^C+G>(L="'";T([
M1OE\YF&->I7<?,5QU1,:=C"'Z,N=XAJB8T[&$/T9<[Q%CH0X3>A':-\OG,PQ
MKU*[CYBN.J)C3L80_1ESO$-43&G8PA^C+G>(G-1*1/I)/GJK4YV4IY,I@H,U
M HU =F 4K)2$B)@5\R-SDX,QMVR#+2LK+@HD>8#Q=VT&!@P]\1>N46[=54J-
M86[H.W&8[2/X^01-'3/-JQCVN>UXH\=0:'3EXT1C<))'KJT\!X!- A5<0*74
MJ05X-6 2Q1W*C$J2W!#4[O Q N^7%[A-Z$=HWR^<S#&O4KN/F)RU1,:=C"'Z
M,N=XAJB8T[&$/T9<[Q&- ?NRM*CPJR0S 9K$YZ')I9;)50XY(YKP<@(9PW&K
ML%:(,D.Y%2*%VRU8EB?7]I?IP:5H\A)%>X@%/FY:H!I!(+([LD4P*[=+U$0O
MY@TT)5B:\9PG<QT@$68]PK)TUXP@9\N4@&0A(!5P9DJ\,R$ /%7=-8N0@VM@
ME+;JXH:8:XRN##T\%<)O0CM&^7SF88UZE=Q\Q<_5$QIV,(?HRYWB&J)C3L80
M_1ESO$5SPSSP5&5STY7-,=XRNFR8+&]?64D5K)>#D=>)7$ 3E4G1!FG*B)1F
MLSNQ0X:4=9/VSY*R/412&1= ,2J+"SNG24),C4.$WH1VC?+YS,,:]2NX^8KC
MJB8T[&$/T9<[Q#5$QIV,(?HRYWB+'0APF]".T;Y?.9AC7J5W'S%<=43&G8PA
M^C+G>(:HF-.QA#]&7.\18Z$.$WH1VC?+YS,,:]2NX^8KCJB8T[&$/T9<[Q#5
M$QIV,(?HRYWB+'0APF]".T;Y?.9AC7J5W'S%<=43&G8PA^C+G>(EQ#M\BFV)
M:TZA$V5I<DN#A)G66%-B=@+4/%T6:!(J=%5=<]^O4![--=7E:)RMT2T2T1W*
M$5!"$F]*4@_M>  =_I$%2C^A42,B28C![6Q+WK9IV6;-A]\K*G9;->MF:&06
MU*\*+RY>I,W2@T<&M3N697;X,.;W!-JW.[;E<KM4T>71Y7E2\PV(ZUW9W#K"
MQL=S*;+<[!][)5F30*TZ"S,4JV;,ZP?J9RRX8DUH>=0TAEV2N*,.0R$,!@&E
MLPA984PLQMAC>[;LF<[R.GZIQRN2I8*N@3%2I\ ,L>1OP0:=%@039WRBF[;W
MT.(%6[UOR[==-RCRZ*?*HJIKITTU2G/XO/I"^5Y7G>D_*_\ F\X27ROCPW3$
MXAGO9^<C"XY&D8"=U$Q+=5LL(]U6?U89LY+/(FUQA/DP%"XXK>^WH=@T&9J-
M+ 1_&B")"A(!UD5VDU64CPB2 FRS.:RXJ.100P&&PBB8N]AS1F#F7VZ(I?"H
MO:S"TSP(3>.^X\OWC^;9"*%0-<$3&1*RR>Q8*4 TB?1 MJSL>HCQM[XXV$N6
M<'I\6!S5+7EDMBY0DQ6J;%H,IO:@XH=CG<0BM;%S;S<+IOEXGS-*K-'*<R(#
M9/*9-G0:L&;$AT6"1=0<<6F 6Y6'%A;U,[=ZU5535+1..52IFTB'32>1J/-D
M$FDJDR(G3":3Y,;D( I(T\GRX,4$A,6 K NFR$+2HL!A0  +:IE:#!0]JS;E
M*BB4HC$G,;]_.1A<<COV*QXM<.,#,F4D.:)7/CBUFRU@S!'<]<JFC42Y?)X\
M*"=ARTY4[ *M"W&Q9%%X\L*7.MD(W2G'#*UV4J5SW3MW$ :%TQ@]0*T[O";J
MMZGN7S"9#95-5N Z?16!)DQB PU5AGDRY^;YD<--)&N<V1E:65NVC$/4ECL0
MOSPZ>HU%6 ;C)54$Y6:$!F "CC0":)VOCV/;^='[7*,G-T\?'R'-B,_+# F.
MBH>=$0D":%1J$O #(O'![@R=L2$' A-\*)L7)3HO6+URW7*=-4Y1U9KBA@64
M0"4:QI;;8MVW*&)["?1Z+2(Y/$R=39*&N7;M@L*"P*+HL @5J[?O7*+%J4J9
M5W;E?/575.;$G,;]_.1A<<COV*QY',7MSMSD1+![F$QRKQ,6*(4.&N[:FC]N
MN?5*1I!Z54#%*(Z=A4AGB3)@FET/&&B<( "@(DR."&9<"4](FH'9*R88 MU\
M"K^<;G_GFEL=P> 5C<QU(XB_:_=6R3+0WSI+U.QUM&.BT)B]]Y5A%^7&9ZJ0
M;BF;@#T@922ZE2L@-8I-(TJ\H\%6AM=)%/W0^?2%TZ?.])Z=.G3YPDVG3^/_
M !WT^_TQIY](6<_*FKTGIGZ9^<!+IYO1S\-T\T,2<QOW\Y&%QR._8K'AR<O<
MJ<T*'XS1Q[56/>:3LI3*?=)3'+=OG@9-[,+VOQEK0:D<4N6A$Y+J.DY[!.[D
M^VKL,@&HN!?,Y%&,P2PM 1A(F26P",!!BL/5QC3N9>*6);R*%]F63J[)5VI4
MTXB.%2/W7<%:IHM2[I.O)\%F3)Q**X]."5-!#1U;ABL_*)@X079,#DS"S$W"
MV[8!!KJS72%G5*J:O2<ZI>BJ:A)?*E_:?#=,O3./UY^(?VQ2O6(F[[#$G,;]
M_.1A<<COV*QVR$=3\_$/[8I7K$3=]AY^(?VQ2O6(F[[#$G,;]_.1A<<COV*Q
MVR$=3\_$/[8I7K$3=]AY^(?VQ2O6(F[[#$G,;]_.1A<<COV*QVR$=3\_$/[8
MI7K$3=]AY^(?VQ2O6(F[[#$G,;]_.1A<<COV*QVR$=3\_$/[8I7K$3=]AY^(
M?VQ2O6(F[[#$G,;]_.1A<<COV*QVR$=3\_$/[8I7K$3=]AY^(?VQ2O6(F[[#
M$G,;]_.1A<<COV*QVR$=3\_$/[8I7K$3=]AY^(?VQ2O6(F[[#$G,;]_.1A<<
MCOV*QVR.CN2C1S@H53HLM7:W;$<HRJ\6AE\VXL@ +I+7;M=NN1LF!BI3BN3P
M<TLRMSHLW#9-G .5%VY*L%<JG351]GGXA_;%*]8B;OL//Q#^V*5ZQ$W?88DY
MC?OYR,+CD=^Q6,+F8!5F>BU"QF+J-EN@3M8LR;I>*[(+)O'X;CN,RX<M9#US
M9#(9A@[A'*E8@&S*8L)P0H3M9.:V*(L.()(02*2"*5:1.1"C5=?9LF<=!SD;
MD/;QYQ1Q97S+R+S+'LK;W&Q94(XB7B533998-6J5!=/;P-PUFGA8\4FDHH'
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MXL4=CS@LLE0\);RYXD91-IFCCNV>3306E,';QU"PV,D^$610'(E0!J(E*=I
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MJWC<8U<()YG,:J'B=IVV*7C=M87I"^ISE6K!G)EC@GP2I$H(D6*:*PJIOF'
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MJ%'.0D"&I/EQV=FB^O SY!)>T8_2R6)"O.G2W/@L16YC$& 3EXAO2HG%R#R
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MVXI:DG'2B>4JK2"E&&)45$!FDRP[K-#PZ("&P&XY4!&!,=AL=VRW.1UFJ?\
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M2O5TF[E#S#0_L<E>KI-W*/BON4A0SB%S37E,5VW'-T6=N(6)"N]<D;#$4G%
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M#>(ZCHY,I.\?E*3,D&&%AUD$)E41.L+3-DB,RL8/R!$*4O+TU,)L:[KH,>?
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M*[2>K7Z9&W+B6598"MUD BD1*FNZ/KFN&0WZ%(1ZN=$O1IGI_#RI]L-$O?\
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M*Z_=TBN/,)1A$-<RTF"FR2$ !9#@5L8>$Y4 #*E;!I!",7?K)K8P,JCH.:<
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M=W&,'KO[AYE(?!<M\8&5S;1C9;GCG1D I<A'O;<Y8NM79"(@R<@_)%(\#?M
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M)0"3I 8*8P/?E;,-@\2YEN@\#='C:) %CPU#P-V;*EI%#-,N2;E]YR'&D"X
MJ1[4DPH(H)EEH18);*I-BTY) *$>A:4I3EIE.<Y3]$Y53G*?^NF$Y2E+3.<Y
M2EZ9SJG*4O\ 73'FXW.7=C+]QE\%FZS!DKC9=OAN:R_S6,<GSP2E@*77)FR1
M^IYN\AKB>*"\IO!%@F$(46EX+&A0U@CNIZ=N<J+0R=?E9$D@_P"\.?>Y9&61
M&/I,ML8WAR'QN7ZYQY#F8M-J99(\^,BA0B&64@VJDK&IH72JY@$XH[9?P$PL
MVR-16 HB=8R5R5"$9---.F4O*YY^B7E3TS_MS\_^D)>3/3HGIT3T3T53GHG^
M$^?FG'A]:_=H<S78<W<;5^2NK<I8H"T6*Q5NDMFHG2P$$KG2RAR/=##0&:*O
MRB&L8E1"6<!H35>"09&-3@2W9.[54PEX#*0.S;?'S=K7-:C'*>0[OA%=E*Y>
MZ)9]Y6IG<Z<?J%DSK')8AQK9-3WTF I.':<"M,HU'(\@N$QJ(,EBL!QT8'!B
M<)\/8E4#J&F85"/67/1+1IGHT\TM-4^>?X2Y^>-=$O?\9]L>;E)[L@G,K%5N
M? Y&3?C']4*[="G/PX?UD2,P9%=$EMS&Y:NXJS9&+U=!Z5$#5C5"0AH3J-)K
MUI!Y4)4,YW:[-Z0<)=M1Q G_ !%MJM) 7Y)MS\R,.L+%]DH48OL5EN'7;4VT
MJZBTO.3-MSD_&H*@<)7"%1E(X(<"TBIC($:$ZO%%(M,7#!/JFW?*PJ$>ER7D
MSTZ)Z=$]$]%4YZ)_A/GYIQKHE[_C/MCR()?=R,D<6'+W415OYCV]F2N*&,VZ
M8J1F3]]TZIV;22<Q?9Y1&B,0K>(HA1XVHL7;O&MA4&=XQ-@1> N<0%IV1B%
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M:"NB U^S37:KZOK0%^Q+)+Y.G'?8:T!?L2R2^3IQWV'%1J%#XZ_.1A@7I/\
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MOF*Q9Z()R>Q\1.5V/#T8W.-686$8]K:JUMSTP)Z[%H[)0ZH*1!>'41!>%61
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M)IK%7*M;M<W9.KVD>Q>J]T6>/W[6%I LB:N@@UHSJ,2YBD%*O31+(56FR/<
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MU#0S5J62MNP+,K: )0[8C:"53BA-0M77*S.\#(P $M "SJW3?+U(NFA$6YB
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M)Q"0K33@'R 1ITN4X1CZS4E(%@:ILL'J<E*#.Y<NW#$K*CL0. %X^N[<K&!
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#1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g310115.jpg
<TEXT>
begin 644 g310115.jpg
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MD9*5E]'2\"A"5I8G-D124V=H>(.'B).AN,+_Q  > 0$  00# 0$
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MI?'IO&CE[>,):]"4^QAQ=&LQ8A,& M8E"KV>F&((3RP;$'MQGZB]?)+3X/\
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M7(DR,IV.XZPXIB0RXT;C+KC2S3O-N+09*-C&,[H\T,8Q@ QC& #&,8 ,8Q@
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MG+G>94/9RJ2UI$[*6)X:ODB5+(43U! 2U)&9:@4FO#<<=MI>V]X)/>'**Q4
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M88QC*V%L@QC& #&,8 ,8Q@ QC& #&,8 ,8Q@ QC& #&,8 ,8Q@ QC& #&,8
M,8Q@ QC& #&,8 ,8Q@ QC& #&,8 ,8Q@ QC& #&,8 0==;9-;BJ(<3RTK)S
ME'$ 7(9P)YQQG@H7-1\B7BKU-5S(NN0)"ZR-1V4IJU/;GI;,ME-#%Q*\V.;+
MT8$1FDHR>]T2$%SM]:<FBWYJY=,'%4SD8>/@^P\[]RH/)YHI@-;PDN7)']-/
M%2V=HJS#;0)=ZCJ6;*12740UL]2'2,]$:=&#U;XK9<BY9VY&&#@[9%RQ5W<Z
M;G^K/B?73HW@XK<)"QTT7"@-K52,R,#,($SM;>YK$3GH7F:&>/*<N:$BV6H
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M=UTY0!;Q0@L=F[NZI)(-:ZI0#92QE-=O9KM[.WLUV]G@[?S]G\W;E< &,8P
M8QC !C&, &,8P 8QC !C&, &,8P 8QC !C&, &,8P 8QC !C&, &,8P 8QC
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MIM)EI0)+*1;="J7$\^IX7)# JO/!DD]!!/ EA"96%6 XC6Q3&$^M%>]@^;K
M#U:>R!5%(/,90B((4K(Y%9&_)$RKS3290I9F9<Y)R5&R1@-T0:<E 6=LH8#/
M,Q"[@01=F]:O9'7IY+G$)SMTU1>MG)R#A:T;879H1I0#!:#VR3M[G6Q;UKM[
M_9K7;W\V9[F]J*TOBYG/V5=L^>B@UVHT&NSM[4:/79X.W_@Y7>R1>PO#\:RB
M)DCE_41[-<.35HBJ?<DHXE+[<U3I)XA]DC)9M-ZFK>TW2T,N41IV^9ED^*S,
M9;QZXDU:)L>U5*2PB.LGE,.5Y,J5Q[+ID:"><(MTT]L>NO)I.7^'GY*=UW'J
M.T3W>P]WH'FU@=WL&M]FQ=SZ9>Z[G6^]W79V=O>[>W*;Z]')0.PA%3M$A$/>
M] "(ZP-"'O7?WH =R76Q;UK>M[T'6]ZUOMWGKCQ5D #PR:8["&N+B<E'!YOY
M+2ARE-"-SHV.<NW/PHI6]L')M(^()4PVXU&^81*)5X% OA!#.0I8GEK6NSN6
M<A\)PKJZ2-9Z6F[CX[-S&TV0\W4P'NL_IWTP/MAS1BJ\\UHJN9S%P2+)-Q;C
MU<J%#=826>I&E,I>3UVE(B5" @:\-<KI]EB:VUL"PB'O5<^3%.$[83XTN5&A
MMJ>>ELM/O(6XHFFW%<3'1):;U2N1+CQDRI,.@$7>U=5I4UJLZG$FU@1)136J
M^#(B1I,UQMEF*\ZPTM#:3==0GCI*HSKA$M$:)(DJB1I=P/P\O);_ $-47_\
MNV#_ +R9*_2_)V8<N.G==-P3B/1J,OJJ(7U'!M<4$ZB: I(VR.*)(>';RK6K
M?/)Y8]B4ZV?LKS37^* $/>S39*T+116ABT,82P!&/6]"",80Z",81:WO0PC%
MK8PCUWAAWH6N\+6;2?3K_)*6_P# >3OU%?E&<(O!<1QS9;=6-'1Q:Z:HGXQR
M&79:U&P[4VBW&]'I#J-U2FFU&9)WM4EH9%J0N%P7<^S')ML>,5U]>R[&$F3
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M3^\$?0EYV<FPD]2(_;(C_P#)#&29:&9>T9E_X/0,8QGT? QC& #&,8 ,8Q@
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M#DKI+U;>FB+ ;HL+X]M^SB=&6@_"8<)-<C)'Q4%>+<7=$47R9B>6HZ(6&3#
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M$JKF4NI:\ZN2X232Z:MTU\>1H+E)*NP)\_50K7_2!"/_ 'MCO^TLIZJ%:_\
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M&, &,8P 9C:FXFT>CY*N'+!-$4I-PN54MM/*74LM$6U^EALGS[9!+@4U 0A
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M+K6M:USKH+LUK6O$EG'YM=GNQ\?@3N7?NZZ"_8EG'[X^3<<.>0IG*_BY1')
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ME[T?]" FA]$O03T3>?0SSQYK[$]%%WF7<]GG@?;WLCL8P 8QC !C&, &,8P
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M)8#1(V&=M#-QI?K6;)2EBHZ*BYUANQ*[:.#&2>?1./PR-2D8'=N?)E()1L8
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M3#65(588^-]?<F5/):EJSX/*8C9::4/-LH;-C3\ELA@=%3R>8J+6$&./T42
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38P 8QC !C&, &,8P 8QC #__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g311426.jpg
<TEXT>
begin 644 g311426.jpg
M_]C_X  02D9)1@ ! 0$!A0&%  #__@ ^1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?5$%"3$5?,E\T0U]40DPN15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MWSU9'P+H)L/LA' TK1H5CW%E@.A39PA]X2"G-$Q\=20")DX7Q+'R(V.07NE
MOD +8Q[0_ 7V0K6#O>]FS9I[-\"NF/F4\$QL+[IE$4V59*)&CJ*2"?5SQ513
M4JR=8!(*AB!*!T\K$@4XK[ F1OVAL\<L,2XU\*-.9X%J3%24IN<'C3- ZZ:K
M$ 8_4I':IF5<%42$M8@H))&45K &+*0QC4  Q?J2;#)*6I3A1E/R2M8C=1%\
M(/?IE2.E$TFQTU::IRN%5$TTA*(XPYP*6D398B^;TL=YK^\6KOGJ?-Z6.\U_
M>+5WSU9T*79,[B)Z,?-!(\8+#P2D6R^IQ(@RFA*<K$T_W-C&=N6\"X::9.8
MY!Y8%2:\/8V(,$63ACID0((36N,",7%%+F 12Y@ 44 <N.$( .7' $R"' '
M%QP% ' %PS!' %PP%!%PS"%PP$PRQM+*GF"4\!<9.I(ID#84P7^C39K"EC $
M4C& I!$$U0(845:!26 AQ2.<"FHAFTNPLD(H!.4)W+!<@<6_UIG: *XH2 J0
M@G, "HB)R ND(XU$3E!4A!.%,@?-Z6.\U_>+5WSU/F]+'>:_O%J[YZH[J7H:
MA%[SFMN5(9WP4B493&<LD/5SNA0&2&JT6:U2GXE26%U4+D5(8OB.+D"G)9<
MB8,'U(P&"'A@"&:,%]]TVDC%NJ[=M)8W;(%KJK*M6Q2$+24 I$4\HF-5*0H
M)CG$I"@8Q@ :YJM.'SA)HS<3!PY7-4212<.#'.:BD: QG_H4I1,<PT%(0#'.
M(% PQ1?F]+'>:_O%J[YZGS>ECO-?WBU=\]4:W,E[8^WD."'CQQM?WHH85\,\
M[>UB&);/*UPQ>'YA9\,[7ME:^/'&_#*76;4";-N%%WI<+)S94CC'(HBBX,7(
MY@6T&&6<)I1)I=R8HQ([8X(*.EF["X6L%8''$+*^>5Q<<:PF">#\I:*OYDA*
M6+)O4QSITW:HH)8Q1-%.NH=,"EK*G33+2.4QBA_ZFRRRX)]-WB,OE:DT?OG
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M!2@(FH'U^;TL=YK^\6KOGJ?-Z6.\U_>+5WSU99/#LQ=X&$TW,^'9"=TIKL]
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MO2QWFO[Q:N^>I\WI8[S7]XM7?/5'=*F^URS_ %S#^FVN_CN"(/N#_P#SGO\
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MQ*89EL?QIC/$H4N,9O8*J<7V!I9B,H,ZP9+-2FJC+#*RL'X&!(%ZHLQ'Z@#
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M_P#G/?[2_P EWO:,2)\WI8[S7]XM7?/4J.Z4^URS_7,/Z;:[^.X(Y^X3 /\
M^][_ &E[OY+@Y$84I2MZ-.-Y&OBG#"5V3(QJ=8E>\T,J^Y*H$ T(_7CK<705
M_-MDKIJWFH$!@1\D]/"Q.A&BU\KABYFP,LL;W#M5FZ8+>LIKM'-9U*+83?,&
M,K-+?"/BCRDO'W&.L2D9:KJY;4TU351Q< KW*F $PB0"%]Y96N7&"+V,& Q<
M\((.WJVGUO98L>0Q*')K0'7E)S"I-F<R%V^:TK@D@% Y<^X6\J*%K#A)Q3&Q
M:QJQ8*X5\@0<,A!;YTB;=SME]B1F.9ER3SCC.1LL&G"QSZ>@MEI*+<7#ED^X
MJH1/M%'1#?XP/-*3QB8XHPF9$P6P'*7!&OGGEY$? B?*N\+&YUD$Y;A,XPB,
M5TEA+.RBT1G+$[9$Q\&@EY90X<I*"055#/2'JTF(J)TDP-[$7#K!])I@@X(B
MX4F6"Z&#0'9K8,2,Q7BTC?I.EBDPG^Y&G#=LLF"@)) Q,0#% IT@(J<2S'>/
M-P5?M I*2(K+/-,V>^:DJJ8#A+C8H9\H0'.KHXBP;<JP5NCE6DH-,P3 3#:A
M[:$>3SJ.03\!,QT\&T7/'7&23#/<4Z2-)T0DU%Q.N4_=I*R]CAI^24[&2]#3
M8>0C1(MQI*#;7#:V];G2" )\<20'&>][FGX8 Y897DQP=J)O,YF4;8BI-YC!
M,4$G%#4%I*:+.17L=3;!W!%"&>*6BEE@$P:!O<,THD!":D+:^>>)L,8047.H
MQ1N4VHTUV4(O&SG5QKMXTD*.$V,5EUM!2UBS4GLY2[A29.%;8B>5=Z2Z&68P
M$/IB67P5LAW!_P"(%G.EDC I *PQ6',O28K%E.#H+HC)Y09*3F4<.UY<U1>?
M4G4F+YBT*S9G<BS^E8?3.$V9/J3J/2BJ"J5;C<!)@L^0-.,)#(+!.)N56=%3
M;M&\Q=+,?IDR2YB_>&>O2MBO?JY@+MN=X?Z8J;(01%):"IBU+E:$&MD['<;8
M"J32W608#\3&4]";H7XHD)5;V+J36+)B6 4*W0'">0[BF@,2 ZTE_B"AQ.$5
M U #\/GE9K^6";G9?[TO)(]W9QNV3X7C!:,AAVN=*,G%4:R@.5L,'Q& )*P[
MD50#> GNRQD.^0>>0E\;>Q&&R6U$7RLT).3HW8[^;CCV%FUL3Y,0CV5VVHH;
M<<S6:RNC%FG&>2#B&I*+>/+KD7G 8676 04P2XI-'!3\L0[F0K8U9G!GM!A[
M)0!+"L=1(LV&C7(J$OE$D^NY,Z6F0/9<C5RC)*66-J9I+-GP\D9:Q3P,A\,?
MA)D7+ J4,YXR.T\))I@NV6FS(_U['"'!^9N6*#<I5W<OEDSE+]^B1J@LZ!0Z
M"R;X&J:9U#O4638Q0.HY Q\&2F#,JPJ<HRE\3Z!]@[A%*VS]=P(HM)A-)7-I
M?+ECNET&F+(X148B[44(F1DL]=%-4(V$I=FAR24.!V7V4R>S(5@A06)W83'2
M)-=KMC-%<+D6V\JN*.T%52BYP7$M@2,JO,QQ14UX8,^K&S)1/+YB?@PS()J1
M(]LAZU3IVPBI&*03::+%+/C=]MY$1PL"::D73BJD^SQ)**!8X@$$_)0'/W*)
MY</ H2 'Q*%0 RH00.&B-=V+F-SEX0+KKMQ-A:Z$4U/AX+!#;P%F<52E%'5R
M('O2J6!FX?PRB@I(N([C^)C"X$L A<L@!1@L[D4MM]@5=5GE:47Y@84MFD(J
MVIL,<KM(*SR121 1+*DL  47 NW+!$!1"WOVR$D&<L,\KY"WRO[5=<7_ .,Y
MJLU7;F<2\WW!!RE-0.[?'(\,;#IA/V9E"G;'*?Z:1(.6)!$I12<*@W3*+<YW
M =C0_P"3I4BZ0<%;S @R]=JK*139L"'9%+@&^P>>E3,1T0Q/J9ZNV?* 4Y@6
M02%PH(.4TVYN25$#%):^[0BDTO/ ,'<S=-[28V1B-@P"*C#[1UE7Y**"%\,/
M]0I.TCR49!QPQQ#!+#%;XWM?,7V;:I-8B99W1_VNT?N$0*S3Y!=TE89&,;7"
M3WLPI$D51:RB7%$OB$7.W-%2X>&5L\!AK%P@\;9X8987PPQWBVCQ=$+O.\I#
MBN/7MN*+3B,^.UV</@UD-71"S<4BPI$5!R(. P<1"95/%47&75%"X0 >=C%A
M;7SRNUN;!MEB:ES>R496,K4[[6R,7QE0W9&-)Y)H1.V#QAP6) *F98NG**O(
MSH5U<8T10\A"J0AF#!<]8L/8H )K-L \()8V7%TLW?S.<FP-8'=L?J3F;KR#
M"-9Y]T7,HW2!%%I@^U8?^4QBBH_1.U(6E1L9;:<X?X.S1PV!J@YE\LDI<-'Y
M&;[Z4A5V^$&#+=D,K;E3<JF66=X1.9B.**002EZZ;HYJ$G)4<(N-[\+WM[-[
MVM>^/Y>S>]N-\?\ _&_T_P"5*7OQO>]_SO\ 6]*]UCP6%*4I"%*4I"%*4I"%
M;&>R9X?^\ @/C_\ %)/_ %^5CQX?_.M<U2M",SOK7R3VS+T:F4HH]6C=5NC&
M%M*P6DP/XTC'T(_^)3,S!7$S[:<HFL O^\!W!&RP&QO?(.UKTF$TN7F^#D^E
M344RN9E)IFP;BL82) N[9+-TA5.4IS%3QBA:YBD,)2TB!3"% WF#$Q;R?"7!
M^;.P4%K*YW*I@Y!$H'5%NR?(.5@2(8Z93J"FF8"%$Y ,:@!,6FD,\]R%31;
MUL6''K]W*,3SSI((15'=)M"PB3FZ[Y/AN@D+8E;!3R; 6-UL)"#QRL+GA@F8
M&/;PN*'G-G:AEF^,\=$60LNA08FHXL!,:[=<:0CC+B$C!&A\2[H<J>WB^8)9
MPN1-:>#0&P)8VP4,B)O+,M[-C9W,330Z7(J/%T.5X+@@ BV['$N.A9%*@6*%
MA%=PJIM94Q"Q7'//$J7S/'1\@"^.>>( 5\ L<LK86O?,R'.T4V0AF-TZ)$\Q
M'D@1^@"Y#-- EQA$G[@SKY7%O8%MFS!]/-%B(&0PER2>=$/E4S#/,NF8DB>=
MRU=)7P.FTN+@V\E3E:;O)*68%7;368I)'*,TE+>7&<2MZ,L<((+2U1#&-".F
M*Q#I.'13F 3@0W>4,,Y1,C83,ILU1D[.=C+3H.I1+%5DSA*9LO,0;S5C]U;+
MKHS--?%NU&KY Z:K9H8A! @G)LNQC-SL_9;LG7:I[$R%/K->B^N@QAG)<9I\
M=.-HLI&;25FG%\P\\>;%(%;*'D\T%9W#&#X!<F5-!B7N>&RR@#>=4T6"EC:,
M,J_=Q@MAL'D_L,$7$XA PT')/XC+'\#A[JV*K9C7.WN%>V.>!O\ !99<<KY6
M]C+#1S;^[//5[0[(CP>**Y7A!+N>#TCQ54VJGVL157L,"(J$5 F1&)%3S?3P
MBQ<BW$4((D AIP )0 07$.V=8S2/(#DE60'E)KP&)F'8_7(INQQ#IY/%.(#+
M"N/^(.B$R&(HV),MD+]0R^(HE@[?3V\OSK3D6 <[2F4L?3F8%;?025XQ4^Q+
M-6I7#A3"A_-D$EDD90S;*M3,'"(.3I-6:B[O&G,F!C&4-NS[#Z1J2R9L)++C
M.0?SMF_3^_(NG8MFY,%);*7*R"JTX>.DG99BV<&:D5=O$T&8I$*H)2D3+NCF
M% UE6]$>SAOL3+$KQ?@5BE]6:N<8L$N]\58,4TV_CN2U8?ZIUDS --R3\0L,
M[F_Q1NWL97+XXWI/:5RQ(D$R]IHX8A6R7+<;ZT)@T%2@M@)SV=3R1EU(3T-<
M77LD/!NB)@2IDF@I5R10RGJ6%LE(9<",DU(>Z<D:HI$GJ1)2C:'8G=QI&,,V
M"4-;;L>ET]&P3U(LF.#,AFI8+*E@9%S5Q\[II6P0V0)7W-L<[VPRR%RRJH35
ML;)^P";%R9)1M"/A0^QB\<LPPD(6",<#:I4%.!+E%<4$V."IF@\4PME8[8L4
M$OGD/EEA>POLX3RS -\WF4F=3%=*8L4'^'*DPE;LR#A@@UPC<OCM!8(@Q246
M4<MW&)F23Y=PB4CAP1$@A5$L$UP_E[F63EK+D%I<_7E^ :3":M"+(/W#K!IK
M+DWA7ZXOUDT4F[AJ*\M58-VRXG;MCK' U<#;2]^2JQL8_NRW(OA?R^.3A"4;
MDG<YL2Y(B)\0D1V,<%P+(18H7 3RAC,14.&BX)<J&3 ,Y!8!E\0<;!U^LWNB
M#4:9M@=+4#L^&^\&;%;1/)30<T.-8V+L<@+::W4%0O+;F>(@@QI1:X(ZWD=,
MYJ&%PQ@\B(JD;52ZB9)6U52AL1*,O$X=).]43<,8(9*4P(W--Y+^ J"6@H@R
M<82Q3ATN;&%.K),=*(C@JN'X47 8'WV 6(N5\ZR->?:8;4OIDN1H*RQ'Q!4>
M[7#93[D]N1N@H$MO9IA@7*_ G ]2.>-\R8I3(0J-DG)B<-< 8QB6$*9CBYY:
MB>!4_:,L'F2)&B[:6(39 &:4ZF4G;RUZ\PA+,6<W0&7)$4>"VEH*-/I1%$4S
MJ"1(V*57.7;6PXP>>/L(GRQWJ#F:+R=<7BTDEDY<3-DRP=^VOI.N69+G(S^J
MF8$=B[#'@J0@*+%QJ"!#8 87O<,.]\L<[W#PO?/#Z89WOA:]\\/K?_1G>]\L
M/K?_ $WM];_G7M7BUK8VMCC:V..-K6QQM:UK8VM;A:UK6X6M:UK6M:UK6M:U
MN%OI7FO8>;(\9YMA2E*0A7MA_P"?'_\ 5C_ZVKUKS:_"]KV_.U[7_P"E(Y#(
M(#8(1R%7\;U<*]GCV==]FW/L,VB>;*=%F9G  J2&:.'L2J?\:P=-U6U\;E 2
MUR&23[C_ %6,9G/>?3V*C_3L\SBT4]J:Y=5%:2EATID2M8M#ZP_1034R Q]F
MW'*.Y![YD+6]TH%U\!6$)_"?=BX7(-X4$"QX,O[6IN0=B9-D^*8;AAVG40PQ
M8')JA&.RQ!$#3U0J76 BX)VRPJ8FALU<3(,J#8//(N6]W>V65\<KY7O5/@N?
M)7UN?Y*3(==9AJNDH5,)IC.Y<!12%M'.9!9FT1PHIRV1%823 @( _P"',8XC
M%#@!=03C))0+@&@_(@_X\F(8/SAK]Q.I,7TX>S-"7.70J8/G3_ZK+/VR"R1&
M8.4_K6R";9X:LN5,SAP)4U2T /L)O^1I:.$4E=_;BIRUC)6,K7F35KBL(2*C
M@C_TZZ<(JG>BV4%BY64=,2"5 R@-FX&41,)C!L2[/F*"LBQA-]HBVTDF.W\;
MBM]JLU1@BQ"1=; 5&2DY*I-"*+[U<US+;,*SM3S(U@;%L,'4 6-K8  F18B=
M$MD:@F];@.R:TS&V4<,[-EKC2)(&3>,0**F8N$5P"+TIB?A%O-6QR#S0\4G\
M<)[6' :ZB&3RRO[/M5@JX>U*VN6<Q0TDS%C$2%!/<I%PMQ@QFGMU"=V;H13R
M"=478#92-'UI1(D5 R*C"YJ()8@HWP4!2IP8/&UL67%L/)CI@6-=;%<XB"1;
M$Z\IN1FDBZ&&77BZHK77+G,U)>L:S$4@,KN)4N&!D4!]W[P&U\\[%\*A7P-P
MGG4P^MF:C:6(JX42B=5&+UFI,V31G*IZP<HEF3>0L?JU4U'C$C$'B;HR+(#I
M&="H0XJS-\-,%9'+_HY6DYF:Z."TWD@F?LGI)6^>/)O@_,&RYI8YP@?_ $:9
MTV+\[TS0[4JST2*E:E3.0$MKW9V#0>H;<[*8Q.YI>4(8OIR^ "J[*UB:E)10
MOF=9/-@HA4E>Q$4,D;S/CH)0&V&(X-@<1O:%$$SRN#6)(@=FZG;[+NGTIR5-
M;MR@,HDO!KS2WQ(X245BGTAT J3M1DDDGFRCC<)9$S<8A$(R>)\32<721S!$
MN=L.9T]0=L!)&O"X['#&9M%)J;U82]&R]FN(H:V *UG(*2&4P2@&9DK8H>R$
M(%L@#ULQ+@VQSQN")B)EC7[PYL/)<%-F6F>P#2&$WYM8F4<2"27$3!8S/-C(
MFKD/=IIJQLD825#$JNJ6&!\ 02]LA0Q?<W$ "RQV9Q@#-':\X4:S)91%P&!A
M6S5VY1%":$D#PBK_ .]"5A]0*ADBF.@9DX:@JL8<;5(- :TF_P"094S;R1)U
M+4DUFPX:F=.VC98J\J/A R,BP^Q@:8?3 F54P%7*];.L2B4N)KG"D=L$%NV1
M$PY 6_\ NK*B3$40PDQ<&3KJP&N6Q0WO."2E(ZBE)Z(U&*74L@\V^?".A9KB
M^=#+8KQ(DD"C%T=K%BZ_:Q&XXXPCW5*5NT)/0'$TJR5.&VSP:C=;LLH_-T9Q
M,TU4\O.,8*R("8*$AE8^,$9*YJF(H I@0ZE9%3(),',D?Q^#[4;:.R TVR<(
MP0M)#';Z<UVN"X8/;2Z*DHB61(IQ8F5&43HUP,,BR<3L8Q+8EP1A ,,[@XVP
M#PPC6+][IXBD>2RZ0%&3D:$M/$[(#QC%]1LBN:,[O$Z9L:NN(#5%&*XMP4OF
M&5P+E$T[BGV"()MAB@PQ J.'HA@=A*I]4X5ETJ;G%Y+TR2R6SE:7R]Q@TQF+
MMZ,@(+:6(KH*N5GAG[U^X<.0=NBF;E2:-%!)&_\ ]:8,I T;I3*;.2 RF"AY
MG-)*A,9@WPG?2YBS#"!0'4U60<)-DF96#)@W0:BR:F*X%5V\2*<:#N!FSU*2
M4!ULK7%XZOI;U8+?<IJ/',0$34)35#>9O$V\XW(C!!"%F(X,/<W(!8X8E?Q9
M4R.4"+X&!"X>*52W-\Y29L3(:G*$LN"SA=BF5(IV(A<B624E)1TL,0-,0T)'
M)8XE$M((8BCY E@_>#"F#!HZ=,FSIHP9%B2O4Y&U<,91+VCL"E<MVJ::Q".W
M;\B9@ 1Q1'KX1=NBHE$$@7<4** 2L)2@(%#R>>NVSZ<3%XS$QFSATHHB<[-I
M+SJ%,/\ ^T[%A_\ AM#*F 5!0;B9-,350,<0$PJ4I5K%3"E*4A&16H/#_BPU
MCX_E_P 0$1<?]N>$:MJ_:"*6B1?8C8G!W/S<A/G@,7*^:.T#: !$@+R^7Z'D
MV"Y>^=K*>#;&O=$S7+XY8F;9BJMP<\+^[SMI(8SR7(Z>S0D!L"E07(QG,ANY
MOC'BN)XD$M-Y1+JB8(;)9YA8FRV!LL%D,6R$#Q'#MD'?/'VO:M<$P2R\ITDM
MW2U((Z::>;W/EE)?,(Z;BD)HIHHEIZ.!<HFXCF<2H>)%,*8986'%OF+B(+EE
M?(2]K=&F^"KF;86,9P9\Z9,&DA=,#C+W)$':KM69M'2:2A5&RY#LC(HJBK08
MAQ5!, _[:1CO<FPL;2?!&828&#5\_>80-9@4LP:G79I,TI6[:'52.FZ;J)O2
MKJIXH1(<@)&4$1K4 &T+;@4VG=FAV<"4TC9I-AU?+KQV4S:9@)DE&9-R_!C#
MYN3$.X81\\453$CFTTDH\;&E$AECA?,V5)WPKLH1+\"U@U%?C$VHDF<( +;7
M1\T(Q9[^B E'Q1%$%<"L*HN!LJBI81X&$4,=.4DE/*Y&LVX8!,#_  T/ !/*
M8X8-Z^;U; :VM)8CMF*#0=,;+9[-6,QY*#2+/EIE%@40,493221@X0-)8QH8
M+ P<*ESMTPV<QLH"D+J.0AS/WE??/9&:49,;C^<K</MUOR>U97:J"FL],14E
MH+[*2[)#<1VR3("AA)K/*%O;&,H&5C&:@H#&5 THYCF!*ZRE@EA2W<M&2)95
M]M9823J=*3!1PW67F3><N';BA5FXDJ[EK-FA78M0?M9J@0S4ATZJN.*"':%<
M+\$W+9V^7&;?<WN#,CDB<N20<HMY8YDC9BVI1>MYZ@V=2=X+('8L'<H7.5V<
MAQ%/$B9QM>[2%1T2+;2R2',SZW%1)=P;#,R-I<4&4 &-PKW9I?)KYDOQN-SU
MLQBWX,1=OQM>YNYCW.>%KX98PI':7"2[V2\: [!2'(<=M?\ XMGL9)KL<-0)
MZKAUSW(NWW*:;('!,?=IADH(IFC"AEED+8T6*A997N9RO6J2>)TD'9"3EN7I
M1-)!UZN DBD%(PAI&"&F9%F^F@I*;B FX&3>(.>!, /$;/\ $9W&$M<2_LWO
MPKZ#L^R.H0*A:V&3:-E%C<D$])R82P1L,%[!V*)=1*F1AU[\3<0=/]TJG+!D
M/PF%L,LP[W&SL#AC4C'_ (^F+3![!:6!-WP/)=,) \F2GUB"J; LLE[YLX+)
M,;+C$* JNB@F1TBJ!TTR"8Q1(-;%]_R++'>$F%LT&3LA93.780,Y8G]$NDJ_
M/-)E+W3<\]Q,R*<P@BS,*AVBZ1B*G,!0,4__ &[C]DS3[9VO'9DI.EQQS2RV
M$]S/%YPY("TB@KLN*\FI15S&KH@L=K:%=)3TQ"25%U#%2%[*1<+-#!(Y$B@*
M$24%>S(W6"SUT1[0A.:KHD(]LTH M]X[=I,VD@0FZF&";A<N;NM%Q=$&Q)IB
MMB:3E8H9YH!"5RPB6&F IQ0B21!BNM8+;Z=BK"@>.TUR)B.DZTNDP\8>5DI"
M+E7.W%PT.I#CYFU;(<8LM$A;JIP$4BHI8@)@IG8H9N.7N-@-)4Q]H9L+-D?N
MR-5X"+&BWI%.E%"43$9QLFLM>D\T2$"'"S?"R"=/F53 4T%B8.8 8D\SO'(H
M9%$3LQ20ND7 ;"!)NP8$0E*N*PA--'$[.YHF*J*.%RL]2":)?05)DBNS4(H#
M%J:7IHS<@J5BMJ!C='#S!U5P^F!W$X2%3!PLI0D9&P&EJ2R^!S>0+#*E1F%>
M6+-WJ9TA>NBS)5:3&Q8@9R(A&PR8+05JW-<=Z4)FC#*V+;*M$C>6G>MIK8-K
MFR<FNYRI*Z;-../W0"+@<3RJ4;1;FABQ$/W94N"H )IE%!2RP>>B9Q$P4YPK
MZ>7(*Z27(+JR1+I3@L'BOI8!-3-E@$Q=L%C@'9;3@@L"2O8/ /#XD :]D,.W
M##'.MO=IOM>VF:BM<DNL(XO-AIB,5IRTL1PA*DS-=H"%K%/@:,_!\K9X!8 8
MX8X'#B6=/YBAAF39@V<#Q,VU_B""#""C#""###"B##CC"9BC#CC9Y"C#C"B9
M9"###"YYBC"B99""BYYB"999Y997[9@5(IQ)0=A-RI&740;)+O23F93,\X?)
MK.U',U4:O")MI<+@BR)020(94:IDE3XENV".H8<3Z2SLS09,*I4$UW2J#%22
M2N6%DS%5%DFVE*;MD=5S,@;G07$57!B)!6*LD3'N78QZ4I2N^1T"%*4I"%*4
MI"-X?9Y"QB#V>^^HLRJ4@(\8X/&/+NY2BS(KA(!0C^!;-BN;:R/6N4L;R4[D
M0S'OO]/P_,W[/^OV:I.H.>G"MV@FJY:$W1/KF0"XDEGU8/8DRE#7+R*29ZD-
M'F;6!3<?PV.?#!7&$S'QN/BJ%DC(L-CEPPMK$9>Q,G,&%Y9@)N'40&.)J-HY
MU^%#B(&<63(Z'D0R3[I2SD:"S2L,;II2XV&)4Q[WV<^%\/>95$2(N+396DER
M-Q54$)P(*F2641;238Q%42%9-,AFR"BG'0,L!BIPF9"#& &#RMECGC:U_:QO
MEC?S%; 1V\<X<.%9J[9&PC4>IR]%LY S$J+S!QG* <OVPM@5,X2<)K' J3D"
MXM- 0&M6"/4D</V;)O@$@E*6CT,&4V"DQ6=-A!\99EA,\G0M6#H'(I%;*MU$
M4S"LU$<:HN @):HQM%BY&69#[1&5,9-V$E&"=F,9P6D>-3[2CDW(KB55U0<[
MA1KHQHKD+=/;S+0V:$CB Y*X8K/%:@X@PV-DTED+GGC";8:[ :/;'-C8&09#
M=K:0GLS0I.DIB)""W)*<.!EN**DJ.)#1B&&#?35XX:/87S!+!X%,\K#&+VL*
M.)QUKKO:N;?KR38 59C1+=^:>62C<LH,8(:5*QQ/ OA80ODYPS A0E8Z#AB5
M.Y)2,G^T7N)@3Q)9BW$Q@U3W5GA63]EDPXIM2Y3;0^04IEP!:@069\TFDK)Y
M6[:$NHYY-W#$K;V,\,?Q]\\^(M\K9WXU0/<#,+IQ_P"-VE*I6V*PP<EY$&3Q
MLNHV&23R2O5EI<\)(&CQLR4:,WBS-@Z</2I/C 8Y4RF("78&.&N!\E-C&BLV
MFSDS["5^=P^9.D4W(3W!^=,$49FR/A"\9.7J;UXR1>OVC9D95B4Q2&4,0^-R
MGB\_JN9W/TH"UD=NR+D"M/;=$>X4_&$H0$J+BJ)F+>$:P23?$/W@F.2S@JB&
M<<A, \2.(&>.(@V.6P^)FEJC?M4'XMM2;YE/[%%I(FA5+Q<M-3)HQ@HO#!O+
M7QEKBOU/3E<X;;Q4D(>.@7%("8G_ ,!@8]P<,%04\WQS8Y?[DBJ0&9)K/&)E
MW8PG(F.QN#J)+%1( K*0/^()"'"&8@.)POB+]1"^0H=A+?3V\?SJ4VWM)+S3
MV-.;5(JD@@3 ?<[G=QI0';P!EO"+#O33Z4N<&]F9L%@3')*1H,$M@<MF6SR#
M%#']L.W&TG^ $R?G>D83A\5(^!<QD:*SEVW,Z?3!T_<.TT)F<9:<!EIB+ DH
MHU!NZ*F4I"'I+7-58/?\A2R7E8'?R5B94F&\MGRZ+5HY(U82YHP;-%'$J(69
MI"$S R)EDTG8N&AU#"=0M!J@;@-0H=F$PMRGLPV$5CWG^5-MEZ,W&7P>#802
M<(QFC2R"I3\IM;!PGRAU;<KT,ES##;?P<B,>Q:F!I1Q% -K0A 3!SM9(_<[+
MW>EA<7RY %.DLRDO%IB$U9/4AC*"4;J"UQAE$J2&%'13=EA%4 <$]2P!."%@
MP3N =RQ@+/+!4>17$/*N4RWP1PWOE(>,H8C!I>'PD-VXN:SOL.&F"CC7Q3_C
MEKC_  _(WECB!ED6Q&MAPO;[9@E=X3E)COEN0!DLP\WRHEU1P&$9,P1TT8V5
M2T]' R*IV YFQ;#$@F% \L;F!LL\\,Q,L[WSO:V_),#YS+,, PA7?R]9FO)'
M+!9!-FLDY:@925_12Q!4SU9,[-DFP#%. 31IJ+"=J9P^6=DT)WAE)9G@:.#J
M#"9(O49VU?HKJO4%6KFHG-/KIFNB5BBHF]?*OQQK<5EJ*R($=$;,$6BD;TI2
MO2H\QA2E*0B_?E5*'=K(/@ES_P 53Y52AW:R#X)<_P#%5V$GP!#_ $=*Z<2_
M8I\ 0_T9*Z:2_8KY(Z2,Z[+2OS)W^KIY')]A=&23]K)GY8U_:T\CDZ]OY52A
MW:R#X)<_\53Y52AW:R#X)<_\5782? $/]&2NFDOV*? $/]&2NFDOV*=)&==E
MI7YD[_5T\CD=&23]K)GY8U_:T\CDZ]OY52AW:R#X)<_\53Y52AW:R#X)<_\
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M&2NFDOV*=)&==EI7YD[_ %=/(Y'1DD_:R9^6-?VM/(Y.O;^54H=VL@^"7/\
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MCD4!G%]7#S0-U,C4J.>3W;WINKHK%],TY/=O>FZNBL7TS2N?J5-I+Y-/(Y%
M9Q?5P\T#=3(U>+VM?AQM:_#ZVXV_*_\ >W]JCKD]V]Z;JZ*Q?3-.3W;WINKH
MK%],TKGZE3:2^33R.10&<7U</- W4R->UK_2_P!?_P#E^-K_ .]K_6U_Z7^M
M>/9QX7MPMPO?C?C;CQO_ 'OQ_._TM^?]K?VJ.N3W;WINKHK%],TY/=O>FZNB
ML7TS2N?J5-I+Y-/(Y% 9Q?5P\T#=3(OLX_6W"U^/Y\;<>/\ 3Z\?S^GT^O\
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M)AG>P34[0D2E,C!IR8(M*34II=UM-B S(30+RBH(MBXIK)8(Q\*LX.XVE6+
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M>F@%R0 (.%9YP=O=8ZNM,7U-3G!V]UCJZTQ?4U,:2Q3PE>"\-<*H]W:+OO\
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M&P&W(+H<C;73R"ZD"-[/<V33"R_(3L-)#*99Q5.<G6]K7XVO;C:_YVO];?\
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M'#.X0>5A!/9PO;*O134TU&(&E17/DDM-)!7&.*"B;+D214&V5L;BF39L4$N
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MVC$<\GNWO3=716+Z9IR>[>]-U=%8OIFKY4E)/1TX\KJQXFF):63,J"DI*!D
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M>V"BB3(Y#2E(R;50&TS-3(&A-9P<I05/*!)2GD[XX<0I(J5-J08Z-FFGLS0
MYD4F60C$:$'AVC9/?1"U_?\ M'K/L)%<<Q<I25M&*P]07)!ZNP1WL5.HVOK"
M0G8/L_,8!I_2 KI[H?RPBGFV3";<9,? ^?,W,R$TKYY+;1+N^#@EYJ1;JV;A
MV"XM(Q<X)*E#:N<HY49O0<',5<Q%%:L,,N+&[,T+GRRF92@5QZOU_N1PC(:"
MUP4E.1"!Q:439I)^S1K7V5((C&;'3+EFPK[';$;&3]L+(XB,O&U1N>_=+L/-
M^$&44<IE()*(B+'T!-"(8]PSR2[XI^:&HY% 3.-_>F< MU]?.T/VD>6OG/>M
MFOTX:YHT$IBS-NHYW>&1H.B]T[4JCJS-J8<DJK?UR>BAL?",>-=(2@&,QG>1
M:K,<+H<"TX7TRU[-$;Q0JA&Q[L[]G7/N)I]$&P;S06N@NAY!OA(6\V"?5%2-
MW4=CN2'A&8DDQ8I+88:R>BB5+,_&1XQ-*MS!X5C.A"N8/JF=OB9S-6H7UY%D
M<2&V,%+$1QW!#V3TP='.1+$[^SDR.V0D(A\VD-9):KQSCR*L3Z9RL21S&!$%
MA-\J@B#B(!,$V53 3YJ:*0A2E*0A2E*0A2E*0A2E*0A6&&XR-M>[2$5LK6F3
MD& &ZO/=6.[![$F4=D.][Q7$K:93@7 @XL9,D)RLPE)ZO9Z%VVV1G*\4=?;S
M$:HKB<9ANJIX-.Q S/K5MVGNH>QNXC;@]E0\ZH$SC)H2,J/N<H3V.1I66(JG
M\FFML8A'+.?Q"(G*U%MS,%M.T^,^7!'B^J#,I]*Z&UB+N2%M"(G4DXA&IMS=
MJK,C&A,*,+[@-AR)[_[05^ZKPMVF=H,1'8.^]>(N@,C-LL28P(9C1OGHYG"<
M6I)MU74B.C49L0['DK2$%B[$*/%;-NKJ&>W ]F/,SSF6))0/N':)'VY0F;,S
MB9;)DM9B-4U]V#0TE/;K95%*--JX0.Q]%Q!A30RG"JJ( (B.PV:3=D<GV.ZQ
MVNEGE0P,>Q]>FE>],A,+79_JBYHBS-I]'YT$D;51 C"-)F;.KQR,UZ&%V$GK
M$DB-]5<JZ\FIBI-AY+QAJN>.BXA9EJ3?98Y=KJ98NKDS4OZZ:N;BQ4H33.SJ
M?6M>>SFU^S$*R#/22@-:4EF$&A ,5,MF0Z+',3CJ"\V7NMRH:BYI&%(K*;W*
M$T89]+WNU)C"-5!32 J$:F-I.TUV.8&V^R; 0-JSC#GB'MMX @O6_04'7IJ.
MF ]AXVE@"(#2"NS+M0=9:D+&[YE$!Z/PP :$GF(L8IP:B$4.1XZSJB3"=O*U
MQO>]OKP_\V5OI_:V5[6_K?Z\+6X_Y_I;\K<?B6NS&W3<[<VZU)8\P:T@Z4;K
M3_)TVR%(;U:,B*&VD8IL[/%+?<J,ACI:?[45/A72EE-$3H;D]Y+Z6L1RA&44
MJ8;R]DR4/$;D"A8>[#P#]K++V,<<;99Y99YWMC:V-KYYY7OEGG>UN.>>5^.>
M5[Y7^M^%(1[TI2D(4I2D(4I2D(4I2D(4I2D(59"O)<=M]0,)*X^V:C*A7W7X
ME-574@)I\O[X+ <'WY(ZH@&0?>@B!C!^\"Q]X%G@)A[6&>.5[WK#B5.SNT%G
M-]KDI33I+J;+DEN;X=9QR#)>O,3OAZK]D=+)HB399=#E:BDM*?PQ&3R"40_&
M'1OP::2*$B_NRQ<(/!")^^<D2]YT>>.&K_+U(!(X442950(&BYTB=+@FR9PF
M.$:*&BI@/$4 P6,@9B & !@L\1 A@1,PA,,L<\,\L;VO?7_?LD^RRO:]K]F[
MHE>U[7M>U]3(*X7M?Z7M>W(WUM>WTO;^M9T-%HM5@-5ML9C-M!9K+9R$DM=I
M-)K))! ;38;:"1 3$1OM]#2P"J:CHJ.FEBY!,2T\L7)$"0 )8J"$"%AA9"+A
MI2E(0I2E(0I2E(1:_/#+^[VOU])\W3GAE_=[7Z^D^;I2M7'GL+J'?$M0+1_&
MZ'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3GA
ME_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//87
M4.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[V
MOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D
M^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1_
M&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3G
MAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//8
M74.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[
MVOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^
MD^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1
M_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3
MGAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//
M874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^
M[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z
M^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0+
M1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W
M3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F/
M/874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+
M^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7
MZ^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0
M+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\
MW3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F
M//874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#
M+^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[
M7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%
M0+1_&Z'/#+^[VOU])\W3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])
M\W3GAE_=[7Z^D^;I2F//874.^%0+1_&Z'/#+^[VOU])\W2E*8\]A=0[X5 M'
%\;H__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g354508.jpg
<TEXT>
begin 644 g354508.jpg
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M5K?P0$DA0C7MY2?O8!4D!1Y'GC<_IK30BY\;R.;+@=CLWG52&543$ZDT@X6
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MTWQ4YMBJ*)WN7-5VDVDA]S=UK56I_5RPL "L=N+OA:=6ZH 6J[@,*LF*:IN
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M::::4IIIII2FFFFE*::::4IIIII2FFFFE*::::4IIIII2FFFFE*:::"(!U$
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MN;*)V"H&GJDW Q]$,:'<T'6;E>FKM1KQJ159(M<4>YB&;A5B@2MX,U,)E=I
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MW(X((>0VU"&_',1@UPUTUS#9FNV;3T&5JN_,D)?@6I3:8=O43@?;-Y>(M]L
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M"0)6FYBSC/KNGGEIB(X@.$O6U=NDCB*NU4K%8ILQ?^SFX6EDJRLY<"GZ[@C
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MK9)A16D7^TE<#4<EUN/%;=CW2)^U^GTHCA33K383-NJ0RS%6'F0X8D3]0?\
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MJRRGE,;R)ID4$QS>4IC>4H"."B/0!UKU$ SCKGG@ #G.1#WX#MG/;C5\6V
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MA3V=275MQ.D8$D/:3L[R>!%X=9)"=471A8XG&EKXC8X;P"41\3W6NT>;P
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M<N',BHA(2+P56NZD,YQGZCG(\9]A^73& SR ]Z  8+CDN # ?3.!Z"(Y'/R
M,CR(Z8 ,CC. SCH/4,9#Y!UXQ\QSJRM:EG*CD@ #P & !4[9_ISY<^\\AD[]
M!RIP/(@ !SG]X>O0?H/'L(\XXU7'0," ]<],]^W.0#OCJ/( (ZID Z\AUZCR
M(XZ\!GI[8 >!YT#GIUZ\AT$>_P!/X@...<#33\=OK_8_TJOUX ![A\N!#(<8
M[] P'0.0T\N/;D/D'7L'4!'_ -&!#01$?? 9$!QUP&>_(8Z9[YTYX$ Z#@.
M#(8X[\!GI]0ZCP*GG\*#W W4 XXX#(9[9#(\YZ_(>-. #Y<#G// AD.@#QS_
M .L=.>@CD._3&/83>X?@(^^1 -!#'/USD?;C';@0X#OT'C'*GGR:9 !'^]#
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MGIWP(!QUZ8Z_TACCGG.KJ_5>X]1Y$,Y#CH XXY'MQCC'OJH= #Y8Y]Q$1P/
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M<AVY#G.,!UR/.!ZX[ .<<A7@<C\@R(=1'D,!G&!'V[ACIWJ"E#DI0]Q(_.F
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MF5N55-$3>HH!A$XJ*ID A2^;D3")2@(ZO@;)W _V%&<#D!^UD _AZ'3C^O/
M:M)0M0RE!(Y9 \_3]:J) YGSY^%8F#/M@<=<<_AC'(\\CUZ9'61;3,%7]?0
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M5-NUG(F-FVS<A5DW $;(2K1ZBV2!RDFX!-!-,GKI)K 7U$R&+C+DI0KA2GB
M^\<XW\-CG'7Y56$$CH,\O=M^OG-?FF[6K4>+GXZE46\M'=[<!N3N'M>HJ=:S
MU6W5O95U;SUHZ%;1R8Q3^0AUY<B\57%V5HQ=W#TI$-@F:B.\D5W$H[B8 \Y+
M)?I,4'0]-6SH:BK;T8Q"+H^WM(4S0M)QH^018TS1\&PIR";*F2(FDHNG%QK8
M72I"$(L[%58A" I@+H232002:MTTT&S?S_#M&Z239FW]0?.I\,S0*DW0]4<F
M4!!)/U#<J9ZZYB' 9Z9SC\.@8#M[AP/.<#K%==+A&P2!R _$G;.P Y56E./S
M]_GE]<[8T@/5W?\ ;QHPWPB(J_L11@_2^S$A(-*FMV[G#U0+?T?*,P2J0_5@
M+AB49-&(S;XLL6,S$ZVC7]W1;>MJ\!3M4[C+O4A9ZG:LG5Z7IF5K \R5M-U
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MTE :*TK3+:9GFKI1-= Z2#QBW.J"R)DP$#D$<V#@2X'&!]P[#GWZYZ\ 'SP
M\=2R@8.-?R$M'04+'2LNN#R5EF$1&L924=@0A/BI*3:M4WT@Y]--,H+NW"JH
M%3(4# !"@&/!7;D.K5<F9LAD-G@9@RF(;JW>)...1(ASTH;">(D)BN*4KA *
M!E0M3TW);2$VM^#'>+@XWI\61-:2U@YX(\>; 6MPJX<$RFT)3Q*(40$F,/\
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MK2T;2V\JO+H5S/5)2LO*4!(P-!-@I]\: 81OG:M%Z3NXS?4Z'Q7+MTS=3=U
M4#M;NKXBS2@:NCYW:U4&UNEU;%VZ\MLK82%*5G2,AN&C*@IZ==L:C3?4\Y/1
M2LDI"M'C4L<6>*OZ3*AMK;>K:@IVK*KMW0%5551QU3TC4U3T/2M15'2QUA$Z
MQZ<GIF(?RL$8Z@F4'[+=-0*L(KD JPBIK^O[.[?%AJOIP*%HP*>N _J"5KV
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MD2B(9 1 IA#/(9*0<8R4H_=#B 9 /PQG&.@^P]Q'&>O3OSISG(\". $0ZYR
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MVY;Z%UYRDBF(X1B*,NZ61=&^R4E5,,4@/-2:T0)4!*<L'6%&ME!]*$12#>J
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MU(>#I)1BW,)7E0JFBTS!GS)LQ3%214*.0\HBVPW*8,B!G(&* &* A##IQ@0
M!Z!SQR&!SQGV#G(8 .PZS#>Z<&4K$\>F?S-8%HFR( &\Q!>N0*[>G$. *<H'
M;MC .<"W$ X$0'#W?RY''U'OC&.H8Z@ #\^>VM:^OB</<GV1W;<S\35Y(P!\
M_G_3%.!YZX$0Z!TP.,!T'&,]OISI@<X_ !XSQG'OQ@!Z8ST'N.@CT ><&^8?
M/CGKTQUQW$,Z!CC'(B ] [9#@0'MG/.0S_'5FJN[\O/TS],TZ=0#KSUZ=NO
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M?8<:8Z"(8$,AR&0Z!VXXQG !G'41ZZBGGSYWH'R$,Y]PQD>G&!YX'IS[#@>
M!SD #@,=<!["8.V ^F/QXU3MCW[Y$<!CH./H(#TX#.. U4>_4!'C ]/Q]A'
M@ ],>VE*BYNDVO4IN2H]-NLH2G;CTPFL\MW7[43H/X*2(H5ZE&2+A 4W2]-/
MWZ2"CI--0'<*]!.H8-1K)MS ZQWL[W&5#7@U+8F]91A]Q%H%EXJI6SPQ2+5I
M"Q8HMB56V4'R)OY)%-5L>H'#4A4)1H]C*O:)$83"_P /.7&<9X$1Z]<YQ\QY
MY <8#ZZUW[Y+05(P_5O=G9X18W?L6*$K+)H(^=*K:!8&64?HR#-!/UY1Q MG
M3A-RW.<POJ-=S; <J1T6+?T32]P8U!"3H6^OH0Q(<6K2ET?/_P AOCY'9Q5.
M$%2;->G>"-/9SV4>2MFX(2AQ#RU^;ZJM\C3TY>O;#'4N1';;1JRUQT__ *@L
M; _S)0:!"57JRM!<B __ +LB,EZWK4M"V&T[$AX#GC/7 <?T?CGD0[!UT[B&
M0P.> '.1'Z\_7 @'S# ZQ?9>ZU/7NMC2-SJ8 $XZIXPJR\>*Q57$+,-%!9SL
M Z4*(^=Q#RB+AIZAO*+EJ#5Z4/2=I&-FRFH)Q4L[&0;8#9D7)4EE +D4&I<G
M>.1'L"+4BIP'^<!2X\QRYX27#DP9DB!+97'F1)#L63'< #C,AAPM.M+ R.)#
MB2DX)&1L3S/?PYD:?$C3X;R)$.9'9EQI#9);>COMI=:=0< E*VU)4G(!P=P#
MM4M+*P?V31;=XH7#B><*RI\E$# V, -V)><8*+9$JX!C(?$"&=9<U_%LW2:-
MT&J!?(@V12;HD#H1)%,J:90^12%*'X:_MK-0GA2E/< /U/Q.]5$Y)/\ 6FFF
MFJJBFFFFE*_FJF15)1)1,BJ:A#$424*!R*$, E.F<A@$IB*%$2'*8!*8IA P
M" B Z3_#J'^QOW?[SMD"JZ[>EV51-;W6@C71E (E3=0)1OVNW8^83)&1;0T]
M1;0P@8%%W$*_<& R@+B7=IK2?O?,VL!XB^Q3<LW=HQ47<9[+V"N$J)5DVKB/
M>*!'1;N3% P"Z,FC77J-R+%4215@&3D">9H7'=Z)_P#,$:DTRH%0OMAEOPT
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MT,]OLAMG/TSG_+YZ!>NO@$!%[&G !R(#$-\#C X'RG*8 Y !$! 0[#G3#/\
M$Y_*GP\??W_J]O\ X_6OMINR=53"B:TR!:=8#Y1.+@4G,DH3/WR),DCF31.(
M 8 .\5)Y#>4WH*E'RZE;3U/15+QB,3#MP;M41$YA,83K.%CX]1RY5'[RKA40
M 3G$ *  4B9$TB$3+'ZF;^J@H1"JXQ,$!^Z,E#D4 R9NQEXY9503)\B)S-7
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M*+5+"H,Z95,F@1A&SCMS) G"N3(*M2M6TTLT>.4U6ZJ9%063,?@]>VW2D=<
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M+@03\X\E;=,W^\LSG[3:9MQ3;"T)S<-DR),<.ATI4J(WF6IL!ESM'&V5MLD
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MU)4Q4DI,3,6W:L':8/R.I%P5Q*'>ND/30722+G$,],]@R(_O8'VS[#QUX'/
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M#XUT7(8P[<IE03,&,)-3B&2K (Z1_$3HR;84/;S<C2#-VM5&VRNX2IWZL<F
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M'MVJ2HJ)GYIXNH1%K"Q4@ZEG*@^5!FK@<<;7H-;>M-4 0,&0Z?,! 0^0@.!
M?<! !#OJNE*::::4IK43XU%)J/\ : UN.P0\\U96[5N[@1ZQ$Q.J":TDK2Z[
M?S@8!216<SL:NNIY3 7X-,QO*4#*$V[:A1XC=.EJG8YN<B3% _DM3/3*8""Y
M@^(II1G4;8WD;_RB@D7BDS@F8#(G,4"N"'0%0H]1HF9ZAK#3$HGV&[Y;$O#.
M.*,]+:8DH..BX[CJ#WA6*Y+7L+[1T5JJ(!E;EAN:V=LXDQXKDB*OWHD--+!Z
M%.>E2HM_5+>N:$HNM6?I"TK"E*=JEJ*)O.B+>H8=E,)"D?(^9/RO \ALCDH
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MQ_\ A/C/_&PG/YR.L7L'.Y/\R?U\X]V;G$#U/R/?[NNWSZ&L #D!$?QR/4<
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MAMI5DBNH864L2/6BFXIB&WWR%ZJ[*,5;,A*';[,GM+=B$HE.2 $EE\-LUO\
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M&VO-3&EL2"DL-N(><96E*F%*?]:CJ862XVN*HKP%I%29V[Y]*K<]EX;C.?\
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M#R/_  AY^>NZB>F*]1T2$O0D352$6EOM9-PG.NMIM5HMUKPD.+6PL3#!=DR
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M0&DH;F-RK:D*4Y(MLJ2EF0UBJ]&4=;<9M=S"@S;E6YTF"<RF@Y)<:[4IFI*
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MA0GT:T0OLRV0+<9!DJAQ6HZI!90P72VD)XRTT.S;XM_9!4>7$M:BI2NAS[]
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MJPE^(HJ9:I ":)3J&\RZZ1/NE''F\PX* B&PM*2JZVQ*05*5<(24I R23):
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M8N(2.?G^_NKB)0#D"ER(Y'!2B)L^XCD1''<0R.!'G CJHE+T\I0X$<^4OO\
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M>FN1!,4Y3A@3$,0Y<X$!,0Q3%$P#P8N0 ! <@(9 0'(YX@(8Z<9SV#'8!XP
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M#J4[ 6Q@%ER.58.F_LA5PDF9))PI&,(9BHLFD<QSID6,W%0A#G,8A3%*8QA
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MZ?D=OZBLCUM=:?JT%F3830T&<0#X%LJ;XIT0 $O^:#U/TS*$/D3':(>FV !
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M,4@??:+F#CXAJ8AQ$ !8%R )!EK1=S*>K(I6Z"HQ\N!!.I$O3%!<P%_>.R6
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M'3@<#WSGJ(CV[8Y'G(=>= Q\N1XQGMR(AG&,],\8QW ,A7/(@'WA_P 7'<,
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M<_/ CD.<]^G]>0' B&!4JN!''7(_3G\0Z<<@ 9Z".,AD:#SWY_$0[=>O CR
M]!Z=M.,!GV$0SC' <X .P]1_, YR#.<#D,<#VZ\9 /;';J'<PX'2GGSW4^8]
M@ <<Y[\Y$>V/? _4= #WZEP/;L''(\AGN Y#KT'5 $,8Y'H&/X<9Y#MTY^0
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M*HJ$*HFLD<BB1RE4(8IB@(;!ED-C)W6>9[O ?F>M65$D^?U-93*<IAP '_\
MJDU"A^9B@'\=?S=.FS)!1T\<(-6R( *KARLF@@F!C 0HJ++&(F0#',4H"8P
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MZC\_8>H  :5&._F/)V_O5/\ "[_,/Q >@=,!R//S#0 ]N.XX^7;KD,_GR/3
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M-Q1DFC&I6BI1#[4>1[0S)&H':)1+)-7$15J(?!SBGH3LXR.!X[^;@1$/;O\
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MYB(8SY<]_<0QSP/MGGFHB(C\L"&0P.?8.F0'MC(9'H.E//RJ@=N?D ]1XSD
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ME%?*7)&H)Q38#!UQZ?Q#H0XX_NDH_P!&LKP=&TQ3F!AX5@T5QY1= B"SPP8
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M\DD!4Y-D=BY4+D?,[CS@9(5., 91FN":8^;)BMC!C!!-K >! > P..G';.!
M 'KCY8#G&=:IQ/ M2>X[>X[CZ&KR<8&#TP>[;'R^F>>],8'GIG(@ =.<AYL
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MYXP',1);RK>JC6O_ ,0-Y$_6,:U-JRU8[8RVXD=)EP/KCQ^,54%)'>@ULO\
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M>H*^)E'#*[#MSK4">H*5LWLD!01%<V8:5B98#$3*4PE5)\%YDEO*/PZ@%7'
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M( '4/I@/8.V,YYSCIL?DF*4G'/HY8 %)\S<M% , &#R.43HF$0$! < ?(?,
MUKD514;++-E2B5=LLHV5*/[Q56ZAT%0-SU Z9LB/<<FYYU@RDX4E7\0(/O']
M#]*N(.Q'CGPWP/GW5_,,9Z=^O<,!WSWZB(AW#KWU3KT 0YYSVSD!Y'KG/3@<
M],\Z#CKR!NORSQVQU$.?;IG7+OQUXXQD!#KD1$0^@#G/'SUB^?.:N#SCK7$!
MQG@1\OSZ"/'?CW[#S\M5#W <<<C@1ZCC( '?(  \\CD>V19ZAC'7KGV'G(\A
MW[#GGISIT]^,"(CG(A@<Y]L= 'M[AG.E.=! .O?D>?EW'\," 8X$<=. H(@(
MCU'@0Y$0YSP''^/'SP/.JAD0[B(8SG =NGO@> '/ ]??0,8QC/\ .[_/MD,"
M(<X#H'(9QIY\^?G4?GOCX>_O[MOQH(!GD!-GG@/J&,YSU["/'\-5QGY9'(\9
MP// Y[CGCC =NH9IT'/SYY$ R(AU#.0SQQCJ.1X - #'./D'?'L(9QWSWQGI
MGKI4U7@._3(8$?YHAT#/;YCGZZIGI[AW#' #TX]L>X\#UXZT$  /W>F,9ZY'
M.,AR XZXX'ID,:K@?? B(]^![_D ]0P(]<\#I4;^?A[@/KD<J=Q_@'0 P(!S
M[^7N'(?/3 B&1'/7@P?7J&>..?ID.G6F,Y[AUZ@ #COU[]!^8B(XQC77S$Q$
MTY#S%13T@TB(.GXF3G9R7D%2MH^)A82/<2DO*OES (-V,;&M'3]XN(>5)J@L
MJ("!!#2I]_GS].^OE>T] /Y:)J1_!1#VH:;2?I0,ZZCFBTS#(2+11E(-HN44
M2%\R;OFBJC=TU07*W534/E/SB!@T;59XP=RFF\Z_&T^D[1[-6*%D;[4E9-&>
MOWO]H[;_ ''N$M5;&(?(3=!VEJZDSR-6G;A)'C_@J=DI BDU]G0X+_'22"0[
MM[=UQ1]XJ#IBY=JZDC+AV[KB)";I&M:156F*=J6(57<-2R<1((H 1VT%RU<H
M>8"$,"J"A3E*)<ZTS5IX/MW9#=9?_=+:G=3:ZBPOS>>G+QR--W$\/6PNXZ9I
M":I>.BHR/CJ2NC=22DJAIWR%CSN <4TC3X%E%6DF9F>4C6KL;X<*P$O+4H--
M]FR%J6H-I[13A;0,G@1QK<7PIPGC6M6.)1S;2VV@J4VA""ZL.NJ2E*5.J"$-
M\;A !6L-MMM\2B5<"$(R$I2!FB \:C8'56XQQM8B*\N2RNR%YZWV],0J>S57
MPE#KW@H^2?PS>BEZZ3,_AD)&J)1BHTILH&,#DYTCR@P:+EHLM';PZ_'DV\;Q
M(&TM%7283=K=SERVMX':%OZ6MO<R=MJ^6M<ZJ67)2U$U[(-W[BKZ]D[>PC6I
M/U7AVTBJM+ODZ:9.@FW+")6NFNO#<MIM_L?.UW=O<:>FK?V5\4.K/%UK.XDO
M:AZX2IEJ[6*YG[5NF43-3$PDV!JHFT<UE%-GDQ((@FD6BUDRE0+@/;YX:UD:
MVM!MIV66QWC5M.U'X=$O<V[]85K1=H:EH>J)NF/$;L[6E36TFZ,J!_-DB*7E
MHRCJU9U9%5#!RM8/$7D"VCJEB*;D3)BPD)9*3][I[0R<8!R?N 8R4@@XZ8(S
M5>",;CX\^8V\3C/+IS[Q,I#QO-@IJ!O;<.4J.]=*L+ 4[;VMJ\IFNK 5S1%P
M'% 73JZ+H:C+@4?1E2FCY"JJ-?U'-P[1Y*MU6JT:A*1[QRR^'>MA4DG9[QY/
M"[A;'7%NHC=*X1)BBKJV^L].6ZE;)7"B[XU17UTV,G*6MIR@;1KQAZLJ5G5<
M;$3KR%=-T4"&"-?+RQ8Q5=@W<:U+6?HI;<;/WYI6IMX+1B\OW8*T=BT'\%M2
MI.BEX&/M-?&VUWV5?3L/"7-(6LJRK)I;IO"U3+U"X3J.9EII_5TI,N5 0A"2
M@K?PE-M6\[?3OJW"6(\1)I [NJ)W$[3;I0:-J:;HVL*AV77IVZ6FG[2LH:Y5
M*R]4/6-Q(.X[1JZ=2],2S"C58Y_3!H=&1=E:R[9QD-M(00M()R/9XN@.,[$
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M5B^\G[.KM(RJ!H*L;*7>;@DM]H6_N'!-RPT@QE6TO2RZJA4ZII^4C#%6C9!
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M!ULA<1L>[,)G3)FY,.,F7:MUAX# <JIG'@,@'/ #@.-?/]A0O^U,9_R>S_\
M,:QO5#_&/Y3^M5]IX?7^E:Y?43SGU$\!SGSEXR& SR//SY >..N@*%R(>HGC
MC/WR"/RR.1'(_,.,CQVUL:^PH7_:F,_Y/9_^8T^PH7_:F,_Y/9_^8T]4/\8^
M1_6G'X?7G]*UR^H3(X43'/ ")T\C\AR/(#TY]OEC5?43SCSD'I_V0H],Y#D0
M$>H?G@1QK8>]84U&M'#]^QAFC-JD=9PY79,4TD4B!DYSG,B   <!CJ8P@4H"
M82@.!9B\E(MUE$8*CFLF0@X!X^;LHU%3!Q QDVX,W#H4S$#S)F6*@<1,'F2
M '5"V$H^\ZD9Z<))^0R:D*)Y#/Q^?X_KFHU>=, _?((B(=5"AD>V.<YZ]!ZY
MZAC5?.4<@4Y3#CH!BB..G !SP/&/KW'6=_VU,\9_9]3_ /XY/ID X_S)^G'X
M#JWJJN6VJ6&7B24?"19UE6ZA7Z!BJ.6_H* H(M_*R;>150 %+U!4$OI'5*)#
M>?);92@ D.9.-AP*&3W9Y>?=F05?P_4;5BH>^#9-P <<]\X^H\Y[=-7S;F=4
MIVL81X4XD;N'9(M\7S"!%&LD<C<0, &*!@27.@Y)Y^ .@4PAD  ;%'WQ@.,B
M&<AD<8_A[  <EZY >U@FRCR:A6B ',JXEXU),$APKYCOD  Q1YP<A0,H4PAP
M)0XQG5*20I)',$$>_/X5) (([ZV,::!_C'^G_'IK;58IK!.Z&G$ZNVWWZIE4
MBR@3=GKD,"$;JG06.LK2$N9N4BJ9%#D$S@B0")4U!$HF+Y#9QK.VOF>M47S1
MTR<E\[=XW6:+D QR"9%RF9!4H'3,0Y1,10P 8ABG 1R4Q3  AD1'S%EQ92<\
M4:0R^G!P<LN)<&"-P<IV/0[UBS8R9D.7$4 4RHS\=7$,IX7VU-*R.HPH[5KA
M\(RH6D_X?UA"MUDE5X)C6%.OR)J"H=L[C:[J50K58@ID^'.FS>-#D;!YP014
M2*!S . V3ZTU>"H^=0]AKTVCE#J_;-GMR5PZ:>H*"H)&Q'J$2Y]! #N7'D3+
M(M)0133$$R*BKYE'#@5UC;E==1Z0&$Q];:I2@Y;>O4Z8RKHIFX/*G,*!VRE3
M4E!2>J2#7)^C>2J5H/22U@)<9L5O@NI'-+UN83;WT*YX4EZ,M*AT((IIIIKC
MZ[:FFFFE*::::4IJ!ES(\(RNZE;E3\A%7XOTPZ )9%LB],(<C]T5EE0ZAR!N
M #@)YZB+?M@#>JXU\0I@"1A2$,81 "BLP=+)"   ^;A%=$1$>H &!'& QI0R
MV#_"H?([?CBJD?>]_P#?\JP:'O@!_B(8]Q$0'GG' B& [AH'01'L&!#IGJ&!
MZ?T>P!R YH'&. XR(=\]!' \\\<#[9#.0SIUR/? #D>,=,#GY]<<_(<\:P*O
M540Z]\Y /8,CCIUX$ ]PZ8#/.G'' AQG@. ZB(Y'GOVZ=,B.@ASR(=,!D<#[
MAG_+IUP/&G;@,\_='^/L'3/.1Z\XX'"GGO\ G\!S-/Q$1#W#L.,!D ' C[\#
M\@$1'3@<@/'/T#V[AR/ \X[8R&1T !#/U]\!C'(B'L&><9#/ <=0\YR; ]0#
M@< '3Z#SUSSI3X<^?X57GCGIUP.?;KGG.>F.0X#OG5.>H!^(]<8'D1'CC/MG
M''&@XZ=?D \AT# <<\#CD1X 0XT'G "/T]AYX'K[<!W'J(XY%3Z>[^U5$ ]P
M'(^P#\Q'( '. Z<Y[Y#5,Y'/MUQC@!'D<#GIT'CGKG @&J //<>W7@1ZAG.,
M#\^XY$ SH \X#J =0QR(!\^V.OT 0 -*C/+.WZGI50ZB&.N.H9'@.HX$,9SU
M]QZA@=8BW!0<Q5-@+\4Q3L<ZEZAJ2QUY*<@(E@D*S^5G9^V550\+%,40$!6>
MR<F]:,6B0"7U7+A)/(>8!UEP/WNO7&>W(AGVQ_7TYYTXY 0^Z( &!#(8'GG
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MO33P(>0F!QD/*7 XZ9#'..V>FJ^0F!#R%P.,AY0P..F>.<=O;MJ.$#W;[>_
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M>;!P?73IM%,"8'E,S*F'RAC^8 ^Z9,A/*(CZGF "CK?_  ;]).<?LTX3R_\
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MRI8X54_]'29B'1.JB!O^PL"F,(K%R NS$33,(HK 6Z::L(@W7(ZJF33D"I'
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M;:H%GTSM[NC-VX=J)J*-J-KMJM7-)?$F. D0:U FY9UC$LP)G_1BE4J%-P4
M+@I=1MV/"TWNVF,\7<6>=7!A&GQ!PGK42K*MDE6Z"AR@N,"E]G5@F95(I7 -
MR4XX.FF<""<ZA3 'MGU00 1 1 !$.@XY#Z#U#\->MV'TXZYLR4,R94:^QT8
M1=F2N0$  $";&7'DN+./]R4N4K/0C8^,ZA] >@;VM;\2+*T_)7DE5G>2B,5D
MC!,&4W)C-H3C'9Q$Q4GO!WK\Z>HZ?GZ.DEX:L(*;I&7:B0',55</)4U(H"H
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M"9N[4--L;=766:J53?RI;;252-J<O<I3$/6Z]8P=+.5JA9OHEV@WI=I(Q)9
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MG(B.,]1#L XY&-CSJNJ!G'7Y]Q^>>N.V0R 9'(<!H&0'/<>.0'@>> QUYZB
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M-0514P*AB(";TBXJ707:K'0=-UVJY/*!T'"*J"I!,0#!YT%2D4)YB&*8@F(
M&(8#  @(#K6*2I!(4"GIOR/N/(]_/%7LC;Q\X..7.OY]/N_3ICG/'0<]>HYZ
M=.F,TST#Y8'(#@ Z  \=^XY#D.H@ !ID SU'(AR'OR/M@1#L'0<_3%1SSSSQ
MD!$..^!P 9XY$0[ /MS34CSCI7#R@(8,4I@ ?,&>>0QR7YA_3]-<@*4N1*
M CDV QST$1 ,9  SVSGOUU0![X#@>@" !V^>/;..@!SP.JC\AY_@..^<XSCD
M<YX$ TIY[O/NJN<AP XY[B.>.,]\]ORZ_=$.(@ \]@#H';/0,^^1ZX^N1 =5
M#'(\^^1 >.<AT'IWX#'(9QQIC@ P.<YXX <=P'GJ'T#\>JHV/C01XP/8 X#H
M(8SU'W , /80ZAG7=T_3TK4\D6*AT$EGADCKB59RBV2(@D<A5EC'5,41*D*A
M3&(D15; Y(F.!UTN '&," !]?F&>1'CL ?,. '&L@6J,X+<&FQ:E$1,Y=D7
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M[I0!OR\ZPJ1ER$2M(W+"C[:1_P"VH_? Z)5A6!LI9.*@KQ\L?CQ_1D0^6=5
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M#R2S<% -Y?,91%J=0I>1352*</*J753:"XH)&V>9[@.O2A.!GZ?+Q_7]8VI
M*QRHH%,NJ<WE(DAYEE#F,( 4")) <YQ$>@ 0P^_&=2NL];=Y!'/4\^@+:27;
M&;1L>H.5F39;RBX<NRB'\D[<@4J9&^1,W;^H"W\LL9)#.*$;'MC^JW8M$%,"
M4%$&J"*@ /4 .DF0P /00S@0ZZ^W68W'"%!2CQ$<AC ![_>.E6BK( &VV#]-
MO ?C3333635--?P%LV%P5X+= 79$#MB.A23%P5NJ=-51 JXE]4J*BB2:AT@.
M"9SID.8HF(40_OII2O@-%1ABOB&CF(DDS@I)%%FW$L@H"9$0.^**0@[/Z*::
M7F< H;TR$)GRD* ?R90D-&MUVD=$QK!JYR+ALR8-&B"XF+Y#"LBW1335\Q!\
MAO4*;S$^Z.2B(:[333 [J5U4=!0D0=92*AXN,.X "KGCXYFR,L!1$2@L9L@D
M90"B(B '$P (B(<CK^ 4S3@2OV[]@0OVWC'VQ]EL?M3'F\V!?^A\4/WOO9]7
M/FYSKO--1@=PID]_A\.ZNGD:>@)=4B\K"1$DNFF"1%I",8O52)%,8Q4R*.4%
M3E3 QSF A3 4#',(!DPB/UL(V/BFX-(QBSCFI3G4*V8M4&;<#J#YE#@BV323
M YS?>.8"^8P\F$1U]NFF!W"E----32FFFFE*::::4IIIII2FFFFE*::::4II
MIII2FFFFE*::::4IIIII2FFFFE*::::4IJP[GVTHR\5 U5;*X4*VJ&C:RB7$
M-.Q3H,%7;+"51)9!8 %1H_8.DT)",?H"5S'R+5J];'(L@00OS35QIUUAUI]A
MQ;+S+B'676U%#C3K:@MMQM:2%(6A:0I"DD%*@"""*MO,M2&78\AIMYA]M;+S
M+J$N-.M.)*'&W$*!2M"T**5I4"E22000:\_UG;I7!\*.[[?;)N%DYVJ=H-=R
MZ[JQE[WS=51I0*KPPKO*?FQ;@JV81[5<ZCBKX5N*9H5RJ:NJ?8_JK)2[*$W[
ML7S.29M9"/=-GS%\V0>,GC-=)TT=M'215VSIJY0.H@X;.$3D60<(J*(K)'*H
MD<Y#%,.-;SV6MMN M[.6PNM3+.JJ0GBHF<,G(J(.63]H<58Z9AY%N9-[$3<6
MXPXC91BJDY:J@(9.@JN@KI+C'^ZGPC9G[)GF<_N.V$JRAU&4\P("U<6782#@
M3*%<(B=-I"(-EU#+NF;D$[?U"NN+F,EJ'F'2\6MZ0ZU#](:?6HJXUOUR$CUV
M LMQ86K5)2!Z[;G"41XM^<Q_J[>KLV;DXKUF(I$A3S"O+F7IWHU5ZI+1*N6@
M"O\ T-Q0'9<_1R%*),&Y(2')$O3S6?\ 1W%/:2+:V#&F)7'2P^GT$::PC8C<
M79S<G1J-<6<KB)J^'$$"2+9L<[6=IUXX(<Y(VJ*>>%1EZ>D<)J>5M)M4"N"I
MF69JNFXE6-F[7G4J+)A2'HDR.]%E1UEM^/(:6R^RXG[R'6G$I6A0ZI4D&O38
MDR)/C,S(,EB9$D(#K$F,ZA]AYM7);3K:E(6D]Z5$9R.8IIIIJQ6133332E--
M?-\8U XIBX0 Y3^0Q/72\Q3YQY1+Y_,!LB >40\W.,9U] F*'<._?GCKQ\N_
MMWT.W/;WU (/(@XYX.<57373P%10%51+2>IB;B*BA'X+BQF(*38S$4\!LY69
M.1:2,<NY9N0;O&[AJN**QP2<H+(*>55(Y"]OYBXSY@Q[Y#&I4E2%*0M)2I)*
M5)4"E25)."E0."""""" 01@U"5)6E*T*2M"TA2%I(4E25#*5)4"0I*@0002"
M#D'%5TU3(8SD,>^0Q^>F0XY#G@.0Y'V#WU%5573705#55,4DT;OZJJ*"IIB\
MD6$.T>U!+QT*T=2THM\/&1;=S).6J"\C(K_R+%BDH9T[5_DVZ2A_NZ[_ /R_
M+KJHI4$I64J"5%02H@A*BG'$$JQ@E/$GB .1Q#/,52%H*E("TE: DK0% J2%
MYX"I(.4A7"KA) "N$XS@TTTTU355----*5:574/3%<QPQM21:#Y(H'%LXP*+
MYBH<N/68O4\+M5,@ F AO25\H%725)]W6**RVPVAKNRMTK#5)3A)*AKR6]JZ
MV=P07.FI,SM,5K OZ=FDE))5(QD7 ,)%91@9!-%!B[(@NW13.D4P2$TU>$A\
M,F.'G0P5<19XU=F5<\E&>'.=^7/!Y@5;[%KM0]V:.U P'.$<8'=Q8SRV&^PR
M!L37Y(6]&D/&P\"QQ5VT2"OWN0MMM(_6.J'=JKFVCDIR M!<"#K5^=R,FPK.
M(BFR]*U[(HE13J^D'4Y&U!!SA781Q7D(ZC9F2U.;-4-]=P;WU!#;*V-[*XOE
M>.EZQMG67[+HR2JFIZHHV[Q?L>O6-:RZK61;,*<J=-R8:KJ:J7\='M417E)2
M;9D26>$_<-EX:(GV#F*G(R/F(MZF*3R-E&3:1CW:0B ^FZ8O4EVK@F0 ?*LB
M< QP&NKIRBJ0I!-TE2E+4Y3*3Y1-5ZG3T'%0:;Q1(@II*.R131H5R=,@B0AE
MP4$I1$I<!QJQ\N_]/[_2KE:C_ G\,A_X5VPRE+%5I)0TW>FN*HE[P7RE*?4%
MU!-Z_J>/AXE&E8&1401<2<-1-+P$%3J<DH4$I:6;3,RS2;LI)L@GN7TTU-*:
M:::4IIKB)@#D<XSC( )@#OR( . ^8X#YZCK=#=UMDLQ\2G<V^ELZ3>LU54',
M.\JJ->5 DNBGZIT!IV*5D)T5P(("5#[.]4XF*4A3&, #DQ(4R>\F/!B29CZO
MNL1&'9#RNGLMLH6L[[;)K$F3X-O95)GS8D&.G[S\R2S&93U]IUY:$#;?=52,
MTZ==:<ZE\9FRLP^-3VVRT-[=S-6&<$;MV5'T=)P,,8RQQ21%P_>Q\I4+4JR@
M "2AZ1% 0,(J*I8YMC]</&1W%K%2IF@;2[.J*E&CPI)BKW+:I*Z9-U#^4AC-
M%QJ>5;3 (B8&P'HV&;%4**AUD1$@DZ]OT?7]I(=O:K9I=@CB"]27&/;9"@!Q
M'L[7EV[O''(-6]?%L <Y XM?I)TZ^LLV%%TU;(2>%3>F+9)N<=!) ':W3A9L
M[*23@J<N"<8R1C>MS$_4M.TI%N9RJ)Z&IR%9E [N8GI1C#Q34@C@#N)&27;,
MT2YXRHL4,\==:VKR>+?M(MI)*TK14[4-_P"OC.3L&=)65AE*G!R_(<I?ARU*
MN+2G7/W1,IY85Y-N#ID.*#982B4,0P?@_0MPG[>JMX^Y"]&Y.JR 4XLE:@>4
MO2++*Q%C-&#95S-3:300)Z:J<;(0+97/J)L6P@! V66=VT6#V_QXQUG;3T50
M)3D%-Q(0D,@$^^3$QS@22J5X+NHI(I#*'%,KZ4<%2\Y@2*0HB757J^@;1O(G
M7C5TI!.(]N9&G[.5#&RY\U$JZ2&\YV:ML%:AR=1LHV_6?2/>MH]OLNBX:P/]
M1<GSJ.^)20#Q(M\%<6TQW1R(=N4Y"3S:7N*U:+76\6'=XFLA::U=*;*K;/DU
M3M*TNBLN_N.]:*%_D1:Q[^'>2D>NNG_*$,A;Z.%NIDI)Q5(Z*YL@6Z\(2U[V
MHOVB[LKH7#W8W'=*$<NUZUEI.'HY!4R9_4:H0;64=R[YF0ZGI@V?SQ(@Z:"!
MT8!C]]$VWP  .@?7W'ZCU$?F/.JZI=UY=&&EQ=.1+=I.&M);4+$PINY.MG'L
MR;[)7(O#Q.!QA,QIE9S_ )(&$BXQZ.[2^\W+U--N>L9R%)<2J_R Y;&G1GVH
MU@BHC65D GV..$\ZG;_.4<DVA1%OZ'MI3S2DK?4C3=%4PP##2 I:&CX*)1-Z
M::1E08QR#= ZZA$DP6<JE4<KB4#++*&#.KOTTUQ3CCCJUNNK6ZXXHK<<<4I:
MUK4<J4M:B5*43N5$DD[DUW;333#:&66T---(2VVTVA*&VT)&$H0A("4I2  E
M*0  , 4TTTU15RFFFFE*XG(10IB*%*<A@$#$.4#%, ]0,40$! >X" AKKV\-
M$-507;1<<W6#.%D&+5%4/,.38431(<,B&1^]R/779::8'=2FL'U?9*(G'2TE
M"//L)XN<RKAK\.#B,76,(F.J1 AT56BBAA$Z@(',@8V3 V*<QCCG#35*T)6,
M*&1T[Q[CS'G-2"1RJ-</M]3(Y*I.U +AJF<#"TC&AVIW!<"(E4=KJJG0#S
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MR'X#KMH^N)CS#4/4ENMVK(;#8:85>$/)ND5H A+<6^0W8]S0VG;@9D/RHR0
M$L# QP4C0$)B2].TO<[EH^:^X7I";,ME=HENDI)<EV&8U(M:UJ (4]&8BR%%
M2BI\DG.J*AO&9V55(X"+K6=KVS%0)G(B[AKGT%,-%&JPF%-05GE-!4C9LV2.
M4WF<2(QYBI@*BB*8$4 DC8WQ%=CDJ0IVVZ*SR)3MQ<A]IU6WA3E3+@3 JG,I
ML#H+  ^86RP$<>0!/Z7E*80D?6%I+67" Q:]MM0=;%."0&"K:0I^HA-Z!RJ(
M^8\O'NU!])0A#IY/]PQ2B7 @&H[OO#SV0R!_.XVN67+E,R0D:T5',4C$,)C&
M\R+ &R)C&$Y@,<R8J"7!1-Y2E *O6/1U)RMRV:NM:SS:BW2U72.DX_<5*MT"
M0$@\@XXZK'-9-4B-Z3XN&V[KHN[MIV#\RTWBU25@$;N)B7*X1RHC.2VTVG/)
M&",3#;.6[QN@[:+)N&KI%)PW<(G!1)9!=,JJ*R9RB)3IJI'(H0P"(&(8#!P(
M:_J?]TW_ !1_H'6+KNU(\MC92Y]7TNVCTY&W]KJTJ2GFCUNJO%$>TI2<E)1+
M=VU1<-5EH\JT>W27;I.FRJC8#)IN$3""A=6J_BN2M#6SM_+538"NKH5<KM2M
M7N@NG-6Q6IN$HNEZ6K<9!E./_AJEG7<JQ;Q4DQ229,%%)!9_\<!4G7P\;)OF
M^HM&E[S?FU/6F*F4E,M$3LU2(["^T6CC05&0XRT$'*49+@)<6E"4G-;F\ZNL
M>G7D,7J4N(M4-<PN(BRI+79MK"' !%:?>*@>)S'9$!I"UK4G&# 1RXMS$[\[
M]KW,I:SCM=3>=%O(F3NA;_=+/5NC"EEZ.$75O).TT.[MV@BB[(JO%'K!<$2U
M$/Q$D!J> 1+)"T5W-Y!ZSLC<^H;]W#GZ2KSQ [D[:IRSTM;JFDX%C;5@[KY=
MM.NYEK332>!1+[ ;MHV44<MXUDV.P!JZ64(L9_*UQXJ5#+W8K:W%/V=KF:C:
M)H:1KEY4KBL+<4V_?Q;"T1KO@_BJ!J&I&%8RE-+10H0/ZSP["49(5 N5!9L5
MJ47&K3W-^(_)P=C9!_:BFIZC;D5?LG9[NZ)JB<)2]0Q-+,GM6TU %I>9A7"S
ME.4F2)32J@KI-G,&8A#"57U 3'7K[TC45R7:K<]HQDO7"VVJW-.W>Z6VY1XT
M5VV.0VY$9A=N=DV</)4U<) :S-1ZJVE&,CB\49C:9M:+O<F-<OEBV7.[7-YF
MS6BZ6R1*E-71B:N-*D(N;,6]EA27;;%4Z$P5&6ZI?LI5PP(V^5]N8VT6@VHU
M'"W%NI4-MKKT7O'27L135KJ85<6_2MVA7E04W)T>H^IPS]U6TA4X'J1N>LE%
MXI\H<T=\&_B5!9&L.DMZN]&2M/?@D=?2MZG>Q26U>;HVLT:;AJBF("1N)<I&
MG*WAT9.-M51L1((H1;HB-4TVG 2;>!?LEF[*?%$KEVMLP>^(+4EI*XOV2L8*
MXMYVT7?':]9B@* I*%M_"/H:<O'8(M>.DJ>>_:#.0JEM*U(R>*')4JK>19O9
M)LRC"I1+914DSMMF[&F;\4%<VII>C)^SE062K2J*&NO0=:2$*YE*+E:5CT)E
M\X<2$"[<12\:M%+BZ2>)*))F4;O"AZC=)-VO%SODF*W)O=S]'UDGB9*M4U5P
M0[;#Q)E75.HH[3D55H3+=68=RC6*9.4P$25@*DO2C(:0M:=/Q)KL2QVGTDWV
MVF'#NT%%L<8N@"3#M/[-2GFI:+TJ$T@SK5*U!"MZ))7#0I3<9B)ZN\XC457U
M_MW=J9N[]G:IW%W04MU0FZRTM%5ONA"S\%+5O;RU=96IF:OE9)E$4[22L >&
M?5HTBH(THA!2Y(!!5P4RB15R,38VNKO W7P\M2\/1>XVZ:U'A:]A-V-NI4]F
MFM"*W]K-2N)./F0K>CCV3K"6J4L(FW:4Q'4S2S2CGM20R1*R:NWWV@=127>W
MSQ85:A6OK4FXJFX2C+<1MK)7<38A.FTT7%3S]FHRKY>CEX.HVBU2OTWU>.')
M8%R@S!K3Q/AWSMPZ9)1A6SY2^+L>(]>BD[54A<&-V;74HAY4-V;1TFP+<Y2D
MG\+4-*7.2*[9*4I(4W6S1<U:S+10D+#,'B1(R#J%TV9U:X9-SJD3OH:N<6XQ
MX,ST>Z?<DH7#BN.&7IN+ F7!ZWPP^^P7K/QN2P_Q-W"/%<>ML)#ZXSD!$PMW
M%6,X]:9ELDSX7I*U$Q%<1,ELMB%J>7<H%N8N4HQX\@,WSLVX*F.%RWR)C;%S
MFK81*;N"H0<MJ-;VZ"ZUZKG5S-49>VYE<LZ_I+>[9IG$;5(JU2CVV<;;.&J"
MFGE/W8@[@)TFI,.43K.S."/)&>;I.',DHQ79N52)FC?5,7H/_&/_ /WFUIV;
M>(7/4+=.^%(S]#W8NA6TO?\ MO:>REC6$/:^G)V >5%96&N!/TNM5K2H#0[I
M&#=JOW4[*U1-N 2D7)V\&Z?0K9=^A<2OBKQ4B%OX2B=LMZJRN563R\L!,6P:
MO:*B*DH>KK&.(DE;P<^XE)=.,=-&S*6)*)SD2Y=,Q:(F;BB,DHDQ-S&IK1J*
M_1+#$AZ:B6^+ B*E(7$G6QF$XBX6F!-=D)0N/:UQX;#-M>"YTY4SM'VY#"KK
M,6PE:NLTE>],:=F:AFSM53+C+N,M$1:)MONKTYM=MO$^WM,+<;DW=N3.D/7.
M/P0("8):C+CR$VB&A]:4[:=-81VX7SI[<I9&WE\*6BY:$A+@PIY1O#S@-PE8
MIRUD'L3)QKP[115HNHQDXYVW*Z:J&;NTB)N4<$5 I8K;@K0^(O5EU)V<V^[K
M;;6NM6Z80*4'1=1VOBJEEXU^TBD4)YRO,.:7E%7*<G*E6>MTSNU0;)* @0J1
M2^0/.H=E4]<Y5JN-PM]@?A*D-2'+N9B642HKZ6'8>;?#N#OK 65X_P KLL-.
M9=!X$K]1FWY+-JAW>V6VY:BCSQ%=C-V5,)3[D26P9#,T"XS;<UZNIOLQGMB[
MQ/-8:*>,HV+ZH(@'40#ZCC^G6H =OWB_X_Z^VS(#V_\ 83A/Z?U(Y_+Y:ZF9
MVS>+O.-2-'&_FV3(B:Y' +0=JV,([.<A%" FHZ844FL=N8%!,=N8PI'.5-02
M^9,FMZC2%M*DA6O=&I22,J"]2J(&V^/V;&3N-LY-<^K6MT"24>CS6ZU 9"2W
MIA(4?9VXCJ<XYG?!Z;5N4\Y/YY?\(/Z]5R AD!R'RY_HSK24ZV,^)Y.+L$IS
MQ+W[)@BN)W"M-45)Q,@5-0@$5\HQ[Z,3?&)Y2BBD]4! IO,H4J1SF$;@9^&O
MNSDVZJ=9^*%N,<F.]26%&G&\E'-U6Z94S8$7%<F,W=>IZH$%LF1D4GI"=HH8
M% -6O2^FV4I+OI#T^LG!*8EKU1)(&<?O65@9QO@E.#@;C>K;6KM4R%%+/HTU
M$@ ;*FW?2L4$A(.X1>Y) ). 1Q>[.U;DS*$(4QCCY2E 3&,8! I2@&1,8P@!
M0  Y$1$  ,B(@&K&GKI6UI4JYZFN#1%/%;)BLX-.593\4""0(&="HJ#^1;BF
M0&Q#N/,8  4"&5#) $=:HA\&NBZE.JO=3=ENRN$Z<O7SMTLK7[*,!Q\8B5,1
M,D]CZB*#DP@8';@!\CQ$WPYVR:8")KXIOP6MB4(/J35%US7KH01 S^L;DU(+
MH_HM?A@ ?U94IM'RF.(O"E]+RMG/E!F#=L0C<L?9.@H^[^L+Q-P-T6O2N,G(
MR4NW*\P?9.^"IE)P<E.1@U?;/I$DGAC:*LT $[.7;5W%@8S[35KLD_VN0(2\
MH<\*VR),U/XA.R:D#+IS.YRT)E6PF*NC#56UJ9P0Q/((E!"FB2ZIQPH0WW"#
M]P1.&2%,8L7*I\:?91#K&94A)70NQ)>0PD8V^MK,G5%7S$(5,_ZU*TPH >8X
MB=1)%P!"I+!@RI2I'DU37AU[(*3.W4B=L=I5%6IR*(JS5-DJ94%4S)&(H8]2
M+RPG,4R)#!Y_, &%40 /76\\G:8MQ;ZB4R(T;0U(4FBFBFW33IFF82!(1!(I
M")(E^RF+0032(FF4A '!03( !]T,1ZQZ.HN%-6S5UW4/W9ETM5G85_\ <W$M
M]S>P>>$R4D<LGG3U;TGRP4NW;1EE2<85"M5WO3Z.6>%R9<;6P2#R*HI"M\@
M@#48_P#$TW25ZW*IM\\.2^U1,WJX)Q52W#3D:;AG""B@I)N5T&4"+9N0%"*@
MJ"E1@D0I/,+@H>80HLZ\:V]/#2.V[;58=Z1)+U'+EI5E4M&ZJ13"[1,);EH
MZ+D"*-G3&/5(J!P $_*'FW3>4N,8R'_"$3?Q,(CKEJ1JZU0P/LG0^F8RDDD/
MW07*_O\ 3!*+C.5;U$$9.;?PDDX0D;52=%7B:3]M:_U5*20D*CVDVS3D?;[P
M"[9!%P"5<MKB%@ 96H[C2F[\*^^-WRM7.Z+?S>VO@%XF[?4K1"8TM28%(!"'
M29,W\F]CFQET@.F==O3+40R"A4Q$3E&1]J_"?V-6K7+()6=;5_-@<RAYJZLO
M(UVLL8QQ. KQ4BJC3"IRB( 54T *P 0G\J(AD=CNFL:7K[5TI@Q!>I$&&01Z
ME9VX]DB<).2A4>TLPFEHY>RXE8K,A^CG1<-\2S8HUPF@A7KM[<DWV9Q@8[02
M+P]-<0LXSQ-E&^XP:MZG:2I>D(].)I.G(*F(M( *E&T[$1T&P2*7/E(1G%MF
MC<I2Y'RE!/ 9'W'5P   &   #V ,!_#5=-<BM:W%*6M2EK4<J4M14I1/,J42
M22>\G-=FAM#24H;0AM"!PI0A(0E*1R"4I   [@ *::::IJNFFFFE*::::4II
MIII2FFFFE*::::4IIIII2FFFFE*:". $?8,Z:H;H/T'^C2E:T[U^*YM6L'=2
MLK/UX6Z'ZW4*_91TX,'09Y6(%R_A8N>0^!D0EFX.DP8R[3U#@BGY%P61P(I^
M8V+O[=ULH]KR?^3-3_IS7G_\3W_K^-RW_A;2^/\ R94+_E_#MJ--K+/35W(V
M[;FG)2/1EK3VIG;P+TZZ;/59"JJ8I*1BF]7(03AN MD). BI5.?.W>%-]H,&
MSM%F'KI&,7ZZL_H7T"_IFRWNZ2+RPJ=:+/-EN(GM)90_<8T1:N%(@.*;:]8D
M8!42EI!XG%A"%.#XRO?IR](<?5-]L5KCV5],"\WF%$;7 <4^N/;94I*.)1G-
MI<=]7C9*4@+=7E+:"XM+9]2W]NZV4_S;R_\ DS4X_P#TYI_;N]E/\V\GU_9F
MI_TYG^&O,O5.V>O:4VV6XW.NW$:\HZY58S%(1D(S3=C/10LCU W@IN7.J4K-
M.)K-_2L^PILZ0C\4JP Y5%2JF*W[ZL]F]^J>KFX%"TE0-87<=6H9TZ%R9BVE
M%5-.0M(U),TO'5/*4>^=H-7!'<Y2R<A\!*IQAW9W*S-Z\:-2LD3'+>3Z(/1.
MI13]L7-'"].847+M':0AZVRHT*<TXZ[ 0VVMB7+C,$+4GM')#?9=HE0-6%>F
MCTOI2E7V/;5<35O?0&K1(><6S=(C\Z XVTU/<<<1(AQ),CB0A0;;9=[;LBDB
MO25_;N]E/'W;R<__ #9J<?7$Y_Z=/[=ULI]KR!__  S4_P"F]>7(;-S+^@[1
M5+2K:LZMJR[57W$I"-H>)MS4BQCOZ$=0C9)"EJ@;"[0KJ6D?MCS2T%#1J3ZD
MSHI)2IE1>$,ED6D=G=[WMV+36SN;;^O;-,[KW1AK5,*LK6BY%HQ9SDJT^TE!
M:-7B\:6;69Q8ED3-F;Y-%9N)O*^(=-4J=;OH<]%;#3KKUTNS(93/4IMZZ1VY
M"DVQQ]J<MF,NWID2$LKC/IXF&G4N<'$T5I*2JAGTV^EI]UEIBUVE\OFWH0XU
M:WW(Z5W1N,[!0]*1/5&CJ?1)85PONMJ;[3#P;(6!Z2/[=WLH]KR?^3-7_IO5
M!\;O90'][>4>,\6S4_Z<ZZ\PDQMDW!0,W1<'+V6NG$N+E3YZ=MT>7H*I(X:U
M>@X.4@03=9@+EVI]G$-.JLR)&?)P9%90C=5BGZYNDO18ZY6W^XLO;&Z--R%.
MU#&/G2#-P[8RC2'J>*;RSJ&1JRD7LK'QJT]2$F]9.RQ,^W:)MGY6ZWIE*=(Z
M9;K'H6]%LAYF/'NMQD/R&7I##3-[@N+=8CN):?6A*(9*@RX>S<QNA86E0!;6
M$V7_ $Y>EB,R](D6FW1V([S$=]YZR36D-/R&^UCMN*<F)"5/-)[1K. XVI*T
MY2M)5ZE_[=ULI_FWE[<_LS4XSV'_ #<ZZ?V[K91[7D_\F:G_ $YKS\7'V W:
MM?N:M5MIJ.=IE1[>:2AX^A;DL$))>BI$9!4[.5%1MD)=![2TLD:*J"'6!)^W
M559.TP,R?MU1C91MA[VW&I^?JVWEHKDUW2E+N'C:>J2DJ,G9R%CEF'F.\25>
ML6:J:SAJW*#QXS9_%.V3,P.GB""/WQQXOHA]$TR,U,CWFXKBO1XLIN2N[QF&
M%,37I$:*>T?@-H2X](ARF RI27T/,K;<:0L!)RI7IH]+\*2Y#DV6W(ELR9<1
MV*FT27GTOP6(DF4GLF9SBU-LQYD607TA3"V7T.(=6@E5>IK^W=;*/:\G_DS4
M_P"F]/[=ULIY^[>7C_YLU/\ IO7D_1MW7CDUORMZ/J!<UUU3(VS*G'JF&O%B
M5$:DCI4N'644+5":E/F(GY3%EB&9B'G#645-K-]T[-FOLG;JIW5OVU:UK0TP
M]9P,ZZ<TX]M^+5K4L[40HQ9HV*I1I.K/*3+/+28M_P!;(2=@UDT'$:H)LI_T
M)^C",60_=+DT9+XB,!R]0D]K)XGD=BG_ $>[A<C2&N#8AUEUK_<0I(PV/3MZ
M59(>,>UVU_U>/ZX^6[+-5V<4)CN%]>)9PUV<F,YQ\NR?:=SP.!2O3?\ V[O9
M3_-O+_Y,U/\ IS5/[=WLIX^[>7G_ .;-3^/^;G;7F+)M4W.*U"QI-/;W>0]2
MR9Z@+'PI;?U +QXG2;MC'U.[1'X3X?[,@)&3CXZ3F#N"1"$@]08 ^.\,*!>4
M?M[JL+?;B*PJTDO0E0[=W5J&-06_J>F9&,J)\\NC6#RDTVSQ*158.H!6%!J2
M4,5S'.PE&[A,C<4$Q(Y4LJ]#?HJ"4*3=KB\%N0VDB->8<E95/G,VV(KLX\)U
M8;=G/(C=J4AI#BE=HM"6UJ3='IO]+7$I*[3;F>!N6XHR+++C("8$%RYRQVDB
M8V@NM0&'))9XBZML#LVUJ6A*O3F'C=;*1$  MY,B. _]C-3N./\ ;S6SJU-S
MZ9O);6A[JT>$F%+7!IN,JJ "78C'2?V7+-RN6GQ['U5Q:.O3,'JH"JH*9ON^
M<>NOSU2?O%_XP?TAKW1; L!LEVL@':R5"]?^]".O.?2]Z-=.:(M-IFV55R4_
M-N*XKWKLII]'9)C..@H2B.R4JXTC<E0P2,<J]/\ 0QZ4=3:\O5W@7P6U+$*U
MHF,^I17&%ETRF6%<:ER'@I' LX 2"%'.3RJ9FFFFO :^BZ::::4IIIII2FFF
MFE*::::4IIIII2FFFFE*::::4IIIII2FFFFE*::::4IIIII2FFFFE*MFM:3B
M:]HVK*&GOBA@ZSIF=I.9^!<"T>_9511;J(D?@W12G%LZ^$>+?#N (<45?(H!
M3"7 Q++L"L&2C*HH,I:X^P:NVXT3M;E@&K5OC?V74"O-N( K5V#'S-ZD!2?D
M/CIX"'4=E%$!;)^D FFUIK8P[O<[>V6H,Z5%;4\U(4AAU3:2^RMMQITA)'MM
MK:;6A7-*D)(W K5SK+:;DZEZ?;XDMU##T9+C[*'%!A]"VWF0I0)[-QMQQ"T\
ME)6H$;U %3PV-MS^K8BJZC&YU7DIZ*?QE/4Q5=S*BF:4I\TI0);;/WT'%JF(
MXB5EZ8 R2<>P?H4^QD55)6.AF;[R*EL6)\)C:M$0]2PI7UYY)K55IGMDGRD[
M=F=G'#*WCN8B)I"$@U)-!P2#2BG,*T1B21J3=JT;G=@+51=VLX-LXTUM4:RU
M6VE*&]075"$(90E"9CJ4)3'<<=9"4A7".!UUQP$ $N+4M1*CFM0YH;1SJE+<
MTW9UK4MYQ2U0F2I2Y"&FGBI122KM&F6FR"2 V@(3PIR*AF^V)V*?UD_KIP%:
MA.25YK,7V<^G5:R;(:[L31*EOZ$]-H#,03A?L%4Q9F)*<22K[#LRJ!LIC]+O
M9[99:G]RU!(S-;Q:.[2I)*M[K$C:T%E/KK2S9G&3"%+JE:_&4_"2$>R^S'C9
MNBX [5R]1!P0[@3%\WGCV>)WO=JC=-1/@V^%*F]0W27!H"0KN[]>4S5%/4C7
MD!#&I>3KIA;J@:NJ>8@H>@ILUO(.0KBKJI._;SY(25IV+I-_%OW+]RMXGKE^
M&=XPMO\ <?MZI6MK?W=?W\W65#,0-AJX@;[TU<(UPZAA'(2M4MF5ZJ.N945/
MQKJG/O5%5:\[5\8G L$5ZAEU6[-LY>(X1U#?#V>;K-/9)B(;"GUJ"$05QG(B
M "<<,=<.*IH<D*CM$#V!6<G3&GD]KPV> GME2UNE,=*2MR>W*:F*40 >*2U-
MF(=4-UID.@GVU5^J[.>%OLFF3T\=C9Z,I$L)'34+*)4,Z7I0M=0M00'ZO2L3
M<(\:!5ZH07; F^3<NE491I,I)RK5\BZ 3#]!O#:L$XMQ4%LY6IK\S\7.SEN9
M]M-5#?*NINI:4?6G!Z2@ HI_(O5V=,)4\C(.FZ/V=&D7>( S+(.'1HR+.R\G
M'Z-1XXVXVI=QRGA7[[:T=70J<5Z\@[(WEJJK6]5UTSK:VZ#UQ/VBJVN#2C]K
M<B$?QE.U"^H*KC24I.DD(Y6&^U:B@Y>#4@_>2 @( (<@(9 ?<!UE?MAJDAI*
MM0W=08<;=:[2?(<+;C+_ *TVI"G%J4"B1AT;X*DHR"$)"<3]B=(<;JQIJRH4
M\VXT[V=NC-A;;T<1'$*2VVE)"HX+1VR$J7C!6LF LWX;^W>?//2#]W=4M5S5
M=T-<QM7[2YU0,K@TW75 T,VMW%U'3=8-_),,I&3IML4M1JNEWPSDD899UA\F
M@LCW]N?#]V[VKGK>5+1\?63::MRRNV@QD).M9><=U%(WN;L&MP*AK%W+_%NZ
M@GY%&,9%9O57#=&-! I6K4I,E&;>FK:]5:D<8,9R^7-<<MJ:+)EO%LM*B+@%
MHHXN$M>IN.1^SQP!MQP  K43<;T?I9I],ENP6I$A+B7DOIALAT/)F-W!+W'P
M\7:B:TU([3/&7&F\J(0@#$=B;*T7MWM12%F[>!,!1U$M7[2%">DS3$L"4C+R
M$VY^,DCHMSNC_&R;GTSF2()$?33P/D\QLN:::TTB0_+D/RI+JWY,EYV1(?=4
M5N//O+4XZZXL[J6XXI2UJ.ZE$D[FM[&C1X4:/#B,MQXL5AJ-&8:2$-,,,(2T
MRRV@;);;;2E"$C8)  Y4TTTU9J_33332E----*4TTTTI33332E----*4TTTT
MI33332E----*4TTTTI33332E----*4TTTTI33332E----*4U0W0?H/\ 1JNJ
M#T'Z#I2O$#XGO_7\;EO_  MI?_\ UE0HZP9M<NTWLE?FW=?2OF5I)&57IFXK
M $/BB2ML*X8N*2N''':ARN<],2KUXU*4#*)2#%DY1(9=!,!V.>(%L>W=7/WD
MWYK^WNW^O*NHNIJCI]Y 5'$JTD6.E6S6@*0BW"K4)"J6#P"HR#!ZT/\ $,T#
M>JW/Y2BF)%#P[_M<6^S_ .U;N;T_[O0O7V_U:?T9U]^V"^:2E:'L5IN&H;"A
M+^E+5 F,.7FVM/-\=HCQWVEH7("VGFR5)*5)"VW$[@*3BOSGU%8M81->7^[6
M_3FH'%1]77:X0I#5DN;C#O9WB1(CNH6W&*'67 $*"D**'$'8D'-2ZHO=!MC2
MO[7]L:TE7#W9O1MLK'45:!92/?2 SLCL_J.)KRW<DLU"+/*?$76FWEQHEZH]
M:MCFCZR.RD3MDUB'3_E;S=W:FX-N;:R5SJKMU0EX;8WPNS>>?>7(I?<1499>
M2N9<).OF=66N&QE;4A'3%>4Z0WZK'IVO"9<1$>R09U'&P)G[5]$O^UQ;[.H;
M7+G9[_R]"@.!SG_MUYX[9YSCY:?VN+?9@?\ VKMS?IZ]#<AG_P - Y_HZZU+
MMD]'3B1PZRA,NA, B0WJ2S%[MXEO?MDF4>U4ZVM^[0W@FZ*<;6F2XQ'="4+;
M]K;,WOTD-*PK14YYDFX!49W35Z[ QYEQCW6-$ :#3B(]HFL%=I0AQ"HS<F4R
M5N)<'!,"TNX*GKB2MHX>%)5DK<6K*I\2QU5L;8.@)AW7EL([<3'T[)4[<VWM
M$*N3.G!V3.)FY=&EX6H9*IV$423CT7"\P#/XR\HM2C-L-M/#RCJ_K^O?LRG-
M\55W;DY&ZMM*VM=(PEO8FEHV*DYF"M[5KJ6KJ-H5I*O6I4'4DP9*3-3O:B<0
M\<XC@1>O(+,O#PW]1KMK(1NVF[4:_9K%<,W\;)T?'/V3A,?,1PT?,:[0=M5R
MFY(LV725(.1*H Z[&H-A'B)U;(C,598&^%5RYDRH&EJIJ:GJDE/0(8QR(#(S
MEPW[WT"'.<Y$"K@@10YS%3*8YC#8D6G1[LE#;&M[#'M*_7%RXPNUE7)==DC4
M/!V3ZG/\E,8ZA?#'  @-,A#[4EQWMFLF/=]9MQ5N2-"7^1=T>I(AR3:+XB*T
MS$.F^/M8Z6_\]<D:;CF05DK4X\5LO1FV0P[T\'?X#V,O-$U/<RJ).N9K=I8&
M[M*MW\Y4\E./82F7]R5J^J>(?KK*A'//@).!;/BD?1[Z21<,F::2Z*!R(VOO
M3JBC*YW(W!N'05V$;MTM<.J)JO8MZA&UK&#14?4M32,JRM^X;UJU:+@]@62R
M2S]."1" :NW:[-H7XE!P(W+_ &N+?;@0_L7+F]> ]:AL#\_]6O?I\NNJ_P!K
MBWV#UVN7-SP ?R]#?3O6@<!TZ]N@<:Z>))T1"N1N<?5EC;<4):5L)O-B$=2)
M46TQBC'%VS:6A:&'6^R>;)=>?[0K;4E".5EQ==3K6+5)TA?G&T&(I$A5EO\
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MW%3EP.O/?\0%YLUTL-B:MEWM=Q=;N[JW&H%PB3%MH,-U(<<3'><*$<1"0I0
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* 8#V#3345-?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g363172.jpg
<TEXT>
begin 644 g363172.jpg
M_]C_X  02D9)1@ ! 0$!A0&%  #__@!!1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?1DE'55)%7S$X7S1#7TQ)3D4N15!3_]L
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ML8QC&,939SX_M,NAQ^D7S0_P";GRY/*;.?']IET./TB^:'^ 3<^,9<D7T#[
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M/%S6T=BR@EF-A7.ROFL>HSK[YR:QUM"=6WHO;2AM>T>(V;==[<N8&Y;%C*G
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M:(9TNK-XI]!1<32&Z%1:P$>Y*Y1!.N)0"3!*!4:^\*+,5HM-L=FY\+E 2+%
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MJB(%8SC&,E<H.,8QC&,ILY\?VF70X_2+YH?X!-SY<GE-G/C^TRZ''Z1?-#_
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M[!SB<A#@ '(4P 8I@ Q0, &*(&*/80$.Y3  @/J @ AV$ '(5;7V)R;TYO2
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M=N-.A3]EJ'GY)W=S8$K9Z]9>(>%VDK7TZUY:3/U/5I&FZY 0!+MVBF0C?8"
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M3@F4I .Z.J;P%*3OX0[9&<@U[MWQG><?K[&]J&[E>N3^):]@@]":NUI7K*C
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M?/RW?= 3?A-RK7;ZLX#UIRCH?8JC>>XL\B.9<SR.B%2P2_AD-(1:/'ROJO\
M9S0!,O46I+!!G5E"(E)*-CB43>AV@;"I.TZE"7O7EGAKA4+$S3?PT_!/D7\>
M\04* F*"B1A,@[;'[MW[!R1%]'.TU6;YN@Y242+W(0[AV\_/Z!$!_:'80_4.
M8&+8EAJ<LU-49+8I@$#%F$R)@8%$$!B43!"41(S$Q,1,9JJ:IZEN2P&I< L4
MU9BQ;%F,$!@83(F!C,$)#,B43$Q,Q.4CTZT=?TU2JQQTOTI7)C5FO&.XL7)C
MF4E/K*&A&(J*3B)N-!Q3F3G$QI4@J+>"1%R .'/8'"GW'%GZ_@-W AI'I(%$
M&Z_FCR:YD&5 ?8*=A3+_ $9NQE>_84^_814\/X11_#+<YFD.1&^Z)QMU+;]L
M7Z58L8ZN1+Y:*C'#U!H_M5B*T75AJG I*G!5_-S;Q,C5LU;)K*))"L]6(1HU
M763R5:MB[913J)98M6G+170H9)C7-* 6L!CYDB*8B(_O_3,=NW6HU;%VXY=>
MK52RQ8>TH!:4J&38PRGX@1&)F9_M\?.>?CIL6_[H%><%.,3E[K#A#:GBVL69
MW4_S#Y \RZYR9E%AFIL/>MRP9] 6,8ZY&(! <MQL$T(,2QZGOPB?V#>7MQL_
M7\+4;2(:6Z4C82UFQ&*XKW)?F2O/I'"%?B12%2+QH*9:8(< -%)BHD!I &Q?
M>&P#[=/L&BNM'QDLFNZ>XWI.2^M]EFBV;>]MV-"N<S26M@ [A%TXA9V)937B
MB78(HO&R+HPO&I7J3-3VZR*IPE37NISP*L_LRQO)[6C=10 'V4\\E:NJ011%
M<2J%L<5%@F8A $B@&-V37[-S#[<Q4QLM_@G,]:YZ;7&-['MV,6;E:NZ^J7IS
M,2:K24FAJBB/(& R0,)@AF8GO*MK_J#PC9H0^KRK0_XA:V A^UI5[8>H(E"V
MU7O!ZG#Y0+%&$&!Q(%$3$QE3_ .V?= *_"7BHLXU9P&LKE70^N3N)[E+R(YF
M0W(V65-!(>)_NZ*7X^6!2/V:[ "K6YJ>?G#)2AU2'E'1@$2R]"T=?WQ%_P"!
M#I%_C%_[9KF,(?C!ZA_1E-W#Z0\)O+O^"/H-D,#R;XXV9(%:]OO3<T3P&4'X
M=LZF.E"))HIN%E%$RS7MB%004(LN)R![$@]U/"(" ?8TENW7G(/7<1M'6,S\
M:J,T[G&#1X=,&[@CNO33^"D4';45#J-%"NV!UD4U_ =9BNS>%+[%TD(P#M;L
M*ZF/L4;B$J:I#6NK.4"W/%QI49& P+&A7>2PF8(A2R8B8 NK$G::RRY5>OL*
M5A[DNL)4BTEIL17- /: K,I):CLUQ84=P).7$S$F/?G=X%W#[H&<TWD.9WK'
MA+8E4N;G+MLDKRAY <RH.>BV:&VY$C2"U*B?0$_\0XX0Y/$RT-,E=L2RM#39
M.@K\$4P-33I+:.OV)TP-I'I%E**J0&-_2:YC]@**A0$3=N,:H^$ [^/LFH/A
M[]DSC^"-R0=OF'N ^?J(^OT=Q'R^@ \@^;,YI9OYYB^G];_N@1QH^W*.=8\'
M[*L')GEBF#[E3R$YF0NR&Z"7(*^%0BX!HKH&Q"KIR'+WB]&OBR:9'^JFE7=I
MP\&DJG')3?&T=?WL/_ ATB_0?3DUS'[_ *O^+-ER@!V^GZ?,1'U^T1_9Z!\V
M9QC/,)QON/W0,MRPZAR*^L>$DHBUVOH,C"&V]O\ YE1NB:VBKQKHZSAKQ/E!
MX_R1)ZD2#@WQ3:#DL76/<-PNK/'?#Y,432IIS#:.O[V'_@0Z1?H/IR:YC]_U
M?\6;+E.W81'S\_K$0\OH 1[!^KMW]1\\SC&>83C?<?N@9;EAU#D5]8\))1%K
MM?09&$-M[?\ S*C=$UM%7C71UG#7B?*#Q_DB3U(D'!OBFT')8NL>X;A=6>.^
M'R8HFE33G^5'7]_YD.D7_P"<US&_]F;+D^W81'S\_K$0\OH 1[!^KMW]1\\S
MC&>82&N/W0,/4HV,T/K+A*=D3A#J%RC5G^_^92?#MN]/O?:J2L[5+%_1_53<
M<D'C<A6%]AODTQ,VUDQHKX;"_P#>BQJ$Y_E1U_?^9#I%_P#G-<QO_9FRY/MY
M]_/OV[>H]OV=^W?Z^W?YN_;,XQGF$AKC]T##U*-C-#ZRX2G9$X0ZA<HU9_O_
M )E)\.V[T^]]JI*SM4L7]']5-QR0>-R%87V&^33$S;63&BOAL+_WHL:A.?Y4
M=?W_ )D.D7_YS7,;_P!F;+D^WGW\^_;MZCV_9W[=_K[=_F[]LSC&>83<=Q^Z
M!B<\^$[8FLN$K!DXU3S$.ZKVO-_\RG?&">6;QFF19NN1TZ7C^U+#W:&.H<=
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M<GQ_Z:^YDFJ*I3*U'96TJ%(R1FCL0$Q?E++,8UN[EFANS%,S<C)B8H+/3E.
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MY'V2,>J>:,]QLX\6D#!9-%:>GA/X0,>6UI3'JH@3VO@#VJT,*H> 5E1)V/\
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M5- EM4P"D36Q9Q!@8%$B0%$$)1,3$3&=.2Y5A2WH:MZ' +4N28M4U9C! Q;
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M!+1"SY1JX@I)I+*17U(G7T/K'KN:<;I%3U?*J\7]QI:]807HB7&JXIR/J:H
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M/?;I2.4O39K#FWPC218MIV)A^HEQC9UUT[;2AU7A99*"38,I5<ZRQ7KUJJ^
MY1<F3)^_D9SSYHZ;=T1C:..U:U.M-323]LJ]GS;+8WQJQ5*BYH\<_@4TFL/,
M/SK)F4*W5=6($3M%XUB*1E#K;"ZKT[)6?I[U.QS%:E*=*SO*+ID2\C5)L[92
M7K;Z1Z@/%ETZA)([0YT#/8Q94[1P*?A[J)#XTT5/&BG]1]<?])17.(1#E1Q
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MM(O*L1LJSG:?4[PJD]I;A@HVH[NL+QC)82JH55>'58M7#@/;F*HE"G,V067
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MW#IW]/"X.Z;H.FO/@'.CG3 >)Q$0$0X.JWEM&Z-EFZB3>P7"P-DWD7,3$6\
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M\6--HHB?_&5$FDMSMXCYD)JT:]!\1'AM B?..9^4E_*,S'Q^8NQC_A$QW/\
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M4226]3V!Q$"U#!97</Y7*,>HBO+@/U*^/7/^J2I]?NY2A[DHOB8[CXZ[&1"
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M&R[6/3.+=FB4LI\I_(]FC8WX71@@U.M0O6:=1_!10K27B]@_'C8OO-VPM_\
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M0^;/'$W$UQ"!)B:DKV&OE2B;$FV5@KUS_.P>Q7Z=<[;K#\,#K&;R4MMFOJ^
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M^83)HUJ%76402 PF I4I5(I2#X"D*'GDK-;\8>/NHTD2:[U#0ZVNW,!DI-"
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MIL H--S?.#]+=;4)@2!'4ZG7,CNLNW8 =A-L\9+J3C[3$P'?<1_22G_>+_\
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M>Q3K<&5((-&K^S^%LA*-;;%(1"!, H#XH=(B9"IQQO$T*!0[)>HCRX#TO_2
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MF1-LW%55.-CD6<8V/[NT()MWXQE[H4*6KI5-;KJRJ=&BA56I50/@I"$A +6
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M@Y;FWUL=0[C4K;7":YDH8%&U@0.!C[+2$&WA&UN""=-0I^Z(^/QE5 Q">&-
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MQ1VF4X&%H8>Q1U[X>8N\1_#/$<8:*Z !$I!):-I.VJO<0 3?U#6%6$H!XO\
M]R/FQA#\%8/$ ;CXUZ2A=+ZSK<+[I7'=N5CS.;1:89BV*M-/9!RL_%,LK[!-
M\_C6"2Z3&.46.5-9JV(X(@E[82%D1EGIZ/D_):=6WRW=6=4BU60]O&.-$S5
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M'(HP#=A*/6D7-L[6HS%\I3WT8Z7(L%E0;$67"/:^]>_,T3248H\C3I.C[Q$
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M)C>]D;*@\C]=QBSJMZ;K"P]A]W80#+W!>8]EX2 +E9")2=@422#20 14-8;
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M_P >.56K^4+!S.:D^44M6&=2UO9G%FD(4\5$IR.RJ\O;6='%1=<RQKI6:PI
M3=PC$DE&<,TM]8*G)/5GZJ;: '/@?_VF70X]?+D7S0^8>WY >YA]>W;Y_I^D
M/4![,9<D7T#[ _=F<P7T#[ _=F<8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QGY7;%F_(1)ZT;/$TU2+$3=-T7!"+)@8"*D(L0Y2J$
M Y@(H4 .4#& HAW'O^K&?)B)B8F(F)^\3'<3_G$Y]B9&8D9D9C[3$S$Q_E,?
M,9\TT-$&\?BBXXWM'OQ(_B8M1\<@'B[/C]T?PG@>,_\ I0]U_P ,W]9^$/?Z
M6,9\$1'OQ$1[^_C$1W]_OU'S]Y_YSGTC,NO(B+K[>13/7Q$?'<SU\1$?Y1']
M(QC&,]9YS^:J8+)*)&,H4JJ9TS&24414*!RB43)JI&(JD< $1(HF<BA#=C$,
M4P (:"@N.U;@$M?)-KEM!S][EW<WD4=]?)I=254NY719 EA.51(TFG'>^.#0
MH +<[ QBB)UNP@:0.,TK6NHW6*;;K+>Q$1"3.)F5Q%FK<B!ZF/\ XS1J.^>_
MSH#]HF)D:6VV6N4]-&XZLJS,S8!11 MF:=ZA,G$Q/?\ @]E?K_\ X=IL?>8F
M.C:WH4=K*FP]*BI6Q33"%*[(WDK5,N9Z<<%=O7#TP/))UV46!([@R*!2D3(D
M@1,A2=P,8W><8S/70FJA-6NL55ZREH0H/@5I2$+6L>YF?$ $1CN9GJ/F<U;5
MFQ=LV+EMIOM6WMLV7LGLW/>PFN:<_$23&$1E,1'S,_&,8QF;,&,8QC&,P( /
MF(!W#T'YP^P?4/U9G&,9$S;UXXN[#A+M0]K*P4_&Q-KA-5V1M)P<DNZB+7<D
MTCPC*-DDXXSR/D#BI[PUEHIRD=@X9JKI. .W 3]GXWP&C*#6K#J71R*#9AK"
MR+5^WMQ3?JRIK<NU0>OGL_+R*"3F=F'29TR.9$ZJP$*W(R1!!HU;(EWPI"0Z
MIEC*Q4:H9PX3=.#*,&AS+ND04!)PL)D1%5=(%50364\2A 4.!3!XS=_U-V+-
MHHX5:M&S=5VJ*[I1!NBBHY6$3"*K@Z9"F65$3F$5%1.<1,;S\Q[UQ.F=&Y#=
M65:%EP$OI^]3IC5M/P]K'M&H.P.\XQ#SB@38E9+8=9Y0H/<KBM;K'(U3QUG&
MZC^4JUIV*VQ_"['(@?HIVZ4UD%L3U"]7743O3+:K2?JP]2K=196&Q3;-W]6,
M8RQY4<8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,95AUDOR)4
MOTP>F]_F'\8,M/RK'K(@(\)D@ !$?Z8/3?'L =_(.H=Q@$1_4 "(_0'GC&6E
MI_BC^>I_$-G/."?XH_GJ?Q#9SQC&,8QC&,8QC&,8QC&=5N]-A-A5.>I5C/.D
M@[)'+1<F>LVRUT6?*T7$@J#%6ZCS5=MM?>=R%]G)0$Y&2*(>($7:8'-W[5C&
M,C&GQO;GWW7MMR5K>3%2H7'IQHS7&O)="2F'=8>V:S-I/9%_=7F:G9*;GK!<
MZQ5M;T\SJ305G6+2KS#YQ8Y-2X2K=.,6C^GO)TB(6A=[; H')."J7&*M<0M4
M4NTZ9:P]$/INH3?QZ/5W369JX; C=G7JPKP]$C+9,1+.EU=>/IJ;B%ID6_FG
MJJ-G.,8RK;1_3RO.E][ZTVPQY'S3ZKU:KK?+>AM8"SPZ-TO=@K]O;;!.V;1^
MRT=6Q6M[K=;5&["&MOM/SEYJLCKO754J.RH:AUME76V_Y'@'Q8F.7L!SKEZ!
M.2W)FJ,'D=5KI*[3VS)5JLIR-$6UI(/*YJ=[=UM1P,R^I#EU O9Z)H[29=H/
M'CER^5?.EW)YE8QC'IF/$ " =_,?M_9W]._T!W[C\V9RB#<5UFF_4%F&;;8F
MX&G(2(Y1<,ZGH?54;.6U.H6'AG<:+5GO)JQH:P0D$*);**B\5WW(;)VG+P4I
M,4BXT37,:,]$2,70F#MC+W\P)@ 0 ?4?J$0#[1 .P=_F[B'?S[>F8+W\)>_<
M1\(=Q$.P]^WSAY=A^D.P=ARB_F-;]=V7GOKW7D7R L.M]UT\_&N>86:Z\DY'
M36J=/UJ5V=.24G5-7Z,A)J.;\L-T\D(F->4BW5O8%7L-"IM-<U)_)VZ$>?":
M/<&,O2S B >OSCV#[1_G]GGZ8+Z>8@/F/IZ!YCY>7;\7\7T[^7GYY3SU1]B<
MIZW)Z18ZFUGO)WIJJ[6XY[(V'>-'SNKFDY?[0ERFU/6H30$RWMVT:19(JAS-
M?>SL_>G$?#NHZY.7=(ITE8Z_3#;)< QEP^8$P%]1]?J$?M'R[^0?./H'SCG\
MFZAUD$55$%FJBJ1%#MG!D#+MSJ% YD%C-EG+8543&%)44'"Z G(845E4_"H:
MD#K!66\Q,_HN-5ND10--FUKR5MLG+S^U]UZ983^^:4RU?(:6I=<MVC"!8W^V
MYFON=JKZCK<\Z=5PUB9O+6WUYMZU52N4])C+Q<P(@'K\_D   B(_8  (_;Y>
M7J.=)UG*RDYKJAS4W%V.#F)>F564E86X T+;(B2D(".>/XRS@P91K$+#'NUU
MF<Y[G'L6OQ1%W[NR:(^!NE4CUE+?8(:I\=:TSO=4UI5K)L#:TA:[9MC;NX=#
M:3,M4= ;"E:9#7+:&A4R[*:6LMS<Q%OUO5V3UG%V24I<PJ)7UHA:DP<,9=+Z
M^F8[AZ?K_5](_1^O(_<39ZQ6CB[QSLEO/=%;7.Z+U++65?8\>,1L!U/OJ# .
M)AY=HH0*:,M;Z1.Y>S[!0B2K23<.$5D$%BG1)"3GO([YJFVJE:-*WS:YIE7A
M[SS+5-75=M$252<[;JFK:I/ZON"$$A6S3-AV$%A=)PU=CK!8I2M> 3(1%8;2
MK^3D'C&6N (#W[?-Y#Y" _L'L/G\P^@AYAY9GN'< ^<?0/L]<J3Z8]AK$I8-
MZQFD=C[*VMQD94[C/,T^WWZVW'9#8-[6FCW"0Y"PL/L&^RLY9'TLDV0U+8=E
M5(TF#"C[/LMIC5(V%LKVS1;:1'),+=#\E.#UHC=FW^O4M39FY:Y>J'&.(9'7
M$W'AQ5WW;(ZUW1$E<5LC]_6)JN1GP-NYM*-2166]Z=5M_/I0TG',9.,# /I^
MX0[_ %AW#S#ZP[A]>9[@';Z_3*..E#8:'?K_ +*V-J7>]CLU#M.L*2X>:]VA
MR4E-\;XV5;U;)-.Y+E-N'7;NQ3]9XKR]W0<?!H+3FOQB"*P;QNK>ZK1)2O5J
MAUN</,%.\-=A<)INJ7Z_UV(1Y:5. NM+J[B+:U6_5VP:]V<(IWXWP%W97,;7
M9",92<6QB[+ P;B4.DM9F$_[K$I,F,G+W#N(?.';O]7?T_\ =]GTAF>_;]V4
MX\*-D<J;3SMY.CR*U9OC7J%VT=I^TU6E6J?U/+Z9TU7ZUM[D;4ZI7:<>D;6M
M[J5MNPJHA#VB]V[X2>0L=O93;-^UJ=+KFN&<G+GG<SN/WI:+/4S8.P:,[KG)
MCB2XF&-#<Q+,EXJTWR@U!5;33[>X<UZ8GBT][7YR2=3"54E*O)NTFH,Y*7<5
MMQ,P\DQDU , CV[^8?4/;R]>P^@B'S@ B(?/VS(B >O\_5]OU90+Q"O6RG/4
M4V,VOMA?6"^V38W-"L7.D5W:VX)*PZRU7KW9K8W':P;JTW:HUQIRI4"T:R-2
M&^CYK7#*I2ZSR?6FOEGN1;8.RE:K8GU($KP3AYMR6UYL#86N[/6F<#96LGK5
MQ%,Y^;0B;-#F>5%V\?P$](M:_8VRRC.=4JRD!:C,2F1B;+$ JZ.LQDYO$'?P
M_/\ 8/;[._;MW[>?;OW[>?;MYX$0 .X_W (C^H [B/Z@SSPM=J7U3K%.F"ET
M=%;I\D76L0UBTV?N1QNDVG&_"1G-I/)7C^!D>/D=Q)+M=\79"&XU6RUY4ORK
M2/0FE)MXK HS_P"I[>-84W0=/0VS8]@1M=N>Y*73V=/HNVT= --J3CV&MLI&
MT+9>\S358=:CU"D>)/=]C7",M,))?"*6G7FB=I4G@HMK8RQ[Q%[@'?S'ZA_8
M/EY#]0]A\A\O(<Y"(!YC_/\ K$?F#U$<\O.AK18X;:NI(8W)G8&W^1,#O+AY
M4]!Q]"VKL39NJ[GPEO$8WE^0IZV6=EACMZZQUJU>;NHE^Y*;(A9'9A+9I/6\
ME<)2M70M5@!NKZA=YH&ON)NP)W:%KV;5:8YEM;5^8-J&U,J#L*UELNRJE"HZ
MYB;[(3=6;:_CME+/"TBX7T]MIIJ32IRR6<ERJ1HL)^/8R;/C+Y>OG]1O+\[R
M_!_^5VSD(]O,<\H6JK!K:5VSJK6\!S)9!M*L;(UE<*1/)=0&YV[07$C6%GW)
M)3K?C+IQQ*6%K9.H/NG9T"R?4R]J;AK,[2*)7+17(IK9:W6H&AT*W^@OG+=:
M?KOB5O2W[ O>R=<4Z)I#DM@MFG5&;;:39C)2<=$##T"2?&;M(.U6A:02J,/8
MUI&"^3;F<+/EL=94C2V",8R6/B 0 ?/S'L'<! >_V" "'T^8>GGZ>>9]/7/*
MY&7KD16:YI]+1Z&U;MQ>@>;/'W9/P?C+RJI?*=K6)2R;DU!0B\,+SO3:V\8G
M8$U76%?)9MZ[(CV2<UKAYLC=-*UK6[R73>N[-/6ST3\H;= T7C1OBZ6J[W+6
M%=K6G-AS<WL"@-FSW85)CF52E%W=DH[-PVD6KR[0R8"ZJK95F^27L*4>06ZY
M3  L9OKQE#U$0^H0-W^T0[=P#ZQ#MV\^_;.6>.RWV:395QFO1MYUJJ<5;"GN
MR_U_5\]SVY";6E]2[QI>MM2N]5Z^G^1VJ;/=[0IR>W9%.-GWFHZ/1O%QTY0+
MM!25GIL#R"OK%Q$K>IUU<3-.-CF_7.5N>JC-M(K6^TS<S'1\IL#70HZ^-.3D
MK*Q2$"K%2%PIXE=O'[!&LJ1[R>C%FR<&9LJ6-QC-Z>,OU^O8 \)NX_8';N(?
M6 =NWGW[9R]?3/&E:+_$N=<U1[J/D9"4_2.SK:WG9*H\BN?^^;4WKT]4.-6[
M+#$;4Y2;?TU;;K>-&;[WA;INIVFJ<9]:VDVM0F-'3,N^<O-O-6=.KWJIXHS]
MBL_%KCI9;>:[+VN<T5J67LJVQ8_X3L)Y8'M!@',PZNL4;P#&VR0DC.7<]'JE
M14;2;EP@NB@L4Z1&,D%XR^?KY?481'ZRAV[F#ZR]PSD @/F ]P^D,\D"&SM>
M#R;J-.D-_P"Z);@=L0:?,<I=F/\ =&_8JQUZY)Q^[%(2%YRV.9=4-SQ,VK<-
MSC5*RRUUJY.A0DQ4:LI6]DQE?KL)KZ$=^AG@#/['M'#O0TYM9Y<9.W/Z:)@E
M]@QRT7?IVJ(S\RUUW/W9D[(1^G:Y_72%3F;&I*I)3#F4?NWDPDC)KNR$8R8G
MC+Y^?I]0^?YOE^%]'8O?S$ ]1#,@("'</W" _K >P@/U"'?/*5N+>.I*?O+9
M"*^[>1=ETSL.NW*.W9&5?=VSJ/O1]NLW*K6\; Z4Y0DV-):TUKPPH4][2YZP
MTU;M</\ 6$ZYX]1U]D)&R-ZG%Q<[)7I].UF9CQ8J*)-KU?;$6I9MDNJ\^I>W
M9_?]8H=9?7ZP/(#3\+O2X$)==ML]1Q:[>C%O=N3;S4NI$G#W*-C&\;'-&,G%
MX@$>WS_8/;Z^P]NPB'S@ B(?/VS(" ^8>G\_W?0/H/J'EGF]V/M[95*YQV)S
MPT=[/Y#;=L:7*:K[$U3*[ MKG8='O47*0K&I2NV-+[4G-8:*HG$/4<2DWG^/
M]GK,I W[=<BM6*M3+3/,]L7N[.++>EG,[ D>(4+%[-;;U6M=.V[R2ISFU\BI
M*FRNS[\S@N0^T$(^US+BD6VW0R1Q9F1@5H]LXC(R,?P;V.J<:>C-:Q*R;&6)
MB8H#V$>WTCV'L'U";MX0'MY]A'OV\^W;,@(#YA]GF @(?: ]A#Z?3S#L(>0A
MGF,ZG&V;[1=\6Z;XF;&VK/<GD)ZST^RZS1O.Y&>SJI4G?&9\I!N=1:295]?5
M,EQ(8^\#M'9.^AK-[N=6VXE+N:(YM6Q*[7J!'63]*VQLI/7.Z:_7)]K=Z'5M
MQ-DJ3?J?M?:NYM.61A8-7:^LDLVU3<]W/)_9 -J].R+^+O\ %/KO>(5+97RG
ME8J2K;R9F=?4YC+3!, #V_\ 4/8/M'MV#ZNXAW^; & WI^X0^P?, [@/S"'D
M/S#E 7/[9S6@<M*19=9W_<D]O:K;&TK'RVE(2S;.9[)=ZGE(*7>NS<0-'-8R
M*TMO*M6DSBRNN2=MV8M9XFG,ZN]*:5C[12*-7FWT^B+<KE/Q^XXJP;+A=J1R
M>M>*-M<SFO-M[NWAK./V5;Z!;U]I(2MXWL"5@AM^V&791=HW%K6L(HU6I1S_
M %_*NF$3<+196AV,OJ$0#MW^<>P?;_/[ \QP!@'T'T^T/+Z0[^H#\PAW ?F'
M*;.H;L;E-!\@^*[2B:RWXMHFE;YX[SDE,:=G]0L&6[K]>;G:JE)ZROXV?;U+
MM45KC7]7(SL+F/<PJ%:O-XME<=3MCBJ_KIVRLVO>E9=9*P7V'2JFQML[(8S_
M  ZU;=.8@['L5RM:5,YVO;O)QUV@GQ;M)/E-8;,<,4;LQN^H*PSKL)6JO5=;
M/!K$0P=5UQ)L9>J(@'F/T@'ZQ\@P @/< ^;ZA !^P1#L/UB'?ME/O5BO_*2N
MU6@1.F-=[I=:QB+7J[9&RK_I6=UA'62PSM:Y#:>84_03KY6[0H]IAZ7L-M(S
M\GLN=KL:^-*UR)CZ$I*0D):[A-PVKNG!=-?[6Y0[,V9JS=ML>PTS4=J!>*'M
MODJ[V3N_=%R7W##BAMJS<;XVQS>MN+E TX1C-ZWU;%TB/J\Y>*K>&:UEJ58K
ML#31L3&7J"(!YC_/^L1^8/41S'<._;Y^W?\ 5]OI_K[#]&5']8FW\F87C%9X
M'0-1W&2O/Z+LVX;4V[HZ<H4;?:+&Z[@F,Y4:5$(6J_4FPL$MJ69=)I;+E2VE
MIG:YK>L76'A8="W6^K2\5TOCMM+E7<>IA9I#=>H.1>K*3=^.%\;4?6MIG]*/
M=1ZQJ&O=W0S*EVZ1+KO==Y/.;:VJRE'\C=9-*/?O(%*6I^OX=F%6I4[>)YC+
MI!$  1'R /,<>(._;Y_L'[>W?MV[]O/MW[]O/MVRL_JKV?D?%<5KS6N.]2VH
MNK<Z9M9GLK:NFI?74;L?3E#@M3W"QGFZ.2_7JF')<+=88^$I$18J\E89FC1\
MO.W**A)"R0]:8/JWN-VX=LV;G=KN=V42W0%RG-@5&CU;2DEN'9B.YZ]QRE>&
M4'96=_N.G8B8N?&Z;T ;9[*VR%BM"#F5NKG:$K#23K=$';JTVT<HQGI2]/7.
M/B+W[=_/R^8?G] $>W8!'Y@'L/U9#+G=/;]C="2$'QYINPI^UWR61I5HM^K'
MVN$=@Z<UU*0LX\N>T:9%[/NM"KD[=8UC')5FC-#32X0USM,'<9*%G(&L2L._
M\]O'K=FZ;)R3X0R%IM>PJC9(^L].:@!JR_[=VA(<F+A2[?QPG'FU[A5M,U*7
ML>C=DZ!N$_+1]XW1MS9,U(;"J_R%V0]L7R<OE"UI74&,]< CV#N/?R^@!$?V
M  B/Z@S'C*/;U#O])3!]0=^X!X>X^0=^WB'R#N.0-ZEI'CGAELZ.:[20TJ27
MF=1Q4SM*1B]GR<%4ZJ\W)K_Y9KV@VGRHWF&JTO4TYJNV2T,IFHQ55AYEY/V:
M]4:ML)2UQ-&.N]ISI[I.Q;&UV2$VQK_:/&&M=/6/T]?-\K:9Y+4:Q\HK*PY-
M;DUG2+[L"S_?&I-WIS^5K>ZB[%L.TXO4-#IS2TT:ZMZ2I4+;(L9ZPA'L C]'
MGY (C^P/,?L#SSCXP\O7S^DI@'[1 0 0#ZQ[!]>0SZA1Y\.$G)=O6]A.-32T
MGJFQP:.SFT#L6RGH#2>%O"2%Q5C-2PT]L7W2OQ+]Y)OI2K,"OX)D@XGE9*%9
M1KN;CO/I9;[K*8(TTHVWM T2TP]BV?(<>M^TGEENG07#IG NY37*)>9<0ZN&
MV;=LS>.VJ?;'$QIRF<>&U]W1IJU3>J-@/UY>AT>UVF738SUL_P _3^[.(& 0
M$?, #R\RF ?/T[ ( (_J#(Y\L5YQGQ.Y&JURVR=3LI=!;83K]\BH&WVB4JTZ
MOK^=;Q-R:5O6M?LUWFW,!(+(6 D32*S-6)V9G[O7X=Z]%LV/YMK9L7DA6N).
MW]=\:X:R[-TQ2INC7VU<T>&5ZG';+:CZN5[4TE&Z>C4>2G(RP7Z DWEH2?1N
M^+?J:UW>$>4UA\DDHZCWZ\W%O1V,]:^<?&7_ ,+Z.PD, C]@"7N;Z^W?L'F/
M8,ZF\FI(*0\L(1$K"RP5IY-! OF19R;B9 (M9^6'>1]-5M*<M*QSKLQ<LJLO
M8DW[Q [>"6F"K-#N?'77K/=X2LZ=U67>^E[UH>=I]8L?)'F&IMKG'I_7\INV
M,U3<W%-TUOR2>7^4V;4]P+7-.:OS>L5JP:+3<6"3@XK9>IZ];J?K[6^P&,]H
M7KZ9KW9FK]>;CJWR)V?5(NYU4MEI%O"#FD'"K'Y3:WND#L.CS!2(J(',]K5U
MJ\!8XPP*"1.1BFJJB:J1#I'Z7QCL,U;>-F@+188NZPEAL.F-63<W$;&DCS.P
M8^5D:7!O9%E=I=:$JZTI;".5%B3TBZK-8=/I0SET]KL"Z66BFGE;+=K56*.U
MJB>Z]8;9;;3V?K)_R)Y#/-A\R]#U;5CQ_P B=A3D[H#F9)6R=DK;J(EYB_#%
M5$:74-"6-G9*A%:[V7KUCJ2SM)=ZQGL9#MV_!]!$1_6(B(_W]^_UYG(,=-2R
M6NV\&N.DY=9ZQVJQKTETQ>VFS.;-(N+2C"VBPPD79X&<NR:5XM5!L41'1\QK
M&Z7E,EVNVN'E4MMO*%CF9/)SXQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC,>$
M._?S[_:/;R\O3OV_N^8!]0#MG&,8S';S[^?[1[?L[]O[LSC&,9@0 ?4,SC&,
M9@0 ?7O\_H(AZ_6 A_/GZYG&,8S @ ^O?]0B'U?,(=_U_;ZYG&,8 .P=OH\L
M"'?^?IQC&,P  'IW_6(B/D';U$1'_;W'U$<SC&,9@ [?3^L1']XCF<8QC,=@
M#T#^?Y_GRS.,8QF.P=^_G\_SCV\_7R[]O[OG'Z1[YQC&,QV#OW\^_P!H]O3M
MZ=^W]WKY^OGF1#O]/ZA$/W8QC&8\(=^_G_TC=O+O\W?L/K]'S!] =LB'?_8(
MA^[&,8S'8/K_ &C_ *\SC&,9CL'T?M\Q_:/S?5Z9G^?H_=C(O\LN6FMN'FO*
M[?=AQ%ZMCR];(IVG=::]UC7$;1L'9FT[ZH_+5J-48U_*U^"+*R3>)EWPO;+9
M*[ LV48[6>R[<_L$EV,D^)0'Z?G_ .48!\_K >_^WS]<SE;E3ZJO$J7M6FM>
M["F[EQTV?NFA[XV'%:OY-U%71]\I\'QQ<L$MFC?8>Y2#5*&(W9KR\Y5YR+>3
MU/N]:IM[L=4LTI#U":=MI-6GEYQ3H\#8[5=.2NA*A6*>SUO(VVQVG;U KL!5
MX_<22B^IY"PS,Q/LHZ&9;*;HK.*(ZD'+=&V-T5EH,[Y-)0Q6,D1X0'Z?^D8/
MJ^8?Y]?4 S(!V#M]'ED&-)=2#AQO33Z>[83>% IM1)$H6.5:[*NU'J-@K=5F
M-Q6[1%)M]EC3VA^C#U79NR:5,P6L9YP]^'WA<6;:$57D7 L$NH\K^I%0.*6V
M8'2:W'_E;R"V#,:;M>_'T/QFU7 ;,6J^KJ9:XVF3EBL#63O]0D_$E/2S)LUC
MH./FY![[3PMFYU_"@9C+$_ 'EZ^7I^$;R_O^OS^GR[^@9R .P=@^;]8_K$?,
M1^D1\Q^?(7Z]ZB?!S9S#5;BL<JM%%F-U:@C=\ZWH\]LVH5C95BU/)5V2M7RS
M3UM8)>/N[6*CH.$GWDV=W!HGA0KMA3D2-SPDD#;?%%WQI+9\G'0VM]NZTOTM
M+ZUIVY8J-IEXK=F?26H]B+2#>@;/8M8:1>+.J!=UXF52J-O1(:!L:D9(%B'S
MP6;CV;&;6\(?7_TC?3W\@[^7T?4'EZ>6<L8QC./A#OW\_G'L(B(>?KY"/;[/
M+R\^WJ.<NW;TQC&,XB4![]^_GY]O$;MZ=O3OV#Z?(/7\+U\\R  'IW_6(C]7
MSB/[/I[CZB.9QC&<1* ^8]_/M_RA /+Z@'M_=Y^7?T#,@ !Z=_F]1$?3[1']
M?T_/F<8QF! !]0_G_5]7I@"@'IW].WF(CY?5W$>WZO7R[^@=LXQC," #ZA_K
M_;CMV^G]HC^\<SC&," #Z_S]GT9CL'?OV#OF<8Q@0 ?7^?L^C./A ![^?T]N
MX]O3MZ=^W]WKV'U !SEC&,=@'U#OF/"'?OY^O?\ &-V[]NWF'?L/U]P\Q\Q\
M\SC&,P( (=A[_J$0']H" _ZP\O3,> OU_3^,;L/GW\P[]A^CS^8 #T  #EC&
M,P(=P[#_ '"(#^T.PA]H8\(!]/T_C&_U_P#N#R#RS.,8P(=P[#\_ZA_4(>8#
M] AYA\V<?"'T=_M$1']HB(A]@?/W'U$<Y8QC&<? 'U]_3OXC=^W;MV[]^_V_
M2/81\P <Y8QC !V#M]'EG'PA]?EZ?A&\NW?Z_K\_I\N_H';EC&, '8.WGY?2
M(B/[1[B/ZQQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8R%'/WBO8.8
M?'M_IVN6#4D0\5N--MCN%WWH6I\C]*[ C*I*C(/M?;,UM8W<),FK=B3,'@M.
MM[G0-FU"891<Y4KA'J-GC*1FOC&,\Z="Z'-^I^O]34,W)2G$AX?6W4ATU?JQ
M$ZKORU$HFINH+4-;1"6N^*43==W7:SZJJ.C+#JR&EZC!7VY;*CY1"UWY!-"O
MDEXM"'^3!=%?DJ1!M?;ARGX^6K>--V9P*V/K91[Q6LSS192\(-&[GX]1M:V/
MK*6WF_LMO;7*G;CD+>I-PNP*I)5W9,6QFZ^C$Q[*+81WI"QC&>4NM=&'9VO.
M0?2LTZU^-W#4W'JE[*E.:^[:]4J-0-);AIE(Y52_,CBOI"-UZ^O5BNT7+4SD
MJ:/GQK#&)=5&-U_(2)$;:Z 75>-:_P L>&O+.^\I8+E!Q+Y":2TO:S<4K[Q3
MLGWX]&7/<AX^$O.S*_L@+]1F]5W!JM@QN%>D:\T",0M)++77!P,61AW"2O\
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M"&8D2L/*)<<;-T\MXO27(K3VL[+'V"2HFS]+[AO9'] U)MW<5L"TT*_Z$K<
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M>[E#;3KUF=2"IGIS3T7+0NYM@QZT-, \CTDI=NHU10<1<:LV8R28#W !].X
M/;OW_O\ G^W,X .P 'T!VQC&,8QC&:&><I>-$?9UZ4_Y!Z497!K.C5W-6=;1
MI;>Q-[*#\L4-?7AE9DD@E-!)F+'#%J(%>@^,#0407$"9VG86[M-ZD6BF^T]K
MZWUPXG$WBT*A>KM7*FM+(QRC=)^K&I3DBR4?),E7;5-VHV*H1NHY0(J)3*D
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L*IU>/B%'"C-)*'7>JI(/C$/(*-2I-UW2J:10S=.,8QC&,8QC&,8QC&,9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g374807.jpg
<TEXT>
begin 644 g374807.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ _1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?1DE"4D]325-?-$-?0D%2+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( .X!W0,!(@ "$0$#$0'_Q  ?  $  @(# 0$! 0          "0H!" ,&
M!P4$ @O_Q !J$   !00  @,(" P/"P@+   #! 4&!P ! @@)$1,A,1(4%18X
M05%W%S=Q=K&UMM(S-#9A=(&'D9.8LK,*&!DB)#)35E=XM[C4U]@C)4156)25
MH=/6\"<H0E27F;3!)C5'2$EB9W)SX?'_Q  > 0$  P " P$!
M!P@)!08! @H$ __$ %T1   % @($! X,!PL-       ! @,$!08'$0@2$[44
M-V%U%2$Q-38X07%S=':QL[8)%Q@B5E=EA9&6M/ 9,E5RE-35%B,T0T5&461F
ME=8D)T135&*2DZ&ET>3Q_]H # ,!  (1 Q$ /P"_Q2HPMF^(P[XEE-6@W771
M3<'=*2VMDDXOM1B5DHK"A-B&UA'2W$2;ZS/LR*[-CY<=P[>6DM7S;[!'>-D<
M$V&3=:BVU3,,@)WO4;?,79!U*L4R?JQM-I_.*(VSKM%CW8:-<BK;=+;2E%'2
M%A=C*:V0<=$/O\HD*:^C$U%')NI->I3$\$HC-+%&O=3L 2!4I2@",'?_ &=V
M-@-Z1&FQ$T7,'%9^.YRD6<I>1]57[L\1CLK'1N+"K23C*2T9<AXLC^%DUUO]
MV* &"HZG>L(K -EF@S5(? \8+],9NZ\[.2:6@XP\H86=6WMN$OZ7(:8@HZL)
M*1@XCPHM/M&V"+O["2CK24&T\) ;*BA%8J*1_942XY6D!]X/I4-@**5GN1L)
MJ+'NQJP@+KF=TP,M226PZ8_61(HE%QQ\7?,9O@RD&W?'CV(I>8Q%70EH=#3\
MPU8H72WNWK=_AM%WMX-96<#_ %IM:'0$T9S*3F@$G>GF4EP"/QNQ: \E4*$&
MO*H\8DX6,RTW8P"Z-'3'\8B<GXCW/8C"(A8D=6%HB@%':N*[B. &VR\X4)JH
M"RZG.L)C>;3<1U%P.!>6SQ9,1T-#2"0RDK*ZLI'! BB>FIB>6,'3YTT*$6*%
M0!C XF 0>>5N@0W.\*;$-$1_P)+<;30Q@E<ZWQ'A%CV;C];(:ZG E#*@C"K;
M845-/"521<^1'-)X@^)L  X4&$"Q",@YY^J"88"!B!YX8YAYX989X98VRPRP
MRQOCEAECE:^.6.6-[VOC>U[7M>]KVO:H]=+002^PG%'! "" !PW@9-\ @0\
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M_!4>^F?E$\4G^.^QOY@6E-;W.)4/(S<7%I.0%5U**4B*:H1:Z$*D%UMQG2)
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M*^2L?[N:XAFCQ[!6#.JADX&OERA1<P-1,X3.*R5(89!D2RMB,@"64BY,/++
MJ >L8"+8WOB!@':][5]DKQ+=/"18N2)NU?*E"H(18J5+1P[@"Y<N!AB$
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MS\HGBD_QWV-_,"TIH D)I2E "E*4 *4I0 I2E "E*4 *4I0 I2E "E<60P6
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MA$>WK)GJEM\LT"K"5:8Z,O%)2.<Z[O-\8BZ;O;"7)S+:FX(04I2I_%20I2E
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M+I[27ILYY+$9I;K+"5NJ(S))O/K;9;(\C]\XXE)=TQQU6JL*B4V95JDZIF#
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M]CF8UC-IZ\LG<]>WD2)&17.AW5B1)?@U;921KXB1RF-LL:3G&T)">*JE"/G
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MT;KQ2N<H/VIH4PROTJ5^QB_YG"N>N K]*E?L8O\ F<*YZQ<3U"[Q>8?3 O\
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MC8\X9RBS<Z$51Y'>(Z[DQ@ZJ83,KK*7NPI2NR"D#*II3A>P9ET1VO)B:]W%
M"[)A?+7MRI2L.?F2X&8B&#>SORMZ.SL^M6+XXW[;6\_F\U^VWN7\]NR_GKD&
M&M@RRSM''=BTVUM7E:[SFS02-HZO(M=Q>6LM61:RC,\BS'$2'N$2'Y&R98V[
MSKVQCHV4=G:K4O9,-YJV;+>MJ-(S/4024YGEF(8XZCK<<O)+8EAT."9A)14=
MK5YCN1%674^3NOZ/"9S1@Z9,XA1BG*99F9Q?CM@B)BXF/LJGY/,JOGC+>;#V
M3VVJXM_+UU'?$B0WMFJN>?6._',K2%JOKRR1GKKKKS/LD13D]&G.NS)]P)??
M;9;LA*+1P2&\_P!F*AT-Y*P(F150,J1840D -B7E Y6]'U_M^FL<K7[;6O\
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M( N &&""'@'ACC;<EF/!O2 U6^]6FH>%6TZ$DFMH:CWL;)]^IB@%88H9[U/
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M7F7U%A_RA-NK5E48QVXQJEXA1]W,"_& /%K3.<*QO!X*4I4/": I2E "E*4
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MME*UKTY\EF ?56T/BL*ME*V.M#L2M?R=HF[(H^;[$'L]O;RMN/?$P5F>/O\
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M2YWO?S6M7>ZZ#*J@=28QD5433(A-036(\#Y$V%;"XI4X3;BF9*F ["X"!WS
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MM3/$$_D%T5E$T$&4N9S"+6$Z84/"]6'N,/W,/\'A\VIQ> S;&VRTR\L<<?\
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M_%CWZ_L>5=0Z/'TY_A!/G5\%TN1N,ALN)YNY:(MQJ-)"5W.YG KGN\DE";Z
MGF59:650X-G8(HG)::4-'CIH6]@RY8 47.]L<+WJ%KMP$L&]+@GW+6T5HZG4
MN"\).)4DQX_^20X\%G9LG%<-'[Q&:UO?GK+UE=+/(K+8?Z6&+>&=I4JRK8>M
MQ%#HW#N!)GT3A<HNB%2EU21M9'"VMIG*FOZGO$ZC9H1TS3K'3-[T:'[_ !1_
M%CWZ_L>4[T:'[_%'\6/?K^QY5IYM[SZ@.IJ/5]I>PL:@LF.2#?4WR\%QQY-9
MKM<B[%+)';)A77G4$B)9?%>5K8IB3A8UF*?4!2Y,L&(8-%@Q=D&B[&D_VP@O
M5BN9#>3.=*437&RZFLN$W W'"BJ(.)A/5T1;239M-5$T\7SP&*'B)D<L.%E;
M,,3*U^==<]RWA9_J[B_OE/ZD.Y^[KQY_VBT/JW_[_P!\SY,JTFBL]0GK9+:^
M^9#>CX-(JI'RHURP;4U-WO6%&RD<7F\J YBECFJ20'@3L72C.(@]C.>> N0.
M%@<["7RPEF_56]+OWR3Q^)3N[_9TJ1?H\?3G^$$^=3H\?3G^$$^=4P679E%L
M*AMV_0"EE3FY,B4DIL@I+^UE*)3N;I-M$:<TEJIU"R+NF*Z8E8DW-BO=#UWW
M:N"NL/PX<%Q5.B<"C;""V;3!$QM7LEZIGKJU_?'W"Z@C">G%'TP6V@Z4?!Q[
M WS56VO)N%B6D.[!HY?(\DG"F-BA4?7XD"9-7N-:Q<N*<*ACC=P#F8 QSN+A
M7I!?>JX8((??_$/MT8(6%^ZX5NR=LN> >.-^ZM8?*ULN=OUUK996M?G:V67+
MG>ZGT>/IS_""?.IT>/IS_""?.K^=T8=V)?#D-Z\;;;KSM.0^W 6Y5:W3N#(D
MFTJ0DDTFHP4N[53#)F;Y.&C9Y-F@E+UOUV%C%BEA8S4X^'5XOVLQ6G8CU5;9
MHELU<IKL%+Z(:U*N"BU9;!L(E2$D453"7-J9O)<-#9HI8>/VJ_\ C#B'?]U;
MLI_MJ>/VJ_\ C#B'?]U;LI_MJM>3#MYK1 3H),J7IB:3&=J@W0G:5;BL=4A5
MC-LF%)01RR[F0321\<!+-*B2J)Y0X8Q!"-&TX\ 7R$S*#VP]O)NUI*"WBV2;
MD1S#DS;A!WV;H:N7NO6:JJ;,)Z:X\T:YBRD&B'E H;(%%,0K@3'.E#10,;(P
M6'"#ZK[0."'Q=Q_K/>7^(!W_ -USI-?&W,^IF'')_8_D\W]'3IJV?VJ_.W]\
M.(=VV_\ A7;*?[6IV( XE6FD?0G%K),N'9 ,PUV0@(HP;AT4W11%S 0@2P!R
MP5D=/@QPD4T_C?&]C),JMJH  EKX!'C.%K"7EVZ/'TY_A!/G4Z/'TY_A!/G5
MV:V,-L/[)DR9MGVPU09<Q@HLM]%6KM1-^,EQ+J6C;JU2G--D3J4KUVD(</+5
M-1I,R'1;[QJQ8Q0A0:;B%>K]SP*;*7-@1G:%:U)3&EK9-A;Y.T"ATI]TU,J4
MWLWW76B(\R;)9$H1T?JK>EW[Y)X_$IW=_LZ5"3QA]KXKV9SU\R@]O[%/WQ,]
MD^[F\'Z;[ADKI?A_%D62.E\+0,G])WYX)4.XZ#I;X][9]);#GA?.V;T>/IS_
M  @GSJ='CZ<_P@GSJE2U[BF6G78-?@,QI$N <@VFIB75QU\)B/PU[1++K#AZ
MK<A:D:KJ<EDDSUDD:3@^Z[:A7?0)]NU%Z4Q#J'!=L["6TB2G@LR/-;V:WV9#
M1:SL9"5ZS2\T&HBR49*+_.!Z=S_P-;._BB;5_P!3%.G<_P# UL[^*)M7_4Q7
M^C Z7(W&0V7$\W<M$6XU&DA*[G<S@5SW>22A-] 3S*LM+*H<&SL$43DM-*&C
MQTT+>P9<L *+G>V.%[UK:V-X]1'>V'D]D;8&.;,Z/23>4'JZU=P"-IN-LF[%
M'-(;(RFMN<%&30?#ZKAX-2 \#(@Q\^( 4+!B&#)<,67_ '15X?DBV_T>I\GR
MKR']/((:]S797Y8NC]*I7)\C\A_3R"ACT[G_ (&MG?Q1-J_ZF*E<X1>QK#UN
MG.3G=-32V-8K?7HFP;J0HJ&G6WQP,XLV>:&IW(X!I4%'Q\,[$2A@QW8@6(7<
MAWQ[ONKVQJWNQWNR)-:2"_8Y=[<?C'=2<$K-IX,YPD'*V' ECWSQ!4$9=1CA
MQ,4R0F08F&)DF9&"Z0,0.^5A \\<>U]'CZ<_P@GSJX6XL;KFN6B5"A3:;0F8
MM290R^[%8GI?0E#S+Y&TIVH.MDHULD1ZS:BU5&66>1ESEM8$VK:]<IU?@U.X
M'Y=,>4^PU+D4Y<=:ULN,&3J6:8PZ:22ZI1$AU!ZV69F1&1QT?JK>EW[Y)X_$
MIW=_LZ5T>3N*)IZO1P_T-)7)Z-JBRR7:E)I3#2O=K#,TH*+>4B9(MCF+KN&'
MCD.9&""QRSSQQM?.U\KVM4I_1X^G/\()\ZG1X^G/\()\ZH>:<4RZVZDB-33B
M'$D>>1J0HE$1Y&1Y9ET\C(\NZ)G>:2\TZRHS)+K:VU&G+6(EI-)F69&69$?2
MS(RS[@_S>BPCI#*E0\X:V=MF&5+!YV_2B;5]6>  >.6/5#%[<[96O:_*][<[
M=5[VZZY^G<_\#6SOXHFU?]3%?Z/W1X^G/\()\ZM;)AV\UG@)T$F5+\QM)BNT
M^W0G<5;JN=4A%C)L#J2@D%UX0BFDCXY=+-*B2J)Y4X9Q!"-&TT\ 7R$S*#VP
MGP](N\#//H1;?3//^#U/D^5>_P#3R"OA:-=E$1%T8NCI9?Z52NYE\C\A_3R"
M@IT[G_@:V=_%$VK_ *F*S8=S\[?\C>SO;;_W1-J_ZF*_T&&GL+ ;\D9RP^RY
MGC)TRPS"-U)W1F@/YO*K^:Y#&R7<4TX&@35!7 CA%O#B+B<N?3P,B.:PE!G<
M2XBB3Q&]EZ/'TY_A!/G5X]T5>!?R1;>9?U>I\GRKR']/('N:[*_+%T?I5*Y/
MD?D/Z>00L:?<2'5>,]6X!C][GI^0G>SXH9K><B*8TMW4&'2UE,202Q\B**4U
MZ,%A!"XV.0>68 PH65[7OAGECRROLA^JMZ7?ODGC\2G=W^SI4B_1X^G/\()\
MZG1X^G/\()\ZH)FRG)TR7-=2A+LR2_*<2V2B;2Y(=6\M*"4I2B02EF224I2B
M219J,^F<^P8C=/A0X#*EJ:A18\1I3AI-Q3<9E#*%.&E*4FLTH(U&E*4FHS,D
MD72*HEQ@MHHTV6=<$*4(-K8M^DVBW9#).(9/TXW!)V3#2TK-(PF!"XJT$)^8
MES0*:=SPN!B);'H,K"7POEAW<-W3N?\ @:V=_%$VK_J8K_1^Z/'TY_A!/G5\
M%TN1N,ALN)YNY:(MQJ-)"5W.YG KGN\DE";Z GF59:650X-G8(HG)::4-'CI
MH6]@RY8 47.]L<+WJ6+8QIN6U:' H$"G4-^)3TOI9=ELSU2%E(EORU[53-09
M;,R6^M*=1I&2"3GFHC4<173@=:UVUZH7#4*E7V)E15'4\U#D4]$9!QXL>(C9
M)?IK[I$;<=)JUG5YK4HRR+))?YS_ $[G_@:V=_%$VK_J8IT[G_@:V=_%$VK_
M *F*OZQ/M=KG.)=U'(LEMKN\DR$<HX'8>(FU(H10$,\&>%+*RD=5R::4 3Q
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EE*4 *4I0 I2E "E*4 *4I0 I2E "E*4 *4I0 I2E "E*4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g387862.jpg
<TEXT>
begin 644 g387862.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@ ^1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?5$%"3$5?-%\T0U]40DPN15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M]3;UR/U)05)!HR=*R;G'=+,LE;H8<FG$RTO-J$HU,<)V:"9::EWE+ET.("'
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M:Y\(O'#7;I*DP6[D+!1+I7FL@]!@I%0:"#4V$V@EKB 8:8B_5Y-@&"L_ZD$
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M$T(:F#B'PPNM&M5TSF&(4T,HJM5C9<I@"@<3 C83;'WI6;F*G3.4],ISE/\
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M;#PPH#RH$%WU8+MAQ-\17?#TXZU"W=94VR)<PM,YFI0HE&L4$I+,K%NFE,.
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M@3!W/;U -^NEV0B:PI6<!0=V0XW11@E#\#=&#;R-4X0[M!JJQ@"U._X^>D:
MD0B6DJ5>:I*A9=-(2QF02T6/IV7^GZ/G%!Q%&S#3SK#% ,(<;;8F5IFC/J1+
M'@V97U\C/?4$^53$[13+M&4U,JHZ9$J0ET3'U%,4_2$DDMN4E+N-,O3%/O+;
M<=>EVURHD4KFAQK4UU#.4\O)S,0U."8V%G1NA2'&ZNV:*$$(!FHA3H1FFMO5
MU*<J%5W1A>;\L%=$U 4#:[@\O%UBR\;54-LW]'8C=(8CO6\RQ=M79'@FL:]T
M!JF79\BKZ;6IH\K=+I5F-!V;I.PGP:+.4TXJ4M'@X[#%JG(E:5B+I ,+S$6'
M!F12/*1U QAF9GHL0=&XX>:FQQ?N&9D9&8P49&1@/'U><BQH\P&W;XP<,$W[
ME=T2+%7KH@1=JJNW;E5=4YQ8Y.L"F!211INNWO2;8*IT$R=K!MDPI$T?BD^+
M3I69'Q&4&3AN&%$V"9M+*]/4P>E*$F*+%#28705@:<U$9>8@Q%=[,45+T11-
M"2[],4C1\W(44U0*9ZBY5#\Q,H1*,+?6)3^7TBE :_EYG$/B7")1"70\M3#C
MB'**7I69I>E:;F&:&HV?E)^E7*?7(TK-KEY>66N;>0RV9S^84:I?%_F(DW&#
M,<2<4IHM)2^TTXW<8_<MG!:^=]\4XZN/"1R.5S]+B^1*)?$;G.>G&J;!+V20
MH;$_9^I/-@JD2I%NHPP*LRN.$J2\2.2@< $H3I"4G0X8/"1QC/D(A6?#Y)A'
M$6\ELH2XUL/@Q2N !U28@EQD6FB%Q405'5(H\(PQX#H.P3FW%9=-E4!(150I
M+6:QMVR.JL!;],%H@*DPEFM6Q<8"#5,NBE!QJ"%" =($24JQ+'%Y-N C1UJV
M($6KHI.&] $8#'6Z[<C1/* B'UA@PBZ*L6XWC5+?1]$3E%S$F9Z?G)293+22
MU.?&0_+M4+.-MHH]A\R:9MF5E5R;DBJ4<=<0EM<T37-/.S*]LQ]8TQ)4K+3H
MD:/E)R55,SJ0V)E;$R[3<FIQRD7V/EJE'IJ;;FVI],XAE"U.)E;-F599ED7V
M,L@4%=P2*6QL&0R\_0L<G634EJX$,.+NXZ-VOE4]J2'5FE021?>$BEPJK";N
M@9&5X;27D(:JX7APMJ@1?H3"$>FHNB)2B!/IE"Z12-)S=+3'%4E54S.<,+0U
M90BPPTAIMIAK_2X;: FT?Q,>9I6F)NF#1YFPT/Y;1<I1,OPDJ37+2?$*%NVE
MK*YAU;KCK[E8XCBRJRG^D(0A%I%5"$(0A"$(0A"+ -$MTNEVLRK3AX8R!'3D
MM,A$RC GF8L1,Y.B5\V[61B!F(#![P<#(.G2$T,./,KP4-=\V\ULW;@N]8L7
M*_PCEG)1N>8##JEI0F9D)H%LI"N)1\_+4@RFM25"PIZ5;2Z*K1:*TI4A12M/
M7)3CL@^J892A2U2T]*D.!13PZ0D9F0>54E2#;2S,N*;-=D.!!4E:04*R*LKE
M4SI8F+R2<9G@8,*C\4'G:),C2MSG#+0*R/%P&M&!L7B4T2D@L GU.[9]75<4
M:\D(OBBNH 5T6Q=@N+"P($Y5!NJS4UMC!DJ=N00IPXQN:],IA2,S?+5>+7ZN
M5[+TJD(UMI!W@Q"*2IFFEF!-4E0H#\[4Y)>2]90J;AD7"+EPLD,QJQ^:ZZ;=
M%==<YRHMT57*YRE.J<J**9U53E3+UU3E3*<Y4RE.<YRT2E.>B/-/_15%.KFW
M&'Z2E%3Z7VID-SKDPA;$XW.-SS#;<^)M+*9PSKKSJV0AQ,PAEUM: E2'/2,?
M6U*M(DT/L4;-ID%,.RI<DFY9:'Y-V3=D7W7*/,FI]4G\%IEI#Q6VJ76\TZA9
M6E;>0QNGU;0C<K"%2G"GI"@V=QH<5"KX?:*CROT87"COY'W@9:#HL *Q8KSV
MZO$E7Y^2T"@E'*-J8L714 &3"]BQ]722/L<25B AT.)E+7CUE\F5DHP:94YL
M2M* 63I,8NR52+:M.%!B9VF_4Q<B#1+JXZ2X(]NIP*?61AZ5W"VL73/H+882
MC')6CIM=2O@B><ILF91:SK*#<*"L$AJ\*[.$R6D;)S-ZQLI@1MT2L4\E>7+M
M$]*_$B2F82V LT"+D*IA*K!NVK%9#)=:K!OU\C7Z!,S8 $=T<F3\G$#VY/5<
M9F5P[ C0AL7F(0047DX8D-5B8>];N":1MRJ=NH-70OR/TW28>9H^E'OGR\S1
M#TN'$D-)FIY5/S]"ND&15;EI@_5$VXAT)>9"6I3CH6E$PU-^AEY[ZEHTLO4A
M1C'\OF9:EF9E3:@7E2LBGZ>H^F601.H+<U+I^F)1M314P\2[-EAQM:Y9Z5EO
M*LF )9E,(4>&5@-95D[4/*,Y4+0AZ *;A4?/H>WBST:LJ4J)#D0C::P9F"2Q
MT(*"X*>A0 LS*0=HKNA)U;XRXR&1%QD56M7C3K1*!&H=MFC>I-JX*JB^\>)A
ML EI+DKA-.HR)&K@C,#4T0(8K!FJ,4 (K&@%045B@M9D5'''A:LC31RGM7Y3
M0>GZH<9Q%L=)]*%@]4'IB>G9L:&Q@%)" KF9FX@3>M!9#!M@,&LRN4 @%JY7
M5:M6K4JY1*JP9MIT?>M2M9&IQ54IUQBYOW1 $Z+/2(X)@E\6. G*_:ZRHC&5
MEWT"G!A2< S0Y#R2@R@2'*ZYE%!>H  ZBV^ S1\K1TA-TI.L4REVF)U$Y1<F
MN9<'\ZGIF:FVG0BC7Y5MAU^:;;EG9B7DC,3<JPN52VM"Y<4YI!Z?FJ0GI6BY
M)ZA5,T+(KDZ4G$RS9-"R,I*2CS5JD69IQ]#$JX[,-,3$Z)>4FGT3*G$*1,&W
MIX:8F7%"6!;;HM&M25B\>6G;K&P<[:>=(6B5N>&RK6BK=!=N^B40D#<\+3E+
M'!V;\DLV?2L$8RHQ38L],3PDMW@@J.VO=M& LISL=D8]Q"ZC5O4UJC:UWG 0
MR<5P4B*4F=$MB:=(RA)F*"2@\M!HHX1Z1"E1*G$900$Q=6%H)K=5 <5.S2-Q
M$,?-BO%@W:EIM4'R*41FG#*L+756#%7"^_.D.8@+E4I572TW UA#<LNU2\JZ
M7#PMRJ4JJIRET[3/VZ9Z?QTQ,K](R#\B_52])3K-)489=F<4J04\RS-MLO?-
MHZ83(A<J_,324TNX62F7>I)8F%2Y;;EV&$U]84BS/,$T11LB_1E)B8>E$)GT
MLOO2CCK(D:2EU3ZD3;$O**50[:7@9AFC4?&3,<5R9??R@(+,E(B"C,-8KH8*
M .6?J]S':QH V@YC?M!%J]B)53&JLHD*"@Q <L"IULSA,FX+SX05!*KR1"VK
M-^^)M6 %W%Y113;HHMT2T46Z*+=$OPHMTRHHE_E3*4?J$7E$T!1]"NSSLBEQ
M GOAI4TI84U+LR,JF68EI5(2DML!7'FE)45J5-S<T[: <"$T5+_4%(TVU(M3
MZFE_ $X4NH04NS#T_-*F7YB:65J#CY2&)1"DA"4RDG*M626RM:$(1=120CTI
M< !_R9RF_P"E#4_^ J^/-;'I2X #_DSE-_TH:G_P%7Q\H_C;_NVI[_BT1_WF
M0CZ]_ G_ 'G4!_P:9_[+/Q@UR[_YU>2/_7<X_P#YD&17>+ 9># =.5F25-0P
M'352][CTU4U"@]-5-4E(,TTU4SN2G35+V3E.4IRGZIRBNWGH+^>!?W8;[L?0
MZ!2HT%0E22?_ $BC.1_),>1G'S6GB/YY37XC_:])\Q^=?CZ81\WGH+^>!?W8
M;[L//07\\"_NPWW8MK*L*LCOF,XJJQ>,Q'TPCYO/07\\"_NPWW8>>@OYX%_=
MAONPLJPJR.^8SA6+QF(^F$?-YZ"_G@7]V&^[#ST%_/ O[L-]V%E6%61WS&<*
MQ>,Q'TPCYO/07\\"_NPWW8>>@OYX%_=AONPLJPJR.^8SA6+QF(^F$?-YZ"_G
M@7]V&^[#ST%_/ O[L-]V%E6%61WS&<*Q>,Q'TPCYO/07\\"_NPWW8>>@OYX%
M_=AONPLJPJR.^8SA6+QF(^F$?-YZ"_G@7]V&^[#ST%_/ O[L-]V%E6%61WS&
M<*Q>,Q'TPCYO/07\\"_NPWW8>>@OYX%_=AONPLJPJR.^8SA6+QF(^F$?-YZ"
M_G@7]V&^[#ST%_/ O[L-]V%E6%61WS&<*Q>,Q'TPCYO/07\\"_NPWW8>>@OY
MX%_=AONPLJPJR.^8SA6+QF(^F$?-YZ"_G@7]V&^[#ST%_/ O[L-]V%E6%61W
MS&<*Q>,Q%J9#;!MAL5EP#R:!+=97#CM6V;<JYW+A4Z+3D16C3D7*6BF08(9-
MJJR$/=KE7.@2/H#TW**A5-N[?)N,KF-$9JNC<<U769L,+RA&Y),TZ-H :BK*
M$7Y!>MSK'6@4@<S>VC7@25B\CU8 H+97;9T%2"ANAJ+I9?O2P[@E,*+09R7%
MZ@\R+U&""EQ^"#&=JT$.@ (S"'(((9AY7>*%V09N !&825VF=08:%M7[%5NN
M5?E<9YZ"TZ?/@6F?KG/SP/IT_CIXV/'TA]&2E*MS[$X[,I;F12J)5R64$/RJ
M:8=HR<F'DN+:75,-3LDX&?\ W,+DGU2LPR\VXM!]C1WUG-T2Y1[TFS++7+&B
M5S3<TE3DO-&AVJ1DY=A3;;K?_EG9*=:XW_MF$3LNF<EGF7DMK%Y&T>=ADTC$
M\3JHBD,/B^0R1H)GB+C.X_'U73D>,M5^F2[6A4JE%I!WP]/'G@ )?M^3R?13
M,$&L7*IZ:;( OOI+&T*"?I!M,WK,*9?%S[MBIPEPG.78;HU=D_<8%8!HDF3I
M\4.N3J)"*@Y0 !LN5:2I%J:Z-NAPX4 :6E%3BA\]!?SP+^[#?=C60X'*4Y2'
M@Y2G[92&!]$_Z_ZV$[]$T=.AZVY,A;\VY-DK9D7T(<=E9^378:=DR@E+-)S"
MF5N<1;3Z9=Y));4ES&1^M:2D5,EMN7*695N4LH=G6%+::FJ/G$!;K,XEP!3]
M&2Z7D-EM#S"YAE0'$2INWIP:$P'$95!P9?64EKIY@U*1MB(3?I$"B1(M@VRF
M+C^Y37Y=SC* ];G(I("A=J=-(H:3"+<[PF02=-FI4?2-4HDR"$X P/\ ST"G
M@(@M(08DRLW I.7C#,8<BP9=8G=XL+8%FY@.,A--NF50@:+O7[M5==4O)XWS
MT%_/ O[L-]V+^CJ/7(HF@I2G%S4],32B+9 2JPQ+)K7_ *16F38EDO*)(7,!
MUP?@L10TE2"9Y<K92&VY61EY5"?] $J3;?F55( 2$*G'YDL( '#ERRU_5%<?
M3"/F\]!?SP+^[#?=AYZ"_G@7]V&^[%C95A5D=\QG%=6+QF(^F$?-YZ"_G@7]
MV&^[#ST%_/ O[L-]V%E6%61WS&<*Q>,Q'TPCYO/07\\"_NPWW8>>@OYX%_=A
MONPLJPJR.^8SA6+QF(^F$?-YZ"_G@7]V&^[#ST%_/ O[L-]V%E6%61WS&<*Q
M>,Q'TQK3/15*<_X3E/Z3CY?/07\\"_NPWW8>>@OYX%_=AONPLJPJR.^8SA6+
MQF(R9)1PDBEW@PE=M1FX4@;\+B08((48W+(R^!)E6A$.^35J,HN6P=@5=\\&
MK0W)3*];LAY^3Z9 !HB5%@34*JX%NG];0\Q(=E*N<;72E_4NP):PC:&%X,*&
M\Z36#',;I;$J1-A=-%^U;4;."DD>@D^+'UV XY#* (2^<5<@!Z98_KBG%728
M(G;BAG<(0!H/.P)-6:6JRX$<&H0  ,S,(%JO3H#C#$$5%@8?=M>1YW:+P4K\
MJZ@UJJGC//07K_X<"]?M_P"&!_7_ %_UL>./T9*OAM4R[,AZ7F*/<EG9=24*
M;8HJEJ3I&4945LJ*_DL4HN3I$.<1#X0A]D,S"&WD^R3]9S;!<3+,RRF)B6GV
MYIF92I:77Z5HFBJ.FW4AMU ;^-,46W.T:IL-K8*UL/<>66XRN]#@O.P*B02P
M3Z?(J0Y^=)DT*BD3/#C%Y'2L&0P).P'O35R67 Y3IZ5%RJ=4SHC "C<)+_6A
M@]R[/R96 </(8B7!>X:V4KUHD[9E<8V@TH28PV19A4M"5]+;=)E*%1F+1-Q.
M4%I.<H]RR04XXE[J5%<OFZ6#A"H,8"9F=M.!\2_GH+^>!?W8;[L*AH*JBJW4
M.!5452G351,8'G3535*<JI3IG=T3E.4YRG*<M$Y3G*?M@KZ(HU1EB')NU+N.
MJ0XMN3<<2F85)+>X"OB)^,^52$L69Q@(FI<<0,NHXE8AOZWI)L3 +4J4S"&$
MK0ER<0VI<LB=;9XZ/EJ^3+V9^9#TD\52LP2T7FE!NI5JLBA= 5&8FHD5HFI$
M1C66B%).<I2OA).8Y3A.HDB453ZZ[5TM0ZJ3PVD/75_P>R=VK=%JQ_ITSJ]'
MU'*G%*(U'GI^H9G)T:7Y"3$U,C.R*'#K]-FT'INB;]R[Y5RJ@/8L![<O51:L
M6;-BU31:M6Z*>,\]!?SP+^[#?=CT5&2+DC)-2ZS;=+DS,OJ0E0;,S/33T[-<
M($ AD3$RX&4D5I:L)/XB/.TG/(GYUR80DH:#<M+,)64EP2TC*L2,KQ2DE)>,
MO+M%Y220ITK()!KCZ81\WGH+^>!?W8;[L//07\\"_NPWW8[[*L*LCOF,XX*Q
M>,Q'TPCYO/07\\"_NPWW8>>@OYX%_=AONPLJPJR.^8SA6+QF(^F$?-YZ"_G@
M7]V&^[#ST%_/ O[L-]V%E6%61WS&<*Q>,Q'TPCYO/07\\"_NPWW8>>@OYX%_
M=AONPLJPJR.^8SA6+QF(^F$?-YZ"_G@7]V&^[#ST%_/ O[L-]V%E6%61WS&<
M*Q>,Q%^$>JR( A^#[6@\=9*DPSF1JY(W$%SH$7+)*-N/ VKPVS\PMAK=ZY.9
MB@!%ZJQ*R'NB10='#K5BD16"XFU+C(9+-%6<O.1.XH9@0J.OY;+#&)>^:F R
MW.3XIER4LH6C'RMV+HL,EU\*59 X"5JNAK=HA5Q6;ROR#4*(33&+ZPIA08H,
M2 .H)V2,V'%9F9D]LTM4EH\R)*#"T3F H)QO%7!I7:-C2R"%:*;UBR8C;--<
M[0BY15QGGH+^>!?W@?[L>.FOHN4GV9UF;=FD_(>GEL/2RDMORZ)^D9VDGBA2
MVEV7%JI2>H]T5N-OT<Z6UI"GW0/92GUI.4>])/RC,LKX[,@B88FDJ<8F%T?1
MTA1C"5I0\BTTE-%2%(-&IMQBD6DNH40RVHWM23V8_E2#39(;)^5Q0%R0*RHQ
MO3PVQ:/_ "C@,2VP@FY-7G*Z#*8XTC::JO2,S!63T7_^9"0M ^JJS$Z->_Y)
M=2^- Y0/<ATVS+3-%?;7(;'4WO&/I2[7HX+6UJ0(*BZ4X. .I:<1-'J9*$@=
M#SH/;;,S"F0JN:<J+*S$?B>\]!?SP+^[#?=C60\'+U2'@Y2]NB0P/+U_C_[6
M$W]$4=-H=2IR:"GGW'E+4U)N%LO2TW*N< +E*FG0W.K<EYBI3\N^VPXVNR'&
MW8DOK:DI-QI:6I90:8:9#8<G&TN!B:DYMOCE$W:=:4Y)-MS$O6EB8EW7VW$6
ME-N-6H78NR5XCXX),;3H.CQT,@G8+;%R[*\(+D(9V6Z;8K\JY5IN3#GRK0"M
M%6+DIVZ!DR6Z,G;NSN47HJ_'TF:E$'-8&X;G\C*LK*"Q/EM0PRLWN3R(EL3#
M%)0#E5=\D.7%UBJNV$"VI4V[4KEVO1.Y=NUU\;YZ"_G@7]V&^['H:-D5R,NX
MTHVUO3M(3JRE*K(5/STQ.<--8!(92^EFV0DNE'%4E*G"D>=I*>1/3#;J04(9
MD:.DD!13;4FCY"6DN(JS^ +RF%/6 5!H+#25*2@*/TPCYO/07\\"_NPWW8>>
M@OYX%_=AONQ865859'?,9QP5B\9B/IA'S>>@OYX%_=AONP\]!?SP+^[#?=A9
M5A5D=\QG"L7C,1],(^;ST%_/ O[L-]V'GH+^>!?W8;[L+*L*LCOF,X5B\9B/
MIA'S>>@OYX%_=AONP\]!?SP+^[#?=A95A5D=\QG"L7C,1],(^;ST%_/ O[L-
M]V'GH+^>!?W8;[L+*L*LCOF,X5B\9B/ICZ 8JT &@A]\-2,L%XX$8" =4M-(
MP.!%61=\'5+15II%V;-8><M$Y3E=G*<IRGHGQWGH+^>!?W8;[L//04O8.!?W
M@?[L06RH%)2HA0((%H$@BHU$?B#4?P(_$5@CE$I794% IK20H5U$5@UBL'\"
M*_Z@_@?Z&,D[O+P@3+K<)#<&*CS Q>LL22J9\:&J,+8I2A50^S6/>F!1".#V
M[OFMP$W]=LX CKX@-;L\DSH"W_/+-D//FG$R,9-PV2;U5&@JR$>A49,I-R\C
M$-911.J )N9HQJU&A39VB5+J6X!1)^$="V,(S=0I,\-00.I;>D=P112!'^<1
MC0,5,*.*"NV;*&9E02$X1/$](XSM".3"$OO"KX F!3N79U62T#=&BZ@8254[
M060BY;L4V[/D6Z.-\]!?SP+^\#_=CQC7T3*%F1^0]-?+E%RBUORQ0A+Z9:B:
M-HDRZD+84/B3 HJ1GEL*"E-SC2.&\64V5^S=^MIP.SPEV)7XDXW-(2Q,!QQ3
M*YFEZ0I=,RE:7D'YDN:5GI!M]-E+DD^OB,\906C(E8R28E/JYJE>F4U=N#$$
M\C5K\PL!\6\>6H$#$\CU< .5 "#J]MUB;*B@0)*P]Z@.3V@E)<=7^+"&0D+9
MIHNQ^L@U]94;4N>DE4^*%R-4BU>!+F^.A<@KPXSNM@CK5U6VU#;D!&)=/4-8
M6+$E.D6B@+.E\[E%)R45&5XML<A6C,?CK\]!?SP+^[#?=CD"I1WB,T+3LF/:
M"LX)AX,T*3,$8![(TM,B\1;%@!X*]*Y.=@6#%6K0D->IEY5F_;MW:-%=%,Y;
M4?1DBP_*S<NI\S$FMIUM3R)4J6N7F&IN7;$PW)AZ594^W8FOBA*IJ5>=EWPZ
M@MA&I7UE//2\U*3"&?CS:'6G$LKF;*$S,LN3F'"PY-J9FG0PL+E?E%:)2;:9
MF9?A.!979K,XU!&>2*_# Q%D;<29:W#<')E8N4WK9JJFO:U%-ZL3*5ZFJJ5^
MJ^JDV<6J[]5R]7>K#SN57[OE2KG5Z-BX8!;MRY=NF(6[=NW+EV[=N#K%=R[=
MNUU7+MVY75=G5<NW;E55RY<KG.NY<JJKKG.JJ<Y_GST%_/ O[L-]V/0T9(&C
MJ-H^CTE3J9"1E)(.%!27!*R[; <*:S9MV JR"0FU9!(JCSU)SW\RI*D*14E+
M2I^=FIPMA5H-F9?<>X854FU8MV;1 *JJR 3'TPCYO/07\\"_NPWW8>>@OYX%
M_=AONQW65859'?,9QPUB\9B/IA'S>>@OYX%_=AONP\]!?SP+^[#?=A95A5D=
M\QG"L7C,1],>E+@ /^3.4W_2AJ?_  %7QYI//07\\"_NPWW8]*_^'\O6;J8R
MGG9O6;TJ50U/E3LW;=V5.DA5^CRIVZJO)G/1.<I3T3G+UR]4?)_XW C^&U/5
M@C_6T1_4$?\ \S(1]>_@21_^IU ?B/\ ]FF>?_\ BS\9X1C2M:8BQ(\>VZ!&
MCAM^Z*&#!:-30D4*$WJYUWA D3?*[EZ_?NUSG7<NW:Z[ERJ<ZJZISG.<?-S,
MM%LM;G<9*^$QWTR,B\G+QQL;#0A:5E@,48&)B/$608$  !6+@H8-&"Q%=NP&
M"! UFZ($B+U=%JS8M7+MRJFBB<Y><W_^(%4JC02NRO:;@S\L'8X.!#*H[(#S
M,U/JAJ2PT."1+'M:;4CD-]CB<F]AS%NV189V[M=Q5A1P"R&!A3/ENT1F90:%
M0+\+"=G$@ 34P    'G  !4  +50  %0Z1^^3(R1)49.5))))+#1))())-G\
M22*R>9_^3&?7F9:+9:W.XR5\)AS,M%LM;G<9*^$Q2),<)RQRCRW6&,]^W),I
M-(8/-_G>*R!5ZD)4HVTFI<!65)T!;-+2DI*1R9J+P$PZA,C<_$@@ ,!=KL#;
M0,18KG.\05WVF'*)') "Y[>#%8XB1$K] )<(M4T)42Y0@.V"NBUHCB2R9UF:
MG286T9%UP0HR0*.)K-!@"KN#::1=B=R?G3OYN9_ON]/U=!$? D?R<K_CM=/T
M=!&US,M%LM;G<9*^$PYF6BV6MSN,E?"8Z:UF56,;Y*Y9H!ELB&/=Q<MS<JM.
M C6R=="+Q4HB[0+F7UVU:0)8^-35/U4#Z:@-?*@4-*@;*82N=(C1:G\S<Y;X
MKO X2G:1I\DV%<UTT3YUZ9-LWSOM\LEXE/,;U(8;Z1)).J$Q/B>0(352&&3'
M +-(01538$SM7:J:)OG3OYN9_ON]/U=!#X$C^3E?\=KI^CH([WS,M%LM;G<9
M*^$PYF6BV6MSN,E?"8Z(A\M\5W-=%2L>W&2;"+YYT9,=)7M(BW@;U4.6EIEE
MSB3*E0H8C4(Y3%%1=>_U)A2.++-0&[.5L7*Q7_HQQ11F?B6I5$Z"+1^2#++U
M>LJ2J%0.LW#<N.EG%<Q"%B5#WA"@N*!MT.9J!<AA1;(/<#W2VVG[QE6/G:++
M(.X8B+ 6Z^=._FYG^^[T_5T$/@2/Y.5_QVNGZ.@B4.9EHMEK<[C)7PF',RT6
MRUN=QDKX3$"8:YVXZ9XI!;K/'=1J,[+FX6EA K,"K$*K&_/"11CDBFUX6AQ!
M,KBPM&7+!DDE:0G 818INTVZ1M8$;2#- 8T"'N+#YT[^;F?[[O3]700^!(_D
MY7_':Z?HZ"(UYF6BV6MSN,E?"8<S+1;+6YW&2OA,25"'SIW\W,_WW>GZN@A\
M"1_)RO\ CM=/T=!$:\S+1;+6YW&2OA,.9EHMEK<[C)7PF)*A#YT[^;F?[[O3
M]700^!(_DY7_ !VNGZ.@B->9EHMEK<[C)7PF',RT6RUN=QDKX3$E0A\Z=_-S
M/]]WI^KH(? D?R<K_CM=/T=!$:\S+1;+6YW&2OA,.9EHMEK<[C)7PF)*A#YT
M[^;F?[[O3]700^!(_DY7_':Z?HZ"(UYF6BV6MSN,E?"8<S+1;+6YW&2OA,25
M"'SIW\W,_P!]WI^KH(? D?R<K_CM=/T=!$:\S+1;+6YW&2OA,.9EHMEK<[C)
M7PF)*A#YT[^;F?[[O3]700^!(_DY7_':Z?HZ"(UYF6BV6MSN,E?"8<S+1;+6
MYW&2OA,25"'SIW\W,_WW>GZN@A\"1_)RO^.UT_1T$1KS,M%LM;G<9*^$PYF6
MBV6MSN,E?"8KGDSERHV/=1EF0;7'9R,D75>I+.ZO"Q+M^JFL1=A-(=EQ+:ER
ML4BD4#LK!&D-BQ>.772!.3@0@X08F P4(G;#<0%O7:+.MJI%4KT(F%*MV\.6
MG5AR5VAI\W*@/DDISI(&%==VFZ3&)^A#E0)$U$AZ:**ZQ9 =&)?7*[33;$UU
MTW)4OG3OYN9_ON]/U=!#X$C^3E?\=KI^CH(X[F9:+9:W.XR5\)AS,M%LM;G<
M9*^$Q)4(?.G?S<S_ 'W>GZN@A\"1_)RO^.UT_1T$1KS,M%LM;G<9*^$PYF6B
MV6MSN,E?"8DJ$/G3OYN9_ON]/U=!#X$C^3E?\=KI^CH(C7F9:+9:W.XR5\)A
MS,M%LM;G<9*^$Q)4(?.G?S<S_?=Z?JZ"'P)'\G*_X[73]'01&O,RT6RUN=QD
MKX3#F9:+9:W.XR5\)B2H0^=._FYG^^[T_5T$/@2/Y.5_QVNGZ.@B->9EHMEK
M<[C)7PF',RT6RUN=QDKX3$E0A\Z=_-S/]]WI^KH(? D?R<K_ ([73]'01&O,
MRT6RUN=QDKX3#F9:+9:W.XR5\)B2H0^=._FYG^^[T_5T$/@2/Y.5_P =KI^C
MH(C7F9:+9:W.XR5\)AS,M%LM;G<9*^$Q)4(?.G?S<S_?=Z?JZ"'P)'\G*_X[
M73]'01&O,RT6RUN=QDKX3#F9:+9:W.XR5\)CZW1=!#LRV;C/ XY\'3C>-.B5
M8XB_45^W>$V$\D400#E.IC80'!V[XN]26DA<*&5!@UFZ+ORHIM![-R[<MT54
MC8#A#@SN.VW+0.5C._>,AT_35J1Z<<S)X[S1F):[J%1]"3&JHOXIJW,<$Q;Q
MR4\0KI)JHU;9P0A(=VDZ:WKX<0*,B-1%92^=._FYG^^[T_5T$/@2/Y.5_P =
MKI^CH(NCS,M%LM;G<9*^$PYF6BV6MSN,E?"8DJ$/G3OYN9_ON]/U=!#X$C^3
ME?\ ':Z?HZ"(UYF6BV6MSN,E?"8<S+1;+6YW&2OA,25"'SIW\W,_WW>GZN@A
M\"1_)RO^.UT_1T$1KS,M%LM;G<9*^$PYF6BV6MSN,E?"8DJ$/G3OYN9_ON]/
MU=!#X$C^3E?\=KI^CH(C7F9:+9:W.XR5\)AS,M%LM;G<9*^$Q)4(?.G?S<S_
M 'W>GZN@A\"1_)RO^.UT_1T$1KS,M%LM;G<9*^$PYF6BV6MSN,E?"8DJ$/G3
MOYN9_ON]/U=!#X$C^3E?\=KI^CH(C7F9:+9:W.XR5\)AS,M%LM;G<9*^$Q)4
M(?.G?S<S_?=Z?JZ"'P)'\G*_X[73]'01&O,RT6RUN=QDKX3#F9:+9:W.XR5\
M)B2H3_II]G_?[?\ +VP^=._FYG^^[T_5T$/@2/Y.5_QVNGZ.@B->9EHMEK<[
MC)7PF',RT6RUN=QDKX3% 3OA!7K0[P,4TKF<'Z^:-$9!O!0TR&.0KS8I+:[*
MV% &RB5#A&*01;Q'*SL-Z@T22#UBMSZ@EKY +:BPM$6JE =DQ4/RD2GIEI]?
MK_&6B?TGZY?TGZY?QE*</G3OYN9_ON]/U=!#X$C^3E?\=KI^CH(C7F9:+9:W
M.XR5\)AS,M%LM;G<9*^$Q)4(?.G?S<S_ 'W>GZN@A\"1_)RO^.UT_1T$1KS,
MM%LM;G<9*^$PYF6BV6MSN,E?"8DJ$/G3OYN9_ON]/U=!#X$C^3E?\=KI^CH(
MC7F9:+9:W.XR5\)AS,M%LM;G<9*^$Q)4(?.G?S<S_?=Z?JZ"'P)'\G*_X[73
M]'01&O,RT6RUN=QDKX3#F9:+9:W.XR5\)B2H0^=._FYG^^[T_5T$/@2/Y.5_
MQVNGZ.@B->9EHMEK<[C)7PF',RT6RUN=QDKX3$E0A\Z=_-S/]]WI^KH(? D?
MR<K_ ([73]'01&O,RT6RUN=QDKX3#F9:+9:W.XR5\)B2H0^=._FYG^^[T_5T
M$/@2/Y.5_P =KI^CH(C7F9:+9:W.XR5\)AS,M%LM;G<9*^$Q)4(?.G?S<S_?
M=Z?JZ"'P)'\G*_X[73]'01&O,RT6RUN=QDKX3#F9:+9:W.XR5\)C;>9Y6SQ\
M;)7/(\:M (5M$&7V356JLSLF D$3%]\P!E=F_=#%0,P,1%5X>8 PE@."!"1-
M\0(M6K5JJJKU19AEE>WN<&-C<91M27J(M;IU)*\2DK*L!62P^$%247RJ0=!H
M-+;5\1474'=Y+7CD" %U6C,&7CP@<V" 32V,!!WSIW\W,_WW>GZN@A\"1_)R
MO^.UT_1T$2OS,M%LM;G<9*^$PYF6BV6MSN,E?"8DJ$/G3OYN9_ON]/U=!#X$
MC^3E?\=KI^CH(C7F9:+9:W.XR5\)AS,M%LM;G<9*^$Q)4(?.G?S<S_?=Z?JZ
M"'P)'\G*_P".UT_1T$1KS,M%LM;G<9*^$PYF6BV6MSN,E?"8DJ$/G3OYN9_O
MN]/U=!#X$C^3E?\ ':Z?HZ"(UYF6BV6MSN,E?"8<S+1;+6YW&2OA,25"'SIW
M\W,_WW>GZN@A\"1_)RO^.UT_1T$1KS,M%LM;G<9*^$PYF6BV6MSN,E?"8DJ$
M/G3OYN9_ON]/U=!#X$C^3E?\=KI^CH(C7F9:+9:W.XR5\)CLZ>1Z325 NVE4
MPGDU0/JLUC:" D*R6@96'IKHL5BJ2P(%D(JLTW+E-JJ]*N=NFNN5$Z9552GV
M.$8+FIEU)0Y,/N(-5:5NK4DU555I4H@U$ BL?@17_6,VY25:4%M2S#:TU@+0
MRVE0K%DU*2D$5C\#4?Q%8YF(E?QL>>MC7E9SE6LBD[+4N*V=1W:MSNW2>2]1
MITE)FMJW+UUW"[E?SRFB7KKG9\F4ISG*4>+X(8<(DW_!FMQP6*/Q)X69C,]L
M0P:\3K7O+A;-.(?$-ZK9))<B$BLE[DX=7*B<U:T82'=*D,6U++1&OU4OB\B)
MR0P+30V$!2GW+U7;5,YTU7+=-4O;*JNF4Y:9:9:93G*<M,O7_2/QQH;WEGVZ
M='ET:-/MTZ-.C3\_;\XT1T1XOU1ASG:^8_(PW5C-O*>.:]'^%T8QA357N(1G
M!>,6>8%^5)VN6M/U.>VK0:Z\M\Z\^OJ,C,A=!L'-1<[IO,+3?\XGU1 (S,_,
M1V<3K;=X6YDXQ"F7X#O*G"2P[F0S6"6B*"O*HR9,G0Q%60BQ!F),BE/AEB'*
MKB05RG#I:M653,!J>++H)/F VGVV<<'][9]FC_;H]GX>WV?+V0XT/*>F5VSI
M_'RZ-/UTZ?\ [T0A'B>PFQB-'$:MGF 9O@=7KPTS'8+@W<C\>W$S[=0&=8QI
MQ-9$+ACS)M 8A+@TS:ND>9M#KN$87E9-:*L=>DTP$?=6">N7C4'31'5L,<75
MVJ7(X&9I66X*A],(LB>#Q6(8^SHRM<9F$TT[?KU-IEMS9*N.D$R^),.&B<D:
M<C%@(O& (0"F?64N&/+EX-I(+YV.">XJ5T/+V7;,M$M$M%='JEZO5+U^J7JE
MZI>J$KH>6C1=LRT>S_3H]6GVZ/7ZM/\ '1HT_P 80C^?GBCAKFDBGT8]GL>L
M:<E4.+3*ERF*#(KS2PW0I?J*7W<1#D%AT]C/<*PW05$7<DAQHHU26C$F1W$\
M?6S0-7<M4D%J86T(O[O!D\&&OU4Z^(;"/WBKG*U2C81)/HA,DE;=Q1QRQJ9.
MPDG0;Q<-XY2>$9K-^*+7DRU('=*U+>+TS44G!^I4R*-Y'00U" 08LXL?T!Y7
M0\M&B[9EH]<O].CU3GITSEZ_5ITSTZ-&G3/3"5T/+1HNV9:-.C_3H]6GVZ/7
MZM/\=&C3_&$(I5A5@0R>!Y X) RXYP!]AT% E%2KQ2_5(94#1A\CV]3C7E(P
M'<"DA('++<D:D4V5WB\"%LEE/)-B^$!A+ET5,1=N-KC['OK7ZE';#C['OK7Z
ME';"$;L(VN/L>^M?J4=L./L>^M?J4=L(1NPC:X^Q[ZU^I1VPX^Q[ZU^I1VPA
M&["-KC['OK7ZE';#C['OK7ZE';"$;L(VN/L>^M?J4=L./L>^M?J4=L(1NPC:
MX^Q[ZU^I1VPX^Q[ZU^I1VPA&["-KC['OK7ZE';#C['OK7ZE';"$;L=&<I-JI
M7H14)I$.$<-0K#DJO B)Q4^0I)3G*1'W*[=5LY+B!=$Z@2)J)L4T5VZ0A^3&
M)?7*[55<#5UTVYT]TX^Q[ZU^I1VPX^Q[ZU^I1VPA&!W+-A&0+G98"]P@..V1
M&=9.FF#>=($F5Z5:Q:N7;!*M7.0G5*9M:O,7\/F_M6TV=GB8)TT-;=X9)":>
M#&"*NEUX:G%K4"/#B]O!?HE[&[P98M(Y 6UT#<$M"KZ^#)'24=U7.>DFO-W4
M7!TQ:%<E2WS,YOG#@(-DC%OD>LA0DT,15"@)1P088F0H->'"+Z3O!Y^V[:TR
MTZ)\91I]?MEI\KV3_C+^,:RO6)2T2O6I2EZI2E<HT2E^'MA"-V$;7'V/?6OU
M*.V''V/?6OU*.V$(W81M<?8]]:_4H[8<?8]]:_4H[80C=A&UQ]CWUK]2CMAQ
M]CWUK]2CMA"-V$;7'V/?6OU*.V''V/?6OU*.V$(W81M<?8]]:_4H[8<?8]]:
M_4H[80C=A&UQ]CWUK]2CMAQ]CWUK]2CMA"-V.HKT&MC!%JD"VY\FTNO19$9!
MT@HE@ES%:I<E4-T-725F1^DBA4H@T492$$SHNC2< KDX+'V956+)R KJE>I[
M3Q]CWUK]2CMAQ]CWUK]2CMA","[ E'" 8[D_"A.ZXA6@G_)BU[L@'&3S H+$
MYTD,O,FUB&QE8(,A+K1'RCR&<PN!-RJSHBJ0=U.R1+B"A9X5J<586XBJFLD*
MN<X/VX+<?( A?'*,FS*7V8IBTJE310>.9AJ\F..(6,B./Q:>4R\:3' H5Z4!
ME)+6>F96G",X<1R%>N'D=@*BRZU-1E28L64> SF<=8GIE.]:G*?\)W*)R_[X
MTE=#R]<KEF4_QE7;E_\ K"$;T(VN/L>^M?J4=L./L>^M?J4=L(1NPC:X^Q[Z
MU^I1VPX^Q[ZU^I1VPA&["-KC['OK7ZE';#C['OK7ZE';"$;L(VN/L>^M?J4=
ML./L>^M?J4=L(1NPC:X^Q[ZU^I1VPX^Q[ZU^I1VPA&["-KC['OK7ZE';#C['
MOK7ZE';"$;L5_<!KW?4[KMZN4ADJN&V;Y*2!36++$;>,VH4TY_FQJ)'"I'BN
M6*(.W&3DS$ONV2:[Z%*8BX@,%MBPG$F%V^)N3WQ]CWUK]2CMAQ]CWUK]2CMA
M",<[#H)PG(SLRUR2=I%GZ?3S2VTCB5B1:510+*I"6WM)-(NSD"[R3#B[E5 D
M"\+O*,E05U1!+=NT;$&/:>#6*N)M"^.R.QM<=8E[+UKU^N?^LH]<_P ?;#C[
M'OK7ZE';"$;L(VN/L>^M?J4=L./L>^M?J4=L(1NPC:X^Q[ZU^I1VPX^Q[ZU^
MI1VPA&["-KC['OK7ZE';#C['OK7ZE';"$;L(VN/L>^M?J4=L./L>^M?J4=L(
M1NPC:X^Q[ZU^I1VPX^Q[ZU^I1VPA&["-KC['OK7ZE';#C['OK7ZE';"$;L)_
M*>CUR_[)^N7K_&7J_P _5ZXVN/L>^M?J4=L./L>^M?J4=L(1 +,M:[[>FB^&
MN=DJN']+U0< AR0)5:WC-H<,VI?8,C<5?)R06U:(2)BH0P@(8%@"X+60H\,+
M=D@"7[(F@4.-;HNK7!%MJOVAP':5 .>CU$@EJ4+?)4<9I=5%8DF/  -2Y3/8
MJB 2*+Q=% BS9.$X=E!V77*Z92%%AD#%V]-J_1.>2/C['OK7ZE';"5ZQ+V7K
M4OZ7*.V$(W81M<?8]]:_4H[8<?8]]:_4H[80C=A&UQ]CWUK]2CMAQ]CWUK]2
MCMA"-V$;7'V/?6OU*.V''V/?6OU*.V$(W81M<?8]]:_4H[8<?8]]:_4H[80C
M=A&UQ]CWUK]2CMAQ]CWUK]2CMA"-V$;7'V/?6OU*.V/W3537+31535+3HTTS
ME5+3^&F4YRTPA$'+#&MD5\HC%6*Y EYTH37S7E ROF)_8NB?,@=@ %\JT"-@
MP:GB08:Q8IXNQ1IIMRJK\JN=5576=3K&S9:5=+JCQZ)==)<VFQ;1PG'OEUPW
MLH%#JY:WBJR)H!W3.TDTZ9*"X7VQ=RR(H"W!M!=4%H$UA[]-BJ[*[59NRHG1
M5CCQ?X7O$]YL-,>,NWT<MG\0:,AF[7#E$+;/&^"( '(5/-VLC-&*L:5&AW0C
MKZM+R<:#+KI@/*D]9\RN'I6 OAJ18D/3?P+;9));023624I))O)J_K&06L?@
M%J '] %$5?OT&46_U.L;-EI5TNJ/'H:G6-FRTJZ75'CT<*I\\<+$6Q:6R;5>
M5F/B?Q\7 FV 13RFCM(H*W*O,KEP=9Y)2ZIK-YEJ@.+=TK-;8@H*;HLT"W"H
MTH% [%1<-E8[FF<L,8%F!9HR261#)*4!D4(/0;!BR)T46:V'H&I<!>-%.!:Z
ML$<WI+H<FR\,)&* $G.4!9)8#"*S.P%XB[*B.$U]MO0GQT&43Q%XUZCYZ#*.
M&U.L;-EI5TNJ/'H:G6-FRTJZ75'CT5GRIX3MFL>M76:$FF,AJ'MX1)J^#D5U
M;<.:FK\F5=IP^69GDEOR<$4GD*5OY%8::A;@9R&HI2- G'"2[31QO:VLX0QJ
M#DF?)1Y!*%C\94XU68SDXAI(_5F4[&*XE<<^0X,*8E T2:)U0V0+;N J"[E<
M>(89:B [I)$$2B12B++-B[;N2<)K[;>A/CH,H<1>->H^>@RB;=3K&S9:5=+J
MCQZ&IUC9LM*NEU1X]%<W-X6?!A XXB\J$L]*??YGP3B FJ%J#&\P)'BM@%T-
M+1YU22'8PB.@Y&E;EHF+KYC,0KCHA"BJ!!."++H\T4*> &EVF8=M$OZT#6OD
MVP\4:MX\;=HQT4*9#BX83C1Z07J=+E0G18PI,+=H>6"Q!2:!+@DO&VK8H'?J
MK#WZ*;ENJ4.$U]MO0GQT&4.(O&O4?/091&.IUC9LM*NEU1X]#4ZQLV6E72ZH
M\>BS,(<)K[;>A/CH,H<1>->H^>@RBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>BS
M,(<)K[;>A/CH,H<1>->H^>@RBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>BS,(<)
MK[;>A/CH,H<1>->H^>@RBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>BS,(<)K[;>
MA/CH,H<1>->H^>@RBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>BS,(<)K[;>A/CH
M,H<1>->H^>@RBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>BS,(<)K[;>A/CH,H<1
M>->H^>@RBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>BS,(<)K[;>A/CH,H<1>->H
M^>@RBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>BS,(<)K[;>A/CH,H<1>->H^>@R
MBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>CH^3669^S2Z;5DV>8I7Y+9!NJFU^OD
M^V:45R&;\K(6T:T4DBU;. O5\OC,&2I<DMGZ\1J/302R".3A4*Y1A (0 %)B
MY1J CG1AG8J?)HT.ZEUNG-:04KRFL88MH\B3$(ERT0;@AXTH.$VK$]>O";5@
M>6FI<,LV#$K&F:?4!=($H4T;&R>-2PR%.$U]MO0GQT&4.(O&O4?/091T/4ZQ
MLV6E72ZH\>AJ=8V;+2KI=4>/19F$.$U]MO0GQT&4.(O&O4?/0916;4ZQLV6E
M72ZH\>AJ=8V;+2KI=4>/19F$.$U]MO0GQT&4.(O&O4?/0916;4ZQLV6E72ZH
M\>AJ=8V;+2KI=4>/19F$.$U]MO0GQT&4.(O&O4?/0916;4ZQLV6E72ZH\>AJ
M=8V;+2KI=4>/19F$.$U]MO0GQT&4.(O&O4?/0916;4ZQLV6E72ZH\>AJ=8V;
M+2KI=4>/19F$.$U]MO0GQT&4.(O&O4?/0916;4ZQLV6E72ZH\>AJ=8V;+2KI
M=4>/19F$.$U]MO0GQT&4.(O&O4?/0916;4ZQLV6E72ZH\>AJ=8V;+2KI=4>/
M19F$.$U]MO0GQT&4.(O&O4?/0916;4ZQLV6E72ZH\>AJ=8V;+2KI=4>/1&62
MN8Q^TCL-_CJR3"*[)C(1?M^M7?D@T^LT*V*;1[3((]3*2-E@M'$<0>%)B^^>
MK)8$*11":*"\\.U$<7#,2)M$J>(S8\"UY*N%4!.RG6' 8OXS.T]CW/:AGE<4
MP9,[4K;L^/9E.8].M2PKO!G<72O4 Y'%ZD)GT\Y:A-$:.$++TP4)::G  :$1
M9:,4UIPFOMMZ$^.@RAQ%XUZCYZ#*+IZG6-FRTJZ75'CT-3K&S9:5=+JCQZ.1
MQ3R21^6[$(I^$21JI*E:J$*XD-4<N01>7K1#+AN5NHVT<="*H(4F1R44GZ*<
M!(*5,&(@G-S4E'WRR9@3&9@5B@@N[8B'":^VWH3XZ#*'$7C7J/GH,HK-J=8V
M;+2KI=4>/0U.L;-EI5TNJ/'HLS"'":^VWH3XZ#*'$7C7J/GH,HK-J=8V;+2K
MI=4>/0U.L;-EI5TNJ/'HLS"'":^VWH3XZ#*'$7C7J/GH,HK-J=8V;+2KI=4>
M/0U.L;-EI5TNJ/'HLS"'":^VWH3XZ#*'$7C7J/GH,HK-J=8V;+2KI=4>/0U.
ML;-EI5TNJ/'HLS"'":^VWH3XZ#*'$7C7J/GH,HK-J=8V;+2KI=4>/0U.L;-E
MI5TNJ/'HLS"'":^VWH3XZ#*'$7C7J/GH,HK-J=8V;+2KI=4>/0U.L;-EI5TN
MJ/'HLS&FF4OXPX37VV]"?'090XB\:]1\]!E%9]3K&S9:5=+JCQZ&IUC9LM*N
MEU1X]$0M!PB#(/MF:\V%[9AE<<K%@VV#K=R5<:)93)%+@#ZXYY^V M#D/IB0
MD(Q9B2PP3PLP&K%(2.T#<MWK!<6*(Q,[)C8 _8(S\:6[GL0\'Z0%BA4;F7V>
M7[LK)7%]NQ)"(,2B[K:7PS;FQG5.NH8Y!LFW03BV%IL)Q8E-(\X2IV=2ILK(
MBIN.$U]MO0GQT&4.(O&O4?/091*6IUC9LM*NEU1X]#4ZQLV6E72ZH\>BS,(<
M)K[;>A/CH,H<1>->H^>@RBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>BS,(<)K[;
M>A/CH,H<1>->H^>@RBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>BS,(<)K[;>A/C
MH,H<1>->H^>@RBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>BS,(<)K[;>A/CH,H<
M1>->H^>@RBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>BS,(<)K[;>A/CH,H<1>->
MH^>@RBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>BS,(<)K[;>A/CH,H<1>->H^>@
MRBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>BS,(<)K[;>A/CH,H<1>->H^>@RBLV
MIUC9LM*NEU1X]#4ZQLV6E72ZH\>C7*_)Q,XI-78<(Y2JL<10J9>MVT37->@[
M9/4L7/=QVU87HEO$.1BU(:$27)9FIX94"#=2*@[*4\F4Z .#\V&TA2ZNU=J^
MB,\'J7UI\VU*,+U:799X]F#0CUQC\H7O:8N(3EL'NMJH0A';0;W ZS-'J),#
M*$.LBP:4CR8@5!>I$N;DXLHMAYE9J9N$U]MO0GQT&4.(O&O4?/0919_4ZQLV
M6E72ZH\>AJ=8V;+2KI=4>/1#>'>8CGY*N+D.W2_QD-V1OX['B.1BA55IW$*[
MB,/'%4A!)6'K=DYZC ("UZ5MXF3))&2Z"56[P<D$K(E)KPGEBT9 P=_8<)K[
M;>A/CH,H<1>->H^>@RBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>BS,(<)K[;>A/
MCH,H<1>->H^>@RBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>BS,(<)K[;>A/CH,H
M<1>->H^>@RBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>BS,(<)K[;>A/CH,H<1>-
M>H^>@RBLVIUC9LM*NEU1X]#4ZQLV6E72ZH\>BS,(<)K[;>A/CH,H<1>->H^>
M@RBLVIUC9LM*NEU1X]$QH-N46V)'6FT*16$\27# 4:5@ X@<)MU#QE-F@2(G
M<,!8R_Y5VD/9E.F5V5NGR)>113.=4Y]VA&00A)K2A*3_ $K"0#5^'X5@=!D(
M@J4145*(N))&1,0OD<GSE5X^ODETZ7B#<_4;/.@0DA4$IIK%&1N<(10%I8 #
M4UU44U"!HX4'#6::JZ:9W;M$JJJ93G.7DNP%X-1^@BK_ ,/"!R0Q.-AJ,Q;Q
MLS^+7\*G,1Y&>I]JEZN5*<&K3!5D4FU8\$'.S>Z+"F28\H*+NAQ=-D9;\U%!
MI7+'LHOFQ4&NUV!)B L7J-'EV;XP+:N4^53*JGRK=R[373Y5-4JI>53+33.4
MY:93E.-B1V0RT:#4IEY,IRIT#P,O)E/VREHO>J4_XZ/;&58OWLC.(J-QW[&<
M>&ZQ@/DVTN&N+U8_%/-9'*_'?A&<]760ZZQ!!-<K'DQO2[A**H,TJM)<0G$(
MS)*Y!M:X@+R@0TN*E*B#5 E .@W+JSDN/AI,,[ U[#\(<R+?<%UEFYV";BKP
M#B1P@&9JX4+58Y,(TC5Y/+5@,@6N(4HWSUN)C(@507-XDW;42F#J@6O4L2GY
M>&)P=M+\O#+(@://ZO;CRV0Z-'*I3HT^5H\_ Z/*GITU:..]L],_7[?7.'+9
M#HE3RJ4^3*<YREY^!T2G/3IG*7':)3GIGI_K/\8BL7C?L9PJ-QW[&<>*5L\(
MLZ56V[?JA88CNJVJL4?^*]2_""*9NCNM,'!T@L9S<F!CS1QC@W3YV-(3-,IL
M5?N%)F=DHP79OCPHBH!8$AI6[]SE%CP;.4JZ2*H1*OQ?5RH2:O\ \6D;Y@J9
M,GA$3F9(HL*SH#> &KN')8+'70ADUYH#O701A2+M7;HT)>NAA)5<L7;E%7M&
MY;(9>PU*?]KRO_?P/^U_\7_MO]KY^WYPY;(?S4I_VO+_ /?P/^W_ /%_[;_:
M_P#ZO;\X5B\;]C.%1N._8SCS;X_<$LCG,S2X5FT_S%+-MF#.\L\<GRQ1.&Z4
M:@9(I-3<'BVM6J=50(4<UYPGA-1<: W!5B160>NU8LC[Q\,%2E2;VK!@%]!S
M(,ZB,>F=:YB6T"&!<W3.H)*MF@BPT-AIZ/*T:B28(GTR5B#DSN7C$SJ+"8 #
M 4C3"]?&B+8>BX*OW[\[EVOO<CTCE.<Y&Q5*<_;.1@"E.>CV:9\?Z]'SC7EX
MD_-ROI$%]^%8O&_8SA4;COV,XY:$<3R\2?FY7TB"^_#EXD_-ROI$%]^%8O&_
M8SA4;COV,XY:$<3R\2?FY7TB"^_#EXD_-ROI$%]^%8O&_8SA4;COV,XY:$<3
MR\2?FY7TB"^_#EXD_-ROI$%]^%8O&_8SA4;COV,XY:$<3R\2?FY7TB"^_#EX
MD_-ROI$%]^%8O&_8SA4;COV,XY:$<3R\2?FY7TB"^_#EXD_-ROI$%]^%8O&_
M8SA4;COV,XY:$<3R\2?FY7TB"^_#EXD_-ROI$%]^%8O&_8SA4;COV,XY:$<3
MR\2?FY7TB"^_#EXD_-ROI$%]^%8O&_8SA4;COV,XY:.E.*ECM:HA2I5-N"K&
MJ/#PLN@"QQ$*$1H]7)$5<KMU4'! #<)*+A%B#"Q3151:MJ-)GQ9.F[<G>+[M
M<K=5'/\ +Q)^;E?2(+[\.7B3\W*^D07WX5B\;]C.%1N._8SCS_9@X<EB9RAQ
MH>?*5#Y0<(2PQ/C"^6/[@7DRW0=QEO>=,V>1%O,U"M>1E,<$RW!8LDD&38-<
M(I%'">;820M^LRA'*-5%U"A,2];EV2W@U$6]S>X4LJDLA+:N!N,6V%Y?#D3A
M*6I9N&C6S-G.6ARQS>N&K:C8^K4:_;IE#!OT.M#>X>'EX4HR QD(/S\1;NG(
MZZ<STCG[38JGH]FDP!3T?6_&LCTDE+1(W*Y2EZI2D8@M$I?A_P"WA6+QOV,X
M5&X[]C..6A'$\O$GYN5](@OOPY>)/S<KZ1!??A6+QOV,X5&X[]C..6A'$\O$
MGYN5](@OOPY>)/S<KZ1!??A6+QOV,X5&X[]C..6A'$\O$GYN5](@OOPY>)/S
M<KZ1!??A6+QOV,X5&X[]C..6A'$\O$GYN5](@OOPY>)/S<KZ1!??A6+QOV,X
M5&X[]C..6A'$\O$GYN5](@OOPY>)/S<KZ1!??A6+QOV,X5&X[]C..6A'$\O$
MGYN5](@OOPY>)/S<KZ1!??A6+QOV,X5&X[]C..6CI3BI8[6J(4J53;@JQJCP
M\++H L<1"A$:/5R1%7*[=5!P0 W"2BX18@PL4T546K:C29\63INW)WB^[7*W
M51S_ "\2?FY7TB"^_#EXD_-ROI$%]^%8O&_8SA4;COV,XPA9F*+,MNE&QV+J
M<.L[UXR!@W"\6.0F:./K+-$N\I5F<BUQ9+$0P*.-T>GFX;5C+UQ/"U >JUUB
M1IC!6 TR1H\G1 D@7!R9KT%#[FJIVD$WN)N+6)>,F>^*V$TF<79JYBQ8QA@:
MJR[*QY8XMU*I]C2PV72O4(EG5.XLO35YW-?HZ"KYQS\$9)T8D3E-KE6F2P*/
M0W4=D-4]-1J4U3EZI3J'@9ST?AZ[TXTF<D$]$IF91.4O5*4QP#U2TZ=$O]=Z
MO7.<_P"L],*Q>-^QG"HW'?L9Q7/"M+-@A\86D1K-,TX; -FEB,>1)5J77(#%
M..,G0Q>?FUH<.60$Y.U(=C5 JS:9@KS-1GA\;GJM%GMY4'1@),S<5<JM+'$2
M/2.F6BDV*J92]DI& *4I?Q]DK^CV^N->7B3\W*^D07WX5B\;]C.%1N._8SCE
MH1Q/+Q)^;E?2(+[\.7B3\W*^D07WX5B\;]C.%1N._8SCEH1Q/+Q)^;E?2(+[
M\.7B3\W*^D07WX5B\;]C.%1N._8SCEH1Q/+Q)^;E?2(+[\.7B3\W*^D07WX5
MB\;]C.%1N._8SCEH1Q/+Q)^;E?2(+[\.7B3\W*^D07WX5B\;]C.%1N._8SCE
MH1Q/+Q)^;E?2(+[\.7B3\W*^D07WX5B\;]C.%1N._8SCEH@A=M(O5:Z:!< A
MR3>1MDHC_,O2!F4<3,<-;IS?-300/O\ IH9+AGU>YP+E +>MDXOT$<)&^07!
M;%P'YJ9U7S"],/+Q)^;E?2(+[\.7B3\W*^D07WX5B\;]C.%1N._8SC'-<9]T
M;G"O+MYP*=-"UN#3@VD.TA(Y8@#:'IT.Z1?DRZ"NN$-5B8T/='&121')0HA)
M;5YN'$EXBU9\[M\;5*WC[8_@_,YL<LY,"C 8[C/.\VC=M7G48O<]@#&->II4
MK);ORO<9E<X9JZJB-,JU9(R>M_3I+"35'K4$5ADDWI0@#1-6FY/TY:3!4GO0
MYRZ1Z=/*Y5IT:-/* +3H]NC3Q^G1I_A#ETCTRGRN5:9:92GR@"TRE/1IE*?'
M^K3HEI_'1*%8O&_8SA4;COV,XY?^O_W_ -\(XGEXD_-ROI$%]^'+Q)^;E?2(
M+[\*Q>-^QG"HW'?L9QRT(XGEXD_-ROI$%]^'+Q)^;E?2(+[\*Q>-^QG"HW'?
ML9QRT(XGEXD_-ROI$%]^'+Q)^;E?2(+[\*Q>-^QG"HW'?L9QRT(XGEXD_-RO
MI$%]^'+Q)^;E?2(+[\*Q>-^QG"HW'?L9QRT(XGEXD_-ROI$%]^'+Q)^;E?2(
M+[\*Q>-^QG"HW'?L9QRT(XGEXD_-ROI$%]^'+Q)^;E?2(+[\*Q>-^QG"HW'?
ML9QRT)^O^,Y>N7LT?PGIT>N4_5/V3_CHGZIRGHG+B>7B3\W*^D07WX<O$GYN
M5](@OOPK%XW[&<*C<=^QG&+'+*69^*C$KU2L*X.0V8CHNP[#:(]-65>T;'.1
M9Q50BB5!Q><-V4@US/(7'XZ=*PWZ*OB)D*26JW.A1XJ2M"!3 XM%PA67S>-<
M7[XIE<><V'99C'C.AP\N!B)&.>IUMFD@@2>>++EY"%OU* :E'D<R4S+D>7)!
M-C2@ E"-NF_($&WC;$ZAG,E)+(H[.#(7F7J/"*J6BHV*JI>W148 IRT_CHG?
MC\R.B&4IRD:%$I5>JJ4AX&4IR_"<I7O7[9^W\85B\;]C.%1N._8SBM6$3 ",
M9L7FC:D\$U&[A DU;5#SJX17:OF3@OPO[]Y</@X9P+MTRF,-%HZ)^J3V_>KJ
MN<58%!@5FOS0&&HHM='$\O$GYN5](@OOPY>)/S<KZ1!??A6+QOV,X5&X[]C.
M.6A'$\O$GYN5](@OOPY>)/S<KZ1!??A6+QOV,X5&X[]C..6A'$\O$GYN5](@
MOOPY>)/S<KZ1!??A6+QOV,X5&X[]C..6A'$\O$GYN5](@OOPY>)/S<KZ1!??
MA6+QOV,X5&X[]C..6A'$\O$GYN5](@OOPY>)/S<KZ1!??A6+QOV,X5&X[]C.
M.6A'$\O$GYN5](@OOQ]P86&&6YW@@BP)M2JG1.X'O6K]ORZ92G53Y=JNNGRI
M2G+33ITRTRTR]<HFL7[V1$1#JLQS8]=* >JE>V254"B-/-N4#<R UWAHOS,)
M9 !>.N2O42JX@&'L![>BF6BU:HI]>C3'6]43&G8PA^C+G>(G-2J0C1R=/E8I
MC,,3)Q,$QJH3\W&U54 RHD)  @T-C(7733750& %X02+OU4T554VK-<Z::IZ
M*9^<9*\.!F$Y+86<W&GX*]P7)X-X:X=Q-D3FIAX 1KE@KFR"K6X@![Y);% J
M0Q@9&:<"J"R)E2DK:MJ/+A>#$FETT#$UD4<!,"VV364))/XDE(K)O/X<^?\
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MN<B)8/@PF.5>)BQ1"APUX;4T?MUSZI2-(/2J@8I1'3L*D,\29,$TNAXPT3A
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MP,Q"$QA=3.8WS329<]2?38]OTJZQFK5$U@B2P:ATBA2FLSXXFG*JY-0I#<S
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M)\(:-BFE4KF7;3B9!6O1DDZC#HU*0^</G<:F?M<QOI__ #HFO$XTYVVH]?\
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MA)?PN',$QFQMKMPDOX7'*&2UFI4VYEAF3MO5DXB(N'Z3H)S157;2<)'3!)P
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MZ**94R<1&-&H>>HSA87A5I/B/.?DY@#PG/"G8TY6(3(_''"S"]5&C$,BW+#
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MKNZ3=RAZ!H?X.2N[I-W*,$*RX:QSL9VUQ8"YDX3+A Y&.<7!!.0K9(5PD H
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MLSCR. O\3*9SX$Y99-&#YX?A^$X*U8:%A!CM571:O"R4+D26HT.+J9VI=5+
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MA4> PUQ<;-J15T0J/ 8<5K[C>M/GJ,X<->!>D^.HSBS,(K-KBXV;4BKHA4>
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ML C)@GE:TV/;QJ?+A)AG0#BCH<)1-  +"^'&0^9.;2BX/9#J/,=VV@H=;@C
M&7;HJ%GD%C1:/5\](AZFW0ETX-><UAG,)2<IJ3ZF-I4$B0)TX H'7 XOBZZ
M_F]U"/3'HE\_]Z?;#1+Y_6?;&-O!5[WN-'3R[Q R+5I<ZSF8BK1L+Y ^)<F2
M=$C'>9)_4.+7C6GJW2";H#I4C<],C"1:(%<U)$N($NH;Z7+5@3)A.!U#,JL9
M)80C31+Y_6?;#1+Y_6?;&L(0C31+Y_6?;#1+Y_6?;&L(0C31+Y_6?;#1+Y_6
M?;&L(0C31+Y_6?;#1+Y_6?;&L(0C31+Y_6?;&NC1_P#O.?\ WPA"$=37H58#
M4.L0C>&),4+X2EE#80YJHPH@<GBQ87B@9:3)B>@@<IBQ9.!.ZP(LR#!93$B
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MN+8CM$2C+%$1B0*N!2-!J;4!&"&U7CGP0&9.'J\(%[P6^2C#I(0J<,& PR?
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MG^>YB34Q1--&V'J0QJM(Z0,=(\LG:;>]:.K>4E8^<^3:BD27J@.56@=-/GM
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MKY^& T-D];>.S?#5E08P*[PBHW#H>Z2VKM(ZU('?,;8ZN@3;#5AKW,ZV2'^
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MW;%MDN7D=E3@T4V;:IDU62Y5IF',+P!.)@C#U"S8X'6"T&.,*@@ -17?$>;
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M'=@2%%7+@:NU%&CS@Z<R" K22K2[GHU=N ZSW9!9&YD)).Y!Y$8:HM1O$[Q
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M1B[^/' C90,4&4A:HQ:)Q9=(B"*6RE:4T5#!AH+,3((,N)*1ZHZ0H(,(-K5
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M>.P[ 4U*VSO&*.H;@:8WJ3F_8]-<$HHD(GL@66 .@@W3:_*MFGR:%SLC'K0
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H0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g401598.jpg
<TEXT>
begin 644 g401598.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@! 1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?1DE'55)%7S$T7TM?3$E.12Y%4%/_VP!#
M  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  +" %4 G$! 1$ _\0 '@ !  ,  P$!
M 0$           <("0$%!@H$ @/_Q !+$   !@,   ,% P@(!@$"! <" P0%
M!@<  0@)$1(3%!4A,19!@1<B-U%A>+&X&"-7<9&8V/ *)"<R.*$EP=$9*$*(
M-#9#4F+A\?_:  @! 0  /P#[^,8QC&,8QC&,8QC&,8QC&/\ U_O]N?/5U5T%
MTOR]V?UU) =27;.Z0YJ\-F:^(VV<WKF+F1BB,GE,;L*W& 5*K)TCYO56FWU2
M;'(*VE(%14O46$C?##'5=-W9#H;(9&4[\>>U*2N:<51=7,=4LP*GI%18UE/$
M=Z+6K%*1V<.4GGK&.R2'Q=XK%LGL\I!$W)VFGYO/XO!7-Z8[!!+'9'&%S/&O
MA:Z!!^/UT@:B*MMSJ.A8M$*OI_Q3%=@5."UEKVOMRT^&XYS)-8JGKFP]17S9
MT[U';RT8ICB5OD2\2-GG#NY&:!&FI.*;K!\=GH>CW:^&2W^1JD5*:H>.DJ[9
MW"K^@YD_M:FQ.<K+XWB,DD4U.E])0W42I@J,=KPB5/$R :O>60NOIQMR9&]J
M6-#F1WT&\<._9RHACBDY1J%)$6E!RR==3L#IA1(#?7T]X@MC>'[&'BCET*K6
M5Q.?QD,GB#5:6UTCDD45)HTK>XH>4HD3:F4J=-?"FZ.MSJKC&(6Y>KG7;E:A
M]F="P>5?DT":F8D!M7WW8U=-C8K:SRRCV=Z1LT9;PKT)X J3B3$3JJ 2J<SB
M"M',8QC&,8QC&,8QC&,8QC&,8QC&,8QC&99^,+8O0-&<1VKT-SI>;Q3$UI%I
M*EGNZ*OZJGS/.RG-_CD6+8)(ELZ(2H3<VH-/2AX(4Q<UD=CG A.2J<#F_1J$
M^I=L>*=;_&[ATA4<LK(?2NN4I]R/0Y_0,TLN+U=(;9N/LL$=DD+73: UG094
M"JRM*_C\F.;9=-&;:Y>O<4$4;V&"NCA)WE>P06L_X@B8S5UKR"5ARY&FV76C
M1[T\FN<JO0N0)*IO91S=T1T#%XD^HH163W&IU 5C/0PE2&3Q^=H']]9)8Q.)
M\1C^C#$^_.1KQ\>CRJ?ALOWR)2=H*B:XBPY5,H_U6\0MBDUDI/"T9/%$G@HU
M' \\S8++%@5@1,8<VEGR=V6H;&0M<=/VH8C'"5HO:R7_ (B$]&]7PGB7'CA(
M&6KV@HN&FO=\1N*2J4S%-*N9HTN:YI$#80Y+H)#GD/2C4MA$^8U%A)74#"D%
M(VB+I)@RJR+-\R^);?U_=V5SSS**PIBK(5J(>(1#;2:4-FO\]D:R\^*.@Z=J
M@Y954J<*]K\,DA#RP6,F?T[.]Q*.2-2A521T<R&/4!0))ON/C&,8QC&,8QC&
M,8QC&,8QC&,8QG5+&-E<#%9JYI;%AK@V#95QBMO1J3%C.:,TPQK5C/(,$I;1
MC/.&- ?LQ(,9QHA$[$8/>_RJ(K&E:T3DJC[(I<!LI\<&N/:6XY8*/J1>M0Q"
M5&IAGB9CQZT,]JV9MO-'K0S$PA?/.J!7=?EI$K>7"8>!$BTJTB1 C+"%*DTL
M;26=9I*F"WZ)3Z4M*=.V*=$E@]NWD$H3O6E*+)#VIL5C)XU8SH^QFC7 =BUH
MS&AN,&K+?24B=Z J$-+L2@#N0@0D.@#MC"XDHTI2W1Y:<D(/Y)B,63IR$I$<
M824R9$SMJ9.4S-A9"=OCRS;@PH2"0)=%DHF5=O:QH2%A"G;%7_,H2TY_]9G[
MFQI:&4I00SMK<UDJUJQR4E-R)*@*4N*\W:A>O/+2%$@/6K#]B.6*C C4*#=[
M,/,&/>Q9V7GK]>OIY_7[OU_W?MSGZ_3&,8QC&,8QC&,8QC&,8QC&,8QC&,8S
MJ'Y@8I2TK6"2LS3(6-R*"2XLSXVHG=J7DA-+/"4L;G$A2B5%A.**-"6>08#1
MI99FM:& .]="]UO7LD13!MD,%ASZWV"0D2SQ"\Q=B=$<U3($93<B32Y*O;U!
M$E(2-Y)*%*2]EKBTZ,HM,2$LDL  ]+JDZ<T]M4EU5%:ZD3$S-D=9'[[!1/XR
MT1]E1*VYG8VMU^#^_M[.U-Z]<A;6M&H)0H$:Q4E2$$IU!Q8_X;*/IEE:B&)G
MJ6LFID3;4B3L[; (B@:R!+8JH@RP1+<D9B496U4+5JXBIV62'9\84J(^;ZV<
MXU$+_4=+4^8X.[L.JZW&ZR!ICC"_.0X)%!+WICAYZ15$V9W6B:-J7)JC"E A
M41UM6FGHF,]&D.:R$AB8@1?;$5I725];I.F@4+3R1H<92\-4@(BK 2]MKM.-
M$ZF;FWNQ;<%P1.$MTF3ZDRU,I*5/^B"=.YJS11?I]OC&,8QC&,8QC&,8QC&,
M8QC&,8RK=U=!3RK)2CCT8YIN2WD"EE3NALG@:9E.8TZD]4K3C:!B4JQ*]+TI
M:8M2H"<G3@]DK3;(V?K9HBZSB[4Z;U/0)]<-W']@1,^QB3;:EWVX^*_/_F@K
M=%;AVFP)NO8?#AJ-.8RM^^Z4!%K2$4P0GJZSY3+8['';CCH6(-KT[)&Y;*7M
M)'BV:/IU)F@&.[L,2Y-L+:AUOVZW9)@U/L C]V3JC_9IC<S[/LB:T L[FZPY
MXLBT)G#N1&E'S;%:UO#H>_;9J6TNF)U-*I=[2F,K99;.WA0T1^C6^91&L(>7
M!S&<\F4++F2N(%FFF.E(_%6QXJ78/-RNX'&Q6;G>SX]4UT]2\W%)8O#9]6"Z
M1RZHN7X;TS7MMO;Z\VI/&N#0;89G]B+5B6FZ1&L<:CKI:[5.PB-,@K;>>@NI
M^K7Q[\0NG+'1T1;-S<:-L +@SK1,9FT48;-E%B\\G7(T1V1022V-8KO$WL$A
M/;(V4P))FO4+&)4UR':X@V1$(FVAD;G;;'JZ\,>QX!V/<ME=0]O2.HT=L1-P
MON:R$-^5I>C L2=-RR#4@MD*N&TT5R>O<EL_C3I3,/ABJAC:];8),CC6N0NS
M8^4>0>(AV3$ZC27VY6393D5S[1CWX25F15<<N=D<K\4+\EUBN+5=3TW[)]:N
M:COF%455/QU4( 4X;K>3!B,VI/+!]<].Q!^KVI:P@4IF#U84F@]>PJ'R*>R1
M:I<I%-GZ,QIL9'F7/SBL&8K7O4D<T*MY=%JD8SU2U:<<:(0Q;WDCXQC&,8QC
M&,8QC&,8QC&,8QC&,8QD46C>=14J6RFVK8,9@H9&8N*8_M"O]S$Z#; )C'#2
M, 2S1FZ1@6)=J!Z#H!>U) 1"]1H-;K>]^(YR2S22/1XNS$KX0_;WH^3QY(8Y
MQ.-_UVR2]RAWT,@;9HX6O7K9*-;[$CR4JO=TX@F"]G_3LY"\M[WT%6H=:UO>
MQ#>AA"'6M>>Q#%M+H(0AU\Q"$+00AUO>Q:UK>\@V\>@.EZ[Z)J:&P23\^3:M
MYZ>_VG+(L95UC GL Y6K",)'*T;(76:VW:IBBV2.<I=8I":L0&56A:I,_P T
M( K,):H=)WK4=P7Q>:HFJVOM'\\]/Q".V&AY(E228RR-U.D88Y6/<\K.KSF*
MSI66UW$[O#6QSVQDJ^'.T:3-;C8, .;E4CG,28XCM.^J)>YQ\1^JNF+:C-51
M.KKVB9-F5+8-]T;9<^B,6:JTO.DZYG4*KMTL:!NK-.9#(FYO=WZ?1Q=&X]/X
MM"YDZ1%Q;IH..I8X^,"USKY-.Q^OCJIZH[)KAGHL/.'*]@7ZQIZ3E4=F)]O7
M77W(TLEL*Z#F2:Y&ZPD44JF2/+S7\].IN)+J@G"!4ACK']N'U$=.3/L3&=C>
M(CVK&[$L^.Q.I>>I,H>J(ZQN*AZ99WN732[8+#Z1@ITJY]NSIU5$I0;$V&L>
MN'=$3%HE#$*&$S>%/,SB;80]V ],MCM<0\',O&GF9JR_5M3UA!95$M<W57(>
M/7=P<WC9EO=2S9-S8*3U7)-HW5*4?'HTL[:YD2@2Q\#9)!F%6D6<LWMD"-I^
M@]+[Q[N3I6,DQ4$H 5)B<HPA.8H '03QD$FG*#"B1G:&(DLP\X8"M@",TP6M
MC%^C&,8QC&,8QC&,8QC&,8QC&,XWY??KS_#>_P#Z9YATFD197^/11WD;(VR6
M6[<?LPPKG%*F=G_;2GTJ<_A* TP*A=[BG$$U3M.6/V8-Z\_G\L]+O8/+YA\]
M;V'7_9O?_=O6M?=]//>O/?TUKY[^6LRPJ;N3E6XQ3F!N/.=C5[6,K@5J]-PY
MXL>D8J;".GZZK^U6B.VO;T'KN&.<WL1Q<R+!D$,DXV:TZTAEH3A),XG.8W&9
M 0O,6(^N>NE/#KOGDJ,71/)A">;H3UJQVL]P&66 5 JBNLQR<V-945AV,P)W
M=,[.26:-T)+2(YDZ.:!V-9X&>C9K20DQD+JQE=!R.[>&AQ%5EUV5!.K*171B
M2W%$(I;5J.$FH> Q=#82"%L47K:LVF*TO%*RJN+)R(60E>(LSQ2&D*I6B=WF
M?J'*0$.:IZ+D6QD_AMU/#6CN6(T505HR2;6)$5]06!S]7M2RFSKON^R)8=$8
M,W53.6@QI0/LUL"8/:Q KDJB9-4>V6<_22?25#&VM^>D?@#^R>>XE+$5#] <
M9/\ 3-C3OH#GN4K*^=XG1$\C#W*>A[6#!ZOZ>'*(1)W>*R0QHZ 88M!9O)P!
M/MB V<[U^[+&8UBD$2F+A*D!\4CGRS%:=OAL:M5R<5_>3SP TMXXXPI5+U8C
M'$I18"VU&D!TG#I91)T#A4MES;-M;"Z.K2P.&T,;/4@ 2/2<._4'0M>>M;UK
M>M;^6]>>O/YZ^[?Z\YQC&,8QC&,8QC&,8QC&,8QC&,8QGFY)#8C,24R>71:.
M2E.B-&>C(D;&UOA*0XP&BS#DQ3HE5 (-,+UH S"@@&,&M!%O>M:UGBC:%HTT
M].I-INJS%"7VGNQPJ]B6S"/:AT WV8OA'F'0PZT$6_IY?JS].J1I@.]"#4E8
MA$'>A!$& Q/0@B#OS"(.]-'GH0=ZUO6]?/6]:WK*VN"/D,?6EG1)UO"%"ZJO
M'GJ(5<KI19:D(!8K52D#,L^1$+8#6(A@ES2@=%-CRF029YTB<4KMIF95H@$M
M\>#K?A8APERDZM>XI$Y;(I,15$;X5H)_1-\XCSTKC^_#HL$%]T?&9>0B8S?<
M)6K7S1O6V6W.!"-1)(F\M!:-MC@%I"\^NO#/A^W]1'14-LZV9PUCK.A.:+1Y
M@HBN6.T7NR&1IB5D6_7LZ(^S3<]T_6SU7L3AL6J>(Q=B8YS->@++4%+2X^Y6
MR;&X&QZD,G]">%-65Y-EJ1E/T+TK3M1W#83W<ECTO5\M@C56DBLR2M*]NG;T
MYAD5=OLQ%"[2^(+7"YJ=^V9=068X+'EPD4. MD4E5.O5\5MG&Y%K7(]\V]W*
M[G42F7V;?=QUJFF/-LFC<G56$\N#>XSAX?H]3C+:4GKJ%*RBH37;F59[U!(*
MQ1MEKQK7!86<EDW$G/G''A+R.N.,:]H&\H)9L<YOZ^LN[N>G.%7[7T\=YC>[
M8DDEFSBO'-XC^E@9NU06/RAAE1\!;2DCI'8I JQ=5RH3/'2E3AK5&[[HZ7IH
M$JB5PUC*$EHR"91&M54?G<9>B+ E-=!D@Y_'8<<W.2@$E?82&&RT4N:VC:M;
M'?LQ(/BY*3;0O]A+F,8QC&,8QC&,8QC&,8QC&,95NZN0JEOF4HYA.%$_)>$3
M*G82@QFPY-&V[:%*J5K"=B:V]7I"%5[5:?HU4424:H![(*C9NR"=@JO)?"MJ
M5TG$+?&::V"UQ9H]\^U;$X29S?GUY]&MG-/V>ER\[;E%O2J&,+I[N%3[9+H
MVWX<O$:K,F^%<!T5 99'9JPJ[3,>XLZI'MJ Y6U,E3<->@,T<F"N2>^! L1B
M-"'2E&?[1*J)V,E40H(&829$_%O,G1=467-[3Z=<*?M6V)_&E3;++\999;KW
M.U9*><*Y1&ZV@D'G+"B@=(T7'4;LJ*1UW6JM.2Y/C6VRN8'3*8+G64"A)I\+
MR8):FYXKQ78L*6+J4YL\0FCU;D8P/(T[B]=FJF <>?VPD_U*$2&(HVQ:DD*<
M_>ECF4NV6WBT2(T(J[3?BRW>,[%HGI*%MH[C<Z[?Z%BQ,1B%46;.HVTMM>\$
MS/E:52J31ZJ6.:6HW+#E8D1U:/\ "*TG2=M)>W: SE/#8[-EECPV=N:^%;B'
MX5O&U,/QK!3?3?/:ZKK^@Z-YCPE4&B=M06QGVRF6"S>&1E]V<DA;PPR-QKJ7
MQZ,R58Y0U ]+=QIZ=7>-MRE7Y*V?#X[5ZLD?3DVO^RZ-@DJE/.S?67')M/.=
M@/Q7.-@1R[H/T1&9+.5THKV'&VV8EN*HZDE[?*&YA@JZ/,L3/A1L:E*U<=-C
MI9HKPLOR)]4\PW>W6.D/KN@^2(_53U7:9I7)U$VZ>C,9=JP;^C3UHS!)R5:J
MHI]:T3=$APC%R@V2MYH3 D(3=;V)QC&,8QC&,8QC&,8QC&,8QC&,8QC($O2+
M] R5+'-4+:,2K56C4N0I+N5P<$Q+>DQY*4+:%&,9X?A@T!Q2H9P0IS/?0J@>
MHXG2719]"+GIOQ*7+\G_ ,*O*+3#W*=-2TS<)8T=:?9\\GS]TD,G]L$7VHBJ
M#S4?%&(.EGM/:%>IC=_:A]SFW\EOB(?074E/^CS_ #M:I$D>_3Y_G>DOVQ?K
M_-\_(OVQ7J^0?:E^?K#3$-9JIYWXI22CGNSZKK. =7QF]D4SBE#31Z4]3=(Q
M[GIIK9NZ$L>_C7]RC55T7#V1>KKF*5;'$1C[)ED,)=)1)6&%O*J"ROPS;Q=9
MM>Q2T*6J&M[%JBGYYXT4(LEZ8:DD;]7 '_D][J2GQ6D[*'J(R!H?]UQ*YFS2
M-NFQ)3D2H>S=NY"DD8%'M=U$>*7["H2L6I\E$AZM8('+HR_P+I18Y7[/E4W=
MZX:?%<K6&5O#JK<Y18VU+%=LCX7?I'!*H' %K+9DXBC@)F8G-XMY9$##K3\Y
M0&S.F?#U\6F@*IE-U& ?N@^OZ&YF1]$6'.7N7,,(3T]5\?CM:J9;-WUYG,7A
M&Y0?*HHF;I(Z'2Z MCLO:YN@231HDS01T'3\W=^EYKSK'F;PS^H@5S0E(]0.
MD]BTFJJ1UFBF\9F_'5Q5))/#PA[TU$IVY,KL21*:X&7.8VN<*!=$D(85,7L5
M;,4<78UL96!073"RC9EV#1E1SMR[[K2\N;++CM3HJ"D'.57H8U&J3L3DI!4E
M%L<\6KWJ5,57U-?$_=YC9LF=$[M-CH\U[TP0R+-4&KZ,V#X9\/BQN:^Y&^OU
MT*-UR3R+3<GFO-4_V?LI#(KQZZB-&0Z^DR-!KT@3N$7D=&W//5HO9"-$/J%5
M[=2:<(0A?03C&,8QC&,8QC&,8QC&,8QC&5<N:X;[@4J2LU9\P/-PQ\YF2KSY
M4BL6*Q9.0YG*5A*AG"V.A"E<(Q&0G3*#%1FBB3M+0 ("/V)HLH-97B2W3 +3
MBT.D?/ (8L;=&[EL'<+ 97=P?-2A G*A_HD[<Q'-D5V@5F:<U6E.U6UB-246
MMTUD:"J'<.'= ]1/DMCK)*.+)#$8ZYO*) ]RH=N0ET)CC:>=HM6]&MY"0DYP
M(;B_4I,2I3=*%)8-E)=#.&6$6.5]1)KB<<\0+I/G2<V93T!HMUB7&6G>.VU:
M[L2,^4772*GNR_E@Y=,) T,:ZI(')W:M:ZEC:C;G2GW.$7+,6UP*4.34I8^@
M!U%>]42&[J*Y*NUL)H^O;$\0F857-[!;7/H5?]C>4>4^,K6*JJ%S69RT:A\@
MJ#HZXK?A4E=G9TECPT,#8ZP*+/\ ''2/-CFP>MA?B#=B2N20VDYE>M%U*KMJ
M?4!)#.FY%42$J(5!&+=X;=^LUU-(8F^SYNBSZ]/LYC+K#*TD<UE"1[_)FBF
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MNR%(#VZDX9IYWL-J#O(L)AH@$DA+F5L9FIH;6]I0)2BD+6@1MJ(HT0U1A2-
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M1ZRKJE$/L=(T.;1/[+FKFMCBLTI@;%[W7U85M(IB-;.W>2F%[TXQC&4S[?\
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M*C==14S*YJ3XFG*RZ@X_:K+3/5?$'.<)ZKKVT8M><?K(ZP(A-T;36UV3FMI
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MOQ?%=NNEK4BU)Y<(95EUHX+JNLQ"I,#M>1+(<,+:8N5%[W[;6WI !(X[.,+
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MI)S#6$.DM+DSV;W PS-WD[E:$+;1LA\=@::/EC=F.1I$KRIV])!.>BPLH&Y
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MQ;%YZ$'>6)SR\UF<9KR*ODUF3N0PQ>.(#'-[>%1:DU.WH2A  8I-+1DJ%(P
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MK]19I?K *S%=,?V8@$'C6@^C4>B$98P@UK>O1II8T"#T^6][\O+V&]>7GO\
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M D+V$SUF.*)4)]U687A-(61G?D8#RDCTUMSLE+4A !06G<D9"X@!X"QF@"<
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M0]Z5)U!"M.0J2G%*4RDDI0G4$& .(/(. $PDXDTL0BS2C2Q!,+,+$(!@!!&
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M.#V "Q>H0NW$E3#/*4C(*$H) 862>( 1'%%F[#LT!9N];& !NP V:$(M!-V
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MF*9QUEE<8=$CU'I$V(WAF=40_:)5S<O) H2J"M[\A!T,L>O669H)I)FADF@
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M:(U <6Y"[MZYJ<TB=P;7-&J;W! K* >D6H5I!B96D5$&:$6<F4IS3"#RAA$
MPH8@"UO6]YF_23BX<@WD=RY*U2D=+6@N<Y'S1(G T1A3*ZJ505#_ %.L6'"W
MH)Q2I5HUC",S0CSS4Y@0C/D.RTVEN9P=%%&\T]$U]U<UZV3 + ,::;Z$3 +W
M[!,C6G!!"I^=H Q"]LSJ2BD"U2(H.@)4:9($7K<Q[UHX68 TL!A8P&%F!",
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M"V8!U G!HDK>UI8B_4D84^]-"3BE!11Y!I9Q)Q8#23B1A,*-*,#H99A1@-[
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MIQ4FG#\D4^G-:H7<F%S"<59MT5F062O;0I<&8\ED4B&J4Q2)&L2B^(.>><[
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MXGFBN:#:H/XG%S\+-7+%F2R2,=+#CSK7E<*4)$W4W+<<TB4A!:R(F1NS(2I
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MB\:V[&+W%,ECM9)1>SA[(J1*DKFUM8RDJK:)<2L6H&Y8K/0)M$<8QC*9]O\
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M[^\Q:U</).]:$+6M[YXM[6]ZUO>M;WK71@M:WO7S\M"%K7G\A;U\]\?9OO\
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M^=[CW'HBNAJJ'IVJ///IOXTG3C,PR=>H9?:N2(SV,8=MDI'#R'M+(?V;[_\
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MTI]A68NHJVM(;XG>:9E:*PI\)^0JH^AEK?#WR5-#:+2,6]!UO>_NUY_=\_\
M'>M:_OWO6M?7>]:UO>8UHO%S:IM*+)B=44P;(# ]&\Y\Y<Y2V96"GA$$O-3T
M+!I7-6JWESR5%9&OA%/$I8!-?L4[HFB922UT:&-K8A'@@GD7TJOOR-T>GZAJ
M(VP#6!OBDFC5D6_35AQEEDY<XCS)9=&6;**HGB2,38EH8"I=%C9#%5:^./\
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MHO*N+CBZJMZJC-5Q12@JDU^(AE>M]>,[J[,<3C+:RO!#,';$KULLAN)&C2)
M&;3%7="'T@"#6_\ M#H.M^7ZM>6M^7_ORS-B2\$2J2]2V5T<X7LF<@60W)80
MG:W^H6EYL&I*=.@B:&R:J: N/4W0/M.,\N<=O$_D+W%HZ!]>IV\:=9"I?43'
M'&UI[?D+@U7S/*HU+I-;_P"4UQKCG6)<IUD6S5LSU4D34]#7XF0-CA9J9ED,
MB)LZVE2M V@6SD((C'&XOX\.'U[%3YG+37:W5XUP_6U5<O@$5M";TQ*'Q&B,
MC=GUX>B*E,/?V9W;G]F<TZ9R(/;GEJ,<6I,AD\:<0!;Y7%ECU&EQR9*[&J"J
M'H^#+Y8!V)-X;V BBMSW+8DYF=L.J/G>/KJ/>FR5T]"*686>+T<X62:YQ5ZK
MJ/UW&Y!%I>LMB3+'N7+98HLALG49?$$78;Y433T5Y[I2HJ'@PW(R%TO6<%JJ
M)FO*DM8[FQROXPV15F-=%1)*8E0XG(&H@U:<0F3$#4C-V0G3D^S)+JUU/X<?
M/G5LC*G<NU/XM89TDYN7OLO@MJVS$3))$N:;J271$(.[QZ*S^/1<]$-V.E*%
MOD'PC<FB2J6N,IC#BBDZ%K7INOYAXIF_.]PV=:KI=[':*ZX)+-9-8K_(*-CK
M9<4O&]R1S?('&WZYR)FYO*B"4XUN>H;6T$0,#9%8_%D"-,W-:%P.=7%SO+-(
M='+#ATK@,P;M.\3F\:?HA)VG:M<@^)QZ3-2MD>V_WYK5(7-%[ZV+E27WMN6I
M%R?VOMDBI.H 6:#+P'A(5#$TG0B6J9@\-#;>9',S?J 70C>NH*7:XWS$A3MT
M6@4FK.Z)L^:F<#>T*9.WJTB&1PN8Q-K2-J&N9Q$ M3>81<_D7F.+\CTDST_&
M7 IZ&"33Z>RA^31MDAC>]SFT)L^3^8KF2%QDLJ/0N,%/;^H;8E#V;1R.,15O
M9F3WYT4(CW5;^?I&E+?M?[*N--= "HY^8FJPHV\%/%8,5NPF51ZQ(\F9E"AS
MB3G((<N3S&'+F] ^P&0I95IF0JAO#9+XC-F!Z/:R*00OPC856SI#HG!;65-O
M/+)-^-+5DU:N];1=ZLN2V9PS :^K^G'=NO4#FVN,8C;FAI^JG"=QXN#.[JM5
MQM[00R5P9@G4I:%FO_I\P^6]^>]>6_/?WBUO0M;WK7E_^K7GO6O+7W?+68_G
M^%(L+>2OLSTQ)ZXB]:3GI^W.7=5I6L8B]ETK:_54O5S>=O<ILXYZ=MW#$6UV
M?)@TMT&<HI$2I+$I6L9K.?9VXLT8?6:ZW,7-[Q12R[I?-+"16/9G0-I$6C/7
MB.0<%7P%M5M,"AU91QA@E=%RB;'1]K;HE!V83JO>9A*9')I$H=7IU>MDGM[6
MU^UZ9HY/TI1EAT4X2Y^A#)9S2CBTI>HT6E,=U,+5O36?-HP5I9_4%)9Q$DSS
M"713KS/2-,B7*DFMJR2=;JIU-X>:+I*;REY16X[5M!;GJ6LZ#Z3@35#VQW,L
MJGZDLZ1V;$&&$2?XRR*:J?U YS/H-)I!MJG*%UK^7+$+?'&24-C'+&_2'Y_K
MU_AO_P"^<XQC&,8QC&,8QC&,^:GO;Q".[N9^T+&*=7ANY_XPJT^B5$)M.1<?
M6!T-S99C#*2(WNXOZ3O35.S%[G?'\E9WU_7QF @<ZA-C@B&UAE+VY+F:0FJ4
M\Y\L>+;;$^MN4U5T#037%CI'XK_1'AXTV]P63H3R$C#3=13"W29#/T*M<\GK
MWU$U0XIK=G)C/:FE]6RQO4,[2W)V%R"NIATA_P 0W.9;Q?==O<8\N64HF59<
MS,UZ6-9$F>*B=81S<&P+JL.I*KW+(B_2I@DML?:0-32^3/J:O&9T+B,>5-9J
MS3BY <$2#4>N?%:BL\ZQ;N+!TO-6F\R.F>A*)F;.HD4<4)(=7U"TG!;N(Z+<
M!IBO>#JYL]CM6KVB$MX4Z=W&_P PTA5F!VT+/70WL+L_Q!8K=OBZ3"CN@*<@
M-3>%I3W/=T-=*6#S\VS<F\$LOH-[NJ=Q%[M1//(K)X:H>=Q5PC\;5LS<YJ2'
M!X;PEZU['0#9?>O'CBB3IEJYACO+-B3*82F'N!L,.CULTRO6O=KIN5U?5396
M;O$FY^=)1!B9%&T2B&L;_-4;.]J)@$/MX*2P>IX#=G@OQ*:V\0=UF@J>A,E1
MPB#TYRQ9#I/'=S9SVLR8]-5>=;VZB)1M^C#M2^JH<JBYD^4"4>YIW24(6U,5
MHU.>,6DN,8QC&,8QC&,8QC&,8QC&,8QC&,8QGS4][>(1W=S/VA8Q3J\-W/\
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3)E+JX'Z-5&[OXQC&,8QC&,__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g419522kw05i001.jpg
<TEXT>
begin 644 g419522kw05i001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" /: M # 2(  A$! Q$!_\0
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MBZH0&*98R%MQ"]AV[<5JT 0VO^K;_KH__H1I;B=;:%I9,[5ZX[>]):_ZMO\
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MG:?#I=C%9VWF>3%G;YDC2-R2>68DGK5J@"&U_P!2?]]__0C4U0VO^I/^^_\
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MSBGV*EM0\T0[ T"@L V#PN,9X Y/3TYI@7O^7\?]<C_.IZ@_Y?Q_UR/\ZGI
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MB?\ T8E>]T 8FMR117UKYA8))\K>6!GJ,=1Q]1S6W6=J%RMO(!-<0(I^95>
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M_P!Q/YM0 6WWI_\ KJ?Y"H5_Y!#?]<V_K4UM]Z?_ *ZG^0J%?^00W_7-OZT
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MPJZ*&VMSEMO&"#S^F.^:T(AB)!Z*.V* $GE\B"27:6V*6P.IJ*QNQ?6HF";
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ME.[)(QQ@[><<]^_2HM4NA8^&1/@D):,/EP.2 /4=SZUT#*&4JP!!Z@]Z
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MJ>B@""V^]/\ ]=3_ "%0K_R"&_ZYM_6KM% $$_\ J$_WT_\ 0A1-_P ?-O\
M[Q_]!-3T4 0?\O\ _P!LOZT0_P#'Q<?[P_\ 014]% %*6,S:9<(J%V8R84$
MD[CC&<4S2H98$"3\R^6I<D=6+,3W/K6A10 AK@?BAXANO#TWAZ:"]DM;>2^
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M)O[NC_G+_A6W10!B9\3?W='_ #E_PHSXF_NZ/^<O^%;=% &)GQ-_=T?\Y?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y]O\ DHL?_8*?
M_P!&K705S[?\E%C_ .P4_P#Z-6N@H *Y]?\ DHLG_8*3_P!&M705SZ_\E%D_
M[!2?^C6H Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MGV_Y*+'_ -@I_P#T:M=!7/M_R46/_L%/_P"C5KH* "N?7_DHLG_8*3_T:U=!
M7/K_ ,E%D_[!2?\ HUJ .@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH Y]O\ DHL?_8*?_P!&K705S[?\E%C_ .P4_P#Z-6N@H *Y]?\
MDHLG_8*3_P!&M705SZ_\E%D_[!2?^C6H Z"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#GV_Y*+'_ -@I_P#T:M=!7/M_R46/_L%/_P"C
M5KH* "N?7_DHLG_8*3_T:U=!7/K_ ,E%D_[!2?\ HUJ .@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH Y]O\ DHL?_8*?_P!&K705S[?\
ME%C_ .P4_P#Z-6N@H *Y]?\ DHLG_8*3_P!&M705SZ_\E%D_[!2?^C6H Z"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBD/% "T4F<#)Z4PS ?PL1ZXH&DV244U6#9QU'4&G4""BBB@
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MC_[!3_\ HU:Z"@ KGU_Y*+)_V"D_]&M705SZ_P#)19/^P4G_ *-:@#H****
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MN?\ GG#_ -]G_"C=<_\ /.'_ +[/^% $]0O_ ,?D7^X_\UI-US_SSA_[[/\
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M</\ WV?\*-US_P \X?\ OL_X4 3T5!NN?^></_?9_P *-US_ ,\X?^^S_A0
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M4_O4>:G]Z@!]%,\U/[U'FIZT /IIQYB\<X//Y4GF*>A)_"D,G[Q1S@@]C[4
M244PRH#@G!]Q1YJ?WJ 'T4SS4_O4>:G]Z@!]%,\U/[U'FI_>H ?13/-3^]1Y
MJ?WJ %? C;(R,'CUI1TICR 1,RYX&1P:7S% R<@?0T /HIGFI_>I!/$7*!P7
M R5'4#Z4 244SS4_O4>:G]Z@!]%,\U/[U'G(/XA0 ^BHUGB=0RN&4\@CD&E$
MBGH<X]!0 JXW/QCG\^!3JC63+.#G@X'!]!2^:G/S=* 'T4SS4_O4><A_BH ?
M13/.0?Q4N\>_Y&@!U%-WCW_(T;Q[_D: '4UL93(SS^7%&\>_Y&FM)@IC/)P>
M#Z&@"2BD!!&1TI: "FMC>G&3GKZ<4ZF,Q#H!T)Y_*@!]%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!S[?\E%C_[!3_\ HU:Z"N?;_DHL?_8*?_T:
MM=!0 5SZ_P#)19/^P4G_ *-:N@KGU_Y*+)_V"D_]&M0!OGD50> 3B)&NY[=H
M5*LD;A0WN>/;C%:%-9%?[R@X]10!65!<2!DDD"(NW>I^\?Z]*D^S'_GO-_WT
M/\*GHH @^S'_ )[S?]]#_"E6 K_RVE/U-344 4=0MC+ @6XFC82H59&Y'S#\
MQ[&K>SY0-S<=\\TRZ_U:?]=$_P#0A4U %&&W(U&Z<3R[&"_N]V5!QU'IGCCI
M5L1X/WW_ #J.+_C[G_X#_*IZ &A?F)W'GMVIOE?]-'_.I** &!, C<QSZFC9
M\H&YN.^>:?10!'Y7_31_SIQ3./F;CWZTZB@!ACR2=[#V!JK%;E-5EE$\I4Q+
MF,ME<Y//M5VH5_X_)/\ KFG\VH 9-'NR-S?>!Z]*2&(2KEV;(^E1WTDT;*;>
M$RR%@NW?M 'J?:I4:6,$+:X!_P!L4Q#+ZU5["==[KE#\RG!''8U)'; 1(&=G
M8* 6( )/K4=U+/\ 9)O]'_@;^,>E2++/M'^C]O\ GH*0Q_V=?[S4>0N<\TWS
M9_\ GW_\?%'FS_\ /O\ ^/B@!WV=?5J! H.<FF^;/_S[_P#CXH\V?_GW_P#'
MQ0 [R%QC)I/LZ@'#,,TQ[B6-&=X JJ,DF0<"HTU$28V(AR2 ?,'..M $L5OA
M"&8]3_.G_9U[$CZ5!%>.[O&L:O(ARP$@R,DX_P ^U2^;/_S[_P#CXH =]G7U
M)I?(7.>?I3/-G_Y]_P#Q\4>;/_S[_P#CXH 7[.OJWZ4H@4=S3?-G_P"??_Q\
M4>;/_P ^_P#X^* '>0I&,FF&V0N,LV0.*7S9_P#GW_\ 'Q3?-FWC_1N<?\]!
M0!D:E H\06)4A"'3#9ZY$F1^.!6O);%Y00[*,'H..U8E_-,_B:R6:W*1!H\/
MO!RV)<8]O7\*MZ]=RVUSIRPW:P&:?8RG/SCCI\IY^N.O6F(O_9".1(2>VX<5
M&T,J/MW(=P)Z'BIH[Q)6555QO&5)'!I) PE3D?=;K0F#1#]FE_YZ#]?2E%O+
MC&]>3UP<],U8PV>HZ^GM0H;CD=?3VIW"Q7^SRL -Z#Z \TGV:4X_>#G'K5A0
MW'([=O:@!N.1V[47 @2&1Y" R#:!Q@X.:7[',<YD7GT!J6$-YK\C[J]JG4Y4
M'U%#8)&+JJ266F27$T\8CBPQW*2",_6K=M);I:HA=SQG+1D$?ACBI[\.;*01
M$!^,$X]?>EO[F*TL99YV=8D7+,@R0/6DWH"6I%YML1GS7P?]D_X5@>*7L<VK
MG)GWA$(4ACD_3D#K[=:U[>>VDM;>:W\\PJ RMC@Y'&?P-9VM77VS3X9=NT^8
M%(R#R#SC':D,Z)H58]Q]*3[.N0<DX^E2T4 1^4NXG'X=JC,2@K@D[N^13I/F
M*GYMJGG%(H.001C<< C&!BE<I1*FF6\=O8NL4850S'&>^<G''%7/)7@!L$C\
M:K6.3:R@;1\QS^53L"=X.YB?NE>WXT7'RHHVT#1:E<1G+  $$8!.>>_Y59,1
M5Q@2_,3U9?2HHR/[6N SOG8O !JP^W>GS2]3V/I]*=R+6&F)@BX9^2.N#371
MC$VTNN.XVYITI"J@WRD[AP >:1P/+?\ >2'\#2*(KB)EFB0L^ULY!Q5M59OX
MVZ>M5KV,-"'+R[E8;<;AW JVJJ&(#'  [U70E[B881GYOUI65OE&[\J3 \H_
M.?SI2!N7YS^= A C$D;VX]Z1PY*/G[K<@=.]. &]OG/;O32/D&'/7IGK0 Y8
M\C[[]?6G*FTYW,?J:5/NTZD,9L^4C<W/?-,:(ET^=\ G//M4U-.=R\X]O6@!
M-GR@;F^N>:&3<?O,/H:?10 P1\_??\Z7;\Q.X_3M3J* (_*_Z:/^=(T.X8\V
M0>X-2T4 0?9C_P ]YO\ OH?X4?9C_P ]YO\ OH?X5/10!$D!1@WFRM[,>*EH
MHH **** "BBB@ HHHH Y]O\ DHL?_8*?_P!&K705S[?\E%C_ .P4_P#Z-6N@
MH *Y]?\ DHLG_8*3_P!&M705SZ_\E%D_[!2?^C6H Z"BBB@ HHHH **** (;
MK_5I_P!=$_\ 0A4U0W7^K3_KHG_H0J:@""+_ (^Y_P#@/\JGJ"+_ (^Y_P#@
M/\JGH **** "BBB@ HHHH *A7_C\D_ZYI_-JFJ%?^/R3_KFG\VH ;+_KE^H_
MF*L57D ,ZD^H_I5BFP(;O_CTF_ZYM_*I5^Z/I45TP^RSKD9\MCC\*E7[H^E(
M!:**:K*V=K X.#@]* '4444 -DC25=LBAE]",BFK!$C!EC0,"3D#UZU)10!!
M;01PHWE1JF6;.![FIZ:@ 4X.>3_.G4 %%%% "$[02>@JFE^=XWKQQD*C<9Z8
M./F_"KM1K!&C JIXZ#)P/H.U #1<QGM)^,;?X5 FI0RWDEM&)/-B&6W0N!TS
MPQ&#^!J)M4<W(\B%9K;RV9G60!D9>H(-27%]]GCB>YA=%D;: I!()Z9Q^-"
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M"6=N?.4;(D&P'.[Y5Z8X--UIT?3X?+D\Q0Z\X _0 8X]JZ4$,H(P01QBN?\
M$4*06L21+M4.O&:0SH:9(2J$@$GT%/I",C!H!%;SI-S?Z/(O(YR.?UI5D8[L
MVS]>^*D.0?N@DGCFL3Q(!):6\>XAFN0O&[@E3_=Y]_2I-;JVQ<TUCY<G^CEO
MWA]/EJ[YT@'%L_TRO^-9EG>I!:2R,)Q'O?YMHP<9[=>QK2ANEN(A+"PDCQG=
MTH02=WL9\$[#6+L$E/N\';Z"KSN/,C_TA>I]/2H( W]K710C!5201WQ5I_,\
MR/E.I['TJC-LBFD4%2+A"01D<>M1RD$,QGB).#U'%2L[A$&4&&''X_6EE=_*
M?F/_ !_6D5JB.[D5K8XG5N5X&.?F%61C>WR'MVJM>%F@?/ED?+G'^\*M#?O;
M[O:FB&-X\H_(?RI3C<OR'\J3YO*/W:<V[<OW>M,0@QO;Y#V[5&^-J?(?O'M]
M:E&_>WW>U,8$HN2!ACC]: )4^[3J:GW:=2&%1O\ ZR/ZG^524Q@-Z9."#P/7
MB@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S[?\E%C_[!3_\
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MC^I_E0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 <^W_)18_\
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MH **** "BBB@ HHHH Y]O^2BQ_\ 8*?_ -&K705S[?\ )18_^P4__HU:Z"@
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M9F+*2A!!X&1S0!-13-S;0=ASZ9%#,P/"$_C0 ^BF!WS_ *L_F*7)W$;>/7-
M#J*CWO\ \\S^8I&DD R(23Z;A0!+14'G3?\ /LW_ 'VM'G3?\^S?]]K0!/14
M222,P#0E!ZE@:EH **** "BBB@ HHHH Y]O^2BQ_]@I__1JUT%<^W_)18_\
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MTF93(^"$_P!H^]2,V:Y/P]GR9&\@N3.Y*D!B%PN.G&,8Q[5M?VW!_P \I_\
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M<=S[T +?0-_:"S;#M" ;LK_>],9[UHR=4^M4)BMS*\\4^5CQ&\8)^]N[C/\
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M?;_DHL?_ &"G_P#1JUT% !7/K_R463_L%)_Z-:N@KGU_Y*+)_P!@I/\ T:U
M'04444 %%%% !1110!#=?ZM/^NB?^A"IJANO]6G_ %T3_P!"%34 01?\?<__
M  '^53U!%_Q]S_\  ?Y5/0 4444 %%%% !1110 5"O\ Q^2?]<T_FU35"O\
MQ^2?]<T_FU %;4%W;><#S(S_ ./K4]UTB_ZZ"HK[HO\ UTC_ /0UJ:ZZ1?\
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MQES.!F0\*-R\^_TJW-IUTUJR07:QRE@Y)3<I.<D8)Z'VJ'6@?M&GYY/G#/\
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M 3FFH&!7/RAB2!CH,4[(GGE;<H:=;0&W??$^!(V.O J[]BM<XV'/H6/^-0V
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MU:T^D,*:=VY<=.].J-_]9']3_*@"2BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH Y]O\ DHL?_8*?_P!&K705S[?\E%C_ .P4_P#Z-6N@H *Y]?\
MDHLG_8*3_P!&M705SZ_\E%D_[!2?^C6H Z"BBB@ HHHH @NON1_]=$_G4]07
M7W(_^NB?SJ>@"&Z_U:?]=$_]"%35#=?ZM/\ KHG_ *$*FH @B_X^Y_\ @/\
M*IZ@B_X^Y_\ @/\ *IZ (+W_ (\Y/I2P_P"NN/\ ?'_H(I+W_CSD^E+#_KKC
M_?'_ *"* $N_]0/]]/\ T(5/4%W_ *@?[Z?^A"IZ "BBB@ J%?\ C\D_ZYI_
M-JFJ%?\ C\D_ZYI_-J *VH'&T\G]Y&/_ !]:L772+_KJM0:AG"[>OFQ_^AK4
M]UTB_P"NJTV MW_QZ3?]<V_E4J_='TJ*[_X])O\ KFW\JE7[H^E("&UZ2_\
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M",6SM5TK2[V[+-/M9Y0DG #*,']5/] *SX-0-_#9W4NR-WF+,F[[G[R+K77
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M0MG.2,UFW,@_LUEE P+D=3G_ );"@"SHTF=&M3_$(0<5*T(NQ&9XD( R,L2
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M.T =1USW!Z_A0E<&RW9:7-::IJEW=D&&5P\.QSN'7/IZTS6[N'2K K.9_-N
MP3RV.$;U)SZD<FII+&=Y+<_VJZA9 [*!D.!SM.2>/UJ35-/AU*'R[B>)NJJP
M7E,]QSUX% R/4;Z&QU&%KII!$T;C*-@ Y!R>?0&I;S3Y;J]M&^T,GD$N&&<N
M.,@X(!].?7VJF-#7<TE_J)O@$"JDP& >YZ]36A>0/<(I34# R$G=&%R1CISG
M_(I 3P6C1/&S.I"+M&U,9Z=>?:L&_D6#7KN=H5E,0B*JWJ2H_K5\:?<,H/\
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M)!&7E;:HZF@"2H+L9C3VE3_T(4QM0MU1'RY5_NX0G/Z5%>76[;''%+)(KJV
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MX"Y8C&>M7: (I4&QR <D>M(D*[WX;D\?,?05(^=IVG![4#.6R<C/'M0!#)&
M<*#R5SR?6I3&NW!S@>YIL@)D&#@\?UIQ^<X_A'7WH 8L*,=Q!]AN-2%%..O'
M3FEQR#W%% $;Q*6WX.>^">:CBC07CLN?]6O<^K5.[+&C.QPJC)/H*KQ%1=N4
M.49%P<]\M0 R[>WA(\\D;V^4 ,23CT%4]'@1GGWJ<\'G(ZLW:KUS!%-,OG1)
M)@C&]0<=*GAMX;<$0Q)&"<G8H&:J^EB;:D5U!&+*<;>-C?RJ001LB@KT%0WE
MS$JR6[-B1XF90?XN#TJTOW1]*DHC^S1?W?U-.\E-P;:,BGU7M(KF)6%S<+/S
M\I$>P@>_)R??B@!YMXB<[?U-.6-5.1G\S5.#5%GU>YL!#(K0*&,AQM;..!],
M\U?H 9Y2[2O.#[FL76XH!?Z;YL7F*TA4@D]\5NUCZYY@NM-,/+^=C'MW_2FM
MQ/8L"TA60E8U"(< XY7\?2IGMXU^;JS<#:HRU.60*TAQDEL #O0B& [WP0>N
M/X/I[4[@95^US:6T[1D(=ZJK[20JD?-T_P .N*?+<2"(K'*SS @!&4'(SCZY
MJ/6+:XN(+U;&9EN&9& 3.5P/J.OUIUQ$L86.0QQ3. 0YR6 ]"?K_ (T=1=#1
MC1@%WN1N'!'3Z5(RF,8#L2W11WI(FS;QHH#ML&3V'%.53!R<NIZGN/\ ZU(9
M!=+MTZ;S5$NP9VY(!]JL+$A4'GD?WC39][6LWDGYR#L/OCBI(L^4F[KM&:.@
M%:_N5LK<2LFY$!+$O@* ,D^_2N>N]2@U:6)+;:))WVJS.=A(!![9SS^E=3/"
ML\11OPXSS6=<26VF*LUQ8H-A)#PQ@G/<@=1QUIQ?837<ISW5S%XCF@,K):I
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M%%% !1110 4444 <^W_)18_^P4__ *-6N@KGV_Y*+'_V"G_]&K704 %<^O\
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M'K4EE(/LMJH())/0_6A!+<O)]Q?I3J:GW%^E.H$%%%% !1110 4444 %%%%
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M?\L_;ZU(L=QM'[].G_//_P"O2 L45!Y=Q_SW3_OW_P#7H\NX_P">Z?\ ?O\
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MH **** "BBB@ HHHH **** "BBB@ HHHH Y]O^2BQ_\ 8*?_ -&K705S[?\
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M F/ZU+0 4444 %%%% !1110!S[?\E%C_ .P4_P#Z-6N@KGV_Y*+'_P!@I_\
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MN,94=,]"1Z>F:!M&A9?\>D?TJ23[T?\ O?T-5K1F%LG/S8X7UYJ20G>H9MK
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M#S,7,6TQ-E/+]CSUJX!+L3#H"!\V5Z_3GB@!OVN+_II_WZ;_  H^UQ?]-/\
MOTW^%28?S"=R[/3;S^>:0++L8%T+=CLX'X9H 9]KB_Z:?]^F_P *:]_!& 79
MU#$*,QMR3T'2I2)<+AT!'WODZ_3GBN?\7:G<:<-.$/ED3WD2?,IR/F'O]: -
M+5M5^Q:9//!M\U%^03*RIGW)Q@59T^X:[TZVN'V[I8U<[1@9([>U9&HWAOM*
MWL&C0_.O[LEE(SCY<C=VZ$4EE=F2VM]V_P QT1@P=L#A?3C\/>JE%Q=F!LS$
M& 8&/WJ_^ABJ7B#_ (\D_P!YO_1;U<E_X]Q_UU'_ *&*I^(/^/)/]YO_ $6]
M2 EN5,P"W'F'>N8]H&P[3[9/XUS^CW5W%8:=;V<X$7VIED!&#(F5/&3Q][M_
M6NG6".-;=T7#2,I8YZ_*:SM%TTW-KG4)9KB6"X9HY&D?I\I'4#/3N,9S0!9T
MZ0M<H#&4PI&[GY^!SSUK5;''UX/I6,MA/'/!LU:=VBEV;"B;0I7H1C/0#G-6
MKP^68DGOA&CDD[]@R!VY^M "Z@SW-C-':QO,Q'RXP%)!]3]*FTV*2#3H(YEV
MR!!N7.<'TS6?_;VW5%M%BC:WR!]I\Y<=/3Z\5L@@@$'(/0B@".XWB%F0C*@G
MGZ54N=0CT^UCN;V2*.,@*7.<98@ ?B2*O.N^-ESC<"*P-<BO(8%9[F%[93&!
M$("&)#KSNW?3C% %MC=2Z['+#+ ;()B0!_FW<]1W'3]:UJRM)1>4VA65.5'\
M.68BKJ3()&19%;8?F ()7Z^E $5EYF/W@YW28^F1BLO0[ 2VL@>W>VV2'$<J
MEO3G+$^G:KUFRI'(RNKJ9&.[!XR>F:F3SY%S'*HSG W=/TJFM24R81^3#%&"
M3M(&3WJC9PQ1VMN\)<AY>K$^_;H*EFDE@VR331E%;G_.*J'4[:UM+'SCY0DF
MP JD@<G'X$_SHMH%]1^FZ?>QW-R]VT<8,A,1@QR#Z@CKTK5BC$,80$G&>3U/
M>DCFCE9E1P2APP[@TYG5/OL%SZG%2417FW[%/NSM\MLX],4D(!L$"+N'E# /
M?BDO9HQ93_,A/EMA<]>*+6>(VL1WQCY!P#TXI]!=3)T.R)L09;:2S99,")E4
MX]^<_G6K&@B+HI.%P!G_ ':F,T./FDCQ[L*J_:+;S9/WL7)&/F'I0@99SSU[
M_P!*:<D#'48(_*HA<VN<B:'(/7</2E%W;Y!\^+''\8]*=@N6@00".AI:KP7$
M)7:LJ$#'1A4OG1_\]$_[Z%*P[C+?_EI_O?T%357MW4>9\R\MZ^PJ1IHU',B#
MZFAB*]JF;Z[FXP2J#!ST'_UZ?)9(\P?H.XQ_(]L]_6F:8J"V+1EBLCE\MUYY
MJY0]P1C>+ !X2U,#@"W;^56;41RQ6.0KKY!QT/91_C4?B0 ^'KT$ @Q\@_6H
M-$A$+K@OAE)PR%<' Z9/(I#+FI:K#I36B212-]IE$*>6!\I/K[5<D.% ]3U]
M*P_$SA9],!7.^X"9R!Z?GTZ?X5=M;EIID5G=@<APVW'3/&!F@:W(-1)^U@,1
MGRF'0$$8.3^''YTM@5^V1)%++Y2P@@  1MGV[$5/>-,ET!%L""%B25SM/:HK
M*=OM\4>U,O!O9MA4]>/;\* ;+5HV+9&';@KW/-22N&92>@;CW.*+)1]FC;'.
M.OXU)( 7C)'(;^AI#NA9&'E\@\_I3!(4!4C)'0CO4O6@ *  , 4P35AD9PQ&
M<GJ2*K1<VD8]2W/XFK@ '08JG%_QZQ?[S?S-");N6T^X/I3J:GW!]*=0 444
M4 %%%% !1110 4444 %%%% !1110 4444 <^W_)18_\ L%/_ .C5KH*Y]O\
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M5*@$=A0)+38BF>Y5X_)".,Y8$XR.WZTV$!K:($9!8_S--N+/[3L7S3$R-O\
MDIT+ 00DD ;S_,TT*1:C_P!6OTIU-C_U:_2G4""BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#GV_Y*+'_ -@I_P#T:M=!7/M_R46/_L%/_P"C5KH* "N?
M7_DHLG_8*3_T:U=!7/K_ ,E%D_[!2?\ HUJ .@HHHH **** (Y>B_P"\/YU)
M3'( &1GD4^@"&Z_U:?\ 71/_ $(5-4-U_JT_ZZ)_Z$*FH @B_P"/N?\ X#_*
MIZ@B_P"/N?\ X#_*IZ (KG_CVD_W:(OO2?[W]*6?'D/NZ8YQ1'C+X'.[GWH
M67[G_ A_,4^FR8"\C(R/YTZ@ HHHH *A7_C\D_ZYI_-JFJ%?^/R3_KFG\VH
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M/N#Z4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y]O^2BQ_P#8*?\
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MMV["X^;@<=O;DU8.G0F*.(%PD?8-U^M-"DVW=DOVE/[DO_?IO\*/M2?W9?\
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M3CDBJNI07E_,T:VQCR%"AN3@9.<YQCFIM8C1-=TW8BK\IZ#'_+:"MT_ZY?\
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MK3_KHG_H0J:@""+_ (^Y_P#@/\JGJ"+_ (^Y_P#@/\JGH CG&Z!P3C(ZFB,
M%SGDMS[43X\A]V2,<XHC(R^!SNY]Z '2 %>3@9'\Z=39" OS#(R/YTZ@ HHH
MH BNE5[297^Z4(.?3%5-*(*DARX*+R<^K<<\U=F+B"0Q\OM.WZ]JJV/F^8_G
MKMD"*",?[3>YH ;J6?L\V/\ GFW_ *":YS3)4BGU=T*1MM59"1G(\O.2 <Y[
M?XFNBU3/V>;TV-_*L"S5;BYU% KNR0)N5E"KMV'HV3G\A3$:LQ^TN)RN\)&R
MK(D>!@KGN<CKZ5IQ_P#'V_\ UR3^;50>UN8D9EPD(5LIOSQM/M]*OQ_\?;_]
M<D_FU(9QWB3_ )"\WREL7,!P#C^$5U=Y.WV27_1I?N]?E_QKDO$^X:G<LL32
ME)X7V*<$X7/6K-WXTF:VD5-%N6.,8\U>?I0!TMTHO+=H9;>?:<'Y2H/!SZT^
M)S#$D:6TVU%"C)!.![YKG/\ A.'PV-'N3CTD3FE/C>09_P")-<G'_31>: .@
M&H(6"B*7)..W7ZYKD;)&N_%=\R22P 7HR!C)(0CGKQD?C3U\3%+IIAIFH$<?
MN_.39UR,#ZFH_#C/-KUU<20M#Y]YY@4G/!5^_P"%5)1^R!TUK+=VI$,T<]P[
M,6>5L #G  QQC%7%N)-JEH&!9]N!V&2,_ES4L7W3_O'^9I]2 4444 %%%% !
M4$W_ !]6_P!6_E4]03?\?5O]6_E0!DZU_P AS3?]UO\ T=!6V<[A_=P<UB:U
M_P AS3?]UO\ T=!6T?\ 7+_NG^E '/:@H;Q02&;*6VXC+8/WAVX[]^>*N6JF
M>56:)8RK [#N'<\@9_G5J?2+>XU 7CEQ*(_+!!'3GVSW_E3I--CFFCDD>1F0
M@@G';MTH K:@,^&9 >081_2M&W_X]XO]P?RK.U#_ )%J3_KD/Z5HP?\ 'O'_
M +H_E0!)1158Q/N'[^49SQQ_A0-*Y9HJL(V! :YD'&>=O^%,8E9D47+%6SDD
MKQZ=J5RE"_4MMG:=OWL<45!(A,3XG<_*>F/\*7RW!7]](1CGI_A1<7+YD]%9
M^IZDVE6T3F$SEFVG#A<<$YY^E79 60A20?4=:8NH^BJWE298"XE//^SQ^E 0
M_-FZD'/^SQ^E*Y7(NY/M7<6VC)ZG%*%5?N@#Z"JL3%G<&Y;"M@=.>/I4HB8C
MB=S[\?X47!QMU)JA?_C\B_W'_FM(J/NYE<X;H<=/RI7_ ./R+_<?^:TR6K$@
MSEL],\4ZJIB+2R$RRKEQ@*W'04IBP1NEE&3_ 'J5RN5=RS15.0^7)#Y<LC;I
M ""<\8-7*$Q2C8AN_P#CTF_W#_*L+4G:/P=;,@8MMBQM)W=NF.<_2MR\(6RF
M). $))_"JVF)%<Z):HP213"F58!AT':F25+<',31RI]G#* @?K\PQQ]*O7BR
M.T2QJC%9 6!8C ]>.M6A%&""(TR.AQ4%U9+=O$S,5\M@PQW(Z4#0EE+FT0JI
M; [8I9R6967[I'7VI+.+_1$P3]W%%T-OE@=N*%N$K6T+$?\ JUI],B_U:T^@
M04T[MRXZ=Z=4;_ZR/ZG^5 $E%%% !1110 4444 %%%% !1110 4444 %%%%
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M %:T^F1_ZL4^D 4QERZ'/0_TI],;&],]<\?E0 ^BBB@ HHHH **** "BBB@
MHHHH ***0D#&2!G@4 +1110 4444 <^W_)18_P#L%/\ ^C5KH*Y]O^2BQ_\
M8*?_ -&K704 %<^O_)19/^P4G_HUJZ"N?7_DHLG_ &"D_P#1K4 =!1110 44
M44 ,D) 7!_B I],D4L!CLP-/H ANO]6G_71/_0A3KAF2WD:-=[A20N.I]*;=
M?ZM/^NB?^A"IJ *.FN[^89(3"^%!0]NM7J@B_P"/N?\ X#_*IZ (YV*P.1U
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MH **** .?;_DHL?_ &"G_P#1JUT%<^W_ "46/_L%/_Z-6N@H *Y]?^2BR?\
M8*3_ -&M705SZ_\ )19/^P4G_HUJ .@HHHH **** &N 0,G'(IU1R]%_WA_.
MI* (;K_5I_UT3_T(5-4-U_JT_P"NB?\ H0J:@""+_C[G_P" _P JGJ"+_C[G
M_P" _P JGH CF&87YV\=:(OX^>2W(]*2Y_X]I/\ =HB^])_O?TH >X!7DXY'
M/XTZF2_<_P"!#^8I] !1110 C,$4L>@&35:VN(KJ9Y87#HT:8(/NU6) 6C8
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MP.M-0'*E<;03M'3 Q3!<@,1LD7/<XI%GC.,QMDD^E(NUD/7)^T #^+GGV%#
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MKDG/M^M("ZHP,=:6BB@ IC %TR<$'@>O%/IC$;TR,DG@^G% #Z*** "BBB@
MHHHH **** "BBB@!*YK5=1^V7NBK]EGA!OT96D &1L?T/'7O[^E=*>E<3/J$
MVHZGHDCR3/&+T<&$H@/ED]>A.21^!]: .WHHHH **** .?;_ )*+'_V"G_\
M1JUT%<^W_)18_P#L%/\ ^C5KH* "N?7_ )*+)_V"D_\ 1K5T%<^O_)19/^P4
MG_HUJ .@HHHH **** &2]%_WA_.GTQUW <XP0:?0 4444 %%%% $%[_QYR?2
MI$^_)]?Z"H+V0>2T?4D9;'\(]:L*N&<YZG^E "2_<_$?SI]-==RXSCD?SIU
M!1110 4444 ,E^Z/]X?SI]-8D 8&>13J "BBB@ HHHH **** "BBB@!D7W3_
M +S?S-/IJDD<C')_G3J "BBB@ HHHH **** "F'_ %R_[I_I3Z:2=XXXP>:
M'4444 %%%% !1110 4444 ,E_P!2_P#NFG#H*1\A&P,G'3UI10 M%%% !111
M0 4444 %%%% #$^])_O?T%/IJDY;C'/Y\4Z@ HHHH **** "BBB@ IDGWH_]
M[^AI]-8G*X&>?RH =1110 5&_P#K(_J?Y5)36)W+QD=SZ4 .HHHH **** "B
MBB@ HHHH **** $/3CK7$W*RQZUHQN;0Q7$MX"\CR*Q?$9Z8)&-Q;L.,5V]<
MC?R63:QIJVD C=+^/=BVV8^23(+8P2>..M '74444 %%%% '/M_R46/_ +!3
M_P#HU:Z"N?;_ )*+'_V"G_\ 1JUT% !7/K_R463_ +!2?^C6KH*Y]?\ DHLG
M_8*3_P!&M0!T%%%% !1110!5ODN'CC6VDCC/F+N9UW8'L/7ZU)LN/^>T7_?L
M_P#Q5+.VU4XZNH_6I: (=EQ_SVB_[]G_ .*J#SY_/>(,"$4%G\DX^GWJNT4
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M10!5MWN9X%D+HFX9VF,Y'ZU)LN/^>T7_ '[/_P 54U% $.RX_P">T7_?L_\
MQ5&RX_Y[1?\ ?L__ !5344 4H$OC+.9;B';NPBK$>!@>_6I]EQ_SVB_[]G_X
MJG1MF28>CX_\=%24 0[+C_GM%_W[/_Q5&RX_Y[1?]^S_ /%5-10!2EFGBGCB
MW!V?/W8C@#_OJFP7-Q/<R1*54)_&T1 /TYJ_10!#LN/^>T7_ '[/_P 51LN/
M^>T7_?L__%5-10!#LN/^>T7_ '[/_P 54%PE^9(!%<0HA?\ >'RB21CH.>]7
M:BE;:\(_O/C]#0 FRX_Y[1?]^S_\557[9-LF8<K$<9\D_-].:T** *L+7$T2
MR;U3=_"T1!'_ (]39%O?M4 $\(AR3(!&=S<< <U<J*1L30C'WB?Y&@"6BBB@
M HHHH **** "BBB@ HHHH *X'[/:V^NZ;]DN(KA'OEYBB\M8R%?(('RY)/UX
M-=Z>AKA89K9[O3$LWGV+J$>Y)9(VP?*;& O/W<9SWR.30!W=%%% !1110!S[
M?\E%C_[!3_\ HU:Z"N?;_DHL?_8*?_T:M=!0 5SZ_P#)19/^P4G_ *-:N@KG
MU_Y*+)_V"D_]&M0!T%%%% !1110!2U.!YXH56>2$"9"WEXRPSTR>E3^2_P#S
M\R_DO^%)=?<C_P"NB?SJ>@"'R7_Y^9?R7_"CR7_Y^9?R7_"IJ* (?)?_ )^9
M?R7_  J"2%_M<'^D2]&[+[>U7:@E_P"/R#Z-_2@!?)?_ )^9?R7_  JE#]I^
MV7@W3>6C AODRQVC../I6G4,/^NN/]\?^@B@"F5N9;3=/)+&WF)A<+TW#VJY
MY+_\_,OY+_A27?\ J!_OI_Z$*GH A\E_^?F7\E_PH\E_^?F7\E_PJ:B@"'R7
M_P"?F7\E_P */)?_ )^9?R7_  J:B@"A?6LDD"*+R=!YJ9VA<D;AQG'%7ZAN
M?]6O_71/_0A4U !1110 4444 %%%% !1110!#;?ZH_\ 71__ $(U-4-M_JC_
M -='_P#0C4U !1110 4444 %%%% !4+_ /'Y%_N/_-:FJ%_^/R+_ ''_ )K0
M!-1110 4444 %%%% !1110!#=_\ 'I-_US;^52K]T?2HKO\ X])O^N;?RJ5?
MNCZ4 +1110 4444 %%%% !1110!##_K;C_KH/_05J:H8?];<?]=!_P"@K4U
M!1110 4444 %%%% !4,_^LM_^NG_ +*U35#/_K+?_KI_[*U $U%%% !4$W_'
MQ;_[Q_\ 034]03?\?%O_ +Q_]!- $]%%% !1110 4444 %%%% !1110 AZ'K
M^%<+\O\ :6BD"+F[7!CQO(VO_KO]O_[*NZKC[H7<FHZ1)?+.LJ7Z* SQ%.8V
M)X3G.0<9[#WH [&BBB@ HHHH Y]O^2BQ_P#8*?\ ]&K705S[?\E%C_[!3_\
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M!0SDAE.1R20#^=6:SXUN8[=X;R:*>20G9L0J>2>O)X&>OM6A0 4444 %%%%
M!1110 C,$4LQP ,DU6+3/,DJP_(JD8+88YQV_#UJ6X!:$X7<00<>N#FL^2VN
MY;LW$6HHMH6#%"AR -F1G=@?=/;^(T :<<BR(&7./?J*=4-N=P=P,*[97Z8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2?\ HUJZ"N?7_DHLG_8*3_T:U '04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %4+W0]+U&837NGVL\H&-\D0)QZ$]Q5^B@!D<:0QK'$BI&@PJJ, #T I]%%
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g471160.jpg
<TEXT>
begin 644 g471160.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!!1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?1DE'55)%7S$Y7S1#7TQ)3D4N15!3_]L
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MO+E@)*,.$(S6BRQCZ!W%V5%9V/"HK,Q^Y5!)/[@#GM7@EM3P5H$,D]B:."%
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M^YCX^7N!S^3YYXD;WY[<B(@@UX#'V!]?;;X:2HE77)#(DBD".WV'E-1G*_\
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M+.'E1,&5@CCU,VR 2N=S-V3+Q3)-(&*'(1M[?&%[W(8-6YKRAY ;JML;W!9
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M=1;WBKD@QGVRJQ/PG_=/P08'(N1:>P("FD+=ORHV84;.5F+-Z7!?"20[0&Z
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M&1XHHD<+,>3PT<\MA53VZH0W'+DG3V++'KM'4CGV)'PMK86JMM3'4KW[MZ:
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MKFQGMZU0,[>J8]V! %GH,5B(G9TE7R2^1N&"JGLOB"<A63ES( %#(\=XEO\
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M;K 6Z$L+,4^'^:>2FEL ZJ?#)+\PYEHD^EY_A)2RDX/&6!.,[B<HLD/>[I(
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M9%8J)%202Q1[4QC&6&<AC&,8QC->6Q5D*NNNI;5MAM!;W#YHT'L[PA&+91P
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M:D;,ZR0Q:Z* E)'M:L<7/5FEEB4&*!I^9&[A65>BA6(/N2Q+.%3A5) 8L?H
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MZLZ[B4C7I'60Q>"Q&./SH@ :6A<GECCS<UNB]$ \H@X"18N2'J$P32"3 DF
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M*Q#%8@D2:">*.:&:-@\<L4JAXY(W4D,CHRLK D,I!!X.?B8G(-+,*-(),*-
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MN<E0C\#?A ,RZU44(OU=A;JVKE#36:NSOUZH0^6NMN"DD5D.Z#X.>U=K5[3
MEXHI3-&KR1HC44LEF2EMM-1MZBCL/46EW.KHW-N75*\]76V=^\NNDCCD9-RM
M726#JD*B.U;\=*=XX+,DB[MX7PRI:J*DU"PR(:3V#QRA=.539ED'-C42HGKB
MZ1%19Y?A.I!PGAQ3(G:;/SL<%U3)RT[A(E&D1JS0CS"YV9'^C'2H).ZWC+*M
M9%3>ZK+KD\6M1V5I%R44DLFMVMB@CJX(QJU:HA6V(6YF;&9*J;-)4!AR!9WD
MI:_2X1D@,KOBK%^2Q>M3QV;%ZY=N33Q\=97M6YIRY( #2$./,_'SR]V]^<L-
MC1J:N:MJZ5.]KZVKU.CUBTM@2;->37Z:A4L(%9G,=4V89GHP%OR%)J\/"].H
MQ^5RJ/0>-/TPECNB88S&&AP?7YY<3@IT+8TM:8Q6N6JCA>@"B""ACWTUL0M]
MT  B,&$(O@5;:$&N> 1:SZW?DTEA4Q:RG9B=TQ9Y&CTXQ#*.(4I%19*QO<4*
MHH]"YMBXDA<VKTZA$L()4$F UB7(>K8'<5032$V0PZDT44-*IV5,AKF\-J1:
MM84RAV:=KMLS@W'+4R1R3)EVD*HTU":I3)S3TYHB"M@TKV>U6P2LN)-(&P9C
M]@_9 K&NK'EQ13F\K4KK-I1!H^ID,@ C<W%:E;5;RI"%0O*:24*,]1K1XDWB
M_P +-)IK0V45<)!\&].:9G+R?$B>.6%  G0Q>+K(.>7#ECR. G#W46MT3^C+
MNW>SMAZCK^HJ&OAK+6IG2MK+5"]8=Y+!M"\+WGJ,1UK?#I$JH?*]@R59K9Q&
M'O!V'?7H+73?06P[Z;]!=!!WK>M]-[Z;UO6];Z;UO6]:WKEG@77IOIZ[Z;Z:
M^GIF]G+9'#B/6,VIGC[ *OL)P1NLFA>I2SC<D3JN>B5C$&:R-5$3A.#BG3K3
M%/NFJ90+"5&CS$BH!R3:Q;X'FC9(9'#CS$[2B*V_T]E+%KB@?>1,]EM7*E\A
MT^F!K"3-,5<6A G)\PI&P(&E]%(VM"Q&;(VE)2Z4%)22%97>D?FK24)4@C6.
M6)8HUA5)N3*%A_)*7) [%E0-VXX8$,.00<N_4DKV-]M;DMNG=EV%R3936=>
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MU<)5+'M M?3QKCCEIABX1BPXQ2,T>^O'_E&DL-KU7Q4F=G2Z;AX^$,]^M;+
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M9(6G0M"V$JI&6;WHA]>X+IK0M]T70._@+?3?36_HWOTWG4QE$14%=M&&PE7
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M!:=HO9:1$E4*U BTY!I@+!0?#?YYG]8+,-KB;MUFU_"K#:43FVM<XBS#+&Y
M[A1%N:-$_-R9T2IEHFM>Z-1QY1*D 1J6EU=&A9K6E+6YN+<<G6'YKC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,A=R_P"6#KQJ20]'$ZZ3V5+9,SVQ.E+4[2_4%9&R
MMJ(@9MB6:Z^\ 8]*CE$J-:A-;'!HYMG(;GR2/2?;_(HO'T#H])YHYI"\>.=/
M<C65D8+?B6Y,W1]S7.;9M*_26+KRP/+$YQ63,BEVB3PQNJ^)S2)O3O$YU#EZ
MQ3%IM&'-:PRAI=&T[:?3&0[H'M%"+<L=BKF=5<=1;G*79Z51D-GRG48<)!#W
M0M."H=1YED3"QN$GG]CJ2Y 9[MQLMTC")GBCR\L$WEB<2("C.^4%TU37/(7B
M4EG,]C474-$LLJ3N9+PX 2F(6!TI.R(ZVNR@.PBV6B7/HM-28[?H:M_S(-"%
MUUK<C]Q$X]R6=L-E.]>(SYG&YPRV"U/!+J_(ME/L:9X6SQQ&<B1.B= KBT?^
MQS!'MDA:E*;$FR615HEZ-F*DA)CF=NUXAL9?WR)21W:25KW!7!T=8FX&&J0&
MLS@],+C&'-2G 2>62:-6PNK@W#TK*4  4I&,H #PEF@BP)' X'NI]_N# G^&
M9! /OS]"/;](X_3D?OMW>)O^_P!K7_GX?_ S2JSM"J8*Y#Q^"IK7JTRH5E,R
MN6N\QTX*S%*2Q&^;1=FCT;VY@.TW)B5\=6R!R\@>@$M5F(M'D*BR4PR3[$-]
M-:WO?>Z:UO>^FQ;WZ>OIK6^N]_1KXY"FM^0U-V;R@D\59H',D$X:(]:L!C-M
M/"5N30^QD-"6+$8_><1B(").J?R3:OLR<QQI=%DIAT<325>:ZGP9UDS1'WD]
M'YRI*X0)*(^LL;L0G/=$8,\?NWL) "I/U /Z/?>HVJE5K+6:*W1-1MUH5DEZ
M"O9L0F.&ZO$;%WJN?-&A*AF4!F YYS#[=WB;_O\ :U_Y^'_P,_,'.+B.8,TL
MOD'6!AA @@4%ER,H9B<9@ FE@4%A*V,@9A0P'%@-" 1A(P&@T(L01;E5OIK7
M7?7]>_U:]?COX:U\N\B[QWM^E+DF/)9RJ-J>"W.#W.AK6S)8X-ZM TSV8QNK
M:_7I9##5"E>H"_1)!&7UEBJ.2HD3<UO#I'W<;7IT;R4SVX^GS>WNOZ?E/^GS
M?\_=[Z7R_<W^8?H_L_K_ -,_/[=WB;_O]K7_ )^'_P #.!?.+B.<'8R>0=7G
M@T,PK8R)(2<#1I)@BCBMC**&'1I!H!DG%;WH9)H!E&!"8 0=;]GLR9ZY@TRL
M&0%.A[%!8I(IB]$LC8L?'DYIB[,M?7(IH94 #5[NYF(D!X6]K1%&*UZO9*1,
M6,XT =QSX4WK4'(>F3[!I2.K(Q$U%AV*2Y-I[[#Y8D,F:^2J93,W1IF==36Q
M*^EK>\OLF4NHG:&31\9TSBK<6$T38[LKHS-SYOO7_*?T?VOU_P"F/E^YOL_K
M#]_]7_#_ /7O]$7-[B6'6Q"O^M A#K8A"%( !"$(==1"$+9&M!"'6M[$+>]:
M#K6][WK6M[SB7SAXDFEEFD\@JQ.)-  THXF1%&DFE&!T,LTHTLH19I1@-Z&6
M86(0!@%H0!;#O6]_>Y!\@:ZI'=91VP8_8,@(O*?HZB9P0J#2*6-S>XR)N7["
MJF#HTDZ0QIH5Z* SMVE*S3[)'US;F&(,[\\'B3$8[Q+O*$VY#7V)1.L+$I55
M1:Z*5D\U79:!E32.&)3ZWATVA#:K41>5SAD+5&5Y*8LJ7Q]7)1S&**SQLTU9
MV=X+"6I?-]Z_Y3^C^U^O]7M]<?+]S?YA_P#7]?\ P>_,WG'Q'(+$:HY"5>G)
M!TV,Y1)"2"2]"$$ =F''% +!H0Q! '8Q:[PQ!!KJ(0=;_3[=WB;_ +_:UUO7
MIO6WX.MZWKTWK>MD==;UOTWK?PWFL>8W+7CA3 CJGOZ-SI]:I+5LMM$X2"*.
M9<'6I:_EM?-35#3+ <'*,Q4NP)5,)A%R8W&BI%HQ F)42*<JXC$?+/*Z3=&6
MXR7O5,1MB.MB]H9Y>C6+4C>N=XE(#"](W1>UG&I)'7\FF,&DK6K4(#5;-(HA
M*GZ.OC6>C<FMR/3J0]U\WWK]G]4_O_K?X?\ Z]WR_<W^8?H_L_K_ -,U</G%
MQ'*V4$WD'6!0CS-$D!-D9)8CSQ!&,)!&AE!V<>(!9@PDE:&:(!9@P@V$L>P_
MI]N[Q-_W^UK_ ,_#_P"!D>+FYMU8QW)%:;F?':]Y%:2>?NJ_C*Q :82TJ[MG
M$%)4QB7O5=%OMEQ\R-1^,L<ID"I%.+L3UU7DY9$;^NKY\EAS<G 9.^K+)BMQ
M5E7]M0A0L5PVRH7&9Y%SUB0] X&L$K9D;XU[7-IN]J$"\"):4!:WG:\PC5@.
M2F:V87OJ^;[U_P I_1_:_7_ICY?N;]/S#]']G]?^GUX]]*;YQ<1]&@(%R#J\
M)Y@##2R!20G1YA10@!.-+(V5HTPHD1I03C0 $64(TH)@@B-+T+G]N[Q-_P!_
MM:_\_#_X&1K.Y_\ '\J6MTFL.HKIKZW&";4]146BDLBS0=/P,',.6QDB)2!Q
M9(O-7YNA4>5:BK/+['9K).C%D5@PLS6;*HDSK)9$FV56'3R6E0.$RR:FQ^6R
MP$4CSN_^Z\$85LJFDC&U(SE9;%%(ZAV%0\R!V,* A:4 34Y:A:>2%0I2I_&4
ME/F^]?\ *?T?VO;[?O\ LQ\OW-^GYA]?\OW9H$/.+B.(PPD/(.L!'DA+&<0&
M1E"/) =H>R!G$Z*V84 _19FR!F!"$[19FRMCT6/N_I]N[Q-_W^UK_P _#_X&
M15K3M$..,@Y,,%5E5A9$&ONXW955TW2R!172A8PRRH%]K-R6)J2H_:4AU8K?
M&E,6GQ,DG%%-]C06NEK@U,]M2>(/SFG:D-@5Q65]B*N9!8(89+K &Q@;O#BD
M+U'RGMP$XNB)LVI-<YC(8G#8XQ,Y:P;U*95+Y1'XS%HTW.K\].B9$@,V)\WV
ME?\ *?\ [?\ /W>[Y?N;_,/T<_U?U_Z?OU&'G%Q'&,PH'(.KQFD^'XY()(2,
MXCQ0[&3XY02MF$^,7K9A/BA!XQ>MC+[P-;WGZ?;N\3?]_M:_\_#_ .!FD>-'
M,BC+PM9M.@=36S#%G(VLR[4A5H3*/MK9'+FC57,T$0.ZR.HD<P>Y&4Q0]+:<
M::&FP%L49JRL,]2L-KR:31,4WKG'?_*3DU&N*=?EV9,87.I5$DR\8)4ZQ$$4
M(;X/'TR0U6OE$H=YM+8:RDI>^!,RQ^.MKDYS:=2UU9(?!8S(9"ZIT6GS?:5_
MRG_[?\_=[OE^YO\ ,/T<_P!7]?\ I^_Y1?.+B.=H0B>0=8'! 8828(F1DFA+
M/)%L!Q!FRRA:+/('K8#R1[":2/6P& "+73/T^W=XF?[_ *M=:UZ[WM_#K6M:
M]=[WO9'36M:]=[W\,P3AUR?H;D"X7,S4+'G9OC\0GSZ^.TB/<XHN;IB_3.6R
MP+_(RVAEFTFF,'5O,CC[T[$1FTHY7<E7L*UHDS-&11]T(-)SODGR\I7BZKKE
MLME<^D?90=Y2V)C&-C6/J:,L$.KZ76'+)Q,QHQZ,9(<U,T24-(%Q8%CF\2IZ
MCT9C[4Z.;GLM,^;[U_RG]']K]?\ I]WN^7[F_P P'W?V3^G_ $^[W_,OG#Q'
M/*+.)Y!5>H(. $PHXB1DGD'%#UH0#23BBAE&E##O0@&%B$ 8=Z$$6];UO,?E
MG+;@]+F%<QSJWZ1DD84@UMS:9:L:'9@/*!UUK:]$](5#<(H.Q>@U!?=!L7H+
M6]^N4<3+:@]EUP?'876TTILNFU<=K-PJJ? 8M2.&(QUU")]!4YBB-2N:LRUO
M=ZRG,+?4)A$D<%[?MP41^1EMLI97MJ1XK>?)/CDBG<DXO6P2\/(7+C]8ET3_
M &G9W-;#V:OX6]P=A51U]>FI44O]^I:IG+4HA\(82%\D>D*4]3X"/3A'0/N"
MI92K="&'#*5)4\CW!!;W!]Q[CZ'Z??..5H9$EA>6*2-U>.6.0I)&ZD%71U 9
M74CE64@@\$$<9J%QM'A,TU *G*2Y-Q+C4SI70UZ8'.F76.M2F/.*AZ.D"\M&
MU2"/OS$8TN[DH/\ :[.8W!3J$IYJ9,)$'N;!^27FK"ZLIX\D_DK2_)VVF]V$
M%K->)%&>/NI8U+'8'EVTY2F1R2-$REN9-*!)Q)T+8@D[DG"5I,Q%'C-)F[1]
MM1Z^J;JV[HHW2%FC-M0"*6,PM$L0%-$I:FF8,J-]0MTD:4ZUP):WY"G6@3.[
M:6N5A0KRE"7S!NRMCW7]R@[1SB96#S83+8T5FTS4<:+,J QP=46HE&XBFL.3
MQ.XYLTCCDYGM@0*'NSM"&:H)VUN[:J>2_:]B',]1Q-+*[/7CBR'7^$4'M$S0
M,(/AT\+.L<48_-*5F9ZG>/\ ^-GKN5'R>Z%E:W&^MR((K\=7:POM/QO:_&5:
M*:Y=M,1\0EG=1+!Z@%:X ?BX*VWKK*Y$_*V429<WC_:=<?CZG>['F>G2'2!A
M,7A/J9*ZQ.<6*\$(CD1 5D600]]7MCZG7"5''("M.*-><D0JE!B(K6B@&>]
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MBM<0'FIV6#[<7)6G>0?,/DCQ@>XK/+KD<&M9@VU\RX:Q7K3\\2M H_/^1U0
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MB+=?T_\ I;*^;/['3A59DF,DA45D-:EF-:)K]V:D6QN#1+046U(O/B9$T36
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M$BMV;&1%1)4*UQ9 [BDV?0+DC<804M%H^,QMZ(3FD#4D:VE5&D*QA,T,L@8
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M+D/;%9-?&WC_ !JJD<GY"6I1UF]GVIKN\IZ\O?B4G-JSY13IRE3MIU@:FO;
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?IR2O%/-,.,[G?-,&8(0ML9]3&,8QC&,8QC&,8QG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g480743.jpg
<TEXT>
begin 644 g480743.jpg
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MD&[2.F=@^L<35!JCUX41.6 G9I!$"+N$EDO/0B)A$1\1_P  #ZP '@  'D
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M KHN>T,'8H-X^AV--PAV0$/WA1TV4[0QD^Z]4H*G O1:Q.0JA1*8 $! 0\H
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M%LJF[U7NM;LNBV;3GLY%M"E+>EE_M^S3^QD_5+\&CLT_L9/U2_!JIY?N+YQ
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MM)R.;9;I,I#"096T3DQ)'+Y#NC!SUZ9$ (4>7,1#R%ZQS>4PCR* F$1'RF$
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ME4<*U&;< HH];8PQ9$0<[.)1AS<B-6-CR'9U4Y8B8"9ZYHT3VP]5@B 7;-
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M_$-R%?9.Q@Q,<J3>302*#K(./FHG6K2QU)^ 37IRZB5=VKTH?U#O>G^# /\
MY+X@U0/HV",:85MD'EG$T=9,>9+QV]"WT>[U3(F1HBQ5BRPB*KR,EXF1:VPB
MS=TV7('/RF270.LU<IK-5UT5&$7&8BF&9>";EQODA ;&C<\>;;)NRD[9>'\T
MI1SD_$4\NYZT"K%F9@I+ #OL&!FK8O\ P"HE;"*.@$ZIO$?PC^W7&IWC;.=N
M/,?]G9_$?Z97[Z_Y4ZX^<YVX_:[/[,K]\:= 01:-3N_.<[<?M=G]F5^^-.CY
MSG;C]KL_LROWQIT!!%HU.[\YSMQ^UV?V97[XTZ/G.=N/VNS^S*_?&G0$$9?$
M/PA^W3?CHO'J'>RO\&?O_)?+^E\A=G.W'F'^SL_B'],K]]?\J=,D. 93JY0>
M%#M9JE2CO,F BT\P"Q8=\?O^P[YG3)+]S_I4FZ>O5.T=N5U>2SE0"=?LT^HD
M4A"@+T>E>^K7;C/6_P!N7O'4W5;_ %>/Z0OMSPWD7BI9PL]RIYIB<>4;!:;E
M\%CMD=VA&F+(-FW+W:)G6+,G9MFZ*?--N43"43G$RASG-";\YSMQ^UV?V97[
MXTZ ]O=#A]5JLGYH&:O=EA_33W2_7HSNW[$>,>([+6&CU,T),*[9\LQRCP;!
M:)3K,W%JQ:HLB#>9FI!J7KG13'M"H J'5Y%. "8!8%: -&C1H \?'5<CC;='
MBP-Q5(YYF+'4C"X&WHQ,4W91^5AC73BFY6CXEIW>'JF:X6* 7CON2!$XV"R3
M"-75QK4=V#%^QN5?BXJN,K&^C0"/7?!PT]Z?#NO3RD;JL&6^@-_-)2/KV0T6
M*\YB2]%Y*JMG5'R=%I*U2>[RT3!X:)%\SLT6F<&\] Q#]-=FEX2$IB\N8"',
M.8<P$.8#X"'/Q#[^GY%ZH]+R+5I>F9!J%7O=/L#<6$]4KG7XFT5B<8K& %6D
MO 3C1]$R;90/(=%ZT73,'B75.'CG\%WAA8AQ@;,&)]I%*QC>I?S4.]<X]L^2
MJ96^L@F==+NE KEVC:!&@50XCU8VL-"B4"IF 4R$(4!:IHULJUP$1&V6<CV3
M3L6C.160;I=X=*=FD4"]4O:++**GY<Q^F4.8P_5$==MCFKP4[=ZW$2K'O4>_
MDT&[MN#IXAVJ)Q$#$[9LX173Y_\ ,DJ0X?4,&@-0 41YB "(!Y1$ \@!]<1\
M #[XZD@V \)S?+Q*;I'UO;+A>>EJB>0.RL>;+8UD*M@VDD;G*5\K8\D.H]>+
M</F93E4\Z]72L=S>E$0CJX[ZJ@IWV^"AP5^%S=,4L,TWW9YCW(^06?F,=N]R
M;-9 R572G.W[T90] O=PL./UE!7(4_77JZAP .S 03YD&VY5JW7:C7XBM52
MA:O7(-DE&PE>KL4QA(*&CVP"FW81,/&(-8Z-9H)@!$FS)L@BF4.J4@!Y- 0?
M<&C@,;:N$O4//4BLTS3NRM4.K&W[<#-0B<>,5&/3D5=4;$L Y7D%:12_Y%N2
86=G?.K1=G;?OU@D&\6$55H.>'1HT!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g524389.jpg
<TEXT>
begin 644 g524389.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!!1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?1DE'55)%7S$P7S1#7TQ)3D4N15!3_]L
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M)7*2HO_:  P# 0 "$0,1 #\ ]_&,8PB8QC")C&,(F;3"(  A^,0/\#'*4?\
MD.;LT$ 'T'YP'_$H@(?\P#"+RD:NZN'+@&/*[D3LNS/9K4W%:U<_99_H^I]-
M#?\ !4J\TCB18]J0%6K#3J/2&U9+0M?MUG)5JXO,.S:[FG4?,FDZD6ON)M5N
M0W=KEU.^:?'6#VLPW=OW@M?=R2W3BY"\QJ3I*DZ"Y-:SF=?;&UUH"7WM3*[1
M]DS<QL;2O)_6+&&C7:&SG;_8&G+Y!-$8R>CXIVA,)0I[\M9<3-$:GT_?M#5F
MD-WFI]HV?=UKOU,M;]_;XJT/^1-MM%TVXQEDY]=X+J!M<S<;"5>!.(QC6-?F
MBVJ"3)--(N"T7T.^G]&-4(Y6I[NL41#ZDW=H*DP5ZY5\DMB0&L-(\A-92FH]
MF:KU7!7S9EBB-=4Z5I<NX9LV5591SN,>MHF1;/A<PL2+,BJ+LG5/YX4SC5JG
M<LKO!H1UN'D)PTTO)R%^Z,W+73C76<-R+@M@V>TV[6-0L6[9:U<REJ^TJB$>
MP@=--F#MV"L7)M5U"6R#05DL.KSSF@.GKU%^3%'C.,_(>4X/[O3HL/MB[:XW
MEQ"):Z&AK;7UON,A/\/[6YO.X*]LBD6^]-:DPIFP+KIR(O$ <USC+.FWC$V=
MC]!%\XAZ,V34..U&MM:DG]<XL;.U!M_3+-"S3S%6O7O1D4\A=<R;]VS?).;"
MVB(]\Y2=QDVH\82YC@K)H.%"%,$;WOIW<7MD4OF3KVW5&P250YYS\79^2$0G
M>+2Q):9R)IU1H:#Z#=LWZ+ZG&5K%$JK!RC7'+)NN:*(Y%(KAPZ46(HR7ZD31
MYRKL?&:A<5N3^W8;5^T]6Z-WOR!UI6*+,ZFTUM;;='A]AP,19(AU?F>UI6K5
MRJV& E-E;"K=!E:9KI*<C4YZ5\Y0Y"]_B.1U_NW48N'&2FHUM?3NA>*U5V7O
M&:]WKN[&CNG?&QY",TC1V,O[>FSBV\;K'6&S+K:8[W:^=/T[10G";UBV*HD^
M^*P],KB%9N41>7LC2+>CMMQ;]>[(GV<3MW:T'JRZ[2U) +5;5VU+[IB(N#/5
MUVV-0*^N>,J]LL=7?R,>F5%P)EGK=%R3)K7FA];:OOF[]FU*'=-[QR(O%=O^
MTY^1EI&7=SDU4M?576%9;-/>"ZY(6!@J=3XEA%UZ**VB6CM66E$VWO&:DW#@
MB\CNL>O5SFM5'Y);1MD3H^"@I?I]<Y>77&N!>Z3O%5BHB^\8]\RVM:KK*N;.
MF=G2T/RM<1U#AG5PWNWK<!KA_KB553C':+95B\CU\P8_J^\H-J\2>4?-W72.
MIJ)4=6<C.*7%37'':_Z_LA-YP,Y?>2FA-9[1VCR'CY:P03BD.-@4[9TI-Z6U
ME%QOE0%;=P%KL=JL,H+R!9SCP_\ ]'IXO:?TJWJ'(B3O.\-ARVG>2&E+,JCM
MW;2&HZ_6>3UYL<SMB5TQK:;GUV&H;9L&GO*U6KQ/TY*)/++PBTBV:-7K]X^>
M6 ;+Z6/#;:MWV)?[)0[,TGMOU+C[4-KIUG95ZJ\+LAOQ8V)4-G:#L%Q@H::;
M14S=]<6&D0+&&NZS4MF5J:3JFR$B[K3US''(JZ>0W7QA:CI/;VP=.\9=S.&D
M[JWFM.<)=Y['8:Y)H3DC>N%=7O$_LXXP4+MAIN"J5"%BZ!<;O$)WZKZ]E-I4
MVEV!K2'"-F>0<<]ZC3.M[N"E;DN*'(/C#=Y#2T;H[I7VZSSVI&^K%'7'2^<\
M'5DI<DIM9W8-UIO+K6)W8[VCM*#'ZJC;A+0E>)8G]G637031/8DVZ-_3_;V7
M:%@4U%8)"/VC6.0M35U_*[<VU*:EUQ&\L(V1B.1[G1>IWUR7H&BIK<$=+R3*
MVSNK("L2IF3]ZPBG49'O'317L#3I/\-D*7=Z,]J=]GHW8U1X?TFZ2=DVYL2<
MM$_!\%+JM?\ C85[9Y"<6F3/Z9852J2$H5T5]:V"#:,LBT@S;II@11QH7J[Z
MHWUO74VK(O1V_*EK7DM<.0-#XH<E;5&ZZ#4G(:S<8_LH/M5I7HB$V#+[7HK,
M6-*MLQ19+:.O:@UO,/7I!W&&06]F:KVV?'*^].=,#AOH;?2G(K6^N[#%WAC,
M[4L=$@)/:.S;)J;3ECWH^-([GL&B]+V&UR.KM,S.T'*BQ+?(:\JT"N^8.W\0
MV%E#R#Y@XL$PB8QC")C&,(F,8PB8QC")C&,(F,8PB9Y[NHUSXY4Z=Y_4_BKI
M>Y.*#0WO#(_(J6GJ;T[=[=1'8+RW?;RE=8A$NJ'HG95"F:/3O="31X6W3974
M.,XBG!F5%_-L$T_0CD%#QPU.;DH/+48-Z.[QT:/'0;)[\E_=PZI'8'VS1@QK
M?M7N+VS[+_\ ?_??L7O;V?\ \/\ :O8_]CA%Y]]H=43F)7X'D=O1#>/#C3&C
MN&G)I#A;*1^\^-')RRON1VX-;:[JEUW=L"ZV_15DV#/\-]>SJ$S)&UFT?ZIV
M\:J^[TSWN8E?>,:R=<[1NHAS,V[S5Y2ZQ@=G,Z?K#1'*JRZGJ=>@>F/R!WG1
M[3KZJZ?H6VBK[!YM5;<-<U#IBRV%*RR<,<EQJ2SJL,@KEHD8MRSLK".+9'R!
MZ0'!_DK<MR7+8E/VG&&Y%1+>-W_3]8\BM]:AU?NY[&PB4! 6;:NJM:["K6OK
MQ;J\Q:QYHJQSM>=OA>Q,.^D_>;J,:*)Y8:FXIZ6TDQWI'Z]KTC%MN1VR9K;.
MURN['.2YYV[V#7=,U;*2;162>N%(1!>FT&LQY8^)%JR1<,UI%)$KUXZ64(O,
M?PIZQ_/G>-AXDP\!8-$<D=D<JN+V_=ORFAI[B1OO@E&:NN6M-1M[I2V])Y-[
MAO=EUUR6J4IL21@:+;7^H*Y-*Q-8E'>P"D90T8H[)E5QNZT^^'$I==8[5TY5
MN9^SI[?CO2_%2T=/>#"E:QY(OM;Z*+MWE2I5Y?DIN8:BI6N+DZW<Z^L.T(_:
M#ZN[*LDI Q5)A#2HR+9M9Q:NE7P[MVJ..NF9"H75C2.*^E]K<?\ 3*4#M.^0
M4W7=6[KU6EIC8\ ZL<;,(3,NYG=?(DATYQ^[4FXI7QR,4_9OE#K&AF,Z'O!V
M*H5'UV@ZY3GA-1OHIYHI\KS3Y1!9>/;>/J\Y1WT'H&RM]G-Y;3U6M5-L#RLW
M:K49>(@+A$M89*=CW:T##KLR*0^2_-C8$-Q@XQ733NO+3K+??,W>'&[26J]8
M<B=?/HFYZ[E=IVIM.[8-M'72$TV>-)C4.C:KMNYS+!I-.(\KVKM%TG[^+<)*
M.JP>J]U>.6'$7F#-ZET;&:I::OTII[BKMS8S_8FG]BWJ.M27(?DR_P!26)6^
M[AJ]QKM5XK:MUYK^$DK&XVK<X.T1[RUC'UPS<'4Y%H-[U*[POX[U$_%,E8HZ
ML)&<*X:R0G'6":6.R*PE(0M.OU-72<@Z8OI1X-JL!:.[EX1I9;4M,3S8MALC
MT) \A.R3I>MKE-T3];<U.=6T^2/(&_WI32^PN+FF^/SS4NK=G;(U9(6XNO=I
M6G8-GA-KJU218P-]U;:B2-; :E*INED)B 1E&JD8Z10>&(L8^/W5PY*<E.HY
M=NGE#FU'JY>@<S^6+65W#=:+8_=FQ^,O&R6UVA%:&X]M33Y:]L3D_/1EN<6_
M9MU?2S:#U/K(&5H2H-KE))I&M^:T+UYW9^/KNY[2X][5W=>M55WDOO7E7-\;
MJ_0(2C\<^,6M.7O(71&OKY8X_:VU*K*W*?DZ?I.9L4A3M9K7"TNHZJV:SN(V
M(:KL&*EHLITO.'$FV[)Z]F8>7:\PY+G=7[77[U;8.WT[DA-)1+.:M%-LD=)H
MR-<K<U$0S* F=>,%"T66@2FBI"!<-O 5.(9WHC]/"?C*[#K:KNT1'0\3L>IV
M!K4-Y;FHJ6U=;[6W1:N0-RU)NTE+NT"7<>IWFUKI9;)'T#8 3<#")2SR%B4&
MD(X68*$5<;WK4\M9*R.UZMQD:66J(]:&G\#Z!$5,U#<7/<NB+EQ3LF\85A!G
MM>ZX2M5;<*KLE*N3^]7.9IFMH[7US90JK0EKKEO(PR/8]?\ TG8M8([2H/%?
ME?L2*H6C[=R+Y51E;B],,Y3BCJ:B;<V=I.RS=^&S[>@(V^RY+CIC:,E&U;3L
MA>)Q[2Z>_M*[9BW6:-EL\6W3%XBLMHNMLL:=;64ZORDH_,UM M=G7U*@0_(R
M@ZKG]+Q.PJ_0/?AJO K/M<V!6NV"&BX]M!SS:(K!I"/.:L0@,X8E^B)T[YF)
MK$&IJN\1,9!0VQ*A/-JIO3=%*+M;6VTMS6GD!<=2[Q^P^[P7VY]4O=K7.RV5
MC0MAA.04.27>PT6@UA7*[!0BM*J5J@KS5JW=*P]"2K=N@(6SP$B"*[<'\)8(
MQK,1+T&[I-%R@#J/>MEP1<))KI>9Y:J9%"F*'8<^..CF$0P9144Q9QD9&M&S
M"/CH]LBR8,&+)!-LS9,F;8B;=JT:-DDF[9L@FFBW03312(1,A2A]F$3&,81,
M8QA$QC&$3&,81,8QA$QC&$3&,81,V$4(IXO <I_ <R9_"8IO"<O;Q$-X1'PF
M+W#N4>Q@[^H!FBWWI7^K/^R.5N=.)0ZBO._QG,?P=1_E.F3Q&,;PD*:@^$A?
M$(^$I>X]BAV*'<>P!A%9/C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,T[A\X
M?I#-<(F,^-618(/6D<L\;I/WZ3M9DS45(5PZ18@@+U1!(1 ZA&H.6XKF* @D
M"R?C$/&7O]G</G#'^GE$QC&$3&,81,8QA%M$Y .5,3% YBF.4@F #F*02 <Q
M2]_$)2B<@&, "!1,4!$!,7ONROC9!SAU1.(Z8',"9N$?/(YB 8P$,8FZ. @$
M,8O?PB8H'.!3" B4#& ! ##WL'PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC"
M)C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F/AC-! !#L/S@/X0]2B!@^'YP#\
MP_ ?3"+#VA<Z>-VS-S<F]#UN\IIV[B:OK>+W!,3;<L!1&$UM)*VD@X* NTJY
M;0EEEXJ2I-DK]J:1BQPKEHBWU9>JC.1\DQ8P9TT)!A+-^=,E%/F<E'/.H_RI
M5:/X]RB\9.DBK4-(5&SIL=1!=,%$SD$Z2AR@<AB"(&*8 XW6'2#X7ZKVMOC9
M"=*FMDU?>]2U[7K!I'>=JL.]]-0DAK[8.TMI)6J IFX)2[,DIZ1N^U[)-LA>
ME=,*,Y=3'VN6E43N5U)/_ETL:?4M?5WFM2*%5JY2*96>HKRGC*W4:A"1E:K%
M?C0<45P6/@X"%:LHJ)8E7<+K@T8-&Z ++*J^7XU#F,16FXQC")C&,(F,8PB8
MQC")C&,(F,8PB9#VRMPP>MYNDPTEY9U+1+>SOE#*@3W/"^$S8TPJ4.XF3+*+
MLD?"8 *9N5^J ^)KV&0[':("HQ:\S9)5G#QC8!%1T]5\LIC 4QP20( &5<KF
M*4QBH-DUEC 4PE3$ 'M79:]_/=_3R<3H;6VO'D>LZ5KJF_-W,XQ&E(JM5CD7
MC:;'NO\ Q.]2C9=18"1T(9XQ;.5O+E'$:L<Q1TV7S=+$-A9/*]UNTYS:-"K#
M)<R%YT9;[C:M*!KYI&1A[?B+!:RK4C>)K<\$(,@L&!XWD^0/L.IPQ1T:#6/R
M>6OV8<?B,7'*'F)U_)6G,KPR3".04ZC727LC*PUL=5MV7-A=B)R2Y)\JJ-RN
MME=@KK>H'5$;L6EQ[<"U-A]B[> =MJHM,IEGWM772,T,#F4.Z<&E3F0*9QV6
M2\D 2LCG.<NDDI!Q Z\4MF[;(@JLB,1J&J3-S3*LD=0#%6F(YHI$I)E$@@98
MKE9, [& 3%]<VU[AI49%RTGM\V^W<A;0W,FLDC>)!=GKN(5*4 !O7]6PZZ%6
M:,$_4J24PE.+@4I!,OX@S)Q!:BT2.;Q396J4Z):AX&L:@I#5R.;E'MV(@R3,
MR;)%^Z+V*1(H?=!Z>H9S;B/%N>XK(<HR%GD992Y'E79*C1Y";6?O8.N^>W-^
M'5:]?,18K'AC;+8F_"W<E7Z*T),(_P!W'VGU!YSZ49S$<%Q%/AC7Y+AN CPN
M4RO$/@.*8SE5V.KC:_XSD+ESCD^=S#IGT9)W_'8S"W&RW; ;8/>6:@+>._\
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M6M:XBW\+X5R#G_(\5Q#C5.*YG,U+89CJTMFO3$SZE*Q?F:^U;EAJP-;5JSR
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M@X%4L)S 4L>6;DDDT$TT44R)))$*FDDF4I$TTR% I"$(0 *0A"@!2$* %*4
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MHE'G*]K:NU]_]D#U1_9K7Y1BJVRT.@DY=,A_51./ 2)1T"T[=R^RPC*/0!(
M*IYG83"ZG._@&O\ F>"!^S>SG?OT@_)R: _B/[#N?W/@?]3]0H>@-;&GY4\Q
M5J@GIN <I.6[B;32%+9UD8O3@H[3;I*+.6],9/Q*515R]*\LIC 11%"(7 %0
MP<ZAVD=JN5=-H:%C9>.KT2UL\1(,:S="UQ[)V.=E(%6,)[M]_1\O:IEZDU?+
MN'I$)-VF0BR[YRB0YCGL,/OB$L<NK4=8MPMUL,=Z0IG8JPU:8HL? 1U+/95R
MF"S]@V54*4$(1L\>/3%$$?)1,#L.ZU;7Y8V4&VVF2-:[PN@HW&:<(^SL(5HL
M/B4B:G$"HLE!1GP(J<JB\I)>'S9-^X$WEDJG+N*8_FO'KW&[MN_4J7WU737,
M5-#7MQ&I<KW&M@EEKV8F]<E=C)&^R[JB+@7-<0\7KT[Y[E?3/F&*YIB:&(R.
M0Q++[:]#/5;%S&SC(8^UC939@KVZ4[S'!;DD@<++ R=L;RU[&NC=CMQ4X[.M
M?ZNIYK_$M8>_DK@%D&$4=L56$L$HQ.WL-E?RS-=[]D&Q9TRAE9RY.W;]R0H(
MQD6LBP;G!>?M=Z@J6L%Y->K&FD@ET6R3Y"0F',@V5,T.H=NN"*Y0 KE,%EB>
M> ^,R:IR&\0"':4\9O,5BJF'QN/Q=-A%?&4Z]*NYXC$ACKPLA#Y#$R*,RR-9
MU2N9&QKGEQ#&@AHK6=S=[D6:R^=R#P;N:R-S)6Q&Z4Q-FN6'V'QQ">6:40Q.
M?[<#9)I7LB:QKI'D%Q8QC-DM0F,8PB8QC")C&,(F,8PB9L4("A#IF$P%.4Q!
M$IC$, & 2CX3E$#%-V$?"8H@)1[& >X!F_&$6,NI>.B.L+E(VD;.M+IF8/HV
M*9 Q%D=%L_<H+J*2;@':Y7RZ:3=)(@)HH(F5\;HY04\LB?=>1FL'>[N/F]=,
MQ\DUAG^V]-[/UBQEWR;E9E%/+]1YVIMI)XBR,1XJU8K2Y'3A-J<CDZ*1RH&*
MJ)!"9<9!C&QCI8.D;)ULGN?U)4G.<\[<=G0&_P!%2_L_I-0ED5V KKP^IJ >
MPL&M9J"T=1C,7=1HJ/ S=O$M>G,WD4W0=M8)S<ML(W]>+CUDF#AFSD2KHJ3C
MM-P,P;(X'SE!KNH9SAV-0BM@ZDG+NY<T_==_W)(438=>VOK"(U;L.*'8[9_?
MMH:JGTF%:JD]4+73F4LWBWL"[CG5:7"R/9=C:!C)J*IQX[],*?@MA)[(Y1;#
M-MJ2B(RRLJ'%06T.22PZ^CYG;Q-I0-/2N-WV?*7F^URFIIH1#9Q>YN3"6D"2
M,RW@JW'3CBLLY>WIPIOEWF]Z7JD3=$&XWO=6@-QZ_"<FMM4!]59#4^MFFL;,
M:/V-J"P0EOI]GLE?<V2/9V*-86R'5@)N4K%JIT_$3;Y-O9AC"*D>G=$O44;4
M:M'6S:=XF+2PKD&RLLO'MVRC"4L#6,:H3,BR4M[JV6Q1H^D4W+EL>T6FRV(Z
M*I#3<_,R0N9%RR[C&$6T2$$>XD*(C\1$H"(_XB&;O0/S?@_]@#_VQC"*&]?<
M@-*;?L6U:9JW9]+V%9M*V!G3=K15.G6=A6H5MDHLTNVK-D6C#N6D?/ECP%=Y
M$&<F?QH@+>2;LW0"@&'/3@^^\\?[R+E1^W0,U9=.#7,EMKF[=-A2CZ6U_P M
M[_H#8S6CZ\L.Q]*3%-F=(Z@C-=.%'EXU1>:A8)D]HF&"]E?)LW<4R=%="PG&
MDP)17-T_I0T:NZRJ',W7]13ET:S4^HCRHBH5.?L]GNDT1G[72'?:3MEUF+#;
M)]T*[I8QI"?FY.0.4Q$C.A12133(K6<XB?G8NL0TE/S;HK**B6BKU\Z.4YP2
M01#N82IIE,HJH8PE3223*9150Y$TRF,8 SE\X2QUZ*M<'*5V;;BZBYAFJR>H
M@H=(YDE>P^)-5,2G262.4BJ*I!\2:I"'#OX>PX.]'6MZ.M^-_+>N^M^=+(UL
M;WK??7G7SU]U%\!R%U//QZK\MJ:1(HN3-CL)TIHR4.8" <JC=@<55G:"A1^Y
M5: L4I^Z2GEK *8<F;;L2]#PU6MW>Y*F#LF:&JTBQCA.;Q 3QS5D)!Q)4Q$O
M<5".E0*7U IA$ 'Z=;ZCJ&K6CYM74GJZ\BX*N\D99PF\D%02(9-! JJ:#=)!
MN@4Y_ D@@GXSJ**K&54-XBR=V#YN_P#3Z_\ 7OGFT2EHZW,:==PUI.OW+M?_
M ,J1,?4>D.(WVZB.X^X WY^_A8V;#JVW]KU25@E&E9H<<X!!=*,7F7\W-2RS
M-<BR3"5?Q:+>'B8]<2^-P1NG/&5.FDF<2)@H8>:T+J)35];7).%B7=ID7:RK
MJ08)&5,TC/ B1G"H2"Z23E5FB=)1X=---NV]J=*^!$PD\Y2>L8$3>L2$N<\#
M6W'?;]  !KOK0 [GMM#(XMZ!H-WO0'SUKSW)_<E,8QGJH)C&,(F,8PB8QC")
MC&,(F,8PB8QC")C&,(F1%;-^:6HNT=8Z2MVSZ3 ;>W,K/$U;K.1L#!*\WE.K
MP$U9[$]K]8*J>7=Q4+"5Z7>24R9JG$-!:"T5? _7;-5Y=S#W?G%=/<_(?A5O
MEM/1$ ^XG[7V5?Y%NM7A?35U@K]QUV_I(M38SZ+QHO MX^7V<UN"AUDY%HY-
M"':D9(O72$@U(HVV.8#=4?B+V[_^2#GH/J40_P#WIX!A^$ ^;]'8?@(=["\I
MKI?%73/&;JD<<#:CCKVP-=>$/-X;#]FNZ=V;?!88/=O!=6/]UEW#L2^EK@$/
M,OQ=%K@102(';ED?:R,8\K6Y3")D6V+:E4@;*6K(-Y6R6\S('!H*KQ@2LDBT
M*8QNSQP*S9FR\/?SS-WCU$Y$54W)D@25(<TI9B[#\<SQFY%]F&M2BT<,U)V-
M"+!HHG)&D)0CHJC-S(>TF14CT3O%! Q4//<-R)-%2D*4ZI_.0R#I$;=[< X[
M'Y6[[G1\]OUU]"IL#3U=1UII+1_4[Y#YZVI&-8ML37^S@J'$U9 P]RR-ZL"#
MIR0@AW Y:]4O> J'#XBDXG67KV QBAW,&W[5KN?$3['N$M<D#&[_ &.LTPJM
M. /00(O"Q3@SV6*4>X>&<F)% X?\3;)> .P  ?@#M^C&9Z ?XG.?]G'3?_RT
M!I'Z@K'5KP W]!W_ &))(_8A0?0M T?7EKD+9"&E5';E%VV8,WKI%5C#-GRA
M%'2+$J39%=4# F5!$[U9P=NU#R4Q$PF5&<,8S+6-8.EC0T;WH?58<YSCMQ).
M@-D[.A_Y_JF,8R2PF,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,
M8PB8QC"+\UOO2O\ 5G_9'*V>G!]]YX_WD7*C]J@99,M]Z5_JS_LCE;/3@^^\
M\?[R+E1^U0,(K*L8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA
M$QC&$3&,815Z[(_E1^(O]B'GI_G3P"RPK*]=D?RH_$7^Q#ST_P Z> 66%81,
M8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$
MQC&$3 CV^.,VF+X@[=^W8Q#?J&*;M_CX>WYN_?"*"M9\FN/6[;7M77^H=U:Q
MV7==*S 5K;%7I%S@K)-Z]GE'$G'A%6N/BWCA>(=EDX6:B%4W!0!&9A9F'6,G
M*14@T;8E]. Q05YX]S '_P!R+E1\1 /@:@=\P^XI]&VWZ?N^UW&T.1D^O1E:
M*]U#I.0XZ3NS./FWVNOI7E]O3F/(2VS=C5BVIR*]M6M>[G- D8^FKLZK9:S7
MS34PU"2GE(V,RGJ_2<T91QL8TS>_/6J#<+7,WNV# <\>3$8-DNMC]E&?M<S[
M->B>W3LS[$S]XOU>ZKCV9'Q?\&$5H?C)^,7]8/KQXR?C%_6#Z\KF^35H/\Z/
MJ*_2"\H?W]Q\FO0""4QN4/43,4ITQ,4W4%Y1 4Q/&7Q@82[ 3, "7N ^$Y#>
MOW)BCV$"*QGQD_&+^L'UX\9/QB_K!]>4N<6.G==IO3,4^Y(\D.HI$;:/>-T-
MI%D3GMR&8%"FQ^[=BL-2.3-ZWL)>'3.^U UH;P5$SIO'0K^TRZ1)M>1#,BOD
MU:#_ #H^HK](+RA_?W"*QGQD_&+^L'UX\9/QB_K!]>5S?)JT'^='U%?I!>4/
M[^X^35H/\Z/J*_2"\H?W]PBL9\9/QB_K!]>/&3\8OZP?7E<WR:M!_G1]17Z0
M7E#^_N03RAZ=-GA.-N_)?CIR3ZB<KO\ C=.['?:2BS\^>1#\LCM9I4Y1Q060
ML;'L)&ONP<V9..1,WG%"Q*Q3B20,1J94Y2*X_P 9/QB_K!]>/&3\8OZP?7E;
M;'ILT@[1J+OE#U%BO!:-1=%^4"Y0% '(H)BX /#?C)^B_F ()F$H#Z% I>P!
M]?R:M!_G1]17Z07E#^_N$5C/C)^,7]8/KQXR?C%_6#Z\KF^35H/\Z/J*_2"\
MH?W]Q\FK0?YT?45^D%Y0_O[A%8SXR?C%_6#Z\>,GXQ?U@^O*YODU:#_.CZBO
MT@O*']_<QYWOT[;M%6+C:EICD=U$I."EN1<!%[^4/SXY#N_=NB#ZSVN\FGY3
MR^QF[AEVV&RUFU,]KP*6$A7(HMO+C7$JH!%<_P",GXQ?U@^O'C)^,7]8/KRN
M0G36H0E*)N4745\0E 1_^X)RA#U[>OI]GOIZ_@S=\FK0?YT?45^D%Y0_O[A%
M8SXR?C%_6#Z\>,GXQ?U@^O*YODU:#_.CZBOT@O*']_<?)JT'^='U%?I!>4/[
M^X16,^,GXQ?U@^O-0,4?@(#_ $" _P#3*Y?DU:#_ #H^HK](+RA_?W.(T-QM
MVUQ^YH3I8/8_)O8O&:P\7F17+O>_(B_[RB6&]F6XES$3@F^R+7.S,!)KZX<!
M[8M$L6<2\8HHD<KJ/DA Q%9EC&,(F09>^3?'G6.U-::/V'NO6%*W#N,[@FK=
M9V:ZP,/=[X+94[8PUFN/7B4E)D5>)J1[0Z2'@?R29XQ@9U(%,U"<\IXY>=-C
M9'(KFIK3D/6-M4FKZR53X:-]SU2?I<W+[!*CP9Y17/E=K0VI+1'SC.$B3;%M
MER7I^PDK/%.0BH.,83U>6=RI31X$4^;(,4>J-Q%$#%$!X0<]! 0$.PA]NG@'
MZ]_F]!_0/S983XR?C%_6#Z\K"?=*324E<XC8K[?//9Q?*]!V>KUZW'YY<F33
MT#6+K)5V8MM<AY ;WY[&$L4I3ZD^E8](P(NW%9@U% $8]#P]D^35H/\ .CZB
MOT@O*']_<(K&?&3\8OZP?7CQD_&+^L'UY7-\FK0?YT?45^D%Y0_O[F.S#IW7
M8W*ZWPC[D=U$@XSM^.^N9.KS)>?'(?S%M[N]I;2:WUA[>CL4;,J+77+'7*WL
M3IL%?;@[,NQ\4JXDE"$5T7C)^,7]8/KQXR?C%_6#Z\KF#IK4 0[ARCZBO8?_
M .03E#^_N/DU:#_.CZBOT@O*']_<(K&?&3\8OZP?7CQD_&+^L'UY7-\FK0?Y
MT?45^D%Y0_O[CY-6@_SH^HK](+RA_?W"*QGQD_&+^L'UX\9/QB_K!]>5R'Z:
MU" AQ+RCZBOB IA+WZ@O*#MW ![=^]][?'Y_3Y\QSX\=/&]3!]Z_;VY%]1&)
M)'\D=K1>F!2Y[\B&@/M!-#5X-:OS#";'=>TE6 \Z)'\YY=C<@ C+&4 C42D5
MT_C)^,7]8/KQXR?C%_6#Z\KF^35H/\Z/J*_2"\H?W]Q\FK0?YT?45^D%Y0_O
M[A%8SXR?C%_6#Z\>,GXQ?U@^O*YODU:#_.CZBOT@O*']_<?)JT'^='U%?I!>
M4/[^X16,^,GXQ?U@^O'C)^,7]8/KRL"Z]-R":TZV.*CR<ZB;FU(UBPJUE W4
M"Y-*%5L)(9\:#(*;K8*34_>5!F $='!J<>Q70&;BH4W0^/'3FEI?0.CI3>G)
M3J*1>[I'3NL'VXXXO/OD<Q*QVJ[HT"XV*T*SA-A+PC4&]P4F4O9H592(0$@H
MQAO82( !%;WXR?C%_6#Z\>,GXQ?U@^O*YODU:#_.CZBOT@O*']_<?)JT'^='
MU%?I!>4/[^X16,^,GXQ?U@^O'C)^,7]8/KRN;Y-6@_SH^HK](+RA_?W'R:M!
M_G1]17Z07E#^_N$5C/B*/P,7](?7F[*A]R\#[QK2(UU>N.F_N>-OV'6N1?%V
M2DJ[<>;&\KW4Y+5!.0^M4]ZI66GWN]JUBQ026F%;TXE(I^V=KNFB*I8QJYDP
M:-U;=P'N'?U]>X^H" ]NX]O0?4/3\ X1:XQC")C&,(F,8PB8QC")C&,(F,8P
MB9C;N>F[NV%8&M(K\]6JQH:ST"ZP^R;!6;3L>D\C8FU.F_:GO-26ZIKMH*NM
MDU2@$U+/7+>P- ,8\$LFI]V&26,(O*AH[B]S+A]G]'MGLK3W+JLV31?'3C(G
MR&Y PNU&E[@XBZ5A6^1USX_R-%/N^MUVO0]Z"PISG+3=TG [FG;Y6H;7]&HE
M9-)QJMO@?5<7N!2@/<1  [B/Q[]OP^H^OS^H_P!(YIX"=P'PE[A\!\(=P[?#
ML/;T[?FS=A$QC(PM&Y]94S96L]/V>V,HC9&XH[8$KK:KKM9-1U:8_5D;"2]^
M<M';9BO&-"5N.L<*Z=%DWS%1P1^F6/(\437(D12>/?L/;MW[>G?X=_P=_P V
M5!=2C1_,W>^A=V5VBNDC+5_;O&*W\<(#06PK_K[8MHK\)N#7CC<\5OE>4G*[
M3++ (5(EGE8RL1DB,&^9, 5DV;R;1CT36Y^W,_+16]J0\IQ]X5\U/RUON1/_
M +)3Q>!4/ 4Q^Y#&#P%,?OX"F,&%]VZB_#'7&NK%MK8.[8REZSK&_E>+\G=[
M54]A05:<;R:VI]27U)@9.3J#="UEB[5$S,-,VBK#,TR%<P4^>5L3-M S"[(B
MKEX*<=^8U ZF?)K:.UJ=MN UG8U>9QK9LBX[B:7+6N]&>P^5=%NG!%#5U$1O
M]D5K)./_ !?B[IKJPHKT?72E7D)A:$ +2$M[S+?IGSF<M4U02.LBFLIX>Q#'
M(10_B/Y1! IA QP$_P#LR" "!C_<%$3"!<V"_9 0R@NFX)D441,<5D@(55(#
M&52$PG\(*)%(<54Q$#I 4QE"E HB!%]>,C& W'KJS7G8VN(>>55MVIQI(7IB
M\@K'$Q\8.Q85Q8:@$?8Y>(85FS#*139994*K,3?NI<I6$S[ND5$FAXP<<R>-
MK;9$=J4=FLW5[D]S2/'@D9%UVY3$=&[MB];1^X%]966T1-<>U.I6UUK63;6^
M'C;1.0XS\65[[B4D7<9)MF9%D[E#G6;TGSXWQK)"H:7K$;<-01NY-5V=*!TX
M]L+O>#Z"C]>;2C[BELG7EEW%Q^UYMFA!L&5H*T-4H3<=*EZ\\1CMG.C6!Y1$
MJ[(VU[/Y-Z*TSLK1.H-G;#BZCL;DS9;)3]&UE^QG%U[_ &2HP2=EL,2P?QT4
M]B8QPPAET')3V!_$-WJJZ#%@LZD%DFI_CXT\J./_ #%ULIMSC?L:-VEKE.UV
MJD'LT9%6*(:A::3)C$6:*!G:(:#DC&C'X E[61B9@]3.FZCG;MHJFN8BV<1:
MIL6B<4^,](W![R^VS3N/^G*MLX9J[.ME3)MA5_7E=BKF:7V(]32=WJ4-8VDB
M:0M[A,BMB=BK+&+_ +UW'(?&,(F,8PBT'O\ @[=^X?'YNX=_A^'MW[?G[=_3
M/-)S'X[]5#8_/?AUM=W6*YL#6FO+354X:#TY;+C :4H;B/Y84ZS7&_;?7G=V
M:IV-6[@YXMM)5O'V2HU'===L]IKRNI'U)9TV\3OOWTN9H( (@(@ B'P$0]0_
MH^;"('?MZ^GJ/;^CN/;X_F[=P_ /IFN,81,8QA$QC&$49;B^W%]KFQ?:#^UK
M]MCP1WV)_;=^RO[7OF>]6/O7[(?L(_\ B?P>Y?>/N_W9]U[T]C]J_P!S]HSS
MP\N.+G+2/MG44DXK2G(_E#4]W7W@5/ZAHT?R*L[#7SF;B:MN1#>2LQ#EVS1K
MJ[XWZEGYFNVF5X^U.PZ^-L:<94ZN14O$M',O9H3TUYH)2CW[E*/?MW[@ ]^W
MP[]_F_!A%C/PQJ%GU_Q,XWT:ZSFV+/;Z?I/6]8L]BWJWAF>X9V>@JM'1DI+[
M(9U^T7B'9VZ0=ME7,NS976X$:KJ>SJ6JPK)JR[S)G   !V    ^ !Z '^&,(
MF,CC;VV]=:%UA?-S;;L[2EZRUE5Y>Z7JUOFLD]9UZL038SR6EG+2(92,HX19
M-B&5.BP8.W1P#LB@H;L7.^)OF:I3G3<)'*FDFLKV.7NDDLF"R1UBB(&1*HD/
MF%%4"=R 8X?<E,($4.;;B]VSDOK^%UH\U]':]F)"P16\)"PR%ZB=CL*A(PAF
M<8]TQ*U Z<=&71I)+*N!D;,<C1DFFV=1QBOT@$/+-;.#/4T9U?B'68:N<C;1
M+Z\OG)UG0[DXY%E-(Z6V=-=7*"VW1N0N_I25VBPF-BURU]/Z,M]8C9APSVU,
M(DGWM$E:/#N[HY/GJDD-_:HC-R5[0#FRN5-KV>@3FTHVN,:Q;I1DWU]794L'
M)VJ?MD7 O*94XL)LY8=@>U6*%6F90P,(9%^Z'RLZ_P <>4_'KEQK!ON;CEM&
MM;6UBO9;+44;=7_>"$?]DM1F%8*P11T)EA%R"+EG))^%$ZK--&39N&,I%*OH
MN2CWKDBR!( @7[KX^(XA_P#U$YA*'YNQ1 .WX/AF[/E!ZT,8I2N4!,9$S@H
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M%L.:Y1\\%-\[UHVX:[3N84)-6FAUVRPFK:G59344#$UC8=DDI.J6*1/1PHK
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M' 3D<E+PTU$RT4LH=)&3C))E(1RJJ:@I*)I/F:Z[110BH"F<A%A,50!3$ .
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MC&,(F,VF,!2F,/J!2B80#X]@#OD$:*W_ %O?1MQ%KD-.0XZ8WML70DZ,V$>
M2ECUP,*$I,1'N]V[[PC[WVW]WB]]FD!\I;VEHC]QXR*><8QA$QC&$6G8 #M\
M0]?B(C\?G$>XC]7I\,T A0^'?X"'_$;T ?P!Z^@?, =@ ?4.PYNQA%IV^'Q]
M.WX1_!\_KZ_G[]^_X<T$@#\?%_@8P?X!V$.P?. =@$0 1#N 9NQA%M\)>_?M
MV[?@ 1 /S")0'PB(=@["(=P[!V^&:&3(<IR'*!R*%,4Y3?=%,4Q1*8H@/</"
M)1$!+\/4?3U'-^,(HWU)I_5VAM=UG4FF*%5M8:RIC5VQJE$I$.UKU6KS1])O
MIEXWAX:/(DT8I.I63D)!<J"9?,=O'"QNYU3",C"4!^?_  ,8/^@AW'T^/Q[>
MGPS=C"+;X"@(CV'U[_A'L'?X^$._8HCW]1+V''A#X=S?@_\ 4;\'P]>_?^GY
M_P /?-V,(MH%* ]P#_F(@'] "/8OY^P!W_#F[&,(F,8PB8QC")C&,(F,8PB8
MR))G=%0@]X:_X_O4ID;ULG6>U-KUY9!B@I $K&H+)JFK6M.1D3/2.&LJI)[C
MJ1HAFDP<I/6J<PLLZ:'9(I/);PB8QC")F@AW]![_ ! ?01#X#W^(" ]OG#X#
M\![AFN,(M#% P=A[_P!(&,4?TE$![>GJ'?L/X<T H /?N;T[_$QA#U[?$!$0
M'X>G?X>HAV$1[[L81:"4![_'[KT'[HP?F].P_<_TE[#^'XX\(=P'U]/SCZ_T
MAW[&'YA-W$!]0]<UQA%P5FK4'<:Y8*C98].5KMIA9:O3\8LJX32D8:=CW,5*
ML%%6RR#E))Y'NW#8YVZZ*R9%1,BHFH!3EZEI[3^N-!:LU]I345:1IFL-65"#
MH="JC20EY)O7JG6V24="Q",A.2$I,O$V+-%- KJ3DGS]<"^)TZ74$QQDK&$6
MWP%[]_NNX]NX 8P!Z?\ X@/A]>_KZ?=?A[]@S3RR@ A]UZ^G_&?N ?,4?%W(
M'YBB7X!\P9OQA%M\(?\ Y?$!]3F'X!V_";U#YP^ CZB CZX*0I>_;OZ_.8QN
MWYB^(1\(?F+V#T#T] S=C")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,9H8
M1 /0!$>X!Z!W[=Q .XAW#T#OW'U^ #A%L6^]*_U9_P!D<K9Z<'WWGC_>1<J/
MVJ!F#?'+J*<X-H\N^H=K<_&K8=M8:P@^.]HX^<>KK34^-LA3*'9-@;YUG<K)
M:MU;$KQX6WS=_8:[J6UZZS3=/X)_%2TY5]>.I :':YE[EGTG9JVV.F<RYZ^T
MK[7%SE>HARH=62A_9)&7#[%9'VRDI#%_91"I(1,YV;I(.?;6"*:'^\>0)?,1
M4$2*UO&,81,8QA$QC&$3&,81,8QA$QC&$3&,81,8Q\,(F,Q\L?*OCQ4;F[U[
M9=M5"&NC&480KNN/7C@DDA*2A69X]BHD5H=,%W99!D9(H*" @X3[F#N/:?%W
M+=JDHX<K)-T$2F.JNN<J**1"=Q.=1902ID*4 $3&,<   $1'-?3RV*R$ER*A
MDL?=EQ\I@OQ5+E>S)2G:Y[70VV0R/=6E:Z*1ICF#'AT<C2-L<!MLA@,[B(<=
M8RN%RV,KY>!MK$SY#'6Z4.3JN9%(VSCY;,,3+M=S)X'B:LZ2,MFB<':>TG]\
M9M*8IRE.0P&*8 ,4Q1 Q3%, " @("(" @(" @(@(" @/;-V;!:E,8QA$QC*7
M.H1U -T<:^97 ?0]$I-J8ZMW'OK5-1W)LA;2&SK]7K9&[=7V968+5U#NM;J<
MK3:[<ZV[HRM\O1).:;6II6']6=04.^KYKO+5\BR9V1_*C\1?[$//3_.G@%EA
M64Z5+<6Q-L=4?C:6_<7]U\<#5[A#S@+&GV_/: G$[H9]N[@LD\/63:-W9N'R
M4X8(]LJ_-9@KOGIS$<:("3\$A[%<7A$QC&$3&,81,8QA$QC&$3&,81,8QA$Q
MC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA%^"B292KJE3(50Z(E.H!
M"@<Y2%.)"F. >(Q2"<WA 1$"^(WA /$/>MSIP??>>/\ >1<J/VJ!EDRWWI7^
MK/\ LCE;/3@^^\\?[R+E1^U0,(K*L8QA$QC&$3&,81,8QA$QC&$3&,81,8S#
M'D'N+8]'OD%7J<5N5H:$;S*C0D468=32JCQ\BX;+$(DJZ0:((M2%$K$$W &6
M,Y,X "I$"$DC8F]3MD; [#9V3KZA38PR.Z6ZWHGN=#LLS!, >GK^J;M^GMV_
MQ[Y"&V>0>NM1J-(B9=R-ANTLBJM!:XI;'[(KW-)))F44=I0J"R1(J(2(4QG-
MBL3N'KK4I1]HE$S=BC1'N:'Y$[;YA[(;:N;;&*X;7*I/EX>O7,73"H)^Z*T)
MADA:3WV+L7+ S=5])Q#GN+18#M)1F94ZB2]P.IN'-.J#::D;W(2M^M=M>&DK
M;)2LQ(N3SLCYAA3=SLH4S&3L;A @B1L5Y[)"QZ8@C#P,<B0F<JX]SCD?-+_)
M,;BN./X]4P.9MXD<ERSI;=7(,J7+M*6?#T16I-MSF2D\.ZK;JM R,?.;;V?!
MS=XYAZ8\/]-L3PO-9KF,/+\CROC>.Y!_Z+P#8*%_"S9'&XO)P5>1Y-US).Q]
M9L.38^,1X]M[+,ADCJC'QR?B5:H?96H+7NCD#8MKRDLPUFYM]RK4S#PS9RC;
M7<'[,C ,(]R]FVGLL&HX14C4WJXQI)=@@X!5))S)MT 6<S!S6X]FB]21,S%[
M8OV_=FN+S&QT^F]O;BSHQ]=6BY]9\9"IHR2C%FU++$C6YW"4<W21%8J0-D"+
MB7+GX_4>L(LI 9T*J$%, *0ZL(Q=JE*4!* ><\2<*B %,)0[G'L7T^ !VC?>
M>HUK10BQ&OH&NL91M+L'JC5!C%1!GL>@5R"S-L\*V23;* X60=^$RB";@&YT
M%%0!3PF^&UZ)\1EP_)Z+8K/Q_*G3V<IF99WVKLF0L6);,F0@J2AN*JVS)/-T
MNI8^JR-DCHXV-80!L*'^TUZC5N0\&RLMB@_%< 93IX#C->HRCBXL13JUJ<6'
MLWH"[/WZ'LU*YD;D\O?EFDA;+-)))MQB[I\/]F2?'"&>;5=VI[8S6BVHM5[>
MJLK*>X6DBFTAD43+_=A'-D4%&[%,  B2:1DRE "YF]D0:+IU@HFN8BO686H2
MB#B2<G;M#I+$9(O7JCA!H=TB0I'2R1#=UEP$X>(_E%55(D0XR_G3..8DX+ X
MC#&Y<R!QF.J43=OR>[=M?#0LB]^U)_/-)T]4COFXDKB_+\^.5<IY!R48W'X<
M9W+WLI^%8F+V,9C_ (V=\_PE"'_AU8.OVX6?)C0$QC&;I5Q,^-W'L'YFAGK)
MH\,P=I/V1G39%P+-\@15-%XU%9-3V=VDFLL1-RCX%TR*J%(H4JAP'[,815Z[
M(  ZH_$7L !_]$//3X?_ .T\ LL*RO79'\J/Q%_L0\]/\Z> 66%81,8QA$QC
M&$3&,81,8QA$QC&$3&,81,8QA$QCN ?$>V="OVRZCK5@SD+7(*-"2+DS5@W:
MM'#YX[52(51<46S8ASBDV2,51PL82)I@9,GB%55),^"0T$N( 'DDZ _=9 )(
M !)/@#RN^XSA(^R0<K M[.PDFJ\"ZCAE49,#BFV]@*B9=1PH*A2'1*BF105R
MK$(H@9-0BQ"'(<H=4HNUZ+L=:2;U*9]X+Q0(J.D%6;U@M[.X,<B#M!-\@@=P
MU4.F8@+H@8I3^$J@$$Z8'QU-VT=3=N[M&QMP\[;W[]OHFCHG1T/)T=#]3\OW
M4C8QC)+"8QC")C&,(F,8PB8QC"+03  ]A[_/Z%,/_0![?XYKGDKZ^Y8Q#EGI
M2QS&K:=RJJU'XI;%LFS=&[ K/,._4SC[KXNQTEI'EW9X7C$D2/I=93;1<M3K
M/:)MO;[C/0=;=MZ=5V[&H6"1<>J6AOHN2HU/DH-S"NX:0JU;>1+RNN5WT ZC
M'D,P6CW,&\<@#AW$.&BJ*D4Y< "J[$[998 4.<,(NUK?>E?ZL_[(Y6STX/OO
M/'^\BY4?M4#,).*_4@Y 7;D[SBUB@M&<\ZCJBNZFN.N(7BK4=04&=K,M<=Q;
MSUCLO7+Z2V5R AHN(3TVWU_58VQ0F^+!0]X6BU-[M<Z30Y35CVLN$<L^E58)
M:U5?FG8YVDV;6TQ,=17E4[D:%='5/?6RJ. >4A#W7/O-?6N]4AS( DBFZ,K5
M[E9(D47*((RBR@*D3(K4L8QA$QC&$3&,81,8QA$QC&$3&,Z7>[>G3H3VQ%J>
M4FY%VA#UF"1'LXG)]]XBL6!!#OY2!?"=W(NS!X&,:V=NS^B0%-@D-!).@.Y_
M\_T'<_)9 )( [D]@N%N]UD6,@RI=+:-9:^338[INB\,H$17(@JGDK6:RJ(=U
M4X])7NDQ8I"#R:>A[(T "$<+)8HV^R29[JYT3HV:5L&][4P]JVUN^310D":B
MIRBHM7<NF@ D9%GU5@-&T"B1AD(Y"0(,E*"L2)?&/$=\Y:ZYH4C;M4PEP=6;
M<+YX=K>9*&C9=*:NNPG:C>,AM7T264C_ '5",A>/6L$G9'CU*+JL&5VXCP>3
MIC"3,WC3HY/2E'71EE64GL6Z2 VK94^R2,1L]LCI,"$AHDZYE'9:M4VG@@:R
MV<K** R;JOU_]^DGAST.QFJW*KLO'^/9:O.RN^1G)LCBKL4TN&KLD="[$Q6*
MTCG5,YD9HIJY<TLLXVG#=LM?7MC'/FZA3XW>X-0@Y;S#C]RI+;ABEX1AL_C+
M%>'D5J:*&RSD$E6] QF0XQAZT]>W^9LE+-9&SC*!9>QQS4=;N^HM-472=3;U
M*CQAT$/-5>R\Q(KFD;%9IATH9Q(3UEF5P%U*R\D[46>.UU1!,%UE/9TD2#X<
ME3&,NU6K6HUH*=."*K4JQ1P5Z\#&Q0P0Q-#(XHHV -8QC0&M:T  !<YO7KN3
MNVLCD;4]Z_>L2VKERU*^:Q9LSO=)-//+(7/DED>YSGO<22224QC&>Z^1,8QA
M$QC&$3&,INYV\XMP\;N97#C5U%V/Q]4H6UMM<?=<;2TK.P3F=WTXK6_MAWG7
M1-K1ZK79D'9(>FQDW7H*L4I:BZAVNV>79S9'&VI77% B$K")%D/LC^5'XB_V
M(>>G^=/ ++"LIKI>^K'N[JD<<"V#C9R'X]C6.$7-XK8V^876$02WC)[MX+IK
MC4AUOMC:'M)8?W8D>5&9]R>6G*Q9F7MXJNBL[E,(F,8PB8QC")C&,(F,8PB8
MQC")@1 /CZ?]_P#?^'KGX.G39DV</'BZ+5HU15<.7+E4B#=NW1(919==90Q4
MTD4DRF.HH<P%(0IC&$  <A%LVD]S_P#B$BJ_A=5"H;W3#-U7$=+;!0(82^]I
MURBHD\CJDX,3Q14(W.@ZFVX@^E52LE4&1XN=H@ ;<? \=AK9)[Z WW.B?D 3
MV60-[)[ >3_H/J?M_<@=UMNW(*F5-D_=1R,A;O=KE-@^<P"9#P+&06,)$6#V
MR+F)$@],8I_&P8*R,BD4ASJ,RE(80UK-BV5LB(:6" FM=5Z D/.,W58MYJ[2
MB9DCG14;.#NE*K'M7C=4IB.$C-7 )J%  \9! 3=FOVIJO>Z:E2U$A@8UBY;/
M8@8)!HT)%NFA%DD1;L_)]C,W,BX716;"D4JB:@B4R:H$5+RVN:!$ZUJS.K0Z
M[MV@W6=.W#U\9,SEX]>J^<Y74*B1-%(HCX4TD42%(DBFF3N<X'4/Y],ID_.X
M>WT_R'IT[8[?U'M\P1^WA3VP,[ ]?5\QL=/;]O/V/T^YX4E'O+@0]Y;=LOA$
MZ9C)PM=ID03[D3"8I#N(:6<%*81*'8RZ@^$@ 85!$39U*U\>8*ZMV2-FNNP9
MA2..JHQ</I>'6,V.X\H'1DT20"2)?:"(I%.4"^ GED,F0HE]<@<9(Q,(((+@
M?(<YSM^/J3] HA[@=@@$=^P:/I]!]@H6::.KK&%+7&EFV$W@BLU8_P!THW)^
MDP%DX*H1PV%LFD5+RG *K"L0"@4XJJ>@ ;MF_5VCZEJEY+R,&XEG[Z623:"X
MEG#=4S2/26%P1DV*U:M2>$RW@.NNJ51=<440$Q0)V-,V,R(XP6D- +?X3].V
MNW[=DZWZ(ZCIWD;\_K_;_P V4QC&344QC&$3&,81,8QA$QC&$7CBZU<?8-L\
MOIW6,^KL64GZ!J"P6NOQ>J.F_P _=J#MS15H4I!DN,EUV-QGY+ZDK&\J?+[#
M2EGMF;W.*-IR&G;A%TB8F*S:$+,VG/7I1R&3IM43/%IP9B5J (:%2B$X!*),
M2'9%-&)P2+AVC#)QX@+,D4DZ<IQI409$76*@"I_,[U]:/LR-N2VVJ;KOD)=M
M>V3@[O;0?(FS4_BKKSDQKK4F@YRU1U]OMYH\I<N6/&]SIW>C5&M,YX]D&+NU
M?F8>F4B5DBLGU!CF[KTH:O-''UM0#Q$Y,6:*/2:D:-L=ADVDU/3\>:NQHLIJ
M:F(]9=C*R\LU%*0DY)FNLT?OG#AVV54063.8B["U@82*5F7T9$1<<\G%Q?S+
MMC'LV;F6?$;@W(]DUVR*2L@[*@0B!73PZZY42%2!0"% N5W].#[[SQ_O(N5'
M[5 RR9;[TK_5G_9'*V>G!]]YX_WD7*C]J@81658QC")C&,(F,8PB8QC")C&,
M(M#&*0HF,(%*4!$3&$ *  '<1$1]    1$1]  !$?0,PZ9K3N^-@SDE$N7,5
MKVMBZJS"SH&,@\.T7(0ME+53CW%"9M'A(Q=V( !6 JZ0-F(%DI=51#@.2VZW
M@&4U[2':_;QN6MLEX\COS2N$5$$CUU@];&+]T45?)GQ;^,Y170BBK)KJ.D@W
M[*GYJ6H^IN-NNVAZ%?-R5M(UB")(=!QJC4\>W:CL:VE 5"N&<L\]L+4ZH=V<
M';BRSWM9W"BT6\.729G+0XVG8M.9)8= 8HX*D):V;(W[,L=:ACX'._();=N6
M*NQTA;&Q\@DE<R&-\C;!QW!SYS*5<?'+%49/[T]O(3M>ZOBL71ADN97+6FQ@
MR.KX^A!8MRQQ-?-*R(PP1R3R11OPWU]PCK^^=WW7D/5KL[JVL(O<T7(ZU;-*
MPT<M[HUH+V)3GWL><\DV(UJ2EBA'<)7Y<A73N:3;2$V=$B*C,'%U0!V_2(_I
M'OG U:L05+K<%4JQ&MXBO5J)80<)%M">!NPC(QLFT9-4P[B(@D@D0#'.8RBI
M_$JH8QSF,//9I^&<*Q7$*U^2I6BCRN>MORW(K4$MIT-W+699[,[Z\5F:05ZL
M,MJ:&I$QK'BJV(6'33A\KK1ZC^I6=]0[F*AR%V>; \4QT/'^'4;,%&.SC./T
M:]6E4BM3TJ\)MWIX*->QD)Y'2,==?.ZJRO7<R!C&,9<US=,8QA$QC&$3&,81
M,ZE+4&CSUGK5UFZ=59BX4PLB6H6J4KL-(V2K%ET!:RI:Y//&2TM!!)M1%M(A
M%/&@/FXBBZ!5(1+G;<815Z;'*4O5'XB@4H%#_4@YZ!V  #T^W3P#'MZ?@[B(
M_P!(C\^6%Y7KLC^5'XB_V(>>G^=/ ++"L(F,8PB8QC")C&,(F,8PB9P5FLD/
M4(*2LD^[!E$Q2'GNW'EJ+& #*$123211*=59===5)!!%,HG564(0.W?N'.Y#
M^[3-)"EK4P62<I,WUVVK->C5%54BC)J'!\,NNH@<BZ3*MMF:LZ\4*/8Q&)&P
MB(N2E-%[BUCB-; /3O>B[PT'7<[.AH=S\E)HVX [T2-Z\@?,_L.ZZ:PLT9R$
MDD8^',]#6=?%N]MA':*D>YM,Z<QEHJK+M#&!88%DDF68F1,/DR:HQ\>'C0*\
M*.2!2E(4I"% I2@!2E*  4I0                        R.=8ZOKNK(-:
M'@3/')WKDKZ3D9!0AW;]X5!-N!Q(D1)%NW3(02MFJ28%1(8?&=54RBIY(R,8
M<!M^NMW=VO';L /L!\OJ2?GM'EI.F[#1_#OS]R?N?K] !\M)C&,]%%,8QA$Q
MC&$3.#LU@CJE6[!:I<RQ8FM0DM8),S9$SEP6/AF#B2>BW;D$#KK V;*BDB40
M,JH!4RCW,&<YG7[;6V5QJMEJ,DJZ0CK37YFN/UF1TTWB+*<C7,6Z5:*+)+HI
MN4T'2AVYU45DRJ@0QTE"@)!\;)G%><U@PV1#*:XD_P!V9^AWM!^B/R&3IZNX
M_+ON%]-,5C;JBZ9&TS9@%LPZ]T5C*WWS%L$>X(NLLV".K78^%C5H?FII+D9;
M'U,UN[M*\U'UUQ:'!9NJOH1J$4V?1L>J8CIRH=,[CVB5: 5N >,Q!4. ]DS
M.4TI*1T)&OYB7>M8R*BF3J2DY%\X2:,H^.8H*.WSYXZ7.1%NT9M45G+E=4Y4
MTD$E%#F I1',.N.?!;5/&:YR%XHUAO\ *RLC5W-37;VF4@WK L>ZD(N14622
MC*_%+E> O$MRD4,X.B"1UBBB8QDS)SER"U UW_I39^DI&TV.F1&U:9-4*>L5
M1-'I61G7+.V&*L:$0XE&;YHT=2L"XDH;V[V8[ADC(JNV1D7R+9=*K<'?S23
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M%B%53,F8Z*R8@HDJ4#"*:I! Z9P*<H@8H#A%T^G7^O7A:S(03D5U*M/N("0
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M4LG[2<T33&1E"HK+-I=9HH\GGB)#-1BFQ8Y)P=205 D7.#=#MU.[-:3KJ/\
MV'DD>!W4FC??OH:ZC]!O_,^!]2NR:V:N+-)S&UI1!5$]F01C*8S<D.1>+H3-
M4RS!<Z9_5N\M3LQI]\F =P;'B6Z@^)J(!,.;2$(F0J:92D(0I2$(0H%(0I0
MI2E*'H4I2@!2E#T*4     #-V&MZ1K>SY)UK;CW)U]S\OD- =@L$[._T 'T
M[ ?V3&,9)83&,81,8S&_D!RIU1QI&JALUS86XW'WU[F]Q5YW.^+W#[M]O]J]
ME.3V7P^]6GD^/OYW=7P]O*-WUV6R^+P6/GRN9OU<9C:OM?$WKLS*]:#WYHZ\
M7NS2%K&>Y/+'$S9'4][6C9("W. X]G.59:I@>-XF_G,U?]_X/%XNM+<O6OAJ
M\MNQ[%:!KY9/9JP36).AIZ(8I'G36DC)#-._?Y_T"'_4,KSNG+>)WIJ"YPG&
MBE[9V9;+/2+-&I/ZY77M284-\^C7S-!S.W&?<1$6RL#3N20CJ_7G\M97)S-
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MF?'A$QC&$3&,81,8QA$QC&$3&,81,8QA$QC-IC>$._;OW,0OZYBE[_X>+O\
MG[=L(MJWWI7^K/\ LCE;/3@^^\\?[R+E1^U0,Q XH]927W#>=MM]PZ4?5W6I
M*#(;>THMH6L[FY%[65U['\O=Z<-C16U-9ZWUW8["WMCRX:2=7A>3H\5)TZLU
MZ>4A+#(HO8$\Q*_1PNYG:WT^IRU-?=3\V(<-F\WN0>V:2*?3QYVR/OK7ER-3
M1J]E#V#CPX%@C,!&R'E1LG['-M/9#^\XQCYC?SR*^'&5[?*9<>/R?<W?HX.?
MG\.&;B=2_CVJ<B2>O.;ZBBIR))IDZ;_/TQU%%# 1-,A0XX"8QSG,4I"E 3&,
M(% !$0#"*P?&5JU3JP<3;Y78RWT>#Y?W&J39':L-9JQT]N=TY RR;"2>P[Y2
M-EHWCNY8O2,Y:-D8MT9NNH5"08/&:@E7;+)D[#\IEQX_)]S=^C@Y^?PX816$
MXRO;Y3+CQ^3[F[]'!S\_APQ\IEQX_)]S=^C@Y^?PX816$XRO;Y3+CQ^3[F[]
M'!S\_APSK]LZK_$ZAUF=NEX@N8%.I]8CEIBRVJS]/7G?!UVOQ+<R9%Y.:F)+
MCNW81K! ZJ157;Q=%!,RA"F. G* D5E.,KX-U,./1#&(?7G-XIR&,0Y3=-_G
MX!BG*(E,4P#QP[@8I@$# /J @(#ZAFWY3+CQ^3[F[]'!S\_APPBL)QE>WRF7
M'C\GW-WZ.#GY_#ACY3+CQ^3[F[]'!S\_APPBL)QE>WRF7'C\GW-WZ.#GY_#A
MG S?5=XHUES6F=C@.84"[NEF:4NGM9CIZ<[XUQ:K@_C)>:956O(N^.R2DQ8G
MD-7YZ5;0[ J[]>.A95XD@9NP=*)$5D^,KV#J9\>!#N&O^;H@/J ATX.?G80^
M?_RXX^4RX\?D^YN_1P<_/X<,(K"<97M\IEQX_)]S=^C@Y^?PX8^4RX\?D^YN
M_1P<_/X<,(K"<97M\IEQX_)]S=^C@Y^?PX9*&CN;VA^06Q9K4U''<$!L6!H[
M39+NI[BXX\@M RCRC/;(XJ"5E@B[NUI04K'&IV5JO#NU(%61.Q>% CPB '(8
MQ%ESC&,(F,93SRZZE6P..O-76?':MZOHECUJDGPW7W1:+#<YR*V(=/G/R?NG
M%75J.HJM&P;V&EU:!:Z2]NFPU+1)M2R5<=M86N)(RXB[,13YLC^5'XB_V(>>
MG^=/ ++"LHTO/-G6DGSWX\;D9:EYM.-<Z_XN<N]:6RQ$Z>7.D"1EUV3M'B-/
M4J')''X]EEGY9N*U7>'B<C'L746T)#E3D7K-:1C4W687RF7'C\GW-WZ.#GY_
M#AA%83C*]OE,N/'Y/N;OT<'/S^'#. ;=5WBB\M$O2&D!S!<W.OP<!9YZIM^G
MISO6LD+6[4]GHVL6"5A4^.QI!A#6*0JUF8P<FZ;I,Y1W7IINR665C'A$2*RC
M&5[?*9<>/R?<W?HX.?G\.&/E,N/'Y/N;OT<'/S^'#"*PG&5[?*9<>/R?<W?H
MX.?G\.&/E,N/'Y/N;OT<'/S^'#"*PG&5[?*9\> ^.ON;OT<'/S^'#. KW5=X
MHVYO*.ZI <P;*U@[+8Z7-.8'IZ<[Y9"(N%.DU82VU6258\=EB,K#6)E!>)L$
M.X,F_B)%%5D^00<$,F!%91C*]OE,N/'Y/N;OT<'/S^'#'RF7'C\GW-WZ.#GY
M_#AA%83C*]OE,N/'Y/N;OT<'/S^'#'RF7'C\GW-WZ.#GY_#AA%83C*YY;JD<
M9(&*E9Z<I_,^&@X*+DIR;F)3IU<]F,9$0L,Q<2<O+2;YSQS3;,8V+C6CJ0D'
MKE1-NS9-EW+A1-%(YRHGJD<9)Z*BIZ#I_,^9@YV+C9R$F(OIU<]GT9+PLRQ;
MR<1+1CYMQS4;/HV4C7;60CWK911N\9.4'+=11%4AS$5C&,KV^4RX\?D^YN_1
MP<_/X<,?*9<>/R?<W?HX.?G\.&$5A.,KV^4RX\?D^YN_1P<_/X<,?*9<>/R?
M<W?HX.?G\.&$5A.,P%@>I3QFF[EK^C.X_DO29?:%YA=:4F0VIPIY@ZDJ$K>K
M(WDW5?K*][V5I"K4R(DII*&DPC"3,ZP(\5:*(('.N)$S9\@(& # /<#  @/S
M@(=P'U]?A\^$6N,8PB8QC")C&,(F,8PB8$._QQC"*#-6\9./6D;?L^_Z?TKK
M'65UW3.)V7:]HHU,@ZS-[!G4W4D_"4M4A$LVR\L[-)S4U+*G<&$JTQ-3$PL5
M23E9!VXG+L'Y_P!(_7FN,(M.P?G_ $C]>=.V!=H+6],LE[LJ-D<P-3B7,]*H
M5&H6V_V59E'@555.$IE%A;';K)('[%*A$U^$DY-R(B"#4X%.8O<LB:Q:*U':
M]HU#=D_0:Y)[;H%;L]0I.PW+ JEIJU;N:(H6>(AI$3=VC.:3'L^2\LX+=@[B
M !A%5+Q*YV\0='ZDX,::UM6N4CC3_).OZSD]1;DOVM&(T^&G.5]KV;;=/Z_V
M';XF0CF9[]=9J(MK%.$U_7[FWH3%I#NMI25/82\7+R5V(=C  @(]A !#U'X#
MZA^'*G=9](_5FH]A<-;U3M_<A31_![2-/T-I_7MI+HF[T,E7KII)*R6@\?;M
M(S,K3]I[3B'S:K;(VAJN8U_=9*G0T55(*8KT$5^Q?VR '8 #Y@[?@_\ ;L'Z
M [81:=@_/^D?KQV#\_Z1^O-<81:=@_/^D?KROCJ>[ X_4WA_LBN<F%=P-M4[
MC5K>CYE]I:DRUMMD>ZVK:X"F1+P\F6#EZC1XXDO,QR2UMV$YAZJ@JJE%IO'L
M_)0T+)6$"'<! ?@/H.85;UX!<<M[4[>U7D:L>@RG)*RZ:MFX[_K@D7#WRZ3&
MB+S5+WKY:6E9>,G8]V$<\J#"'4\^*4.$$[D&K8[9TLB\;D7!Z-ZA^AM_\E-G
M\7J5%[087/7"FX$V-KM=)/ ZWV@MQZV? Z9W^EJRS&EG3NPFTUM:TP%&N)I:
M%KJ3B8D@5JBEEBV,G(LL\.P?G_2/UY7YH7IQ:;X]\G-E\HJI==O3]COJF\U:
M_0+C9X"4UKJ-7D]M^ WWR'/K6,CZG$65(-L;:J\%;Y<ESM-Q+7EF1HFE!6X-
MX[CE;!,(M.P?G_2/UX[!^?\ 2/UYKC"+3L'Y_P!(_7E:_4RW#QYX]47CIO7D
M*3:CUGJGE/3[3J^"U6C3P>V3:RNK=R5V,A[5*[$F:I1H*I?8;/WB3</K'>*4
MF^GHROP,-,O['+1-8G[*<KEY@=+SC'S%<O;/:(R1UOM62LM+LLIN#7D+K>6M
M]@-0JG<*-7(*XP.WZ%M/6-ZK,=6;U8FL?"W&@S2$+*J1EH@3Q=H@H>79D6:^
MI=DUC<VK-;;>I7OG[#MIT*G[%J@V&$E*S/#6[M7HZRP8S5<FD&DO RHQDFU%
M_#RC5N_CG0JM72)%4C!DA=@_/^D?KR.=.ZLJNC=2ZOTK10EPI.H=>4O6%/+/
MS+ZQ3A:O0JY&U: )+STHJM(S,F6*BVH/I1\JH[?.?-<KF$Z@]I'PBT[!^?\
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MCZEK;5C5=1T+5VM()"+HFNZO'OGL%1HZ<M\RA)7"\RUEMTS)S3@BS>[!^?\
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MZX[H]XV-K?GYN"ZT6=2JRL:,+4FM7M<7&SL57*0RK=70?L&B@PIP;I%+E_\
MZ3A4Z/J[C?3]KTW7&KVVP]R\AZ=&[3M,[K#7]S?WIOKS0^Y(ZB+6!.Z5NP,W
MDG4(R2D8FNS(MBR\3$R#Z*9/D8]VX;*$635;Z_\ KFS:RA]]L^+VWDN/\PU"
MCI;/7N6LQ40Y+!P]7YGJZ25H:<L:]&@T]?-U*N.X$X4U8-<NRQ(8:7_\6YUZ
M0ZX-C?;(I<$/&W;-$=UVL7?<-QTZ@RUIMF];IU')<$[MRRT^SUO9*QL6)CJ;
ML">>5=U#OZT]C+*Y-*Q9:^10R%@:3+*P/CKT\>#;35>CKC_JK:4?7-+BCKG1
MJEUFJ/$S]U?ZK<:.B=7NZI,6^<1D+).)2&MG#B@R<K,2;Z=DZ:X<5J0E',.N
MJS//MCX*<-+<[=/K7QATC973^I,Z"^//:\KDN5[2F.OI+4[.JO$7[%P@Z@FN
MM9F5I#>-734;)5Q\XC2)E0/X0(J0E.M;OCD(YIT5QYU'5M314]QPZC-WOUFO
M\Q";(M>K=O<+(;4-KK$:ZHC>6I4TC7Y^*V55VMDJ-_JU*V"[;;,A9J-85^-I
M;N0M>>O-+F/R(U=TJ:]RHT:UU\;DA>:[PU:5=E;:[(SU!2O/)796D:&^;.ZZ
MSGHF358D5V<Z+%M_?B:S0YF*ZJCPJ)DW$7=3#BOQIXJ]-_DALGCSH+3^JK]I
M'4F[)K55NK>O*L$]3)C?%?A]9;CEHV0D(Q\NM)[&H)D*M:'\@9X[D(J,@TC*
ME/ 0BD?DCP9T'IF<XS.JS-ZWJLU7;5L;5FU;!"2\<23BY39&M]?:!?4>[+LG
MIEVY;%7)765$G6,DB1-P-CKC.QN#+3JKR0<D6*O2ZZHFT>?/*_D]4'<926O'
MNCZ#XK[#TS(PD0\;6J0MUTBK'5>0C.R2JLR]:/653W=3+O0X9HVCV:S$U3?$
M>K+NA5*G?#D#:CXO\==#2,C,:6TKK;5TI+0YZ_)OZ/5(FNN7T(M>;ILY2*<J
M1K= 56)]A;(OMR,W/W3&P6Z>D>WGR"YC3SA$QC&$3&,81,8QA$QC&$3&,81,
)8QA$QC&$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g685001.jpg
<TEXT>
begin 644 g685001.jpg
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M43T+A-F[%F[.X,,BC?%TBRJ5>TJ_C*YQYEU$ )J!(BZ2B>I@H(1]L*.)B0
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MR46];2,>];JE Z:[1\S57:.D3D$#D5064(8H@8#" @/&FOI<<<<::<<ZA?-
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M &5B+2@R^&H"I&$C,-D1?'TQ2=)K)"F@[371,/O^&@Z*LB(^0\G]B2ADA'R
M>3"41\@'U\^.=Q5&8K/TUW\+D*]NJ]A.]S58-A92X1%@% E$J9$#$$ID"Q9=
M0, 2YB.#K!Y;;=YN/SF,L5+E9*JWM;:CJM&*[))1QUC,.">9D'+ZEM'H-9D/
M$SM-U_UV#SSL;4M$F9B[0,%#OU4B3V>K5Y&Y1)DHYXSCI6%"V-7M;<>UZO\
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MZ>(D?4:Z?*'$%M8&/2*D=4[N5I-^C6*9"(_,>57KJLD03 Z/^53\F\JD_>2
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MH Q#P<]+UV&E)J&,FK\<AHF5?L7$A&B1;_*D%DX0$BG[Y?!OKSMH  ?8/O\
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MP=%ABPT:6)!R"_S0. C2M09 N#G_ #@%@0^*"_\ E@/\3][GT1B8LRPN!C6
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MKOXO!S,>L)2"LQE(QXU>M%1(45&ZZ9_:'N\!?8R[:QN2H9"DWL7*5RO:J.D
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MW*8MF6&@==MA)2-I#NBP4OD&B(VRJC#N[2]M-ZBU*9&J($G$_@I,2+_=/8.
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MP^WV^_WGYC]/+Q]N?C[_ &G_ %C]TZ@OQ?J[ZU6M:9G>K]R^_P!DF$4BH7>
MO;GJUTHQYF^A[?&L)1C+K9]IFT:L1W8Y"$<-VZM<GFE?C72,DR<O73*7075;
MJH2:=S,1<=BNL&RY#'E3//6JGO%*H*@MDP"XP2Z%BJ1!<.A*BT(O/13!DNZ,
M<@(-G*RAC  &'FSW'W^_+JA<L8V]3R-4^BU1M5[E8YCF ?5:#E%,>.8A@#,Q
MXYCQSQJRR-&OE<?=QEP.NID*EFC9".!DZ]I)H<,3QXDEF407F8GB8^-?G,OF
M+^,?/8R58NHN4C7CN.E(M\BHV?1<FP<*LY&->ME0*JW>1[U!=FZ05*51)=%0
MA@ 2\]8/'D/(^ \AY'] _,>6G_4P]+-;<)&<[!]>&K1MKBZ"#B\9T/R<;%Z<
M+-+X)IZ%?*"@VBM$!FF@@X"052B;@FV0(^>1DPD1^\J\6"O3]1GI6L6F#EZU
M9H!XHPG*[8(UY#S<.^1,)5&DI%/TD'C-8#%$ !9(I52A\1 ZJ0E4']"=D;ZP
MV^,6NY0<M5Y:P_,L4;(FU1=,1!\A/!-JD<S[>T(]MH\07;<+4K_-S?>P,WL/
M+,HY%+&T6,9.-RP++VE^O$\B4''4*K0!(^YJ$7=2?,Q!H)3FR$M.G.3Q&=P6
MFZ3>]&K%1J?5K)>PFPR%3A:S:+#+6+L3>)ZOY#G>:0DPO$1,01C$PI5;39+;
M(OV"L@\1%)2,2%06?7T>M5VUBRQ>T=<-NG- HKVUV&)/LVFSEAI.DY/.9EE1
M-+GGFP2L<,RXKS>"K+-PSJ]OJ\S*(38,$6\0RCDS-$E,=P_=35ZR;.7-985)
MD]I>%1776UM;%#,[Y3M?S.L3LK,TV,T&A69DI#J+U=.8<Q[9Q'.RN':9$7(N
M&0?'9K]N?=X;*_R+L!4EX661T[LLUJ-4T:W0TM7JGF,=FE(.=G 5:C9)5*S$
MDKTH2JG4I3^:6G7I']==.@=)N7@HG3PI4M_)8UO<1<-]HJJ(L.I/K5:%VRA-
ML[%(JBGF"!"SE4L3ESDT10Q+,7$PQE7+A=]/W+0DEV*85ZD6;!5U7DV;>0HU
M7.IKK71MN0MEDIJXAX/PP"MY9#,+R\Q*E6LCV3I[JE))9H.K]M<]BL@E\ARS
M7]NML]KUNI5&BC[!',E:U'Z75H!"8<V).YRSIPQH,O(1$JXMT9&24O+-8%-J
M+17L\KU)[.9UAZ5[3UB\9O9>M]M[%0&A6AYM-J9Y5D.>U*I4"QU0N<.*I\>:
M8O\ 57-K03;15803;VOXL>C)Q\)^&NUT]:HWO;V"CR1#=5QF,VQ89M!9+-1=
MFR*D3\5H%'J:T>O2X_2V+]B9*YOJ0I&-C5&6=_+/(3XC\J1E"R<B#KP/WQ[.
M.7$VO*7IE.)VF9U>9N$=,U]FYA+F.S5B)I]SAK7!-EF,1+5Q* @H=G5X8&;5
M.K#'H*1ZQQ%4JGC.']0BE M9MEP*=#K!FJ(;>Z:95#AD+QZE0UXLM1)F!H6'
MY9'MBBO?7;]_S?TY&+)I5NA#'*E58%NCM4)F\NZN5DS(M?*:\KJ\+!B[#3C+
M3[L"M8]E+9^7Z4Z]8;D[KM!VF/RZKF_N>IAV6S[S<UW%CU'M+F<3;IBO0J]?
MJIDYE33Y#X<3*0JK$[N841;)6!>:C6/S+'H\9U [R%R><N3+19B,BI"!?0\A
MG7][^A1\I9<RHUN-FBCQX9-)+-U*' RCM\E$UJQVMD]1J19*<BJX2$!R4<#/
MNZN]R$A%RB\S6 =PV@8GIT>9*IM2)HVSK[6RU/,W!TS/#@LPCX8A$9B/5$R<
MVN7YA=1 1,F;^R_=_L*[HZM ?SM0E84)^7G8U]-9S49JQU\D]?6FF2U;@9R6
M8/56E.>7%D@^/6W;>0;A'@>"*X_!3_(E^PP^_P!2:BP9M=T S%Q8][68\^TA
M$%D#[O8[KW/O<.ZF&)] ]2FJ=Y+Y9F/3QK;;35NE1&K*E6]E94@.\]XCCURJ
M6RJNE%&"3 K EPPH%JGI\!DW0>C;_&8GL35M(M,0^UC(,AK6W02=)<V(U8_9
MIKIL3GEYK5F97&E5:0<2BZ%CB9NF6*M.WU>>)LGA?COF[P@M8_3%]IA*/W*8
M0\_R'Q^?Z\W(NW>'7-%IE[IULBZ1\O;\^B\JB#U.O,Z/"4&@AH#32;E#5>G0
M3;\+4>Z'9(F &=EWSX!C&$*BTA6")7*HDU:J50MF@66)I](K<[<+;/N!;PU;
MK48YF)R46#]Y3Y2/9D.L9)$O[[ITI\)DS3\K/'#=$!4#:MNQGZM*\W=5BK%B
M'@WOJ<N*8UUX^F+7+F03[5$O!YL4X8E3N^4&U)+>W4]R?V?M7J*=IHMS6)!)
M%#DL]\=AN1NDE+8ACIM6(KLJJ6Y)3#E0D26I\-KJ]2N5Z?MM@@JK5(EU/VFS
M3$;7JU!,2"H\F9^9>),(B+;$ !$57SY=%$#"'M2(8ZZGA)(Y@OO]9<?#!^ON
M/8\9PFY=9]0:_7I1V@4"(O9Q!F1>?>I%(82@F\FW$@X3'W'$Q%"G,<PF$PQI
M^FIZ7Z76]=AN.YIQ\QN+F.53KE7;*-).!R9M(I"F[40D$RJ(S%^=,E#1\C.L
M5!BX5FN^B(!9X5V]EWLTG.5/6KU#I;KO5,)A&C8Q&'<US+P<]N_D#'M==>9_
MO5:JNM:G1$0\W.,.M,(8?7OH5Z;7MHT+F>SJ2K9C-)4E-!GAN/QHF+^FR/R%
MJVX5,:@IDJZT)!D \GJ6XXYXJ"($.)0 1 HB "82 (^/H G !$@"/T$P (E#
MR(!].05KH+7/D//CR'G]/(>?Z<YY2MMOJ*^H3GFSZ$O8=EM=7N$9:I^"L.<R
MT-7).E59Y'/W#,T'&4Z7B'D>R:1Z)$2,GK947DDU^!**R;XSP':NWV6>O!MD
M$5JRU[':!H+5+X*2TO3)67SV>5(4H@LY682!+; .G2A_:<J3?\#:E#W%$"AX
M$)KO>@V]T54V\>>&S0.0I\+H9"%LX8L3^@KRJE9P3!<K8JP7<'@A&.8Y@FA^
M(;8EBTZID59O!FJPQ'<R&.[B_H,@CN!0=<M)9],]U3*P]DOH(YF)F+2G,$]H
MQ_\ HS]B  #"/]QFM>/!3#_^0,_^8 (?[OSY&=3/7/ZGS3)(]RJ.RT*2$Q@6
M;*56+N#),H>WVF(_JDZ[75]_DW[OX:F<OM\F+]0YB[4.QGI4=C[5/7J^=E=X
MK+ZQ1<5$2]986?L'0ZLX8-HH(P6Q*="PQX$Q5V@&0G !!1)\NHJ9T"WQ3":,
M-S>G7J37Q]JM4V3E[=AX-JS!)MC7 '*8$N&U2I9(&]!2'  /2P9(H;'3]4Y>
MF?JAZ,MW1B,EN3U)HX/%XVS2RXMI5J63OOL4KU2PNB>.R.;V\587I%_59.P1
MH8M:YJGW9)<LW3D?_HF]90\#Y_N"R/\ \TWC_P A(3\_'CZ_</K]0\"'T$/.
MR(B !Y'_ (\_0 _B(C] #[B/T#E<*D]M/2\ZSVJ$N66Z1VYT.3ID?(,J[5BV
M36IJB*(JQKN$1CQ@[](UZH@S0:G*,6"R0-8X/E'31,AT2$)J]VJ]9?=-JCY&
MFXQ$GP2C2#=9D^E6LFE,:I,-%R_#52_:5LDC&4Q)5,?"A*ND[F2#[P0M:9%!
M(&9V'Z/>IF7J4:64VU.W1K*K5CMY"PT:W82A2_<0%BG3N,,R%D0A%1T#P$FX
M8.9'#^M7KAZ+X[<^=S6T-Z6]Z5LS?R68"LK#5\?>3<R&2N62QQ#4S6<Q_:KI
M97*;[\C6EI,:"Z<RF.[O%ZL7J0,*C%67JOA,^JM>Y-$L7K5^@GJ!FM)AG::I
M92@0S]NH=4;Q,-%$T)]VU,4*C#N5F7Q2V*0($16MI]KL% M-8NU.D#PUHID]
M#6:L2* B3\.FJ^^;R$2M[2^ ,V2<-4DW#<0%-9F*S4Y#)*&(/7Q'R(B/D1,8
MQC"(B8QCG,8YSG,81.=10YC***',9150QU%#&.<QAXYW%L[9&'V;@HPM-8V>
M^,EE+;UCW,F\U]MIN#DX&OT<K35ZC6E,R,DQAN:W\Y]Z;[S>]L_.=OM*M*"@
M<53KL*%8JNMG<4M!Q $3^N(8^W(@U[H@N%K!*57\>KV_UKL[AE V:LBB@G:X
M=,T[#$<)+N*Q;& BRM-9>@FLL=%Q#S*+E!(K@2++QYF+X4RIO$O.?^4C.A7?
M2[=*;N^,#!S<<@N3ELIH%!2<(MGH/&Z -&EPJ#IT(-&-ICVQ2-731T=&,L\4
MDE&R:[1PRB92.L81/K%=#I*O*3CK3K'!O$S$*:KR^:WHMF$QP+Y!%I&PLE'N
M2D$WM.LVE%F_D!$BIB![AY&WSZ2;EP&;LAAL1D,QA;+B;C7XZL^\Q*FG,A3N
M+0#&J?7Y[4,,878"!:!]1,4KLO8/K+M?<.!JGG<UC<+G:J 5DT9*RB@NPY0#
M!W:3'FM3DV>);*5E+:QR:3"0%37:L^J;E':[OYV%PSTV*72]#S'H];(1#<.]
M/9EBJ>(B=$S*O65.,C^I^>V%DHX*A:[S)(E>75@_01>!7UHR42;NJ[%S2$Q-
MC4*E0,;SZN4BG0U>S_-\YJ\77*W QB;6&K52J5;CTH^+C6A#"BTCXJ*CFJ2"
M0J'(0B:0G5.*ACG-!YMWKNYI$,UV/7O*;->)M5N8K>R:5XI%49.#?$ BIH)D
MO(VZ9*GX3.9JH6M$6*)T_P 1;J 4309]B^ZG9+M.N*6OZ,^D*RFN==EG]>;I
MU?/V0F5.HD"E;C3^V<6:@?X39]:G<^_2(0AR.2* !@N]L>AF\<V:VY50;;H3
M,2;+\0V^8_?LXU1PP3CQ$Q<;2CCZAD^.)M-U_B V7@UFG#L9N;(#$]"Z'*<<
M!SQQ+\DT.@QF/,%15=YF($NCF2BQUV1]:'KKCLXK5,LB9#L'/,EP1EI.IS3"
M$SV.,43%60;W=RVE"6)ZD8 *8E9B92,(8?8M,)J%42)OSU+[,5?MKB%9VBK1
M$A7$9EW-P\Q695=!X_KMBKLFO%R\4J_:$3:2"1%4DW3%^W33([8.VJQT&ZYE
M6Z5"/]/X  !_  ^P!_ /R#EE/T&-G8+UK:>OD@^.67BYUEKE79*G]P.H*:91
ME5M8-"B/DH14U%P3IX4/("-C14#P(J"&Z^I'I!M_:^QCR>%5=?D\99J,O7K%
MAC&6:;SFL_JJATU5 M[D-&4I$UJ ^XUD=9SHGIAZT;DW7OX,7G7448K+5KBZ
M&/K55J75NH ;-> M'U6VDQ"+"BA[S!KF#VU!/0$6'>..1#]O>WGJ65W:9[K_
M -&?3B)K*L7!0LN/:7?]CKV7]:FYYN+;O2M(N,B#N]"NLE#/5'$7/0C(]?>M
M73-15)11FX9.7/,.NL(CG_KXU+L)BE^X_7P(@ >1,(!]_!0\F'Q^?@!YIGVA
M]1'I#TOC32'9[L[D.1+"*I6M=G[6T?7F541("BJ,'GE?_&+U.."E,GY;Q5>=
M*^5$R^WW'* Q;,?3/]47MDB<WJ,>J1:J30GZSA1]UR].BKM,$KBS"0^7=*P4
M]NLU'N-.L46W4(,>=H>.^*LW*=9*;!1P?FZW5KT9_39Z?R2-HR/JU0GNCE<&
M?.=<U,K_ &;6'<H=RD[4E1OFG.K-,,'QW""2P*PIHHJ2A/>@1(1-Y?U_7]3J
MO \>9GGCXB/OQS',_I]I^\>?W<Z4,_6MWWM*]=PGIE>F/V<[%QBXIMHOL%V!
M29]3^M9%0<@5[(EL5[37M=B8LFHD<%CXB+:3CX%0!&/("9Q'P_Y"_K2]NW+*
M2[C^I; ]0J(N9L]=87Z;5)=5J>*DJJ)7<3)]B=#5<W([C\/$4%'48S?Q(/!^
M:;1I2% @V&?:7SY\>1\B("(B;P(_?V^X1]H?P#P'Y '/+C5.>/B./\Y_PG]/
MW>?F>>=5Q=6_LQWIWW2A5*OUN#NI-&1VO(="U3?=2O\ ==?VK7:'2[*1[HN<
MSUMM4VHUAVFFUI>1BWRM<AHF+929F$F:'<)LRMAL*3#%G&5"4CHYHV8,&-<?
MLV3%D@BU9LF;6*60:M&C9 B:#=JU0330;H(ID3113(FF4I"@ =FYC'9-(SS)
M<VM5ZU2W1M'H\3''1F;)*?&.@R"5.6*:)HM6R3AX_?.GCQ!LPCF39P\?.E$V
M[=!0Y_ 7%5;7V:Z4K:]S7J6I*0-K6L,Q$%J6$$;&&4P(  R1%,",3,Q&K:XY
M2*MFQ8<I"$H:USWL!*4J6$F;&M80K6H!B2,S(0 8DIF(B9U5#ZL_2%](C\O_
M *9G87_^KXJ'^O\ K_#Z\^57NT3?#_3[VK F3%);2>P'8;5X=:.EX[W'K6:,
MV=5C;59G$?() )7TE(-W%2K0J-S"WF4Y>3 2K5WX:GN)[/U(Z_YIURB<_P!'
MT/L1L/6#6M0U&@/H.B.LLR.8E;Z\A3L$+TXN[=S;7<-#!4Z^\<MZ:D$G*NE9
M%BD\CXURC(-NL]7>MNX^IUV*GM)U&9EGM-_:!C(;1IZJ/X<@9J@EX:9S0D4"
ME9-Y9:-;)Q+"-BS_ "M%@UAFY QI)5BE,]K/32,<AGMQUGX[;&-OORQ.R:K&
M/MW+=+=NY<SB4U\;:2JTU%A68J.GO"ACGBNBJO8[M@JW!U5^066.V_MAZ,CN
MK)X^KAA1BW5LC4IT[NR]IX+,.L9.H]M5-BL_"74\HFRI%<VWW6*T)KC9UCZK
M[?/]3=^RG<EJRY?QT=\61=Q;^+]J]GSFR_B-9L+ZIN9!$OEZH@VERUZ=CE?A
MJS$.YBC.E&B\JV5F=[.6F#T3NAKFC4UZ$]2;AZ0.O3]=LC-!8\5*1<G&6M=J
MNB[ @MRF'XI4%VYU 7;.RJ,UTR.4SIAO-ZA'IU5WLAB%4C,=A:]4]1Q"#2B<
MG:% D5#2M-9MT$%\K?/0$$V,:Z2:-7-<DWI'"4)/-2*K"BQEIE?E?_K=W(O/
M6>O:WU,W.#NCW$[M'W//;S3FQ&D?IV,3%F:/8>SR]':6(@QI7)E'*LE*4V5.
MA#2SY,D[$/4EWKLTW@*^6H^I"2W=MZF,;GQU&U@LO@F6P"TS"V;@/K7:TROH
MLNK!!M2'2@+#6V:<N%B:T,V2WALAZ9/5LW<EXO[+9'(4]PX;<"ZALJ#G*=(D
M6:5@89W*J;+"6I[(EQUE)J71KRI]J5Y<S#_RLZ2??S_S7?9S[!]?_P %]J_^
M/R^OCGEU1E8^J3OI*7>Q./PBH52%[8SECLCU-=.&A8B"N]WDYA](/P2,W;(Q
M\?X=."'4!4J:B( 43.$2J9#@--]/"OVG!;HP[):6K3<9ZN:-URD,_E<1MPZ?
M:/[P&VA-5;"WFHZ/2J<6N@GH\ZJNU*V69(.H^$2:.E&SMX9#232>RLS;\CSO
MI)UO9:,3!H*<=$C8BQH14GKFXW.;M#J=8*V6-J"'X8RC&LH[14K= K_S*7S"
M3>5LL@_<LVR$9F%4LAG66*BL5DZ-:Q[L,A=R]&YB$T:%U7J%2N.65VN'N[E:
MON.A8360)I<3.AMJLL'O1@"N8_;XU;K<KBK]JM%-F.HX:_3S+KV0H/\ 36_3
M2T:%D_:4K5C;.1K.LO,'I%<FFI9:==#^C]N-ZF^WO8C2=HC*N[9Q*T>!X2)C
MXL[A]!YA1&Q6,?.VM5B@<P+D9+DEK',2!_EHD\HWB#NDV4>Q)R1'->UL5J?I
M(]F>LTNB@TT?#<P8&@63%D*1K9EY] KZS6:0;,TQ%65J;IP>)MJH) JHBI$6
M)X<ZDJ^51E1].+T[8?K9D%G>['#0]AUW:Z\M!Z/%+E;2T-6J&^24(7+6[CV"
ME)(.B*F?79ZB(-)::4(Q:BO&04:[7@U[?]5=B]-CL!!ZMD<K,QN=#:%I/%M+
M:&^>5KSA9!0ZV:W@K@BK99XE'+NX84)<JD5H=6!4Q@&2_%(]ECJNY-E[QO)V
M-B(55+:%[#W]E7'6"&KEK6 D);5%T+8<+< ,K0SHLLLUF,R2E-:@%%F+>V-\
M[*Q[]_9CO6E[TQ^:Q^]Z::L3;Q%7<4%"[;$=U82U;&+M]J2IKK6U+Q;FJ58)
M@YDM9%$]4[.)JD.DJGZ.N8$435(=-5-0M!R IR*)J 51,Y# )3D.4IR& 2F
M# (<F?Z=XQDV_P#IL]?,LV[-Z3K&<V3(H%&<I.@UJ)M=:DBD6D/A*.8F9:NF
MOS+<QQ4:/$B)O&:OA9JX15 #\AB9]MNI_8*9W+4]JMFBX+O>Y=;'77>Q(-*<
MOHF(,E"DAP:7>OGKC$]Y9D=FA697E9GE -&E,]!I*2H_ =C8.Z)(YVPZF8A
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MPSK4+-L]RNN,Z=F-&J&=5*.$PL*O1:U"U"NLA/X _P M"UYC'1J0G\![Q*V
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MS*RP54F;2*3UE[GJ&0OT\C>KBOH61VV$G%W((* VIAH0J)(^N AB 1 0$/N
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MY<KJFG'''&FG'''&FG'''&FO$Y?<4Q?)B^XHE\E$2F#R AY*8/J4P>?("'U
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M*ZJ.Y'9ES6).(BV*R8LM30      *4H 4I2@!2E*4  I2E   I2@  4H  %
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M3K1<'V!=A4VE9A'<PJ21H;*,;+_+G02(@H_)/R/R1#'7!1=VHS51:-4G#I8
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M?M31VOP*[/QIE4R@Z*T;0\T"9E#,9EJL(&&M7EWUT_,A^H?^$O._'W'Z?MO
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ML"#%C[D87[D/H:P!8AL0$')&A\B QH^^=GGN_'+JKR+*;:S(L(48 RDYX@P
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MR4BJJ9A7](8PT1;#LOH9)^_A8><GQAR.1,8$6,HY:RQ"IBHZCVY%$14R+S@
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M+7/'''+#61TXXXXTTXXXXTTXXXXTTXXXXTTXXXXTTXXXXTTXXXXTUX* 82&
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MIGF.(^.>-=YT#1Z%DM2DKMI-N@*34H1O\62G[')-XR/;@5,YR(E5<'*9R\<
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M<3Q/?Q6YKW5G+M+(7IRDOR#;PA-LF]<%:=9LRB6E7@@DW\V!3$J@FA':&2C
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MXZ^>/8GK_0@,99P5-C"48IYYJW06%-NE9T&1@.+!-0T]'']?U^NJS_7'^?\
MU_R\:<<<<:IIQQQQIIQQQQIIQQQQIIQQQQIIQQQQIIQQQQIIQQQQIIQQQQII
MQQQQIIQQQQIIQQQQIIQQQQIIQQQQIIQQQQIIQSCSX_7^@C_L#CR'\?Z#_NXT
MYC]?Z_J8_GKGCG@HH1),RJABD(0HF.<X@4A"@'DQSF'Z$(0/)CF'Z$* F'Z
M/*%W??\ M(/J5ZWK"E8]*'KB=GUW9J[8:K=@[1F2.E6#8HWK>M&([9H40UE9
M+]A,ZR>FC/0)%7-CCWDTLA.5UZ_FX:4L3:I-&G&KZG'*G7I'>N%W6OFX9%TP
M]7#JG9>N&O=AJ]*RW5_:G>:6?**UL,E7(]67FZ-;:A8U%F,!>RQJ9EFJD$YC
M"%D5(^M3M+KTG+PCN7MA@8HAY 0'Z /T^H^!^WT#Z_ZN4B>?/_+_ $YTF./\
MI_G'.L)[YO.7=>**M>-=GGU7J"SLD&>?0K%ILC!C)2:*Z<<E*C5H::5B6[]P
M4&;5_)IM(Y5^JW8?-E=NFR*V@?I";ME=MZMYSB%7G'4EI&7U^Q2.APK>LV5"
M/K!;'HMLDH4LC97$.A5UI";9ODWK%@SF'<BZ03>+@W^&Q>&0D'UBX8,2"F:)
MM5ORUC7[3$/8N;K&B6>K1C*:AGJ)D'S1W&S\BU%TT52.)5 ^$/M-[3D,14A#
MEP9USF>BV&5!GEG7_3L(BH<T@J^4C875ZA.3L[,R1BD/(S$DXL3R:GY9P1))
MFBY?+N7";1LV8-OAM6R*!-UI%3G9V4Q\XC<#LG;RN,R%>[7[<X<58]&2KB3H
MFD;X(0R5D"6#I%QDAL/K17:FUH5\+W]N<1DAS6VT8FGB,KC;%&S+(S1-R-C%
M63!$Q="O,&S%U3!IJ$D+BPHJ]J;"G5=UN.>!%4U"E.0Y3IG*4Q%"B IG*8 $
MIB'#]TY3 ("42B(" ^0'QSSYI>M]YB?B>=....--....--....--....--.!
M$ ^HCX#]1XY"7ZCG<+M'E2+2HU"AO<6I5N>2D1"ZD]GZQ*WNU&A44%9C]FXR
M!EYA.B1YDGC<[:4E 4LCANH55F2!=@<B.O[FW)1VKB;&7R"KCD(B/V=.JVP9
M&1""Q,QCLUP-A@'>LM2KJ(1@I,A$L'N'/T]MXUV3O+MM2J(CHJ5F/(C*8$!,
MQ'LUQ,R$(;98I740A!29"!30,YN&D7TI&,):->R4(JV0FH]H^:N7T.N];E>,
MT95HBJ=Q'*NVAR.6R;Q- [AN<JR13IF P_4Y1YSW7--RN[HZ)G]UGZY=".S.
MG4VA(+.G$T=94%7*-D1D#NFMF9OE!\O6<\F_1<>1./M6 BI+5W2CL#LF^YE
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ML;[-X?JEW7>MJC0[XTL%A<1K!>5?HQJ,5+M#G:1S4!</%OCO$"@BB J>PQU
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MTC!R/-YUBF[UWDO^[NKU8Z]1&^58=68<F7ZQ*5>7F+=2;9;[1,0&BP$"5/\
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M2Y[G\1L&>W=Y&M',G5X75K#556\J=9*=6FF#"$6FRJ$0(DVWBYM/94/B:V]
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MMVCRK5<_H-[ME)K&&W2C3;_,KG@]8NK.R3MF+(1S9JCO<=/59>+,S(9:17_
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MR'*81RF]ALSSZ(>)'^(F[BZ566#E,_V]Y%VL6DJ0P   !BG 0  #S].9#
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M+15(]N9-@D) U@E@\AMK!91J;%W&5FV:Y7CKV0$D64LR53V-UR[%<E.%UBI
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DQIIQQQQIIQQQQIIQQQQIIQQQQIIQQQQIIQQQQIIQQQQIK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g815469.jpg
<TEXT>
begin 644 g815469.jpg
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M+3.<^":9LL:]=AD1$>U%5$1W I>7[L%^VA_Q\?ST[L%^VA_Q\?SU1H[RWO\
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M'QDI+IMYOA120F0!IG,ZWFDHS&4'(:83>,G5-$232JM-YL);@6<DXF$JJAP
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M:M+UL]4@#Q<PRBBPL#O2G:BAZME6Z"KV;^$5J&LIW"1E%F!HX:*JO12QET\
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ME<LR!1&@!*N;.RD0%LWLAAN;%.QQ QR>]-<X2D8:41G_ !PW7KZ]$<)4128
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M$WR[=C9.:#?(,-"+-16(KS9+)#1)IX#?3RR M)B<K(Y<HGA IZB1*'2P89@
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MMO%2)\,#QFAODR>/^LFO4=E2)\,#QFAODR>/^LFO62M#G;1P+X14']]3#W5
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M'E[%GL Z?F<<3C;[0;RZ[76N)#::S81U1PN1QKZB41T)OH"(1'4UE:6E8^*
M12TE)3BID^I*!T<$H1)EQS)D4,$+//&+60N$3"+V28\;23)DO,5J)$-H6OTU
M(3?-,13SV6B5&D<U,AE&DQ>=[)<3C;CH<TK*SJ>#MD2*E1BO1?,/AV!FE2QH
M5NJ3;E/6$1'<2.JMYP)2:NH"ZG*".MHBR1*JB0L)*J6&)*:6J)AX(P24$U1)
MF!R9XB< &*FRHPI<P$(")GAD!7^X94QQ)/7&&XV,H0=*$>3)&J['W"_*HL@Q
M8\V[(#)5S2/#LTIZP5372U%%51#II)4 Q2"H7+'A!D\\$*3.!@F0\PL=@N)C
M[8,7_$QQ>D)*L'<-^,XXB'C*<;9A1/'[)C!C),><+H=*9D>-1!93431U*&9H
M-J(Z>W6T03$<D,?-YYFCHA8F%F:,Y9#CWS$ROE?./$Q]L&+_ (F.+TA)5P5/
MN2]UOE.:#W5OKQ$:5*4JW%R%;7:0>,_&OP7;Z&+U:HUM=I!XS\:_!=OH8O5]
MQ^Z1_P#&W^\AQR^Y/_X5+"5:Z[<>+).OR8NS_5HM;%5KKMQXLDZ_)B[/]6BU
MT\7;J8G\'KUZ-J2[8%WWP;X58>]+T952R[;^>_W:XKG+MOY[_=KBM.!^@84]
MS+X.7WMZ4]S+X.7WMZH[@7N+Y 6SM;_%]A#Y)8]]%4RLU5A76_Q?80^26/?1
M5,K-5;EL,[N8?YDM70*<_/AB[>O$_A#>O252*4I5[//"E*4 I2E *5K5LTYM
M@RD=@I6J**Q%R6G$^F.SQG(_Q E9E1 SEU>"+ON772SB+M9:Z_@F(UP%,\DQ
M\A.A!576XQD=.$5$Y)LK'BL4[+WLVND2Z3K+'DG:WOZ:7-N7).O#8W';\9.(
MW!:Q#<,Z^(D]3-)*3$*9*ZB"ORM&KC7RFM*DW4>7C$=#RV"JKPZH5":[K8"6
M!/;2JW\D<4G=IDM=#;A1@1,<EB.W'ME%+W54J#-B939NT.R&N$GMYI1OKK"J
M-%:^>5M?W?LA&[A2I217+)ZM)"4TCRD::*0DODFR'TX$B7S638-PS\Y94<X^
M361HM#<&+1A!% -%33Q=Y>-[#-R:I-,G054P$K,D27S"Q&K(.I*4723Z;' S
MW**BLD2 @9%@-P1/H8GP,OO;U'1H+[8O$K^J+/G\F'4ZI$C9@ J6&',C!  X
M87Z8HPF 06/2_6X](03+'#'I996QMSRMSRO:UN=[VM4=6@(F LA\2O,//$3"
M_$7?>-LL,L<\;Y8:QZH!YVZ6-[VYX9XY896Y\\<L<L<K6RM>U@)':4I0"E*4
M I2E 0(<5[V[(Y^2K+TR6ZBVJ4GBO>W9'/R59>F2W46U:J-.O;;QOSG3^C*
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MB)^)_+7F9GIZV*W9K2;B)^)_+7F9GIZV*E+A7>?#O/EIZ? 0UQ5NQB+F.[=
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M5<,GQKD/XA/_ /%$JK*M1BTO[UQ<T4?GZPDYH?W4FYXK.C40I2E8L,J"E*4
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M\<7HF)4$]2MT6;EV[Y>X=.G(HZ4M]+G\C;N@4XI2E9#,>D@?#)\:Y#^(3_\
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M"ZF8 )BC7*A63*@QTC_PX''&^3?A6_[$9FJ<Z@%*4H!2E* 4I2@%*4H!2E*
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M6&"N1"(J A@H6'Q+J(!0[@(6#LCT I2E *4I0"E*4 I2E *4I0"N,NR_FO\
M<KFE 5;=YD=8,[9S8.61U@R (XD>X8Y=)4AP!+69K9QO<,8$KF$):V5KXWOA
MGE:V5KXWOSM>U:G^ %__ -@+W\AJW^YU=!Y>?[-_STY6]_\ C7_/69[;I?EM
MUNH+>E@CF2AHJ6C25;DYBRI2P1PI(K.P7ZBO2/65NL[55<LURS7#-RT017"X
MU]>M^DB6NK:JK6)+:UZ1]DSOFZWK]G-U]375NOJMUOV6JW@2E]X 7_\ V O?
MR&K?[G3P O\ _L!>_D-6_P!SJY<06495'4RJ6KIJD913UTQ9+D% L<'25*P
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M+AEEEE;DF=)ZXP&DKR(TR65S5\R;9>Z@CF7.@%<[GCO2+I*H4"O<V9O;"US
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M2I'$1-4VIET4LY9/?+68#?,+!L,44HD@++M54=-&4C08 ^98@&9R-CX BYA
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MP75IC%)!0Y481D@;R,D 60\(DD)!*O&,7M'!5FN-!<PYQPJ)Y<6Q\5 *4>E
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ME*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E
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M*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E ?'R%=]V83VO%V+6SDNS1<MX\#?
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M4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4
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M,8W<$(+)4#S+X%A#-P@\+F \A^YXVSZ-:W2Z<)CG[]4 RH\YPU5D?3]W$.$
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MTZ=0$\$J,8[AF7>,5&$3LEL1S'3,XF"\C-)D,U&)-]KMM)PUYA0P&F(B*G!
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M6WH-@OM%1<;@LQ!S[?>EFFA..R4Q29TZG+@YI.$%62UQ;9 R(<[>6WV;5TZ
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MQ[WMO0*<E7HKW+M_?-QZ=.*4I6.S(HI2E *4I0"E*4 I2E *4I0"E*4 I2E
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MQ&\]-'V LD_T'P?P)_\ 6+)R?Q'D3Q&?/FJ-E/W^)6^W%1_/7%]I]E+VR_\
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M)[XT<UBJGZD:+(Q;BD666_'3$0E<GW7O151F@WDM2*]W!$+C][GB*< : [L
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M,,Z,?&DT4<J1RM1LK$D8CT9(U%<C7M1<GM1RHCD5$5<LQ2E*XSE%*4H!2E*
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M"*<RM8N'F+C7/D'2*)9LVSV2U]U))0!'\;,N&^'#L2Z(QQC9$?6I+JF5F/\
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MBB29693,D69SJHG1BT%]<*$%IWFT<IF:.!IA4;/&_1RRPP3B(ABX(:HN&22
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M25X64DSI*&).YLR74H#W,BZ.R([GQLRZTUW,HL#-.ZW#VV;;98_DO7$26QJ
MK:OJ+Q0%S$!+%"LO.?&#%_!LXD,S2;G=81_#!U/M<]<K"^PY44C\\ZQZ$QZ\
M(?=[0B#C+SB]$?,0"84O8$4@R9 V6G:46:_4)?CPG""2:BQ7=3DN!*C.G>1%
M&:6L5; ($9,=TJ[DP0U* MNA6O8,.U^J]L,+7M[]L;6O7>E* ^"E,D_U*,I$
M3XH5$-#E$ZQ7<4C99= 9@5M)+^,MY1 9JFX@R910.9H:<XQ$TZK8%"!TUD0
M'Q *&1;X@YQVNG1B16#JAI+'>N;@8N4W:)O.*Y+9@LBG7 CL.9'0CQX\XMG!
M+?KJ0T-SNAMCS8VI7E)9&?9-INI02'ZLICC4FTN%L%).,*4!\U#6CVP)69HP
MV0F=V127D8QNE/NV,N,I@J#M7&HVTF0=.K:>QA&<=NE>;+=4GB;9C,:L?GW>
M['"VF*6<*S9UJ20WDLN(E)5:ZSSPWW&GZBD6S(TGMY'9<11!Q?Q)3<#13%QP
M.#!G[JI4T+R&HL9!4?4T47EUB(;Q!%741=7&XG*YY.,I1)6$(F['+J4!\7PX
M=E7QN'ORSI,6U> UQ-BGAF$&HJ&8$RF41$%/S)-D:.-INL_G.$50NX$G"0DF
M)W&HIL:H#5=I"*@D$PGKDIO XY4JQ*QE2E *4I0"E*4 I2E *4I0"E*4 I2E
* *4I0"E*4!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g819588.jpg
<TEXT>
begin 644 g819588.jpg
M_]C_X  02D9)1@ ! 0$!60%9  #__@!!1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?1DE'55)%7SA?-$-?4$A/5$\N15!3_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@ P %H P$B  (1 0,1 ?_$ !\  0 !! ,! 0$            *!@<(
M"0$"!00+ __$ &,0   & @$!!0$%#PP,"PD   $" P0%!@ '"!$)$A,A,105
M(D%1EPH6&!D:.%-887&!D]'2UA<C,E97=I&2H;;5US,U4E19<I25L;.W\"0G
M.4)#8G5W>+3!)30V-W."F+*X_\0 '0$!  $$ P$               8!!0<(
M @,)!/_$ %$1  (" 0," @8#" T)" ,   (# 00%  81!Q(3(0@4,4%1\!5A
M<187&")6@9&A(S(V1&)E=I25EK'!\0DD0E17M+71U3=&4E5CTM/49'+A_]H
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M^?9U_<CO;_:9D/=_W<P?\'^!]4_J^'E$-^J,>:G^"YM?^7;P_J1Q]48\U/\
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MRT%5/Q^^6)[M_3M_T9=Y&@[&A%(>;9"99HNGWEHB?C!,(-YNO2/=*C(Q;HH
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MJUMR"8F\C* V5.4!Z@4W3IF LUZ,'4S&D<XY>&SZHYD)H9(*KIB(Y_&3E0H
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M(E4^<F*3>1]$8NN\0_1^Z.HWF+:5("F3%)VE$P[@#&\>)<% @AMU I2^0!T
M/0/@#[@!Z 'W Z!G.;%;+]&[86UFINY0'[LR:9$P9E@6&,4P9B8-6(7W)/V?
MM;[KXQ/!! %$3&F/4[TV.KF_46<7@FU>GV$L"2V)VZU[,Z])QP2K&XG^'97_
M /OB*V(,AF5LE@$0S\C!@QBF32-C6;6/CV#5!DQ8LFZ35FS9M4BHMFK5L@4B
M+=LW2(5-%!(A$TDR@0A2E  SZ\8S8,1$1@1B!$8@1$8B!$8CB(B(\HB(\HB/
M*(\HUIZ1$9$9D1F4R1$4R1$4SS)$4S,S,SYS,S,S/G.F,8RNN.F,8QIIC&,:
M:8QC&FF8Y7[ZY7CQ^\C?_P#J]5YD;F.5^^N5X\?O(W__ *O5>4GV?G'^V-5C
MV_F+^R=?T#ZZX/\ P^*?[32YD3F.P?76@/P?0^*?[3"YD3B/:7V_W1I/M_,/
M]D:8QC*ZIIC&,::8QC&FF:*NU.T[RTE>7_9U\G>,?&Z2Y)M^,$IN^<N=2C]B
M436_BJ7&*I\+!QYYVZ2: MS/4TI9V1RPAYHB/N8*+M%#VI YMZN<" #Z@ _?
M !_TY?=N9YVV\J&514IWR&GDZ#:=_P!:]4L5<OC+>)N*;-*U2MCW5+KNPT6D
ML!G8<%^+Q-JS6)5FJ!46V;-2/6:-M=FGZOZPE^.O5LC68N+=>U7+BQ55W"ZN
MT"#N&1\^8C:[.TGSJY5[XE^0M[X@2^D']C[*CFAQF<T0^V=;7T(S:]MM-C1U
M?71L,;+Q"3IS?X5RQF4'A8Q."@@=>Q34TU724Z4;K'LSMJZSA^PPGJ?QCKU,
MV-Q]NTG/\S;-70UK$VN$&8J*"<D^OEECIM.1V"+B?7DDP+#R%M,CXRQ&Q$6"
MO0TGP"E#T  ^#R /0?4/PXZ!Y>0>7IY!Y?>^+);'5#-*K*HTJ&*H8]*K-=5*
MM]*2@:UC&9S%#685G*6'6%5ZV>M$CUEKF>,FL;6-[70ZQ1LC%FTK-FS>N6S-
M;3MV/48=+UW<=>)X^#12I+&NQJ(9X"U!X9M  #E<KAH<0NRVYU<6;?IS>KC5
MUIMDOLU7EEH#=% 4FM2R=RXMZWVF_G&.MMY:/G)2[%CV3E5Q,O;E=X^JSC>R
M2;!Y)UT8Q5Q/NS-ZOX5=D_RSH.Q./=*W5J/;5>8\2UMM3T'NBJ\C./'ZC$_+
M2%?L;>KQ^KM>PFFFN]9:&V>XD&<)L>(VA>(L$H=U*O$G\8L+>)+, [I>@!W0
MZ!Z!T#H'WOBQT#J(] ZCZCT\Q^^.76]UJW3D(R<V*.#\;*(.NZRJM=2]01.8
M"O*95D "2J5,Y?H+]86\'U95%T+30-K+96Z98"K-*$V<I"J#H>I!6*[%&<QC
MI=#.^H1=KW8NK9/PB42G0?JQ(64+'4-V*G#*0X@<(=95_:.DJYJGDE*#=%-P
MOR-JE)7::%2_6!>JM[%<ZR^FDYEBUJJ=?]RXY&<=1T8@1---LV> Y =O6
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MV1.OI13MVA>56K9LC62=BR2$-<->NL9)CWRL2A25C$D;6=H ,3)%$1K9QCH
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M+Y1=C6&"B=9*1\38[]*A6:0Z8;$GW24@]M\1!5*BJR=:CP:,9)-X3W,F&[%
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M;/Q<E R*1S)JQ\['O89\F<HB4Q#,Y-!HX 0$HAY)CUZ=0ZAGP" AZ@(=?3J
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M%'\E! 8"I 4Y#F2*)E!%,R92E!0W-'0OJS8* #961"9][[.,K#'VD^\L??\
M'S\^.>-=5OTKO1ZI!)MZGX=D1$3,5*&?O'Q/LX"EB'E,Q[XB.8]\1S'.GK&;
MT8KL=($@IFG=\S[H/>^*E"42'C>OD'>!-:2G)@2]1[P )D3= [HB41 0&^-2
M[*+C/! 4]B>[&O*P& 3%F+2E"L^@=1$A6M3C8102&$>AO%=*FZ '0P#U$TFQ
M_HS]5KIB-C&8K%#/M9D,U28(_:.,+(LY]WDN?/ZO/4&R_IQ^C_C%F=/-[@W
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M-$$GLLS@X*>LIZ_&K@H="2L9J_&R)(!DLBF9=-64%N*B!3KI$403.J%T1#J
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>O:M0#%>%!QXA@PU,6PE+[H&&,8R5ZCVF,8QIK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g894662.jpg
<TEXT>
begin 644 g894662.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!!1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?1DE'55)%7S%?-$-?4$A/5$\N15!3_]L
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MFK&*_.I^U&7Q,'F1(EG(R*/:8W9"#42N.;-VLBSQ8JC1^>^2 PEQIH*=4D
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MYP:N[IJA(FYN S/[UE52@\]I$EY4(@]O=_Y8W']./X7Y/=RD$J'&JEBWU'.
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MCBRI2@#VI(2.5*(2"1"%YUR0ZM^0M;[[A*G'GU*?><4?=3CKI6XM7'IRI1/
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MTUQ9TWZ-A3;+R6Y/T;!G6?PSRE)9D_1L-^?\,\I'SI9D?#^0ZI'SI;<4I/S
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M. 9!F45<M'<&GG:?*,.H+BL0\"43X;);4%JX5^BYD74'$CSF&,7J6[2"R_\
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M( QOZ5O^CZX2@?M=6\15JP-T7#3+8SC<X.EE]3T&=AWFLV_^ZQZ>O_M(B_\
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M,&KK8+2GIMA8RX\&#$91^6[*F2G&HT=M ]5+==0E(]20-8I,H\03<K>+(9N
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M&F;<O)3P1\1=6!E6;I[AW]OQ26TJ)[&T)X2+A$E1[E$J40 5*)4K@>@'))/
M^H<ZM56#B#?#SZAULU8V%CVK7H:V,QUH!_PG4%]1<IJU ;*<BP+<21S)"354
M:RX-Z6RC1W"J1JR8VH%N_P#%B_2IK3A  4I.C=(NV.U--J4"I#-PO%["0>5:
MG-ZA4-M>L;,$)7E6^&-8'&?:[7JW#:Q+C['>$(6@N55=7H<6ALN<.,WJN5\\
M.CO\UO0='UI:(0<OZAMV;YY+X>4&)3D>-W!A+)6TFQM[9;3YX4@O)'S,]B%(
M*^YQ4S)LV'6PIMG93(E=6UL1Z?965C+C5];60(R>Z1/LK&:ZQ!KH,=)!?FS9
M$>*R""Z\@$:B'2>(?T#9)F$?;['^M?I3N<WESUU<3%Z_?G;E^TE62..8,7_A
MY,.1*)(2AIF6LN+Y;:[W$E(B.%.E9/M78ZBU&[@!3U]U3J*<5=#O'1<6(205
M#F*6XJ$9)PD#:I#Z0G$.)E&G4Z*T5&R>6-I'A]HJTA .0 )CEDEW19"3RA;U
MP<<Q@E95[5<&+T+[8(<?=L<PW*ME/'N!7=5\%:'"LK<<6\Q6.K?4\3PHN^J2
M"L*4I9X^".AS#XC;J:K=/=.K6MP.H5&GUH0A:5)*%*998BAU:$)"$N*<2L$)
M7W$C@S:!Y (]E(;<2?J4VZ@.,N(/LMIYI27674DMNM*2XVI2%)46I?\ PAX;
M!*$C2<!/)S<JT/W!MWV]R5/MS$/+._LE;BBC_A\HJ/\ YDN.14M2N(]Y=#G9
ME33T>SR(O[+')RQ'[:Y$0-ASAME(=(RZ%FH6'INWOQ]UY_!>J/,&Q\P8AY7&
ML9Z5 NJ= D2?I6VC#E79YBD5!#A+G*0UVLJ^+ECUR80YWRJ;;S=NKB([W/HP
M0H%K.0@J"DH2T[C=FY(5W!1**Z0M7 " H<G4V=-1/#.TQA_Z#?=9:94#S)3:
MM4W.3%Y@KF]NWWUR\P%HYL$M^K)2H#E/LDBHIX\:BG^SJ_2/"_7;:AR+7J#A
M_88-PY/9![*\Z28TS=VG>4$)>]=6M!5S#<#$,JCK-QJLGMT>[^!9IM3=DE*S
M-KY-K5DCM 6A)BU]R$$GE99K9[;8]Y"CZ"4^*9IB.=U_TKAF24^35XX\Q^HF
M-R51S]:)D7Y)D%8/*2B9'85R#P"/77:V]149!"<K;^IK+RN=06W8%S7Q+.(M
M"O523'FLOM@'WY0E*@0"% @'42\PZ.<1>L#DVTN27VT66,!3D1ZFG3Y-&7_3
MM!8$MJYK6C\R5)K[)V-PH?\ !Y;1V:HJ3Q/TZ.=#MGXAV]!RMEQIO2NJ C8#
MLGFUO:>N"T)!4I+C%G4ZK 2L$XJNVO@+K4]D['U+P8O+N W)9DO\0=!*</7U
MB,^W%UG9VW%X2EQF5J1$=!)6RL)YJF+IJ"K>^6^&Q;\:JZ@<,5EF)AQ$5C=+
M#FV7%*;Y#;;EBE#<6LDR  7'(]@SC=LZ./+3+7\[DO,+SW#=Q*=-]A60U^05
MG*$/KAN%$J ^L<B+:5SZ6I]7+X(/PTZ.RX004>8@A9SVGM;V+44AZW-+E6N^
MQ4\TS3E\C*ME\BIQDN>IO$B5&QN)D!V7#4DI(?\ :3GR.L^%6K-%PX][DMP+
M]I*>YV=LUMI6<W?=*3UY #/TG%'-;II)Y3;+RQ;KDE86DQ,H415VFFFO7UK>
MFFFFE*:WMN*:<:>1V^8RZV\WW)"T][2TN([T'T6GN2.Y!]%)Y2?0G6S75W%W
M48]!<L[NPCUT%I00IZ0H@K<4%%###20IZ1(<"%!IAAMQU9!X3P"1;RY<2!%?
MFSI4>%#BM+?E2Y;S<:+&8;25.//R'E(:9:;2"I;CBTH0D$J( S5:/&D37V8D
M2._+E27$,QXT9IQ^0^ZX0E#3++25NNNK40E#;:5+4H@)!)K\S/QP_"CW0Z"N
MI#-MUL-Q:_N>DG=S,I^4[:;BQF#.K<(O,IG2;NQVBS.8PGNIK[&[%^4UC$VT
M;CP\OQGZ.FU<R7:Q+ZOJX;[K>+;XE.^6UN3;)[M]:&_.X&U&84L7'LGP'),T
M,[&;ND@R(,N+6SZ\1&TO16)-9 ?0@+22N*V5*5PKN_3;W*W?=S*!8XS65L9C
M%[%M42R1;PH5E(O89/!8EP9K4NOC0G3\PC%J1(4"/,>:5W-F"..=)?2SA^4N
MYQB?3;L-C>9/O.R7,II-I,$K[TR'W/.=D(L8]$E]E]QW\8IYA33G=ZA0Y(/)
M6KO3;T!I^YRK98K'=]7MQ&U(%WBO,6RV2IB%8+49R6VY*=BCE]J<(@0M?M1F
M9#'(^OI'3?HI:TO%O8G7B[6W33DE:5?1LAIV?/CQE)!#DE,9Q$9N0221$$A2
MDI&'W&7>9E/G"\ ;PZMS<.S>1UJ;T8M9X=5JPZQI=BJ.^:^!NLB.8L?!7VXK
M]4ZGXZNH&L=^+IL;59,Q7KUZ[?NX#2ZVOBRIGK UH ![#_8  >OOZ  #[  !
MZ #6NOG;Q7XFWKBUK&9JZ],LQ%NL,0;=;8REN1[9;(I<,:&VZYAQY7.Z](DO
MJ2@/RY#[K;,=I:([7;'#O0=JX<:8BZ;M3CLE+;KLN;.?2E#T^?(" _)6A'L-
MIY6VF6&@5=E'9:;4XZM*G5_5AYZ,^S)C/.QY,=Q+K$AAQ;+[+J#REQIYI27&
MUI(]%(4#]1Y!(U(["-^'VBU79NA4AGA+;5_$9_NEL < VL-H!,H'CE<N&A$@
M*)6['>'S"-FFJ/#SBGK7A?=/I/25W=B(=6A4^U2.:19KJA&P;N%O4M+;I"24
M-R6BS-CA2C&DLJ)-5=:\/M*\0+?ZAJ6V-R5-I6(=P9(8NEN4L@E<*:E*EM@J
M 4MAP.Q'BD>L1W4@"LET&="LXD>PKI<:=!E([XTN(ZE^.\GZRAQ/H2D^BT$!
M;:@4K2E0(URM8\<4S3(,,F&51S2TVXH&772 I^MG)!!*9$0J2GO_ (LEA34I
MHGE#P'*52\P;=C'LR\F"Z4TF0.<I%3)>[VIBP"HFJF*"4RN4A2A%<#<U"4J/
MDN(3YA^GO![TG-&\3?5;/= C26L'>1I-JG/@VZZOD)3_ .B7)Q+:'7'5G+=M
ME!F<"H-1O7PA;YX$XG< M4Z!]8N=NY]2:8;YG%7&(SB=;FAE6;M 05J;;;0#
MSSXQ=A\J2X_ZD5H9J#G78-RY5G0JETCK.U%,&UU-Q!>^+BR<FL(X;G2,C\OA
M55*9:[JVCCRVQ%<C_%R(TIR5.?9;QZ:]'4F-&FQY$.;&CS8<MER/*B2V&I,6
M3'=24.,28TA#C$AAQ*B%LO-K;6#\R2>",=6^/12AQ,[*=F$=KH*I$K;I]Y*6
MEI/*G58A/D. ,J2?F;Q^R=+)2"U6SVU%J$OQW&[@AJ6Z7:YZWT]+E:B,LA^=
M9G^55SAMLM)0VW:0VE")L-AIL-M0D(3.;2E"6_I!UQQ:>OO14]*K0UAT[8N%
M>LK=;]%)MJ3%M&IHI<18;H])?4Z\]J%3[CKMJNDN2\M^5='75VE]Q;JW39V6
MF65XV20/4D ?:3QK:AQMQ:6VW&W'%$!+;2TNN*)]0$MME2U*/U!*23[@< ZO
M%LY%A5&]V!5.;8\S(C)S.#CU_CF25B%);>MO-ITQ[.KM&@E+L6;.BR4-R&>Y
M+K3;K7*O+4<Y\&DI:E"6*VDI:U#1(2BOIZV"$'N4HE(BQ6>T]ZE*]/92E$<$
MGG5?"W@H]Q)@W.<K4*+$;5<3;I$-RU.397/V#+P<4#-A):2HK=:Y5%2TN,+"
MDI!&>@>/WI21>!UVL-J3HM_5@U!9#>H5R9U Q:K>6Q*?C%AM:;7=7'UH2VQ(
M4XE*&BS+9+:UDD#S^UF!9U<J83485E]G\264L*A8Q>/MO&1ZL>6\F!Y*DO#U
M:7Y@;6/F"^/75>0>G3?>Q+7PVTV:I0]WEMZ96LUS'".X*+CUA+C)9Y*%)0'@
M@N+X2@**D]V=SS7> /-=[1Z!)<7V@>W:$]W:$\>G: $_HU\N!SSP.?MX]?L_
MU:WA#]%'3;>/I#5=\E' SZE$@6\9R,[/BYG!', .8;D'.Q!Y2N7](;K9TJ^A
M^'>E("<'E^D[G>+NH'! ),0V,'!P3[.X!3MD*3A3B](O4)*90\,!$8+*@&IV
M38I#D)"5*3W.1W;CS$)5VE2"0>]!"T\@Z[,=&?4 ??%Z$<>__=MCI_EY#_MK
M,UIK.(]%OAVE("[EJUQ6$Y*KE:P,@;E(19$8"CU!*L;8(W)\H]Z?G&AQ1+=C
MX=,)YE%*4V74*R$D@I!4YJM7,4@8R G.3D=,89?]QGO_ /FQ0_\ KMCW_;ZV
MKZ->H%"%*3BM(X4@D(;S7&RM?'\% <E-H*C]04X@?\KG@',YIJ;_ ,KO#K_]
M]JOWBY6W/O&;,1GOW!&>H(VJD/3YXU@@_1/#PX(.#8[[@X(V.-4@X.,'!!P3
M@@G-82)W2=U!P"@+VYER^]M;G-9>8U9!'8?5#OP]Q^+<7ZEIL@K< )2#[:H>
MRV0WDIFB]:;5Y]";"4**U8W.E) <7Y:.37HF$$K^7M("P?524IX5K/?K5*E(
M/*%*0?M02DCD<'@I((]#Q^K6-E^BKHQP'U+4.IHJC]4R%VN:A)P.J&[;"4H9
MR2 XG(V!'49VW_T@_$YDI^E-&:$GH!'.(3>H+8XI/,2H)<>O5T;0HIV22PL)
M(YBE6<#SD3X,ZI<+-K!FU3PXY:M(4JM='<DJ3RW.9CK'<D%2?3@I'<.4^NN(
ME25_D*2L?:A04/3]*2=>CV2RS-3VS6(\U/IRF;'9F(/'MRB2VZD@>P!! '''
ML-6IR3879C+>]5YMIB;K[A!7,KZX44\E([4GXVA<K)'RCTX+A"AZ*!X''BKG
MZ)]R0A2K-K&#*7OR,W2U2("<;8"I$25<SGJ"1% VR.N!M&P_TB%C=6VC4_#.
M[0&_9#LBP:AAWA8.1S*1"N-OL2<8R0DSR<X23_B.!G365S*>@W;>R\Y[$LIR
MK%'RA99B3E1,HJTNJ5RCGXM,&T;CH![0TBP><[0#WJ5R3%G-^B_>7%4O2J.+
M4Y_7-=R@K&9*X]SY2?X9Q^W^&D.N'G^\U\NQ7\JB!QVE6HM0<#.)FG4NO.Z>
M<NL1K),JQ.HNB2D=5B(SRW-* -U*<@H"0"5$#>ND-&>EEP*UJXS&C:S9T_<'
MBD)M^KHSVGUI6K #9N,H*L2W"HA*6V;LZI9V0%':HI0YDRNFLV5=,EUUC&5W
M1["OE/P9["A[*9F1'&9+9'VH=3J6^W/6CNIB#D2'EBX^XE"T4-NHMRF#DS4=
M/">(F116C\0XVD H1<0IX60>]])(6(G6E79T=B_47=;84]M&4I$BLM84FOL&
M%)/"O,B2VF7TI!]._L+9/HE9UP->)L&J]5:+G*>L5WN-EDM.XD1FUJ2RXXTK
M=N=;WTJC2.4CE4W*CKQN, UM/6'#WA]Q/M;<;5VG+'JF"\QF',?9;<E,,O)R
MEZU7F*IN?"YTJ"DO6^8R5@@\RDG?.?M5U#[8[NAN'C]NNKR0MH6]B60H;K[H
M%1*2*Y7FN0KU"2.2:B3)>0A25/1F2>!?'_Y>A_6/<?R:\X"5*0I"T*4AQI:7
M6G$*4AQIU!Y0ZTX@I<:=0?5#C:DN(/JE0/KJ;NRW6=E>(K@X]N<9F9XNGRXS
M=^ 'LRI6!V-H4Z\XM",FA,)'<MF:INY2@*#%C*5V1SUKP\])F%/6Q:M?1VK9
M)44--Z@@H7]'.K)"0;A#_:.P2=BN1'6_&*E%2V8;*21\Z.,WH)72T-2[_P (
M)TB_0FPM]W1UV<:%[90D<RDV6YX9C78)]KLX,U$2<&T)0W+N<I80K+%IKH<9
MRC'<SI8>18K<P+ZDGH4J-85[P=:4I 3YT=Y!"7HLR.I01*A2FF)<99"7V6R1
MSWVNKV'V)3+4F,\U(COMH=8?8<0\R\TXD*;=:=;*D.-K20I"T**5)(()!S7S
MREQ)4"5(A3HTB%-B/.1I<26RY&E19#*BAYB1'>2AYAYI:2AQIU"7&U@I4D$$
M4TTTU5JWJX&V>3N8OEM;)*RF%/=:JK-//"3$F/-MH=/ORN))+4EOT)X2X@<>
M:K4^![#GW^O6,?N* 5I/"D K21[A2!WI(_2%)!'Z0#K)-3RESJFLFN<]\NO@
MRE<\<]TB*R\KGM 3SW+//:./LX'H+V*K9:? @C[\@_D*M7QA0/B/Q'^V*[+3
M335W5&FFFFE*::::4IIIII2K(;YXNY<XVQ<Q6RY+QYUV0ZE*5*<762$(1-"
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MM=E.A0[D#BP&MAJ2TRAN-':;9CQT)::990AMIM* $I0VA "4(0D!*4I "0,
M8K1ZG7Y3SLR6^])E27%O/R)#BWGWG7%%3CKSSBE..N.*)4M:U*4I1)42JFMR
M4..+0TT@N.NK0TRVG\IQUQ00TVG_ )3CBDH'Z2-;=?6.XAJ1&==4I#34F.ZZ
MM )<0TV\A;BVP/4N(0E2FP/4K"1R-4ZC7ATZ^L_ZH/&^ZO.KKI/V$ZC-ENG3
MHZZ <8OLISRZWKW#R7:_;'.T83EE;@.?;H[B9#48S=HL(U5E<R9&Q:LR5EG&
M,:Q2M591EKO[>PDS,2MEX G5K0;JTV&9/OCT.8MM;D.QU9U'4/5;D75+AM3T
MR7FT-UFT7 *O**3.;"#'N;D3<AL:F.B)78K)0VB[HUOS&S<5R9$V.@CJ2VN\
M*#Q O%KVKZL=T,EV9R?<#!-UMC,&W*;V/K>ISX#+KK>6JS7'LSR';&TDHQK-
MJJ?B"H^3.5N2R&Z:\^,1$EN?CNU4JL^\2[P6.I;K7Z+MUNK[,MW-\:KHHZ9;
M#';3>&=TQQ]OL!ZEMYX^?P+;:?';KI/P6XF4&%[4[/5;V0Y')IJN=15N>W%A
M"QFYCR:*G4NYRB!@ )R$@#'0@[#?(ZY[_'?!\+'(.">I.2=\D;=?#O[L["KV
M>$;U!]87AN]>2_!@Z]\@@Y?6Y?1U]UT[9?!SMS<*DQB[N,6=R_$:7"<JD*3*
M?VMW2H8-E"IL<GQ:V5C&>18"(%57QKJX;?\ 8$""$GE("R$HY4$]RE E*4@D
M%2U 'A*05'U/' )'YU^U&9Q>K;Q_ME>HG:/J5W(ZS&6\SQGJ)W)W7S;:*9T[
M.8Q$VZ9LGIF 5& KR7-OO?VYP^J@87@V)-1+(19<6WBX^RAM\+GR?:#D>:Y-
ME<MB;<V3O=$<#L")#6Y$@5K@/*5P&&U\MO(]!\8M;DQ?:"I\^H/-_''TB-+<
M&Y,*U/V^7?\ 4T^,S/;LT1Y$-B/;W)#C'K<^XN-/ICESL) BL,Q93SRVLNIC
ML+0^=X<)>"6H.)S,JXM38UEL$20Y$7=)+2Y3STU#"'3'A04.,%]*.U8]8><D
MQVFDN'LR^\A;(R'Z:BA@^^T^"6Z[- ]9P@GM;O&&_,MF%#G@SV$J0BS;X]"\
MV&IJ 25)E^@3*&MLZZY@L655-C6$&2D*:DQ74N-DE(46U@?,R\@'\9'>2V^T
M?1QM)XUZOAIQAT-Q6M_K6E[H#/9:2Y<+!/#<6]VXGE"B_#[5P/1PI02F=#=D
MPEJ(;[</!;2/.Z\X9:NX=3?5]06\^INN%$*\PN>1:)V,D!J46VRR_P H)5$E
MML2D@%8:4T4N*YVFFFMHUK^OC)C1YL:1"FQV)D*8RN-,ARV6I,27'<24N1Y4
M9]#C$AAQ)*5M/-K;4#P4G4-LZZ7I^-W#NXO3?>N;>9@P%NR<43*+6+7S">QU
M5;$#X=8KFY*T=JZFU3,QU\K[6Q3]J7=3/TUYO4>D['JIAIJ[129$1?:VZZ1'
M%P[O:I W3)MER8Y9,-Y*@%$-K+3O*$OM/-Y0?;Z(XB:KX>S'Y.G9Z4PY[?J]
MZL%Q8;N>FM0PC[+D&_6.6%P+C&<;*FPIUH26$K4N)(C/<KJ8I;1=3$?)KI6W
M&Z].=MMU8+IA.UUBVY I;R4D I17.S7%*K;!]/XR/62I,F)8)^:DLYH4W&$K
M2".01P02#S]1!X(/V$'T(]P??5H=WMD<'WII16Y3$7'M(;+J*/**YMD7=,XO
ME26D+=243ZM;I#DFGF%45U0\V.J',#<MN->$;OYWL%DM?M-U$R%SL=G=C&#;
MJ(6J3"-?&/DI3;RW0)DJL8"X[3[TU/TWC2>UNR1.JDLSF_'L:BO>AY+%LUW)
M%SL,EYN+:=>(92PEEQPI;CP-81V@&;?)6LI8CWIC%NFJ+?K2(3ZG%'9DO16E
M>+$&;?\ A)"-BUA!C.S]1<'W9+DMR2RPDNS;QPTFOJ,F\P&F@N7,TM*YKU:T
M(>$!VYQ$QT)GEIKC_%PQ$%@J9#37*BHFBQ5*CIK_ ();0?1-^.4Z(GP:F%!Y
M,KSOAU,D.APMD*U8R5OO"R"7*I-F,:L=W[N(Z&9=G62$4FW-0Z>.X6^X$]I=
M:XXT>4K@TD>TEJ)2I/#7*Q[ZY7RU6D,^O3$-NRL^IQ&4NR[A/*0%*3 MT1#\
MZ<I*2%*3$CO%*2%JY4^U6GK'I/4.HU2OHFV.O1X'(;G<I+C%MLUH0M10AR\W
MNY.Q+3:&UJ!0A=RFQDN+!;;*W,(-^];5(0L +0VX >0'$(6 >".0%A0!X)'(
M]>"1]>K!;?9ON%$W$N-M=WG<8%_>8_$SO!7<3CR6*-=/'*J[*,78=FCXZ?88
MU/0S*=GS%*DSXLB1+0AJ$B.V+@;H[K;9[)8->[F[OY[BFV>WN,LMOW^99K<Q
M:+'ZM#R_*CHD3I:AYDJ6[^(@5T-N596,@B/7PY3_ .+TM%UBWV&Y(98DL]E*
MDP94*>PEF9%E17.1;,J.%NAM3C99E, K5VL21&?3[+J:AJ33L_2EQ:@RY$&8
MF3;X%UM]SM$E<RUW*!<&0XS*M\PLL&0VT^F1 D$-)+%PA38BOVD==5ZW'C%Q
MH&-&X+K8/]SL_P =/_\ #UC=O !=W0   N;<  <  6<L  #T  ] !Z >@U<+
M"/$PZ!=PMKL^WOPOJNVER+:S:613)W/RROGWRT8 U>VK=11S\LHET",JJ*>X
MM%HKZZ^>H31ORW&V/I)#B^T0ESOK)Z7,9RNVK+K?+ 8TYW K3?,,,V$RR*-G
MGUOVL;<>0Y4U\]F)BLJM>8FQ9TQV.Y)CR8BH\=PRXR7>+/3:L5RN=KX=QK+9
MYUPDIGZF==8MEOD2WTLHC6,%QQJ*TXXEI!4 5J2$)*AD@JWZ9]%&[0H-PUN]
M<[E&AL+AZ?:;=GRVX[:G5/W8A"%2'$)4M21D)222!GH*A%X@G67NQTX;S]/6
MVN![C=.>T.-;K8?NG?Y3N/U'X]EUSB-).P>7CS=) 3)Q'(*F="<OOI2171D*
MA3DR+)R("[&:2L.1]ZAO$ZWHV9P7IY1MZYLGU'YK/VZR+J+ZBLOVKH<L_!DC
MI^H,U3C$:VP!BTOV;K'IUWW3(L>RR)5FAB;2N2FJV7#GA+-_M_-X_#XMNI;I
M[WEW;ZI]LJ"^VPVPR5W%MO,IC1)V.9KB'4-0U-CCN5V2K>BE^2U]&1X5UCRV
MD@*0\'9R8JD$)Z#=GI&\//'K?</JHZL\WP/,,/WPM,*Q_;F\RBS9Q7;G ,<:
MH9D+$L*VM5MQ/CU]G7RZYARX%U(9G=ZH#]JZMB.F6ZK1VE&>'=IM/#F/K3AG
MJ:5,;M$UZ3&8T7+7*UQJ*9>;W!8M$);T&T3+B;?IZY0+VN0SJ,V\+@0668+\
MQMQ*MQ7]S65PN&LI&F-;V1B,J?&8:=>U*PAC2]HC6ZV2WKG)0W)N$>&)=UA2
MK8EERT>M%,J4XY(:C+0M/!W9ZCNO ]2VR6UFR.>=(,S;OJPQ[<?<78;(,HVY
MW.NIE%@&$8C5YC#3G]G3YA"8M;FYK;-E$:5C%<JO\T*+Z6&P-9?Z5%NW35#>
M0/5\B_155R+V14LR(]4_=)A,)MGZN/+<=E1ZUZP$ERO8DN.2&8:F6GW%NH6H
MX2J*!T,='VYO3%B^Z/7;6-YUT1XQNQC>.8IG;%9#LY6&[^TD6QI:_)Y=+52T
MMQL6QZRBOXM/@/'Z0JI4)F=Y3$>.VC)=CG69TKY=C&>9ICN_&W-CB6V%-C60
M;@9)]-.0:;$Z?,H/TCBDZVG6<2$RVWD4,H<IVHZI$J>MQF.Q'5*>:87KWB=I
MZ1+A:33I'15Q78XEJ=;=U-"X?W>Q?U@E2M3W2#8ISLIZVQQ-^D]..:36R&U.
M-.7*X+0VIR9)<"O7Z%N[4:7J#^L6J(@NLB>A3=DE:L@W46AF-8X$N[16V42G
M#',"\HU VZ7 EQ$.&A2@F.RA0RM=/[32\-L2MEEP_?','<XRVXK@0*W@=RT*
M('J3P"!SZZOH&6$D*2Q'2H'D*2PRE23]12H(!21]1!!'VZQG])G7_P!%N?[*
M;O[D8AU*;7W6%[+N2LMW6N&+6>R[@.)N-5\%G*<BI)58QD;&.R)S:H<>YB4\
MR _*[(S;ZI#C;2Y<-]4W3HZ_T_QV-Y,'DN=50D*Z<?@YTR<UO*F)40KV8<)D
MPX#\65\)4V$.9*^DGZLQP]\,Z$3FGXK7U!X%V:7:^$>@(%UM4BW7.%866ID.
M?"<B3HKZ7WUEN3'D--OLO)'*HI=0E:1@X Q7S[XMW-B?Q*UG*@3VID&3>75Q
MI$.2F1$?:4PP MEUA:V76U$$<R%*2<=:OY[E*>1W+)2A/([EJ *BE"?REJ"0
M5%*02$@J(X!.GV_L/^D$'_2./UZB_F%!2;U[W-X/9O6#V.;188G(K3Z"N[&D
MLVL\SJ4PS1F/85+[,UEVEQNK?GNH"D^2[8L>8E3;JD'OWL-WSPP^;@6Y4+<6
MI96M0Q'>.(/I8LDM_P!RP-QZ!EBP2IM(4F*J[K)++//,A4GE1/JT:GFK?N+C
M&GIEQLT*X/VUNXVJ5&ERW'X/9LW)QVTO^IO]A$N'K4!(MS]TFONPWE"$V.3G
MF7H.UM1+)'E:TM=EU/=;+#OKMEU%;Y]MMK$2[%V38V&-1Q!<XHEW*S*M]X4N
M]Q+!:XD:Y1DKNKI#I:[K=78O"MUOAK2?&%-FE2Y$E4.:5C+:;6))KGVY4!BS
M00&KRJ;?9;2J%.[G([17]'R8CG'-Z%*4M2EJ[0M9*UA'=V!:CW*[.[E7;W$]
MO<2KMX[B5<G5@COU"QA3<7>#",NVID*D?#*O)D(Y5MZZOYNUZ/G..(D18T5Y
M22B.+BOK9#AX4I('/;>BDO*3):YFXQNXJL@J9"2IFSI)\6T@N)![3Q)ANO-)
M4E7RK0M27$+^1:4K!3JO9).E)-RNDJRF"S>;BF*Y>8X97;KNZ8H>3&?N=IE-
MQI[3R4R'$>L2H;;SJ.S0MQQ#3(1:ZK@\0X-CL$#5*;K(TQ9ESV=+3E2&;UIQ
M@7 Q53H=AU';W9UIDQEKA,.^H0;F]&C/!YYIAEV3)4[VFFN)83X55 GVMB\(
MU?5P9EE/D$<^1"@1G9<MWMY'>6V&7%)0""XH!"?F4-4?MEN!3[I8)CN=4@\N
M)>1%K?AJ<#CU98QGG(]A5R3VI4)$)]LI45)07&EL/A"6WF^<ZJX0D3V;6J2R
M+A(B29[$0K';N0XCT6/(D)1WMM/38S9/4J='*"$K*?)-V>Z.VB5?VX$E=EA7
M&#:)5R#9]59N5RC7"9"AK<S_ 'TB-:YSR4@$)0P><I*VPNN]---7E8VFFFN%
M86-?40G[&TF1X$&,DK>E2G4LLHX]DA2ORW%GY6VFPMUQ1"6VUJX2:3\AB*P]
M*E/LQHT=I;\B1(=0RPPRTDK<>>><4EMIIM *EN.*2A"05*( )JHRR](>:CQV
MG'Y#[B6F&&6UNO/.K4$H:::;"EN.+40E"$)4I2B D$D"N;I_&]CVJ[%<$'M7
MP%=BN">U8!!*5<* ()'!!,4\XWWES Y780EVOB*"D/7LME*;%])!2H5\5SN3
M7MD$E,E]+DTD<MHBCU59S',TR7%;%VSJ+1]+TISS)[,Q2YL2S42238,/.?W0
MX25%,D+1+;*BIJ0@ZY(U7Z9/#?3^IHMDMD.Y:HM3;ZV;UJ*U+81#AX 2E5I8
MD<BKX$.9#[B7H,4M#M8,F?S!-=):=]%[7-YL,BZW"5 T]<5M(=M=CN*'G)4C
M.%*%S>8*DV@J0<M-]E.D!S]G+CPR"1D/TU:C!MW<=R_R($PHHK]SY/@)+O,.
M:YZ#_@N<YV)=4L\D0Y ;EI_)1\3Z+-UR""0001Z$$<$$>X(/J"/K!]M=+Z4U
MCIG7%H9ONE+S"O5L>P.WB.$KCNE"5F--C.!$F#+0E25.19;+,A 4E2FPE22=
M#:CTS?M)7-VSZCM<JU7!H%78R4>P\US%(?BR$%<>7&600B1&==9400%\R5 -
M--->EK!52>88'AFX%?\ 1F:XS3Y+$ 4&?I2&AV7#)0IL.5]BCR["O=0E:_+<
MARF2@J*AZZ@/NKT*N-IEW&T%T7PE*GOO+R>3R^H@CEBDR98;0X>WN+,:^;2M
M:@EHVRE*[CDDTUX76'#?1VN65HU!9X[LLHY6KM%2F)=XY (26YS:.T=2WG*6
M)8DQ"<%<=8VK;'#7C?Q,X32FW=':FEQ[>EP+D:=N"EW'3<P%04XEZTOK[%A;
MH'*N9;U0;@$DAN8V3FO.I>45WC-K+HLCJ+*BN8*@B95VT1Z#-CD\%*EL/I2I
M3;B2%M/M][#R"%LNK203U6L^NYVT6"[NTXJ<SJ4R'8S;HJ+R&H1;^C== !<K
M;%*%+#)4 MZNE)D5DKCA^*I1#B</^]VP.8;)6C7TGQ=8G9R5L4.6PF"U%EK
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M8W_.F_U:L+IIVSGVC\!^GD/A3L4>!^)^?YGRQ?K\/MW^;&-_SIO]6GX?;O\
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MVE<[CE]=4LV11IF<R3]&&0IL)\AU<]6FFV6T--(2VVVA+;:$ )0A" $H0A(
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M_P"'EZ;>/?U_"HJ[3/L\N-NN<]=^\?/3Q'<?@8W&_P 1L_TM5_O>GX&-QO\
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M0E+;:$MMMI2E#;3:!PAMI"0$--('HAIM*6T#T2D#TTTUA[-8+-I]A4:S6Z-
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MVDZ+<'V:H^AZCGX[A75/7=0]ILK7Y7E6\&YEU83ZK\!B,EW/3FEC9NS)M?\
M&2/O53#=O!-^'D*JVE>U':^^M-P]I]N,JS6@PNNOLOP3#LHR/',2R&NW(P*I
MN[FCK[B578GF"(;=9F6.5DF2&:'*(L-J+;PVH]E"2&7675UM*J*B<Z'YU/3S
MWTH#27Y]/63WTM)*E):2_,B/NI:2I2E);"PVE2E*2D%2B>_Q)4DD*!7N[GVL
M \_*-L @<O+MUV)QCOXM2,I!\0<$'H"E( VVPD@D8VP0!C J.'1/*VQF](73
M3,V8:PAC:V5LQA3^&,;:1\QB[=-5ZX"OI)O!(VX3,?.V<11DHO4T",P89R+Z
M.#"K-M,A2N90:^3+#$9IMB,PQ&CLH#;,>,PS&CLMIY[6V8\=#;#+8Y/#;3:$
M DD)!)U]=6Q.23ON2=SD[^>V:B!@ >%----0J--0RZTMJ1F6WZ,]JX[:\BV[
M;>E3%);6J388>^ONM8: TE9<74R7$7<<. );83;=JT><LJF;KXR(T:;&DPIK
M"),*;'?AS(SB>YN3$EM+CRH[B?X3;[#CC2T_PDK(^S7F]7Z9A:PTW=].3TI[
M&YQ'&4.J3S&+*3AV%,0-O;B2D,R$@$<W9E"CRJ4#[?AOKJZ<-=<:;UO:%+,J
MPW)J2['2LH3/M[F6+I;'3N.RN-O=DQ%$@]F74NHPXVA0\XO[#^D>H/ZC]8U?
MSI@W,B;2[[;<Y?;K_P"Y9&0P:?,F5=RF7L7N93$2P=>:2M =36/F'<H2M00%
MUP*OE[M4'NI@C^V>XF6X.\'"S16[S=6ZZ2I4JBEA,VBE]_:D.>=5R(P<6D &
M0V^D?D$FWRDI6E2%CE#B5(6!]:%@I6/Y4DC7RQCOW;1NIFGT@Q;SIJ\A10<_
MLIUKEX<:7TYFRZRIMQ/1QLJ2=E5^@.9%T]Q,T,_%6I-PTOKG3*DI=0$Y?M&H
M+;S,R&N;F#;XCRD/LJW4R^E"P0M (]NC#B766W4+0XEQ"5I<:4%MN)6D*#C:
MTDI4VL$+0H'A25 CT(U]=1,Z'MT5[M],FU^12I!DW-12)PK(EK*%/F\PQ9H9
M$B04*/XRQB18-HGO"7%-3D.*3\X)D_=7E-C=39WV0VU;1T=+7S+:XN+B?%K*
MJIJJZ.Y+L+.SL9SS$.OKX$1IV3-FRWV8L6.VMY]UMM"E#ZZV*[1K]9;3>X9S
M%N]NA7&/ODAJ9';D(2K_ %H#G(L'<*20=P:_.GJG3T[26IM0:7N2>6X:=O5S
MLDP8(!D6R8]#=6@'JVXIDK;.X4A25 D$&NTTU@QS[[I,\%?;G,7<'NNN##[:
MUBV4BKG66#8!O!N'B421&EB&ZX,TPO;^ZQ>?"\SO<;L::TM*]^.A4B/)>:[%
M+R<]+W6)TP]:6WJ-U.EG>[;_ 'MP;XE,&9;X3=(ERJ.R6'5-U&58],;@Y/B%
MTXRRJ4U3932T]D]#4W-9C.176WE96L#4E=---*4TTTTI33332E4MF>+Q<PQ^
M;225!I3P#T25V=ZH<Y@*5&DI3[J[5$MNI!!6PXZA*DJ4"(#W='9X[92:JVBK
MB3(JRE:#W%IU'/R2(KJ@!(C.CA33R.1P>Q80XE;:<D.J;R3$J#+(@B7D!J4E
M'<6'QW-3(JU#@KBRFREYDG^$D*+;GIYC:P.-4'F0YN-E ?<? 'PQ[JJ(64'R
M/4?#^7WUCKTU*"UV JD/%<++'J^.MQ02W:Q(TA2>02$(D-R8!</HH\K;4KM'
MN0"==3^ 6)^?M;_1S?\ ;.K,L. D<HV_U)'YD5<!Y!&YQY8.WP&*CKIJ17X!
M8GY^UO\ 1S?]LZ?@%B?G[6_T<W_;.G8N?9'[Z/\ [4[5O[7X*_2HZZ:D5^ 6
M)^?M;_1S?]LZ?@%B?G[6_P!'-_VSIV+GV1^^C_[4[5O[7X*_2HZZ:D5^ 6)^
M?M;_ $<W_;.GX!8GY^UO]'-_VSIV+GV1^^C_ .U.U;^U^"OTJ.NGH?0CD'W!
M]B/K!_7JJ,QQM&*7C].W:1;A#3+#PF1 E">7DDEAYI+T@,R&B.5H\Y?*%M+^
M7O[12^J9!!(.Q'6IP00".AZ5,W93,I&1T<BILGE/6- 6&4ON+[GI=<^%"(ZY
MSRI3L=3;D1UTD^8E#*UDN*6I5Z]0RV&E.LYN['3WJ:ETD]#H3R4I\AZ&^VXZ
M.0D(2I);2H^SCJ4@CN/,S=9%A14V,]1E.?''3\-ONJS<3RJ('3K\?GY%----
M5JDIIIII2FFFFE*::::4KYO.!IIQU7LVVMP^A/ 0DK)('J?R?J]>?;6-*2^J
M5)D25<%4F0_(41W>JI#RWB?G)4>2LGYB5?:2?761ZZ=#%/:/*<#26JZ<X720
MD-A$1Y7>2?0=O'=R?0<:QL(_(1_S$<_K[1S_ *??].K*6=T#_J/Y?/PVVJX8
M&ZCY 5NTTTU:5<5&OK%Z<H?5WTO;V],UCETO X&].%.89,S"!2Q\CF8^PY<U
M%NJ='I)5E3Q[)PFI$4QW;.$ B0MT/!;24*Q\UWA6[T7=3T]4.^'B$;C;[4G3
M'U+].'4'M/6Y'L1MSB[..5G3U M:MG;&$YBV21GS59E7R**),R6S<MK.C;QF
M(J+!L7)TQ6LS6FITN+0,)( SGZJ20=MP2"1T&<'?OJ!&>\]_0D YP#G[ACW9
MK%QTJ>$?TH].N4YEN1E>W>V&_&]&3;_;J[W4&\6=;44L?,\)C;FW[][&P2I<
MDW.21Y59B+TZS15W+HC37GK.5-CPZE\,AO$MD/A"5L1S-MF,>ZL]]\8Z-\BW
M'N\KMNE:JBXW]#EF3D3]Q-Q*OW%=4K)8.(2K%F*MRL%<\XMF,V[)>EVZ$6Z?
M5FW_ 'QO_GI_]H:QMY!_X>O/_/-M_P#$9.N-/3&UUJG1EGT(_INYI@.SKM>5
M/J<M]LN'*_;X]K>M\V*FY0IB8-RM[KKKD"YP4Q[A"6ZXJ+):+BB>H_1ATI8=
M3W+6#=[A*F(BVZTI:")<V(2U*>GMRXSZH4B,J5#EH:;1+@R2[#E);0'V' D8
MP[[D>%+#N;'>&GV5ZF]T.GK97J)[5;W[%8OB^(Y=B&3//0(]-;.XU89,I-EA
MXN:5@Q);32;4!YPJ[W*Y+54VS;PP,SE;UYWO)L]U<Y#LY)SK"=J\#FTKFQ&U
MNYZFJ;:/!*'!\==7:9S(?:,U]-$FYF2*JGHUJE2W8?<J&Q'2C+CIK@>/QPXF
MQPV!J&-("(#EL=^D-.:7NAGQ'39BOZ75<K+*5>I(&GK*AN?=S-G--6V,TU)0
MVE25=BN<+-#.*<4+.\P5S$3T>IWB^0A$DMIN*4FW"'<F!;&3]+W)2XMN$6*X
MN8\XXRMPA0QCY[X9&!;L8OU2X_NCN%;9;9=2F0[5YU%RI.*U57=;8[D;6[:Q
M-OX>;T*6K)^);2[Y]F;;758\U50'JVXLL7X7"<9FM6TN?"ORYC,L!SK;/JWN
MML[[#.G#:WIPF/HV&VWSUK(,?VSC!M-PN)GEM<5]3)O9;46:[%A0G)%;\.(C
M-O*C//I<S!Z:IPN-?$R WV#&I$KB!I#(@3;)IZXVU+*+5:K*&D6VX6F5 0TJ
MVV2UQW&T1TH<5$3)6E4I;K[E23PQT1*<[9VRE$CM%.F7&N5VAS%.JGSKF7%S
M(D]B4MP3;E.>2M3Q4@/J920PEMM&/;_>?-S.I;;+(\#W!\1C?27M_EWWJ4F\
M&"V6S>S&2XQE$S&ZJFCL9'M;76L=MK8&YE5-3709/WBB1&>D0V9,U-A"4_5.
MRK=\(16-2]];/8SK*WYZ>;C=#,>G?+,'MMMZG'W)>#1NG;8R3L)28AG*+JQD
MP]ZL1RG%YLJSR&FN(N)P57'PRUQ)\:,EE617IX_XM9#_ .D+'_PB/J_ZEH;2
MI;BT-MI'*W'%I;;0.0.5K64H2.2!RH@<D#GDZ^M? 2\W"[\'-!7*X/-+E2K.
M\M]3,2'"8]BZ36T):B0F(T.,TVVRTA#4=AIIM#:4I0E(Q7S>XPP(]NXG:P@0
MTNICL7*.EI#DB1*=)<ML!Y96_)=>D/N..K4M3CSKCJU*)*B:QX>'OX>F.=!5
M1O?+1NKD6]&YG45N-#W(W4SZWPW$=M*B;95$*S@4=?C.VV!H3BF*0HC-U;2)
MQK2$6$R:$QXU96P8%<SD1UN4A2#PM*D$^P4DI)_5R!S_ "?I^S6W6VU*4M14
MHY4<9. .[ V& !C&,;8K6@QC8Y V\>E----2U&FFFFE*I?,D9NYCTUK;R3B\
M+*G.U,"=ES5D_40@>>^5\/5M//R);/"51&7D?!EWYI*76TEAS&9A?2GO!"WI
MQ"VSO'ZV9CZLQ^^7(\CH[&JDU!1"D/7KB7(D1,"37?25@RQ'C0T53+*5OI92
MVTT/ERMZ<<G@ D_4 .3_ " >O/ZM:^UAPVL6N+C8[C>9-WYK#,CS(<*/,0FV
MNJ:DLR'&Y,)Z.^VL2@PAE]UHLR%,X0'@E*0-R\-...K>%-EU79=,0--]GJ^V
MR[=<KI-MCR[Y';D0GXC#L&Z1IL5UHV]4AR5#8?1)AHDDNJCJ4M95J25$J4>5
M*)4H_:I1)4?Y22=<&QLJZGAO6-K.BUT&..7I<MU++*3P2$ GYG'5\$-LM)6\
MZKY6VU*]-6RSG=_'\1+\""6[[(&_D,&.[Q!@N_7])SF^]*5MG@JA1@Y*/HET
MQB2I,1LGR_(,PF)F7LY4CRB3%AM)\BO@!7'<F'#2I3;1/\-Y9=DN?^,?6/36
MG^,'I2:+X;F59K(6=7ZO:YVEP(4A)M-JD)/*H7FY-%0[9I7,5VV%VLSG;4S*
M7;BM#U9KAEZ/FJ=<B-=+LEW3.F'.1:9DE@BYW%@@*2;5 ="3V3B2GDGR^SB\
MJ@[&1.Y%-5>?.=]Y<P.UN$I>KHO)2Y?26O+LI"?;_@^,X%"O:4."'WPN:?7L
M1&YY,=G'''G''GG''7GEJ<>>=<6X\ZXL\K<==6I3CKBCZJ<<4I:CZE1.MFFO
MF/Q!XG:TXG74W75UX>FEM2_4;<SS1[1:VUD99MUO2HLL I2A+CZ^UF2 A"I4
ME]P<]=\:,T%I;0-N^CM-6QJ&%A'K<US#URN"T#9R=-4 Z\0HJ4AD<D9@J4(S
M#*#RU7&';A9)A+Z?HR5Y]8MT+E4DU2W:Z1SR%*;1SWPGR"2)$0MJ[_F=0\.4
MF7^%;EXWFR$LQ'S7W*4!3U)/4A$HGD@K@O#L9LF?0'NC /-A0\Z.UPKM@1K<
MA:VUH<;6IMQI:7&W$*4AQMQ![D.-K00M"T$<I6A25)/J"-;&X1>DAKGA4MBW
M=LK4NDDJ <TY=)#G]D;)W-DGE+SUK6#E7JX;?MRU*<4N%VR^W3X?B5P-TCQ$
M2[.[(6'4BDY1?+>RC,E8Z"[0P6VKBG ">V4MF<A*4(1,#22TK)MIJ)N#;ZSZ
M\LUN9I>M8 '8B[CH"[>/[!!FL@I1:-#DA3R?+G)3QR):AP91U=K6W<%BSJ)T
M>Q@2 "U)C.)<1W=H46G #WL/H!'F1WTMOMGT6V/<_4'AGQBT+Q6M_K.F+HD7
M!EI+EPT_/+<:]V[/*%*>A]HL/Q@M24B="<DPU*4E!>2]S-)X!U[PQU=PZF=A
MJ"WDP77"B%>H7/(M,[J4I;D\B"Q(*0HF'+0Q* 2I8:4URNJY^FFFMI5KZFFF
MJ$SG<S"-MX\9W+[UFOE6"PU4TD5F1:Y+=OJ/:AFEQVN;D6UDM:N$)6Q&^'"C
MPM]'!U:S9L.W1G9EPEQH,1D O2I;[<>.V"0E/.\ZI#:2I1"4@J!4HA*05$"K
M^V6JYWN='M=FMTZ[7*4HIC0+;%?FS'RD%2^RC1T./+"$ K<*4$(0E2UD)22*
M7WWG[B46WEGE>V$U+61XDKZ=DU3];#MX=_C\=M8O8+T"4GO=E0X1-K7F&_&D
MEV$ZPAP^?QJDZK=3=F#2UM]D&U<'<'';6J@W4#*]DK]%H)-7.B-2FI;F'96J
MNND<,K"_(@6$]:E%QAM!6TGOW.V._&Z#JF*6L1L/@[J%(7>Y+'K[[=>TC.)*
M%JJL92[(HL3+J3RT_=.S)K:7 L(<]6D76P#"<>VNQ>BP2BG3UU\0V"ZIN_MV
MYUI*6XZNPLS"#@C]\=E]Y^8N#6QQ#K$O.J0VRRHJ/@&T76^:AD72T7'4MDLC
MEM:8$F6W'CPI-T8D!,=VWV*^1)4A<:;&?4U-E*AVCM5P[>Y;)$L293R=PO/:
M=TGHR'I_4=DT)JK5;%^?FF#;W9TRZP=/RX/:3(UZU?I.XV^$U.M<Z&U(M5N:
MN>I!';NEY:OT*W*@P(SG18=O1MWFUFC'JRWF565K96^<.RVDML3RH(:;4Z\4
M5%U%CJE!EM"W5F"]+'DMN/C\2A2Q=35@X+JLOZD+Z6HOO5FSNW=;CL5Q0!81
MF.XLD7-N@J65*7(AXK7UC32T!)C_ !DADDA7:N_FO3Z;G7"?%GJN#T228EXN
M-MC3(<1V"B8S;7$PI#SD5V9.[-YNYLW"*HMR%-.HC(?0VSVI91X37-ILUHGV
M=%FC7& FY:9LE^G6RYW&/=GK;)OL==TAQF9\>V6CMXSUBE6:XH#T)+\=R<[$
M<>D^KB0[C[\1[8C)]_-F<-H<,WUW*Z?LHQG<Z%E--F.W0J9[4Z0C%LFIWJ/-
M<5O&5569XE*AVDI4C'I\B/$>E>6]($EM'D'"U2>$YC%3TP]3NP,C?')[;*^J
MW(J')MPMTGL!Q*GA5UACMS#M:]O&=K\9E4V.5<5QMB0Q,:9M&PMV6%Q1#@PH
M=8WZ-.H3_B94_P#I/'_^%6NH>:^=GI4<3=;Z8XKR+-8;RBW6^-%T;?6VV[59
MG)"KE:'VKQ;5O3W[>[/DQ8ETBQYS5MD2G;;ZRV'51%*4LJ[#]'C0VE[YPYCW
M2ZVU4R8_)U1:7%.3[BED0K@VNW3$MQ&I:(C,B1 D/1%S66&YO8++:9"4@ 8_
MM]_#TVMZC]T-@,WW:FP\NQ#8[:S,=L96V=WBL6PJ,X&4U5? @Y-(ME6S+V/6
MV,3:Z/>4PC5MH&[1J.]\0UY \R,DKPE,C8PSIGQ?&.K>\QRUZ4IN[C6UV6N;
M$[?9!8HQK=&=53&:.]I[J]D8Y=SL:;BVT49#9U4N7>IN$R9D2)-JXLER6?6[
MXAW3IT%8M67&\=U9V669,S(>PO:_#HT:SSK*6(KR8TJS;C2Y4*MHL>B/J+4C
M(+^=!@O2&GX-4FTLF7(2,(37W3MC1M4MO='%XFC^,*%RVM\8#EL(/<0'DPE[
M8MP%3.WA1CF:A@JY0)"00L>(X=6[TI-2Z=ML[0\*X3],6OUEFS_2471S=J(>
M3J*/.5;HFJ&VV)Z9*-4:@A3Y,=F2F2B7ZC*=<$"$S$];K2Y\ ]/7F;#U5,AP
M[[-]7<N"83^HW)Z2VNRR(8FOV-;CL-3"[':)41I]UDL*C^M,(094AQ_*9F?A
MU;VYI@]%C4_K]W8;N(^-Y3@N7J.T&T[VV.;81>W-G=5<&5LLEJ/A])E&.N6K
M\*)FM2\+=V"U&#**Z9';EZI"Z\(=Z1MQBFQVVG6)O3@&U?W@4.VF;8'?8E@F
MZ&(90(EE92I&8T6/Y*B%%V^S"RFY%<R9EMC:Q-"G8*8\YDPE.2)A=&_7;T\=
M<^$3,OV/R>0]8T(@HS3 ,EC,U.>8/)L4N_!MWU0U)F19%?-7'D-UN04LZRI+
M%R.^PU,;F,/Q&IJUG_A*N_\ .$#_ /W&->+<XH\8=)W]G3EWD-6*;;+ZW+EV
M63HS24(-W!Y\O-R)$'^KZ&)!83*6]9W7&W6;>RZVY9U1V>Q(]2WH7AOJ.SN7
MNV-N7>)/M2H\>YL:FU!+[2&AM+;C+,KZ76ZT'2PENY-H6VY,<;6BXAY?:),W
M-E-I<9V$V=VJV.PM^TDX?L[MYB.V6+2;R0S+NI-#A=+%HZV3;RH[$6/(LI,>
M(E^8Y'BQH_GN+3'8:92VA-SM;E_EJ_YRO]9UMU]H5=3[S^=?*]/U4_\ 2/RI
MIIIJ%34TTTTI3335P=NL'DYM=HCE*VZB%Y;]Q+3\I0PHJ\N(RKZI<PH4ALC^
M\M!R03\B J*4E1"1N2<"H*4$@DUB*Z_MMYU->[=;H_!EFNSJGM\;7(/=S)L<
M+DL.L/E/Y*&7:NW$>,L\?$&ND%'<AKG6//7H\\5'"X,WI;@VT6,EC\'^?X;.
MAI92E#;$"U^+P]^.!P>&NRYB]O!3\[+9Y5^2?.'KYP^D5846/BC=EM)"&;W$
MM][0D# [22R8LQ6VQ4[.A2GU'J5.DG)W/V\]"W5;VJ. >G&9*R[)TM<;OI1Q
MQ2BHEF"^BX6YO?HF-:;K B-C)PB.GIT&<OP?<^<=J-X=KGWR45UK0Y]5L$(
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M%:LBQ/3O'D3,"EY_90Q"N-W<IR#<N;&*U/*A0;N7\+CE9YSB4.N-UN/0*]I
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M73OZ=_\  W'[<G_[74>]-1[7_EM?N#Y[OS\34O9?ZU_'W?I^7AO(3OZ=_P#
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M"2'8[[9"N2DAQI:"%  \I/=P1P>03[GTUC0[2CY#[H^0\>W*/E/'V#D>@(!
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MWI[7&+RX9]5"""NFKW>$N_24ELJ9GK[  < )2E"0  $I0D)0D   )2D!*4@
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MO'?@["#&C,-,,QHE> P]'BM-(0W&91 <=2AAE+;26VPA*0D!)N\ $@    <
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MO&"R6GYN%[AX0U88_D$%^%(07GJ2Z=<1%EH:L(\5;JHX_78U]&GWV H,2)#
M4>Y08D/,I4K^,I+2T G])!/Z=5VGU-C!',G.<9P1[COMY?E5);7.2H$ ]^>_
M_?\ WK\LKH'\&+KA\0+="CE6&W6X>U>S%A?MR-QNHO=+&;BHIJ^J5(=<N9N+
M1LJ<IK?=','RQ+B5M10.2V7;HMIR.YI*]N7.9_3;V*V:P?IVV8VLV'VT@R:[
M -H,#QS;[$HLU\2K#Z'QV B*B9:2P )EO:ROBK>WE\ 2;2?,>2 E:0) 8?2.
M97E5-42%27VYDI*9COFN+?;KV$J?F*0\X7"V4LMJ""?1*U)(!( .S+\7G8A>
MRZ::E12VHNPI13VMSH*U*\B4UQR/0#R9" 2IF2AQM0 [23KBW1S8P@$C WWP
M#N>\^'0>500E*%<N<JQ^?=TV[OCBJ8TTTU0JM33332E----*4TTTTI33332E
M----*4TTU4^-X=D66/AFDK7I+??V.3E@L5T<@\*\^:XGR>Y/K^)9+KZCP UZ
M@ZB 20 "2>@'6H%03U('SBJ8U6F)X#DF8NH^BH2D0>\I>MI06U7,A//=VO %
M4IU)!3Y$1#RPK@.%H<J$B<1V*IJLMS,F?3>S4\*$-"%LU#2A_&;)#\X\^_Q!
M;85Z<Q24A1OLPPQ&::8CLM,,LH#;33+:&FFD <!#;: E"$CZDI  ^S5RB,HX
M*R /L]_WG^'XBJ"GOL_$U;#"=I\=Q'RYCJ?IBZ2/_",QI"41U?7]'PQW-Q?3
MT\Y2GI2AZ^>A*O+%U---7B4I0 $@ #X_>>^J!).Y.:::::FJ%----*4TTUHH
M\ G[ 3^P<Z4K!!XPF7>?ENRV!-JX^C*'+,REH '!5<3JV@KBH\D]R6Z>S*4@
M#Y7%%15RCLPSZG)XC6:-YEU:;A-L..KC8; QG!&PY^0B32U2;&T#/J06S9W<
MI!4."I31"DA2-0< Y( ]R0/VZ^4O&:\"^<4-9S4J"FVKNY;&B#E/9V=IJT@I
M.!D*,-2\XWYB=^I_0%Z,FFSI7@/PSM:VRV](TZU?7P4E*R[J:3(U$0L'?G;1
M<T-'/<V ,) %9P?!YQ$)B;VYZXROF1/Q'#8<@MD-ENOAV606"$.]H[E(>M*\
M.(2M03W-E:4GM[\VVL?7AD80O#^E'%K"0R&9F?7^39V\"$^8N)8SQ44SJE!2
MB4NTU'!?;![.U+Q^0*4I2L@NOH3P6LYL?"[1L-22AQZTHNCH(*5<]Y>=NN%
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MUL[5U;]E8SY[RRHJ<F3)$DGN(*APZXI*0>!RE"4I/ Y'H..N[4_Q4_L']6K
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MV5DV1PZ%,3'LOQ%ZP-K>4U'0V&/LV4R#,K%W$=20LA6 %# STSD$#[ZHO D
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M76.#U'HKD*  4#[A0'S _I"N1_)K)P?ZO]?_ ,]8XLEA&MR*]KU>\.XLV?\
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MXG_0KUV3;"DZ9^H#'<SS"K9?ES-N[^LO-OMR/@(K3;LNT@85FD&HM+^IA)<
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MS?4NG/'._N[4TM5Y?(X 25S20GT]07"YR3_"Y ]M6:U*??[%7Y4>ORN&R7!
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M&K",J//KDJL9UBY%F-.!N7 =;\M@/I5\0E7<E:+E7/SY .$D#&?K X*CC'N
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M8!K77U_&P'N%?,^FFFFHTIIIII2GOJ(>]^$2:ZX=RR"RIRJM2VJR4V@=E?9
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M\M!3S5?/2/4E+K#ZDQ7%)''SL21WGV91[#HH>R^X4IX-.4[$)!([I$NS@AE
M/OR(SLI]7U_D,J^KGW]+#LG,XY%? D=W>,^/Y^!JZ[1'VA\X_+._?L:M5IJ5
MT#82OBT-JW-G_'Y!+@J;@R@@L5]9+24NMJCM$EYSS'&TLNR9!*T,+<\EELJ.
MHNV%?-JYDFOL8SL.;$=4U)C/)*7&G$DC@_4M"ORFG4E3;S92XVI2% Z@MM2
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I  R<=3BF3XTTTTU-2FFFFE*::::4IIIII2FFFFE*::::4IIIII2O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g919117.jpg
<TEXT>
begin 644 g919117.jpg
M_]C_X  02D9)1@ ! 0$!FP&;  #__@!!1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?1DE'55)%7S)?-$-?4$A/5$\N15!3_]L
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M,::8QC&FNKW>WPVOZ;:[U8UQ:P%-KDW:9IP I@9&*@(US*OSD\U1),5/3-5
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MY6%?9N'4@]DW["):/I9TXE'#Q91^O\O^O\M<?K]??S'W\Q$>\<3/OQ)_/ B
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M$78:K:X6-L5<GHQVF*3J/F8.7;/(R39N$A%-9N\:K)'((E$O8<[,(@ =Q$
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M>P$S.QXB1W'K-G[!TY;/&RQTC(%>MC*.$JNW-T[W'MQN2858LEB,:%%K,[1
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M]L5CMZM(DTXP6CK"YB=8NF5MV!$%N>Q[BWJTI)REVFZRE7Q>WU$J+U2I+7"
M^D.0KEE8I32B;'V6<YAQJOK5]]Y"R5,;7H&6,3$(M+?CW&Y!UCQS9"+=D44F
M,<4E-9CJK%S6:PM>.IM[-E;1:L=.L;5"\=6,@FMF>;%0Z^2KBFR-I>23WS3K
M%9O*4@ $;:T6@:-E2@UR5JZ=[.@Z(W9JKC@>&D7.Y*SINC%8[CLLXQA*1$Z@
MJ?X:KMNKT_2Z\\LZ]QBY9!A?&Q7H"P<6=!1-JK"QQD6R<\-#ZDA=$Z>UYJ.
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M)C6RQLE^JAK.]R<8\.BLC1K2^8/V*XE4253KD@Y:.VCE _<ITSE37;KI']C
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M<21VBZSLVGU-O0G4VYBVM(1L<Q.P=CV?&.)%M!%@&S"RS,,Z=JO,OO[!^O\
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MHHHD*DDDDD4")IIID I$TTR%*0A"% I"@!2@   9[,KRRT'V;#E*%"W/:U:
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MJ&W)FHG>KBNBL_AWPPN7)BS,9J592$#IF*D"#9K<H4S4]@*U/XW%8IQU2?\
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M5Q0S_9WU4'>_C[2Z3^H]OT#L @/V[>WL  ';L'V#MV[9Y[!^7R(_IV /;O\
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MJK76HZ;&MD6C"L:SIE=H\$V;MR^%)-..K<?'-S=ODQE2J*'.)E%#&4,8PY3
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M+EHK8TJ_,"D3+NUVSR*7<54(."<10S*9[]O\_P">V?R!2AV[% /"  '8 ]@
M.P 'Y  >W\,_K(YN//CN"VJR&)Q>'!*B4%?%UAKK*):9P;9&(\C."B"+@1D^
M\P!<'V#*-K;;/;5-U5F9R^;8]H..SE[166B0I6J05!3,+7,A,B,<EVR F;)#
MOEC&,CVI/IC&,::^.0_Z"[_\*Y_\A3-)E0!%0_;O_P ZK[_8.ZA_\B/V#M_/
M=FD/^@O/_"N?_(4S3RUIJ"9VDPV7*Q\@VCV&N:RUG7Q56;J0>3DK8[(UJ=0J
M$,T:F2\4Q:I]\G'M7#I=!DR JBSDQBB4IM-_BPQUW*V^G=''USM6VAO!BTA(
MC)+JU\';L')'(@()K(<YA$41 +*>?;7TI_V?69Q>W\?UERN8N+HX]#>FZ&V6
M"PQ%U^YNG'TU0"@8PV6;MJO64  4DUP#$>_.IAU'A*6P\/Y7:YH2X+;7EJ?:
M=N4IRS\\U/3HM4?PJ3>K2C<I@16MUUA3S=DKI0 ZIF2*(&%(S=1%?*<QPXX^
M+0=:BEWKK6TK;JIHE[4-A/\ ;\+9E[1=-GR$(UFJT&GW"))M@Q;,WSI\QG#N
M4F(AX5TC>DCW2*N)RZ,Y'(;)I,2RY4:Z6W(Q?PFI%:Y%;5FG-MUB5_79A1G5
MW\8S@18/(F*BFLG&3#>NM91*,\Q07":S?Q.0QG=>.NQ+3+VF8D-Y:WV?8M>:
MELUTFWK%_>#R\33-4+1,6A (+35(@3@N527%K6D&PC'$^GOP</F@IMQ7KB:&
M(QV-&$])'V[-:C4P-F,I<V_ 7&T:[YOY(V*-^2K9ISKQ-OUL?VVZ15*2FY-(
M5FU=74.3W%FLR96?B+JXZC=RN1W;0+ X[>)MQ5?,7JB\/A05855PMW:U>MB1
M3B+><\F.RD9'*6$X*R=^O?U)UAQ0T!>[)L"KP=!VYK(='[BUQ09N>NML7>,M
MMP-INJ58EB-"JQ;-.OVEVT52F*Z: 47;*Q3R,<*(@#WRD?7>../%6B7VBU.9
MJUB"<N>\7NG6-%B.0D=9))>I.)./CXO<TFXAH9V_JYVKQ12-7U_+&0<N%GX$
M5=I.H\PEB!<[MR65U;J+:EIWA<I^N35VL2=#C75NFWLK6K3K!5@F$^Y0<M2,
M =-S/TC04@+N3>HF*LHJ5L<P&5[=2.,6V[VTU[N>(V_K*+V5M^3M-VUS#6"V
M2L#M"ZVVH6)R$J\BWJU>& 7M S3<7[51Q,I^<NX04%0ASJE3Z!S&"R+2QNW^
ME=:]EO%C<Q8=;Q.V:W&"OW:MBBROC0!]<[#J64Q>)HIK6$'DVFFW>39MVCIQ
MZ6;<W7A4CF=X?$!=Q6WO/G-MTZN-W%OJ['[68C%W:>63;SK6U;@4Z^4P&?W%
ME;-VG:7@JZ;>.Q;Z>.H*R,YRN6BN-=#AMF[ +J+:][AZ;O9[QV94*M;+?NGS
M:0B <F?[$G)9M GEFBU@%=@TJ=:!)6-3?D;I.7CD\H*C?(;#A=QYK=RV)0)%
M&T7RWNKO&0NL(*Q727UH@Z@Y"EP]J?5Z+N<96I*K3FVZ\I(K$D8*:58H&CAB
MW*J;(7BJIXUI4/D/J:JO-VFY.1>N;)M.J/-DS4 %CV QO]L.U>ORK-)TC.G.
MZLK:@F2/&!3OI= B4@NHD#])NHHH/*0=(Y<4"AT+8JO(Y?5-*WY,NYZ7FIK8
MMJ8-J[,6.'?SL18]F*MXJ2/%/MB1L8)X.4C3NWL@N=@VD%&JHI^5E:YX1=M<
MW>E$22DJRCT+P^TS#&8RZ^W4"V^/6H5)9,,IBC!&;6-7;[,?ZFK7MTXM2."N
MUMT-Q[(QOQ"%V6;5C!4[=C<G4%;,YF\75QF0;CZG.-MV17@V8'<"76MJN+(;
MP3EXH9"[CLAZ 2R%3N,?'F.>4I]L9A9F*<WH&M7 \=.6>S15)/M*R7NT5<D+
M<-@UJ"FCTYN9"$190J8-$(F3D6\DY*94S=-JX@7O:CIZUV_L"BH5V2J;:MSA
M6+>O2MA;VI_&ME8YB]1*O8FC9JA+IN"NO5M7(-DE"LW"#=R0'22PY,^>U!RN
MTW(V]A7>3\4_LVH=0$G)^LZ[NMW>6"$H$<_C'=?K!HH]5;IJ*R:ML5F:RU>I
MKE.E]6<>M;** 1? U[X[[.-6+7MNZ75E8+/_ $=:]WI/1\DI/N[5)4W9D](U
MKZK*24NV:F"P5R5CVZ<_$JHJD*P>-5F3TY4%&Q(CO?#>KPJ\7BNGUC!93$N=
MD<A;&K@4Q-*A1N+R2[%^G;?8M/78JF<44Q477*I8%E2S;8,IL+I;N7Y?N=V>
MS_6*INW [AK5<'A<>>0W=8[,KELIB7X1M+$Y+'U*>/JOIY%0%D[19)UM61HD
MK(4L<AD6KB^DS_ZL4S_^+UU__BJI^@??^_+.\K%Z30=N,4R'Y;?NW?O]A"+J
M@#[Y"WE-UWJ+QLZG"O N-TMM[?*U>T \G9FL\?J"\V3N:T\C+4[K%MUUK"FU
MDDE$QA8*/T^VMEGNEFE9!")8OY>(;N7T8%=EB/-Y^CW_ +KMB\<^VV\=_*$Q
M[^_ZG[N=?*GXC^(Z[]5^9X_]MLS]9^^;,Q$>_P",SQ$?W1K8,S^#*)D QC&
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MSS2*J:B,F5D_-65?1D%NY,W>+%23LSXZ<)^)'$>'-!\9^..FM(,E?"+Q;7-
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MY#;?37IQ7^79'!#8RD8EF%G&77;NS^XPI!MU.83@ZE9]_,Y %TL97W!E%5:
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M%W%&.X,J$8>DU_ZL4Q^FWKJ'L';_ .JZI_G^/?+.L^D_1_\ ]U^Q/_VWCO\
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MQW3^Z+GB>.=_?@:ZI=/^FW^\W]NMTX[;7SG]COE?KXLSZSY?^T_K/%Z>N_\
M^C^MJ]_?V_VP=O/OQ56 _';\P#N'S^?8._Y]Q^WN/?W$/8 ?Q !#X$ ^>_SW
M[_8 _3^WMEJ/_%&\A/C\>:>]_P#[RN'\O_LIGD>D;R$^/QYIW\O^LKA^??\
M]U/U^V:I_P"Y/JM[?^Q&8^G''%6/NCZ_TGCV]^(GV_A]^_W_ &H_A^_^*6W?
M_+D__E^JK1 >_?MW_3O[_E\_<>X_K_#MVS^BD.8/$5)0Y>P_O%24,40#Y$#
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MJ>E)6+H,<[B*.P>N050J$6_EUI]ZPKOA335C6[J<<+2ZH)*BK]15,Y(J0P$
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MLP=-2.Y-:,-J@@HN.OGES@FUL B,4K.JD&&6>$=E<)PB"\R=J8@.B1**LD9
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M@]>LP3.(;KT9J75L*\2D8?6]!BI!#Q>2^C:;6F+Q+Q@ &\ITUBTET_$  !O
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MZFE)S*I1181\=8(FDFB0B:29$TTRE(FF0H$(F0H>$I4R% "D*!0[ 4@  ![
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M)%$K(U>ILVV"M!/,2V2N/YI8>3W1_.H83/%."FR"2@R(N0='B$ZJP%J4G?\
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M*:ZE37@](ZQLMW3C%%_3#8;"T:>DIM2;KB4X)/KA<7D#5X\1(?N]ED  A_\
M5&*G1IXM7#BMP)U9$;:%5SR&W=(VCE'R9EG2KA5_+;XY!28WRX!* N!0))UY
M@]@J<\*W*5KZBN+*("<JHJJ-/[_\_?GGG^[_ *>WWQ:?\?&,8QIIC&,::8QC
M&FF,8QIIC&,::8QC&FF,8QIIC&,::8QC&FF,8QIIC&,::8QC&FF,8QIIC&,:
M:8QC&FF1SY<\9-=<S.-&Z^+NUT'"M#W;0)NC3;AD<Q)&'5?ID<0MFB1\Q),9
MFJ6!I$V:&!P8S0\G$M4WB:K4ZR1Y&8QIK\O3?G1V_: .#&[)J%TWR8VK>Z_=
M'-<D8W<^F-[;)K 6&)UY4CZFH+Z[P!UD+!6K-4-8.AH;&,3-/IQ%-5>52MSD
MQ7 %)2\SIV<<-]</:#LA:P[\Y=;6Y$\C['!; Y)[9KNH7,%)VRSP$,,%7( N
MX-XR\1:W<'3XQX\9MI=XRCUY1](/I0\:T:^C11V)N;>E=F;.L]&EZ)JV>V"V
MAJ]-QCYW6^0TMI:7B7$C)LUD2LV"1S0LN51!NHLZ=R#=94IR,VY0,W2624A)
M_P !G?=T,W9O= 5>(212$!DM\<I-A[61*J!C$37+!5!ZSCC'3_YTS91B=FJ!
M@*)2E.=$-:NIF4ZC9++9';N)QV2^3)?7*HW$8W>-"S<&:JB,&9_'XJQBR5#6
MM$E2XZ92L LQ)@01NWT/P?1C#;>PN\=PY;"QN5]:ZK(5]Q9CIEF*&/.,@X5.
M5L_-;DI;@%_I:]8EO"K7R*Y<QM(O$T3*)<ZK!R4HL:^N*(:UG/V,ZWIN"\<D
MMDK+I@!4T&.N-4I)P2*PB KE:R99!L4# BH<Y?8>]P:%P%N*<*TWBDW3*0H/
M-9\,M-T",4*!?W?IZEN=15A=M5! GFBX23.HB0H.4P,8@EL-U]TZ=@1R+;\3
M;[9Z\:B@=-]7.->N*WK)-4QR@0?'<E&RUA?]D_&GY[IF5<2G'P"EW-XLS(=-
M7BVJ!5++#7^\O0*('D[CM6]RCY4YA**BYC(3#%!-502B)P0023_>, $ /#X8
M#B^CN_[<S9+&5\8QO,M/(YD<)=?$]O$V';69DD72]YF67<13M3,EWC$E/;;>
M>^(_I%0B*'SVWG4)[12G#;7+=V(IR!3W#3J=0E8&[BQG@>U&+W+E<?$>ZYD0
M'NI>M*+'U?F7]O L$DS'3*'(CC \U:DJZ'PJ$,AM/09O(;"(E$J*[R0(V2,<
M#*(J$[GSO.O]P;=U@@B_UGL'9E%JQ5#-D$XB5:\K]#I-T1*NY.DV:@K>Z@Q*
M0Q4DO%"/GB*0@"CT3BH(6I2W3CUI'M%B:BV;NG3;I0AB A WN2LU:6+V#RR/
MZM;5))FZ03.4I@13<M1, > 3@7MX8:7;@)ONA3B=FK<+3]LJMDR)M;9I^:#C
M/NAH<OB54?N 8 K1)U4RQ2"X/)MY9V\$QOZM$3&/GAR/3;J+MFQ&1KXR\3!9
MWLR>W+]_(68CVGAU^I8+>%H(B)XJT,=C*I% P^Q =TQE<)ULZ,[WISAK><Q@
MI8N%HP&],1A\+0(N.WNJX:]4#ICC6&7'?D<WF]Q9!:Y*:U4W1 3R]8YQ[LN-
MRUU7D]^:&=M9&ZUAM-,=4Z9W#;+2ZB%9=LC(MK)&346W;UB,7;JG1DW:+MK(
M,4BF=-ER>6<AKQ _M]Q_Q_W?&4,:]U1RAD;_ $L9?77+]W&PEQK4Q,?C3=VN
MJC7VJ,9*,7ZTBK)UZ$8R=J.Q0.JNDR%V5-^NDJU<=SJN4"7SA_O'_'_/\,OK
MHW;W#=IYUVX&YMK(MTEUBS5//43@ KMAHUTYFY=5V0<QY"I-B9+CU8PR F=2
MOB1Q^SL;D=J5]H(VO73./R;;P;9RFT,LJ6,MHFN5RQMC&8JP+95!2I>5KD(K
M]\:R42Z(8QC+GUK3IC&,::8QC&FF,8QIIC&,::8QC&FF,8QIIC&,::8QC&FL
M+\B-*USD3I/96E[44 A]@U:0@S.>PB>-D#D!S"S"7A_>\Z'F6[&23 ON?TPI
M>X*" ZS>[]1WCDYHA>KSL2L;G3T_HM;6VX*8@@JO-;@T-%J&-6M@5(O@4?6Q
MS"MP:RC,[(@FE$9:6%$AG%CK+9WMF97CS'X?VC8UAJ_)3C38&>L^6VJ45#5R
M?,FDA [3K::9O4ZSV,  5-Y%OD?,:1,B^*X0CP<+Q[PA8]RB]A[*Z>;N+ 75
M56V@IA%T<AC+SX,JM')RF:CTWX7RR,1F:)31R9J FUC70R*Q(L?XSJOJ7LR-
MPTFW45#NG-$\=EJ"/'%R_BX>-RN_'2WA<YG"7@B_BUM,$V@9D,:R1C(^0-)P
M! P 8I@,4P 8IBCW*8HAW Q1#V$!#W <\Y<UM'C[I_F%;[$G3&49PTYR,UG#
MC9W%;:J@UNB;*LAQ\]]:-4614@M6#FQNE!6(FS1>1<LY<@\78D\;FV2M8FX>
M/^[= .W[3<VK;IKHD:W=O7,O88=8E6"/9"MZJ22N;(7E15C42-UEU'I9L$DF
MR9G"_DIE,(;JX7=V)R\"AC0QN5A0M?B;SDA8@"'N]12;!S7RN/,?MU\ECF6*
MCE2)]X')+#1;-[.R^'DGK464Q)-)2,O02YE:3$NV:]U4A%C$Y%9?8L8S)+K7
M$M@A\9A L/$&,@U(]1WB'&V0:V?94@[ KA1JI8XVFV)_4BK)J))^).82; X=
M,S"H8WU%E&.F0)H*J J9,4CJ6$:LI]MWD:##2]7L6V"65%LY@7&O(61MC*4:
MO$A7:ND9&);N(Y!LJB J"X?.VB* %.5RH@HFH0GMI;GVYDHMS0SN(N11B9NE
M7R-5HU1B9CO>0-F%KYB8\I3"^8G[7M.O'?VIN?%^C^8[?S-*<A,#2BSC;:9M
M',1,+1!JB6-X(9\0Q+(@HF1XF-=< !$>P!W$?8 #Y$?RRT[A'18SCM1I3J$;
M=B/5Q=6/(U#BG05TU!E-R;SFVKV%82<4Q!(ZCFMU@AY))&2(0P*R*,M*1_B5
MKD>,G]E.X4:QXT(5_8W/BRHA./O3/*'PPUL^2M&Z-HRZHIFBX*V#!N%$J[$/
M%%V1WT?%O%#.VZJS)S8FZI5(A_<YQ>XJ;-W%L^I\L>6E6BZ&UH<<G'\6^)L6
MW13J.@*ZW!NC#S<O&H(M(T]X*S:H+M&WTY)6)7]&]>H1CZ(@*_5JNZ@=0L3&
M(>BO8EF$?!INY!)RN<Z(SPW [>.8@[<7/[#+9M(GC<90-X*L6,BU" M;IUTX
MS)9FN]]<5YU!*?1Q[@AL;?(NTE;AW(N.1IS2B?/B,$\EY/*9 $&ZNC&)>]DB
MNGIQSLN@-&K2.SE"/-Y[KM,ON7=4B9,A7)+I<3@\_#ZRA $#!6&1TXY1,AU$
M$9,\J#4YVYDE#SPRJWF]L+J:\?\ :E>WSQ=UEK;EUQ=C*6P@]N<1HY)2A<F6
MTRUG9)])[7TEL20>/JQ?)4T$Z:1SG55B9PY7:<*W3@%',M*NI)KF7A1U'.+/
M/2O2CO25T=L=A5 "-MJ:$V/$.J!OS3DV"AT'<#LO5\[Y4["N&;M-1J,LR+*5
ME\<H*1LVZ343$=-,KDK.9R-S*7)";%UYO8*Q@%+@IX!*5Q/"T(7 )0N/LK2L
M%C[#K>'#XJK@\71Q-*#]-0KKKK)I2;FR,<L>]D\2RQ8;)OL-F.6O8QD^Y3J=
MN,8S'ZR6F?SXR_G_ /\ ?^[_ -KY_P!GQ>_M\^V0EZD/+!?@WP6Y/\KV4.UL
M$OI75$[9JS"OE%$HZ4N;Q1K7:0QDSHD46+%N+;-0P2?E%\PT>5R0ATS&!4GY
MQ^^.$NU-]<D:M)<Q^J'OI[R0=EX_WSE5LZ4U/(!QNXR4/DAI'8G(G7!J3O*7
MWO2*@#6"95.(JS&M)4_4^N&<[/2;:J6(S:ERZI^)GC^4S_+7/'^/M'\=?JF
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MMF$C6EV:RVR7<$_E463*6K4BSBUH]W7V7TJ;8MTK$FR6>1KJ5<LE2))8YC>
MTE(;)LJ-MG8IMH15AMYC6*/7+);G4LW';*$>A)OD6<JQ0AZ?(D=-%;"\<P[Z
M:2>3PHE:-HZ( \=EG.,\=GIGLJU8&R>$0#/45WOA1M$+D52[TUK8$90VGY8!
MS:L=B;#5K.P+>WB?=1ZV]3,?4.DK<]IB8J7:E0G+0;<=.1B%VKE!@K"4Y$D=
M]5-\_+9IUVM7397[H*(;5GA3KVN,XU(UHN,I(L$-G-UYE="EQKV43V?3(ZB/
MPD$H&IQ+-4T'!QB)X)0K<%"2+A\[D#OB.S-R=HF>)NM+!6]0U*>>V62@-0:V
MM^J8M@M(,4 L=9N]"9:\F LBS:.164D/HK%-=HXASQ149$ZBPHJ(^! DH<JQ
MZI6]MAZ/:=/UOK>^S-%D-Q=4'A]I6UDADVACW+6]RG+.XOM'DC/8Y^DG#3L'
M$'&1,B9B],FU!-D_07.4I\LK9VV$I.N&%IREO@AJS%C8;Z=M!RI=Y3.6R+<7
M084LDI858)9)S)]V"=U)WW8LIM'N;(C9KS;FLU))K36FZC+5K,58KJ4-:#KY
MW+) 40L4A=:*(5 K[,_5/A'0:W-5VT2-ZV9<;36;5KF?C[!:96ON'AHK5$/8
MH2CT]=O'5R.CA@HUM9Y)RZ=)-$K!)/Q2<NI@P$\LW+I\-]=)D8$+8;L(1T+R
M'A$>[V%[F;\DI,)6Y+J=H0 %U$+E!.LJ% I6R/[LH24, &"7 ?[Q_N$<\Y^$
M[)VHA<*5A*@A!^2>?,9$R;56[+&,-I,8PK=*K8)C"(R:D3(IF2Y[+'5#?]JQ
M-I^Z,B3I7"8D?3K!:!Q][$@A*5(!*4+QN3OTE)2L%*KV6+6 CV]L&*WP(UC6
M[>PM25RV3(DC8B:B6D-*2D"[:IIV+6!]4S A)&KP3Z;4\ )7L9#-Y5&"@I<7
M"\3&MFSI=J?^V?!2FMVL6LOM';+VUUV!UK"5.[+2%21GJP?4LO8).E2+!%I5
M$(AZNR:6-] OFLU'23"3A022=MCO0,]-.3&>=?3_ &:H>Q6!J+#S6;':!V1&
M'VDIKN=$0^(AL)KI6AD<'5@(]+*9DIGUMZN]2'F+';KR#3&M1IP;%4C*:F.L
MV;E:J4E5F3KE:MV'6TGW+R!LGUXV8$(&$#+@7J9C$W>+)8]@KJ[%H"E%N$NY
MEH5Q+RZKZ_/]C3EN.Y5@3(I6><L$@J5Z9-N$(BP1:-64.W%N50V=]*:I<:LB
M;J64F&D]8-@;-NFS+%(L8U2*8^NL[U%-A'LV2[Q^N1"&K\=#Q/G*NCF=K-%G
MG@0!P"">:,9[L=M+;F)LU[>-Q5>D^J@ZR"1+!$%&;3F)7WRLC@K%GL:8DP(L
MV8$XA[(+%9GJ'O/<-&WCLWG[F3JWK2KMD+4(-C'I572,PZ%0Y:B"G2AB%F*6
ME1I$Q9%53(,8QDCU#-,8QC33&,8TTQC&--,8QC33&,8TTQC&--,8QC33&,8T
MTQC&--,8QC33&,8TTQC&--,_DXE*43''PE* F$?$)0 "@(B(CW .P!W$>X]@
M .X_'?!CE( B80 "@)A[_8H?)A_(H?<P]@#[B&4@=1KJ<\>ZS1-A<>J3Z_<E
MRLT8]J-N5I=TEZ74*BDZ.FC(QTKLFL+$E7LHL01CWM>I2SA19%5_#3<U"*J*
M-E<_MO;>6W3E*^,Q-*S:8QB_4,KJ$QJ5R,199<;6(KK!8S,C+[" 8?:J&01C
MJ.;HW3A]I8FSE<O>J5 6MGIE67$L[MD5R2ZJ 4JQ98;"[8+P5K!J"2:2Y "U
MB[J ]2&R["L3GA_P?"<N%WL3Y>LW#8&OTCR,@X4%0[&5I^LG$>)S'6(L)VEM
MV.15K"UUL1TSB)0KOUDW#0HL-1K?2VUD\*_FH>P=0+:]3<LH9:#6"1@^+.M+
M @=E,S<?*&*FT7V+-LDW<6QG$A!8%3K+PX&I\;(/+9F^A\PJ)P<XMU:MT;C;
M1->\SML-G;IA3(*-L\S+0-*F'HI4.V[.<V5W.7PT]/Q+=M)5?3QIMQ(2#?Z9
M+.HRMP,BBW-'MOIIGQM16Y>]05RYN^^KN^<W+37&:QOTI2V;!N)1(NPOV]0;
M*+$K]#@7PL%B4T#-TFZ#)M .FQG2+.C)[,X+'5,32##*Q;J.WIOL0C'BZM:W
M-U.RU,^R2858V5J^UTF/>\EM/'S6B?/:]$RS#=5,_D[F8NEG'Y5-_<D4%OL9
M$DVJ>UNEF(N@)P"XM NS9W4\"%=<34&0&U/]'IGD%U23&"2KKOC)H=>0LR*[
M;?7*>J';PT0X!X-FUCQKD'23R>LDH"B8/65VY!2#1& C&:JHR)-:,I]9ZEZJ
MSK($V;.*3'4W3FX):]?\EME:UT>Q,BXN6R;?L:V0-%KC6\7U1Q8?P^YF+ ]8
M,W<U$0R+*M(-FZJSQ^6N*&8MC))@FG4KTY^+FQ^;7(F6YK<C#.Y6F0]U+;FC
MJ18BBRV=L:(<D-"P\&S7\:*.N=;*M&(&3:F68^NAX>K-E'0-K(H798V3J/5>
MY8-C6=NZVH>T:Y&3L;:(^ V)4*_=(1E98;U'TB?;1-CCY&/1F8L7;D8^2(V!
MTS,X6%NHF*AA&"]9]S^6*^U1LIM9$+GS?=#ZI25563A'IJ.&J%,#,U\13(U%
M$Q'D<0O>"[TVQBPNANT_%-G=Q575,:=+Y+M1%H8&V[%^<;-_-VPB2&+.8N +
M F"GQ)$ZZ#9CQIG-0-B_:!N LA(O:[QN;\D><5O;+@P;5_AWQJVOM=A)2AS
MFFQ8[!>P59UDH'F"(+/ MYF2!2G,JN4"^_SK<RNKQR 0;,] =*"K:.I]A;KM
M OW4%Y*5.J+LTG9#MSGG=":-C]B7L[$B"OC<Q[J?CWKQ,%6A4T/&5R%UT#6J
M]58II!UF$B:["L"B1E$0,<RA8IH0P@(D;1T6@T9(D$0[B5- H"/VSF@*4H=B
ME H?D   ?W90.MC>>/NY_C_=_#^'O]T_C[ZUR/V?#4G4LU'3N3M$YM;;?6[3
MNI]V7+1G'BG6./DYZ5*MK*U2\3>[O0]BVH$+TYT*[?%:U34]9M9IA1*/@WS^
M(5@8=!FSE;%NHIM7:$/&:'XYZ5L$A1]D\LMJHZT0V+&=S2=!I,2U0F+]9(?P
M+H+HRZ$2X02;NVZB3AJR-)'8N64H,>];V0@ !W[?<>X_Q_S_ &![!E5_4I4G
M]7V?B#R\:1+N:I7&3<DHOMAO&-%G\G%ZWVG"M*=.V=!FF  LG""DF10?&44G
M$BR4/X6I72Z$KV4M3]S8X&J0]G;?.C6LB!U[&77C;;,+78MG*VQ8RP4E>%@D
MMQ'"C P.1F';]:Y&U,FQ+;%9<%CEW[-4V!8K89N5HJSEE30GRJE&'.\Z7+,&
M)$):LP,!(8BUJ;C^*O/+3.A^-7(G?6^G,W9VFON4^F=D/[ALR-I<?*02,HQV
M<2SNHIO$5B2CDWK"5>MX]8Z#5H!DGKPL:Z/'DV"@$!#V$!_/M^?8/M[]OX#[
MY$J\\J>+^JM.6+DH6]:[>5*2@RV!M.5J3KYI;8<@5AW@X*/,T,$C,6&3430C
M4&+PAW,6?S1DRQ[5@[4;]0Z=R.\G7&2MW;D+9[5/[!VK/V?:"<9;E05D*/4[
MA)"[I]*:E\E%=M'1\$FTDVT>[ [J,-,*1IQ2(S3;(9/<I6<UBZ^=M4V8]N,]
M)@;3\A(_,MP94_66[KXA%"DKMQ8"NNP6@RQ6K-QZ+%NPP@XQ&U!JX++6=O4[
MB\DG*^MW%5KXSOG%[<Q >@IT:\E9R%]TEEC([*R2Q=>S:3DK%:G74+.8C]:C
MI,I=5#1NO8VB;2=:)Y.\=[JYV9QQW(W5G4F];LKQLQ3F("8<5MXTGX>(L:\+
M6WQ+77 <6:H3E<AIZ(:2)6[Z'D]2/5G[-MU\MJ;YOIN1W-V8U_3=IP\?0]^[
MO'EIM?:]LW-JR,=J-"U%Q7FCYK8MA1J$>^D5H*J[7=UVK,P<+INO3^H<-5M^
M)GRZT2]B8*=+;'+:'L6YKIH1A(R$!-QS1'8^OAM@VQA)+O6:*<5#12=)L:RE
MG?F;P"C=B5=)^9)PW.IPNT>;G&K5NMIS:#C9M;O4'!3%6KBT9JV<@+Y875CN
MHI&JT$VCXB8%!N^F&BHR;<\L]C&1(A%Q*.'B+) ZP18,%FF.57#%9$GN<*%K
MBF_N-Q.FO"XB0C@Y?$IXF8X9$A/$Q,1+CW%@5H;:/,XP:Z4S8:V;M?M!$5XM
M2V>&<]GIIA\3$3RN8..8F.<B\;] :YXK:&U'QSU)&KQ6M]+T&MZ[J#1XY.]D
M#0]:CTF*3V5?* !WTQ*KE7E9A\8I1>2CUVY\)04 I<V9&NZ<M-'4BC7Z[O+E
M%3BFKH:&F]@TBI3%<LFPZBWG7D6P9MIZIQTXH[BWI7<LV162>K()%,1;RUUO
M 0%/LG.4^DX/<5,T4-SB9?8MP<7-LO$0$K!2PT=2C5%6ZRP[&3;R_KJ8FZ@T
M%SQ!Y1B /W""R0>21)14OX##98QDPQUTA$+39**[9@54:R;EMA3V^RT5;"'L
M9/V?$Y9Q,P8\]AYW#+(0/*41(F4U",V5<DV_:;1IJB.[W98N(?7!<?;\J6C,
M1*RXD1C,+N.1FA$*BC?"[GU6YI[N6<5Z/L;78=.5A96RMD3+'K,7*_6BQSZQ
MF*!2IPJ#HS\YU$P!'LH41[)J79U<W/K.B[7J"<HC6-A5B)MD$E-LBQTNG%S+
M8KIH228D<.B-'A4S@"[<KE<$C@)04/V[YT-H74I*PZI92@'Q5)K4L6 V)%A0
MF9,1_>]JF3(?UH["YB.->A.2Q]AX547:K[!UYM@E+EL,JHDH)?$ 1?NNYZH@
M_P"J4L'MF??C(F,8SR:]NF,8QIIC&,::8QC&FF,8QIIC&,::8QC&FF,8QIIC
M&,::8QC&FF,8QIIC&,::8QC&FF,96[U=^85KX%].3E3RGH+9BZV%K77R".O0
MDV RD8SO=ULD'0JG,24<8/(?Q]>F;*VL#Q@Z,1H_1C!8N!%)R8AFFI^R%SJ4
M3-1=<E+-7XVP3G<8:"D)J+8S,N &,01BXIV[1D)$/&4Q0%DW7 3%$._<!SL@
M"!@[A\?J @(?H(#V$!_,! !#[Y^59R'Z5#=GM/C1O?FWSFWE;I+G)?:6^;\A
M8ZOUJWMM$Q,UQTUIOZXW?DO>;#LEL75KN(L.U/7T^@1:"<@EHVI3&T2)LO40
M=/6V_P#]GXY.[G6?\[^GEO\ NNR-DO.G'M*EU76^X=TDK+;8MGTAL:'L#VF-
M;S(5R\7R)?+1'X1?35;DQM4TJ6B6>NQ;V3.XAS-FG',?7Z1^,^T?=^/\?\-<
M\3SQ]_/'$>\_A^O_ $ULJYK3=<#FEQ)J>\.FWIB][UU]5=AZ/ZGW%#?FW*C9
MI9Q7W]%TW#U#9KU3:4ZXD6K1@C2&#Z5A2NI]!\M&INE19+K^<@_0;;(B$["N
M4VZS:7BW"3LA56JJ$@S53<IF #%4;G37,58A@$!*=,3%$! 0$0R#W,#IQ<,.
M?\WI6U\E-50FRI;1%T:W*DR2;T[4[YL016>T6W*QI_%;=93K]*/E9VBRYUH2
M3D8E@X43*47R;T)#,Q[P4?A$Q//_ #US(F$\R$Q,>W!1,1[^TQ/M^'/]_OJ7
M.K]G4'<^OZGM/5MKB+SKV\Q"$_4;A7W!G<'9(5V90K67B'@II%>QKWRS*LGJ
M11;O&XD<M5%6RJ2I^^Y\K-JT8-6S%BW19LVB"+5HT;HD;-VS9NF5%!NW;I$3
M20;H)$(DBBBF1%%(A$TR$3(4H?2)@#_M?_E,/^ 9SK\Z\XSQXB]^W<._Y=P[
M_P!GSGG&FF,8QIIC&,::8QC&FF,8QIIC&,::8QC&FF,8QIIC&,::8QC&FF,8
MQIIC&,::8QC&FF,8QIIG\F\7A'P" &[#X1, B7Q=A[>( $!$._;N " B'< $
M!]PZI9+]1J<HW1MMRJE75=I*+M4K%8X:#4<HI' BJK<DH^:&623.8"**)@8A
M#B!3& 1 ,[*U>-7S9L]9.4';-X@BZ:.VRJ;AJZ;.$RK(.&[A(QT5T%TCD516
M2.=-5,Q3IF,4P"/[E;! &$LQ6?/C,@* /MG@NTICM+B?:>)GC[]=8N49FL&K
M)BXCR+$QDP@HY&3&)[A[HGF)F(Y^[5%'(KAWU ]PL[5+\B.<^LM>Z*B$)6?L
ML3KZ"N%9K413HPKUV_6EXQN:O.99!E""JH]):[C/1RRJ9CKME"$3\$#:/L+@
M?QJF:O6N&>MI[GCRIFGC5E1+[>X5PTHL#8G"J:<<:HTWZ?%>8JW$/5INXB#\
M445$)1]L&+CTW*Z.UU]7@7DF^K/U.)<S3:+:2<C7_6,UY1O#2RSYBQD'L3YA
MW:49).(Z2:-';AN5H\68OD$5%3MG!$^FU#3FH=>R3V9H.K-<T>7DBG"2EJA1
MZS6I*0*=0RJ@/W\+%LG3DIU3'4.5=4Q3'.<Q@$3".6KB^I;*^.?CLO0>RF*P
MFIA<"=':^&MR2YB9S<8O'JR=]1\@9@%]060Y!T%!0<4_ENE:K.21D\)D:ZKA
M,,;N;W"-_=F;IP#8D8P19;(NQ=!P<&L39CVMJL@6(,2'MC7GN_+#4&H+A)PG
M#KCS4=Y\\;8AZC=F[*?7+7LZNUO;TL!VNQEZ*=\^M5DFC(VQ652:)1+^)HD<
MU39Q[^:E6S)6*3YKCCTFMT[XV"._.H%:)I=>8?(2DIKMU/(RM\N/D%*9FQNU
MBA'!H>F59-,WD(TZEK^J;L0-'M7-7055:YL+54]"6-.FI*E26-'SK^$LQJJ:
M%4,RLL:*8R<1.C#=Q;3; 7"0OX^1$C]J*Z8N42>:7Q=P 0[>WP'M[ /;\O;V
M]_Y9UNZFW<?3=3V[CCP^0MUPK9'<%ZZW*[A<@0CMJT[;DH7B:"XXBO5J(YK@
M"32X'!+2[*W2FCD;J+NYLFO-8ZG8.SC=N8ZBG$;<2^2^U;O5$.>S,7VS$E:M
MW'_TAAN!RC0<)#A*S6:_3:_#52J0T;7JW7HUG#P<'$-$6$7$Q<>B1NR8,&;<
MI$6[5LB0J:2290  #N/<PF,/.9P%IM5;I%:GKC<)R+K-5J\1(3UBL,X]1C8>
M%AHMLH[D9.3?N3)H-&;-LDHNX75.4J:9!,/Z\PV=-WK=!VT63<-72*3ELX1,
M!T5T%TRK(K)*%[E.FJD<JA#%$0,0P&#V'*O.&G$O9#"AC#B7'W%#&QVFR)87
M/<R(8)''=)1!C,^Q1S;82@)BLN5!*EKX0$@,K3/<"N%#Q(+GQD"^!@?L$(_U
M9B/?C&,Z]=NF?'(QT?+Q[Z*E6+23BY-HY82,=(-D7K!^Q>(G;NV3UFY(JW=M
M'3=11!RV<)J(+HJ'253.F<Q1^S&<Q,Q,3$S$Q,3$Q/$Q,>\3$Q[Q,3[Q,?37
M$Q!1(E$2,Q,3$Q$Q,3'$Q,3[3$Q[3$^TQJ#<%TU>"U:O*&QH;C7KQI:FLH::
M:*G0EWD(TDS+*."NVE2?2KFIMSI+*"JW(E"%0:J$2,V12%%'RYQ]O;M_#^X>
M_O\ <??Y]_?/./CYSWW\ME,J2CRF2OY(T+\2#OW+%PDJ]OW:BL,9*P]H^P$P
M/,1/&L?CL/B<.#5XG%X[%A89Y7ACZ5:D+FQ$Q#&C66N&'$3,=YQ)<3/O[ZIE
MW%Q-J^EFLA-[=Y9P.O\ C<7=&XMJT.LV6C,V4LRW9OZKW^*)'6'8))Q52PUB
M#?6^T3\#"1]?A)=Z/:.DIE=HW2 O7-==.O4.RZGJZ[:>V]JFP4!IK_AE6%I&
MHT"+>P=YG>*.UI2[7ZQO3LIPA%9';/K7E8G6DBFYDH<_J"32\XD<[ )M\H->
M)\L(#5E4U%MNGQ<SK/D/J7;=CFX"S0DI8J]7J1)2IY%W76S>-M\86W)*.B'K
MK>T0RM><2#<4I4#H%.BI%"Z]*EL\F+4O1;\[9NGFC-N1=4V;;I5\^V3&<D]M
M['DKA8MIOFM:B*]66C*1@960K"CJO-8Q_!L)!W^'HIJ].:25M'&[C86,KQD-
MWV<'EF6.'IC#TGU@K5F^IKV+=9=.JP[+;;!L,N%:M6G+E\S5;(A#*?RNUE#E
M;,XS957/X9=>)0Z<W?1:.S93%:Q6I6V7;BPJ(J =8*(U*E-!Q7B+:N3\?3)?
MIA5:!>-Z8^Y%4Z%"PQNX:/Q\BS:TKL!=)ISLZX1^V[LSV188VPMY#=3JI1-:
M>)5EHU:UX(N.34FI KA5AX1;!Z<=8J5D\^V[Q2::SO%YW_3*XT@-(/9;;OXF
MYI1TS +,;ALBNR,L,[%5FP3/J(F1M%8BJ_&U] S.QR#=)1)\W^.!Z8^V(R9J
M%S6BN-#-6L[RAKO&Z-CG>QW&F:A3_P"BA"@VB7J$M)5XT^GL*=MC"O;+78_0
MF%96L%2KPK./5E>OE^/U-TOM_4*6BY"8V/1Y-Q%[LX_WV8E65KMA#;%A]4[B
MM&P[-:;?!$U_%_\ I'EH6<;QT<O,6*YO7+U::92=Q)!*QC9CF8SW >0NI:CD
M%3YE?(\6LVOR#;";OIF +A2U%=@F^R(V8=8MVF5'M4;W*P7[/$1PL>E3U^1H
MPA\[@RK5JK8U-5]#U2C*N;T.M*D*]0BJDBM4J*N5TM4A+>\1O2:<-"0EE0V_
M076SV;FSQ=@EY73+FV4"=IEGU]!ZU(937MHV;,-F>P8*(KY',!=&<HT9MA<'
M@EX!S!,&31*T#CIJ9;1&BM3:;<3B=E6UG0JY2U)])@>,3F#0#!-D,@6/4=/C
MLP=>7YGIS.W IB(@*Q_G(%<*. %MXM7S7%W=R-)(\1TALFB;F7JTW;G2U\OL
M_MQC<:-/E;2\:T9/(^N4]%U""NY)'NX]TJ5I'L5V0BY"UWOWROMYYZ]><.,+
M<8[CQM<_,BU\MJX\H8EMU A )EK(0(M<VJN;)K&M97PI)1*EV7L3;F.QR"R@
M;8+;&3>KP/I_-+F2$E/KXZP;)-\)7+R-24W&Q6%A6JK>6N&?*QC&,@VK#TQC
M&--,8QC33&,8TTQC&--,8QC33&,8TTQC&--,8QC33&,8TTQC&--,8QC33&,8
MTTR//++C1KGF-QMW3Q@VRV<N-?[MH$[1)]5BIY4G%?4T 4B;'#J&,"1)RK3K
M>+LL(9P55H$M$L_5H+M1614D-C&FORZN5715ZZ'3VM-KN="Y=VB5U!)VZGL&
M.]:%RQN&LI>P/*W5 UYJO\2T)W8X_8!;A!Z^*>A0\96F5V2@*F@\K<5,'J0
MF>RG@9T\MO:3U#=+GMS9>UKO?M])AN#=^QYVTRQUKG+-WCF'9M9V$LKB0M&T
M&B\1-+)-#7%%^J^>R\Y)NT88'Q&>6T=?;;KJ(VUQSUX]E&2=4K5+L^W#M1JD
M]87+.\+S9*O5CN30ZGA L[&MK"PBB."H Q78/WYEEFP+H!5[8.6#*CU,\9:]
MEIQD=-R:24C*VN8<35U=SD-&1Q$:_7X.G*M31E7JZ"J!U&K9TBR<(^G.=1=8
MKA4NM_5;=>5L9*WM:CYU4JZT>:*D&M]VR2A<0M>'$Q60)KY2L@@SCO;)0(B&
M]?0#I" ;4Q/4,)HLS.3LVI6[( 3$X?#(M33(Z:V2JO&1ML18[[+":Q224JN*
MX<\F8MO%/:UY60>Q4(RD?PP]L4:TD)68FX%I2RIOE7CQ..91AFOJ[(@11-FI
M&P;8K-H$F4Q4 3;IG-\],M]CJT!5?H5UNE);R4=&1\$:D6NYU5Z\?.A0D%%G
MD;"6MI+$9Q;$XMQ<JQ8_5T7R:C C812'(FWSES2E[&Z)KB&MDI''DF)49BRN
MOI,$[CE99*:D2_052N7K<59%,K1HX;S(KNV1"GD2NUS@4D>[%REL<#,K6(:B
MVD%E;":0],FBM!LXM@"P). @EHM923AE&8 3T<L[37%-#SD&OHEA*J6J<)@L
MTRRH'/MU(8$E+@M&!P7?R"QD&1,%(S[SWC$<<<3K<7<F5Q2,$0UL=A\S<F$1
M*K2E,&3"5 M[J[A>#JZ^9-T!,S$A,=D_35SM0Y@<R4F<,QI._>04%KB+EI5T
MV8-[NYFY68<>B60E9>2LUP:6::8T&MNHY15,7,BH8RRJJK=)QX$TS]#V=S(=
M1E6B9&T<Q=[.;!8461K'6OZ7]C0SM".DE#K/G44K'2B$BVD7*J+8RK%!NB5G
M&@!FR[5PX!(:HIOE_>]C)(UJLM:?4:DS26E92.AIJ,KBSIC&Q9R&C%)==9)P
MBV2;$,#5CW.L]6, I&4>&(J3NW$'@!R-Z@TR@AQ^K,[,+B^%C?=C6Q%PQU%5
M$G#D54)9?83DCI.74;,@$AZM"A.VU5V11,L>D@FFHK-*V*WCFK!JN9G,A E*
M44,9;M>1"XXA?F8#8&&1$<DTI*"GDIB)F.(3?5TIV=1^:GA=GHA4S;R&7NXC
M#5\?=<<P5D2"U3E]B":TE(KU9$Y "D._[7-B-;ZZ/(#6SJ%&(WWMVS042^D_
MJ)IJ,K-O8GB4FGEPE?9I7&,076+&J"D:4E9-\O*.4$R&!50ZRJH7V]*/K0;
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MI)!W<:3;YU2AN^,NO]A[%B[.BKL3T,S%6B44D7LE-P=>8O&D',3[UH51-:^
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MV->J=?A*Q 1:!&T9!5V*80D-&MDR@1-NPBXQNU8LT$R%*0B3=!,A2%*4 [%
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=M6!F.Z(F3EEMO<9R9R$ '= A$:[%C&,CNI3K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g977903.jpg
<TEXT>
begin 644 g977903.jpg
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MV.$PUE,QV.,))"09+E4)F#&PSK2B+)"DZK"$O))12[<CQP"A%B7I^=P7?=?
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MGIYZ?EFS'OU-S'<;;,EMTAB_6>&RO)7#S3;-2NUUPK-EUSOWJ=]HZ,'7.O\
MEN%P4=ENAR-#;X_*6O9VUDL&<3MYE7\+#-[H.IGJ;ZQV8[535$-3NJ];Z_R&
MW=LNO%'CENS*;7N,:X]0I=Q!7"YS'7Z=K,<WL%4MKYF>21K=%EY2S9Q4)BLV
MVYO'4;*@4-U+-Z:WIX71* 0N'1;J%:V]48OHRKM[)URR2<0KD9)VF=O$A&P*
M,G4W*41'O+G9[);'#&/(W:JV2?FILR0R,H]<+3/6^L76^FZ_:>P=1P'%ZOO%
MX8FC+GM->R^DPVKVV-4*Q*HPLNA1T(WMDVS4+%Q@*MY&6<)K!',06*H#1#X9
M%4S<NW.\H9/ZZ_;Z@WMPM2.J%(UG(.I]7F8ED]J43J/3CKM8[9LVE!%'2!.Q
M'FNQ-ME,ZEDWSI=HZ:8JUC"-FI1? YH[9>H/ZB>0TU.FT_9-@[(ZZU[N>E1:
M<AS'0+]CCNR[GC/<#KUI]I=5=_NU0JM7I<5F>_:]3) 8S/YFOQD_D-:@D4@G
M9)A88]TV[ANK=5\AU'K3N?51""1S/+]_H.TT.Y)Y5'0%2DV0;ZSM">DVZ"*$
M,]A4+M.2]PG[8[G)*&E/M&V/W,W,MI-PY= O@N+>GUTQP*H5VG9OUIQ"&;5Z
MU9UHA9=#*,]8S<MJ^5UM.KTK7I9U$5N.05U"&8"^68W!HU9R4>_F9QY&'9*R
M\@+@BZWD9ZG6H8K@/IP]OI?LALO98^DW'U$-@[K92,/#9Z[C[W@/1G7=$F.G
ML+EAX]97(*OA.E4J.CXF(EW<O/J*QRNEV*:L36;:MRY9LGK!^H+)#EN65=+I
M[F^KO=_]+R]2FF8]IDYN^%6#KAWHU>Q4%GDEWF+)16#^EWA*4KB:ESF890CR
M:RB2<W;-'M=D$HYVY[,S3JQUG86E]>677[%VMSD[S:].D;6WS&F)6%]I%\I;
MC.+Q?G<L2&!ZXN=RSYVYH]KLRJIYBQU%=6NS+Q[$G,T' HOH)T9A,VM.-0O3
M?JU$9'=[/%W:Y9?%X#E<=GUKN,&X0=PMKL=/955" FK'#N6K9:*FI%@XD(Y1
MNB9DNA\,H<(NN?1O6;[8]5K3OTQV"SZN[[UW4[I>LQ1,[G(709XN_09.C4+I
MVUUZ@H5)S1FU%8Y@UJ="<YW7'@V>;LD>V*:V2Z9&[0\.[MA].[U#]D[+[3I/
M7K?*)@#&[5KKW@?:FJWSJKKT[LV3N\T["N;4QK]&M\Q8:U77M>U&O.*HO("F
MV,]AKI5I%I:8-"-C@1^>L6:=9>N;!_&RC'!\=9R4-=-)T>(D&V;4]%Y%Z#L<
M7*0>M7A@X)$ HUMNG0TY-1.@6!$Q92XQLO),; YD&KYTDK^F)=:NN_6F(G8#
MKKA&.8/!6B9&Q66&QS,Z9F<78)\4"M1FYMA3(6%:RLJ#4A&Q7[Y)=R1N4J":
MA$@ G"*;....$3CCCA$XXXX1....$3CCCA$XXXX1.>B@B5-0P#X$"'$!_((%
M$0'_ !Y[\" " @( ("'@0'Z@(#]X"'\H#PBZM^6;7ZBNG]Z>\UFAI?N+HW7_
M *M=VM.SJ!A,PU;I73\ B:QFN#Y_J<1E%]RB[XC9.U.@K6&PV)"(F);,+S'N
MWD5<HAM JM)BOS+M6*.I_?3>I*Q>FIH]W[];7LUA]0O(M7MM[RV'R[I3*=6J
M+IK;"]&T53$*,E6+)1>UF'7#KK/U9M'S]JL-;WBLV7X+&NW%Y'6*QG^2[6E2
MSF@4)U<GU'I-3I[W1;@\T&_NZQ7HJ"<W:]R,7$0C^YVM>,:ME;!:GL- 044Z
MGY4SJ4<1T-%LE71F[!JFE"D!TFZ<570YO7*QU1ZWUS5;+/*VFQ:5 XCFL/?9
MZRKLIJ.7L$Q;XZM-I^1FEV%DL#->3=/U7B[><EDEU5"R#KXA%U':KVC]5B#]
M)J8[M6[5>\S"VZ+C?35YG^DVG6/3QM><W&S[UVPZ\4>RK8CEE+P: T3-[5/T
M*S6>/I;S>;%/52OM)]VVM;9S+I,I6/V/SKLGWAD9ON_UVT?NMV+ZZS^-[5UI
MK^2YMV)>>GHOWUU>>T#K7J^O2G7_ #GL%6X*)Z.U0VRR<#5[#0KA(PVGRU3K
M=.O,+/-H->=0?-^THKU_PM?*(+"%L;RY;$ZNUI[&MY$K0ZPIFD SSV7B;!0V
ML-1S1@UN-;4R=@829JJ+..13@)2(C'\65JZ8ME4\/TKI]U/V52^JZ[UGP/43
MZHK1W&F#H>14*YAH3G,F\BTSEU=2V*!D2V=W0FDQ+-*<[F0>.:TTDY!I#JLV
MSQPDH1=>#J#ZU?9;4<UZRQ1/Q2+Y*U#JOT^U?MIJW87<T^J,WJ]O[)Z;<L>>
M077"$?4\V:R]AHUBHC]"R3DO+P=-T.^2434\QAVS*SUB1?7+:ILVH6#U(NK7
M6#-K.ZK]%I>*;-VJ[1H-V$:N2R51Z[983UUSUR_=,W;V.0M.DS>A:((QJL6Z
M>?N)_)'>N(Y229+;%S74#J?8[+DESL'67K_.6[ HZ)A\,M$MCF=R%@QN)@5$
MUH.+RR8=5U5_0(V%6116B6%67BVD8LBFLP1;JD _)?9T*DQURL&B1]1K;&_6
MR$K5:M%V:0D:WM=BKM-=SK^I0,W8$FQ964AJR]M%E=P,8\=+,XES89M=@B@K
M*/3K$734KOJ,]T(_9-VOMB[+:+&5W7\V]<^HYE6')LDN64UC:N@TA:I+#*KF
M.?0U,87O$IW+,:J*^CW"XZ/8K_"[4[L,;'/&+60&/7<_/6?5)[OWGH1W'W+2
M-UN77[MWAO7SH$7+>NAH'+G$>[R/<K+US56[TO+>6M2[+7+)V,7MMPAGS.OI
MPM%Z_1APS=[3/W057-I<=DSKSZ5_2?KHMH4U!XG0K[?M2GNP\A>=4TS/\XL.
MEV*K]F-&LVC:-F$Q:F-.AW4OFHN;0\J\;7)8CXQZ:T8P<T]F"D<+.=AK/T^Z
MHW4D&G<.M6#VE.L9HPQBN)V')Z-,)P>0Q<K"SL9EL41_"+@QSN.G*W7IIA3&
M_LKK.7@H>2;1R3V-9K)$5#FI>M!V9=VG3X?-<PZ]0=#M6]]V^CV'.W&MSU@[
M.9]V%ZK9?K%J+L&T8@G2UJ^SQR3E<KE'CF)82ZD]4:Y.T6QV5R_96$D8YTXS
MCU?O4CRVG5GL+H"V']B,WK'IE^E1V.WFNR-DDLZ?EF.U>NW[.;%<<T9U'-GD
M2OK-J9/ZL_TR)G)2MYK49FG2T?2:\=G(-V3;M;->IO5QCK-GWMEUPPAIN-VA
MI"NW+8FV1T!#4;9 2[1)A*PEDOJ5?):)N*DV#=NRD6$E*.6[]FW0:O"+MTB)
MEQJ"Z-]+ZO4)G/ZUU,ZW5^BV*LUNES],A<3SF+JLU3Z;<9C0ZE5I6 95U&+?
MUVL7VPSUU@(9TU5CHBUS4K8&#="5D'3I4BJDSCUA]5N/;NDY_(X[BZ77/5>]
MG8+T\Z>T@-BF9?M]4-7Z]Q5Z>S6I:AC)JHC6HK*K YSJ7568L+ 6PTJLV*E6
MB=>O4YYK'..P 4WN*4P ( 8H&\#]X>0\^!_G_+R"H;JYUJKFSSG8VO\ 7S$H
M/L%9F#B+L>XQ&5T:-UZ>C7:39!TPF-'902%ODF;I!DS0=(/)=8CE%HU27!1-
MND0D[<(G'''")QQQPB<<<<(G'''")QQQPB<<<<(G'''")QQQPBQ>[W2K9O2[
M=H=YFV-:I5#K$_<[?8Y,YTXZ J]6B7<[8)N042354(RBHA@\?NSII*'*@W4,
M1,Y@ H_;6;)!W&N0-MK$FVFJW:(6*L4!+LC&.SE82<8-Y2)DFICD3.9L^CW;
M9V@8Y"&,DL03%*(B :C^I&(AZ=_?,0'P(=,.TH@(?> _N%WSZ\D+IS]>I/5_
MS_\ MVP__*ZJ<(MD>...$3CCCA$XXXX1....$3CCCA$XXX\^/^P1_5PB<<>?
M/_8(?KXX1..!'Q^7_ 1_5QY#^C^GZ?KX1..>/<7[O(>1^X/(?7GGA$XXXX1.
M...$3C_K_CQSP/W?WE_6'"+ ,YU3/=;BIR<S>UQ-OB:W>;[FDZ^AU554(R]Y
MA;)2C7ZL.C+(HF+*5:VPLK!2J92G23?L5R)*K)E*H:0.57^D@(CA_9/R(C_S
MEWJ?A]1\_0.\NU  ?T 'T /Y Y:APB<<<<(G'''")QQQPB<<<<(G'''")QQQ
MPB<<<<(G'''")QQQPB<<<<(G'''")R/VFJ9Z_P!0GL6:6N)<:E6*+5=+GZ2F
MJJ,W%T2[SULK%4L[I$401+%SD_1K;%L5"KG5.Z@7Y5$DR$3.I('*KJ*(_P"V
MF[/AY'Q_LT.D8^//T\CV>[S (^/N\B !Y'^8.$5J/'''")QQQPB<<<<(G'''
M")QQQPB<<<<(G'''")QQQPB<<<<(G'''")QQQPB<<<<(G'''")QQQPB<<<<(
MG(8[$[O0^L>'ZAONFOPCJ-E-.E[C8%P41145;1J0 VCT%W2B+)LZEI%9E$M7
M4BY:1K5R^2<R3QFP2<NDIGYZG(10HD.4IRCX\E, &*(@(&#R @(#X$ $/(?>
M #PBZR.E^KI!=A_2*[ 6?1,CTU_I.N];_4'H$BXZH8UN7:'KS393-I3>,2C_
M ,(^P.?T::I%:92$96(:].YFWR< P+2[#'7\21](E(R2/?#T[(*?4SK"01*(
MDZ\8B01(8#D$2Y?5 $2G*(E,4?'DIBB(&#P("(#R N\&9Y_DOIE=\Z=F5-KE
M$JWXIW=&T?@_58IK"Q'X17O--4NURFOD69$T/M*S6Z?FK'-.O;\1_,2CY\L)
MEG!Q&>^G'\$GJ_\ U=L/_P K:GPBV1XXXX1....$3CCCA$XXXX1..?'(/V<4
MP>R<BX3:,(YHY?/72PB5)LT9H*.7+A40 1!-%!)14X@ B!2"( /W<U6-WDZP
MNDOAUK3XZ]S;@I"Q%2H4;-VRW6%TMX!NP@H",C3NW[I<3!]?]TU;)B9R^<M6
MB:SA/$Y+/X/#.A9E\QB\9)8:]U>*_?JU); C+!)\O%/*R2<L,D8<(FO(<]@U
MMS0<_A>*<GY&RQ+Q_CN<S<--T3+D^*Q5Z_!3=.'F'YR>K!+#5$C8Y'-=8?&T
MLCD?OIC>1MKS1KU"Z?9+SUTDH2JRD)#R9+?4)-1]8;I$4&,1CXU^JN_46L4Y
M(Q;!+VI&*8$#.P.X\>PA#B'CF6)N>T>Q)E59I176"E.A'V'DVL7H6XOF9@_>
MJ_9X++9S0%W*)_WB;M2]R;)1/RNU;+>4@X.VXABV.P#W4;;697;;O&J-4&EC
MV*PNK[-*R$D]200,Q+8"NJ[6$D#*&5$M7K<8"#9(R;9$ \>-5Y ;?,L%EL'3
MQ-VOBLQ0L4+.7RD[\$\5K<;H99L=1?3NY9\\37%S6Y#'8R"0 .BL2-(*WGB;
ML?Z;\GP7*<CG\;;SG'<M2RM/C^#JQ\IC=<Q]AEF&#,9*+(XW ,J3NC:Q[\1F
M,W9B+G,GIQ/:6K33H!HSC%J!?JO-PM^URQRU\3F(U/'(>:UF&&+_  ?BHD3G
MO;<6]%9^V18.R'0/:"@!2 X #)JE.._A=5[%3@'6@.MS.JQ)RJ*(S&OZ]6ZV
MNBB'N B[Z HD1HCMM]  RC=:015(4P>3 (?3#X+>]*T>.2A\LS1LRD4$3(2$
ML^=@XK,.4# F@1HH=&-9$4(W$JY4'1E5P]HIHQ;Q(OQ!S-IU[E;4L21V/0;#
M<ES*%6&NQ;M6%JS4?K[FY6[<$5%TP\B ';H18F+]#%-Y$1\_%^'Y+CV!QF J
M\IR)HXJ UZ[J6/Q=5TD;I7S$6Y\I7S4\T@,KFE]8U>VB&L/97^<>HV(YCRG-
M\LM\%Q'ZGGK0MW6Y/+9NU'!,((8 <?6P=OC=:"(-A#A%;9>\D.?(JL>]E?[
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MSIA6,4]VGC\-C6UW5YH[4K0^S=)=;D <P#ZO?CCCG15R%....$7@P@4/(_E
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M[)_VE_J@?ZY=JY:CPB<<<<(G'''")QQQPB<<<<(G'''")QQQPB<<<<(G''/
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M%(0A $QC&,80*4I2@)C&,(   (B( '.,8SL+)JF0CI>+?KE3%8R+*09NU2I
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MY4Y@ U:VG!0%(_,(,Q_)$A29VB\.4 'P'QC',I58!54AO=\,A;&L@</!S%,
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MS>/<8PCDA"$3(1-,I2$(4I"$*  4I"@!2E* ?0 *4   #Z    <]N.5T!L@
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MS;JB?X+BUV=P08^FPHE]QF\2P;ME'*1"DBX-T80-S[I"GLR-%KCN-E833>-
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MLU2%T%\_3LOLZF=82>XIO9UXQ$ON(8#$-[<OJ@>XA@^ABCX\E,'T$/ A]_(
M[LY=FN,^ESW6S;(L_I>7YY5^E/:QM6Z-GU7A:=48%!UBNAOG24/7:^RCXF/(
MZ?.7+UT#5HF+EXX7=+BHNLHH:?>G'\$GJ_\ U=L/_P K:GPBV1XXXX1....$
M3G%3DY#UF'D[!8)-C"P<*P=2<M+2;I%E'QL<R2,N[>O7:YB(MVS9$AE%E5#
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M,@Z/Y5>2,@Z.HZ>NU1%1==0YA\%]I2Y!R\UI'U.[N/G[-';Z1^.W<_W'OV[
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M>+-:D*ZJNH=92$2EB1BBISJ&:B8QA&O*B  >M/V?\  ?\V?TB^[^L]WF#]0
M']'"*U+CCCA$XXXX1....$3CCCA$Y"NF=B\1QV8CX#3=)K-,F92-^V(^.FW2
MZ#AW&?-+,?G$2I-EBBC\VW60]QC%'XB9@\> \\FH1\??RH/L3UV4[X[ZZ>TB
MW#6L_P DJ+W-['H1X<LW&2VB(3KZ4>UBHM$I6-&;&N)R -K;,?--XZ)DRDB&
M9Y*03?I,-&]0,]R+!86-W$,94S?)[UZM5Q>(N2?#CML+P^]*7?-4VQQU*@DF
MDGEL101:8)';>QKNH>DO%>'\HY-*SU#SF1XOP;&XV[>SO(L=!\>7'O;$8\7
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MHH<! RBA#&(HH)CE$2F >=1?UJ>N'9.X=OBW!UE3#LO7Y?'XU?J='-_3<?\
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M<7;E ?)4;)9RII/9<_U68L?DH<IB DZ*I,'+@:'N$A'[=_#'<:!&BXCMW</
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MJSM6K5BYX]F4[GV7S]HC;WO9[&PQVEKQ,<58;#?6E5(YM3R ADOB.C5Z!_\
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M.2%TX_@D]7_ZNV'_ .5M3Y'OJ2?Q=_?/^IAVE_R+OG)"Z<?P2>K_ /5VP_\
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M4Z$A'4YBU<Q=)B%/!%D#.8ET87]CD&YA ?FK*8Z*"H>YO$,E2"/)B   /
M 'W 'W!^0/Z #Z '\@?0/IR\UFQVVUIT3L_6_MH;([-;H =+>^M#Z1L&T2!^
M7?C?2W^-]R?N3VWW^H]UCD73JK"H,&T5785BE%I((L/EXQF51J1L4"H_"7%$
M5P4(  /QC*F6,<14.H90QC#DG''+H '@ ?QV4$XXXY5$XXXX1....$3CCCA$
MXXXX1....$3CCCA$YX'[O[R_K#GGG@?N_O+^L.$55_I'_P# _LG_ &E_J@?Z
MY=JY9#H%'@M+I-IH%F([4K]P@Y"OS)&#M1@\-'22!F[D&SU(#*-5Q3,/PUB
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M@*+HZ3HA7%HG4/'DDQ+)$;M51,>)BF(^%C?'I.\4/,SBQD72TM."BLH$)#?
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MX-Q$T6[-4FTQ48RS6T(55K(3B\@3/IGJ?BUNNNEW30:M'Z4.IJ8^[GZQ?HF
MLE192V()V$M'FX>'>1'EO+MG%C>/UGCIP]%-Z@S6CB, 24*KI3CW>G3(&Y5<
MG<*T];<VH^@=;%^PC9Q!0.ZTIAEYT%J7+K5)WMVBL9#"MWC8VJZ#"DM%KJ-B
MS"R56PM8\KK+GT+=(Y[ Q/>O48['Q&M;+'9_3*9H>?99J^J4MY"Q^"]@F[>$
MS.B=7PVUMMT_VO"T+]=9!BWLSR!CI#.&,5%V:=A[#'0M<DPMRK4CTBWWM'2/
M,;#C!L?9V"YUI9CN+GL;5=(AS5)>^5'7"]AIGLQ"6*/&;JDO4IEI7=#FW;9A
M!6VK6"(?5D"Q4VUDG"BTBI#,3Z=D 32YB8NUWM>IU2RDZR7ZU3]^DZ]*:#<=
MOZRWO19V(F[FV0HK2IRM2M]<O$+"/(&%85QE56= A86IQL9%+H_9\1T;NOV=
ML^9YRLT:T:<U7>[_ (7FV<+7GJ-VFZIYS09+0\^OFIWVR6 =EO\ .3.WQU5I
M^=V1*!@LOE*NM)6@E;AYZPP47<&\_#898_42[+US-W<E&5OKU?KY2MDT+,9J
M.+"=DLGM.RV>(KV<7C),0R7KE?:>ZVNN[?L-.T!_,&DG*^HY)0ZQ3D]'D;9.
M5"XE"HD6REA]-6FL;%8[IAVSZ=U]MEGT;2;I)JT^LXC;ZBK5]CCLF0TO)39O
MIN5VZD'H,Y8L?K^BQA_LDEKK^B2]OG6=C6C[;8862BUMZ163/4ZG1K+<+Y)Y
M1D68P-$RHJ]E9+WIW+2&@:OHNDV6[R,?5(&%74F9&^5^+A641&H(,VE:<.3D
M1&2(U0W9PW=;IINN]H<UN% C:.CA.@4>LU5TTM!;.^N-8NF85Z_L[-,E;Q[%
MA7I [J8=Q@UUFO,E9(1Z;I6:>'? FWVDX1.8A?SW).D6U3/'%9:7HE=ESU!U
M<V,M)U-O8R,5CQ*UCCH&2AYI]"IO"I&D6D5*QS]PV Z35\U5,58F7\" " @(
M ("'@0'Z@(#]X"'\H#PBZUNL]YNU6P>B@TTF5Z@Z3O+WLGZ5VE:-L6WY9;^N
M>?YEF5GNN&WI&R&E*3I6PU#0G4?",Q&U*LZ+6+:HI"G3C8<)FQ@:(/>'T[*4
MO4SK"4IP4*7KQB)2J% P%.4,OJ@ <H& I@ P?O@ Q0, #X$ 'R'(P]15@QB_
M3C[U1\:S:L&++I5VA;-&;)L@T:-6Z6%7PJ:#9LW320013+^](DDF1,@?0I0#
MDF]./X)/5_\ J[8?_E;4^$7KVIA74YEX-&*,N\>IV.'<-HZ(C'4J:1,0KM-1
M%Z@T(HHBS;H*JOOF5$SI)NFK9/V"HJGXQ7"<E,&?Q3M6SW:N.'PO#R<-&QL9
M37[9Y\THFY:.I,8/\*7B!/AD,R54EB(_ .15FDW*8")[>^//_:(?JX\>/^T1
M_7RR86F4R'OMG3KO]][WO[=M:UK_ #NX)"&= _U;WV_';6OQ]]_X[*.(S)J#
M&NB2)X%.9E2?4)>T.WUJE0/]0%1-[87,BJW,("/_ -&^"4 $0*4 'DBD(4A2
MD(4"D* %*4H !2E*  !2E#P!2@   %    ^@  <]N.7 UK?VM _@ *!)/DD_
MR=IQQQR2HG'''")QQQPB<<<<(G'''")QQQPB<<<<(G'''")QQQPB\#] \_D^
MO]W\O]_C[OY^4]4#N;W 9:-Z@-3=]>GG;2;Z[]R\ZQO/,[ZXR&697+P6.WSJ
MMENZL;1:9OL7K=*@I^1B)2[(PEF7:6D))[-3*"U:K#.KM%@C+AN?$C'L6J[U
MTV9M&[F2<(N9!P@V017?.46Z#))P\633*HZ62:-T&J:K@RBA&Z*2!#%223(4
MBJ3]%B;FK-U:V2R66H2^>V.P>H1ZD<W/T"P2%?EI^CS4IW3V%[)U"<E:E*SM
M4DI>N/%EHF2?UB<FJ^[=M%5X:6D8]1N[5M6N$:,Q5++$A(A$_:<#+,!E!]OM
MCP=,%T1>']PE 4VX'%50/<0?AE/[3D-X,%:/I'_\#^R?]I?ZH'^N7:N6C/V+
M.49.XZ0;)/&+YNLT>-'! 40<MG!#)+(+)C]%$E4S&(H0?WIR&$H@("(<H1L$
M>=@C_FJCL1_*K2P/.[5.-[!-T^5KWO9O48H'!I).,E6QVPF<(O&RCNDV9ZR8
MR2)TUFRK%Q%N5B)B593XK8");*'Q^]R94PGW-<ES![/>-DN6J6ML)A,!CB$4
ME*U>)]I/ ^$@:@FMY^] H"!Y[KE(J-0,[/6*W#0!GY4"/!B6"#(716PJF;@O
M\$I04!$5E12]WGV?$/[?'N'F4\\\==K6!KB7'7<;VWS[ C8]O_S2NOE+G$CL
M"1W/GL!V.CKV_P"_E:Q2/7Y]-P[B"<SE.J\4^%+YYOG^<,H%X[(V<$<MF[J7
M?S4H\<M05215724(!W!TR@JJ8@?7+X#$VT%#1L"70-)7BHQ#X#:/;6)&";)I
MBLHN=,IX&/82 I&.H?V)J2"OPB#\-(Q2%(4DW<<NB&,'8;WUK9<X]O.M;UK?
M?6M*'Q'D:WVWOP//C9[=SKW4=QF39W%. >(U6,>/P$!"3FRKV*4 P>! P2,^
MM)/"F\AY\D6* &$1  \CR0@(4I0*4H%*4  I0  *4 #P %*'T* !]    .>W
M')AK6_M:&_P /^BB23Y)/\G:<<<<JJ)QQQPB<<<<(G'''")QQQPB<<<<(G''
M'")QQQPBK+U#LKV*H7J)PV%0E?KFC8_.^GYV/[%4_+JC%Q\-L5SV7&-5P*H,
M:R-^O-PB*$Q965EJ"\15VST:K#,I)TM(W&Q&:(LE6&LW3K5-1U_U;^V%GUOK
M7I'5BR,_3TZ60K/.]1N.-7>Q2L.AV)[GOD+<UEL-T33:@A$/GT@_B$&#ZP-K
M D\A'R[N(;1[F,<O+PC1[$[Y*3.S:&D4&KAB@_,V0,]19.E6Z[EHD[%,7";9
MPLU;++MR*E165;H**$,=%,Q:N*)_'3]G_P"S/Z1?ZGN\W"*U(?\ WA^OZ<IG
M@<CJCGM')RE&J=2JES5OEK=14XXCWLTE$22:TTL[G!CY*5>M59*0 'JZZRB2
MS;YM[[V;5N1)N1&YCGS%9M".#NB-FY7*A")J."H)%7.1,3"0AU@("IB$$QA(
M4QQ*43&$  1'F*R6%Q>7DHR9''T+S\=9;;I/N4J]J2I8:6.;/4DFC>^K.'1L
M+9H2R0%K7 [8W6:Q/(L[@HLE#ALSEL5#EZ;Z&4AQN2N4(<E2D#FOJ9"*K-$R
M]5>U[VOK61)"YKWM<PA[@=:!Q34Y7WC8]TFGR:GT.S9Q+J.9B3V>/:*,7/Q)
M#@81\'!0IRB0/WGM.8QN<M$=>8Z/3<IJVN4)\X@JV=J0L!3H9X[;KH@@NBXE
MU8*5GE$UR"I\4OVJ7W_$, C]_NV*XYD!!&#O1)^[GO=[:]W%8GXCSL;&C[!K
M0/\ 8*!8#K9E5?47,E$R4BDX32359RTY)O&!Q1$WPU%6)%F[9PH4#G*472:Y
M4RG."9">\PC+D)5JW6TA1K\!#0:1@ IB1,8RC@. >/\ PQ:HI&4'Z!Y$YC"(
M_41YSW')M8QG[6M;_  42YSOW.)W]S_Y]@O'@/R!_?\ 7GGP ?<'CCCDE%..
M..$3CCCA$XXXX1....$3CCCA$XXXX18#;\OHE]=-7ENKK:;<,6RC-HHY<2"8
M(-UE/C*D33:O&Z0"HH!3'4$@J&]A $XE(0"YNV;I-&Z#5 HE0;(I-T2F.HJ8
MJ2*94DRF45.HJH($(4!.H<ZAQ#W'.8PB8?WXY0-:"2  3Y( !/\ )\G_ "JD
MD@ DD#P">PWYT/90/:>LF%75/6D[1G<5+CN;^@RFI.%GDTD]M+_+$85+.G)I
M!K*(/H8]+4KT4_KH5YQ$$C)E!:=;D+-/Y!^ZPFM]'>J=0N);_7,9KD7<2L\P
MCQGDGUC5=J,L:_=,#-FRY'4VNV<)5HFP:(D4JZ"GVJA8"H3OVHC#P"<5M=QR
MJHM.\8Z%=8,"MT+=\TI-E8SM3AK36,_+9M<V/0H/+*?=1@C6BBY%5M"O]HK&
M4T*6/6*Z96DY_$5ZLH?8,*FTC6Z,3')-9S3Q?,4H'3ZP2I,@@MGE+5-:;'"Z
MDS(VR3NU?956TNWIS/C+-32]?CF4:N2,58HI)( HU30<'46/*/'"+2XWI^]8
M%<\G,M>5S3)BFS9*.*+.R=CNR=JE:D_S1Y\_09_,[/9]<F+/D]KJ;H"*0UMS
M*8J=D;$20;FE%6B"3<N.QGII=0H>89VB,IVEQUW;#95'FC1O9;L[&:=9'5SB
M\^A+?(7;2(S8F=VO,E:(C*<YC)^0MTY,NI./IT&R<J':LR(COGQPBPNOYW3:
MK9KK<8"#0CK+HKJOO;I+$<OEEYYU5:^UJT LY(Z=+MT3QT R:QR?R:+8%4T@
M5<@NY,=8V:<<<(G'''"+2SU)/XN_OG_4P[2_Y%WSDA=./X)/5_\ J[8?_E;4
M^1[ZDG\7?WS_ *F':7_(N^<D+IQ_!)ZO_P!7;#_\K:GPBV1XXXX1....$3CC
MCA$XXXX1....$3CCCA$XXXX1....$3CCCA$XXXX1....$3G@?N_O+^L.>>>!
M^[^\OZPX157^D?\ \#^R?]I?ZH'^N7:N6H\JN](__@?V3_M+_5 _UR[5RU'A
M$XXXX1....$3CCCA$XXXX1....$3CCCA$XXXX1....$3CCCA$XXXX1....$3
ME5M$_CI^S_\ 9G](O]3W>?EJ7*K:)_'3]G_[,_I%_J>[S\(K4N...$3CCCA$
MXXXX1....$3CCCA$XXXX1....$3CCCA$XXXX1....$3CCCA$XXXX1....$3C
MCCA$XXXX1.:2>I!N&K];>BW:/<\/B&TQJF99#9;13B/8![:6,3(-0;(.+5(5
MQ@8B\W'TN,<O[@^C#*)MGC2"61?*I,3.5"[M\\&*4Y3%, &*8!*8!^X0$/ @
M(?R@(?00_E#Z<(NK+?\ N[W?T[TM>XR*6 N>[.;GSOU'\G3[Q4?1\ QBHW+'
M\\/J- H^VDS=U,1R%Y1F:,@K9G$MBL>>FVH(192IMBN)--D3<+J]V[]1**ZU
M=>HR ])/0K/"1^&8^RB+&CW.ZAPZ,_&M,XK*#&:2BI6V$DXU*4;)I/TV,@1-
MZU(X*@Z227343+.WJ4=W<AQK"=VS-A2:;V0L,&VQ[.>P_7XVB)45_4<.[67:
MOXFXM]H,U:KSGV(]CKZ#>.BJND$Y**NT0:NXAJDZE64V=<>P+Z1[3]F>D#?%
M4<NHO3_)>J\MF5D+=T+.K?Z/KC?7ZW#J)PC=LHI4XZL)XJ:(CVDQ.2MCD@,L
M_E46"9F0NR*$OQR_4I_,[:-^G!TT_:[C\<OU*?S.VC?IP=-/VNY;)QPBI'W#
MU->\/7'(=(W?8/21U"MY=DE.F[[?9YEW'ZD6%W$5:NM3/9=^WA(2RO):46;-
MB&4(QCVJ[MP(>Q!,Z@E*,H)=S_4F62363]'?1S)JIIJIB/=_IJ41(H0JA!$I
MK< AY*8!\#]WGGY^I/VUQ.,R'3L&=YY3^TJ,AI_6'KGVMQE;2QI+G,\N[G:K
M2<?AK9<21I!M+UK)_ARR-#PE6,C)R*BR+AQ)P\4B^?H?IU4]1^V;[W(TOK3-
M8A!T?/&!^X#7$]$C-)>6>SVL.B79BG]4=K#0J0O2H6.I03]\N4=/YL,';;=\
M[5&;P+&,5+&1;F(OT_'+]2G\SMHWZ<'33]KN/QR_4I_,[:-^G!TT_:[ELG'"
M*C_=_4_[M=:,ENVY;-Z2FH5C,L[BT)FW3K+N+U+L;N.CW,I'PR*R$+!6-[*O
MSFD91DB*31LH<I%3*F $TSB$N?CE^I3]0_V.^C#X$0'_ )<'37[P$0'[[: _
M>'\H /\ -S,O5+[ =>,PZN[%G^R4:,WVR7#&-%N]1ZIIS\S!VO=HO*4XNTV1
ME#*5M%Q9"0]3!!C:+?(P#60E8BMQ4E(MHJ3%L9DMGOIR]TR=Z^OLCK2]>K5>
MGZCL6QXC;2T2QS5OSB=LF/79[5'=NS:S6>JT6TR]%MS-./L$ M9:76IILB_5
M8.H]8C1&1?$4(?CE^I3^9VT;].#II^UW'XY?J4_F=M&_3@Z:?M=RV3CA%1_N
M?J?]V^MN93NQ;%Z2FH5K/:W(U"*F)EEW%ZE6)RV?WNZUW/:NB2)@[(]DG!7]
MMM<%'+*HMS),D7:C]V9-HU74)+@=R_4H'SX]'?1A\&,41_'@Z:A]2&$H^/-M
M ?'D!\>0 ?Y@YR?JP]H.L^,=9-0IFU0%)V.VO:/%:E4.M=BO,C2)33$\\U6@
M.(N<9NX))Q9W<91[V>KV5_%U"/G[G83Q"=8J%3MMDF(RMR>PG0+M/*=RNK].
MW.QT9MF-P?VS7J!=\^0DYQ^I5KCCNNW?)I]L[9VZKT:^5EU)O*:-A-2M%H]-
MT2EHS"%:N]9B+'&R#4I%K1^.7ZE/YG;1OTX.FG[7<?CE^I3^9VT;].#II^UW
M+9..$5(FT^ISW>Z]48-)UKTDM0KM.-<\SS\))GW&ZDSZXVO8-'JV39]'_9\-
M97;T$9F^72N1#A\*/R<2W>JRLDJWCF;IPE*_XY?J4_7_ )G;1OH)BC_RX.FO
MWE,)1^^V@/W@/W@ _P P<E;O]IV&JYQ:\3N4[U\F-.B*A"]K8;,.P.@7O/JA
M^!'6;1ZYJ\KK=@FLTKUHN;*!RV5H:=N16C(.3:O9VOL(J8:'AW;X>37TKV+5
M.P?5O%]PV?,8?';]J].;7YWG4)89.SM:_7K.Z=2U&,[D)F#K<LTFIBC.:[/S
M]>D8=J]JDS*O:R[,Y<1*KA0BT^_'+]2G\SMHWZ<'33]KN/QR_4I_,[:-^G!T
MT_:[ELG'"*F^Q^I#VYRB:RA;L)Z8>CX[F^F;QAV".=''M7UBT)"JV+>].KF4
MT^3?5.C3\E9I2.2LEGCOM L:V,JBU%18QTTR'4)<@ ^?\1#_  'QRG3U;^Z7
M7KK_ )]1LXM5%K_8;L3,[9U9M.']<C2U[2L2]Z7WJ$1RO75H++("W:7/0&<W
MRM&LB<%2:=<)RU3,"SJK>NO EC'3L'ZG[S&=G^MN)=@H@]:%IKF;UB[J(5":
MF+#7&$A,,"'F(F+E[#6*587:,-+IOXI3\(*?5YUNY9+M)FOQ$DW=,42+83CC
MCA%ZF$0 ! /(^X@>/YC'*41^GY $1_N^OTYUA^F/J:>HGJ&N]@H1EC#;N:[A
M6\C.6/"*0_R3KO/=-+E']M.S>*,\1MEXT"4BFU@?2&/Y1G&GGA=!64U)TM:E
M;;%@2@V2":Q_9ZYJUOO9ZA8<,M38E:N6_L-,YAHFJ9A@AK9#TZV:NRS:)5DI
M\8N5FDCQC%DQ2;>R4FWP+$CD">X&[DQ4FYR*BSTT>U'?>M9!O#2E>EO?-&8R
M'?SU"I^6E6?;GJM5DX.U6#MYJLQ;**JTLMH;NI%U0K$[D:F[L,>F>!L3B*4F
MH!RYAWK-4;%/QR_4I_,[:-^G!TT_:[D9=1NX<9&SOIO9_GG5V)S3/O4[Z^;;
MWRM-KC],>S;.G;5=(.F]B-0J,; 2K!:PS[BP678W4W)V>1/58%#YI)M7X,I_
MF8Z+NQX15-_CE^I3^9VT;].#II^UW'XY?J4_3_F=M&^HE*'_ "X.FOWF,!0^
MZVB/WB'W (_S#RV3FG7:KN'2>NM:T2'A#5W0^Q%;P;1=^HO7A2YQ=-M6B5+-
M63QW.R+.5F&SEC%P;!1@Y))2ZJ#L[<&ZJ31@]>';ME2+0G%O4Y[O=A:,.DY+
MZ26H6*G%N>F9^,D\[C=28!<+7C^CVG)M!C_L^9LK1Z*,-?*78XAN^!'Y.6;L
MDI6-5<1SQJX5E?\ '+]2G\SMHWZ<'33]KN::=:/4YKE%TCJUU_R7JI6*+@^U
M'ZK632IMCK-C>VFD]A_5+SOL+W(C_P #:;,U"00N%"8V>C7$="L$W>JG,MI?
M0XM2IT\\/ 2#(.Q:4WN*4P!X Q0-X_)Y#SXX15._CE^I3^9VT;].#II^UW ]
MR_4H#QY]'?1@\F*4!_'@Z:C]3F H>?%M$?'D0\^ $?YAY;)R'-QWG*NO%.;7
M?6[=$5&%D[#$T^O&EGB312RWBP Z"JTN#^,8B;NR6A\S/'03 QTQ>OS)H <!
M, "15189ZG_=OLEF4%L6.^DIJ%ESVR2-OBH>9>]Q>I5=<N7]$NMBSVT(J1,Y
M9&4DW*PMM4G8Y%59N5)ZBT3?M#*-'2"AY<_'+]2G\SMHWZ<'33]KN1)Z)?=2
MD]D\SU?&:;U]K77!'KT^H-K/G=1N]]O$?6T.TS2W[6]I=P=:92:):H3:J%>5
M[Y6]GK+9A.U"'N"*B-0M<G&">/B+O^$53?XY?J4_F=M&_3@Z:?M=Q^.7ZE/T
M#_8[Z,'D0 /^7!TU^\1  ^ZVB/WC_( C_-RV3D!]A.R63=::FPLFHV^N5MQ9
M7TC7L_AI^PP]86OUX:5Z7LD=28.6L#IA!-9B7:PKL$',S(Q\4R3(H]DGK9DW
M76(15=X1ZG_=KLODM)W+&?24U"SYEHD6O,U&=>]Q>I=<=R,>VE)"&667A9VQ
MLI5@<LC%O402=MDSF(D54H"FH01ES\<OU*?S.VC?IP=-/VNY'?H=]N:IV8ZP
MSU0I_7F"ZPU_ YRB5VJ9="6S0K BG0-BQ^B]C*7/),M?I= TQJP<M-5?0;6Q
MOX&0HNB.J])7?([A;\YE8*6/=1PBJ;_'+]2G\SMHWZ<'33]KN<9,]XO49K\1
M*3LMZ/FD-XN%C7\O)."=VNG+@Z#",9K/WJQ$$+8=98R;5NJ<J21#**&*!"@)
MC!RW?D ;[KN<9_#PE"MMMSZ&O.[.)W+L8J.B3\C78G3=)E*\_-%4@'\.PE)=
M)&2$Y$Y1>*8/))G%J.7;%HZ=))(*$5:N0>I%WNWC*,SV[+O2,TZ>S78*#4=/
MSZ<=]S.HD&ZF:5>X%C9JO*.(:7L[64B5W\+),W2L;(MF[YBHJ9L[12<)*)ED
M7\<OU*?S.VC?IP=-/VNYE_I0:M:M0ZN-V*V19%DV08S<)SKCUV#%-$OFC4"\
M9-U]3:92%NJDKH]1J=M"GMKG5[53*;(S2+U[;8"I-[D5R:.G8U5Q9KPBJ;_'
M+]2G\SMHWZ<'33]KN8Q=N_?J%9Y3;;?K5Z0.E,:S2*O8;A8GB/=;IZ^6:P=7
MAWL[+N$F;.U+.G2J,='N5$V[=)19<Y2I)E,<P!RXOFC_ '][8]=.JO7K3IKL
M))0<BPG<;W>3@LE?3H0-@VUGGV5S]NNF>U)R(D\2TM645V1W/QVX1Z4@#X52
M@CY BV'P768S>\-QG<H6,>PD-LV49UJ\3#22J*\C$QFBTZ&N+",?K-RE;K/6
M#291:.E4"E14714.D4""4.2SRL_TG>R+3L7U)@$T,OJV'N<,EF. KXS6936G
MI\QBJ3GU"EZ-5)UAN.89/I4/+-LZM-1<-TINN2#.>@5X6YP-GGX.SL'*=F'"
M)QQQPBZ\.V]U>[--]6)?#,]<V*[4Z+GZ'#4[I^QH%+@8W9L.G>F>\Z]?>QY-
MQM-<3DJU)U/M%2\WP-E,KZ!$9C"KS(5ZS5Q[/V)G(I1)3.U/?A/U6>P=M1]+
M6^.+_(^G_P!18*7RPO;GJNB^K]7BNP7;J1@KPM<%K2%4D6MIEYFQP*%?8.EI
MV(6J;B1E&R,?.0RBG8OUW7LPP7/K!K&QW> SK.JH2/4L5QM+_P"SH&')*2;.
M%CCOW8E.5$'<I(LF* B0WO<N42!]1 0I3UWU"WF/O_5M[05[I; V#5^B-.PN
MB&L1-?B(^8VWK\[S^8[!U&SSLRG$/F%6J]7'3;388>G0[2RW)T2;<I."H2SP
M8^/(MDOQR_4I_,[:-^G!TT_:[C\<OU*?S.VC?IP=-/VNY:XT7%RU;.!*!!70
M16$@#Y HJI$4$H#X#R!1-X ?'U\>>?1PBJ;_ !R_4I_,[:-^G!TT_:[D/5SU
M/>]=IV[4>OT1Z16C.-%R"B9-HETB?QT>IZ/V?6]G?:+'4AV+]U+MX%V$BZRZ
MVI@A$S4F_:?(>^88Q2;N+4D;=-BVK*>OU$D--VB^5S-J!$OH:.D[9:GP1T,R
M>V"4:PL,V7=&(<"K2,H\:L6B?M\JN5TTP$!-YY13??4EM&8W'LOH-!Z2T!IV
MM=]O[KT?<HW+;W$&QOV3],^CUM]05G<[M>ZG0KJC%/E,[MU^A\ZI$%799NSL
MMV9A:K2U2;RZ;8BW#_'+]2G\SMHWZ<'33]KN/QR_4I_,[:-^G!TT_:[EAF#:
MS%;WA^.;E!1CZ%A-ERK.]7AH>3415DHJ*T6GPUQCHV14;^6YWS!I-(M'9T!%
M$[A%0Z7[PQ>2QPBJ;_'+]2G\SMHWZ<'33]KN0U1?5"[SZ)JVYXW6?2,T9Y=^
MO,KG</I$;^.AU1;?9+S3J$ST:KD%[(RS&'?_ #E;?MG8&@)6;20 _P "15CW
MY5&)+MYB7C*_$RD[-/6\;#PL<^EI61=G^&U81L:U5>OWKE3P/L0:M$%G"Q_
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M477*);<QTVK0UVH%\K\I5;?4K"T(_A;! 3+8[21C)!H<0!5!P@<0]Q#)KHG
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MB<<<<(G'''")QQQPB<<<<(G'''")S6/NC_ Y[:_U:]Y_RJM7''"+HJ^E5_\
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;3CCCA$XXXX1....$3CCCA$XXXX1....$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g991841.jpg
<TEXT>
begin 644 g991841.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!!1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?4$1?149&14-47S1#7T9,3U<N15!3_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@!" *L P$B  (1 0,1 ?_$ !\  0 " @(# 0$            '"0@*
M 08$!0L" __$ %00  $#! $"  @+!P,"! (&"P8$!0<! @,(  D1$A47(3%7
MEM43%!88&4%189&5T5-66)/2T]8*(G$R@2,D);%"<B8H,SF"H39%4F)E<X.2
MLL'P_\0 ' $!  (# 0$!              ,$ @4&" $)_\0 0Q$   4! @8/
M" (" @(#      $" P0%$F$&$R%!<9('$14845)35F*1E);1TO 45%5C9:'3
MU@@B%B,7)#$S)S)F_]H # ,!  (1 Q$ /P#%+RT3#ZU9%]LR#WAS^5TWRS96
MM+Y>/;*V]_"I>=/=E;>WII=2YSI6VM/KI6E.W([M_P"JW_YJ?^_-JX-.W6,H
M9Z:#@MV9U-A"#E&O((^3K&DV,@HO.9;%TBAKH07!Z1> O;PX5S,.1:Q750E3
M#?XX6X,F3"NR4NLS_HCA=5X."Z:;B<':;47:B],:0VM)QC+V.$[--#91*157
MGGY!,8B.V3"$&\M&->;;M+3^:.!M$F85+J9/X0U"FM4UB$\MU!HDVBFU!B 2
MG#F5BDL,L,&^3[[AR%K)E"\4RZY90K66NFV6[*^#DEL_QW=J5I;D.'W'=6E?
M16E+W*VM:5[5[5I3MYN?JV:I>OMI?9+$AWV74[VWV&K_ 'V74I6M*UMOM<:V
MW4I6E:5[5KVK2M*^>E>72*-D:P1HI-\VZA9&&-AXMZH)^/ V=\ 0@AN01(\Q
M981M+#B9SQC?DK0BI>VMZ]$BQ8\*UI16V-MN1/;15AKBMU.&0>5/&H\RX0\;
M 9%V*U3!I6E\9$VA./,F<S5J*),9>G8$MMB=LREB2_-?GMQ8Z?&?%6//GR*5
M7QA3EJTFOQ:A58\"1@I!@QYLNI0(;ZEQW9J)E)AL3I+50IYTYE$1.*6M"7&9
MTRR^UBG$(QJ%G:JV#DBGTF1/C85S)\F#$I=0EL)9?9@K@U:<]3XKU/J!5%Y<
MM>.;;<4T_!A6H[INMJ7BG$C &Z;Y:MK6V^73ZRZE>U;;SI[LNI7[*TN<J5I6
MGUTK3O3Z^?UMFB8;Z7762K(M]MMMM]UUAF0WVVV7UK2R^ZZQ?6EME]:74LON
MK2R^ZVMMMU;J=N; K),Z*']0]!46'>6-M0LA'KM>[+1\IU/P3XX&^5*8*4GR
MFQOM@H]U9[&FS+<V9&S,IPWK\F?XW6R_P+LE(E")5BS%TUY!*BX>,CE9/W43
MP1].)2$O02!5F*BI2@/<+G@0JX_<J"4=N8XD0T1Q^@P)5;03*%+EA=$[2I7#
MV;5?Y>W8<>1@1%=9W?10XYM)D-+>,JC,A.R<=4,':?2WB0W3GGD-4VJ5+:>6
MS&DN1B4X^WMCP*42VV5X;R&7BP>57I&-]E=;:(Z;3YS,3$T[".HU5E2W*BPT
MMZITJFD;*'Y,5N6:$,.TJUF>8J4MK65)&I2ZVE]E:F)%2E]EWGMOLK5?2E]E
MU//;DLK=9=3SVW5ISCRT3#ZU9%]LR#WAS8[VKU\BO8[97;J5)%8#$E$]1TL+
M:_!$0I)MB""64D(R9K2E]?%TAER 180"/QT?*TM6H97.;F1O15>\7)7C.ARM
M; GP5)M*=3(B6[2383DQC,^O4)BL$.87'D<2@"92]R-IZ7.+70$/)8$/E +H
M[8T<FA8E<W-BOK>\85C6X5S*,=GP#OE2L/L$YT:.<B@ICU%Z+37=SXT.!-M2
MZKN4<*G1WC]F-<AU-8IRDO26(<(\8^29)G#F$SC5=CK"N!)DE'KI2*:Q*J;.
MZ,F5.A68=(W5*;4GV"*22(S2J)4DFS&?F32)IA2HQ%-AF_5;6:I?MK;2Z5Y#
MMK?7P;*7&K_;6^[T^#92KC2M]W;S]K:5KV\_;G/EHF'UJR+[9D'O#EM,&"ND
M"4%ZC3F)@<O2-'K/K,#2 *YY#HS!T@AK6\/%4;L*#[D^""RVPD:RG%16WRRR
M8*M[\*Y<3+C3*E2/*\JZ3*TNI6M+JTK=3S75MIX-M;J>:ZMMO_PVUKWK;;6M
M:VT[4K6O;O7KJ),I5:D51E&#Q02ICE/;MSJ?#:6\<ZFQ:C8-@DJ=8=C)D(:>
M;=+:-5E;:UDI1(X^NT^IT.-27UX0)G'5&Z@X2($V6\AA,"IR:;;*09I9?:DJ
MC+=8<:49V;27$(-*37)7EHF'UJR+[9D'O#CRT3#ZU9%]LR#WAR-..=!N73/A
MT#L<:[Y=Q#G-TJC[_-[4_P#D$E^6B8?6K(OMF0>\./+1,/K5D7VS(/>'(TXX
MW+IGPZ!V.-=\NX@W2J/O\WM3_P"027Y:)A]:LB^V9![PX\M$P^M61?;,@]X<
MC3CC<NF?#H'8XUWR[B#=*H^_S>U/_D$E^6B8?6K(OMF0>\./+1,/K5D7VS(/
M>'(TXXW+IGPZ!V.-=\NX@W2J/O\ -[4_^027Y:)A]:LB^V9![PX\M$P^M61?
M;,@]X<C3CC<NF?#H'8XUWR[B#=*H^_S>U/\ Y!)?EHF'UJR+[9D'O#CRT3#Z
MU9%]LR#WAR-..-RZ9\.@=CC7?+N(-TJC[_-[4_\ D$E^6B8?6K(OMF0>\./+
M1,/K5D7VS(/>'(TXXW+IGPZ!V.-=\NX@W2J/O\WM3_Y!)-TUR]93PLDL2%CM
M[]O"R&S]CM[U]%/"O<:4[U^JG?O7GYLFV6\E:TQRV?Y*TIWK3&</F2M*>CO6
MECE=6E._F[U\W?EB?1]S(T6Q\KNJU\:Q2QCU)GQ]PF#R-X2]O#%+5A$5>$O4
M#.9*LH^6#?@7.V1JL39LCEA396^W'DHJNQWRV;RE&6S,OZKPS-V];!MA$!M*
MF1H*L<3:[H-6R"-7LA'KA8(,,Y.K!D=SZV.1(0)T#@S_  *E$C0V*5:RS#D^
M)J</#5"O0X->G4E."L63$ID!JH3)K$.8\]BEQ)<LVV&8V#\FF)?)$)2&FZE6
MZ:<EQ:$,6U_U/O*=@[*GX/P*NK"E^-,JE1=IL*"_*@,LXUN7 AI=D/2L(8M4
M4P:YR5NN4VAU,HS;:W)&+01K*I:V9ICONI;9*<CWW75[6VV&)%?==7[+;;5]
M;KJ_=;2M?NYQ6:)AIW[RK(M.W?OW,R&G;MZ>_=PIV[=J]^_;MVKWY;[K_J$P
MZ]S1I3A*W8W&]CY%W@F<.9'!H<F*UN&H=@I62@64H3BY -/J!:^E1LD\)H=W
M7 K:;V6]5BQM.?+BL4V]0;(#U@BH:A*8)\2S$9R#M%M[+;"!/0,2#K.R1DPQ
M1/E@I\HR4:<&:QO/7M])<B14^#5%#<F4L3@KL9/$>=OQ95\"\,<%\>;<6B-S
MFG4DBGJBP8JWJC(;?KC<GV=M3:6O8XS6#TYXY2I&,=)AU#<52B8]JLHP(PG*
M.3LJM' =94:ZBF7,DH8IL9QC!]V(<AU"UO',DNX1T]@HJ8V*:4^TMV4E!R#C
M584FF7[J4NME>0[K;J=[;K31_NMNI]MMUKA6E:??2M:<Y\M$P^M61?;,@]X<
MV")DTD@HLE[:#8.8V1_+TIGN211.,"(W/40:Z-82)L JP9S"1%CW*3JQI# A
M0N%RG(S@[.IN^,(4OQQ:ERXU2A2DPT4:EZ=0I&^Q$J2DXR5L".Q'N"-P-'ZF
M&Y,$QYBD$),0%F,&9T>GY*UNZ'"L;D[PJRO*X86V7J'AFHP)+$"=4K4IJT##
MS!"<TSBZ(IV8XBG)]CBT^G/FN9..&TN(PZXY'(U19<IJ*MV8B"AXR4]'QK#;
MRV[%0V/<+Z>^\3M:9:AMKJ*O;94ZH1THAP2EO(F/M-LR3LRXD-V4VS"7/=9*
MPS))I]UAMVL+RT3#ZU9%]LR#WAQY:)A]:LB^V9![PY;#*.C.L&L9ENP;RS67
M).AW70ZA./XUCT6*F<.+"9\G,18S5/>:GM[?EM1-@4U/5$>)4@;DMS\MLLR+
M?]UE4ZG\1!I-JB<LFP4_CN.6Y3A ,,HY!HCC0WDF/M5S5<]F;"@(RNTZD.5%
M VPJ$P>C<,6 54,F5':=9+;\N"Q99BR9N6_\TP-]CW012'5P5(IV)F;D0FHK
M\JI,4J3'@)?D.,M,RTQZO">=.8J+$2CVBS+6<623=4L!<,BF[G+JT9NH)<J6
M.A;K3'94>+2WJK&DU%;$9E]U^&<BC3F6BA)E3%K)@E1$%+BF]5#Y:)A]:LB^
MV9#[PYSY9YBI2R[RJ2/X.2VE^.ZIB14MR65[]K\=U5U+<EE>U>U]E;K*_5=7
MDY[.1!#4 [4* 45*%,P07A6@10GS#QL'N).K#B?"B7OP(K-A2C^(8S)@R^-1
MK.]H4ZY#==A1.^1!?:JKANN7WRC6#Y(V2VFD:7VJ1\\)]/\ @N!1-+%8(3B@
MQG+'Z8+VU0$#H@X)!5/D 8_:[G:MQ->MS/3ME>;\RUM<D315./\ ))V$]!AO
M4!36#R)4&N4MVIMR40XC<EO;E4:GP(34%UI*WILVHUNGQ%(==BM1E.I6X\I!
M/&U% P3KLQG" G<(#B3Z!56:6[%7*E.QW"*)6JC4)SDYIQ2&H4&FT&H3"4RS
M+>E)9-MME+BF2>U]/+1,/K5D7VS(/>'.*S3,%M*UNE:1+:4I6M:U-""E*4IY
MZUK6KA2E*4IYZUK7M2GGKRW $T.U0D8]CB0$CM,HUK7,NF$W[+-8YF?6-TE*
M-2F%7UB8BABN><37<@-1Y->YYUC!>K2IE3U7'\76+[L5,>6[!/7_ "Q>][^P
M)FB5C)6F)'/9V'?D6P2"I0O!4F&,YB,X[$A4I2YUS<N<5&;XWE56X,ZE)\'G
MQX++KL>.EM+4/"#!RHMU14&AFM=(IKU0E^T4R)'9:=8<E,*ISCQ8XTSDR($I
MIQ+;;S2?9G'$NN(-HW:DS!K".G.TE$ZMMH36*HQ3H?L]1E27G69#4*0BIM,F
M35J"J-4(3S:G'&75^T-MJ:;<2\36.]LW2U?=2RR7#Z^^O?M98=/=]]>U*UKV
MLM<JW5[4I6M>U*]J4K6OFI7G]?+1,/K5D7VS(/>'-C#<J5A9@;=_078W875.
M7 YS;BT3U@UWCE@&<DZ19*]'WP0S,2.3, CKD-J!#'=BN(W)T(7[X'#A45R.
M=O:]*[XBNVBVI>&8B?1%%69;-JQ>"U$DUG;,7,&2)W:26^-$<I+0G)&U6O$H
M0 &=D78T:4HQ+Z/&)3;VN5Y\EE,R[04O#FA2(:952P73")3*IJ7(,-$^(5+8
MBTR3.J2WYE/H[IL4M=3B19Y,19)D^K:AJF(2ZIOH:K@!7(TPXE+PH*:I+R(*
MFYTKV"6=6?EU.-3Z8F/"J%9:2_5D4J7*IYR)4<C81_W2A+6TEVHGRT3#ZU9%
M]LR#WAQ?-$PXJ6W995D7%;?2E;+LQD0XK;Z75K2VMEV1?;;?2ZM.UM;*W4NK
MYJ5K7O3EMX7H5KP=:K#)Y'C-(DTFKIKJNE(TD>)YF G0DBV8\:7,MMBE\U5=
M<#42.@8RVTQ(WLE;7E:7**XLRMM:LMJE-FQY%00'1DOD+2]#,+(_RXA=^D85
M%XRUO.<'L8PO UU?'!\:6Q'\B;+G&ZY!E^#"WUXS.3\,NMV1R5.;G@OQ),.<
MW#K!EA$M4+!]N8NGOU%B7&7&@191' B2)).-LV7[*'?9'-M$Y4&4VRDWO9EF
MMEIZ.#L?X32'8;<VOG"146*:_$E(?G2HFU49<2+8=>VV+:F3F-%C("9\5Q]1
M,>THL/N,T#UF:8Z4MNK*<D4MN[^#=4P(Z6W>#7M=X%]5U+;_  :^:[P*W>#7
MS7=J^;G'EHF'UJR+[9D'O#EPP5"\,S9$?2FCV1">3FB+YX5[I"D;,^4B&;U$
M9%*J04](L3W/C4$HG,EM>'6QM9S'*]J5^)W>%N)<RV,"*M6V[J,&=-Z,BY?J
M]'\I.IN/RB< ^Q4_SJW(']G'Z,L,Q 4J04)&QK"3I,32Q$)\2X+EN<N>W"C:
MU#R!S47X<-W@*DMM6&>"45N2JI4AN&[&?JC9LMT^-(ML4R=A%$6^ES%M$9I_
MQF24E!$I$>5(B1D.R4R&9#M5. N%LMR*5,JIS&94>D+2ZN>_'-$FJP,&)B(Z
MF\8ZHB4>%$0XSBC2N1%C3)+C,5<=^,U5/Y:)A]:LB^V9![PY^:35+U:W6VRQ
M(=UUO;PK;35_K=9W]'AVT<:UM[]JUIX5*=Z4K6G?F9.Z^N\(1:'0W)4.JL8B
MO.W$J&Y @MRGV)]AGP"<6&F!<-E* YBQ\>4RP:-&;)FOR)W:^U0U.Z>Q+AOI
MB56X,=@,?ZZQSLK%'19AV0,3LWB\@A>X^0F<1!2B8R9144M5$[7?C=LK>OI?
M=A7-."VZU4G46Y$U^=/97#7-7-9-+PKP9BTREUE-%:<I\Z1669!^R02DPD4.
MD5FJRUI;:2_'FJ5N(XPS[/+]G>)Y$AJ4XUM8R"%@?A++JE5HIUE;=1@1J(_&
M(I,PXTU5>K-!I$-"G738D0B2==:??*1$*0PIAR,_%;=M8NC?RT3#ZU9%]LR#
MWAQY:)A]:LB^V9![PY<!%^K'3VDEBU4-TX3M W,NS$W%VJZ,:5RL'Y58X:#B
ME;;CF)T?THY6Y7:J2X$%+ 9L08&'"I<%.7/ASXFBS \1(SZU:=0S ZV7=AV2
M;Y*<4&\$L:J86V.SED!6Q4.@UV7'A,7'"K:5JRUS;F] X.MK0T.&&Y^<\B1M
MR9D;?BS7W8)PPP6-Q<<L')WMB92(;<'<>F>TOR#D3XCC;/\ VS8/$2:7):=4
MM]"-LFU-J<;4M:,U8$X4);;D*PCII0EQ3FN3MUZE[-'C>S4V8VZ_MPR?+'QJ
MK%>:0VPXYM8Q+B&W$I0NMKRT3#ZU9%]LR#WAQY:)A]:LB^V9![PY<2W].6%(
MOEK9P2DL6E.5A"+):CP%$2Y1,48:WQNP!\A";&;VNIC)ITX-ORJE)F:"5 DL
MC\58<N);\2QN"E.FO?T^!MZ[*6D>I&HF*9C:?JS9+8.V[7)M:XN'@,F90I_:
M62Z/!^37X]+WJUIS8"!^8VA_R-+(P($S8A?UK-3+F0XJO7=GB:PZP(D/MQ8=
M+5-D2&(<B S&I4!;M03,:@/H;CMK>;6RZTS/CNNIGE"2:"<4RMXFUF4KFQ_A
MO'CNRIM29@QXLB9'J#TJIST-TU4)Z='6Y)<1'<0\TZ_3Y#3*J<J<HEXM+Z63
M<3MU+^6J7Z74LK*\ATONI6ZVRIJ_TONMIZ;K;*N/A5MI]=:4K2GUUISGRT3#
MZU9%]LR#WARSZP2U48>GSNJJ%@P_-\XQL_'HU'DG%J=J!SO&G)V;&NCO,XL;
MN*4?Q]J'\"B]!(@K@S(L<AJD]SRW7L"9?B2X*=O^/_\ O_;G34*32JX524B@
M-PT4ZH%!(Y<&(A<C;@P9R729)!NL'8F-I4R^A#J#25LB6:VV^7KT.IT+<LEU
MY4U=2IQU RAS)3B(UF?-@*9-ZUB9'^R"XI+\=:V5D9V%*02'')+\M$P^M61?
M;,@]X<>6B8?6K(OMF0>\.1IQS>[ETSX= ['&N^7<0T&Z51]_F]J?_()+\M$P
M^M61?;,@]X<>6B8?6K(OMF0>\.1IQQN73/AT#L<:[Y=Q!NE4??YO:G_R"2_+
M1,/K5D7VS(/>''EHF'UJR+[9D'O#D:<<;ETSX= ['&N^7<0;I5'W^;VI_P#(
M)+\M$P^M61?;,@]X<>6B8?6K(OMF0>\.1IQQN73/AT#L<:[Y=Q!NE4??YO:G
M_P @DORT3#ZU9%]LR#WAQY:)A]:LB^V9![PY&G'&Y=,^'0.QQKOEW$&Z51]_
MF]J?_()+\M$P^M61?;,@]X<>6B8?6K(OMF0>\.1IQQN73/AT#L<:[Y=Q!NE4
M??YO:G_R"2_+1,/K5D7VS(/>''EHF'UJR+[9D'O#D:<<;ETSX= ['&N^7<0;
MI5'W^;VI_P#()+\M$P^M61?;,@]X<>6B8?6K(OMF0>\.1IQQN73/AT#L<:[Y
M=Q!NE4??YO:G_P @DORT3#ZU9%]LR#WAQY:)A]:LB^V9![PY&G'&Y=,^'0.Q
MQKOEW$&Z51]_F]J?_()+\M$P^M61?;,@]X<>6B8?6K(OMF0>\.1IQQN73/AT
M#L<:[Y=Q!NE4??YO:G_R"2_+1,/K5D7VS(/>''EHF'UJR+[9D'O#D:<<;ETS
MX= ['&N^7<0;I5'W^;VI_P#()+\M$P^M61?;,@]X<>6B8?6K(OMF0>\.1IQQ
MN73/AT#L<:[Y=Q!NE4??YO:G_P @DORT3#ZU9%]LR#WAQY:)A]:LB^V9![PY
M&G'&Y=,^'0.QQKOEW$&Z51]_F]J?_()+\M$P^M61?;,@]X<>6B8?6K(OMF0>
M\.1IQQN73/AT#L<:[Y=Q!NE4??YO:G_R"2_+1,/K5D7VS(/>''EHF'UJR+[9
MD'O#D:<<;ETSX= ['&N^7<0;I5'W^;VI_P#()+\M$P^M61?;,@]X<>6B8?6K
M(OMF0>\.1IQQN73/AT#L<:[Y=Q!NE4??YO:G_P @DORT3#ZU9%]LR#WAQY:)
MA]:LB^V9![PY&G'&Y=,^'0.QQKOEW$&Z51]_F]J?_()+\M$P^M61?;,@]X<>
M6B8?6K(OMF0>\.1IQQN73/AT#L<:[Y=Q!NE4??YO:G_R#]TMR4K2M,>3O2M*
M_P#V=_U?_AY,LI3Q),Q#4-B9OG:\[/ \>8HOCVQJ9*M2E,)X5.!59A>5%BC/
M5W<:9$V&E5]V-+6MEM:5P>%???=O-_1F:+?P[BGYP:?Y/Q]&9HM_#N*?G!I_
MD_/+KG\CF'GHTA[ 1EQ^&IQ<5Y=?)3D=;S2F'E,J.A[:#<96XTLTF5I"C2>0
MS'K=K^,;K#$J,SLA2&X\U#3<ME&#5EN2AAY$AE+R"PCVEDV^VAU!*([*TI46
M4ML:7\([NS9 D8KH=$V*'RB/G Z421E8I6B!ADS'A,%+,WL%[JC^4.6J='DQ
MM3=A3)[L*6F=/3*L^"44M5Y;.0Q-DWRGL/(3G*,ND:DI+W-.A04440)FMJ:&
M9JQW86D>'6-MP8&QA8&K%?DM1-B##9CIDS*5BG(I7JU:O/O3_1F:+?P[BGYP
M:?Y/Q]&9HM_#N*?G!I_D_*,?9\I,6>_58^QS!9J4G&8^<W6FTR7<<;1O6GBH
M-O\ VFT@W-I18PVV[=JPG:O2/X[5673X])D[)]1>ID7%8B"N@+.*WB"63-ED
M\),7_I)UTF=M)XLG5V-JTJUIUB'4.GL0CJ.XOH':[F O%8S:(!.22M?!&0'Y
MJ8+5>5=<B\>$.10INIE59;LV?X#&EQ9LEN/)DPW9;/A*Q"4[32T6@;U&:S %
MM02^3_=LOF8A<%0CB-OD^K/B8;*LB=!F^*M C@;<&/$G%$J?XG@OI=DL4?[J
MV\W<OHS-%OX=Q3\X-/\ )^/HS-%OX=Q3\X-/\GY SLY4!A]<EG8SI[;[D@Y2
MW$5ELE*DFZ;ZGS/<+_VF\MQVW_Y-:U*,]M1BR]L UZ0PW&?V5*FZPU'3$0VN
M@*-*8R6FV"8(CPC_ /43+:&R0>V1(2E.UM)(:<+3U!]B4,G31)CTEB\\MV'S
M#ZF98TD.+FLOAXW5":-$A&%JT!<U5V%,O8L*#!>@6)7.S-\+7+<JJILNQ68.
M!_J#[$LDBR6?JTL5E:"7AL:#3Z)RZ)!QUA%W$0F[)<$#N&,TUC<UH$(?\+F\
M29L*FY?6JA5>ZK'/*HNR6[C_ -&9HM_#N*?G!I_D_'T9FBW\.XI^<&G^3\B/
M9KP:43A'L7TS:=BQH2R*L-D1QHA14QFRVJ$5DV$PH:6G$[3J"AQ")9%&9)$B
M=@C"1)MF6RS5]MJ7)G(,Z$X>U)F*E*E.':PD.T4A4Z<IYM5IM:ILLU),Y+YN
M::7S_=D\\E2Q*#PO RAUFH!;(M.Q8KC =?HY4Q\P=ODR*- 0JPVMS,U#-U+\
MS/B39;Z_&<RA6YU<U6>_-S"JF.^E*4\#+7M2E.]UE]UU>U*4[W75M[W75[=[
MKJ^>ZZM:U\]>?0"^C,T6_AW%/S@T_P GX^C,T6_AW%/S@T_R?FQ@_P @Z=3+
M>Y^Q[$A8QJ*RX46MH9);4)E,>*A1(H22-,=@L2UME_1M*$%_5)$6LG_QNGU2
MQNCLE3IQM.RGVSE8/*?-#LY[VB8M)N82*,CD2#4\[E_NZI2U;:C49_/^\"_]
MGD_EW_T\>!?^SR?R[_Z>?0!^C,T6_AW%/S@T_P GX^C,T6_AW%/S@T_R?FPW
MS!\RR[PG=]#T_:\:[>L-<^W.ZZ?V+3Z++\_[P+_V>3^7?_3QX%_[/)_+O_IY
M] 'Z,S1;^'<4_.#3_)^/HS-%OX=Q3\X-/\GXWS!\RR[PG=]#T_:\-ZPUS[<[
MKI_8M/HLOS_O O\ V>3^7?\ T\>!?^SR?R[_ .GGT ?HS-%OX=Q3\X-/\GX^
MC,T6_AW%/S@T_P GXWS!\RR[PG=]#T_:\-ZPUS[<[KI_8M/HLOS_ +P+_P!G
MD_EW_P!/'@7_ +/)_+O_ *>?0!^C,T6_AW%/S@T_R?CZ,S1;^'<4_.#3_)^-
M\P?,LN\)W?0]/VO#>L-<^W.ZZ?V+3Z++\_[P+_V>3^7?_3QX%_[/)_+O_IY]
M 'Z,S1;^'<4_.#3_ "?CZ,S1;^'<4_.#3_)^-\P?,LN\)W?0]/VO#>L-<^W.
MZZ?V+3Z++\_[P+_V>3^7?_3QX%_[/)_+O_IY] 'Z,S1;^'<4_.#3_)^/HS-%
MOX=Q3\X-/\GXWS!\RR[PG=]#T_:\-ZPUS[<[KI_8M/HLOS_O O\ V>3^7?\
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MRQB[6G2P]0W8,<$V)D;F:'*FXK&5T,"<]JH>8E.P0Q%=6N]CQ!3/)5V:VN)
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M++O"=WT/3]KPWK#7/MSNNG]BT^BR_/\ O O_ &>3^7?_ $\>!?\ L\G\N_\
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MS4Z'X"-QV8&N5&'BK*XAS4@"2)^=PIU)C0R>6EF +:YJZBFCVNSYC&9FV?B
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MR:@<L@E7/43&\<'8&XQN[R*$G=AHCLBX@9TH^N>FU[5G;1A>DB$2R_%:7NQ
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MZ!YH8<PT;LLW!:M-A;Y, 5[#>G$&E_Q."H OVP=2S559M\#Z=-TBC3F:2+K
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MR7*N2.MQ!5O6BNE2<ZDPD&"%^%20:MSCI("$4S.B9WB86<VY&3%26P=R.N,
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M>E*>/<?RV<(I;>JW:3XIJ4KL2&KLK%4NNU<[DE+JJ+TUL79<UF%30?4Y<.0
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M!4B1V0!CD5*4CXH<G9:34+D;3B$A14R>)S!Y0*G+*-OKRP-3BWXE3M@MI/\
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M$6:W J3X%&*EF;%COM_DW1K'#0 8XI:@,*;8OQ#N<0Q1P@%F!$!XA-2DRH%
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M1?E39<F*Z+BG6O70X,W.1C2!H6+I">A-Q G@[)XL R R=05W;%;*[!;D4.[
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M S2&0F02U*N<17/V6%9-V<FUS&60$*RYV;==-;XN'")PD4_O<FAB^4+P58[
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MM1U""82"'T3@R,9+$YK(-G8#U"CPRV.@*5P.&+3.?YA615BE5@7/Z01LFH)
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M<X,A1S1,$"2>6S1#;T'.(R\-2L+.XZE$R=C4:.AE0@)43UA:\EZW+@:DN"T
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M9$ !6:]>HE;7]HCB/)DQ#[DG>C!(+MI64-V)VP/;,^N[41/+(1.3RQN&=MO
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M(_MND]&%@P<)0S!^08&72PL+21NDZ-HWG<\>B*.!".&A5'C%017N1 ^9T+
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M]#4;H00F*6YP$D<<_'GLB)G:0W0CSR!C9R)I ,$V;K%S*KUNV+.<#'K^;OT
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M/<BJJ3L"=O2N"QR78E+BJPLC;I7B ([P@./&Q$[R%K5J](C=*FM^K15BBA(
M1J8#&1[SQK1S.A>.&&9)(&X94D+BIB@8.SYT;650F'E1+\KU8PQJ$@!5[ IG
M)C)"'2\ZEN::ID*)OWKV\AT<V#&'B63IXATDAS;]QD4='H?8H2<G]=%H"WZW
MXU$?.(,ZA JR%:9P ":]_?GC,<%REP]\ E/4>URL>Q^9CR2@V2)_C>Z'%!7L
M;.T7RI&SAM3:5%IU+FY6MK &+U.6"-2=?-6V(ZD9Z%#A'$K.L=\$.1_EC-*6
M)"4V+[*8PZ5D<1E),8.:>;IK(M?( F([G_734=\K&=L.P[*Y]C-:*'=L?FN/
MV^6BL<!E,DGZZ)@DR/WD>CU44Y:H\#AA8!'"/Y,RWIS&<[%$KOLJN144-$I:
MS%6J=@C5TQ(&$'C:2LKKEEU>%T3)OC: QE*S*(HR@B5YUM^-NC8'1-*9#B1.
MGC4 XTUG76*9H:9VS5F9FZ:0:)&X>C-2^7E+R5%Z?(SB[2H8U1RYE%F$L<WL
MJ&E#678"M\Q9?ET@><)>V.;NW.N%PS5(!V]$RM$GM\ ZL0Q$[.;[#=3SJ1P4
M[E$PR3-!D)BV379A7R,132H9E#\N?E^1^QM*BN*$PQY"@["L4(6,3<P1GRKG
M9#:YJIJ#CUM<Y/,R::Y0V&EB6\4>LY;*4JH8X9'S(%Q$PN8W&(<A8(H!X_#D
MB$=1/I&Z+W3Q%E?"(F)WYV<E]$F1K:6F/ ?IL0> S&%S:T%$G*2D%V;VUVK:
MD#@\#.5B42!N.*+A"2VA>F3BB9=D$F1M<,V<*0X'!,[-ZRW'D>7E]PTNP7@'
M9]!MFI"V7BB15DNC0:.RU!VQD]ZR23?'"I[RQV3%D&':H3S&(,G*,F<F:!\K
M05;73"PD"UR<6);F6M=[N\)TR=T5ZZ))U$Q%/U=<.V=VT>#Y!C.[S5TG::QX
MC:F-OSZ^N(4M$BS9A2+I\N5H4U0;].K4W83+P,BCR;#2C#>IPHZX;K-H&"]8
MPW7EDFMG "(P\.<9WFG8<@='M4Q."YA/9P?*D)%B&K<3"D0X6)E<J8\@VA>$
MCPIP8\=N-U7.M*W5N@BG36U^LZ=JGIJT6GN6$U$1KXNRE^5[:;Y8R.SBYYRI
M3+]Q%5@HP5EV^1U&24J$7R6\5T/:T=*L54E/B' #".8^HAO>Q//4&DZ(8.UJ
M(=;.FG(S^QRPVF)O)2&;9T% R!(OV&D+!%.1F;LH7'I8%@ITKR-F8Q0ES-(#
MY1O'\& 2Q85KYF_M*74WV85"NXNU&NL80@6Z9Z'.J!+)K:=NQ^W3W.S,*PY'
MD\3R^Q2M:\B8%C2D; 4DMZ4,;C-C/+Y3*1Q^;LZL#:L[6\9NBCO2?E2;)4ZE
MR:7=D=IX:@;:79EE:3:* 9T@N@CMCKVRZK:W@J]\>7E=&9+(,8NL@$;+)8!)
M+S&!)&3R6CB3(U9&A"W)6!PLRTF#I+QW)[W.3*PS[/$2Z[;6NX2\[4:N1YFC
M5/&,P*@L3$(_684)$^@#S*,6(9+CX!#@.74<9FS!C-1ABQ8L-6-T<7EU<0"I
MV2V..)AW$ZL+P8:4[J;C/;%)<$W0P9ZTR1F!*1VUO.@.N1X.BPV^*MD8>?00
MI4E3UD.<#@.AKUF0*W_ LK<Y/&>]FMMOUWV!F#%T=8[V&!RMKVPV!"M)K3"K
MP0(2L;LF:;HKCA9:7C9"E7H&@S:"9W/Q1^#'VYX9V=_3EV%8H>69M655-V'N
M;_T[G/'+VP<M0[NCM5KGDV7(PPLD<+B9LU97BN$A!8<"(*9'$34ROK7)A<,7
MX@*/AI/1.A)ZH4SHC\9(DB;+3%;CR\U]U_C+6.% " 8E9U33'<<L561E2NKF
MM?WAQO5KECP_/I*^.F3.X$),6D#H\$I8^N&2]8^O[RZ.:JOPJN^V@!1N9]>"
MC>5['9PN'VPCBX(T/&]A=>"S.^K,2N;-E2(*UZ.L>NUF--?DP8LB1JV^UMQK
M%#>GM>4V8J>J6XE5[;FP(O=;=]6J;]5I/*6EZ<](%B6+#_7( )M;T<CFYAL]
M)J*6UT3#AO);$M!W)S&8 8!LMD]:F!@Z9PAW?S07"[RY[=Q!$:#::F0PCT-]
M+@P(UU 6[-*2QFUIW (-R0O.Z$H^L<G\O?%N!4FC(V4U$\>-[AH>3L,<-3$)
M)L#:Y6-411LD<7]Q\2K;W/V$U=(D>E]#L8$(-KMC(RA/9*6%&Q1;#@,@@_(S
MMVQ%74,)D<B)34HB8@DEW'TIK'XJ97Q<1%;F%+'-NM9,Z?Y$TP"N  Z NZF$
MP6;_ +YJVJNU6C-O8)\#(C8X%G(L/HQV<G2+R-D'ECELI IL1U;(9/6E$L(%
MN0:A429C0I*V\-($*XZ$S#/C&F[-W?K98LU>B$7,A(BUX E!3)XZ!.\H;0R!
MC"XHC)C<V8E>UI4H'D3V/%\ODZC*/)!D3B(">V<F(G8@QN^9W;!T=?E>.%2O
MID5/S#)0^VWV-,X)=Y]C?: HUR)<<3O@<X3/&I$'GK<J&Y >8\<9ECF.W640
M5AD5?%@&?,HLV.F5]&Q*@V"OJT8YDCM1J:GV/60N8C\K','3!KT?/<AQ)*0,
MT !8K870L B:,2]O=0J51,V R%K( LM>&_X58Q87UD6U2.@Z]M>?&JQK0"G)
M#UGIC<M=$)\N;=<0>YDW?EW4&3]P'IDGHDT^!V6,8_:I 'I@=0=HQ-4JCK;+
MJA_:0$6:3(]8@X?(Z+'9UE-R;U TVD,IS/U4)GCZ']/"YP(]'H?;]A!*8WLH
MVU-#N29KT7^4T9E#2,@ ,$2?$=S$E9ED_M3DLD9B()0-AUMC@;&"H74II&-V
M58WXYU#>D^\Q:YE97%6^>WH?()-/95L9F,E.:%27&O/I5CIDCV<$1H#NT56Q
MQ(0C)'R8%BMG8"42R5ALD'&W'#*X*'KW!C7]I'NF"JBT2C=NU^W&V3A4W$_+
MTHD U:D$)&3'-[ULI*6:;92*9"A4YBQX@YM*J2>I5O0,]1^!!^8(85R\%06*
MPY7E:> '1+]TMUYU/6"&M4X[U4:I)#=-H2VLG0@D^13.4XDSD^PJX];8HA*'
M#*(_DWA*&8GK%)P_J=@KLCP.,PLI$5[?'90N=G% U])C7J3;-;N)HY1Z)17"
MX^_5TOB/;Z8+=F'@Z6M;403<0RB& .MHC?'.1B5T?\Y5"$HXBJ:G*UT&19G0
MC#BVQZ7*7Y:@994;^D6#Q<R1<AU0V6V,U/?@#6)EU (BV.5,4ESI)T,#Q&2F
M8_G*6V5(U,AMEDP4,3@_(PR1@-G%%PUG/"5I3-F<;JS,S/[A?TH (+01V@U.
MV"GO32@=K&(:=$JF'5$;$JJ1X& 5S^Z@R8DNF  D'$VRD%.ID?.0M,@UA:35
M&KD LN<<[MC4MF-K ,6<^])U'#YOR<8H=AG7:8Q<MZ>S+*;QLUM"Y8(KC-\G
M'6P&(B5>>Y%)=0*=%4&XG5:%M@#K?0?<=@R-M;<B%;<^$&<C2XVR1U-=R)OU
MY?;H)-=<L4I0IU7-&-6GB88WMEYFAR<8[G0D@0F95#&-$GC4Y%6-^72TTQU*
MK1G?BM(Z!:,L>@ L4*7(?R6V:O\ TC85MN<7N,Y6FR,#Y'(VK4KQP<8W<-DI
M?&IIJ/KZKUEC58D02R'&*0\3.\4N;TA-KI/O+GAV(G?,8-3TQ$J%I<D'4W3I
M#MSPPSXG<]PMDG<VGV:M7=HGB2WQH@9Q)179S5A\"G43E(7;,,2-XE8ROC?&
MD=##C%+NP.<=L@\((DHJU-"E>[K%X!B!*?7+<PB4YA5,CQJPY1WK[L;DUO)]
M=EA*?9-S9E6!9VS19,DEQ.B;,N0&&TPN;N+\HC>+2,?)GB5A (<7Y8=Q_E?V
MQ&AZ!U!MMMZ9ZUMVS.8G"89"M/HDW($]7E+K8:R8AVQ>%L!;K11%TL34P*AS
M#=&[<!6'[$2C6"-W&Y*2/4<X'4S6&2/+<G#':TY5TT\. \-UH;MEL[&D(RW-
M+;L3,.NT>O4?C0F:2W1S'R,W7LLDI 7RY1D%S&7#*(MF"/XZD=A8RMY=3&QO
MRC[6;E#>X="DWI# DB.LPC:'9G9./=;IWG%'LW)&KP2KB2D>N$]8S48DE[+&
M8O*(M)96'18UD82;)"-8Q:C7"%/9KF=W;$B;TKV[-JL MUQ_]-?_ .9E_P#R
MRWTI_P#ES^G.+;:6T[4[_P#5==Y_MNNK=7_MWK7M]WV\YX .... ''@V]Z7=
MJ>%2E:4N[4[TI7TTI7TTI7ZZ<YXXX .<5I2O;O2E>U:5IWI2O:M/16G?T5I]
M5:>>G.>. #G%:4K2M*TI6E?-6E:=Z5I]E:5]/.>. "E*4IVI3M2GFI2GHI3[
M.... #CCC@ XXXX .... #CCC@ XXXX .... #CCC@!C;+NT(#"<PZ[P^<-I
M,F4[)N4M,8>;ID;9<!CY#$47NLPNS&:.JMV2.#4N(0$:,GD7N0M3JF64#7_"
MX9VR[&CJLK3IUJM:9FU1%I@C*S88&RSK&F][P(N*".(\=I/AENTLBPN,Y$E$
ME#2HN5A-;4EJ4'SQJU/"UY;"HBDN,&TK0-#&^/ZIFRLZGVE9=O5K"IB:,I-3
M0U+@^<C1Y&$H+&]<ZI1)UQ(GT".:94#=EPK,U2J&3^3@;%EQ77?$\Y-A77X\
MN--=97#BG1KQLDH;^$X;([&TQSL;IP::U:U1BI8U>1H@ JFB%P**I[.UV;%9
M\*XV2.J@N"7A3@9LN+/CQCI!@^!PY'3PE(!C)LQU7MH!J-=_V&,1<S86O6CI
M[Z2[-1%LZ]"4/YB(E*)Z<'>K^XE@0D/2QOSK)!;&=2W@HLQQ5@2L16&RHG(,
MS<S+XI7D5QVO>[B69YRD'7$Z@2:=<I=$(W%9Q'QB7?)FY4/81."HC"F X9W2
M*)"D5K871"4"[DQE8 9*F$R'%MZ*^]O<$:C(K3UPRSTFI].&C9..&22(>31]
MLAT[],M5'(F=;#G&8B$LZ?%1<XMK\B&$3&I9'^.SID/GZBU1G)V<H'W1L:,6
M!H=D:M;GP6<I-8WU/O\ /^X=2=IN&WC3X3UKQB%J)=1]PO@[.)M*^8EO<*U\
M6W-2AO*L#5B1VV_';%J7-GOK\7R8Z< (@VMZC>/55REIW=M4MEY#A77,8'3'
M8F?1)LC0?C^/F$C;O'=<HDCDZ104JG!8)C]V%^/D<0,I1\F$JM&RX\SJ8Y,P
MNGRAVE<=AL4!&U^I:$+7ST\6BC''JN0K<>40':%)B.,)(>N[6H>!VTAI'@4Z
M$)X@#[GEJO,G0>0BM%J:]V\.E,^_G2+G;<$[W%KC<M7#)DV9#4+#%LR[#)9=
M.I5U%:VV*6,1RQC"45-V/R4-C ]'HZKD/!*C&_!IH/D,ADC\_BLF.@PP8W&W
M&88\V2D76AC8 &216$-FVA/$9C1]'[B(MB7.> ! +%A='#O52C%C)^AB2/$S
MW'3^MQHF$OM#"+,\)D.!Z28V[( 4NMG4GGP#:MW(UC#8:-]Z7:+2W2:!H'V(
M(XY'8X;QW;K<::%\!O$)2RQ1;09$CY!"^50'S8N7AK0#Y[1<@RQ@_.ZPIP8"
M#)*LF;=;I:C$.R6LY=)S'L:>!D0ZG["1YL<ZZ\J%#T 0U-$_D6O^RAK)L#0
MJ8,<DMVMWR7R2T*L0"G%WM_"GR]H*W)TH$OI4Y=PDGIK;([1NNR4V3K(4*0K
ML/($<ZOAD$(( 2FI['4=%>GD_+=J(@E6324_8P LE$F4R^JQ#ZUK:!D'2BT1
M6O(JQ.;B\$S@])LMM8-;=A4NQ\P[A[;.L+VS ?1%$^O0. P%G.7D CN*8R)3
MV079=F,Y%9QDE)C"1I#D9S=G6S$(CK..#XT'L&"XA7(W @5@&.FL6YFR6Q7D
M(C+(J96XC\H4G29*<ZMT7.T<L$A:7Q3(+J$Q+([3#DI.3R3Q0Z[DEB6P6$$3
MRZNE]0P"F:3H_</%&()5VV&;ER;BA;4/:*8LY<9 .&*]>9DD7,=1V,"!D?AV
M,+CX@(LA0$A\AYL (4%C!:WW.@Z.&N?"*/+LF2-Q#EQM2A7?2N?8'IKRE,0M
MG.7['KO-$TDNUJR>I8B&=4A?GU?F&,AX#D"'H,@HLO8AEU)[Q^! @C&)!$,[
MR%%8NZ3BVF)LY N%R,TSV-Y"JM'CM7TI##I\NDLX"602K3.0]:+I6?TY$L9$
MC^<QJ1!B-RPH')V?"W(%"6=]3M@\W.CZ]$]@@QM2-S>7-XM4+LP!#4F=7@0B
MASGYB:]:]I)K8-,8SB:6-KI<%FB%F(6 XQDB(VV7<1FAP$LJC"TZ(V@.S.)"
M61V"LRA_:TC.ZJ6Y*I1J1BU^EB5NIN&@9Q*+(!Z_;"S]'FNB./EVT,PP^PA2
M\8A&DFB[,>CS;02*#89E"6B)DC<D&Y-/QR' DT=0P&(650IPKR9?B%:1@1=-
M,V>XUZK(-CDD4PJNH3KR"PP'KLC.]W)X^<A+39/K*H>2;%;?\*ZH5;[AJ3X$
M[/X*K&TW41Y*_'J>%SU^733?&(#G81MU.FV PB.]N":)9%/9(.1DK>9CUYDP
M8AR*H#D\GAT+R,I#&LNIS$$AT4?0EFD]W"FP".E+NJ=TIP-Y4S'A .\6=6J+
M,Z[9[.F@+912&:OS(YZQN9Q@&(^RH)EVJ\J8Y%(CKQK^/VR1\K9%-CAX*65Q
M;GK.R#X(--J[':=%0PN2.Z5K[RR]1=-8Q3RSG^KNR /L3K^TQ&_OVK+>TQY*
M$JG8Y/Q2X@\-%,5O,7'Q/&Q6*%1DRD N0$:\Q'VN+W(6)U\FYQ88:\9$MQME
M3I-.LGZK[+P>[&<<NQ;)'4/-^H%%&8O$7TCC!*0*II9I9$HTET2Q.C4YDXB]
MM;<Z 4@W,;DD48VXB4/HYW<FQ%@R0^V]):8\4+[&- N,Z7:UF,O%&M5Z"(-;
MVN4AV.C2+().%YL>Q'.6R:%D"=@"89V'\>.@R0IQD39V*.AE,F;FT;-<1&?6
M% !EY;U5Q =&Y]1ROKI.D73IKZ=:Y1J^Z^N+E"A23&AAMT^81K71(!2((2LZ
M0[E;#Y\S7MRYW-3D(3!.1"XJ2^QL08T*MQ[\X=0O(*QIC>)$U0V: YV>)V:M
M:X_UD=&,"6G$P2L_B%L@,V>)9(;SK)!)A&%H'B?# HECRE-PG'[2%G:(ZO82
M447C]];H3TG-I0/!N#:(#G3E$ [:T<U96.VMR.*2LJUZRJ-='PF92.#)$:"T
M$5J#L-F:.G^C@][&-K((2:(2"B:,[1%;DW,>!R7^LR=$N0WJ%,K*ZXM:&US!
M=PAC9Z"-0'!RFB5]+0$5;80=H(D*%['XV3-<CLK1,C<5$\G+WH2!&]AC&4+!
MER%X^?43>0VE !='J_M:Q[(V2J-KP WA>98%-D,>S9"LCYA%<6@A"]B+&?"K
MA@>P,D+@HM#C8*(V@E#RT9(%J!R29EC<OP-)"S/;*W8"LG5"90TW5PXP!NTN
MW$R2QN+O/"43A[4#0$!XQERU4<QA:8!:@GN/1,9:H>#F@EP80V5S]1D+2%$E
MSV&:?"3+6)N=<E.GCINYZF"<O9B,&UIC(BE^2,!;Y/=60=8P1Z$## )LXB,#
MJ\[)6EED"8RBMK>Z/[R>F#0.V8,C_8*C JQ#C BHM@6%>F:<1;MH![%+Y+$G
M1F$=GNIA/2@=1L[Y@=%;3O2IC3.*,.!7GOJBQN0+:"J[2)5DI\4<ZKDU6JEO
MP67N 9\:G;.BNVL-HI:&18R 528TDN,#B.I"3,B<UCN4(<D(BBV2P@AR##V2
MBS@K'306=D6%X&2)Z8GE!1(Z-J_)@54QXL$XOZP0/-$/B4OQOJOM*ZI)JDU-
M#>JP:[-<0,!KLZ?-[8>N\D*0)N62S>@%8SA]MCDE<S^79.<0T'JUMRE8)+BB
MMS?@<LP],=;'O6&/Y2#GTD:B=0?[5[9;!HUC0C6HL#>S;$[!G<R,H\IQKJW9
M,KF.MI:G9G17AK1&K7I,ZA%;1-DQTI6 5=&]]<M)M!X/5+('E^6-#S$F)FX>
MF<>,,NO\T,,A-4B"AZ$%.)EM7& ;G4,)RWOH<>MK*3KQ,T$&Q1G&'UE<')#>
M 3(9=0HM/SG2L:C]H.((,E?4PKIYN'"$CM( [&8SX&ENP&P",/6/(^Y' NN'
MBK"U1/)P7(<<D]^$B&LJ9/C=$>2XH'4TMAW4LJ_RM$4?D^H6TD:"^R;[*(IK
M-)$@MT1#F&7RB)0<WD9V95<:.$JI)<B:\T#H\*'Z-W"6@P3:WE!@;LI*K#LC
MPVX%$!PMTMC,&:]=W)5BUDAQ[C/J!.NY91'^ML<.0Y'[0*V:J2YK.)QX/D[R
MW(RF4#AFM/VPO=98DYD;;G?+B<1QO%& 7;A]EQ8Y0/TB]GXGFS2V8G.FF;B;
M:HS*X$\G3A53/)3LAN2PR#&4C0Y)LFRE)IRW.KD!GE!\X\H#=$"%;(@ 12!B
M1MM)! A(:9D^< [' O5P/#V%M8-AYW YRC@G*0GJ<F[AKS$@!!I..3V,Z9JL
M.>Y4@=G272XT%"H78TMX^&L;>4,-D@RNB/L) F11Y2.7]]L)E;JCZQ11<-*E
MN<U+V EU(KN?@(P(?1D:)/$Y 6Q_'\.-5K=1Y1OSO(6Q1](C:&P8(,#6YYR]
M]92;"K6,Z=IJIS8N:C=,V:X8(]-5,J&<0/(_IJ7]1E RI@_&8N2F3XRW-+VL
MT"UI"D)&)I0BI>,J\Q SF0\FS% \J08FM6SD"K(L6HD45B70WR(]1MR-:C:;
M4!@\3$NB<"UM+WH24/;/"VL6HQ]CE'3&#3$64KF^XY8P$Q5D5),P(G1K3G;*
M_*TB3,VJ;$RE. 6;:\;GTE^62G7V4H)E76">A^.F69FR,Y7=8L*,YG#[\1K1
M#&;BI;#1_(X<KR#98CL%ST76O* C$7IR8[\J-P8B!D?%\";']1T=$9#VUUM$
MHYV22DNM.L1+.LT;&QZ'Q"^@D!B#Y!TI2( EK?AD8[0)S>0W%WC]4R!4;*11
MPP/1-CQKR;"ECAN)B-!Z;I_:!$VMDPR--1C#VD\&+B.-1V,&$'U%"B-PRJL6
M AR%AB6F$QR0+B9TH1D#M@9$@]$[,RI1$23,N1X<7LP(73&M:>XR'H26FA5U
M3B!,>C:+#U =9(Z@@/3J&MVR98_=@J$IIBM4_$MV*ZECHW+5\HH'5.F:/!5X
MT;6LP9:USYL%: '5&3J:I?AVX4C_ %ZVJV=;8SC;6H@V)EN/Q&)LC['V38H#
M&S (=7.&FP^;I$D)[O%GM)(4E-D$@A>QAK,K781_,0+6=P8FZ/=;>I$Y+9YV
M1UR/,Q=.LW9NH?.L10I$L;L(.G(XXU@C(+@Y:]2M(JU4N#&4;AB-WXY<$KD>
M%[LN+2XF(6L$!T)P5YV\?P8[[$=(G8Z67,=;61SU&HY#D0:[1G#^WUC+)T2[
MGZ=YHN"1@2.LL3%\3-*=5.@\XD#$[RE'@Y*TC!C<.$QD_BI"E( NF%'?.=O2
M6?!&598VKB@SC<.W!>>H,0[:1_+5PDYWT>X*-PB.HPD+4^9U::MK^31Z7@P^
M69TJ=MSY6T+D)6)R(-(,;ZT.-7  L)VGVY8]:5,0AS=&Y]-\U[!&;T#0O"L9
M9@U"4%K@+B3J<F9&YO\ (92&!(>! @JTY78O+2 @P8D%5K.U-J!X?7MK:E57
M^P_4RE&2D&C@[KC'NQ<7$LK=1]PT_P!KAI SZR9YBA8@B*-9 DHXA)9DE,X(
MHMN=CI&/CQPW2$'Y# ;?(!1D[R(%K&;D\>HW;/;<G6.89-E'5;9;74BCI#-^
MJA5*'BX/F&XI1QC*,7SB"X@6309\) IO>RD'?L5[2(&0>:M@T68F]\%+6EU&
MG%G?%UR?&&,>FQ,J-UAV6)9E2/7*:OI.2[J.SVE#64DLCVU2^ZJ2!JJ,P_$F
M9WM3O^9K!PAPCC!:6EZ)O6%*L?)7M8T-"AZ0-B( L1V,GU[@QC"K0Z#9<V&D
M"23*@2&1[$S>.X,GQW$//I6YD)N=G+Z*1S&@,S,8\NN5E!F3-^-<[J6,5'T;
MX5/[4T*?6:E[4#.V<<D1LRA)S&9  RM)4&2=&TBVBF4J I8B(DR"9V,JW8#*
M#0'(DB%VQVY6PC$BIZ9'AM4)U6!1BSU4(TV.G45T_E3:I' ^4#S1@=C,5FY0
M02%K5.Y5)@5!LYHW\*6#@TM.7R*VPE>U;C%3_DL*Q,;(0LN"7E>M6YW1L;W]
ML&")G_/3+TZE72F/9UC*05,$JA\ZV7DR?(]QP*.DP$*CK5,V9J+"0!QQN_8E
MR,.: $LM<QL,HREI+B(!1,W/[MC'GI:M8DH!"V7K'CBG*)O ]IOMB01M(^Q4
MFZ=Q?(Z;#!")KD3:6.3&1@BR-F-C<9I3DC>+E+U%Q:G:IB)F]BC-FS-ZE.6O
M3%>@<;DLRP=U/XRELMC"-B6))BAZ2#_83834]]&SI.!.#9'.Q.NH FE9]CDD
M, XW(!QXO/XUO<3.+'\.5$#,2MC(ZI''.Q/&).W*(R%^FN;,$,ZDQAFDD44+
M]=.IG*F]CTZ8V=ZL2$8I($S;32<C!6O#??7.D(V]!/[.UJ7-;6K5E5C[EFPV
MT3JD=*8-=1'58ZAO62?Q:,Y#=[]RMI>J@S;8:"+HU"BYZ>@>9".R(P:N$CR)
M6AT9VIF$XL;95=I$,B!0UB34$.+FJ^%6+4EK:L + 4O5F I$4!X[K+KS/&SD
M@'^78=_$PL"6PL)570YK;,BJ!R>=EA5*$KAPHSQW(DE(5@]"&%R<\);)>3%>
MX8!QH8TKD[M_M4?59C*2!V!,FL$)SCLY)D^Q>932W0L&)XVC\ZC2-XT,K8TD
M=QF!QF20@('"2(9E>Q;$"<-H5.CZ0R4UO34S8<S /D).T]!4]/F8M8CW7"4.
MG^X0EF50MI8W:*$D7;&*S\?$"V.0E_:S>*Y(;#>-F4P(6@\%37 3J"EK<!AW
M;I&9CMXM5/@Z^-C<[WQ5$?34VPTY4PG*NLTH03+<Z-L#S'#FQ2/81%( #')\
M0S)L@>;@J9/CU=&C6:D@C41G24Y%;T\?NK4YHRN-B%N;%)8-$ VE=%P!D\<=
M37$W  M)T3Z>;:S4&J]?,.STCN;<*1_$E(CC2BLF0N(X399\D*,VU]FIG4!1
MA<[0\&N3Z0-B$?JZ.BQ V$06J)OYJ^J_".>58[C05C6:RQF,=2HUWM+YA3L
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M_"OZ<=Z??^%?TX <\<X[T^_\*_IQWI]_X5_3@!SQSCO3[_PK^G'>GW_A7].
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MAO6.SJZN:M.A;FUK;DV5:O<5RQ3DQITB%$CP9E2M5GR68$Z?#ES9;[,=EUU
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M.1^: +>I1/QGB*2(P5T -ICO3[:>GMZ?K^S_ )^[G'A6]^WA4]/;TT]/V?\
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M<D0)?D$V9<F;(B"%F)6*)[U"N[&STN5JJYI>4Z>ZLK+9QLSZ_P 2WX]EA$5
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MKN9-K*TM;2A*EV/.^HVIM0MV!PQHDF#!9X,5 FKS3A;1&%@^#&_!K(YOT7M
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M2<"?D<I.DL,1NSNZ1[/&[.1IKKUF G3QAV3CIIZ%P6T;03( K2/2OJEOKQ)
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M!S .N8NRBCTC<U*E+8-MC,^/>-&RMF) W8'!]?7JS!1\>7-Q5:ZD=]5X^C&
M='QZ.F74[6<*.]$8%G&.&S<65YZQB<^%YHN*&QUUEB/:,Q=EPV$ET<M0PRV/
MLA3Z6GY@[.\EAF;+'JH=Q+RI5)0KOT7QSU-=VM/H\3MA!.\_[J:[HPK-,#R9
MH((A>-\/3GU^D,NM6$S*C6H'F1##$&2;CAZ$ MS:7R22AG)S!S7#P:S/)"J
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M712$,38W(L:91BM;XX 5ZRIT_FHHED6ER%YWEC5IW;8%&]6BIKAMEB%<W$T
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M%63$LPY%<< *E1CI-"<-,,(V:N;-;":ZG\+PJ]ZYUDT?3PR?.\DPR[G[S*"
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MZN^_)@;TUE:8Z2#QP <<<< '''' !QQQP <<<< '''' !QQQP <<<< ''''
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K #U%_<X\M$3^L0/\_P#_ !U#_<XXX]I7DR(RF68^!)\:\,0CA5UEX#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g997105.jpg
<TEXT>
begin 644 g997105.jpg
M_]C_X  02D9)1@ ! 0$!+P$O  #__@ ^1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?5$%"3$5?,5\T0U]40DPN15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@!6@'@ P$B  (1 0,1 ?_$ !X   (" @,! 0             '" D&"@$$
M!0(#_\0 6!   00" 0(!!@L&! (&!@8+!@,$!0<! @@ $0D2%A<A,5<3%!51
M5966E]35UAE!6'&1TB)488$8,B0F)Z&Q\",E-392DC=B<K;1\3-"1G-V=WB'
MLK?!_\0 ' $!  (# 0$!              ($ 04& P@'_\0 1!$   0!" <%
M!P,"!@$%      $" V$$!08146*2T1(3(5)QH? '(I&5U!87&%9DL=(4,985
M00@E)C(U131"0T9C9?_:  P# 0 "$0,1 #\ FG8_BG\\H*PCJ#B;URUC(<O(
MHN.:^CBK%_B[%C+.FS5#X9<-475^"03TT^$6445W[>5OOMMG.V<+_:R^(#[_
M '/W9U/^BNN* KFIRODO?AS?>@<XINIGI3,DT4=&+@&@"(@,#M,,#X-6>8YS
M(H+I*/YPH0T9IJ?#N!ALT<^0V=J;ZM)7P\P*,&R5Z0&)TR>1=A7,-,#2.D*_
M5K#$=7]LUX)UW%.D'G<O?DET"![HZ$'$$I(,&L^RT^-M7;;+MBC]RK]V,V+D
MLWSC1.9"E"9'-1*E!4;FQYM^52N1E*764+)@W7)1)V#DTHE):!J5_4)&ADWW
MW5-H^!6U]J,ZM/SE-U+Y^4PJ53H92<Z33JRZQ)I'*TR5M]:52A++<GE,H_42
M>3*)RI)S=+''R88:0XM7?M9?$!]_N?NSJ?\ 171^UE\0'W^Y^[.I_P!%=,6V
M.#U"U6W/W\\>VK >:J2T4Q&R25JC<C2?..1:M&#5E3BT&@Z8:U22Q"Z=B-F+
M=NR+$(8=(6V'*OQEDZ9YI#>''3[ZQH\:DCVSH6"PH2Q4G'R<Q563)^SB[6#J
MU$[J'M!UD5-MZCL=H2R)2.,'<-L[C&< [W(#AE YV(\>9SCV1)DZ94JB\R$P
MM3Z&U^RD@/6N2=EA]UMJJ2GK32B4,U.(K94IQ!)=,EH-7J4@[83E!R4J5SZ;
MZ$R=;B/:Z7D;3<I>=89<=KEA:LC<D[VDVNIY"6G#4T6K7HH;]K+X@/O]S]V=
M3_HKH_:R^(#[_<_=G4_Z*Z:[+AM1-;[:2YHZ/K$&TZ;N@BD"U*9JJ.!RP@@:
M4L@PU8U3'M23)LQ/*J)Q..AI'4JCYX4<$SC+>9VC.T9#SM?'(6N!^I;B,@ 4
MFI A&H;S8?0<K+[1BDLK&E04-&3=I*K0VJ<2XDHG!#F'?.H]!JU=N6"CE-DR
M^%RT1V\SR3LTGV6KD4WT1F!:DR1<L0\Y1N:T,NM-2A,F>22CDQK;>:6XPIQA
M]#3J4O)2I"76WVVM//$N[3YBD*)=.%,:0H0<L1(5LMTGG1QYIYR3'*F5&DI4
M27&74-O$V^PMUE2F%*2LVG).X[+#]K+X@/O]S]V=3_HKH_:R^(#[_<_=G4_Z
M*ZKHZ.NG]AJ%?*%&/(9K]*.7]O*<?.5*OY!.WJX%X"Q?]K+X@/O]S]V=3_HK
MH_:R^(#[_<_=G4_Z*ZKHZ.GL-0KY0HQY#-?I0]O*<?.5*OY!.WJX%X"Q?]K+
MX@/O]S]V=3_HKH_:R^(#[_<_=G4_Z*ZKHZ.GL-0KY0HQY#-?I0]O*<?.5*OY
M!.WJX%X"Q?\ :R^(#[_<_=G4_P"BNC]K+X@/O]S]V=3_ **ZKHZ.GL-0KY0H
MQY#-?I0]O*<?.5*OY!.WJX%X"TJN/%0YY3UCUS RU[9=Q4[88'!RK7T<58A\
M:BYDNA8N2:_#H!J:Z/QEB[<(?#(*)KI?"?"(J)JZZ;Z^]>'BA\Z1&[+F$1R\
M=H\?%+<LT9@8_P!'=7N_B$(/G$]$1#+XT[#UW;GXI',FS?XP[77<K_!_"N%E
M5MMU-JVJ@_\ I>J+_P#FS5__ -_AWJ: L-UN1\TN8N]ILAAZ,BR/,\Y9Y,8D
MA(1U@4"A9-/1V5D!H4G1HB)](]TJJI@>B)ID]E,;;(H[YVQCMS,Z49H7-DXO
M2ERA\PO2:2S!*Y6J22>89L6IUQN6R1"3;8_3DE;YI4:$&1:9Z1I37I5'U,U4
MHIO.DVLR9NF=(&)3*I_DLD3+)12"=$)9;7(I0I1./_J34A@E)2XLC,D$:26J
MK1TB_3]K+X@/O]S]V=3_ **Z/VLOB ^_W/W9U/\ HKK+9'CKQCMX;LFY*RF"
M\8"(ID;Z[;#Z8X, 5;S-34\-%TC)%HW8A$4V+##?(8[<S@M2D*WDY"1&%TDO
ME7<F7U4@D'";<!^.,B2G4K#F9N!P"EO0(6,P,(XB"^!"8B2Q3+>(:ETT]8.W
MVBUE-[!FY\1('LTR;1:;%KC$,5,]);,9IW)=V52=;34KH7-LE>6A6M9=HA-Y
MO25]"I*AR22AIJ3..HE*%RDR-!(46BPI9*T)3-YRS;MR/M8E"'79)3>=)4RA
M:-2\U3&<4LRMA:)2XB5R9UV5-M.292),FIPW$GI/)1HZ<EG I%'']K+X@/O]
MS]V=3_HKH_:R^(#[_<_=G4_Z*Z?E9\1>,#B;QHAJ7FS":FZ85BLGQ*+H+"\4
MSYP3''.SW$U&B&(=C-01.,0*<_NENZ;N8" F\)(OM7V$"#3S:_X14NA7D1:Q
M-+R$M(20M9,RZ#I64A]PQ9":J?D3/ CJ"<Q+:/?LI,((JW%EUF:Q<3N%GSU"
M.)8H=>+-HMUYNSGV5-?JR<H7-23DKR9,2547F@EORE4G6^;32";-2=!;9R9;
MCY--D^9&2CDYD^<VIO[67OTFA3>=U%*F52DU)I7.YH8DR90VSK7%ZXDK-3:T
MRI+;!O.')R,C24H2;!);]K)X@7;OZ?-NWS^C.I^W_P!RNN/VLOB ^_W/W9U/
M^BNF?Q*H:FK!XQ#Q8;  [-2\K/<EXTO-Y6&(-<B[(0JT>F:WD)BR8^R1R(IR
M*C"EXZ=_+$C7UB;$VGQF*1B]-D?_ $WG%G"?CN QB$U-6G:1+'1-(E5IR6PZ
MV"XU&P]1Z*JM^QF*RGIB%4A$8&8D#Z3@EHMQ@K>,%(M!^B0/'3>7@V_NN5=E
MS4YRR:7J%S2B5R662B1))%%9M>1*'9,]*&%ZI;,G622-<GK3KM7I-O,K(]CY
M,>"&.U1V;)'.S--YX7))5))-+%&JEDYL+D[4I8DLH;UB'I4A2ZD2BI9LDYHN
M2=Y!EMDYOX#^UE\0'W^Y^[.I_P!%=<_M9/$"Q[;]VQ__ &SJ?]%=2+'. /'
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M'R<DTW2F4MII9.^ND"9U89?D")8T3RG&ERA+IH;(DJ,W&E%L0N3+?4'[67Q
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M?V!*\X]TU3\#?M=V@2C>VX)2T>:$I,R;V*1"P*7L)>5GTGR !M']'L]O6OM
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M$M!/XI#-0!;'GBJ</ZNW25L<ALX'AW5?O+!8SI31-P03&10CZT=W#(BD8QE
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M= !T='1T '1T='0!$[E1?/'RFXL3C[S@7ALH4+DTN/!4'5LK<1%O# ,)K-V
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M@>/(Y(),W&6>-FDO\F\8JMPVEM-=EFSEI-.=4]MII?5+Q^*/A\SM"<ESF\"
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M QC$&5KUPYY=6"2SI_<L-Q3OL2+[[8FXV;;SS4*L_D(5TN1C@%B;B7Z+FO\
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M%QDPV&P#8CZ.J Y/QKGJ 1)V]!U37A57(]#QHQ)PT):!2E9,[:TIP_(N6OG
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M+3B \&O'N8FS)2A-G-+2EMPX! 6VY)I\7&3!,FJPC9RX!?)T=4B1_B16U;/
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M*K\C);$HX&%+Y6>STA*L'X-54+-1$+OK!09&&LI=^P?+3PT-#Q3>"VK=G/\
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M8[/1L9 SOR?-,GL,)F(I,?(Q+$KOA2Q00#-(Q93=5P-[P;J"GIM"UU5'A:G
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MIEE*1=GZE<!/RAILNVBGWR<A:&#Q=5@]I)FY -G;.4]?^;.F/YYUQ^_M^_\
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M$_-4N)#O&W#PNY1Z545<;6DC<K6/'R"J;DQ=&PD76[/M*TEW-4%,<E3^SXL
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M),@ #K:+8P)/;@B0EPVT%IJ(("6'3D0)M%Q3S=>::29#.W.='0!2FCX(=$+
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M*G-Y&%4+_'E$.[>\2RX]'L7WI\HWWQU?]O!?\TZ/3Y1OOCJ_[>"_YITP?-V
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M"6'>[1%9)NJYT:YW^'V;IN%T$%%M4\I:++));;X44TUV .WT=<>5CY\>O_\
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M%!U7LZ=4[RF>% YR2H$N?"2<"85P[?$X:I>MT7GO>E3EHXUR_>LA"1YBOAY
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M$)$.1AZ2T_LR@2=G.C1'&$<6_<BQK%RD0JED E:6>)5P7"9!S%D/)6N6[UK
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MO9H";#6DZXC)=&2)9?& _P &&H8%E:.\Q;UB2DY<-:WU6Y<Y@QT%%(-BSO\
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M^V<EX^--FNT1'U[6.]=[.3=\JWDU784B=$24D/.P1*/*0"/%E\;/%8UGYUT
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MQ8MZ/[;2_1T :WAOPWY\3"M;J4^.651=>QC:480%:2/+60M\UK.YEYBF%?\
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M%)X65X_D4K!-F1A'ST3,?+<T-M63?>2?*KW$='0!J]2?AW<_"L,(*UL!M/6
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M/6CEO\LCOQ'6>&N#I9P&8M-4_-;X?Y)5J(QDB-TCEQEVI8:#*53>)#Z:PTN
M),Y\4OB0!S)'!.Q,G/8]E&SDQ%SM+UW)7 -S8I)DW%"'T<.Y(1''$?%2AA)<
MHJW(4QE==ZY?C\>TFG2RTC/!L7*.,DY?^']+,">')" *(&6LN+5LM!NJ:,";
MTBN2$_)H .A*V@TZYDE;Q@I6TADF'H%W5K,Z&UK(CGD"U>8+M]&BRB@?"%I(
M0%D!4,MZ]AQNA /X+Y03?5=+OU,Y%N($"/2F^LY6$C'_ !\3EN$U/ET8EJQQ
M&R4P]-8\D83(W-Q\-"]>J?!SXV5&5CY*.D!EHF#V;7%D@$<R':='7$#FMS@M
ML>/%YTJ&:PB#2PH:3)S%TA(/SHAFR-$:@!.$CYAJXC9*6F@"1=*<J.*U_619
M,I6K!O(OJDJ>GSV1NF1KQ>"'9&N+6@C0C&$AFP)J$8.W3<=8CA&D4P'QAJY$
MY121BI*-:2+::;-5U+<Y/#I5'S^P)\B&M4RQMYJ6DUG:!LQ&PI\5A*I7MC#^
MQ*]E*HTLR2J:*IQ\N<:G14,+U<Q!7^TKH0)1;WNKF5'>'[7/'\7/0H#LRYT!
MNPJ6C:9DD\D@_$D,(E$S=MRS(_$C,7%8$J'+!;HW#.1S249RN8J-U@QB6BX9
ME/LY&5E*Y[(\%F2"A(@SQ<L9[I:=EP)B 'I^63-=5/F$"C'CXA03Y(9'@'C4
M;B4LRG6L4-F5G-)@;:V29ED&@1#%R@DBXDVTJ 3$WY#^%\)6D;WDN65W"'4)
M3T# S%ENQ,V:C+.MP-)^39'J_)EA?4#4)A1ER76>V0.U@]7L2$BCZ.;V7&M8
M]FQ0C>E4/*+@'QW% BHZF:0@150*+-(L2@XX-L-W;+8Z$S;?CEK7[JDW@*\Y
M"S5K-%A]:$EG4R/R!^^8QZZLN@ZB]5);;#OV--'R0<VK@FMBXY2N8E"3FQ0&
MC5@2'A JU#..$HZT;3&WZP;+%RLH=)C,GE(9*2@E%1+0_.M("-TV<BZ@EEMA
M^$E1QO-V^4MSVPH^>N4@*"(F9$$#3MF@:JY9;D-<TG$R%<656)**D8_H504?
MK'L"!L^>Q235E*1<HR)XR-G6H!D!IS;\,H=P3!Y02UV_:S#]M917#1U$&IG#
MSY0C6HM?F)F43'*LG8@AL6+J*7'KED&"VS\]@ZZCW]A23)B."4[*P[=M?E1P
M>X\3$83609UT(R]QC,!:F"V."I(@V*@H<F103'+/+"T,$YU%L%C<X?!<%&V
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MKV]>,X]>?7ZLY]6?]N_K]7MQUSWQ\^.FK3>QKA>@0:1W<*<H?>TPC/1A9?\
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M\<XJ0#; 5D15':-GRIE74*M751 ;P@5>DM8;1G(1K**U1'2FM97<"N;$'H=
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M%X[>N=U7+A97?O\ DZ]^_DX[]\Y]F/;GVY_GG]^?;G]_0!K#USX8%TB5+\*
M:%JWA0U,)M]J<VJD3<&['>T[&/(CA9,"4/&\EJX><J)&7,[-2LB;?1$?:#4S
M#&T/(O919"MW\V]V3T8G'*8YJ563<(Z/E13D-Z*T ](*O:LR"ITFX2-SSFU+
MSC;G42L6>KZQ0V>X[5]&*"473<2_O>DBR!H.#JN1KQMR.>&I(/06QKVQ\WL]
MG^G75>,6<@T=,'[1L]8O6Z[-XS=H).&KMJZ2W0<MG+=;3=%=!PBJHBLBKINF
MJDHHGOKMIOMC(!"WPY)XN)N%]&S!@N_>K+0A(U$)24W56D9VI(H]+8BCB1^Y
M<HH.WKTDI=@ SKE^\3^./U9#+QWNHY754WFYUUF3)I',VL?'M6[%BQ;(,V3-
MH@DV:M&C9+1!LV;-T-$T6[=NBGHB@@EIHDBEIHFGIKIKKKCL] !T='1T '41
M^86.-ZP?6K'D@E.88/[K!VU3/Q)W8,.;1-V:QY.[#'8445>^BC,4(746T*(;
M67C)>*1=Q<K)CDBZWCYYPS=2XZA3SGXFR',"M P CC5D#*BMG1E@*R3Z#<3Z
M3U&/"; $MHO1JVDXO=!550U2>X=;+J:::1ZB&4-MG.BB0 EASA3X;2($(3;$
M.'(6LX>M9MK!"Q!;UB10) PD('D8P2%\D#S]C:#L7:8 'GA4*R]L2D=I:E>1
MTL^AW!=#[,FF&7N"O"_P\MB4-7'V X1&<PWC[<^.+WZ=%Q7>L;#EL-8 ^?W(
MN^LR5EN3<"+F2,"4B<[;V+$@163TC74 M'([I)*Q%E?!MG'(J7PC._$$-&0K
MQN=4R/L!&1&AP(LRNR.D37DO)2KR"(=9YZ*<L2CCC53XA9QJS28!GN2Z:9.2
M-Q/N8]62' OPY$>(Y]9-K%,^&FIK9 *"#+9>/'R!V_KW>,L:][*.H 8-SN?)
M2YV'DLM<,8BI'ZK0+-\^$]YQ> B])1E P0 J:IJ3PA>0@"U*QZ$"YH1.$;B9
MUZC8UCG$?(/:] V]F 9LXI 9,S[$\,T@+-R"RY4,C:]C(,&"WDC(GHC$CLPF
MPFF[9@^-GAD3%'C5U).15Q3MQ-IL]B;?,.0%F,T;$?<@TZHG79=-6"9V<TF9
MXS(Y.FJC)QJ3GI90L#3FOQTF#LC)E#;/4X=BG@P'PO.<=XE*Z*V4KFE2VBS-
M\V85A(P$W+9J.[+AM$C$\,H2891Y$RL-I;*C!K/V'+%"-=)QI!#C(8Y9'<G*
M1LB+4\.NX3OAOQ*XR15FU-#R''H'=5L4/DJ[F8\:*HS:CR>C(,M&7$=*;V $
M2,+'SB160"8\50S:R,.2  G#&'&9=5[D =$KPT\/F4FH<2GV\3*E==,6AY-1
M4KR+LEV9D,>'VXG?<:97AJO:N26W&0E<KOTC14[<N2U@-E$FZ=L5V",HX;+_
M )D 1X<7-Y>V[D,(2L;895EM%<<+)LD@EY%@((Q5>FU6<I8,<3),S<8)3@Q$
M'CVN3UD1QCEW&N)3"D*I*+M<34.I!!UX'LHZJ?4#VO@>0*EYHM>S-@-JS>)R
MQ+!3? ^I^([$,)<X*]).;#'9;5# Y,AEY,YCR0/EGX1KEE(82)-9'0_AHDTU
MQ=Y14;8)13K"2Y3\PA+E(30]?5E)-:G&XB&->.!+/UB@*SDRHY)FY-&T5)1T
MT0O](MK,R1F]EGHPD@FXBW( ]DZ*\.A\?IV(V7J50VK$I5OY\]87>^3;#Q':
M-@O+F8V46CK.Q=!]=N0'QC(&(=*EL0YAFK@H>8#OB<;.*M7631(]P@!1.KX)
MDT!A^L>.:</==/DL@2.TZQA'=]1UT5TRE14]ER!09,GYC$E=HPFT(XF)Y%1H
M7M=V['X21@U$:EN3WA%<A2"RG5P5W.4K8"45R!:$8C3T@ ^;8;*UW8?,3B=<
M#MO8 VT(!BOV@]15?48XBIQL/0I =W5B*1,W<X@7KM@M1MLO!]L. ,H^WHNS
M:8(31*3U+'M1&M5D4AQPT(3 CYTRQR.Q@BU*?E-L @R'--16EHY351]$R@),
M.YC+7>R72HJ 25!>)GAHG=-4A8XO'N1\%MYO4IQQZ+7MZ7=6AU'1TD EHK3H
M344[)68/V%70U$ EV&@J&TB$OH,8'VQY,Q,8&MWK[777@_XT^%,-B4WR$)8F
MK&=> \+."6[@8MXF;5?$RH514_14LP&*\#[#;5YK<3*BFCRJ]7\ />E94<@!
MZ 0?8<"P_F-\*6\*UH541P(HTJLZ.6:<,^,-A4"N3Q0.FC*RI(9<:HN@86UZ
M[0E):22KXE!GC)<S%MUE9I_&.=VS%K*I*H*/EHD[>"K:V*[F(WTK4Q+F4N%G
M=.N(8Z$+5L.HUPHSXOPO&72T-Q0E/E5V-O0D; HSL(RA4XR$8!\O-U&X(Y5L
MLU/4 "T>@ZBX6@C0"NJJ'2#"2D0X\(XX]++:L"3-"^#M&/ [+L*<M9]89N^(
M+ G]HX> IZ6EK6TGB0%8Q<7HU=#C'3=%1+:5KX9,H7U!6(8E 3).!CU>RX2,
MT[8]C.T7=7V_;Y:8A+H\5KTTUB[,I>3N8#(B3$983HO!X,E:H/',>P;3[;66
MAO*>"];DMNJ)+\@ZZTK*!=669BC96L25^4$1[:M8T6)$,%96%#-L/RE1YFZ0
M^)$ K&M-)D]K\^G1V2F8)_&X>S;*/O"=LFVY+:8(+(HZI'QHX$IT^6X]TR\
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%HZ /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g1011603.jpg
<TEXT>
begin 644 g1011603.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ ^1$E32S$Q-#I;,3A:1D<Q+C$X6D9'
M-#4R,#$N3U544%54730Q.34R7S%?5$%"3$5?-5\T0U]40DPN15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M^D$_[^O@\'(]\1,WU6A^XT>#D>^(F;ZK0_<:;W=O/+CD;2^_NY%\+2_2"?\
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M>]JSB.7>U9V0B(CEWN5]D(B XB(Y=S\>(XCV(CQXCCT#T=&CO:L[$,.]JSL
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M&WHTZ8OLLAP+ <A$5-[L_:#^=/MP_?K57M;HBDOKCF(XX9CB'$0QR$ Z^(@
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MOD=K3.M[ L2H[>CGA5'71V;V>$N<OBO:V3)0_HR+]%?L\?&(?KQR ./5P$1
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ME4]  / 1'^B71P'H'Q#T:R&S': /5M9VWCT\.BBZJ'I#K#HB77JB&Q;OLK*
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M(Y16D#D#^Q[C93;4C=8Z\UPZ2M@5*S$E>5I%\1>)-%W'!.\V18<HB9.&(QF
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M-KKR[B/I"U>M:^8VP*N..3J3IC"#5"7([-,>8],IAR?-04)!^1!N9^1A.1Q
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MO"/+MMS_ "J,7(6+(XL220.1<1>85)$N*AI:UR=^+;P5QPUV1K$1ZB2^8"(
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MB.!7;C<2@S-[5@(X%=LRR[5@(X%]CB(AKOYV*Y\L6+Z9_)IP0'$1X!V7O_\
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MUB8>[Q,?Z!>"^R=@C)2<Y_=D324J-S)3F+3@)Q.-PP[9F7@/ >.6)8#F(='
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M$!#O\'3T=#8]@/G!MXA^L.G1SKP$.I^#ZK>OPS3796;B'-(&@W%.+HTW7.O
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M)S6\OJJNHS#W;=(GD]8NS3%&TBV_> ?/YQ^W1P#Y_./VZXE\>QZ?^]GPZO\
M![/+L.'#HX=AV/#YM<]$6. ?/YQ^W1P#Y_./VZSH'J'W]$7'B #P_*_7^7P]
M\>OJ][I'CT=0](AI"V%9U=5-'<Y;9TWC$ C):Q(W"^R]\11]LR<%XF C0EJW
M,].6<L4@2?F4E)$P_(H@\X"^U$'9X:]5Y(5:CE479_*<FC"?,6Z?:Z@B5;)8
MA,U.[N94[[F10VS694#:)3\3#(CM(:WR7OJ^V8BLA#TPO,PA-P>%=I1"6O\
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M+N6;G/\ T18X!\_G'[=' /G\X_;K.C1%C@'S^<?MUQ$<0XB(B !PZ1'(.L>
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MPS$%3JU(TPY@)F' H#A-SXY98%Y!CF(*W7PHG%N<0-R;UZ-=B3F!9V2160J
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M!2^]/3^5$)MD/BZ\H^(\.CJX\./'W^.EUBL1YYJ2\%).9B,0!7AB?CEFE'+
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MJ)$Q0*8UC<P((\JFE77P=&"G&5RU\NQ\@U-]E*'6*P[;=&Q8^(<.X)KU<.B
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MRBMIQ#[UB=D/5LQ9]1S/<]>3P^RJ)W] K,?4"PW:U"T:IM<XM#'%/,H8Z2*
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M*Y3MO<FM@*=,UB\MP@V&4U;R$N)JQ=$ \)TB8YC$%XLON Y3_:=1U.(+@:K
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MZ_HYPA\A[#]&!]?TUVT^!Y) T9V<PJ*8[R'TOQ@>XAEL'<PRS>;7SM5Y0*L
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MH4=:]FW0_F1*$WBN:YKLX/J:&94W5,?M&-WC9"R^FV9*J$ON3/[4]F[>*Q%
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MS":,UNQ8Y8[0]/12:U4[<<_1Q$WY48YL$E=;)-V!, $,,0$  0QQ 0 >( (
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M/:BLN'889\<NR,$,> =>DSSA#Y#V'Z,#Z_J%P!@3X%6!V;/;[+X>93BZ! !
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M0/5VO2).<ZQK)UIJ&I%;JL*6GM:DBGR'#WN'OAT<.L!X"'1XAX@/B'6=8
M  .H/G$1_:(\1$1ZQ$1$1'I$>.LZ(@0 >L ']>L< \0>8-9T:(L< \0>8-'
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M6I=:Q5W6N3$G1,TB>) 2VMKP120CELU7+ZW*N**V-!)'4Q[&YR8JS&26,#G
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M2C>6R/*D:U(8<U75W7-Z>.1M1% \>:EGX7/W1_R93+\GJ_OR"]'ZOZ8]'[-
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MF5GV/':"GNY=O/=HI6<@<GV9E1YI<+DFM+0)XFUD1J'%0.#,MGR2%J<8$\6
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M(#64R$!Z! 5L%$!#Q" S'ITOM&FJZNZYO3QR-J(H'CS2!\+7X X!6,R   0
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M VXS:&/4_P :6=4TUC5C40B:D4DK.Y)*L=*[WI%KY"L=+ VUIH@L:YZQQFI
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1$1HT:-$1HT:-$1HT:-$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g1014474.jpg
<TEXT>
begin 644 g1014474.jpg
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MO8=;UO?;OK+-@@%+9,P4'1/+&%  //I$D4^@QS,1S.KU=;6O4M*F.:;!@%*
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M'>%>.ZA3E\AEC'TD,7A[Y<S$S$]+;RJ-<N./B+IB8F)&9CUUU; _(G^4%FH
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M4!9;FW('$!0A"* N1IE@"Q"UK0A%A4E&Z (6M:UO8=:WO6M:WO>M:S[\ZS3
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M0JTL.6HBB@[,5IPF>(W\\^,;C''R3@G3FF01Q='4+NE7P:<(GA-N7J3DD45
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M*6H1:2(?1K5Q3<J,VI):?1A$4.8+&46_"'9=\(&W6NND:H4P9-PA:%<#SQR
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M.J$UJ=6-D=6MKAO(2L)K*7]K<I+H3(2YQN+1YY?V\I>0L+6+&TA$4W.1Z@I
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MJ:0[&ZQE%(&A7(6T&O!W$X,B=88YH@Z](#OM2E*UKQA[[UXM=Y:(&<'( 10
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MV6?$HZ">L\MK127*2&[VH=:^DKS&%86I4G"DQUH7K. 2Q7VKY!,$HGSS+D/
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M)>RW5*T-FQ>]Y1$H[QH;&&KA6JWU/& V'(%,LFGJB1!)#AQ2'M3O&$Y=P*]
M7N2 ,Y*GKA<7?@(@YDI_EO++!:S+:,M"CXO1X'*X:*:*-6M2&RI'<$<'*TS5
M'61B.>D(DZAJ?WU4ZA&:%O2F'IE))5#1'KH4>[S;DS\,U;::FE:?3T8=4]I0
M**.LO.NI;?+*UJX#%$<;-+:#V&:6"[O*9!5[&>H4$REO;W]T>W"+Z9CDYF76
MS6_!"X4^&E,E]P7M62I2;!C(8K'4P$9F&VS3DHISCUC#$- FN"K8KJ<T;3\;
MM<RK@.\G+,U2A9+F3B)BK;N69F?I+0)TPL><DH!JSF -Z;#%!,-$HHKGT^HN
M0,WL2"<VY9>_(;I44^B3)B*Q1N\1E%TPI([()I6UCIT<.&!F?(F$ALD$+C!Q
MK?(G:?2AV7J#WQM< HT^0UO5IUEF)PNFGJ6?>3"B)\;VZRN0U*VH?)Y(I>;N
M270PU,WQ#CTC<GUS4HYC(./A3O<ZZ/1%\];1D/T9C9"ANT$]E+,E#D/7,XGP
MII6.-B5ARFKIP:'N;0.41F7TXE1RB)7)$(VW2]IHQ_:$4O7"!9]H1AV;WNHT
MC>:OC$U2&*RBY.W+&MU3(Z88^L#&(E9]Z5_84,N&S;!(Y AK*F>-=+4*%;?#
M2SLE&1*TYXCE9.[4>8Q+5$)^%U!\FE3>\1Y D5'Z8&QH=--RAQU:^?=]--3F
M>'6'-=5+;%:K<QLNHL"M.)Q9LJ $"CRM'%IFNTVOBFFI??=EPE&/[5V<3MB
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M%GMP:JQ;JG2,YD;D==R=H5LQ$=;0+VTYV3.4@CLC5+GJ,/K,<H]$7*EC)O\
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M&V9N"3!+K@QK =6)%<@-A21(^*YL!?5+"4/TI99G@&7Z0 !^C,UH)@/&'0O
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MDT=+6YW;5#U8T0K=[!,6J2I;):FM2V'LBR31A-'E(TKR2#2PU.2$V[,,Z1G
M^S:PHF75#8-X AC)7#RU5+9%:WD\(W!\H.T)(HL]IKLF5%M9RQ96K2YOJ]?7
M^R/4I-$T+JH1M4C(*T0!/<S_ .CMQ(*LUNL1"Z7JVM35?#7R5;ZA27-(]T>G
MNA"$DMQFP:W6D+&LQTDY)1I$E&:I,&M)6.!:8Q %<HT/ZF9=\'$6WNC#Y\'
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M21<7^2=9<NJ,@7(*H5;JI@M@(5Y[>1(&PQED3.Y,KNOCTBCTB:###MMSY'I
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MKV=*HBR&R65)H=*%$9CI#P9'CGZ0D,2\UD9B7XH91K(:Z.8$J$IW+,+,;#%
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MXGP.KXJ3$J;N6I>5[G8L<G+0WK;)CUH<=YHT1338VRN*RMUAZN.&>OZ6:6-
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MRQ@D]A5ER M6P2KAZ.\QDMCG01N(E<A^P] ^0V[$?G71,CDD5/E%8>T$.8;
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M5)=<K2 K&3@ 7US Q$270L!F?C,#'/PTQC&8&LK3&,8TU9:8_=IIK_T2V/\
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MIM'E=]^C.T7HP'??A%KOGO>D#_Q;_( >^WXM]@[[;^/MOMOMO6^W;>L>,/\
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MF.57'BSI9>1+HQD)9$CLD25NCXE3DE1_ QS(Q;-<&I<%8(OU=N0)$*U[(4)
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=,8TTQC&--,8QC33&,8TTQC&--,8QC33&,8TU_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
